Abstracts of the 8th International Conference of Anticancer Research, 17-22 October 2008, Kos, Greece
1
BREAST CARCINOMA-ASSOCIATED FIBROBLASTS
AND THEIR ADJACENT COUNTERPARTS DISPLAY
TUMOR-ASSOCIATED FEATURES
Nahed M. Hawsawi, Hazem Ghebeh, Siti-Faujiah
Hendrayani, Asma Tulbah, Maha Al-Eid, Taher Al-Tweigeri,
Dahish Ajareem, Ayodele Alaiya, Said Dermime and
Abdelilah Aboussekhra
King Faisal Specialist Hospital and Research Center,
Department of Biological and Medical Research, MBC # 03,
PO BOX 3354, Riyadh 11211, KSA
It has become clear that the genesis and thrive of carcinomas
depend not only on genetic and epigenetic alterations in
epithelial cells, but also on changes in the stroma. In order to
identify these changes, we have undertaken cellular and
molecular characterization of carcinoma-associated fibroblasts
(CAFs) and their adjacent counterparts (TCFs) isolated from
12 breast cancer patients. Normal breast fibroblasts (NBF)
from plastic surgery were used as normal control. While the αSMA protein was undetectable in NBF cells, CAFs and TCFs
were both positive for this myofibroblast marker. Furthermore,
the p53/p21 response pathway to γ-rays was defective in 70%
CAFs, whilst it was normal in all the TCF and NBF cells. In
addition, the basal levels of p53 and p21 tumor suppressor
proteins were lower in 83% of CAFs, and modulated in the
majority of TCFs, as compared to NBFs. Interestingly, both
TCFs and CAFs expressed high levels of the cancer marker
survivin, and consequently exhibited high resistance to the
killing effects of cisplatin and UV light. Moreover, most CAFs
were positive for the proliferation marker Ki-67 and exhibited
high proliferation rate as compared to NBF and TCF cells.
Using the 2 dimensional gel electrophoresis technique, we have
also shown that CAFs, TCFs and NBF present different
proteome profiles, with many proteins differentially expressed
between these cells, indicating that different genetic alterations
occur in breast carcinoma-associated fibroblasts and also their
corresponding adjacent counterparts.
2
INTRODUCTION TO RADIONUCLIDE THERAPY
Gregory P. Adams1, Jorgen Carlsson2 and Torgny Stigbrand3
1Department
of Medical Oncology, Fox Chase Cancer
Center, Philadelphia, BA, USA;
2Biomedical Radiation Sciences, Uppsala University,
Sweden;
3Department of Immunology and Clinical Microbiology,
University of Umea, Sweden
Targeted radionuclide therapy can provide an effective method
of selectively focusing cytotoxic effects on tumor cells. These
methods have been successfully employed in the clinical
treatment of diffuse (liquid) malignancies but have, as of yet,
failed to achieve similar successes in the setting of solid
tumors. This talk will provide an overview of the successes of
targeted radionuclide therapy, outline some of the hurdles that
remain and discuss possible approaches that can be taken to
enhance therapeutic outcomes.
3
OPTIMIZING ANTIBODY-BASED MOLECULES
FOR RADIOIMMUNOTHERAPY AND
RADIOIMMUNOIMAGING
Gregory P. Adams
Department of Medical Oncology, Fox Chase Cancer Center,
333 Cottman Ave, Philadelphia, PA 19111, USA
Due to prolonged retention in the circulation and restricted
ability to penetrate into solid tumors, intact antibodies are
often not the most effective vehicles for the delivery of
radioisotopes to tumors for therapeutic and imaging
applications. However, antibody-based molecules can be
rationally modified to improve their ability to selectively
deliver radioisotopes to tumor tissue. This presentation will
review our experience and that of others on the impact of
altering antibody size, affinity and ability to interact with FcRn
on targeting efficiency.
4
CETUXIMAB WITH HEPATIC ARTERIAL INFUSION
OF CHEMOTHERAPY FOR THE TREATMENT OF
COLORECTAL CANCER LIVER METASTASES
B. Neyns, M. Aerts, Y. Van Nieuwenhove, C. Fontaine,
L. De Coster, D. Schallier, J. Vanderauwera, F. De Munck,
F. Vandenbroucke, H. Everaert, V. Meert, J. De Mey,
M. De Ridder, G. Delvaux and J. De Grève
UZ-Brussel, Laarbeeklaan 101, 1090 Jette, Belgium
Background: Both hepatic arterial infusion (HAI) of
chemotherapy and cetuximab (CET) have interesting activity
for the treatment of colorectal cancer liver metastases (CRCLM). Patients and Methods: Intravenous CET with HAI
oxaliplatin (OXA) or i.v. Irinotecan (IRI) followed by HAI of
infusion of folic acid modulated 5-fluorouracil 5-FU/l-FA was
administered to patients (pts) with CRC-LM who had failed
at least one line of prior chemotherapy. Results: Eight pts
received i.v. CET with HAI-OXA (5 pts) and i.v.-IRI (3 pts)
and HAI-5-FU/l-FA. Adverse events: repeated grade 3 skin
toxicity (1 pt), abdominal pain with elevated liver enzymes
and asthenia (2 pts), duodenal ulcer (2 pts) with catheter
migration and intestinal bleeding (1 pt), reversible interstitial
pneumonitis (1 pt), and cystic bile duct dilatation (2 pts) with
3185
ANTICANCER RESEARCH 28: 3157-3556 (2008)
arteriobiliary fistulisation (1 pt). A partial response was
documented in 5 pts (62%). The median time to progression
was 8.7 months (95% confidence interval 8-14 months).
Conclusion: Intravenous administration of CET with HAI of
chemotherapy is feasible and has promising activity but is
associated with specific toxicity.
5
PATHOLOGY AS A BRIDGE
BETWEEN RESEARCH AND CLINICAL PRACTICE
Niki J. Agnantis
Department of Pathology, University of Ioannina Medical
School, Greece
The word “Pathology” originates from the Greek words Pathos
(suffering) and Logos (study) and, as its name implies, it is a
discipline devoted to the study of the cause, the pathogenesis,
the morphological changes and functional derangement of
cells, tissues and organs in disease. Anatomic pathology has
originated in Europe 245 years ago and it has come a long
way since the time that Morgagni encouraged the postmortem
search for the cause and nature of disease. During this long
course the histological techniques have been continuously
improving and pathologists have been incorporating a variety
of methods in their every-day practice, making diagnosis more
refined and definite. Today, pathologists are able to make
diagnoses by examining a whole organ, a fragment of tissue,
or even a few cells. Advances in facing cancer range widely,
from basic research designed to understand the molecular
causes of cancer, through the application of this knowledge for
the patients’ benefit. Both basic and clinical research, the latter
being dependent on the former, are now developing at a fast
pace. Pathology is the discipline that acts as a bridge between
Clinical Medicine and Basic Sciences.
A classical paradigm on the role of the pathologist in basic
research is his contribution in elucidating the pathogenesis of
colorectal carcinoma. Every stage of adenocarcinoma
development has been identified and the progressive
accumulation of genetic changes at the molecular level has
been shown to parallel the clinical and histopathologic
progression defined as “adenoma-carcinoma sequence”.
Another example is that of breast cancer. Subclassification
of breast carcinomas is important, since some types such as
tubular and medullary carcinomas, have better prognosis than
others. However, the morphological features of the neoplasm
do not always reveal its underlying biology, as patients with
the same tumor type can demonstrate different courses of their
disease. Several molecular markers have recently been
developed to predict the response of neoplastic cells to a
certain type of therapy. Immunohistochemical analysis of
estrogen receptors α (ERα) and ERBB2/HER2/NEU
expression can be used to predict responses to tamoxifen or
3186
aromatic inhibitors and trastuzumab/hesrceptin respectively, as
these therapies are designed to target these molecules. FISH
has proved to be a powerful molecular DNA technique in
pathology. Another technique that is used with increasing
frequency is CGH. New technology using DNA microarrays
provides a systemic method to identify key markers for
prognosis and treatment response by profiling thousands of
genes expressed in a single tumor. Microarrays have the
potential to revolutionize the practice of pathology by
providing a molecular “signature” that is characteristic of each
neoplasm.
All these new molecular pathology techniques are
necessary, but they should be applied with caution. They
should be critically appraised and analyzed in detail regarding
cost/benefit, in order to contribute the most to patient care.
6
EFFECTS OF THERAPY WITH THE
RADIOLABELLED SOMATOSTATIN ANALOGUE
[90Y-DOTA0,TYR3]OCTREOTATE IN PATIENTS WITH
MENINGIOMA: REVIEW OF 16 CASES
M. Agostini1, F. De Lauro1, M. Casi1, V. Mattone1,
S. Severi1, C. Fabbri2 and G. Sarti2
1Nuclear
Medicine Unit, Imaging Department, M. Bufalini
Hospital, viale Ghirotti 286, 47023 Cesena;
2Health Physics, Imaging Department, M. Bufalini Hospital,
viale Ghirotti 286, 47023 Cesena, Italy
Aim: Therapy using the radiolabeled somatostatin analog [90YDOTA0,Tyr3] octreotate (90Y DOTA-TOC) (DOTA is 1,4,7,10tetraazacyclododecane-N,N’,N’‘,N’‘’-tetraacetic acid) has been
used primarily in gastroenteropancreatic neuroendocrine
tumors. Here we present the effects of this therapy in a small
number of patients with meningiomas. In these patients the
therapy of choice is surgery and radiotherapy, however, the
presence of cellular structures for amine uptake and storage
allow targeted therapy. Meningiomas are tumors derived from
cap cells adherent to the dura mater, mostly close to the
arachnoid villi or skull base foramina; they express different
kinds of receptors. Meningiomas are frequently somatostatin
receptor-positive, and somatostatin receptor scintigrafy may
be used to differentiate remnant or recurrent meningioma from
non-specific hyperperfusion during postsurgical follow-up.
Treatment with 90Y-labeled somatostatin analogs in patients
with meningioma has been undertaken in selected cases.
Materials and Methods: We evaluated 16 consecutive patients
(7 male/9 female; mean age 64 yrs, range 39-78 yrs.) treated
in our unit with 90Y DOTA-TOC in the period 01-03-03 to 1504-07. Eight patients received surgical treatments before
nuclear medicine therapy, 4 had radiotherapy, 3 surgical
treatments and radiotherapy and one patient no treatment. The
mean cumulative administered activity for each patient was
Abstracts of the 8th International Conference of Anticancer Research, 17-22 October 2008, Kos, Greece
6400 MBq (range 1480-12987 MBq), divided into 4 cycles.
The interval between each single treatment was 6-9 weeks.
Mean follow-up was 12 months (range 6-24 mo.). Renal
scintigraphy with GFR study was performed before each
treatment cycle. Routine haematology, liver and kidney
function tests were applied prior to each therapy, as well as at
follow-up visits. CT scan or MRI and somatostatin receptor
imaging was performed within 3 months before the first
therapy and 4-5 months after the last treatment to evaluate the
effects of the therapy on tumour size and metastases. Results:
Partial remission was found in 3 patients (19%), stable disease
in 8 (50%) and progressive disease in 5 (31%). None of the
patients presented bone marrow and renal toxicity after any
treatment. The patient-assessed quality of life was judged as
stable by 5 patients (31%), better by 6 (38%) and worse by 5
(31%). Conclusion: 90Y DOTA-TOC can be effective in
patients with meningioma. Response rates are lower than those
in patients with gastroenteropancreatic neuroendocrine tumors.
Most meningiomas were very large. Further studies are needed
to confirm the treatment outcome because of the limited
number of patients in our study. The side-effects of therapy
are few and mostly transient, and neither renal nor marrow
function seriously deteriorated in any of our patients.
7
GROWTH OF HUMAN TUMOUR CELLS
IN A CELLULAR MICROENVIRONMENT
SUPPLIED BY HUMAN EMBRYONIC
STEM CELL INDUCED TERATOMAS
J. Cedervall1, S. Jamil1, B. Sveinbjörnsson1,
Kanter-L. Lewensohn2, M. Eskandarpour2,
M. Gulyas3, U. Ringborg2, J. Hansson2,
P. Kogner1 and L. Ährlund-Richter1
1Department
of Woman and Child Health, and
of Oncology-Pathology, Karolinska Institutet,
171 76 Stockholm;
3Department of Pathology and Cytology, Central Hospital,
80187 Gävle, Sweden
2Department
Objectives: For clinically relevant studies on tumour
progression, in vivo experimental systems with a human
cellular microenvironment would be advantageous. We have for
this purpose studied growth support for adult vs. paediatric
neuroectoderm-derived human tumours (melanomas and
medulloblastomas/neuroblastomas), following injections into a
predominantly species-specific environment consisting of
human embryonic stem cell derived teratoma, induced in the
mouse (the hEST-model). Results: A mature hESC-teratoma
environment was permissive for the integration and growth of
all the injected tumours (Cedervall et al. submitted), in line
with previous results of Tzukerman et al., in a similar
experimental system (Cancer Res, 66(7): 3792-3801, 2006). In
addition, we found the resulting tumour histology similar to
conventional xeno-graft models, with predominantly areas of
densely packed tumour cells. Uniquely for the hEST-model,
some tumours also showed areas with less dense growth
appearing in a surrounding of loose mesenchymal or fibrous
stroma. The latter tumour population, but not the former,
showed markers and morphology indicative of dedifferentiation
and migration. An enhanced neovascularisation was indicated
in areas of human mesenchymal tissues facing the tumour
growth. The results furthermore indicated a specificity in the
process of integration, distinct for each tumour type. The
unique experimental advantage of a human cellular
microenvironment revealed species-specific interactions of the
tumour cells with the surrounding microenvironment, as
indicated by differential appearances of a selection of markers
linked to differentiation/migration/malignancy. In conclusion,
the hEST-model provides new exciting options for molecular
in vivo studies on differentiation, invasiveness and malignancy,
opening also possibilities for improved clinical relevance in
studies and evaluations of novel therapeutic interventions.
This work was performed with financial support from: The
Swedish Childhood Cancer Foundation, Petrus och Augusta
Hedlunds Stiftelse, Swedish Research Council and Karolinska
Institutet.
Part of the melanoma study was also performed in
collaboration with Drs L. Prasmickaite and G. Maelandsmo,
Dept. of Tumor Biology, Cancer Stem Cell Innovation Center,
Institute for Cancer Research, Norwegian Radium Hospital,
Rikshospitalet University Hospital, 0310 Oslo, Norway, and
Dr Z. Suo, Department of Pathology, Norwegian Radium
Hospital, Rikshospitalet University Hospital; Faculty Division
the Norwegian Radium Hospital, University of Oslo, 0310
Oslo, Norway.
8
REGULATION OF FOCAL ADHESION TURNOVER
BY ERBB RECEPTOR SIGNALING AND
PRECLINICAL IMPLICATIONS FOR ERBB-2+
INVASIVE BREAST CANCER MODELS
Moulay Alaoui-Jamali
Segall Comprehensive Cancer Center, Lady Davis Institute
of the Sir Mortimer B. Davis Jewish General Hospital,
Departments of Medicine and Oncology, McGill University,
3755 Cote Ste-Catherine, Montreal, Canada H3T 1E2
An early event by which cancer cells switch from localized to
invasive phenotype is initiated by the acquisition of motile
properties; a process driven by dynamic assembly and
disassembly of multiple focal adhesion (FA) and cell
cytoskeleton proteins, which mediate cell–matrix attachments,
extracellular matrix degradation, and can serve as traction sites
for motile cells. These processes are regulated by the
3187
ANTICANCER RESEARCH 28: 3157-3556 (2008)
activation of integrins, as well as by growth factor receptors,
including the ErbB/Her tyrosine kinases. We previously
reported that cancer cell invasion induced by overexpression
of the ErbB-2 receptor is dependent on focal adhesion kinase
(FAK), a major kinase and adapter protein of the FA signaling
pathway. Here, we report that ErbB receptor signaling
regulates FA turnover via the Src-FAK pathway. Using
biochemical and confocal imaging assays, we demonstrated
that selective inhibition of the Src-FAK signaling in a panel
of ErbB-2-positive cells regulates FA turnover, leading to
enhanced number and size of peripherally localized adhesions
and inhibition of cell invasion. These phenotypes were not
observed following inhibition of ErbB signaling in cells
lacking Src or FAK, but are restored after re-expression of Src
and FAK in these deficient cells. Furthermore, molecular
studies on downstream events revealed that ErbB signaling
regulates the turnover of several FA-associated proteins,
including FAK, in part via increased calpain 2 activity.
Immunohistochemical analysis on progression tissue
microarray, composed of a large breast tissue bank from
patients treated at this institution for various stages of breast
disease, showed a correlation between overexpression of FAK
and specific FAK-partners in FA signaling and cancer
progression and outcome. The implications of these
downstream targets for invasive breast cancer models and the
impact on novel FA inhibitors in preclinical trials will be
discussed.
Supported by the Canadian Breast Cancer Alliance, the
Canadian Institutes for Health Research, and US Army
Research Initiative on Prostate Cancer.
1 American J Pathology, 2008, in press; J Cell Biology, 171:
505, 2005.
2 Oncogene, 23: 350, 2004; Cancer Res, 63: 3764, 2003.
3 Molecular Biology of the Cell, 13: 4029, 2002.
4 Journal Clinical Oncology, 21: 232, 2003.
5 Oncogene, 26: 4319, 2007; Frontiers in Biosciences, 2008,
in press.
9
REAL TIME PCR (ReT-PCR): A NOVEL METHOD
FOR THE DETECTION OF ESTROGEN
RECEPTOR (ER) ALPHA AND BETA
ISOFORMS AND THEIR VARIANTS
S.B. Al-Saji1 and M.D. Al-Bader2
1College
of Graduate Studies, Molecular Biology MSc
Program;
2Department of Physiology, Faculty of Medicine, Kuwait
University, Kuwait
Introduction: Estrogen receptors -alpha and -beta mediate the
actions of estrogens. Several mRNA splice variants exist for
both receptors and the normal estrogen function results from a
3188
balance between the wild-type ERs and their functional
variants that may interfere with the coexpressed wild-type
forms in a dominant negative manner, or by becoming ligandindependently activated. In addition, ER-alpha and ER-beta
isoforms can exert opposite biological activities, as it is
evident that ER-alpha stimulates cell proliferation while ERbeta can inhibit ER-alpha-stimulated cell proliferation.
Methods: 45 FFPE breast cancer samples were used in this
study. ReT-PCR analysis was conducted using ER-alpha
primer sets detecting wild-type (wt) and exon deleted 3, 5, 6
and 7 variants. The ER-beta primer sets used detected the wt
ER-beta 1 and the ER-beta 2 and ER-beta 5 variants. At the
end of the ReT-PCR cycles a dissociation curve (melting
curve) was generated which showed the number of peaks for
each sample at specific melting temperatures (Tm). If more
than one peak is obtained at the higher melting temperatures
then this indicates the presence of variants for the specific
gene of interest. In addition the dissociation curves provide us
with a peak derivative that reflects the intensity of the band.
Results: Using this method minimal amounts of mRNA could
be detected and many samples expressed not only the wt ER
isoforms but also their variants. The Tm value served as a cutoff point for determination of wt versus variant ER expression.
Wild-type to variant ratio was easily calculated from the peak
derivatives. Conclusion: This method allowed us to detect both
ER isoforms and their variants in FFPE breast cancer tissue.
This method, by showing wt and variants, can be used as an
invaluable tool in the clinical field to predict the response of
patients to antiestrogen therapy.
10
EXPRESSION OF GROWTH HORMONE RECEPTOR
IN NEOPLASMS OF THE PROSTATE
Anwar Al-Banaw1 and David T. Lincoln2
1Faculty
of Allied Health Sciences, Kuwait University,
Kuwait;
2Entity Systems, Independent Research Foundation, Chapel
Hill, QLD, Australia
Knowledge of the mechanisms initiating and regulating
prostate neoplasm and mesenchymal–epithelial interaction
during its development is limited and information about
potential trophic agents incomplete. Apart from regulating the
growth and functions of the normal human prostate gland,
androgens are also involved in the growth of prostate cancer.
In addition, receptors for steroid hormone, including insulinlike growth factor-I (IGF-I), have been shown to exert a
regulatory effect in the normal prostate gland. Recent evidence
indicates that growth hormone (GH) may play an important
role in tumour cell growth. Somatostatin analogues have been
found to retard the growth of experimental prostate
carcinomas.
Abstracts of the 8th International Conference of Anticancer Research, 17-22 October 2008, Kos, Greece
This study further investigates the expression of growth
hormone receptor (GHR) in human benign prostate
hyperplasia (n=20) and in prostate carcinomas (n=62) using
immunohistochemical assays with a well-characterized
monoclonal antibody (mAb 263) reactive against human GHR.
Tumours, consisting of grade 1 (n=8), grade 2 (n=10), grade
3a (n=7), grade 3b (n=8), grade 4a (n=8), grade 5a (n=7),
grade 5b (n=6), were classified according to the grading
system of Gleason and based on the degree of glandular
differentiation and the growth pattern of the tumour in relation
to the stroma, as evaluated on low-power examination. To
delineate tumour cell growth, immunohistochemical analysis
of proliferating cell nuclear antigen, using PCNA polyclonal
antibody, was used to investigate proliferative indexes.
Results from this investigation confirm the presence of
specific receptors for GH in prostate tissue from patients
affected by benign prostate hyperplasia (BHP) and
carcinoma. GHR Immunoreactivity showed sub-cellular
localization of the receptor in cell membranes, and
cytoplasm and nuclei were also reactive in some cases. In
cases of BHP, the GHR expression was localized throughout
the epithelium of the tumour acini. Of the BHP investigated,
40% were weakly reactive with mAb 263. In prostate
carcinomas, regular distinct expression of GHR was
observed in the epithelium of the small, atypically formed
glands in irregular arrangement. Heterogeneity of
immunoreactivity was present with a variable range of
positive cells. Of the 62 cases studied, 77% were moderately
to strongly positive, In foci within higher Gleason grade and
correlating with prostate-specific antigen (PSA), the relative
proportion of positive cells and intensity of immunoreactivity
was increased in higher grade carcinomas, compared to
lower grades and BHP. In contrast to BHP and prostate
carcinomas, GHR expression was absent in normal prostate
epithelial cells. Furthermore, there was a positive correlation
of GHR immunoreactivity with neoplastic cellular
proliferation, as measured by PCNA, the percentage of
PCNA-positive tumour cells, representing the average of 10
fields each tumour case was 1.97% in prostate hyperplasia;
6.3% for grade I; 9.6% in grade 2; 15.6% in grade 3a; 18.3%
in grade 3b; 20.5% in grade 3c; 23.7% in grade 4a; 36.2%
in grade 5a and 61.1% in grade 5b prostate carcinomas. In
conclusion, the presence of GHRs in human BHP and
carcinoma strongly supports the concept that GH, known to
increase mRNA levels of androgen receptor, IGF-1 and IGF1 receptors in immature prostate, reacts on prostate target
tissue to facilitate cellular proliferation. Our results are
consistent with the hypothesis that GH acts locally to
generate IGF-1 which then acts as mitogenic factor for these
cells. Whether these effects of GH on prostate tissue are
mediated by a direct action of IGF-I in an autocrine
mechanism regulating tumour cell growth remains to be
investigated.
11
ENDOTHELIAL CELL PROLIFERATION AND
ANGIOGENESIS IN VASCULAR TUMOURS: A
DIRECT ROLE FOR GROWTH HORMONE
Anwar Al-Banaw1, Fred Sinowatz2 and David T. Lincoln3
1Department of Medical Laboratory Sciences, Faculty of
Allied Health Sciences, Kuwait University, Kuwait;
2Institute of veterinary Anatomy, University of Munich,
Germany;
3Entity Systems, Independent Research Foundation, Chapel
Hill, QLD, Australia
Introduction: Vascular tumours are common lesions of the
skin and subcutaneous tissue, but also occur in many other
tissues and internal organs. Well-differentiated tumours consist
of irregular anastomosing, blood-filled vascular channels that
are lined by variably atypical endothelial cells. Less
differentiated tumours may show solid strands and sheets,
resembling carcinoma or lymphoma. Several growth factors,
including basic fibroblast growth factor, transforming growth
factors and vascular endothelial growth factor, play a role in
tumour angiogenesis. Growth hormone (GH) is mitogenic for
a variety of vascular tissue cells, including smooth muscle
cells, fibroblasts and endothelial cells and exerts its regulatory
functions in controlling metabolism, balanced growth and
differentiated cell expression by acting on specific membranebound receptors, which trigger a phosphorylation cascade
resulting in the modulation of numerous signalling pathways
and of gene expression. Materials and Methods: To address
the site/mode of action through which GH exerts its effects in
vascular tumours, a well-characterized monoclonal antibody,
obtained by hybridoma technology from Balb/c mice
immunized with purified rabbit and rat liver GH-receptor
(GHR) and directed against the hormone-binding site of the
receptor, was applied to total of 64 benign and malignant
vascular tumours from different human organs to determine
GHR expression. Quantitative immunohistochemical analysis
of GHR expression, cycling nuclear protein (Ki-67) and
proliferating cell nuclear antigen (PCNA) was carried out by
calculating the percentage of stained cells using a Zeiss
microscope connected to a computer with image analysis
software. To ensure reproducible and objective assessment of
staining, 10 representative areas, each containing 1,000 tumour
cells, were observed under high-power field (objective lens
x40) in a vertical section taken from the centre of the lesion.
The proportion of positive cells was expressed as percentage
of total cells counted. Grading of microvascular density
(MVD) was according to a scoring system: up to 25 vessels =
1+, 26-50 vessels = 2+, 51-75 vessels = 3+, 76-100 vessels =
4+, while >100 vessels was graded as 5+. Results: Compared
to their normal tissue counterparts, nuclear and cytoplasmic
expression of GHR consistently resulted in strong receptor
3189
ANTICANCER RESEARCH 28: 3157-3556 (2008)
immunoreactivity in the highly malignant angiosarcomas and
Kaposi’s sarcomas, and was localized in the cell membranes
and cytoplasm, but strong nuclear immunoreactivity was also
identified. The presence of intracellular GHRs is the result of
endoplasmic reticulum and Golgi localization. Nuclear
localization is due to identical nuclear GHR-binding protein.
The receptor expression was especially prominent in the solid
buds of newly forming capillaries of infiltrating vascular
tumours, indicating a role of GH in tumour angiogenesis.
There was a positive correlation of GHR expression and
cellular proliferation and cycling, both Ki-67 and PCNA being
significantly higher in vascular tumours with high GHR
expression. The median grade MVD score of the vascular
tumours varied from 2.4 for benign haemangiomas to 4.7 in
highly malignant haemangiopericytomas. Conclusion: Our
findings demonstrate that GHRs are strongly expressed in
malignant vascular tumour cells. The importance of
endothelial cells in angiogenesis and vascular tumour growth
is emphasized by the positive correlation between vascular
tumour cells having endothelial cell characteristics and both
tumour vascularity and tumour growth rates. Malignant
tumour cells, which are highly expressive of the receptor, have
a greater proliferation rate compared to benign tumours. The
presence of GHRs in endothelial cells of vascular neoplasm
indicates that they are target cells and GH is of importance in
the proliferation of vascular tumour angiogenesis. GH is
necessary not only for differentiation of progenitor cells, but
also for their subsequent clonal expansion and maintenance.
This study supports the hypothesis that GH is involved in
paracrine-autocrine mechanism, acting locally in regulating
vascular tumour growth and will be useful for site-specific
studies of the evolution of vascular cancer. The use of antiGHR antibodies to block tumour progression is an intriguing
possibility.
12
MOLECULAR ANALYSIS OF CIRCULATING
TUMOR CELLS (CTC): CLINICAL IMPLICATIONS
Tanja Fehm1, Sabine Kasimir-Bauer2, Erich Solomayer1,
Bahriye Aktas2, Siegfried Hauch3 and Winfried H. Albert3
1University
of Tübingen, Department of Obstetrics and
Gynaecology, Calwerstr. 7, 72076 Tübingen;
2University Hospital Essen, Department of Gynaecology,
Hufelandstr. 55, 45122 Essen;
3AdnaGen AG, Ostpassage 7, 30853 Langenhagen, Germany
Background: Therapy is typically based on distinct properties
of the primary tumor like HER2 or hormone status. However,
metastases exhibit frequently a different phenotype leading to
resistance towards therapy. The (re-)appearance of CTC may
reflect this situation. Objectives: The studies were designed to
evaluate the phenotype of CTC, to compare it with the one of
3190
the primary tumors in the same patients and to correlate the
presence of CTC in metastatic breast cancer patients with the
clinical outcome. Methods: Duplicate samples of 5.5 ml blood
were drawn from patients and tested for the presence of CTC
with the AdnaTest BreastCancer according to the
manufacturer’s instruction (AdnaGen AG) in a multiplex RTPCR. This test reveals the over-expression of HER2, EpCAM
and MUC1. The over-expression of the estrogen receptor (ER)
and of the progesterone receptor (PR) was determined with the
AdnaTest ER/PR in a separate multiplex RT-PCR using the
same cDNA. The over-expression of HER2, ER and PR in the
primary tumor was evaluated by IHC. Results: The primary
tumors of 30 CTC positive patients were analysed for ERα and
PR over-expression. 21 (70%) tumors were positive and 6
(20%) negative for both, ERα and PR. 2 (7%) tumors overexpressed ERα only. One tumor was negative for ER but
positive for PR. 2 patients had ERα/PR positive, 22 (73%)
negative CTC. 6 (20%) CTC were ERα positive but PR
negative. None of the patients with an ERα/PR negative
primary tumor developed positive CTC. Similarly, the primary
tumors of 47 patients were analysed for HER2 over-expression.
7 (15%) cases were defined as triple positive, 40 (85%) as
negative. However, 16 (40%) of the patients with HER2
negative tumors harboured HER2 positive CTC. The overall
concordance of the histological findings on the primary tumors
with the results obtained with the AdnaTest BreastCancer was
55% for HER2 and 50% for ER, strongly indicating that
phenotypic changes may occur during the course of the disease.
In a separate cohort of 32 metastatic patients therapy response
was predicted in 78% of all cases. The persistence of CTC
correlated significantly (p=0.005) with shorter survival.
Conclusion: There is often HER2 over-expression on CTC in
patients with HER2 negative primary tumors. This might offer
the possibility to treat patients with Herceptin® who so far
would not be eligible to it. On the other hand, the overexpression of ERα/PR is rarer on CTC, which might reflect
resistance to hormone therapy. Testing for CTC may offer
additional information with respect to prognosis, risk
assessment for recurrence and prediction of therapy response.
13
IMPLICATION OF OXIDATIVE STRESS IN THE
ANTITUMOR EFFECT OF TAXANES: FROM BASIC
RESEARCH TO CLINICAL PERSPECTIVES
Jérôme Alexandre
Université Paris Descartes, Faculté de Médecine, EA 1833,
Hôtel-Dieu, AP-HP, Paris, France
The taxanes (T), paclitaxel and docetaxel, are microtubuletargeted agents (MTA) widely used in cancer therapy. Their
primary cellular effect is to cause abnormal stabilization of the
dynamic microtubule polymerization. T induce failure of
Abstracts of the 8th International Conference of Anticancer Research, 17-22 October 2008, Kos, Greece
mitosis but also alter intracellular signaling that involves
microtubules.
Recently, oxidative stress has emerged as a major
component of the intracellular signals controlling cell death and
proliferation. We showed that paclitaxel (PCX) induces early
hydrogen peroxide (H2O2) accumulation in human cancer cells.
PCX cytotoxicity is inversely correlated to intracellular content
of reduced glutathione (GSH), a key component of H2O2
scavenging. The GSH precursor, N-acetylcysteine, abolishes
PCX antitumor activity in mice, confirming that H2O2
generation is a crucial step for T-induced cancer cell-death.
We showed that PCX promotes oxidative stress through
enhancing the activity of NADPH oxidase (NOX) associated
with plasma membranes. Treatment of breast cancer cells
causes an increased translocation of Rac1 to the membrane
fraction. Rac1 is a positive regulatory protein of NOX and
may be associated with microtubules in cytosol. By activating
NOX, PCX induces H2O2 accumulation outside the cells.
Using co-culture systems, we observed that extracellular H2O2
causes lethal damage and proliferation inhibition to the
bystander cancer cells not exposed to PCX. This may
contribute to the anticancer activity of PCX. The bystander
effect was also observed with other MTA but not with 5fluorouracil or doxorubicin.
The superoxide dismutase (SOD) catalyzes the dismutation
of superoxide anion to H2O2, constituting a rationale to
develop therapeutic combinations of T and SOD mimics.
Mangafodipir, a contrast agent used in magnetic resonance
imaging, has SOD-, catalase-, and GSH reductase-like
properties, allowing it to act at multiple steps of the reactive
oxygen species cascade. We observed that mangafodipir
amplifies the inhibitory effect of PCX on tumor growth and
protects mice against PCX-induced leucopenia and sepsis,
improving its therapeutic index. This differential effect
between normal and cancer cells may be related to the
observation that, in cancer cells, basal H2O2 concentration is
increased and antioxidant systems are overwhelmed.
These findings open important clinical perspectives.
Expression of proteins controlling the cellular redox
environment may influence the sensitivity of tumor cells to T
and other anticancer agents. Finally, oxidative stressmodulating agents may improve the therapeutic index of T.
14
LOW MOLECULAR WEIGHT PROTEIN TYROSINE
PHOSPHATASE ISOFORMS AND CANCER
PROGRESSION
Irina Alho, M. Clara Bicho, Raquel Carvalho, Alda Pereira
da Silva, Luís Costa and Manuel Bicho
Genetics Laboratory, Metabolism and Endocrinology Center,
Faculdade de Medicina de Lisboa, Av. Prof. Egas Moniz,
Edifício Egas Moniz, P1C 1649-028 Lisboa, Portugal
Protein tyrosine phosphorylation is recognized as crucial for
the generation of signals necessary for cellular metabolism,
proliferation, growth, migration, and invasion of malignant
cells. The contribution of protein tyrosine phosphatases (PTPs)
for the control of cell phosphorylation state is as relevant as
that of phosphotyrosine protein kinase.
Low molecular weight protein tyrosines (LMW-PTPs) are
a family of 18 kDa enzymes that have been implicated in the
regulation of cell growth without tissue specifity. Human red
cell acid phosphatase (ACP1; EC 3.1.3.2) is a polymorphic
enzyme member of the cytosolic LMW-PTPs: three common
alleles (A, B and C) segregating at the ACP1 locus on the
short arm of chromosome 2 (2p25) give rise to six genotypes.
Each allele encodes two electrophoretically different isozymes,
fast and slow (according to their relatively fast or slow anodal
electrophoretic mobility), derived by alternative splicing of the
primary RNA transcript and differing only in the sequence
spanning residues 40-73. These isozymes are produced in
allele specific ratios. These two isozymes may have different
roles in the progression of oncologic pathology: fast are
involved in migration, invasion and cell adhesion, activating
different substrates after PDGF-R stimulation; slow isozymes,
acting directly on PDGF-R, have growth factors as substrates,
e.g. PDGF, leading to a decrease of cellular growth through
its dephosphorylation.
ACP1 seems to have an oncogenic role through the increase
of fast genotypes in cancer patients. Fast isozymes, associated
with cytoskeletal organization, are the only ones activated by
tyrosine phosphorylation in two positions of tyrosine after
growth factor stimulus, which promotes adhesion and cellular
migration and facilitates metastasis and invasion.
15
A GENETIC LOOK AT MIDDLE EASTERN
COLORECTAL CANCER
Khawla S. Al-Kuraya1, Shahab Uddin1, Maqbool Ahmed1,
Azhar Hussain1, Fouad Al-Dayel2 and Nasser Al-Sanea3
1Department
of Human Cancer Genomic Research, Research
Center at KFNCCC&R, 2Department of Pathology,
3Colorectal Unit, Department of Surgery, King Faisal
Specialist Hospital and Research Center, P.O. Box 3354,
Riyadh, 11211 Saudi Arabia
Colorectal Cancer (CRC) is a major cause of mortality and
morbidity worldwide. In Saudi Arabia, the incidence of CRC
is increasing, whereas the incidence rate was originally lower
than in Western countries. According to latest statistics, CRC
is considered the second most common cancer among Saudi
males and the third most common among Saudi females.
Significant improvements have been made in the management
of this disease mainly through the introduction of adjuvant
chemotherapy agents such as flurouracil and oxaliplatin. More
3191
ANTICANCER RESEARCH 28: 3157-3556 (2008)
recently, advances in the understanding of tumor biology have
led to the development of targeted therapies, allowing progress
in the treatment of colorectal cancer.
The ubiquitin-proteasome system (UPS) regulates a number
of intracellular proteins that govern cell cycle tumor, growth
and survival via degrading a number of different polypeptides
important for cell cycle progression and apoptosis. SKP2, an
F-box protein targets cell cycle regulators, including cycledependent kinase inhibitor p27Kip1, via ubiquitin-mediated
degradation. SKP2 is frequently overexpressed in general
types of cancer. We investigated the role of SKP2 and its
ubiquitin-proteasome pathway in CRC using a panel of cell
lines, clinical samples and a nude mouse model. Using
immunohistochemical analysis on a large tissue microarray of
448 samples, an inverse association of SKP2 expression with
p27Kip1 protein levels was seen. A CRC subset with high level
of SKP2 and low level of p27Kip1 showed a decreased overall
survival (p=0.0057). Treatment of CRC cell lines with
bortezomib or expression of siRNA of SKP2 caused downregulation of SKP2 and accumulation of p27Kip1. Furthermore,
treatment of CRC cells with bortezomib caused apoptosis via
mitochondrial pathway and activation of caspases. In addition,
treatment of CRC cells with bortezomib down-regulated the
expression of XIAP, cIAP1 and survivin.
Finally, treatment of CRC cell line xenografts with
bortezomib resulted in growth inhibition of tumors in nude
mice via down-regulation of SKP2 and accumulation of
p27Kip1. Altogether, our results suggest that SKP2 and
ubiquitin-proteasome pathway may be a potential target for
therapeutic intervention for treatment of CRC.
16
DOMAIN I OF THE UROKINASE PLASMINOGEN
ACTIVATOR RECEPTOR IN SERUM IS AN
INDEPENDENT PROGNOSTIC FACTOR IN NONSMALL CELL LUNG CANCER
Charlotte E. Almasi1, Ib J. Christensen1,
Gunilla Høyer-Hansen1, Helle Pappot1,2,
Hendrik Dienemann3 and Thomas Muley4
1The
Finsen Laboratory, Rigshospitalet, Copenhagen;
of Oncology, Rigshospitalet, Copenhagen,
Denmark;
3Department of Thoracic Surgery, Thoraxklinik Heidelberg
gGmbH, University of Heidelberg;
4Translational Research Unit, Thoraxklinik-Heidelberg
gGmbH, University of Heidelberg, Germany
2Department
Introduction: The urokinase plasminogen activator (uPA)
system is a cascade of reactions participating in the
degradation of extracellular matrix during cancer invasion. The
uPA receptor, uPAR, is a key enzyme consisting of three
domains denoted I, II and III. In addition to its involvement in
3192
the plasminogen activation, uPA can cleave a neighbouring
uPAR molecule between domains I and II. We have previously
shown that high blood levels of both intact and cleaved uPAR
forms are associated to short survival in patients operated for
non-small cell lung cancer (NSCLC). Purpose: To validate the
prognostic impact of intact and cleaved uPAR forms measured
in serum from NSCLC patients. Methods: Serum sampled
preoperatively was available from 171 patients radically
operated for NSCLC (population A). The median observation
time was 3.8 years. A subpopulation of 124 lung cancer
patients was selected with squamous cell carcinomas (SCC)
or adenocarcinomas (AC) in stage I-III (population B). This
subpopulation was further restricted to those patients (n=90)
having no other treatment than operation (population C). The
levels of the different uPAR forms (intact+cleaved: uPAR(IIII)+(II-III), intact: uPAR(I-III), domain I: uPAR(I)) in the
samples were measured by three in-house time-resolved
fluoroimmunoassays. Results: Significant associations were
found between both uPAR(I-III) and uPAR(I) and gender.
uPAR(I) was the uPAR form with the most significant
association to survival, and was therefore used for further
analyses. High serum levels of uPAR(I) were associated to
short survival in the three populations. These associations were
independent of stage, histology, age, WHO performance status
and therapy (Population A: HR=1.85, C.I.: 1.18-2,89,
p=0.007; Population B: HR=2.03, C.I.:1.18-3.52, p=0.01;
Population C: HR=3.05, C.I.: 1.47-6.34, p=0.003). In addition
to uPAR(I), only stage was a significant prognostic factor in
all three populations. No interactions between uPAR(I) and
histological subtype could be detected. Conclusion and
Perspectives: This study validates that uPAR(I) in serum is an
independent prognostic factor in patients radically operated for
NSCLC. A possible application of uPAR(I) is as a
supplementary tool in the selection of early-stage NSCLC
patients for adjuvant therapy.
17
THE THIOREDOXIN-THIOREDOXIN
REDUCTASE SYSTEM: OVEREXPRESSION
IN THYROID CANCER
Fatma Al-Yatama1, Maie Al-Bader2 Fawziah M.A.
Mohammed1, Anwar G. Al-Banaw1 and David T. Lincoln3
1Department
of Medical Laboratory Sciences, Faculty of
Allied Health Sciences, Kuwait University, Kuwait;
2Department of Physiology, Faculty of Medicine, Kuwait
University, Kuwait;
3Entity Systems, Independent Research Foundation, Chapel
Hill, Australia
Oxidation-reduction has emerged as a fundamental biological
control mechanism. One of the major redox control systems
consists of thioredoxin (TRX) and thioredoxin reductase (TRX-
Abstracts of the 8th International Conference of Anticancer Research, 17-22 October 2008, Kos, Greece
R). Together, they form a powerful system involved in many
central intracellular and extracellular processes, including cell
proliferation, redox regulation of gene expression and signal
transduction, protection against oxidative stress, anti-apoptotic
functions, growth factor and co-cytokine effects, and the
regulation of the redox state of the extracellular environment. In
recent times, this system has increasingly been linked to the
development and expression of cancer phenotypes, cancer cells
secreting thioredoxin in varied amounts. The secreted TRX
tends to sensitize the cells to growth factors, produced by the
cancer cells themselves, by increasing the potentiation of the
growth factors, making the cells more susceptible to them and
therefore leading to increased cellular proliferation. Thus, TRX
acts like an enhancement for growth factors and stimulates the
growth of cancer cells. In this investigation, we have used
immunocytochemical approaches to simultaneously determine
the expression and localization of both TRX and TRX-R in
neoplasms of the thyroid gland. Thyroid cancer is the second
most common malignancy following breast cancer in Kuwaiti
females. The incidence of thyroid cancer per every 100,000
females is 7.4 and constitutes ten percent of all common
malignancies. This retrospective study of thyroid cancers,
involving 111 female and 55 male patients, consisted of benign
colloid nodule (n=15), colloid goiter (n=14), multinodular
goiter (n=21), papillary oncocytic neoplasm (n=10), follicular
adenoma (n=16), follicular carcinoma (n=24), invasive
follicular carcinoma (n=18) and papillary carcinoma (n=48),
Immunohistochemical identification and localization of TRX
was performed using purified mouse anti-human TRX
monoclonal antibody. Expression of TRX-R was demonstrated
using an anti-human TRX-R antiserum prepared by
immunization of rabbits against purified human placental
thioredoxin reductase. The antiserum was assessed for
specificity by Western Blot analysis against purified human
TRX-R and human cell and tissue extracts and detected as
single 56K band of human TRX-R. The results from this
investigation show increased staining intensity of both TRX
and TRX-R in the cytoplasm and nuclei of thyroid cancer cells,
compared to normal thyroid tissue. Expression of increased
TRX immunoreactivity was found in 15% of the benign colloid
nodule cases, in 45% of colloid goiters, in 52% of multinodular
goiters, in 45% of papillary oncocytic neoplasm, in 30% of
follicular adenomas, in 65% of the follicular carcinomas, in
72% of the papillary and in 85% of all invasive follicular
thyroid carcinomas. Furthermore, increased levels of TRX
immunoreactivity positively correlated with thioredoxin
reductase (TRX-R) expression and localization. This enzyme,
involved in the reduction of thioredoxin, was also highly
expressed in thyroid cancer cells, reflecting that a large amount
of its thioredoxin substrate is also present. Of the 166 thyroid
cancer cases investigated, overexpression of TRX-R was found
in 12% of the benign colloid nodule cases, in 40% of colloid
goiters, in 50% of multinodular goiters, in 40% of the papillary
oncocytic neoplasms, in 30% of follicular adenomas, in 52%
of the follicular carcinomas, in 66% of the papillary and in
80% of all invasive follicular thyroid carcinomas. In the case
of invasive follicular carcinomas, the majority showed a
correlation between strongly positive thioredoxin and
thioredoxin reductase expression, and number of positive
lymph nodes. In conclusion, the correlation of TRX and TRXR immunoreactivity with advanced malignancy suggests a
positive association of enhanced expression of these two
proteins with the more aggressive tumour phenotypes. Such
tumours have a high proliferation rate, a low apoptosis rate and
an elevated metastatic potential, all of which can be influenced
by the actions of the thioredoxin–thioredoxin reductase system.
Results from this investigation also indicate that thyroid tumour
cells use thioredoxin as an autocrine growth stimulate.
Occurrence of oxidative stress within the cells induces TRX-R
release which, due to its anti-apoptotic activity, causes
inhibition of apoptosis, resulting in abnormal cell proliferation
initiating cancer development. Aggressive tumours display
intense immunoreactivity of thioredoxin and thioredoxin
reductase and due to the former, have a high proliferation rate
and low apoptosis rate. This indicates that increased TRX and
TRX-R expression is associated with tumourigenesis. In
addition, secreted TRX can also act as an extracellular growth
factor for both normal and tumour cells and enhance the
sensitivity of the cells to other growth factors. As such, this
study further emphasizes the potential benefits of antiTRX/TRX-R agents in cancer therapeutics in the treatment of
thyroid cancers.
18
ASSESSMENT AND COMPARISON OF EFFLUX
PUMPS OF CANCER CELLS AND MDR BACTERIA
UNDER PHYSIOLOGICAL CONDITIONS BY A
REAL-TIME SEMI-AUTOMATED SYSTEM
Leonard Amaral1,2, Gabriella Spengler1,2, Miguel Viveiros1,
Liliana Rodrigues1,2, Ana Martins1,2, Isabel Couto1,3,
Marta Martins1,2, Séamus Fanning4,
Jean-Marie Pagès5 and Joseph Molnar6
1Unit
of Mycobacteriology, Instituto de Higiene e Medicina
Tropical, Universidade Nova de Lisboa (UNL), Lisbon,
Portugal;
2UPMM, Instituto de Higiene e Medicina Tropical, UNL,
Lisbon, Portugal;
3Centro de Recursos Microbiológicos (CREM), Faculdade de
Ciências e Tecnologia, UNL, Caparica, Portugal;
4Centre for Food Safety, School of Agriculture, Food
Science and Veterinary Medicine, University College Dublin,
Dublin, Ireland;
5UMR-MD1, Transporteurs Membranaires, Chimiorésistance
et Drug-Design Facultés de Médecine et de Pharmacie,
Marseille, France;
3193
ANTICANCER RESEARCH 28: 3157-3556 (2008)
6Institute
of Medical Microbiology, University of Szeged H6720, Szeged, Hungary
Assessment of overexpressed efflux pumps (EPs) is usually
conducted with the common EP substrate fluorochrome
ethidium bromide (EB) in the absence and presence of agents
that are believed to inhibit EPs and hence promote the
accumulation of EB. This method is conducted at room
temperature with a buffer of pH 7 and usually without any
source of metabolic energy. These conditions are far from
those under which EPs are expected to function optimally. The
semi-automated method to be presented utilises a buffer whose
pH ranges from 5 to 8, contains a source of metabolic energy
and is maintained at 37˚C. These are conditions that favour
efflux and hence should be suitable for the study of EPs of
multidrug-resistant (MDR) bacteria. Accumulation of EB, its
efflux, and the effects of agents that increase accumulation and
inhibit efflux, has been followed on a real-time basis with the
aid of the Rotor-Gene 3000™. The method has been applied
for the study of EPs of MDR strains of Escherichia coli,
Salmonella, Enterobacter, Enterococcus, Staphylococcus and
mycobacteria. Overall, whereas at pH 5 CCCP, PAβN and
phenothiazines do not increase the accumulation of EB or
prevent its efflux under conditions that favor efflux, with
increasing pH, these agents cause increased accumulation of
EB, although the medium is highly supportive of efflux. The
results suggest that at low pH, the energy (protons) that is used
for driving efflux is supplied by the proton gradient, whereas
at high pH the needed protons are provided by metabolic
energy. Evaluation of the efflux pump of cancer cells was also
conducted by the same methodology. The results presented
show that the assessment and inhibition of efflux pumps of
cancer cells that render the cells immune to cytotoxic agents
can be conducted on a real-time basis with a degree of
precision not possible with flow cytometry. Moreover, because
of the capacity of the system, a large number of cell systems
can be evaluated and compared with any one run of the
method.
19
AN ARTIFICIAL NEURAL NETWORK-BASED
EVALUATION OF TUMOUR BIOMARKERS FOR
THE PREDICTION OF NODAL SPREAD AND
PROGNOSIS OF BREAST CANCER
Shirin Ameiryan, Gajanan V. Sherbet, Wai L. Woo and
Satnam S. Dlay
School of Electrical, Electronic and Computer Engineering,
University of Newcastle upon Tyne, UK
The presence of tumour cells in the regional lymph nodes is
routinely employed to determine tumour spread and predict
prognosis. Minimally invasive methods to achieve this have
3194
been keenly sought. Many biomarkers have been identified
that appear to relate to the aggressive behaviour of cancer.
This study aims to assess four biomarkers using an Artificial
Neural Network (ANN) to predict the presence of metastatic
tumour in the regional lymph nodes and to predict 5-year
survival of patients with breast carcinoma. Evaluation of the
impact of individual markers on predicting outcome and
determining an optimum subset that can yield a high level of
prediction accuracy in both cases is another objective of this
study. The data set used for the analysis consists of four input
markers viz. DNA ploidy, S-Phase Fraction (SPF),
G0G1/G2M Ratio, oestrogen and progesterone receptor
expression status (ER/PR) and two corresponding outputs to
be predicted, one related to the nodal involvement and the
other to 5-year survival of patients. The results indicate that
amongst individual biomarkers, ER/PR provides the best
accuracy of performance for both survival and nodal
involvement of the tumour with 89% and 70% of accuracy
respectively. Inspecting the accuracy outcome of different
biomarker combinations for survival analysis, the best results
have been obtained from the two biomarker subset consisting
of SPF and G0G1/G2M ratio which provided 89% prediction
accuracy. In the case of nodal involvement prediction, the
three marker subset containing DNA ploidy, ER/PR and
G0G1/G2M ratio demonstrated the highest accuracy which is
73%. Hence, for predicting prognosis in breast carcinomas,
identifying two markers instead of all markers is sufficient to
obtain more accurate prediction for survival analysis whilst the
three-marker configuration is more suitable for nodal
assessment. In addition, when all four markers were
combined, the highest predictive accuracy is found to be 90%
for both survival and nodal prediction. These findings suggest
that ANN-based analysis commends itself as a highly accurate
method for the prediction of lymph nodes metastases and
prognosis.
The authors thank Dr C. Bartoli and Professor F. Cajone of
University of Milan for clinical collaboration.
20
MECHANISMS OF RALT-DEPENDENT INHIBITION
OF ERBB SIGNALLING
Sergio Anastasi
Laboratory of Immunology, Regina Elena Cancer Institute,
Viale delle Messi D’Oro, 156-158 00158, Rome, Italy
RALT/MIG6/ERRFI-1 (hereafter referred to as RALT) is a
transcriptionally-induced feed-back inhibitor of receptors
belonging to the epidermal growth factor receptor family
(EGFR/ErbB1, ErbB2, ErbB3 and ErbB4). Overexpression of
RALT in cultured cells inhibits activation of ERK and AKT
downstream to ErbB receptors and attenuates the mitogenic
and transforming activity of ErbB oncoproteins. Conversely,
Abstracts of the 8th International Conference of Anticancer Research, 17-22 October 2008, Kos, Greece
RNAi-mediated knock-down of RALT expression in EGFtreated cells causes a) extended duration of ERK and AKT
activation; b) higher expression of G1/S cyclins; c) increased
recruitment of cells into the mitotic cell cycle. Ralt null mice
show a fully penetrant skin phenotype, characterized by
aberrant proliferation of keratinocytes and enhanced sensitivity
to skin carcinogens. Consistent with studies in cultured cells,
skin lesions in Ralt null mice are reversed by Iressa, a
clinically used inhibitor of the EGFR kinase. Thus, RALT is
an essential negative regulator of ErbB signals and a potential
tumour suppressor.
Herein we present our most recent work aimed at clarifying
the molecular mechanisms which account for the essential role
of RALT in the regulation of ErbB signalling. RALT binds to
ligand-activated ErbB receptors via a region spanning aa. 325375 (EBR, ErbB-binding region). The EBR is necessary and
sufficient to inhibit the kinase activity of ErbB RTKs in in
vitro assays, as well as in intact cells. Deletion mutagenesis
studies indicate that the EBR binds to the –COOH lobe of the
kinase domain of EGFR, a region known to be essential for
the allosteric activation of the EGFR kinase induced by liganddriven receptor dimerization. The EBR function is
evolutionarily conserved, as the EBR module of the D. rerio
RALT ortholog is capable of suppressing human EGFR.
Surprisingly, we observed that RALT-bound EGFR
molecules undergo a seemingly normal endocytic traffic. This
appears to contradict the consolidated notions that EGFR
signalling is required for receptor down-regulation and
inhibition of EGFR kinase blocks receptor endocytosis. We
will present data supporting a role of RALT as effector of the
endocytosis of kinase-suppressed EGFR. A model entailing a
two-tiered mechanism of EGFR inhibition by RALT, namely
kinase suppression and receptor down-regulation, will be
discussed.
21
FREE RADICALS AND CANCER
Jane Anastassopoulou
National Technical University of Athens, Chemical
Engineering Department, Radiation Chemistry and
Biospectroscopy, Zorgafou Campus, 15780 Zografou,
Athens, Greece
It is well documented that lifestyle, environmental factors,
exposure to chemicals, radiation (UV, X-rays γ-rays) and
metabolic abnormalities can induce oxidative stress leading to
the formation of free radicals, such as hydroxyl (HO•),
hydroperoxyl anions (O2–•), peroxyl (OO•), organic carbon
radicals (R•), etc. Because of their very fast biochemical
reactivity, free radicals can damage directly or indirectly DNA
and then this damaged DNA, when in excess, can cause
mutations, which alter cell signalling pathways creating
cancer. The primary sites of attack are the heterocyclic purine
and pyrimidine bases. Several investigations, in vitro and in
vivo, have shown that the most important reaction in these
cases is the addition of hydroxyl free radicals to imidazole
rings of DNA, producing 8-OHdG, which also is used as a
biomarker. It was found that the amount of 8-OHdG is higher
in tissues of women with breast cancer than to those with no
cancer. Free radicals can also induce DNA strand breaks,
single (ssb) or double (dsb), which are characterized by the 3phosphoglycolate-ended fragments.
We have used micro-Fourier Transform Infrared
spectroscopy, an easy-to-use and non destructive technique, to
investigate the very early-stages of breast cancer through the
infrared spectra. Considerable changes were observed in the
spectra in the region 1650-1500 cm–1 of amide I and amide II
absorptions, as well as in the region of 1200-900 cm–1, where
the phosphate groups of DNA absorb. Spectral analysis allows
us to conclude that mapping of the spectra of breast tissues
could give us information about damages in the tertiary and
secondary structures of proteins and in particular the
functional groups of biological molecules, which are indicative
of early-stages of development of cancer.
For the early diagnosis (pre-diagnosis) and therapy of breast
cancer it is crucial to develop a non-destructive bioanalytical
technique, such as micro-FT-IR spectroscopy, to obtain images
of the breast, which are independent of breast shape and mass
density in order to detect lesions, which are difficult to scan
with the existing techniques.
22
DNA TOPOISOMERASES – CELLULAR TOOLS
WITH HUGE IMPACT ON GENOME STABILITY
Kamilla Kristensen, Jakob M. Pedersen, Simon Bendsen,
Lotte Andreasen, Birgitta R. Knudsen,
Lotte Bjergbaek and Anni H. Andersen
Department of Molecular Biology, University of Aarhus,
C.F. Møllers Allé, Bldg. 130, DK-8000 Aarhus C, Denmark
DNA topoisomerases are ubiquitous enzymes which have
evolved to solve the topological problems generated whenever
the two DNA strands are separated to expose the encoded
genetic information. This is the case during DNA
transcription, where the separation of the strands is local and
transient, and during DNA replication, where the separation is
permanent.
Two types of topoisomerases exist, type I, including
eukaryotic topoisomerase I and type II, including eukaryotic
topoisomerase II. The enzymes remove topological problems
manifested as changes in the number of windings in the DNA
double helix, DNA interlinks, and DNA knots. Type I enzymes
operate by introducing a transient cleavage in one of the DNA
strands, whereas type II enzymes introduce a transient double-
3195
ANTICANCER RESEARCH 28: 3157-3556 (2008)
strand break. During the DNA cleavage event, the enzymes
become covalently linked to the generated DNA ends and
topological structures are solved by passage of intact DNA
through the breaks. After DNA passage, the breaks are
resealed and the enzymes leave the DNA or go through a new
catalytic cycle.
The covalently linked topoisomerase-DNA complex
generated as an intermediate in the catalytic cycle of DNA
topoisomerases presents a potential danger to the cell as the
breaks can become permanent if DNA tracking machineries
collide with the complexes. Balanced enzyme activities and
efficient repair systems are therefore crucial to avoid
genomic instability as a cause of topoisomerase action.
Advantage is taken of the intermediate topoisomerase-DNA
complexes by antitumor agents targeting DNA
topoisomerases. These drugs change the enzyme into a
cellular poison by stabilizing the complex, the result being
chromosomal fragmentation and cell death. Lack of
topoisomerase activity is another cause of genomic
instability. In this case accumulating, unresolved topological
structures may act as roadblocks and result in DNA breaks
during replication and transcription.
We are currently investigating the role of DNA
topoisomerases for global gene expression and the impact of
the enzymes for genome stability during replication. Aspects
of topoisomerase action and biological functions, as well as
implications for genomic stability will be discussed.
23
S100A4 IN MAMMARY GLAND BRANCHING
MORPHOGENESIS
Kristin Andersen1, Hidetoshi Mori2, Jimmie Fata3, Gunhild
Mælandsmo1 and Mina Bissell2
1Department
of Tumor Biology, Institute for Cancer
Research, Norwegian Radium Hospital, Oslo, Norway;
2Life Science Division, Lawrence Berkeley National
Laboratory, CA;
3University of New York, College of Staten Island, NY, USA
S100A4, also called FSP1, belongs to the S100 family of
small (10-12 kDa), calcium binding proteins. The members in
this family have no known enzymatic activity, but undergo
conformational changes during calcium binding, opening
hydrophobic domains responsible for binding target proteins.
S100 proteins are expressed both intra-, and extracellularly, in
a cell- and tissue-specific manner. The evidence linking the
expression of S100A4 in cancer cells to increased metastatic
capacity is, after almost 20 years since its discovery, quite
convincing. In addition, numerous publications on clinical
material from several types of cancer have confirmed the
association between S100A4 expression in primary carcinoma
cells and a more severe prognosis. This was previously
3196
demonstrated in a panel of 349 early-stage breast cancer
biopsies, where expression of S100A4 was a stronger
prognostic marker than both lymph node infiltration and
hormone receptor status. Interestingly, both the intracellular
and extracellular version of the protein have been coupled to
increased metastatic capacity of cancer cells. Both versions
have been shown to induce MMP expression, and studies
suggest that extracellular S100A4 activated NF-κB through an
as yet unknown receptor.
The mammary gland undergoes extreme morphological
changes throughout puberty. Hormones trigger the epithelial
cells to proliferate and invade the mesenchyme, giving rise to
a defined tree-like structure of ducts, with complex tissue
architecture, in a highly regulated branching morphogenesis.
Interestingly, the highly controlled branching morphogenesis
and the metastatic spread of breast carcinoma cells have
several similarities, they both require cell proliferation and
invasion of the surrounding extracellular matrix. In this study,
our goal was to elucidate the expression of S100A4 in normal
breast tissue and to investigate whether S100A4 has a role in
the normal mammary development. Mammary glands from
mice and humans were analyzed for in vivo S100A4 protein
expression by immunohistochemistry and RT PCR,
respectively. Furthermore, organotypic 3D cultures of primary
mouse mammary epithelial cells, and mammary epithelial cell
lines from mice, were employed as functional model systems.
We found S100A4 expressed in some mammary epithelial
cells and its mRNA expression peaked during the period of
ductal elongation in mice mammary gland. Using 3dimensional organotypic in vitro models and shRNA, we
furthermore demonstrated that both extracellular and
endogenously expressed S100A4 up-regulated MMP
expression, and contributed to a branching phenotype in
normal epithelial cells. We propose the stimulatory effects of
S100A4 on branching morphogenesis as an explanation as to
why S100A4 promotes a metastatic phenotype in early-stage
mammary carcinoma cells.
24
CROSSTALK BETWEEN ADHESION MOLECULES
AND TUMOR PROGRESSION
Alexandra Canonici1, Wim Steelant2, Véronique Rigot1, Erik
Bruyneel4, Frans Van Roy5, Françoise Garrouste1, Gilbert
Pommier1 and Frédéric André1
1INSERM
UMR 911, Aix-Marseille Université, Marseille,
France;
2New Mexico Tech, Laboratory of Biochemical and
Biomedical Research. Socorro, NM, USA;
3Department of Experimental Cancerology, Ghent University
Hospital, Ghent;
4Department for Molecular Biomedical Research, VIB Ghent University, Ghent, Belgium
Abstracts of the 8th International Conference of Anticancer Research, 17-22 October 2008, Kos, Greece
Dynamic crosstalk between cell adhesion molecules,
extracellular matrix and soluble informative factors is
essential for cancer cell migration and invasion. Here, we
investigated the mechanisms by which the Ecadherin/catenin complex and αv integrin can modulate
insulin-like growth factor-I (IGF-I)-induced cell migration.
Human colon mucosa, human colon cancer cell lines, HT29D4 and HCT-8 derivatives that differ in their expression of
α-catenin were used as models. Interactions between Ecadherin, αv integrin and IGF-I receptor (IGF-IR) were
analyzed
by
co-immunoprecipitation
and
immunolocalization experiments. The impact of these
interactions on cell mobility was determined by haptotaxis
assays. We report that αv integrin, E-cadherin and IGF-IR
form a ternary complex in both cultured cancer cells and
human normal colonic mucosa. Alpha-catenin regulates the
scaffolding of this complex. IGF-IR ligation by IGF-I
induces the disruption of the complex and the relocalization
of αv integrin from cell–cell contacts to focal contact sites.
This perturbation is correlated with the observed increase in
cell migration. These results suggest that regulation of the
αv integrin/E-cadherin/IGF-IR scaffolding is essential for
the modulation of cell mobility. Its alteration could be of
major importance to sustain alterations in cell adhesion that
occur during cancer cell invasion and metastasis.
25
ADVANCES IN THE TREATMENT OF
AMYOTROPHIC LATERAL SCLEROSIS (ALS)
E. Andreadou
Department of Neurology, Athens National University,
“Aeginition” Hospital, Athens, Greece
Motor neurone disease or amyotrophic lateral sclerosis (ALS)
is a progressive neurodegenerative disease that specifically
affects upper and lower motor neurones (MNs) and causes loss
of power and function of skeletal muscles, with an annual
incidence 0.3-2 per 100,000 population. The course of the
disease is relatively rapid, with an average duration of around
3.5 years. Death is most frequently due to respiratory failure.
Although the cause of ALS remains unknown, several
pathways have been implicated in disease pathogenesis
including glutamate mediated excitotoxicity, mitochondrial
dysfunction, neuro-inflammation, apoptosis, oxidative stress,
protein aggregation, aberrant axonal transport, and
autoimmunity.
The management of patients with ALS has changed rapidly
over the past 20 years. Although ALS is incurable, it is
treatable. Advances in understanding the biology of ALS has
led to the development of one marketed treatment, improved
clinical management of people with ALS, and many clinical
trials of novel therapies. This lecture will focus on recent
advances in the development of new pharmacological agents,
the combination of drug therapies, the new promising
treatment strategies such as the transplantation of stem cells
for the replacement of the damaged or lost MNs and the
symptomatic care of patients with ALS.
Until now, the only drug that has shown evidence of
neuroprotective effects in clinical trials in MND is riluzole.
The drug has only marginal effects on survival and quality of
life of ALS patients, as it prolongs survival by an average of
only 3-4 months. Although it is considered an antiglutamate
agent, its mechanism of action is obscure. In a recent study
we have confirmed the lower rate of disease progression after
treatment with riluzole, both in the spinal and the bulbar
subtype of ALS, without any significant impact on plasma
levels of the aminoacids glutamate and glycine. Our results
possibly indicate additional mechanisms of action of the drug,
besides its antiglutamatergic properties. Although many other
agents have been tried in ALS without clear benefit, several
new promising therapies are under development. Encouraging
data are available from human studies for several agents
including talampanel, tamoxifen, sodium phenylbutrate,
arimoclomol and lithium. However, recent results suggest that
addressing multiple components of ALS pathology in
combination therapies might be the most effective way of
tackling the disease. Combinations of anti-inflammatory and
anti-excitotoxic drugs as treatments in animal models of ALS
(mSOD1 mice) have been shown to be superior to application
of their single components alone. Recently, in a face II trial
the celecoxib-creatine combination was selected as preferable
to the minocycline-creatine combination for further evaluation,
although each of the three drugs individually has failed a
phase III trial in ALS.
Other therapies besides the administration of
pharmacological agents include viral vectors for gene delivery,
other therapeutic factors that reduce endogenous motor neuron
loss, minimize reactive astrocytosis and enhance connectivity
of new neurons with host circuitry, as well as training
regimens that modify these new spinal cord circuits. Moreover,
transplantation of stem cells (adult, embryonic or neural)
offers an intriguing strategy for slowing disease progression
and/or promoting recovery of function because engrafted cells
have the potential of replacing lost or dysfunctional neuronal
and glial cell types as well as non-neural elements which
contribute to recovery. Stem cell grafts can also provide
additional benefits, including neuroprotection, modification of
the immune response, reprogramming of endogenous stem
cells, generation of new bridges or lost circuitries and delivery
of therapeutic factors such as neurotrophic proteins and
missing gene products. However, stem cell therapy remains
entirely speculative at present. It is uncertain whether cellbased therapies will succeed without firstly interrupting the
systemic disease process. Therefore progress in the field will
accompany understanding of the underlying disease-specific
3197
ANTICANCER RESEARCH 28: 3157-3556 (2008)
pathways and cell-replacement may need to be combined with
immunosuppressant or neuroprotective approaches.
More realistically at present, a multidisciplinary approach
can prolong survival and improve or maintain quality of life
of patients with ALS. Disease progression gives rise to severe
disability, respiratory impairment, speaking and swallowing
difficulties.
The management of respiratory impairment in patients with
ALS comprises ventilatory support. Assisted non-invasive
ventilation is usually provided by a bilevel positive pressure
device (BiPAP) and is a major advance in the management of
ALS, as it has a survival benefit much greater than that of
riluzole. Starting non-invasive ventilation is recommended
when patients with ALS have symptoms related to nocturnal
hypoventilation, frequently with dyspnoea and orthopnoea.
Tracheostomy ventilation is an option when non-invasive
ventilation is not able to compensate for respiratory
impairment; however it is beyond the means for most patients.
Swallowing difficulties lead to malnutrition and weight loss.
Since nutritional status is a risk factor for survival, nutritional
support is essential to the care of patients with ALS. Enteric
feeding maintains good nutrition and hydration, stabilises
weight, provides a way to give drugs, and might improve
quality of life. Enteric feeding can be done by nasogastric
tube, percutaneous endoscopic gastrostomy, or radiologically
inserted gastrostomy. Patients with ALS also develop deficits
that impair their ability to communicate. Development of
brain-computer interfaces that provide connection between the
brain and a computer can help to restore communication in
severely impaired patients, through voluntary regulation of
brain activity as a response to sensory stimulation.
Despite remarkable progress in understanding the
underlying biology, ALS is a progressive, devastating and
ultimately fatal disease and all patients will reach the terminal
phase of respiratory insufficiency, inadequate nutrition and
hydration and severe psychological distress. Consequently,
there remains a critical need to develop additional treatments
that will slow disease progression and ultimately turn ALS
into a long-term treatable illness. Until more effective, diseasemodifying therapies will be developed, improved clinical
standards of care will play a major role in survival and quality
of life of patients with ALS.
26
MULTIPLE PATHS TO DRUG RESISTANCE
PHENOTYPE IN CHRONIC MYELOID LEUKEMIA
PATIENTS UNDERGOING IMATINIB MESYLATE
TREATMENT
Ravindran Ankathil, Mohd Khairi Zahry, Rosline Hassan,
Abu Dzarr, Hoh Boon Peng and Abdul Aziz Baba
School of Medical Sciences, Health Campus, University
Sains Malaysia, 16150, Kubang Kerian, Kelantan, Malaysia
3198
The introduction of Imatinib mesylate (Gleevec/Glivec) to the
therapeutic armamentarium has changed the current
management of Chronic Myeloid Leukemia (CML) patients.
Despite being the first line treatment for CML, resistance to
Imatinib is emerging as a real clinical problem in the
management of CML. Therapeutic resistance to Imatinib may
be primary or secondary. Resistance development is a
multifactorial phenomenon in patients with CML, mediated by
a diversity of mechanisms. There are two broad mechanisms
of resistance (1) BCR-ABL dependent and (2) BCR-ABL
independent. BCR-ABL dependent pathways include ABL
kinase domain mutations and BCR-ABL amplification. Data
on cytogenetic and molecular response of 42 CML patients
treated with Imatinib, at Hospital University Sains Malaysia
and the data on dHPLC based mutation analysis performed on
16 CML patients showing signs of disease resistance will be
presented. BCR-ABL independent pathways may include
several mechanisms. Various genetic and epigenetic alterations
are proposed as candidate mechanisms involved in BCR-ABL
independent pathways to IM resistance in CML patients and
these multiple paths to IM resistance phenotype will also be
discussed.
27
SAHA ANTICANCER ACTIVITY THROUGH
DEREPRESSION EFFECT ON CRITICAL GENES IN
HPV CELL LINES
Gabriela Anton1, Lorelei I. Brasoveanu1, Anca Botezatu1,
Iancu Iulia1, Stoian Mihai1 and Natalia Cucu2
1Stefan
S. Nicolau -Institute of Virology, Bucharest;
of Bucharest, Romania
2University
The interaction between DNA and histones is crucial for
modulating the accessibility of transcription factors to DNA
regulatory sequence. The chromatin structure is important for
transcription regulation, the balance between active or silenced
status being coordinated by the activity of enzyme effectors
involved in chromatin remodeling, which modify DNA (DNA
methyltransferase – DNMT) and histones (histone
acetyltransferase – HAT and histone deacetylase – HDAC).
New anticancer drugs are therefore currently targeting these
epigenetic factors by their inhibitors, aiming at reactivation of
the aberrantly silenced tumor suppressor genes. Current
experimental and epidemiologic data confirmed that the
human papillomavirus (HPV) is the causal agent in the
development of cervical carcinoma. Taking into account HPV
role in carcinogenesis, the aim of our study was to investigate
the antitumor effect of SAHA (suberoylanilide hydroxamic
acid, a histone deacetylase inhibitor) in cell culture models.
HPV immortalized cell lines CaSki and Hela and a low risk
HPV cell line obtained from a cervical xenograft, were treated
with increasing doses of SAHA (0.5-2.5 μM) for 24 through
Abstracts of the 8th International Conference of Anticancer Research, 17-22 October 2008, Kos, Greece
48 h. We noticed that SAHA has an antitumor activity by
blocking cell proliferation and inducing tumor cell apoptosis
in HeLa and CasKi cell lines. p21(WAF1) and p53 expression
levels were higher at 2.5 μM/24h SAHA as appreciated in
real-time PCR. mRNA levels of Dnmt1 were slightly
increased at the same concentration of SAHA and were
appreciated in the same conditions. By contrast, in lrHPV line,
DNMT1 activity seems to increase at 2.5 μM SAHA after 48
of SAHA treatment. An interestingly effect upon DNA
methyltransferases has been also observed. While DNMT1
mRNA levels slightly increased, DNMT3b immunoreactivity
presented a rather constant feature. The only affected enzyme
was DNMT3a whose immunoreactivity decreased significantly
at high SAHA concentrations.
28
SIMPLE STRUCTURAL CHROMOSOMAL
ABNORMALITIES IN OVARIAN CANCER
Xristos Aravidis1, Anna D. Panani1, Zoi Kosmaidou2 and
Aristides Antsanklis3
1The
Critical Care Department, Medical School of Athens
University, Cytogenetics Unit, Εvangelismos Ηοspital,
Athens;
2Department of Genetics, Alexandra Maternity Hospital,
Athens University, Athens;
3First Department of Obstetrics and Gynecology, Alexandra
Maternity Hospital, Athens University, Athens, Greece
Ovarian cancer represents the leading cause of death among
patients with gynecological cancer. The identification of
chromosomal abnormalities is a useful strategy toward
understanding tumorigenesis and specific chromosomal
associations. Since single chromosomal changes might be
primary events implicated in the initiation of the neoplastic
process, the aim of the present study was to investigate the
presence of simple structural chromosomal changes in ovarian
cancer. Reviewing samples of ascitic effusions cytogenetically
studied in our laboratory by direct culture of tumour cells and
a G-banding technique, we found two cases with a diagnosis
of ovarian cancer, which presented simple chromosomal
abnormalities. The first case presented an abnormal clone of
cells with an acquired pericentric inversion of chromosome
9, inv(9)(p11q13), as a sole anomaly. The second case
presented simple chromosomal changes with involvement of
the Xq23 chromosomal region, while a translocation
t(X;11)(q23;q23) was also defined. The significance of the
acquired pericentric inversion 9 in the development of the
neoplastic process remains unknown. It is necessary, the
chromosomal regions Xq23 and 11q23 to be molecularly
further investigated in ovarian cancer. The documentation of
more ovarian cancer cases with simple chromosomal
abnormalities is considered of major importance facilitating
the identification of candidate genes involved in the
neoplastic process.
29
TAUROLIDINE AND HONOKIOL: NOVEL
POTENTIAL ANTI-NEOPLASTIC AGENTS FOR
OSTEOSARCOMA THERAPY?
Matthias J.E. Arlt, Denise K. Walters, Patrick Steinmann,
Ingo J. Banke, Roman Muff, Walter Born and Bruno Fuchs
University Hospital Balgrist, Orthopaedic Research,
Forchstrasse 340, 8008 Zurich, Switzerland
Osteosarcoma (OS) is the most common primary bone cancer
and pulmonary metastasis the leading cause of death in OS
patients. The currently used chemotherapeutics exhibit severe,
toxic side-effects which may cause life-threatening conditions.
Thus, the development of novel agents with anti-metastatic
potential and reduced toxicity is essential. Honokiol, an extract
of the Magnolia tree, has recently been shown to have antineoplastic properties against several malignancies including
multiple myeloma, breast, gastric and prostate cancer.
Taurolidine (active agent of Taurolin®) is a well-known broad
spectrum antibiotic that has been used for over 15 years for
the treatment of severe surgical infections. It has also recently
been shown to possess anti-neoplastic properties against a
variety of human cancers. Therefore, in the present study, we
investigated the therapeutic potential of these two novel
anticancer drugs in our OS models. In vitro, both compounds
showed pro-apoptotic and growth-inhibitory activity in a dosedependent manner against all 9 human and 2 murine
osteosarcoma cell lines tested. The IC50 values ranged between
8 and 16 μg/ml for honokiol and between 19 and 64 μM for
taurolidine. Subsequently, we examined the effects of honokiol
and taurolidine on OS metastasis in our two syngeneic OS
mouse models. Highly metastatic, lacZ-tagged LM8 and
K7M2 OS cells were injected s.c. into C3H mice and i.v. into
BALB/c mice, respectively. Treatment with honokiol (3
mg/mouse/day) significantly reduced lung and liver metastases
by 41% to 75% in both OS models. In contrast, treatment with
taurolidine (15 mg/every other day) enhanced experimental
K7M2 lung (1.7-fold) and liver (up to 50-fold) metastasis.
Also in the LM8 model, taurolidine treatment significantly
increased spontaneous LM8 lung (up to 2.8-fold) and liver (up
to 20-fold) metastasis. Interestingly, dose-dependent severe
hepatic deformations and atrophies could be observed in
tumor-bearing as well as healthy mice upon treatment with
taurolidine. Histological examinations revealed that liver
lesions consisted of a multifocal fibrous thickening of the liver
capsule, which was most pronounced in the strongly atrophic
left median liver lobe. The liver deformations were
accompanied by up to 10 times increased blood serum levels
of the liver parameters ALT, AST and GLDH in the taurolidine
3199
ANTICANCER RESEARCH 28: 3157-3556 (2008)
treated mice. These data indicate for the first time an
unexpected, lung and liver metastasis promoting activity of
taurolidine, accompanied with severe liver deformations.
These organ-specific side-effects need to be taken into account
regarding clinical introduction of taurolidine in cancer
treatment. On the other hand, the natural compound honokiol
was shown to possess potent antineoplastic and antimetastatic
activity against osteosarcoma cell lines and may have potential
as a novel OS chemotherapeutic agent.
30
SCINTIGRAPHY WITH 99mTc- TEKTROTYD IN THE
DETECTION OF NEUROENDOCRINE TUMORS
Vera Artiko, Vladimir Obradović, Nebojša Petrović,
Dragana Šobić, Smiljana Pavlović, Bojana Popović,
Djuro Macut and Svetozar Damjanović
predictive value 95%, negative predictive value 64% and
accuracy 85%. Conclusion: These preliminary results show that
scintigraphy of neuroendocrine tumors with 99mTc-Tektrotyd is
a useful method in diagnosis, staging and follow up of the
patients suspected to have neuroendocrine tumors. It is also
helpful in the appropriate choice and monitoring of the therapy,
including radionuclides.
31
THERAPY OF NEUROENDOCRINE TUMORS WITH
90Y DOTA TATE –FIRST RESULTS
Vera Artiko, Vladimir Obradović, Nebojša Petrović,
Dragana Šobić-Šaranović, Divna Đokić, Drina Janković,
Nadežda Nikolić, Bojana Popović and Svetozar Damjanović
Institute for Nuclear Medicine, Institute for Endocrinology,
Diabetes and Metabolic Diseases, CCS, Belgrade, Serbia
Institute for Nuclear Medicine, Institute for Endocrinology,
Diabetes and Metabolic Diseases Clinical Center of Serbia,
Laboratory for radioisotopes "Vinča", Institute for Nuclear
Sciences Vinča, Serbia
Aim: The aim of the study is the detection of neuroendocrine
tumors with 99mTc-Tektrotyd, a radiopharmaceutical indicated
for the diagnosis of tumors with overexpression of somatostatin
receptors. Patients and Methods: Whole body scintigraphy was
performed in 66 patients up to 24h after i.v. administration of
740MBq 99mTc-Tektrotyd, as well as SPECT of particular
regions. Results: From 18 patients with neuroendocrine tumors
of unknown origin there were 14 true positive findings (TP) (8
with liver metastases, 6 with lung metastases, 4 with bone
metastases and one with mediastinal gland metastases), 4 false
negative findings (FN) (2 with liver metastases of the poorly
differentiated tumors, and two second with very small lung
metastases <1 cm). In 12 patients scintigraphy contributed to
the further management of the patients. In the group of 16
patients with gut carcinoids there were 8 TP (6 with liver
metastases), 4 true negative findings (TN) (after surgery), 2 FN
(after surgery, small lung metastases <1 cm) and 2 FP
(physiological accumulation of the activity in the bowel). In 8
patients scintigraphy contributed to the further management of
the patients. In the group of 14 patients with neuroendocrine
pancreatic carcinomas there were 8 TP (6 with liver metastases
and one with metastases in paraortal lymph nodes) and 6 TN
(somatostatinoma, insulinoma and carcinoid after surgery). In 6
patients scintigraphy contributed to the further management of
the patients. In the group of 12 patients with lung carcinoids
there were 8 TP (4 with liver, 2 with lung metastases and 2
with bone metastases), 2 TN (after surgery) and 2 FN (poorly
differentiated). In 4 patients scintigraphy contributed to the
further management of the patients. In the group of 6 patients
with gastrinomas (jejunal, paraduodenal and pancreatic) there
were 4 TP findings and two TN. In 4 patients scintigraphy
contributed to the further management of the patients. Overall,
the sensitivity of the method is 84%, specificity 88%, positive
Aim: Preliminary results of the therapy of NETs with 90Y
DOTA TATE (Polatom, Poland) are presented. Patients and
Methods: We investigated 15 patients with various
neuroendocrine tumors. In all of them, together with other
laboratory analyses and imaging methods, scintigraphy with
somatostatin analogues was performed (in 3 with 111In
Octreoscan and in the other 4 with 99mTc Tektrotyd) and a
high tumor was uptake observed. The therapy was performed
with 2-4,5 GBq 90Y DOTA TATE per patient per one cycle,
by slow infusion in physiological liquid (150 ml/15
min).Between the cycles, there was a time delay of 6-8 weeks.
Thirty min before therapy, patients began receiving an infusion
of amino acids (arginine and lysine) for 4h. Before that, all
therapies with somatostatin analogues were withdrawn. 24h96 h after therapy, "bremsstrahlung" whole body imaging,
SPECT and particular planar images were performed with a
gamma camera. Results: Analysis of the "bremsstrahlung"
images showed uptake of the radiopharmaceutical in the liver,
but the most of the activity was observed in the regions of the
"hot spots" registered with previous 99mTc Tektrotyd and 111In
Octreoscan images. According to our results, after therapy, in
two patients progressive disease (PD), in seven stable disease
(SD), and in six partial remission (PR) occured. Up to now,
there were no major clinical side-effects in the hepatic
function. Transient pancytopenia occurred in two patients, and
impairment of kidney function in one. Conclusion: In spite of
insufficient data, beneficial effects on clinical symptoms,
hormone production and tumor proliferation were found,
without major clinical side-effects. Thus, according to these
preliminary results, treatment with 90Y DOTA TATE is a
feasible method and might be useful for the management of
patients with inoperable or disseminated neuroendocrine
tumors.
3200
Abstracts of the 8th International Conference of Anticancer Research, 17-22 October 2008, Kos, Greece
32
SETUP AND CHARACTERIZATION OF ANIMAL
MODELS OF HEAD AND NECK CANCER IN
IMMUNOCOMPETENT RATS
Karine Aubry1 and Michel Rigaud2
1E.N.T.
Department and 2Biochemistry and Molecular
Biology, Limoges University Hospital Center 2, Avenue
Martin Luther-King, 87000 Limoges, France
Setup of animal models of cancer is indispensable for preclinic therapeutic assays. We developed a new animal
model of squamous cell carcinoma from a tumor induced
by 4-nitroquinoline-1-oxyde (4-NQO) by successive
tumoral grafts in Sprague Dawley immunocompetent rats
aged 21 days. Using the same protocol, a model of
mandible osteosarcoma was obtained by grafting
osteosarcoma tumors. These tumors were characterized by
pathological, immunohistochemical analysis and imaging
using positron emission tomography coupled with
computed tomography (PET/CT). They presented similar
characteristics as human ones. We report a therapeutic test
using bevacizumab (Avastin®) on osteosarcoma rat models.
Bevacizumab showed a statistically significant effect
(p<0.001) on development of osteosarcoma.
We propose a protocol to produce animal models of cancer
in immunocompetent rats.
33
TPA SERUM LEVELS IN PATIENTS WITH
SUSPICIOUS SIGNS OF LUNG CANCER:
COMPARISON WITH OTHER TUMOR MARKERS
USED IN THIS MALIGNANCY (CEA, SCC, NSE,
CYFRA 21-1, CA 125, CA 19.9, CA 15.3 AND TAG-72.3)
J.M. Auge1, R. Molina1, J.M. Escudero1, X. Filella1,
R. Marrades2 and N. Vinolas3
Departments of 1Biochemistry, 2Pneumology and Medical
3Oncology Hospital Clinic, Barcelona, Spain
Tumor marker serum levels were prospectively studied in 267
patients with suspicious signs of lung cancer, being the final
diagnosis, in 58 patients with no malignancy (15 infectious,
43 non infectious diseases), 28 patients with malignancies
excluding lung cancer and lung cancer in the remaining 181
patients (146 NSCLC, 35 SCLC). Slightly high abnormal
serum levels were found in CEA 8,6%, CA 19.9 and CA 125
in 22.4%, NSE 0%, CYFRA 3.4%, TAG 72.3 12.1%, SCC
1.7%, CA 15.3 in 3.4% and TPA in 13.7% of the patients with
benign diseases. Significantly higher concentrations of TPA,
CA 19.9 and CYFRA 21.1 were found in patients with
infectious diseases than in other benign pathologies. (p=0.002,
0.01 and 0.02, respectively).
Tumor marker sensitivity was related to cancer histology
and tumor extension. Significantly higher NSE serum levels
and sensitivity was found in SCLC than in NSCLC (p=0.001).
SCC, CEA, CA 15.3 and CA 125 were also related to the
histological type, with significantly higher values in patients
with NSCLC (p<0.02 in all of them). CYFRA and TPA, show
a high concordance of results in patients with lung cancer, in
both NSCLC and SCLC (85.5% and 91.4%, respectively). The
best combination of tumor markers was CEA, CA 15.3 and
one cytokeratin in adenocarcinomas and CEA, SCC and one
cytokeratin in squamous tumors.
34
ANTICANCER STRATEGIES TARGETING
TELOMERASE AND TELOMERES
C. Autexier1,2, M.E. Brault1, P. Englebienne3, J. Fakhoury2,
R. Kieltyka3, N. Moitessier3 and H. Sleiman3
Departments of 1Anatomy and Cell Biology, 2Medicine,
McGill University, Montreal QC, Canada
3Chemistry,
Infinite replicative potential requires telomere maintenance,
which, in most eukaryotic organisms, is mediated by
telomerase. Telomerase is a ribonucleoprotein that consists of
a catalytic reverse transcriptase TERT, associated proteins and
an integral RNA subunit (hTR in humans) that carries the
template to generate telomeres de novo. Eighty-five percent of
tumor cells maintain telomeres through an active telomerase
complex. Telomere dysfunction can lead to senescence or
apoptosis and impair the continued growth of immortal cancer
cell lines. Thus anticancer strategies which target telomerase
and telomeres are actively investigated.
An alternative to telomerase inhibition-based therapy
consists of targeting the integrity of telomeres rather than
telomerase activity. One of theses approaches has been
validated by us and others and consists of destabilizing
telomeres with a mutant human telomerase RNA (hTR)
template that dictates the synthesis of mutant telomere
sequences. Cell lines expressing a mutant hTR (MuAhTR)
exhibit increased sensitivity to chemotherapeutic drugs such
as DNA damaging or cytotoxic agents, manifested by
decreased cell proliferation. Consistent with the hypothesis
that MuAhTR expression engages a DNA damage response,
we found increased 53BP1 and ATM-P foci at the telomeres
by immunofluorescence in MuAhTR expressing cells
compared to cells not expressing MuAhTR. We are currently
analyzing the mechanisms implicated in the increased
sensitivity of these cells to drugs and the requirement for p53
activation. For example, treatment with doxorubicin leads to
altered cell cycle profile and apoptosis in one cell line. We are
also validating the specificity of MuAhTR-mediated telomere
destabilization in telomerase-positive cells. Since telomerase
is absent or weakly active in primary cells, we hypothesize
3201
ANTICANCER RESEARCH 28: 3157-3556 (2008)
that expression of a mutant hTR should minimally affect the
proliferation of primary cells.
Telomere integrity can also be compromised via telomere
disruption by G-quadruplex ligands. Such ligands typically
stabilize the G-quadruplex structures that can form at
telomeres. Such structures are poor substrates for telomerase
and several G-quadruplex ligands have been reported to
mediate antiproliferative responses in cancer cells. Molecules
with distinct structural features, unattainable using
conventional covalent synthesis, can be generated using
supramolecular self-assembly, and would be particularly
useful for targeting higher-order biological motifs such as the
G-quadruplex. The generation of such a molecule, and
evidence that it is an efficient G-quadruplex binder and
telomerase inhibitor will be discussed.
35
EURYCOMANOL FROM EURYCOMA LONGIFOLIA
JACK EXHIBITS ANTIPROLIFERATIVE ACTIVITY
ON HUMAN BREAST CANCER CELLS MCF-7 VIA
APOPTOSIS INDUCTION
eurycomanol, and remained lower than controls throughout the
experiment, resulting in a shift in the BAX to BCL-2 ratio
which eventually induced disruption of the mitochondrial
membrane potential thus favouring apoptosis. Next, the
processing of the 35 kDa executioner procaspase-7 was
detected, but initiator procaspase-9 was found not to play a
role in caspase-7 activation in MCF-7 cells. Active caspase-7
then cleaved and inactivated poly (ADP-ribose) polymerase
(PARP-1), resulting in nuclear fragmentation. These results,
therefore, suggest eurycomanol exerts antiproliferative effects
on MCF-7 cells by inducing apoptosis through the downregulation of BCL-2 protein levels, increased BAX to BCL-2
ratio, activation of caspase-7 and inactivation of PARP-1,
without the involvement of p53 and caspase-9.
36
NANOTECHNOLOGY APPLICATIONS IN siRNA AND
ANTISENSE DELIVERY TO SILENCE MDR1 AND
EGFR IN RESISTANT BREAST CANCER CELLS
Tee Thiam Tsui1, Cheah Yew Hoong1, Meenakshii
Nallappan2 and Hawariah Lope Pihie Azimahtol1
E. Azizi1,2,5, N. Ashrafi-Shahmirzadi1, A. Jahangiri1,
Sh. Fouladdel1,2, F. Talaee1,3, A.R. Nomani1,3, T. Gazori1,3,
F. Atyabi2,3, E. Haririan3, R. Dinarvand2,3, A. Shafiee4,
L. Bazargan1,6 and M. Shahbazi7
1School
1Molecular
The present study investigated the antiproliferative effect,
mode of cell death and the mechanism of action of
eurycomanol, a quassinoid from the root of Eurycoma
longifolia Jack on the human breast cancer cell line MCF-7.
Eurycomanol exhibites cytotoxic activity towards MCF-7
(IC50=15.23±0.66 μg/ml) and is less sensitive against a normal
breast cell line MCF-10A (IC50=66.31±0.47 μg/ml). Based on
the IC50 values obtained, eurycomanol displayed a certain
extent of cytoselectivity towards normal breast cells. The
antiproliferative activity of eurycomanol was due to apoptosis
induced in MCF-7 cells and not necrosis. This was
demonstrated by the Hoechst 33258 nuclear staining assay,
Tdt-mediated dUTP nick end labeling assay (TUNEL), and
double staining (mixture of Hoechst 33258 and propidium
iodide). The apoptotic index was found to increase from 0% at
0 h, to ~50% by 24 h and then to >75% after 72 h. The
eurycomanol-treated MCF-7 cells also showed typical
apoptotic morphology such as DNA fragmentation, cell
shrinkage, and nuclear condensation. The apoptosis triggered
by eurycomanol in MCF-7 cells was associated with the
down-regulation of the antiapoptotic BCL-2 protein
expression, but not with BAX and p53. BCL-2 protein
expression levels decreased 2 h after treatment with
Drug resistance has been an important obstacle in cancer
chemotherapy for many years. Advances in nanotechnology
applications for gene and drug delivery open new hopes to
overcome the old problem of drug resistance in cancer cells.
For many years, chemical and biological compounds have
been investigated to reverse mdr1 over-expression that is the
most important cause of failure of chemotherapy in different
cancers. There is a high homology between the P-gp, encoded
by mdr1 gene, and the cytochrome p450 3A4 (CYP 3A4), that
is essential for metabolism of certain endogenous and
exogenous compounds. In addition, over-expression of certain
genes such as EGFR, a proto-oncogene that induce cell
proliferation, in cancer cells significantly decreases the
efficiency of anticancer drugs. Nanotechnology has employed
tiny structures including liposomes, polymers or dendrimers
at nanoscale to combat cancer cell proliferation. Recently
many research centers have jointly investigated applications of
of Biosciences and Biotechnology, Faculty of
Science and Technology, Universiti Kebangsaan Malaysia,
43600 UKM Bangi, Selangor;
2Department of Biology, Faculty of Science, Universiti Putra
Malaysia, 43400 UPM Serdang, Selangor, Malaysia
3202
Research Lab., Department of Pharmacology and
Toxicology, 2Medical Nanotechnology Research Center,
3Department of Pharmaceutics, 4Department of Medicinal
Chemistry, Faculty of Pharmacy, 5Department of Medical
Biotechnology, Faculty of Advanced Medical Technologies,
Tehran University of Medical Sciences (TUMS),
6Department of Biochemistry, IBB, University of Tehran,
Tehran;
7Cellular and Molecular Research Center, Faculty of
Medicine, Golestan University of Medical Sciences, Gorgan,
Iran
Abstracts of the 8th International Conference of Anticancer Research, 17-22 October 2008, Kos, Greece
nanoparticles loaded with siRNA or antisense with or without
anticancer drugs to enhance therapeutic efficiency of
chemotherapy in mdr1 and/or EGFR over-expressing cancer
cells. Several new dihydropyridines as P-gp reversal
compounds were synthesized and evaluated in vitro on human
breast cancer T47D cells resistant to Tamoxifen and cross
resistant to Doxorubicin. Two of these compounds showed
partial P-gp reversal activity in human breast cancer T47D
cells using various methods including MTT assay, Rh123
accumulation/efflux assay by flow cytometry, RT-PCR, and
immunocytochemistry. Also, new drug delivery systems, were
prepared and evaluated using nanoparticles with different
structures containing siRNA and antisense to down-regulate
the mdr1 and/or EGFR mRNA in the same resistant T47D
cells. We used the MTT assay, RT-PCR and flow cytometric
analysis of cell cycle and apoptosis induction to assess the
response of parent and resistant T47D cells with or without
transfection with siRNA or antisense to Doxorubicin. The
results of RT-PCR studies indicated significant reduction (up
to 90%) in both mdr1 and EGFR mRNA in cancer cells. The
effect of Doxorubicin has also increased significantly (up to
35%) in the MTT assay although at less extent to mRNA
reduction. Flow cytometric analysis showed significant S
phase arrest by DOX in mdr1 silenced versus G2/M arrest by
DOX alone and different levels of apoptosis versus necrosis in
treated resistant cells compare to RPMI control. In conclusion,
the new gene and drug delivery systems using nanotechnology
can improve cancer chemotherapy at a great extent.
37
EFFECTIVENESS OF NEOADJUVANT
CHEMOTHERAPY IN JAPANESE PATIENTS WITH
COLORECTAL CANCER LIVER METASTASES
H. Baba, T. Beppu, M. Watanabe, H. Komori,
N. Hayashi, E. Toyama, K. Horino and H. Takamori
Department of Gastroenterological Surgery, Graduate School
of Medical Sciences, Kumamoto University, Kumamoto,
Japan
Background: Patients (Pts) with colorectal liver metastases
have a poor prognosis even after curative resection because of
high incidence of recurrence in the remnant liver and thus may
benefit from preoperative chemotherapy and curative
resection. However, neoadjuvant settings of chemotherapy for
pts with CRC liver metastases have not yet been established
in Japan and need to be assessed. Methods: Pts with CRC liver
only metastasis initially unresectable were eligible for the
single institute, non-randomized phase II trial. Eligible criteria
were synchronous or metachronous liver metastases, primally
unresectable, organs function preserved, and PS less than 2.
Pts received FOLFOX for 6-8 cycles preoperatively. Clinical
response, adverse effects, histopathological analysis of tumoral
and nontumoral liver, primary lesion and lymph nodes and
survival data were assessed. Results: Sixty pts with colorectal
liver metastasis were admitted to our hospital from May 2005
to March 2008. Of those, 35 pts initially unresectable received
FOLFOX and 17 pts turned out to be respectable after a
median of 7.5 cycles of FOLFOX and underwent hepatectomy,
and 8 pts also had primary tumor resection. There was no
severe perioperative complication, and intra-operative
increased bleeding. Mean number of tumors was 6.8 and mean
tumor size reduced form 5.8 cm to 3.5 cm. Clinical and
histopathological response rates were 81.0% and 29.2%,
respectively. Complete tumor necrosis of liver metastases was
observed in 2 pts and of primary tumor was in 1 pt. Half life
time of CEA in responder and nonresponder was 17.9 and
38.5 days, respectively. Two-year progression free and over all
survival rates was 50% and 100%, respectively. Conclusion:
These data suggest that FOLFOX can be safely administered
for Japanese as an neoadjuvant setting in CRC liver metastases
without increasing perioperative complications. Moreover,
high response, respectability, and superior survival data were
obtained with this preoperative chemotherapy and
keratectomy, suggesting that a future nationwide clinical trial
can be warranted.
38
MELANOMA VS. NEVI PROBLEM IN
THE EYES OF THE TRANSCUTANEOUS
ELECTRODYNAMIC IMAGING
Yurii F. Babich, Eduard A. Bakai and Maya A. Nuzhdina
Centre of Biomedical Electroengineering, Kiev, Ukraine
Purpose: Further development of early diagnostic criteria of
malignancy. Materials and Methods: Our approach was based
on analysis of initial and hypoxia-induced electrical dynamics,
which reflects relative metabolic differences between the
tumour and its microenvironment at the background of the
adjacent tissues. We have developed a new functional imaging
modality of broad application – transcutaneous electrodynamic
introscopy (TEI), which enables in vivo non-invasive 3-4D
visualization (extremely low-intensive electromagnetic fields
are used) of the integral spatial electrobiochemical dynamics
in normal conditions and pathology. Adequate resolution (less
than 1 mm) had already enabled us firstly (20 years ago) to
non-invasively read and monitor the skin electrical landscape
(SEL) and discover a new class of initial and induced spatial
and temporal phenomenological features (reflecting in vivo
deep processes of tissue metabolism and intercellular
signalling), which may be used as novel diagnostics signs, as
for real-time assessment of individual reactions and thus for
purposes of targeted/controlled therapy. Currently, we are
using a portable experimental TEI setup designed for
investigation of superficial tissues, specifically for chosen
3203
ANTICANCER RESEARCH 28: 3157-3556 (2008)
model objects, i.e. directly visible ones: cutaneous melanoma
and nevi. This TEI setup enables the tissue (scan-area 32×64
mm) to be scaned simultaneous in six spectral electrical
bioimpedance/potential parameters of the tissue at 1 kHz – 1
MHz-band, making thus possible tissue characterization at
tissue, cellular and sub-cellular levels. Fifteen healthy
volunteers, thirteen nevi and seven malignant melanomas were
investigated. The hypoxic test, e.g. simple breath-holding for
20-60 s, was used as contrast factors (various mild
physicochemical factors and that of X-ray therapy were
studied before). Results: No abnormal reactions to the hypoxia
test were registered in healthy subjects nor in most of those
with nevi. Noticeable hypoxia induced SEL dynamics were
registered in all melanomas. Distinct SEL local changes
appeared one by one around the pigmented zones, thus making
visible the tumours’ true microenvironment. The hypoxia test
also revealed prospective metastasis, i.e. remote areas of
supposedly chronic or transient hypoxia with characteristic
relaxation times (specifically in comparison with those of the
tumour microenvironment). A coherent zone of abnormal
mitochondrial electropotential was also detected. The zone
crossed the area of supposed metastasis and had an epicentre
inside the melanoma. Under the test circumstances, the zone
was of less variable character. It was also possible to trace
phase differences between intercellular media, cellular
membranes and sub-cellular responses to the tests. Suspicious
SEL changes were also registered in 3 out of 13 nevi, e.g.
sound spatially directed dynamics taking its start from the nevi
boundary. Subsequent histological analysis was effective
enough to confirm only the TEI-revealed heterogeneities of
the primary melanomas. Conclusion: TEI demonstrates an
intriguing ability to reveal in vivo a unique set of basically
important anatomic and particularly functional features which
may be used both for: (i) earlier tumour and metastasis
diagnosis and, (ii) for targeted therapy (providing an effective
biofeedback for real-time assessment of individual sensitivity
to therapeutic factors). Any proposition as to joint research
particularly that aiming to identify the TEI findings (e.g. with
the aid of PET, sMRI, in vivo confocal laser imaging
techniques) would be highly welcomed.
39
MITOCHONDRIA AND CANCER: PROSPECTS FOR
NOVEL THERAPEUTIC TARGETS
Gyorgy Baffy
Harvard Medical School and VA Boston Healthcare System,
Boston, MA, USA
Acquisition of mitochondria was a defining step in the
evolution of eukaryotic cells. Mitochondria regulate pivotal
cellular functions such as metabolism, bioenergetics, and
programmed cell death. Along with this evolutionary milestone,
3204
cancer has taken a seemingly inherent position in our life.
Selfishly defiant of the rules of multicellular existence, cancer
cells may hijack all the robust homeostatic functions of higherlevel organisms. By defining aerobic glycolysis, Warburg was
the first to link mitochondria and cancer, but the importance of
altered energy metabolism in cancer cells has not been fully
appreciated for a long time. Recent advances have transformed
our concept on the role of mitochondria in cancer cells and
invite a review of new approaches for metabolic targeting of
cancer cells including aerobic glycolysis and beyond.
In contrast to high-yield oxidative phosphorylation,
glycolysis provides high-rate ATP production with a selective
advantage to rapidly growing cells that compete for shared
resources. Also, excess lactate production may promote
interstitial acidification and invasiveness. Moreover, glycolysis
may improve redox control via the pentose phosphate cycle (a
major source of NADPH). Based on these considerations and
experimental validation, inhibitors of hexokinase (e.g., 3bromopyruvate, 2-deoxyglucose, lonidamine) have entered
pre-clinical and clinical testing, while additional research is
focused on molecular regulators of the metabolic and
bioenergetic phenotype in cancer cells.
One of the metabolic regulators is hypoxia-inducible factor
(HIF)-1, a transcription factor commonly activated in cancer
cells even in the absence of overt hypoxia. By activating
pyruvate dehydrogenase (PDH) kinase (PDK), HIF-1 blocks
pyruvate entry to the Krebs cycle and limits mitochondrial
electron transport. Recent studies indicate that cellular energy
metabolism is also regulated by the tumor suppressor p53. By
gene-level suppression of glycolysis (TIGAR) and promotion
of electron transport (SCO2), p53 shifts ATP production back
to the mitochondria. Thus, successful adaptation of energy
metabolism in cancer cells is linked to purposeful restraint of
mitochondrial respiration, while tumor suppression may rely
on an opposite action.
To fully understand the impact of ‘mitochondrial neglect’ in
cancer cells, it is also important to recall that mitochondrial
electron transport is a major source of intracellular reactive
oxygen species (ROS) and cancer cells often struggle with
increased oxidative stress. Thus, decreased mitochondrial ROS
output may be another benefit of aerobic glycolysis. This is
well illustrated by the PDK inhibitor dichloroacetate (DCA),
which enforces mitochondrial flux of pyruvate, inducing
apoptosis of cancer cells via increased ROS production and
caspase activation.
Our recent observations on the role of mitochondrial
uncoupling protein-2 (UCP2) in cancer cells provide a new
aspect to the metabolic adaptation of cancer cells. UCP2 is a
mitochondrial anion carrier protein located in the inner
membrane along with the respiratory complexes. By mediating
proton leak, UCP2 controls the rate of superoxide production
and acts as a potent suppressor of oxidative stress. Cancer
cells may exploit this effect and increased UCP2 expression
Abstracts of the 8th International Conference of Anticancer Research, 17-22 October 2008, Kos, Greece
has indeed been linked to advanced neoplastic changes and
chemoresistance. We found that overexpression of UCP2 in
colon cancer cells inhibits ROS accumulation and apoptosis
induced by cytotoxic treatment. The protective effect was also
observed in tumor xenografts. By contrast, UCP2 silencing
appears to enhance the efficacy of chemotherapy. Also, UCP2
overexpression interferes with post-translational modification
of p53 and preferentially induces the glycolytic phenotype.
Accordingly, inhibition of UCP2 modulates energy
metabolism in cancer cells and this approach may be
considered in combination treatment of chemoresistance.
In summary, recent advances confirm that oncogenic and
metabolic regulatory pathways are strongly interconnected.
New therapeutic strategies may become available through
better understanding of metabolic and energetic adaptation of
cancer cells, with a particular attention to the role of
mitochondria in this process.
40
IN VITRO MODELING FOR THE EVALUATION OF
Lu-177 ANTISENSE RADIOTHERAPY
Ethan R. Balkin1, Fang Jia2,3, William H. Miller3,4 and
Michael R. Lewis2,3,4
1Veterinary
Pathobiology, University of Missouri-Columbia,
Columbia, MO, USA;
2Veterinary Medicine and Surgery, University of MissouriColumbia, Columbia, MO, USA;
3Research, Harry S Truman Memorial Veterans’ Hospital,
Columbia, MO, USA;
4Nuclear Science and Engineering Institute, University of
Missouri-Columbia, Columbia, MO, USA;
5Missouri University Research Reactor, University of
Missouri-Columbia, Columbia, MO, USA
The protein product of the B-cell lymphoma/leukemia-2 (bcl2) proto-oncogene in non-Hodgkin’s lymphoma (NHL) is a
dominant inhibitor of apoptosis. In aggressive lymphoma,
large cohort studies have shown that the overexpression of the
bcl-2 gene correlates strongly with resistance to radiation and
chemotherapy, increased survival of cancer cells, high relapse
rate, and poor cause free survival rate or disease free interval.
Thus, patients who are found to overexpress bcl-2 might
respond better to alternative treatments like targeted
immunotherapy, radioimmunotherapy, or antisense therapy, all
of which act through mechanisms that down-regulate bcl-2.
Human NHL also expresses Type 2 Somatostatin Receptors
(SSTR2) in approximately 87% of cases. Previous work
indicates that 177Lu-DOTA-Tyr3-octreotate provides effective,
selectively targeted radiotherapy in human SSTR expressing
tumors. Furthermore, this peptide is an attractive vehicle for
delivery of other tumor-targeting agents, such as those
designed to act against bcl-2.
In vitro uptake, efflux, proliferation and viability assays are
designed to assess the bcl-2 mRNA targeting of a 177Lulabeled bcl-2 antisense peptide nucleic acid (PNA)-Tyr3octreotate conjugate against the human NHL cell line Mec-1
in suspension culture. In vitro cell uptake and efflux was
evaluated by assaying the 177Lu-labeled anti-bcl-2 PNApeptide conjugate. The percent uptake of the total radioactivity
was found to increase from 1.1±0.5% at 1 min to 2.5±1.1% at
4 hr. The percent retention versus time was found to decrease
from 71.0±8.5% of the cell-associated radioactivity at 1 min
to 29.5±2.6% at 4 hr.
41
ARSENIC INDUCED APOPTOSIS IN THE
LYMPHOCYTES OF INDIVIDUALS EXPOSED TO
ARSENIC THROUGH DRINKING WATER IN WEST
BENGAL, INDIA
Apurba K. Bandyopadhyay, Nilanjana Banerjee and
Ashok K. Giri
Molecuar and Human Genetics Division, Indian Institute of
Chemical Biology, Kolkata- 700 032, India
In West Bengal, India, more than 6 million people in nine
districts are exposed to arsenic through drinking water. It is
regarded as the greatest arsenic calamity in the world.
Arsenic is a well-documented human carcinogen, which does
not induce cancer in any other animal model. Interestingly, at
lower concentrations, arsenic is known to induce apoptosis
in various cancer cell lines in vitro. We have studied
apoptosis in human peripheral blood mononuclear cells
(PBMC) of arsenic exposed skin lesion individuals by
annexin V-FITC staining and compared it with that in
unexposed individuals. The percentage of apoptotic cells in
individuals with skin lesions was significantly higher
(p<0.001) in comparison to unexposed individuals. In the
exposed individuals with skin lesions, there were elevated
levels of intracellular reactive oxygen species (ROS),
mitochondrial membrane permeability and increased
cytochrome c release, leading to increased downstream
caspase activity. Arsenic-induced DNA damage was
confirmed by DNA ladder formation and confocal
microscopy. These findings suggest that chronic arsenic
exposure causes cell cycle arrest at the G1-phase. Arsenic
causes significant DNA damage, and DNA damage is known
to trigger apoptosis. Results of DNA laddering and confocal
microscopy confirm that chronic arsenic exposure leads to
DNA damage and thus might lead to enhanced apoptosis in
the exposed group. Cell apoptosis is a normal physiological
process by which correct functional cellular populations are
maintained, by removal of cells with abnormal genetic
information. Arsenic, like some other metals, plays a dual
role in that they have apoptotic effects on the cells but also
3205
ANTICANCER RESEARCH 28: 3157-3556 (2008)
contribute to cell transformation and carcinogenesis. The
exact mechanism of how this switching occurs is not known
yet. It may so happen that increased apoptosis of certain
immune cells, such as NK cells and cytotoxic T-cells, could
impair the immune surveillance against cancer in various
organs and thus explain the increased risk of cancer. Another
possible explanation is that metals under certain conditions
cause greater apoptosis, but it is not known whether this
apoptosis induced by the metal is a perfect process or an
imperfect process. An imperfect apoptotic process might
result in the escape of cells that would be potentially
carcinogenic. This may be true in the case of arsenic-induced
apoptosis also, which ultimately leads to the various types of
cancer. Further research is required to determine exactly
whether increased apoptosis of immune cells or defective
apoptosis is responsible for arsenic-induced cancer of skin
and other internal organs.
treatment. Conclusion: At present in our clinics in Kolkata,
India, we use these ultra-diluted medicines as the sole
specific therapy in cases of malignant tumors, with
encouraging results. From our results, it is apparent that
these medicines can also be given as an adjunct therapy in
other countries in all such malignant cases where
conventional therapy fails. We will present here some cases
of lung, brain and oesophageal malignancies treated solely
by the Banerji Protocols to show the remarkable efficiency
of these ultra-diluted medicines.
42
THE BANERJI PROTOCOLS: THE REGRESSION OF
MALIGNANT TUMOURS BY A NON-INVASIVE AND
NON-TOXIC ORAL MEDICAL APPROACH
Department of Immunology, Institute of Biomedical
Sciences, University of Sao Paulo, Av. Prof. Lineu Prestes
1730, 05508-000 - Sao Paulo, SP, Brazil
Prasanta Banerji and Pratip Banerji
PBH Research Foundation, 10/3/1 Elgin Road, Kolkata700020, India
Background: Although there is significant improvement of
treatment outcomes of most malignant tumours by
conventional therapy, in many neoplasms, particularly
oesophageal, brain and lung tumours, there is still a
persistent grim outlook of conventional therapy results. To
obviate this long lasting problem, we have treated many
patients belonging to this group with ultra diluted medicines
(under Government-regulated standard pharmacopeias in
different countries) which are commonly used in
homeopathic practice. In the course of our relationship with
various scientific bodies, we have previously presented
before the NCI, USA, a Best Case Series on Cancer, which
was unanimously accepted by the Advisory Panel. The
outcome of our treatment with these ultra-diluted medicines
is described here. Materials and Methods: During the past
year, we have treated 1132 malignant tumour cases
belonging to these categories, in our busy clinic located in
Kolkata, India: 689 cases of brain tumours were treated with
Ruta 6 and Calcarea Phosphorica 3x; 367 lung cancer cases
were treated with Kali Carbonicum 200c and 76
oesophageal carcinoma cases were treated with Condurango
30c. All available clinical, histological and radiological
records for diagnosis and follow-ups were analyzed.
Results: Complete regression was noted in 32% cases of
brain tumours, 22% lung cancer cases and 28% oesophageal
carcinoma cases and we are aiming to discontinue their
3206
43
FUNCTIONAL MODULATION OF DENDRITIC
CELLS AND THEIR PRECURSORS IN THE TUMOR
MICROENVIRONMENT
J.A.M. Barbuto, P.C. Bergami-Santos, A.P.S. Azevedo,
R.B. Baleeiro and M. Tregia
Dendritic cells (DC) have a unique role in the establishment
of immune responses. Their ability to recognize the “status”
of the environment and translate it into specific activation
signals for clonally selected lymphocytes allows the
immune system to react appropriately to microbial
challenges at the same time as it tolerates innocuous
antigens. Accordingly, the decision to tolerate or to react
against tumor cells should also depend on the DC reaction
to the tumor microenvironment. Since clinically significant
tumors frequently generate potentially activating signals for
DC, which, in turn, should trigger an immune reaction
against tumors, the development of progressive cancer in
immunocompetent individuals could be a sign of an altered
DC activation. Indeed, we show here that the antigenpresenting cells’ phenotype (expression of HLA-DR, S100,
CD1a, CD11c, CD14, CD68, CD80, CD86 and CD83)
within tumors was altered, with an imbalance between
macrophages, immature and mature DC, a phenomenon that
could be correlated to the pattern of cytokine secretion (IL4
and TNF-alpha) within the tumor environment.
Furthermore, the analysis of the differentiation of cancer
patients’ monocytes into DC suggested that this
phenomenon was not restricted to the tumor site.
Monocyte-derived DC from cancer patients also presented
an altered membrane phenotype and responded poorly to
environmental challenges found in cancer, as low local pH,
jaundice or the presence of tumor cells. The mechanisms
responsible for these phenomena still need to be
characterized, but preliminary data suggest that they may
depend on low levels of phosphorylated STAT-1 in cancer
patients’ DC.
Abstracts of the 8th International Conference of Anticancer Research, 17-22 October 2008, Kos, Greece
44
NOSCAPINE INHIBITS PROSTATE CANCER
Israel Barken
Prostate Cancer Research and Education Foundation, La
Mesa, CA, USA
Background: Noscapine, a non-toxic, alkaloid and common
constituent of cough medicine, stabilizes tubulin. It inhibits
the growth of several human and murine neoplasms, with no
significant toxicity. Its effect on prostate cancer has not been
evaluated. Materials and Methods: Noscapine was
administered orally (300 mg/Kg per day) for 56 days to PC3
humans prostate cancer-bearing immunodeficient mice (n=10).
Immunodeficient control mice (n=10) received only diluent in
an identical regimen. Results: Mean total tumour weight was
0.42±0.23 g and 0.97±0.31 g (p<0.001) in the noscapine
treated group and the control group, respectively, without
evidence of toxicity. Metastases occurred less frequently in the
treatment than the control group (30% vs. 90%; p<0.05).
Conclusion: Oral administration of noscapine limited tumour
growth and lymphatic metastasis of PC3 human prostate
cancer in this mouse model, supporting its therapeutic
potential as a nontoxic and easily administered treatment for
metastatic cancer.
45
EXPRESSION PATTERN OF THE UBIQUITIN CTERMINAL HYDROLASE IN RAT COLON AND THE
HUMAN COLON CARCINOMA CELL LINE HT-29
Torsten Bartz, Juergen Bartel, Anja Soete,
Elzbieta Charkiewicz and Antonios Kyriakopoulos
Helmholtz Centre Berlin for Materials and Energy,
Department” Molecular Trace Element Research in the Life
Sciences”, Glienicker Str. 100, D-14109 Berlin, Germany
The ubiquitin proteasome system (UPS) contains the
components for one of the major mechanisms for the
regulation of protein levels in eukaryotic cells. Simplified,
protein designated for degradation forms a complex with
chains from ubiquitin or polyubiquitin and the complex is
transferred to the 26S proteasome under contribution of
several enzymes, where – after removal of the ubiquitin – the
targeted protein is cleaved. A member of the family of the
deubiquitinating enzymes (ubiquitin c-terminal hydrolase
isozyme L3; UCH-L3), is suggested to have anti-apoptotic
properties, and autoantibodies were detected in sera from
colon cancer patients.
We have recently demonstrated altered expression profiles
of UCH-L3 in hepatocytes grown under conditions of
moderate, non-toxic oxidative stress and in rat livers exposed
to oxidative stress by selenium deficiency. Here we
investigated the expression pattern of this enzyme in colons
obtained from rats with varying selenium status and the colon
cancer cell line HT-29 cultured in the presence of various
metal ions.
Therefore cells were incubated individually with high
concentrations of molybdenum, manganese, selenium,
cadmium, or other metals for 72 hour each. As determined by
tetrazolium assay the applied concentrations lead to minor cell
proliferation. Harvested cells and colon tissues from selenium
adequate or selenium deficient rats were homogenised and
UCH-L3 was detected by western blotting and
immunochemistry.
By using beta-actine as an internal standard our results
showed that the expression of UCH-L3 was elevated in HT-29
cell line and selenium deficient colon tissue about 1.5-fold
compared to rats fed with an adequate selenium diet.
Admittedly this increase was much lower then that caused by
the incubation with high concentrations of manganese (4fold). A possible explanation might be the involvement of
manganese in the protection against reactive oxygen species
as a compound in the superoxide-dismutase.
Although further investigations will be needed to
understand the involvement of UCH-L3 in selenium’s cancer
protective effects, we propose that selenium deficiency causes
at least two changes in the cell that can lead to cancer in the
end: Primary a reduction in the protection against specific
oxidants by the loss of selenoproteins. And secondly the
induction of UCH-L3 would prevent a removal of oxidatively
damaged cells by apoptosis.
46
ANTI-ANGIOGENIC ISOFORMS OF VEGF –
A KEY TO ANTI-ANGIOGENIC THERAPY
D.O. Bates and S.J. Harper
Microvascular Research Laboratories, Department of
Physiology and Pharmacology, Bristol Heart Institute,
Southwell Street, Bristol BS2 8EJ, UK
VEGF is generated from differential splicing of 8 exons, with
exons 6 and 7 being differentially spliced to generate isoforms
with altered heparin and neuropilin binding affinities. An
additional alternate splice site exists in exon 8, which results
in a more distal splice site selection in this final exon. This
results in a sister family of isoforms termed VEGFxxxb, which
differ only in their terminal 6 amino acids from conventional
VEGF isoforms. Using antibodies generated to the unique cterminal protein sequence, we have found that the VEGFxxxb
isoforms are widely expressed at the protein level in normal
human tissues. In fact in most tissues studied, they appear to
be the predominant isoforms with tissues varying from 96% of
total VEGF being VEGFxxxb (colonic mucosa), to 40%
(bladder). In contrast, the placenta, an angiogenic tissue does
3207
ANTICANCER RESEARCH 28: 3157-3556 (2008)
not express much VEGFxxxb (1.5% of total VEGF). These
isoforms are downregulated in cancers and other pathologies
associated with abnormal angiogenesis (cancer, diabetic
retinopathy, retinal vein occlusion, Denys Drash syndrome, and
pre-eclampsia). Using human recombinant VEGF165b, we have
shown that this terminal splice site selection causes these
isoforms to lose angiogenic activity, and to inhibit VEGF165b
mediated angiogenesis in the rabbit corneal eyepocket, the rat
mesentery and the mouse retina and choroid. Furthermore these
isoforms, when over-expressed by tumour cells inhibit growth
of colorectal carcinoma, renal cell carcinoma, prostate cancer,
malignant melanoma and Ewing’s sarcoma. Furthermore, local
administration of recombinant VEGF165b inhibits the growth of
colorectal carcinoma cells in vivo. Recombinant VEGF121b also
appears to inhibit migration of endothelial cells stimulated by
VEGF165. Thus these isoforms form a family of antiangiogenic VEGFs. We have identified a number of cytokines
that alter the regulation of the splice site, such that cells can
switch from the anti-angiogenic VEGFxxxb isoforms to the proangiogenic VEGFxxx isoforms, including IGF1, TNF-α and
PDGF-AB. The reverse switch can be induced by treatment
with TGF-β1. These isoforms are recognize by most VEGF
antibodies, including bevacizumab, and over-expression of
VEGF165b inhibits the anti-angiogenic action of bevacizumab
in mouse models of human cancers. In summary, C terminal
distal splicing is a key component of VEGF biology,
overlooked by the vast majority of publications in the field, and
these findings require a radical revision of our understanding
of VEGF biology in normal human physiology.
Harper SJ and Bates DO: VEGF splicing – the key to antiangiogenic therapy? Nature Cancer Reviews. 2008. In press.
47
MOLECULAR PATHOLOGY OF
DUCTAL BREAST CANCER
Anna Batistatou
Department of Pathology, University of Ioannina, Medical
School, Ioannina, Greece
Based on the multistep model of breast cancer progression
sequential steps in the development of invasive ductal
carcinoma (IDC) are usual ductal hyperplasia, atypical ductal
hyperplasia, ductal carcinoma in situ (DCIS) and IDC.
Although this theory of “linear progression” is appealing,
there are no consistent molecular data to support the
correlation between premalignant, preinvasive and invasive
ductal carcinoma. The alternative theory of breast cancer
development is that of “parallel disease”. According to this
theory, DCIS is classified as low- and high-grade and is
believed to progress in low- and high grade IDC respectively,
independently, in parallel fashion. Today, despite intensive
molecular research, we are not able to predict with certainty
3208
the risk of DCIS progression to IDC or recurrence. Besides
standard histopathological parameters, such as nuclear grade
and necrosis, biological markers that appear promising are: the
status of steroid receptors (ER, PgR), markers of proliferation
and regulators of cell cycle such as MIB-1, bcl-2, p53, p21,
cyclin D1 and cyclin A, adhesion molecules, such as Ecadherin, matrix metalloproteinases, regulators of angiogenesis
(growth factors and their receptors), such as VEGF-A, VEFGC, and VEGFR-1 (Flt-1), VEGFR-2 (Flk-1) and VEGF-R3
(Flt-4).
The great progress in understanding invasive breast cancer
has come during the last decade from gene expression
profiling studies, which have established a molecular
classification, with relevance to patient outcomes. So, it has
become apparent that the morphological heterogeneity of
invasive breast cancer, which has been appreciated by
pathologists for the last 4-5 decades, is reflected at the
transcriptomic level. The molecular classification has been
developed based mainly on cases of IDC, and distinguishes
five main groups: luminal A and luminal B (both ER+), basallike, HER2+ (ERBB2) and normal breast-like. The last three
subtypes are usually ER–. Furthermore, prognostic gene sets
have been developed, including a 70-gene prognosis profile
and a 21-gene recurrence score. Pathologists follow closely
the molecular progress in IDC classification and have
incorporated much of this new information in every-day
pathology practice. Today, besides ER and PgR,
characterization of HER2 expression has become an integral
part of the work-up of a breast cancer patient in the Pathology
laboratory and of the corresponding pathology report. This
practice has led to identification of new entities and use of
novel terms, such as triple-negative cancer, which
encompasses a heterogeneous group of neoplasms with
distinctive, but quite variable, pathologic and clinical features.
Wiechmann L and Kuerer HM: Cancer 112: 2130-2142, 2008.
Weigelt B, Horlings HM, Kreike B et al: J Pathol
DOI:10.1002/path.2407.
Perou CM, Sorlie T, Eisen MB et al: Nature 406: 747-752,
2000.
Sorlie T, Perou CM, Tibshirani R et al: PNAS 98: 1086910874, 2001.
Van’t Veer LJ, Dai H et al: Nature 415: 530-536, 2002.
Paik S, Shak S, Tang G et al: NEJM 351: 2817-2826, 2004.
48
SURGICAL APPROACH OF BREAST CANCER: AN
UPDATE
Ch. Batsis
Medical School, University of Ioannina, Ioannina, Greece
Since 1894 when William Halsted introduced the radical
mastectomy as the definitive surgical procedure for the
Abstracts of the 8th International Conference of Anticancer Research, 17-22 October 2008, Kos, Greece
treatment of breast cancer, remarkable progress has been made
in the local treatment of this disease in the last 100years,
reflecting changes in our understanding of the biology of
breast cancer and improvements in diagnostic and therapeutic
modalities. The breast conserving surgery (BCS) and
radiotherapy has become more common, as surgeons have
become convinced of the efficacy of this treatment through
data from large prospective randomized trials. Veronesi, Fisher
and others have shown the surgical rates with mastectomy and
BCS plus radiotherapy to be equivalent. Because of the
complexity of the disease process, the availability of multiple
treatment options and the need to individualize each woman’s
care, a multidisciplinary approach is essential to optimize the
treatment.
Discussion of the local treatment of breast cancer should be
divided into treatment of invasive breast cancer and treatment
of ductal carcinoma in situ (DCIS). Invasive breast cancer and
DCIS are clinicopathologic entities that require different
treatments. Furthermore, treatment of invasive cancer must be
divided into early breast cancer (stage I-II) and advanced
breast cancer (stage III-IV). Most women with stage I-II breast
cancers are good candidates for BCS and radiation but there
are certain situations where the mastectomy is probably the
best choice of therapy. The standard of care in treatment of the
axilla for patients with invasive breast cancer is currently a
level I and II axillary dissection. Sentinel node biopsy of the
axilla would decrease the risk of side-effects from dissection,
while still accurately staging the axillary nodes in appropriate
clinical situations. The treatment of stage III breast cancer
should be decided after multidisciplinary consultation, with a
combination of neoadjuvant chemotherapy or initial hormonal
treatment, making surgery feasible some weeks or months
later. The local treatment of stage IV is palliative and not life
saving.
The treatment of DCIS consists of local treatment alone.
Most women are good candidates for BCS alone or BCS and
radiotherapy but there are some contraindications where
simple mastectomy with or without reconstruction is
preferable. Lobular carcinoma in situ (LCIS) is a rare
pathologic entity poorly understood by patients and this is
considered rather as a marker that places a woman at
inscreased risk for the subsequent development of invasive
cancer. The treatment options include close follow-up or
bilateral prophylactic mastectomy with or without
reconstruction.
49
THE ROLE OF XRCC4 IN CARCINOGENESIS AND
ANTICANCER DRUG DISCOVERY
Da-Tian Bau
Departments of Terry Fox Cancer Research Lab, China
Medical University Hospital, Taichung, Taiwan, ROC
In the past decades, the incidence of cancer continues to rise
rapidly all over the world and is always an important threat to
public health. It is believed that cancer results from a series of
genetic alterations leading to progressive disorder of the
normal mechanisms controlling cell proliferation,
differentiation, death, and/or genomic stability. The response
of the cell to genetic injury and its ability to maintain genomic
stability by means of a variety of DNA repair mechanisms are
therefore essential in preventing tumor initiation and
progression. From the same viewpoint, the relative role of
DNA repair as a biomarker for prognosis, predicator of drug
and therapy responses, or indeed as target for novel gene
therapy (recently patented) and is very promising. Here, we
summarize and evaluate associations between the SNPs of
XRCC4, one of the NHEJ genes, and the susceptibility of
multiple types of cancer, and discuss its role in carcinogenesis
and application in anticancer drug discovery.
50
SENSITIZATION OF TUMOR CELLS FOR ROS MEDIATED INTERCELLULAR APOPTOSIS
INDUCTION: A NOVEL CHANCE TO ESTABLISH
SELECTIVE ANTITUMOR MECHANISMS
Georg Bauer
Department of Virology, University of Freiburg, Freiburg,
Germany
Transformed cells are subject to the control by intercellular
induction of apoptosis, a TGF-beta-triggered, reactive oxygen
species (ROS)-mediated control mechanism that selectively
removes precancerous cells. The efficiency of intercellular
induction of apoptosis, as well as its selectivity with respect
to the transformed state of target cells, is driven by
extracellular superoxide anions that are generated by
transformed cells. Four ROS-based intercellular signaling
pathways contribute to intercellular induction of apoptosis.
During tumor progression, transformed cells acquire resistance
mechanisms against intercellular induction of apoptosis. This
resistance is based on active interference of tumor cells with
intercellular ROS-mediated signaling through membraneassociated enzymes. Resistance against intercellular ROSsignaling is found in all tumor cell systems tested, including
the most frequent and the most aggressive human tumors.
Resistant tumor cells can be sensitized for intercellular ROS
signaling and subsequent selective apoptosis induction through
several distinct approaches established by our group. Among
them are: i) siRNA-mediated knock down of the major
interfering enzyme; ii) inhibition of interfering enzymes by
defined small molecules; iii) inhibition of interfering enzymes
by monoclonal antibodies; iv) generation of singlet oxygen
through modulation of the tumor cells ROS signaling
chemistry. The latter approach utilizes tumor cell specific ROS
3209
ANTICANCER RESEARCH 28: 3157-3556 (2008)
interactions for singlet oxygen generation as a first step,
followed by inactivation of the major interfering enzyme and
subsequent efficient intercellular ROS signaling, leading to
selective tumor cell apoptosis.
Ligand-dependent and independent death receptor
activation as well as low-dose gamma irradiation show
synergistic interactions with the sensitization of tumor cells
and with intercellular ROS signaling. These synergistic
effects may be utilized for further optimization of the
sensitization process.
As intercellular ROS-signaling is specific and typical for
cells with the transformed phenotype and as resistance against
ROS signaling seems to represent a regular phenotypic
characteristic of tumor cells, sensitization of tumor cells for
intercellular ROS signaling should allow to establish novel
tumor therapeutic approaches that bear the chance for high
selectivity and efficiency.
51
REACTIVE OXYGEN AND NITROGEN SPECIES
(ROS AND RNS) IN ANTICANCER MECHANISMS
Georg Bauer
Department of Virology, University of Freiburg, Freiburg,
Germany
Transformed and tumor cells are characterized by membraneassociated NADPH oxidase and extracellular superoxide anion
generation. Extracellular superoxide anions drive the
efficiency and selectivity of intercellular induction of
apoptosis, an ROS-mediated mechanism that leads to the
selective elimination of transformed cells. Intercellular
induction of apoptosis is based on four ROS/RNS-based
signaling pathways, which may either interact synergistically
or in an inhibitory mode. During tumor progression, tumor
cells acquire resistance against intercellular ROS signaling
through specific interference with intercellular ROS signaling
by defined mechanisms.
Our data allow the following conclusions: i) multistep
oncogenesis: ROS/RNS-driven intercellular induction of
apoptosis might lead to the elimination of premalignant, ROSsensitive transformed cells during multistep oncogenesis and
thus represent a hitherto unrecognized natural control system.
The interaction of certain secondary plant products and
intercellular ROS signaling leads to the sensitization of ROSresistant tumor cells (at later stages of oncogenesis) for
intercellular induction of apoptosis. ii) Tumor therapy:
Apoptosis induction in tumor cells by established
chemotherapeutics like taxol or epothilone B depends on
functional intercellular ROS signaling. Besides its direct
apoptosis-inducing effect, mediated by singlet oxygen,
photodynamic therapy leads to sensitization of tumor cells for
intercellular ROS signaling. Death receptor activation and
3210
intercellular ROS signaling are interconnected and thus
amplify apoptosis induction.
The knowledge of the functional role of ROS/RNS during
multistep oncogenesis and tumor therapy may be useful to
optimize tumor prevention and to improve tumor treatment.
52
ANTIOXIDANTS IN MULTISTEP ONCOGENESIS
Anna Burcza and Georg Bauer
Department of Virology, University of Freiburg, Freiburg,
Germany
Natural antioxidants from food are well–known for their
scavenging activity for reactive oxygen and nitrogen species
(ROS and RNS) such as hydroxyl radicals, hydrogen peroxide
or peroxynitrite. This scavenging activity may inhibit
ROS/RNS-mediated mutagenesis and thus prevent the
initiation step of multistep oncogenesis.
Certain flavonoids have been shown to exhibit
chemopreventive as well as therapeutic potential through
induction of apoptosis in tumor cells (please see the
contribution by C. Gerhäuser in this symposium).
Here we report on the potential of flavonoids and other
antioxidants to sensitize ROS-resistant tumor cells for
intercellular induction of apoptosis, an ROS-driven
intercellular signaling system with possible relevance for
multistep oncogenesis and tumor therapy. At the first sight, it
seems a paradox that antioxidants can trigger and enhance
this prooxidative mechanism which is directed against
transformed and tumor cells. Our detailed analysis
demonstrates a complex network of ROS/RNS/antioxidant
interactions. As the first step, antioxidants increase the
available nitric oxide (NO) concentration through inhibition
of the consumption reaction between hydrogen peroxide and
NO. In addition, certain compounds inhibit NO dioxygenase
and thus prevent consumption of NO. In a complex series of
biochemical reactions, the increased NO concentration
finally leads to singlet oxygen generation. Singlet oxgen
restores the ability of tumor cells for intercellular ROS
signaling. Ongoing ROS signaling first leads to the
consumption of the antioxidant which is the prerequisite for
subsequent ROS-mediated apoptosis induction. Overall,
tumor cells that have escaped ROS-mediated intercellular
induction of apoptosis through establishment of specific
resistance mechanisms are rendered sensitive for ROSdependent apoptosis induction through the action of the
antioxidant.
These data add an unexpected aspect to the multifaceted
picture of antioxidant action during multistep oncogenesis.
Our findings may be useful for the understanding of the role of
nutritional antioxidants in tumor prevention as well as in
tumor therapy.
Abstracts of the 8th International Conference of Anticancer Research, 17-22 October 2008, Kos, Greece
53
CANCER CHEMOPREVENTION WITH
MICRONUTRIENTS – DNA-PROTECTIVE
EFFECTS IN HUMAN MUCOSAL CELL CULTURES
P. Baumeister, N. Kleinsasser and U. Harréus
Department of Otolaryngology/Head and Neck Surgery,
Ludwig Maximilians University Munich, Germany
Objectives: In the past decades, large interventional trials were
carried out to test cancer chemopreventive effects of nutrional
supplementation with micronutrients such as vitamins or trace
elements. Unfortunately, no positive influence on cancer
incidence could be shown. On the other hand, epidemiological
studies suggest that a diet rich in fruits and vegetables has
strong cancer chemopreventive effects. We here present an
overview of our studies evaluating DNA protection of different
vitamins, several polyphenols and zinc. Methods: Miniorgan
cultures (MOCs), completely epithelised tissue cubes from
fresh biopsies of nasal and oropharyngeal mucosa, were
pretreated with micronutrients. DNA damage was then
introduced oxidatively or with a metabolically activated
carcinogen. DNA protective effects were evaluated using the
alkaline single cell microgel electrophoresis (Comet) assay.
Results: All tested micronutrients show remarkable DNA
protective action against oxidative or carcinogen-induced
damage in our model. Our results indicate their potential to
prevent DNA fragmentation from endogenous and/or
xenobiotic sources. The lack of this effect in interventional
trails could be due to their metabolism.
54
CANCER PATIENTS SUFFERING FROM
TUMOR-INDUCED EVASION OF THE ADAPTIVE
IMMUNITY BY INCREASED IL-4, IL-6 AND IL-10
MAY BENEFIT FROM ANTICANCER TH2
CYTOKINES ANTAGONISTS
Yechiel Becker
Department of Molecular Virology, Facultty of Medicine,
The Hebrew University of Jerusalem, Jerusalem, Israel
Background: human tumors release antigenic glycoproteins
that are processed by dendritic cells and presented by HLA
class I and HLA class II to CD4+ T-cells in the lymph nodes.
CD4+ T-cells that interact with HLA class I polarize into two
types of T helper 1 cells: Th1 cells produce Th1 cytokines IL2, IL-12 and interferon gamma while Th17 cells produce the
cytokine IL-17. Th1 cells activate the antitumor cytotoxic
CD8+ T-cells. Th17 cells are involved in autoimmunity. In
addition to the CD4+ and CD8+ T-cells, members of the
adaptive immune system, innate system cells, mast cells,
basophils, monocytes and dendritic cells, are regulators of the
adaptive immune cells, due to their ability to release large
amounts of Th2 cytokines that induce B-cells to switch to IgE
synthesis. A new test for simultaneous analysis of Th1, Th17
and Th2 cytokines was developed. Passive immunotherapy
with humanized monoclonal antibodies: J. King et al.
reviewed the use of humanized anti tumor antigens
monoclonal antibodies (DOI:10.1093/qjmed.hcn050) for
treatment of cancer patients. The monoclonal antibody
Herceptin (Trastuzumab) binds to the HER2 receptor on
metastatic breast cancer leading to 20% reduction of risk of
death, but caused 27% increase in cardiac disfunction. The
nuclear splicing mechanism of cytokine genes mRNA and
splice variants of the genes: The Th2 cytokine IL-4 was found
to inhibit antitumor and cytotoxic CD8+ T-cells. Deletion of
intron 2 sequnce from IL-4 mRNA yields an IL-4delta2
antagonist that is able to bind to IL-4 receptor alpha on TH2
cells and B-cells and prevents the effects of IL-4 on the
adaptive immune response. Conclusion: The splice variants of
the inhibitory Th2 cytokine IL-4 and IL-6 have potential for
use in anticancer treatment.
55
“INCLONALS”: IgG ANTIBODIES PRODUCED
IN E. COLI IN THE CONTEXT OF TARGETED
ANTICANCER THERAPY
Rahely Hakim and Itai Benhar
Department of Molecular Microbiology and Biotechnology,
the George S. Wise Faculty of Life Sciences, Ramat Aviv
69978, Israel
Antibodies are among the most powerful tools in biological
and biomedical research and are presently the fastest growing
category of new bio-pharmaceutics. With regard to anticancer
immunotherapy, antibodies can be used "naked" as are most
FDA approved ones, or as immunoconjugates to direct
cytotoxic moieties to tumor cells. Recombinant forms of small
antibody fragments fused to cytotoxic moieties, named
recombinant immunotoxins, are also being developed as an
additional approach for an antibody-targeted cancer therapy.
For treating solid tumors, tumor penetration, which is
inversely proportional to the size of the drug, is currently
regarded as the prime factor for its efficacy, while other
parameters such as binding affinity and residence time in the
body are of lesser importance. This dogma may be challenged
by recent study from our lab when immunotoxins that target
the tumor-associated antigen ErbB2 were evaluated. We found
that, a bivalent antibody-toxin conjugate (200 kDa) was much
superior to the corresponding recombinant immunotoxin
(scFv-toxin fusion, 66 kDa), in killing ErbB2 expressing
tumor cells in culture and as xenografts in nude mice. These
results suggest that higher avidity and longer residence time
may outweigh tumor penetration. This led us to design
3211
ANTICANCER RESEARCH 28: 3157-3556 (2008)
additional models to study whether our previous observation
was a peculiarity of the model system we used, or a more
general phenomenon.
While looking for an easier and more rapid way to achieve
the full-length IgGs that are required to this study, we
developed an expression and purification protocol for fulllength IgGs in E. coli, called “Inclonals”. By using this
protocol, we can obtain a yield of up to 50 mg pure IgG from
1 liter of shake flask culture and highly purified IgGs that are
free of contaminating and partially assembled species. The
“Inclonals” we produced equaled the performance of the same
IgGs that were produced using conventional mammalian cell
culture. Antibodies that are produced in E. coli are
aglycosylated and hence are not useful for purposes that
require effector functions such as ADCC and CDC. However,
the large majority of antibodies that can be potentially used
for therapy, diagnostics or research purposes are not dependent
on Fc glycosylation to be effective (some examples are as
virus neutralizing antibodies, antibodies that are used to ferry
a cargo to the target cells, or bi-specific antibodies). We
believe that our rapid and cost-effective IgG production
process and the high quality of the resultant product may make
bacterial production of full-length IgG, and IgG-based fusion
proteins a viable and attractive option for antibody production.
56
CIRCULATING TUMOR CELL DETECTION BY
CELLSEARCH SYSTEM DURING BREAST CANCER
NEOADJUVANT CHEMOTHERAPY
F.C. Bidard1, C. Mathiot1, A. Vincent-Salomon1,
R. Salmon1, M Marty2 and J.Y. Pierga1
1Institut
2Hôpital
Curie, 26 rue d’Ulm, 75005 Paris;
Saint Louis, Av Vellefaux, 75010 Paris, France
Background and Aim: Circulating Tumor Cells (CTCs),
detected by the CellSearch system in metastatic breast cancer
patients have been reported as a surrogate marker for tumor
response and shorter survival. The aim of this study was to
determine whether CTC are present in the blood of patients
with large operable or locally advanced breast cancer before
neoadjuvant chemotherapy (pre-CT) and after neoadjuvant
chemotherapy, prior to surgery (post-CT). Patients and
Methods: 7.5 ml blood samples were obtained on CellSave
tubes from patients included in a phase II trial (REMAGUS
02). CTCs were immunomagnetically separated and
fluorescently stained by the CellSearch® system. Twenty
metastatic breast cancer patients were screened as positive
controls. Results: From 10/2004 to 7/2006, pre-CT and/or
post-CT blood samples were obtained from 118 patients. At
least one CTC was detected in 22 out of 97 patients with preCT sample (23%, 95%CI=[15-31%], median 2 cells, range [117 cells]). CTC positivity rates were 17% in 86 post-CT
3212
samples and 27% in all 118 patients. Persistence of CTC at
the end of CT was not correlated with treatment response.
After a short median follow up of 18 months, the presence of
CTC (p=0.017), hormone receptor negativity and large tumor
size were independent prognostic factors for shorter
metastasis-free survival. Conclusion: The CellSearch® system
can detect CTCs in 27% of patients receiving neoadjuvant
chemotherapy, using a low cut-off of 1 cell/tube. CTCs
detection was not correlated to the primary tumor response but
is an independent prognostic factor for early relapse.
57
DAVID PAUL HANSEMANN, CHROMOSOMES AND
CANCER
Leon P. Bignold, Brian Coghlan and Hubertus Jersmann
University of Adelaide, SA 5005, Australia
Chromosomes were described, named and identified as the
basis of the cellular hereditary material in the 1870s-80s. In
the same period Weismann’s theory that ‘differentiation’
(conversion of blastula cells into the various types of adult
tissue cells) occurs by progressive loss of chromosomes during
mitoses of the cells was popular. Also, studies of
chromosomes during oogenesis showed that the ‘polar bodies’
associated with this process involve loss of chromosomes from
the egg cell. In 1890, David Paul Hansemann (1858-1920)
noted asymmetric mitoses in cancer cells while recognising
loss of tissue differentiation and increased capacity for
independent existence (i.e. "autonomy" – ability to grow in
remote tissues and form metastases) as features of cancer cells.
Probably because Virchow insisted that tumour formation must
involve only an abnormality of a “physiological” tissue
process (not a new process), Hansemann thought that
oogenesis might be a counterpart of this particular
combination of changes because (i) the egg loses
chromosomes as it ripens (ii) it is less ‘differentiated’ than
ovarian epithelial cells (in fact, it is ‘de-differentiated’) and
(iii) the egg can survive for days free in the endometrial cavity.
Hansemann called the normal process “anaplasia”, and
proposed that it could occur to variable degrees in different
cases of tumour according to the degrees of chromosome
imbalance in the tumour cells. He considered that populations
of chromosomally unbalanced cells would arise, some of
which have the (ovum-like) anaplastic features, but still have
features of the cell type from which they arose.
Hansemann’s ideas were criticized by many authors
(summarized in (1)) but several authors (Hauser, 1903; Moore
and Farmer, 1904; and Boveri, 1914, see (1)) produced
theories of tumors involving alterations of cellular hereditary
material. None of these was as comprehensive as
Hansemann’s, and Boveri’s in particular was largely based on
only one mitotic abnormality (quadripolarity) and one new cell
Abstracts of the 8th International Conference of Anticancer Research, 17-22 October 2008, Kos, Greece
biological observation (wandering of cells of the blastomere
in doubly-fertilized - ‘dispermic’ - eggs) (1). Also in the early
twentieth century, the directions of cancer research moved
towards investigating Mendelian genetics in relation to
tumours, and the mechanisms of action of viral, physical and
chemical carcinogens. Only in the last 30 or so years, have the
roles of chromosomal abnormalities in tumour formation –
which were first studied by Hansemann – again received
significant attention.
1 Bignold LP, Coghlan BLD, Jersmann HPA. David Paul von
Hansemann: Contributions to Oncology. Context, Comments
and Translations. Birkhäuser, Basel, 2007.
58
DNA-PROTEIN CLAMP DYSFUNCTION AS A
MECHANISM OF CHROMOSOMAL ABBERATIONS
INDUCED BY X-RAYS AND ALKYLATING AGENTS
IN CANCER
Leon P. Bignold
University of Adelaide, SA 5005, Australia
Chromosomal abnormalities occur spontaneously in cancer
cells. However also, they are inducible in normal cells by
agents which affect covalent bonds relating only to DNA (e.g.
bromodeoxyuridine), only to proteins (e.g. etoposide), to DNA
and proteins (e.g. X-rays, alkylating agents) or to neither DNA
nor proteins (e.g. higher phenols and acridines). Although it
does not explain non-genotoxic clastogens, a widely held
theory of chromosomal aberrations (1) is that the agents cause
double strand breaks during interphase, and translocations etc
arise if two breaks are followed by inappropriate rejoinings to
concurrently doubly broken DNA strands from the same or
another chromosome.
In recent years, it has become clear that (i) during
interphase, DNA strands are clothed by chromatin proteins,
and so are rarely so ‘proximate’ that two fibers could interact
as a result of one ionizing event (2); (ii) DNA synthesis occurs
in intranuclear ‘factories’, where clusters of DNA polymerase
complexes act on ‘proximate’ and ‘bare’ DNA strands; (iii)
several steps of DNA synthesis, proof-reading, mismatch and
other repair involve active strand-breaking, including ‘doublestrand breaking’ by nucleases especially at the ‘replication
fork’ and during various repair mechanisms (3) and (v) all
processes of synthesis or repair of DNA involve complexes of
proteins which maintain strand alignment (DNA-protein
‘clamps’).
Here, it is suggested that DNA damage caused at any time
in interphase including G2 leads to double and single strand
breaking by repair or synthesis-related enzymes. While these
strand breaks are in existence, ‘clamp protein’ function may
fail, either due to excessive persisting abnormal DNA or due to
damaged clamp proteins (many of which are present in the
nucleus throughout the cell cycle) or both. This results in
simple chromosome “breaks”. However also at this point, the
strands are being processed naked of other proteins, so that
when the clamps on two adjacent DNA strands fail, swapping
of strands may occur. If the swap involves another part of the
same arm of a chromosome, an ‘intrachange’ occurs; if to
another chromsome entirely a ‘translocation’ (‘factories’ are
not chromosome-specific).
This hypothesis that the ‘DNA-protein clamp complexes’
are the ‘target’ of agents which cause aberrations would
account for aberration-causing agents which do not react with
DNA. Mutation(s) of clamp protein genes may contribute to
chromosomal aberrations in cancer.
1 Genetics 23: 494, 1938.
2 Mut Res 512: 93, 2002.
3 DNA Repair (Amst.) 5: 404, 2006.
59
177LU
RADIOLABELLING AND QUALITY CONTROL
OF PAMAM DENDRIMERS MODIFIED WITH
PYRIDINE-N-OXIDE DERIVATIVE OF DOTA
V. Biricova, A. Laznickova, P. Hermann,
M. Polasek and I. Lukes
Veronika Biricova, Francisciho 27, Levoca 054 01, Slovakia
Dendritic highly branched polymeric materials seem to be
potential antitumour drug carriers. Their huge surface areas as
well as an ability to encapsulate guest molecules in the
macromolecule interior make them useful for cancer diagnosis
and treatment. The new conjugates of pyridine-N-oxide
derivative of DOTA, 10-[(4-carboxy-1-oxidopyridin-2yl)methyl]-1,4,7,10-tetraazacyclododecane-1,4,7-triacetic acid,
with ethylenediamine-core polyamidoamine (PAMAM)
dendrimers of the first and fourth generations (containing 8
and 64 amino groups on their surface) were prepared and
radiolabelled with lutetium-177. The non-radioactive lutetium
chloride was concurrently used with radioactive isotope Lu177 to fully saturate the free ligand groups on the surface of
the dendrimers. To obtain a higher saturation degree of
radiometal, the reaction mixture was incubated at 40˚C
overnight. Diethylenetriaminepentaacetic acid was added to
the mixture before analysis to scavenge excess of lutetium
possibly non-specifically bound to the dendrimers.
Radiolabelled products were analysed using gel permeation
chromatography
(GPC)
and
polyacrylamide
gel
electrophoresis (PAGE). We have produced and separated the
product in a sufficient quality. Radioactivity of the samples
was measured on gamma spectrometer. PAGE analysis of
products indicates that radiolabelled conjugates with the
dendrimers have negative charges. This study clearly shows
that gel permeation chromatography is an effective technique
for separation and consecutive quality control of the PAMAM
3213
ANTICANCER RESEARCH 28: 3157-3556 (2008)
dendrimer conjugates and polyacrylamide gel electrophoresis
is a suitable method for its partial characterisation.
60
MANIPULATION OF GLIOMA CELL SURFACE
GANGLIOSIDES: POTENTIAL THERAPEUTIC
IMPLICATIONS
Suzanne Birks1, John Danquah2, Richard Hitchman2,
Linda King2, Reinhard Vlasak3, Darek Gorecki1 and
Geoffrey J. Pilkington1
1Cellular
and Molecular Neuro-oncology Research Group
Institute of Biomedical and Biomolecular Sciences School of
Pharmacy and Biomedical Sciences, University of
Portsmouth, St Michael’s Building, White Swan Road,
Portsmouth, Hampshire, PO1 2DT;
2School of Life Sciences, Oxford Brookes University,
Headington Campus, Gipsy Lane, Oxford OX3 0BP, UK;
3Applied Biotechnology, Department of Cell Biology,
University Salzburg, A-5050 Salzburg, Austria
Background: The ganglioside GD3 is highly expressed in the
embryonic brain but markedly decreases in latter stages of
development. It plays a pivotal role in the regulation of cell
proliferation and migration. In neoplastic cells, GD3 expression
is once again up-regulated but becomes acetylated at the
terminal sialic acid residue to form 9-O-acetyl GD3 (GD3A).
Whilst the accumulation of GD3 in cell cytoplasm induces
mitochondrially mediated apoptosis, this phenomenon does not
occur when GD3 is acetylated. GD3A appears to promote
tumour cell growth and survival. However, exogenous addition
of the enzyme acetylesterase deacetylates GD3A and restores
pro-apoptotic native GD3. The baculovirus Autographa
californica multiple nuclear polyhedrosis virus (AcMNPV) can
efficiently transduce mammalian cell lines leading to stable and
transient gene expression whilst remaining non-pathogenic and
may be a suitable expression system for in vivo therapeutic
targeting of GD3A. Aims: Target GD3A expressing braintumour cells with acetylesterase in vitro by exogenous addition
and transfection with influenza c virus HE protein cDNA to
assess the effect on levels of GD3/GD3A expression, apoptosis
and invasion and to determine whether the baculovirus
AcMNPV can transduce human brain-tumour cells and may
therefore be a suitable vector system for therapeutic targeting
of GD3A. Materials and Methods: Recombinant acetylesterase
from influenza C virus, produced in SF9 cells and supplied by
R. Vlasak, was used at 10 mU in all assays. Cells used in all
assays were from a glioblastoma multiforme biopsy-derived
cell culture. The pCHE4 plasmid encoding the acetylesterase
(hemagglutinin esterase (HE) protein) from the influenza
C/California/78 virus was also supplied by R. Vlasak.
Transductions with the baculovirus were performed by J.
Danquah using recombinant baculovirus AcEGFP-VP39 at
3214
multiplicity of infection (MOI) 50, cells were then fixed and
lablelled with anti-VP39. GD3/GD3A expression studies were
carried out by incubating cells with acetylesterase followed by
staining with anti-GD3, anti-GD3A and analysis by flow
cytometry. Apoptosis assays were performed by incubating
cells with acetylesterase followed by either staining with
Annexin V or the JC-1 probe and analysis by flow cytometry or
running lysed cells on SDS-PAGE and Western
immunoblotting for the release of cytochrome c and caspase-9
and caspase-3. Invasion assays were carried out either by the
modified transwell-Boyden chamber invasion assay where cells
applied to the upper surface were suspended in SFM +
acetylesterase (SFM + PDGF was used as a chemoattractant) or
by live cell imaging for 24 hours in the presence of
acetylesterase. Results: The exogenous addition of
acetylesterase results in a decreased expression of GD3A and
an increase in the expression of GD3. This is correlated to a
decrease in cell survival since the percentage of dead/apoptotic
cells was significantly more when pre-treated with the enzyme.
Discussion: Since exogenous addition of acetylesterase only
targets GD3A on the surface of the brain tumour cells, we
expect to see much more convincing effects when the enzyme
is active within the cell. Since the baculovirus transductions are
so far very promising we hope to start work cloning
acetylesterase cDNA into the baculovirus.
This work was supported by Charlie’s Challenge and Ali’s
Dream brain tumour research charities.
61
DETECTION AND REPAIR OF A REPLICATION
FORK ENCOUNTERED SINGLE-STRAND BREAK –
A MODEL SYSTEM FOR DAMAGE GENERATED
VIA TOPOI-DNA CLEAVAGE INTERMEDIATES
Ida Nielsen, Iben Bach Bentsen,
Anni H. Andersen and Lotte Bjergbaek
Department of Molecular Biology, University of Aarhus,
C.F. Möllers Allé building 130, DK-8000 Aarhus, Denmark
The S-phase is a period of great vulnerability for the genome
of eukaryotic cells. Many complicated processes are
undertaken during this critical phase of the cell cycle,
including the complete unwinding and duplication of
enormously complex DNA molecules. During this process,
replication forks frequently encounter obstacles that impede
their progression. The replication fork must be able to cope
with such obstacles as this otherwise it can cause replication
fork stalling and eventually lead to collapse of the replication
fork with the result of single- or double-strand break
formation. Replication fork stalling or damage will therefore
compromise genomic integrity if not properly processed.
Single-strand breaks (SSB) are frequent endogenous DNA
lesions in cells and impose a great danger to an advancing
Abstracts of the 8th International Conference of Anticancer Research, 17-22 October 2008, Kos, Greece
replication fork. SSBs can be induced directly by free radicals
or damaged bases. Furthermore, poisons against DNA
topoisomerase I (TopoI) will also generate nicks in the DNA
as the enzyme gets trapped in a cleavage intermediate being
covalently linked to the DNA at the 3’ end of the nick. Not
only do anticancer drugs such as camptothecin stimulate
TopoI-DNA cleavage intermediates, but so do endogenous and
exogenous DNA lesions including UV-induced base
modification, guanine methylation and oxidation, base
mismatches and abasic sites. It is believed that TopoI-DNA
cleavage intermediates damage DNA and kill cells by
generating replication-mediated double-strand breaks (DSB)
and by stalling transcription complexes. Topoisomerase I is an
abundant enzyme and is furthermore known to travel along
with the DNA replication machinery, possibly removing
topological strain in front of the replication fork, it is therefore
likely that TopoI can induced damage arise in every S-phase.
In order to identify and characterize pathways engaged in
repair of topoisomerase-induced DNA damage, we have
designed an in vivo system where we can induce an SSB at a
single locus in the genome. The induced SSB mimics a TopoIDNA cleavage intermediate. Using this system, we have a
unique opportunity to examine which stress response factors
get activated and to study in detail how the DNA replication
fork copes with these challenges. Data obtained with the
system will be presented.
62
RESISTANCE OF FRESHLY ISOLATED
PERIPHERAL BLOOD LEUKOCYTES TO VIRAL
INFECTIONS AS ONE OF THE INNATE IMMUNITY
MECHANISMS IN HEALTH AND
DISEASE–POSSIBLE THERAPEUTIC EFFECT OF
PLANT PREPARATIONS
Z. Błach-Olszewska1, E. Zaczyńska1, M. Sochocka1,
B. Jatczak1, A. Wiśniewska1, I. Frydecka3,
M. Kiełbiński2 and J. Robaczyński3
1Ludwik
Hirszfeld Institute of Immunology and
Experimental Therapy, Polish Academy of Sciences,
Wrocław;
2Department of Hematology, Medical University, Wrocław;
3Department of Fertility and Obstetrics, Medical University,
Wrocław, Poland
The aim of this study was to compare the resistance of healthy
blood donors leukocytes ex vivo to viral infection with the
resistance of leukocytes isolated from cancer patients. The
resistance is individually differentiated, age-dependent and
relies on TNFα and IFNs (α, β, γ).
The degree of resistance was measured by using a direct
method of infection of leukocytes with vesicular stomatitis
virus (VSV), which is an indicatory virus in the test. The lack
of VSV replication by infected leukocytes (0-1 log TCID50)
was taken as a complete resistance; a low level of VSV (2-3
log) for partial, and a high VSV titer (4 or more log) for no or
very low resistance.
Results showed statistically significant differences between
the resistance of the healthy and leukemia groups at diagnosis
and the importance of the degree of the resistance for
induction of remission after chemotherapy and survival time.
Very low immunity was also found in leukocytes of cancer
patients (ovarian and endometrial cancer). With respect to
potential therapeutic usefulness, intensification of the
resistance by plant preparations from Scutellaria baikalensis,
Ginkgo biloba, Echinacea purpurea and donepezil (used in
Alzheimer’s disease therapy) was found.
63
ASSESSING THE ROLE OF HUMAN
PAPILLOMAVIRUS (HPV) ONCOPROTEINS IN
REGULATING CELL-MEDIATED IMMUNITY:
IMPLICATIONS FOR CERVICAL CANCER
Oliver Watherston1, Paul Bowles1,2, Graham Bottley1,
Bodil Norrild3 Graham P. Cook2 and G. Eric Blair1
1Institute of Molecular and Cellular Biology, Faculty of
Biological Sciences, University of Leeds, LS2 9JT, UK,
2Leeds Institute of Molecular Medicine, St James’s
University Hospital, Leeds LS9 7TF, UK;
3Health Science Faculty, University of Copenhagen, DK2200, Copenhagen, Denmark
Previous work from this laboratory has investigated the
modulation of cell surface Major Histocompatability
Complex class I (MHC class I) expression by the E7
oncoprotein from high risk Human Papillomavirus 16
(HPV16). We utilized two complementary cell-based systems
to induce or knock-down expression of the E7 protein, and
determined changes to MHC class I expression. We have
already shown that siRNA-mediated inhibition of E7 in
HPV16- and HPV18-transformed cells results in significant
up-regulation of cell-surface MHC class I molecules. We have
also shown that induction of HPV16 E7 using a tetracyclinerepressor system results in a significant down-regulation of
cell surface MHC class I molecules. In addition, analysis of
total cell MHC class I heavy chain protein by Western
blotting has confirmed the results obtained by flow cytometry
on cell-surface MHC class I. Interestingly, total cellular levels
of the invariant chain of the MHC class I heterodimer, β2microglobulin, appeared to be unaffected by E7 expression,
suggesting a selective effect on molecules encoded in the
MHC locus (since β2-microglobulin is located outside the
MHC locus). We are currently examining levels of other
components of the antigen processing and presentation
pathway (TAP, LMP2, LMP7 etc).
3215
ANTICANCER RESEARCH 28: 3157-3556 (2008)
We have also examined the functional implications of MHC
class I down-regulation by HPV E7 using a co-culture system
with peripheral blood Natural Killer (NK) cells. These coculture experiments revealed that the cell surfaces changes in
MHC class I levels mediated by E7 observed have a
significant effect on susceptibility to NK mediated lysis,
consistent with “the missing self hypothesis”. Thus, E7expressing cells having reduced MHC class I were less
resistant to NK cell mediated lysis. Conversely, E7-knockout
cells having increased cell surface MHC class I were more
resistant to NK cell lysis. We are now investigating inhibitory
and activating NK cell ligands on HPV-transformed cells to
elucidate the mechanism of the NK interaction with these
malignant cervical cells.
64
NESTED MORPHOLOGY IN UROTHELIAL
CARCINOMAS: AN ELEMENTARY LESION
SHARED BY MANY DIFFERENT SUB-TYPES OF
URINARY BLADDER CANCER
Enrico Bollito
Division of Pathological Anatomy, University of Turin at San
Luigi Gonzaga Hospital- Orbassano, Turin, Italy
The incidence of bladder cancer has markedly increased,
mainly as a result of smoking, particularly within women.
Recently, the new 2004-WHO classification of these tumors
has re-opened the debate on many aspects of these lesions,
improving the distinction of the different variants of bladder
cancer. The existence of a group of bladder cancers that seems
to have special features has become more evident: they are
carcinomas frequently showing an inverted or endophytic
growth pattern, and presenting heterogeneous histological
aspects and different grades, sometimes high, of
aggressiveness, but they seem to share the same elementary
lesion: the nest.
The group of urothelial lesions with nested morpholgy
may include different benign or malignant conditions
ranging from von Brunn nests, inverted urothelial
papillomas to inverted, nested type, microcystic and
micropapillary carcinomas. Among the latter, some
malignant forms were recognized as malignant tumors
having a worse prognosis than conventional urothelial
carcinomas. The study of bladder cancer with nested
morphology is therefore of interest for a better knowledge
of the development of these tumors and because the nested
variants may represent, if not a true separate sub-type, at
least a separate growth pattern with possible prognostic and
therapeutic implications. Further investigations, particularly
with molecular techniques are needed to assess the existence
of a true difference beetween tumors with nested or
esophytic morphology.
3216
65
P53 FAMILY TUMOR SUPPRESSOR NETWORK
LINKS MULTIPLE TUMOR SUPPRESSOR
PATHWAYS: P63/P73-DEPENDENT TUMOR
SUPPRESSOR PATHWAYS
Lakshmanane Boominathan
46 III Cross Street, Nehru Nagar, Mudaliarpet, Puducherry,
605 004, India
It is known for years that several tumor suppressor genes exist
in a cell. However, it remains elusive whether there is any
coordination among the established tumor suppressor genes
to determine the fate of the cell in response to aberrant
proliferative signals/DNA damage. Every gene in a cell needs
to be linked to another gene through gene network. Genes
that perform similar functions may be functionally linked and
they could be coordinately regulated. If this is true, then
genes that are classified under the title of tumor suppressor
genes may not be an exception to this possibility. Hence, I
propose that it is very important to understand how one tumor
suppressor gene is connected to another tumor suppressor
gene – through tumor suppressor network – within the cell.
Any biological or chemical agent that disrupts the tumor
suppressor network will result in the initiation of
tumorigenesis. A single nucleotide/codon alteration can
change the fate of the cell. For example, missense mutation
in the tumor suppressor p53 results in cancer. The p53 and
INK4s(a,b,c)-ARF tumor suppressors are the most prominent
among all the tumor suppressor genes known so far. It
appears that in most of the cancer cell types, if not all, acquire
a mutation in the pathway leading to the induction of p53- or
INK4s(a,b,c)-ARF tumor suppressors. Having realized the
importance of these tumor suppressor genes, it is of
paramount importance to identify other tumor suppressor
genes that link both p53- and INK4s(a,b,c)-ARF genes
together within the cell. With the arrival of two p53 related
genes, p73 and p63, the p53 tumor suppressor family network
appears to have enlarged in scope and significance. I have
identified several tumor suppressor genes that link both p53and INK4s(a,b,c)-ARF-family genes together. The
bioinformatics approach was used to identify the potential
tumor suppressor network. The models that emerge from this
study will mainly explain how p63 and p73 function as tumor
suppressors. Then, the identified tumor suppressor network
will be classified to illuminate the specific tumor suppressor
pathways. Additionally, the concept of “tumor suppressome”
will be elaborated. In aggregate, this study was aimed to
identify: a) Networks among the established tumor
suppressors that directly link the p53 family tumor suppressor
proteins together; b) p63/p73-dependent tumor suppressor
pathways; c) the unidentified tumor suppressor networks that
directly link several tumor suppressors.
Abstracts of the 8th International Conference of Anticancer Research, 17-22 October 2008, Kos, Greece
66
A REVIEW OF PROGNOSTIC FACTORS OF EARLY
CERVICAL CARCINOMA
J. Bouda1, L. Boudova2, Z. Rokyta1,
B. Gabriel3, G. Gitsch3 and E. Stickeler3
Departments of 1OBGYN and 2Department of Pathology,
Medical Faculty Hospital, Plzeň, Czech Republic;
3OBGYN, Freiburg University Medical Center, Freiburg,
Germany
Establishing prognosis is an important step for therapy
planning in malignant diseases. The classical morphological
prognostic factors in cervical carcinoma are: stage, type,
grade, tumor volume or diameter, depth of stromal invasion,
lymphovascular invasion, regional lymph node status, and
positivity of surgical margins. Recently, the focus of research
moved to novel factors such as oncogenes, tumor suppressor
genes, oncomarkers, aneuploidy and microsatellite instability,
neovascularisation, proliferative activity, HPV infection,
adhesion molecules.
In this review, we analyse the role of classical prognostic
factors of early cervical carcinoma and the role of novel
factors such as CD 44v6 adhesion molecule, focal adhesion
kinase (FAK) and hTra2-beta1 splicing factor. We also discuss
the impact of prognostic factors for treatment individualisation
and outline the future directions in this field of research.
67
CAS MEDIATES CROSSTALK OF SRC AND mTOR
SIGNALING
Kristýna Bicanová, Lucie Teglová,
Daniel Rösel and Jan Brábek
Department of Cell Biology, Faculty of Science, Charles
University in Prague, Prague, Czech Republic
mTOR signaling was found to contribute to various aspects of
Src mediated transformation, especially anchorage
independent growth. CAS (Crk associated substrate) is a major
tyrosine phosphorylated protein in cells transformed by v src
oncogene and was found to be critical for invasion and
metastasis of src transformed cells. CAS was recently
documented to contribute to the activation of PI3 kinase, an
upstream regulator of mTOR signaling.
To analyze the role of CAS in crosstalk of mTOR and Src
pathways, we employed CAS null and CAS re expressing Src
transformed MEFs. We found that CAS profoundly enhanced
the phosphorylation of mTOR/Raptor substrate 4E BP1 as
well as mTOR/Rictor-dependent Akt 473 phosphorylation.
Using CAS null Src transformed MEFs, reexpressing CAS
mutant with all 15 tyrosines in substrate domain mutated to
phenylalanines, we showed that functional CAS substrate
domain is necessary for 4E BP1 and to lesser extent also for
Akt 473 phosphorylation.
CAS mediated invasiveness of Src transformed MEFs is
accompanied by great elevation of MMP 2 activity (Brábek et
al., 2004). We analyzed whether mTOR signaling participates
in regulation of MMP 2 activity. Remarkably, we found that
MMP 2 activation in Src transformed MEFs was downregulated by mTOR inhibitors rapamycin and LY294002 and
unaffected by PI3 kinase inhibitor wortmanin. In addition, we
found that while mTOR inhibitors inhibited growth of Src
transformed cells under both non adhesive and adhesive
conditions, PI3 kinase inhibitor wortmanin inhibited the
growth of Src transformed cells only under non adhesive
conditions, suggesting that under adhesive conditions the
crosstalk of Src and mTOR signaling is independent of PI3
kinase.
To summarize, we found that CAS mediated crosstalk of
Src and mTOR signaling and that this crosstalk is at least in
part PI3 kinase independent.
68
MOLECULAR-TARGETED THERAPY FOR
ADVANCED RENAL CELL CARCINOMA
Sergio Bracarda1, Marta Rossi1, Alketa Hamzay1,
Claudia Caserta2, Valeria De Simone1 and Lucio Crinò1
1Department
of Medical Oncology, Ospedale S. Maria della
Misericordia, Perugia;
2Department of Medical Oncology, Ospedale S. Maria, Terni,
Italy
Metastatic advanced renal cell carcinoma (mRCC) is
historically refractory to conventional available treatments
such as radiotherapy and chemotherapy. As a result, until
recently, immunotherapy (interleukin-2 and or interferon-α)
has been considered the treatment of choice for advanced
disease.
Recent advances in understanding the biology and genetics
of RCC have led to the identification of a number of molecular
targets, with several novel drugs developed for these targets,
particularly tumor-associated angiogenesis, a key step in the
pathogenesis and progression of RCC.
Several angiogenic growth factors are highly expressed in
RCC, but vascular endothelial growth factor (VEGF), because
of the inactivation of the von Hippel-Lindau (VHL) tumorsuppressor gene and the subsequent activation of the hypoxia
response pathway, and mammalian target of rapamycin
(mTOR), for its central metabolic and angiogenic role, are of
particular importance. As a consequence, VEGF-targeted
therapies and mTOR inhibitors have been identified as
promising treatment strategies in patients with mRCC. To date,
three main treatment approaches have emerged: VEGF ligand
blockade, through anti-VEGF monoclonal antibodies (such as
3217
ANTICANCER RESEARCH 28: 3157-3556 (2008)
bevacizumab); VEGF signal blockade, by targeting VEGF
receptors with small molecule tyrosine kinase inhibitors such
as sunitinib and sorafenib; and, more recently, mTOR
inhibition with intravenous or oral agents such as temsirolimus
(CCI-779) and everolimus (RAD001).
Recent data about clinical efficacy and significant toxicities
of these agents and actual innovative treatment strategies for
advanced renal cell carcinoma will be presented and discussed.
1 Motzer RJ, Hutson TE, Tomczak P et al: Sunitinib versus
interferon alpha in metastatic renal-cell carcinoma. N Engl J
Med 356: 115-124, 2007.
2 Escudier B, Eisen T, Stadler WM et al: Sorafenib in
advanced clear–cell renal–cell carcinoma. N Engl J Med
356: 125-134, 2007.
3 Bracarda S, Porta C, Boni C et al: Randomized prospective
phase II trial of two schedules of sorafenib daily and
interferon-α2a (IFN) in metastatic renal cell carcinoma
(RAPSODY): GOIRC Study 0681. J Clin Oncol 25: 259s,
2007.
4 Hudes G, Carducci M, Tomczak P et al: Temsirolimus,
interferon alpha, or both for advanced renal-cell carcinoma.
N Engl J Med 356: 2271-2281, 2007.
5 Escudier B, Pluzanska A, Koralewski P, Ravaud A, Bracarda
S et al: Bevacizumab plus interferon alfa-2a for treatment of
metastatic renal cell carcinoma: a randomised, double-blind
phase III trial. Lancet 370(9605): 2103-2111, 2007.
6 Motzer RJ, Escudier B, Oudard S, Hutson TE, Porta C,
Bracarda S et al: RECORD-1 Study Group. Efficacy of
everolimus in advanced renal cell carcinoma: a double-blind,
randomised, placebo-controlled phase III trial. Lancet
372(9637): 449-456, 2008.
69
EXPRESSION OF INSULIN LIKE GROWTH
FACTORS (IGFS) IGF RECEPTORS GENES, AND
IGFBP-3 IN RENAL CANCER
Michał Białożyt1, Ryszard S.Braczkowski2, Marta Plato3,
Bogumiła Braczkowska4, Elżbieta Mazurek3
and Wiesław Duda1
1Prof.
Michałowski Memory Hospital Strzelecka ST. 9, 40073 Katowice;
2Medical University of Silesia in Katowice, Department of
Public Health Bytom, Piekarska ST. 18;
3Medical University of Silesia in Katowice, Department of
Molecular Biology, Sosnowiec Narcyzów St.1;
4Medical University of Silesia in Katowice, Department of
Epidemiology, 41-702 Katowice, Medyków ST.10, Poland
Insulin like growth factors I and II play important roles in
regulation of cell proliferation. They both have strong
promitotic and antiapoptotic effects. The actions of IGFs are
mediated by their activation of the specfic cell membrane
3218
receptor with tyrosine- kinase activity called IGF-I receptor
(IGF-IR). There is also another type of IGF receptor – IGF II
receptor (IGF-IIR). This receptor has no tyrosine-kinase
activity, and does not exert mitogenic and antiapoptotic action.
The activity of IGFs is regulated by their binding proteins.
Because of their mitogenic and antiapoptotic actions IGFs can
act on tumor growth. There are many epidemiological studies
showing that incresed circulating levels of IGFs are connected
with increased risk of several cancers. Not only circulating but
also locally produced IGFs, can act on tumor growth in a
paracrine-autocrine way. Production of IGFs, and presence of
IGF-IR has been observed in several cancer cells. IGF-I and
IGF-II have strong mitogenic and antiapoptopic effects on
normal and transformed kidney cells. This evidence suggests
that IGFs may promote the development and growth of renal
cancer. Renal cancer represents 3-4% of all human malignant
neoplasms. Recent studies suggest that the incidence of RCC
is increasing. About 2500 new cases of renal cancer per year
are registred in Poland. The most frequent among them is
renal cell carcinoma and among them 70-80% are clear cell
carcinoma.Radical nephrectomy is stil the main therapy of this
cancer. Materials and Methods: Patients qualified to radical
nephrectomy, aged 25-65, were included to the study. Patients
under 25, and over 60 were excluded. Production of IGFs
decreases with age, being highest in young people, and
strongly decreases in older patients, so this exclusion was used
in order to have an homogeneous. Patients qualified for
nephrectomy because of cancer were included to examined
group, and patients qualified for other reason were included
to the control group. All patients signed informed consent as
per institutional guidelines. After radical nephrectomy tumor
specimens were histopatologicaly evaluated. Only materials
obtained from patients with tumors qualified as ca
clarocellulare were subject to further examination. Finally 49
(age 40-65) patient were included into examined group, and
15 (age 32-63) patients to control group. Material from tumors
was subsequently evaluated according to Fuhrman malignancy
scale. Then specimens coming from tumors, health tissue of
tumor area and from kidney nephrectomized because of other
than cancer reasons were processed according to gene
expression. Expressions of genes for IGFs, IGF receptors and
IGFBP were evaluated by QRT-PCR (Taqman). Data analysis
was performed by means of standard statistical procedures
using STATISTICA 7.1. Results: IGF-I. Only in 19 samples
of tumor tissue and in 3 samples of tumor area, expression of
IGF-I gene was observed. The expression in tumor is inversly
correlated with tumor grade. IGF-II. Expression of IGF-II
gene was observed only in tumors with high Fuhrman grade
(3 and 4). Expression was observed also in 3 samples from
tumor area and in 5 samples from kidney nephretomized
because of non cancer reasons. IGF-IR. Expression of IGF-IR
gene was noted only in 2 samples from non cancer kidney and
only in 2 (of 16) samples from the tumor area of patients with
Abstracts of the 8th International Conference of Anticancer Research, 17-22 October 2008, Kos, Greece
cancer Fuhrman grade 1. Expression was observed in all other
cases. Expression in cancer tissue with Furhrman grade 2, 3
and 4 was higher (statistically significant) than in cancers with
Fuhman 1. IGF-IIR. Expression of IGF-IIR gene was present
in all samples from non cancer tissues. Expression was
observed only in five samples from a healthy area from kidney
with cancer (4 with Fuhrman 1 and 1 with Fuhrman 3).
Expression was observed in 3 tumors with Furhman 1. In all
other tumors no expression of IGF-IIR was observed. IGFBP3. IGFBP -3 gene expression was not present in all samples
from non tumor kidney, and was observed in all (excluding 2)
samples from cancer and cancer area.
70
MODULATION BY STIMULI TREATMENT OF CAM
EXPRESSION, PROLIFERATION AND APOPTOSIS
ASSOCIATED TO CERVIX TUMOR CELLS
Lorelei I. Brasoveanu1, Gabriela Anton2,
Mirela Hirt1 and Mihai Stoian2
1Center
of Immunology, Bucharest;
of Virology “Stefan S. Nicolau”, Bucharest,
Romania
2Institute
Proliferation of mammalian cells is tightly regulated by
multiple environmental influences, adhesion to extracellular
matrix (ECM), cell-cell adhesion and soluble factors
(cytokines or activators of kinases); loss of adhesion generally
results in complete G1 phase cell cycle arrest or apoptosis. In
contrast, formation and spread of tumors are closely associated
with decreased dependence on adhesion for growth and
survival. Cervical cancer represents the second malignancy as
frequency among women and is due by persistent infection
with high risk human papilloma viruses (hrHPV). Coexpression of certain cell adhesion molecules (CAMs) by
cervix tumor cells, which might be involved in cellular
interactions, changes in adhesivity and cellular mobility, could
influence the aggressiveness and metastatic potential of a
certain tumor. The present study focused on the potential
influence of treatment with several stimuli as cytokines or
drugs(doxorubicin) on proliferation by cell cycle phases and
apoptosis of cervix tumor cells using as models the HPV+
immortalized CaSKi and HeLa cell lines. In addition, the
effect of stimuli treatment on expression of several CAMs (Ecadherin, ICAM-1, MUC-1, VCAM-1) was analyzed.
Expression of cellular associated antigens was evaluated by
indirect immunofluorescence followed by flow cytometry
analysis. Percentages of apoptotic cells were detected by using
annexin V/FITC and propidium iodide (PI) double staining,
while progression through cell cycle phases was evaluated by
using PI staining. Data obtained showed that both the
expression of CAMs associated to the human cervix cell lines
taken under study and proliferation thorough cell cycle phases
or apoptosis were differentially influenced depending on the
stimuli used. All these data bring new information regarding
CAMs and proliferation profile associated to cervical tumor
cells and their possible involvement in regulating the
interaction between tumor cells and host immune system,
leading to new antitumor gene- and immuno-therapeutical
strategies.
71
ROLE OF PKC ISOFORMS IN THE FORMATION OF
METASTASIS
Walburgis Brenner, Isabelle Greber, Silke Beitz,
Justine Gudejko-Thiel, Frederik Roos, Joachim W. Thüroff
Department of Urology, University of Mainz, Germany
Background: The most common reason for death in cancer
patients is the development of metastases. The formation of
metastases depends on adhesion of tumor cells to the
endothelium, migration into the subendothelial tissue and
proliferation versus apoptosis in the secondary organ. These
processes depend on many intracellular signaling mechanisms,
which are partly regulated by protein kinase C (PKC). Different
PKC isoforms have various regulatory effects in processes of
metastases. We analysed the role of PKC isoforms in
progression and metastases of renal cancer. Materials and
Methods: The expression of all PKC isoforms was determined
in the human renal carcinoma cell line CCF-RC1 and in tissue
specimens of renal tumor and normal renal tissue. For
functional analyses, cells were treated with the PKC specific
inhibitors RO31-8220, GF109203X, GÖ6976 and Rottlerin.
Afterwards, cell adhesion on monolayer of human umbilical
vein endothelial cells (HUVECs) was investigated. The
migration was quantified using a microchemotaxis chamber
and proliferation was determined by BrdU incorporation. The
cellular expression and phosphorylation of beta-1 integrins and
the downstream target focal adhesion kinase (FAK) was
quantified by Western blot. The expression of beta-1 integrins
on the cell membrane was quantified by flow cytometry.
Results: With the exception of PKC lambda and theta, all PKC
isoforms were expressed in the renal carcinoma cell line CCFRC1, in renal tumor specimens and in normal renal tissue. Cell
adhesion and proliferation were unaffected by all PKC
inhibitors. Cell migration was reduced after treatment with
GF109203X or Rottlerin down to 69% or 29% of untreated
cells, respectively. The cellular expression and phosphorylation
of beta-1 integrins and FAK are also inhibited by Rottlerin, a
PKC delta specific inhibitor. In contrast, the expression of beta1 integrins on the cell membrane was most potently reduced
by RO31-8220 down to 8% of untreated cells. Conclusion:
Treatment with PKC inhibitor GF109203X demonstrated a
clear influence on cell migration. PKC delta is the only isoform
which is inhibited by GF109203X but not by RO31-8220 or
3219
ANTICANCER RESEARCH 28: 3157-3556 (2008)
GÖ6976. Since also Rottlerin, a strong PKC delta inhibitor,
reduces cell migration, it is feasible to assume that PKC delta
regulates migration, but not adhesion and proliferation of renal
carcinoma cells. On the other hand, the only PKC isoform
which is inhibited by RO31-8220, but not by one of the other
used PKC inhibitors, is PKC epsilon, this isoform seems to
regulate the membrane expression of beta-1 integrins, although
it has no influence on cell migration. Our results suggest that
the inhibition of cell migration depends on the regulation of the
activity of beta-1 integrins and its downstream target FAK.
72
THE USE OF MULTIPLEXED APTAMER
MEASUREMENTS OF PROTEINS FOR THE
DIAGNOSIS AND SCREENING OF LUNG CANCER
Edward N. Brody
SomaLogic, Inc., 2945 Wilderness Place, Boulder, Colorado,
80301, USA
Aptamers are single stranded nucleic acids that are evolved
through the SELEX procedure to bind tightly and specifically
to cognate proteins. Recent advances in the SELEX protocol
have led to a new kind of aptamer (called SLaptamers);
SLaptamers have very high affinity and specificity for cognate
proteins, and not others, due to very long dissociation rates
(>30 min) for the cognate protein. By coupling the new
protocol with the use of chemically modified bases in starting
libraries, SomaLogic has evolved new specific binding reagents
for multiplexed measurements of proteins in blood and other
biological fluids. Because one SLaptamer can give the same
specificity and sensitivity that requires two antibodies in the
ELISA format, SLaptamer arrays reduce cross-reactivity
between reagents in a multiplexed array; there is essentially no
limit on how many measurements can be made simultaneously.
SomaLogic now has the capacity to measure over 600 proteins
in blood. Using blood samples from smokers without cancer,
early-stage (I and II) lung cancer, and late stage (III) lung
cancer, measurement of serum proteins has detected
biomarkers which, within this study, can discriminate smokers
without cancer from both early and later stage lung cancer.
73
FUNCTIONAL FOOD SCIENCE AND SELENIUM IN
CANCER PREVENTION. A SHORT-TERM
INTERVENTION TRIAL WITH SELENIUMENRICHED FOOD: EFFECTS ON BIOAVAILABILITY
AND OXIDATIVE DEFENCE REGULATION
M. Rondanelli1, A. Opizzi1, A. Giacosa2 and G. Broich3
1Dipartimento
di Scienze Sanitarie Applicate e
Psicocomportamentali, Sezione di Nutrizione, Azienda di
Servizi alla Persona di Pavia, Università di Pavia;
3220
2Dipartimento
3IRCCS
di Gastroenterologia, Policlinico di Monza;
Istituto Ortopedico Galeazzi, Milan, Italy
Results from several but mostly small observational studies as
well as the secondary analysis of an intervention trial provide
support for a chemopreventive effect of selenium against
cancer, in particular prostate, lung, liver and colorectal
cancers. Several cancer preventive mechanisms have been
described and it is likely that selenium acts through multiple
pathways. In particular, the anti-oxidative and antiinflammatory effects mediated through activity of selenoenzymes are discussed, given the relevance of oxidative stress
and inflammation in these cancers. The effect seems to be
strongest in those individuals with the lowest Se status. There
is some evidence that Se may affect not only cancer risk but
also progression and metastasis. Current primary and
secondary prevention trials of Se are underway in the USA,
including the Selenium and Vitamin E Cancer Prevention Trial
(SELECT) relating to prostate cancer, although a large
European trial is still desirable given the likelihood of a
stronger effect in populations of lower Se status. If Se may
protect against cancer, an adequate intake of Se is desirable.
However, the level of intake in Europe and some parts of the
world is not adequate for full expression of protective
selenoproteins. Selenium levels in soil generally reflect its
presence in food and the Se levels in human populations.
Thus, food content is influenced by geographical location,
seasonal changes, protein content and food processing.
Periodic monitoring of Se levels in soil and food is necessary.
Diet is the major Se source and approximately 80% of dietary
Se is absorbed depending on the type of food consumed. Se
bioavailability varies according to the Se source and
nutritional status of the subject, being significantly higher for
organic forms of Se. Se supplements can be beneficial for
subjects living in regions with very low environmental levels
of Se. Several strategies have been followed: (1) employment
of Se-enriched fertilizers; (2) supplementation of farm animals
with Se; (3) consumption of multimicronutrient supplements
with Se. Nevertheless, detailed investigations of possible
interactions between Se supplements and other food
components and their influence on Se bioavailability are
needed. Given this background, in a 3 week randomised,
double-blind study, 7 healthy young women (age 25±2 years,
Body Mass Index 23±1) supplemented their usual diet with
Se-enriched food and 7 were supplied with a similar diet but
not supplemented with Se. Before and after 21 days of
supplementation serum Se level and erythrocyte glutathione
peroxidase (GPX) activity were evaluated. Serum Se levels
were significantly increased in the intervention group
(99.3±17.7 microgram/ml at time 0 and 114.1±28.6
microgram/ml at time +21 day, p<0.003 by Man-Withney
test), while the control group did not show any significant
difference (98.2±18.7 microgram/ml at time 0 and 100.2±23.4
Abstracts of the 8th International Conference of Anticancer Research, 17-22 October 2008, Kos, Greece
microgram/ml at time +21 day). Similar results were observed
when erythrocyte glutathione peroxidase (GPX) activity was
evaluated. The group supplemented with food enriched
Selenium showed a significant increase in GPX activity after
21 days of intervention (19.1±3.1 at time 0 and 22.1±4.0 at
time +21 day, p<0.01), while its value did not change in the
control group (20.2±2.8 at time 0 and 19.1±2.9 at time +21
day). Moreover, the follow-up of the supplemented subjects,
showed that ten days after the end of the supplementation,
both the serum selenium levels and GPX activity decreased
and did not differ significantly when compared with values at
time 0. In conclusion, this study demonstrated the
bioavailability of Selenium supplemented through fortified
food, thus proving that this approach could be helpful to
favour the optimal intake of Selenium in the population and
therefore to favour cancer prevention.
74
THE SERINE/THREONINE KINASE AKT
ACTIVATED BY FIBROBLAST GROWTH FACTOR
RECEPTORS FROM OESTROGEN-INDEPENDENT
BREAST CANCER CELLS REGULATES THE G2/M
CHEKPOINT
Edith Browaeys-Poly1, Arlette Lescuyer1,
Dominique Perdereau2, Jean Pierre Vilain1,
Anne-Françoise Burnol2 and Katia Cailliau-Maggio1
1Université
des Sciences et Technologies de Lille,
Laboratoire de Régulation des Signaux de Division, EA
4020, IFR 147, SN3, Villeneuve d’Ascq Cedex, France;
2Institut Cochin INSERM U567-CNRS UMR 8104Université René Descartes, Département Endocrinologie,
Métabolisme, Cancer 24 rue du Faubourg Saint-Jacques,
75674 Paris, France
Hormone-independent breast cancers proliferate in response
to "fibroblast growth factor". The oestrogen-independent
breast cancer cell line, MDA-MB-231, expresses fibroblast
growth factor receptors (FGFRs), and secretes FGF1 that
exerts an autocrine mitogenic effect. Analysis of FGFRs
signalling is rendered difficult by the concomitant expression
of several tyrosine kinase receptors and their shared
transduction cascades. To specifically investigate FGFR
signalling, we used a biological system the Xenopus oocyte, a
giant cell, devoid of endogenous FGFRs, that allows
microinjections and expression of various RNAs. This
paradigm offers a powerful experimental approaches to
question cascade transduction regulation in relation to the cell
cycle G2/M checkpoint. Oocytes expressing FGFRs from
MDA-MB-231 enter in M phase, after stimulation by
exogenous FGF1. This G2/M transition involves Rasdependent and Ras-independent cascades. The phospholipase
C gamma (PLCγ) and the serine/threonine kinase (Akt), two
enzymatic effectors activated by FGFRs, are involved in breast
cancer growth. In oocytes expressing FGFRs from MDA-MB231, inhibitors of PI3Kinase-Akt pathway (Wortmannin, LY
294002, N terminal SH2 domain of p85 PI3Kinase) and an
inhibitor of PLCγ (a mimetic peptide of the SH2 domain)
block FGF1-FGFR transduction. Activation of PLCγ is the
result of a direct binding to the FGFRs p(Y)766 site. A
PLCγ/calcium dependent chlorure current, measured by
electrophysiological techniques, starts 2 to 4 minutes after
FGF1 addition, and displays a duration of 20 minutes. A
kinetic analysis shows that PLCγ is phosphorylated on
tyrosine 5 minutes and on serine 30 minutes after FGFRs
activation. PLCγ immunoprecipitations show that the serine
phosphorylated PLCγ is associated with active phosphorylated
Akt (serine 473). A PLCγ mimetic peptide of the SH3 domain
disrupts the PLCγ-Akt interaction, the serine phosphorylation
of PLCγ and favours Akt binding to an other downstream
target: Chfr, a mitotic checkpoint protein deregulated in breast
cancers. Moreover, an acceleration of the G2/M transition
occurs when the Akt-PLCγ interaction is substituted for the
Akt-Chfr interaction. In conclusion, in the oestrogenindependent breast cancer line, MDA-MB-231, cell cycle
progression in the M phase induced by FGF receptors is
controlled by a time regulated interaction of activated Akt with
two partners PLCγ and Chfr.
75
INCREASED CYTOPLASMIC EXPRESSION OF THE
RECEPTOR (R) FOR INTERLEUKIN (IL)-23 IS A
MARKER FOR EPITHELIAL PROLIFERATION,
PROSTATIC INTRAEPITHELIAL NEOPLASIA (PIN),
AND PROSTATE CANCER (CAP)
Dieter Mitteregger1, Wolfgang Brozek1,2, Martin Susani3,
Igor Stancik1,4, Michael Marberger1,5 and Gero Kramer1,5
1The
Ludwig Boltzmann Society, Cluster Urology, Vienna;
of Pathophysiology and 3Clinical Institute for
Pathology, 5Medical University of Vienna;
4Department of Urology, Hospital Hietzing, Vienna, Austria
2Department
Benign prostatic hyperplasia (BPH) and prostate cancer (CaP)
were found to be related to chronic inflammation and cytokine
production. We previously reported the expression of the
inflammatory master cytokine IL-23 and its receptor in the
prostate. In this study we investigated the association between
IL-23R expression and prostatic carcinogenesis.
IL-23R was localized immunohistochemically in 28
prostate carcinoma sections and 14 carcinoma-surrounding
prostate sections from 20 patients, and 1 benign prostate
biopsy core. Tissue IL-23R expression was evaluated
particularly with regard to the sequential stages of prostate
carcinogenesis, ranging from normal glands to carcinoma in
situ and invasive cancer. IL-23R expression of 3 CaP cell lines
3221
ANTICANCER RESEARCH 28: 3157-3556 (2008)
(PC3, LNCaP, and DU145) was compared to the benign
prostate epithelial cell line PNT2 by flow cytometry, real-time
PCR, immunoflourescence, and immunocytochemistry. The
association between IL-23R and proliferating cell nuclear
antigen (PCNA) expression was analyzed by flow cytometry,
and growth effects of recombinant human (rh) IL-23 or a
neutralizing anti-IL-23 antibody were assessed in a
[3H]thymidine incorporation assay in PNT2 cells and all
malignant cell lines.
Two expression patterns of IL-23R were identified: Cells of
normal glands expressed IL-23R restricted to the luminal cell
membrane and in apocrine secretion structures. Glandular
sectors showing morphological signs of proliferation, atrophic
glands, PIN, and prostate cancer cells displayed a clearly
increased staining intensity as well as distribution of IL-23R
expression over the whole cytoplasm. In accordance, 3 CaP
cell lines displayed higher cytoplasmic IL-23R expression than
the benign prostate epithelial cell line. 18/28 carcinomatous
and 7/14 surrounding sections contained 30 (high grade) PIN
lesions. One was found in the benign prostate biopsy. 100%
of these were clearly marked by increased cytoplasmic IL-23R
staining, as were 26/28 (93%) of prostate carcinomas. 7/26
prostate carcinoma sections showed areas of partial loss of IL23R expression. In tissue sections, malignant and proliferating
cells were characterized by a shift of IL-23R localization from
the luminal membrane to the cytoplasm. Proliferation of 2/3
carcinoma cell lines and of PNT2 cells was significantly
inhibited by rhIL-23, and on the contrary increased by IL-23
immuno-depletion.
IL-23R expression level and pattern is a marker for
epithelial proliferation, prostatic carcinoma in situ and invasive
cancer. IL-23R signaling from the cellular surface might relay
growth inhibitory stimuli. In accordance, intracellular
translocation and hence accumulation of the receptor
withdraws proliferating and malignant cells from antiproliferative signals. Interfering with the (dysregulated) IL23R signaling pathway might therefore serve as a potential
molecular therapeutic target in prostate cancer.
76
EXPRESSION OF THE VITAMIN D SYSTEM AND
COX-2 IN HUMAN COLORECTAL CANCER TISSUE
Wolfgang Brozek1, Teresa Manhardt1, Stephan Kriwanek2,
Elisabeth Bonner3, Enikö Kállay1 and Heide S. Cross1
1Department
of Pathophysiology, Medical University of
Vienna;
Departments of 2Surgery and 3Pathology, Hospital
Rudolfstiftung, Vienna, Austria
We suggested that the balance between colonic synthesis and
degradation of 1,25-dihydroxyvitamin D3 (1,25-D3) may
determine concentrations of the active metabolite locally, and
3222
thus may be crucial for growth regulation of colorectal tissue
and prevention of tumor progression. Chronic inflammation as
indicated by over-expression of cyclooxygenase (COX)-2
often precedes and accompanies colorectal tumorigenesis. In
the present study we investigated differences in mRNA
expression related to the vitamin D system (CYP27B1, the
synthesizing hydroxylase; VDR, the vitamin D receptor; and
two splice variants of CYP24A1, the catabolic hydroxylase),
and to inflammation (COX-2). These were evaluated
statistically in relation to patient age, sex, tumor subsite and
grading.
113 patients with colorectal tumors and 10 diverticulitis
patients (controls) were randomly chosen for this study.
Colorectal tissues were analyzed by semiquantitative RT-PCR
and results were quantified by densitometry. Parametrical and
non-parametrical methods were used for statistical evaluation.
In a multivariate factor analytical model, the number of factors
was chosen based on a scree plot of eigenvalues from the
correlation matrix. Maximum likelihood and principal factor
methods were used for generation of the initial factor matrix,
which was rotated applying the varimax method. Expression
of the two splice variants of CYP24A1 was significantly
elevated in tumor tissues of all grades compared with that in
normal mucosa (p<0.001), though in moderately differentiated
low-grade tumors (G1/2) from the left colon (LC) of female
patients reduced levels of both splice variants occurred
(p<0.05). While expression of CYP27B1 mRNA was also
increased in tumors of all grades over that of normal mucosa,
statistical significance was only reached in differentiated G1/2
tumors primarily derived from male patients (p<0.05).
However, in female patients even high-grade (G3/4) tumors
exhibited increased CYP27B1 expression compared with G1/2
tumors as long as they were derived from LC (p<0.05), while
VDR expression was lowest there (p<0.05). Rectal tumor
tissue, especially from females (p<0.01), exhibited lowest
CYP27B1 gene expression (p<0.05) and a significant decrease
of VDR expression during progression towards higher grades
(p<0.05). Significant age-related expression changes were
observed in male right colon (RC) tumors: Those graded G1/2
displayed higher VDR levels with advanced age of patients
(p<0.05), whereas in those graded G3/4 this correlation was
inverse (p<0.05). Compared with females, tumor resections
from male patients expressed COX-2 mRNA at significantly
higher levels (p<0.05) especially in G1/2 tumors from LC
(p<0.01), even higher than in G3/4 tumors (p<0.05). Subsite
specificity of COX-2 expression was preserved in female
patients (p<0.01).
Factor analysis of this evaluation indicated four mutually
not exclusive patient or tumor types: i) old patients are female,
ii) correlated VDR, CYP27B1, COX-2, and, to a lesser extent,
wildtype CYP24 activity in tumor tissue, iii) an increase of
CYP24 splice variants in undifferentiated tumors, and iv) a
site-dependent increase in COX-2 expression in male patients.
Abstracts of the 8th International Conference of Anticancer Research, 17-22 October 2008, Kos, Greece
Collectively, our data confirm the concept of distinct
expression patterns of the vitamin D system and of a marker
for inflammation in colorectal tumors, which are not only
variable during progression, but are also depending on factors
like tumor subsite, gender and age.
77
MUTUAL ASSOCIATIONS BETWEEN AGE,
GENDER, ANATOMICAL LOCATION AND
MALIGNANCY OF COLORECTAL CANCERS –
RELATIONSHIP TO 1,25-DIHYDROXYVITAMIN D3
TISSUE CONCENTRATIONS
Wolfgang Brozek1, Thomas Nittke1, Stephan Kriwanek2,
Elisabeth Bonner3, Meinrad Peterlik1 and Heide S. Cross1
1Department
of Pathophysiology, Medical University of
Vienna, Waehringer Guertel 18-20, A-1090 Vienna;
Departments of 2Surgery and 3Pathology, Hospital
Rudolfstiftung, Juchgasse 25, A-1030 Vienna, Austria
We addressed the question whether age- and gender-related
incidence of colorectal cancer (CRC) at specific anatomical
subsites is associated with different degrees of malignancy by
analyzing data from 107 patients presenting with colorectal
tumors at a Vienna hospital in 2001/2002. Data were pooled
according to anatomical subsites, i.e. proximal or right colon
(cecum, ascending and transverse), distal or left colon
(descending and sigmoid), and rectum. Parametrical and nonparametrical statistical methods were used for multivariate
analysis of associations between age, sex, tumor site and
tumor grading.
On the average, female CRC patients were significantly
older than male patients (median age 73 vs. 63 yrs, p<0.05).
The more advanced age of female cancer patients compared
with males was primarily the result of age differences in
proximal colon tumor patients (p<0.05): Men presented at a
median age of 60, whereas the women’s median age was 75
years. Male patients with high grade (G3+G4) cancers were
significantly younger than those with low grade (G1+G2)
lesions (71 vs. 59 years, p<0.01). This was not observed in
women, whose median age, regardless whether they had low
or high grade cancers, was around 75 years. However, at age
70-80 years more than 80% of patients with a G3 and G4
cancer were female, and at age of ≥80 years, all high grade
cancer patients were women. By contrast, at age 60 years and
younger, the majority, i.e. 67%, of G3 and G4 patients were
men.
No association was found between age and a specific
anatomical sub-site in male high grade cancer patients,
whereas female patients with proximal colon tumors were
significantly older than women with rectal cancers (p<0.05).
Both men and women presented with high grade rectal cancers
at the early mean age of slightly above 60 years.
The observation that women are protected from highly
malignant cancers in the proximal colon for a long period of
time, might be due to enhanced anti-proliferative potential of
1,25-dihydroxyvitamin D3 (1,25-OH2D3). We found (Nittke et
al., manuscript in preparation) that under cancer-promoting
conditions, concentrations of 1,25-OH2D3 in human and
mouse colonic tissue were in general significantly higher in
females than in males, with values in the right colon exceeding
those at any other site of the colorectum.
78
EARLY MODIFICATION OF C-MYC, HA-RAS AND
P53 EXPRESSIONS BY N-METHYL-NNITROSOUREA
F. Budán1, Gy. Gőbel2, I. Szanyi2, M. Bauer2,
G. Nowrasteh1, Zs. Varga3, J. Cseh4, G. Horváth1,
I. Prantner1, P. Perjési5, I. Ember1 and Z. Gyöngyi1
1Institute
of Public Health, University Medical School of
Pécs, Szigeti str. 12, H-7643 Pécs;
2Institute of Otolaryngology Head and Neck Surgery, Faculty
of Medicine, University of Pécs, Munkácsy str. 2, H-7621
Pécs;
3Country Hospital of Baranya, Department of Oncology, H7623 Pécs;
4Szent György Country Hospital, Department of Oncology,
H-8000, Székesfehérvár;
5Institute of Pharmaceutical Chemistry, University of Pécs
School of Medicine, Rókus str. 2, H-7623 Pécs, Hungary
Methylnitrosourea (MNU) is a well known pluripotent directacting carcinogen. Formation of MNU following incubation
of various meats with additional nitrite under in vitro acidic
conditions is possible. It is possible that many species,
including humans, are exposed to carcinogenic MNU,
generated in their gastrointestinal tract. Previously, an animal
model was developed by our research group to investigate the
expression of three key onco/suppressor genes c-myc, Ha-ras
and p53 as early molecular epidemiological biomarkers of
carcinogenic exposure or carcinogenesis induced by DMBA
(dimethylbenz[α]anthracene). The aim of this study was to
investigate the early effect of MNU on the gene expression
levels, in order to compare the initializing role of these genes
in MNU/DMBA-induced carcinogenesis. MNU is a directacting carcinogen which spontaneously and rapidly degrades,
so any effect on the gene expression is observed within 24
hours. Our results show the maximum effect in vivo on the
gene expression at 12 hours after the MNU treatment; on the
other hand, 24 hours after the treatment, the elevated gene
expressions decreased in target organs (bone marrow, lung,
lymph nodes). Our results correspond to “long-term”
experiments of the carcinogenic effect of MNU in different
target organs. Our findings suggest that MNU has an impact
3223
ANTICANCER RESEARCH 28: 3157-3556 (2008)
on the expression of c-myc, Ha-ras and p53 genes in 12 hours,
especially in bone marrow. This corresponds to the fact the
DMBA has a delayed effect on the gene expression profile in
comparison to MNU because DMBA is a metabolically
activated carcinogen. Overexpression of these genes occurs as
an early biological effect to exposure to chemical carcinogens.
According to our results, these genes could indicate MNU
exposure and they could be the member of genes which take
part in MNU-induced tumorigenesis.
79
TRANSCRIPTIONAL REGULATOR, BRN-3B/POU4F2
AND ITS TARGET GENES IN CONTROLLING
GROWTH AND BEHAVIOUR OF BREAST CANCER
CELLS
Vishwanie Budhram-Mahadeo
Medical Molecular Biology Unit, UCL Institute of Child
Health, 30 Guilford St, London WC1N 1EH, UK
Regulation of gene expression controls all aspects of tumour
growth, progression and response to treatment. By identifying
the mechanisms that control such behaviour, it may be possible
to specifically target these tumours to reverse growth effects.
The Brn-3b transcription factor is an important regulator of
growth in breast cancers and neuroblastomas because it
controls expression of key target genes e.g. by transactivation
of cyclinD1/CDK4, Brn-3b increases proliferation and
anchorage independent growth in vitro, and tumour growth in
vivo. Reducing Brn-3b reverses these growth effects. Brn-3b
also confers drug resistance and may increase migratory
potential in these cells by its effects on other target genes e.g.
HSP 27, and gamma catenin. Brn-3b is highly expressed in
>60% breast cancers and ~75% of neuroblastomas so reducing
Brn-3b may be a useful for reversing its effects in such cancers.
We have identified mechanisms that control the expression of
Brn-3b in these cancer cells and that may be used to control its
expression, under different conditions.
80
PACLITAXEL/CARBOPLATINUM + CETUXIMAB AS
SECOND LINE CHEMOTHERAPY FOR PATIENTS
WITH RECURRENT OR METASTATIC HEAD AND
NECK CANCER
J. Büntzel1, R. Stritzel4, A. deVries2, R. Mücke5,
A. Garayev1, F. Bruns5 and O. Micke3
1Department
of Otolaryngology, Municipal Hospital
Nordhausen;
2Department of Radiotherapy, Landeskrankenhaus Feldkirch;
3Department of Radiotherapy, Franziskus Hospital Bielefeld;
4Pharmacy, Municipal Hospital Nordhausen;
5AKTE, Germany
3224
Background: In patients with platinum-resistant recurrent head
and neck cancer the anti-EGF-receptor antibody cetuximab
could be used as a treatment option. There are only limited
data about results of this therapeutic option. The objective of
this study was to evaluate therapeutic benefit of this indication.
Methods: Thirty-three patients with histological confirmed
recurrent head and neck cancer (30 male, 3 female, mean age
was 59±12 years) were included in this exploratory study. All
recurrences had occurred after chemotherapy with platinum
derivates. Thirty patients received radiation therapy during
primary treatment. No surgical or radiotherapeutic option in
recurrent disease was possible. Fifteen patients were suffering
from local or locoregional recurrences; 18 patients had distant
metastasis (17 pulmonary and 1 cerebral). The 2nd-line
therapy consisted of carboplatinum (200 mg/m2) + paclitaxel
(200 mg/m2) every three weeks (week 1, 4, and 7) and
additionally cetuximab, which was given with 400 mg/.
Results: A significant tumor response was observed in 19/33
patients (56%): 13 partial, 5 minor and one complete
remission were registered. The median survival time was 7
months (range 1-14), 10 patients are still alive. Median time
to progression was 5 months (range 2-8). Side-effects were
rash (21/33), fever (12/33) and typical chemotherapy-induced
toxicities such as neuropathy (10/33) and (pan)cytopenia
(7/33). All side-effects were moderate and easily managed.
Conclusion: The described combined chemoimmuntherapy
with cetuximab and paclitaxel + carboplatinum seems to offer
new strategies in 2nd- and 3rd-line chemotherapy for patients
with platinum-resistant head and neck cancer, potentially
overcoming primary platinum resistance.
81
MYC AND GASTRIC ADENOCARCINOMA
CARCINOGENESIS: STUDY IN INDIVIDUALS FROM
NORTHERN BRAZIL
Rommel Rodríguez Burbano
Laboratório de Citogenética Humana, Departamento de
Biologia, Instituto de Ciências Biológicas, Campus
Universitário do Guamá/Universidade Federal do Pará, Av.
Augusto Correa 01, CEP 66075-900, Belém, PA, Brazil
MYC is an oncogene that participates in cell cycle regulation,
cell growth arrest, cell adhesion, metabolism, ribosome
biogenesis, protein synthesis, and mitochondrial function.
MYC has been highlighted as a key element of several
carcinogenesis processes in humans. Many studies reported
an association between MYC deregulation and gastric cancer.
MYC deregulation is also observed in gastric preneoplasic
lesion. Thus, MYC may be involved in the beginning of
gastric carcinogenesis. Our results suggest that amplification
is the main mechanism of MYC deregulation in gastric
cancer. In this review, we focus on oncogene MYC
Abstracts of the 8th International Conference of Anticancer Research, 17-22 October 2008, Kos, Greece
deregulation in gastric adenocarcinoma carcinogenesis,
including its relation with Helicobacter pylori and clinical
applications.
82
CHANGES IN POST-TRANSLATIONAL
MODIFICATIONS (O-LINKED GLYCOSYLATION)
OF BREAST CANCER CAN AFFECT TUMOUR
BEHAVIOUR AND IMMUNE RECOGNITION
Sylvain Julien, Gianfranco Picco, Julia Colman,
Richard Beatson, Joyce Taylor-Papadimitriou
and Joy Burchell
Breast Cancer Biology Laboratory, Research Oncology,
King’s College London, 3rd Floor, Bermondsey Wing, Guy’s
Hospital, Great maze Pond, London SE1 9RT, UK
Glycosylation is one of the most frequent forms of post
translation modifications and is essential for many protein and
cellular functions. Changes in the composition of glycans
added to glycoproteins and glycolipids are common events in
malignancy and these changes can influence the course of the
disease. Dramatic alterations occur in glycans attached to
serine and threonines in mucin-type O-linkage and this has
been particularly studied in breast cancer. We have shown that
this can be attributed, at least in part, to changes in the
expression of key glycosyltransferases involved in the
synthesis of O-glycans.
Greater than 90% of breast carcinomas show changes in
the expression of their O-linked glycan and this raises the
hypothesis that altered O-linked glycans is advantageous for
breast cancer. That this is indeed the case is demonstrated by
our data that show that transplantable and spontaneous
murine mammary tumours expressing tumour-associated Olinked glycans grown significantly faster than the parental
control. Interestingly, we have also shown that when
monocyte derived dendritic cells are induced to mature and
migrate to the lymph nodes, the composition of their O-linked
glycans changes in a way that mirrors the change in breast
cancer.
Changes in glycans attached to the MUC1 glycoprotein, a
membrane mucin that carries a large amount of O-linked
sugars, alters how this glycoprotein interacts with lectin-like
receptors of the immune system. Indeed, certain tumourassociated glycoforms of MUC1 can bind to the macrophage
galactose receptor and be internalised into antigen presenting
cells, while a different tumour-associated glycoform can be
immunosuppressive.
Thus changes in O-linked glycosylation can affect the
behaviour of tumour cells and how tumours are recognised by
the immune system. Understanding the mechanisms that
induce these changes may eventually lead to identifying
targets for therapeutic interventions.
83
ROLE OF HEDGEHOG SIGNALING
IN PROSTATE CANCER
Aubie Shaw1,2, Jerry Gipp1,3 and Wade Bushman1,2,3
1Department of Urology, 2The McArdle Laboratory for
Cancer Research, 3Paul P. Carbone Comprehensive Cancer
Center, University of Wisconsin, Madison, WI, USA
The Hedgehog (Hh) pathway contributes to prostate cancer
growth and progression. Hh responses in tumors may arise
from autocrine signaling in cancer cells or paracrine
interactions with stromal cells. The evidence for autocrine and
paracrine signaling will be reviewed and we will then show
using a xenograft model that paracrine is sufficient to drive
tumor growth. Paracrine Hh signaling occurs in embryonic
prostate development and we used the developing prostate to
identify mesenchymal factors that are regulated by Hh
signaling. Using a xenograft model, we identified nine such
factors that are aberrantly expressed in the stroma of Hh overexpressing tumors. Five of these factors correlate with
Hedgehog signaling in human prostate cancer but not in
benign tissue. In tumors with reactive stroma, each of the nine
factors correlate with Hh signaling. We conclude that changes
in the prostate stroma associated with the presence of cancer
result in an altered transcriptional response to Hh ligands that
mimics the growth promoting actions of the fetal
mesenchyme.
84
DIAGNOSTIC AND PROGNOSTIC VALUE OF CD10
IN NEUROFIBROMAS, TYPE 1
NEUROFIBROMATOSIS AND MALIGNANT
PERIPHERAL NERVE SHEATH TUMORS
Daniela Cabibi
Department of Human Pathology, University of Palermo,
Italy
Neurofibromas are the most common benign peripheral
tumors. They arise from the cutaneous and more rarely from
the visceral, peripheral nerve sheath. In 90% of cases they are
solitary, sporadic, localized, superficial tumors which are
usually benign, with a very low probability of becoming
malignant. In other cases they may be diffuse or plexiform and
are frequently associated with Type 1 neurofibromatosis
(NF1), with a higher risk of malignant transformation.
NF1, also known as Von Recklinghausen’s disease or
peripheral neurofibromatosis, is the most common form of
neurofibromatosis, with an incidence of 1/2,500-3,000
newborns (about 1.5 million people affected throughout the
world) and is one of the most frequent, progressive genetic
diseases, with serious medical and social consequences. It is
3225
ANTICANCER RESEARCH 28: 3157-3556 (2008)
transmitted in an autosomic dominant manner in about 50%
of cases and is sporadic in the remaining cases due to new
mutations (small deletions or puntiform mutations) on the
germinal cells of paternal origin, involving the NF1 gene,
mapping on the long arm of the chromosome 17 (17q11.2).
The NF1 gene is an oncosuppressor gene with a probability
of mutations 10-100 times greater than the mean of the other
genes; it encodes neurofibromin, a protein that inhibits cell
proliferation by modulating mitogenic pathway signaling
through inactivation of p21-ras. Inactivating mutations of the
NF1 gene, with the production of truncated, inactive protein,
determines hyper-activation of p21 Ras and proliferation of
neoplastic cells.
The clinical presentation of NF1 is not always clear since
the onset of the clinical signs is age-dependent and there is a
strong variability both among patients and in the same patient
during different stages of the disease, with no relation between
genotype and phenotype. Due to the strong inter- and intrafamiliar phenotypic variability and its different clinical
courses, NF1 may sometimes require a long follow-up, lasting
for more than 4 years, before being diagnosed with certainty.
The most serious risk of NF1 is the malignant
transformation of neurofibromas (mainly diffuse and
plexiform neurofibromas) into malignant peripheral nerve
sheath tumors (MPNSTs). These represent about 5-10% of
soft tissue sarcomas and are extremely aggressive, with only
34% of patients reaching a 5-year survival rate. Histologically,
neurofibromas consist of Schwann cells, positive for S100
immunostain, together with perineural cells and fibroblasts,
which are CD34 positive, but S100 negative.
The S100 protein is the most useful marker in the diagnosis
of neurofibromas, but in some low-grade MPNSTs and in
more than 2/3 of high-grade MPNSTs, it is reduced or absent.
Nestin and PGP9.5 are more sensitive markers than S100,
although they are not specific since they are expressed in other
mesenchymal neoplasias (1, 2). As it is extremely important
to reach a correct, early diagnosis, several markers have been
investigated with the aim of distinguishing benign
neurofibromas from those with a greater malignant potential
and from MPNSTs. For example, malignant transformation of
neurofibromas has been associated with CDKN2A/p16
inactivation and loss of p16 expression. P16 is an
oncosuppressor gene involved in cell cycle regulation by
inhibiting CDK4, the cyclin D1-dependent kinase which
enhances the progression of the cell cycle by the
phosphorylation of the Retinoblastoma protein. (3, 4).
Furthermore, overexpression and mutations of P53 have been
reported in high grade MPNST, but late appearance of them
precludes their use as predictive markers of malignancy (3, 5).
Recently, the CD10 antigen, (also known as neutral
endopeptidase (NEP), neprilisine or CALLA Antigen), first
identified on the precursors of B and T lymphocytes, has been
found in several hematopoietic neoplasias (B and T acute
3226
lymphoblastic leukaemias, follicular lymphoma and Burkitt’s
lymphoma) and in some non-hematopoietic neoplasias, such
as renal cell carcinoma, endometrial stromal sarcoma,
melanoma, prostatic cancer and mesenchymal neoplasia (610) In many tumors, such as melanomas, gastric cancer and
breast cancer, a relation between CD10 expression and a
greater potential of neoplastic invasiveness has been observed,
probably related to the similarity of CD10 to the matrix
metalloproteinases (MMPs) in creating a micro-environment
facilitating neoplastic invasion (8, 11, 12). CD10 is normally
expressed in breast myoepithelial cells, in kidney proximal
tubules and glomerular cells, in the apical membranes of
intestinal gland epithelium, in stromal cells of the
endometrium and bone marrow, in biliary canalicules of the
liver, in mesenchymal dermal cells (fibroblasts and
dendrocytes) and, noteworthy, in the normal myelin sheath of
peripheral nerves (13). Nevertheless, CD10 expression in
lesions arising from the peripheral nerve sheath has still not
been sufficiently investigated.
We retrospectively performed an immunohistochemical
assay, by using CD10, S100 and CD34 antibodies, on
formalin-fixed, paraffin-embedded seriated sections from 38
neoplastic lesions, 18 of which (Group A) consisted of
localized, sporadic, solitary neurofibromas, and 20 (Group B)
consisting of MPNSTs and of neurofibromas with a higher
risk of malignant transformation (myxoid, plexiform, diffuse
with atypias). In group B, 7 patients had a well-known history
of NF1, 3 had a relapse history, 2 had undergone the surgical
excision of more than one neurofibroma and 3 were affected
by MPNSTs (one of whom developed pulmonary metastases a
year later).
The group A lesions were smaller than the Group B lesions:
group A mean diameter=0.84 cm (range 0.3-2 cm), 15/18
(83%) had a diameter <1 cm; group B mean diameter=3.8 cm
(range 0.3-17 cm), 14/20 (70%) had diameter >1 cm (p<0.05,
Mann-Whitney U-test).
CD10 expression was significantly different in the two
groups: In group A 13/18 cases (73%) stained negatively and
only a weak, focal CD10 positivity was present in 5/18 (27%);
in group B, 19/20 cases (95%) stained positively for CD10;
(p<0.0001, paired t-test).
On the contrary, the immunohistochemical assay performed
with S100 and CD34 showed no statistically significant
difference between the two groups: S100 stained positively in
all of the group A cases and in 18/20 cases (90%) of the group
B cases (the two negative ones consisting of 2/3 MPNSTs).
CD34 stained positively in 17/18 (94%) of group A cases and
in 15/20 cases (75%) of group B cases.
It is interesting to note that in a patient who underwent
surgical removal of two neurofibromas, both were CD10
positive and in one of them CD10 highlighted just the
peripheral plexiform areas that were not well evident on
haematoxylin-eosin staining.
Abstracts of the 8th International Conference of Anticancer Research, 17-22 October 2008, Kos, Greece
Furthermore, in another patient with primary cutaneous
MPNST, there was positive staining both for S100 and CD10,
nevertheless, pulmonary metastases observed one year later
lacked S100 expression but stained positively with CD10, just
like the primary tumor, suggesting for CD10 may be useful in
the diagnosis of metastatic MPNSTs, mainly when S100
positivity has been lost.
In conclusion, CD10 proved to be able to distinguish Group
A lesions from Group B lesions, with 95% sensitivity and 72%
specificity; it proved negative in benign, localized
neurofibromas and positive in higher risk lesions, in NF1 cases,
in recurrent neurofibromas (as early as at the first removal), in
MPNST and their metastases (including those negative for
S100 and CD34). Moreover CD10-positive immunostaining
was related to the size of the lesions and was able to highlight
histological areas (myxoid, plexiform, atypical areas) with
features suggesting a greater risk of malignant potential. As
recently evidenced in melanoma progression, these
observations could be related to the synergetic increase of NEP
gene transcription (the gene encoding CD10 antigen), together
with the co-expression of many genes involved in cell
proliferation and cancerogenetic mechanisms, such as the
MAP-kinase pathway, apopotosis and WNT signaling
inhibition, hyper-expression of the proliferation marker Ki 67
and so on (8, 14). It is not clear, however, if CD10 hyperexpression could have a causal role in these cancerogenetic
events or if it represents only an epiphenomenon of them, or if
the synergetic gene over-expression observed in melanomas
also applies to neurofibromas. In any case, whatever the
mechanism underlying CD10 over-expression, its diagnostic
and predictive value cannot be ignored.
Thus, although not specific because it is expressed in other
neoplasias of different origin, prompt assessment of CD10 at
the first resection, together with S100, might help in the
histological diagnosis of NF1 and might allow a more correct
management of higher-risk CD10-positive cases, with a followup aimed at limiting any serious complications of NF1 by early
identification of any eventual malignant transformation.
1 Campbell LK, Thomas JR and Lamps LW: Protein gene
product 9.5 (PGP 9.5) is not a specific marker of neural and
nerve sheath tumors: an immunohistochemical study of 95
mesenchymal neoplasms. Mod Pathol 16(10): 963-969,
2003.
2 Shimada S, Tsuzuki T and Kuroda M: Nestin expression as
a new marker in malignant peripheral nerve sheath tumors.
Pathol Int 57(2): 60-67, 2007.
3 Zhou H, Coffin CM and Perkins SL: Malignant peripheral
nerve sheath tumor: a comparison of grade, immunophenotype, and cell cycle/growth activation marker
expression in sporadic and neurofibromatosis 1-related
lesions. Am J Surg Pathol 27(10): 1337-1345, 2003.
4 Nielsen GP and Stemmer-Rachamimov AO: Malignant
transformation of neurofibromas in neurofibromatosis 1 is
associated with CDKN2A/p16 inactivation. Am J Pathol
155(6): 1879-1884, 1999.
5 Leroy K, Dumas V and Martin-Garcia N: Malignant
peripheral nerve sheath tumors associated with
neurofibromatosis type 1: a clinicopathologic and molecular
study of 17 patients. Arch Dermatol 137(7): 908-913, 2001.
6 Chu P and Arber DA: Paraffin-section detection of CD10 in
505 nonhematopoietic neoplasms. Frequent expression in
renal cell carcinoma and endometrial stromal sarcoma. Am
J Clin Pathol, 2000.
7 Dall’Era MA, True LD and Siegel AF: Differential
expression of CD10 in prostate cancer and its clinical
implication. BMC Urology 7: 3, 2007.
8 Nurija B, Berit S and Rastko Golouh: CD10 protein
expression in tumor and stromal cells of malignant
melanoma is associated with tumor progression. Modern
Pathology 17: 1251-1258, 2004.
9 Kanitakis J, Bourchany D and Claudy A: Expression of the
CD10 antigen (neutral endopeptidase) by mesenchymal
tumors of the skin. Anticancer Res 20: 35-39, 2000.
10 Chu PG, Arber DA, Weiss LM and Chang KL: Utility of
CD10 in distinguishing between endometrial stromal
sarcoma and uterine smooth muscle tumors: an immunohistochemical comparison of 34 cases. Mod Pathol 14:
465-471, 2001.
11 Iwaya K, Ogawa H and Izumi M: Stromal expression of
CD10 in invasive breast carcinoma: a new predictor of
clinical outcome. Virchows Arch 440: 589-593, 2002.
12 Huang W-B, Zhou X-J and Chen J-Y: CD10-positive
stromal cells in gastric carcinoma: correlation with invasion
and metastasis. Jpn J Clin Oncol 35: 245-250, 2005.
13 Cadoni A, Mancardi GL and Zaccheo D: Expression of
common acute lymphoblastic leukemia antigen (CD 10) by
myelinated fibers of the peripheral nervous system. J
Neuroimmunol 45(1-2): 61-66, 1993.
14 Velazquez EF, Yancovitz M, Pavlick A et al: Clinical
relevance of neutral endopeptidase (NEP/CD10) in
melanoma. J Translat Med 5: 2, 2007.
85
TARGETING THE MOLECULAR CDC37 INHIBITS
MULTIPLE PROTEIN KINASES AND INHIBITS
GROWTH OF PROSTATE CARCINOMA
Phillip J. Gray, JR, Thomas Prince, Jinrong Cheng,
Mary Ann Stevenson and Stuart K. Calderwood
Department of Radiation Oncology, Beth Israel Deaconess
Medical Center, Harvard Medical School, Boston, MA
02215, USA
Members of the ninety kilodalton heat shock protein (HSP90)
family are known to bind and stabilize intermediates in a wide
variety of cell signaling pathways and contribute to their
3227
ANTICANCER RESEARCH 28: 3157-3556 (2008)
dysregulation in cancer. An important intracellular co-factor
for HSP90 is Cdc37, a protein with a broad role in fostering
the activities of protein kinases. By targeting Cdc37 using
RNA interference approaches, we have shown that that loss of
Cdc37 function induces irreversible growth arrest in androgen
receptor positive and negative prostate carcinoma cells and
sensitizes such cells to chemotherapeutic drugs. In contrast to
HSP90-directed agents, Cdc37 targeting appears to affect
cancer cells through a distinct mechanism, and does not
significantly deplete the intracellular levels of most known
HSP90 client proteins. Instead, Cdc37 depletion inhibits
cellular kinase activity and flux through growth promoting
signal transduction cascades. We show that loss of Cdc37
leads to reduced activity of the Erk, Akt, mTOR and
androgen-induced pathways. Cdc37 inactivation proved to be
more effective in inhibiting prostate carcinoma growth than
individual tyrosine kinases, indicating the power of multitarget therapy through Cdc37 inhibition. We have also
discovered synergistic interactions between Cdc37 inactivation
and the HSP90-inhibitory anticancer drug 17AAG. These
interactions involve enhanced degradation of proteins essential
for growth and inhibition of 17AAG-induced expression of the
anti-apoptotic heat shock protein 70. Thus Cdc37 is essential
for maintaining prostate tumor cell growth and may represent
a novel target in the search for multi-targeted therapies based
on the HSP90 chaperone system.
(HRG) (patients with domitialiry O2-therapy n=2 patients or
patients with previous lobectomy n=2). To evaluate results and
complications, the SIR reporting standards for image-guided
tumour ablation were followed. Results: 5 complications were
detected (23% of the procediments) Only 2 patients in the
NRG presented complications (11.7%) meanwhile
complications were appreciated in 3 patients of the HRG
(75%). Main complications were: NRG 1 case with dyspnea
+ pleural effussion, 1 case with secondary stroke; HRG 2
pneumothorax, both needing drainage and 1 infection.
Treatment was completed in all the cases and no deaths were
related with the procedure. A initial complete ablation was
obtained in 21 of the 21 tumours (100%). Mean follow-up is
17 months (range 4-31). 85% of the patients are alive and 69%
free of disease. 1 patients died due to tumour progression, and
a patient died due to ARI. Conclusion: RF is an efficient
method to treat patients with “non-surgical” lung tumours
(both primary or secondary lesions). The procedure is, in
general, well tolerated with a low incidence of severe
complications. Good results in terms of local tumour control
were received in our short-term follow up-evaluation.
86
SAFETY AND EFFICACY OF RADIOFREQUENCY
(RF) IN LUNG TUMOURS
1Department
Nahúm Calvo Malvar1, Lidón Millá Rallo1,
Juan Escobar Ulloa1, Elena Rebenaque Figueras1
and Alfredo Millá-Santos2
1CRC
Corporación Sanitaria, Hospital Universitario San
Joan de Reus. C/President Companys s/n. Reus (Tarragona)
C.P 43201;
2Servicio de Oncología Clínica, Hospital Nuestra Señora del
Remei Barcelona, C.P. 08024, Spain
Purpose: To determine the feasibility and safety of treating 21
lung tumours with a multiple-tine electrode switchinggenerator RF ablation system (Le Veen, Boston Scientifics).
Materials and Methods: Between January 2006 and July 2008,
17 patients (mean age 68 years, range 50-80) with 21
pulmonary lesions (13 primitive non-small cell lung cancers
and 8 metastases from corectal cancer) underwent the ablation
procedure. All the patients had absolute contraindications to
surgery. The method was performed under CT scan guidance
using a expansible Le Veen needle electrode. To evaluate
safety, 2 different groups were defined: i) “Normal” risk
(NRG) (n=17 lesions) with adequate respiratory reserve (n=9)
or insuficient respiratory reserve (n=8). ii) High risk group
3228
87
PRO AND CONS FOR LYMPH NODE DISSECTION
IN OVARIAN CANCER
Oumar Camara1 and Jalid Sehouli2
Obstetrics and Gynecology; Friedrich-SchillerUniversity,
2Charité, Department of Gynecology and Obstetrics, Charité,
University Medicine of Berlin, Germany
Up-front maximal surgical effort at cytoreduction with the
goal of no residual disease is necessary for a better outcome.
Systematic resection of para-aortic and pelvic lymph nodes is
now over decades part of the surgical procedure. In early stage
ovarian cancer the goal of the lymphadenectomy as a key part
of surgical staging is accepted. Controversies remain on the
value of systematic lymphadenectomy in patients with
advanced ovarian cancer. The effect of lymph node dissection
on progression free survival and overall survival in patients
with advanced ovarian cancer is unknown. In patients with
residual tumor, there is no indication for systematic lymph
node dissection. To date there is no randomised study
comparing systematic lymphadenectomy versus no
lymphadenectomy in patients with no residual tumor. The
Lymphadenectomy In Ovarian Neoplasms (LION) study
address this Question and will be discussed. Furthermore, the
techniques (e.g. sampling and systematic lymh node
dissection), the indication as well as the pros and cons of
pelvic and paraaortal lymph node dissection in early and
advanced stage based on the available evidence, will be
discussed.
Abstracts of the 8th International Conference of Anticancer Research, 17-22 October 2008, Kos, Greece
88
EXTRACELLULAR RELEASE OF HSP60 FROM
TUMOR CELLS
F. Cappello1, A.M. Merendino1, F. Bucchieri1, A. Ribbene1,
S. David1, C. Campanella1, G. Burgio2, D. Corona2, M.
Renis3, G. Li Volti3, E. Conway de Macario4, A.J.L.
Macario4 and G. Zummo1
1Dipartimento di Medicina Sperimentale, Università degli
Studi di Palermo;
2Dipartimento di Biochimica, Università degli Studi di
Palermo;
3Dipartimento di Chimica Biologica, Chimica Medica e
Biologia Molecolare, Università di Catania, Italy;
4University of Maryland Biotechnology Institute, Centre of
Marine Biotechnology, Baltimore, MD, USA
2 Calderwood SK et al: Trends Bioch Sci 31: 164-172, 2006.
3 Cappello F et al: Cancer Biol Ther 7, in press, 2008.
4 Johnstone RM. Blood Cells Mol Dis 34: 214-219, 2005.
5 Macario AJ and Conway de Macario E. FEBS Lett. 581:
3681-3688, 2007.
89
TWO ISOELECTRIC VARIANTS OF HSP10 ARE
DOWN-REGULATED BY CIGARETTE SMOKE
EXPOSURE IN AIRWAY CELLS: A PROTEOMIC
STUDY
G. La Rocca1, R. Anzalone1, S. Corrao1, F. Magno1,
T. Loria1, M. Lo Iacono1, F. Farina1, A.M. Timperio2,
L. Zolla2, E. Conway de Macario3, A.J.L. Macario3,
G. Zummo1 and F. Cappello1
1Dipartimento
Heat-shock proteins (Hsps) are often overexpressed during
carcinogenesis and recent studies show that when expressed
extracellularly, Hsps can mediate anticancer immune responses
(1-3). However, the mechanisms by which Hsps are released
from tumor cells into the extracellular space are not fully
understood. We are investigating the pathways involved in Hsps
release, including the Golgi-mediated and the exosomal and
lipid-rafts pathways. For the present study, we examined NCIH292 (mucoepidermoid carcinoma) and 16HBE (normal
bronchial epithelial) cells. Both cell lines show normally low
levels of apoptosis (annexin V assessment), while NCI-H292
cells present higher levels of Hsp60 and Hsp70 than 16HBE
cells. Cells were therefore treated for 1 h with secretion
inhibitors: Brefeldin A (BFA, 1 μg/ml), dimethylamiloride
(DMA, 5 nM) or methylcyclodextrin (MCB, 1 mM).
Extracellular supernatants from 50-80×106 treated or untreated
control tumor cells were collected, dialyzed, lyophilized and
resuspended in RIPA buffer; whole cell lysates were used as
controls. Exosomes were separated from the surnatants by
ultracentrifugation (2 h at 110,000×g). Released exosomes
were quantified by measuring the activity of acetylcholine
esterase. Hsp expressions in various cellular compartments
were detected by Western blotting with anti-Hsp60 and antiHsp70 monoclonal antibodies. We found Hsp60 and Hsp70
[the latter is considered an exosomal marker (4)] in the
exosomal fractions of the NCI-H292 cells, but only Hsp70 was
detected in the 16HBE-derived exosomes. DMA and MCB but
not BFA inhibited Hsp60 secretion (p<0.05), indicating that
the preferential secretory route for this protein is through
exosomes. Elucidation of the secretory pathways for Hsp60 and
other Hsps is fundamental in understanding their role in
antitumor immune responses and in tumor survival, as well as
spread mechanisms that may represent a novel target for
treatment (5).
1 Ciocca DR and Calderwood SK: Cell Stress Chaper 10: 86103, 2005.
di Medicina Sperimentale, Università di
Palermo;
2Departimento di Scienze Ambientali, Università della
Tuscia, Viterbo, Italy;
3Center of Marine Biotechnology, University of Maryland
Biotechnology Institute, Baltimore, MD, USA
Hsp10 expression has been investigated in several cancer
models, with contrasting results. It is homologue to early
pregnancy factor (EPF), a secreted protein which modulates
the immune response of the mother versus the fetus. The
impact of cigarette smoke (a major risk factor for lung
diseases) on Hsp10 expression by airway cells has not been
characterized yet.
In this work we studied the effects of non-lethal doses of
cigarette smoke extract (CSE) on the expression of Hsp60 and
Hsp10 in human lung cells. Proteomics was carried out by 2DIPG, silver stain, Western blotting, and mass-spectrometry
(MS). Database searches and chaperonomics were used to
identify the proteins and genes of interest.
Following CSE cell exposure as compared with unstressed
cells, significant variations in Hsp10 did occur, in both lung
fibroblasts and epithelial cells. In unstressed cells, three
isoelectric variants of Hsp10 were found, which have not been
reported for any other system, yet. After CSE exposure, only
the most basic isoform was still expressed. To characterize the
three variants found in unstressed cells, we performed MS
analyses. Digested spots were analysed by nano-RP-HPLCESI-MS/MS to determine the fragments’ amino acid
sequences. Database searches showed that the most basic
variant was human Hsp10 with 56% sequence coverage, and
the other two isoforms had the same amino acid sequence,
even if with a lower sequence coverage.
The data thus far indicate probably that Hsp10 protein
variants are due to post-translational modifications. We recently
showed the in vivo correlation between lung cancer
development and down-regulation of Hsp10 expression (1), and
3229
ANTICANCER RESEARCH 28: 3157-3556 (2008)
proposed a model for the antitumoral role for Hsp10, together
with Hsp60 (2). The precise role of Hsp10 in carcinogenesis is
still unclear. The immunosuppressive activity of EPF/Hsp10
points towards a tumor-promoting role, mediating immune
evasion and apoptosis resistance. On the other hand, the in vivo
and in vitro evidences obtained in human lung models suggest
that different Hsp10 isoforms may mediate diverse processes
and should be differentially regulated.
1 Cappello et al: Cancer, 2006.
2 Cappello et al: Cancer Biol Ther, 2007.
90
HUMAN ZN(II) DEPENDENT HDACs: STRUCTURES,
CATALYTIC ACTIVITY AND INHIBITION
High expression in the primary tumor of receptors in the
EGFR-family is most often also accompanied by a similar
high expression in corresponding metastases. This makes
these receptors interesting as putative targets for targeted
radionuclide therapy of metastases and disseminated tumor
cells. The expression of all four family members, EGFR,
HER2, HER3 and HER4 is reviewed in this chapter. Studies
on breast, urinary bladder, colorectal, prostate, head and neck,
esophageal and glioma tumors are described and possible
strategies for targeted radionuclide therapy are discussed.
Quantification of receptor expression and the possible
influence of genomic stability on the expression are also
discussed.
Matthew J. Bottomley, Paola Lo Surdo, Philip Jones,
Christian Steinkühler, Paola Gallinari and Andrea Carfí
92
EFFECTS OF LOW DOSE-RATE RADIATION ON
CELLULAR SURVIVAL
IRBM P. Angeletti, Viale Pontina Km 30,600, I-00040,
Pomezia, Rome, Italy
J. Carlsson
An intense interest in histone deacetylases (HDACs) has
grown in the last few years following discoveries that aberrant
epigenetics associated with cancer involve the overrecruitment of HDACs, and that over-expression of HDACs is
linked with various cancers. Consequently, HDACs have
become appealing targets for the development of anticancer
agents. One compound, Vorinostat (suberoylanilide
hydroxamic acid, SAHA), has been recently approved for the
treatment of cutaneous T-cell lymphomas. More recently,
HDACs inhibitors have been shown to be effective both in
vitro and in vivo as anti-inflammatory agents and in the
treatment of cardiac hypertrophy.
Here we describe the structure of the catalytic domain of a
class IIa histone deacetylase, human HDAC4, in both
inhibitor-bound and inhibitor-free states and compare it with a
class I enzyme, HDAC8. The structures and accompanying
biochemical data explain the intrinsic low enzymatic activity
of class IIa HDACs towards acetylated lysines and provide the
molecular basis for the design of class-specific HDAC
inhibitors. Finally, the structure of the HDAC4 catalytic
domain reveals a conformationally flexible structural zincbinding domain conserved only in the class IIa HDACs.
Biochemical and functional data suggest that this domain is
critical for HDAC4 function and for its association with
partner proteins in repressor complexes.
91
EGFR-FAMILY EXPRESSION AND IMPLICATIONS
FOR TARGETED RADIONUCLIDE THERAPY
J. Carlsson
Biomedical Radiation Sciences, Uppsala University, SE75185, Uppsala, Sweden
3230
Biomedical Radiation Sciences, Uppsala University, SE75185, Uppsala, Sweden
The experience of external radiotherapy can only to a limited
extent be used to understand therapeutic effects of
radionuclide therapy. A major difference is that the dose-rate
at radionuclide therapy is at least two orders of magnitude
lower. Part of this chapter deals with estimates of the
necessary dose-rate and exposure time in combination in
order to deliver therapeutic effects to tumour cells. It is
proposed that combinations of about 0.1-0.2 Gy/h for several
days or about 1 Gy/h for at least 1 day is necessary. Such
dose-rates can be achieved with the help of cross fire
radiation. Effects of radionuclide therapy in terms of
apoptosis, cell-cycle blocks and hyperradiosensitivity are
also discussed.
93
ROLE OF LESION BYPASS BY DNA POLYMERASE
ETA, AND PIK KINASE SIGNALLING, IN THE
RESPONSE OF HUMAN CELLS TO PLATINUMBASED CHEMOTHERAPEUTIC AGENTS
Séverine Cruet-Hennequart, Sangamitra Villalan, Elaine
O’Meara and Michael P. Carty
DNA Damage Response Laboratory, Biochemistry
Department, School of Natural Sciences, National University
of Ireland Galway, Galway, Ireland
The widely-used cancer chemotherapeutic agents cisplatin,
oxaliplatin and carboplatin, act primarily by induction of
DNA damage, including monoadducts, intrastrand and
interstrand crosslinks, leading to inhibition of DNA
replication and ultimately to cell death. Targeting pathways
Abstracts of the 8th International Conference of Anticancer Research, 17-22 October 2008, Kos, Greece
used by cells to overcome DNA damage is one approach to
increasing the effectiveness of these anticancer agents. The
capacity of cells to carry out replication of damaged DNA,
using the process of translesion synthesis (TLS), is one
mechanism by which cells can tolerate DNA damage. The
DNA damage response (DDR) activated by damageinduced replication arrest plays a key role in determining
the response of human cells to DNA damage. Activation of
the DDR is mediated in part by phosphorylation of
downstream substrates by the phosphatidylinositol-3kinase-related protein kinases (PIKKs), ATM, ATR and
DNA-PK.
The relationship between TLS and PIKK signalling in the
response of human cell lines to cisplatin and carboplatin
was investigated. Human XP30RO fibroblasts that lack the
TLS enzyme DNA polymerase η (polη) as a result of a
mutation in the POLH gene are more sensitive than normal
GM00637 fibroblasts to cisplatin, oxaliplatin and
carboplatin. To characterise the influence of cell cycle phase
on the outcome of exposure to platinum-based drugs, polηdeficient XP30RO cells were synchronised in mitosis by
treatment with nocodazole, and released for varying periods
to generate cell populations in M-, G1-, or S-phase. Cells in
each phase were treated with equitoxic doses of cisplatin
(1.66 μM) or carboplatin (50 μM). In XP30RO cells, drug
treatment led to delayed S-phase progression, and arrest in
the G2 phase of the cell cycle. Resumption of cell cycle
progression was delayed in cells treated with carboplatin
compared to cisplatin-treated cells. In polη-deficient cells,
platinum-induced DNA damage led to increased activation
of the PIK kinases ATR, ATM and DNA-PK as
demonstrated by increased phosphorylation of a number of
protein substrates including chk1, nbs1 and replication
protein A (RPA2). These phosphorylation events were
mediated by ATR, ATM and DNA-PK respectively, as
determined using a series of small molecule inhibitors of
individual PIK kinases. To define the sequence of events in
PIK kinase activation, the kinetics of phosphorylation of
chk1 on serine 317, and of RPA2 on serines 4/8 were
examined by Western blotting, following DNA damage by
cisplatin and carboplatin. ATR-mediated phosphorylation of
chk1 on serine 317 preceded DNA-PK-mediated RPA2
phosphorylation on serines 4/8 in all cases. The kinetics of
RPA2 phosphorylation on serines 4/8 differed following
treatment of XP30RO cells with equitoxic doses of cisplatin
and carboplatin. Comparison of RPA2 phosphorylation in
response to the two platinum agents with their effects on
cell
cycle
progression
indicated
that
RPA2
hyperphosphorylation on serines 4/8 correlated with
resumption of cell cycle progression after drug-induced
replication arrest in polη-deficient cells. Elucidation of the
precise sequence of events that occur in response to DNA
damage by cisplatin and carboplatin may help identify key
DDR pathways that can be targeted to potentiate the effects
of these cancer chemotherapeutic drugs.
94
IMBALANCE BETWEEN SYNTHETIC LOAD AND
PROTEASOMAL CAPACITY SENSITIZES NORMAL
AND MALIGNANT PLASMA CELLS TO
PROTEASOME INHIBITORS
Paolo Cascio1, Giada Bianchi2, Laura Oliva3, Fulvia Cerruti1,
Roberto Sitia3 and Simone Cenci3
1Department
of Morphophysiology, School of Veterinary
Medicine, University of Turin, via L. da Vinci 44, 10095
Grugliasco (TO);
2Department of Biology and Technology, DiBiT, San
Raffaele Scientific Institute, Via Olgettina 58, 20132 Milano,
Italy;
3Department of Medical Oncology, Dana-Farber Cancer
Institute, Harvard Medical School, 44 Binney Street, Boston,
MA 02115, USA
Introduction: Multiple Myeloma (MM) is an aggressive,
debilitating and still incurable hematological malignancy,
arising from clonal expansion of plasma cells at multiple
sites in the bone marrow. Recently, MM proved sensitive to
a new class of drugs, proteasome inhibitors (PI), but the
mechanisms of action and bases of individual susceptibility
remain still largely unclear. Obviously, their clarification
would improve the clinical application of PI, and open
novel therapeutic strategies. Recent work linked PI
sensitivity to protein synthesis and proteasome activity (13), raising the question whether different levels of
proteasome expression and workload underlie PI sensitivity
in normal and transformed plasma cells. Results: To test
this hypothesis we first adopted different models of mouse
B cell activation in vivo, and observed that following
polyclonal activation, proteasome activity decreases even
more than previously reported in vitro. This decrease is
linked to enhanced apoptosis after treatment with the firstin-class anti-myeloma proteasome inhibitor bortezomib
(PS-341, Velcade™). Accordingly, in vivo treatment with
bortezomib decreases Ab titres in T-dependent and independent mouse immunization models, therefore
providing the rationale for limiting the activity of Absecreting cells in vivo by impacting proteasome function.
Next, to asses whether the exquisite sensitivity of certain
MM cells (MMC) to PI is also due to an imbalance
between limited proteasome capacity and high workload
due to intense protein production, we directly assessed
protein degradation by proteasomes using radioactive
metabolic labeling and pulse-chase assays in two human
MM cell lines – U266 and MM.1S – that display a
differential apoptotic sensitivity to bortezomib. These two
3231
ANTICANCER RESEARCH 28: 3157-3556 (2008)
lines reveal a striking direct correlation between the
degradative flux of proteins through proteasomes and the
apoptotic response to bortezomib. In particular, proteasomal
degradation within 30 minutes of chase is almost 20 times
higher in MM.1S, the far more sensitive line, indicating
that these cells are intensively degrading short-lived protein
species through the ubiquitin-proteasome pathway.
Paradoxically, cell extracts from MM.1S cells show 2.5
times lower proteasomal activity than U266 cells,
suggesting a decreased pool of proteasomes as compared to
the resistant line. In this scenario, accumulation of polyubiquitinated proteins and the accompanying decrease of
free ubiquitin reveal proteasome stress in PI-sensitive
MMC. Finally, to establish cause-effect relationships, we
manipulated proteasome workload, by means of ER
stressors, and proteasome capacity, via treatment with
rapidly reversible PI, achieving profound alterations of PI
sensitivity. Altogether, our data demonstrate that the
balance between proteasome workload and degradative
capacity represents a critical determinant of apoptotic
sensitivity of MMC to PI, providing both a novel predictive
tool of potential prognostic value and the framework for
novel combination therapies.
1 Cenci S et al: EMBO J 25: 1104-1113, 2006.
2 Meister S et al: Cancer Res 67: 1783-1792, 2007.
3 Cascio P et al: Eur J Immunol 38: 658-667, 2008.
95
HE4 – A NEW MARKER FOR
OVARIAN CANCER IN ROUTINE?
M. Casova, Z. Novotny, J. Vrzalova, O. Topolcan,
L. Holubec, M. Prazakova, M. Nekulova, L. Pecen,
J. Finek, V. Kokes and Z. Rokyta
Teaching Hospital and Medical Faculty in Pilsen, E. Benese
13, 305 99 Plzen, Czech Republic
Introduction: HE 4 is a novel biomarker for the management
of patients with a known or suspected ovarian cancer. Tumor
marker CA 125 commonly used in routine has a low
specificity. Aim: i) to validate the sensitivity and the specificity
of the tumor marker HE4 for ovarian cancer in follow-up; ii)
to find an optimal multiparametric combination of tumor
markers for the follow up of ovarian cancer; iii) to compare
the new tumor marker HE4 with CA125 used in routine.
Groups of the study: i) pathological group: 19 women with a
malignant ovarian tumor; ii) control groups: 72 women with
a benign ovarian tumor, 50 women with other malignant
gynecological tumors, 20 women with a gynecological benign
disease (endometritis, salphingitis, etc.), 40 pregnant women,
20 women with non-gynecological benign diseases (renal,
cardial, liver failure) which can increase values of the tumor
markers CA 125.
3232
Methods:
Parameter
Assay
Company
Units
HE 4
CA 125
TK
Monototal
TPS
EIA
LIA
REA
IRMA
IRMA
FUJIREBIO Diagnostics
Beckman
Immunotech
IDL
IDL
pM
kIU/L
IU/L
IU/L
IU/L
Cut-off
Specificity
Senzitivity
AUC
89
47
17
212
315
97
97
97
97
97
89
74
63
42
39
0.9814
0.8638
0.8559
0.7686
0.7863
Results:
Marker
HE4
CA 125
TK
TPS
Monototal
Conclusion: All measured marker values were statistically
different between ovarian cancer group and the other control
groups. HE4 had the highest sensitivity of 89%. Optimal cutoff for HE4 appears to be 89 ng/L. HE4 is a new prognostic
tumor marker for ovarian cancer.
Study supported by the research project VZ MSM
0021620819.
96
MEMBRANE STEROID RECEPTORS AS
POTENTIAL DIAGNOSTIC AND THERAPEUTIC
TARGETS IN BREAST AND PROSTATE CANCER
Marilena Kampa, Vassiliki Pelekanou, George Notas and
Elias Castanas
Laboratory of Experimental Endocrinology, University of
Crete, School of Medicine, Heraklion, 7100, Greece
Rapid, non-genomic, steroid actions (RSA) have been
identified since 1962. However, only in the last decade this
particular mode of steroid action has been explored in depth.
RSA trigger a number of very rapid effects, including ion
movement, signaling cascade activation, leading to specific
subsequent gene activation, cytoskeletal changes and secretion.
The nature of steroid membrane binding sites remains
controversary. The most compelling theories integrate the
existence of either new (possibly G-protein-coupled), or
classical steroid receptors, docked to the plasma membrane
through post-transcriptional modifications (palmitoylation). In
breast and prostate cancer, specific binding of estrogen and
androgen has been identified in tumors, but not in the
peritumoral non-cancerous tissue. Activation of these sites,
through non-permeable steroid analogs leads to cell survival
Abstracts of the 8th International Conference of Anticancer Research, 17-22 October 2008, Kos, Greece
(estrogen) or apoptosis (androgen). In this latter case, specific
signaling molecules mediate actin cytoskeleton reorganization,
while a potentiation of cytoskeleton acting drugs (Taxol®) is
found in vitro and in vivo. Interestingly, in the same tissues,
membrane-acting steroids interact with growth factors (EGF).
We have also identified an interaction of these steroids with
the system EPO-EPOR, promoting cell survival, through a
specific signaling cascade switch. Additionally, steroids affect
the transcription of EPOR gene, interacting on the EPOR
promoter, suggesting a potential drawback of a concomitant
EPO-aromatase inhibitor administration. The above
characteristics make membrane steroid receptor agonists a new
therapeutic target in breast and prostate neoplasia.
98
ELECTROCHEMOTHERAPY OF CANINE MAST
CELL TUMOURS: COMPARISON WITH SURGICAL
TREATMENT
97
A NEW PARADIGM IN RECEPTOR TYROSINE
KINASE REGULATION AND ITS IMPLICATIONS
FOR CANCER PROGRESSION
Electrochemotherapy (ECT) is a novel local tumour treatment
that combines administration of chemotherapeutic drugs,
cisplatin or bleomycin with application of electric pulses to
the tumour. It is based on the local application of short and
intense electric pulses to the cells or tissues that makes the cell
membrane transiently permeable and thus allow influx of
foreign molecules from extracellular space into the cytoplasm.
The aim of our study was to evaluate the effectiveness of
electrochemotherapy (ECT) with cisplatin and to compare it
with effectiveness of surgery of mast cell tumours (MCT) in
dogs.
In the present retrospective study, between January 2002
and August 2004, 25 dogs of different breeds with MCT were
included into the study. The dogs were divided in two
treatment groups, surgery (16 dogs with 16 tumours) and those
whose owners refused surgery being included in an ECT
group (9 dogs with 12 tumours). ECT was performed by
intratumoral injection of cisplatin (1 mg/cm3 tumour) and 1-2
min thereafter exposed to electric pulses (8 electric pulses of
100 μs pulse duration, amplitude to electrode distance ratio
1300 V/cm and frequency 1 Hz) that were generated by an
electric pulses generator (Jouan GHT 1287) and delivered
through two parallel stainless steel electrodes with an inner
distance between them of 7 mm. Response rate and duration
of response to the treatment were evaluated and comparison
between groups was made.
The clinical stages of the tumours were stage I in 4 (45%)
and stage III in 5 (55%) in dogs treated by ECT, 12 (75%) dogs
treated by surgery were stage I and 4 (25%) dogs were in
clinical stage III. Median size of the tumours treated by surgery
was 5.2 cm3 and 2.9 cm3 of tumours treated by ECT. ECT
resulted in comparable antitumour effectiveness as surgical
treatment. In 8/16 dogs that were surgically treated, tumours
recurred after 0.7 to 22.5 months, while tumour recurrence was
obtained only in 2/9 dogs treated by ECT (2 and 8 months).
ECT is an easy, highly effective, and well tolerated
treatment of MCT. It can be an alternative treatment to
surgery, especially for small nodules in which the complete
response with long duration can be obtained.
Ugo Cavallaro
IFOM-IEO Campus, Via Adamello 16, I-20139 Milan, Italy
Receptor tyrosine kinases (RTKs) are transmembrane
glycoproteins that control a variety of cellular functions. The
deregulated expression and/or activity of RTKs leads to
different pathological conditions, with cancer being a
prominent example.
The stimulation of RTK-mediated signalling is classically
triggered by the binding of soluble ligands, best exemplified
by polypeptide growth factors. Other membrane proteins, such
as adhesion molecules, are thought to exert a regulatory
function on RTK activity by modulating their localization
and/or their response to ligands.
We have recently obtained evidence that instead assign a
more direct role to adhesion molecules in controlling RTK
function. Indeed, working on specific adhesion molecules of
the immunoglobulin superfamily (Ig-CAMs), we
demonstrated their activity as molecular switches for
fibroblast growth factor receptor (FGFR), a prototypical RTK.
On one hand, Ig-CAMs interefere with the binding of FGF to
FGFR, thus repressing FGF-induced cellular response
(Francavilla et al., 2007). On the other hand, Ig-CAMs
themselves bind to and activate FGFR, emerging as novel,
unconventional RTK ligands. It is intriguing that Ig-CAMs
and FGF stimulate divergent signalling cascades downstream
of FGFR, implying differential mechanism of FGFR
activation.
Finally, our data implicate this novel interplay between
adhesion molecules and FGFR in specific events associated
with tumor progression, in particular in ovarian carcinoma.
These findings offer a solid rationale to explore the feasibility
of targeting the Ig-CAM/FGFR crosstalk as a novel approach
to cancer therapy.
M. Cemazar1, N. Tozon2, A. Cör3 and G. Sersa1
1Institute
of Oncology Ljubljana, Zaloska 2, SI-1000
Ljubljana;
2University of Ljubljana, Veterinary Faculty, Clinic for Small
Animal Medicine and Surgery, Cesta v mestni log 47, SI-1000
Ljubljana;
3University of Ljubljana, Faculty of Medicine, Korytkova 2,
SI-1000 Ljubljana, Slovenia
3233
ANTICANCER RESEARCH 28: 3157-3556 (2008)
99
PREDICTION OF RESPONSE IN CANCER
IMMUNOTHERAPY
Dainius Characiejus
Institute of Oncology, Vilnius University, Santariškių 1, LT08660 Vilnius, Lithuania
Various parameters of the immune system have been studied
in an attempt to predict clinical response to immunotherapy,
mostly in renal cell carcinoma and melanoma. These
parameters include profile of peripheral blood lymphocyte
subsets, circulating monocytes and neutrophils, blood natural
killer cell function, T-cell function, types and quantities of
tumour infiltrating lymphocytes and serum autoantibodies.
Despite observed discrepancies between immunological
response to therapy and clinical outcome, the following
conclusions can be drawn from the literature. Firstly, in vivo
numbers and/or proportions of cells of the immune system
seem to better correlate with clinical outcome than their
function in vitro. Secondly, types and quantities of tumour
infiltrating lymphocytes may have predictive value for
immunotherapy, but probably do not have an advantage over
peripheral blood lymphocyte subsets. Thirdly, development of
autoimmunity, as measured by the increase in serum
autoantibodies, correlates with positive outcome of
immunotherapy, but does not help to select patients for this
type of treatment.
A biomarker that would strongly predict the response in
cancer immunotherapy remains desirable. Theoretical
considerations and clinical evidence suggest that the most
important prerequisite of antitumour immune response is the
proliferation of cytotoxic T lymphocytes. Clonal expansion of
CD8+ T lymphocytes is associated with the loss of costimulatory molecule CD28 and acquisition of CD57 antigen.
Thus, expression of CD57 antigen on CD8+ T lymphocytes
may indicate the “proliferative history” of these cells. The
positive relationship between CD8+CD57+ T lymphocyte
expansions and survival has been observed in leukaemia and
multiple myeloma. In solid tumours, this lymphocyte subset
has not yet received much attention. Our recent results suggest
that high risk melanoma patients with low (<23% in CD8+
subset) pre-treatment levels of CD8+CD57+ T lymphocytes
may benefit from adjuvant interferon-α. Interferon-α probably
acts by increasing the numbers of these lymphocytes early
during treatment.
In contrast to our results with melanoma, benefit of
interferon-α treatment in renal cell carcinoma is limited to
patients with high (>30% in CD8+ subset) levels of
CD8+CD57+ T lymphocytes. This contradiction may be
explained by the fact that the expression of CD57 antigen by
CD8+ T lymphocytes has been associated not only with
cytotoxic potential, but also with an immunosuppressive
3234
effect. Further studies are needed to determine more precisely
the predictive value of CD8+CD57+ T lymphocytes in cancer
immunotherapy.
100
THE CLINICAL SIGNIFICANCE OF
COLLABORATION BETWEEN DISCIPLINES IN
CANCER
Konstantinos Charalabopoulos
Department of Physiology, Clinical Unit, Medical Faculty,
University of Ioannina, Ioannina, Greece
Recent advances in understanding malignant disease have
been dominated by creation of genetic models. Many human
neoplasms develop through genetic and epigenetic alterations
of oncogenes and tumour suppressor genes. The accumulation
of various molecular alterations is a multistep process, which
leads to carcinogenesis. The most studied model of
carcinogenesis is colorectal carcinoma. With the advent of
endoscopic techniques, it became possible to excise lesions in
all stages of colon cancer development. Pathologists have
described specific morphological features for each step and
molecular studies have defined the corresponding genetic
alterations. This close collaboration enabled the creation of the
multi-step model of carcinogenesis.
Another example is human breast cancer. In this model,
each step of tumour progression correlates with one or more
distinct mutations in major regulatory genes. Furthermore,
recently, molecular studies have determined specific sets of
genes, whose expression is correlated with survival and risk
of recurrence. Again, pathologists are closely collaborating
with clinicians and basic scientists in order to optimize the
characterization of the disease.
101
IMPLICATIONS OF INTRANUCLEAR ORDER ON
DIAGNOSIS AND THERAPY OF GENETIC
DISORDERS
Jyoti P. Chaudhuri, Liliana Scott, Li Song and
John R. McGill
Genzyme Genetics, 4310 E. Cotton Center Blvd, Suite 120,
Phoenix, AZ 85040, USA
Cytogenetic and genetic observations indicate the existence of
intranuclear order (1-3). The first level of order is the genomic
integrity – maternal and paternal chromosomes comprise two
exclusive groups, each controlled by one of the two centrioles
of a diploid cell (4). At the second level the chromosomes of
a genome generally maintain some spatial order (5).
A selection of our new data from metaphase and interphase
cells of specimens of cancer cases using GTG-banding and
Abstracts of the 8th International Conference of Anticancer Research, 17-22 October 2008, Kos, Greece
FISH on translocations, deletions, duplications, amplifications,
trisomies, polyploidies etc will be presented as an additional
support to the aforesaid orders of chromosomes.
Profound implications of these observations on diagnosis
and therapy procedures will be discussed to define the
rationale of more realistic and realizable protocols of
personalized medicine with further aim towards the target gene
therapy.
1 Ashley T and Pocock N: Genetics 55: 161, 1981.
2 Chaudhuri JP et al: Cellular Oncol 27: 327, 2005.
3 Kmita M and Duboule D: Science 301: 331, 2003.
4 Chaudhuri JP and Walther JU: Int J Oncol 23: 1257, 2003.
5 Chaudhuri JP et al: Europ J Hum Genet 15 s1: 118, 2007.
102
TNF/TRAF-2/NIK/JNK/P38 TRANSDUCTION
PATHWAY AND CANCER PROSTATE
PROGRESSION
B. Fraile1, C. Chaves1, Gonzalo Rodríguez-Berruguete1,
P. Martínez-Onsurbe2, F. Bethecourt3, R. Cansino3,
R. Paniagua3 and M. Royuela1
1Department
of Cell Biology and Genetics, University of
Alcalá;
2Department of Pathology, Príncipe de Asturias Hospital.
Alcalá de Henares;
3Department Urología del Hospital La Paz. Madrid, Spain
Aims: TNFα exerts apoptosis throughout an intracellular
transduction pathway that involves the kinase proteins TRAF2 (integration point of apoptotic and survival signals), ASK1
(pro-apoptotic protein), MEK-4 (p38 activator and metastasis
suppressor gene), JNK (stress mitogen activated protein
kinase) and the transcription factor AP-1. TNFα also exerts
proliferation by p38 activation, or when TRAF-2
simultaneously induces the transcription factor NF-κB by
NIK. NIK and p38 may also be activated by IL-1. P38
activated several transcription factors such as Elk-1, ATF-2
and NF-κB. NIK also may activate NF-κB. The aim of this
study was to elucidate the possible involvement of this
transduction pathway in prostate cancer development and its
role in the breakdown of the apoptosis-proliferation
equilibrium. Methods: Immunohistochemical and Western blot
analyses were performed in 20 samples of normal prostates,
35 samples of BPH, and 93 samples of PC (low, medium or
high Gleason grades). Results: 60%, 100% and 100% normal
prostates showed positive immunostaining to TRAF-2, JNK,
and NIK (respectively) and immunoreaction were observed in
cytoplasm of epithelial cells. Immunoreaction to p38 (18%) in
NP was found in the nucleus of epithelial cell. The same
location was observed in PC to TRAF-2 and NIK. No
immunoreaction to JNK was found in PC samples. To TRAF-
2, percentages of positive patient samples decreased with the
malignancy, but the immunoreaction intensity was increased
in PC (no differences were found between Gleason groups).
For NIK, percentages and optical density were higher in PC
samples, but no differences were observed between the three
Gleason groups. P-p38 was found with cytoplasmic and
nuclear location in the 89% of PC samples. Conclusion: In PC
we sugget that TNF-α/AP-1 pathway is probably inactivated
by other factors such as p21 (at ASK-1 level), or bcl-2 (at JNK
level) whereas proliferation and/or apoptosis inhibition
pathways mediate by NIK and p38 might be activated. P38
and NIK activate different transcription factors related with
cell proliferation and survival such as ATF-2, Elk-1 or NF-κB.
This activation increased in patient with high Gleason score.
Additional fundamental research with these different pathway
members and their correlation with clinical experimentation
will be required in the field of prostate cancer.
Supported by grants from the “Ministerio de Educación y
Ciencia”, Spain (SAF2007-61928).
103
IL-1/NIK/NF-κB TRANSDUCTION PATHWAY: A
COMPARATIVE STUDY IN NORMAL AND
PATHOLOGICAL HUMAN PROSTATE (BENIGN
HYPERPLASIA AND CARCINOMA)
B. Fraile1, C. Chaves1, Gonzalo Rodríguez-Berruguete1,
P. Martínez-Onsurbe2, G. Olmedilla2,
R. Paniagua1 and M. Royuela1
1Department
of Cell Biology and Genetics, University of
Alcalá;
2Department of Pathology, Príncipe de Asturias Hospital.
Alcalá de Henares. Madrid, Spain
Aims: It has been proposed that TNFα induces cell death, but
also cell proliferation by activation of NF-κB, which may also
be activated by IL-1-α. The aim of this study was investigate
upstream (TRAF-6, IRAK-1) and downstream (Ikkα/β, IκBα,
p-IκB, NF-κB-p50 and NF-κB-p65) components of NIK
transduction pathway in normal prostate, benign prostatic
hyperplasia (BPH) and prostatic carcinoma (PC). Methods:
Immunohistochemical and Western blot analyses were
performed in 20 samples of normal prostate, 35 samples of
BPH, and 93 samples of PC (low, medium or high Gleason
grades). Results: In normal prostates, cytoplasm of epithelial
cells immunostained intensely to IRAK (100% of samples),
TRAF-6 (80%), NIK (100%), Ikkα/β (80%), IκBα (40%) and
p-IκB (60%); weakly to NF-κB-p50 (60%); and negative to
NF-κB-p65. In BPH cytoplasm of epithelial cells
immunostained was intensely to IRAK (99%), TRAF-6 (87%),
NIK (94%), Ikkα/β (54%), IκBα (69%), p-IκB (81%); and
weakly to NF-κB-p50 (100%) and NF-κB-p65 (71%). In PC,
cytoplasm of epithelial cells immunostained intensely to
3235
ANTICANCER RESEARCH 28: 3157-3556 (2008)
IRAK, TRAF-6, NIK, Ikkα/β (increased with Gleason), IκBα
(increased with malignancy) and p-IκB (decreased with
Gleason); and weakly to NF-κB-p50 (increased with
malignancy) and NF-κB-p65 (decreased with Gleason).
Nuclear inmmunostaining was only observed for NF-κB (p50
and p65), only in PC and independently of Gleason grade.
Conclusion: We concluded that NF-κB (p50 and p65)
enhances cell proliferation, but also several transcription
factors, such as ATF-2 or Elk-1. In this way, several multiple
transduction pathways may be involved in the uncontrolled
apoptosis/cell proliferation balance. Since another study
carried out on the same patients revealed that
immunoexpression of proinflammatory cytokines, such as IL1α or TNFα, increased in PC, inhibition of these cytokines
might be a possible target for PC treatment, because such
inhibition could decrease the activity of all transduction
pathway members that activate transcription factors such as
NF-κB, Elk-1 or ATF-2.
Supported by grants from the “Ministerio de Educación y
Ciencia”, Spain (SAF2007-61928).
104
BIOASSAY-GUIDED IDENTIFICATION AND
ISOLATION OF ANTICANCER COMPONENTS IN
HYPHOLOMA FASCICULARE EXTRACT
Wai San Kitty Pang1, Ming Chen2, Lin Zhai2 and
S. Brøgger Christensen1
1Department
of Medicinal Chemistry, Faculty of
Pharmaceutical Sciences, University of Copenhagen,
Universitetsparken 2, DK-2100 Copenhagen Ø;
2Department of Clinical Microbiology, University Hospital
of Copenhagen (Rigshospitalet), Tagensvej 20, DK-2200
Copenhagen N, Denmark
Previously we have found that the crude extract of Hypholoma
fasciculare has potent in vitro anticancer activity against EL4
(murine leukemia), MCF7 (breast cancer) and PC3 (prostate
cancer) cell lines. This study is to identify and isolate active
anticancer components from the mushroom.
A bioassay-guided fractionation was used to identify and
purify active agents from the mushroom. Twenty different
fractions were isolated from the mushroom and their in vitro
anticancer activity was tested against EL4, MCF7 and PC3
cancer cell lines with a standard high-flux anticancer-drug
screening method.
Two triterpenes (fasciculol C and fasciculic acid B) were
identified and isolated from the apolar fractions of the mushroom
extract with IC50 against EL4 at 25.5 and 19.6 μg/ml, MCF7 at
55.5 and 40.0 μg/ml, and PC3 at 57.0 and 60.5 μg/ml.
A polar fraction of the mushroom extract exhibits more
potent in vitro anticancer activity than the two triterpenes with
IC50 against EL4 at 10.0 μg/ml, MCF7 at 15.5 μg/ml, and PC3
3236
at 25.3 μg/ml. The active constituents have not been identified
yet.
The results illustrate that Hypholoma fasciculare has a
potent in vitro anticancer activity and the active agents isolated
from the mushroom could be used as a starting point for
developing of anticancer agents.
105
ANTICANCER ACTIVITIES OF DIFFERENT TEAS
Lin Zhai, Ming Chen and Arsalan Kharazmi
Department of Clinical Microbiology, 7602, University
Hospital of Copenhagen (Rigshospitalet), Tagensvej 20,
Copenhagen, DK-2200 N, Denmark
There are many reports on the anticancer activity of green tea
in the recent years. In this study, we have investigated the in
vitro anticancer activity of other teas, including 25 different
Chinese teas, which belong to five different tea groups
(fermentation tea, non-fermentation tea, half-fermentation tea,
flower tea, and white tea), and four European teas, and one
coffee.
Water extractions of the teas and coffee were made and
were sterile filtered through a 0.22-μm-pore-size Millipore
filter. The in vitro anticancer activity of these tea water
extractions have been tested against three different cancer cell
lines, EL4 (leukemic cell line), MCF7 (human breast cancer
cell line), and PC3 (human prostate cancer cell line). McCoy
cell (mouse fibroblasts cell line) has been used as a non-cancer
cell control. A standard assay (sulforhodamine B staining
method) for anticancer-drug screening recommended by
National Cancer Institute has been employed for the study.
The results show that most of tested teas exhibit potent
inhibitory activity on the in vitro growth of the three tested
cancer cell lines. The anticancer activity of non-fermentation
tea, half-fermentation tea, and white tea are stronger than other
teas. Among three tested Jasmine teas, one of them has much
stronger anticancer activity than other two, which indicates
that where tea grow and the way of tea preparation may play
an important role, too. Water extraction of coffee also shows a
slight inhibitory effect on EL4 cell, but no effect on other two
cancer cells. The anticancer activity of teas is significantly
stronger than that of coffee.
Preliminary toxicity studies show the tested teas have no
toxicity on the human mononuclear cells at the concentration
16 times higher than the IC50 against EL4 cell. The in vitro
inhibitory effect of the tested teas on a mouse fibroblasts cell
line, McCoy, is also at least four times less than that on EL4
cell.
Our data indicate that other teas have also potent anticancer
activity. Since tea is a very popular beverage, further study on
identifying and isolating active components from these teas
and study on mechanism of action are necessary.
Abstracts of the 8th International Conference of Anticancer Research, 17-22 October 2008, Kos, Greece
106
CRUDE EXTRACT OF DESMODIUM GANGETICUM
INDUCES HUMAN A549 LUNG CANCER CELL
DEATH THROUGH CELL-CYCLE ARREST IN G1
PHASE
Yuh-Fung Chen1,2,4, Yi-Hsien Lu1 and Huei-Yann Tsai2,3,4
1Graduate
Institute of Chinese Pharmaceutical Sciences,
of Pharmacology, and 3College of Pharmacy,
China Medical University, 91 Hsueh-Shih Road, Taichung,
40402, Taiwan;
4Department of Pharmacy, China Medical University
Hospital, 2 Yuh-Der Road, Taichung, 40402 Taiwan, ROC
2Department
Background: Desmodium gangeticum, Leguminosae, has been
widely used as a traditional herb in Taiwan and other countries.
In past decades, it has been reported to have anti-inflammatory
activity in carrageenan-induced inflamed rats, and to improve
the severity of myocardial infarction and anti-ulcer potential in
pyloric ligation and histamine induced gastric ulcer in rats and
pigs. In this study, we explored its anti-nociceptive and
antitumor activities in lung cancer cells. Methods: As an in vivo
test, the formalin-induced nociceptive behavior was employed.
In vitro, the growth of various various bacteria was evaluated.
The MTT viability assay was used for the evaluation of growth
inhibition in In lung cancer cells. Flow cytometric analysis and
Western blot were used to detect the cell cycle arrest and
apoptosis in Desmodium gangeticum treated lung cancer cells.
Results: In this preliminary study, Desmodium gangeticum
inhibited the biting and licking behavior induced by formalin in
a dose-dependent manner. Additionally, it was shown that
Desmodium gangeticum could completely inhibit the growth of
Pseudomonas and partly that of E. coli at higher
concentrations. However, it had no effective on the Klebsiella
species. Additionally, Desmodium gangeticum dosedependently inhibited cell viability and induced G1 phase arrest
with down-regulation of cyclin A and B1, and up-regulation of
P21, P27 in lung cancer cells. Conclusion: Desmodium
gangeticum exhibited anti-nociceptive and anti-bacterial effects.
It also inhibited cell viability and induced cell cycle arrest in
G1 phase in lung cancer cells.
of Medicine, Kaohsiung, Taiwan, ROC;
3Department of Pathology, Case Western Reserve University,
Cleveland, OH, USA;
4Department of Pathology, Cordoba University, Cordoba,
Spain;
5Institute of Pathological Anatomy and Histopathology,
School of Medicine, Polytechnic University of the Marche
Region (Ancona), United Hospitals, Ancona, Italy;
6Department of Pathology, Singapore General Hospital,
Singapore
Clear cell adenocarcinoma in the urinary tract is an extremely
rare neoplasm predominantly occurring in adult females, and
morphologically identical to tumors of the same name that arise
in female genital organs. Its precise histogenesis has remained
controversial. We analyzed molecular genetic evaluation by
fluorescence in situ hybridization (FISH) and X-chromosome
inactivation with conventional morphological and immunohistochemical analyses in 12 patients with clear cell
adenocarcinomas in the urinary tract. Concurrent urothelial
carcinoma or urothelial carcinoma in situ were present in 6
cases (50%) and foci of cystitis glandularis were observed in 4
cases (33%). Neither intestinal metaplasia nor Müllerian
component was identified in any case. Cytoplasmic expression
of α-methylacyl-CoA racemase (AMACR) was demonstrable
in 10 of 12 tumors (83%). Moderate to diffuse immunostaining
for CK7 was identified in all 12 tumors (100%), whereas only
3 of 12 (25%) tumors showed positive immunostaining for
CK20. Focal uroplakin III staining was seen in 6 of 12 tumors
(50%). In 5 cases (42%), focal to moderate CD10
immunoreactivity was observed. Immunostains for OCT4 and
CDX-2 were completely negative in all tumors. In UroVysion
FISH assays, all tumors displayed chromosomal alterations
similar to those commonly found in urothelial carcinoma.
Identical patterns of nonrandom X-chromosome inactivation in
concurrent clear cell adenocarcinoma and urothelial neoplasia
were identified in two informative female cases. Our data
support an urothelial origin for most clear cell adenocarcinomas
of the urinary tract, despite their morphologic resemblance to
certain Müllerian-derived tumors of the female genital tract.
107
UROTHELIAL ORIGIN OF CLEAR CELL
ADENOCARCINOMA OF THE URINARY BLADDER
108
SCHWANNOMA OF THE KIDNEY: A
CLINICOPATHOLOGICAL AND
IMMUNOHISTOCHEMICAL ANALYSIS
Liang Cheng1, Ming-Tse Sung2, Shaobo Zhang2,
Gregory T. MacLennan3, Antonio Lopez-Beltran4,
Rodolfo Montironi5, Mingsheng Wang2 and Puay-Hoon Tan6
Liang Cheng1, Stefano Gobbo1,2, Jiaoti Huang3,
David J. Grignon1, Mingsheng Wang1,
Guido Martignoni2, Matteo Brunelli2 and John N. Eble1
1Departments
1Departments of Pathology and Laboratory Medicine,
Indiana University, Indianapolis, IN, USA;
2Dipartimento di Patologia, Universitá di Verona, Verona,
Italy;
of Pathology and Urology, Indiana University
School of Medicine, Indianapolis, IN, USA;
2Department of Pathology, Chang Gung Memorial HospitalKaohsiung Medical Center, Chang Gung University College
3237
ANTICANCER RESEARCH 28: 3157-3556 (2008)
3Department
of Pathology, University of Rochester Medical
Center, Rochester, NY, USA
Schwannomas of the kidney are rare, with only a few
reported cases. We report three additional cases with
immunohistochemical analysis. All three tumors were from
females (aged 27, 35, and 59 years) and ranged from 4.8 to
8 cm in diameter. All of the patients underwent
nephrectomy. The tumors were totally or partially
encapsulated; two were in the hilum and one was centered
in the renal cortex. All tumors were diffusely positive for S100 protein. Two were positive for neuron-specific enolase.
Immunostaining for neurofilament, HMB45, microphthalmia
transcription factor, smooth muscle actin, CD34, cytokeratin
AE1/3, cytokeratin 7 and CD10 were negative. Follow-up
data were available for two patients; neither had tumor
recurrence or metastasis. In conclusion, renal schwannoma
is rare, usually arises centrally, impinging on the hilum or
the pelvis and is cured by resection. Sarcomatoid carcinoma
and other spindle cell tumors should be considered in the
differential diagnosis.
109
RENAL CELL CARCINOMAS WITH
PAPILLARY ARCHITECTURE AND CLEAR CELL
COMPONENTS: DIAGNOSTIC UTILITY OF
CYTOGENETICAL ANALYSES
Liang Cheng1, Stefano Gobbo1,4, Gregory T. MacLennan2,
David J. Grignon1, Rajal B. Shah3, Shaobo Zhang1,
Guido Martignoni4, Matteo Brunelli4 and John N. Eble1
1Departments
of Pathology and Laboratory Medicine,
Indiana University School of Medicine, Indianapolis,
Indiana;
2Departments of Pathology and Laboratory Medicine, Case
Western Reserve University, Cleveland, Ohio;
3Departments of Pathology and Laboratory Medicine,
University of Michigan, Ann Arbor, MI, USA;
4Dipartimento di Patologia, Universitá di Verona, Verona,
Italy
Although histological features enable an accurate diagnosis
in most renal carcinomas, overlapping morphologic findings
between some renal neoplasms make subclassification
difficult. Some renal carcinomas show papillary architecture
but are composed extensively of cells with clear cytoplasm,
and it is unclear whether they should be classified as clear
cell renal cell carcinomas or papillary renal cell carcinomas.
We analysed the immunohistochemical profiles and the
cytogenetic patterns of fourteen renal carcinomas showing
papillary architecture in which there were variable amounts
of cells with clear cytoplasm. The patients were eight women
and six men (mean age: 54 years). Immunohistochemistry
3238
and fluorescence in situ hybridization analysis distinguished
two different groups. The first consisted of ten renal cell
carcinomas with strong immunoreactivity for alpha-methyl
CoA racemase (AMACR), of which 9 also expressed
cytokeratin 7. All of these neoplasms showed gains of
chromosome 7 or 17 and chromosome Y was lost in all the
male patients whereas 3p deletion was detected only in one
case. In the other four renal cell carcinomas, cytokeratin 7
was not detected and AMACR was positive in only one. In
these neoplasms, no gains of chromosomes 7 or 17 and no
loss of chromosome Y were observed whereas 3p deletion
was detected in three of them. None of the 14 neoplasms
showed immunoreactivity for TFE3. The combined use of
immunohistochemistry and cytogenetics enabled us to
provide a definitive diagnosis for 12 of 14 renal cell
carcinomas with papillary architecture and clear cell
components: 9 cases were confirmed to be papillary renal
cell carcinomas and 3 cases were confirmed to be clear cell
renal cell carcinomas. Despite these ancillary techniques, two
cases remained unclassified. Our study establishes the utility
of these procedures in accurately classifying the great
majority of renal cell carcinomas with these findings.
110
THE UROVYSION FISH ANALYSIS OFFERS A
PROMISING SURVEILLANCE STRATEGY IN
PATIENTS WHO UNDERWENT AUGMENTATION
CYSTOPLASTY
Liang Cheng2,3, Ming-Tse Sung1, Shaobo Zhang2,
Mingsheng Wang2, Michael O. Koch3,
Mark P. Cain3 and Richard C. Rink3
1Department
of Pathology, Chang Gung Memorial HospitalKaohsiung Medical Center, Chang Gung University College
of Medicine, Kaohsiung, Taiwan, ROC; 2Departments of
Pathology and Laboratory Medicine and 3Urology, Indiana
University School of Medicine, Indianapolis, IN, USA
Patients who have undergone intestinal augmentation
cystoplasty are at risk for developing latent vesical
malignancy. The present study was conducted to evaluate the
histological and immunohistochemical characteristics and
molecular genetic alterations in these neoplasms.
Four patients developing urothelial neoplams after
augmentation cystoplasty were included in the current study.
Tumor specimens were assessed for morphological features
and immunohistochemical expression of uroplakin III, CDX2,
β-catenin, and cytokeratin 7 and 20. Gene mutations in
fibroblast growth factor receptor 3 (FGFR3) gene and p53
gene were analyzed and the UroVysion fluorescence in situ
hybridization (FISH) tests were performed. The mean age of
the patients, including two men and two women, was 37. The
latency from bladder augmentation to developing malignancy
Abstracts of the 8th International Conference of Anticancer Research, 17-22 October 2008, Kos, Greece
ranged from 17 to 21 years (mean 19 years). All patients died
of widespread metastasis months after cancer diagnosis
(mean, 5 months). In the morphological evaluation, all tumors
were high-grade (grade 3) invasive urothelial carcinoma
comprising various architectural patterns with brisk mitoses
and tumor necrosis. Three harbored glandular differentiation
(75%) and the remaining one showed squamous
differentiation (25%). All cases revealed abnormal decreasing
β-catenin expression with moderate to strong membranous
staining in 30~60% of tumor cells. Two tumors (50%)
showed nuclear expression of CDX2, with variable staining
intensity and percentages. Moderate uroplakin III staining
was focally identified in one case. All but one tumors (75%)
were intensely stained by cytokeratin 7. One case (25%)
displayed focal cytokeratin 20 expression. In UroVysion
FISH analysis, all tumors displayed characteristic
chromosomal abnormalities (100%). Point mutations of both
FGFR3 and p53 genes were identified in one case. In
summary, neoplasms developed after augmentation
cystoplasty were extremely aggressive urothelial carcinomas
and exhibited distinct morphologic, immunohistochemical
and genetic characteristics. These neoplasms represent a rare
and specific variant of urothelial carcinoma which is
uniformly lethal. The UroVysion FISH analysis may offer an
attractive surveillance strategy in patients who underwent
augmentation cystoplasty.
111
SENSITIZATION OF LIVER CANCER CELLS TO
CHEMOAGENTS THROUGH GEP-TARGETED
THERAPY
Siu Tim Cheung
Department of Surgery, The University of Hong Kong
Primary liver cancer, hepatocellular carcinoma (HCC), is the
fifth most common cancer and the third cancer killer in the
world, with about half a million individuals dying from HCC
annually. The disease is frequently diagnosed at an advanced
stage and thus precludes curative surgical treatment.
Chemotherapy has shown marginal efficacy and is
accompanied with severe side-effects. A new therapeutic
strategy is essential to sensitize cancer cells to chemotoxic
agents.
Granulin-epithelin precursor (GEP) was shown to be a
therapeutic target for HCC treatment in our earlier studies (1).
We firstly identified GEP overexpression through genomic
expression profiling studies using the microarray approach (23). The GEP expression at the mRNA level (2-3) was
subsequently validated at the protein level in more than 200
HCCs and liver tissue adjacent to tumor samples, and
confirmed that more than 70% of HCC tissues revealed GEP
overexpression (4-5). We showed that GEP controls HCC cell
proliferation, invasion and tumorigenicity (4). These
biological roles correspond to the clinical findings that
expression of GEP is associated with aggressive cancer
features including large tumors, venous infiltration
(micrometastasis) and early recurrence after curative surgery
(4). We then examined the therapeutic potential of GEPtargeted therapy using the in-house made anti-GEP
monoclonal antibody (mAb) A23. The GEP mAb inhibited
the growth of human hepatoma cells Hep3B and HepG2, but
revealed no significant effect on normal liver cells MIHA. In
a nude mice model transplanted with human HCC cells
Hep3B, GEP mAb decreased the serum GEP level and
inhibited the growth of established tumors in a dosedependent manner (1). There are reports showing that GEP
mediates drug resistance in some cancer types (6-8). We
therefore hypothesize that GEP targeted therapy will enhance
the sensitivity of HCC cells to chemotoxic agents.
We investigated the effect of GEP neutralization on the
chemosensitivity of HCC cells. The biological responses of
GEP mAb A23, alone and in combination with cisplatin, on
HCC cells Hep3B in vitro and in vivo have been examined.
Hep3B cells treated with GEP mAb A23 in combination with
cisplatin demonstrated synergistic effect on induction of cell
apoptosis (25.1%) compared to cisplatin alone (10.0%), GEP
mAb A23 alone (0.1%) and control treatment (0%) by flow
cytometry analysis. The combination therapy approach was
then examined in in vivo system with the Hep3B xenograft in
nude mouse model. We demonstrated that GEP mAb plus
cisplatin can further inhibit the tumor growth (74.7%) when
compared to cisplatin alone (53.8%), GEP mAb A23 alone
(45.4%) with the control treatment.
In summary, the current data indicated that the GEP
targeted therapy in combination with cisplatin demonstrated
synergistic cytotoxic effect. The cell apoptotic event induced
by cisplatin was further amplified by neutralization of GEP,
and the combination treatment approach further enhanced the
growth inhibitory effect of tumor xenograft in nude mice
model. The mechanism of GEP-targeted therapy in sensitizing
HCC cells to chemodrugs is currently underway.
1 Ho JC, Ip YC, Cheung ST, Lee YT, Chan KF, Wong SY and
Fan ST: Granulin-epithelin precursor as a therapeutic target
for hepatocellular carcinoma. Hepatology 2008 Jan 7; [Epub
ahead of print]
2 Cheung ST, Chen X, Guan XY, Wong SY, Tai LS, Ng IO, So
S, Brown PO and Fan ST: Identify metastasis-associated
genes in hepatocellular carcinoma through clonality
delineation for multi-nodular tumor. Cancer Res 62: 47114721, 2002.
3 Chen X (equal contribution), Cheung ST (equal
contribution), So S, Fan ST, Barry C, Higgins J, Lai KM, Ji
J, Ng IO, van de Rijn M, Botstein D and Brown PO: Gene
expression profiles in human liver cancers. Mol Biol Cell
13: 1929-1939, 2002.
3239
ANTICANCER RESEARCH 28: 3157-3556 (2008)
4 Cheung ST, Wong SY, Leung KL, Chen X, So S, Ng IO and
Fan ST: Granulin-epithelin precursor over-expression
promotes growth and invasion of hepatocellular carcinoma.
Clin Cancer Res 10: 7629-7636, 2004.
5 Cheung ST, Wong SY, Lee YT and Fan ST: GEP associates
with wild-type p53 in hepatocellular carcinoma. Oncol Rep
15: 1507-1511, 2006.
6 Pizarro GO, Zhou XC, Koch A, Gharib M, Raval S, Bible
K and Jones MB: Prosurvival function of the granulin
epithelin precursor is important in tumor progression and
chemoresponse. Int J Cancer 120: 2339-2343, 2007.
7 Kamrava M, Simpkins F, Alejandro E, Michener C, Meltzer
E and Kohn EC: Lysophosphatidic acid and endothelin
induced proliferation of ovarian cancer cell lines is mitigated
by neutralization of granulin-epithelin precursor (GEP), a
prosurvival factor for ovarian cancer. Oncogene 24: 70847093, 2005.
8 Tangkeangsirisin W, Hayashi J and Serrero G: PC cellderived growth factor mediates tamoxifen resistance and
promotes tumor growth of human breast cancer cells. Cancer
Res 64: 1737-1743, 2004.
112
DMXAA: A VASCULAR-DISRUPTING
AGENT WITH CYTOKINE/IMMUNE
MODULATORY ACTIVITY
Lai-Ming Ching
Auckland Cancer Society Research Centre, Faculty of
Medical and Health Sciences, University of Auckland,
Auckland, NZ, USA
DMXAA, the first in its class of anticancer/vascular
disrupting agents, is currently in Phase III clinical trials. We
previously established that DMXAA has two distinct
activities that appear critical to its potent antitumour effects
in mice: the induction of tumour vascular endothelial
apoptosis, followed by the production of cytokines within the
tumour. Multiplex assays were used to screen for cytokines
produced by human blood leucocytes (HBLs) cultured with
DMXAA, with the aim of identifying a select panel of
cytokines that could be used as surrogate markers of
response. HBLs were cultured with DMXAA for 16 h, and
the supernatants assayed using a 42-plex human cytokine kit
and the Luminex 100™ MAP platform. While quantitative
differences were observed between donors, a consistent
pattern of modulation of a panel of 7 cytokines could be
observed amongst the donors tested thus far. DMXAA
inhibited constitutively-produced IP-10, MCP-1 and
sCD40L, but increased the production of TNF, MIP1-α, IL6 and IL-8 in 50% of the donors, who were designated as
high responders. Our data suggest that the pattern of
modulation of this panel of cytokines may be used to select
3240
for patients who will best respond to DMXAA treatment.
Inclusion of such multiplex cytokine assays in the clinical
trials, we suggest would also be useful in providing surrogate
markers of response.
113
EP2 RECEPTOR-MEDIATED ACTIVATION OF
EXTRACELLULAR SIGNAL-REGULATED KINASE
SIGNALING IS REQUIRED FOR THE MITOGENIC
ACTION OF PROSTAGLANDIN E2 IN ESOPHAGEAL
SQUAMOUS CELL CARCINOMA
C.H. Cho and L. Yu
Department of Pharmacology, Faculty of Medicine,
The Chinese University of Hong Kong, Shatin, N.T., Hong
Kong, China
The use of non-steroidal anti-inflammatory drugs is associated
with a lower risk for esophageal squamous cell carcinoma, in
which overexpression of cyclooxygenase-2 (COX-2) is
frequently reported. Prostaglandin E2 (PGE2), a COX-2-derived
eicosanoid, is implicated in the promotion of cancer growth.
The precise role of PGE2 in the disease development of
esophageal squamous cell carcinoma, however, remains
elusive. In this study, we investigated the effect of PGE2 on the
proliferation of cultured esophageal squamous cell carcinoma
cells (HKESC-1). Results showed that HKESC-1 cells
expressed all four PGE2 receptors, namely EP1 to EP4
receptors. In this regard, PGE2 and the EP2 receptor agonist
butaprost markedly increased HKESC-1 cell proliferation.
Moreover, the mitogenic effect of PGE2 was significantly
attenuated by RNA interference-mediated knockdown of EP2
receptor, indicating that this receptor mediated the mitogenic
effect of PGE2. In this connection, PGE2 and butaprost induced
phosphorylation of extracellular signal-regulated kinases-1/2
(Erk1/2), whose down-regulation by RNA interference
significantly attenuated PGE2-induced cell proliferation. In
addition, PGE2 and butaprost increased c-Myc and c-Fos
expression and activator protein-1 (AP-1) transcriptional
activity, which were abolished by the mitogen-activated protein
kinase/ERK kinase (MEK) inhibitor U0126. AP-1 binding
inhibitor curcumin and RNA interference-mediated knockdown
of c-Myc also partially reversed the mitogenic effect of PGE2.
Taken together, these data demonstrate for the first time that
EP2 receptor mediates the mitogenic effect of PGE2 in
esophageal squamous cell carcinoma via activation Erk/AP-1
and c-Myc pathway. This study supports the growth-promoting
action of PGE2 in esophageal squamous cell carcinoma and the
potential application of EP2 receptor antagonists in the
treatment of this disease.
The work was supported in part by the Hong Kong Research
Grant Council (7499/05M) and the Direct Grant from the
Chinese University of Hong Kong.
Abstracts of the 8th International Conference of Anticancer Research, 17-22 October 2008, Kos, Greece
114
CANCER BIOMARKER DISCOVERY BY
ONCOPROTEOMICS
William C.S. Cho
Department of Clinical Oncology, Queen Elizabeth Hospital,
Room 1305, 13/F, Block R, 30 Gascoigne Road, Kowloon,
Hong Kong
Cancer is the leading cause of death in most of the developed
countries. Early diagnosis and prevention are key factors needed
to reduce the mortality and morbidity of all types of cancer.
Traditional diagnostic methodologies, to a certain extent, have
their limitations of sensitivity and specificity. It is imperative
that more useful and specific cancer biomarkers are discovered.
Proteomics is the large-scale study of proteins. With the
advent of new and improved proteomics technologies, such as
the development of quantitative proteomics methods, highresolution, -speed and -sensitivity mass spectrometry and
protein arrays, as well as advanced bioinformatics for data
handling and interpretation, it is now possible to discover
biomarkers that can reliably and accurately predict outcomes
during cancer management and treatment.
Oncoproteomics is the study of proteins and their
interactions in a cancer cell by proteomics technologies. By
studying the interrelationships of protein expressions and
modifications in cancer and normal cells, proteomics
contributes important insights into the pathophysiological
basis of cancer. Oncoproteomics has the potential to be
applicable for clinical practice, including cancer diagnosis and
screening based on proteomics platforms as a complement to
histopathology, individualized selection of therapeutic
combinations that target the entire cancer-specific protein
network, assessment of therapeutic efficacy and toxicity, and
rational modulation of therapy based on changes in the cancer
protein network associated with prognosis and drug resistance.
In addition, protein biomarkers identified can also serve as
therapeutic targets and provide mechanistic approach for the
study of drug effects as well as effective drug design.
In this presentation, some remarkable discoveries of cancer
biomarkers as well as the challenges ahead and perspectives of
oncoproteomics for biomarker development will be overviewed.
115
EMODIN-INDUCED MULTIPLE DRUG-RESISTANCE
GENE EXPRESSION IN RAT C6 GLIOMA CELLS
THROUGH AFFECTING MAPK SURVIVAL AND NFKAPPAB SIGNALING PATHWAYS
Jing-Gung Chung1,2,3
1Departments
of Microbiology, 2Pharmacology, 3Biological
Science and Technology, China Medical University,
Taichung, Taiwan, ROC
We wanted to test whether or not emodin has suppressive
effects on glioma cells. In the present study, emodin inhibited
the proliferation and induced apoptosis of C6 cells at a 12 h
treatment, but surprising results showed that C6 cells survived
a 72 h drug treatment and resistance to emodin occurred. C6
cells overcame emodin-induced apoptosis by inhibition of the
expression and activation of apoptosis-associated proteins
including p53, Bax, Bcl-2, Fas and caspase-3. C6 cells were
able to express antioxidant proteins (SOD and catalase) to
reduce ROS-induced cytotoxity of emodin and overexpress
multi-drug resistance genes (Mdr1a, MRP2, MRP3 and
MRP6) to decrease the intracellular accumulation of emodin.
EMSA analysis showed that emodin decreased NF-κB
expression at 24-h treatment but at 48 h treatment, emodin
increased NF-κB activity. Confocal microscopy showed that
emodin induced NF-κB translocation from cytoplasma to
nuclei. C6 cells activated the MAPK survival pathway and
expressed DNA repair gene (MGMT) and associated proteins
(PARP and XRCC1) to recover cell activity. C6 cells also
expressed GRP78 to decrease emodin-induced ER stress
which would cause apoptosis in C6 cells, and GRP78 inhibited
the expression of GADD153 to enhance the expression of Bcl2 which could balance the ER-induced and mitochondriainduced apoptosis of C6 cells.
116
THE ROLE OF PROTEIN PHOSPORYLATION IN
BREAST CANCER
Jonas Cicenas
Evolutionary Biology, Zoological Institute, University of
Basel, Vesalgasse 1, CH-4051, Basel, Switzerland
Molecular analysis of cancer tissue samples, carried out for
diagnostic and prognostic purposes, provides valuable data
about the expression of individual proteins or genes. The most
frequent method for extracting molecular information from
human tissues is to visualize protein levels in tissue either by
immunohistochemistry or enzyme immunoassay approaches.
Such analysis, however, remains limited in its ability to
elucidate the function of such proteins. Protein function is
regulated not only by transcription and translation, but also by
such posttranslational modifications. On of the most important
of these modifications is phosphorylation, which lies behind
most pathways cell signal transduction and is thus fundamental
both normal physiology and disease. Given these considerations,
the number of proteins in the activated (phosphorylated) state
may be more important biologically than the total number of
proteins present. Our data suggests that protein phosphorylation,
provides either additional or independent prognostic value for
primary breast cancer patients.
In this overview we will demonstrate, that increased levels
of phosphorylated akt predicts poor prognosis in breast cancer.
3241
ANTICANCER RESEARCH 28: 3157-3556 (2008)
We will also discuss some data showing, that phosphorylation
of ErbB-2 is an independent predictor of poor prognosis in
primary breast cancer patients. In addition we will show some
new, unexpected and yet unpublished results on SchA
phopsorylation in breast cancer.
117
INFLUENCE OF THE STRUCTURE OF NEW
ANTHRACYCLINE ANTIBIOTICS IN THEIR
STABILITY IN COMMONLY USED
I.V. INFUSION SOLUTIONS
Judyta Cielecka-Piontek1, Anna Jelińska1,
Agnieszka Dołhań1, Irena Oszczapowicz2
and Małgorzata Wąsowska2
1Poznan
University of Medical Sciences, Department of
Pharmaceutical Chemistry, Faculty of Pharmacy, Poznań;
2Department of Modified Antibiotics, Institute of
Biotechnology and Antibiotics, Warsaw, Poland
The aim of this study was to determine the influence of the
structure of new derivatives of daunorubicin, which were
synthesized at the Institute of Biotechnology and Antibiotics in
Warsaw (Poland) (1), on their stability in various commonly
used i.v. infusions solutions. This study is a continuation of
biological activity investigations of these derivatives (2, 3).
The stability of daunorubicin derivatives containing at
position C-3’ daunosamine a piperidine (DD–1), morpholine
(DD–2), pyrrolidine (DD–3) or hexahydroazepine (DD–4)
moiety was studied in aqua pro injectione, 0.9% sodium
chloride, 5%, 10%, 20% glucose, Ringer’s solution, lactated
Ringer’s injection, mixture of 0.9% sodium chloride and
glucose (1:1; 1:2), pediatric solution, multielectrolic solution,
Jonosteril®Basic solution and 20% mannitol after store: at
room temperature (2, 4, 6, 24 h), at 2-8˚C (2, 6 24 h) and at
–16˚C (30 days).
The derivatives were recognized as stable when changes in
their initial concentration did not exceed 10%. After storage
at room temperature the derivative with pyrrolidine moiety
was the most stable (in 84.6% of the solutions) whereas the
morpholine derivative was stable only in two of the solutions
during 2 h.
After storage at 2-8˚C stability of DD–1 in seven solutions,
DD–2 in three solutions, DD–3 in four solutions and DD–4 in
nine solutions were bigger. However, storage of DD–3
solutions in aqua pro injection, 0.9% sodium chloride and
DD–4 in multielectrolic, Jonosteril®Basic and 5% glucose
solutions at –16˚C 30 days decreased their stability.
A previous study showed that the derivative with
morpholine moiety had the highest biological activity,
whereas it was the less stable in i.v. infusions solutions
therefore solutions of this derivative have been prepared ex
tempore.
3242
1 Wąsowska M, Oszczapowicz J, Oszczapowicz I and Owoc
A: Patent C07H 15/252 (2006.01).
2 Wąsowska M, Oszczapowicz I, Wietrzyk J, Opolski A,
Madej J, Dzimira S and Oszczapowicz J: Influence of the
Structure of New Anthracycline Antibiotics on their
Biological Properties, Anticancer Res 25: 2043-2048, 2005.
3 Wąsowska M, Wietrzyk J, Opolski A, Oszczapowicz J and
Oszczapowicz I: Effect of structural modifications of
anthracyclines on the ability to overcome drug resistance of
cancer cells, Anticancer Res 26: 2009-2012, 2006.
118
THE CHICK EMBRYO CHORIOALLANTOIC
MEMBRANE AS AN IN VIVO MODEL FOR STUDY
TUMOR ANGIOGENESIS AND METASTASIS
Anca Maria Cimpean1, Domenico Ribatti2 and Marius Raica1
1“Victor
Babes” University of Medicine and Pharmacy
Timisoara, Department of Histology, Piata Eftimie Murgu,
nr. 2, 300041, Timisoara, Timis, Romania;
2University of Bari Medical School, Department of Human
Anatomy and Histology, Piazza G. Cesare, 11, Policlinico,
70124 Bari, Italy
Tumor angiogenesis and metastasis – two sides of the same
coin, two processes which are directly involved in the
progression of malignant tumors. Many unresolved problems
concerning these two aspects impair the clinical management
of the tumors and also the choice of proper therapy. Most
heterologous transplants of human and rodents tumors can
survive on chick CAM by several passages with different
patterns, and the intravascular and extravascular pathways of
tumor metastasis can be easily differentiated on CAM model.
The behaviour of a tumor and its metastasis are different
concerning therapy response and prognosis because of an
incomplete molecular characterization of the tumors and
their microcirculation. Metastases and their vascularization
are not well understood. The chick embryo chorioallantoic
membrane (CAM) represents an experimental model for
dynamic study of tumor metastasis and angiogenesis. The
rich vascular network of the CAM provides a useful tool for
studying the recruitment of the neovessels by the tumors
implanted on the CAM. The daily direct observation of
macroscopic changes of a tumor and its vascular network
represents an advantage for this in vivo model. Many
antiangiogenic agents were studied using the CAM model.
Fluorescent labelled tumor cells can be directly monitored
for their capability of local invasion and metastasis on chick
CAM. The lack of a inflamatory response which
characterizes this model in early-stages of embryonic
development can help us to study tumor angiogenesis and
metastasis in the absence of this process. Morphological
changes and molecular characterization of metastatic cells
Abstracts of the 8th International Conference of Anticancer Research, 17-22 October 2008, Kos, Greece
are little studied and could be a starting point for a better
understanding of differences in the behaviour of a primary
tumor and its metastasis in different organs. The reduced
number of antibodies and reagents available with specificity
for chick CAM blood and lymphatic vessels limits the fine
characterization of the angiogenic response by using this
model, but the relatively recent complete characterisation of
the chick embryo genome will be helpful to synthesize a
broad panel of antibodies with high specificity for chicken
tissues, especially for blood and lymphatic endothelial cells
and stroma components. This aspect could be useful to better
characterize the interactions between implanted human
and/or mouse tumors and chicken tissues. Embryonic
microenvironments have been shown to inhibit the
tumorigenicity of a variety of cancer cell lines. In this
context, the embryonic microenvironment of the chick CAM
could provide an opportunity to study the influence of such
microenvironment on cancer cell development and their
metastatic properties.
119
PROTEOMIC ANALYSIS OF PROSTATE TUMOR
TISSUE AND PROXIMAL FLUID FOR CANCER
BIOMARKER DISCOVER
Brian L. Hood1,2, Joel B. Nelson3 and Thomas P. Conrads1,2
1Department
of Pharmacology and Chemical Biology,
Proteomics Facility, University of Pittsburgh
Cancer Institute, 3Department of Urology, University of
Pittsburgh School of Medicine, Pittsburgh, PA, USA
2Clinical
Armed with sequence information of the human and mouse
genomes, a major aim of biological science is toward
unraveling the underlying molecular events that lead to
cellular function/dysfunction in cancer, with the goal of
discovering better diagnostic markers and therapeutic targets.
Proteomics aims to facilitate this process by applying newly
developed methods and advanced analytical tools, such as
mass spectrometry, for the investigation of the protein
complement en masse. Conventional protein biomarker
discovery investigations are predominantly performed with
samples such as serum/plasma. While serum/plasma is more
desirable from a clinical standpoint, tissue likely possesses a
greater abundance of readily identifiable proteins directly
reflective of disease; however, most of these proteins are
unlikely to be released from the tissue into the circulatory
system, thereby limiting their clinical utility. We propose that
investigation of proximal fluids may provide a novel
connection between tissue and serum to permit the
identification of proteins that posses a high likelihood of being
directly related to pathophysiology and that are readily
assayable from serum. This lecture will highlight our efforts
in applying advanced proteomic discovery methodologies in
identification and validation of prostate cancer biomarkers
from prostate tissue and expressed prostatic secretions, a novel
proximal fluid for proteomic discovery.
120
PET IN BREAST CANCER
A. Constantinidou
The Royal Marsden Hospital, London, UK
Background: Positron Emission Tomography (PET) has been
an exciting development in recent years, providing accurate
functional information on disease status as well as anatomical
information when combined with Computed Tomography
(CT). The role of PET/CT in breast cancer is not yet clearly
defined. Aim: To summarize the current data on the utility of
PET in breast cancer and to assess its contribution in
optimising management. Methods: Available data on the role
of PET in breast cancer come from rather small predominately
retrospective studies. Results: The principal areas where
PET/CT appears useful in breast cancer management have
been identified. It is currently the most accurate modality to
define/ restage metastatic breast cancer. It is often revealing
unsuspected metastases in up to 30% of patients. It is
particularly useful in detecting bony lytic metastatic disease
and the entity of “bone scan negative, PET/CT positive”
disease is now clearly recognised. PET/CT is effective in
assessing response to chemotherapy and hormonal treatment
earlier than any other method currently available. It has
successfully been used in the evaluation of indeterminate
lesions on conventional imaging. Conclusion: As PET/CT
becomes more widely available it is likely to be used early and
extensively in the management of breast cancer. Evidence
suggests it can play a key role in a number of areas. Formal
guidelines for the use of this modality in breast cancer are
warranted.
121
SMALL RENAL TUMORS: ALTERNATIVE NON
SURGICAL TREATMENTS
G. Conti
Department of Urology, St. Anna Hospital, Como, Italy
In the last two decades surgical conservative approach has
become an accepted standard treatment in patients with
small renal tumours either in presence of a normal
contralateral kidney or in case of a solitary one or if
multiple neoplastic lesions are present. More recently the
development of new technologies as cryotherapy,
radiofrequency and high intensity focused ultrasounds has
offered an alternative way to conservatively manage small
renal masses. Cryoablation is the most diffuse and
3243
ANTICANCER RESEARCH 28: 3157-3556 (2008)
experimented technique. By a creation of a well controlled
ice-ball cellular damage and necrosis are obtained
(immediately related to ice crystals formation inside the
sphere, late by coagulative necrosis, apoptosis regulation
and vascular damage). Real time step by step control may
be obtained by sonography. The preferred way is the
laparoscopic one but percutaneous approach is nowadays
available with the new generation’s probes. Radiofrequency
induces a thermal damage by the insertion of needle probes
(single, multiple or spiral shaped) inside the tumour
delivering a high frequency (300-800 kHz), high powered
(90-200 W) electrical current that drives the temperature up
to 105˚C with a non reversible coagulative necrosis. The
real time control by sonography is possible but less
accurate. Percutaneous approach is easily feasible with this
technique. In a series presented by the Cleveland Clinic
Team local failure was 1.8% for Cryo and 11.1% for
radiofrequency without any difference in renal function
preservation. Cancer specific survival range between 97%
and 100% at a median follow-up of 3 years for both
treatments in four different series of patients, and overall
survival between 80% and 100% at 3 years. Tumour
recurrence is 24.3% after Radiofrequency and 9.0% after
Cryo 70% of recurrences is diagnosed after 3-4 months of
follow-up and 92% at 1 year. Bleeding and perirenal
haematoma as well as capsular fractures are the most
common cryo-related morbidities; upper urinary tract
damage and UPJ obstruction are more frequent after
radiofrequency procedures. Post Cryo fibrosis appeared
more extensive than that following primary radiofrequency
when salvage surgery was performed. The principal
indication for alternative techniques is very similar to that
for nephron sparing surgery regarding tumours dimension,
presence of solitary kidney, multiple bilateral lesions;
Cryoablation and radiofrequency are more simple than
surgery, morbidity is significantly decreased and, when
percutaneously performed, hospital stay is very short (day
or one-day surgery procedures) with comparable results in
terms of cancer specific and overall survival in particular
with last generation’s Cryo probes.
Rehman J, Landman J, Lee D, Venkatesh R V, Bostwick DG,
Sundaram C and Clayman RV: Needle-based ablation of renal
parenchyma usinmicrowave and cryoablation. J Endourol
18(1): 83-104, 2004.
Gervais DA et al: Indications, results, and role in patient
management over a 6-year period and ablation of 100 tumors.
AJR Am J Roentgenol 185: 64-71, 2005.
Weld KJ and Landman J: Comparison of cryoablation,
radiofrequency ablation and high-intensity focused ultrasound
for treating small renal tumours. BJU International 96: 12241229, 2005.
Hegarty NJ, Gill IS, Desai MM, Remer EM, O’Malley CM
and Kaouk JH: Probe ablative nephron-sparing surgery:
3244
cryoablation versus radiofrequency ablation. Urology 68(Suppl
1A): 7-13, 2006.
Mouraviev V, Joniau S, Van Poppel H and Polascik TJ:
Current Status of Minimally Invasive Ablative Techniques in
the Treatment of Small Renal Tumours. Eur Urol 51: 328-336,
2007.
Kunkle DA, Egleston BL and Uzzo RG: Excision, ablation, or
surveillance of small renal masses:meta-analysis and
contemporary literature review - Abstr # 640. Proc AUA
Anaheim 2007.
122
SYNTHESIS AND EVALUATION
OF IMIDO-SUBSTITUTED-NAPHTHOQUINONE
DERIVATIVES AS INHIBITOR
OF MAPK SIGNALING CASCADE
IN PROSTATE CANCER CELLS
Robert L. Copeland Jr.1, Jharna R. Das1, Oladapo Bakare2,
YaYin Fang3, Desta Beyene4 and Yasmine M. Kanaan3
Departments of 1Pharmacology, 2Chemistry, 3Biochemisty
and 4Microbiology College of Medicine and Cancer Center,
Howard University, Washington, D.C. 20059, USA
Prostate cancer (PC) is the most commonly diagnosed cancer
in American men with an estimated 186,320 new cases
diagnosed in 2008. Androgen ablation is highly effective
palliative therapy; however, most men eventually relapse due
to the presence of androgen independent cancer cells.
Currently there are no therapies that effectively eliminate
these androgen-independent PC cells. It has been reported
that MAPK pathways play a critical role for survival and
proliferation of androgen-independent cells. Our hypothesis
is that enhanced response in PC therapy may require
inhibitors that affect multiple signal transduction pathways.
In our studies, imido-substituted chloronaphthoquinones have
been synthesized that are selective inhibitors of MAPK.
Experiments showed that 2-chloro-3-(N-succinimidyl)-1,4naphthoquinone and analogs have IC50s against purified
MEK in the range of 0.4-10 μM. Subsequently these imidosubstituted chloronaphthoquinone analogs were tested in cell
proliferation assays in androgen-sensitive (LNCaP, CWR22), androgen-insensitive (PC-3, DU-145) cells, normal bone
marrow cells, HS5 and normal prostate cells, RWPE1.
Growth inhibition of each cell line revealed significant
antitumor activities within concentration ranges of 1-3 μM
for the cancer cells. The effect of 2,3-dichloro-5,8dimethoxy-1,4-naphthoquinone (DCDMNQ) on LNCaP,
CWR22, PC3, DU145 HS5 and RWPE1 cells revealed
significant antitumor activities with IC50s, of 1±0.1, 3±0.3,
1.5±0.1, 3±0.3, 10±0.5 and 15±0.6 μM respectively.
On the basis of this cell-based cytotoxicity screen,
DCDMNQ demonstrated the best efficacy. Cell cycle analysis
Abstracts of the 8th International Conference of Anticancer Research, 17-22 October 2008, Kos, Greece
showed that DCDMNQ inhibited progression through the cell
cycle in PC-3 and DU-145 cell lines in a time-dependent
manner stopping at the S-phase. The result for LNCaP cell
line was inconsistent; whereas, in CWR-22 cell line the drug
arrested cells in G1 phase of cell cycle with greatest
proportion of cells in G1 phase by day 5. The compound
showed no effect on the cell cycle progression in bone
marrow HS-5 cell line. In addition, DCDMNQ induced
apoptosis in the androgen-independent cells preferentially
over that of the androgen-dependent cell lines in a timedependent manner.
These findings were further validated by Western blot
analysis. To verify that DCDMNQ maintains ability to inhibit
MAP kinases, Western blot analysis was performed to evaluate
the effect of this compound on generation of phosphorylated
MAPK protein in PC-3 and DU-145 cell lines. The results
revealed that the initial insult of DCDMNQ decreased AKT
activity and at later time points inhibited other cell survival
pathways such as MEK 1/2, ERK 1/2, and JNK 1/2 in
androgen-independent cell lines (PC3 and DU145), whereas
androgen-dependent LNCap showed significant decrease in
ERK 1/2 and AKT in time-dependent manner but MEK 1/2,
and JNK 1/2 showed activation at 3 days following significant
decrease at 5 days exposure. It was demonstrated that
DCDMNQ can inhibit MEK, ERK, AKT and p38
phosphorylation either through inhibition of multiple kinases
or via direct inhibition which would then prevent downstream
phosphorylation.
Furthermore, active small molecule kinase inhibitors to date
are ATP mimics that bind to the intracellular ATP-binding
domain within the kinase. It has been proposed that MEK1/2
can be inhibited through a novel, noncompetitive mechanism.
X-ray crystallography structure of MEK1/2 in complex with
MgATP reveals that the enzyme has a unique inhibitor binding
pocket adjacent to the ATP binding site. We carried out
molecular modeling using DCDMNQ in concurrence with the
published structure of the complex of MEK with MgATP, and
the MEK inhibitor 5-bromo-N-(2,3-dihydroxypropoxy)-3,4difluoro-2-[(2-fluoro-4-iodophenyl)amino]-benzamide (BBM)
to explore whether imido-substituted 1,4-naphthoquinones
might bind via a similar non-competitive mechanism. Our
studies showed that in the crystal structure a binding pocket
for DCDMNQ is deep inside of MEK. Evaluation of hydrogen
bonding for DCDMNQ when docked to this pocket
demonstrates that it can form hydrogen bonds with LYS97,
SER212 and water (HOH97). Thus the presence of DCDMNQ
induces conformational changes in the unphosphorylated
MEK1/2 that locks it into a closed but catalytically inactive
species.
Thus cytotoxicity of DCDMNQ is mediated via inhibition
of MAPK/AKT pathways in prostate cancer cells in vitro.
Therefore, this compound represents a novel class of
compounds which might lead to future therapeutic
interventions of prostate cancer while protecting bone marrow
and normal prostate epithelial cells.
Supported by NCI grant U54-CA914-31 and G12 RR003048
RCMI.
123
EXPRESSION OF VITAMIN D-24-HYDROXYLASE
(CYP24) IN BENIGN AND MALIGNANT BREAST
TISSUES AND CELL LINES
T. Cordes1, M. Friedrich2, S. Becker1,
K. Diedrich1, D. Fischer1 and M. Thill1
1Klinik
für Frauenheilkunde und Geburtshilfe,
UKSH Campus Lübeck;
2Klinik für Frauenheilkunde und Geburtshilfe,
Helios Klinikum Krefeld, Germany
Introduction: It is well known that vitamin D and its
metabolites have a protective effect against cancers, 1,25Dihydroxyvitamin D3, the biological active metabolite of
Vitamin D, is known to regulate cell proliferation in various
cell lines. It is also essential for the regulation of calcium and
phosphate levels and of the bone metabolism. Vitamin D3 is a
secosteroid
hormone
which
derives
from
7dehydrocholesterole. In the skin it is synthesized in
combination with UV-radiation from the precursors 7dehydrocholesterole and provitamine D3. Hepatocytes
transform it to 25-hydroxyvitamin D3. Six cytochrome P450
hydroxylases can exhibit this 25-hydroxylation, with the main
enzyme being CYP27A1 (25-hydroxylase). The subsequent
step is a 1-hydroxylation by CYP27B1 (1α-hydroxylase)
which produces the most active form of vitamin D3, 1,25dihydroxyvitamin-D3 (calcitriol). This metabolite is inactivated
by a 24-hydroxylation by CYP24 40 (24-hydroxylase).
Alternative splicing frequently occurs in breast cancer cells;
different splice variants of a given protein can display different
biological functions and may cause tissue-specific variations.
In this study we describe the expression of 24-OHase in
human benign and malign breast tissue. Methods: Expression
of 24-OHase RNA and protein was assessed by real-timepolymerase chain reaction (RT-PCR). To determine which
variants are translated in protein we accomplished western blot
analysis. Results: The expression of 24-OHase RNA was
reduced by more than 50% in RT-PCR as well as in western
blotting compared to benign breast tissues. Discussion: Breast
cancer tissue has a reduced activity of 24-OHase which leads
to higher levels of active metabolites of Vitamin D. Alternative
splicing of 24-OHase might play a role in regulating levels of
the active enzyme. High levels of splice variants might lead to
a reduction of the active protein. We found less splice variants
in malignant breast cancer tissue. These results correspond
with the data found in previous studies we performed in
malignant and benign gynaecologic cell lines.
3245
ANTICANCER RESEARCH 28: 3157-3556 (2008)
124
LIGAND-DIRECTED DELIVERY OF CYTOKINES TO
TUMOR VASCULATURE USING NGR/isoDGR
PEPTIDES
Angelo Corti
Department of Oncology, Cancer Immunotherapy and Gene
Therapy Program, San Raffaele Scientific Institute,
via Olgettina 58, 20132 Milan, Italy
UNRESECTABLE, CHEMOREFRACTORY
COLORECTAL LIVER METASTASES
Maurizio Cosimelli1, Pierpaolo Cagol2,
Livio Carpanese1, Francesco Fiore3,
Daniele Gasparini2, Onelio Geatti2,
Rita Golfieri4, Francesco Izzo3,
Rosa Sciuto1 and Carlo L. Maini1 on behalf of the Italian
Society of Locoregional Therapies in Oncology
1Regina
The use of cytokines, such as tumor necrosis factor-α (TNF)
and interferon-γ (IFNγ), in cancer therapy is often limited by
strong systemic toxicity and poor efficacy. To improve the
therapeutic index of these drugs we have developed, in the last
years, a vascular targeting approach based on cytokine fusion
with peptides containing Asn-Gly-Arg (NGR) or isoAsp-GlyArg (isoDGR) motives, i.e. ligands capable to bind CD13 or
specific integrins expressed by angiogenic endothelial cells
and, consequently, to deliver these cytokines to tumor
neovasculature. Studies in various animal models have shown
that the therapeutic index of these fusion proteins is greater
than that of non-targeted cytokines. Furthermore, we also
observed that systemic administration of very low doses
(picograms) of NGR-TNF or isoDGR-TNF fusion proteins
can increase the penetration of chemotherapeutic drugs in
tumors, by altering endothelial barrier function. NGR-TNF is
now under investigation in phase II clinical studies for cancer
treatment, alone and in combination with chemotherapy. Since
early preclinical studies we soon realized that the dose-reponse
curve of these peptide-cytokine fusion products is complex,
either when used alone or in combination with chemotherapy.
For instance, while synergy with chemotherapy can occur with
doses of NGR-TNF in the picogram range (about 106-fold
lower than the LD50) increasing the dose to nanograms leads,
paradoxically,
to
lower
responses.
Furthermore,
coadministration of NGR-TNF with endothelial-monocyte
activating polypeptide-II (EMAP-II), an inflammatory
cytokine known to sensitize tumor blood vessels to TNF, can
induce synergistic pro-apoptotic effects with low-dose EMAPII (picograms), but not with high doses (nanogramsmicrograms). This behavior has been observed also with
IFNγ-NGR. Studies on the mechanism of action have shown
that high doses of targeted or non-targeted TNF, IFNγ or
EMAP-II can activate counter-regulatory mechanisms that
efficiently block or counteract cytokine activity. Thus, targeted
delivery of low doses of cytokines to tumor blood vessels is a
novel strategy for avoiding not only toxic reactions, but also
for overcoming counter-regulatory mechanisms.
125
A PHASE II MULTICENTRIC PROSPECTIVE TRIAL
ON HEPATIC ARTERIAL YTTHRIUM
MICROSPHERES AS SALVAGE THERAPY IN
3246
Elena National Cancer Institute, Rome;
of Udine;
3Cancer Institute of Naples;
4University of Bologna, Italy
2University
Background: Intra-arterial injection of 90Y resin
microspheres radiotherapy (SIRT) enables delivery of
tumorcidal doses of radiation to malignant tumor, with
minimal damage to adjacent tissue. This multicentre phase
II study is the first prospective evaluation of SIRT as salvage
therapy for patients with colorectal liver metastases who had
failed prior oxaliplatin- and irinotecan-based regimens.
Methods: Eligible patients had a life expectancy of >6
months, adequate hepatic and renal function and an absence
of major vascular anomalies and pulmonary shunt >10%.
The gastroduodenal and right gastric arteries were
embolized before injection of microspheres (median dose
1.7 GBq; range 0.9-2.2) into the hepatic artery by
arteriography. Results: Patients were enrolled and followed
up for a median of 11 months (mos) (range 2-27). Of 50
eligible patients, 38 (76%) had received at least 4 lines of
chemotherapy. Most patients had synchronous disease
(72%), >4 hepatic metastases (58%) (median size 50 mm;
range 8-120), involving 25-50% of the liver tissue (60%)
and bilateral spread (70%). Early and late (after 48 h) WHO
G1-2 toxic events (mostly fever and pain) were observed in
16% and 22% of patients, respectively. One responding
patient died after 60 days due to liver failure. Of 46 patients
who were evaluable for response using RECIST criteria, 1
patient (2%) had a complete response (CR), 11 (22%) a
partial response (PR), 12 (24%) stable disease (SD) and 22
(44%) progressive disease (PD). In responders (CR + PR +
SD), the maximum diameter of nodules diminished to 35
mm. The Kaplan-Meyer overall median survival was 13 (CI
7-18) mos, with a significant difference (p=0.0006) between
responders 16 (CI 13-19) mos and PD 8 (CI 4-12) mos. At
2 years, survival was 40.3% and 0% in responders and PD,
respectively. The median time to progression (mostly
extrahepatic) was 4 (CI 3-5) mos. Conclusion: In heavily
pretreated patients, 90Y resin microspheres produced an
encouraging median survival, with acceptable toxicity, that
compares favorably with previous phase II/III studies of
chemotherapy regimens used as third- or subsequent lines
of therapy.
Abstracts of the 8th International Conference of Anticancer Research, 17-22 October 2008, Kos, Greece
126
ULTRACONSERVATIVE SURGERY AFTER
NEOADJUVANT CHEMORADIATION
IN LOCALLY ADVANCED RECTAL CANCER
M. Cosimelli, R. Mancini, F. Ambesi Impiombato, C. Garufi,
M. Zeuli, G. Paoletti, F. Graziano, I. Sperduti, V. Stigliano
and M. Caterino
The Colorectal Disease Management Team, Regina Elena
National Cancer Institute, Rome, Italy
Neoadjuvant chemoradiation (CHRT) downstages up to two
thirds of low rectal cancer patients (pts.) clinically staged T34, any N or any T, node-positive (N+); risk of positive lymph
nodes in major responders (pT0-1) ranges from 0 to 17%. In
our experience on 186 consecutive pts who had undergone
neoadjuvant chemoradiation for locally advanced, low rectal
cancer, the pathologically complete (pT0) or almost complete
(pTmic, pT1) response was 27.9%. Clinical, pathological and
biological predicting factors for response such as number of
endoscopic quadrants involved, TRG classification, low score
of thymidylate aynthase, p53 negativity and bcl-2 positivity
were identified. Chances of sphincter-saving surgery and
pelvic control of disease were significantly high (88% and
92% respectively) after CHRT (oxaliplatin, capecitabine and
5,040 cGy) and total mesorectal excision surgery (TME);
also risk of metastatic mesorectal lymph nodes was
particularly low (3.1%) in the 52 pts. pT0-1. A subset of 20
pts. cT0-1 underwent a transanal local excision (LE) for
different reasons (elderly or refusal of TME surgery): 11
(55%) were staged pT0, another 8 (40%) pT1 and only one
pT2 (5%). No deaths have been observed as yet (median
following, 18 months); three local relapses (median time, 9
months) occurred in the pT2 patient and in two other pT1.
All the 3 patients are free of disease after a salvage TME
sphincter-saving surgery (one node-positive); another patient
developed distant metastasis. In conclusion, ultraconservative
rectal surgery is feasible and oncologically safe in wellselected rectal cancer pts. after major response to CHRT.
127
MECHANISMS OF REDOX-MODULATED
RESISTANCE TO APOPTOSIS IN TUMOUR CELLS
Thomas G. Cotter, Christopher Pettigrew, Ruth Naughton
and Claire Quiney
Tumour Biology Laboratory, Department of Biochemistry,
University College Cork, Ireland
There is increasing evidence within the literature that the
decreased susceptibility of tumour cells to stimuli that induce
apoptosis can be linked to their inherently increased redox
potential. This research work focuses on the PI3-kinase/Akt
pathway, and the multiple points along this signalling pathway
that may be redox regulated. The PI3-kinase/Akt pathway can
influence a cell’s sensitivity to death-inducing signals, through
direct manipulation of apoptosis regulating molecules or by
regulating the activity of key transcription factors. Proteins
involved in the control of apoptosis that are directly regulated
by the PI3-kinase/Akt pathway include caspase-9, Bad and the
transcription factor GSK-3beta. Lately, it is becoming
increasingly obvious that phosphatases are a major counter
balance to the PI3-kinase/Akt pathway. Phosphatases such as
PP2A and PP1alpha can dephosphorylate signalling molecules
within the PI3-kinase/Akt pathway, blocking their activity. It is
the balance between the kinase activity and the phosphatase
activity that determines the presence and strength of the PI3kinase/Akt signal. This is one reason why any protein
modifications that hinder dephosphorylation can increase the
tumour survival advantage. One such modification is the
oxidation of the sulphydryl group in key cysteine residues
present within the active site of the phosphatases. The
generation of H2O2 by the Nox (NADPH oxidase) system is
central to this effect in prostate and CML leukaemia cells.
128
REGULATORY MECHANISMS OF VITAMIN D
SYNTHESIS AND CATABOLISM FOR
COLORECTAL CANCER PREVENTION
Heide S. Cross, Thomas Nittke, Maya Khorchide and
Enikö Kallay
Department of Pathophysiology, Medical University Vienna,
A-1090, Austria
Occurrence of non-familial sporadic colorectal cancer (CRC)
is frequent, especially in rich industrialized countries. High
incidence has been related to environmental nutritional factors
and progression into clinically manifest disease may take
several decades. Epidemiological studies indicate that vitamin
D insufficiency may also play a role in its etiology. Vitamin D
insufficiency is determined by serum 25-hydroxy vitamin D3
(25-D3) concentration (<75 nmol/l). Lifestyle and nutrition
may contribute to insufficiency, though a major part of vitamin
D is produced in skin cells by UV-B, and only fatty fish and
egg yolk contain vitamin D in appreciable amounts. 25-D3 is
converted by hydroxylation in kidney proximal tubule cells to
the active metabolite 1,25-dihydroxy vitamin D3 (1,25-D3).
Serum 1,25-D3 does not exceed picomole concentrations and
seems not to correlate with cancer incidence. Since in vitro
only nanomolar levels have been shown to display antimitotic
activity, we hypothesized that localized 1,25-D3 synthesis
could occur in extrarenal tissues, reaching nanomole
concentrations, and the prerequisite condition for this is the
availability of sufficient 25-D3 serum levels. We demonstrated
that indeed there is active 25-D3 1α-hydroxylase (CYP27B1)
3247
ANTICANCER RESEARCH 28: 3157-3556 (2008)
in colon mucosal cells and that early during human colon
tumor progression expression of the synthesizing enzyme as
well as of the vitamin D receptor (VDR) is enhanced. In highgrade undifferentiated tumors this expression is diminished and
the vitamin D catabolizing hydroxylase CYP24A1 becomes
prominent. Thus enhanced expression of the vitamin D system
may be an innate defense against further progression of
malignancy, and raising extrarenal local production in organs
prone to malignancy could curb progression.
We established that (phyto)estrogens improved expression
and activity of CYP27B1, and decreased that of CYP24A1.
This could conceivably account for reduced CRC incidence in
women compared with men, and also for reduced incidence in
soy-consuming countries. Dietary calcium is a well-accepted
inhibitor of colonic hyperproliferation. We demonstrated in a
mouse model that low dietary calcium led to
hyperproliferation and to enhanced expression of CYP24A1
in colon mucosa. Interestingly this occurs only in the right
(proximal) colon in both genders. However, only in female
mice on low dietary calcium is CYP27B1 as well as VDR
expression raised, again only in the right colon. In females,
enhanced vitamin D synthesis may override its enhanced
degradation since 1,25-D3 measured in colon mucosa was at
least doubled. This paralleled raised apoptotic activity.
High expression of the catabolic CYP24A1 in
undifferentiated tumors is apparently not associated with gene
duplication, but rather with epigenetic regulation. CpG islands
in the CYP24A1 promoter of cells derived from advanced
human colon tumors are not methylated whereas those of cells
derived from early well-differentiated malignancies are highly
methylated and they do not possess CYP24A1 mRNA or
activity. When the latter cells were treated with a
demethylation agent, they expressed not only CYP24A1
mRNA but also the capacity to degrade 1,25-D3.
This demonstrates that colonic 1,25-D3 could be harnessed
as a biological weapon against tumor progression by enhancing
its mucosal synthesis and by curbing its degradation. While
high doses of active 1,25-D3 given to tumor patients generally
result in hypercalcemia, improving local production in organs
prone to malignancy could slow down progression without
leading to enhanced serum levels and to hypercalcemia.
129
EFFECT OF AN ALLELIC POLYMORPHISM IN THE
DOPAMIN RECEPTOR D2 GENE ON THE RISK OF
CERVICAL CANCER
József Cseh1, István Ember2, Zsuzsanna Orsós2, Antal
Tibold2, Zsuzsanna Varga3, Emese Pázsit4 and István Kiss2
3Department
of Oncotherapy, Pécs University of Sciences,
Pécs;
4Department of Obstetrics and Gynecology, Diósgyőr
Hospital, Miskolc, Hungary
In spite of the decreased mortality rates, cervical cancer is still
an important tumor in developed countries, because of its high
incidence, including precancerous lesions. Human
papillomavirus infection, particularly with high-risk strains is
considered to be the most important risk factor for cervical
cancer. However, in spite of the infection, the cancer will not
develop in several women, which suggests that other risk
factors play also an important role in cervical carcinogenesis.
During the recent years a few studies tried to find an
association between dopamine metabolism and cancer risks.
Since dopamine is an important neurotransmitter, this
connection is probably mediated by causing changes in
cancer-risk modifying behavioral patterns like alcohol
consumption and smoking, but direct molecular effects cannot
be excluded, either. Dopamine receptor D2 (DRD2) takes part
in the intracellular transmission of dopamine effects. The
TaqIA polymorphism (a C32806T substitution) in the DRD2
gene was shown to affect the receptor function, personality
traits and the occurrence of certain mental diseases.
In our case-control study we investigated the effect of
DRD2 TaqIA polymorphism on the risk of cervical cancer.
Altogether 143 women participated in the study. Their HPV
status was determined, and their disease progression was also
recorded. The HPV positive cases were genotyped for DRD2
TaqIA polymorphism by PCR-RFLP, and allele frequencies
were compared between individuals who remained diseasefree and who developed cancer or precancerous lesion. Our
results indicate a moderate risk modifying effect of the TaqIA
polymorphism, which, together with other low penetrance
genetic factors, might have an influence on the risk of cervical
cancer.
130
POLY(ADENOSINE DIPHOSPHATE-RIBOSE)
POLYMERASE-1 EXPRESSION IN CUTENEOUS
MALIGNANT MELANOMAS AS A NEW
MOLECULAR MARKER OF AGGRESSIVE TUMOR
Béla Csete1, Zsuzsanna Lengyel1, Zsolt Kádár1 and
Zita Battyáni1,2
1Department
of Dermatology, Venereology and
Oncodermatology, University of Pécs, Pécs;
2Department of Dermatology, Kaposi Mór Teaching
Hospital, Kaposvár, Hungary
1Department
of Oncology, Fejér County “Szent György”
Hospital, Veszprém;
2Institute of Preventive Medicine, Faculty of Medicine, Pécs
University of Sciences, Pécs;
3248
Poly(adenosine diphosphate-ribose) polymerases (PARPs) are
a family of enzymes which catalyse poly (ADP-ribosyl)ation
of DNA-binding proteins and are directly involved in genomic
Abstracts of the 8th International Conference of Anticancer Research, 17-22 October 2008, Kos, Greece
stability, DNA repair and apoptosis. In this study, we evaluated
the immunomorphology of PARP-1 in melanoma and its
prognostic importance.
We studied PARP-1 expression by immunohistochemistry
in a selected series of 54 primary cutaneous malignant
melanoma (CMM). The findings of the present study suggest
that the neoplastic progression toward the invasive (both
horizontal and vertical) growth phase of CMM cells is
characterized by the loss of cleavage of PARP-1, probably
signaling an imbalance of the apoptotic process in these cells
and leading to further gain to aggression. Overexpression of
full-length PARP-1 was correlated with recurrence and
progression of the disease and so acts as a promising new
biological marker of CMM.
Our study represents the evidence of a direct correlation
between the PARP-1–mediated apoptotic process and the
biological behavior of CMM.
131
LGALS3BP, A TUMOR-ASSOCIATED ANTIGEN,
UPREGULATES VEGF IN HUMAN BREAST
CANCER: POSSIBLE IMPLICATIONS IN
ANGIOGENESIS
Albana Cumashi, Nicola Tinari, Enza Piccolo,
Cosmo Rossi, Rossano Lattanzio, Armida D’Incecco,
Antonino Grassadonia, Maurizia D’Egidio,
Daniela Semeraro, Mauro Piantelli,
Clara Natoli and Stefano Iacobelli
Department of Oncology and Neurosciences, University “G.
D’Annunzio” Chieti-Pescara, Via Colle Dell’Ara, 6100,
Chieti, Italy
Vascular Endothelial Cell Growth Factor (VEGF) represents a
key regulator factor on angiogenesis occurring in a variety of
malignancies, including breast cancer (1). Similarly,
LGALS3BP, a lectin galactoside-binding soluble 3 binding
protein, has emerged as a novel feature that may favour breast
cancer progression and metastasis, since its high expression
levels in patients significantly correlates with poor prognosis
(2-3). So far, how LGALS3BP overexpression intervenes in
tumor progression and metastasis remains still to be
elucidated, but a link between LGALS3BP and tumor
angiogenesis has been recently suggested (4). With the
aforementioned, we sought to study the possible interplay
between LGALS3BP and the proangiogenic molecule, VEGF
in breast cancer. To this end, we initially performed
immunohistochemical studies on the tissue specimens
obtained by biopsies of a group of 40 patients affected by
breast carcinomas, indicating that LGALS3BP expression in
tumor tissues was directly correlated with VEGF expression
in 72.5% of cases. Moreover, in vitro experiments showed that
LGALS3BP treatment could increase VEGF mRNA levels in
MDA-MB-231 breast cancer cells, but not in non tumorigenic
HBL-100 cells. This evidence suggested that LGALS3BP
might represent a new upregulator factor for VEGF
expression/activity in human breast cancer. For a further
confirmation, a stable down-regulation of LGALS3BP in
MDA-MB-231 cells was obtained by using siRNA expression
plasmids: the protein level found in the Conditioned Medium
(CM) of LGALS3BP-silenced cells was 80% less when
compared to the CM-derived from oligo control cells. Very
interestingly, Real Time PCR studies demonstrated that the
level of VEGF mRNA expression in LGALS3BP-silenced
MDA-MB-231 was significantly lower in respect to that
expressed by oligo control cells (55%, p=0.011). Similar
results were obtained also by measuring VEGF protein level
as indicated by using either confocal microscopy or
immunoprecipitation studies. Because VEGF is a principal
regulator factor for endothelial cells, we also studied the
exogenous LGALS3BP-induced effects on human umbilical
vein endothelial cells (HUVECs). Our results show that
LGALS3BP specifically upregulated VEGF mRNA
expression, but did not affect the expression level of other
important growth factors for HUVEC. In addition,
LGALS3BP, but not the denaturated protein, could activate the
VEGF-promoter transfected in endothelial cells. Finally,
supernatants collected from LGALS3BP-silenced or oligo
control MDA-MB-231 cells, were tested for their capability to
induce in vitro HUVEC tubulogenesis. Our data indicated an
evident decrease of the number of tubuli found onto Matrigel
when HUVEC were incubated with the supernatant of cells
that lack LGALS3BP, thus signifying a promoting role of this
protein on angiogenesis in vitro. Taken together, these results
lead to the conclusion that LGALS3BP might be depicted as a
novel candidate that promotes angiogenesis. Further studies
are in progress for investigating any potential effect of
antibodies directed against human LGALS3BP on the in vivo
growth of MDA-MB-231 breast cancer cell xenografts and on
the related tumor-angiogenesis. This information could lead to
the development of novel antiangiogenic therapy.
1 Folkman J: Angiogenesis in cancer, vascular, rheumatoid
and other diseases. Nat Med pp. 27-31, 1995
2 Grassadonia A, Tinari N, Iurisci I, Piccolo E, Cumashi A,
Innominato P, D’Egidio M, Natoli C, Piantelli M and
Iacobelli S: 90K (Mac-2 BP) and galectins in tumor
progression and metastasis. Glycoconj J 19(7-9): 551-556,
2004.
3 Tinari N, Lattanzio R, Querzoli P, Natoli C, Grassadonia A,
Alberti S, Nenci I, Bruzzi P, Piantelli M, Iacobelli S and on
behalf of the Consorzio Interuniversitario Nazionale per la
Bio-Oncologia (CINBO): High expression of 90K(Mac-2BP)
is associated with an inferior distant recurrence free and
overall survival in node-negative breast cancer patients not
receiving adjuvant systemic therapies. Int J Cancer, (2008),
in press.
3249
ANTICANCER RESEARCH 28: 3157-3556 (2008)
4 Lee JH, Cho ES, Kim MY, Seo YW, Kho DH, Chung IJ,
Kook H, Kim NS, Ahn KY and Kim KK: Suppression of
progression and metastasis of established colon tumors in
mice by intravenous delivery of short interfering RNA
targeting KITENIN, a metastasis-enhancing protein. Cancer
Res 65(19): 8993-9003, 2005.
132
HUMAN PAPILLOMAVIRUS (HPV) INFECTION
ACCOUNTS FOR AN INCREASE IN THE
INCIDENCE AND THE BETTER PROGNOSIS IN
TONSILLAR CANCER IN SWEDEN
Tina Dalianis
Department of Oncology-Pathology, Karolinska Institutet,
Cancer Center Karolinska, Karolinska University Hospital
R8:01, S-171 76 Stockholm, Sweden
We previously reported a parallel three-fold increase in the
incidence of tonsillar cancer and in the proportion of human
papilloma virus (HPV)-positive tumours in the Stockholm
area, between 1970-2002. Notably, while only 23% of the
cases were HPV positive in the 1970s, 68% were HPVpositive during 2000-2002, when testing 203 available pretreatment tonsillar cancer biopsies with both general and typespecific HPV PCRs and sequencing. Moreover, 87% of the
HPV-positive cases were HPV type 16. These results
suggested that HPV infection, with a dominance of HPV 16,
was responsible for the increase in the incidence of tonsillar
cancer, a disease also more common in men than women in
Sweden.
In continuation, we analysed the clinical outcome in these
203 patients and reported that overall disease-free survival was
longer in patients with HPV-positive tumours as compared to
patients with HPV-negative tonsillar cancer. However, a
correlation between prognosis and high viral load, previously
reported in a pilot study, could not be confirmed. Nonetheless,
94% of all tested HPV 16-positive tumours expressed E7
mRNA and the majority of these also expressed E6 mRNA,
indeed supporting the oncogenic role of HPV in tonsillar
cancer.
In parallel, we conducted a smaller study in collaboration
with colleagues from the Metaxas Cancer Hospital in Piraeus,
Greece, where we analysed an additional 103 pre-treatment
samples from 115 patients with head neck cancer, and of these
28 were diagnosed with tonsillar cancer between 1992-2007.
Again, we see a tendency for an increase in the proportion of
HPV-positive tumours from 17% during the years 1992-1998
as compared to 50% between 2000-2007, although
unfortunately the numbers of tumours were too few to allow
for a statistical significance.
Since these studies, the incidence in tonsillar cancer seems
to have increased further in Sweden and particularly in the
3250
Stockholm area. The aim of the present study was therefore to
examine the proportion of HPV-positive tonsillar cancer cases
between 2003-2007 within the Stockholm area. During this
period, 150 pre-treatment tonsillar cancer biopsies were
collected and the samples were analyzed in a similar way to
the samples of the 203 patients above. In this study, we found
that the proportion of HPV-positive tumours between 20032007 was around 80%, with the proportion of HPV-positive
tumours being 86% during 2006-2007.
In summary, the data support that the continued increase in
incidence of tonsillar cancer seems to be due to a continued
increase in the proportion of HPV-positive tumours, at least in
Sweden. Based on recent data, that patients with HPV-positive
tonsillar cancer do better than patients with HPV-negative
tonsillar cancer, we suggest that the presence or absence of
HPV in tonsillar cancer should be considered when tailoring
treatment. Finally, the more recent, very strong association of
HPV with tonsillar cancer should also possibly pave the way
for the development of preventative strategies, such as possible
vaccination against HPV infection in both young women and
men.
133
REACTIVE OXYGEN SPECIES (ROS) COMPRISE A
MOLECULAR TARGET IN PREVENTION OF ORAL
CELL CANCER
Steven D’Ambrosio, Chunhua Han and Haiming Ding
Department of Radiology, Division of Radiobiology, The
Ohio State University, Columbus, Ohio, USA
Redox is a normal physiological process balancing the
intracellular levels of endogenously and exogenously produced
oxidants and antioxidants. The levels of reactive oxygen
species (ROS) are often maintained in a narrow range and
perturbing the balance between pro- and antioxidants in cells
can lead to apoptosis. Due to high levels of metabolism and
other factors, cancer cells often exhibit high levels of ROS.
This may contribute to their high proliferation rates, genomic
instability and promote invasion by killing adjacent normal
cells. To survive, cancer cells maintain a delicate balance
between pro- and antioxidants and perturbing this balance may
offer an opportunity for cancer prevention. A number of
studies indicate that many cancer preventative and therapeutic
agents induce apoptosis via ROS. It is thought that ROS act
as signals to initiate apoptosis via either the intrinsic and/or
extrinsic pathways.
We have been investigating the cancer protective affects of
phytochemicals extracted from a number of fruits. In the
present study, we used organic extracts prepared from avocados
to determine ROS mechanisms involved in prevention using a
human oral cancer cell culture model. Phytochemicals
extracted from avocado flesh using chloroform (D003 extract)
Abstracts of the 8th International Conference of Anticancer Research, 17-22 October 2008, Kos, Greece
selectively inhibit the growth and induce apoptosis in
premalignant and malignant, but not normal, human oral
epithelial cell lines. A number of cellular and molecular
approaches were used to determine mechanisms responsible for
the selective activity of avocado extracts. The premalignant and
malignant oral cell lines contained significantly higher basal
levels of ROS than did the normal oral cell lines. Upon
treatment of the cancer cell lines with the D003 extract, ROS
levels increased 3-fold and induced apoptosis. ROS levels only
increased 1.3-fold in the apoptosis-resistant normal oral cell
line. The increased levels of ROS induced by D003 in the
cancer cell lines appeared to be mediated via mitochondrial
complex I in the electron transport chain. The involvement of
ROS in the selective killing of the cancer cell lines was further
substantiated when these cell lines became resistant to D003induced apoptosis upon reduction of cellular ROS levels by Nacetyl-L-cysteine (NAC). NAC also delayed the induction of
apoptosis in dominant negative FADD-expressing cancer cell
lines, suggesting the role of ROS in this signaling pathway. To
further confirm the role of ROS in extract induced apoptosis,
we transformed the resistant normal oral epithelial cell line
with HPV16 E6 or E7. These cell lines exhibited characteristics
of the oral cancer cell lines, including increased levels of ROS,
and sensitivity to apoptosis induced by the D003 extract.
In summary, the data suggest that: i) ROS may be
regulatory molecules activated by the phytochemicals in
avocado; and ii) perturbing the ROS levels in human oral and
other cancer cells may be a key factor in selective apoptosis
and molecular targeting for chemoprevention by
phytochemicals.
diagnostic imaging of breast cancer. The conjugation is
achieved using standard peptide coupling reactions between
an amino modification on the aptamer and the carboxylic
group on the ligands. An efficient and convenient labelling of
the aptamer with short half-life radioisotopes was achieved as
the last step of the synthesis. Both conjugation and labelling
reactions were monitored by HPLC. The labelled aptamers
were separated from free 99mTc using ultrafiltration, before
injection and imaging for analysis of their tumour localising
potential and pharmacokinetic properties. For the analysis of
the pharmacokinetic properties of the aptamer-radionucleotide
conjugate, we have used gamma-camera imaging in MCF-7
breast cancer tumour model systems.
Stability tests showed that the aptamer-chelator conjugates
have strong 99mTc binding properties and the resulting
complexes are highly stable in vivo, both in terms of nuclease
degradation and leaching of the metal. We analysed the uptake
of two different radiolabelled aptamers, selected against the
naked MUC1 tandem repeat sequence and the tumour
glycosylated Tn antigen respectively, in the tumour at 3, 5, 16,
and 24 hours after the injection. It has been previously shown
that conjugation of aptamers to high molecular weight
polyethylene glycol (PEG) modifies the pharmacokinetic
properties of the radiolabeled product, allowing the complex
longer circulation times and thus offering improved tumour
imaging properties. This approach gave us further possibilities
for development of efficient targeted radiopharmaceuticals for
breast cancer imaging and therapy.
We thank the Breast Cancer Campaign and The Open
University for financial support.
134
DEVELOPMENT OF APTAMERS AS TARGETED
RADIOPHARMACEUTICALS FOR THE
DIAGNOSTIC IMAGING AND
RADIOTHERAPY OF BREAST CANCER
135
ENVIRONMENTAL OESTROGENS
AND BREAST CANCER
C. Da Pieve1, A. Perkins2 and S. Missailidis1
Philippa D. Darbre
School of Biological Sciences, University of Reading,
Reading RG6 6AJ, UK
1Chemistry
Department, The Open University, Walton Hall,
Milton Keynes, MK7 6AA;
2Department of Medical Physics, Medical School, University
of Nottingham, Nottingham, NG7 2RD, UK
Aptamers have shown great potential as novel targeted
radiopharmaceutical entities for the diagnosis and medical
imaging of disease. They offer reduced immunogenicity, good
tumour penetration, rapid uptake and clearance compared to
their monoclonal antibody counterparts. In previous work, we
have reported on the labelling of such aptamers against breast
cancer related biomarkers with radionuclide ligands.
We have successfully conjugated selected aptamers against
the protein core or the tumour glycosylated MUC1
glycoprotein to MAG2 and labelled them with 99mTc, for the
The established role of oestrogen in the development,
progression and treatment of breast cancer raises questions
concerning a potential contribution from the many chemicals
in the environment which enter the human breast and which
possess oestrogenic activity. This may include the plantderived phytoestrogens, synthetic pharmacological oestrogens
of oral contraceptives/hormone replacement therapy, and manmade oestrogen-mimicking chemicals. A range of ubiquitous
environmental contaminants (organochlorine pesticides and
polychlorinated biphenyls) and compounds widely used in the
domestic environment (alkyl phenols, phthalates,
polybrominated diphenyl ethers) possess oestrogenic activity
and have been measured in human breast adipose tissue and/or
in human milk. However, an extensive array of cosmetic
3251
ANTICANCER RESEARCH 28: 3157-3556 (2008)
chemicals are applied to the human breast area on a daily basis
and are left on the skin allowing for accumulation in the
underarm and upper outer breast area. Our work is showing
that an increasing number of these cosmetic chemicals possess
oestrogenic activity and are measurable in human breast
including parabens, aluminium salts, triclosan, phthalates,
sunscreens, polycyclic musks and other fragrance compounds.
The disproportionate number of breast cancers in the upper
outer quadrant of the breast, just the local area to which these
chemicals are applied, remains strong supportive evidence of
a causal link (Darbre, Anticancer Res 25: 2543, 2005). This
lecture will review evidence for a functional role of the
combined actions of environmental oestrogens in the rising
incidence of breast cancer.
more efficiently than those with mutant p53. A search for the
underlying mechanism revealed disruption of the membrane
lipid raft-associated integrin-signalling pathway. The outcome
of this study might expand our knowledge in developing a
“new” strategy of multi-targeted therapy of the “age-old”
disease cancer utilizing the “age-old” remedies.
136
A MULTI-TARGETED THERAPY FOR CANCER:
AN "AGE-OLD" REMEDY FOR AN "AGE-OLD"
DISEASE
Aims: The ERCC2 gene encodes a DNA repair enzyme that
has multiple regulatory cellular functions. The ERCC2
polymorphism Lys751Gln may alter the capacity for DNA
repair, which could affect the risk of certain types of cancer.
Methods: We examined whether the Lys751Gln polymorphism
was associated with the risk of ovarian cancer in Isfahanian
women by analysing the genotype frequencies in 86 patients
with ovarian cancer and 120 cancer-free controls. Results: The
Gln /Gln genotype was associated with a 53% increased risk
of ovarian cancer. Conclusion: Our results demonstrated that
ERCC2 polymorphisms might be potential risk markers for
ovarian cancer in Isfahan.
Tanya Das1, Gaurisankar Sa1, Charles Tannembaum2 and
Samit Chattopadhyay3
1Division
of Molecular Medicine, Bose Institute, Kolkata,
India;
2Department of Immunology, Cleveland Clinic, Ohio, USA;
3National Centre for Cell Science, Pune, India
Cancer is a multifactorial disease that requires modulation of
multiple pathways and multiple targets. In the recent past,
dietary plant polyphenols, e.g., theaflavins and curcumin, have
provided opportunities to develop strategies for curing cancer
by directly or indirectly altering specific cellular targets. We
attempted to develop a multiple signal modulation therapy of
cancer by targeting signalling pathways leading to (i)
apoptosis and (ii) metastasis. Our approaches centred around
tumour suppressor protein p53. Using human cancer cells of
varying p53 status, we found a definitive co-relation between
p53 status and the signalling pathways targeted by these
polyphenols. Apoptosis was induced in wild-type p53expressing cancer cells by p53-mediated Bax trans-activation
and stimulation of intrinsic death pathway, while in cancer
cells containing mutant p53, activation of death receptordependent extrinsic apoptotic pathway and inhibition of
survival pathway initiated intrinsic mitochondrial death
cascade. In HPV-infected cancer cells, these polyphenols
resisted E6-dependent p53 degradation not only by downregulating E6 via activation of the transcription repressor
Cux/CDP, but also by up-regulating MAR-binding protein
SMAR1. SMAR1 in turn inhibited Mdm2-mediated p53degradation and stabilized p53 through phosphorylation at its
Ser15 residue with simultaneous deacetylation of this tumour
suppressor. Moreover, these plant polyphenols were found to
retard the migration of wild-type p53-expressing cancer cells
3252
137
DNA REPAIR ENZYME POLYMORPHISM
AND RISK OF OVARIAN CANCER IN ISFAHAN
Mehdi Nikbahkt Dastjerdi
Department of Anatomical Sciences, Isfahan University of
Medical Sciences, Isfahan, Iran
138
PTEN AND BCL-2 EXPRESSION IN COLORECTAL
CARCINOMAS WITH MICROSATELLITE
INSTABILITY
Mehdi Nikbahkt Dastjerdi
Department of Anatomical Sciences, Isfahan University of
Medical Sciences, Isfahan, Iran
Aim: The aim of this study was to examine the relationship of
PTEN (phosphatase and tensin homolog deleted on
chromosome 10) and bcl-2 protein expression to microsatellite
instability, as well as to other clinicopathological variables in
colorectal adenocarcinomas. Materials and Methods: We
evaluated the expression patterns of antiapoptotic Bcl-2 and
PTEN proteins, as potential prognostic markers in colorectal
cancer by immunohistochemical staining. To identify highfrequency microsatellite instability (MSI+) specimens, we
performed single-strand conformation polymorphism-based
analysis for BAT26. A total of 100 colorectal specimens were
evaluated. Results: Increased expression of bcl-2 (>50% cells)
was seen in 17 specimens (17%) and loss of PTEN was seen in
14 specimens (14%). No significant correlation was observed
between the proteins or with clinicopathological factors. Loss
of PTEN was more frequent in MSI-positive tumors (8/24
Abstracts of the 8th International Conference of Anticancer Research, 17-22 October 2008, Kos, Greece
[32%]) than in negative tumors (6/76 [8%]; p=0.012).
Conclusion: Our data demonstrate that bcl-2 overexpression
occured in a subset of colorectal carcinomas, while loss of
PTEN often was associated with the MSI phenotype.
139
TP53 CODON 72 POLYMORPHISM AND
MICROSATELLITE INSTABILITY IN
SPORADIC COLORECTAL CANCER
Mehdi Nikbahkt Dastjerdi
Department of Anatomical Sciences, Isfahan University of
Medical Sciences, Isfahan, Iran
Aim: The polymorphic variants at codon 72 of the p53 gene,
encoding either proline or arginine at residue 72, produces
marked change in the structure of p53. From the evidence that
the DNA mismatch repair system and p53 interact to maintain
genomic integrity, we hypothesized that the codon 72 variation
may influence the prevalence of microsatellite instability, a
feature of malignancies associated with mismatch repair
deficiency in sporadic colorectal cancer. Materials and
Methods: We investigated the frequency of microsatellite
instability in three genotypes of P53 codon 72 using genomic
DNAs from 190 paraffin blocks of the sporadic colorectal
adenocarcinomas by testing the BAT-26 marker. Results: MSI
analysis revealed that 27.6% of the tumors were MSI-positive
and 72.4% showed no change (MSI-negative). The frequency
of microsatellite instability in the arginine/arginine,
arginine/proline and proline/proline genotypes were 17.9%,
66.1% and 16% respectively. A significant difference in
distribution of MSI was found for the arginine/proline
genotype as compared with (grouped) arginine/arginine and
proline/proline genotypes (p=0.05). Conclusion: Our findings
suggested that colorectal adenocarcinomas arising in
individuals with p53 codon 72 heterozygosity
(arginine/proline) are preferentially prone to microsatellite
instability more than other genotypes.
140
ANNEXIN A1 EXPRESSION IN
COLORECTAL CANCER
Mehdi Nikbahkt Dastjerdi
Department of Anatomical Sciences, Isfahan University of
Medical Sciences, Isfahan, Iran
Aim: The role of annexin A1 (ANXA1) in tumor development
and progression is controversial. We investigated ANXA1
expression and determined its clinical significance in
colorectal cancer. Methods: Blocks containing primary
colorectal cancer, lymph node metastases, and adjacent normal
mucosa specimens were obtained from 120 Isfahanian
patients. Expression of ANXA1 in these specimens was
analyzed using immunohistochemistry. Results: Complete loss
of ANXA1 expression was observed in 63% of the 120
primary tumors and 85% of the nodal metastases. Loss of
ANXA1 expression was significantly associated lymph node
metastasis and poor histological differentiation. Conclusion:
ANXA1 expression decreased significantly as colorectal
cancer progressed and metastasized, suggesting the importance
of ANXA1 as a negative biomarker for colorectal cancer
development and progression.
141
DETECTION OF LYMPH NODE
MICROMETASTASES IN EARLY BREAST CANCER
Mehdi Nikbahkt Dastjerdi
Department of Anatomical Sciences, Isfahan University of
Medical Sciences, Isfahan, Iran
Aim: The purpose of this study was to examine the usefulness of
the biopsy of the lymph nodes for effective detection of lymph
node micrometastasis in early breast cancer and to clarify the
spread of lymph node micrometastasis. Methods: One hundred
local and regional lymph nodes from 30 patients with early
breast cancer were evaluated by staining with haematoxylin and
eosin and immunohistochemically for antibodies to
pancytokeratin (AE1/AE3) and cytokeratin 14. Results: The
immunohistochemical tests detected occult micrometastases in
16% of the lymph nodes that were negative by haematoxylin
and eosin staining. Conclusion: Routine systematic
lymphadenectomy with immunohistochemical detection of
lymph node micrometastasis contributes to identification of a
larger population at risk of early breast cancer.
142
A NEW NEGATIVE BIOMARKER FOR
BREAST CANCER DEVELOPMENT
Mehdi Nikbahkt Dastjerdi
Department of Anatomical Sciences, Isfahan University of
Medical Sciences, Isfahan, Iran
Aim: The role of annexin A1 (ANXA1) in tumor development
and progression is controversial. We investigated ANXA1
expression and determined its clinical significance in breast
cancer. Methods: Blocks containing primary breast cancer,
lymph node metastases, and adjacent normal mucosa
specimens were obtained from 100 Isfahanian patients.
Expression of ANXA1 in these specimens was analyzed using
immunohistochemistry. Results: Complete loss of ANXA1
expression was observed in 59% of the 100 primary tumors
and 75% of the nodal metastases. Loss of ANXA1 expression
was significantly associated lymph node metastasis and poor
3253
ANTICANCER RESEARCH 28: 3157-3556 (2008)
histological differentiation. Conclusion: ANXA1 expression
decreased significantly as breast cancer progressed and
metastasized, suggesting the importance of ANXA1 as a
negative biomarker for breast cancer development and
progression.
143
DO SHARK LIVER OILS INFLUENCE THE
GROWTH OF NORMAL AND TRANSFORMED
MAMMALIAN CELLS IN CULTURE?
B.C. Davidson1, G. Cliff2, W. Prinz1 and D. Rottanburg1
1School
of Physiology, University of the Witwatersrand
Medical School, Johannesburg, Gauteng;
2Natal Sharks Board, Umhlanga Rocks, KwaZuluNatal,
South Africa
Several reports have indicated an extremely low incidence of
cancer in sharks, although other reports indicate carcinogenesis
in some shark species. Many authors have published reports of
polyunsaturated fatty acids exerting growth inhibitory effects
on transformed cells but not normal cells in culture. It has thus
been hypothesised that n3 polyunsaturated fatty acids, present
in high concentrations in many marine oils, especially shark
liver oils, may exert anticarcinogenic effects, and these n3
polyunsaturated fatty acids have been shown to have
anticarcinogenic effects on mammalian carcinomas. The aim
of this study was to assess whether shark liver oil, from four
Indian Ocean shark species, exerted antiproliferative effects on
certain transformed and normal mammalian cells in culture,
and to assess whether the ratio of n3 to n6 polyunsaturates
influenced the results. Although certain concentrations of the
oils did induce growth inhibition, this was not consistent
between the oils nor did they show a concentration dependence
with either transformed or normal cells. Moreover, the ratio of
n3 to n6 did not seem to be a significant factor. Fatty acid
mixtures mimicking the composition of the shark liver oils also
did not induce any significant profiles of growth inhibition. It
would seem unlikely for the liver oils from these four species
of shark to be of use in anticancer therapy.
144
RUNX1 TRANSLOCATIONS IN MALIGNANT
HEMOPATHIES
Etienne De Braekeleer, Claude Férec
and Marc De Braekeleer
Faculté de Médecine et des Sciences de la Santé & INSERM
U-613, 22 avenue Camille Desmoulins, CS 93837, F-29238
Brest cedex 3, France
The RUNX gene family includes three evolutionarily
conserved genes (RUNX1, RUNX2 and RUNX3) encoding
3254
transcription factors involved in cell lineage differentiation
during development and various forms of cancer. The RUNX1
gene, located in chromosome 21q22, is crucial for the
establishment of definite hematopoiesis and the generation of
hematopoietic stem cells in the embryo. It contains a “Runt
homology domain” (RHD) and a transactivation domain.
RUNX1 can act as activator or repressor of target gene
expression depending upon the large number of transcription
factors, coactivators and corepressors that interact with it.
Three modes of leukemogenesis due to acquired alterations
of the RUNX1 gene have been recognized: point mutations,
amplification and translocations. Some translocations have
been shown to be recurrent, whereas others have been only
reported in a few cases or in a sole case.
At present, 32 partner chromosomes have been described
but the partner gene has solely been identified in 17
translocations at the molecular level. Most of the
translocations involving RUNX1 lead to the formation of a
fusion transcript made of the 5’ region of RUNX1, including
the RHD, fused to the 3’ region of a partner gene, with the
exception of RUNX1-ETV6 in which the 3’ sequences of
RUNX1, including the RHD, is fused to the 5’ region of ETV6,
including its promotor. Three RUNX1 translocations (retaining
RHD) that are fused out of frame to partner genes are also
known. All the translocations that retain RHD but remove the
transcription activation domain have a leukemogenic effect by
acting as dominant negative inhibitors of wildtype RUNX1b in
transcription activation.
145
DELTANp63 EXPRESSION IS
ACTIVATED BY BETA-CATENIN
Charlotte Ruptier1, Alexia De Gaspéris1,
Aurélie Granjon1, Ilta Lafosse1, Philippe Tanière2,
Hong Shi2, Audrey Petitjean2, Estelle Taranchon2,
Catherine Cavard3, Violaine Tribollet1, Thibault Voeltzel1,
Stéphane Ansieau1, Alain Puisieux1, Pierre Hainaut2
and Claude Caron de Fromentel1
1INSERM
U590, Université Lyon, Centre Léon Bérard,
Lyon;
2Molecular Carcinogenesis and Biomarkers Group,
International Agency for Research on Cancer, Lyon;
3INSERM U-567 CNRS UMR 8104, Institut Cochin, Paris,
France
TP63 gene is, with TP53 and TP73, a member of the TP53
family. It may encode both long (TAp63) and truncated
(DeltaNp63) isoforms, by the use of promoters P1 and P2,
respectively. TAp63 isoforms act as transcription factors. They
activate genes involved in cell cycle arrest or apoptosis.
DeltaNp63 isoforms lack the main transactivation domain but
retain the DNA-binding domain. Thereby, they are able to bind
Abstracts of the 8th International Conference of Anticancer Research, 17-22 October 2008, Kos, Greece
p53 responsive elements (p53RE) and to prevent both p53 and
TA isoforms from binding on p53RE. This latter property
could be a mechanism of tumour initiation and/or progression
in some tumour types.
When deregulated in tumours, as squamous cell carcinomas
(SCC), TP63 expression mainly results in the accumulation of
DeltaNp63 variant. The amplification of TP63 gene, observed
in about 30% of SCC, cannot explain all the cases of
accumulation observed. Therefore, we hypothesized that
DeltaNp63 overexpression could also result from P2 promoter
deregulation.
Several sites were already identified in the P2 promoter,
among them a p53RE, suggesting a regulation of P2 promoter
by p53. Actually, it has been demonstrated that p53 represses
P2 promoter independently from the p53RE, but through
CAAT boxes present near the TATA box.
By in silico analysis, we identified two sites for TCF/LEF
transcription factors in the P2 promoter. Therefore, we tested
the modulation of P2 by beta-catenin (the co-activator of
TCF/LEF), but also by p53 and DeltaNp63 itself. We
confirmed the repression of P2 by p53 and its activation by
DeltaNp63alpha, both independently of the p53RE. Moreover,
we showed an activation of P2 by beta-catenin. All these
effects are through a direct binding of p53, DeltaNp63 and
beta-catenin on P2 promoter. We are currently mapping the
TCF/LEF binding sites involved in the activation of
DeltaNp63 by beta- catenin.
Since stabilization and delocalization of beta-catenin is
frequently observed in tumours, we searched for the association
between DeltaNp63 overexpression and beta-catenin
delocalization in oesophageal SCC. Beta-catenin delocalization
was found in 13 out of the 16 samples tested (81%).
Furthermore, 11 of these 13 tumours also exhibited DeltaNp63
accumulation (84%). Our results suggest that beta-catenin could
be responsible for DeltaNp63 overexpression in SCC. The
functional cross-talk between these two proteins is currently
under investigation, in order to determine if they are able to
promote together abnormal cell proliferation and tumorigenesis.
146
NARRATIONS OF “INQUIRING AND CONFUSED”
CANCER PATIENTS
Sandra Degli Esposti Elisi
Researcher and Professor of Cultural Anthropology,
Department of Sciences of Education “Giovanni Maria
Bertin”, Alma Mater Studiorum, University of Bologna, Italy
Contemporary anthropological and sociological literature on
health places attention frequently on patients’ everyday life
narrations; through these, they make sense of their pathology,
their recovery, to the necessity to share their own experiences,
their own convictions and expectations.
In particular in our modern time often these narrations are
mediated via new technologies, I would point out how these
become patient’s genuine diary of life in which he tells about
the daily challenge of cancer and the suffering, but also of the
search for information, advice and aid. Narrations that are
important to outline the figure of a “inquiring” but at the same
time “confused” patient in the face of the multiplicity of inputs
he receives.
In this context research has investigated some telematic
‘spaces’ (born at the border of magazines on health and
wellness), from discussion forums to chat-lines, from sites
dedicated to different pathologies to blogs to outline the
patient’s universe, that the health professionals and of weaving
of consequent relations.
Member of: AISEA, Italian Association of Ethnoanthropological
Sciences; SSE/SGE, Societé Suisse d’Ethnologie;
PARACELSUS, Centre of Social Studies on Health, Care and
Quality of Life, University of Ferrara, Italy.
147
SINGLET OXYGEN (1O2) FORMED BY
RESVERATROL AS A CAUSATIVE
FACTOR OF CYTOTOXICITY
Despina Fotiou, Stelios Fotiou and George Deliconstantinos
Department of Experimental Physiology, University of
Athens Medical School, Athens 11527, Greece
Resveratrol (3,4,5-trihydroxystilbene), a natural phytoalexin
found in the grape skin and wine, expresses a wide range of
pharmacological properties including antioxidant activity. Our
present experiments showed that resveratrol as a stable radical
gives a concentration dependent luminol chemiluminescence
response (~8×108 cpm) while the antioxidant Trolox (~1 mM)
suppresses and shifts the chemiluminescence spectrum to the
right at ~4×105 cpm, clearly showing its scavenging activity.
In chemiluminescence studies, in the presence of a stable
amount of nitrosoglutathione (~10–6 M), low concentrations of
resveratrol (10–6 M) act as prooxidants releasing singlet
oxygen (1O2) that reacts with nitric oxide (NO) originating
from nitrosoglutathione producing peroxynitrite (ONOO–).
Beta-carotene acts as an acceptor of 1O2 formed by resveratrol
as tested in fluorometric studies (a) by inhibition of
hydroxylation of terepthalic acid and (b) by an increase of the
oxidation rate of resveratrol shown by the decrease of its
fluorescence spectrum Ex 330, Em 374).
Synaptosomes isolated from rabbit brain release nitric oxide
(NO) and resveratrol increases NO synthase (NOS) activity
while NO was converted to ONOO– verifying the formation
of singlet oxygen (NO + 1O2 ¡ ONOO–). Similar results were
also obtained with xanthine oxidase (XO) using pterin as a
substrate and/or oxypurinol as an inhibitor (XO). Fluorescence
polarization studies using diphenyl-hexatriene (TMA-DPH)
3255
ANTICANCER RESEARCH 28: 3157-3556 (2008)
showed a decrease in the fluorescence polarization of TMADPH incorporated in the synaptosomal membranes from
r=0.205 to r=0.157, consistent with an increase in membrane
fluidity thus relieving the physical constrain imposed by the
lipids on enzymes, pumps, channels etc. The oxidative damage
to biomolecules induced by 1O2 and the protective effects of
beta-carotene were evaluated by the enhanced peak
chemiluminescence response of resveratrol in the presence of
DNA and/or beta carotene. The concentration-dependent
enhancement
of
resveratrol-DNA
complex
peak
chemiluminescence observed was decreased in the presence
of beta-carotene clearly showing the damaging effects of
resveratrol due to the formation of 1O2.
In conclusion we showed that at low concentrations,
resveratrol acts as a prooxidant while at high concentrations
as an antioxidant and that damages of biomolecules by
resveratrol could result from the formation of singlet oxygen
that may act alone and/or in combination with nitric oxide to
form the cytotoxic ONOO–.
148
OXIDATIVE STRESS CAUSED BY ULTRAVIOLET C
IN RAT SKIN MICROVESSELS AND MICROSOMES
WITH RESPECT TO SKIN PHOTOAGING AND
CANCER
Despina Fotiou, Stelios Fotiou and George Deliconstantinos
Department of Experimental Physiology, University of
Athens Medical School, Athens 11527, Greece
The aim of the present study was to investigate whether UVC
irradiation of the skin could result in the formation of oxygen
and/or nitrogen free radicals. When heme-iron is present in the
skin it can act both as a strong oxidative agent itself and as a
source of continuous free radical production having therefore
the potential to cause skin damages.
In our experiments UVC irradiated microvessels isolated
from rat skin produce NO and ONOO–. When irradiation takes
place ONOO– is attached to OH group in the Fe3+ of hematin
to form the stable radical hematin-Fe-[(OH)ONOO]2– as
follows:
Hematin-Fe-NO + O2– ¡ Hematin-Fe-(OH)ONOO2–
The stable radical hematin-Fe-(OH)ONOO2– was detected
by UV diode array spectroscopy at 420 nm. ONOO– was
determined either spectrophotometrically at 302 nm or
fluorometrically by dihydrorhodamine 123 oxidation to
rhodamine at excitation 500 nm and emission at 528 nm.
Microsomes isolated from rat skin released nitric oxide
(NO), which was enhanced by arginine and reduced by nitroarginine. UVC irradiation activated both NO synthase and
xanthine oxidase activities leading to the formation of
ONOO–. Fluorescence polarization studies using diphenylhexatriene (TMA-DPH) for the estimation of the membrane
3256
fluidity, showed an increase in the fluorescence polarization
of TMA-DPH incorporated in the microsomal membranes
from r=0.179 to r=0.600 consistent with a decrease in
membrane lipid fluidity suggesting a constrain imposed by the
lipid bilayer on the function of enzymes, pumps and/or
channels.
As shown herein UVC exposure causes the generation of
the free radical Fe-[(OH)ONOO-]2– and NO and oxygen free
radicals in the skin microcirculation and skin layers. The vast
majority of people daily spent some time in the daylight and
because it is not the conventional “sun bathing”, it would not
have been expected that daily, suberythemal exposure to the
sun causes photodamage and possibly cancer as a result, in
part, of UV-mediated increase of skin oxidative stress.
Therefore, our studies are broadly viewed as refocusing the
concept of preventing photoaging and skin cancer using a
topical application of a composition having a Fenton reaction
blocker.
149
CANCER CELLS PHAGOCYTOSIS BY MAST CELLS
Filippo della Rovere1, Angelo Granata1, Maurizio Monaco1
and Giacomo Basile2
1U.O.C.
di Chirurgia Toracica, 2Anatomia Patologica,
Università degli Studi di Messina, Azienda Ospedaliera
Universitaria “G. Martino”, Messina, Italy
The data in the literature confirm the hypothesis that incidence
of cancer disease is lower in allergic individuals. In a previous
study, we too confirmed that histamine plays a role in
protecting against cancer. Briefly, Sprague-Dawley rats were
first inoculated with histamine i.p., followed by 1,000 cells of
Yoshida ascites sarcoma. In 80% of the rats treated in this
way, no cancer disease onset was reported. In a different study,
histamine and selenium were assayed in subjects with lung
cancer. In tumor subjects, significant decreases in both
histamine and selenium were reported (p<0.0001) as
compared with healthy control subjects.
Our present study focused on mast cell activity in breast
carcinoma. We found that mast cell numbers were higher in
high hormone receptive cancer, and we focused mainly on
cytolysis of neoplastic cells that help the body to protect itself
from oncogenic aggression. It was demonstrated that cancer
cells are first surrounded by the mast cell pseudopodium; they
are then engulfed in the mast cell cytoplasm, where toxic
granulations trigger the cytolytic process. The phagocytosed
cell progressively loses its chromatic and volumetric
characteristics until complete achromia and almost complete
reduction of its volume and consistency occur. The cell
nucleus soon degenerates to pyknosis, and is no more
detectable. The phagocytosis can occur simultaneously in
different neoplastic cells.
Abstracts of the 8th International Conference of Anticancer Research, 17-22 October 2008, Kos, Greece
150
TUMOUR DORMANCY IN BREAST CANCER
Romano Demicheli
Istituto Nazionale Tumori, Milan, Italy
The review analyzes the recent evolution of two paradigms
related to the development of breast cancer metastases. The
continuous growth model is required to yield to an interrupted
growth model, the tantamount of which are episodes of
“tumour dormancy”. Primary tumour removal, usually
considered as intrinsically beneficial, proves to be able to
perturb metastatic homeostasis and to result, for some patients,
in the acceleration of metastatic cancer spread. Paradigm
evolution is supported by a growing body of findings from
experimental models and is required to explain breast cancer
recurrence dynamics for patients undergoing surgery without
or with adjuvant chemotherapy.
Classical models that were proposed to explain breast
cancer metastasis dynamics after primary tumour removal
assumed the implicit hypothesis that tumours must always
grow. The concept of uninterrupted growth failed to explain
findings from both local and local plus distant recurrences. In
particular, the bimodal recurrence pattern, which presents an
early peak at the second year after surgery, a second peak at
about 5 years and a tapered plateau-like tail extending up to
15 years, should be explained. This pattern is independent of
the seeded organ, and may be observed in all metastatic sites.
On the contrary, a new dormancy-based model of metastasis
development was found to better fit clinical data. According
to this model, metastatic tumour may either continuously grow
or even sojourn in two dormant states, i.e. single cells and
avascular micrometastases, with orderly transitions between
these two dormant states eventually resulting in progressive
appearance of clinical metastases. Moreover, some
precipitating event at the time of primary tumour surgical
removal may have a triggering effect. In spite of a century of
investigations, the effects of primary tumour surgical removal
on metastases have practically been ignored by clinicians.
Single cells may be induced to proliferate via the conversion
of non-cycling G0 cells or by switching avascular micrometastatic foci to active angiogenesis. These processes occur
to different extent in pre- and post-menopausal patients. The
model found confirmation by the analysis of the recurrence
risk for patients receiving adjuvant CMF, where the recurrence
reduction occurred at specific, temporally separate recurrence
clusters at the first and third year, for both menopausal
statuses.
The proposed dormancy-based metastasis development
model implies some kind of control on tumour growth from
the microenvironment, some kind of homeostatic effect upon
distant metastases. These concepts are poorly understandable
within the classical frame, where cancer is a genome-driven
disease, i.e. a cell-autonomous irreversible process and where
the tumour microenvironment is an idle bystander, sometimes
forced to provide factors supporting tumour progression.
However, all these views (epitheliocentric somatic mutation
paradigm, irreversibility of the neoplastic phenotype,
insignificant role of the microenvironment) have been
challenged by experimental evidence both in vitro and in vivo.
A new image of breast cancer is emerging. Cells that we label
“cancer cells” go on with their peculiar ability to have crosstalk with the environment. This trait accounts for the
neoplastic behaviour, ranging from quiescence to open growth,
in different sites and/or at different times. Tumour dormancy
and the counterintuitive consequence of primary tumour
removal have a logical place in this context. The traditional
image of breast cancer is changing.
151
PROTEOMIC ANALYSIS OF TELOMERASE
INHIBITION BY TELOMERE SPECIFIC LIGANDS
Gabriel Mazzucchelli1, Valérie Gabelica1,
Nicolas Smargiasso1, Frédéric Rosu1, Marie-Claire
De Pauw-Gillet2, Jean-François Riou3 and Edwin De Pauw1
1Laboratory
of Mass Spectrometry and 2Histology and
Cytology Laboratory; CART, GIGA, University of Liège,
BAT. B6C, allée de la Chimie, 3, 4000 Liège 1, Belgium;
3Regulation et Dynamique des Genomes, Museum National
d’Histoire Naturelle, USM 503, INSERM U565, CNRS
UMR 5153, Paris, France
Telomeres consist of protein complexes and repeated
‘TTAGGG’ double strand DNA sequences ended by a 3’
single strand DNA of the same sequence. Progressive telomere
shortening is observed in vitro upon cell divisions and with
ageing in vivo. At a critical telomere length, shortened
telomeres trigger a permanent growth arrest known as
replicative senescence. Telomerase is an RNA-dependent DNA
polymerase that extends telomeres by adding ‘TTAGGG’
repeats. It consists of a functional RNA component (hTR)
which serves as template and a catalytic protein (hTERT) with
reverse transcriptase activity. The expression of hTERT alone
is sufficient for the immortalisation of cells. Telomerase is
highly expressed in tumor cells but at very low level in most
somatic cells. These observations make the telomerase an
attractive target for anticancer strategies. One of these
strategies relies on the use of drug candidates able to stabilize
the particular telomere G-quadruplex DNA structures. The
stabilization of these structures makes the telomere
inaccessible for telomerase and thus inhibits telomerase
activity.
The effect of the hTERT transfection was first studied on
the proteome of human WI38 fibroblast cells (1). Then, the
proteome alteration response of hTERT transfected WI38 cells
3257
ANTICANCER RESEARCH 28: 3157-3556 (2008)
induced by the treatment of two G-quadruplexes ligands,
telomestatin and TMPyP4, was analyzed. Both compounds
can inhibit telomerase but have different selectivity for the
different G-quadruplexes structures.
Proteome analysis of the treated cells reveals that TMPyP4
induces much more protein expression alterations than
telomestatin probably due to its poor selectivity. TMPyP4
induces especially a drastic down expression of the hnRNPs, a
modulation of the proteasome pathway, an apparent decrease
of the translation and an over expression of several molecular
chaperones. Telomestatin induces in particular an over
expression of the protein BCL2A1 which is involved in drugresistance of cancer cells and a probable increase of the
translation. Both treatments have a common effect particularly
on the molecular chaperone CCT (down expression), HSP90
alpha (over expression) and hnRNP D (down expression). The
protein HSP90 alpha is also over expressed in hTERT
transfected cells compared to parental cells. This protein is
already a promising anticancer target protein due to its central
role in oncogenesis and in telomerase activity regulation.
1 Mazzucchelli et al: Proteome Science 6: 12, 2008.
152
LNCaP PROSTATE CANCER IMAGING WITH
BIOLOGICALLY FUNCTIONALIZED GOLD
NANOPARTICLES IN 2D AND 3D CELL CULTURES
D. Schol1, M. Fléron1, J.F. Greisch1, M.C. De Pauw-Gillet1,
E. De Pauw1, M. Jaeger2, M. Frenz2, S.A. Eccles3,
J. Bamber3, S. Frosini4, L. Masotti4,
M. Fournelle5 and R. Lemor5
1University
of Liège, Liège, Belgium;
of Bern, Bern, Switzerland;
3The Institute of Cancer Research, Sutton, Surrey, England;
4El.En. S.p.A., Calenzano, Italy;
5Fraunhofer-Institut fuer Biomedizinische Technik IBMT, St.
Ingbert, Germany
2University
A major challenge in oncology is to develop more accurate
imaging assessments. The ADONIS Project intends to prove
the concept of using optoacoustic imaging with biologically
functionalized nanoparticles as an integrated biosensor based
imaging system for the production of specific and sensitive
data for accurate diagnosis of prostate cancer. This concept
involves using contrast agents which upon photoactivation
induce the local heating of their environment, generating
pressure waves that are detectable by piezoelectric transducers.
One of the main objectives of this project is to produce and
validate a versatile lab system composed of functionalized
nanoparticles for diagnosis of different superficial and
accessible cancers, e.g. prostate cancer. Gold nanorods have
been synthesized and functionalized with antibodies targeting
specific antigens on cancer cell lines. The foremost challenge
3258
consists in synthesizing rod-like nanoparticles absorbing about
1064 nm, the spectral range where biological tissues absorb the
least. A wet chemical approach in solution, using surfactants
as dynamic template and silver nitrate as growth inhibitor, is
used for synthesis. Once the particles have been synthesized,
the surfactant is replaced by a biocompatible polymer for use in
in vitro tests. The polymer-coated nanoparticles are then
coupled with an antibody directed against the cancer cells to
guarantee the selective detection of the particles.
Prostate Specific Membrane Antigen (PSMA), a
transmembrane protein considered as a suitable biomarker for
prostate cancer, was selected as the primary target.
Recognition and successful binding of the biosensor to PSMA
is demonstrated by various techniques using cell monolayers
and 3D cell cultures. PSMA localization on the LNCaP cell
membranes was identified by immunocytochemistry (HRP, QDots). Backscattered electron (BSE) microscopy and twophoton luminescence imaging proved that the biosensor is
bound to the viable and fixed cells expressing PSMA.
Gold particles attached to cancer cells serve as contrast
agents for optoacoustic detection. The concept of detecting
PSMA-expressing tumours using this integrated optoacoustic
biosensor system was confirmed on LNCaP spheroids (cell
aggregates) in gelatine phantoms. This system is currently
being tested on in vivo human tumour xenograft animal models
and in the future will be tested on human tumour biopsies.
6th Framework Programme of the European Commission,
STREP n˚ NMP4-CT-2005-016880.
153
CLINICAL AND BIOLOGICAL ASPECTS OF
PERITONEAL MESOTHELIOMAS
Marcello Deraco1, Nadia Zaffaroni3, Federica Perrone2,
Dario Baratti1, Raffaella Villa3, Shigeki Kusamura1,
Genny Jocollé2, Antonello D. Cabras2 and Silvana Pilotti2
1Department
of Surgery, Fondazione IRCCS Istituto
Nazionale Tumori, Milano;
2Department of Pathology, Fondazione IRCCS Istituto
Nazionale Tumori, Milano;
3Department of Experimental Oncology, Fondazione IRCCS
Istituto Nazionale Tumori, Milano, Italy
Background: Diffuse malignant peritoneal mesothelioma
(DMPM) is a rare and rapidly lethal neoplasm. In recent years,
the combination of cytoreductive surgery and hyperthermic
intraperitoneal chemotherapy (CRS+HIPEC) has resulted in a
significant survival improvement, as compared to historical
controls. Little is known about DMPM genetic and molecular
features. In the present study, we assessed new prognostic
indicators and therapeutic targets in a large series of DMPM
undergoing CRS+HIPEC. Methods: From a prospective database of 86 cases, we selected 66 DMPM. Cases with well-
Abstracts of the 8th International Conference of Anticancer Research, 17-22 October 2008, Kos, Greece
differentiated histology or second malignancies were
excluded. All the patients underwent peritonectomy
procedures and closed-abdomen HIPEC with cisplatin and
doxorubicin. The prognostic significance of age, sex,
carcinomatosis extension, completeness of cytoreduction (CC)
and HIPEC drug schedule was tested by multivariate analysis.
We evaluated the expression of members of the Inhibitor of
Apoptosis Protein (IAP) family (survivin, IAP-1, IAP-2, XIAP) and the presence of telomere maintenance mechanisms
(telomerase activity and alternative lengthening of telomeres
[ALT]). In 15 patients, EGFR, PDGFRA and PDGFRB
expression and phosphorylation were immunohistochemically
and biochemically analysed and automatically sequenced. The
cognate ligand expression was investigated by real-time PCR.
Additionally, we explored RTK downstream pathways status
through mutational and biochemical analysis of PI3KCA gene
PTEN/AKT, ERK, mTOR and its effector S6. Results: Median
follow-up, overall (OS) and progression-free survival (PFS)
were 30.5 (range: 1-118), 40 and 17 months. Median. CC
independently correlated to OS and age to PFS. IAPs were
simultaneously up-regulated in a high percentage of DMPMs
(survivin was present in >90% of cases). Survivin gene
knockdown in mesothelioma cells resulted in a significant and
time-dependent decline of in vitro growth and enhanced rate
of spontaneous and drug-induced apoptosis. At least one
telomere maintenance mechanism was present in 86% of
DMPMs. Telomerase activity correlated to poor OS and PFS,
whereas ALT failed to significantly affect clinical outcome.
Immunohistochemical and western blot analyses showed
EGFR, PDGFRA and PDGFRB expression and activation in
most cases. Autocrine loop activation of these receptors was
suggested in all cases by the expression of the related cognate
ligands, in absence of receptor gain of function mutations. No
PI3KCA mutations were found, while all DMPMs showed
expression of PTEN and expression/activation of AKT, ERK,
mTOR and S6. Conclusion: CRS+HIPEC is associated to
encouraging survival results. Both telomere maintenance
mechanisms, telomerase activity and ALT are present in
DMPM and differentially affect prognosis. EGFR, PDGFRA
and PDGFRB are promising molecular targets for tailored
treatments.
154
PERITONEAL SURFACE MALIGNANCIES: FROM
BIOLOGY TO INNOVATIVE TREATMENTS
Marcello Deraco, Dario Baratti, Barbara Laterza,
Domenico Sabia and Shigeki Kusamura
Peritoneal Malignancies Unit, Department of Surgery,
Fondazione IRCCS Istituto Nazionale Tumori, Milano, Italy
Peritoneal surface malignancies (PSM) represent the end-stage
of many intrabdominal tumors. Better knowledge of biology,
natural history and pattern of dissemination (PSM remain
confined within the peritoneal cavity for most of their clinical
course), makes a locoregional approach combining
Cytoreductive Surgery (CRS) and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) attractive. The
intraperitoneal chemotherapy maximizes the dose intensity
and simultaneously minimizes systemic toxicity. Hyperthermia
increases tumor cell chemosensitivity. Due to the limited
HIPEC penetration into tumor tissue, peritonectomy
procedures and multi-visceral resections are required for
cytoreduction down to microscopic/minimal residual disease.
Colorectal cancer is the second most common cause of
cancer death, with peritoneal carcinomatosis (PC) occurring
in 50% of patients. Median survival in PC patients is about 6
months. A prospective randomized study has shown the
superiority of CRS+HIPEC over standard treatment.
Ovarian cancer accounts for the greatest number of deaths
from gynecological malignancy. 75% of cases are diagnosed at
stage III/IVwith a median survival of 36 months.
According to several phase II studies the treatment of
ovarian cancer PC with CRS+IPHP has provided 5-year
survival rates of 15-63%.
Peritoneal mesothelioma is an uncommon tumor with a
median survival of less than 1 year. CRS and HIPEC have
reportedly resulted into a survival improvement to 32-94
months. Pseudomyxoma peritonei is a rare condition
originating from an appendiceal mucinous tumor. This
minimally invasive disease is associated to poor long term
prognosis, due to its tendency of locoregional relapse. CRS
and HIPEC have been advocated as the treatment of choice.
155
BRAIN TUMOURS EX VIVO AND
THEIR CLINICAL APPLICATION
Leo De Ridder
Department of Histology, Ghent University, Belgium
Introduction: Several special features are specific for brain
tumours: poor definition followed by infiltrative growth,rich
in various cell types,progression towards malignancy, nearly
complete absence of metastasis and finally brain tumour kill
at the site of origin. These characteristics can be analysed ex
vivo especially infiltration and progression. Although
morphological as well as other observations on biopsies give a
framework for research, investigations outside the body are not
only useful but mandatory. Materials and Methods: Several
model systems are available. Animal and human brain tumours
can be propagated over varying periods in cell, tissue and
organotypical cultures. However since the development of
culture techniques, it is clear that the closer the model
resembles the in vivo situation the more reliable the results are
With this in mind, it is essential to select a given ex vivo
3259
ANTICANCER RESEARCH 28: 3157-3556 (2008)
method to answer a given question. Results: Monolayers of
primary cultures and cell lines, spheroidal aggregates,
organotypical and confronting cultures will answer different
questions concerning the biological behaviour of brain tumour
derived cells. Monolayer cultures of cell lines answer general
metabolic problems, primary monolayer cultures will give
answers for the individual tumour cells and pharmacological
substances can be tested but are not applicable for infiltration
studies. Tumour cell aggregates, formed by reassociation of
tumour derived cells, consist of viable cells including non
transformed normal brain cells. They are tridimensional and
spheroidal. These aggregates can be used for testing
antimitotic and radioprotective substances at the individual
level and every single tumour can be evaluated for its
proliferation characteristics. Organotypical cultures are tumour
fragments freshly collected from the surgical amphitheatre.
They are difficult to keep in vitro as they are contaminated by
necrotic material. On the other hand, confrontations between
tumour derived aggregates and host tissue aggregates seem to
answer the problems of infiltration and proliferation. Different
variations in confrontation cultures are available. Heterologous
and autologous confrontations are at hand. The most
promising technique might be the confrontation of brain
tumour aggregates with aggregates of normal cells of the
patient the tumour is derived from (called: homologous
confrontation). The optimal condition is not yet realised.
Conclusion: The actual ex vivo techniques allow to evaluate
the effects of therapy at the individual level, to distinguish the
radioprotective capacity of substances, to analyse the
infiltrative and proliferative capacity of the individual brain
tumour and to study basic mechanisms of infiltration.
156
DYNAMIC REGULATION OF LOW MOLECULAR
WEIGHT PROTEIN TYROSINE PHOSPHATASE
(LMW-PTP) TRANSIENT NATURE OF ACTIVITY
ENSURE THE GM-CSF DEPENDENT STAT5
ACTIVATION
Roberta R.R. de Sousa, Karla C. S. Queiroz, Gweeny M.
Fuhler, Carmen V. Ferreira and Maikel P. Peppelenbosch
Department of Cell Biology, University of Groningen
Antonius Deusinglaan, Groningen, the Netherlands
LMW-PTP (Low Molecular Protein Tyrosine Phosphatase) is
frequently overexpressed in various human cancers. LMW-PTP
localizes predominantly to the cytoplasm and functions as
phosphatase, but its function in cellular signaling remains
unknown. In this work we investigated the role of LMWPTP
in JAK/STAT pathway in GMCSF dependent erythroleukemic
cells. LMWPTP activity is temporally dynamic modulated by
GMSCF. TF1 cells deprived of GM-CSF for 2 h and stimulated
with GM-CSF for 5 min show a 5-fold decrease in LMWPTP
3260
activity, coinciding with binding of the inactive phosphatase to
STAT5. This initial phase is followed by a 2-fold up-regulation
of LMWPTP activity after 20 min of GM-CSF stimulation, and
a release of STAT5 binding. Interestingly, we demonstrate for
the first time that LMW-PTP is present in the nucleus in an
inactive state, and shuttles to the cytosol upon GM-CSF
stimulation. These results suggest a dual role for LMW-PTP,
in which an inactive form of the protein binds to STAT5 in the
cytosol followed by activation of the phosphatase enzymatic
activity and STAT5 dephosphorylation. Hence LMW-PTP
seems a cardinal mediator of GM-CSF-dependent STAT5
activation, ensuring the transient nature of the response.
157
CISPLATIN OTOTOXICITY – FROM DOSE TO
MOLECULAR BIOLOGY
Dirk Deuster
Department of Phoniatrics and Pediatric Audiology,
University Hospital of Muenster, Kardinal-von-Galen-Ring
10, D-48149 Muenster, Germany
Cisplatin is effectively used for the treatment of several
childhood malignancies, but its use is limited by its
ototoxicity. It includes a usually permanent sensory hearing
loss, tinnitus, and alterations in vestibular function. The risk
estimates for ototoxicity after cisplatin range from 23 to 53%
depending on the criteria used and the diligence of the search.
To answer specific questions, such as individual tolerance, a
hearing loss classification relating to intensity and the affected
frequencies are required. We developed our own classification
system based on pure tone audiometry, which detects hearing
loss earlier and maps progression of hearing loss more
precisely than the existing high frequency classifications. This
classification system is now used in all our research.
In animals, damage of various structures of the inner ear
like hair cells, stria vascularis, and spiral ganglion could be
observed. The mechanisms of cisplatin-induced ototoxicity are
poorly understood so far. High rates of cisplatin delivery,
cumulative dosage, pre-existing sensorineural hearing loss, age
<5 were identified as risk factors for ototoxicity, but apart
from these factors interindividual susceptibility to the
ototoxicity was observed in clinical studies and animal tests.
So genetic predispositions could be possible causes for
ototoxocity: i) Oxidative stress has been implicated in cisplatin
ototoxicity. Therefore, differences in protection mechanisms
against oxidative stress may be one possible reason for the
individual susceptibility. We found significant inter-group
difference of glutathione S-transferase, an enzyme, which
plays an important role in protecting cells from the deleterious
effects of oxidative stress. ii) Moreover, genetic variants in
transporters for platinum uptake may be responsible for the
individual platin tolerance. We found differences in a non-
Abstracts of the 8th International Conference of Anticancer Research, 17-22 October 2008, Kos, Greece
synonymous single nucleotide polymorphism (SNP) at the
megalin gene as another possible risk factor for ototoxicity. At
present, we search specific transporters and their inhibition.
Prevention of cisplatin-induced hearing loss needs both
more knowledge about the mechanisms of ototoxicity and
early detection with professional audiological examinations.
We will decide in favour of an interdisciplinary team to
investigate further aspects of cisplatin-induces ototoxicity.
Lanvers-Kaminsky C, Krefeld B, Dinnesen AG et al:
Continuous or repeated prolonged cisplatin infusion in
children: a prospective study in ototoxicity, platinum
concentration, and standard serum oparameters. Pediatric
Blood and Cancer 47: 183-193, 2005.
Peters U, Preisler-Adams S, HebeisenA et al: Glutathione Stransferase genetic polymorphisms and individual sensitivity
to the ototoxic effect of cisplatin. Anti-Cancer Drugs 11: 639643, 2000.
Riedemann L, Lanvers C, Deuster D et al: Megalin genetic
polymorphisms and individual sensitivity to the ototoxic effect
of cisplatin. The Pharmacogenetics Journal 8: 23-28, 2007.
Rybak LP: Mechanisms of cisplatin ototoxicity and progress
in otoprotection. Current Opinion in Otolaryngology & Head
and Neck Surgery 15: 364-369, 2007.
Schmidt CM, Bartholomaeus E, Deuster D et al: The
“Muenster classification” of high frequency hearing loss
following cisplatin chemotherapie. HNO 55: 299-306, 2007.
analysis showed 19%/18% high-level amplifications of
FOXA1 and NKX2-1 respectively, and 27%/35% of all tumors
were positive for NKX2-1 and FOXA1 protein expression.
Patients with distant metastases showed significantly higher
expression of FOXA1 than patients without distant spread
(p=0.003). Time to metastasis was significantly shorter in
patients with high level expression of NKX2-1 than in patients
with low level or no expression of NKX2-1 (p=0.032),
especially in LCLC (p=0.008). Conclusion: The results of our
study of a large series of lung tumors indicate a negative
prognostic function of FOXA1 and NKX2-1 in lung cancer,
especially in LCLC. NKX2-1 could be a useful marker for
selection of patients who should undergo systemic treatment
for prevention of early systemic spread.
158
HIGH LEVEL AMPLIFICATION AND
OVEREXPRESSION OF FOXA1 AND NKX2-1 IN
PULMONARY CARCINOMAS CORRELATE
WITH UNFAVOURABLE PROGNOSIS
We have used phage display libraries of both fully human
antibodies and variants of a Kunitz domain derived from
human tissue factor pathway inhibitor (TFPI) to select potent
and selective inhibitors of proteases. These have allowed us to
assess the contributions of a number of proteases to cancer
progression in preclinical models. The success of this
approach and the therapeutic potential of these protease
inhibitors will be illustrated by our work with plasmin and
matrix metalloproteinase-14.
Plasmin is a serine protease predominantly present in the
body in its inactive zymogen form (plasminogen). Its
activation mainly occurs locally, at the tumor site by urokinase
overproduced by cancer or stromal cells. Using phage display,
we have identified DX-1000, a variant Kunitz domain derived
from TFPI which is a specific and high affinity inhibitor of
plasmin (Ki 99 pM). We increased the molecular mass of DX1000 by chemically coupling four 5 kDa polyethylene glycol
(PEG) moieties in order to improve its pharmacokinetic
properties. 4PEG-DX-1000 efficiently blocks plasminmediated proMMP-9 activation on cells while not significantly
affecting haemostasis and coagulation in vitro. In a human
breast cancer MDA-MB-231 xenograft model, 4PEG-DX1000 treatment resulted in a significant reduction of primary
tumor growth and a decreased incidence of metastases.
Together, our results demonstrate the potential of plasmin
inhibitors for blocking cancer growth and metastases.
Lena S. Deutsch
Klinik und Poliklinik für Allgemein- Viszeral- und
Thoraxchirurgie, Universitätsklinikum Hamburg Eppendorf
Martinistrasse 52, 20246 Hamburg, Germany
Background: Lung cancer is the leading cause of cancer death
worldwide. The failure of clinical staging in prediction of the
course of disease in many patients shows the need to consider
additional predictive factors. Several chromosomal regions are
amplified or deleted in lung tumors, but little is known about
the underlying genes, which could be important mediators in
tumor formation or progression. Patients and Methods: Highlevel amplifications were screened by array-CGH and verified
by fluorescence in situ hybridization (FISH) and the protein
expression of two amplified genes, FOXA1 and NKX2-1, was
studied on a TMA containing 613 tumor samples. Results:
40% of the lung adenocarcinomas showed narrow high level
amplifications. A narrow high-level amplicon at 14q13.3-q21.1
containing FOXA1 and NKX2-1, two important genes for lung
morphogenesis, was found in two cases by array-CGH. FISH
159
HUMAN ANTIBODY AND KUNITZ DOMAIN-BASED
PROTEASE INHIBITORS FOR CANCER THERAPY
Laetitia Devy1, Art Ley1, Robert C. Ladner1,
Shafaat A. Rabbani2, Clive R. Wood1
and Daniel T. Dransfield1
1Dyax
Corp., 300 Technology Square, Cambridge, MA,
USA;
2Department of Medicine, McGill University Health Centre,
Montreal, QC, Canada
3261
ANTICANCER RESEARCH 28: 3157-3556 (2008)
MMP-14 is a membrane-bound zinc endopeptidase that has
been proposed to play a central role in tumor growth, invasion
and neovascularization. Besides cleaving matrix proteins,
MMP-14 activates proMMP-2 leading to an amplification of
pericellular proteolytic activity. To examine the contribution
of MMP-14 to tumor growth and angiogenesis, we used DX2400, a highly selective MMP-14 inhibitory antibody. DX2400 blocked proMMP-2 processing on tumor and endothelial
cells, inhibited angiogenesis and slowed tumor progression
and formation of metastatic lesions. This combination of
potency, selectivity and in vivo activity demonstrate the
potential of a selective MMP-14 inhibitor for the treatment of
solid tumors.
160
STROMAL MYOFIBROBLASTS DRIVE INVASIVE
CANCER GROWTH
Olivier De Wever
Laboratory of Experimental Cancer Research, Department of
Radiotherapy and Nuclear Medicine, Ghent University
Hospital, 9000 Gent, Belgium
Tumor-associated myofibroblasts drive tissue invasion, a
hallmark of malignancy (4). The origin of myofibroblasts at
the tumor invasion front remains controversial although
fibroblasts and bone marrow-derived precursors are considered
to be the main progenitor cells. To better understand the
mechanisms underlying such effects, we established a
heterotypic model of human colon tumor-derived
myofibroblasts in co-culture with human colon cancer cells
(HCT8/E11), using three-dimensional collagen type-I and
Matrigel matrices. We analysed the myofibroblast secreted
proteins using a combination of proteomics and antibody
arrays. We identified two convergent proinvasive agents
secreted by myofibroblasts: namely scatter factor/hepatocyte
growth factor (SF/HGF) and the TGF-β-upregulated
extracellular matrix glycoprotein tenascin-C (TNC), each of
which is necessary though not sufficient for invasion.
Myofibroblast-stimulated invasion into collagen type I is
characterized by a change from a round, nonmigratory
morphotype with high RhoA and low Rac activity to an
elongated, migratory morphotype with low RhoA and high
Rac activity (2). The myofibroblasts are themselves invasive
and this activity is stimulated by TGF-β. N-cadherin is
implicated in the invasion response of myofibroblasts (3). In
conclusion, the mutual interaction between cancer cells and
myofibroblasts is dependent on multiple invasive growth
promoting factors (through direct cell-cell contacts and
paracrine signals) (1). Our data predict that inhibitors directed
at this reciprocal molecular and cellular crosstalk will have
therapeutic applications for targeting the invasive growth of
human primary tumors and their metastatic spread (5).
3262
1 Denys H, Derycke L, Hendrix A, Westbroek W, Gheldof A,
Narine K, Pauwels P, Gespach C, Bracke M and De Wever
O: Differential impact of TGF-β and EGF on fibroblast
differentiation and invasion reciprocally promotes colon
cancer cell invasion. Cancer Lett 266: 263-274, 2008.
2 De Wever O, Nguyen Q-D, Van Hoorde L, Bracke M,
Bruyneel E, Gespach C and Mareel M: Tenascin-C and
SF/HGF produced by myofibroblasts in vitro provide
convergent pro-invasive signals to human colon cancer cells
through RhoA and Rac. FASEB J 18: 1016-1018, 2004a.
3 De Wever O, Westbroek W, Verloes A, Bloemen N, Bracke
M, Gespach C, Bruyneel E and Mareel M: Critical role of
N-cadherin in myofibroblast invasion and migration in vitro
stimulated by colon-cancer-cell-derived TGF-β or wounding.
J Cell Sci 117: 4691-4703, 2004b.
4 De Wever O, Demetter P, Mareel M and Bracke M: Stromal
myofibroblasts are drivers of invasive cancer growth. Int J
Cancer In press.
5 Rodrigues S, De Wever O, Bruyneel E, Rooney R and
Gespach C: Opposing roles of netrin and the dependence
receptor DCC in cancer cell invasion, tumor growth, and
metastasis. Oncogene 26: 5615-5625, 2007.
161
INDUCTION OF P21WAF1 EXPRESSION
AND WILD-TYPE P53 BY GYNURA
PROCUMBENS LEAVES IN ORAL
CARCINOGENESIS (IN VIVO STUDY)
Dewi Agustina
Oral Medicine Department, Faculty of Dentistry, Gadjah
Mada University,
Jalan Denta, Sekip Utara, Jogjakarta 55281 Indonesia
Anticarcinogenic effect of Gynura procumbens leaves has
been evidenced in various types of cells either related with its
antiproliferative effect or apoptotic induction. Proliferative
inhibition is one of mechanisms to inhibit malignancy. The
p53 gene can activate the transcription of downstream effector
genes such as p21WAF1 to induce cell cycle arrest. The aim of
this study was to elucidate the anticarcinogenic potency of G.
procumbens leaves through the induction of p21WAF1 and p53
expressions in chemical carcinogen induced-oral
carcinogenesis. Ninety-two male Sprague Dawley rats were
divided into 11 groups consisting of control groups and groups
treated with the chemical carcinogen, 4 nitroquinoline 1-oxide,
and by ethanolic extract of G. procumbens leaves. Chemical
carcinogen was administered thrice weekly for 8, 16 or 24
weeks, whereas the extract was given twice weekly in certain
periods commencing either before or after the carcinogen
administration. At the end of the 36th week, histopathological
examination (H&E) and immunohistochemical analysis using
labeled streptavidin biotin method to detect the expression of
Abstracts of the 8th International Conference of Anticancer Research, 17-22 October 2008, Kos, Greece
P21WAF1 and P53 were conducted. Histopathological analysis
showed that the ethanolic extract of G. procumbens leaves had
an oral anticarcinogenic effect in initiation phase either
through its preventative (Group II) or prophylactic effect
(Group III). Inhibitory mechanism of the ethanolic extract of
G. procumbens leaves in oral carcinogenesis occurred by
inducing P21WAF1 expression. This mechanism was
demonstrated by the expression of P21WAF1 in tissues which
P53 expression was not found. From these results, it is
apparent that the ethanolic extract of G. procumbens leaves
could inhibit oral carcinogenenesis through its preventive and
prophylactic effects in initiation phase by inducing P21WAF1
expression independently of wt P53.
162
P90 RIBOSOMAL S6 KINASES:
POTENTIAL NEW TARGETS FOR
PROMISING ANTICANCER THERAPIES?
C. Dimas
Laboratory of Pharmacology-Pharmacotechnology, Basic
Sciences Center, Biomedical Research Foundation of
Academy of Athens (BRFAA), Athens, Greece
The p90 ribosomal S6 kinase (RSK) is a family of
serine/threonine kinases of the MAPK (mitogen-activated
protein kinase) pathway. The family is constituted of four genes
in humans and other mammals (RSK1, 2, 3 and 4). Those
enzymes are composed of two distinct and functional kinase
domains, located in the carboxy-terminal (CTKD) and another
one located at the amino-terminal domain (NTKD) that are
activated by a series of sequential phosphorylation events.
RSKs function as mediators of ERK signal transduction and
have been found so far to be expressed in all cell lines and
tissues studied. Numerous substrates have been reported such
as GSK3β (proliferation and metabolism), p27kip1 (CDKcyclin inhibitor), bad (pro-apoptotic protein), IκB and p65
(NFκB-pathway). Thus, studies so far suggest that RSKs may
promote cell survival by inactivating apoptotic effectors and
mediating cell growth and proliferation by regulating factors
involved in transcription and mRNA translation.
Among RSK isoforms, rsk2 mutations and dysfunction have
been linked in humans to Coffin-Lowry Syndrome (CLS, Xlinked mental retardation syndrome) that is often accompanied
by dysmorphisms in face and digits and by progressive
skeletal deformations. Recent studies point towards a link
between RSK activity and cancer as they demonstrate that
RSK1 and 2 are overexpressed among different types of
cancer. The recent identification of specific RSK inhibitors,
such as small molecule inhibitors and RNAi, may help to shed
light on the role of these enzymes in oncogenesis and their
potential usefulness as targets for the development of novel
anticancer drugs.
163
VISUALIZATION OF ANGIOGENESIS
IN BRAIN TUMORS USING
123I-VASCULAR ENDOTHELIAL
GROWTH FACTOR SCINTIGRAPHY
Elke Dimou1, Georg Widhalm2, Alexander Bertalanffy2,
Karl Roessler2, Christian Nasel3, Peter Angelberger4,
Christine Marosi5, Robert Dudczak1 and Shuren Li1
1Department of Nuclear Medicine, Medical University of
Vienna;
2Department of Neuro-Surgery, Medical University of
Vienna;
3Department of Radiology, Medical University of Vienna;
4Austrian Research Center, Seibersdorf;
5Department of Internal Medicine I, Division of Oncology,
Medical University of Vienna, Vienna, Austria
Aim: Vascular endothelial growth factor (VEGF) is a major
angiogenic factor. VEGF receptors have been shown to be
over-expressed in a variety of tumor vessels including
glioblastoma, which may provide the molecular basis for a
successful use of radiolabeled VEGF as tumor angiogenesis
tracer. In this study we investigated the use of 123I-VEGF as
angiogenesis tracer for imaging brain tumors in vivo.
Methods and Results: SPECT examinations were performed
10 minutes after intravenous administration of 123I-VEGF
(191±15 MBq) and 18 hours post injection in 20 patients
with brain tumor. Glioblastomas were visualized in 7 of 8
patients (88%) shortly after application of 123I-VEGF and
were still clearly shown 18 hours post injection. Negative
scan results were obtained in one patient with a small
glioblastoma size (diameter <2.0 cm) and in 3 patients with
benign glioma as well as in 5 patients with glioblastoma after
receiving radiotherapy and /or chemotherapy. Weak positive
results were obtained in 3 patients with brain lymphoma or
other tumors. No side-effects were observed in patients after
i.v. administration of 123I-VEGF. Conclusion: Our results
indicate that 123I-VEGF scintigraphy may be useful to
visualize the angiogenesis of brain tumors and to monitor the
treatment response.
This study was partly supported by the Jubiläumsfonds of
Austrian Nationalbank (Project No: 11707).
164
GENETICS IN RENAL CANCER
Martina Olivero, Annalisa Lorenzato and
Maria Flavia Di Renzo
Laboratory of Cancer Genetics, Department of Oncological
Sciences at the Institute for Cancer Research and Treatment
(IRCC), University of Torino Medical School, SP 142, Km.
95, 10060 Candiolo, TO, Italy
3263
ANTICANCER RESEARCH 28: 3157-3556 (2008)
Cancer is a genetic disease, due to the accumulation of
mutations in genes (oncogenes and tumour suppressor genes)
that control the balance between cell birth and cell death. In
some cases these are germline and inherited, while the large
majority are somatic mutations. Interestingly, in most cases,
such as in inherited kidney cancer syndromes, the same genes
cause both inherited and sporadic (non-inherited) forms of
cancer.
As the molecular basis of disease continues to be
elucidated, familial cancer syndromes, which consist of a
range of neoplastic and non-neoplastic features, are emerging.
The usual pathway of referral to a genetics clinic or familial
cancer centre is via either a surgeon or an oncologist, when
high-risk features that suggest a possible hereditary basis for
the presenting cancer are recognized. Traditionally, these highrisk features include more than two family members with
similar types of cancer over two or more generations, a young
age of onset, and more than one synchronous or metachronous
tumour. These features are effective in ascertaining a
substantial proportion of families with hereditary cancer.
However, there are a range of familial cancer syndromes that
are not easily detected and can remain undiagnosed when
history and examination are not extended to include cancer in
other sites and non-malignant features.
Identification of predisposition to develop cancer is
particularly important in the case of inherited kidney cancer
syndromes, as it provides individuals and their families with
the opportunity to undertake early surveillance for malignant
complications that might in time be shown to undertake
nephron-sparing surgery and to improve outcomes. Kidney
cancer with diverse aggressiveness has been associated with
germline mutations of one of the following genes: VHL, MET,
FH, BHD or TSC. The genetic mechanism, histopathology and
clinical history of kidney cancer associated with each of the
above gene mutation will be discussed.
165
NOVEL ROLES OF ETS1 IN CANCER
PROGRESSION
Jürgen Dittmer
Clinic for Gynaecology, University of Halle, Halle (Saale),
Germany
Ets transcription factors, such as Ets1, play an important role
in cancer progression. Ras-responsive Ets1 promotes invasion
of tumor cells by orchestrating the expression of ECMdegradating proteases. Ets1 is also involved in tumor-induced
neo-angiogenesis. A search for additional targets for Ets1
revealed a link between Ets1 and Rho-GTPases. Ets1 upregulates the expression of Rho-GDIβ, an inhibitor of RhoGTPases. In primary breast cancer, Ets1 and Rho-GDIβ are
coexpressed. An analysis of Rho-GDIβ function in breast
3264
cancer cells revealed that Rho-GDIβ has a dual effect. By
inhibiting cellular migration, Rho-GDIβ acts tumorsuppressively; by inducing the expression of the oncogene
Cox-2 Rho-GDIβ likely promotes tumor progression. RhoGDIβ regulates Cox-2, by cooperating with the Rho-GTPase
guanine exchange factor Vav1, which is coexpressed with
Rho-GDIβ in primary breast cancer. Despite its positive effect
on Cox-2, Rho-GDIβ was not found to negatively affect the
survival of breast cancer patients, rather, patients with RhoGDIβ-positive breast cancer tend to have a better outcome.
This tendency was more pronounced when breast tumors were
negative for Rho-GDIα, a ubiquitously expressed close
relative of Rho-GDIβ. In contrast to Rho-GDIβ, Rho-GDIα
significantly increased survival of breast cancer patients. This
effect, however, was absent when Rho-GDIβ was expressed.
It seems that both the Ets1-regulated Rho-GDIβ and RhoGDIα are capable of slowing down cancer progression.
However, the effect of Rho-GDIβ is compromised by its
ability to induce Cox-2 expression.
166
TUMOR RECOVERY BY ANGIOGENIC SWITCH
FROM SPROUTING TO INTUSSUSCEPTIVE
ANGIOGENESIS AFTER TREATMENT WITH
PTK787/ZK222584 OR IONIZING RADIATION
Ruslan Hlushchuk1,5, Oliver Riesterer2, Oliver Baum1,
Jeanette Wood3, Guenther Gruber4, Martin Pruschy2 and
Valentin Djonov1,5
1Institute
of Anatomy, University of Bern, Bern;
of Radiation Oncology, University Hospital,
2Department
Zurich;
3Novartis Pharma AG, Basel;
4Department of Radiation Oncology, University Hospital,
Bern;
5Institute of Anatomy, University of Fribourg, Fribourg,
Switzerland
Background: Inhibitors of angiogenesis and radiation induce
compensatory changes in the tumor vasculature not only
during treatment, but also after its cessation. Methods: To
assess the response to the treatment, the tumors were
analyzed immediately after cessation of therapy and during
the recovery phase. Mammary carcinoma allografts were
investigated by vascular casting, electron, light, confocal
microscopy, and immunoblotting after fractionated
irradiation or treatment with the VEGF-receptor tyrosine
kinase inhibitor, PTK787/ZK222854. Results: Irradiation and
antiangiogenic therapy had similar effects on the tumor
vasculature in the recovery phase. Both treatments reduced
the tumor vascularization, particularly in the tumor medulla.
After cessation of therapy, the tumor vasculature expanded
predominantly by intussusception, with a plexus composed
Abstracts of the 8th International Conference of Anticancer Research, 17-22 October 2008, Kos, Greece
of enlarged sinusoidal-like vessels containing multiple
transluminal tissue pillars. Tumor revascularization
originated from preserved SMA-positive vessels in tumor
cortex. Quantification revealed that recovery was
characterized by an angiogenic switch from sprouting to
intussusception. The up-regulated SMA-expression during
the recovery reflected the recruitment of SMA-positive cells
for intussusception as a part of the angioadaptive mechanism.
Tumor recovery was associated with a dramatic decrease (by
30-40%) in the intratumoral microvascular density, probably
as result of intussusceptive pruning, surprisingly with only a
minimal reduction of the total microvascular (exchange)
area. Therefore, the vascular supply to the tumor was not
severely compromised as demonstrated by HIF-1-alpha
expression. Conclusion: Irradiation and antiangiogenic
therapy causes a switch from sprouting to intussusceptive
angiogenesis as part of a compensatory response to preserve
and restore perfusion. Intussusceptive angiogenesis, with an
associated low endothelial proliferation rate and
permeability, may represent an escape mechanism and
account for the development of resistance to therapy, as well
as the rapid recovery of tumor vasculature after cessation of
therapy.
167
CHEMOSENSITIVITY TESTING: PREDICTING THE
UNPREDICTABLE
Ralph Dollner
Department Otorhinolaryngology, Head and Neck Surgery,
Rikshospitalet University Clinic Oslo, N-0027 Oslo, Norway
Objective: According to a recent assessment of the working
group for technology assessment by the American Society of
Clinical Oncology (ASCO), a reliable assay for detecting
chemosensitivity in tumour tissue and selecting
chemotherapeutic agents for individual patients is still
missing (Schrag et al. 2004, JCO). Therefore, it seems
advisable to reassess the major issues for a reliable test
system. Particularly for testing solid tumours, three basic
considerations should be addressed: (i) how to provide
“reproducibility” in performing chemosensibility tests with
unique biopsy specimens, (ii) whether inevitable nonmalignant cells present in processed biopsies affect the
analysis of the malignant cells, and (iii) whether single biopsy
analyses allow us to draw conclusions valid for a presumably
cellular very heterogeneous tumour mass. Materials and
Methods: The introduction of flavin-protecting cell culture
methods was a breakthrough, since for the first time it was
possible to perform chemosensitivity tests that are not
affected by photochemical “chaotropic” artefacts (Granzow
et al. 1995, Cancer Res). Subsequently an ex vivo test has
been developed to address the above mentioned issues
(Dollner et al. 2004, Anticancer Res). This new assay was
performed on 60 tumour biopsy specimens of head and neck
squamous cell carcinomas (HNSCC) totalling a number of
436 tests. The assay allows for the selective evaluation of
chemoreactivity of both epithelial and stromal cells from a
given biopsy specimen. Results: Reproducibility of single
tests was demonstrated by parallel chemosensitivity tests with
established cell lines performing under the same conditions
as used for testing the biopsies. The selective analysis of
epithelial and stromal cells revealed that stromal cells were
equally or less sensitive to cytostatic drugs compared to the
epithelial tumour cells in almost 90% of the tests. For
comparative chemosensitivity tests, three separate biopsies
from the same tumour were tested in parallel (n=10). Here,
we consistently found the same chemosensitivities for
epithelial cells from within one tumour. The chemosensitivity
of stromal cells, however, varied widely among biopsies taken
from different locations within the same tumour. Conclusion:
Beside flavin-protecting culture conditions, a robust and cell
type-specific evaluation of malignant cells from tumour
tissues is required for reliable and meaningful
chemosensitivity testing. According to our data, the cell typespecific chemosensitivity testing of a single tumour biopsy
provides representative results for the epithelial cell
population of a tumour.
168
THE ROLE OF LYMPHANGIOGENESIS IN HUMAN
NON-SMALL CELL LUNG CANCER
Balazs Dome
Department of Tumor Biology, National Koranyi Institute of
Pulmonology, Piheno u. 1., Budapest, H-1529, Hungary
Although N status is a major determinant for the clinical
management of non-small cell lung cancer (NSCLC), current
strategies for lymph node (LN) staging is not sensitive enough,
many cases are understaged, and we are unable to identify
those patients who will ultimately have poor outcome.
Consequently, there is a need for clinically useful approaches
to better stratify patients with respect to the risk of LN
metastasis and recurrence after surgery. Unfortunately, because
no specific markers for lymphatic endothelium were available
until recently, our knowledge of the lymphatic system of
malignant tumors lags far behind that of the vascular system.
However, the recent discovery of LYVE-1 and M2A antigen
(D2-40) as specific markers for lymphatics has now provided
tools for a detailed analysis of lymphangiogenesis. In a recent
study, our group analyzed how NSCLC acquires its lymphatic
network and investigated whether the extent of
lymphangiogenesis might be related to the angiogenic
phenotype (angiogenic versus nonangiogenic) and/or to the
risk of lymph node metastasis and to patient survival, using
3265
ANTICANCER RESEARCH 28: 3157-3556 (2008)
tumor samples obtained from NSCLC patients. For the first
time in the literature, we demonstrated that lymphangiogenesis
occurs exclusively in the angiogenic growth type of human
NSCLCs, and that lymph vessel density is correlated to
clinical behavior and to lymph node status only in this growth
type of NSCLCs. However, this study also provided the first
evidence that the risk of lymph node metastasis as well as a
shorter survival is more likely to occur in the patient
population with nonangiogenic tumors, and that these tumors
mainly co-opt host tissue lymphatics during their growth, in
contrast to most of the angiogenic ones, which expand with
concomitant lymphangiogenesis. The current presentation
provides an update on the biology of lymph vessels in human
NSCLC, and explores the utility of lymphangiogenesis for
pulmonary oncology.
169
HEALTH-RELATED QUALITY OF LIFE:
THE PARADIGM OF VACUUM-ASSISTED
BREAST BIOPSY
SF-36 role functioning-physical was observed four days after
VABB.
The results clearly indicate for the first time a significant
effect of VABB on HRQoL. Breast biopsy represents a
significant event in a woman’s life, with multidimensional
physical, psychological and health care-related implications.
Although the minimally invasive character of modern breast
biopsy techniques might lead some health care providers to
overlook its effect on HRQoL, measurement of the latter
should be integrated in the global clinical assessment of
patients.
170
INFLUENCE OF GROWTH FACTORS ON THE
FORMATION OF CD133-POSITIVE STEM CELLS
FROM CD133-NEGATIVE POPULATIONS
AND LOW PASSAGE HIGH-GRADE
GLIOBLASTOMA MULTIFORME
Laura Donovan and Geoffrey J Pilkington
1st Department of surgery, School of Medicine, Athens
University, Greece
Cellular and Molecular Neuro-Oncology Research Group,
Institute of Biomedical Sciences, School of Pharmacy and
Biomedical Sciences, University of Portsmouth, St Michael’s
Building, White Swan Road, Portsmouth PO1 2DT, UK
Health-related quality of life (HRQoL) is an important
parameter in cancer care and assessment of novel
therapeutic strategies, as reflected upon numerous ongoing
trials. Nevertheless, there is a relative scarcity of data
regarding HRQoL in bioptical procedures, which are an
indispensable part of early cancer diagnosis and subsequent
management.
In this presentation the main point of focus is HRQoL in
breast biopsy; vacuum-assisted breast biopsy (VABB) has been
chosen as a recent, minimally invasive and reliable paradigm.
VABB (11G needle) is capable of obtaining tissue for
histopathological diagnosis of non-palpable mammographic
lesions, so as to ensure early breast cancer diagnosis. Although
its role is already well established, the impact of VABB on
HRQoL has never been investigated.
The herein summarized research project has adopted two
independent tools for the optimal assessment of HRQoL,
namely SF-36 and EQ-5D. SF-36 comprises 36 items covering
eight health dimensions. The EQ-5D is a short questionnaire
which evaluates the patient’s quality of life according to five
dimensions, each one with three levels. EQ-5D also contains a
visual analogue scale (VAS) on which patients rate their own
health between 0 and 100. These questionnaires were
completed by 128 patients, both in the morning of the VABB
procedure and four days after VABB.
In the morning of VABB patients reported worse HRQoL
scores in EQ-5D anxiety/depression and SF-36 general health
subscales; a significant decline in EQ-5D usual activities and
Background: A small subset of cells displaying stem-like
properties, with the ability to self-renew and sustain the
growth of tumours has been identified in brain tumours.
CD133 has been identified as a marker for a subpopulation
of neural stem cells and facilitates an active role in local brain
tumour cell invasion. Growth factors play a vital role in the
modulation and behaviour of stem cells, in particular Human
transforming growth factor β1 (TGFβ1), Epidermal growth
factor (EGF) and basic-Fibroblast growth factor (bFGF/FGF2). Initial research into the dependency of CD133-negative
cells and low passage high-grade glioblastoma multiforme
upon these particular growth factors will help to assess the
formation and properties of CD133-positive stem cells. Aim:
To isolate CD133-positive stem cell populations from
glioblastoma multifoprme biopsies and to assess the role of
growth factors in controlly CD133 positivity and biological
activity of glioblastoma multiforme in vitro. Flow cytometry
and immunocytochemistry will be used to characterise the
varying levels of growth factor concentrations, using the
appropriate immuno-markers CD133/1 and Ki-67. Materials
and Methods: CD133-positive populations have been
extracted by magnetic bead immuno-cell segregation
(autoMACS™), from low-passage high-grade biopsy-derived
glioblastoma multiforme cells and CD133-negative stem cell
populations, and transformed into neurospheres by using stem
cell defined growth media supplemented with the appropriate
growth factors concentrations. The positive and negative
isolated stem cell populations were characterised using flow
Philip J. Domeyer
3266
Abstracts of the 8th International Conference of Anticancer Research, 17-22 October 2008, Kos, Greece
cytometry and immunocytochemistry with the CD133/1
antibody. Results: The influence of 10 ng/ml of TGFβ1, FGF2 and EGF on CD133-positive stem cells was seen to effect
cell proliferation rates, cell migration and CD133-positive
expression. Discussion: The in vitro microenvironment
dictates the behaviour of cultured neoplastic glia as well as
influencing CD133 expression. Furthermore, studies are
aimed at elucidating the precise role of multiple drug
resistance of CD133-positive stem cells on the behaviour of
glioma.
This work was supported by Charlie’s Challenge and Ali’s
Dream brain tumour research charities.
171
COMBINATION THERAPY TARGETING G1
CYCLINS FOR PATIENTS WITH PREVIOUSLY
TREATED ADVANCED NON-SMALL
CELL LUNG CANCER (NSCLC)
Konstantin H. Dragnev, James R. Rigas, Marc Seltzer,
David Johnstone, William Nugent, Wendye M. DiSalvo,
Sara Simeone and Ethan Dmitrovsky
Dartmouth-Hitchcock Medical Center, Lebanon, NH 03756;
Dartmouth Medical School, Hanover, NH 03755, USA
G1 cyclins are often aberrantly expressed in bronchial
preneoplasia and lung cancer. This implicates these species as
novel molecular pharmacological targets of several anticancer
agents for lung cancer therapy and chemoprevention. We
previously reported a targeted combination regimen that
cooperatively affected D-type cyclins. A phase I trial of the
EGFR tyrosine kinase inhibitor, erlotinib, and the rexinoid,
bexarotene, in patients with advanced aerodigestive tract
cancer showed minimal toxicities and preliminary evidence of
clinical activity. Combining erlotinib with bexarotene also
induced at least additive suppression of growth and cyclin D1
expression in human bronchial epithelial cells and in some
lung cancer cell lines.
A phase II trial of erlotinib and bexarotene was conducted
in patients with stage IV NSCLC. The primary objective was
radiographic response rate; secondary objectives were
survival, time to progression, toxicities, and correlation of
early metabolic response by PET at 8-12 days and 2 months.
Dosing was erlotinib 150 mg and bexarotene 400 mg/m2 daily
orally.
Forty-two patients were enrolled including 52% women
and 62% with adenocarcinoma; the median age was 67 (4677) years, 12% were current smokers and 17% were never
smokers. The median number of prior therapies was 2 (range
0-5), 21% had had prior anti-EGFR therapy. Common
toxicities were hypertriglyceridemia and skin rash. Grade 3
pulmonary hemorrhage (1), rash/mouth sores (1), cough (1),
hypereosinophilic syndrome (1), and abdominal pain (1) led
to treatment discontinuation. There were 2 objective partial
responses; 7 patients had stable disease including one patient
with prior gefitinib (35 weeks on study). Median time to
progression was 7 weeks and median overall survival was 21
weeks (intent-to-treat). Decreased metabolic activity on PET
imaging at 10 days was associated with radiographic response
at 2 months. Correlation between the severity of hypertriglyceridemia and clinical outcome will be presented. The effect
of this combined regimen on the levels of EGFR and/or
cyclin D1 expression will be assessed in a proof-of-principle
pilot study.
The combination of erlotinib and bexarotene is well
tolerated and shows evidence of activity in heavily pretreated
patients with NSCLC. These results implicate clinical benefit
of dual targeting of EGFR and cyclin D1 in NSCLC. Future
work should assess the effects of combinations of anticancer
agents targeting cell cycle progression at G1.
172
DNA-PKcs-PIDDOSOME: A NOVEL NUCLEAR
CASPASE-2-ACTIVATING PROTEIN COMPLEX
THAT FUNCTIONS IN DNA DAMAGE RESPONSE
Mingan Shi1, Carolyn J. Vivian1, Kyung-Jong Lee2,
Chunmin Ge1, Keiko Morotomi-Yano2, Shigeo Sato1,
Chieri Sato1, Ruihong Zhu1, Joshua Wunderlich1,
Selene K. Swanson1, Jeffrey S. Haug1, David J. Chen2,
Benjamin P. C. Chen2, Michael P. Washburn1,
Laurence Florens1 and Chunying Du1
1Stowers
Institute for Medical Research, Kansas City,
Missouri 64110;
2Division of Molecular Radiation Biology, University of
Texas Southwestern Medical Center, Dallas, Texas, 75390,
USA
Caspase-2 plays an apoptotic role in apoptosis. The
identification of the protein complex PIDDosome has
accelerated our understanding of caspase-2 activation.
Caspase-2 is unique among all the mammalian caspases in
that it is the only caspase that is present constitutively in the
cell nucleus, in addition to other cellular compartments.
However, the functional significance of this nuclear
localization is unknown. We have found that DNA damage
induced by γ-radiation triggers the phosphorylation of
nuclear caspase-2, leading to its cleavage and activation.
This phosphorylation is carried out by the nuclear
serine/threonine protein kinase DNA-PKcs and is promoted
by the death-domain protein PIDD within a large nuclear
protein complex consisting of DNA-PKcs, PIDD, and
caspase-2, which we have named DNA-PKcs-PIDDosome.
Characterization of this DNA-PKcs-PIDDosome has
revealed unexpected novel functions of it in DNA damage
response pathway. Data will be presented to show the
3267
ANTICANCER RESEARCH 28: 3157-3556 (2008)
molecular mechanism of this protein complex in the cellular
response to DNA damage.
In conclusion, our data reveal a new role and a new
activation mechanism of caspase-2. The ability of caspase-2
to participate in both pro-apoptotic and pro-survival processes
means that caspase-2 may stand at the crossroads of a DNAdamage response network, coordinating apoptosis and cell
survival to determine cell fate.
173
THE ROLE OF THE RETINOBLASTOMA
TUMOR SUPPRESSOR GENE IN CELL
PROLIFERATION, DIFFERENTIATION,
AND APOPTOSIS DURING NORMAL
DEVELOPMENT AND IMPLICATIONS
FOR TARGETED CANCER THERAPY
Wei Du
The University of Chicago, USA
The retinoblastoma gene (Rb) is a prototype tumor
suppressor gene often mutated or inactivated in cancer. The
Rb protein (pRb) regulates a variety of normal cellular
processes including cell proliferation, differentiation, as well
as apoptosis. Extensive studies have shown that pRb exerts
its diverse functions by forming complexes with other
proteins. Of the large number of proteins that can bind to
pRb, the best studied are the E2F transcription factors,
which are heterodimers composed of a subunit of the E2F
family and a subunit of the DP family. In mammalian
systems, there are eight E2F and three DP family members.
While it is well established that E2F proteins mediate most,
if not all, of the effects of Rb loss on cell proliferation and
apoptosis, the mechanism by which Rb regulates cell
differentiation is less clear. In addition to E2F, pRb also
binds to a large number of other proteins including a
number of transcription factors involved in the
differentiation of specific cell types such as MyoD and
C/EBP β. In vitro studies using cell culture systems have
suggested that pRb directly interacted with and enhanced
the activities of these differentiation promoting transcription
factors to promote differentiation. However, the significance
of these observations has not been demonstrated in vivo in
animal models. The presence of large numbers of E2F
proteins also makes it difficult to evaluate the contribution
of E2F to the differentiation defects of Rb loss in
mammalian systems.
The function and regulation of the Rb/E2F proteins are
highly conserved and much simpler in Drosophila. We have
used this model system to characterize the in vivo role of
Rbf (fly Rb) in cell proliferation, differentiation, and
apoptosis. Our analysis of developing fly tissues with rbf
mutant clones revealed that the consequences of Rbf loss are
3268
distinct in different cell types, suggesting that additional
signaling pathways or cell-intrinsic factors modulate the
effect of Rbf removal. To identify genes that can
preferentially affect the differentiation or death of rbf
mutant cells, we carried out a genetic screen by generating
double mutant clones. We found that mutation of rno leads
to synergistic differentiation defects in conjunction with loss
of Rbf. Further characterization revealed that the
differentiation role of Rbf and Rno are mediated by their
cooperative regulation of the Notch and EGFR signaling,
and that this differentiation role of Rbf is E2F dependent.
Characterization of the mutations that affected the apoptosis
of rbf mutant cells revealed that hid, which is directly
repressed by the Rbf/E2F repression complex, is a key
player that mediates the apoptosis effect of rbf mutant cells.
Genes and pathways that can modulate the activities of Hid
can also modulate the apoptosis of rbf mutant cells. The
conservation of these genes and pathways between flies and
mammals suggest potential new approaches against cancer
with Rb mutations.
174
T-LYMPHOCYTE CYTOKINE
PRODUCTION PATTERN OF
THYROID CARCINOMA VERSUS
NODULAR THYROID DISEASE
H. Duan, E. Maldonado-Gonzalez, M. Schuetz, K. Kaserer,
B. Niederle, R. Dudczak, M. Willheim and G. Karanikas
Departments of Nuclear Medicine, Pathology, Surgery –
Section of Endocrine Surgery and Pathophysiology, Medical
University of Vienna, A-1090 Vienna, Austria
Aim: The balance of efficiency of immune reactions against
transformed cells and impairment of the immune system
caused by malignant cells plays a decisive role for the
outcome of tumour disease. We evaluated of T-lymphocyte
cytokine production pattern in patients with verified thyroid
carcinomas and nodular thyroid diesease. Materials and
Methods: Twenty-six patients (19 females, 7 male, aged 2880 years) with nodular thyroid disease assigned for
thyroidectomy were included in the present study. They were
divided into two groups: Group I: 13 patients with
histologically verified thyroid carcinoma (8 papillary, 2
papillary/follicular, 3 medullary carcinomas) and Group II:
13 patients with benign nodular thyroid. The control group
(Group III) consisted of thirteen age-matched healthy
volunteers free of thyroid disease. All patients underwent
measurement of intracellular cytokine detection in CD4+ and
CD8+ T-cells of peripheral blood mononuclear cells (PBMC)
by flow cytometry before undergoing surgery. Results: No
significant differences were found in the cytokine production
pattern between thyorid cancer and nodular thyroid disease
Abstracts of the 8th International Conference of Anticancer Research, 17-22 October 2008, Kos, Greece
or the control group. On the other hand, benign nodular
disease, in comparison to the control group, showed a
significant increase of CD8+ cells producing TNF-α, IFN-γ
and IL2/IFN-γ. Conclusion: According to our data, no
change in the cytokine production pattern can be detected in
blood lymphocytes of patients with thyroid carcinoma.
Remarkably, benign nodular disease showed increased
production of cytokines associated with cellular immunity by
cytotoxic T-cells. This suggests that the immune system
responds to benign transformation of thyroid cells, a
response that may be impaired by malignant cells.
175
11β-HYDROXYLASE-INHIBITOR
[18F]FETO FOR VISUALIZATION/
VERIFICATION OF ADRENOCORTICAL
TUMOUR MASSES IN POSITRON
EMISSION TOMOGRAPHY
H. Duan, M. Schuetz, W. Wadsak, M. Mitterhauser,
L. Key Mien, B. Niederle, A. Gessl, R. Dudczak,
K. Kletter and G. Karanikas
Departments of Nuclear Medicine and Surgery – Section of
Endocrine Surgery, Medical University of Vienna, A-1090
Vienna, Austria
We aimed to investigate the novel PET radiopharmaceutical
[18F]FETO, an 11β-hydroxylase-inhibitor, in patients with
adrenocortical masses. Twenty-five patients (14 females and
11 males, aged 15-72 years) with adrenocortical lesions (n=22,
verified by CT and/or MRI) or as follow-up after
adrenocortical carcinoma (ACC, n=3) were included in the
present study. Dynamic and whole body images were
performed after administration of 370 MBq [18F]FETO. Visual
interpretation, as well as semi-quantitative analysis using
standardised uptake values (SUVs) was conducted.
In 19 out of 25 patients, [18F]FETO uptake was massive
in adrenal lesions, pronounced in contralateral adrenals and
moderate in liver. In 2/25 patients, FETO showed intense
bilateral accumulation (CT/MRI negative), one with
adrenogenital syndrome, the other with bilateral hyperplasia
(histologically verified). In follow-up of the three patients
with ACC, FETO revealed one liver metastasis of ACC
(inconclusive in CT/MRI, verified by histology). A patient
with an adrenocortical lesion verified by CT/MRI was true
negative in the FETO PET scan (rhabdomyosarcoma,
verified by histology). The median SUV of adrenal masses
was 22.4 (range 8.3-41.1), of contralateral adrenocortex 15.8
(range 8.1-23.7), and of liver 2.9 (range 2.0-4.1). No
significant difference was found between the median SUV
of biochemically active (n=10, median SUV 21.0) and nonactive adrenocortical lesions (n=11, median SUV 23.1).
Due to the intense uptake of [18F]FETO in the adrenal
masses, a clear tumour visualization was achieved. FETO is
an excellent imaging tool for the visualization of benign
adrenocortical diseases, as it visualizes adrenal adenomas as
well as hyperplasia.
176
18F-FLUOROAZOMYCINARABINOSIDE
(FAZA) IN PATIENTS WITH CERVICAL
CANCER FOR DETECTION OF HYPOXIA AREAS
IN POSITRON EMISSION
TOMOGRAPHY – A PILOT STUDY
H. Duan, M. Schuetz, S. Kommata, D. Lukic,
E. Maldonado-Gonzalez, P. Angelberger, R. Schoen,
R. Dudczak, K. Kletter, B. Bachtiary and G. Karanikas
Departments of Nuclear Medicine and
Radiotherapy/Radiobiology, Medical University of Vienna,
and Austrian Research Centers Seibersdorf, Austria
Background: Hypoxia has emerged as an important factor in
tumour biology and response to cancer treatment. 18Ffluoroazomycinarabinoside (18FAZA) was recently introduced
as a novel hypoxia tracer. The aim of our study was to
evaluate the potential value of FAZA in visualisation of
tumour hypoxia and in the individual treatment planning of
patients with cervical cancer. Materials and Methods: Twelve
patients (mean age, 53 years) with cervical carcinoma (T2Nx
or TxN1) were included in our study. In addition to their
routine pre-therapeutical staging, 18FAZA PET was
performed before, during (short before brachytherapy) and
three months after radio-chemotherapy. The patients were
scanned subsequently by the administration of 370 MBq
18FAZA (dynamic scan) and 1, and 2 hours afterwards (static
scan). Any tumour visualisations by FAZA were judged as
hypoxic area. Standardized uptake values (SUV) and ratios to
normal tissue (muscle) were calculated. Results: In the initial
static scan (before therapy), 5 out of 12 patients showed
hypoxic areas in the tumour side (SUV range: 1.6-2.6; T/M
ratio range: 1.2-3.6). No hypoxic areas were found in the
remaining 7 patients nor in the initial nor in the follow-up
scans. Four out of the 5 positive patients showed a decreased
FAZA uptake during the therapy (short before brachytherapy)
(SUV range: 1.4-1.9; T/M ratio range: 1.2-2.1) and a further
reduced accumulation after the radio-chemotherapy (SUV
range: 1.1-1.9; T/N ratio range: 1.0-2.3). One patient showed
no change in hypoxic areas neither during the therapy nor in
the follow up scan. In contrast to the other patients, this
patient was a non-responder to radio-chemotherapy.
Discussion: According to our preliminary results, 18FAZA
PET is able to visualise hypoxic tissue in cervical cancer.
Following the time course of tumour oxygenation by FAZA
scans as in our study could be a potential tool in treatment
planning.
3269
ANTICANCER RESEARCH 28: 3157-3556 (2008)
177
ALKALINE SPHINGOMYELINASE (NPP7)
AND ITS IMPLICATIONS IN INTESTINAL
TUMORIGENESIS AND INFLAMMATION
Rui-Dong Duan
Biomedical Centre B11, Institution of Clinical Sciences,
University of Lund, S-221 84 Lund, Sweden
Alkaline sphingomyelinase (Alk-SMase) is an enzyme
expressed in the intestinal mucosa and human liver. It is an
ectoenzyme localized on the surface of the cell plasma
membrane and is released into the intestinal lumen and bile
by both bile acids and trypsin. The enzyme belongs to
nucleotide pyrophosphatase/phosphodiesterase (NPP) family
with specific activities against phospholipids including
sphingomyelin, platelet-activating factor (PAF), and
lysophosphatidylcholine. The enzyme generates the
antiproliferative molecule ceramide, inactivates PAF, and
competes with phospholipase D and reduces the formation of
lysophosphatidic acid. Expression of the enzyme is inhibited
by a high fat diet and stimulated by water-soluble fiber
psyllium and also by some anti-inflammatory drugs such as
5-ASA and ursodeoxycholic acid. The levels of the enzyme
in the intestinal mucosa are positively correlated with caspase
3, the key enzyme responsible for apoptosis. In vitro studies
showed that alk-SMase inhibits cell proliferation in a dosedependent manner accompanied by a reduction of
sphingomyelin and formation of ceramide. Development of
human colonic adenocarcinoma is associated with a
progressive reduction of alk-SMase activity. Such reductions
have also been identified in human hepatic diseases such as
primary sclerosing cholangitis and steatosis, which increase
the risk of liver cancer. The results above indicate that alkSMase may serve as a tumour suppressor in both colon and
liver.
By analysing alk-SMase in cancer cell lines and biopsy
samples, we identified two aberrant forms of alk-SMase
mRNA in human colon and liver cancer. The formation of the
aberrant forms are caused by a skipping of one exon at the
splicing level, resulting in destruction of the substrate binding
sites and total inactivation of the enzyme. The findings provide
a molecular background for the reduced enzyme activity found
previously in cancer tissues.
We have developed a method to express the recombinant
alk-SMase with full activity in yeast cells. We are also able
to increase alk-SMase activity 2- to 4-fold through a single
site mutation based on a 3-D structure predicted by molecular
modulation. In studies with a rat ulcerative colitis model
induced by dextran sulfate sodium, we found that injection of
the yeast-expressed human alk-SMase in the colon
significantly reduced the inflammation score and the
expression of TNF-alpha. Histological examination showed
3270
that alk-SMase protected the colonic membrane from
inflammatory destruction.
In conclusion, alk-SMase may play important roles in
protecting both colon and liver from tumorigenesis. The
recombinant enzyme may be used as a protein therapeutic tool
to replace the mutant enzyme in cancer and inflammatory
conditions.
178
BLOOD OUTGROWTH ENDOTHELIAL CELLBASED DELIVERY OF CANCER GENE THERAPY
Arkadiusz Z. Dudek
Division of Hematology, Oncology and Transplantation,
University of Minnesota, Minneapolis, MN, USA
Angiogenesis and postnatal vasculogenesis are two processes
involved in the formation of new vessels, an essential
requirement for tumor growth and metastasis. We isolated
endothelial cells from human blood mononuclear cells by
selective culture. These blood outgrowth cells express
endothelial cell markers and respond correctly to functional
assays. To evaluate the potential of blood outgrowth
endothelial cells to construct functional vessels in vivo, NODSCID mice were implanted with Lewis lung carcinoma cells
subcutaneously. Blood outgrowth endothelial cells were then
injected through the tail vein. Initial distribution of these cells
occurred throughout the lung, liver, spleen, and tumor vessels,
but 48 hours after injection they were only found in liver and
tumor tissue. By day 24, they could mostly be found in tumor
vasculature and this tumor selectivity correlated with an
increase in tumor vessel counts as compared with control
injections. We engineered blood outgrowth endothelial cells to
deliver an angiogenic inhibitor directly to tumor endothelium
by transducing these cells with the gene for human endostatin,
and the soluble receptor for vascular endothelial growth factor.
These cells maintained an endothelial phenotype and
decreased tumor vascularization and tumor volume in a
subcutaneous murine tumor model, as well as in spontaneous
orthotopic breast cancer and glioma models. We conclude that
blood outgrowth endothelial cells have the potential for tumorspecific delivery of cancer gene therapy.
179
LARGE MULTIVALENT IMMUNOGEN VACCINE IN
PATIENTS WITH METASTATIC MELANOMA
Arkadiusz Z. Dudek
Division of Hematology, Oncology and Transplantation,
University of Minnesota, Minneapolis, MN, USA
Metastatic melanoma is an incurable malignancy with a median
survival of 6-8 months. While melanoma is refractory to most
Abstracts of the 8th International Conference of Anticancer Research, 17-22 October 2008, Kos, Greece
chemotherapy drugs, its growth may be regulated by immune
mechanisms as shown by the rare occurrence of spontaneous
remissions, the presence of cytotoxic tumor infiltrating
lymphocytes (TIL) in resected tumors, and the demonstration
of TIL cytotoxicity toward autologous tumor cells in vitro.
Notably, interferon (IFN)-α2b and interleukin (IL)-2 have
demonstrated modest efficacy in the treatment of advanced
melanoma. Phase II studies using biochemotherapy for the
treatment of metastatic melanoma resulted in response rates of
~50%, median time to disease progression of 5 months and an
extended median survival of approximately 12 months. These
results are consistent with the notion that progression of
melanoma can be affected by immune stimulation.
Therapeutic benefit has also been demonstrated recently for
vaccines in metastatic melanoma. There are various strategies
for development and administration of tumor vaccines
including those generated from tumor-derived peptides,
irradiated autologous tumor cells, allogeneic cell lysates,
dendritic cells, and gene-modified tumor or dendritic cells. A
novel approach for vaccine-induced augmentation of tumorspecific cytotoxic T lymphocyte (CTL) responses has been
developed utilizing cell-sized (5-μm diameter) latex or silica
microspheres that function as a solid support for tumor antigen
presentation. These artificial antigen-presenting cells are
termed large multivalent immunogen (LMI).
A phase II study of autologous LMI vaccine for the
treatment of stage IV melanoma has been completed.
Vaccine production involved isolating tumor cell membranes
obtained from melanoma specimens which were then
attached to microspheres. Eligible patients were randomly
assigned to one of three treatment groups, in cohorts of three
to ensure balanced samples between treatment groups in each
stratum. Group 1 received LMI; Group 2 received
cyclophosphamide and LMI; and Group 3 received
cyclophosphamide, LMI, and IL-2. LMI were coated with
autologous tumor cell membrane. Patients received LMI
(1×107, 5–μm silica spheres) vaccination by intradermal
injection beginning on day 1 and continuing at 4-week
intervals until the supply of tissue for producing additional
doses of LMI vaccine was depleted. Cyclophosphamide
infusions at 300 mg/m2/d were given intravenously 7 days
before vaccine. IL-2 infusions at 1.75×106 IU/m2/d were
given subcutaneously 5 days after each LMI administration
for 1 week (i.e., days 6-12, 34- 40, etc.). This trial evaluated
the safety of LMI. No grade 4 toxicities (by NCI CTCAE v
3.0) were observed in any arm. Patients with malignant
melanoma had median overall survival time of 15.4 months
(95%; CI>7.99) and median overall time to disease
progression of 2.8 months (95% CI: 1.87, 6.25). One patient
with melanoma had documented partial response (by
RECIST criteria). Multiple regression analysis showed that
the number of LMI doses was inversely correlated with risk
of death. Based on our results that demonstrate the safety
and tolerability of LMI vaccine, further development of this
therapy in the allogeneic setting is now being performed in a
randomized placebo-controlled study.
180
EARLY PREDICTION OF OSTEOSARCOMA
HISTOLOGIC RESPONSE BY 18F-FDG PET:
PRECLINICAL EVALUATION
IN AN ORTHOTOPIC RAT MODEL
Aurélie Dutour2,5, Anne-Valérie Decouvelaere4,5*,
Jacques Monteil6*, Raphaël Rousseau1,2,3,5
and Perrine Marec-Berard3,5
1Université
de Lyon, Lyon, F-69003;
U590, Lyon, F-69008;
3Institut d’Hématologie-Oncologie Pédiatrique, Lyon, F69008;
4Département d’Anatomopathologie et Cytologie, Lyon, F69008;
5Centre Léon Bérard, Lyon, F-69008, 6 Service de Médecine
Nucléaire, Centre Hospitalier Universitaire Dupuytren,
Limoges, F-87000, France
*Both authors contributed equally to this work
2Inserm,
The assessment of osteosarcoma response to neoadjuvant
chemotherapy is performed after surgical resection of the
primary tumor by histological analysis according to a method
described by Huvos. The purpose of this study was to evaluate
whether 18F-FDG PET could be a non-invasive surrogate of
histopathological analysis and enable an early identification of
response to neoadjuvant chemotherapy in osteosarcoma.
Rat orthototopic osteosarcoma model was used. Animals
with well-established tumors were examined using 18F-FDG
PET before being divided into a control and ifosfamide-treated
group (n=10 animals/group). After two cycles of
chemotherapy, all the animals were submitted to a second
18F-FDG PET exam. Tumors were then submitted to
histological analysis. Image reconstructions of FDG PET were
analysed semiquantitatively by using a volume of interest
(VOI)-based method. Metabolic and histological responses to
chemotherapy were compared. Histological analysis classified
the rats from the control group as non-reponders, whereas
animals from the ifosfamide-treated group were classified as
partial (n=5) and good responders (n=5). Data analysis showed
that the SUV Max value of the 18F-FDG PET performed after
two cycles of chemotherapy correlated to the histological
classification (p<0.01). We showed that an SUV Max <15
corresponded to a good responder, 15<SUV Max<20 to a
partial responder and SUV Max>20 corresponded to nonresponder. Moreover, analysis established that a 40%
diminution of SUV Max between PET 1 and 2 is the cut-off
value to distinguish a partial response from a good response
to chemotherapy, with a specificity and sensitivity of 100%.
3271
ANTICANCER RESEARCH 28: 3157-3556 (2008)
Semi-quantitative 18F-FDG PET using the SUV parameters
seems to be able to predict the response to chemotherapy
earlier than histological analysis.
3Department
181
ROLE OF COLLAGEN- AND LAMININ-BINDING
INTEGRINS IN LIVER METASTASIS
Quinolones or quinolonecarboxylic acids are a group of
synthetic antibacterial agents that effectively inhibit DNA
replication and are commonly used as treatment for many
infections (1). Sparfloxacin (=Hsf), a third-generation quinolone
antimicrobial drug, is mainly used for the treatment of acute
exacerbations of chronic bronchitis and community-acquired
pneumonia (2). Sparfloxacin presents increased activity against
Gram-positive species such as Streptococcus pneumoniae and
Staphylococci. It has good bioavailability and its long half-life
permits once-daily dosing, which may contribute to improved
adherence to therapy and cost-effectiveness. DNA gyrase
(topoisomerase II) and topoisomerase IV are targets of
sparfloxacin against Str. pneumoniae and Staph. aureus (3, 4).
We present the structural and biological properties of the
copper-sparfloxacinato complexes in the absence or presence
of the N-donor heterocyclic ligands 2,2’-bipyridine or 1,10phenanthroline as well as of the binary sparfloxacinato
complexes with diverse transition metal ions. The antibacterial
activity of the complexes against three microorganisms is
presented and their DNA-binding behavior is evaluated.
Additionally, some complexes have been tested as potential
anticancer agents against human leukemia cell line HL-60
(peripheral blood human promyelocytic leukemia) and the
cytotoxic effects are reported.
This work was supported by the ELKE Kapodistrias.
1 I. Turel, Coord. Chem Rev 232: 27-47, 2002.
2 Efthimiadou EK, Sanakis Y, Raptopoulou CP, Karaliota A,
Katsaros N and Psomas G: Bioorg Med Chem Lett 16:
3864-3867, 2006.
3 Efthimiadou EK, Katsarou ME, Karaliota A and Psomas G:
J Inorg Biochem 102: 910-920, 2008.
4 Efthimiadou EK, Karaliota A and Psomas G: Bioorg Med
Chem Lett 18: 4033-4037, 2008.
Johannes A. Eble
Center for Molecular Medicine, Department of Vascular
Matrix Biology, Excellence Cluster Cardio-Pulmonary
System, Frankfurt University Hospital, Frankfurt, Germany
Integrins, a versatile family of cell adhesion molecules, not
only mediate the anchorage of cells within their surrounding
extracellular matrix (ECM) but also act as important signal
transduction molecules. Thus, they trigger a variety of
matrix-induced cell functions, such as adhesion, force
transmission, migration, differentiation, survival and
apoptosis. In a physiological context, these integrin-mediated
cell functions are vital. However, tumor cells also use
integrins, albeit in an altered expression pattern, to
disseminate from the primary tumor node through the
interstitial stromal tissue and to penetrate the basement
membrane, thus intra- and extravasating, and eventually
colonizing distant organs.
The interstitial stroma tissue is rich in fibril-forming
collagens, among them collagen I. The network-forming
collagen IV and laminins are abundant constituents of the
basement membrane. Hence, interactions of tumor cells with
these matrix components via collagen- and laminin-binding
integrins is of major importance in metastasis and may be a
target for anticancer therapy.
The use of novel RGD-independent inhibitors of collagenand laminin-binding integrins from snake venoms were tested
for their ability to prevent tumor cells from extravasating liver
sinusoids in an in vivo model. By comparison with in vivo
models, the role of collagen- and laminin-binding integrins in
the metastatic cascade could be defined. This may lead to new
ways to curb metastasis.
182
CYTOTOXICITY, DNA-BINDING PROPERTIES AND
ANTIBACTERIAL ACTIVITY OF METALSPARFLOXACINATO COMPLEXES
Eleni K. Efthimiadou1,2, Maria E. Katsarou2,
George Psomas3 and Alexandra Karaliota1
1Department
of Inorganic Chemistry, Faculty of Chemistry,
National University of Athens, Panepistimioupoli
Zographou, GR-15701 Athens;
2Institute of Physical Chemistry, NCSR ‘’Demokritos”, GR15310 Aghia Paraskevi Attikis;
3272
of General and Inorganic Chemistry, Faculty of
Chemistry, P.O. Box 135, Aristotle University of Thessaloniki,
GR-54124 Thessaloniki, Greece
183
NEW CONTRAST AGENTS FOR MAGNETIC
RESONANCE IMAGING TARGETING CANCER
CELLS
Eleni Efthimiadou1, Maria Katsarou1, Μichael Fardis2,
Christos Zikos1, Emmanuel N. Pitsinos1,
Athanasios Kazantzis1, Alexandra Karaliota1,
Leondios Leondiadis3 and Dionisios Vourloumis1
1Chemical
Biology, Institute of Physical Chemistry, NCSR
“Demokritos”, 15310 Aghia Paraskevi Attikis;
2Institute of Material Sciences, NCSR “Demokritos”, 15310
Aghia Paraskevi Attikis;
3Institute of ΙRRP, Mass Spectrometry and Dioxin Analysis,
NCSR “Demokritos”, 15310 Aghia Paraskevi Attikis, Greece
Abstracts of the 8th International Conference of Anticancer Research, 17-22 October 2008, Kos, Greece
Magnetic resonance imaging (MRI) is a non-invasive clinical
imaging technique, which relies on the detection of NMR
signals emitted by hydrogen protons in the body placed in a
magnetic field. MRI contrast agent (CA) is a unique class of
pharmaceuticals that enhances the image contrast between
normal and diseased tissue, and indicates the status of organ
function or blood flow after administration, by increasing the
relaxation rates of water protons in the tissue, in which the
agent accumulates. Contrast agents are being used in MRI
since 1983 when the first injection of gadolinium (Gd) DTPA
was performed in men (1). Since then CA have gained great
acceptance. They function by shortening of T1-relaxation
time, thereby increasing signal intensity (SI) (positive contrast
enhancement).
Conceptually, antibodies or other tissue-specific molecules
may be combined with paramagnetic centers to provide
disease-specific MRI agents. The challenge with regard to
delivering sufficient quantity of paramagnetic label is
substantial. On that front, we have synthesized a series of
gadolinium conjugates with Colchicine, Taxol™ and Thyroxin
(Figure), known for their tubulin- and hormone receptorbinding properties respectively, targeting the discovery of
novel, cancer specific CA. Cytotoxicity and relaxation time
measurements have been performed for all these new
complexes.
1 Caravan P, Ellison JJ, McMurry TJ and Lauffer RB:
“Gadolinium(III) Chelates as MRI Contrast Agents:
Structure, Dynamics, and Applications”. Chem Rev 99:
2293-2352, 1999.
184
MELANOMA CELLS REMEMBER
THEIR ORIGINS
Ossia M. Eichhoff1, Keith S. Hoek1, Natalie C. Schlegel1,
Marie Zipser1, Silvio Hemmi2 and Reinhard Dummer1
1Department of Dermatology, University Hospital of Zurich,
Zurich;
2Institute of Molecular Biology, University of Zurich,
Zurich, Switzerland
Human primary and metastatic melanoma lesions frequently
show heterogeneous staining pattern for melanocytic marker
genes (e.g. Tyr, Melan-A). Cell cultures derived from
metastases also show variable expression for these markers,
and microarray analyses reveal two major expression
signatures present in melanoma cell line libraries. One
signature (proliferative) shows up-regulation of genes
involved in melanocytic differentiation, while the other
(invasive) shows up-regulation of factors involved in
modifying the extracellular environment. These expression
profiles correlate with phenotypic characteristics of
proliferation, motility and growth factor sensitivity. We
believe that expression of the melanocytic master-regulator
Mitf is critical to the phenotype. Indeed, interruption of Mitf
expression via siRNA reduced growth factor susceptibility
by 60%, a characteristic of the invasive phenotype. We have
derived a model in which melanoma cells may switch
between proliferation and invasion to drive disease
progression. Here we interpret a clinical case (thick primary
and metastasis to the gall bladder) in the context of our
phenotype switching model. Both primary and metastatic
lesions show heterogeneity of staining for melanocytic
markers, an aspect explained by our model. However, we
also show evidence for microenvironment-dependent
behaviour in the metastasis which demonstrates that
programs reminiscent of healthy melanocytes may yet be
recalled by melanoma cells. Melanoma cells encountering
basal membrane structures in distal locations seek isolation
from their peers and re-express dendritic structures. These
are in vivo behaviours which are often reported to be lost
during progression.
185
CONCURRENT VERSUS SEQUENTIAL
CHEMORADIOTHERAPY IN LIMITED-DISEASE
SMALL-CELL LUNG CANCER:
A RETROSPECTIVE COMPARATIVE STUDY
3273
ANTICANCER RESEARCH 28: 3157-3556 (2008)
Sherif Y. El Sharouni1, Henk B. Kal1, Angeliqué Barten-Van
Rijbroek1, Henk Struikmans2, Jan J. Battermann1 and Franz
M.N.H. Schramel3
1Department
of Radiotherapy, University Medical Centre,
Utrecht, Utrecht;
2Department of Radiotherapy, Leiden University Medical
Centre, Leiden;
3Department of Pulmonary Diseases, St Antonius Hospital,
Nieuwegein, the Netherlands
Introduction: Patients with limited-disease (LD) small-cell
lung cancer (SCLC) received palliative treatment with
chemotherapy (CT) or chemotherapy combined with
radiotherapy. The treatment schemes with curative intention
were sequential and concurrent chemoradiotherapy, both
combined with prophylactic cranial irradiation (PCI). It is
unclear which scheme is superior: sequential or concurrent
chemoradiotherapy. Methods: Patient-, treatment- and
outcome-related items were retrospectively assessed. Up till
2001, LD-SCLC patients received 4-5 cycles of
cyclophosphamide, doxorubicin and etoposide. In cases of
no complete response, either radiotherapy was given in 13
fractions of 3 Gy (CT-RT group) or no RT (CT group).
After complete remission, radiotherapy was given in 16
fractions of 2.5 Gy, concurrently with PCI in 15 fractions
of 2 Gy (SCT-RT group). From 2001, patients received 4-5
cycles of cisplatin and etoposide concurrently with
radiotherapy in 25 fractions of 1.8 Gy. PCI was applied to
patients with complete remission (CCT-RT group). Primary
endpoints were median survival time (MST) and overall
survival (OS); secondary endpoints included causes of
death and frequency of metastases. Results: Median
survival times of CT, CT-RT, SCT-RT and CCT-RT schemes
were 8.1, 12.5, 14.0 and 21.8 months, and the 5-year OS
was 3.5, 4.8, 10.5 and 26.9%, respectively. The cause of
death of SCT-RT and CCT-RT patients was tumor related
in 76.3% and 89.3% of the patients, respectively. Brain
metastasis frequencies after PCI in SCT-RT and in CCT-RT
patients were 16.4% and 8.7%, respectively. Conclusion:
CCT-RT results in longer MST and higher OS than SCTRT, CT or CT-RT.
186
EFFECT OF NANO-FRUIT-CAFE ON THE
EXPRESSION OF ONCOGENES AND TUMOR
SUPPRESSOR GENES
László Szabó1, István Kiss2, Zsuzsanna Orsós2 and István
Ember2
1Crystal
Institute, Eger;
of Preventive Medicine, Faculty of Medicine, Pécs
University of Sciences, Pécs, Hungary
2Institute
3274
Fruit Café is a ground mixture of dried fruits and fruit seeds,
intended for use in regular coffe-maker, to produce a highflavonoid containing drink – a healthy alternative for coffee.
Our earlier animal experiments demonstrated the cancer
preventive effect of Fruit Café by using gene expressions as
early biomarkers, and also in experiments with transplanted
tumors.
The Fruit Café has been further developed by applying a
nano-grinding technology, in order to reach a smaller particle
size. This lead to an increased flavonoid content, and
preparation of the drink became easier.
In the present study we examined the effect of this new
Nano-Fruit-Café on the expression of oncogenes and tumor
suppressor genes, in order to make a first evaluation of its
possible cancer preventive characteristic.
Male CBA/Ca mice were intraperitoneally treated with
Nano-Fruit-Café, with the body weight equivalent of the
suggested human doses for everyday consumption. At different
time points (5, 10, 15, 30 minutes, 1, 3, 6, 12, 18 and 24
hours) after the ip. injection the animals were overnarcotized,
and RNA was isolated from their liver, spleen, kidneys, lung,
thymus, bone marrow and lymph nodes. The RNA was blotted
onto Hybond N+ membranes and hybridized with
chemiluminescently labeled probes for c-myc, p53, Ha-ras,
Ki-ras and Bcl-2 genes.
The expression pattern of the studied oncogenes and
suppressor genes indicated a potential cancer chemopreventive
effect for the new flavonoid containing drink. If these
anticarcinogenic characteristics will be confirmed by using
transplanted and chemically induced models, its widespread
production and consumption might contribute to the
chemopreventive strategies against cancer.
187
CAN WE INCREASE CD34+ STEM CELL NUMBERS
IN CIRCULATING PERIPHERAL BLOOD USING
NATURAL COMPOUNDS IN ANIMALS?
I. Ember1, L. Szabó2, I. Kiss1, T. Varjas1 and Z. Gyöngyi1
1University
of Pécs – Medical School, Institute of Public
Health Medicine. Szigeti str. 12. Pécs;
2Crystal Institute. Grónay str. 12. Eger, Hungary
Stem cells were isolated from embryonic umbilical cord and
various tissues (spleen, liver, lung, bone marrow, fat tissue) of
CBA/Ca inbred H-2k mice. Mice were treated with a mixture
of
natural
components
(Antrodia
camphorate,
Aphanizomenon, Fucoidan, Ganoderma lucidum, Zea mays,
Lycium, cartilage of shark, hempseed and chlorophyll) to test
its effect on stem cells. In every group, 6 male and female 46 week old mice were treated intraperitoneally with the
mixture. After 1, 2, 3, 6, 18 and 24 h, CD34+ cells in
peripheral blood were measured by flow cytometry and the
Abstracts of the 8th International Conference of Anticancer Research, 17-22 October 2008, Kos, Greece
expression of several marker genes was also determined (p53,
bcl-2, Ha- and K-ras, c-myc), in the various tissues. It was
observed that stem cells from fat tissue and possibly from
other sources may be activated.
188
P38 MAP KINASE AS A POSSIBLE BIOMARKER OF
EXPOSURE TO POLYCYCLIC AROMATIC
HYDROCARBONS
István Ember1, István Arany2, Edit Nádasi3, Tímea Varjas1
and Zoltán Gyöngyi1
1University of Pécs Medical School Department of Public
Health, Pécs, Hungary;
2Department of International Medicine Division of
Nephrology, University of Arkansas for Medical Sciences,
Markham Little Rock, AR, USA;
3Quintiles Magyarország, Budapest, Hungary
Health risk prediction and prevention of environmental
diseases are highlighted topics of modern age. MAP kinases
play a role in mitogenic and stress responses. In this manner,
they could be appropriate candidates as biomarkers in the field
of chemical carcinogenesis research. Polycyclic aromatic
hydrocarbons (PAHs) are potent and abundant environmental
carcinogens. Elevated expression of MAP (mitogen-activated
protein) kinases may indicate tumour initiation, but also
carcinogenic exposure. Some of them have also proven to be
mutagenic. DMBA (7,12-dimethylbenz(alpha)anthracene) and
1-NP (1-nitropyrene) are important members of PAHs with
carcinogenic potential. Since the family of MAP kinases play
a role in diverse cellular events as proliferation and apoptosis,
genes from that group could be candidates as biomarkers of
exposure to chemical carcinogenes.
In the family of MAP kinases we focused on the activity of
P38 protein. Rats, which are sensitive to chemical carcinogens,
were administered with DMBA and 1-NP and the activity of
P38 was detected in white blood cells by flow cytometry. Our
results do not preclude that the activity of P38 could be a
possible biomarker of exposure to chemical carcinogens, but
further research is needed for verifying this aspect.
189
THE CO-EXPRESSION OF JNK INTERACTING
PROTEIN JIP-1 AND INSULIN LIKE FACTOR II CAN
BE DISSOCIATED IN WILMS TUMOUR LINES BUT
NOT IN PRIMARY WILMS TUMOURS
Wilhelm Engström
Division of Pathology, Department of Biomedical Sciences
and Veterinary Public Health, Faculty of Veterinary
Medicine, Swedish University of Agricultural Sciences, PO
Box 7028, 75007 Uppsala, Sweden
JNK interacting Protein 1 (JIP-1) is an important scaffolding
protein in the JNK signalling pathway. It is also believed to
play a role in the mediation of mitogenic messages from the
plasma membrane to the cell interior. Previous studies suggest
that the JIP-gene is co-regulated with the insulin like growth
factor II (IGF II) gene, thereby contributing to the growth
stimulatory effects of this potent growth factor. The striking
co-expression of these two genes was found in murine fetuses
as well as in primary human embryonic tumours. When ten
primary Wilms Tumours were examined, the two genes
showed a high degree of co-variation in the sense that high
expression of IGF II was followed by high expression of JIP1 and vice versa. However when the human Wilms Tumour
cell line WCCS-1 was examined, a very modest intrinsic
expression of IGF II was accompanied by a high expression
of JIP-1. When exogenous IGF I was added, (which has
previously been shown to induce apoptosis in this cell line),
the JIP-expressiowas reduced to barely measureable levels.
This data suggests that JIP-1 has a more complex role in the
regulation of proliferation as well as programmed cell death.
190
QUANTITATIVE MEMBRANE PROTEOMICS
APPLYING NARROW RANGE PEPTIDE
ISOELECTRIC FOCUSING FOR STUDIES OF
SMALL CELL LUNG CANCER RESISTANCE
MECHANISMS
Hanna Eriksson1,2, Johan Lengqvist1,3, Joel Hedlund4,
Kristina Uhlén5, Lukas M Orre1,3, Bengt Bjellqvist5, Bengt
Persson4,6, Janne Lehtiö1,3 and Per-Johan Jakobsson1,2
1Karolinska
Biomics Center, Karolinska University Hospital,
S-171 76 Stockholm;
2Department of Medicine, Rheumatology unit, Karolinska
Institutet, S-171 76 Stockholm;
3Department of Oncology and Pathology, Karolinska
Institutet, S-171 76 Stockholm;
4IFM Bioinformatics, Linköping University, S-581 83
Linköping;
5GE Healthcare Bio-Sciences AB, S-751 84 Uppsala;
6Department of Cell and Molecular Biology, Karolinska
Institutet, S-171 77 Stockholm, Sweden
Drug resistance is often associated with up-regulation of
membrane-associated drug efflux systems, and thus global
membrane proteomics methods are valuable tools in the search
for novel components of drug resistance phenotypes. Herein
we have compared the microsomal proteome from the lung
cancer cell line H69 and its isogenic Doxorubicin-resistant
sub-cell line H69AR. The method used includes microsome
preparation, iTRAQ labeling followed by narrow range peptide
isoelectric focusing in an immobilized pH-gradient (IPG-IEF)
and LC-MS/MS analysis. We demonstrate that the microsomal
3275
ANTICANCER RESEARCH 28: 3157-3556 (2008)
preparation and iTRAQ labeling is reproducible regarding
protein content and composition. The rationale using narrow
range peptide IPG-IEF separation is demonstrated by its
ability to: i) lowering the complexity of the sample by 2/3
while keeping high proteome coverage (96%), ii) providing
high separation efficiency and iii) allowing for peptide
validation and possibly identifications of post transcriptional
modifications. After analyzing 1/5 of the IEF fractions
(effective pH range 4.0-4.5), a total of 3704 proteins were
identified, among which 527 were predicted to be membrane
proteins. One of the proteins found to be differentially
expressed was Serca 2, a calcium pump located in the ER
membrane that potentially could result in changes of apoptotic
response towards Doxorubicin.
191
CURRENT STATUS OF FECAL TUMOR M2
PYRUVATE KINASE IN COLORECTAL CANCER
SCREENING
N. Ewald1, C. Tonus2, K. Koss3, R.M. McLoughlin4 and P.D.
Hardt1
1Third
Medical Department, University Hospital of Giessen
and Marburg, Giessen;
2Herz-Jesu Hospital, Fulda, Germany,
3Gastroenterology Department, Macclesfield District General
Hospital, UK;
4Adelaide & Meath Hospital and Trinity College, Dublin,
Ireland
Introduction: Colorectal cancer is a disease with major impact
on public health and public health costs. Colonoscopy is
currently supposed to be the best screening tool for colorectal
cancer. However, the acceptance of this method is very poor,
although it has been included in screening programs in the
German health system since 2002. Thus, evaluation of
additional screening tools seems to be of great interest.
Recently, testing for fecal occult blood, genetic alterations or
alterations in tumor metabolism (e.g. Tumor M2-PK) is under
investigation. Tumor M2 Pyruvate Kinase: The use of M2-PK
measurement in the feces has been reported in several studies
to date. The data of these studies were analysed and critically
reviewed. All available studies demonstrated a good
performance of Tumor M2-PK in CRC screening, with an
overall sensitivity ranging from 68.8% to 91.0%, and an
overall specificity ranging from 71.9% to 100%. It might even
be of some use in detection of larger adenomas, yet its
sensitivity for adenomas is far lower (25.8-61.5%, depending
on size). It should not be used for CRC screening in patients
with inflammatory bowel disease since false-positive results
can be expected in up to 90% (due to proliferation of epithelial
cells and leucocytes in the inflammatory area). Since IBD
patients, however, are subject to endoscopic surveillance
3276
anyway, they are not part of the population to be included in
general CRC screening programs. Furthermore, a clear
correlation between Tumor M2-PK levels in the feces and the
stage of the tumor according to the Dukes’ classification was
demonstrated. Additionally it was noted that Tumor M2-PK
level reduction is associated with successful surgical
intervention. Other non-invasive screening tests: At the present
time, the fecal occult blood test is still most commonly used as
a non-invasive screening parameter for colorectal carcinoma.
Yet fecal occult blood testing seems to be inferior, with a
reported sensitivity of 40% for CRC and <20% for larger
adenomas. Despite the improvement of diagnostic
performance of FOBT obtained by immunological methods
(iFOBT), one major limitation remains the fact that many
carcinomas do not bleed at all or bleed only intermittently.
Another available non-invasive screening method for CRC is
testing for genetic alterations. Yet, the major shortcomings of
this screening tool are its high costs, time consuming and
tedious sample preparation, and the very limited handling and
shipping time of the feces. Conclusion: Concerning handling,
effectiveness and costs, fecal M2-PK therefore seems to be
good for large-scale screening of colorectal carcinoma and
should be recommended for inclusion in large-scale screening
programs.
192
THE RESPONSE OF THE CENTRAL NERVOUS
SYSTEM TO IONIZING RADIATION: A
CHALLENGE FOR RADIOBIOLOGY
A. Facoetti1,2, R. Nano2,3 and A. Ottolenghi1,2
1Department
of Nuclear and Theoretical Physics, University
of Pavia;
2INFN Pavia;
3Department of Animal Biology, University of Pavia, Italy
Ionizing radiation remains a major treatment modality for
primary and metastatic tumours of the central nervous system
(CNS) however the potential for injury to normal, non-targeted
critical CNS structures limits the dose used in radiotherapy.
Although the sequential histological changes associated with
radiation injury have been well characterized, the cellular and
biochemical processes responsible for the expression of
radiation-induced CNS injury remain poorly defined,
particularly at low doses. Much of the radiobiology efforts has
been focused on the radiation response of the vascular
endothelial cells and on cells of the oligodendrocyte lineage
which remain the major cell type candidate for radiation
induced demyelination and necrosis. However, not only the
vasculature and glial progenitors are irradiated but also
astrocytes, microglia, neurons and neural stem cells. Indeed
the CNS is comprised of a number of disparate phenotypes
networking to form a highly integrate system. Thus, the
Abstracts of the 8th International Conference of Anticancer Research, 17-22 October 2008, Kos, Greece
implication of this nature of the CNS and its reliance on cellcell interaction is that endocrine, paracrine, juxtacrine and
contact-mediated processes should play a key role in the
transmission of signals after irradiation and in the development
of late effects. The purpose of this talk is to critically
summarize the available information on the mechanisms
responsible for the development of radiation-induced CNS
injury and to suggest a framework for future research in this
field. In addition, some experimental results on cell
communication with normal and tumoural cells will be
presented.
This work was partially supported by the NOTE IP 036465
(FI6R), Euratom specific programme for research and training
on nuclear energy, 6th FP of the EC.
193
ROLE OF CHROMATIN STRUCTURE IN
TELOMERE MAINTENANCE
Zuzana Kunická1,2, Eva Polanská2, Martina Dvořáčková2,
Michal Štros2 and Jiří Fajkus1,2
1Department of Functional Genomics and Proteomics,
Institute of Experimental Biology, Faculty of Science,
Masaryk University. CZ-62500 Brno;
2Institute of Biophysics, Czech Academy of Sciences,
Královopolská 135, CZ-61265 Brno, Czech Republic
Nucleoprotein structures at chromosome ends, telomeres,
protect chromosomes from degradation and fusions, and
prevent natural chromosome ends from being recognized as
chromosome breaks by repair mechanisms. The protective
function of telomeres depends on maintenance of a certain
minimum length of their DNA composed of (TTAGGG)n
repeats (in vertebrates) and on telomere-associated proteins,
which together constitute protective (capping) structures on
telomeric DNA. Replicative shortening of telomeres or
dysfunction of associated proteins results in genome
instability.
In human cells, telomere maintenance is typically achieved
by telomerase, a nucleoprotein enzyme complex elongating
telomeres by reverse-transcription mechanism. In the absence
of telomerase, an alternative mechanism associated with
homologous recombination can be activated, which is called
ALT (alternative lengthening of telomeres).
Since the major part of the telomere is folded in
nucleosomes, forming a specific heterochromatin structure,
epigenetic mechanisms can be involved in maintenance of
telomere length homeostasis. Indeed, recent experimental
studies have shown telomere length changes induced by
changed levels of heterochromatin marks (including DNA
methylation, H3K9me3 and H4K20me3). Telomere function
is thus apparently tightly linked to chromatin architecture, and
analysis of the contribution of other factors involved in
chromatin dynamics is of special interest to current telomere
biology.
Many of the chromatin structural changes are mediated by
the large and diverse superfamily of HMG (high mobility
group) proteins, including the HMGB-type proteins. In our
study, we analyze the effect of a deficiency of HMGB1 protein
in mouse embryonic fibroblasts (MEFs) derived from normal
and HMGB1–/– knockout mice. We report a significantly lower
telomerase activity, changes in telomere lengths, and increased
occurrence of cytogenetic abnormalities in HMGB1–/– MEFs
relative to the parental cell lines. Analyses of molecular causes
of these effects identified HMGB1 as a telomerase-interacting
factor.
This research was supported by the Grant Agency of the
Czech Republic (project no. 204/08/1530), the Czech Ministry
of Education (MSM0021622415) and the Czech Academy of
Sciences (AV0Z50040507 and AV0Z50040702).
194
GASTRITIS OLGA STAGING AND GASTRIC
CANCER SECONDARY PREVENTION
Matteo Fassan1, Alberto Meggio2, Gianmaria Pennelli1,4,
Claudia Mescoli1, David Y. Graham3 and Massimo Rugge1,4
1Department of Medical Diagnostic Sciences and Special
Therapies (Pathology Section), University of Padova;
2Department of Gastroenterology, Rovereto Hospital, Italy;
3Digestive Disease Division, Veterans Affairs Medical Center
and Baylor College of Medicine, Houston, Texas, USA;
4IOV-IRCCS, Padova, Italy
Objectives: Atrophic gastritis (mainly resulting from longstanding Helicobacter pylori infection) is a major risk factor
for (intestinal-type) gastric cancer development. The
extent/topography of atrophic changes significantly correlate
with the degree of cancer risk. We previously proposed a new
system for reporting gastritis in terms of staging (the OLGA
staging system). Gastritis staging arranges the histological
phenotypes of gastritis along a scale of progressively
increasing gastric cancer risk, from the lowest (stage 0) to the
highest (stage IV). In this study, we first tested the OLGA
staging system in populations with different cancer risk.
Secondly, we validated the staging system in a prospective
cross-sectional study considering a large series of Italian
patients. Materials and Methods: Mapped gastric biopsies
were obtained from 755 dyspeptic adults, from 8 worldwide
geographic areas (484 Italian) with different gastric cancer
risk. Gastric atrophy was assessed according to internationally
validated criteria. Gastric stage was established according to
the OLGA staging system. Results were presented as stage
(including antral and corpus atrophy scores) and Helicobacter
pilory status. Results: The most prevalent gastritis stages were
0 to II. In populations at different cancer risk, the gastritis
3277
ANTICANCER RESEARCH 28: 3157-3556 (2008)
OLGA stage mirrored the gastric cancer incidence.
Helicobacter pilory infection was associated with a higher
gastritis stage incidence. In the Italian series, benign
conditions (including duodenal ulcers) consistently clustered
in stages 0-II, whereas all neoplastic (invasive and noninvasive) lesions clustered in stages III-IV. Conclusion: OLGA
gastritis staging, combined with Helicobacter pilory status,
provided clinically relevant information on the overall status
of the gastric mucosa with implications for prognosis, therapy
and management.
195
EVOLUTIONARY CONSERVATION OF
METALLOPANSTIMULIN-1 (S27E RIBOSOMAL
PROTEIN) SHOWS A KEY ROLE IN GROWTH
REGULATION IN ARCHEA AND CARCINOGENESIS
IN EUKARYOTIC CELLS
J. Alberto Fernandez-Pol
Metalloproteomics, Chesterfield, MO, USA
When the function of a protein serves a survival purpose,
evolutionary laws of nature, conserves such protein, in
phylogenetically
related
genus
and
species.
Metallopanstimulin-1(MPS-1; S27E) Ribosomal Protein (RP),
is involved in growth regulation, and carcinogenesis and
conserved through evolution. Berthon et al. (2008) have shown
in Archaea by genomic context analysis, a conserved cluster
of genes coding for proteins involved in translation and
ribosome biogenesis. These cluster of RP are S27E (MPS-1),
L44E, aIF-2 alpha and Nop10, and are systematically
contiguous to the group of genes coding for PCNA, PriS, and
Gins15, which are involved in DNA replication. The two
distinct sets of genes are involved in translation and ribosome
biogenesis (Ribosomal cluster) and DNA replication
(Replication cluster). Fernandez-Pol et al. (J Biol Chem &
Mol Biol, 1993) was first to describe the gene encoding MPS1 (S27E) and subsequently have shown that MPS-1 is
overexpressed in many human cancer tissues. MPS-1 is being
used as a target for some novel cancer therapies; aim to eject
the zinc from the zinc finger motif of the MPS-1 protein, thus
yielding it inactive. These and other therapies have shown
promise for the treatment of cancer in humans, for example
gastric cancer (Wang et al. 2006) and in lymphomas
(Fernandez-Pol, 2001). Revenkova et al. (1999) found
unexpected functions of MPS-1 RP in genotoxic stress
responses in plants. These results indicate that an isoform of
RP S27E (mutant MPS-1/ARS27E) is dispensable for the
function of ribosomes, but is required for the elimination of
damaged mRNA transcripts after exposure to chemical
carcinogens or UV irradiation. MPS-1 is a RP with extraribosomal functions such as DNA repair and transcription. The
results obtained with archaea (Berthon et al., 2008) and the
3278
functions of MPS-1 and other RP proteins studied in this
laboratory indicate a previously unrecognized regulatory
network coupling DNA replication, DNA repair, DNA
transcription, translation and biogenesis of ribosomes that exist
in both Archaea and Eukarya. Overexpression of RP genes
observed in cancer is the result of increased translation of
individual mRNAs rather than in up-regulation of global
protein synthesis. We show that in association with increases
in MPS-1 after growth factor stimulation, there is an increase
of numerous ribosomal proteins as well as initiation factors
(IF). Elimination of MPS-1 in cancer cells in eukaryotic
animal and plant cells by novel and specific therapies may
result in the cure or control of most cancers in animals,
humans and plants.
196
CHEMOSENSITIZING EFFECT OF
NORDIHYDROGUAIARETIC ACID (NDGA) AND ITS
TETRA ACETYLATED DERIVATIVE (NDGATA) ON
PARENTAL AND MULTIRESISTANT TA3 MOUSE
MAMMARY ADENOCARCINOMA CELL LINES
Jorge Ferreira1, Mario Pavani1, Fabián Jaña1, Paula Burgos1,
Antonio Morello1, Juan Diego Maya1, Mario Faúndez1,
Américo López1, Alfredo De Ioannes2 and María Inés
Becker2
1Programa de Farmacología Molecular y Clínica, ICBM,
Facultad de Medicina, Universidad de Chile, Independencia
1027 Casilla 70086, Santiago 7;
2Departamento de Investigación y Desarrollo, Biosonda S.A.,
Eduardo Castillo Velasco 2902, Ñuñoa-Santiago, Chile
The clinical utility of several chemotherapeutic agents often
limited by development of drug resistance, which is found in
the multidrug-resistance (MDR) phenotype. It is frequently
associated with overexpression of various ATP-binding
cassette transporters which operate as drug-efflux pumps in
MDR cells. The identification of agents able to synergistically
modulate antineoplastic activity may be useful in overcoming
resistance at non-toxic doses, especially those capable of
circumventing cross-resistance to a large number of unrelated
antineoplastic agents. Among these chemosensitizers, NDGA
and its derivatives may be a class of great interest. Both
NDGA and NDGATA can modulate the MDR phenotype,
provoking selective induction of mitochondrial dysfunctions.
Although both NDGA and NDGATA inhibited tumour growth
of TA3 and TA3-MTX-R cell lines, they also strongly
enhanced the toxicity of doxorubicin, cisplatin and
methotrexate in a dose-dependent manner, with a more evident
effect in the TA3-MTX-R cells than in the parental cells.
NDGATA was more effective than NDGA. Analysis of the
data by the isobole method showed that the combination of a
chemotherapeutic agent with either NDGA or NDGATA
Abstracts of the 8th International Conference of Anticancer Research, 17-22 October 2008, Kos, Greece
produced synergistic antiproliferative activities in both cell
lines. The combination of NDGATA and DOX strongly
reduced the tumor growth rate in mice and was the best
treatment against the sensitive TA3 cell line and the resistant
variant TA3-MTX-R. The inhibitory activity of this
combination on the rates of solid tumor growth appeared to be
synergistic. The combination of NDGATA and DOX did not
prolong median survival time of mice with TA3 or TA3-MTXR cells, but it rendered 30% of the mice with TA3 or TA3MTX-R cells tumor free. On the other hand, NDGA and
NDGATA inhibited primarily mitochondrial electron flow;
therefore, transmembrane potential decreased and
mitochondrial ATP synthesis was interrupted. They also
increased the accumulation of doxorubicin and inhibited the
efflux of rhodamine 123 from both the parental TA3 cell line,
and from the resistant, TA3-MTX-R cell line. In addition,
mitochondrial permeability transition pore was opened,
cytochrome c was released and an increase of caspase 3
activity was detected. Consequently, cell viability and growth
rate also decreased. In conclusion, NDGA and NDGATA are
selective cytotoxic compounds to tumour cells. They inhibited
the production of energy necessary for ATP-dependent
transporter function, representing a new class of compounds
that could be exploited for use in malignancies that display the
phenomenon of MDR.
This work was supported by Grants N˚ 1061086 from
FONDECYT and ACT 29 Anillo Bicentenario.
197
MACROCYCLIC DITERPENES AS LEAD
COMPOUNDS FOR THE DEVELOPMENT OF PGLYCOPROTEIN MODULATORS IN MULTIDRUGRESISTANT CANCER CELLS
Maria-José U. Ferreira1, Noélia Duarte1, Anett Járdánházy2,
Ana-Margarida Madureira1, Cátia Ramalhete1, Imre
Ocsovszki3 and Joseph Molnar2
1Institute
for Medicines and Pharmaceutical Sciences
(iMed.UL), Faculty of Pharmacy, University of Lisbon,
Lisbon, Portugal;
2Department of Medical Microbiology, Faculty of Medicine,
University of Szeged, Szeged;
3Institute of Biochemistry, University of Szeged, Szeged,
Hungary
Chemotherapy remains the treatment of choice in many
malignant diseases. However, the emergence of resistance to
anticancer drugs (MDR) has made many of the available
anticancer drugs ineffective. The most significant mechanism
of MDR is that resulting from the overexpression of Pglycoprotein (Pgp), a member of ABC transporters that
decreases the intracellular concentration of chemotherapeutics.
Therefore, when used in combination, MDR modulators or
inhibitors may restore the cytotoxicity of the anticancer drugs
against MDR tumour cells.
In our search for anticancer agents from Euphorbia species,
traditionally used to treat cancer, we have isolated and
characterized, by spectroscopic methods, several macrocyclic
lathyrane and jatrophane diterpenes, which were evaluated as
Pgp modulators.
The ability of compounds to reduce the transport activity of
Pgp on the L5178 mouse lymphoma cell line containing the
human MDR1 gene was studied by flow-cytometry. The
reversal of MDR was investigated by measuring the
rhodamine-123 accumulation, a fluorescent substrate analogue
of doxorubicin, in cancer cells. Verapamil was applied as a
positive control.
In order to obtain evidence for synergistic interactions, the
in vitro antiproliferative effects of some resistance modifiers
were studied in combination with doxorubicine/epirubicine,
on human MDR1 gene-transfected mouse lymphoma cells,
using the checkerboard microplate method.
The majority of the macrocyclic diterpenes tested showed
to be very strong modulators of Pgp. The results obtained
highlighted the importance of the involvement of ring A of
lathyranes and jatrophanes in the modulation of Pgp. The
importance of general requirements, such as lipophilicity and
the potential ability to form H-bonds, was also corroborated
by these results. All the diterpenes assayed for their
antiproliferative
effects
in
combination
with
doxorubicine/epirubicine, have shown synergistic interaction
with the antitumour drug.
According to these results, macrocyclic diterpenes may be
valuable as lead compounds for the development of Pgp
inhibitors in different multidrug-resistant cancer cells.
198
ANTINEOPLASIC ACTIVITY OF PHENOLIC
COMPOUNDS AGAINST SENSITIVE AND
RESISTANT HUMAN CANCER CELLS
Noélia Duarte1, Hermann Lage2 and Maria-José U. Ferreira1
1Institute
for Medicines and Pharmaceutical Sciences
(iMed.UL), Faculty of Pharmacy, University of Lisbon,
Lisbon, Portugal;
2Charité Campus Mitte, Institute of Pathology, Berlin,
Germany
Multidrug resistance (MDR) is one of the major problems
in clinical oncology. This phenomenon is due to various
biochemical mechanisms including overexpression of the
well-known ABC transporter MDR1/P-gp. One possible
approach to overcome MDR is to find out new anticancer
drugs without cross resistance in cancer cells exhibiting a
multidrug-resistant phenotype. The aim of this work was to
analyze the antineoplasic activity of several phenolic
3279
ANTICANCER RESEARCH 28: 3157-3556 (2008)
compounds isolated from Euphorbia species. The tested
compounds, including stilbenes, flavanoids and coumarins,
were investigated for their potential antiproliferative activity
in several human cancer cell lines derived from three
different tumour entities: gastric (EPG85-257), pancreatic
(EPP85-181) and colon (HT-29) cancer cells. Furthermore,
in each case, two different multidrug-resistant variants of
these cells were also investigated: cell lines with a classical
MDR phenotype (associated with the overexpression of
MDR1/P-gp) and cell lines with an atypical MDR
phenotype (no enhanced expression of MDR1/P-gp). For
assessment of cytotoxicity of the tested compounds, the IC50
values of each agent were determined by proliferation
assays in each of the different cell variants. The etoposidespecific IC50 values were measured as positive control for
maintenance of the drug-resistant phenotype. Relative
resistance (RR) values were also determined as the relation
between the IC50 of the resistant cell line and the IC50 of the
parental drug-sensitive cell line. In parental drug sensitive
cell lines, all the tested compounds showed a weak
antiproliferative effect. However, most of the multidrugresistant cancer sublines showed increased sensitivities to
the studied compounds when compared to the parental
sublines. One flavanoid was found to be highly effective
against the atypical MDR subline of gastric carcinoma, in
which the flavanoid was 15-fold more effective than in
parental “drug-sensitive” cells. The results obtained indicate
that some of the phenolic compounds tested may be
interesting for the development of new drugs against
resistant human cancer cells.
aimed to use FISH technology to identify the genomic status
in chagasic megaesophagus of genes showing recurrent
imbalances in ESCC. This study cohort included 40 patients
with diagnosis of chagasic megaesophagus. FISH probes
were developed for the genes FGFR1, PIK3CA, TP63, YES1
and NCOA3. Commercial probes were used for EGFR/CEP7,
and c-MYC. Dual-color FISH assays were performed in
formalin-fixed, paraffin-embedded tissue sectioned at 4 um.
The analyses were carried out using single and dual band
pass interference filters. For each specimen, signals were
scored in 100 epithelial nuclei (50 in superficial layer – S,
and 50 in basal layer – B). Descriptive statistics were
calculated and the range of the mean copy number per cell
was 1.58-1.94 (S) and 1.60-2.22 (B) for FGFR1, 1.56-1.96
(S) and 1.60-1.90 (B) for PIK3CA, 1.58-1.92 (S) and 1.601.90 (B) for TP63, 1.40-1.84 (S) and 1.28-1.80 (B) for YES1,
1.44-1.84 (S) and 1.44-1.76 (B) for NCOA3, 1.28-1.80 (S)
and 1.18-1.80 (B) for EGFR, 1.22-1.74 (S) and 1.30-1.64 (B)
for CEP7, 1.56-1.94 (S) and 1.60-1.84 (B) for MYC. The
scoring was performed in both histological layers to check
for differences between proliferative activity, since the basal
cells have higher level of proliferative activity; however no
difference was observed. Despite the involvement of
genomic imbalances in esophageal carcinogenesis, none of
the above genes were found unbalanced in chagasic
megaesophagus.
199
INVESTIGATION OF CHROMOSOMAL GAINS AND
LOSSES IN CHAGASIC MEGAESOPHAGUS BY
FLUORESCENCE IN SITU HYBRIDIZATION
Marilanda Ferreira Bellini1,2, Fernanda da Silva ManoelCaetano1, Patrícia Maluf Cury3, Henrique de Olveira3,
Kenji Miyazaki3, Marileila Varella Garcia2
and Ana Elizabete Silva1
Marilanda Ferreira Bellini1,2, Patrícia Maluf Cury3,
Marileila Varella Garcia2 and Ana Elizabete Silva1
1Department
of Biology, UNESP, São Paulo State University,
Campus São José do Rio Preto, SP, Brazil;
2Medicine/Medical Oncology, University of Colorado,
Aurora, Colorado, USA;
3Hospital de Base/FAMERP – Medicine School, São José do
Rio Preto, SP, Brazil
Chagasic megaesophagus is a dilation of the esophagus
caused by the impact of the protozoa Trypanosoma cruzi in
the mioenteric plexus. One of the most serious complications
of megaesophagus is the increased risk (3%-8%) to develop
esophageal squamous cell carcinoma, ESCC. While
numerous genetic alterations have been reported in the initial
and advanced steps of esophageal carcinogenesis, studies in
chagasic megaesophagus are scarce, and this investigation
3280
200
MOLECULAR CYTOGENETICS, MUTATIONS AND
IMMUNOHISTOCHEMICAL STUDIES OF P16 AND
FHIT IN CHAGASIC MEGAESOPHAGUS
1Department
of Biology, UNESP, São Paulo State University,
Campus São José do Rio Preto, SP, Brazil;
2Medicine/Medical Oncology, University of Colorado,
Aurora, Colorado, USA;
3Hospital de Base/FAMERP – Medicine School, São José do
Rio Preto, SP, Brazil
Chagasic megaesophagus is a dilation of the esophagus caused
by the impact of the protozoa Trypanosoma cruzi, etiological
agent of Chagas disease. One of the most serious
complications of megaesophagus is the increased risk (3%8%) to develop esophageal squamous cell carcinoma, ESCC.
While numerous genetic alterations have been reported in the
initial and advanced steps of esophageal carcinogenesis,
studies in chagasic megaesophagus are scarce. So, this
investigation aimed to use FISH, PCR-SSCP/sequencing of
DNA and immunohistochemistry technologies to identify the
Abstracts of the 8th International Conference of Anticancer Research, 17-22 October 2008, Kos, Greece
genomic and protein status of P16 and FHIT in chagasic
megaesophagus. This study cohort included 20 esophageal
biopsies of patients with diagnosis of chagasic megaesophagus
and 10 normal esophageal mucosa biopsies. For FISH, signals
were scored in 100 epithelial nuclei (50 in superficial layer –
S, and 50 in basal layer – B). Descriptive statistics were
calculated and the range of the mean copy number per cell
was 1.28-1.74 (S) and 1.30-1.82 (B) for P16 and 1.58-1.92 (S)
and 1.60-1.92 (B) for FHIT. The analysis of mutation in the
exons 1 and 2 of P16 and 5 and 7 of FHIT shown a silent
mutation (polymorphism) at codon 88 (exon 7) in the FHIT
gene in a sample of megaesophagus. Immunostaining for p16
(brown nuclear and cytoplasmic staining) and Fhit (brown
cytoplasmic staining) proteins was graded by intensity of
staining as negative i.e. (–) absence brown staining, or (+)
weakly stained; or as positive i.e. (++) moderately stained and
(+++) strongly stained. Positive scores (++/+++) correspond
to normal protein expression, while negative immunostaining
(–/+) is associated with loss of protein expression. Descriptive
statistics, Kruskall-Wallis test with Dunn post-test was used to
determined statistical significance. Despite the progressive loss
of expression of p16 protein, none statistical difference was
observed. The absence of stain was not observed for Fhit
protein: the immunostaining was diffuse, ranging from weak
to strongly stained. However, statistical significance was not
found for Fhit expression. We can concluded the three
techniques showed similar results, indicating that genetic
alterations in P16 and FHIT are not common events in
chagasic megaesophagus, although they are related to ESCC
development.
201
DETERMINANTS OF HOMOCYSTEINE LEVELS IN
COLORECTAL AND BREAST CANCER PATIENTS
P. Ferroni1, R. Palmirotta1, F. Martini1, F. Ciatti1,
S. Riondino1, A. Magnapera1, V. Sini2, S. Mariotti2,
G. Del Monte2, M. Roselli2 and F. Guadagni1
suggesting a role for this cytokine in Hcy metabolism.
Therefore, we analyzed the possible associations between
tHcy levels and MTHFR polymorphisms or inflammatory
markers in patients with breast or colorectal cancer.
Methods: Forty-seven patients (15 males, mean age 59±14
years) with primary (n=35) or relapsing (n=12) breast (n=18)
or colorectal cancer (n=29), treated at the Medical Oncology
of “Tor Vergata” Clinical Center, were enrolled into the
study. All patients were followed up for a median period of
14 months. Informed consent was obtained from all patients.
MTHFR 677C¡T and 1298A¡C substitutions were
analyzed by RT-PCR (Roche). Serum tHcy, high sensitive Creactive protein (hsCRP), IL-6, TNF-alpha, fibrinogen and
D-dimer levels were also analyzed. Results: MTHFR
genotypes distribution was similar in patients compared to
controls. Plasma tHcy (p<0.05), IL-6 (p<0.05), TNF-alpha
(p<0.05) and D-dimer (p<0.05) levels were all significantly
higher in patients compared to healthy controls. No
differences were observed between breast and colorectal
cancer patients for all laboratory variables. THcy levels
significantly correlated with both IL-6 and TNF-alpha
(Figure). Analysis of variance by Anova test showed that
serum tHcy levels were not associated to either MTHFR
677C¡T or 1298A¡C. Multiple regression analysis
including tHcy as the dependent variable and sex, age,
diagnosis, metastasis, fibrinogen, D-dimer, hsCRP, IL-6,
TNF and MTHFR polymorphisms as the predictor variables
showed that metastatic disease (beta=0.50, p<0.01) and TNF
(beta=0.34, p<0.05) were the only independent predictors of
elevated tHcy levels. TNF, in turn, was significantly
associated to the presence of lymph node involvement
(beta=0.54, p<0.005). Conclusion: Our data indicate that the
MTHFR polymorphisms do not significantly contribute to
tHcy levels in breast and colorectal cancer, while we show
some evidence that cancer-related inflammation may be
associated with elevated tHcy levels, possibly involving a
TNF-alpha mediated pathway.
1Department
of Laboratory Medicine and Advanced
Biotechnologies, IRCCS San Raffaele, Rome;
2Medical Oncology, Department of Internal Medicine,
University of Rome “Tor Vergata”, Rome, Italy
Background: Methylation abnormalities appear to be
important for the pathogenesis of many cancer types.
Methylenetetrahydrofolate reductase (MTHFR) is a key
enzyme in the homocysteine (Hcy) metabolism pathway and
regulates the intracellular folate pool for synthesis and
methylation of DNA. Accordingly, MTHFR 677TT variant
increases Hcy concentration and reduces DNA methylation
in cancer patients. However, Hcy metabolism is dependent
not only on genetic, but also on acquired factors. Targeting
TNF pathway can significantly decrease total Hcy (tHcy),
Partially supported by Grant RFPS-2006-7-342220 by the
Italian Ministry of Health.
3281
ANTICANCER RESEARCH 28: 3157-3556 (2008)
202
MILLIMETER WAVES EXPOSURE SET-UP FOR
REAL-TIME MONITORING OF BIOLOGICAL
PROCESSES AT A MOLECULAR LEVEL BY
NUCLEAR MAGNETIC RESONANCE
SPECTROSCOPY
L. Filippelli1, A. Beneduci1, K. Cosentino1,
P.W. Westerman2 and Giuseppe Chidichimo1
1Department
of Chemistry, University of Calabria, Via P.
Bucci, Cubo 17/D, Arcavacata di Rende (CS), Italy;
2Department of Biochemistry and Molecular pathology,
NEOUCOM, Rootstown, Ohio, USA
Millimetre wave therapy (30-80 GHz) has been reported to
significantly reduce in vitro cell proliferation of MCF-7 breast
cancer cells as well as RPMI 7932 human melanoma cell line
(1-3). Many experiments suggested that cell membranes might
be one of the relevant targets of the radiation and studies on
models showed that the water balance around the membrane is
altered by exposing samples to low power millimetre waves
(4). When we deal with the study of the interaction between
millimeter wave and biological systems, one of the main
challenges is to monitor relevant biological processes that
characterize a system during its exposure to the above
electromagnetic radiation. This condition should allow one to
observe, in real-time, any significant variation of those
properties and then to evaluate the biological effects induced
by the radiation and its dependence on various exposure
parameters such as frequency, power density and irradiation
time, that might affect the response of the system. Nuclear
magnetic resonance spectroscopy (NMR) is a very versatile
technique for investigating, at a molecular level, several
functional properties of various biological systems. Here we
describe the experimental set-up used for the exposure of
various biosystems to millimeter waves contextually to the
acquisition of NMR spectra. The enormous potentiality of our
method is underlined by showing some noticeable examples
of its application, such as in the study of the metabolism of
perfused living cells, or for the characterization of the
structural and kinetic properties of bilayer membrane models.
A brief discussion on millimeter wave-induced effects
observed is also presented.
Regione Calabria, POR CALABRIA 2000/2006MISURA 3.7
“FORMAZIONE SUPERIORE E UNIVERSITARIA” Azione
3.7.b - POR FSE CALABRIA 2007/2013 ASSE IV
CAPITALE UMANO Obiettivo Operativo M.2.
1 Beneduci A, Chidichimo G, De Rose R, Filippelli L,
Straface SV and Venuta S: Anticancer Res 25: 1023-1028,
2005.
2 Chidichimo G, Beneduci A, Nicoletta M, Critelli M, De
Rose R, Tkatchenko Y, Abonante S, Tripepi S and Perrotta
E: Anticancer Res 22: 1681-1688, 2002.
3282
3 Beneduci A, Chidichimo G, Tripepi S and Perrotta E:
Anticancer Res 25: 1009-1014, 2005.
4 Filippelli L, Beneduci A and Chidichimo G: Proceedings of
the 4th International Workshop on Biological Effects of
EMFs, 2006, Vol. I, pag. 574-581 Crete, Greece, 16-20
October.
203
NEW RESULTS ON BISPHOSPHONATES RELATED
OSTEONECROSIS OF THE JAWS: TREATMENT
COMPARISON AND EPIDEMIOLOGY
Olivier Filleul and Sven Saussez
Laboratory of anatomy, University of Mons-Hainaut,
Pentagone 1B – Avenue du Champ de Mars, 6, B-7000
Mons, Belgium
Introduction: Bisphosphonate-related osteonecrosis of the jaws
(BROJ) is a severe complication of bisphosphonate treatment.
At this time, the best therapy as well as the epidemiology of
this pathology are still unclear. Methods: A retrospective study
of all cases of BROJ treated in four Belgian institutions was
performed, aimed to compare medical to surgical treatment
and find pronostic factors. Results: 34 cases were retrieved, of
whom 88.5% were treated for disseminated cancers and 11.5%
for osteoporosis. In our study, the most frequently used
bisphosphonate was zoledronic acid (83%), either alone or in
combination with pamidronate or ibandronate. 57% of patients
were cured with only medical treatment, which was
significantly different from the 20% obtained with surgical
management (p=0.02). This study also revealed that lesions
smaller than 1 cm had a better prognosis (p=0.0009).
Discussion: Although limited and retrospective, this study
indicates that current surgical procedures are not beneficial in
management of BROJ. Further studies, especially prospective,
will have to be conducted to propose better approaches. In our
search for epidemiological and clinical data on this disease,
we are conducting an exhaustive review of all described cases
of BROJ, hoping this will lead to new enlightments on the
pathophysiology and treatment of this condition. This study
has already reached nearly 2000 cases.
204
TAp63 IS A KEY REGULATOR OF DNA DAMAGE,
GENOMIC STABILITY AND STEM CELL
MAINTENANCE STEM CELL MAINTENANCE
Xiaohua Su1, Min Soon Cho1,2, Young Jin Gi1, Yu-Li Lin1,
Wei X. Zhang1 and Elsa R. Flores1,2
1The
University of Texas M.D. Anderson Cancer Center,
Department of Molecular and Cellular Oncology and 2The
University of Texas Graduate School of Biomedical
Sciences, Houston, 77030, TX, USA
Abstracts of the 8th International Conference of Anticancer Research, 17-22 October 2008, Kos, Greece
p63 is critical for the maintenance of epidermal stem cell
proliferation, differentiation, and also plays a role in the
suppression of tumorigenesis and metastasis. The existence of
multiple isoforms (TA and ΔN) of p63 with apparently
opposing functions has complicated the study of p63. To begin
to decipher the roles of these isoforms in vivo, we have
generated TAp63 conditional knockout mice (TAp63fl/fl) using
the cre-loxP system and intercrossed them with zp3-cre
transgenic mice to generate TAp63–/– mice. Interestingly, some
of the TAp63–/– mice have an early embryonic lethal
phenotype at E6.5. The mice that survive to birth develop
severe ulcerated wounds by the age of 1 to 3 months. These
mice also exhibit signs of premature aging, increased DNA
damage, and genomic instability in dermal and epidermal
cells. These defects result from a hyperproliferation and
subsequent premature depletion of stem cells involved in
wound healing. We also found that levels of TAp63 are
induced in the wound healing process. In addition to the
striking role that TAp63 plays in epidermal repair, we have
found that mice deficient for this isoform are tumor prone.
TAp63 deletion in combination with p53 results in a highly
metastatic tumor phenotype. These studies have unveiled
previously unrecognized roles for TAp63 in DNA damage,
epithelial wound repair, and in cancer.
205
ASSOCIATION OF PROSTATE-SPECIFIC ANTIGEN
AND PROINFLAMMATORY CYTOKINES IN
PATHOLOGICAL HUMAN PROSTATE (BENIGN
HYPERPLASIA AND CARCINOMA): A STUDY OF
TUNISSIAN PATIENTS
B. Fraile1, Y. Bouraoui1,2, Gonzalo Rodríguez-Berruguete1,
R. Oueslati2, R. Paniagua1 and M. Royuela1
1Department
of Cell Biology and Genetics. University of
Alcalá, E-28871. Alcalá de Henares, Madrid, Spain;
2Unit of Immunology and Microbiology Environnemental
and Carcinogenesis IMEC, Faculty of Sciences of Bizerte
7021 Zarzouna, Tunisia
Aim: Serum prostate-specific antigen (PSA) level is more
reflective of the presence of benign prostatic hyperplasia
(BPH) than of the extent of cancer and, therefore, does not
provide additional information. At present, several research
groups are focusing on the search for new biochemical
markers capable of predicting prostate cancer and prognosis.
In addition, pro-inflammatory cytokines are related to the
production of PSA and progression of prostate cancer The aim
of this study was to relate the serum PSA levels with the
expression of several pro-inflammatory cytokines (IL-1, IL-6
and TNF-α) and their receptors in normal and pathological
(hyperplasia and cancer) prostatic tissue to elucidate their
possible role in tumor progression. We also discuss the
possible use of these cytokines as potential therapeutics.
Methods: The study was carried out in 5 normal, 25 benign
prostatic hyperplastic (BPH) and 18 carcinomatous (PC)
human prostates. Immunohistochemical and Western blot
analysis were performed. Serum levels of PSA were assayed
by IMMULITE autoanalyser. Results: The results most
relevant showed that in BPH, IL-1α, IL-6 and TNF were only
expressed in the patients included in the groups with PSA
serum levels of 0-4 ng/ml PSA or 4-20 ng/ml PSA, but not in
the group with PSA >20 ngml. In PC, these cytoines were
only expressed in the patients included in the groups with PSA
serum levels >4 ng/ml, increasing the expression when these
patients were included in the group with most elevated PSA
level (>20 ng/ml). Conclusion: In PC there was an association
between the high expression of TNFα, IL-6, IL-1, elevated
PSA serum levels and tumor progression. A better
understanding of the biological mechanism and role played by
the elevation of circulating PSA related with the tissue
expression of these cytokines may possibly improve clinical
management and provide new targets for therapy in these
patients.
Supported by grants from the “Ministerio de Educación y
Ciencia” (SAF2007-61928) and the “Agencia Española de
Cooperación Internacional para el Desarrollo (PCIMediterráneo) 2007 (A/011430/07)” (Spain).
206
CANCER PROGRESSION:
IMMUNOHISTOCHEMICAL STUDY OF SURVIVIN
AND XIAP IN NORMAL AND PATHOLOGICAL
(BENIGN HYPERPLASTIC AND CANCER) HUMAN
PROSTATE
B. Fraile1, C. Chaves1, Gonzalo Rodríguez-Berruguete1,
C. Nuñez1, P. Martínez-Onsurbe2, G. Olmedilla2,
F. Bethecourt3, R. Cansino3, R. Paniagua3 and M. Royuela1
1Department
of Cell Biology and Genetics, University of
Alcalá;
2Department of Pathology, Príncipe de Asturias Hospital.
Alcalá de Henares;
3Department of Urología del Hospital La Paz. Madrid, Spain
Aim: Inhibitor of apoptosis proteins (IAPs) is a gene family
that plays an essential role in the negative regulation of
apoptosis. The IAP family comprises eight proteins: survivin,
XIAP (ILP-1), cIAP1, cIAP2, NAIP, ILP-2, apollon (BRUCE)
and ML-IAP (LIVIN). The IAPs are potent inhibitors of
caspases and inhibit apoptosis by a variety of stimuli
(Deveraux, 1999). XIAP and survivin have been identified as
the most potent inhibitors of caspases and apoptosis. The aim
of this study was to elucidate the possible involvement of these
IAPs in prostate cancer development and their role in the
breakdown of the apoptosis-proliferation equilibrium.
3283
ANTICANCER RESEARCH 28: 3157-3556 (2008)
Methods: Immunohistochemical and Western blot analyses
were performed in 20 samples of normal prostate (NP), 35
samples of benign hyperplasia (BPH), and 93 samples of
prostate cancer (PC) diagnosed with low (grades 1 to 6, 21
men), medium (grades 7-8, 51 men) and high (grades >8, 21
men) Gleason grades. Results: Immunoreaction to survivin
was absent in normal prostates. Cytoplasmic immunoreaction
to survivin in epithelial cells was observed in 9.1% of BPH
patients and 19.35% of PC patients (optic density was
increased with Gleason grade). Immunoreaction to XIAP was
observed in the cytoplasm of epithelial cells in 20% of normal
prostates, 27.27% of BPH patients and 32% of PC patients.
Optical density was higher in BPH than in normal prostates,
and even higher in PC, but no differences between Gleason
groups were found. Conclusion: Survivin in several
malignances has been associated with higher tumor grade,
advanced disease stage, and as an unfavourable marker of
disease progression. XIAP overexpression in tumor cells has
been shown to cause an inhibitory effect on cell death. In this
way, inhibition of these IAPs might be a possible target for PC
treatment.
Supported by grants from the “Ministerio de Educación y
Ciencia”, Spain (SAF2007-61928) and the “Agencia Española
de Cooperación Internacional para el Desarrollo (PCIMediterráneo) 2007 (A/011430/07)” (Spain).
207
INHIBITION OF HIF-2α PREVENTS
TUMORIGENESIS
Aleksandra Franovic and Stephen Lee
Department of Cellular and Molecular Medicine, Faculty of
Medicine, University of Ottawa, Ottawa, Ontario, Canada,
K1H 8M5
The ability of cancer cells to proliferate autonomously is
perhaps the most critical hallmark of malignancies. An
example of how a genetic mutation can confer this oncogenic
trait is the stabilization of hypoxia-inducible factor-2 alpha
(HIF-2α) and its activation of the TGFα/EGFR growth circuit
that drives VHL-loss clear cell renal carcinoma (VHL–/– RCC)
tumor formation. HIF-2α is similarly expressed in the core of
most solid tumors as a consequence of microenvironmental
stressors such as hypoxia. This raises the possibility that the
tumor microenvironment can promote the persistent
proliferation of tumor cells under otherwise non-permissive
conditions by stabilizing HIF-2α in a manner analogous to
VHL-loss. Here, we show that silencing HIF-2α, but not the
predominantly pro-angiogenic HIF-1α isoform, prevents in
vivo proliferation and tumorigenesis of a panel of genetically
diverse human cancers. Furthermore, treatment of xenograft
tumors by intratumoral injection of siRNA against HIF-2α
results in their regression, highlighting its importance in tumor
3284
maintenance. These results suggest that HIF-2α activation, as
a result of genetic alterations or physiological stimuli,
represents a common oncogenic event that is required for the
establishment of an overt carcinoma. As such, we propose that
targeting HIF-2α may be of broad clinical interest in the
treatment of human cancer.
208
ALLEVIATION OF SIDE-EFFECTS OF
ANTICANCER THERAPEUTICS BY HMG-COA
REDUCTASE INHIBITORS (STATINS)
Julia Damrot, Christian Ostrau, Johannes Hülsenbeck,
Melanie Herzog, Tobias Nübel, Bernd Kaina
and Gerhard Fritz
Institute of Toxicology, Johannes Gutenberg University of
Mainz, Obere Zahlbacher Straße 67, D-55131 Mainz,
Germany
Apart from their lipid-lowering activity, HMG-CoA reductase
inhibitors (statins) also impact various genotoxic stressinduced signaling mechanims by inhibiting the function of
regulatory proteins, in particular Ras and Rho GTPases. By
this means, statins sensitize tumor cells to killing by anticancer
drugs. Here we address the question whether statins are
beneficial in anticancer therapy by alleviating side-effects of
radiotherapy and the anticancer drug doxorubicin on normal
tissue. To this end, we investigated the effect of lovastatin on
ionizing radiation (IR)- and doxorubicin-induced signaling and
apoptosis in primary human endothelial cells (HUVECs) in
vitro. Moreover, initial in vivo studies were performed.
Low-dose pre-treatment with lovastatin protected
HUVECs from IR- and doxorubicin-induced cytotoxicity, as
measured by cell viability, cell proliferation and FACS-based
apoptosis assays. IR- and doxorubicin-provoked increase in
CD95L and CD95R mRNA expression was partially blocked
by lovastatin. Activation of executor caspases was not
detected 48-72 h after exposure, yet IR-stimulated apoptosis
was blocked by the pan-caspase inhibitor Z-VAD. Examining
the effect of lovastatin on DNA strand break induction (using
the comet assay) and ATM/ATR-mediated H2AX
phosphorylation (γ-H2AX), we found radioprotection by
lovastatin to be independent of the formation and repair of
DNA damage. In contrast, doxorubicin-triggered DNA strand
break induction was attenuated by lovastatin, which was not
due to alterations in doxorubicin uptake or efflux.
Doxorubicin and IR-inducible DNA damage-related stress
responses, including accumulation of p53 and p21 protein as
well as activation of checkpoint kinase (Chk-1), stress
kinases (SAPK/JNK) and NF-κB, were impaired upon statin
pretreatment. Moreover, IR-induced NF-κB-dependent upregulation of the cell adhesion molecule E-selectin was
reduced by lovastatin.
Abstracts of the 8th International Conference of Anticancer Research, 17-22 October 2008, Kos, Greece
Overall, the data show that the HMG-CoA reductase
inhibitor lovastatin has pleiotropic inhibitory effects on IRand doxorubicin-induced stress responses in HUVEC and
eventually operates in an antiapoptotic manner. Preliminary in
vivo data are in line with the in vitro results. Therefore, we
suggest that lovastatin might be clinically useful in alleviating
side-effects of IR and doxorubicin on normal tissue during
tumor therapy.
209
DEVELOPMENT OF A THREE-DIMENSIONAL (3D)
ALL-HUMAN, IN VITRO MODEL OF THE BLOODBRAIN BARRIER FOR CANCER METASTASIS
STUDIES USING ELECTRIC CELL-SUBSTRATE
IMPEDANCE SENSING SYSTEM (ECIS) AND
TRANSWELLS
K.E. Fry and G.J. Pilkington
Cellular and Molecular Neuro-oncology Research Group,
Institute of Biomedical and Biomolecular Sciences, School
of Pharmacy and Biomedical Sciences, University of
Portsmouth, St Michael’s Building, White Swan Road,
Portsmouth PO1 2DT, UK
Background: Around 25% of cancers will spread to the brain
by passing through the physical blood-brain barrier (B-BB)
and thereby worsen prognosis. Melanoma, breast and lung
cancer are among the most frequent primary tumours which
metastasise to the brain. In vitro models of the B-BB generally
utilise murine or porcine brain endothelium and rat astrocytes.
In addition, these models are grown in foetal calf serum
supplemented conditions which modify growth rates and cell
adhesive properties. Aim: To develop a 3D in vitro model from
human brain-derived cells under human supplementation for
the study of the passage of cancer cells across the cellular BBB using different techniques such as ECIS, Transwells and
Flocel. Materials and Methods: The B-BB model is comprised
of human astrocytes (CC-2565) with human cerebral
microvascular endothelial cells (hCMEC/D3) immortalised
with hTERT/SV40 LargeT antigen, under human serum
supplementation. Non-small lung cancer, breast cancer and
melanoma cells have been chosen to add to the model. All
cells have been characterised with appropriate immuno
markers using flow cytometry and immunocytochemistry
while growth curves and adhesion properties have been
established for the B-BB components. Electric cell-substrate
impedance sensing system (ECIS) has been investigated along
with co-culturing on Transwells. Results: Growth curves,
antigenic expression, adhesive properties and growth on
Transwells have been established. ECIS has demonstrated the
potential of hCMEC/D3 to form a tight barrier and the
difference extracellular matrices and conditioned media has on
the impedance values. Cancer cells have also been assessed
when added to the hCMEC/D3 monolayer. Discussion: We are
currently assessing the model using a combination of live cell
imaging, TIRF microscopy and confocal microscopy. The
model has been developed using Transwells and on going
ECIS experiments of co-culturing with CC-2565 will be
explored. Flocel will be the next technique to be studied. We
aim to identify discrete pathways underlying entry of various
metastatic somatic cancer cells into the brain.
Research is supported by grant funding from the Lord
Dowding Fund and a PhD bursary from the Institute of
Biomedical & Biomolecular Sciences, University of
Portsmouth.
210
QUADRUPLEX DNA STRUCTURES AS
MODULATORS OF GENE EXPRESSION:
MYOGENIC TRANSCRIPTION FACTORS INTERACT
DIFFERENTIALLY WITH TETRAHELICAL
FORMATIONS OF GENE PROMOTER SEQUENCES
Anat Yafe, Jeny Shklover, Shulamit Etzioni, Pnina WeismanShomer, Eyal Bengal and Michael Fry
Department of Biochemistry, Rappaport Faculty of
Medicine, Technion - Israel Institute of Technology, POB
9649 Bat Galim, Haifa 31096, Israel
B-DNA can be readily transformed into non-B-DNA
conformations by positive or negative superhelical stresses, or
by the action of specific proteins. Among non-B-DNA
structures, tetraplex or quadruplex configurations of guaninerich sequences are of growing interest. Tetrahelical structures
in promoter sequences were implicated in the regulation of
expression of multiple genes such as those that encode insulin,
c-MYC, c-kit, bcl-2, VEGF and PDF-A.
We investigated the potential role of quadruplex structures
of upstream sequences of muscle-specific genes in modulating
the action of a family of myogenic regulatory factors (MRFs).
These master transcription factors; MyoD, Myf5, MRF4 and
myogenin, activate muscle gene expression by binding to
conserved E-box elements, d(CANNTG), in their regulatory
regions. We report that promoter and enhancer tracts of several
muscle-specific genes contain, beside E-boxes, a high
frequency of clusters of contiguous guanine residues that
readily form hairpin and parallel-stranded unimolecular and
bimolecular quadruplex structures. Further, homodimers of
MyoD and MRF4 bind tetraplex structures of muscle-specific
regulatory sequences much more tightly than their target Ebox. By contrast, heterodimers of MyoD or MRF4 with an
E47 protein form tighter complexes with E-box than with the
tetraplex DNA structures. Although myogenin-E47
heterodimers also bind E-box preferentially, homodimers of
myogenin bind quadruplex DNA weakly and nonpreferentially. Structure–function analysis identified the E-box
3285
ANTICANCER RESEARCH 28: 3157-3556 (2008)
and quadruplex DNA-binding sites in MyoD and Myogenin
and established that the different basic domains of the two
homodimeric proteins are the sole determinants of their
different affinities for quadruplex DNA.
Based on our results, we offer models for the involvement
of promoter quadruplex structures in the regulation of musclespecific gene transcription.
211
NOVEL STRATEGY OF ANTI-ANGIOGENIC
THERAPY FOR UTERINE CERVICAL CANCER
Jiro Fujimoto
Department of Obstetrics and Gynecology, Graduate School
of Gifu University School of Medicine, 1-1 Yanagido, Gifu
City 501-1194, Japan
Angiogenesis is essential for development, growth and
advancement of the primary tumor and especially its
metastatic lesions. Angiogenic activity in tumors is related to
the prognosis of most patients. Suppression of angiogenic
potential in the tumors leads to inhibition of the primary tumor
and its metastatic lesions. These facts prompted us to study
the behaviour of overexpressed angiogenic factors and
strategies for suppressing angiogenic potential.
The elevation of VEGF contributes to the relatively late
advancement via angiogenic activity in advanced
adenocarcinomas of the cervix (Brit J Cancer, 1999).
Furthermore, VEGF associated with COX-2 works on
advancement of uterine cervical cancer via angiogenesis, and
long-term administration of COX-2 inhibitors might be
effective on the suppression of regrowth or recurrence after
intensive treatment for advanced uterine cervical cancer. IL-8
levels correlate with microvessel and infiltrated macrophage
counts, and the localization of IL-8 is similar to that of CD68
specific to macrophages. The prognosis of patients with high
IL-8 was extremely poor. Consequently, IL-8 can be regarded
as a prognostic indicator as an angiogenic factor supplied from
macrophages in uterine cervical cancer (Cancer Res, 2000).
Thymidine phosphorylase (TP) has a wide range of expression
and is highly expressed in uterine cervical cancer regardless
of clinical stage. The prognosis of patients with high TP in
primary tumors is worse than in those with low TP. Hence, it
is apparent that TP in uterine cervical cancer plays a role of
basic angiogenesis in all processes of advancement of uterine
cervical cancer (Brit J Cancer, 1999). Furthermore, TP
remarkably increased in 8 of 40 metastatic lymph node lesions
of uterine cervical cancer, and the prognosis of the patients
with high TP in metastatic lymph node lesions was extremely
poor. Therefore, TP expressed in stromal cells appears to
contribute to the advancement of metastatic lymph nodes after
the establishment of metastasis, and is recognized as a
prognostic indicator (Cancer Res, 1999). Incidentally, VEGF-
3286
C and osteopontin expressed in cancer cells directly
contributes to lymph node metastasis in uterine cervical cancer
(Brit J Cancer, 2004, Cancer Lett, 2007). In addition, serum
TP is recognized as a novel tumor marker regardless of
histopathological type of the uterine cervical cancer (Cancer
Res, 2000). On the other hand, E 26 transcription-specific
(ETS)-1 levels correlate with microvessel counts, and the
localization of ETS-1 is similar to that of vascular endothelial
cells in uterine cervical cancers. ETS-1 levels correlate with
IL-8 and TP levels associated with HIF-1α levels. ETS-1
might work on angiogenesis as an angiogenic transcription
factor and be a prognostic indicator in uterine cervical cancer.
To avoid inducing alternative angiogenic pathways as a sort of
tolerance to an angiogenic inhibitor, the simultaneous
suppression of the main target angiogenic factors IL-8 and TP,
and the transcription factor ETS-1 might be highly effective
(Ann Oncol, 2002, Cancer Sci 2006). Furthermore, interferonγ-inducible protein (IP)-10 inversely-correlates with
microvessel density associated with VEGF, and might affect
the suppression of angiogenesis in advancement. Therefore,
IP-10 activation might be effective on the suppression of
advanced uterine cervical cancers (Brit J Cancer, 2007). We
are looking forward to proceeding with clinical trials of
antiangiogenic agents in advansed-stage patients and after
curative resection for uterine cervical cancer.
212
THE FIRST IN VIVO EXPERIMENTS WITH THE
COMBINATION OF TAXOL AND SILA-421, A NEW
PROMISING MULTIDRUG RESISTANCE INHIBITOR
IN HUMAN PANCREAS XENOGRAFTS
Andras Füredi1, Attila Zalatnai2 and Joseph Molnar1
1Institute
of Medical Microbiology and Immunobiology,
University of Szeged, Faculty of Medicine, H-6720 Szeged,
Dóm tér 10.;
21st Department of Pathology and Experimental Cancer
Research, Semmelweis University, Faculty of Medicine, H1085 Budapest, Üllői út 26., Hungary
Cancer chemotherapy is one of the most important tools of the
treatment of malignancies. The efficiency of chemotherapy is
often reduced by the appearance of multidrug resistant cells
in the tumour and during the treatment course these multidrug
resistant cells overgrow sensitive cells due to a selective
pressure of chemotherapy. One of the most frequent forms of
MDR is an ABC transporter, the P-glycoprotein mediated
resistance. This efflux pump extrudes chemotherapeutic agents
from the cells, which is the major limitation of chemotherapy.
Since inhibitors of MDR drug efflux can be promising agents
to reverse the multidrug resistance, the effects of disiloxans
were studied in vivo, as resistance modifiers in human
pancreatic cancer xenograft bearing mice.
Abstracts of the 8th International Conference of Anticancer Research, 17-22 October 2008, Kos, Greece
In this work we showed that the combination of the SILA421 MDR retardant and the paclitaxel mitotic inhibitor shows
a synergistic interaction in vivo. After that we compared the
results with the earlier experiments (with SILA-409). SILA421 was more effective than SILA-409. For the in vivo tests
we used immunosuppressed CBA mice with s.c. implanted
pancreatic carcinomas. These animals were treated with a
combination of SILA-421 (10 mg/kg) and Taxol (7 mg/kg
b.w./twice a week) for 4 weeks. Every week, tumours were
measured and the actual tumour volume was calculated. At the
end of the 4th week the mice were sacrificed and the tumours
were removed. The removed tumours were fixed in formalin
and embedded in paraplast. Slides were created from every
tumour and an immunohistochemical method was applied with
Ki-67 and p170 antibodies. Digital photos were made from the
slides after the rates of the Ki-67 positive cells were measured
with an image analysing software (IMAN).
The continuous measure of the tumour volume brought an
interesting result: there was a tumour volume decrease by
more than 50% on the 2nd week and this volume was stable
until the end of the experiment.
SILA-421 has a better inhibiting potential than its
predecessor, SILA-409, and the results show that SILA-421
has also an apoptotic effect, too. The results indicate that the
SILA mdr inhibitor compounds are promising agents in the
future cancer therapy.
213
SITE-SPECIFIC MUTATION IN THE CATALYTIC
DOMAIN OF TOPOISOMERASE IIβ ALTERS
ENZYMATIC ACTIVITY AND DNA DAMAGE
RESPONSE IN VIVO
Kenichi Chikamori, Adrian G. Grozav, Toshiyuki Kozuki,
Michael Kinter, Belinda Willard, Dale R. Grabowski,
Anni H. Andersen*, Ram Ganapathi
and Mahrukh K. Ganapathi
Cleveland Clinic Foundation, Cleveland, Ohio, USA;
*Aarhus University, Aarhus, Denmark
sites in topo IIβ. During the course of these studies, we
serendipitously identified an essential tyrosine (Y661),
located in the catalytic domain, which when mutated to
phenylalanine (F) significantly reduced the decatenation
activity of topo IIβ and reduced topo II-DNA cleavable
complex formation in vitro. Topo IIβ-deficient Jurkat or
topoIIα-depleted HTETOP cells expressing Y661F mutant
protein were less sensitive to topo IIβ-targeted drugs as
compared to cells expressing wild-type (WT) protein.
HTETOP or topo II-depleted BJ201 yeast cells expressing
Y661F topo IIβ were also less sensitive to ionizing radiation
than those expressing WT protein. Although Y661, along with
three other sites, serine (S) 1400, threonine (T) 1431 and
S1550, was initially identified by mass spectrometry as a
potential phosphorylation site (+80 Da modification), the
modification at Y661 was subsequently determined to be due
to oxidative bromination (+80 Da) which occurred during
cleavage of topo IIβ with cyanogen bromide and trypsin.
Nevertheless, this reactive site, which plays a critical role in
topo IIβ function, was the only site found to influence topo
IIβ activity. Interestingly, mutation of the equivalent tyrosine,
Y640, in topo IIα, minimally (~2-fold less) influenced the
decatenation activity of this topo IIα and did not alter drug
sensitivity to topo II-targeted drugs. These data suggest that
topo IIβ is regulated by a novel mechanism, involving
oxidation at Y661. This mechanism may be important for
modulating biological functions that respond to DNA damage
and oxidative stress, wherein an oxidative environment is
present.
214
NOVEL PREDICTOR GENES IN OVARIAN
CARCINOMA
Luis Rojas-Espaillat, Amanda Nickles-Fader, Nabila Rasool,
Susan A.J. Vaziri, Toshiyuki Kozuki, Dale Grabowski,
Charles Biscotti, Richard Drake, Chad Michener, Peter Rose,
Jerome Belinson, Mahrukh K. Ganapathi
and Ram Ganapathi
Cleveland Clinic Foundation, Cleveland, Ohio, USA
The DNA topoisomerase (topo) II enzyme catalyzes
topological transformations of DNA and regulates DNA
metabolic events, such as DNA replication and
recombination, chromosome condensation and segregation
and transcription. Two related topo II isozymes, topo IIα and
topo IIβ, are present in mammals. Although both enzymes
catalyze similar enzymatic reactions in vitro, they exhibit
differential patterns of expression and discrete physiologic
functions in vivo, suggesting that these isozymes are distinctly
regulated. Since, both enzymes are phosphorylated and
phosphorylation, of at least the topo IIα isozyme, regulates
enzyme activity and function, in this study we initiated mass
spectrometry experiments to identify relevant phosphorylation
The high incidence and mortality of ovarian cancer coupled
with the difficulty in detecting the disease in the early-stages
poses a major clinical challenge. Among the 75-80% of the
patients who present with stage III or stage IV ovarian cancer
at the time of diagnosis, 70-80% of the women respond to the
standard treatment protocol, which involves surgery followed
by 6-8 courses of chemotherapy with platinum, e.g.
carboplatin, and a taxane, e.g. paclitaxel. However, ~30% of
patients that exhibit disease progression either during
treatment or within 6 months after the last course of
chemotherapy, also do poorly with second-line treatment. This
remains a major problem in the management of ovarian cancer
3287
ANTICANCER RESEARCH 28: 3157-3556 (2008)
since no markers predicting early relapse or genes functionally
linked to chemo-sensitivity to platinum and/or taxane therapy
have been validated.
Our gene expression profiling studies of stage III ovarian
or peritoneal carcinoma using cDNA microarray technology
have identified a set of three genes that are independent
predictors of response to chemotherapy and clinical outcome.
Two genes, cisplatin resistance-associated over-expressed
protein (CROP) and proteosome subunit alpha type 3
(PSMA3) are significantly up-regulated in ovarian tumors of
patients who have undergone primary surgical cytoreduction
and who respond poorly to first-line therapy, whereas the third
gene, chemokine C-C motif ligand 2 (CCL2), is significantly
down-regulated in this same patient cohort.
In ovarian cancer cell lines the A(-2518)G polymorphism
in the promoter region of the CCL2 gene, which has been
previously reported to affect expression of the CCL2 gene, led
to reduced expression of CCL2 mRNA and protein. Testing
the function of CCL2 in ovarian cancer cell lines demonstrated
that reduced expression was correlated with resistance to
cisplatin and paclitaxel. Ectopic overexpression of CCL2 in an
ovarian cancer cell line led to enhanced sensitivity to
paclitaxel but not cisplatin and also reduced tumor cell
invasion in a Biocoat® Matrigel invasion assay. The
overexpression of CROP and PSMA3 was also correlated with
resistance to cisplatin in several cell culture models of ovarian
cancer. Cisplatin treatment in a dose-dependent manner led to
a 2- to 3-fold increase in accumulation of cells in G2+M phase
(indicative of enhanced DNA damage) in CROP siRNAtransfected cells in which CROP mRNA was down-regulated
>70% compared to similar cells transfected with a scrambled
siRNA.
In the long-term, establishing the functional role of CCL2,
CROP or PSMA3 as predictors of response to chemotherapy
and outcome in patients with advanced stage ovarian cancer
will allow for the development of novel strategies for detection
and treatment.
215
ROLE OF CASEIN KINASE I ISOZYMES δ AND ε IN
REGULATING ENZYME ACTIVITY OF
TOPOISOMERASE IIα
Adrian G. Grozav, Kenichi Chikamori, Toshiyuki Kozuki,
Dale R. Grabowski, Michael Kinter, Anni H. Andersen*,
Mahrukh K. Ganapathi and Ram Ganapathi
Cleveland Clinic Foundation, Cleveland, Ohio, USA;
*Aarhus University, Aarhus, Denmark
Human topoisomerase (topo) IIα is an essential enzyme that
regulates DNA topology. In human leukemia HL-60, cells
resistance to topoisomerase (topo) II targeting drugs, such as
etoposide, was found to be associated with site-specific
3288
hypophosphorylation of topo IIα. Resistance to etoposide was
found to be calcium dependent, since resistance to etoposide
could be mimicked in sensitive cells treated with the
intracellular Ca2+ chelator, 1,2-bis(2-aminophenoxy)ethaneN,NN’,N’-tetraacetic acid (BAPTA-AM). We subsequently
identified serine-1106 (Ser-1106) in the catalytic domain of
topo IIα as a major phosphorylation site, phosphorylation of
which regulated enzymatic activity of topo IIα. Ser-1106 was
found to be hypophosphorylated in sensitive cells treated with
BAPTA-AM or in etoposide-resistant cells. The observed
correlation of Ser-1106 hypophosphorylation with etoposide
resistance in cell culture model systems was confirmed in blast
cells from patients with acute myelogenous leukemia, wherein
hypophosphorylation of Ser-1106 was correlated with reduced
etoposide-induced apoptosis.
Since Ser-1106 lies within the consensus sequence for the
acidotrophic kinases, casein kinase (CK) I and CKII we tested
the functional role of these enzymes to phosphorylate this site
in vivo using HL-60 and colon cancer HCT-116 cells. The CKI
inhibitors, CKI-7 and IC-261, reduced phosphorylation of Ser1106 and decreased formation of etoposide-stabilized topo IIDNA cleavable complex. In contrast, the CKII inhibitor, 5,6dichlorobenzimidazole riboside (DRB), did not affect
formation of etoposide-stabilized topo II-DNA cleavable
complex. Since, IC261 specifically targets the Ca2+-regulated
isozymes, CKIδ and CKIε, we examined the effect of downregulating these enzymes on Ser-1106 phosphorylation.
Down-regulation of these isozymes with targeted si-RNAs led
to hypophosphorylation of the Ser-1106-containing peptide.
However, si-RNA-mediated down-regulation of CKIIα and
CKIIα’ did not alter Ser-1106 phosphorylation. Further,
reduced phosphorylation of Ser-1106, observed in HRR25
(CKIδ/ε homologous gene)-deleted S. cerevisiae cells
transformed with human topo IIα, was enhanced following reexpression of human CKIε. Down-regulation of CKIδ and
CKIε also led to significantly reduced formation of etoposidestabilized topo II-DNA cleavable complex.
These results provide strong support for an essential role of
CKIδ/ε in phosphorylating Ser-1106 in human topo IIα and
in regulating enzyme function.
216
ROLE OF NONCODING RNAS IN TUMORIGENESIS
Alan Garen1 and Xu Song2
1Yale
University School of Medicine, 333 Cedar St., New
Haven, CT 06520, USA;
2Sichuan University, 29 Wangjiang Road, Chengdu, Sichuan
610064, P.R. China
We present a model for generating tumor cells from
differentiated cells and stem cells, based on a mechanism of
gene regulation involving the tumor-suppressor protein PSF
Abstracts of the 8th International Conference of Anticancer Research, 17-22 October 2008, Kos, Greece
and a PSF-binding noncoding RNA (ncRNA). PSF contains a
DNA-binding domain (DBD) that binds to the promoter of a
gene and represses transcription, and two RNA-binding
domains (RBDs) that bind a ncRNA, releasing PSF and
activating transcription. The model has six postulates. (i)
Proliferation of stem cells and tumor cells is driven by
multiple proto-oncogenes, some of which which are repressed
by PSF and activated by PSF-binding RNAs. (ii) The level of
PSF-binding RNAs is high in stem cells and tumor cells,
preventing repression of proto-oncogenes by PSF and
promoting proliferation. (iii) PSF-binding RNAs disappear in
most stem cells at the end of embryogensis, enabling PSF to
repress proto-oncogenes and initiate differentiation. (iv)
Somatic mutations in a stem cell or differentiated cell can
result in a high level of PSF-binding RNAs, generating a clone
of tumor cells. (vi) The level of PSF-binding RNAs is reduced
by miRNAs that degrade PSF-binding RNAs, and is increased
by ras oncogenes that induce synthesis of PSF-binding RNAs.
Thus, the model predicts that PSF and miRNAs that degrade
PSF-binding RNAs act as tumor-suppressors, and PSF-binding
RNAs and ras oncogenes act as tumor-promoters. The
evidence for the model will be discussed.
217
NEW APPROACHES IN COLORECTAL CANCER
GENETICS
Maria Gazouli
Department of Biology, School of Medicine, University of
Athens, Michalakopoulou 176, 11527 Athens, Greece
Colorectal cancer (CRC) is the third most common cancer and
fourth-leading cause of cancer death worldwide. Lifetime risk
in Western European and North American populations is
around 5%. Both genetic and environmental factors contribute
to disease etiology, with about one-third of disease variance
attributed to inherited genetic factors. For complex diseases,
such as CRC, genetics research in human populations,
remarkable progress has been made in recent times with the
publication of a number of genome-wide association scans
(GWAS) and subsequent statistical replications. These studies
have identified new genes and pathways implicated in disease,
many of which were not known before. Until very recently,
the defined genetic contribution to CRC comprised rare, highpenetrance variants in a few genes (DNA mismatch repair
genes, APC, SMAD4, BMPR1A and MUTYH). In a genomewide association study to identify loci associated with CRC,
555,510 single nucleotide polymorphisms were genotyped in
different populations including 747 Greek CRC cases and 850
controls. The GWAS studies revealed that common genetic
variations in the 8q23.3, 8q24, 10p14, 11p23, 15p13, and
18q21 (SMAD7) regions also contribute to CRC risk. As well
as providing risk estimates for population groups,
identification of CRC risk loci provides new insights into
disease causation. Studies of the mechanisms by which these
genetic associations impact CRC risk could lead to the
development of small molecule interventions for
chemoprevention and chemotherapy.
218
CYTOTOXIC AND ANTIPROLIFERATIVE
ACTIVITIES OF COBALT (II) COMPLEXES WITH
DIFFERENT LIGANDS ON CULTURED TUMOR
CELLS
R. Alexandrova1, P. Genova2, E. Gardeva1, R. Toshkova1,
M. Kirilova3, G. Miloshev3, M. Lalia-Kantouri4,
L. Patron5 and O. Costisor6
1Institute of Experimental Pathology and Parasitology,
Bulgarian Academy of Science, Acad. G. Bonchev Str., Bl.,
1113 Sofia;
2National Institute of Infectious and Parasitic Diseases, 44A
Stoletov Blvd, 1233 Sofia;
3Institute of Molecular Biology, BAS, Acad. G. Bonchev
Str., Block 21, 1113, Bulgaria;
4Aristotle University of Thessaloniki, Chemistry Department,
Laboratory of Inorganic Chemistry P.O.Box 135,
Thessaloniki 54124, Greece;
5Institute of Physical Chemistry “I.G.Murgulescu”, Splaiul
Independentei 202, sect. 6, 060021 Bucharest, Romania;
6Institute of Chemistry Timisoara of the Romanian Academy,
24 Mihai Viteazu Blvd, RO-300223, Timisoara, Romania
Cobalt is one of the most important trace elements in the
world of animals and humans. Various cobalt containing
compounds have been reported to express antineoplastic
properties. The aim of this study was to evaluate the influence
of 19 newly synthesized cobalt (II) complexes with different
ligands (aminoacids, cholic acids, Mannich bases, mixed
ligands) on cultured tumor cells. The following model systems
were used in the experiments: 1) Permament cell lines from
human (carcinoma of the larynx Hep-2, rhabdomyosarcoma
RD64, glioblastoma multiforme 8 MG BA, breast cancer
MCF-7 and erythroleukemia K562), rat (transplantable
sarcoma induced by Rous sarcoma virus strain SchmidtRuppin), murine (myeloma P3U1) and chicken (transplantable
hepatoma induced by the myelocytomatosis virus Mc29)
origin; 2) primary cultures from myeloid tumor in hamster
induced by Graffi mouse leukemia virus. The influence of the
compounds on cell viability and proliferation as well as
cytopathological changes were studied by MTT test, neutral
red uptake cytotoxicity assay, colony-forming method,
autoradiography, neutral and alkaline variants of single cell gel
electrophoresis and acridine orange staining. The results
obtained revealed that the compounds tested express time- and
concentration-dependent cytotoxic and antiproliferative
3289
ANTICANCER RESEARCH 28: 3157-3556 (2008)
activities. The compounds with the most promising antitumor
properties were found among the complexes with mixed
ligands 2-hydroxy-benzophenones and nitrogenous bases enR.
Some of them were found to reduce cell viability by 50%
(IC50) when applied at concentrations <5 μg/ml for 24 h.
Supported by: Grant C1402/2004, National Science Fund in
Bulgaria; bilateral projects between the Bulgarian Academy of
Sciences, the Aristotle University of Thessaloniki, Greece and
the Romanian Academy.
reduced the DMBA-induced expression of H-ras in all organs.
The expression of p53 induced by DMBA was elevated in
kidney, in the bone marrow and lung, but decreased in thymus.
Agent 72 alone decreased the expression of H-ras in all
organs. The p53 expression increased significantly in liver and
kidney but decreased in the lung and remained almost the
same in the thymus and in the bone marrow. As previously
described, this method is capable of screening promising antineoplastic molecules.
219
IN VIVO EFFECT OF ASSORTED
CHEMOPREVENTIVE MOLECULES
ON DMBA-INDUCED ONCO-SUPPRESOR
GENE EXPRESSION IN CBA/CA MICE
220
NOVEL ROLE OF NEURONAL CALCIUM SENSOR-1
(NCS-1) AS PROGNOSTIC FACTOR AND
THERAPEUTIC TARGET IN BREAST CANCER
Gergely1,
Péter
Géza
and Istvan Ember4
Mezey2,
László
Őrfi3
1Institute
of Forensic Medicine, University of Debrecen, H4012, Debrecen, Nagyerdei krt. 98.;
2Department of Neurosurgery, University of Debrecen, H4012, Debrecen, Nagyerdei krt. 98.;
3Institute of Pharmaceutical Chemistry, Semmelweis
University of Medicine, H-1092 Budapest, Hőgyes E. Street
7;
4Institute of Public Health, University of Pecs, Szigeti str 12,
H-7624 Pecs, Hungary
We studied six molecules purported to be antineoplastic and
chemoprevenitve protein tyrosine kinase (PTK) inhibitors.
These molecules are plant-derived flavonoids. In order to
determine whether promising antineoplastic activity would
extend to anticarcinogenic properties, the effects of these
molecules on the DMBA (7,12- dimethylbenz[α]anthracene)induced expression of H-ras and p53 in isolated RNA from
liver, lung, kidney, thymus and bone marrow of CBA/Ca
inbred mice was investigated. Elevated expression of
oncogenes after treatment with DMBA has been reported
previously.
Administration of these molecules simultaneously with
DMBA, 24 h prior to or 24 h after the DMBA treatment
characteristically modified the DMBA-induced expression of
the genes in the twenty-four hour “short-term” experiments,
showing the chemoprevenitve and/or antineoplastic effect of
the observed agents. Coadministration of DMBA and agent
72, a styrylacrylonitrile compound, resulted in a significant
decrease of the DMBA induced expression of H-ras in all
organs; p53 expression decreased in liver, lung and bone
marrow, increased in kidney and thymus. Administration of
agent 72 24 h after the DMBA treatment reduced the DMBAinduced H-ras expression in all examined organs. The p53
expression decreased in all organs except the kidney.
Administration of agent 72 24 h prior to the DMBA treatment
3290
S. Germano1, M. Clynes1, S. Kennedy2, J.P. Mehta1,
E. Kenny1, E. Ryan1, P. Doolan1, P. Gammell1, H. Joyce1,
M. Perez de Villarreall1, A. Hill2, B. O’Daly2, R. Linehan1,
D. Cronin1, C. Daly1, S. Glynn1 and L. O’Driscoll1
1National
Institute for Cellular Biotechnology, Dublin City
University, Dublin 9;
2St. Vincent’s University Hospital, Dublin 4, Ireland
Neuronal calcium sensor-1 (NCS-1), formerly known as
Frequenin, is a calmodulin-related EF-hand Ca2+ binding
protein expressed mainly, but not uniquely, in neurons and
neuroendocrine cells. NCS-1 modulates synaptic transmission
and plasticity and has recently been identified as a regulator
of neurite outgrowth and neuronal survival. Notwithstanding
the diverse and well characterised biological functions of this
protein in neurons, its involvement in cancer has never been
studied. Here, the functional and clinical relevance of NCS-1
in breast cancer was investigated. In a microarray analysis of
103 invasive breast tumours and non-cancerous breast
biopsies, we identified NCS-1 to be expressed in a sub-group
of tumours (approximately 12% of cases), but to be
undetectable in normal breast tissue. Multivariate and
univariate analyses revealed NCS-1 expression to be
associated with estrogen receptor (ER)-negativity and
shortened times to relapse (p=0.0421) and death (p=0.0032)
from time of diagnosis. To investigate the possible role of
NCS-1 in breast tumour cell biology, we characterised the
biological effects of this gene in vitro using breast cancer cell
lines. To achieve this, NCS-1 expression was analysed in a
panel of breast cancer cell lines using quantitative reversetranscriptase polymerase chain reaction (qRT-PCR) and,
following initial screening, two highly invasive triple negative
(ER-, PR-, HER-2-) cell lines, Hs578T and HCC1143, as well
as the weakly invasive MCF7 cell line, were selected for gain
of function experiments. NCS-1 cDNA was introduced into
these cells and associated effects on cell proliferation, motility
and invasiveness were evaluated, compared to empty-vector
transfected control cells. While monolayer cell growth rate
Abstracts of the 8th International Conference of Anticancer Research, 17-22 October 2008, Kos, Greece
was not affected, anchorage-independent growth was
significant enhanced by NCS-1, with a remarkable tendency
for NCS-1 transfected cells to form larger colonies compared
to the control cells. Motility of NCS-1 transfected cells was
also significantly enhanced. Interestingly, the invasive ability,
measured by monitoring invasion through matrigel in a
Boyden Chamber assay, was also markedly increased. Our
results suggest that NCS-1 may contribute to the malignant
phenotype of breast cancer cells and may represent a new
prognostic biomarker and potential therapeutic target for a
sub-group of breast cancer patients.
Supported by the from Ireland’s Health Research Board.
221
SURGERY IN BYZANTIUM
S. Geroulanos
Onassis Cardiac Surgery Center, Athens, Greece
Surgery in Byzantium with respect to the research and results
achieved in many other medical fields remained more or less
impenetrable, despite its major contribution in conservation,
development and transfer of ancient knowledge. There are
descriptions of ordinary or even of severe operations, thus
making their study a fascinating subject. At least three of the
most important physicians/authors of Byzantium, like
Oreibassios, Aetios from Amida and Pavlos Aeginitis
described and performed amazing operations. A selection of
them is listed below:
General Surgery: Strumectomy (with reference to the
importance of recurrent nerve), herniotomy and herniorrhaphy,
hydro- and varicocele operation, entero- and omphalocele,
laparocentesis, gastrorrhaphy, lymph node and ganglion
excision, hexadactily operation. Abscess incision and drainage,
liver and “spleen” abscess drainage, scrofulosis, panaritium
incision, ingrowing-nail operation, removal of foreign bodies,
finger-, arm- and leg-amputation.
Neurosurgery: Trepanation, craniotomy, elevation of
impressed bone segments, several operations on cranial
fractures.
Angiology: Ligation of arteries, arteriotomy, arterial resection
in temporal arteriitis, aneurysmectomy, varicectomy (various
methods including stripping), haemostasis by compression,
ligation, cauterization and haemostyptics.
Ophthalmology: Blepharotomy, blepharoplasty of distichiasis,
lagophthalmus
operation,
ektropion
operation,
anabronchismus, hydatic cyst removal, chalazion, pterygium,
catarrhact operations, eyelid-sty treatment.
Ear-Nose-Throat: Rhinoplasty after nose operation, resection
of nose-polyps, retroauricular acoustic pore opening, plastic
ear-reconstruction, reposition of mandibula luxation,
sialolithiasis
operation,
uvulectomy,
tonsillectomy,
tracheostomy.
Breast surgery: Tumorectomy, mastectomy, combined
mamma-preserving tumor resection and cauterization, incision
of breast abscess, removal of milk-stones, excision of necrosis
and fistulas, gynaecomasty operation.
Thoracic surgery: Rib resection, drainage of empyema,
separation of siamese twins (the first in the world).
Gynaecology: Transvaginal hysterectomy, drainage of uterus
empyema, operation of cervix varices, nymphectomy,
operation of hymenal, vaginal and uterus atresia, resection of
pudendal, vaginal and cervical condylomas.
Obstetrics: Major improvements in irregular birth, use of
forceps, embryotomy, support of genitals during birth, manual
extraction of placentar rests, manual cleansing of uterus in
postpartal infection, abortion.
Urology: Circumcision and phimosis operation, hypospadias
operation (building neo-urethra), resection and cauterization
of condylomas, catheterization of bladder and lavage,
transurethral and transvaginal cystolithotrypsie, transvaginal
and transperineal cystolithiasis removal, castration,
hermaphrodites operation.
Proctology: Haemorhoidectomy (incl. ligation and
cauterization), fistulotomy and fistulectomy, seton technique,
perianal abscess drainage, anal atresia operation.
Traumatology: All possible reductions of simple and
complicated bone fractures and repositions of luxation,
extractions of arrows, spears etc. including gastro-, duodeno-,
jejuno-, colono-, and vesico-rrhaphy.
The importance of the Byzantine texts in surgery were
recognized in France, where they became by special decree
obligatory texts for the medical students of the Sorbonne from
the beginning of the 17th century till the end of the 19th
century.
222
IMMUNOMODULATION OF CANCER CELL
MIGRATION AND INVASION USING
RECOMBINANT CAMELID NANOBODIES AGAINST
CYTOSKELETAL PROTEINS
Veerle Delanote1,2, Anske Van den Abbeele1,2,
Sarah De Clercq1,2, Ariane De Ganck1,2, Katrien Van Impe1,2,
Veerle De Corte1,2, Berlinda Vanloo1,2, Ciska Boucherie1,2,
Joël Vandekerckhove1,2 and Jan Gettemans1,2,3
1Department of Medical Protein Research, VIB, B-9000
Ghent;
2Department of Biochemistry, Ghent University, Faculty of
Medicine and Health Sciences, Albert Baertsoenkaai 3, B9000 Ghent, Belgium
Invasion and metastasis of cancer cells relies on dynamic
reorganization of the actin cytoskeleton which is the driving
force for cellular motility. Actin-associated or actin-binding
proteins aid in this process by virtue of their ability to interact
3291
ANTICANCER RESEARCH 28: 3157-3556 (2008)
reversibly with actin and actin filaments. The expression level
of quite a few actin binding proteins is up-regulated in cancer
cells, and many studies have demonstrated a correlation
between the expression of selected actin-binding proteins and
cancer cell motility and/or invasion in vitro and in vivo.
Instead of modulating the expression level of actinassociated proteins, we developed small recombinant
antibodies (so-called nanobodies) raised against cell motility
factors and use these as intrabodies. Obviously these
antibodies do not affect the expression of their target antigen
but inhibit biological functions. Nanobodies (~15 kDa) against
gelsolin and other actin-associated proteins were raised in
llamas or alpacas which have the unique property of
expressing heavy chain antibodies that are devoid of light
chains. The antigen-binding region of these antibodies (VHH)
can be cloned, thus raising the possibility of developing small
protein inhibitors against structural intracellular polypeptides.
In addition, nanobodies can be used for tracing their target in
living cells, thereby circumventing protein overexpression.
They are also suitable for immunoprecipitation and Western
blotting.
We show that selected nanobodies bind their target with
nanomolar affinity. Moreover, epitope mapping demonstrates
their selective interaction with conformational epitopes (i.e.
calcium-induced conformational changes in proteins).
Examples are discussed showing inhibition of biochemical
activities of L-plastin, an actin-bundling protein, by
nanobodies. Moreover, this was associated with inhibition of
filopodia formation in PC-3 cells.
Importantly, expression of nanobodies against L-plastin or
gelsolin in cancer cells reduced motility and in vitro invasion
of these cells to the same extent as siRNA. This approach
allows one to study the role of (actin-associated) proteins in
tumorigenesis at the level of the protein. Nanobodies could be
further developed into bona fide therapeutic molecules.
223
G-QUADRUPLEX STRUCTURES IN ANTICANCER
AND ANTIVIRAL THERAPY
C. Giancola
Department of Chemistry “P. Corradini”, University of
Naples Federico II, Via Cintia 80126, Naples, Italy
Guanine-rich nucleic acid sequences can adopt quadruplex
structures (G-quadruplexes) stabilized by quartet layers of
Hoogsteen paired residues (1). G-quadruplexes are further
stabilized by monovalent cations as sodium and potassium. Grich sequences are found at the ends of chromosomes as
telomeric protein complexes, and in a number of biologically
significant regions of the genome, such as gene promoter
regions and sequences associated with human diseases. The
biomedical relevance of quadruplexes is essentially due to two
3292
potential applications: in anticancer therapy and in the design
of novel aptameric nucleic acids. The first application comes
from the observation that G-quadruplexes formation at the 3’end of telomeres may inhibit the telomerase enzyme, an event
which can induce cancer cells to escape senescence (2, 3). The
second application is due to the ability of aptamers based on
the quadruplex motif to specifically bind selected proteins (4).
A specific quadruplex has been found to bind and inhibit αthrombin, an important protein with multiple function in
homeostasis, and some quadruplexes have resulted to be
potent antiviral inhibitors against HIV. Many structural and
biophysical methods are devoted to study native quadruplexes
and their interactions with both proteins and small molecules
(5). The energetic aspects of both quadruplex assembly and
quadruplex-ligand interactions are discussed here. Recent
studies on physico-chemical properties and antiviral activity
of quadruplex structures obtained from synthetic aptamers are
also discussed.
1 Gellert M, Lipsett MN and Davies DR: Proc Natl Acad Sci
USA 48: 2013, 1962.
2 Mokbel K: Curr Med Res Opin 19: 470, 2003.
3 Hahn WC, Counter CM, Lundberg AS, Beijersbergen RL,
Brooks MW and Weinberg RA: Nature 400: 464-468, 1999.
4 Wenn J-D and Gray DM: Biochemistry 41: 11438-11448,
2002.
5 Pagano B and Giancola C: Current Cancer Drug Targets 7:
520, 2007.
224
ANGIOGENESIS AND MATRIX
METTALLOPROTEINASES: THE COMMON
PATHWAY TO CANCER PROGRESSION AND THEIR
IMPACT ON PANCREATIC DUCTAL AND
AMPULLARY CARCINOMA
George Giannopoulos, Kitty Pavlakis, Aikaterini Parasi,
Nikolaos Kavatzas, Dina Tiniakos, Antigoni Karakosta,
Nikolaos Tzanakis and George Peros
4th Surgical Department, Attikon Hospital, University of
Athens, Athens, Greece, Apostoli 2 st, 185 37 Piraeus,
Greece
Aim: To investigate the expression of metalloproteinase
(MMP)-2, MMP-9 and tissue inhibitor of MMP (TIMP)-2 in
pancreatic ductal and ampullary carcinoma and to test the
findings for correlation with angiogenesis and several
clinicopathological parameters. Materials and Methods:
Paraffin sections from 32 pancreatic ductal adenocarcinomas
and 17 ampullary carcinomas were assessed for the expression
of MMP-2, MMP-9 and TIMP-2, by immunohistochemistry.
Stromal and epithelial staining were evaluated separately.
Moreover, sections stained immunohistochemically with antiCD34 antibody were evaluated by image analysis for the
Abstracts of the 8th International Conference of Anticancer Research, 17-22 October 2008, Kos, Greece
quantification of microvessel density (MVD). Results: In
pancreatic ductal adenocarcinoma, lower levels of glandular
TIMP-2 were found in poorly differentiated tumors, while
high glandular TIMP-2 expression was significantly associated
with better survival. The age of the patients and the degree of
differentiation of the tumor were identified as independent
prognostic parameters. No relation was found between the
expression of MMPs, TIMP or angiogenesis and the
parameters under consideration. In ampullary adenocarcinoma,
strong expression of glandular MMP-2 was associated with
higher MVD values. Moreover, lymph vessel invasion was
associated with higher stromal TIMP-2. Conclusion: In
pancreatic ductal adenocarcinoma, TIMP-2 may have a more
crucial role in prognosis than MMP-2, MMP-9 or
angiogenesis. In ampullary adenocarcinoma, MMP-2
expression correlated with MVD, supporting its postulated
role in angiogenesis.
225
MULTI-TARGETING OF U87 GLIOMA CELLS BY
SUNITINIB AND LAPATINIB
Efstathia Giannopoulou, Andreas A. Argyriou,
Angelos K. Koutras, Fotinos Dimitrakopoulos
and Haralabos P. Kalofonos
Clinical Oncology Laboratory, Division of Oncology,
Department of Medicine, University Hospital of Patras,
Patras Medical School, Greece
Aim: Sunitinib and Lapatinib are currently used for the
treatment of solid tumors. The efficacy of these agents is not
widely tested neither in experimental models nor in clinical
trials of malignant gliomas and therefore we studied the effect
of these agents, applied either alone or combined, on U87
glioma cells. Methods: Sunitinib and lapatinib were applied,
either separately or in combination, in the U87 cells at doses
of 10 nM, 100 nM and 1 μM. To determine whether these
agents affect the proliferation of U87 glioma cell lines, the 3[4,5-dimethylthiazol-2-yl]-2,5 dimethyltetrazolium bromide
assay was used. Apoptosis was detected using annexin
V/propidium iodide detection assay, migration assay was
performed in 24-well microchemotaxis chambers and MMP-2
levels were measured by zymography. Results: Both agents,
administered either alone or combined, decreased cell
proliferation in a dose-dependent manner 48h after their
application. The inhibition of agent’s combination was
statistically different than the inhibition of each agent alone.
We also found that apoptosis was increased and invasion of
U87 cells was inhibited either by each agent alone or their
combination. Finally, the application of both agents did not
result in alteration of MMP-2 levels. Conclusion: Our results
showed that the application of sunitinib and/or lapatinib
appears to exhibit effects on proliferation, apoptosis and
invasion of U87 cell line. When applied alone, sunitinib
appears to be a more potent inhibitor than lapatinib.
226
DIFFERENTIAL EXPRESSION OF
METALLOPROTEINASE BETWEEN NORMAL
MUCOSA OF PATIENTS WITH SPORADIC
COLORECTAL CANCER AND OF NORMAL
SUBJECTS: MAY PLAY A ROLE FOR NEOPLASTIC
TRANSFORMATION?
Francesco Franceschi, Lucia Fini, Giovanni Gigante,
Maria Assunta Zocco, Alberto Manno, Davide Roccarina,
Bianca Giupponi, Guido De Marco, Alessandro Verbo,
Claudio Mattana, Nicolò Gentiloni-Silveri, Claudio Coco,
Giovanni Gasbarrini and Antonio Gasbarrini
Internal Medicine, Department of Surgical Sciences,
Catholic University of Rome, Italy
The matrix metalloproteinase (MMP) family of enzymes
represents a group of about 20 proteins which have been
involved in promoting of human malignancies, including
colorectal cancer (CRC). We hypothesized that a genetic
impairment of MMP and/or their inhibitors in the normal
colonic mucosa may create a favorable environment for
neoplastic transformation. Therefore, we designed a study
aimed at assessing the gene expression profile of MMP and
their inhibitors in samples of sporadic CRC tissue, normal
colonic mucosa of patients with sporadic CRC and normal
mucosa of healthy subjects. Methods: Ten patients with
sporadic CRC and 10 healthy sex and age matched subjects
were enrolled. Samples of CRC, normal mucosa of patients
with CRC and normal mucosa of healthy subjects were
collected. Total RNA was extracted from all samples; cRNA
was hybridized with the human U133A array set (22.000
genes), which also include 20 MMP genes and their inhibitors.
Gene expression profile was compared among groups. The
expression level of MMP and their inhibitors found to be
increased or decreased in gene chip analyses was further
studied by real-time PCR to validate microarray results.
Results: CRC tissue vs. normal mucosa of CRC patients:
overall, a differential expression in 7 MMP genes has been
observed by both microarray analysis and RT-PCR. In
particular, the gene expression of MMP-1, MMP-2, MMP-7,
MMP-8, MMP-9, MMP-12, and MMP-20 was found to be
increased in CRC specimens compared to the normal mucosa
of the same patients. Concerning TIMPs, only TIMP-1 was
increased in CRC tissues. Normal mucosa of CRC patients vs.
normal mucosa of healthy subjects: overall, 6 MMP genes
were differently expressed between groups by both microarray
analysis and RT-PCR. In particular, MMP-11, MMP-12,
MMP-15 and MMP-20 were up-regulated in the normal
mucosa of CRC patients, while MMP-14 and MMP-19 were
3293
ANTICANCER RESEARCH 28: 3157-3556 (2008)
down-regulated in the same samples. Concerning TIMPs,
TIMP-3 was decreased in the normal mucosa of CRC patients.
Conclusion: Several MMP genes are differentially expressed
in CRC tissue, normal mucosa of patients with sporadic CRC
compared to healthy subjects. Interestingly, some of those
genes, such as MMP-11 and MMP-12, which were upregulated in the normal mucosa of CRC patients, have also
been described to play a role in CRC, while MMP-15 and
MMP-20 have been reported to be associated to other kind of
cancers. Furthermore, MMP-19, a protein involved in colonic
epithelial cell proliferation, and TIMP-3, which were downregulated in the normal mucosa of patients with CRC, are
known to decrease during malignant transformation. Based on
these findings, we hypothesize that the pattern of expression of
those genes seen in the normal mucosa of patients with
sporadic CRC may create a favorable environment for
neoplastic transformation and progression.
227
ANTIMUTAGENIC AND ANTICANCER EFFECTS OF
BLACK TEA POLYPHENOLS THEAFLAVINS AND
THEARUBIGINS IN MULTIPLE TEST SYSTEMS
Udayan Bhattacharya, Babli Halder, Rashmi Roy,
Sibabrata Mukhopadhyay and Ashok K. Giri
Molecular and Human Genetics Division, Indian Institute of
Chemical Biology, 4, Raja S.C. Mullick Road, Jadavpur,
Kolkata- 700 032, India
Tea is a highly consumed and popular beverage throughout the
world. During fermentation tea catechins are polymerized by
polyphenols oxidase to form theaflavins (TF) and thearubigins
(TR). TF and TR are the most exclusive polyphenols of black
tea that account for 3-6% and 12-18% of dry weight of black
tea. We have observed significant antimutagenic effects of TF
and TR in multiple test systems. A statistically significant
inhibition of chromosomal aberration and micronuclei
formation was found in vitro in human lymphocyte cultures.
Tea polyphenols exert their potent anticancer activity and
appear to be the ideal agents for chemoprevention. Even
though few previous reports show the anticancer effects of TF
through apoptosis, nevertheless the potential effect of TR has
not been appraised. This study investigated the induction of
apoptosis in human skin cancer cells after treatment of TR and
TF. We report that both TF and TR could exert inhibition of
human A431 (epidermoid carcinoma) and A375 (malignant
melanoma) proliferation without adversely affecting NHEK
(normal human epidermal keratinocytes) cells. Growth
inhibition of A375 cells occurred through apoptosis, as evident
from cell cycle arrest at G0/G1 phase, increase in early
apoptotic cells, externalization of phosphatidyl serine and
DNA fragmentation. In our pursuit to dissect the molecular
mechanism of TF and TR induced apoptosis in A375 cells, we
3294
investigated whether cancer cell death is being mediated by
mitochondria. In our system, Bax translocation to
mitochondria persuaded depolarization of mitochondrial
membrane potential, facilitated ROS (reactive oxygen species)
generation, cytochrome c release in cytosol and induced
activation of caspase -9, caspase -3 as well as PARP (poly
(ADP-ribose) polymerase) cleavage. Our intricate
investigations on apoptosis, also explained that, TF and TR
augmented Bax/Bcl2 ratio and upregulated the expression of
p53 and p21. The TF and TR also inhibited phosphorylation
of the cell survival protein Akt. Furthermore, we have found
that TF and TR can also upregulate phosphorylated JNK and
phosphorylated p38 in A375 cells. These observations raise
speculation that TF as well as TR might exert
chemopreventive effect through cell cycle arrest and induction
of apoptogenic signals via mitochondrial death cascade and
stress activated MAPKinase pathways may also be involved
in inducing apoptosis in human skin cancer cells.
228
CHLOROQUIN CONVERTS MOLECULAR IODINEINDUCED AUTOPHAGY IN MDA-MB-231 TO
APOPTOTIC CELL DEATH: IMPLICATIONS FOR
OVERCOMING CHEMOTHERAPEUTIC
RESISTANCE
M.M. Godbole2, Preeti Singh2, Geeta Rao2,
Vishwamohan, Sanjay Annarao1,
Raja Roy1, Kalyan Mitra3 and V.K. Bajpai3
1Department
of Endocrinology, Centre of Biomedical
Magnetic Resonance,
2Sanjay Gandhi Postgraduate Institute of Medical Sciences,
3Electron Microscopy Facility, Central Drug Research
Institute, Lucknow, India
Autophagic mechanism is known to provide survival
advantage and chemoresistance in various types of cancer.
Molecular iodine (I2) has been shown to cause apoptotic cell
death independent of estrogen receptor and p53 status in breast
cancer cell lines (MCF-7, MDA-MB-231, MDA-MB-453, ZR75-1, T-47D). In MCF-7 cells, apoptotic cell death has been
shown to be independent of caspase activity and is mediated
through AIF. Non-evident apoptosis in MDA-MB-231 in
response to I2 treatment led us to investigate its cell death
mechanism in detail. Electron microscopic observations and
immunofluorescence performed in molecular iodine-treated
MDA-MB-231 cells showed an increase in acidic vacuoles
and autophagosome formation, and subsequent autolysosome
formation confirmed the autophagy. Blocking of various stages
of I2-induced autophagy by PI3 kinase inhibitors (LY294002
and 3-MA), bafilomycin (lysosomal fusion inhibitor) resulted
in enhanced cell death, indicating that autophagy provides
survival advantage to MDA-MB-231 cells. The evidence of
Abstracts of the 8th International Conference of Anticancer Research, 17-22 October 2008, Kos, Greece
autophagy is further supported by enhanced expression of
Beclin, reduced Bcl-2, and increased LC-3 cleavage seen on
Western blot.
Recent evidence that the anti-malarial drug chloroquin
inhibits chemotherapeutic regimen-induced autophagy leading
to increased cell death in CNS lymphoma is promising. To
know whether the chloroquin-mediated increased therapeutic
efficacy is drug/system-specific or is a more generalized
phenomenon, we investigated its effect in I2-treated MDAMB-231 cells. Co-treatment with I2 and chloroquin resulted
in increased cytotoxicity, accumulation of sub-G1 cell
fraction, nuclear fragmentation with enhanced caspase-9
activation and reduced pro-caspase-3, indicating that
chloroquin redirects the cells undergoing autophagy under the
influence of molecular iodine to dominant apoptotic
mechanism of cell death. The evidence provided so far
indicates that the chloroquin probably increases the
therapeutic efficacy of the drug regimen in a ubiquitous
manner. This switch over ability from autophagy to apoptosis
provided by chloroquin makes it a potential adjuvant to
overcome the survival advantage conferred by molecular
iodine on MDA-MB-231 cells.
Supported by Department of Science and Technology,
Government of India, Grant No SR/SO/HS/017/2003.
229
A COMPLEX KARYOTYPE IS AN INDEPENDENT
PROGNOSTIC FACTOR FOR CHILDREN WITH MDS
– DATA FROM THE EUROPEAN WORKING GROUP
OF MDS IN CHILDHOOD (EWOG-MDS)
Gudrun Gohring1, Kyra Michalova2, Berna Beverloo3,
David Betts4, Jochen Harbott5, Oskar Haas6,
Gitte Kerndrup7, Laura Sainati8, Eva Bergstraesser4,
Henrik Hasle9, Jan Starý10, Monika Trebo6,
Marry van den Heuvel-Eibrink3, Marco Zecca11,
Alexandra Fischer12, Peter Noellke12, Franco Locatelli11,
Brigitte Schlegelberger1 and Charlotte M. Niemeyer12
1Institute
of Cell and Molecular Pathology, Medical School
Hannover, Germany;
2Center of Tumor Cytogenetics, Charles University, General
Faculty Hospital, Prague, Czech Republic;
3Department of Clinical Genetics and Sophia Children’s
Hospital, Erasmus University, Rotterdam, the Netherlands;
4Department of Oncology, University Children’s Hospital,
Zuerich, Switzerland;
5Department of Pediatric Medizine, University, Giessen,
Germany;
6St. Anna Children’s Hospital, Vienna, Austria;
7Institute of Pathology, University Hospital, Odense,
Denmark;
8Clinica Oncoematologica Pediatrica, University of Padova,
Italy;
9Department of Pediatrics, Aarhus University Hospital
Skejby, Aarhus, Denmark;
10Deptartment of Pediatric Hematology and Oncology,
University Hospital Motol, Prague, Czech Republic;
11IRCCS Policlinico San Matteo,Department of Pediatrics,
University of Pavia, Italy;
12Department for Pediatric of Adolescent Medicine,
University Hospital, Freiburg, Germany
To study the clinical significance of recurrent chromosome
aberrations in childhood MDS, cytogenetic data of 394
consecutive children with refractory cytopenia (RC) (N=215),
RAEB (N=141) and RAEB-T (N=38) analyzed in the
regional cytogenetic reference centers and registered in the
prospective study EWOG-MDS 98 between 1998 and 2005
were evaluated. At diagnosis, a karyotype could be defined in
279/394 patients (pts) (71%). No karyotype was obtained in
16% of pts with RC as compared to 8% pts with RAEB and
RAEB-t (p<0.001). Clonal chromosome aberrations were
more common in pts with advanced MDS (RAEB and
RAEB-T, 61%) compared to RC (29%), and in pts with
secondary (69%) compared to primary MDS (36%)
(p<0.001). Monosomy 7 was the most frequent aberration
occurring with similar frequency in RC (47% of abnormal
karyotypes) as compared to advanced MDS (49%) and in
primary (53%) compared to secondary (41%) MDS. In
addition, aberrations typical for de novo AML, such as
aberrations involving 11q23 or 3q, t(6;9) and del(9q), were
noted in morphologically and clinically unequivocal MDS
cases. Recurrent aberrations of adult MDS such as isolated
del(5q), del(20q) and -Y were very uncommon, indicating a
different pathogenesis of these cases. In pts with advanced
MDS, there was no significant difference in overall survival
(OS) of pts with normal karyotype (44%±18) as compared to
pts with monosomy 7 (58%±19) and patients with other
karyotypes (61%±22). However, pts with advanced MDS and
a complex karyotype (defined by ≥3 chromosome aberrations,
presence of structural aberrations and excluding clonal
evolution of monosomy 7) had a lower OS (16% ±15,
p<0.01). OS and event-free survival after hematopoietic stem
cell transplantation (HSCT) in pts with complex karyotypes
was inferior compared to that of pts with other cytogenetic
aberrations (p=0.012 and 0.039, respectively). Within the
group of pts with secondary MDS, complex karyotypes were
found in MDS evolving from inherited bone marrow failure
disorders or after radiochemotherapy, but absent in familial
MDS and cases evolving from acquired aplastic anemia. As
shown in a multivariate Cox analysis, advanced MDS,
secondary MDS, the presence of a complex karyotype and
HSCT were identified as independent prognostic factors for
OS. Thus, this study demonstrates the prognostic significance
of cytogenetic findings in advanced childhood MDS
independent of HSCT.
3295
ANTICANCER RESEARCH 28: 3157-3556 (2008)
230
THE EFFECT IN VITRO AND IN VIVO OF HUMAN
GALECTIN-8 VARIANTS; A POSSIBLE NEW
THERAPY FOR INFLAMMATORY AND CANCER
DISEASES
Itshak Golan1,2 and Ira Golan1,2
1Institute
of Life Sciences, Swansea University, Swansea,
Wales;
2Kennedy Institute of Rheumatology, Imperial College,
London, UK
In our recent publication (Eshkar-Sebban et al., J Immunol
179: 1225-1235, 2007) we described a study shows by affinity
chromatography, surface plasmon resonance and flow
cytometry, that galectin-8 is a novel ligand of CD44. We
further demonstrated that synovial fluid cells from rheumatoid
arthritis patients (RA) contain new variants of human galectin8 proteins and cell surface CD44. Both CD44 and galectin-8
proteins, possibly released from the inflammatory cells, were
detected also in the joint fluid of the patients. We further
revealed that at least part of galectin-8 and soluble CD44 form
complexes in the RA synovial fluid that reduce the ability of
the lectin to induce apoptosis in the inflammatory joint cells.
Hence, the RA model not only confirmed the receptorligand relationships between CD44 and galectin-8, but also
unveiled the biological significance of this interaction in the
regulation of the inflammatory cascade.
Knowing that the interaction between galectin-8 and
integrins is mediated by the sugar moieties of the adhesion
receptors and that this interaction can subsequently lead to
apoptotic signaling, we predicted that galectin-8 can also be
ligated to CD44. This assumption was based on the fact that,
like integrins, CD44 is a glycosylated cell surface receptor that
can deliver death signals. Challenging this prediction
experimentally, we not only confirmed the receptor- ligand
relationship between CD44 and galectin-8, but also showed
that this interaction reduced the anti-inflammatory activity of
the lectin.
In the present study, we are reporting our recent findings on
new pro apoptotic agents, human galectin-8 variants, which
can provide a novel diagnostic, prognostic and therapeutic
approach for joint chronic inflammatory diseases and cancer.
231
EFFECTS OF ISOFLURANE ON NFKB1, GADD45Α
JNK1 EXPRESSIONS IN THE VITAL ORGANS OF
CBA/CA MICE
Balázs Kádár1, Katalin Gombos2, Eszter Szele2,
Gyula Gőbel3, István Szanyi3 and István Ember2
1Anaesthesiology
and Intensive care Unit BAZ County
Teaching Hospital, Miskolc;
3296
2University
of Pécs, Faculty of Medicine, Institute of Public
Health, Pécs;
3Department of Otolaryngology Head and Neck Surgery,
Faculty of Medicine, University of Pécs, Hungary
Background: Isoflurane is one of the most widely used volatile
anaesthetics. It is administered to patients during general
anaesthesia with the aim of minimizing the effect of external
stimuli, such as surgical invasions. It was also found to be
beneficial to patients undergoing operation with coronary heart
disease by reducing myocardial stunning and infarct size. On
the other hand isoflurane has also been reported to have
genotoxic effects in humans, male Sprague–Dawley rats and in
cell lines exposed to isoflurane. This genotoxic effect
manifested as an increase in DNA single strand breaks by
alkaline comet assay. In our present study we evaluated the
expression of GADD45α, JNK1 (MAPK8) and NFKB1.
GADD45α is a gene that is induced by DNA damage and
strongly linked to the c-jun-N terminal kinase cascade and to
the NFKB pathway, both playing important role in the
regulation of apoptosis and cell survival. Materials and
Methods: 5-week-old male CBA/CA mice were exposed to 2%
isoflurane anaesthesia for 1 hour. Control animals were
exposed to 90% Oxygen. Lungs, liver and kidneys of the
animals were removed 3 and 6 hours after isoflurane exposure.
Gene expressions were measured by quantitative real-time PCR
on total RNA from the organs. For internal control we used
HPRT. Results: Significant expression alterations of the three
genes were seen 3 hours after the isoflurane exposure in the
lungs and the kidneys. GADD45α and JNK1 showed paralell
correlation in changes of expression, while NFKB1 had inverse
activation compared to the other two genes. Conclusion: By
inducing DNA damage and activating GADD45α, isoflurane
exposure evokes the activation of JNK1 and NFKB1 through
which can have an effect on the cell death program.
232
ANALYSIS OF THE CONNECTIONS BETWEEN
SIGNAL TRANSDUCTION MECHANISMS IN EARLYSTAGE THYROID TUMOURS
Katalin Gombos1, Eszter Szele1, László Puskás2,
László Kozma3, Ferenc Juhász4, Gyula Gőbel5,
István Szanyi5 and István Ember1
1Institute
of Public Health, Faculty of Medicine, University
of Pécs, Szigeti út 12. H-7624 Pécs;
2Functional Genomical Laboratory, Biological Research
Center of Hungarian Academy of Sciences, Szeged;
3Hematology Center of Kenézy County Hospital, Debrecen;
41st Department of Surgery, University of Debrecen, Faculty
of Medicine, Debrecen;
5Department of Otolaryngology Head and Neck Surgery,
Faculty of Medicine, University of Pécs, Pécs, Hungary
Abstracts of the 8th International Conference of Anticancer Research, 17-22 October 2008, Kos, Greece
Introduction: Microarray analysis offers the opportunity of
screening transcriptional expression profile of neoplastic cells
at the genomic level. Analysis and comparison of these
molecular snapshots makes possible to identify characteristic
steps of deregulation and dedifferentiation in tumorigenesis.
This genomewide screening can reflect a momentary picture of
global network of all transcriptional events in tumours
providing wide insight into the connections of the signalling
mechanisms driven in tumour cells. Patients and Methods:
cDNA microarray with 20.000 human gene specific
oligonucleotide was used to analyze benignant and early-stage
malignant thyroid tumours of epithelial origin: follicular
adenoma (n=8), follicular carcinoma (n=7) and papillary
carcinoma (n=10) compared to normal thyroid tissue (n=20).
Results: We compared microarray patterns of early-stage
thyroid tumours looking particularly not for significantly
modulated candidate genes, but a set of genes acting on similar
antiapoptotic and signalling pathway, and the ones showing
overlaps between the early-stage epithelial thyroid tumour
types. We identified significant expression differences of 258
genes- underexpression of 233 and overexpression of 25 genes
and focused on the overlapping genes between the different
histological types. Among these genes we found a limited set
acting on similar transcriptional pathways: through NF-κB and
PPARγ pathway. Conclusion: The role of overlapping genes in
histologically different tumours has not been clarified, but
might represent early or pivotal steps of carcinogenesis. All
investigated histiotypes of tumours contained significantly
modulated genes acting on NF-κB regulatory pathway. Our
findings suggest that modulation of NF-κB signalling plays
crucial role in early thyroid carcinogenesis.
233
FEEDING PURIFIED GLYCEROL FROM BIODIESEL
TO CBA/CA MICE: EFFECTS ON SINGLE STRAND
DNA DAMAGE INDUCIBLE GADD45Α AND NFKB
EXPRESSIONS
Szele1,
Katalin
Eszter
and István Ember1
Gombos1,
András
Kovács2
1University of Pécs, Faculty of Medicine, Institute of Public
Health, Pécs;
2KUKK, K+F Kft., Budapest, Hungary
Background: In the European Union the turn towards
renewable energy sources has increased the production of
biodiesel from rapseed oil (rapseed oil methyl ester) leaving
glycerol as a valuable by-product. Glycerol is a natural liquid
substance registered in the European Union as a feed additive
E422. Glycerol could become attractive for ruminants if the
amount of the by-product exceeds the capacities of the
pharmaceutical and chemical industries to process glycerol. In
the present situation glycerol purification is costy and it is
necessary to evaluate the final glycerol by-product of different
techniques and levels of purification. In our study we aimed
to evaluate a promising, neutralized, filtered and distilled
glycerol with acceptably high purity and with a methanol
content lower than 0.1% called SZME2. We investigated the
effect of this glycerol product on the expressions of DNA
damage inducible genes GADD45α and NFKB, in case it was
added to standard diet of CBA/CA mice, sensitive to
carcinogen exposure. Materials and Methods: 5-week-old
CBA/CA mice were administered SZME2 in the standard
chaw pellet with a glycerol concentration of 10% of diet dry
matter. Animals were given SZME2 fortified diet and tap
water ad libitum for 3, 6 and 24 hours. Control animals
consumed the standard chaw pellet and tap water. Liver, spleen
and bone-marrow of the animals were removed during
autopsy. Quantitative real-time PCR was carried out on
isolated total RNA. Gene expression alterations of GADD45α
and NFKB were calculated in HPRT percentage. Results: No
significant changes were seen in gene expressions of
GADD45α and NFKB in the liver and spleen at the three
timepoints of administration of SZME2 in the diet. However a
consequent and significant down-regulation of the two genes
was observed in the bone marrow in both gender. Conclusion:
Based upon our data we can not declare that methanol content
under 0.1% of purified glycerol byproducts of biodiesel
production have no effect on the homeostatic regulation at
molecular level. Our investigation underline the necessity of
animal carcinogenicity bioassay on large laboratory animal
population before introducing purified glycerol byproducts on
the market.
234
A PERSONALIZED APPROACH TO DETERMINE
PROGNOSTIC AND PREDICTIVE INDICATORS IN
BREAST CANCER WITH GENE EXPRESSION
PROFILING MICROARRAYS
Y. Gong1, K. Yan1, F. Lin1, K. Anderson1, C. Sotiriou2,
F. Andre3, F.A. Holmes4, V. Valero1, D. Booser1,
J.E. Pippen5, S. Vukelja6, H. Gomez7, J. Mejia1,
L.J. Barajas8, K.R. Hess1, N. Sneige1, G.N. Hortobagyi1,
L. Pusztai1 and W.F. Symmans1
1The University of Texas M.D. Anderson Cancer Center,
Houston TX, USA;
2Institut Jules Bordet, Brussels, Belgium;
3Institut Gustave Roussy, Villejuif, France;
4US Oncology-Texas Oncology, Houston, TX;
5US Oncology-Texas Oncology, Sammons Cancer, Dallas,
TX;
6US Oncology-Texas Oncology, Tyler Cancer Center, Tyler,
TX, USA;
7Instituto Nacional de Enfermedades Neoplásicas, Lima,
Peru;
3297
ANTICANCER RESEARCH 28: 3157-3556 (2008)
8Instituto
Mexicano del Seguro Social, Guadalajara, Jalisco,
Mexico
Background: Despite a considerable decline in the mortality
from breast cancer following systemic therapy, the biology of
breast cancer remains poorly understood. This is because that
the routinely-used clinicopathologic variables fail to fully
capture the biologic heterogeneity. Gene expression
microarrays may provide more sophisticate information than
conventional biomarkers in predicting disease outcome and
response to a specific systemic therapy on an individual basis.
However, whether ER and HER2 status, two important
biomakers, can be reliably measured from the comprehensive
microarray data is unclear. Methods: we used gene expression
data of 495 breast carcinomas to assess the correlation
between ER and HER-2 mRNA levels and clinical status of
these genes (as determined by immunohistochemical and/or
fluorescence in situ hybridization). Data from 195 fine-needle
aspiration (FNA) samples was used to define mRNA cutoff
values and the accuracy of these cutoffs was assessed in two
independent data sets: 123 FNA samples and 177 tissue
specimens (ie, resected or core-needle biopsied tissues).
Profiling was conducted at two institutions using the same
platform (the Affymetrix U133A GeneChip). All data were
uniformly normalised using dCHIP software. Results: ER and
HER-2 mRNA levels correlated closely with routine receptor
status measurements in all three data sets. Spearman’s
correlation coefficients ranged from 0.62 to 0.77. The defined
ER mRNA cutoff identified ER-positive status with the overall
accuracy of 88-96%; and the defined HER-2 mRNA cutoff
identified HER-2-positive status with the overall accuracy of
89-93%. Conclusion: ER and HER2 gene expression can be
reliably measured from the comprehensive microarray data.
Integration of ER and HER2 mRNA expression with
multigene signatures from the same microarray data may
refine and improve their predictive power. These findings may
represent an important step towards personalized treatment.
235
XRCC3 GENE POLYMORPHISM IN BLADDER
CANCER
Kamil Fehmi Narter1, Arzu Ergen1, Bedia Agachan1,
Umit Zeybek1, Uzay Gormus1,2 and Turgay Isbir1
1Istanbul
University, Institute for Experimental Medicine,
Department of Molecular Medicine, İstanbul;
2Istanbul Bilim University, Faculty of Medicine, Department
of Biochemistry, İstanbul, Turkey
Smoking is known to be one of the most important factors that
increases the risk of bladder cancer and it is thought to
damage DNA via free oxygen radicals. In this case, the repair
capacity of the DNA is important to protect from cancer.
3298
XRCC3 has roles in double-strand breaks repair of DNA, and
plays a role in maintaining chromosome stability. We aimed
to investigate XRCC3 gene polymorphism that cause
Thr241Met change in bladder cancer. There were 55 bladder
cancer patients and 39 control cases in our study. The
polymorphism analysis was performed by PCR-RFLP. It was
found that there was a significant difference in carrying T
allele of XRCC3 gene between patient and control groups. We
found that the T allele has 4.87 times protective capacity
against bladder cancer risk. Detailed investigations using
larger study groups, may allow the prognosis of patients to be
determined.
236
SERUM MYELOPEROXIDASE LEVEL AND GENE
POLYMORPHISM IN ENDOMETRIUM CANCER
Sibel Bulgurcuoglu Kuran1, Arzu Ergen1, Uzay Gormus1,2,
Bedia Agachan1, Umit Zeybek1 and Turgay Isbir1
1İstanbul
University, Institute for Experimental Medicine,
Department of Molecular Medicine, İstanbul;
2İstanbul Bilim University, Faculty of Medicine, Department
of Biochemistry, İstanbul, Turkey
Endometrial cancer is one of the most frequent types of
cancer of the female genital system. Increasing age, obesity,
hypertension and diabetes mellitus are known to be risk
factors in creating this cancer. It is also thought that free
radicals can activate inflamatory responses and with the
contribution of hypoxia, they can cause DNA damage.
Myeloperoxidase (MPO) is found in neutrophils and
monocytes and catalyses reactions to produce hypochlorous
acid, which is toxic to bacteria and is also a long-lived
oxidant that can lead to activation of some procarcinogens
causing damage to DNA. We aimed to investigate the levels
of MPO activity in endometrial cancer patients while also
determining whether the MPO gene polymorphism can
increase the tendency to create endometrial cancer or not.
There were 39 endometrial cancer patients and 39 control
cases. Serum MPO levels were measured by enzyme-linked
immunosorbent assay (ELISA) and MPO gene -463G/A
polymorphisms were determined by PCR-RFLP. MPO levels
were not significantly different between control and patient
groups. A allele carriers were significantly more frequent in
the patient group than in the control group (p=0.037) but no
difference existed in G allele carriers. MPO levels were
higher in the AA genotype patient group than other
genotypes, but there was no such significance in the control
group. Serum MPO levels were higher in the homozygote AA
genotype group. As MPO is an enzyme that causes
production of hypochlorous acid, our results show that this
activity increment in the AA genotype might contribute to the
increased tendency for endometrial cancer.
Abstracts of the 8th International Conference of Anticancer Research, 17-22 October 2008, Kos, Greece
237
MESENCHYMAL STEM CELLS DERIVED FROM
NON-SMALL CELL LUNG CANCER AND NORMAL
LUNG TISSUE DIFFER IN THEIR GENETIC
STABILITY, GENE EXPRESSION PROFILES, AND
FUNCTIONAL BEHAVIOR
Sandra Gottschling1, Anna Jauch2, Martin Granzow2,
Ruprecht Kuner3, Thomas Muley1, Elizabeth Chang Xu1,
Felix F.J. Herth1, Hans Hoffmann1, Hendrik Dienemann1,
Anthony D. Ho4, Michael Thomas1 and Michael Meister1
1Clinic
for Thoracic Diseases GmbH at University Hospital
Heidelberg, Amalienstr. 5, 69126 Heidelberg;
2Insitute for Human Genetics, University Heidelberg, Im
Neuenheimer Feld 366, 69120 Heidelberg;
3Division of Molecular Genome Analysis, German Cancer
Research Center, Im Neuenheimer Feld 280, Heidelberg;
4Department Medicine V, University Hospital Heidelberg, Im
Neuenheimer Feld 410, 69120 Heidelberg, Germany
Background: The stromal microenvironment plays a vital role
in induction and maintencance of solid tumors (1). Various
studies in prostate, breast, and ovarian cancer showed genetic
and functional alterations in the peritumoral stroma. However,
corresponding data in lung cancer are lacking (2). Here we
provide a systematic and comparative analysis of genetic and
functional properties of autologous non-small cell lung cancer
(NSCLC) and normal lung tissue (NLT) stromal cells with
special respect to mesenchymal stem cells (MSC). Methods:
Stromal cells derived from NSCLC specimens and
microscopically normal lung tissue of newly diagnosed lung
cancer patients were isolated and propagated in culture. Cells
were analyzed for their mesenchymal character by flow
cytometry and their osteogenic and adipogenic differentiation
potential. Genetic analyses were performed by multicolor
FISH. Gene expression was analyzed by Affymetrix HG U133
Plus 2.0-based arrays. The most differentially expressed genes
were confirmed by real-time PCR. Moreover, cells were
analyzed for growth kinetics and colony-forming capacity.
Chemosensitivity towards cisplatin was analyzed by annexin
V/propidium iodide, trypan blue stain, and colony forming
assays. Results: Compared to NLT, cell preparations derived
from NSCLC specimens were four-fold enriched in fibroblast
colony-forming units (CFU-f). In pure NSCLC-MSC cultures,
about twice as many CFU-f (5.5±1.2% vs. 2.8±0.8%) were
present than in NLT-MSC cultures. CFU-f in NLT-MSC
cultures declined significantly from passage 8 on whereas
CFU-f yield in NSCLC-MSC cultures remained stable over
several passages. This was in line with faster growth kinetics
and an up to 27-fold vs. 12-fold expansion of NSCLC-MSC
after 10 passages. NSCLC-MSC displayed a significantly
reduced cisplatin sensitivity, with a delayed onset of apoptosis
and a higher survival of CFU-f. M-FISH analyses of 5 paired
MSC preparations at passage 5 demonstrated polyploidy and
unbalanced translocations in NSCLC-MSC whereas NLTMSC showed either no genetic alterations or at best balanced
translocations, indicating a higher genetic stability. In line with
the functional differences, NSCLC-MSC showed a higher
expression of genes such as ENDOD1 (DNA repair), ANGPT1 (angiogenesis), MTP18 (antiapoptotic), and CD109
(primitive MSC marker) and a lower expression of genes such
as QSOX1 (fibroblast quiescence), SEMA3C (MSC ageing), or
C6orf32 (myogenic differentiation). Conclusion: NSCLC
specimens are enriched in genetically unstable primitive
mesenchymal cells with increased proliferative capacity and
reduced chemosensitivity to cisplatin. These cells might
modulate and sustain the cancerogenic process and affect the
response to chemotherapy.
1 Karnoub AE, Dash AB, Vo AP et al: Mesenchymal stem
cells within tumour stroma promote breast cancer
metastasis. Nature 449: 557-565, 2007.
2 Hill R, Song Y, Cardiff RD et al: Selective evolution of
stromal mesenchyme with p53 loss in response to epithelial
tumorigenesis. Cell 123: 1001-1011, 2005. Tuhkanen H,
Anttila M, Kosma V-M et al: Genetic alterations in the
peritumoral stromal cells of malignant and borderline
epithelial ovarian tumors as indicated by allelic imbalance
on chromosome 3p. Int J Cancer 109: 247-252, 2004.
ENDOD1: endonuclease domain containing 1, ANGPT-1:
angiopoietin-1, MTP18: mitochondrial protein 18 kDa,
QSOX1: quiescin Q6 sulfhydryl oxidase 1, SEMA3C: sema
domain, immunoglobulin domain (Ig), short basic domain,
secreted, (semaphorin), C6orf32: chromosome 6 open reading
frame 32, 3C
238
MOLECULAR PATHOLOGY OF LOBULAR BREAST
CANCER
Anna Goussia
Department of Pathology, Medicine School, University of
Ioannina, Ioannina 45110, Greece
Lobular breast cancer, in situ (LCIS) and invasive (ILC), is a
distinct subset of tumors, based on morphology, genetics and
biology. Morphologically, LCIS and ILC are characterized by
a proliferation of uniform, loosely cohesive cells with mild
nuclear atypia. Cytogenetic studies have shown that LCIS and
ILC have relatively low numbers of changes compared with
ductal breast cancer. Moreover, the molecular genetic profiles
of LCIS and ILC are similar, suggesting the common clonality
of the lesions and the precursor role of LCIS.
The main features of lobular malignancies are gain of 1q,
loss of 16q and loss or down-regulation of E-cadherin. Loss
or down-regulation of E-cadherin occurs by a combination of
loss of heterozygosity, gene mutation or promoter silencing
3299
ANTICANCER RESEARCH 28: 3157-3556 (2008)
leading to inactivation of the gene and it is manifested in
routine histology practice by immunonegativity for Ecadherin. The E-cadherin negativity has been used as a
diagnostic feature of lobular carcinomas. Since some ductal
carcinomas may also be E-cadherin negative, either totally or
partially, E-cadherin immunonegativity must be interpreted
with caution, taking into account the overall morphological
context. Loss of E-cadherin function is thought to contribute to
the histological appearance of lobular breast cancer, i.e. lack of
cohesive architecture with single cells invading through the
stroma, ability of metastatic spread to serosal cavities. Other
distinctive but not unique molecular features of lobular breast
cancer are EGFR1, HER2/neu and cyclin D1 negativity or
absence/rarity of amplification of the above genes as well as
ER and PR positivity.
Recently, a pleomorphic variant of lobular carcinoma (PLC)
has been described. In pleomorphic LCIS and ILC, neoplastic
cells display several of the histological and molecular features
associated with classic lobular carcinomas but exhibit more
conspicuous nuclear atypia and pleomorphism and in addition,
they frequently show apocrine differentiation. Although
molecular data are limited, it is apparent up to now that PLC
have overlapping genetic characteristics with those of classic
lobular carcinomas (1q+/16q-/11q-, E-cadherin negative, Ecadherin mutation) and those of high grade ductal carcinomas
[p53 stabilization, HER2/neu overexpression, gain of 8q, gain
of 17q24-q25, loss of 13q and amplification of 8q24 (MYC),
12q14 (MDM2), 17q12 (HER2/TOPO2A) and 20q13
(ZNF217)]. Therefore, PLC seem to evolve along a similar
molecular pathway to the classic lobular carcinoma, but
moreover, have a high grade phenotype through molecular
changes associated with high grade ductal carcinoma.
Molecular alterations found in PLC, that are typical of high
grade tumors, are likely to drive the more aggressive biology
of PLC.
239
TARGETING THE EUKARYOTIC TRANSLATION
INITIATION FACTOR 4E (EIF4E) FOR CANCER
THERAPY
Jeremy R. Graff
Eli Lilly and Company, Indianapolis, IN, 46285, USA
Eukaryotic Translation Initiation Factor 4E (eIF4E) plays a
pivotal role in cellular mRNA translation, binding the cap
structure at the 5’ end of cellular mRNAs and delivering these
mRNAs to the eIF4F translation initiation complex. A
substantial body of evidence has accumulated in the past 18
years implicating enhanced eIF4E activity in cellular
transformation, tumorigenesis and metastatic progression. In
human cancers, eIF4E expression is commonly elevated with
disease progression in many tumor types including
3300
lymphomas as well as cancers of the head and neck, breast,
colon, bladder and lung. We now show that eIF4E activation is
universally and significantly increased in human and
experimental prostate cancers. In human cancers, elevated
eIF4E activation is significantly associated with reduced
patient survival.
In experimental models, eIF4E overexpression can drive
cellular transformation, tumorigenesis, invasiveness and
metastases by selectively and disproportionately enhancing the
translation of select mRNAs that code for the critical proteins
that promote and sustain the phenotypes necessary for
malignancy-uncontrolled growth (c-myc, cyclin D1),
angiogenesis (VEGF), survival (BCL-2, survivin), and
invasion (MMP-9). In addition, eIF4E overexpression
facilitates autocrine growth and survival via activation of both
the ras and AKT signaling pathways. Reduction of eIF4E
expression in highly metastatic, ras-transformed experimental
cancer models effectively blocks tumor growth and
invasiveness as well as spontaneous and experimental
metastasis, suppressing the expression of MMP-9, CD44v6
and ODC and restoring expression of the metastasis
suppressor nm-23. These data clearly implicate eIF4E as an
attractive anticancer therapeutic target.
Exploiting advances in antisense oligonucleotide (ASO)
chemistry, we have developed eIF4E-specific ASOs with the
tissue stability and nuclease resistance necessary for systemic,
anticancer therapy. These ASOs specifically target the eIF4E
mRNA for RNAse-H mediated destruction, repressing
expression of eIF4E and the eIF4E- regulated proteins VEGF,
cyclin D1, survivin, c-myc, and Bcl-2. In multiple human
cancer cell lines, the 4EASO robustly induces apoptosis
independent of cell cycle phase and, in endothelial cells,
directly blocks the formation of vessel-like structures. Most
importantly, intravenous administration selectively and
significantly reduces eIF4E expression in human tumor
xenografts, significantly suppressing tumor growth. As in
cultured cells, systemic 4EASO administration significantly
induced apoptosis in xenograft tissue (8X vs. control) and
significantly reduced the number of Ki-67 + cells within the
xenograft tumors as well. Because these ASOs also target
murine eIF4E, we assessed the impact of eIF4E reduction in
normal tissues. Despite reducing eIF4E levels by 80% in
mouse liver, eIF4E-ASO administration did not affect body
weight, organ weight or liver transaminase levels.
Collectively, these data therefore provide the first direct, in
vivo evidence that tumor tissues would be more sensitive to
the effects of eIF4E inhibition than normal tissues, a
differential effect consistent with the conceptual
understanding that eIF4E activity is elevated in, and required
by, tumor tissue to sustain the expression of key growth and
survival factors that contribute to malignancy. These data have
now prompted eIF4E-ASO clinical trials for the treatment of
human cancers.
Abstracts of the 8th International Conference of Anticancer Research, 17-22 October 2008, Kos, Greece
240
FOLLOW-UP STUDY OF PATIENTS WITH A NEW
DIAGNOSIS OF GLIOBLASTOMA MULTIFORME
TREATED WITH TEMOZOLOMIDE AND
THALIDOMIDE
A. Gramaglia1, E. Novelli2, A. Ravasio1, S. Nava1,
F. Mattana1, M. Mapelli1, C. Bassetti1, V. Cerreta1
and G.F. Baronzio1
1Department of Radiation Oncology and Medical Physics,
Policlinico di Monza;
2Department of Biostatistics, Gruppo Policlinico di Monza,
Italy
Objective: The chemotherapeutic agent temozolomide and
the antiangiogenetic agent thalidomide have both
demonstrated antitumor effects in patients with glioblastoma
multiforme (GBM). The objective of the study was to
determine if the combined strategy of temozolomide and
thalidomide with radiotherapy is associated with an
improved median survival. The efficacy and tolerability of
temozolomide alone and in combination with thalidomide
were explored in a single-institution 13 years experience.
Methods: From April 1993 to May 2006, one hundred and
seventy patients with GBM underwent microsurgical tumor
extirpation and radioterapy: 82 (48.2%) patients received no
additional treatment (C), in 42 (24.7%) patients
temozolomide was given alone (T) and 46 (27.1%) patients
had a combined chemotherapy of temozolomide and
thalidomide (TT). Radiotherapy parameters were a dose of
45 Gy delivered in 2.5-3 Gy fractions over 3-4 weeks,
followed by a boost dose of 20 Gy delivered in 4-5 Gy
fractions in 1 week. Temozolamide was administered starting
at the end of radiotherapy with a dose of 200 mg/m2 daily
for 5 days, every 4 weeks. Thalidomide was started at the
end of radiotherapy with a dose of 20 mg and escalated by
20 mg every week depending on patient tolerance, to a
maximum of 100 mg daily. Results: Median survival, starting
from the first radiotherapy, was 54 weeks (95% CI, 50-58
weeks) in C-patients, 83 weeks (95% CI, 36-130 weeks) in
T-patients and 86 weeks (95% CI, 65-106 weeks) in TTpatients. Compared to the C-patients, the median survival of
those who received temozolomide alone or in combination
with thalidomide was 86 weeks (95% CI, 70-102 weeks),
with a significant improvement in survival outcome (logrank=6.613, p=0.010) (Figure). Temozolamide and
thalidomide were well tolerated and only mild to moderate
toxicities were observed. Conclusion: The strategy of
combining temozolomide, thalidomide and radiotherapy in
the treatment of GBM appears to be well tolerated and with
favourable survival outcome. The addition of thalidomide in
association with temozolamide does not offer a significant
advantage over temozolamide alone.
Figure. Kaplan-Meier estimates of overall survival from time
of first radiotherapy for patients with temozolomide alone or
in combination with thalidomide (solid line) and patients with
no additional treatment (dotted line).
241
INCREASED SURVIVAL IN GLIOBLASTOMAS AND
ANAPLASTIC ASTROCYTOMAS TREATED WITH
CONFORMAL RADIOTHERAPY AND
HYPERTHERMIA
Gianfranco Baronzio1, Vincenzo Cerreta1, Chiara Bassetti1,
Marco Mapell1, Alessandro Romorini2
and Alberto Gramaglia1
1Radiotherapy and Hyperthermia Department, Policlinico di
Monza, Via Amati 111, Monza;
2Neurology Unit, Magenta Hospital, Magenta (Mi), Italy
Introduction: Malignant gliomas and astrocytomas represent a
class of aggressive neoplasms that are generally resistant to
conventional therapies. The basic approach to treatment
involves a combination of surgery, radiotherapy and
chemotherapy. Among chemotherapeutic agents Nitrosoureas
(CCNU) and Temozolomide (TMZ) have a certain activity
against gliomas and astrocytomas. Recently, TMZ was
demonstrated to be well tolerated and active as a single agent
or in combination with radiotherapy. The median survival
time for high grade gliomas is 10-12 months and the
prognosis is dismal. New therapeutic approaches are justified.
Several studies in vitro on glioblastomas have demonstrated
that hyperthermia plus chemotherapy has a higher
cytotoxicity than chemotherapy alone. Furthermore, heat has
a cytotoxic effect by itself and an anti-vascular effect. This
3301
ANTICANCER RESEARCH 28: 3157-3556 (2008)
last effect is of outmost importance due to the high
neoangiogenesis present in these tumors. Patients and
Methods: Between January 2001 and April 2008, 29 patients
with aggressive brain tumors [11 glioblastomas (GBM), 14
astrocytomas (6 AstroIV, 8 Astro II degree, 1
Oligoastrocytoma), 2 ependymomas and 1 medulloblastoma]
have been treated with conformal radiotherapy (CRT),
chemotherapy and hyperthermia (HT). Twenty five of these
patients (11 GBM and 14 astrocytoma) (9F, 16M; median age
44.6±9.85) have been treated with the CFRT + TMZ + HT
and were eligible to be compared with a group of 27 patients
with 18 GBM and 9 astrocytomas (12F, 15 M median age
50.93±13.9y) treated with CFRT and TMZ alone. All the
patients of the two groups have been resected and later treated
with CRT + TMZ or HT. HT was administered using a
Synchrotherm radiofrequency (RF) device developed by
DUER®, Vigevano, Italy. It consists of the following
components: 1) a RF generator (13.56 MHz) 2) a pair of
mobile plates or electrodes with independent superficial
cooling system, 3) a heat exchanger, 4) a computerized
control console. A thermal profiles to obtain a probable
deposition of the energy were obtained by heating patterns
produced in a static phantom under various conditions. The
25 patients were treated combining chemotherapy,
radiotherapy and hyperthermia with the following sequence.
HT was applied 2 h after CRT administration, and the patients
used orally 120 mg of CCNU two hs prior HT or a median
dose of 200 mg of temozolomide (TMZ). BCNU or TMZ was
administered once per HT cycle, generally at the first
application. A complete cycle of HT consisted of five
applications, applied every 48 hs. Four mg of e.v.
dexamethasone was started 1/2h before HT administered in
the hypertonic solution of glucose 10% 500cc that lasted for
all the treatment period (60’). Results: The group of patients
treated with CFRT+TMZ+HT showed a significant increase
in life survival (p<0.001) (Figure 1) and patients in followup of HT group were also over the median life survival versus
17.89±10.56 months of patients treated only with CRT +
TMZ (p<0.01). 60% of the patients treated with
CFRT+TMZ+HT were alive at 20 months. 36% of them had
a life survival of more than 27 months. Comparing the entire
group treated with HT versus CRT+TMZ the survival curve is
even better (Figure 2). Conclusion: The life prolongation is
clinically significant and these results suggest that effective
HT may soon become a standard therapy associated to
chemotherapy and radiotherapy for glioblastomas and
astrocytomas. Notwithstanding these positive results we think
necessary to increase the number of patients treated with
hyperthermia, to produce a randomized study and to verify
the possible side-effects of hyperthermia. Furthermore, we
think useful to use a predictive method to verify the heat
deposition since normally heat is not easily detected inside
the brain like in other structures.
3302
Figure 1. Comparison of survival curves between patients
treated with conformal radiotherapy plus CCNU/ TMZ (CRT+
CCNU/TMZ) and patients treated with CRT plus CCNU/ TMZ
and capacitive hyperthermia (CRT+ CCNU/ TMZ + HT).
Figure 2. Comparison of survival curves between patients
treated with Conformal radiotherapy plus CCNU/ TMZ (CRT+
CCNU/TMZ) and all patients treated with CRT plus CCNU/
TMZ and capacitive hyperthermia (CRT+ CCNU/ TMZ +
HT).
242
DIACYLGLYCEROL KINASE ALPHA IS REQUIRED
FOR PROLIFERATION AND INVASION INDUCED
BY GROWTH FACTORS AND CHEMOKINES
Paolo E. Porporato, Elena Rainero, Federica Chianale,
Gabriella Ranaldo, Gema Tur Arlandis, Irene Locatelli,
Gianluca Baldanzi, Nicoletta Filigheddu, Sara Traini,
Miriam Gaggianesi and Andrea Graziani
Department of Clinical and Experimental Medicine,
Università del Piemonte Orientale A.Avogadro, Novara, Italy
Abstracts of the 8th International Conference of Anticancer Research, 17-22 October 2008, Kos, Greece
Diacylglycerol kinase enzymes (Dgks) convert diacylglycerol
(DG) into phosphatidic acid (PA), thus acting as molecular
switch between DG- and PA-mediated signalling. We
previously showed that activation of Dgkα is required for
growth factor-induced cell migration and proliferation through
a mechanism involving formation of a complex with Src and
(Cutrupi et al., EMBO J 2000; Baldanzi et al. Oncogene,
2004; Bachiocchi et al. Blood 2005; Baldanzi et al., Oncogene
2008). Moreover we showed that in epithelial cells, Dgkα is
required for HGF-induced membrane ruffling, and regulates
membrane targeting and activation of Rac (Chianale et al. Mol
Biol Cell, 2007).
These data suggest that DGKα may play a role in the
acquisition of an invasive phenotype. In order to set up an
experimental system to investigate the role of DGKα in
tumor progression in vitro and in vivo, we developed a
lentiviral vector for shRNA-mediated constitutive knock
down of DGKα. LV-shRNA-mediated down-regulation of
DGKα in highly tumorigenic and metastatic MDA-MB231 cells breast cancer cells results in the 60-70%
reduction of serum-sustained cell proliferation, as well as
inhibition of EGF-induced DNA synthesis. Expression of
murine DGKα, resistant to human shRNA, rescues cell
proliferation of MDA-MB-231, demonstrating that the
proliferative defect is specifically dependent on DGKa
expression.
In addition, shRNA-mediated knock-down of DGKα
strongly impairs HGF- and SDF-1α- induced cell invasion in
a 3D matrix and secretion of matrix gelatinases. The
specificity of this effect is confirmed by the full rescue of
invasive response to HGF and SDF-1α upon expression of
shRNA-resistant murine DGKα. Furthermore, the signalling
pathways by which DGKa regulates cancer cell invasive
behaviour have been also investigated.
These data strongly suggest that DGKα plays a previously
unrecognized pivotal role in tumor progression of breast
carcinomas in vitro.
243
ANTIPROLIFERATIVE EFFECT OF DGLUCURONYL C5-EPIMERASE TO HUMAN
BREAST CANCER
T. Eshchenko1, N. Domanitskaya1, T. Pavlova2,3,
V.I. Kashuba2,4, G.I. Nepomnyashchikh5,
S.V. Aidagulova3, E.R. Zabarovsky2,3 and E.V. Grigorieva1,2
1Institute
of Molecular Biology and Biophysics, SD RAMS,
Novosibirsk, Russia;
2Karolinska Institute, MTC, Stockholm, Sweden;
3Institute of Molecular Biology, Moscow, Russia;
4Institute of Molecular Biology and Genetics, Kiev, Ukraine;
5Institute of Regional Pathology and Pathomorphology SD
RAMS, Novosibirsk, Russia
Introduction: D-glucuronyl C5-epimerase (GLCE) is one of
the key enzymes in biosynthesis of heparan sulfates – the
polysaccharide part of heparan sulfate proteoglycans (HSPG)
located on the cell surface and in the extracellular matrix.
HSPGs play important roles in cell adhesion, differentiation,
and growth and alterations in their structure/composition may
have important consequences on tumour invasion and
metastasis. Thus, GLCE could be involved in any processes
where appropriate heparan sulfate structure is important.
Materials and Methods: D-glucuronyl C5-epimerase
expression in different human normal tissues and breast
tumours was estimated by multiplex and qreal-time RT-PCR.
For a functional study, GLCE was cloned into the vectors
pETE/Bsd and pCEP4 for expression in mammalian cells. The
effect of the restoration of GLCE expression on cell
proliferation in vitro was investigated for breast cancer cell
line MCF7 using CyQUANT NF Proliferation Assay. Results:
It was shown that GLCE gene was expressed mainly in human
breast and lung tissues, with less expression in thyroid, thymus
and kidney. The significant down-regulation of epimerase
expression was detected in human breast tumours. A
restoration of D-glucuronyl C5-epimerase expression in the
breast cancer cells suppressed their proliferation in vitro.
Conclusion: The obtained results represent the first data about
the possible antimitotic activity of D-glycuronyl C5-epimerase
in breast cancer cells. A decrease of the epimerase expression
in different types of cancer and its ability to suppress the
proliferation of tumour cells reveal D-glycuronyl C5epimerase as a potential new marker and target for cancer
diagnosis and treatment.
This work has been supported by a Russian Foundation for
Basic Research (08-04-00866a); Karolinska Institute; UICC
International Cancer Technology Transfer Fellowship (EG)
and FEBS Fellowship (TE).
244
PROSPECTIVE COHORT COMPARISON OF
FLAVONOID TREATMENT
IN PATIENTS WITH RESECTED COLORECTAL
CANCER TO PREVENT RECURRENCE
Harald Hoensch1, Bertram Groh2, Lutz Edler3
and Wilhelm Kirch2
1Marienhospital
Darmstadt, Martinspfad 72, Darmstadt D64285;
2Department of Clinical Pharmacology, Medical Faculty,
Technical University Dresden, Fiedlerstr. 27, Dresden D01307;
3German Cancer Research Center, Division of Biostatistics,
Im Neuenheimer Feld 280, Heidelberg D-69120, Germany
Aim: To investigate biological cancer prevention with
flavonoids. The recurrence risk of neoplasia was studied in
3303
ANTICANCER RESEARCH 28: 3157-3556 (2008)
patients with resected colorectal cancer and after adenoma
polypectomy. Methods: Eighty-seven patients, 36 patients with
resected colon cancer and 51 patients after polypectomy, were
divided into 2 groups. One group was treated with a flavonoid
mixture (daily standard dose 20 mg apigenin and 20 mg
epigallocatechin-gallate, n=31) and compared with a matched
control group (n=56) without flavonoid intervention. Both
groups were observed for 3-4 years by surveillance
colonoscopy and by questionnaires. Results: Of 87 patients
enrolled in this study, 36 had resected colon cancer and 29 of
these patients had surveillance colonoscopy. Among the
flavonoid-treated patients with resected colon cancer (n=14),
there was no cancer recurrence and only one tubular adenoma
developed. In contrast, the cancer recurrence rate of the 15
matched untreated controls was 20% (3 out of 15), and
adenomas (including 2 advanced adenomas) evolved in 4 of
those patients (27%). The combined recurrence rate for
neoplasia was 7% (1 out of 14) in the treated patients and 47%
(7 out of 15) in the controls (p=0.027). Among the 51
polypectomized adenoma patients, 17 had surveillance
colonoscopies (8 treated and 9 controls) and their adenoma
recurrence rate was 50% in the treated and 30% in the control
group. However, 2 incident adenomas with advanced histology
were found in the untreated patients. Conclusion: Sustained
long-term treatment with a flavonoid-mixture could reduce the
recurrence rate of colon neoplasia in patients with resected
colon cancer.
245
SERUM LEPTIN LEVELS IN COLORECTAL
CANCER PATIENTS
F. Guadagni1, M. Roselli2, A. Spila1, R. D’Alessandro1,
I. Lucci1, L. Polce1, V. Formica2, A. Laudisi2, I. Portarena2,
R. Palmirotta1 and P. Ferroni1
1Department
of Laboratory Medicine and Advanced
Biotechnologies, IRCCS San Raffaele Pisana, Rome;
2Medical Oncology, Department of Internal Medicine,
University of Rome “Tor Vergata”, Rome, Italy
Background: Recent studies have indicated that some
adipokines may significantly influence the growth and
proliferation of tumor stroma and malignant cells within.
Leptin, a product of the ob gene involved in the control of food
intake and energy expenditure, may act as a potent mitogen and
anti-apoptotic cytokine in colon cancer. Epidemiological
studies have suggested that leptin is correlated with the risk of
colorectal cancer (CRC) associated with obesity, the
association being independent of body mass index (BMI), waist
circumference and physical activity. Hence, increased leptin
plasma levels were found in CRC patients. It is well known
that tumor cells and/or tumor-associated leukocytes may
produce inflammatory cytokines, in particular TNF-alpha.
3304
Circulating levels of this cytokine have been associated with
the disease status of CRC patients. Recently, it has been
demonstrated that TNF-alpha administration induced a prompt
and dose-dependent increase in serum leptin levels. Thus, aim
of this study was to evaluate the possible associations between
leptin, TNF-alpha and clinicopathological variables of CRC
patients at time of diagnosis of primary tumor. Moreover, a
follow-up study was performed to analyze the possible
prognostic value of pre-surgical leptin levels in patients with
CRC. Methods: Baseline serum leptin (DBC Inc.) TNF-alpha
(R&D Systems) and carcinoembryonic antigen (CEA, Abbott
Labs.) levels were analyzed in 90 patients with histologically
diagnosed primary (Stages A: 7, B: 34, C: 19 and D: 13, with
a single resectable liver metastasis) or metastatic (liver: 8,
peritoneum: 5, lung: 1 and multiple: 3) CRC treated at “Tor
Vergata” Clinical Centre and followed for a median period of 3
years. As control group, in a 3:1 ratio, 30 control subjects (13
males, 17 females; mean age 59±12, ranging from 37 to 80
years) were also evaluated. The study was performed under the
appropriate ethics approvals, and informed consent was
obtained from each patient. Results: Serum leptin levels were
higher in CRC patients [median (IQR): 8.8 (3.7-17.6) ng/ml]
than control subjects [1.1 (0.3-3.8) ng/ml, p<0.0001].
Similarly, median TNF levels were higher in CRC patients [8.2
pg/ml] than control subjects [0.2 pg/ml, p<0.001]. Leptin
directly correlated with TNF levels (Rho=49, p<0.001).
Median leptin (10.9 ng/ml) levels of metastatic CRC were
higher than those of primary CRC patients (7.7 ng/ml,
p=0.034). Of interest, 47% of non metastatic CRC had leptin
levels above the median compared with 71% of metastatic
patients (p=0.07). Median follow-up of metastatic CRC
patients was shorter (12.6 months) in patients with high leptin
levels compared to those with normal levels (21.7 months,
p=0.07). Cox proportional hazard regression model including
age, sex, leptin, TNF and CEA levels showed that leptin was
an independent predictor for overall survival in metastatic CRC
(Cox-Mantel test 2.03, p=0.042). Conclusion: These results
suggest that serum leptin levels might have a role in the
biology of CRC and may be regarded as a useful prognostic
indicator in patients with metastatic disease.
Partially supported by Grant “Alleanza contro il Cancro” by
the Italian Ministry of Health
246
PRL-3 EXPRESSION AND TUMOR BUDDING IN
COLORECTAL CANCER
Katarzyna Guzińska-Ustymowicz
Departement of General Pathomorphology, ul.Waszyngtona
13, 15-889 Białystok, Poland
Background: Colorectal cancer is one of the most common
types of cancer in Western countries including Poland. The
Abstracts of the 8th International Conference of Anticancer Research, 17-22 October 2008, Kos, Greece
mortality from colorectal cancer is ranked as the second in
Western countries, and third in Poland, amongst all types of
cancer. Recent studies concerning the prognostic factors in
colorectal cancer have paid attention to tumor budding as a
potential prognostic factor. Morodomi et al. defined tumor
budding as either bundles of five or more cancer cells
occurring in a well-differentiated region (mainly the actively
invasive area), showing tubular structures, which were
classified as microtubular cancer nests, or isolated cancer cells
without a distinct structure, which were classified as
undifferentiated cells (1). Several published studies have
indicated that tumor budding is associated with metastasis in
colorectal cancers (2-4). PRL-3 is a newly discovered protein
tyrosine phosphatase which would also degrade the
extracellular matrix and was expressed in liver metastases
derived from colorectal cancer. In this study, we investigated
the relationship between tumor budding at the invasion front of
colorectal cancer and expression of PRL-3 in the main mass of
tumor, buds, lymph nodes and liver metastases. Patients and
Methods: The samples were obtained from 49 selected
patients with colorectal cancer, 20 adjacent normal epithelial
(at least 5 cm distant from the tumor edge), 24 lymph node
metastases, and 10 liver metastases were obtained from the
Department of Pathomorphology, Medical University of
Bialystok. Monoclonal antibody, Clone 3B6, against PRL-3
(Attogen Biomedical Research, USA) was used for
immunohistochemistry. Results: Statistical analysis showed a
correlation between tumor budding and lymph node
metastasis. PRL-3 protein expression was observed in 1 out of
20 (5%) normal colorectal epithelia, 9 out of 49 (18.3%)
primary colorectal cancer, 22 out of 24 (91.6%) lymph node
metastasis and 9 out of 10 (90%) liver metastases, respectively.
Conclusion: These results suggest that high PRL-3 expression
may participate in the progression and metastasis of colorectal
cancer.
1 Morodomi T, Isomoto H, Shirouzu K et al: An index for
estimating the probability of lymph node matastasis in rectal
cancers. Lymph node metastasis and the histopathology of
actively invasive regions of cancers. Cancer 63: 539-543,
1989.
2 Guzińska-Ustymowicz K: The role of tumor budding at the
front of invasion and recurrence of rectal carcinoma.
Anticancer Res 25: 1269-1272, 2005.
3 Zlobec I and Lugli A: Prognostic and predictive factors in
colorectal cancer. J Clin Path 61: 561-569, 2008.
4 Kanazawa H, Mitomi H, Nishiyama Y et al: Tumor budding
at invasive margins and outcome In colorectal cancer.
Colorectal Dis 10: 41-47, 2006.
247
BEAMCATH® APPLICATION OR
CONFORMAL TECHNIQUE IN
RADIOTHERAPY IN EARLY-STAGE
PROSTATE CANCER? BLADDER AND RECTUM
TOXICITY
Solveig Hanssen
Department of Oncology, Section of Radiotherapy, University
Hospital of North Norway, Tromsø, Norway
The aim of this study was to examine the toxicity of two
external radiotherapy regimens employed in early-stage
prostate cancer at the University Hospital of North Norway
(UNN). During the last decade, the incidence of prostate
cancer in Norway has been rising steadily, and a trend from
surgery to radiotherapy in early-stage disease has been
observed. In 1997, a new technique was developed in Sweden
aiming to reduce the side-effects of radiotherapy. This
technique utilises a special catheter, BeamCath®, to achieve a
more accurate determination of the position of the prostate,
and allow an increase in dosage. All ninety men who had
undergone radiotherapy for early-stage prostate cancer at the
Department of Oncology, UNN, in the time period February
2002 to March 2005, were included in a retrospective
questionnaire based study. Eighty patients responded, and
were divided into two treatment regimens. The “treatment
group” (23 patients) had received 76 Gy with BeamCath®
regimen and the “control group” (57 patients) had received 70
Gy employing a conformal technique. The patients were
interviewed by telephone and six selected questions from
validated questionnaires were used to clarify bladder, intestinal
and sexual function. The BeamCath® technique was found to
be associated with a lower median rectal (p=0.004, 50.6 Gy
versus 56.2 Gy) and bladder dose (p=0.017, 48.5 Gy versus
61.5 Gy). There were no difference in scores on masculinity
and sexuality function. In conclusion, this retrospective study
indicates that dose escalation up to 76 Gy employing the
BeamCath® catheter technique does not influence either rectal
or bladder toxicity, compared with conformal technique of 70
Gy.
248
SPECIFIC NUTRIENT SYNERGY IN THE
TREATMENT OF LEUKEMIA
S. Harakeh1,2, J. Khalife1, M. Diab-Assaf1,
E. Baydoun1, A. Niedzwiecki2 and M. Rath2
1Biology
Department, American University of Beirut, Beirut,
Lebanon;
2Dr. Rath Research Institute, Santa Clara, CA, USA
The effects of a specific nutrient synergy (SNS), consisting
of a combination of antioxidants, vitamins and amino-acids
(three of its major components being ascorbic acid (AA),
epigallocatechin gallate (EGCG) and L-lysine) were
investigated on proliferation and induction of apoptosis
3305
ANTICANCER RESEARCH 28: 3157-3556 (2008)
using non-cytotoxic concentrations against HTLV-I-positive
and -negative malignant T-cells. In addition, the effects of
SNS, AA, EGCG and L-lysine were evaluated on the
activity, transcriptional and translational levels of the two
important gelatinases, metalloproteinases-2 and -9, as well
as on the NF-κB pathway and Tax production in HTLV-Ipositive cell lines. The results indicated that the SNS had a
more potent anti-proliferative effect than its individual
ingredients and more pronounced induction of apoptosis in
both HTLV-I-positive and -negative malignant T-cells. The
SNS also inhibited extravasation by significantly downregulating MMP-2 and -9 activity, production and
expression as was shown by zymography, Western blotting
and RT-PCR. Moreover, the SNS inhibited the translocation
of the p65/p50 subunits to the nucleus in a dose-dependent
manner as well as Tax production in HTLV-I-positive
malignant T-cell lines.
In conclusion, the results indicate that the SNS could
constitute a potential anti-invasive treatment in adult T-cell
leukemia and related diseases. Based on the effectiveness of
the SNS in targeting common critical mechanisms involved in
cancer and its minimal cell toxicity, as compared to
pharmaceutical drugs, clinical investigations are highly
recommended.
249
THE ANTIOXIDANT AND ANTI-PROLIFERATIVE
ACTIVITY OF ORIGANUM MAJORANA
AND OLEA EUROPEA EXTRACTS
USING LEUKEMIC CELL LINES
R.M. Abdel-Massih1, R. Fares1, E. Baydoun2
and S. Harakeh3
1Department
of Biology, University of Balamand, Al-Koura;
of Biology, American University of Beirut,
Beirut, Lebanon;
3Dr. Rath Research Institute, Santa Clara, CA 95050, USA
2Department
Plant extracts from Origanum majorana and Olea europea
were evaluated for their antiproliferative and antioxidant
effects using human T-lymphoblastic leukemia cell lines
(CEM and Jurkat). Cytotoxicity of various concentrations of
plant extracts were examined using non-radioactive
cytotoxicity assay and the IC50 was calculated. Olive leaves
were found to be more cytotoxic than majoram since they have
lower IC50. At noncytotoxic concentrations, the viability of
cells decreased with the increase in concentration of plant
extract as determined by the WST-1 proliferation kit. The
antiproliferative effect was further analyzed using the [3H]thymidine incorporation method and was dose dependent. To
investigate whether cell death was due to apoptosis, cells were
stained with annexin V-FITC and PI. Flow cytometry showed
that majoram and olive leaves extracts induced apoptosis. The
3306
antioxidant activity of plant extracts was studied using the
DPPH scavenging method. Majoram (IC50=0.03 mg dry
weight) exhibited a stronger scavenging activity than olive
leaves (IC50=0.1 mg dry weight).
The conclusions from this study suggest that majoram and
olive leave extracts exhibit antiproliferative effect on
malignant T-cells and have a high antioxidant activity. For that
they merit further investigation as a potential therapeutic
agent.
250
ANGIOGENESIS VERSUS
LYMPHANGIOGENESIS IN LUNG
CANCER; A CRASH TEST DEFINING
THE BEGINNING OF A NEW ERA
Georgia Hardavella2,4, Evdokia Arkoumani1,
Yiotanna Dalavanga3, Stavros H. Constantopoulos2
and Dimitrios Stefanou1
1Department
of Pathology, University of Ioannina, Medical
School, Ioannina;
2Department of Pneumonology, University of Ioannina,
Medical School, Ioannina;
3Department of Anatomy, Histology and Embryology,
University of Ioannina, Medical School, Ioannina;
4Respiratory Medicine Department, Medical School, Athens
University, Athens, Greece
Introduction: Tumor angiogenesis is a highly regulated
process influenced by the host microenvironment and
mediators. VEGF and its receptors (VEGF-R1-Flt-1, VEGFR2-KDR/Flk-1) are good markers of vascular proliferation
but their expression and relevance to tumor spread and their
correlation with lymphangiogenesis and patient outcome in
lung carcinomas is yet to be defined. Aim: To investigate the
expression of angiogenesis and lymphangiogenesis in lung
carcinomas (non small cell-NSCLC and small cell-SCLC),
to study their interrelationship and prognostic influence and
to compare it with other carcinomas studied in the literature.
Materials and Methods: One hundred and forty six patients
with lung carcinoma (96 NSCLC and 50 SCLC) were
rectospectively reviewed. Tumor specimens were stained for
VEGF and CD105 (DBS California-Menarini Hellas). VEGF
expression, intratumoral lymphatic microvessel density
(ILMVD) and lymphatic invasion were determined and
thorough study of inpatient medical records followed.
Results: VEGF and CD105 expression were significantly
associated with the basic histological type of lung neoplasms
(df=2, p=0.002 and p=0.04 for NSCLC and SCLC
respectively). High ILMVD was detected in 37/50 SCLC and
in 84/96 NSCLC. In NSCLC, VEGF-R1-Flt1 and VEGF-R2Flk1 were associated with the stage (p=0.026, p=0.005) and
the latter was also associated with metastasis (p=0.021).
Abstracts of the 8th International Conference of Anticancer Research, 17-22 October 2008, Kos, Greece
Significant association was found between CD105 and the
stage of the disease (NSCLC x2=19,5, p=0.003 and SCLC
x2=8,4, p=0.004). CD105 expression was also associated
with the presence of metastasis in both NSCLC (p=0.003)
and SCLCs (p=0.05). In contrast, no significant correlation
was assessed between VEGF and the clinical parameters
mentioned above in both SCLC and NSCLC. Conclusion:
There is a direct association between VEGF and
lymphangiogenesis in NSCLC. SCLCs present a
comparatively lower VEGF expression and increased
lymphangiogenesis, thus displaying a different behavioral
pattern. CD105 expression is strongly associated with the
clinical parameters studied and could be capable of
constituting a significant prognostic role in the overall aspect
of lung cancer prognosis.
251
TUMOR M2 PYRUVATE KINASE: CLINICAL
APPLICATIONS IN GASTRIC CANCER
P.D. Hardt
Third Medical Department, Giessen and Marburg University
Hospital, Giessen, Germany
In tumor cells, a dimeric isoenzyme of pyruvate kinase,
termed Tumor M2 pyruvate kinase (Tumor M2PK) is
overexpressed. Using specific antibodies, histological studies
showed that this particular isoenzyme can be detected in huge
amounts in almost every malignant tissue. Several years ago,
an ELISA was developed to measure Tumor M2PK levels in
EDTA plasma. Later the ELISA was slightly modified to be
used in stool samples.
While a lot of attention has been paid to the possible role of
fecal Tumor M2PK measurements in the screening for
colorectal cancer recently, only a very few studies dealt with
other cancer entities of the gastrointestinal tract. In gastric
cancer, which is one of the most frequent cancer diseases in
the world, no reliable tumor markers have been established as
yet. If any, CEA, Ca19-9 and Ca 72-4 have been discussed;
however, the reported sensitivities were only about 40%. In
contrast to this, Tumor M2PK measurements reported a
sensitivity of about 60% at 95% specificity. Thus,
determination of this marker in EDTA does provide an
instrument to be used in the follow-up and therapy control of
gastric cancer cases which is superior to the markers
previously used. Furthermore, gastric cancer patients do also
show elevated levels of Tumor M2PK in the feces. This is true
for the “classical” assay that has been developed for screening
purposes in colorectal cancer but also for another essay using
a different marker combination that appears to be more
specific for gastric cancer. In populations with a high
prevalence of gastric cancer, fecal Tumor M2PK testing might
be a means for screening.
252
THE PROLIFERATIVE CELL NUCLEAR ANTIGEN
OF SEQUENTIAL PROGRESSION IN COLORECTAL
ADENOMA-DYSPLASIA-CARCINOMA TRANSITION
Revekka Harisi1,2, Janos Weltner2, Balazs Jaray3,
Krisztina Morvay2, Peter Kupcsulik2, Laszlo Harsanyi2,
Tamas Winternitz2, Zsuzsanna Schaff3 and Andras Jeney1
1First
Institute of Pathology and Experimental Cancer
Research, 21st Department of Surgery, 3Second Institute of
Pathology, Semmelweis University, Faculty of Medicine,
Budapest, Hungary
Introduction: The role of proliferating cell nuclear antigen
(PCNA) to colorectal tumorigenesis has not yet been settled;
in fact, while some authors reported a relevant role for PCNA
tumor expression as a direct indicator of poor survival, others
have not confirmed this association. Aim: Examination of the
shift through the adenoma-carcinoma progression sequence of
human colon and rectum in context with the expression
difference of proliferating cell nuclear antigen between
adenoma-carcinoma and the adjacent normal mucosa (PCNAED). Materials and Methods: 178 patients with colorectal
polyp-adenoma and/or colorectal carcinoma underwent
endoscopic polypectomy or surgical resection. The PCNA
expression was examined in 28 non-neoplastic epithelial
polyps, 82 neoplastic adenomatous polyps showing different
degrees of dysplasia, 12 in situ carcinomas, 6 malignant
polyps, 66 colorectal adenocarcinomas and their adjacent
mucosa specimens. The PCNA protein levels were determined
by immunoblot analysis quantified by densitometry. Logistic
regression was used to examine the predictive role of PCNA
on adenoma-carcinoma sequence. Results: The PCNA
expression was detectable in the visibly normal mucosa of 69%
of patients with polyps. This alone is a proliferative zone, but
does not mean bad prognosis. Moving further in the adenomacarcinoma sequence the PCNA-ED was more frequent. This
kind of difference was never found hyperplastic and
hamartomatous polyps or inflammatory pseudopolyps. Low
difference was found in 2% of tubular and in 6% of tubulovillous adenomas, and further 6% of the latter had high
difference. In case of villous adenomas the degree of dysplasia
well correlated with the frequency of difference. In mild
dysplasia the expression difference was found in 3% of the
cases, in moderate it was in 21% and in severe dysplasia the
difference was found in 55% of the cases. The adenoma size
and the increase of PCNA-ED among the patients were linearly
correlated (R2=0.96 for tubular and tubulovillous and 0.99 for
villous adenomas by linear regression). The increasing severity
of the dysplasia, the increasing size of the polyp and the more
frequent detection of PCNA-ED among the patients were
strongly correlated values. The distribution of PCNA-ED along
with the recurrence was highly statistically significant
3307
ANTICANCER RESEARCH 28: 3157-3556 (2008)
(p<<0.005). In all patients with high PCNA-ED recurrence was
developed within the first year. In development of the one- to
three-year recurrence the low PCNA-ED played the dominant
role, while in development of the one-year recurrence the high
PCNA-ED was more dominant. PCNA-ED has been found in
57% of in situ carcinomas grown on base of a polyp, and in
69% of the malignant polyps. In adenocarcinomas, the Dukes
classification paralleled well with PCNA-ED, in contrast with
the only in tumor measured PCNA expression. Conclusion:
These results indicate that PCNA expression difference
between normal and altered tissue progressively increased
along the sequence from normal mucosa via low grade, middle
grade, and high grade dysplasia, adenoma to advanced cancer.
The PCNA-ED is one parameter that contributes to the
definition of the degenerative risk and allows selection of
patients with high expression difference for constant
monitoring.
253
PUTATIVE MOLECULAR TARGETS FOR
ANTIMIGRATORY TUMOR THERAPY
Revekka Harisi, Ferenc Timar, Julia N. Olah,
Istvan Kenessey, Istvan Babo, Tibor Szarvas,
Gabor Pogany, Sandor Paku and Andras Jeney
First Institute of Pathology and Experimental Cancer
Research, Semmelweis University, Faculty of Medicine,
Budapest, Hungary
Background: Metastasis – the spread of tumor cells from the
primary site to distant organs – represents a major
pathobiological event in tumor progression, and decides the
outcome of the malignant disease. Although paramount
progress has currently been witnessed in the control of the
primary tumors, it is a great challenge to develop drugs,
showing specific action against tumor progression.
Metastasis is a multistep process involving shedding of
tumor cells from the primary site, migration and attachment
in a novel microenvironment, where they could settle down
and form a viable growing cell population. Antimetastatic
agents not necessarily act on cell proliferation; rather one of
the above mentioned pathobiological events must be
affected. Purpose: For the identification of chemical
compounds with predominant action on migration relative
to proliferation, we decided to recognize certain molecules
as promising targets, specific to metastatic process. To this
end appropriate in vitro biological assay has been
elaborated. Materials and Methods: As our previous studies
provided further evidence for the contribution of matrix
metalloproteinases (MMPs), proteoglycans and integrins in
the invasive growth, compounds inhibiting these molecules
were selected as promising antimetastatic agents. To
investigate tumor cell migration, three dimensional culture
3308
of human osteosarcoma cells (OSCORT) and human
fibrosarcoma cells (HT-1080) were applied. Tumor cells
grown in monolayer were overlaid with matrigel. After
separating the cells remaining in the monolayer from the
cells migrating into the matrigel, the invasive behavior of
the tumor cell population could be assessed. In addition,
tumor cell migration in certain cases was measured in
Boyden chamber. Results: Invasive growth of osteosarcoma
cells was stimulated in the presence of heparan sulfate
proteoglycan both in three-dimensional culture and Boyden
chamber. Hexyldeoxyuridine a potent inhibitor of heparan
sulfate proteoglycan reduced the invasive growth of tumor
cells. MMP-9 showed high activity in slow-growing HT1080 culture with elevated migratory behavior. Antisense
oligonucleotide against MMP-9 inhibited both MMP-9 and
tumor cell migration. Borrelidin analogs showed a selective
antimigratory activity as well, which may be related to the
remarkable reduced expression of αvβ3 integrin.
Conclusion: MMP-9, heparan sulfate proteoglycan and
integrins showed close relation with the migratory potency
of OSCORT and HT-1080 cell cultures. Chemical
compounds inhibiting one of these molecules were able to
reduce tumor cell migration. The present report
summarizing preclinical studies indicates that targeted
therapy against tumor metastasis could be planned against
these molecules.
254
A MECHANISTIC INVESTIGATION INTO THE
ANTI-INVASIVE EFFECTS OF OLIVE OIL
PHENOLICS
Y.Z.H-Y Hashim1, I.R. Rowland2, M. Servili3,
M.J. McCann4, D. Berrar5 and C.I. Gill6
1UCD
Institute of Food and Health, University College
Dublin, Belfield, Dublin 4, Ireland;
2Department of Food Biosciences, University of Reading,
Whiteknights, PO Box 226 Reading RG6 AP UK;
3Dipartmento di Scienze degli Alimenti, Sezione di
Tecnologie e Biotecnologie degli Alimenti, Via S. Costanzo,
06126 Perugia Italy;
4Food Metabolism and Microbiology, Food & Textiles
Group, AgResearch Limited, Grasslands Research Centre,
Tennent Drive, Private Bag 11008, Palmerston North, New
Zealand;
5System Biology Research Group, Centre for Molecular
Biosciences, School of Biomedical Sciences and
6Northern Ireland Centre for Food and Health (NICHE),
University of Ulster (Coleraine), Cromore Road, Coleraine,
Northern Ireland, UK BT52 1SA
Recently, certain major phenolics from virgin olive oil have
been shown to modulate cellular pathways involved in
Abstracts of the 8th International Conference of Anticancer Research, 17-22 October 2008, Kos, Greece
carcinogenesis, such as cell cycle, apoptosis, invasion and
metastasis. Invasion is an important feature of metastasis
and it comprises adhesion, degradation of basement
membrane via proteolytic enzyme activity; and cell
migration/motility. In this in vitro study, we focused on the
anticancer effects of phenolics from virgin olive oil at the
invasion level using HT115, a metastatic adenocarcinoma
cell line. Olive oil phenolics extract (OVP) inhibited cell
invasion in the Matrigel invasion assay but not migration
through polyethylene membrane devoid of the reconstituted
basement membrane. OVP also inhibited or reduced
adhesion on collagen type IV and spreading on fibronectin.
Interestingly, OVP was observed to inhibit adhesion and/or
cause detachment of adhering cells in the assays performed.
This anti-adhesion effect is proposed to be a genuine effect
since OVP was not cytotoxic at the range tested (0-25
μg/ml) and we observed that OVP caused differential effects
on HT115 cell surface integrin expression. Based on the
clustering and pathway/functional genomics analysis on
gene expression data, we propose that OVP interferes with
the pathways that lead to detachment of cells from substrate.
In conclusion, results from this study suggest that OVP
inhibited integrin-regulated adhesion, spreading and
invasion but not migration of HT115 cells. These studies
revealed novel anticancer targets of phenolics from virgin
olive oil, which may aid understanding in prognosis,
prevention, as well as therapy of cancer at the invasion and
metastasis level.
255
REFINEMENT AND ANIMAL WELFARE IN CANCER
MODELS
Jann Hau
Department of Experimental Medicine, University and
University Hospital of Copenhagen, Denmark
Laboratory animal models have been essential for
understanding tumour biology, for development and testing
of drug therapies, and for risk assessments of potential
carcinogens. Animal models remain pivotal for studies of
biological mechanisms involved in the development of
cancer and for studies of tumours growing in vivo. Scientists
have moral and legal obligations for the welfare of the
animals in their care during experimentation, and proper
consideration should always be given to the ‘three R’s’
(replacement, reduction, and refinement). When animals are
necessary to address a particular question in oncology, pain
and distress must be minimised, and avoidable pain is
unacceptable. Studies of experimentally induced neoplasia
present particular problems, and scientists should make every
effort for implementation of the earliest humane endpoints
possible to minimise the adverse effects on the animals.
Death as an endpoint should obviously no longer be
accepted, and researchers should be encouraged to introduce
the earliest possible endpoints and to disseminate the
information by publishing improvements with respect to
refinement and animal welfare score sheets in experimental
protocols.
Continuous refinement of experimental protocols resulting
in the introduction of the earliest achievable endpoints requires
competence, commitment and collaboration of scientists and
all staff associated with animal care and animal
experimentation. All staff should understand their individual
responsibilities, and an unambiguous chain of communication
and accountability should be established. This allows
immediate action to address animal welfare issues that may
arise as a consequence of experimental protocols.
256
THE EXPRESSION OF EIF3,
LARGE SUBUNIT (P150) IN HUMAN
GLIOBLASTOMA
Johannes Haybaeck1,2, Christoph Schindler1,
Gilbert Spizzo3, Thomas Brunhuber4, Georg Schäfer4,
Sabine Spiegl-Kreinecker5, Johannes Fischer6,
Serge Weis1 and Peter Obrist1
1Laboratory
of Neuropathology, Department of Pathology
and Neuropathology, State Neuropsychiatric Hopsital
Wagner-Jauregg, Linz, Austria;
2Institute of Neuropathology, Department of Pathology,
University Hospital Zürich, Switzerland;
3Division of Hematology and Oncology, and
4Department of Pathology University of Innsbruck,
Innsbruck, Austria;
Departments of 5Theoretical Neurosurgery and
6Neurosurgery, Wagner Jauregg Hospital, Linz, Austria
Glioblastoma multiforme (GBM) is an aggressive brain tumour
associated with poor prognosis. Despite radio- and
chemotherapy, survival is short. EIF3 is a multi-subunit
complex that plays a central role in the translation initiation
pathway. The large subunit of eIF3 that includes p150 is
regarded as a key player in translation initiation and mediates
most of its activities. We investigated the expression of p150
by immunohistochemistry in 46 patients with glioblastoma.
Moreover primary cell lines were analysed for p150 protein
expression by Western blot techniques. P150 expression was
mostly localised in the cytoplasm with strongest expression in
tumour giant cells. Overexpression of p150 was found in 34
tumour samples. Modern therapeutic approaches, for example
Rapamycin or its analogues, may target elongation and
initiation factors of protein synthesis, and thus could lead to a
global cellular down-regulation, including p150 as shown for
the mTor pathway.
3309
ANTICANCER RESEARCH 28: 3157-3556 (2008)
257
P150 - EIF3 LARGE SUBUNIT - PROTEIN
OVEREXPRESSION IN BREAST CANCER
J. Haybaeck1, G. Spizzo2, T. Brunhuber2*, G. Schaefer2,
W. Salvenmoser3, R. Baenziger4, F. Bachmann4, M. Burger4
and P. Obrist2*
4Functional
Genomics Centre Zurich, University Zurich;
of Integrative Biology, Molecular
Biomedicine,Swiss Federal Institute of Technology (ETH),
CH-8952 Zurich, Switzerland;
6University of California, San Diego and University of
California, Los Angeles, USA
*These authors contributed equally to this work.
5Institute
1Institute
of Neuropathology, Department of Pathology,
University Hospital Zürich;
Departments of 2Pathology and 3Zoology, University of
Innsbruck, Austria and
4Friedrich Miescher Institute, Basel, Switzerland
*Peter Obrist and Thomas Brunhuber are now in the
Laboratory of Pathology, Hospital Zams, 6511 Zams, Austria
P150, a protein with an apparent molecular weight of 150
kDa, was isolated from virally and oncogene transformed
mouse cell lines, partially purified and cloned. P150 belongs
to the elongation initiation factor 3 complex, which consists
of 10 subunits. It was shown to be part of the large subunit
complex, described as being a 160 to 180 kDa protein
complex. It is supposed to be a molecular parameter in
predicting disease progression in cervical and oesophageal
cancer. We describe the distribution of P150 in normal and
neoplastic breast tissue and try to elucidate the role of the
eIF3 complex during tumorigenesis. Therefore 43 breast
tissue samples were examined, including benign and
neoplastic tissues and compared with each other by the use
of immunohistochemistry and Western blotting using a
polyclonal
chicken
anti-p150-antibody.
Strong
overexpression in breast cancer was found in nearly all cases.
Exceptionally, in one case of squamous cell carcinoma, an
inverse reaction was found. In contrast to neoplastic tissues,
the adjacent normal one revealed a slight inhomogenous
positivity. The role of p150 as part of the eIF3 complex
during tumorigenesis is strictly related to a selective protein
synthesis in tumor cells. It mainly participates in the
deregulation of the translation process by interaction with
eIF4E, eIF2 and with hPrt1, and also with eIF5.
258
HEPATOCYTE-SPECIFIC LYMPHOTOXIN
EXPRESSION CAUSES CHRONIC HEPATITIS
INDUCED HEPATOCELLULAR CARCINOMA IN
TNFR1–/– BUT NOT IN RAG1–/– OR IKKβΔHEP MICE
Johannes Haybaeck1*, Mathias Heikenwalder1*, Nicolas
Zeller1*, Monika Julia Wolf1, Juliane Bremer1, Achim
Weber2, Michael Kurrer3, Ulrich Wagner4, Manfred Kopf5,
Michael Karin6 and Adriano Aguzzi1
1Department
of Pathology, Institutes of Neuropathology and
Pathology, University Hospital Zurich;
3Department of Pathology, Cantonal Hospital Aarau;
2Clinicial
3310
Hepatocellular carcinoma (HCC), the most common liver
cancer, is mainly induced by chronic hepatitis. Lymphotoxin
(LTαβ) was recently demonstrated to be up-regulated in livers
of patients suffering from virus-induced hepatitis and HCC.
We generated transgenic mice with liver-specific expression
of LTαβ (AlbLTαβ). Characteristic morphological features of
chronic portal and lobular hepatitis were detected in livers
from transgenic mice at the age of 6-9 months, preceded by
hepatocyte-specific expression of chemokines (e.g. IP10,
CXCL1, CCL2). Elevated serum levels of aminotransferases
starting from 8 weeks of age indicated liver damage in
AlbLTαβ mice. Remarkably, at an age of ≥300 days, 30% of
transgenic mice developed HCCs. Hepatitis and HCC genesis
was fully prevented in AlbLTαβ mice backcrossed to rag1–/–
and IkkβΔhep mice. In contrast, tnfr1–/– mice developed
hepatitis and HCC. Here, we describe a new model of chronic
hepatitis-induced HCC. Transcriptome analysis at various
stages of hepatitis and HCC development reveals many
similarities to virus-induced hepatitis and HCC in humans and
enables us to dissect signalling events in AlbLTαβ, AlbLTαβ
× IkkβΔhep and AlbLTαβ × tnfr1–/– mice. Therefore, LTαβ
expression by hepatocytes suffices to induce chronic hepatitis
causing HCC in a lymphocyte- and IKKβ-dependent, but
TNFR1-independent manner, rather than directly acting as an
oncogene.
259
LRIG PROTEINS AS REGULATORS
OF GROWTH FACTOR SIGNALING
Camilla Holmlund, Wei Yi, Roger Henriksson
and Håkan Hedman
Department of Radiation Sciences, Umeå University, SE90187 Umeå, Sweden
Receptor tyrosine kinases are implicated in the etiology of
many cancers. For example, in glioblastoma multiforme the
epidermal growth factor receptor- (EGFR-) gene is
frequently amplified and mutated to yield high levels of
constitutively active receptors with prolonged half-lives. In
a search for endogenous inhibitors of EGFR signaling, we
identified the integral membrane protein, leucine-rich repeats
and immunoglobulin-like domains 1 (LRIG1). Subsequently,
we and others have shown that LRIG1 suppresses the
oncogenic receptor tyrosine kinases EGFR, ERBB2, MET,
Abstracts of the 8th International Conference of Anticancer Research, 17-22 October 2008, Kos, Greece
and RET. LRIG1 is down-regulated in various neoplasms,
including cervical and renal cell carcinoma. We also
identified two human LRIG1 paralogs, LRIG2 and LRIG3.
The LRIG proteins show differential subcellular localization
in normal and pathological tissues, which seems to have
clinical implications. Perinuclear LRIG protein localization
is associated with good survival of astrocytoma patients,
whereas, cytoplasmic LRIG2 expression was associated with
poor survival of oligodendroglioma patients. LRIG1 is
subject to proteolytic processing and the resulting fragments
seemed to have biological activities. Taken together, the
LRIG proteins seem to be important regulators of growth
factor signaling with implications for patient survival in
various malignancies.
260
A MOUSE MODEL OF NEUROFIBROMATOSIS-1
OPTIC GLIOMA: A PRECLINICAL TOOL FOR
ANTI-ANGIOGENESIS RESEARCH?
Balazs Hegedus1, Debasish Banerjee2, Arie Perry3,
Joshua B. Rubin4, Joel R. Garbow2 and David H. Gutmann1
Departments of 1Neurology, 2Radiology, Division of
3Neuropathology and 4Pediatrics, School of Medicine,
Washington University in St. Louis, St. Louis, MO, USA
Individuals affected with the neurofibromatosis 1 (NF1) are
prone to develop tumors of the nervous system, including
optic pathway gliomas (OPG). These tumors are classified as
grade I pilocytic astrocytomas, characterized by low
cellularity and rare mitotic figures. Despite their benign
behavior in general, these gliomas often exhibit increased
angiogenesis. Importantly, the development of prechiasmatic
and chiasmatic optic gliomas has been observed in a
genetically engineered mouse (GEM) model with inactivation
of the neurofibromatosis-1 (Nf1) tumor suppressor gene in
glial cells. Interestingly, the natural history and morphology
of these GEM tumors was similar to their human
counterparts. Furthermore, increased angiogenesis has been
found during OPG development as evidenced by an increased
blood vessel density. We validated this Nf1 optic glioma
model using conventional chemotherapy (temozolomide)
currently used for children with low-grade glioma and
showed that treatment resulted in reduced proliferation and
increased apoptosis of tumor cells in vivo as well as reduced
tumor volume. Collectively, these findings indicate that this
unique Nf1 GEM optic glioma model might be a potent tool
for preclinical assessment of novel anti-angiogenic therapies.
261
ROLE OF HYALURONAN-CD44 COMPLEXES IN
REGULATION OF GROWTH FACTOR RECEPTOR
ACTIVITY AND IN TUMOR PROGRESSION
Paraskevi Heldin, Berit Bernert, Spyridon Skandalis,
Evgenia Karousou, Helena Porsch and Carl-Henrik Heldin
Ludwig Institute for Cancer Research, Uppsala University,
Biomedical Center, Box 595, S-751 24 Uppsala, Sweden
Introduction: The interactions between cells and the host
microenviroment influences cellular behavior. Hyaluronan
levels are determined by synthesizing (HAS) and degrading
(HYAL) enzymes in response to growth factors. The
hyaluronan receptor CD44 affects cell–cell and cell–matrix
interactions. Methods and Results: HAS activity has been
shown to be important for the maintenance of the malignant
and invasive phenotype of the Hs578T breast cancer cells
using specific siRNAs, we showed that HAS interacts with
HYAL and the hyaluronan receptor CD44 to promote the
aggressive character of breast cancer cells. Furthermore, using
a 3D collagen matrix assay we studied in real-time the
mechanisms by which CD44-hyaluronan interactions affect
transendothelial migration; peritumoral hyaluronan is
important for the early adhesion of tumor cells to endothelial
cells. Recently, we investigated the downstream signaling
pathways through which PDGF-BB stimulates hyaluronan
synthesis using inhibitors of different signaling pathways, we
showed that the Erk MAP kinase and PI3 kinase signaling
pathways are necessary for the regulation of hyaluronan
synthesis by PDGF-BB and that hyaluronan affects the
mitogenic response to PDGF-BB. Recent data revealed that
tissue hyaluronan content can be modulated through
ubiquitinylation and possibly oligomerization of HAS
enzymes. In another line of research, we demonstrated that
CD44 forms a complex with both the PDGF β-receptor and
TGFβ type I receptor; hyaluronan-activated CD44 suppressess
the PDGF-BB-mediated activation of the PDGF β-receptor
and TGFβ-mediated activation of Smad2. Conclusion:
Hyaluronan favors the malignant phenotype in malignancies
and modulates receptor tyrosine kinase activity.
262
SINGLE OR COMBINATIONS OF TUMOR
MARKERS IN CERVICAL CANCER –
CORRELATION TO PROGNOSIS, SERUM
PROGESTERONE AND ESTRADIOL, SMOKING AND
ORAL CONTRACEPTIVE USE
Dan Hellberg
Center for Clinical Research, Falun, Sweden
Background: Expression of a single tumor marker is rarely
clinically useful in any cancer type. There is an increasing
interest in using panels of tumor markers to increase prognosis
prediction, differential diagnosis and choice of therapy.
Materials and Methods: One hundred and thirty women with
3311
ANTICANCER RESEARCH 28: 3157-3556 (2008)
squamous epithelial cervical cancer had pre-treatment
progesterone and estradiol, and a complete history including
smoking habits and previous oral contraceptive use. A panel
of 13 novel and traditional tumor markers were selected and
analysed by immunohistochemistry. Follow-up was at least 10
years. Results: Expression of six tumor markers was
significantly associated with 10-year survival, after adjustment
for clinical cancer stage, these were LRIG1, p53, and CD4+,
(favourable prognosis). LRIG2, COX-2 and c-myc expressions
were associated with poor prognosis. LRIG1 and LRIG2 will
be discussed elsewhere at the conference. With Cox
regression, none of the other tumor markers were significantly
associated with prognosis. When combinations of tumor
markers with different functions in carcinogenesis were
combined with Cox regression and adjusted for stage, four
combinations significantly predicted prognosis, while another
four combinations were of borderline significance (p=0.05).
Expression of p53 was strongly reduced in smokers. C-myc
expression was correlated to increased serum progesterone
levels, while p53 expression was reduced. Conclusion:
Combinations of tumor marker expression were more reliable
in predicting prognosis than a single marker. Our results also
provide biological explanations behind the role of risk factors
in cervical cancer. The results of some other studies will be
discussed.
263
THE ROLE OF GENISTEIN DERIVATIVES
STRUCTURE AND SOME MOLECULAR
PROPERTIES IN THEIR INTERACTION WITH
MEMBRANES AND ANTIOXIDANT ACTIVITY
Kamila Środa1, Jadwiga Maniewska1, Krystyna Michalak1,
Grzegorz Grynkiewicz2, Wiesław Szeja3
and Andrzej B. Hendrich1
1Departement
of Biophysics, Wrocław Medical University,
ul. Chałubińskiego 10, 40-368 Wrocław;
2Pharmaceutical Research Institute, ul. Rydygiera 8, 01-793
Warszawa;
3Departement of Organic, Bioorganic Chemistry and
Biotechnology, Silesian Technical University, ul.
Krzywoustego 4, 44-100 Gliwice, Poland
Many of the biological effects exerted by flavonoids, e.g.
antitumoral,
anti-inflammatory,
anti-ischemic,
cardioprotective, are believed to come from the antioxidant
activity of these compounds. As was shown in numerous
experiments, the antioxidant capacity of flavonoids depends
mostly on their structure (i.e. number and positions of
hydroxyl groups) but also on some other factors such as type
of oxidative stress inducer used or ability of certain flavonoid
to intercalate into lipid bilayers (in the case of lipid
peroxidation). According to present knowledge, flavonoid
3312
molecules present in the membrane could directly scavenge
ROS (reactive oxygen species) but also, due to the modulation
of membrane properties, they can reduce the rate of ROS
diffusion in membrane and thus reduce lipid oxidation.
In present work, we studied the interactions of newly
synthesized benzyl and glycosylated genistein derivatives with
lipid membranes. Using microcalorimetry, we found that all
studied compounds interact with lipids and alter the
thermotropic properties of bilayers by decreasing the main
phase transition temperature and enthalpy. For glycosylated
derivatives, calorimetry also showed that increase of the length
of spacer separating genistein moiety and added sugars
increases the perturbation induced by these compounds. ATRIR spectroscopy allowed us to conclude that genistein and its
derivatives interact with lipid polar heads by hydrogen
bonding. An increase of the number of gauche conformers in
lipid acyl chains induced by the presence of studied
polyphenols was also recorded. Both calorimetric and infrared
spectroscopic experiments confirmed that polar head region as
well as the hydrophobic interior of the bilayer are affected by
the presence of flavonoids. Studying the influence of genistein
derivatives on the calcein efflux from liposomes, we found
that all compounds are more active than parent genistein but
glycosylated derivatives permeabilize membranes to a greater
extent than benzyl ones. Analyzing the properties of studied
molecules calculated by computer-aided modeling, we noticed
that among ovality, octanol-water partition coefficient,
polarizability, EHOMO, ELUMO and dipole moment, only the
latter property correlates with the order of permeabilizing
potency of benzyl genistein derivatives. Further analysis of
computer modeling results revealed that in fact the dipole
moment of an added benzyl ring together with its substitutions
(fluorine, chloride, cyanine and methoxy) is the factor
determining the liposome permeability changes induced by
genistein derivatives. Finally, we studied the antioxidant
activity of these compounds (against lipid peroxidation) and
the relation between the effects exerted by the studied
derivatives on lipid membranes and their antioxidant potency
is discussed.
264
TUMOR STEM CELLS IN GLIOMAS: CLINICAL
IMPACT OF THE STEM CELL MARKER CD133 AND
THERAPEUTICAL STRATEGIES
C. Herold-Mende1, B. Campos1, F. Wang1, F.Zeppernick1,
R. Ahmadi1, W. Roth2, P. Lichter2, A. Unterberg1
and B. Radlwimmer2
1Department
2DKFZ
of Neurosurgery, University of Heidelberg,
Heidelberg, Germany
A considerable amount of evidence has been gathered
supporting the existence of tumor stem cells in a variety of
Abstracts of the 8th International Conference of Anticancer Research, 17-22 October 2008, Kos, Greece
cancers. Glioma-derived tumor stem cells (GTSC) can be
enriched by the stem cell surface antigen CD133. Conversely,
a controlled, drug-induced depletion of the CD133-positive
GTSC pool could have profound therapeutic implications.
Retinoids such as all-trans retinoic acid (ATRA) have been
shown to induce differentiation of GTSCs in vitro. However, it
remains unknown whether tumor growth-relevant features of
these cells are affected.
We analyzed expression of CD133 in 95 gliomas of various
grade and histology by immunohistochemistry. Staining data
were correlated with patient outcome. Furthermore, several
GTSC lines with high CD133 content were established to
investigate ATRA-induced differentiation and potential effects
on tumor growth-relevant properties. Proliferation was
monitored by BrDU-incorporation assay and CD133 content
by FACS-analysis. Impact of differentiation on angiogenic
capacity of GTSCs was measured by quantification of
angiogenic cytokines and assessed in a HUVEC-based tube
formation assay. Potential effects on GTSC invasiveness were
studied in a 3D-collagen invasion model. Finally, we studied
whether in vitro effects could be confirmed in vivo using a
NOD/SCID-mouse xenograft model.
By multivariate survival analysis, both the proportion of
CD133-positive cells and their topological organization in
clusters were significant (p<0.001) prognostic factors for
adverse progression-free (PFS) and overall survival (OS).
Furthermore the proportion of CD133-positive cells was an
independent risk factor for tumor regrowth and time to
malignant progression in WHO II and III tumors. Supporting
these clinical data, we present functional evidence that GTSCs
exposed to ATRA lower the expression of CD133 in favor of
incremented expression of lineage markers. This is accompanied
by a significantly reduced secretion of VEGF and bFGF, as well
as a significantly lowered angiogenic activity following
differentiation. Additionally, we show that differentiation elicits
strong anti-invasive effects, reducing invasion of GTSCs
accompanied by a down-regulation of invasion-related MMP2
protein. Finally, we report that xenografted tumors of
differentiated GTSCs are significantly smaller and less invasive
than undifferentiated GTSC tumor xenografts. Correspondingly,
animals bearing differentiated cells show both significantly
better PFS and OS than mice with GTSC xenografts.
These findings constitute the first conclusive evidence that
CD133 expression correlates with patient survival in gliomas,
lending support to the current cancer stem cell hypothesis.
Additionally, we present functional evidence that
differentiation treatment targets the tumor-driving
compartment in glioblastoma and constitutes a potential
therapeutic approach in the eradication of GTSCs.
265
SULFORAPHANGE ERADICATES PANCREATIC
CANCER STEM CELLS BY NF-κB
G. Kallifatidis1, V. Rausch1, B. Baumann2, A. Apel1, J.
Mattern1, M. Buechler3, A.V. Salnikov1 and I. Herr1
1University
of Heidelberg and DKFZ, Heidelberg;
of Ulm, Ulm;
3University of Heidelberg, Heidelberg, Germany
2University
Emerging evidence suggests that cancer stem cells (CSCs)
play a central role in the pathogenesis of pancreatic cancer.
We identified CSCs in pancreatic cancer cell lines and patient
tumors with a CD44+/CD24–, CD44+/CD24+, or
CD44+/CD133+ phenotype and their presence correlated to
high therapy resistance. Mechanistically, we observed specific
binding of transactivation potent c-Rel containing NF-κB
complexes in CSCs but not in non-CSCs. A compound found
in broccoli, sulforaphane, prevented NF-κB binding and
induced IκBa along with strong induction of apoptosis and
prevention of clonogenicity. Other chemopreventive agents,
gemcitabine or the death ligand TRAIL were less effective. In
a xenograft model, sulforaphane strongly blocked tumor
growth and combination with TRAIL, had an additive effect
without obvious cytotoxicity to normal cells and stem cells.
Ex vivo, sulforaphane abrogated resistance of primary patient
tumor cells harboring CSCs. Our data suggest combination of
sulforaphane with TRAIL as promising strategy for targeting
of pancreatic CSCs.
266
AP-1-DEPENDENT GENETIC PROGRAMS IN SKIN
REMODELLING AND CANCER
Jochen Hess, Axel Szabowski and Peter Angel
Deutsches Krebsforschungszentrum, Division Signal
Transduction and Growth Control, Im Neuenheimer Feld
280, D-69120 Heidelberg, Germany
The transcription factor AP-1, which is mainly composed of
members of the Fos and Jun protein families, participates in
physiological and pathophysiological processes due to its
central role as a cellular switch of genetic programs in response
to extracellular signals. AP-1 subunits and their specific target
genes exhibit distinct expression patterns in epidermal
keratinocytes as well as mesenchymal cells. Together with
impaired skin regeneration and carcinogenesis in AP-1
compromised mouse models these findings indicate that AP-1dependent genetic programs play a pivotal role in epidermal
organization, skin homeostasis and tumourigenesis. Employing
genome-wide expression analysis on samples of genetically
modified mouse and cell culture model systems, we are
studying the function of AP-1 and its target genes within a
complex dynamic network of signalling pathways implicated
in the well-coordinated intercellular communication between
keratinocytes, fibroblasts and immune cells. We found trans-
3313
ANTICANCER RESEARCH 28: 3157-3556 (2008)
regulatory functions of Jun family members in the epithelialmesenchymal crosstalk and could identify novel AP-1 target
genes in dermal fibroblasts including cytokines, chemokines
and growth factors. Additionally, we could identify a signalling
pathway triggered by the receptor for advanced glycation end
products RAGE that activates AP-1 in epithelial tumour cells
and is initiated by ligands that are expressed in epithelial as
well as mesenchymal cells under pro-inflammatory conditions.
In the context of tumour cell invasion and malignant
progression, we identified the mucine-like glycoprotein
Podoplanin as a novel AP-1 target gene in epithelial tumour
cells and fibroblasts.
267
IN VITRO MATURATION OF HUMAN MONOCYTEDERIVED DENDRITIC CELLS UNDER SERUMFREE CONDITIONS IN THE PRESENCE OF ACIDTREATED GRAM-NEGATIVE BACTERIA LOADED
WITH PROSTATE-SPECIFIC ANTIGEN
Bernd Hildenbrand1, Frank Neumann3, Dirk R. Lorenzen2,
Victoria Küttner6, Marina Gummenscheimer1,
Stefan F. Martin4, Michael Huber5, Clemens Unger1,
Marina A. Freudenberg6, Chris Galanos6 and Marc Azemar1
1Tumor
Biology Center, D-79106 Freiburg;
for Tumor Therapy, D-37115 Duderstadt,
Germany;
3BIOAXXESS Technology, WR14 3SZ, Malvern, UK;
4University Medical Center, D-79104 Freiburg;
5Molecular Immunology, University Freiburg, D-79108
Freiburg;
6Max-Planck Institute of Immunobiology, D-79108 Freiburg,
Germany
2Institute
Introduction: Acid-treated gram-negative bacteria (ATB) are
powerful immunostimulatory adjuvants in vivo and have been
shown to enhance impaired immune functions in patients (14). As they expose lipid A on their surface they are expected to
mature dendritic cells most efficiently via Toll-like receptor 4.
Moreover, as they are non-infectious, they should serve as
optimal carriers for different antigens suitable as anticancer
vaccines. In this work we tested acid-treated gram-negative
mutant (R-form) Salmonella minnesota bacteria loaded with
the prostate-specific antigen (PSA) or PSA-peptides (PSAP)
for their capacity to induce maturation of human monocytederived dendritic cells (MoDCs) under serum-free conditions.
Methods: MoDCs were generated in serum-free medium
supplemented with GM-CSF and IL-4 for 5 days and matured
for 24 h with ATB (either with R-or S-(wild-type) form)
loaded with the whole PSA protein or PSAP ± IFN-γ. MoDCs
were phenotypically characterised by FACS and cytokineprofiled by ELISA for secreted IL-6, IL-10 and p70
(biological active) IL-12. Results: In particular, R-form ATB
3314
preparations loaded with PSA or PSAP induced phenotypic
characteristics of mature MoDCs such as the up-regulation of
CD83, CD80, CD86, HLA-DR and down-regulation of CD14.
The induced expression of CD83 on MoDCs as well as their
cytokine production, was higher after stimulation with ATB
loaded with PSAP compared to ATB loaded with PSA. Both
approaches led to higher levels of IL-12p70 and lowered IL-10
levels when IFN-γ was added to the maturation protocol. The
highest ratio of IL-12p70 against IL-10 levels was observed in
the presence of IFN-γ using ATB R-form preparations on their
own or loaded with PSAP. Conclusion: ATB preparations
represent suitable agents for the ex vivo maturation and
antigen-loading of human MoDCs under serum-free
conditions as exemplified for PSA and PSAP. In combination
with IFN-γ all ATB preparations tested led to an enhanced
TH1-polarisation, establishing an adjuvant strategy, which
should improve and facilitate future clinical protocols for
cellular anticancer immunotherapy.
1 Miragliotta G, Di Vagno G, Nappi R, Fumarola D, Jirillo E
and Galanos C: Evaluation of procoagulant activity
production and other coagulative functions in cancer patients
receiving acid treated Salmonella minnesota R 595 (Re). Eur
J Epidemiol 4(3): 377-381, 1988.
2 Jirillo A, Disperati A, Balli M, Bonciarelli G, Demicheli R,
Antonaci S and Jirillo E: Pilot study of intravenous
administration of the acid-treated Salmonella minnesota
R595 (Re) in cancer patients. Tumori 73(5): 481-486, 1987.
3 Jirillo E, Miragliotta G, Caretto G, Cedola MC, Nappi R,
Sansone LA, Galanos C and Antonaci S: Relationship
between immune system and gram-negative bacteria. Acidtreated Salmonella minnesota R595 (Re) enhances immune
responsiveness in patients with gynecologic malignancies.Int
J Immunopharmacol 8(8): 881-886, 1986.
4 Bellstedt DU, Van der Merwe KJ and Galanos C: Immune
carrier properties of acid-treated Salmonella minnesota R595
bacteria. The immune response to TNP-bacterial conjugates
in rabbits and mice. J Immunol Methods 108(1-2): 245-254,
1988.
268
DETECTION OF THERAPY-INDUCED TUMOUR
DEATH BIOMARKERS IN PATIENT SERUM
SAMPLES
Bernd Hildenbrand1, Frank Neumann2, Marc Azemar1,
Ulrich Massing1, Clemens Unger1 and Klaus Mross1
1Tumor
Biology Center, Breisacher Str. 117, 79106 Freiburg,
Germany;
2BIOAXXESS Technology, Malvern Hills Science Park,
WR14 3SZ, Malvern, UK
Introduction: M30-Apoptosense and M65 are validated
markers in CE-marked enzyme-linked immunosorbent assays
Abstracts of the 8th International Conference of Anticancer Research, 17-22 October 2008, Kos, Greece
(ELISA) that detect circulating cytokeratin 18 fragments
(CK18F/M30) released into the circulation during caspasedependent (apoptotic) or total cell death, respectively, and have
shown potential as biomarkers in epithelial cancers (1-3). We
present data using the M30 and M65 ELISAs for investigating
the caspase-cleaved neoepitope of cytokeratin 18 fragments
(CK18F/M30) and/or total CK18 (M65). These might
represent useful serum markers in vivo for drug-induced
carcinoma cell death and/or tissue toxicity. The presence of
liver metastases and liver injury prior to treatment may
enhance the CK18 biomarker signal strength and induction
pattern. Furthermore the optimal time window for serum
sampling for this type of cell death biomarker analysis was
evaluated. Methods: M30 and M65 antigen levels were
measured by ELISA (4) in serum samples from 11 patients
suffering from carcinomas of the breast, ovaries, oesophagus
and larynx, that were taken shortly before, during and after
treatment with paclitaxel as part of a pharmacodynamic
clinical study. Results: Significant increases of serum tumor
cell death biomarkers were found over pre-treatment values in
10/11 patients, which peaked or reached plateau after approx.
24 h post drug infusion. Most patients showing an increase in
M65 (total CK18) serum levels also had a concomitant and
comparable increase of the apoptotic M30 (caspase-cleaved
CK18/CK18F) serum biomarker. No effect of the presence of
liver metastases or elevated liver enzymes on baseline or the
extent of treatment-induced increases in M30 or M65 serum
levels were observed. The data obtained suggest that baseline
M30/M65 serum values could have diagnostic potential as
prognostic cancer biomarkers reflecting overall disease activity
and as a predictive clinical response marker. Conclusion:
Monitoring of serum CK18 and CK18F/M30 levels by ELISA
prior, during and after chemotherapy therapy may provide a
simple and minimally-invasive method for the quantitative
assessment of therapy-induced antitumour activity in different
carcinoma types and/or for prognostic purposes. Further
validation of the prognostic and predictive value of these
biomarkers is necessary.
1 Cummings J, Ward TH, Greystoke A, Ranson M and Dive
C: Biomarker method validation in anticancer drug
development. Br J Pharmacol 53(4): 646-656, 2008.
2 Olofsson MH, Ueno T, Pan Y, Xu R, Cai F, van der Kuip H,
Muerdter TE, Sonnenberg M, Aulitzky WE, Schwarz S,
Andersson E, Shoshan MC, Havelka AM, Toi M and Linder
S: Cytokeratin-18 is a useful serum biomarker for early
determination of response of breast carcinomas to
chemotherapy. Clin Cancer Res 13(11): 3198-3206, 2007.
3 Cummings J, Ward TH, LaCasse E, Lefebvre C, St-Jean M,
Durkin J, Ranson M and Dive C: Validation of
pharmacodynamic assays to evaluate the clinical efficacy of
an antisense compound (AEG 35156) targeted to the Xlinked inhibitor of apoptosis protein XIAP. Br J Cancer
92(3): 532-538, 2005.
4 Kramer G, Erdal H, Mertens HJ, Nap M, Mauermann J,
Steiner G, Marberger M, Bivén K, Shoshan MC and Linder
S: Differentiation between cell death modes using
measurements of different soluble forms of extracellular
cytokeratin 18. Cancer Res 64(5): 1751-1756, 2004.
269
2-HYDROXY-OCTADECYLPHOSPHOCHOLINE
ENHANCES CD83 EXPRESSION OF HUMAN
MONOCYTE-DERIVED DENDRITIC CELLS
MATURED WITH LPS AND IFN-γ, INHIBITING
CYTOKINE SECRETION WITHOUT AFFECTING
TH1 POLARISATION
Bernd Hildenbrand1, Dirk R. Lorenzen2, Frank Neumann3,
Barbara Sauer1, Ralf GRAESSER1, Lenka A. Tylor1,
Victoria Küttner5, Marina A. Freudenberg5, Chris Galanos5,
Ulrich Massing1, Clemens Unger1 and Marc Azemar1
1Tumor
Biology Center, Breisacher Str. 117, 79106 Freiburg;
for Tumor Therapy, Hinterstraße 53, 37115
Duderstadt, Germany;
3BIOAXXESS Technology, Malvern Hills Science Park,
WR14 3SZ, Malvern, UK;
4Molecular Immunology, Biology III, University Freiburg,
Stübeweg 51, 79108 Freiburg;
5Max-Planck Institute of Immunobiology, Stübeweg 51,
79108 Freiburg, Germany
2Institute
Introduction: Lysophosphatidylcholine (LPC) is a lipid
signalling messenger molecule which exhibits potent proinflammatory activities and can efficiently stimulate immune
cells, such as macrophages or dendritic cells (DCs) (1). The
R-configured enantiomer of 2-hydroxy-octadecylphosphocholine (R-OH), on the other hand has recently been shown to
be a competitive inhibitor of cellular LPC reacylation and
possess antitumor activity (2). In this study, we investigated
whether R-OH could serve as a potential inhibitor of DCmediated inflammatory processes by analyzing its influence
on the maturation and/or cytokine production of human
monocyte-derived DCs (MoDCs) stimulated with
lipopolysaccharides (LPS) in the presence or absence of
Interferon-gamma (IFN-γ). Methods: Immature human
MoDCs were generated in serum-free medium supplemented
with GM-CSF and IL-4 for 5 days and matured for additional
24 hours with LPS ± IFN-γ. R-OH or LPC (as a control) was
added 24 hours before or simultaneously with LPS. Matured
MoDCs were phenotypically characterised by FACS and
cytokine-profiled by ELISA for secreted IL-6, IL-10 and
IL12p70 (biological active). Results: Immature MoDCs
showed enhanced up-regulation of the co-stimulatory
molecules CD80 and CD86 when incubated with LPC [10-50
μM] or R-OH [10-20 μM] over a period of more than 24 hours
in serum-free medium. However, compared to LPC, pre-
3315
ANTICANCER RESEARCH 28: 3157-3556 (2008)
incubation of immature MoDCs with R-OH followed by
maturation with LPS ± IFN-γ led to twice as high an upregulation of CD83, which was associated with a strong
inhibition of cytokine production. Interestingly, whereas LPC
enhanced TH2-polarisation after maturation by LPS, even in
the presence of IFN-γ, pre-incubation of MoDCs with R-OH
still enhanced the TH2-polarisation when matured with LPS
alone, however, it did not alter the strong TH1-polarisation
seen previously after maturation with LPS in the presence of
IFN-γ (3). Conclusion: Pre-incubation of immature MoDCs
with R-OH at non-toxic concentrations [10-20 μM] efficiently
inhibits the cytokine secretion by MoDCs matured with LPS
and IFN-γ without changing their IL-10/IL-12p70 ratio or
TH1-polarisation. Moreover, R-OH enhanced the up-regulation
of both co-stimulatory cell surface molecules and the
maturation marker CD83, which, in addition to its immune
regulatory functions, may potentiate antitumor immune
responses. In conclusion, these results may form the basis to
explain not only the anti-inflammatory role of R-OH, but also
its antitumor properties.
1 Coutant F, Laure PC, Agougne S, Delair T, Andre P and
Lotteau V: Mature dendritic cell generation promoted by
lysophosphatidylcholine. J Immunol 169: 1688-1695, 2002.
2 Hildenbrand B, Kley JT, Haberstroh F, Freudenberg MA,
Azemar M, Unger C and Massing U: Cytotoxic efficacy and
influence on cellular phospholipid metabolism of 2-hydroxyand 2-O-acetyl-octadecylphosphocholines. Anticancer Res
26(6): 4255-4262, 2006.
3 Hildenbrand B, Lorenzen D, Sauer B, Hertkorn C,
Freudenberg MA, Peters JH, Nesselhut T, Unger C and
Azemar M: IFN-y enhances T(H)1 polarisation of
monocyte-derived dendritic cells matured with clinical-grade
cytokines using serum-free conditions. Anticancer Res
28(3A): 1467-1476, 2008.
270
FOCALIZED MULTI-THERAPIES USING AN
INNOVATIVE INJECTION TECHNIQUE
E. Hiltbrand and S. Humbert
University Hospital Geneva and CERMA, Geneva,
Switzerland
Targeted MULTI Therapy (TMT) primarily developed as a
new thermoablative technique for cancer, is currently being
extended to phlebological applications. As animal
investigations have shown the safety and the efficacy of the
treatment, the technique was applied successfully to humans.
Besides thermoablative procedures, taking advantage of the
MULTI capability of the technique, investigations are
conducted in several therapeutic areas of oncology: delivery
of drugs and radioactive particles under pressure directly into
targeted tumours.
3316
In this context, an experiment in which a new apoptogenic
molecule with proven efficacy on cells in culture, and with the
remarkable property of being irreversibly cytotoxic to human
prostate epithelial cancer cells but reversibly cytostatic to
human prostate epithelial normal cells (Quash G. Eur. J. Med.
Chem. (2007), was successfully carried out on an animal
model.
Additionally, the injection of radioactive particles with the
same technique is currently being investigated on rats
(European project: INBARCA). The delivery of the active
agent directly into the lesion minimizes side-effects, enhances
efficacy and reduces doses. The high pressure ensures an even
better diffusion of the agent.
271
TARGETING NITROSATIVE STRESS FOR CANCER
THERAPY
David G. Hirst, Helen O. McCarthy, Jonathan Coulter,
Natalie Page and Tracy Robson
Experimental Therapeutics Research Group, School of
Pharmacy, Queen’s University Belfast, 97 Lisburn Road,
Belfast BT9 7BL, UK
Nitric oxide (NO•) exhibits many of the desirable properties
of an anticancer molecule. It is highly diffusible through
tissues and demonstrates specificity for the tumour
microenvironment. It is likely that this characteristic results
from the differential production of reactive nitrogen species,
particularly peroxynitrite, in tumours compared with their
normal counterpart and in the downstream consequences of
their generation. The effects of NO• are highly concentrationdependent, but at high therapeutic levels it is strongly proapoptotic, anti-angiogenic and anti-metastatic. In addition, it
has been shown to be one of the most potent radiation
sensitizers known and can also enhance the cytotoxicity of
some chemotherapeutic agents. However, these properties can
be fully exploited only if effective strategies for delivery can
be developed. At present, both NO• donor drugs and inducible
nitric oxide synthase (iNOS) gene therapy have shown
impressive efficacy in experimental animal models of human
cancer. We have used gene promoters that are inducible by
hypoxia, radiation and the tumour microenvironment to target
the expression of iNOS and hence generation of high
concentrations of NO• to the tumour volume. Twice weekly
administration of this therapy in a mouse model of prostate
cancer inhibited tumour growth for several months. Thus,
NO• therapy shows considerable promise as an anticancer
strategy.
272
AKT INHIBITOR INHIBITS CELL PROLIFERATION
IN MALIGNANT FIBROUS HISTIOCYTOMA CELLS
Abstracts of the 8th International Conference of Anticancer Research, 17-22 October 2008, Kos, Greece
Toshiaki Hitora, Sasaki Kanji, Osamu Nakamura,
Kawaguchi Youji and Yamamoto Tetsuji
Department of Orthopaedic Surgery, Kagawa University,
1750-1 Ikenobe, Miki-cho, Kita-gun, Kagawa 761-0793, Japan
Introduction: The phosphatidylinositol 3-kinase (PI3K)/Akt
pathway plays an important role in various cellular processes
including cell growth, survival, and motility. Recently,
accumulating evidence indicated that PI3K/Akt pathway plays
a crucial role in tumorigenesis and tumor progression by
promoting cell proliferation and inhibiting apoptosis (1). In
addition, abnormal function of the PI3K/Akt pathway has been
reported in many human tumors and this signaling pathway
has been suggested to be a potential target for cancer
chemotherapy (2). We examined the expression of Akt and the
existence of PI3K/Akt signaling pathway in human malignant
fibrous histiocytoma (MFH) cell lines, and the inhibitory
effect of Akt inhibitor on the cell proliferation. Materials and
Methods: Cell lines and reagent. Three human MFH cell lines
(Nara-H, GBS-1, TNMY1) were used in this study. TNMY1
was previously established in our laboratory. All cell lines
were grown in culture medium consisting of Dulbecco’s
modified Eagle’s medium (DMEM; Sigma-Aldrich, St. Louis,
MO, USA) supplemented with 10% fetal bovine serum (FBS;
Sigma-Aldrich). The cell lines were routinely maintained at
37˚C in a humidified 5% CO2 atmosphere. Akt inhibitor X, a
specific Akt kinase inhibitor was purchased from Calbiochem
(San Diego, CA, USA). The inhibitory effect of Akt inhibitor.
The cell proliferation was assayed using the MTS assay
(CellTiter 96® Aqueous One Solution Cell Proliferation Assay;
Promega, Madison, WI, USA). Cells were seeded in 96-well
cell culture plates in culture medium with 10% FBS. After 24
hours (h), the medium was refreshed with 1% FBS containing
AKT inhibitor in the indicated concentrations. After 24 and 48
h, the medium was removed and washed with phosphatebuffered saline, then refreshed with fresh medium containing
MTS reagent. The optical density was measured at 490 nm
using an automatic microplate reader after 2 h of further
incubation. The percent age viability of each well was
calculated. At least three independent cultures were performed
for each study. The data were analyzed statistically using
ANOVA with Fisher’s PLSD post hoc test. Western blotting.
Cells were pretreated for 60 min with 1% FBS containing
AKT inhibitor at different concentrations. Whole cell lysates
were collected for protein content, and cell lysates were
separated by SDS polyacrylamide gel electrophoresis under
reducing conditions. Then gels were electrophoretically
transferred to PVDF membrane, and immunoblotted with antiAKT1/2/3 antibody (Santa Cruz Biotechnology, CA, USA)
and anti-phospho-AKT1/2/3 antibody (Ser 473, Thr 308; Santa
Cruz Biotechnology). Bound antibodies were detected using
the ECL plus Western blotting detection system (GE
Healthcare Bio-Sciences, Piscataway, NJ). Results: The effect
of the Akt inhibitor: Akt inhibitor inhibited the cell
proliferation of all 3 cell lines in a dose- and time-dependent
manner; 10 μM AKT inhibitor inhibited the cell proliferation
of Nara-H and GBS-1 at the percent viability of 50% or less;
25 μM AKT inhibitor inhibited the cell proliferation of
TNMY1 at viability of 50% or less. Expression of Akt and
phospho-Akt: Western blotting analysis revealed that not only
Akt but phospho-Akt were expressed in all cell lines under the
normal condition, so it was suggested that Akt signaling
pathway was always activated in all 3 cell lines under the
normal condition. Phosphorylation of Akt was reduced by 25
μM Akt inhibitor in all cell lines. Discussion: The PI3K/Akt
pathway is very important as a target of the molecular
targeting therapy. In our study, Akt inhibitor showed a dosedependent inhibitory effect on the cell proliferation of human
MFH cells. Akt inhibitor reduced the phosphorylation of Akt.
These results suggest that the PI3K/Akt signaling pathway
exists and plays an important role in cell proliferation in MFH
cells. Although further studies are needed to explore the
mechanisms of cell proliferation, Akt inhibitor will be a potent
chemotherapeutic agent for human MFH.
1 Jin S, Pang RP, Shen JN, Huang G, Wang J and Zhou JG:
Grifolin induces apoptosis via inhibition of PI3K/AKT
signalling pathway in human osteosarcoma cells. Apoptosis
12(7): 1317-1326, 2007.
2 Roy HK, Olusola BF, Clemens DL, Karolski WJ, Ratashak
A, Lynch HT and Smyrk TC: AKT proto-oncogene
overexpression is an early event during sporadic colon
carcinogenesis. Carcinogenesis 23(1): 201-205, 2002.
273
DIALLYL DISULFIDE (DADS) INDUCES APOPTOSIS
IN HUMAN CERVICAL CANCER HELA CELLS VIA
REACTIVE OXYGEN SPECIES, ENDOPLASMIC
RETICULUM STRESS AND MITOCHONDRIADEPENDENT PATHWAY
Chin-Chin Ho1, Yueh-Shan Weng2, Jai-Sing Yang3,
Hsu-Feng Lu4 and Jing-Gung Chung2
1Department
of Nursing, Central Taiwan University of
Science and Technology, Buzih District, Taiwan;
Departments of 2Biological Science and Technology and
3School of Pharmacology, China Medical University,
Taichung, Taiwan;
4Department of Clinical Pathology, Cheng Hsin
Rehabilitation Medical Center, Taipei, Taiwan, ROC
Although many studies have shown that diallyl disulfide
(DADS), a substance found in garlic, induced apoptosis in
various human cancer cells, the molecular mechanisms of
apoptosis induced by DADS in human cervical cancer cells
are not clear. In this study, we tested DADS for induction of
3317
ANTICANCER RESEARCH 28: 3157-3556 (2008)
apoptosis in human cervical cancer HeLa cells. DADS
induced morphological changes and reduced the percentage of
viable HeLa cells in a dose- and time-dependent manners.
Flow cytometric analysis demonstrated that DADS induced
apoptosis in HeLa cells. DAPI staining showed morphological
features of apoptosis in HeLa cells treated with 50 μM DADS
for 24 h. ApopTag assay demonstrated DNA fragmentation in
apoptotic cells. DADS induced apoptosis through the
production of reactive oxygen species and Ca2+, and induced
the abrogation of changes in mitochondrial membrane
potential (Δψm) and cleavage of Bid protein (t-Bid). DADS
also promoted the activities of caspase-3 leading to DNA
fragmentation, thus indicating that DADS-induced apoptosis
is caspase-3-dependent. BAPTA attenuated the Δψm
abrogation and significantly diminished the occurrence of
DADS-induced apoptosis in HeLa cells. Activation of caspase9 and caspase-3 indicated involvement of the intrinsic pathway
of apoptosis. Results strongly suggested that the garlic
compound DADS suppressed antiapoptotic factors and
activated intrinsic caspase cascade for apoptosis in HeLa cells.
274
PHENOTYPE SWITCHING, A NEW PARADIGM FOR
METASTATIC PROGRESSION
Keith S. Hoek, Natalie C. Schlegel, Ossia M. Eichhoff,
Daniel Widmer and Reinhard Dummer
Department of Dermatology, University Hospital of Zurich,
8091 Zurich, Switzerland
Metastatic melanoma is a complex and heterogeneous cancer
for which, despite more than 100 clinical trials and over thirty
years of dedicated molecular research, no effective therapy has
yet been realised. Such failure demands we revisit the basic
tenets which underly our assumptions about this disease and
reappraise them in the light of recent findings. Transcription
profiling of cell lines and short-term cultures by our group has
uncovered among melanoma cells a previously unrecognized
molecular taxonomy. In vitro and in vivo experiments show
that this taxonomy is comprised of cells which are either
programmed for proliferation, or programmed for invasion.
Our interpretation of the data and subsequent experimentation
has led us to conclude that the dominating paradigm for
disease progression in melanoma, where weakly metastatic
precursors evolve via the linear accumulation of changes into
strongly metastatic cells, is in error. Instead, we hypothesize
that once transformation has been achieved, melanoma cells
express transcription programs (phenotypes) according to
microenvironmentally derived signals, which in turn allows
them to drive disease progression by switching between
proliferative and invasive programs. This new phenotypeswitching model answers several criticisms leveled at the
present linear accumulation model, offers an explanation for
3318
how gene expression markers for early primary lesions
frequently persist in metastases, and supplies a plausible
reason for therapy escape.
275
IMAGING THE TOTALITY OF CANCER
PROGRESSION IN REAL TIME
Robert M. Hoffman
AntiCancer, Inc., San Diego, CA, USA
The development of GFP for imaging in the live animal has
revolutionized in vivo biology, in particular, the study of
metastasis (Nature Reviews Cancer 5, 796-806, 2005). The
totality of cancer progression can now be followed in real time
in the live animal, with many of the steps imageable noninvasively. GFP-expressing transgenic mice transplanted with
the RFP-expressing cancer cells enable the distinction of
cancer and host cells. This is particularly useful for imaging
the tumor microenvironment, including tumor angiogenesis.
Cancer–cell trafficking through the cardiovascular and
lymphatic systems is the critical means of spread of cancer.
The use of fluorescent proteins to differentially label cancer
calls in the nucleus and cytoplasm and high-powered imaging
technology are used to visualize the nuclear-cytoplasmic
dynamics of cancer-cell trafficking and extravasation in both
blood vessels and lymphatic vessels in the live animal.
Proliferating and dormant cancer cells are readily
distinguished in the live animal. This technology has furthered
our understanding of the spread of cancer at the cellular and
subcellular level in the live mouse. Fluorescent proteins thus
enable both macro and micro imaging technology and thereby
provide the basis for the new field of in vivo cell biology.
276
ETS-1 ONCOGENIC ACTIVITY IS MEDIATED VIA
TGFα
Chet E. Holterman, Aleksandra Franovic, Josianne Payette
and Stephen Lee
Department of Cellular and Molecular Medicine, Faculty of
Medicine, University of Ottawa, Ottawa, Ontario Canada
K1H 8M5
Overt expression of the Ets-1 oncogene has been demonstrated
in a variety of tumors and has been correlated with poor patient
prognosis and clinical outcome. While studies have established
a role for Ets-1 in regulating the expression of genes involved
in extracellular matrix remodeling and angiogenesis, relatively
little is known regarding the mechanisms through which Ets-1
promotes primary tumor establishment. We previously
elucidated a critical role for the TGFα/EGFR autocrine
pathway in establishment of renal clear cell carcinoma (RCC).
Abstracts of the 8th International Conference of Anticancer Research, 17-22 October 2008, Kos, Greece
Examination of the proximal TGFα promoter region revealed
the presence of multiple Ets-1 binding sites. Through the use of
reporter assays and quantitative PCR we demonstrate that the
TGFα promoter is responsive to Ets-1 and that inhibiting Ets1 activity via dominant negative Ets-1 or siRNA silencing of
Ets-1 is sufficient to block both reporter activity and
endogenous TGFα expression in 786-0 VHL–/– RCC cells. To
confirm the physical interaction of Ets-1 with the TGFα
promoter, we performed chromatin immunoprecipitation. In
vitro silencing of Ets-1 blocked autonomous growth of 786-0
cells in a TGFα-dependent manner. Importantly, tumor
xenograft assays demonstrate that silencing of Ets-1 prevents
tumor formation in a manner that is rescuable by reestablishment of TGFα expression. We believe these results to
be the first to clearly establish a role for Ets-1 in primary tumor
formation through its ability to regulate TGFα expression.
277
HORMONE-REFRACTORY PROSTATE CANCERNEW OPTIONS FOR ITS MANAGEMENT
L. Holubec, J. Klecka, O. Topolcan, M. Pesta, V. Eret,
J. Finek and M. Hora
Faculty Hospital and Medical School in Pilsen, E. Benese
13, 305 99 Plzen, Czech Republic
Prostate cancer is the most commonly diagnosed malignancy
in men. Although many patients whose cancer has been
diagnosed and treated at early stage can be cured, the yearly
death toll of prostate is one of the leading causes of death
among males. For the past 60 years, androgen deprivation has
been the mainstay of treatment for advanced prostate cancer.
Whether obtained by orchiectomy or by administration of an
LHRH agonist, castration produces subjective and/or objective
response in more than 80% of patients. Further androgen
deprivation can still be obtained by combined therapy with an
anti-androgen, in order to obtain “maximal androgen
blockade”. In spite of hormone therapy, all patients will
progress and eventually become hormone-refractory. These
patients retain hormonal sensitivity in that they may respond to
secondary hormonal therapy. They belong to the androgenindependent and hormone-sensitive group according to the
classification proposed by Scher. However “hormone refractory
prostate cancer” (HRPC) is the term commonly used to
describe prostate cancer that has progressed in spite of primary
androgen deprivation or maximal androgen blockade. The
standard of care of hormone-refractory prostate cancer is
second-line hormone therapy which consists of antiandrogen
withdrawal, corticosteroids, oestrogens or adrenal enzyme
inhibitors. Second-line hormone therapy has poor activity
which led to the use of chemotherapy. A number of cytotoxic
agents have been tested against HRCP over the years. The aim
of this overview lecture is to compare the efficacy of different
chemotherapeutical regimens in patients with failure of the
second-line hormonal supression and a probable hormonally
independent cancer. Mitoxantrone plus prednisone reduces pain
and improves the quality of life in men with advanced,
hormone-refractory prostate cancer, but it does not improve
survival. A number of clinical studies with a variety of
protocols were initiated to evaluate the potential usefulness of
Navelbine in HRPC. When used alone in a series of phase II
clinical studies, Navelbine demonstrated its efficacy in terms
of relief of bone pain, the major complaint of HRPC patients,
and in terms of PSA response. Significant reductions of serum
PSA levels, by 50% or more, were obtained in a number of
patients. When used in combination with low dose of
corticosteroids, as shown in a large phase III pivotal study,
NAVELBINE appeared significantly more efficacious than
hormone-therapy alone in terms of progression-free survival,
PSA response and clinical benefit (pain intensity, analgesics
consumption and performance status). When given with
prednisone, treatment with docetaxel every three weeks led to
superior survival and improved rates of response in terms of
pain, serum PSA level, and quality of life, as compared with
mitoxantrone plus prednisone. The literature overview and our
personal experience from routine clinical practice provide
evidence that cytotoxic chemotherapy can significantly prolong
survival among men with hormone-refractory prostate cancer.
The obtained data suggest that docetaxel plus prednisone is the
preferred option for most patients with hormone-refractory
prostate cancer. Also Navelbine appeard as a good candidate
for clinical development in the chemotherapy of HRPC. In
conclusion, chemotherapy open new perspectives in the
treatment of HRPC.
This work was supported by the grant IGA NR/8918-3 and the
research project VZ MSM 0021620819.
278
STEM CELL-LIKE SPHERE FORMING CELL
POPULATIONS IN SARCOMAS. IMPLICATIONS IN
CHEMORESISTANCE AND POSSIBLE
THERAPEUTIC TARGETS
Kanya Honoki1, Hiromasa Fujii1, Yoshinori Takakura1 and
Toshifumi Tsujiuchi2
1Department of Orthopedic Surgery, Nara Medical
University, 840 Shijo-cho, Kashihara 634-8521; 2Department
of Life Science, Faculty of Science and Technology, Kinki
University, 3-4-1 Kowakae, Hiagshi-Osaka 577-8502, Japan
The presence of cancer stem cells, in both solid and
hematopoietic malignancies, has been recently linked to their
pathogenesis. Sarcomas are rare, and diversely characterized
by degrees of mesenchymal differentiation. The aim of the
current study was to demonstrate whether the sarcoma cell
lines possess the stem-like properties, using human
3319
ANTICANCER RESEARCH 28: 3157-3556 (2008)
osteosarcoma MG63, Ewing sarcoma HTB166, fibrosarcoma
HT1080, and rat osteosarcoma COS1NR and malignant
fibrous histiocytoma MFH1NR cell lines, both of which were
induced by 4-hydroxy (amino) quinoline 1-oxide in F344 rats.
All cell lines possessed an ability to form spherical,
clonal expanding colonies (‘sarcospheres’) in anchorageindependent, serum-starved conditions at the frequency of
0.2-0.8%. Sarcospheres showed stem-like properties with
the ability of self-renewing, and expressed the stem cellrelated genes including Nanog, Oct3/4 and STAT3. Rat
sarcospheres showed strong tumorigenicity in vivo via their
inoculation into syngeneic rats. Sarcospheres from human
Ewing sarcoma and rat sarcoma cell lines remarkably
reduced INK4a-ARF gene expression which is originally
expressed in adherent cells. Finally, human sarcosphere cells
showed chemoresistance to doxorubicin and cisplatin
compared to adherent monolayered cells. These spheres
showed increased expression of DNA repair enzyme genes,
MLH1 and MSH2, suggesting that the chemoresistance in
stem-like sphere cells is partly due to the increased DNA
repair ability after DNA damage induced by
chemotherapeutic agents.
These results suggest that the stem-like cell populations
exist in various kinds of sarcomas, and could be involved in
chemoresistance, which leads to disease relapse, metastasis,
and pathogenesis as well, and these may possibly provide
novel targets in future sarcoma treatments.
279
MEDICINAL ELECTRONOMICS BRICOLAGE:
DESIGN OF HYPOXIA-TARGETING
ANTINEOPLASTIC DRUGS
Hitoshi Hori1, Yoshihiro Uto1, Eiji Nakata1
and Hideko Nagasawa2
1Department
of Life System, Institute of Technology and
Science, Graduate School, The University of Tokushima,
Tokushima 770-8506;
2Laboratory of Pharmaceutical Chemistry, Gifu
Pharmaceutical University, Mitahorahigashi-5, Gifu 5028585, Japan
The hypoxic tumor microenvironment is now considered as a
major factor that influences not only the response to
antineoplastic therapies but also the potential for malignant
progression and metastasis. We present here our progress in
the development of hypoxia-targeting drugs, including
antiangiogenic hypoxic cell radiosensitizers, sugar-hybrid
hypoxic cell radiosensitizers and hypoxia-targeting 10B
delivery agents.
First, we designed chiral 2-nitroimidazole derivatives
containing a 2-aminomethylene-4-cyclopentene-1,3-dione
moiety as antiangiogenic hypoxic cell radiosensitizers. The
3320
2-aminomethylene-4-cyclopentene-1,3-dione moiety is
expected to show high electrophilicity, comparable to that
of the 2-methylene-4-cyclopentene-1,3-dione moiety
included in TX-1123 and tyrphostin AG17. Among the
compounds tested, TX-2036 proved to be the strongest
antiangiogenic hypoxic cell radiosensitizer by in vitro
radiosensitizing assay, the chick embryo chorioallantoic
membrane (CAM) assay, and protein tyrosine kinase (PTK)
inhibition assay. Our results showed that these chiral 2nitroimidazole derivatives having the 2-aminomethlene-4cyclopentene-1,3-dione moiety as a potent antiangiogenic
pharmacophoric descriptor might be promising lead
candidates for the development of antiangiogenic hypoxic
cell radiosensitizers.
As a second strategy, we designed sugar-hybrid hypoxic cell
radiosensitizers targeting for enhanced tumor glycolysis,
namely Warburg’s effect, which was well characterized in
hypoxic tumor cells. In all eight compounds, their LUMO
coefficients were localized on the 2-nitroimidazole ring.
Among these, fully acetylated-glucose containing hypoxic cell
radiosensitizer TX-2244 was the most active radiosensitizer
having both a higher in vitro radiosensitizing activity and
lower hydrophobicity compared to misonidazole, known as a
classical hypoxic cell radiosensitizer.
We also present here our development of an in vivo model
using developing chick embryo to evaluate the radiosensitizing
activity against solid tumor. Boron neutron capture therapy
(BNCT) is a targeted radiation therapy that significantly
increases the therapeutic ratio relative to conventional
radiotherapeutic modalities and then the development of
efficient tumor-selective 10B delivery agents (boron-10
carriers) is of pivotal importance for the purpose. As a third
strategy, we designed hypoxia-targeting boron-10 carrier
hybrid conjugated a hypoxic cytotoxins such as tirapazamine
or TX-402, or 2-nitroimidazole moiety to sodium borocaptate
(BSH) molecule. Among the 2-nitroimidazole-BSH conjugates
tested, TX-2060 maintained high 10B concentrations in solid
tumors more effectively than any other compound tested, and
showed a significantly stronger in vitro radiosensitizing
activity in the treatment of TX-2060 than that of BSH with
neutron beam irradiation. Among these conjugates tested, TX2100 had the most favorable characteristics for its sufficient
concentration of 10B in tumors and during irradiation. TX2100 also showed significantly stronger in vitro
radiosensitizing effect than BSH when irradiated with neutron
beam. We suggest our hypoxia-targeting hybrid boron-10
carriers might be useful and promising boron-10 carrier
candidates for BNCT.
280
INFLUENCE OF STI571 (IMATINIB, GLIVEC) ON
THE MIGRATORY BEHAVIOR OF HUMAM
GLIOMAS IN VITRO
Abstracts of the 8th International Conference of Anticancer Research, 17-22 October 2008, Kos, Greece
S. Horn1, M. Möhlenbruch1, M. Herr1, A. Schollmayer1, N.
Hopf2 and W. Wagner1
4Department of Microbiology, China Medical University,
Taichung, Taiwan, ROC
1Department of Neurosurgery, University of Mainz,
Langenbeckstr.1, 55101 Mainz;
2Department of Neurosurgery, Katharinenhospital,
Kriegsbergstr. 60, 70174 Stuttgart, Germany
Squamous cell carcinoma of the oral cavity is the sixth most
frequent cancer in the world. Physalis angulata is a traditional
Chinese annual herb which has been reported to exhibit
anticancer effect on several types of human cancer. In this
study, we isolated the active compound PA-42 from Physalis
angulata and found PA-42 caused cell cycle arrest in G2/M
phase, with decreasing cyclin A, cyclin B1 and cdc2 activity,
but increasing wee1, p27 and p53 activity in HSC-3 cells. It
induced DNA fragmentation, formation of DNA ladders in
agarose gel electrophoresis and increased the levels of AIF,
Bax, Bid, cleaved caspase-3, Fas, but reduced Bcl-2 in HSC3 cells. In metastasis assay of cancer cells, PA-42 also
inhibited migration by transwell migration assay and wound
healing assay, and inhibited invasion by matrigel invasion
assay. PA-42 reversed cytoskeleton from mesenchymal-like to
epithelial-like, with increased E-cadherin (epithelial marker)
and reduced α-smooth muscle actin (mesenchymal marker) in
HSC-3 cells. PA-42 also caused a decrease in MMP-3 and
GRB2.
From these results, we found that PA-42 arrests HSC-3 cells
at the G2/M phase by decreased several cyclins, but increasing
p27 and p53 activity. It induced apoptosis via both extrinsic
and intrinsic pathways in HSC-3 cells. It also suppressed
metastasis including migration and invasion via reversed cell
skeleton in HSC-3 cells. We conclude that PA-42 was able to
inhibit cell proliferation, induce apoptosis and inhibit cell
metastasis in HSC-3 cells.
Introduction: STI571 is a tyrosine kinase inhibitor, known to
react toward Bcr-ABL, c-Kit and PDGF tyrosine kinase
receptors (PDGF-R). STI571 acts by disruption of the ligand
receptor autocrine loops for PDGF factor that are a pervasive
feature of malignant astrocytoma. In this study we examined
the influence of tyrosine kinase inhibitor STI571 on the
migratory behavior of human glioma cells. Methods: Using
RT-PCR, immunocytochemistry and flow-cytometry, we
provided evidence of PDGF α/β receptor RNA presence and
its cell surface expression in three human glioblastoma
multiforme (GBM) cell lines and one fibrillary astrocytoma
cell line. Migration rate (MR) was examined by the timelapse individual cell migration assay (TIM-Assay), allowing
continuous observation of cell features up to single cell level
under defined conditions. STI571 was applied in
concentrations corresponding to the drug level in
cerebrospinal fluid and plasma in vivo. Migratory behavior
was examined in a time-frame of 24 hours. One cell line was
analyzed in a cycle conditioned treatment and a period of 8
days. TIM-Assay was performed at day 1, 3, 6 and 8. Results:
All glioma cell lines showed PDGF α/β receptor expression.
In most tested cell lines, MR decreased after treatment with
STI571. The cells showed variable migratory characteristics.
Cells of one glioblastoma multiforme showed an inherently
low MR without STI571 treatment. In the other three cell
lines migration decreased after incubation with the tyrosine
kinase inhibitor, already at the lowest STI571 concentration.
The cyclical treatment with STI571 resulted in a constantly
reduction of the migratory behavior. Conclusion: STI571
affects migratory properties whereas PDGF α/β receptor
expression could be relevant. Targeting of PDGF signaling
pathway by tyrosine kinase inhibitors represents a promising
strategy to interfere with the migration activity of glioma
cells.
281
EFFECTS OF PA-42 ON THE MOLECULAR
MECHANISMS OF APOPTOSIS AND METASTASIS
IN HUMAN ORAL SQUAMOUS CANCER CELLS
(HSC-3)
Wen-Tsong Hsieh1, Yi-Ting Chen2, Hui-Yi Lin3 and
Jing-Gung Chung4
1Department
of Pharmacology, 2Graduate Institute of Basic
Medical Science, 3School of Pharmacy and
282
EXPRESSION OF CASPASE 14 IN HUMAN
EPITHELIAL CANCER CELLS AND ITS POTENTIAL
THERAPEUTIC EFFECTS
Rachel Dulebohn, Douglas Dickinson, Regina Messer,
Mohammad Al-Shabrawy, Amany Tewfik, Kalu Ogbureke,
Jill Lewis and Stephen Hsu
Department of Oral Biology, School of Dentistry, AD1443
Medical College of Georgia, Augusta, GA, 30912, USA
Background: Oral squamous cell carcinoma is a devastating
malignancy with mortality rate consistently at 50%. Treatment
of such oral cancer is often associated with disfigurement,
which can have a traumatic impact patients. Exploration of
novel approaches and innovative therapies is needed to combat
oral cancer. We previously reported that caspase-14, a green
tea polyphenol-activated gene that is expressed during terminal
differentiation of certain epithelial cells, is able to induce cell
death and reduce tumorigenicity in skin cancer cells A431 and
salivary gland cancer cells HSG. However, the underlying
mechanism is unknown and whether adenovirus-delivered
3321
ANTICANCER RESEARCH 28: 3157-3556 (2008)
transient caspase-14 expression induces similar effects in
human oral cancer cells is not known. To express exogenous
human caspase 14 in oral squamous cell carcinoma cells
(OSC2) by adenovirus vector, and determine the effects of
caspase-14 expression on cell growth, cell death and
tumorigenicity. Methods: The human oral cancer cell line
OSC2 was infected by adenovirus-expressing GFP or caspase
14 cDNA. Expression of caspase 14 was confirmed by
Western blotting. Cell morphology was monitored by
microscopic photography, cell growth was measured by cell
counting and BrdU assay, and cell viability was determined
by MTT assay. In addition, the cancer cells were xenografted
into athymic mice to determine the tumorigenicity. Results:
Expression of caspase-14 induced an undefined cell death in
OSC2 cells compared to the control cells. Cell growth and cell
viability were inhibited significantly by caspase-14 expression.
Xenograft of caspase-14-expressing OSC2 cells into athymic
mice resulted in reduced tumorigenicity. This effect could be
due to an inhibitory influence of caspase 14 on tumor
vascularization. Conclusion: Oral cancer cells underwent
growth inhibition and cell death when exogenous caspase-14
was expressed in these undifferentiated tumor cells. Caspase14 expression in OSC2 cells also reduced tumorigenicity in
vivo. Further effort is warranted to explore if caspase 14expressing adenovirus could be used as a potential therapeutic
approach to treat human epithelial cancer.
This study was supported in part by the Dental Research
Foundation of the Medical College of Georgia.
evaluated in vitro and antitumor efficacy was investigated in
vivo as a single agent and in combination with irinotecan
hydrochloride (CPT-11). The fusion protein RGD-L-TRAIL,
but not TRAIL or RGE-L-TRAIL, specifically bound to
microvascular endothelial cells in a dose-dependent manner
and showed enhanced apoptosis-inducing activity (caspase-3
and caspase-8 activation) in αVβ3 and αVβ5 integrin positive
cancer cells. In addition, RGD-L-TRAIL was more effective
in suppressing tumor growth of COLO-205 tumor-bearing
mice than an equivalent dose of TRAIL. The antitumor effect
of RGD-L-TRAIL was further enhanced by combination with
CPT-11 in both TRAIL-sensitive COLO-205 and TRAILresistive HT-29 tumor xenograft models. Our findings suggest
the novel fusion protein RGD-L-TRAIL can directly target
tumor endothelial cells as well as αVβ3 and αVβ5 integrinpositive tumor cells. The tumor-targeted delivery of TRAIL
derivatives, such as RGD-L-TRAIL, may prove to be a
promising lead candidate for cancer therapy.
284
KAEMPFEROL INDUCES APOPTOSIS VIA
MITOCHONDRIAL- AND CASPASE-DEPENDENT
CASPASE SIGNALING PATHWAYS IN HUMAN
OSTEOSARCOMA U2OS CELLS
Wen-Wen Huang1, Meng-Wei Lin2, Kuei-Li Lin3,
Wai-Jane Ho4, Chin-Fen Lin5, Kun-Hong Li6,
Jai-sing Yang7 and Jing-Gung Chung1
1School
283
ENHANCEMENT OF ANTITUMOR PROPERTIES OF
TRAIL BY TARGETED DELIVERY TO THE TUMOR
NEOVASCULATURE
Lin Cao, Pan Du, Shu-Han Jiang, Guang-Hui Jin,
Qi-Lai Huang and Zi-Chun Hua
The State Key Laboratory of Pharmaceutical Biotechnology
and Department of Biochemistry, College of Life Sciences,
Nanjing University, 22 Hankou Road, Nanjing 210093,
Jiangsu, P.R. China
Tumor necrosis factor-related apoptosis-inducing ligand
(TRAIL) is a promising anticancer agent with tumor-selective
apoptotic activity. TRAIL plays a role in the innate and
adaptive immune response, autoimmune disease, and may also
be involved in hepatic cell death and inflammation. For these
reasons, chronic exposure to TRAIL may have deleterious
side-effects in patients as a cancer therapeutic. In this study,
we have improved the antitumor activity of TRAIL by targeted
delivery to the tumor vasculature, leading to dramatic
enhancement of its therapeutic properties. TRAIL was fused
to the ACDCRGDCFC peptide (named RGD-L-TRAIL), a
ligand of αVβ3 and αVβ5 integrins. Biological activity was
3322
of Biological Science and Technology, 2School of
Pharmacy, 5Department of Biochemistry, 6School of
Medicine and 7Department of Microbiology, China Medical
University, Taichung, Taiwan;
3Department of Radiation Oncology, Chimei Medical Center,
Tainan, Taiwan;
4Department of Bioresources, Dayeh University, Changhua,
Taiwan ROC
It is well known that flavonoids can block or suppress
multistage carcinogenesis and also exert anti-neoplastic
activites through the inhibition of cell growth and induction of
apoptosis. Kaempferol is one of the flavonoids that usually
exist in many plants. Recently, antioxidant activity has been
used for cyto-protection. Kaempferol seems not only to
prevent cells from free radical damage via antioxidant activity
but also induce apoptosis via prooxidant activity in cancer cell
lines. Kaempferol induced anti-proliferative activity in many
transformed cancer cell types, such as rat H4IE cells, human
HT29 colon cancer cells, acute leukemia cells, lung non-small
carcinoma H460 cells. In this study, we examined the
apoptotic effect and molecular mechanism of kaemperol in
U2OS osteosarcoma cells. Kaempferol induced dosedependent suppression of cell viability by MTT assay in
U2OS cells. We used comet assay and DNA gel
Abstracts of the 8th International Conference of Anticancer Research, 17-22 October 2008, Kos, Greece
electrophoresis to confirm kaempferol induced DNA damage
and apoptosis. Flow cytometry was used to detect kaempferolincreased Ca+2 production and reduced levels of MMP.
Kaempferol induced the release of cytochrome c, Apaf-1, AIF
from mitochondria accompanied by activation of caspase-9,
caspase-3 by Western blotting and caspase activity assay and
real-time PCR. Specific inhibitors of caspases-9 and caspase3 prevented caspase-9 and -3 activation and led to a decrease
in the percentage of apoptosis. Kaempferol also promoted the
expression of Bax, GRP78 and GADD153 but inhibited the
expression of Bcl-2, Bcl-xL and IAP. Our results suggested
that kaempferol is able to induce ER stress and apoptosis
through the mitochondrial- and caspase-dependent signal
pathways in U2OS cells.
285
OUR CURRENT UNDERSTANDING OF THE
ETIOLOGY OF COLORECTAL TUMORS: ONGOING
RESEARCH FINDINGS FROM THE PLCO TRIAL
Wen-Yi Huang and Richard B. Hayes
for the PLCO research team
Division of Cancer Epidemiology and Genetic, National
Cancer Institute, National Institutes of Health, Department of
Health and Human Services, Bethesda, MD20892, USA
Cancer of the colon and rectum (colorectal) ranks second in
both incidence and mortality in developed countries, and the
incidence is rising in developing countries. Adenomatous
polyps are considered the key premalignant lesion leading to
colorectal cancer, hence risk factors for adenoma are an
important research topic.
We have carried out investigations of colorectal adenoma in
the Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer
Screening Trial, including about 75,000 screened participants
and 75,000 non-screened controls, at ten centers in the United
States recruited between 1993 and 2001. Our studies related
reduced adenoma risks to dietary fiber, dietary calcium, a gene
variant in the calcium-sensing receptor, serum selenium,
circulating vitamin D metabolites, serum insulin-like growth
factor (IGF-1), use of non-steroid anti-inflammatory drugs
(NSAIDs), and recent hormone replacement therapy. We
related increased risks to carbohydrate intake and glycemic
load, meat cooking practices, particularly PhIP exposure, and
high body mass index. Tobacco use was strongly related to
adenoma risk, with evidence of risk modification in relation
to genes involved in the metabolism of tobacco smoke
constituents, including EPHX1, CYP1A1, NQO1, NAT1, NAT2,
and GSTs. We also characterized adenoma risk in relation to
genetic variants in transforming growth factor beta 1 (TGFB1),
nucleotide and base excision repair (NER, BER) genes,
selected P53 response elements, alpha-methylacyl-CoA
racemase (AMACR), the frizzled-related protein (FRZB), the
hemochromatosis gene (HFE), and SNPs at chromosome 8q24
between 128.47 and 128.54. In ongoing work, we are
expanding the questionnaire-based studies to include risk
analysis for colorectal cancer, incident adenoma, and recurrent
adenoma. We are expanding genotyping studies to include
larger numbers of cases and controls and to deepen the
pathway and gene region-specific SNP coverage. With
recently acquired pathology samples, studies are planned to
assess colorectal tumor risk in relation to tumor molecular
sub-types and in relation to epigenetic and genome instability
profiles.
286
PROSTATE CANCER STEM CELLS
Elaine M. Hurt
National Cancer Institute-Frederick, Center for Cancer
Research, Laboratory of Cancer Prevention, Cancer Stem
Cells Section, Frederick, MD 21702, USA
Recently there have been several reports of cancer stem cells
(CSCs) in hematological malignancies as well as in solid
tumors, such as breast, colon, glioblastoma, and prostate
cancer. CSCs are the tumor-initiating cells that give rise to the
multiple cell types present within a heterogeneous tumor.
Moreover, CSCs are resistant to many conventional
chemotherapies, resulting in recurrence of the tumor.
Therefore, the targeting of these cells is central to any therapy
that is to be successful in eradicating cancer. However,
successful targeting of these cells requires an understanding
of the biology governing the CSC’s unique properties of
continued self-renewal, multipotent differentiation, and tumor
initiation. Using prostate CSCs as a model, we are elucidating
the molecular mechanisms underlying these properties.
287
BIOLOGICAL INDICATORS OF PROGNOSIS IN
HUMAN CANCER: AN EMERGING ROLE FOR
LECTIN GALACTOSIDE-BINDING SOLUBLE 3BINDING PROTEIN (LGALS3BP)
Stefano Iacobelli1, Clara Natoli1, Nicola Tinari1, Maurizia1,
D’Egidio1, Antonino Grassadonia1, Alba Cumashi1,
Enza Piccolo1, Diana Zambelli2 and Katia Scotlandi2,
on behalf of the Consorzio Interuniversitario
Nazionale per la Bio-Oncologica (CINBO)
1Department of Oncology and Neurosciences, University “G.
d’Annunzio”, Chieti-Pescara, Chieti;
2Laboratory of Oncologic Research, Istituto Ortopedico
Rizzoli, Bologna, Italy
LGALS3BP, also known as Mac-2-binding protein or 90K,
is a secreted glycoprotein that binds galectins, beta-1
3323
ANTICANCER RESEARCH 28: 3157-3556 (2008)
integrins, collagens, and fibronectin, and has relevance in
cell–cell and cell–extracellular matrix adhesion. Previous
studies have shown that elevated tissue and serum expression
levels of LGALS3BP correlate with a poor prognosis in
several malignancies, including breast cancer, non-small cell
lung cancer, prostate cancer and non-Hodgkin lymphoma. In
a search for a molecular signature of potential prognostic
value in Ewing’s sarcoma (EWS), we identified and
validated eight genes, representative of three different
networks, in 56 EWS patients. High mRNA expression levels
of HINT1, IFITM2, LGALS3BP, STOML2 and c-MYC were
associated with reduced risk of death and lower risk of
developing metastasis. On multivariate analysis, LGALS3BP
was the most important predictor of event-free and overall
survival. The association between LGALS3BP mRNA and
prognosis was confirmed at the protein level when
expression of the molecule was determined in tumor tissues,
but not in serum, indicating a role for the protein in the local
tumor microenvironment. Engineered enhancement of
LGALS3BP expression in EWS cells resulted in an
inhibition of cell adhesion to basal lamina and reduction of
cell migration and in vivo metastasis. Thus, we propose
LGALS3BP as a novel, reliable cancer biomarker which may
be associated with prognosis.
288
INTERACTIONS BETWEEN NORMAL HUMAN
FIBROBLASTS AND HUMAN PROSTATE CANCER
(CaP) CELLS IN A COCULTURE SYSTEM
F. Iacopino, C. Angelucci, S. Ferracuti and G. Sica
Istituto di Istologia ed Embriologia, Facoltà di Medicina e
Chirurgia, Università Cattolica del Sacro Cuore, Largo
Francesco Vito 1, 00168 Roma, Italia
Stroma affects the development of many organs and plays
an important role in regulating epithelial malignancies, such
as prostate cancer. Fibroblasts represent the major cell type
of the stromal compartment. With the aim of clarifying the
relationships between fibroblasts and epithelial cancer cells,
we utilized a coculture system including CaP cell lines both
androgen-sensitive (LNCaP) and -insensitive (PC-3, DU145) and a human gingival fibroblast cell line (FG).
Morphological aspects were analyzed under a phase contrast
inverted microscope, proliferation in conditioned media
(CM) was assessed by cell counts, and E-cadherin (E-cad)
expression by immunocytochemistry. In the cocultures,
androgen-sensitive LNCaP cells grew in a network on the
top of the monolayer formed by the FG, while colonies of
androgen-insensitive PC-3 and DU-145 cells were
surrounded by FG. After six days, LNCaP cell number was
apparently lower in the cocultures than in plates where they
grew alone. Both cell lines underwent morphological
3324
changes. After six days, the growth of PC-3 and DU-145
overcame that of FG which were almost evanished. The CM
of FG inhibited the proliferation of LNCaP cells, after three
days by 33% (p<0.01) and after six days up to 82%
(p<0.01), but had no effect on PC-3 and DU-145 cell
growth. The CM of all three CaP lines reduced the growth
of FG, being that of DU-145 cells the most effective (50%
inhibition after three days, p<0.01, and 55% after six days,
p<0.01). The FG did not express E-cad, while a strong
staining was detected in LNCaP cells. PC-3 cells showed a
nuclear staining while a sporadic membrane expression of
E-cad was observed in DU-145 cells. In the cocultures, a
reduction in the nuclear reactivity of PC-3 cells was found.
The data obtained confirm the existence of a dialogue
between FG and CaP cells, which results in both a peculiar
modality of growth and a regulation of proliferation
probably due to growth factors secreted in the culture
medium.
289
VERIFICATION BIAS OF OCCULT CANCER IN
CASE–CONTROL STUDIES ON THE ASSOCIATION
OF OXIDATIVE STRESS AND PROSTATE CANCER
Taro Iguchi1,3, Ching Y. Wang1, Nicolas B. Delongchamps1,4,
Gustavo de la Roza2, Gabriel P. Haas1 and Tatsuya Nakatani3
Department of 1Urology and 2Pathology, SUNY Upstate
Medical University, Syracuse, NY, USA;
3Department of Urology, Osaka City University School of
Medicine, Osaka, Japan;
4Department of Urology, University of Paris, Paris, France
Introduction and Objective: Epidemiological studies have
correlated prostate cancer (PCa) with oxidative stress related
gene polymorphism. Oxidative damage to nuclear DNA may
result in carcinogenesis. Manganese superoxide dismutase
(MnSOD) plays an important role in protection from
reactive oxygen species-mediated DNA damage. Recent
studies have suggested that MnSOD gene polymorphism is
associated with PCa. However, some studies reported
negative association. Many case–control studies on the
molecular epidemiology of PCa do not take into
consideration that the control group may include a
significant proportion of occult PCa. In this study, we
investigated the association of MnSOD genotypes and PCa
in prostates obtained from deceased men, whose cancer
status could be verified by complete histological evaluation.
Methods: A total of 186 prostate glands from deceased men
(age range 45-92 years) who had no known history of
prostate cancer were eligible for analysis. An 18-core needle
biopsy regimen and whole mount section of the prostate
were performed. Genomic DNA was extracted from the
normal portion of the prostate and MnSOD genotyping was
Abstracts of the 8th International Conference of Anticancer Research, 17-22 October 2008, Kos, Greece
performed using PCR restriction fragment length
polymorphism analysis. Results: When autopsied prostates
were evaluated for cancer based on prostatic-specific antigen
(PSA) <4 ng/ml, negative biopsy or both criteria, the
incidence of PCa was 22%, 15% or 12%, respectively. The
proportion of MnSOD AA genotype was significantly
greater in the PCa than in non-PCa group. However, the
inclusion of occult PCa in the non-PCa group reduced the
odds ratio and increased the p-value. Conclusion: Because
MnSOD AA genotype is associated with occult cancer,
oxidative stress may result in the carcinogenesis of the
prostate. However, this association may be masked in
studies where the “cancer-free” control group contains cases
of occult PCA. It is important to recognize that
contamination of the control population by occult cancer
reduces the reliability of the results. Rigorous
characterization of the experimental and control groups is
needed in order to preserve the integrity of the conclusions.
290
IDENTIFICATION OF NOVEL
GENES INVOLVED IN THE SYNERGISTIC
ANTITUMOR EFFECT OF CAFFEINE IN
OSTEOSARCOMA CELLS USING cDNA
MACROARRAY
Sadao Ii1, Yoshimichi Ueda2, Miyako Shimazaki2,
Shogo Katsuta2, Koutarou Takazawa1,
Yoshimitsu Kanazawa1, Katsuro Tomita1
and Hiroyuki Tsuchiya1
1Department
of Orthopaedic Surgery, Graduate School of
Medical Science, Kanazawa University, 13-1 Takara-machi,
Kanazawa, Ishikawa 920-8641;
2Department of Pathology, Kanazawa Medical University,
Ishikawa, Japan
Background: Caffeine enhances the cytocidal effects of DNAdamaging agents. This study investigated genes involved in the
synergistic effect of caffeine on osteosarcoma cells using
gene-profiling analysis. Materials and Methods: Sensitivity to
cisplatin and the synergistic effect of caffeine were evaluated
in five osteosarcoma cell lines. Gene expression profilings
were analyzed using cDNA macroarray and verified by realtime RT-PCR. Results: The cell lines were grouped into three
types with different cytotoxic patterns. Comparison of
profiling data from these groups identified twelve novel genes
associated with the synergistic effect of caffeine. Real-time
RT-PCR analyses verified up-regulation of two apoptosisenhancing genes and down-regulation of two interferoninducible genes related to the synergy of caffeine. Conclusion:
These findings provide new insights into the molecular
mechanisms of the synergistic effect of caffeine in
osteosarcoma, providing candidates for an assay of
responsiveness to caffeine-potentiated chemotherapy for
osteosarcoma.
291
DEVELOPMENT OF A NEW 3-D
CO-CULTURE SYSTEM FOR HUMAN
BREAST CANCER PROGRESSION
S. Ashraf Imam
Molecular Pathology Program, Huntington Medical Research
Institutes, Pasadena, CA, 91101, USA
Background: Patients with cancer receive therapies that tend
to be directed at cancer cells, while sparing the surrounding
non-cancerous cells which are collectively called stromal
cells. One of the major types of stromal cells in tumor
lesions, referred to as myofibroblast or cancer-associated
fibroblast (CAF), is now recognized as a key factor
influencing cancer progression. Moreover, it is also
recognized that the present strategy of therapies of primary
cancer are inadequate for eradication of every last viable
cancer cell, hence the existence of residual viable cancer cells
that are likely to cause treatment failure and recurrence. Yet,
the CAF-derived contributing mediators of cancer progression
have been overlooked as the potential targets for treatment of
cancer patients. The progress in this newly recognized critical
field of tumor microenvironment has been slow, mainly due
to the technical difficulties of studying the significance of
heterotypic cellular interaction in tumor progression in the
presently available in vitro co-culture system. Methods: We
recently developed a 3-dimensional microgravity co-culture
system by overcoming the major difficulties of the presently
available co-culture system. Using our newly developed
system, breast cancer cell and breast CAF were successfully
co-cultured. The co-cultured preparation, termed breast
cancer histoid (BCH), was harvested, fixed in formalin,
embedded in paraffin, sectioned at 4 μm-thickness and
immunohistochemically (IHC) stained. Results: The sections
of BCH showed invasion of the core CAF by the cancer cells
which were positive for the expression of cytokeratins and CerbB-2, where as the CAFs were negative. Conversely, CAFs
exhibited the expression of α-smooth muscle actin, whereas
the cancer cells were negative. The stroma was positive for
the expression of collagen IV. Conclusion: The system
facilitated generation of BCH in a simulated tissue-like
microenvironment, thereby allowing heterotypic interaction,
invasion of CAF core by the cancer cells and their growth in
the endogeneously produced extracellular matrix. The BCH
has a potential to be used as a basis for the identification of
molecular mediators of breast cancer progression which could
be therapeutically targeted in not only the cancer cells but
also the stromal cells, as a new approach to therapy of
patients with primary breast cancer.
3325
ANTICANCER RESEARCH 28: 3157-3556 (2008)
292
UNMETHYLATED E-CADHERIN GENE
AND OVEREXPRESSION OF E-CADHERIN
PROTEIN ARE ASSOCIATED WITH
METASTATIC HUMAN PROSTATE
CANCER CELLS IN BONE
B. Saha1, P. Kaur1, D. Tsao-Wei2, W.Y. Naritoku3,
S. Groshen2, R.H. Datar3, L.W. Jones1 and S.A. Imam1
1Molecular
Pathology Program, Huntington Medical
Research Insts., Pasadena, CA, 91101;
2Departments of Preventive Medicine, and 3Pathology, USC
Keck School of Medicine, Los Angeles, USA
Background: The hypermethylation of E-cadherin gene and a
reduction and/or loss of E-cadherin protein expression have
been shown to be associated with the poorly differentiated
primary prostate cancer cells. However, the status of their
expression remains elusive in metastatic cancer cells in bone,
the most prevalent site for metastatic growth. Aim: The study
was undertaken to ascertain the methylation status of Ecadherin gene, a most frequent and known epigenetic
mechanism of its regulation, and E-cadherin protein
expression in biopsy prostate tissue specimens. Methods: The
methylation status of E-cadherin gene was determined by
methylation specific-PCR and E-cadherin protein expression
by immunohistochemical staining method in confirmed cases
of benign prostate hyperplasia (BPH) (n=11), primary prostate
carcinoma (n=20) or metastasis to bone (n=15). Results: The
BPH cells expressed unmethylated E-cadherin gene and
homogeneous membraneous expression of E-cadherin protein
in 10 out of 11 (91%) cases, whereas the methylated gene and
heterogeneous protein expression of the protein were
concurrently detected in the remaining case. The primary
prostate cancer cells exhibited methylated gene and
heterogeneous expression of the protein in 14 out of 20 (70%),
where as the unmethylated gene and heterogeneous expression
of the protein was detected in 3 out of 20 (15%) of cases. As
compared to the BPH cells, a statistically significant increase
in methylation of E-cadherin gene and reduction of E-cadherin
protein expression was detected in the primary prostate cancer
cells (p>0.001). In contrast to the primary cancer, a
significantly increased frequency of metastatic prostate cancer
cells in bone exhibited unmethylated E-cadherin gene and
homogeneous expression of E-cadherin protein in 13 out of 15
(87%) of cases, and unmethylated gene with heterogeneous
expression of the protein in the remaining 2 cases (McNemar
p<0.001). Conclusion: This new observation demonstrated
that the unmethylated E-cadherin gene and E-cadherin protein
expression are significantly associated with distant metastatic
prostate cancer cells in bone and that the high frequency of its
expression may have a intercellular adhesion function in the
formation of lesions of metastatic cancer cells in bone.
3326
293
HPV 16-ASSOCIATED TUMOURS: IN VITRO
RESPONSES OF IMMUNE MICE AND MICE CURED
WITH CHEMOTHERAPY AND SUBSEQUENT IL-12
IMMUNOTHERAPY
Marie Indrová, Jana Bieblová, Jan Bubeník and Milan Reiniš
Institute of Molecular Genetics, Academy of Sciences of the
Czech Republic, v. v. i., Vídeňská 1083, Prague 4, Czech
Republic
We have used an animal model for HPV16-associated
tumours with distinct levels of MHC class I expression, TC1 (MHC class I+) and TC-1/A9 (MHC class I–) to examine
the immune responses and production of cytokines after
immunotherapy with irradiated cellular vaccine producing
IL-12 (TC-1-IL-12) of minimal residual tumour disease
induced by ifosfamide derivative CBM-4A. Additionally, we
assessed the immune responses and production of cytokines
after immunization of healthy mice with irradiated TC-1 or
TC-1/A9 tumour cells.
The expression of MHC class I molecules on tumour cells
used for vaccination had no effect on the Th1/Th2 polarization
in the spleen of mice after chemotherapy and subsequent
immunotherapy, nor in the spleens of mice after immunization
with two doses of irradiated TC-1 or TC-1/A9 cells. However,
in both protocols, up-regulation of cytokine production was
detected and compared to control animals. Chemotherapy and
subsequent IL-12 immunotherapy of MHC class I-positive TC1 tumours with the TC-1-IL-12 vaccine, as well as
immunization with irradiated tumour cells, led to significant
up-regulation of Th1 cell-produced cytokines IL-2 and IFNγ
by the spleen cells. Significant up-regulation of IL-5, but not
of IL-4 (Th2 cytokines) was also observed
In the 51Cr microcytotoxicity assay, cytotoxic CD8+ cells
were found in the spleens of TC-1 (MHC class I+) but not of
TC-1/A9 (MHC class I–)-tumour-bearing mice treated by
combined chemo-immunotherapy with CBM-4A and
cellular vaccine producing IL-12, as well as in the spleens
of mice immunized with irradiated tumour cells. In the
spleens of TC-1/A9 but not of TC-1 tumour-treated animals,
NK activity measured as the lysis of NK-sensitive YAC-1
targets was detected.
Grants: No. 301/06/774 (GA CR), No. IAA500520807 (GA
AS CR) and Clinigene project EU-FP6-NOE, No.018933.
294
CELLULAR BIOLOGY OF BREAST
CANCER, FOCUSING ON GENOMIC AND
CLINICOPATHOLOGICAL EVENTS
IN CARRIERS OF A BRCA2 FOUNDER MUTATION
Sigurdur Ingvarsson
Abstracts of the 8th International Conference of Anticancer Research, 17-22 October 2008, Kos, Greece
Institute for Experimental Pathology, University of Iceland at
Keldur, v/Vesturlandsveg, 112 Reykjavik, Iceland
Like other cancer types, breast cancer is considered to be a
genetic disease. While the majority of genetic changes are
somatic, a minority are in germline. About 10-20% of breast
cancer is thought to be due to a germline mutation in highpenetrance genes, where the major focus has been on BRCA1
and BRCA2. Hereditary differs from sporadic breast cancer
with respect to phenotype, chromosomal gains and losses,
somatic mutations and expression pattern. TP53 pathways are
altered in carriers of BRCA1 and BRCA2 mutations, and
BRCA1 carcinomas frequently carry TP53 mutations. There is
strong evidence that genomic instability has a role in breast
cancer pathogenesis, particularly in hereditary breast cancer,
and possibly a role in sensitivity and resistance to therapy.
Some germline mutations are defined as founder mutations.
Founder mutations permit analysis of a large number of cases,
and provide more accurate information on penetrance,
expression, and genetic and environmental modifiers of risk.
Population studies are also valuable due to the possibilities for
evaluating clinicopathological data in a group of patients who
have the same mutation. In Iceland a rare founder mutation
has been detected in BRCA1, and a frequent one in BRCA2. In
addition to population-based studies on genetics and
clinicopathology, an extensive analysis of somatic changes in
tumours of BRCA2 founder mutation carriers has been made.
As the Icelandic carriers of BRCA mutations all have the same
alteration, this can be considered an ideal model population to
analyze the influences of somatic mutations acquired during
carcinogenesis and tumor progression and effects of lowpenetrance modifier genes. This information can be useful in
understanding the role played by these genes in the incidence
of breast cancer, in order to target genetic testing, provide
individual risk assessment, and design better therapeutic
strategies. The evidence of differences in susceptibility and in
age of onset among carriers of a specific mutation makes it
easier to define the role and importance of risk-modifying
factors, leading to improved disease management.
295
BEE VENOM-INDUCED G0/G1 PHASE ARREST AND
APOPTOSIS IN HUMAN BLADDER CANCER TSGH8301 CELLS VIA REACTIVE OXYGEN SPECIES AND
MITOCHONDRIA-DEPENDENT PATHWAY
Siu-Wan Ip1, Yung-Lin Chu1 and Jing-Gung Chung2
Departments of 1Nutrition and 2Biological Science and
Technology, China Medical University, No.91 Hsueh-Shih
Road, Taichung, Taiwan 40402, ROC
Bee venom (BV) has been shown present biological activities
including inhibit growth and induce apoptosis in human cancer
cells. However, there are no reports to address the molecular
mechanisms involved in BV-induced apoptosis in human
bladder cancer TSGH-8301 cells. In this study, we showed that
BV reduced the percentage of viable TSGH-8301 cells and the
IC50 is 10 μg/ml in the BV-induced cell death. Flow cytometer
also demonstrated that BV induced G0/G1 arrest, increased the
levels of reactive oxygen species (ROS) and Ca2+ production
and reduced the change in mitochondrial membrane potential
(ΔΨm) in TSGH-8301 cells. BV-induced apoptosis was also
confirmed by 4,6-diamidino-2-phenylindole (DAPI) staining,
Comet assay and DNA gel electrophoresis. The results indicated
BV induced cytotoxicity and apoptosis in dose-dependent
manners. It is suggested that BV inhibits the proliferation of
human bladder cancer TSGH-8301 cells and induced apoptosis
through induction of ROS. Consequently, BV can be used for
clinical treatment in bladder cancer patients in future.
296
EGFR AMPLIFICATIONS AND
MUTATIONS IN LUNG CANCER
Sofi Isaksson1, Annette Salomonsson1, Pär-Ola Bendahl1,
Leif Johansson2, Per Jönsson3, Mats Jönsson1,
Göran Jönsson1 and Maria Planck1
Departments of 1Oncology, 2Pathology and 3Thoracic
Surgery at Lund University Hospital, Sweden
Epidermal growth factor receptor (EGFR) is one of four
members of the HER family of cell surface receptors. These
are involved in the intracellular signaling which results in
altered gene expression and stimulation of cell proliferation.
EGFR is expressed or overexpressed in a wide variety of solid
human tumors, including lung cancer of the non-small cell
type (NSCLC), which constitutes eighty percent of all lung
cancer. Some patients with advanced NSCLC may benefit
from treatment with tyrosine kinase inhibitors (TKIs) directed
against EGFR. EGFR protein expression, EGFR gene copy
numbers, EGFR mutation status, and alterations in molecules
acting downstream of EGFR, have all been suggested to be
important in predicting response to these drugs, but no
consensus regarding the preferred choice of predictive
biomarkers has yet been achieved.
We analyzed the spectra of EGFR mutations and
amplifications in 62 freshly frozen biopsies of early-stage
primary NSCLC tumors (48 adenocarcinomas and 14
squamous cell carcinomas) using quantitative PCR of EGFR
and direct sequencing of exons 18-21. Furthermore, we
studied the genetic profiles of the tumors in relation to EGFR
status by array-based comparative genomic hybridization
(aCGH) using whole-genome tiling resolution bacterial
artificial chromosome (BAC) microarrays.
Amplification of the EGFR gene (qPCR ratio ≥1.5) was
demonstrated in 3/48 adenocarcinomas and in 4/14
3327
ANTICANCER RESEARCH 28: 3157-3556 (2008)
squamous cell carcinomas. Mutation (substitution, insertion
or deletion) was found in 7 adenocarcinomas. Two of these
harbored both mutation and amplification. Seven EGFR
amplifications (at a level corresponding to at least 4 gene
copies) were detected by aCGH, and all of these could be
confirmed by qPCR, and vice versa. The gene copy number
profiles of the EGFR-altered tumors, as revealed by aCGH,
were complex and harbored frequent alterations in regions
containing known or presumed oncogenes and tumor
suppressor genes.
297
DETAILED PHARMACOLOGICAL EVALUATION OF
A TUMOR-INHIBITING RUTHENIUM (III)
COMPLEX WITH DICHLORO-BIS(ETHYL 2-AMINO4-PHENYL-5-THIAZOLE- CARBOXYLATE)
RUTHENIUM(III) CHLORIDE, CYTO-TOXICITY,
INDUCTION OF APOPTOSIS, DNA-BINDING AND IN
VIVO ANTINEOPLASTIC EFFICACY
Georgi Momekov1, Iva Ugrinov1,2, Evdokia Pashev1,2,
Spiro Konstantrinov1,2, Dilyan Ferdinandov1,
Antonina Nikolov1,3 and Darvin Ivanov3
1Department
of Pharmacology, Pharmacotherapy and
Toxicology, Faculty of Pharmacy, Medical University-Sofia,
2 Dunav Str., 1000 Sofia;
2Institute of Molecular Biology, Bulgarian Academy of
Sciences, Acad. G.Bonchev Str, bl. 21, 1113 Sofia;
3Department of Chemistry, Faculty of Pharmacy, Medical
University-Sofia, 2 Dunav Str., 1000 Sofia, Bulgaria;
4Unit of Toxicology and Chemotherapy, German Cancer
Research Center, 69 120 Heidelberg, Germany
A detailed pharmacological evaluation of a novel ruthenium
(III) coordination compound with dichloro-bis(ethyl 2-amino4-phenyl-5-thiazolecarboxylate) ruthenium (III) chloride (L)
was carried out. The cytotoxic activity of L was tested using
the MTT-dye reduction assay against a broad spectrum of
human tumor cell lines. The tested ruthenium complex
exhibited significant concentration-dependent cytotoxic effects
comparable or even superior to that of cisplatin. As evidenced
by the observed oligonucleosomal fragmentation of genomic
DNA following treatment of tumor cells with L its cytotoxic
effects are at least partly mediated by induction of apoptosis.
The DNA binding of L and cisplatin were assessed using a 40
n.b. fragment (5’ CGCTATCGCTACCTATT-GG-ATCCT
TATGCGT TAGTGTATG 3’), whereby the present GG-motif
is the recognition sequence of the nuclease Bam H1. The level
of DNA modification was determined after Bam H1 treatment,
5% polyacrilamide gel electrophoresis and ethidium bromide
staining. Cisplatin completely inhibited the BamH1-mediated
fragmentation of the target DNA-molecule indicating high
platination capacity. The complex also significantly inhibited
3328
the fragmentation of the target DNA sequence. L exerted
significant antineoplastic activity against the murine
transplantable tumor Lewis lung carcinoma as evidenced by
the observed increase of the life span (ILS) in the treated vs.
untreated animals.
298
SYNTHESIS AND CYTOTOXIC ACTIVITY
OF 3-METHOXY-SALICYLALDEHYDE
BENZOYLHYDRAZONE
Boriana Nikolova-Mladenova1, Georgi Momekov2 and
Darvin Ivanov1
1Department
of Chemistry, Faculty of Pharmacy, Medical
University-Sofia, 2 Dunav Str., 1000 Sofia;
2Department of Pharmacology, Pharmacotherapy and
Toxicology, Faculty of Pharmacy, Medical University-Sofia,
2 Dunav Str., 1000 Sofia, Bulgaria
A new chelating agent 3-methoxy-salicylaldehyde benzoyl hydrazone (m-SBH) was synthesized. The ligand was prepared
by the Schiff base condensation between benzoylhidrazine and
3-methoxy-salicylaldehyde in ethanol. The compound was
characterized by elemental analysis, spectroscopic methods
(IR, NMR) and thermal analysis. The new compound was
investigated for cytotoxicity using MTT-dye reduction assay
on several human cell lines. m-SBH showed a concentrationdependent inhibitory activity on SKW-3, HL-60, BV-173 and
K-562 cell lines. The preliminary mechanistic investigations
showed that the cytotoxicity of the compound is mediated by
induction of apoptosis.
299
RADIOEMBOLIZATION USING 90YTTRIUM
MICROSPHERES IN PRIMARY AND
METASTATIC LIVER CANCER
Tobias F. Jakobs1, Ralf-T. Hoffmann1,
Klaus Tatsch2 and Maximilian F. Reiser1
Departments of 1Clinical Radiology, and 2Nuclear Medicine,
University of Munich, Grosshadern Campus,
Marchioninistrasse 15, 81377 Munich, Germany
Most patients with colorectal, breast, lung, hepatocellular and
pancreatic cancer are at risk for recurrence from metastatic
disease in the liver after potentially curative treatment. When
the liver harbors metastatic or primary cancer, treatment
options are reduced and patient survival rates rapidly decline.
Unfortunately, uncontrolled liver disease is the most common
final pathway for nearly half of all patients with colorectal
cancer and the majority of people diagnosed with
hepatocellular cancer. It is a worldwide health issue and a
leading cause of premature death.
Abstracts of the 8th International Conference of Anticancer Research, 17-22 October 2008, Kos, Greece
Anticancer Treatment Moves Forward with Microspheres:
Today, there is new hope in the push to eradicate cancer from
the liver through use of cutting-edge imaging technology to
assist in delivery of microscopic radioactive spheres. These
microspheres go directly to the tumor site, attacking cancerous
cells while sparing healthy tissue. A multimodality approach,
which utilizes the skills and expertise of several specialties –
including diagnostic radiology, interventional radiology,
radiation oncology and nuclear medicine – enables the
radiation to be safely administered directly into the liver
tumors. There are currently two forms of microspheres: SIRSpheres® microspheres and Nordion’s TheraSpheres. SIRSpheres, which are polymer-based and manufactured by
Sirtex, are currently the only FDA-approved microspheres for
treatment of metastatic liver cancer. Nordion’s TheraSpheres
are made of glass beads that are irradiated. Though they are
not FDA-approved, TheraSpheres have received “humanitarian
device use” in the United States for hepatocellular carcinoma
(HCC). Due to its FDA-approved status, the data presented in
this presentation predominantly refer to SIR-Spheres.
Physicians are encouraged by the early and impressive results
of microspheres therapy, and patients often cite the minimal
side-effects and ease of treatment.
Microspheres Background: Each SIR-Spheres microsphere is
composed of resin and yttrium-90, a pure beta emitter that
only penetrates tissues up to 11 mm. The radioactive source
90Y does not come off of the microspheres, so by restricting
the spheres to the tumor, the radiation is also localized
exclusively to that area. Therefore, when microspheres are in
the tumor – where they remain permanently – they will
destroy only cancerous cells, and spare the surrounding
normal liver tissue. The infusion of microspheres is performed
in the angio suite primarily by an interventional radiologist
who has experience with cheomoembolization. A key feature
of delivering microspheres to the tumor is the fact that 80 to
100 percent of the blood supply to metastases in the liver
comes from the hepatic artery. The latest in microcatheter and
diagnostic interventional radiology C-arm technology allows
for precise placement of radiation into small, peripheral
vessels. During the procedure, the catheter is positioned in the
liver with x-ray guidance by an interventional radiologist to
allow for targeted infusion of the SIR-Spheres to the liver
tumors. Since the treatment has to be precise, the role of
imaging cannot be underestimated. The amount of radiation
delivered can be significant, but because the microspheres are
only about 32 microns in diameter, they enter the tumor from
the hepatic artery supply and preferentially collect in the
periphery of tumor nodules. The capillary beds will only allow
passage of particles that are less than 10 microns, thereby
trapping the microspheres within the tumor.
Imaging Guiding during SIR-Spheres Microspheres Infusion.
Imaging is critical in all phases of internal radiation therapy.
The treatment process starts with establishing the location,
size and volume of tumors in the liver. At the same time,
there also is a search for any extrahepatic tumor deposits.
Using a PET-CT System, complementary information is
obtained on the location and cellular activity of tumor
deposits in three dimensions. High-resolution three-phase
liver imaging is obtained with CT, followed by hepatic
arterial system mapping internally with angiography. Next,
the hepatic vasculature and potential release point of the
microspheres are tested with a macro-aggregated albumin
scan (99mTcMAA), which uses the ubiquitous human serum
protein albumin, processed into the same size as the
radioactive microspheres, but bound to a gamma-emitting
isotope for imaging instead of a beta source that is used for
therapy, which cannot be easily imaged. The albumin
particles lodge in the tumor just like the microspheres do, and
thus a ‘simulation’ of the treatment is performed to detect
deposition of particles in the stomach, small bowel or lungs
instead of the intended target, the liver tumors. Corrective
measures can then be taken to make microsphere delivery
safer by avoiding extrahepatic spread.
Results: In this presentation, we review the results of 90Y
radioembolization in patients with non-resectable, otherwise
non-responding, primary or secondary liver cancer.
300
APPLICATION OF A TRANSMISSION LOWCOHERENCE DIGITAL HOLOGRAPHIC
MICROSCOPE IN CANCER CELL BIOLOGY
Hana Janeckova1, Pavel Vesely2 and Radim Chmelik1
1Institute of Physical Engineering, Faculty of Mechanical
Engineering, BUT, Technicka 2, Brno, 616 69;
2Institute of Molecular Genetics, AS CR, Flemingovo
namesti 2, Prague 6, 166 37, Czech Republic
Initial experiments with the transmission digital holographic
microscope (DHM) proved that the system is a usable
instrument for imaging of cells, especially for monitoring of
fast responses of living cells to external stimuli. Here we
decided to exploit two distinguished properties of the DHM
imaging in an in vitro study of cancer cell behaviour.
The first application was imaging of living cells attached to
a cover slip at the bottom of the imaging chamber and
immersed in an opalescent medium. To simulate these
conditions we made a standard culture medium turbid by
adding of polystyrene micro spheres (with a diameter of 356
nm). So we obtained a strongly scattering medium which
filled the whole chamber and covered the cells with a 0.8 mm
thick diffusing layer. The simulation showed that due to the
capability of the microscope to shorten the coherence length of
the illumination, the DHM can offer information about the
condition of cells in situations where standard microscopy is
failing.
3329
ANTICANCER RESEARCH 28: 3157-3556 (2008)
The second application used a computed 3D presentation of
cellular activity that is deemed to be more informative about
fast cellular reactions that involve sudden and transient
changes of the cell height and the distribution of the cell mass.
Indeed in an experimental series designed to study the
resistance and the type of reaction of various cancer cells to
acute nutritional and energy deprivation we found this type of
visualization advantageous (videos will be demonstrated). We
obtained similar experience with comparative imaging of
apoptosis induced by cisplatinum treatment. The assessment
of DHM imaging of cultured cells performed so far was done
in stationary single-use chambers only. Employment of a
through-flow chamber (under development) is expected to be
even more instrumental.
The project was supported by GACR (project no.
202/08/0590), by application research programmes of the
Ministry of Education of the Czech Republic (project no.
MSM0021630508) and project no. AV0Z50520514 Academy
of Science CR. This work was also supported by the Faculty
of Mechanical Engineering (project no. BD1373002).
301
RELEASE OF CFSE FROM NSCLC CELLS
CULTURED WITH DIFFERENT TYPE OF DC
“VACCINES” AND INFLUENCE OF TUMOUR
LYSATE ON STATE OF LYMPHOCYTE ACTIVATION
Olga Jankowska1, Paweł Krawczyk1, Dariusz Sagan2,
Kamila Wojas-Krawczyk1, Jacek Roliński3
and Janusz Milanowski1
1Department
of Pneumonology, Oncology and Allergology
Medical University of Lublin;
2Department of Thoracic Surgery Medical University of
Lublin;
3Department of Clinical Immunology, Medical University of
Lublin, Poland
Immunotherapy is one of the most promising methods of
cancer treatment. Vaccines against cancer aim to induce
tumour-specific effector T-cells that can change the
immunological system and reduce tumour mass. At present,
there is no standardized methodology for preparing vaccines,
and many questions concerning the optimal source and type
of antigens as well as DC maturation state and activity still
need to be answered.
The aim of our study was to investigate in vitro efficiency
of autologous DCs to destroy NSCLC cells, the state of
lymphocyte activation and ability of lymphocytes for cytotoxic
reaction in two different types of DC stimuli.
After surgical resection, small tumour fragments were
placed in culture dishes containing different growth factors.
Seven days after operation, peripheral blood mononuclear
cells (PBMCs) were cultured in RPMI-1640 medium
3330
supplemented with 10% autologous plasma in the presence
of rhIL-4 and rhGM-CSF to generate immature autologous
DCs. Mature DCs were obtained after incubation with TNFα and tumour cell lysate or only with TNF-α. Cultures
consisted of DCs, lymphocytes and macrophages. Cancer
cells stained with CFSE were co-cultured with different kind
of DCs. Flow cytometry, confocal microscopy and
fluorometry were used in the investigation.
In this study, we found a significant increase in CFSE
fluorescence level in supernatant from culture with tumour
lysate and without tumour lysate in comparison with the pure
tumour cell culture (p=0.03 and p=0.002, respectively). There
was slightly higher CFSE fluorescence in supernatants from
culture without tumour antigens in comparison with tumour
lysate culture. We discovered a significantly positively
correlation between expression of CD83 antigen on DCs and
CFSE fluorescence level in culture without tumour lysate. We
also observed a significantly negative correlation between the
expression of CD83 antigen and percentage of CD83+ cells in
the same culture.
In our study, we discovered a significantly higher
percentage of cells producing IFN-γ in only TNF-α cultures
in comparison with tumour cell lysate cultures (10.91±6.53%
versus 8.95±4.86%; p=0.01). We also found a statistically
significant positive correlation between percentages of CD69+
lymphocytes and percentage of cells producing IFN-γ in only
TNF-α cultures (R=0.61; p=0.01) and (R=0.74; p=0.002) in
culture with tumour cell lysate.
The present study suggests that autologous DCs stimulated
solely by TNF-α were fully competent and may phagocytize
cancer cells. It seems possible that DCs loaded with tumour
antigens become too mature and lose phagocytolytic qualities.
Such a vaccine may serve as a novel immunotherapy method
in lung cancer treatment. Our research showed that mature
DCs have the ability for cancer antigen presentation and could
be able to activate cytotoxic T lymphocytes in both types of
cultures. The significantly lower percentages of CD69+
lymphocytes and cells producing IFN-γ in cultures with
tumour cell lysate confirmed the reduction (depletion) of DC
function. This result suggests that tumour lysate may contain
different compounds, responsible for cell inhibition.
302
ROLE OF LOW PENETRANCE GENES IN FAMILIAL
BREAST CANCER SUSCEPTIBILITY
Lilian Jara
Human Genetics Program, Institute of Biomedical Sciences,
School of Medicine, University of Chile, Chile
Breast cancer (BC) is the most common cancer in women in
the world. It has been estimated that one out of every nine
women will develop BC during their lives. Hereditary BC
Abstracts of the 8th International Conference of Anticancer Research, 17-22 October 2008, Kos, Greece
accounts for around 5-10% of all BC cases. Germline
mutations in the two major susceptibility genes BRCA1 and
BRCA2 (BRCA1/2) account for aproximately 20% of the
familial BC cases. Thus, it was possible to infer the potential
involvement of additional susceptibility genes that would
account for low to moderate breast cancer risk. This is in
accordance with the most widely accepted model which
proposes that familial BC susceptibility is a consequence of a
small number of mutations in BRCA1/2 and a much higher
proportion of mutations in ethnic-specific genes of moderate
and/or low penetrance.
Several studies have reported that mutations in genes
involved in DNA repair and in the maintenance of genome
integrity may be responsible in the increase of cancer risk,
including RAD51, CHEK2, XRCC3 and ATM.
Human RAD51 is known to function in DNA repair and
interacts with a number of proteins implicated in BC, such as
BRCA1/2. Using a case–control design, we have studied the
RAD51 135G>C polymorphism (c.-98G>C, rs1801320) to
evaluate its possible association with BC susceptibility. Our
results showed an association of RAD51 135C genotypes (G/C
and C/C) with an increased BC risk only among women with:
a) a family history of BC, b) BRCA1/2-negative tumors and c)
with age of onset <50 years (p=0.020, OR=2.17 [95%CI 1.114.24]). Therefore, our results allow us to propose that RAD51
135G>C polymorphism increases the risk of familial BC in
women, with age of diagnosis <50 years, and this
polymorphism may be a BC risk variant.
With respect to CHEK2, we analyzed the 1100delC
mutation in 1320 individuals (196 breast cancer patients, 500
healthy Chilean females, and 624 healthy Chilean females but
with at least two first or second degree relatives with BC).
None of the analyzed samples carried the CHEK2 1100delC
mutation. This finding suggests that this mutation is not either
present or is present at an extremely low frequency in Chilean
families with familial BC. Therefore, this variant has no
practical importance for the clinicians in our population. We
also raise the hypothesis that the 1100delC mutation is not
present in some of those contemporary South American
populations that stem from the admixture of Amerindian
peoples with the Spanish settlers.
The ATM gene has been frequently implicated in hereditary
BC as a low-penetrance susceptibility gene. The ATM kinase
has an essential role in maintaining genomic integrity. We
carried out a full mutation analysis of the ATM gene. We
detected two missense variants and eight intronic
polymorphisms. We also perform a case–control study
between a subgroup of BRCA1/2-negative cases and controls
for the 5557G>A missense variant and the IVS38-8T>C and
the IVS24-9delT polymorphisms. Carriers of the IVS249delT/IVS38-8T>C/5557G>A composite triheterozygous
genotype showed an increase in BC risk (OR=3.09 [95%CI
1.11-8.59], p=0.024). This composite genotype alone, or in
combination with certain genetic background and/or
environmental factors, could modify cancer risk by increasing
genetic instability or by altering the effect of the normal DNA
damage response.
Our results show that genetic tests are relevant in defining
individual risks for hereditary BC.
Partially supported by Grants: FONDECYT 1060094; DIUCHILE MULT 05/12-2, and The National Cancer Society
(CONAC)
303
THE COMBI-TARGETING CONCEPT:
ENGINEERING ANTICANCER MOLECULES TO
BLOCK MULTIPLE INTRACELLULAR TARGETS
Bertrand J. Jean-Claude, Qiu Quyi, Zakaria Rachid,
Fouad Brahimi, Anne-Laure Larroque,
Sherin Al-Safadi and Juozas Domarkas
McGill University (MUHC), Royal Victoria Hospital,
Montreal, Quebec, Canada
Overexpression of the epidermal growth factor receptor
(EGFR) and its closest homologue HER2 have been
associated with aggressive tumour progression and reduced
sensitivity to DNA-damaging agents. In order to block the
progression of refractory tumours overexpressing EGFR, we
developed a novel strategy termed “combi-targeting” that
sought to design molecules capable of not only blocking
EGFR tyrosine kinase but also damaging DNA. These
molecules, termed combi-molecules (CMs), in addition to
being EGFR inhibitors on their own, were shown to release
under physiological conditions another inhibitor of EGFR,
and to be potent against EGFR-expressing tumour cells of
various origins. These include breast, prostate carcinoma of
the vulva and brain tumour cells. However, despite their
binary targeting mechanism, their growth inhibitory IC50
values were still in the high micromolar range. In order to
augment the potency of the CMs, we re-designed them to not
only release a quinazoline inhibitor of EGFR, but also bifunctional alkylating moieties prone to induce DNA crosslinks. More importantly, molecules termed “double-armed
combi-molecules” were further designed to contain two
quinazoline moieties and a central N,N-bis(2aminoethyl)methylamine
spacer
which,
following
degradation, yielded higher concentrations of free inhibitors +
cytotoxic bifunctional DNA damaging species. These
molecules (e.g. ZRBA4, JDE52) were proven to be more
effective than their predecessors and corresponding
combinations of classical alkylators+inhibitors of EGFR. In
this presentation, the potency of such type of novel combimolecules against EGFR-overexpressing human tumour cells
and their interactions with EGFR-mediated cell signaling will
be analyzed.
3331
ANTICANCER RESEARCH 28: 3157-3556 (2008)
304
ALTERATION OF HEPATIC STELLATE CELLS IN
ASCORBIC ACID DEFICIENCY AND AGING
Il-Hwa Hong1, Jung-Youn Han1, Jin-Kyu Park1,
Moon-Jung Goo1, Ok-Kyung Hwang1,
Kyung-Sook Hong1, Ae-Ri Ji1, Mi-Ran Ki1,
Sung-Yong Hwa2 and Kyu-Shik Jeong1
Department of Pediatrics, Johns Hopkins University School
of Medicine, 733 N Broadway, Baltimore, Maryland 21205,
USA;
3School of Medicine Kyungpook National University, Daegu
City, Republic of Korea
Aging is an extremely complex, multifactorial process and
represents the gradual deterioration in function that occurs after
maturity and leads to disability or death. The examination of
aging in vital organs including the liver is important for
understanding the aging processes. However, the mechanism
of age-dependent change in vital organ is still unclear.
Therefore, age-dependent changes of the liver were examined
using Senescene marker protein-30 knockout (SMP30–/–) mice
as an aging model. SMP30 has been reported as decreasing
with age and functioning as gluconolactonases in L-ascorbic
acid synthesis. SMP30–/– mice were more sensitive to apoptotic
reagents and shorter in life span than normal mice. In
microscopic findings of the liver from aged SMP30–/– mice
without an ascorbic acid (AA) feeding for 16 weeks, there was
an increased amount of both lipid droplets and glycogen in
hepatocytes, than in those fed AA and hepatic stellate cells
(HSCs) were hypertrophic with lipid droplets which indicated
a hypervitaminosis A condition. Moreover, the level of
peroxisome proliferators-activated receptor gamma (PPARγ)
increased in the liver. Surprisingly, HSC hypertrophy of aged
mice was decreased after treatment with ENA Actimineral A
(ENA), which is alkaline bioactive water and has antioxidant
function, as compared to non-treatment group. In conclusion,
we propose that AA deficiency in aged SMP30–/– mice
accelerate the hypertrophy of HSCs with vitamin A
accumulation as well as the accumulation of lipid and glycogen
in hepatocytes, and increase the expression of PPARγ.
Several therapeutic agents have been shown to inhibit fibrosis
and improve regeneration after injury in skeletal muscle by
antagonizing transforming growth factor-beta1 (TGF-β1).
Angiotensin receptor blockers have been shown to have a
similar antagonizing effect on TGF-β1 in a variety of tissues.
In this study we evaluated the effect of Losartan, angiotensin
Ⅱ type 1 receptor blockade, on skeletal muscle injury via
elevated TGF-β1 produced by CCl4 induced liver injury. Male
C57BL/6 mice were randomly divided into three groups:
control, CCl4-treatment group (CT) and CCl4-treatment group
with adding losartan (CTL). 10% CCl4 in olive oil were
injected intraperitoneally three times a week with or without
losartan (10 mg/kg) in drinking water. At 16 weeks, all mice
were sacrificed and analyzed through the biochemistry,
histopathology, immunohistochemistry and immunoblot tests.
Expression level of creatine kinase (CK) and TGF-β1 in serum
were the highest in CT and their level significantly decreased
in the losartan treated group. On immunohistochemistry and
immunoblot Dystrophin, sarcolemma membrane structural
protein, was significantly decreased in CT (49.3±2.8) group
compared with CTL (87.3±8.5) group. p-Smad2/3 which is the
downstreams of TGF-β1 was significantly increased in CT
(1216.3±105.5) group compared with CTL (547.3±52.5)
group. Pax7, transcription factor of quiescent satellite cell was
increased in CTL (0.63±0.03) group compared with CT
(0.47±0.02) group. Myogenic regulatory factors including
MyoD and Myogenin also showed the same results with pax7.
In conclusion we suggest the skeletal muscle myogenesis was
impaired by producing TGF-β1 from CCl4-induced liver injury
and, angiotensin Ⅱ type 1 receptor blockade (Losartan) has
protective effect on TGF-β1-induced skeletal muscle injury via
the stimulation of muscle regeneration, indicating potential
therapeutic effects in myopathies.
305
EFFECT OF ANGIOTENSIN Ⅱ TYPE 1 RECEPTOR
BLOCKADE ON SKELETAL MUSCLE INJURY BY
TGF-BETA INDUCED FROM CCL4 INJURED LIVER
306
ENA-ACTIMINERAL A EXTEND THE LIFE-SPAN OF
SMP30 KNOCKOUT MICE VIA ANTI-OXIDANT
MECHANISM
Ok-Kyung Hwang1, Jin-Kyu Park1, Il-Hwa Hong1,
Mi-Ran Ki1, Dong-Wei Yuan1, Jung-Youn Han1,
Kyung-Sook Hong1, Ae-Ri Ji1, Ronald D Cohn2,
Soon-Hak Kwon3 and Kyu-Shik Jeong1
Jung-Youn Han1, Jin-Kyu Park1, Mi-Ran Ki1, Dong-Wei
Yuan1, Il-Hwa Hong1, Moon-Jung Goo1, Ok-Kyung Hwang1,
Kyung-Sook Hong1, Ae-Ri Ji1,Yoo-Kyung Kim2,
Sung-Yong Hwa3 and Kyu-Shik Jeong1
1Department
1Department
1Department
of Pathology, College of Veterinary Medicine,
Kyungpook National University, Daegu City 702-701;
2Jinju Bio Food, Jinju City 660-931, Republic of Korea
of Veterinary Pathology, College of Veterinary
Medicine, Kyungpook National University, Daegu City 702701, Republic of Korea;
2McKusick-Nathans Institute of Genetic Medicine,
3332
of Pathology, College of Veterinary Medicine,
of Home Economics Education, Kyungpook
National University, Daegu City 702-701;
3Jinju Bio Food, Jinju City 660-931, Republic of Korea
2Department
Abstracts of the 8th International Conference of Anticancer Research, 17-22 October 2008, Kos, Greece
ENA-Actimineral A (ENA), alkaline mineral water which is
composed of refined edible cuttlefish (Sepia esculenta) and
two different species of seaweed, such as phymatolithon
calcareum and Lithothamnion corallioides, was previously
reported to restore bone loss and bone quality in
ovariectomized rats. To investigate the anti-oxidant effect of
ENA, an experiment was performed with Senescence marker
protein-30 knockout (SMP30 KO) mice as an aging model.
SMP30 was known to maintain calcium homeostasis and upregulate synthesis of vitamin C as an antioxidant in previous
studies, therefore, SMP30 KO mice can be regarded as a good
aging model. Present studies were composed of 18 week-old
mice groups (n=24), 26 week-old mice groups (n=12) and 46
week-old mice groups (n=20). Each differently aged mice
group was divided into three groups again: control group,
5%ENA and 10% ENA treated group. All groups of 18 weekold mice were treated with vitamin C 1.5g/L drinking water.
The experiments were performed for 18 weeks. In the
examination of life span, all vitamin C treated groups revealed
100% of survival rate. However, in non-vitamin C treated
groups, only 10% ENA treated groups showed 100% of
survival rate, as apposed to control group and 5% ENA treated
groups, indicating 0% of survival rate. In vitamin C treated
groups, the concentration of vitamin C in serum was increased
by ENA dose-dependently. In TUNEL assay, a number of
positive hepatocytes decreased significantly ENA dosedependently. In immunoblot analysis of anti-oxidant protein
expression, the expression level of Cu, Zn-SOD was increased
by ENA dose-dependently. These data strongly suggested that
intake of ENA plays a critical role in the anti-aging
mechanism and it can act as a powerful anti-oxidant agent.
307
NEUTRALIZING INTERACTIONS
BETWEEN CYTOTOXIC DRUGS
H. Ehrhardt, L. Pannert, K. Schneider and I. Jeremias
Helmholtz Zentrum München, Marchioninistrasse 25, 81377
Munich and Department of Oncology / Hematology, Dr. von
Haunersches Kinderspital, Lindwurmstr 4, 80337 München,
Germany
Within polychemotherapy protocols, cytotoxic drugs are
applied in combinations in order to overcome drug resistance
and to enhance treatment efficiency. For this purpose,
anthracyclines are frequently given on the same day as vincaalkaloids, e.g. during induction therapy of acute lymphatic
leukemia treatment.
Here we found that anthracyclines inhibited the antitumor
activity of vinca-alkaloids both on tumor cell lines as well as
on primary tumor cells of children with acute lymphatic
leukemia. The inhibitory function of anthracyclines strongly
depended on the activation of defined intracellular signaling
steps and inhibited mitochondrial depolarization and activation
of caspases by vinca-alkaloids. Of great clinical importance,
the anthracycline-induced inhibition of vinca-alkaloidmediated tumor cell death was absent if both drugs were given
at certain intervals.
Our data show for the first time that cytotoxic drugs exert
adverse, antiapoptotic effects on tumor cells which might be
avoided in future polychemotherapy protocols using favorable
application schedules.
308
PHASE III RANDOMIZED STUDY
COMPARING ORAL PILOCARPINE VS.
SUBMANDIBULAR SALIVARY
GLAND TRANSFER PROTOCOL
FOR THE MANAGEMENT OF
RADIATION INDUCED XEROSTOMIA
Naresh Jha, Hadi Seikaly, Jeffrey Harris, David Williams,
Khalil Sultanum, Michael Hier, Sunita Ghosh,
Martin Black, James Butler, Donna Sutherland,
Paul Kerr and Pam Barnaby
Cross Cancer Institute, Edmonton, Alberta, Canada
Objective and Methods: We report results (median follow up 21
months) of a prospective phase III multicenter study comparing
Pilocarpine with submandibular salivary gland transfer
procedure for management of radiation induced xerostomia.
Eligibility criteria included squamous cell carcinoma of Larynx,
Hypopharynx, Oropharynx and unknown primaries with neck
nodes. Patients with carcinoma of the Nasopharynx, Oral cavity,
N3 disease, bilateral neck nodes, level 1 nodes or pre-epiglottic
involvement were ineligible. Treatment strategies included either
surgery as prime modality of treatment followed by
chemoradiation treatment or Chemoradiation treatment as prime
modality with or without planned neck dissection. Patients in
Pilocarpine arm received Pilocarpine 5 mg. three times a day
for 3 months. Salivary functions were evaluated by measuring
salivary flows (baseline and stimulated) and quality of life using
Univ. of Washington Quality of Life (QOL) Questionnaire,
preoperatively, 1,3, 6, 12 and 24 months after treatment.
Primary end point was the salivary functions (amount and
consistency of saliva) at 6 months follow up. Results: This study
was closed as per stopping rules, at interim analysis as the intent
to treat analysis of all patients had shown significantly superior
results in the gland transfer arm. The median follow up of these
patients now is 21 months and results at 16 months follow up
are presented. Significantly superior results are noted in the
gland transfer arm as compared to Pilocarpine arm: for the
median baseline and stimulated salivary flow, p=0.021 and
0.004, respectively, and for patients reporting none or minimal
xerostomia [ score 10 or 20 as per VII A (amount of saliva) of
Univ. of Washington QOL, p=0.005 and for consistency of
3333
ANTICANCER RESEARCH 28: 3157-3556 (2008)
saliva, p=0.008. Conclusion: Salivary gland transfer remains
superior to Pilocarpine in the management of radiation induced
xerostomia.
309
GENETIC ASPECT OF GLIOBLASTOMA
MULTIFORME: INVOLVEMENT OF mTOR
COMPLEXES
Michael A Karsy, Nicholas Gulati, Ladislau Albert,
Raj Murali and Meena Jhanwar-Uniyal
Department of Neurosurgery, New York Medical College,
Valhalla, NY, 10595, USA
Human malignant glioblastoma multiforme (GBM) develops
as the result of multiple stepwise genetic alterations, arising
either de novo (primary GBM) or progressing from lowgrade astrocytoma (secondary GBM). The genetic nature of
GBM echoes the clinical dichotomy that exists between
primary and secondary GBM. Mutation and/or deletion of
the tumor suppressor phosphatase and tensin homolog
deleted on chromosome 10 (PTEN) is one of the most
common genetic alterations in GBM, with an estimated
frequency of 70-90%. This suggests that the
PTEN/PI3K/AKT signaling pathway plays a critical role in
oncogenesis. Furthermore, PTEN loss increases the pool of
self-renewing neural stem cells and induces loss of
homeostatic control of proliferation, which is reminiscent of
the cell-cycle dysregulation that occurs during
gliomagenesis. Activation of the oncogene AKT due to
PTEN loss stimulates the downstream kinase mammalian
target of Rapamycin (mTOR), which has been shown to play
a crucial role in cell survival, growth, and motility through
two distinct multi-protein complexes: mTORC1 (a
mammalian counterpart of TORC1) and mTORC2 (a
mammalian counterpart of TORC2). Rapamycin (RAPA), an
mTOR inhibitor, and its analogs have been considered
potential candidates for the treatment of GBM. However,
GBM still remains incurable. We hypothesize that the
contributions of both mTORC1 and mTORC2 result in
uncontrolled GBM growth and dissemination and therefore
provide a molecular understanding of GBM. The interplay
of mTORC1 and mTORC2 was studied in cell lines LN18,
U87,
and
U373.
Immunohistochemical
analysis
demonstrated activated AKT (pAKTSer473) expression in 85%
of human tumor samples. GBM cells were treated with either
RAPA or PI3K inhibitor LY294002 (LY) in the presence or
absence of platelet-derived growth factor (PDGF) or
extracellular matrix fibronectin (FN). Levels of
phosphorylated AKT, p70S6K, and S6K, downstream
proteins of the PTEN/PI3K pathway, as well as STAT3 and
ERK1/2, proteins parallel to the PTEN/PI3K pathway, were
assessed by immunoblotting. RAPA treatment resulted in
3334
sustained suppression of pS6KSer235/236 (mTORC1 substrate)
through a 24h period. Treatment with RAPA noticeably
reduced activation of AKTSer473 (mTORC2 substrate) by 61%
and 72% at 1 and 3 h, respectively, followed by enhanced
activation up to 24 h. This finding suggests a shift between
mTORC1 and mTORC2 following RAPA treatment. Pretreatment with RAPA or LY diminished PDGF or FN
stimulation of p70S6KThr389. A combined treatment with
RAPA and LY completely blocked the activation of S6K.
Activation of STAT3 by PDGF or FN was totally abolished
by combined pre-treatment with RAPA and LY. Silencing of
Rictor, a mTOR partner, inhibited activation of pAKT, a
downstream component of mTORC2. While both motility
and proliferation were found to be decreased at early time
points (1-3 h) following RAPA treatment, later time points
(6-24 h) showed enhanced motility and proliferation. Both
cellular motility, as assessed by radial monolayer migration,
and cellular proliferation, as analyzed by MTT assay,
exhibited that the changes in cellular dynamics reflected an
enhanced mTORC2 pathway. Treatment with RAPA caused
an initial decrease in mTORC1 activity but then shifted to
enhanced mTORC2 activity inducing AKT signaling. Thus,
deciphering these molecular pathways would provide better
understanding of gliomagenesis.
310
MOLECULAR IMAGING OF BCL-2-POSITIVE
AND -NEGATIVE LYMPHOMA
XENOGRAFTS USING PEPTIDENUCLEIC ACID-PEPTIDE CONJUGATES
F. Jia1, B.S. Balaji1, S.D. Figueroa5, F.Gallazzi2, S.Z. Lever3,
M. Hannink4, T.J. Hoffman6 and M.R. Lewis1,5
1Department
of Veterinary Medicine and Surgery, University
of Missouri-Columbia, Columbia, MO, USA;
2Molecular Biology Program, University of MissouriColumbia, Columbia, MO, USA;
3Department of Chemistry, University of Missouri-Columbia,
Columbia, MO, USA;
4Department of Biochemistry, University of MissouriColumbia, Columbia, MO, USA;
5Radiopharmaceutical Sciences Institute, Research Service,
Harry S Truman Memorial Veterans’ Hospital, Columbia,
MO, 65201, USA
Objective: The bcl-2 gene is overexpressed in non-Hodgkin’s
lymphoma (NHL). Two peptide nucleic acid (PNA)-peptide
conjugates targeting bcl-2 mRNA were investigated for direct
comparison of bcl-2-positive and -negative cell lines and
xenografts. Methods: The human small lymphocytic
lymphoma (SLL) cell lines Mec-1 and Ramos express
comparable levels of somatostatin receptor subtype 2 for
peptide nucleic acid-peptide delivery, but the Mec-1:Ramos
Abstracts of the 8th International Conference of Anticancer Research, 17-22 October 2008, Kos, Greece
bcl-2 mRNA expression ratio was determined by RT-PCR to
be 3821:1. The cell lines were used in cell efflux studies, and
the corresponding xenografts were used for in vivo distribution
and imaging studies in SCID mice. DOTA-anti-bcl-2-PNATyr3-octreotate was labeled with 111In (1). DOTA-anti-bcl-2PNA-Ts14-Tyr3-octreotate was labeled with 64Cu (2) for in vivo
studies because micro-PET with this agent gave superior
imaging quality. Results: The cell associated radioactivity of
conjugate 1 was 15% in Ramos cells, as compared with 60%
in Mec-1 cells at 4 h of incubation. Biodistributions showed a
0.2% ID/g tumor uptake of conjugate 1 in Ramos mice and
1.3% ID/g in Mec-1 mice at 48 h post-injection. The conjugate
2 in Ramos mice showed a 0.7% ID/g tumor uptake and 1.1%
ID/g in Mec-1 mice. Both conjugates could detect Mec-1
tumors by micro-SPECT and micro-PET, but not Ramos
tumors. Conclusion: The significantly (p<0.05) higher
retention of conjugate 1 in Mec-1 cells suggested specific bcl2 mRNA targeting. Biodistribution and imaging studies also
concluded that both conjugates 1 and 2 are specific for bcl-2
mRNA-positive tumor xenografts.
311
YKL-40: A POTENTIAL NEW BIOMARKER
IN CANCER PATIENTS
Julia S. Johansen
Herlev Hospital, University of Copenhagen, Denmark
YKL-40 (Chitinase-3-like-1, CHI3L1) is a 40 kDa heparin-,
chitin- and collagen-binding glycoprotein without chitinase
activity and a member of mammalian chitinase-like proteins.
Its gene is known (1q32.1, 7948 base pairs, 10 exons), but
YKL-40 gene mutations and polymorphisms in cancer patients
are not described. High YKL-40 mRNA and protein
expressions are found in embryonic stem cells, embryonic and
fetal cells, in macrophages, leucocytes and mast cells in areas
with inflammation, in tumour-associated macrophages, and by
several types of cancer cells including adenocarcinoma,
squamous cell carcinoma, melanoma and glioblastoma. In
some, but not all, types of cancer, YKL-40 protein expression
in cancer cells is a biomarker of genetic and histological
subtype, therapeutic response, and prognosis.
Few studies have evaluated the function of YKL-40 in
cancer. It may have a role in proliferation, differentiation,
metastatic potential, angiogenesis and response to hypoxia,
and protection against apoptosis. YKL-40 may also play a role
in the inflammatory response and extracellular tissue
remodelling with development of fibrosis in the area
surrounding the cancer cells. Receptors mediating its effects
are unknown. YKL-40 is regulated by TNFα and IL-6,
requires sustained activation of NF-kappaB, initiates MAP
kinase and PI-3K signalling cascades, leading to AKTmediated signalling cascades. Up-regulated YKL-40
expression is found in glioblastoma cells following stress
stimuli, e.g. hypoxia, ionizing radiation and chemotherapy.
Plasma YKL-40 is elevated (i.e. above the age-adjusted 95th
percentile of healthy individuals) and is related to tumour stage
in some patients with different types of primary or metastatic
solid cancer (breast, cervical, endometrial, glioblastoma, head
and neck, kidney, small and non-small cell lung, melanoma,
ovarian, pancreatic, prostate), and in patients with acute
myeloid leukemia, multiple myeloma, and Hodgkin lymphoma.
Highest plasma YKL-40 is found in patients with metastatic
cancer, the shortest recurrence- or progression-free interval, and
the shortest overall survival. YKL-40 is neither organ- nor
tumour-specific, but plasma YKL-40 may be useful as a
prognosticator of survival, and a predictor of treatment
response. High plasma YKL-40 is an independent prognostic
biomarker of short survival in patients with local or metastatic
cancer, at time of first cancer diagnosis and at relapse, and is
independent of other prognosticators (ER, HER2, CEA,
CA125, LDH, CRP). High plasma YKL-40 predicts: 1) low
response to anthracycline therapy in patients with first
recurrence of breast cancer; and 2) second-line
chemoresistance in ovarian cancer patients. Some studies
suggest that plasma YKL-40 may be useful for monitoring
cancer recurrence or progression after treatment. In the general
population without known cancer, high plasma YKL-40
predicts a 3.4-fold increased risk of gastrointestinal cancer. In
patients referred to endoscopy due to symptoms or other risk
factors for colorectal cancer, plasma YKL-40 independently
predicts colorectal cancer. This suggests a value for plasma
YKL-40 in screening.
Since YKL-40 is not specific for cancer, it is important to
consider co-morbidity and repeated measurements when
evaluating plasma YKL-40 as a biomarker for cancer, and a
normal plasma YKL-40 cannot rule out cancer. Plasma YKL40 may have a place as a biomarker in patients with cancer
and provides new information compared to rutinely used
biomarkers, but more studies are needed. However, YKL-40
is probably more than a biomarker. A major issue to explore is
the question if YKL-40 could become a target for the
development of new cancer therapeutics.
312
CONNECTIONS BETWEEN G-QUADRUPLEXES,
THE WERNER AND BLOOM SYNDROMES, AND
CELLULAR SENESCENCE
Li-San Wang1,5,6, Steven Hershman4, Jasmine S. Smith1,2,
Jay E. Johnson1,5, Marina L. Kozak1,2, Kajia Cao1,
Paul Ryvkin3, Qijun Chen1,5 and F. Brad Johnson1,2,5
1Department
of Pathology and Laboratory Medicine,
and Molecular Biology Graduate Program,
3Genomics and Computational Biology Graduate Program,
4Vagelos Scholar Program, 5Institute on Aging,
2Cell
3335
ANTICANCER RESEARCH 28: 3157-3556 (2008)
6Penn
Center For Bioinformatics, University of
Pennsylvania, Philadelphia, PA 19104, USA
G-quadruplex DNA (G4-DNA) is a family of structures
composed of stacked G-quartets, which themselves comprise
four Hoogsteen-bonded guanines in a planar array. They have
been shown to form in vivo at telomeres in at least one
organism, S. lamnae. Several RecQ DNA helicases, including
the human WRN and BLM proteins and S. cerevisiae Sgs1, are
particularly active in unwinding G4-DNA in vitro. WRN and
BLM are deficient in the Werner and Bloom syndromes,
respectively, which are characterized by elevated rates of
cancer and premature features of aging. The demonstrated roles
for RecQ helicases in telomere maintenance has led to the
hypothesis that these roles might be explained by the resolution
of telomeric G4-DNA by the helicases. New experimental
findings will be presented that support this idea directly.
Outside of telomeres, sequences with intramolecular Gquadruplex forming potential (QFP) are concentrated in the
promoter regions of organisms ranging from bacteria to
humans, raising the possibility that they play roles in
transcriptional regulation. Recently we reported highly
significant correlations in S. cerevisiae between genes having
QFP and those with altered expression in cells lacking Sgs1 or
treated with a selective G4-DNA small molecule ligand Nmethyl mesoporphyrin IX (NMM), thus supporting a direct
role for G4-DNA in transcriptional regulation. We have now
extended these findings to human cells, including analyses of
altered gene expression in cells from individuals with Werner
or Bloom syndrome, or in cells treated with NMM or another
G4-DNA ligand, BRACO19. Similar to our findings in yeast,
there are significant correlations between loci possessing QFP
and those showing altered regulation under these conditions,
each of which is predicted to alter G4-DNA levels or functions.
We wondered if there might be connections between G4DNA at telomeres and that involved in transcriptional
regulation. Cellular senescence can be induced by telomere
shortening and dysfunction in both S. cerevisiae mutants
lacking telomerase and human cultured cells. We have found,
in both yeast and human cells, that there are highly significant
correlations between genes that are upregulated at senescence
caused by telomere shortening and genes with QFP. These
associations are apparently not explained by the binding of
known transcription factors. We therefore propose that 1) there
is competition between G4-DNA at telomeres and promoters
for transcriptional regulators that bind G4-DNA and 2) altered
G4-DNA levels at the telomeres of senescent cells perturbs
this competition, thus providing a novel mechanism for the
regulation of gene expression in senescent cells.
Given the connections between cell senescence, telomere
function, and RecQ helicases in cancer and age-related
diseases, it may be possible to use manipulation of G4-DNA
as a tool to impact these disorders.
3336
313
IMMUNOMODULATORY CAPACITY OF
MYELOMA-DERIVED CHEMOKINE CCL27
Karin Jöhrer1, Angelika Olivier1, Michael Unger1,
Eva Maizner1, Daniel Neureiter2 and Richard Greil1,3
1Tyrolean
Cancer Research Institute, Innrain 66, A 6020
Innsbruck;
2Institute of Pathology at the Private Medical University
Hospital Salzburg, Müllner Hauptstrasse 48, A 5020
Salzburg;
33rd Medical Department with Hematology, Medical
Oncology, Hemostaseology, Rheumatology and Infectious
Disease at the Private Medical University Hospital Salzburg,
Müllner Hauptstrasse 48, A 5020 Salzburg, Austria
Multiple myeloma is still incurable using conventional
chemotherapy and considerable efforts are undertaken to
establish new immunotherapeutic strategies to target this Bcell neoplasm. Chemokines have currently been shown to be
major players in shaping the tumor microenvironment and to
contribute to immune escape of the malignant cells.
In order to reveal important actors of the chemokine
network in multiple myeloma we analyzed the chemokine
profile of myeloma cell lines. We found CCL27, which has
so far only been correlated with skin diseases such as atopic
dermatitis, consistently upregulated in all cell lines
investigated. In bone marrow supernatants of tumor patients
CCL27 expression correlated with the severity of disease.
Additionally, immuno-histochemical analysis of patient bone
marrow showed that CCL27 is expressed by the malignant
cells and also highly expressed (or presented) by human bone
marrow endothelial cells, the main barrier of the favourite
myeloma microenvironment, the bone marrow. We further
investigated the impact of CCL27 on immune cells such as
T-cells and dendritic cells. Dendritic cells differentiated and
matured in the presence of CCL27 exhibited a reduced
capacity to activate T-cells in allogeneic mixed leukocyte
reactions. On T-cell side, in this setting, proliferation as well
as cytokine production was impaired. Treated dendritic cells
showed normal expression of costimulatory molecules but
impaired spontaneous migration as well as cytokine
production which might explain the impaired T-cell function.
In coculture experiments with myeloma cell lines, however,
these dendritic cells induced enhanced growth of the
malignant plasma cells. Since dendritic cells in our hands did
not express relevant amounts of the cognate receptor for
CCL27, i.e. CCR10, we postulate that the ligand is bound by
glycosaminoglycans or by a so far unknown receptor. Binding
studies are currently underway.
In summary, we found that the myeloma-derived chemokine
CCL27 can modulate dendritic cells resulting in impaired
activation of T-cells and enhanced tumor cell growth thus
Abstracts of the 8th International Conference of Anticancer Research, 17-22 October 2008, Kos, Greece
contributing to worse prognosis. Targeting CCL27 therefore
could constitute an essential additional component in myeloma
therapy.
314
BIRTH ORDER EFFECT IN THE INHERITANCE OF
CHRONIC LYMPHOCYTIC LEUKEMIA (CLL)
Viggo Jønsson
Department of Hematology, Aker University Hospital,
University of Oslo, NO 0514 Oslo, Norway
Birth order effect denotes a rank order of affected offspring in
a sibship. In CLL, a birth order effect in affected parentoffspring pairs can reflect epigenetic factors in disease
susceptibility. Thirty-two families segregating CLL and other
lymphoproliferative disorders in a pleiotrophic pattern were
identified. By means of Haldane Smiths’s test and Cox
regression it is shown that a paternal-offspring, but not a
maternal-offspring birth rank order exists: In matrilineal
transmission, affected offspring occur randomly in the sibship
while in patrilineal transmission, mainly sons late in the
sibship are affected. Cox regression analysis provided relative
risks (RR) for paternal and maternal transmission of 3.60
(95% CI: 1.54-8.42; p=0.0005) and 1.64 (95% CI: 0.90-3.01;
p=0.096), respectively. The significance of paternal and
maternal transmission in CLL-CLL pairs employing Haldane
and Smith’s test were 0.006 and 0.63 respectively. There was
no evidence of a relationship between parental age and birth
order. Most likely, the birth order effect is a non-Mendelian
segregation of the CLL monoallelic poly-susceptibility genes
based on parental imprinting and pregnancy related
microchimerism, where different combinations of the
monoallelic polygenes code for the subtypes of
lymphoproliferative disease, such as CLL, non-Hodgkin’s
lymphoma and Hodgkin’s disease, the acute- and chronic
lymphocytic leukemias and myeloma. CLL The impact on
time to treat and intention to treat is discussed.
315
HUMAN CANCER AND GENE MUTATIONS
IN O-GLYCOSYLATION PATHWAY
Tongzhong Ju1, Grainger S. Lanneau2, Tripti Gautam3,
Yingchun Wang1, Baoyun Xia1, Sean R. Stowell1,
Margaret T. Willard1, Wenyi Wang1, Jonathon Y. Xia7,
Rosemary E. Zuna4, Zoltan Laszik4, Doris M. Benbrook2,3,6,
Marie H. Hanigan5,6 and Richard D. Cummings1
1Department of Biochemistry, Emory University School of
Medicine, Atlanta, GA30322;
2Department of OB/GYN, 3Department of Biochemistry and
Molecular Biology, 4Department of Pathology, 5Department
of Cell Biology, 6Cancer Institute, The University of
Oklahoma Health Sciences Center, 7Oklahoma School of
Sciences and Mathematics, Oklahoma City, OK73104, USA
Tn and Sialyl Tn (STn) antigens are tumor-associated
carbohydrate antigens (TACAs) expressed by at least 60~70%
of human carcinomas, including breast, colon, cervical,
ovarian, and pancreatic cancer. Normally, Tn antigen is
modified by Core 1 β3GalT (T-synthase), a key enzyme in
mucin type O-glycosylation, to form the Core 1 structure,
also called T-antigen. The T-antigen can be further elongated
to form complex O-glycans on many cell membrane
glycoproteins and secreted glycoproteins. Recently, we have
identified that Cosmc, the Core 1 β3GalT-specific molecular
chaperone, is required for active T-synthase formation. Cosmc
is located on Xq24 and encodes an ER-localized type-II
membrane protein that prevents aggregation/proteasomal
degradation of T-synthase. Although it has been reported that
Tn and STn antigen expression in human tumors are
associated with poor prognoses, the genetic basis for their
expression in human tumors, as well as the benefit for tumor
cells expressing Tn/STn antigens are not known. We have
now found that all tumor cell lines expressing the Tn and STn
antigens have acquired mutations in Cosmc. The mutations
are nucleotide deletions or insertions in the coding region, or
deletions in the promoter sequence. In all cases, the mutations
in the Cosmc gene result in loss-of-function for Cosmc as a
chaperone and lead to aggregation and enhanced degradation
of the T-synthase. Expression of wild-type Cosmc restores the
T-synthase activity and cells lose expression of both the Tn
and STn antigens. In addition, human cervical cancer
specimens that showed expression of the Tn/STn antigens
were also found to have mutations in Cosmc and loss-ofheterozygosity for the X-linked Cosmc locus. Importantly,
tumor cells with mutated Cosmc were less sensitive to
TRAIL-induced apoptosis than wild-type Cosmc transfected
cells. This is the first example of somatic mutations in
multiple types of cancers that cause global alterations in cell
surface carbohydrate antigen expression. Additionally, this is
the first evidence of an advantage for tumor cells expressing
Tn antigen on the surface. The understanding of the genetic
basis of the unusual expression of Tn and STn antigens in
human tumors will shed new light on the development of new
diagnostic, prognostic, and potentially therapeutic methods.
316
COMPLEX MECHANISMS OF REGULATION OF
PLATELET-DERIVED GROWTH FACTOR-INDUCED
ERK ACTIVATION
Aleksandra Jurek, Carl-Henrik Heldin and
Johan Lennartsson
Ludwig Institute for Cancer Research, Uppsala University,
Box 595, SE-751 24 Uppsala, Sweden
3337
ANTICANCER RESEARCH 28: 3157-3556 (2008)
Extracellular signal regulated kinases (Erks) represent a
signalling hub in many physiological responses and have critical
functions in cell proliferation, differentiation, survival and
apoptosis. The physiological outcome of Erk signalling depends
on both the magnitude and duration of kinase activation which
are tightly controlled by many factors like the association of Erk
with scaffolding proteins, cross-talk with other signalling
pathways and negative regulators such as protein phosphatases.
In this study we investigated the mechanisms regulating the
Erk1/2 activation downstream of platelet-derived growth factor
receptor α and β. Particularly, we were interested in evaluating
an involvement of MAP kinase phosphatases, SHP2, PLCγ, Src
and PI3K in the regulation of the Erk phosphorylation pattern.
We found that MAP kinase phosphatase 3 is an important
regulator of the PDGF-induced Erk activation acting in both a
rapid positive feed-forward and a later negative feed-back loop.
In addition, our results suggest an implication of SHP2 and Src
in the modulation of the strength of Erk phosphorylation. As the
Erk signalling pathway is up-regulated in many cancer cells,
understanding of the complex mechanism of its regulation is of
key importance for therapeutic approaches.
317
ANTITUMOR ACTIVITY OF (–)EPIGALLOCATECHIN-3-O-GALLATE
FATTY ACID DERIVATIVES
Kunihiro Kaihatsu1, Kazuaki Matsumura2, Shuichi Mori1,
Han Hee Cho2, Suong Hyu Hyon2 and Nobuo Kato1
1The
Institute of Scientific and Industrial Research, Osaka
University, 8-1 Mihogaoka, Ibaraki, Osaka, 567-0047;
2Institute for Frontier Medical Sciences, Kyoto University,
53 Kawahara-Cho Shogoin, Sakyo-ku, Kyoto, 606-8507,
Japan
(–)-Epigallocatechin-3-O-gallate(EGCG), a major green tea
catechin component, has been reported to possess antitumor
activity. We developed a method to increase chemical stability
and cell membrane affinity of EGCG using lipase-catalyzed
trans-esterification. EGCG-fatty acid monoesters showed
marked antitumor activities in vitro and in vivo by apoptosis
induction through inhibition of epidermal growth factor
receptor phosphorylation.
318
MGMT, P53 AND DNA DOUBLE-STRAND BREAK
REPAIR IN ALKYLATING DRUG-INDUCED
APOPTOSIS: IMPLICATIONS FOR GLIOMA
THERAPY
Bernd Kaina, Luis Z. Batista, Theodora Nicolova and
Wynand P. Roos
Institut für Toxikologie, Mainz, Germany
3338
An important group of anticancer drugs is represented by
methylating and chloroethylating agents that are being used in
first-line therapy of gliomas and malignant melanomas. These
agents induce a dozen DNA lesions, some of them have been
identified to be carcinogenic, genotoxic and cytotoxic. In cells
lacking the repair enzyme MGMT the DNA adducts O6methylguanine (O6MeG) and O6-chloroethylguanine (O6ChlG)
are the major triggers of genotoxicity and apoptosis. In the
case of O6MeG lesions, this requires MSH2/MSH6-dependent
mismatch repair. O6MeG triggered cell death is regulated in a
cell type specific manner, utilizing both the mitochondrial and
the death receptor pathway. O6MeG triggered apoptosis is
preceded by DNA double-strand break (DSB) formation,
H2AX phosphorylation and ATM/ATR activation. In turn, in
p53-wt-expressing glioma cells, the Fas/CD95/Apo-1 receptor
pathway becomes activated. In p53-mutated glioma cells, a
hallmark of O6MeG triggered apoptosis is decline of Bcl-2,
which is followed by caspase-9, -7 and -3 activation. The
efficiency of O6MeG in triggering the p53-dependent (Fas)
pathway is much higher than the p53-independent endogenous
mitochondrial pathway, which explains why p53-wt glioma
cells are more sensitive to TMZ than p53-mutated cells.
Interestingly, p53-wt glioma cells are more resistant than p53mutant glioma cells to chloroethylating agents, such as BCNU
and ACNU, indicating p53 protects against O6ChlG-induced
apoptosis and necrosis, very likely by up-regulation of repair
genes (notably ddb2). O6MeG and O6ClG are also able to
induce apoptosis in malignant melanoma cells, which is
accompanied by the formation of DSBs. Cells defective in
XRCC2 or BRCA-2 are hypersensitive to O6MeG-triggered
cell death and chromosomal aberrations while DNA-PKCS
mutated cells display only slightly enhanced sensitivity. The
data supports a role for DSBs as most critical downstream
apoptotic lesions and DSB repair by homologous
recombination as a potential predictor of cellular resistance to
monofunctional alkylating drugs.
This work was supported by DFG KA724/13 and SFB724/B7.
319
DOSE-EFFECT RELATIONSHIPS FOR CATARACT
INDUCTION AND LATE RENAL DYSFUNCTION
FOLLOWING TBI AND RECURRENCE OF KELOID
AND PTERYGIUM FOLLOWING SURGERY AND
RADIOTHERAPY
Henk B. Kal, M. Loes van Kempen-Harteveld,
Ronald E. Veen, and Ina M. Jürgenliemk-Schulz
Department of Radiation Oncology, University Medical
Center Utrecht, Heidelberglaan 100, 3584 CX Utrecht, the
Netherlands
Purpose: To demonstrate radiation dose-response relationships
for cataract induction and late renal dysfunction following
Abstracts of the 8th International Conference of Anticancer Research, 17-22 October 2008, Kos, Greece
total body irradiation (TBI) and hematopoietic stem cell
transplantation (HSCT) in patients with haematological
malignancies, and for recurrence of keloid and pterygium after
surgery followed by radiotherapy. Materials and Methods: A
retrospective review using Pubmed was performed of articles
reporting dose-response relationships for cataract induction
and late renal dysfunction following TBI and recurrence of
keloid and pterygium postoperatively following radiotherapy.
The radiation regimens identified were normalized using the
linear-quadratic model; biologically effective doses (BEDs)
were calculated. Results: For cataract induction a dose-effect
relationship after TBI and HSCT for acute leukaemia was
found. A threshold BED of about 45 Gy was indicated. For
late renal toxicity after TBI and HSCT, the threshold BED is
about 16 Gy. For keloid recurrence after keloidectomy
followed by radiotherapy either with teletherapy or
brachytherapy, the recurrence rate following a BED >30 Gy
was less than 10%. For pterygium recurrence following bare
sclera surgery and 90Sr beta irradiation, a BED of about 30-40
Gy seems to be sufficient to reduce the recurrence rate to less
than 10%. Conclusion: Dose-response relationships were
identified for cataract induction and late renal toxicity after
TBI, as well as for keloid and pterygium recurrence after
surgery and radiotherapy. To prevent cataract induction, eye
shielding should be applied for single-dose and
hypofractionated TBI. For almost all TBI schemes in use,
kidney shielding should be applied. Most radiotherapy
schemes used for keloid recurrence prevention after surgery
are not sufficient. A minimal dose with a BED of 30 Gy
should be applied. In contrary, the doses applied in most
regimens to prevent pterygium recurrence are too high. A
scheme with a BED of 30-40 Gy seems to be sufficient.
320
MOLECULAR MECHANISMS OF CALCIUMMEDIATED ANTIMITOGENIC ACTIONS IN COLON
CANCER CELLS
Enikö Kallay
Department for Pathophysiology, Center for Physiology,
Pathophysiology, and Immunology, Medical University of
Vienna, Austria
Epidemiological, experimental, and animal studies indicate
that theoretically, at least 50% of sporadic colorectal cancer
could be prevented by modifications in diet. Primary
prevention of cancer is, therefore, rational, timely and
important, and should be a major priority and responsibility
for international agencies, governments, industry, nongovernmental organizations, medical and health authorities. In
spite of the already significant amount of evidence there is still
reluctance to accept that diet has a fundamental role in colon
tumourigenesis, due to poor understanding of the mechanisms
that regulate this process. Analysis of gene expression profiles
provides important insights into how diets may alter metabolic
profiles and regulatory pathways that influence probability of
tumour formation in the normal intestinal mucosa. Evidence
is accumulating for a prophylactic effect of calcium in
colorectal cancer development. It has been show that a diet
rich in calcium reduces crypt cell hyperproliferation both in
human and animal studies. Calcium-mediated signal
transduction may play a central role in hyperproliferation,
transformation, invasion and metastasis. Effect of extracellular
calcium could involve signal transduction through guanine
nucleotide binding proteins, such as the calcium-sensing
receptor (CaR).
Analysing the effect of extracellular calcium on colon
cancer cell lines showed that calcium had a significant effect
on genes implied in several different functional categories:
Genes involved in cell cycle regulation and nucleic acid
synthesis were down-regulated by calcium treatment,
consistent with the parallel induction of cell cycle arrest.
Coordinate down-regulation of genes involved in RNA
processing, translation, and protein degradation were also
evident. Conversely, genes involved in xenobiotic and drug
detoxification, were up-regulated by calcium. The earliest
changes due to calcium treatment involved tight junctions,
focal adhesion, adherens junctions, with some of the
parameters being up- others down-regulated. A series of
known CaR signalling functions and pathways have been
affected by calcium treatment, amongst them expression of
genes coding for G alpha q, PLC, PLA2.
Our data is further proof for the antiproliferative effect of
calcium in colonocytes, suggesting that the CaR has a major
role in colon tumourigenesis.
This study was supported by a Marie Curie Inter-European
Fellowship.
321
HOW DO TUMOR CELLS REPROGRAM TUMORASSOCIATED BRAIN MACROPHAGES INTO
INVASION-PROMOTING CELLS AND EVADE
IMMUNE RESPONSES?
Bozena Kaminska, Pawel Wisniewski, Maciej Lipko,
Aleksandra Ellert-Miklaszewska and Michal Dabrowski
The Nencki Institute of Experimental Biology, Warsaw,
Poland
Interactions between tumor-infiltrating leukocytes and tumor
cells have been of great interest due to the possibility that
immune cells either interfere with tumor progression or
actively promote tumor growth. Microglia (brain
macrophages) are multifunctional, innate immunity cells
executing protective functions under physiological
conditions. Intracellular inflammatory signaling pathways
3339
ANTICANCER RESEARCH 28: 3157-3556 (2008)
include NFκB and MAP kinases, as critical signal
transducers. On the other hand, the most invasive and
dangerous brain tumors, malignant gliomas, recruit
numerous microglia to the tumor site. Molecular
mechanisms underlying accumulation and activation of
tumor-associated microglia are unknown. We demonstrated
that soluble factors released by glioma cells convert brain
macrophages (microglia) into amoeboid/phagocytic cells
which support glioma invasion, while attenuating
inflammatory responses (Sliwa et al., BRAIN 2007;
Wesolowska et al., Oncogene 2007). To identify those
factors, we employed a proteomic approach and massspectrometry in search for fractions of glioma-conditioned
medium (G-CM) able to induce morphological
transformation of microglia. We identified osteopontin and
lactadherin, two proteins sharing the RGD motif and known
to interact with integrins. Interference with integrin binding
using RGD-containing peptide completely abolished
glioma-induced transformation of microglia and signal
transduction. Analyzing signal pathways and global gene
expression, we demonstrated that glioma-derived factors
induce an alternative, non-immune activation of microglia.
While lipopolysaccharide-induced activation involved NFκB
and MAPKs activation, glioma-derived factors preferentially
induce integrin-linked and TGFβ-driven signaling. Increased
phosphorylation of FAK, pro-survival Akt kinase, JNK and
p38 MAPK and stimulation of STAT3/5 were followed by
release
of
anti-inflammatory
cytokines
and
metalloproteinases stimulating motility, and invasiveness of
glioma cells. Gene profiling and computational analysis
revealed that the most discriminative feature was a lack of
interferon-responsive genes in glioma-exposed microglia
that may explain a lack of effective antitumor immune
response. Our findings suggest that gliomas attract brain
macrophages and employ specific signals, to transform them
into tumor-supportive cells, We show for the first time
molecular signals and mechanisms responsible for “reeducation” of tumour-associated microglia into tumour
supportive cells.
This work was supported by grant S004/P-N/2007/01 from the
Ministry of Science and Higher Education (Poland).
322
DOWN-REGULATION OF PLAKOGLOBIN IN SOFT
TISSUE SARCOMA IS ASSOCIATED WITH A
HIGHER RISK OF PULMONARY METASTASIS
Yoshimitsu Kanazawa1, Yoshimichi Ueda2,
Miyako Shimasaki2, Shogo Katsuda2, Norio Yamamoto1,
Katsuro Tomita1 and Hiroyuki Tsuchiya1
1Department
of Orthopaedic Surgery, Graduate School of
Medical Science, Kanazawa University, 13-1, Takara-machi,
Kanazawa, Ishikawa, 920-8641;
3340
2Department
of Pathology, Kanazawa Medical University, 11 Daigaku, Uchinada-machi, Kahoku-gun, Ishikawa 9200293, Japan
Soft tissue sarcomas (STS) behave with aggressiveness and
metastatic potential, which can vary depending on their
locations. There has been little information on the exact
molecular mechanisms involved in their biological
aggressiveness. To identify genes involved in the differences,
the gene expression profiles were compared between STSorthotopic and heterotopic implanted models, and their
significance in human STS was verified. Human fibrosarcoma
HT1080 cells were implanted either in the quadriceps femoris
muscles or footpads of nude mice, and the gene expression
profiles of the tumors were compared by cDNA arrays. The
mRNA and protein levels of the identified genes were
examined
by
both
real-time
RT-PCR
and
immunohistochemistry, not only in the tumors of the models,
but also in clinical STS. The implanted HT1080 cells
demonstrated different growth and metastatic potentials
depending on their implant locations. cDNA array analyses
showed reduced expression of the plakoglobin gene in the
intramuscle-implanted group, which was statistically
confirmed by real-time RT-PCR (p=0.04). Plakoglobin was
immunolocalized diffusely in the cytoplasm of tumor cells
implanted in the footpads, but not those in the muscle. Realtime RT-PCR assays of clinical STS showed that the mean
plakoglobin/G3PDH ratio in primary sarcoma tissues with
pulmonary metastases (0.92) was significantly lower than in
those without metastasis (6.58) (p<0.0001), and that STS
cases with high plakoglobin gene expression had an excellent
prognosis. These results suggest that plakoglobin gene
expression level might be useful as a new biomarker for
metastasis and prognosis of human STS.
323
MOLECULAR TARGETS IN BREAST CANCER
THERAPY: A DIAGNOSTIC APPROACH
Nikiforos Kapranos
Department of Molecular Pathology, General, Maternity and
Children’s Hospital, Athens, Greece
Targeted therapy is a rapidly evolving field in breast cancer
treatment. The most important therapeutic target is the ErbB
family of receptor tyrosine kinases, especially ErbB2 which is
inhibited by the widely used humanized monoclonal antibody
trastuzumab. Although trastuzumab is successfully used in
metastatic or adjuvant clinical settings, the accurate molecular
testing of ErbB2 is still a major problem in the pathology
laboratory. ErbB2 protein detection by immunohistochemistry
is subjective and technically inaccurate, due to the unstable
nature of proteins and the nonstandardised procedures in the
Abstracts of the 8th International Conference of Anticancer Research, 17-22 October 2008, Kos, Greece
routine pathology laboratory. Immunohistochemical detection
of ErbB2 remains, however, the basic technique for the
selection of patients suitable for an expensive biological
therapy and gene testing is reserved only for a small group of
cases with inconclusive results. Fluorescence in situ
hybridization (FISH) testing was initially used for the
detection of ErbB2 gene amplification, but this technique has
a low discriminative ability in tissues, a temporary signal and
requires special and expensive equipment. Chromogenic in
situ hybridization (CISH) is a powerful, low cost alternative
method for ErbB2 gene analysis which offers a permanent
signal and obvious morphological details under the usual
bright field microscope. In combination with chromosome 17,
ErbB2 CISH analysis provides important information
concerning the presence of true gene amplification or protein
overexpression due to chromosomal polysomy. The CISH
technique, according to a recent international multicenter
quality assurance study, was found to have excellent reliability
and reproducibility. Finally, CISH may be supplemented by
topoisomerase IIa gene analysis and provide further valuable
information of prognostic and therapeutic significance.
324
GENETIC PROFILING IN TUMOR XENOGRAFTS
FROM PAEDIATRIC GLIOMAS BY EXPRESSION
AND HIGH RESOLUTION COMPARATIVE
GENOMIC HYBRIDISATION MICROARRAYS
Katherine Karakoula1, Nicola Potter1, Steven T. Keir2,
Darell D. Bigner2, Kim P. Phipps3, William Harkness3,
Richard Hayward3, Dominic Thompson3,
Thomas S. Jacques4,5, Brian Harding5,
David G.T. Thomas6 and Tracy J. Warr1
1Department
of Molecular Neuroscience, Institute of
Neurology, University College London, National Hospital
for Neurology and Neurosurgery, London, UK;
2Departments of Surgery and Pathology, Duke University
Medical Center, Durham, USA;
3Department of Neurosurgery, Great Ormond Street Hospital
for Children NHS Trust, London;
4Neural Development Unit, Institute of Child Health,
University College London, London;
5Department of Histopathology, Great Ormond Street
Hospital for Children NHS Trust, London;
6National Hospital for Neurology and Neurosurgery, London,
UK
Gliomas are the leading cause of cancer-related mortality in
children, with survival after diagnosis for the most aggressive
subtype, glioblastoma multiforme (GBM), being less than 12
months in most cases. Improving survival rate in paediatric
brain tumor patients continues to be a challenge, and for this,
we still need to understand the molecular pathways involved in
the genesis and progression of these types of cancer. DNA
copy number changes represent molecular fingerprints of solid
tumours and are as such relevant for better understanding of
tumour development and progression. Gliomas are
characterized by changes in the expression of genes, including
amplification of oncogenes and loss of tumor suppressor
genes, often as a result of genomic copy number alterations. In
order to identify recurrent chromosomal regions of gain and
loss, and thereby novel gene targets of potential importance
for paediatric glioma development and/or progression, we
have analyzed DNA copy number changes in ten tumor
xenografts from paediatric gliomas, comprising 7 glioblastoma
multiforme (GBM), 2 ependymomas (Grade II) and 1
primitive neuroectodermal tumor (PNET). The xenograft
models were developed in athymic nude mouse (nu/nu) by
subcutaneous implantation (Duke University, Medical Center).
Gene expression profiles for tumour xenografts were
generated using the Affymetrix U133A plus 2.0 arrays
whereas genomic copy number changes were determined by
high-density oligo microarray-based comparative genomic
hybridisation (244A array-CGH). Results revealed frequently
overexpressed (≥3-fold, p<0.05) genes in chromosomes with
gains of 1, 2, 7, 8 and 20 and regions 12q and 13q.
Furthermore, genes with high-level expression (≥10-fold)
showed amplification. Similarly, deleted genes on
chromosomes 3, 4, 6, 14 and 18 and regions 9p and 11q were
associated with reduced expression (≥2-fold, p<0.05) in the
tumour samples when compared to normal, brain controls.
However, a number of genes with normal copy numbers
showed reduced expression levels (≥2-fold, p<0.05). High
resolution analysis allowed us to identify changes in
expression of genes located within regions of copy number
alterations in paediatric gliomas that could play an important
role in tumour pathology or provide potential new therapeutic
targets.
325
GENE EXPRESSION AND STRUCTURAL
MODIFICATIONS OF MATRIX MACROMOLECULES
IN SOLID CANCERS – MOLECULAR TARGETS
N. Karamanos, O. Kousidou, A. Roussidis,
Ch. Malavaki and P. Dedes
Laboratory of Biochemistry, Department of Chemistry,
University of Patras, 261 10 Patars, Greece
Altered expression of effective matrix macromolecules by
cancer cells is related to tumour growth, invasive properties
and metastatic potential. The structural alteration and
degradation of extracellular matrix (ECM) by neoplastic cells
is a prerequisite for invasion and the formation of tumour
metastases by the malignant cells. Differential synthesis of
proteoglycans (PGs) in stroma and epithelial cells has been
3341
ANTICANCER RESEARCH 28: 3157-3556 (2008)
related to breast tumourigenesis and proliferation,
differentiation and the invasive properties of human epithelial
breast cancer. Tumor cells can release metalloproteinases
(MMPs) that degrade the matrix macromolecules and can
therefore invade through tissue barriers, blood vessel and
lymph channel walls. Modulation of MMP synthesis by
cell–cell contact has been suggested to be a crucial event for
enhancing the ability of breast cancer cells to invade the bone
marrow fibroblasts. Conventional chemotherapy regimens for
the treatment of breast cancer have limited efficacy and are
associated with significant toxicity, highlighting the need for
novel targeted therapies.
In order to examine whether gene expression of PGs and
MMPs is related to growth and functional invasive potential,
we performed in vitro studies on a panel of epithelial of breast
(ER-positive and –negative) and colon cell lines in the
presence of a series of potential inhibitors. The obtained
results clearly showed that PI3/Akt and ERK1/2 signalling
pathways are activated and that breast cancer is associated
with significant changes in gene expression of secreted PGs
as well as cell surface PGs, the expression of which is related
to the balance between ERα/β.
Significant changes in gene expression of MMPs and their
endogenous tissue inhibitors (TIMPs) were also found. The
expression of certain types of MMPs can be related to the
invasive properties of the epithelial breast and colon cancer
cells. Studies to elucidate whether the modified gene
expression of PGs, MMPs and TIMPs are associated with
certain molecular targets and their respective signalling
pathways, using specific tyrosine kinase inhibitors, such as
STI571 (glivec), the phytoestogen genistein, the specific P450
aromatase inhibitor letrozole, as well as siRNA for the ER
isoforms, showed that both tyrosine kinase pathways and
status of ERs are key partners and of crucial importance for
modified gene expression of matrix effectors and cancer cell
growth.
326
INVESTIGATION OF THYMIDYLATE SYNTHASE
(TS) AND TOPOISOMERASE-I EXPRESSION IN
PATIENTS WITH RESECTED COLORECTAL
CANCER (RCRC) TREATED WITH ADJUVANT
CHEMOTHERAPY. A RETROSPECTIVE STUDY OF
THE HELLENIC COOPERATIVE ONCOLOGY
GROUP (HECOG)
I. Kostopoulos1, V. Karavasilis1,2, M. Karina1,2, M. Bobos1,
N. Xiros2, C. Petraki2, G. Pentheroudakis2, G. Kafiri2,
P. Papakostas2 and G. Fountzilas1,2
1Aristotle
University of Thessaloniki, School of Medicine,
Thessaloniki;
2Hellenic Cooperative Oncology Group (HeCoG), Athens,
Greece
3342
Aim: Thymidylate Synthase (TS) and Topoisomerase-I (TopoI) are reasonable chemotherapeutic targets in CRC. We aimed
to study the expression of TS and Topo-I in patients with
rCRC who received adjuvant chemotherapy and correlate it
with the clinical outcome. Patients and Methods: All patients,
who were diagnosed with rCRC between 1989 and 2004 and
treated with adjuvant chemotherapy within HeCOG’s
protocols, were identified from our electronic database.
Archival FFPE tissue blocks obtained from surgical resection
specimens of invasive colorectal adenocarcinoma were arrayed
in multiple TMA blocks. IHC was performed on the TMA
slides using monoclonal antibodies against the antigens TS
and Topo-I. The immunocomplex was visualized using a
polymer detection system and DAB as a chromogen. As
external control of the immunoreaction a known positive and
negative controls was used. In each slide was assigned a score
for intensity and staining pattern using a 4-tier range system.
The results were correlated with survival (OS) and disease free
survival (DFS) in the view of irinotecan based chemotherapy.
Results: A cohort of 498 cases with median age of 61 years,
classified as Dukes stage B (49%) and C (51%), fulfilled the
criteria of the study. In 59% of the cases the tumor was located
in the rectosigmoid area. All patients received adjuvant 5-FU
based chemotherapy and 35% were also treated with
irinotecan, which is a target for Topo-I. TS and Topo-I
expression was found in 43% and 48% of the cases
respectively. Five- years OS was 74% and DFS was 68%.
There was no correlation of TS and Topo-I expression with
OS and DFS. The subgroup of patients who expressed Topo-I
and treated with irinotecan had a better OS (HR=0.47, 95%CI
0.23-0.94, p=0.033). In irinotecan treated patients TS
expression was correlated with shorter DFS (HR=1.50, 95%
CI 1.03-2.19, p=0.036). Conclusion: Our data indicate that
patients with rCRC with elevated levels of Topo-I protein may
benefit from irinotecan containing adjuvant chemotherapy.
However, randomized prospective trials are warranted to
confirm these results.
327
THE ANTITUMOR EFFECT OF LIPOSOMEENCAPSULATED CISPLATIN ON RAT
OSTEOSARCOMA AND ITS ENHANCEMENT BY
CAFFEINE
Michiaki Karita, Hiroyuki Tsuchiya and Katsuro Tomita
Department of Orthopaedic Surgery, Graduate School of
Medical Science, Kanazawa, Japan
Background: Liposomes have been proposed as useful drug
carriers in targeted drug delivery system and are under
investigation in several therapeutic fields. Caffeine has been
identified as belonging to the group of xanthines that enhance
the action of cisplatin. Materials and Methods: In this study,
Abstracts of the 8th International Conference of Anticancer Research, 17-22 October 2008, Kos, Greece
liposomes containing polyethylene glycol encapsulated
cisplatin (CDDP-L) were prepared. The action of CDDP-L on
rat osteosarcoma and the enhancing action of caffeine on the
antitumor effect of CDDP-L were evaluated. Using
osteosarcoma-bearing rats, the retention of CDDP-L in the
blood, its intratumor concentration, cytoreductive effect and
the enhancing action of caffeine on its antitumor effect were
examined. Results: The liposomes were able to remain in the
systemic circulation for a long time and to be concentrated in
the osteosarcoma, but that action did not produce an effect
corresponding to the quantity of cisplatin which was
encapsulated reaching the tumor. In rats administered CDDPL, it was discovered that the antitumor effect was not only
enhanced by the co-administration of caffeine but also further
enhanced when the dosing period of caffeine was increased.
Conclusion: CDDP-L combined with caffeine can produce
better results for osteosarcoma.
328
REGULATION OF MULTIPLE MYELOMA CELL
DIFFERENTIATION BY BONE-MARROW DERIVED
MICROENVIRONMENTAL FACTORS
Ben-Zion Katz
The Hematology Institute, Tel-Aviv Sourasky Medical
Center, Tel-Aviv, Israel
Multiple myeloma is characterized by the malignant growth
of immunoglobulin producing plasma cells, predominantly in
the bone marrow. The disease, at large, remains confined to
the bone marrow throughout its progression, pointing to
essential interactions between the malignant plasma cells and
the bone marrow microenvironment. We studied the effects of
primary human mesenchymal stromal cells, and the
extracellular matrix protein fibronectin, on the phenotype of
multiple myeloma cells. The co-culture of multiple myeloma
cells with mesenchymal stromal cells resulted in significant
reduction of the expression of the predominant plasma cell
differentiation markers CD38 and CD138, and cell surface
immunoglobulin kappa chain, in the malignant plasma cells.
Plasma cell markers were found to be differentially regulated
by adhesive interactions, and stromal-derived soluble factors.
While the down-regulation of CD138 by stromal cells was
completely dependent on their adhesive interactions with the
multiple myeloma cells, interleukin-6 induced specific downregulation of CD38. Mesenchymal stromal cells, or their
conditioned media, inhibited the growth of multiple myeloma
cell line, thereby reducing the overall amounts of secreted
light chains. The expression of plasma cells differentiationassociated genes was regulated by adhesive interactions with
fibronectin. Analysis of primary multiple myeloma bone
marrow samples revealed that the expression of CD138, but
not CD38 was affected by adhesive interactions. The ex vivo
propagation of primary multiple myeloma cells resulted in
significant increase in their differentiation markers. Overall,
the data indicate that the bone marrow derived
microenvironmental factors can revert multiple myeloma cells
to a less differentiated phenotype by the combined activities
of adhesive interactions and interleukin-6. Thus, the sustained,
yet contained outgrowth of multiple myeloma may be tightly
regulated by the bone marrow microenvironment.
329
EXPLORING THE ROLE OF VAV1, A SIGNAL
TRANSDUCER PROTEIN THAT FUNCTIONS ONLY
IN HEMATOPOIETIC CELLS, IN HUMAN SOLID
MALIGNANCIES
G. Lazer, Y. Idelchuk, L. Pe’er, V. Schapira and S. Katzav
The Hubert H. Humphrey Center for Experimental Medicine
and Cancer Research, The Hebrew University-Hadassah
Medical School, Jerusalem 91120, Israel
Aberrant signaling and gene expression is a hallmark of cancer
and can occur because of genetic changes in signaling proteins
or in proteins that modify their signaling activities. New
approaches for the treatment of cancer may become apparent
through the identification of the genes involved in malignant
transformation. An important example of such genes is Vav1,
a cytoplasmic signal transducer protein initially identified as
an oncogene. Physiological expression of Vav1 is restricted to
the hematopoietic system, where its best-known function is as
a GDP/GTP nucleotide exchange factor for Rho/RacGTPases,
an activity strictly controlled by tyrosine phosphorylation.
Vav1 regulates cytoskeletal rearrangement during activation of
hematopoietic cells, as well as activation of JNK, ERK, Ras,
NF-κB, and NFAT pathways. It also associates with numerous
adapter proteins. Since its discovery, research on Vav1 has
cycled between understanding its physiological function in the
hematopoietic system and understanding how it is
dysregulated as a truncated oncogene in fibroblasts. We have
recently shown that wild-type Vav1 is involved in human
cancers such as lung, breast, ovarian, neuroblastoma, uveal
melanoma and prostate cancer. Stimulation of human lung
cancer cells (H358 and H441) with Epidermal Growth Factor
(EGF) leads to increased tyrosine phopshorylation of Vav1,
suggesting that it participates in signal transduction events in
these cells. Depletion of Vav1 by siRNA leads to a dramatic
reduction in the ability of the H358 lung cancer cells to form
foci in agar and develop tumors in mice, indicating that Vav1
can play a decisive role in transformation of lung cancer cells.
It is conceivable that misexpressed Vav1 in tissues other than
the hematopoietic system participates in the pathogenesis of
cancer by activating pathways for both cellular proliferation
and cell survival and/or may contribute to the onset of these
tumors.
3343
ANTICANCER RESEARCH 28: 3157-3556 (2008)
330
MODULATION OF MATURATION AND FUNCTION
OF HUMAN DENDRITIC CELLS: A NOVEL
MECHANISM OF ANTI-TUMOR EFFECT OF
VISCUM ALBUM
Srini V. Kaveri
Centre de Recherche des Cordeliers, 15, Rue de l’Ecole de
Médecine, 75006 Paris, France
Viscum album (VA) is used in cancer as a complimentary
therapy. Despite being used for long time, the mode of action
of VA containing therapeutics remains unresolved. Their
activity has been attributed to immunomodulatory properties
in addition to their cytotoxic properties. Dendritic cells (DCs)
are the professional antigen presenting cells (APCs) which are
crucial in tumor immunosurveillance and in inducing tumor
immunity. The tumor cells have the capacity to evade the
surveillance by inactivating the DCs through tumor factors
such as VEGF, IL-10 and PGE2. We examined the aspect that
the VA preparations exert an immunomodulatory effect on
DCs and favor an effective tumor regression. DCs incubated
with VA M Spez and VA Qu Spez at 10 μg/ml showed an
enhanced expression of antigen presenting HLA-DR molecule
and co-stimulatory CD40, CD80 and CD86 molecules along
with an increased production of IL-6, IL-8 and IL-1β. The
ability of the DCs treated with VA to induce proliferation of
allogeneic CD4+ T-cells further substantiates the
immunostimulatory effect of VA preparations. These findings
should assist in better clarifying the immunomodulatory
characteristics of VA preparations and in designing
ameliorated therapeutic strategies.
331
TREATMENT OF MALIGNANT TUMORS
WITH A COMBINATION OF INTRATUMORAL
224Ra-LOADED WIRES AND CHEMOTHERAPY:
RETARDATION OF PRIMARY TUMOR
GROWTH AND OF LUNG METASTASES
Y. Keisari1, T. Cooks1, G. Horev1, S. Reitkopf1, M. Efrati1,
G. Marshak2, M. Schmidt3, L. Arazi3,4 and I. Kelson3,4
1Department
of Clinical Microbiology and Immunology,
Sackler Faculty of Medicine, 2Davidoff Center, Rabin
Medical Center, 3School of Physics and Astronomy, Sackler
Faculty of Exact Sciences, Tel Aviv University, and 4Althera
Medical, Tel Aviv, Israel
Objectives: Highly lethal alpha particle radiation has so far
not been used in the treatment of solid tumors because of its
short range. We developed a new intratumoral treatment for
solid cancer utilizing 224Ra-loaded wires that continually
release by recoil short-lived daughter atoms that emit alpha
3344
particles. These atoms disperse in the tumor and deliver a
lethal dose over a region measuring 3-7 mm in diameter. The
method was termed Diffusing Alpha-emitters Radiation
Therapy (DART). The present study examines the curative
effects of a combination between the 224Ra-loaded wires and
anti-tumor chemotherapy, against tumors of various
histological types. Methods: Mouse and human tumor cells
from pancreatic, squamous cell (SCC), prostate, and colon
carcinomas, were injected subcutaneously to normal and
athymic mice, respectively. Mouse and human tumors, 4-10
mm in diameter were implanted with stainless steel 224Raloaded wire(s) (0.3 mm-diameter and 3-5 mm long).
Chemotherapeutic agents were administered concurrently
only to mice bearing mouse tumors. Animals were monitored
for tumor development and survival. Also an in vitro set-up
was used to assess killing of cancer cells by alpha particles.
Results: Treatment of mouse SCC with two i.v. doses of
cisplatin (5 mg/kg) given concomitantly with two 224Raloaded wires (11-28 kBq), caused substantial growth arrest of
93%, extended survival from 44 to 87 days, and also reduced
metastatic spread to the lungs. Treatment of mouse pancreatic
tumors with a combination of one 224Ra wire (13-45 kBq) and
Gemcitabine (60 mg/kg) achieved significant reduction in
tumor volume relative to any treatment modality alone. 224Raloaded wires (15-17 kBq/wire), inhibited tumor growth of
colon adenocarcinoma tumors (4-6 mm) by 45%, and even
led to complete cure. Injection of 5-FU (75 mg/kg) with the
224Ra wire augmented tumor destruction and growth
retardation (35%) compared to 224Ra or 5-FU alone. 224Raloaded wires retarded the growth of all human derived tumors
implanted in athymic mice. In vitro experiments with all
tumor cells exposed to alpha particles revealed a dose
dependent killing of the tumor cells. The combined treatment
with alpha particles and chemotherapy achieved the highest
killing rate of tumor cells compared to each cytotoxic
component alone. Conclusion: 224Ra-loaded wires can
effectively destroy mouse and human derived solid malignant
tumors, both by direct destruction of tumor cells and by
causing damage to the tumor microenvironment, mainly the
vasculature. The effect can be further potentiated by a
combination with chemotherapy. This combined treatment
modality holds significant potential for the treatment of nonresectable human cancer.
332
SIGNAL TRANSDUCTION THERAPY OF TUMORS
WITH MULTIPLE TARGET KINASE INHIBITORS
György Kéri1,2, László Őrfi, Zoltán Greff, Zoltán Varga,
Bálint Szokol, Zoltán Horváth, István Peták
and Axel Ullrich3
1Vichem
Chemie Kutató kft., 1022. Herman Ottó u. 15.,
Budapest, Hungary;
Abstracts of the 8th International Conference of Anticancer Research, 17-22 October 2008, Kos, Greece
2Semmelweis
3Max-Planck
University, Budapest, Hungary;
Institute of Biochemistry, Martinsried,
Germany
Signal transduction therapy has become a leading area of
modern drug research aiming to inhibit the pathomechanism
based on validated target molecules in cellular signaling.
Selective inhibition of these false proliferative signals via
targeting receptor tyrosine kinases and other signaling
enzymes, resulting in the induction of apoptosis by depletion
of the “survival factors” is one of the most studied and widely
accepted concept of modern chemotherapy. Our Nested
Chemical Library™ (NCL) technology is based on a
knowledge-base approach where focused libraries of kinase
inhibitors around 108 core structures and several hundreds
scaffolds are used for hit finding and to generate
pharmacophore models. We have established a unique
proprietary kinase inhibitory chemistry and have developed
nM lead molecules against a series of kinases.
Cancer cells have an ability to resist apoptosis and many
tumors are resistant to the apoptosis-inducing effects of
radiation and chemotherapy. In order to overcome treatment
resistance and develop new drugs that target genes and protein
products in the apoptosis pathways we have developed
multiple target kinase inhibitors to inhibit certain survival
factors and induce synthetic lethality in cancer cells. We
perform the discovery and validation of a novel, alternative
class of inhibitors that target multiple kinase targets and/or
protein-protein interactions along some important survival
factors.
We have investigated synthetic lethal interactions for the
identification of new and more powerful classes of drug
targets. The pro-apoptotic effect of the compounds of
Vichem’s Chemical Validation Library (CVL) was tested on
two isogenic cell lines by sub-G1 flow cytometric apoptosis
assay and lead molecules were selected. Our novel “Target
Fishing” technology aims for selectivity profiling of lead
molecules. We have employed proteomic methods to
characterize the cellular targets of kinase inhibitors. In the
process of drug discovery selectivity profiling of kinase
inhibitors is a very important step, inhibiting more than one
relevant target can be advantageous (without inhibiting the
‘untouchables’ such as insulin receptor kinase). So we
perform not only selectivity profiling but also iterative target
re-identification of drug candidates during the early drug
discovery phase, thus providing tools for pharmacology
profiling. Using our kinase inhibitor library for the selected
survival factor kinase targets, with biochemical kinase
assays we have identified several potent hit and lead
compounds and generated joint pharmacophores. With
cellular kinase and proliferation/apoptotic assays we
selected potent multiple target drug candidate lead
molecules.
333
LATENT TGF-BETA BINDING PROTEINS (LTBPS) IN
TARGETING TGF-BETA ACTION
Jorma Keski-Oja, Marko Hyytiainen, Piia Vehvilainen,
Olga Tatti, Anna K. Kantola, Kaisa Lehti,
Harald von Melchner and Katri Koli
Department of Pathology, The Haartman Institute, University
of Helsinki, Haartmaninkatu 8, 00014 Helsinki, Finland
Extracellular matrix (ECM) is a structural framework for cells
and tissues, and provides signals to modulate cell behaviour.
TGF-β is targeted into the ECM as latent complexes with its
LAP-propeptide and via an LTBP molecule. Dysregulation of
TGF-beta activity is associated with almost all forms of
cancer. LTBPs-1, -3 and -4 associate with and regulate the
availability of TGF-b:s 1-3 in tissues. ECM targeting is
essential since the surrounding structures define the
susceptibility of the complexes to activation processes. To
understand these mechanisms we have analyzed LTBP:SLTGF-beta incorporation into the ECM of normal, malignant
and differentiating cells. Using recombinant LTBP fragments
we identified critical domains for this function. All LTBPs got
assembled into the ECM, but with varying kinetics.
Recombinant N-terminal fragments of LTBPs bound readily
to fibroblast ECM whereas the C-terminal domains of bound
divergently indicating specificity. In osteogenic differentiation
of mesenchymal stem cells we observed shift from LTBP-3 to
LTBP-1 in association with increased TGF-beta activity and
ECM mineralization. LTBP-4 knockout work revealed its
regulatory roles in colorectal carcinomas and lung
morphogenesis.
Fibronectin (FN) is central in the matrix targeting of LTBPs
in most cell cultures. FN acts as an organizer for the other
ECM proteins including LTBPs and fibrillin-1. FN plays a
central role in the ECM assembly of LTBP-4. Endogenous
LTBP-4 was not targeted into the matrix of FN(–/–)
fibroblasts. By exogenous FN the LTBP-4 assembly could be
rescued. To characterize the FN binding region of LTBP-4, Nterminally shortened constructs were analyzed for their ECM
association by IF-microscopy. When the N-terminal domain
(first exon area) of the molecule was deleted ECM deposition
of LTBP-4 was reduced and delayed. However, during
extended culture minor quantities of LTBP-4 accumulated into
the ECM, suggestive of alternative protein-protein interactions.
LTBP-4 has a C-terminal ECM binding site. This region binds
fibrillin-1 (Fbn-1) directly, suggesting that the observed minor
binding could be Fbn-1 dependent. LTBP-4/Fbn-1 double
staining profiles support this notion. We identified in LTBP-4
heparin binding sites, which may mediate cell attachment.
Current analyses revealed a direct interaction between FN and
LTBP-4, which evidently plays divergent roles in ECM
assembly. The modulation of structures of LTBPs (protease
3345
ANTICANCER RESEARCH 28: 3157-3556 (2008)
sensitivity, splicing) provides numerous alternatives for
dysregulated TGF-beta deposition in the pathogenesis of
malignant diseases.
H. Khan1, V. Makwana1, N. Courtenay-Luck2
and S. Missailidis1
1Department
334
GENETIC ALTERATIONS
THAT DISRUPT SUBCELLULAR
TRAFFICKING OF THE VHL TUMOR
SUPPRESSOR PROMOTE
TUMORIGENESIS
Mireille Khacho, Karim Mekhail,
Karine Pilon-Larose and Stephen Lee
Department of Cellular and Molecular Medicine, Faculty of
Medicine, University of Ottawa, Ottawa, Ontario, Canada,
K1H 8M5
The von Hippel-Lindau (VHL) tumor suppressor protein is the
substrate recognition component of a Cullin-2-containing E3
ubiquitin ligase that recruits the hypoxia-inducible factor
(HIF) for oxygen-dependent degradation. The subcellular
trafficking properties of VHL are essential for its ability to
mediate efficient degradation of HIF and suppress tumor
formation. Interestingly, nuclear export of VHL requires
ongoing transcription and is independent of the classical
NES/CRM1 nuclear export pathway. Examining this
uncharacterized nuclear export pathway led to the
identification of a discreet motif, reffered to as TD-NEM
(transcription-dependent nuclear export motif), that directs
transcription-dependent nuclear export of VHL. TD-NEM is
targeted by naturally-occurring mutations associated with renal
carcinoma and polycythemia in humans. We have also shown
that nuclear export of VHL by TD-NEM is mediated through
the translation elongation factor eEF1A, a protein implicated
in the nuclear export of tRNA in lower eukaryotes. eEF1A
interacts specifically with TD-NEM and disrupting this
interaction, by point mutations of key TD-NEM residues or
siRNA-mediated knockdown of eEF1A, suppresses nuclear
export of VHL. We show that naturally-occurring and cancercausing mutations targeting key residues of TD-NEM disrupt
the tumor suppressor function of VHL by altering its nuclear
export dynamics. Such mutations restrain the ability of VHL to
efficiently mediate oxygen-dependent degradation of HIF.
These results demonstrate that eEF1A/TD-NEM-mediated
nuclear export is critical to suppress activation of the HIF
oncogenic pathway and highlight the essential role of
subcellular trafficking in the tumor suppressor function of
VHL.
335
DEVELOPMENT AND CHARACTERISATION OF
APTAMERS AS INHIBITORS OF VITAL PATHWAYS
IN CANCER THERAPY
3346
of Chemistry and Analytical Sciences, The
Open University, Walton Hall, Milton Keynes, MK7 6AA;
2Antisoma Research Ltd, Welwyn Garden City, UK
Aptamers can be described as short oligonucleotides that
harbour great potential in their versatile applications, due to
their high affinity and specificity for their target of choice.
Despite their infancy, aptamers have already emerged at the
forefront of clinical research, offering significant contribution
as therapeutic agents for a range of diseases. Thus, our
research is aimed towards generating aptamer(s) for a specific
cancer biomarker that, when blocked, can lead to specific cell
kill and thus offer a novel therapeutic potential against cancer.
Aptamers are traditionally selected using SELEX
technology, which we have adapted to generate high affinity
aptamers on a faster timescale. Aptamer selection experiments
against a synthetic peptide of our tumour marker have led to
the selection of 3 aptamer species, which appeared in two
independent variations of the selection method.
Lack of an initial positive control, in the form or an Ab or
other ligand for our target, and limitations in the physical
properties our host-ligand system resulted in limitations with
regards to characterising the interactions between the aptamer
and its peptide target. To overcome such issues, we have
synthesised a DNA intercalating dye with different
luminescence properties depending on its physical
environment. The utilisation of this dye in a fluorescence
displacement assay has demonstrated that this technique can
provide a suitable means to characterise aptamer-peptide
interactions, without the need for modification. However, the
ability of the peptide to displace the dye from the aptamer
appeared to be dependent on the buffer system used in the
assay. CD experiments have verified that this is ultimately due
to ligand-induced conformational changes of the aptamer
structure, influenced by the buffer system employed. Other
techniques used to study the interaction of our biomolecules
consist of FRET assays, EMSAs and biacore. Stability assays
have demonstrated that the aptamers show remarkable
resistance towards nucleases present in human serum and
reasonable stability in mouse serum. Flow cytometry
experiments further demonstrated that our aptamers are able
to bind to cancer cell lines proposed to express our target
biomarker, offering a viable tumour marker validation assay.
Remarkably, shorter variations of each aptamer, designed on
the basis of computational predictions, showed better binding
to the cancer cells than their full length counterparts. Finally,
our aptamers have shown the ability to effect direct cell kill in
prostate and breast cancer cell lines by the proposed inhibition
of vital cellular pathways leading to cell apoptosis. Our studies
show promising results for these aptamers as cancer
Abstracts of the 8th International Conference of Anticancer Research, 17-22 October 2008, Kos, Greece
therapeutics and as such these aptamers are now in pre-clinical
studies.
336
MECHANISM OF ACTION AND DURATION OF
TRANSLATION OF THE THYMIDINE KINASE
GENE IN ADENOVIRUS-MEDIATED
GENE THERAPY OF OVARIAN CANCER
D.G. Kieback1,2, A.Romano2, B.Delvoux2, S.Ollig1
and D.C. Fischer2
1HELIOS Medical Center, Aue, Gartenstrasse 6, 08280 Aue,
Germany;
2GROW Research Institute, University of Maastricht, the
Netherlands
Adenovirus (ADV)-mediated gene therapy with the thymidine
kinase (TK) Gene under control of the Rous sarcoma virus
(RSV) promotor followed by the administration of acyclovir
has been established in vitro for the treatment of ovarian
cancer cells and has been used as the basis for intraperitoneal
phase I clinical trials.The purpose of this investigation was to
clarify whether cell death after ADV-RSV-TK gene therapy
and acyclovir administration is indeed due to apoptosis
induction.
It was tested if the synergistic effect of ADV-RSV-TK gene
therapy with chemotherapy was limited to the primary
mechanism of action or whether the vector transduction itself
exerted any pro-apoptotic effect. It is unclear how long a
significant degree of transgene translation can be expected
after adenovirus-mediated TK transduction, where the
transcriptional complex is localized in the nucleus in an
episomal fashion and thus without stable integration. The
possible interaction of Acyclovir pretreatment with
subsequent ADV-RSV-TK transduction also remains to be
elucidated.
The epithelial cell lines OVCAR-3 and MDAH-2774 were
established from human poorly differentiated serous ovarian
cancer.Fluorimetric assay of caspase-3 activity was performed
as well as ELISA of the CK 18 split product M30. PARP
cleavage was analysed by Western blotting. Transgene
expression and cell killing efficacy were analysed based on
multiplicity of infection (MOI) and MTT assay.Anti-TKantibody 1397 was used for immunocytochemistry and
Western Blot analysis of TK expression. After transduction
with ADV-RSV-TK at an MOI of 66, TK translation increased
strongly in MDH 2774 and OVCAR-3 cell lines during the
initial 48 hours. Apoptosis induction was established in this
investigation as the mechanism of the ADV-RSV-TK gene
therapy effect of acyclovir administration by caspase activity
and subsequent CK 18 cleavage. Neither acyclovir nor vector
administration alone showed any apoptotic activity. The
synergistic effect of TK gene therapy and chemotherapeutic
agents was shown to be TK induced. Significant anti-PARP 1
activity was found to be an ADV-RSV-TK treatment effect
after acyclovir addition. CAR expression was observed on the
membranes but also intracellular translocation of CAR takes
place dependent on cellular growth patterns TK gene
expression is dependent on multiplicity of infection (MOI) and
thus on vector dose in a linear fashion. Neither TK expression
nor ADV transduction influence CAR expression. Differential
susceptibility of different cell lines to TK induced cell killing
by Acyclovir metabolites was observed.
CAR expression appears not to be influenced by adenoviral
transduction or by the accumulation of the tymidine kinase
gene product. Differences in therapeutic sensitivity are most
likely mediated by intracellular mechanisms and not by
modulation of CAR expression.Virtually constant expression
of the TK transgene was observed by Western blot during
eight days. Cell killing efficacy was increased by repeated
daily administrations of acyclovir. Pretreatment with acyclovir
did not result in significantly increased cell killing efficacy.
No negative effect of acyclovir on ADV-RSV-TK transduction
was observed. The at least week-long expression of the TK
transgene with persistently increasing efficacy of cell killing
after adenovirus-mediated tumor cell transduction provide a
realistic basis for the development of multicycle ADVmediated TK gene therapy approaches in the treatment of
ovarian cancer. Continuous i.v. acyclovir treatment or daily
oral acyclovir-prodrug therapy might simplify the substrate
regimen for the TK gene. Due to its anti-PARP activity it may
in the future play a role specifically in the treatment of
BRCA1- and 2- related familial ovarian cancer.
337
TECHNOLOGICAL ADVANCES IN OVARIAN
CANCER SURGERY
D.G. Kieback, A. Süsse and S. Ollig
HELIOS Medical Center Aue, Gartenstrasse 6, 08280 Aue,
Germany
Most tumors with intraperitoneal dissemination are not
amenable to surgical treatment strategies. In ovarian cancer,
however, patient prognosis can be dramatically improved by
radical surgical removal of all macroscopic disease at the time
of primary surgery. This is necessary in the 75% of patients
presenting with advanced disease at the time of primary
diagnosis. In order to achieve this goal, multiorgan resections,
peritoneal
resection
and
pelvic
and
paraaortic
lymphadenectomy are in many instances warranted in addition
to the routinely performed hysterectomy with bilateral
salpingo-oophorectomy and omentectomy. In view of the long
duration of these surgical interventions of six hours and more,
it is of great importance to optimise the rapidity of each
surgical step while minimizing blood loss.
3347
ANTICANCER RESEARCH 28: 3157-3556 (2008)
To this end, high frequency surgery using electrical energy
(HF-Surgery) has recently made major inroads. Energy
adjustment directly from the handpiece without need for
external help in adjusting generators, computerized energy
dosing with vessel sealing and tissue separation by integrated
cutting devices have become available. Ultrasound surgery
(CUSA) is used in tumor spread to vulnerable surfaces that
are otherwise surgically inaccessible or in diffuse coating of
large parts of the intestine. In combination with advanced
stapling techniques for bowel reconstruction and formation of
organ replacement such as continent conduits these options
make possible a vastly increased degree of radicality with less
complications.
From September 2006 until September 2008 49 patients
with ovarian cancer stage III and IV underwent surgical
exploration for ovarian cancer, 37 with newly diagnosed
disease and 12 with recurrence after more than one year after
completion of primary treatment. Complete radical debulking
surgery to no macroscopic residual was possible in 46 patients
overall, 35 in primary surgery and 11 in recurrent tumors. 3
patients could not be significantly debulked. 1 had extensive
infiltration of the entire muscular anterior abdominal wall, 2
suffered from serious comorbidities that made longer
interventions impossible. Those underwent primary
chemotherapy.
There was no operative mortality. The complete debulking
rate of 94% even in this mixed series is in part due to the still
relatively small numbers. Our serious, however, confirms data
by Eisenkop and colleagues while comparing favourably with
European data i.e. from Germany, where optimal surgical
results are obtained approximately 20% of these cases even in
cooperative study groups.
We conclude, that with adequate surgical training and
optimal utilization of the technological advances made in
surgical instrumentation complete debulking surgery can be
performed in the vast majority of patients with advanced
ovarian cancer.
in which the amino group at 3’ position was replaced by 2
different formamidino groups (-N=CH-N), where one of the
nitrogen atom is a part of morpholine (derivative DOHM) or
hexamethyleneimine (DOXH) ring. All tests were performed
in HL60 sensitive and HL60/VINC resistant cells. HL60/VINC cells retain sensitivity toward vincristine, a drug
which is typically associated with the classical multidrugresistance phenotype. Their resistance to anthracyclines is due
to the lowered activity of DNA topoisomerase II. Results:
Cytotoxic activity of DOX toward resistant cells was ~200
times lower when compared with the sensitive HL60 cell line
(resistance index 200). Formamidine derivatives of DOX also
exhibited decreased cytotoxicity toward HL60/VINC cells but
the resistance index for both compounds was ~2 and these
compounds were more than 20 times more active in resistant
cells than parent drug DOX. It was found that the uptake of
DOX was lowered in resistant cells by 16%. The uptake of
DOXM and DOXH was also lowered by 26% and 19%,
respectively. Thus the changes in the cellular uptake of
anthracyclines are not associated with the loss of their
cytotoxicity and the fact that cytotoxicity of DOXM and
DOXH exceeded the cytotoxicity of DOX. These results
suggests that DOXM and DOXH are much more cytotoxic
then DOX against HL60/VINC cells because the mechanism
of their cytotoxic action is different from that of DOX. This
suggestion was proven by the experiments in a cell-free
system containing human topoisomerase II and supercoiled
pBR322 DNA. DOX strongly stimulated DNA cleavage,
whereas its derivatives were inactive. Conclusion: It is
concluded that the introduction of formamidine moiety
containing morpholine or hexamethyleneimine ring is
promising way to obtain anthracyclines cytotoxic against
tumors cells with altered topoisomerase II activity.
338
CYTOTOXICITY AND CELLULAR UPTAKE OF
DOXORUBICIN AND ITS FORMAMIDINE
DERIVATIVES IN HL60 SENSITIVE
AND RESISTANT CELLS
Akira Kikuchi, Hideki Yamamoto and Manabu Kurayoshi
Krzysztof Kik1, Małgorzata Wasowska-Lukawska2,
Irena Oszczapowicz2 and Leszek Szmigiero1
1Department
of Molecular Pharmacology, Medical
University of Lodz, 6/8 Mazowiecka St., 92-215 Lodz;
2Institute of Biotechnology and Antibiotics, 5 Staroscinska
St., 02-516 Warsaw, Poland
Background: In this work we compared cytotoxicity and
cellular uptake of doxorubicin (DOX) and its two derivatives,
3348
339
TUMOR FORMATION DUE TO ABNORMALITIES
IN THE β-CATENIN-INDEPENDENT
PATHWAY OF WNT SIGNALING
Department of Biochemistry, School of Biomedical
Sciences, Hiroshima University, 1-2-3, Kasumi, Minami-ku,
Hiroshima 734-8551, Japan
Wnt signaling is a complex pathway in which β-catenin is
viewed as a central mediator in regulating cell proliferation
and differentiation. The significance of Wnt signaling in
human cancer has been elucidated by the identification of
mutations in genes coding for the β-catenin-dependent
pathway components, APC, β-catenin, and Axin. Evidence has
been recently presented on the importance of the β-cateninindependent pathway activated by Wnt signaling. It is likely
that this pathway activates several intracellular signaling
Abstracts of the 8th International Conference of Anticancer Research, 17-22 October 2008, Kos, Greece
systems to regulate cell migration, adhesion, and polarity. The
β-catenin-independent pathway has also been shown to be
involved in tumor biology. However, the role of the β-cateninindependent pathway is still unclear. Since Wnt5a is a
representative ligand that activates the β-catenin-independent
pathway, we sought to clarify how Wnt5a is involved in
aggressiveness of gastric cancer. Wnt5a was overexpressed in
71 of 237 gastric cancer cases. The positivity of Wnt5a
expression was correlated with advanced stages and poor
prognosis of gastric cancer. Wnt5a stimulated cell migration
and invasion in gastric cancer cells. Wnt5a activated focal
adhesion kinase and small GTP-binding protein Rac, both of
which are known to play a role in cell migration. Cell
migration, membrane ruffling, and turnover of paxillin were
suppressed in Wnt5a knockdown cells. Furthermore, antiWnt5a antibody suppressed gastric cancer cell migration.
These results suggest that Wnt5a stimulates cell migration by
regulating focal adhesion complexes and that Wnt5a is not
only a prognostic factor but also a good therapeutic target for
gastric cancer. In this talk, we review recent developments in
both the functions and mechanisms of the β-cateninindependent pathway of Wnt signaling, with an emphasis on
its functional contribution to tumor progression.
differentially expressed was by tumor location, and the next
largest number by lymphovascular or neural invasion of tumor
cells and by mismatch repair (MMR) defects. Amongst
biological processes, the immune response was significantly
implicated in entire molecular changes observed during
colorectal tumorigenesis (p<0.001). Amongst 47 differentially
expressed genes, seven (PISD, NIBP, BAI2, STOML1,
MRPL21, MRPL16, and MKKS) were newly found to correlate
with tumorigenesis and tumor growth. Most locationassociated molecular changes had distinct effects on gene
expression, but the effects of the latter were sometimes
contradictory. Conclusion: We show that several differentially
expressed genes were associated with canonical molecular
changes in sporadic colorectal cancer, possibly constituting
alternative or subordinate pathways of tumorigenesis. As
tumor location was the dominant factor influencing differential
gene expression, location-specific analysis may identify
location-associated pathways and enhance the accuracy of
class prediction.
340
GENE EXPRESSION PROFILING: CANONICAL
MOLECULAR CHANGES AND
CLINICOPATHOLOGICAL FEATURES IN
SPORADIC COLORECTAL CANCER
Jin C. Kim1,3, Seon A. Roh1,3, Dong H. Cho1,3,
Sang N. Yoon1,3, Chang S. Yu1,3, Tae W. Kim2,
Seon Y. Kim4 and Yong S. Kim4
Jin C. Kim1,2, Seon Y. Kim1,2, Seon A. Roh1,2,
Dong H. Cho1,2, Dae D. Kim1,2, Jeong H. Kim3
and Yong S. Kim3
1Departments
of Surgery, University of Ulsan College of
Medicine and Asan Medical Center, and 2Laboratory of
Cancer Biology and Genetics, Asan Institute for Life
Sciences, 388-1 Poongnap-2-Dong Sonagpa-Ku, Seoul 138736;
3Medical Genomics Research Center, Korea Research
Institute of Bioscience and Biotechnology, Daejeon 305-806,
Korea
Background: Although various molecular changes have been
identified in colorectal cancer, a clear pattern is detected in
only 6.6% of these tumors, indicating the need to identify
alternative or subordinate pathways involved in colorectal
tumorigenesis and tumor growth. Methods: Using microarray
gene-expression analysis, we therefore assayed patterns of
gene expression, relative to canonical molecular changes and
clinicopathological features, in 84 sporadic colorectal cancer
patients, standardized by tumor location. Subsets of
differentially expressed genes were confirmed by real-time
RT-PCR. Results: The largest number of genes identified as
341
CHEMO-RESPONSIVENESS ASSOCIATED WITH
CANONICAL MOLECULAR CHANGES IN
COLORECTAL CANCER
Departments of 1Surgery and 2Internal Medicine, University
of Ulsan College of Medicine, Asan Medical Center, and
3Laboratory of Cancer Biology and Genetics, Asan Institute
for Life Sciences and 388-1 Poongnap-2-Dong Songpa-Ku,
Seoul 138-736;
4Division of Medical Genetics, Korea Research Institute of
Bioscience and Biotechnology, Daejeon 305-806, Korea
Background: To assess the canonical molecular changes in
colorectal tumorigenesis associated with response to
chemotherapy, in order to identify candidate markers.
Methods: In total, 156 patients received adjuvant
postoperative fluoropyrimidine-based chemotherapy, and 32
patients received oxaliplatin- or irinotecan-based
chemotherapy following palliative surgery or for metastatic
or recurrent colorectal tumors. Representative molecular
changes in tumor tissues, including APC, Wnt, MMR, RAF,
TGF-β, BMP, and p53, had been previously determined in
130 patients, with an additional 42 patients included in this
analysis. Results: Disease-free survival period (mean±SEM)
was significantly longer after fluoropyrimidine-based
adjuvant chemotherapy in tumors with TGF-β2 expression
(42±1.4 vs. 21±4.7 months; p=0.005) and D18S46 LOH or
MSI (45.7±1.5 vs. 40.5±1.4 months; p=0.048). In the
metastatic settings, the high disease control rate correlated
3349
ANTICANCER RESEARCH 28: 3157-3556 (2008)
significantly with wild-type relative to mutant APC and intact
MMR relative to MMR defects (p=0.013, respectively).
Interestingly, specific molecular steps of tumorigenensis were
closely associated with particular toxicities. Conclusion: A
subset of molecular changes occuring during colorectal
tumorigenesis showed significant associations with
therapeutic responses and toxicities to chemotherapy
regimens, suggesting that these changes may be candidate
predictors of response to chemotherapy.
342
FAK/SRC PATHWAY PLAYS A KEY ROLE
IN FARNESIFEROL C INDUCED
ANTIANGIOGENIC AND
ANTITUMOR ACTIVITIES
Jae-Ho Lee1, Sun Choi2, Yoonji Lee2, Hyo-Jeong Lee1,
Kwang Seok Ahn1, Hyo-Jung Lee1, Eun-Ok Lee1,
Seung-Hoon Choi1, Junxuan Lu3 and Sung-Hoon Kim1,3
1Cancer
Preventive Material Development Research Center,
College of Oriental Medicine, Kyunghee University, Seoul
130-701, Republic of Korea;
2College of Pharmacy and National Core Research Center
for Cell Signaling and Drug Discovery, Ewha Womans
University, Seoul, 120-750, Republic of Korea;
3The Hormel Institute, University of Minnesota, 801 16th
Avenue NE, Austin, MN 55912, USA
Farnesiferol C (FC) is a natural compound from Ferula
assafoetida L. that has been used for cancer treatment as a folk
remedy; its anti-tumor efficacy and mechanisms are not yet
determined. Thus, in the present study, we first examined the
anti-angiogenic activities and associated mechanisms of FC
using a battery of in vitro/ex vivo assays. FC exerted
cytotoxicity against non-proliferating human umbilical vein
endothelial cells (HUVECs) with IC50 of ~70 μM. Within the
non-cytotoxic ranges of exposure (10~40 μM), FC inhibited
vascular endothelial growth factor (VEGF) induced cell
proliferation, migration, invasion and tube formation (capillary
differentiation) and also the expression of matrix
metalloproteinase (MMP) 2 in the VEGF-treated HUVECs.
Also, FC decreased the binding of VEGF to VEGFR-1/Flt-1,
but not to VEGFR-2/KDR/Flk-1. Interestingly, the dampened
endothelial cellular responses were preceded by a rapid
inhibitory action (examined within 10 min of VEGF
stimulation) of FC on a number of key VEGF-induced
signaling pathways: decreased VEGF-induced phosphorylation
of Src and FAK without affecting VEGFR-2
autophosphorylation or AKT phosphorylation and decreased
the phosphorylation of mitogen activated protein kinases
(MAPKs), such as ERK1/2, c-JUN N-terminal kinase (JNK)
and p38MAPK. Consistently, molecular modeling studies
predicted that FC can inhibit Src kinase activity via its
3350
preferential docking to the ATP-binding site of Src kinase
rather than VEGFR2. In addition to HUVEC model, FC
inhibited the sprouting of VEGF-treated rat aortic endothelial
cells in a concentration dependent manner in an ex vivo model.
Furthermore, FC significantly inhibited the in vivo growth of
mouse Lewis lung cancer cells inoculated on the flank of
syngenic mice at a dose of 1 mg/kg without any negative
effect on the body weight of the host mice.
Immunohistochemistry also revealed that its anticancer
efficacy is associated with decreased expressions of
microvessel density (CD34), proliferative index (Ki-67) and
Src. Taken together, these findings suggest that Farnesiferol C
possesses strong anti-angiogenic potential via FAK/Src and
MAPK pathways as a cancer chemopreventive or therapeutic
agent.
343
SHIKONIN-INDUCED CELL CYCLE
ARREST AND APOPTOSIS IN HUMAN
BREAST CARCINOMA MCF-7 CELLS
Sun-Joong Kim and Hyo Ihl Chang
College of Life Sciences and Biotechnology, Korea
University, Seoul 136-701, South Korea
Shikonin isolated from Lithospermum erythrorhizon roots has
been reported to confer biological properties including
antibacterial,
wound
healing,
anti-inflammatory,
antithrombotic, and antitumor effects. We investigated,
together with the structurally related naphthoquinone, the
effects on the induction of apoptotic cell death in the human
breast carcinoma cell line, MCF-7. Shikonin was extracted
from Lithospermum erythrorhizon by sonication with n-hexane
followed by hydrolyzed in 1N NaOH, and analyzed by UPLC
coupled with TOF-MS/MS. Chromatographic separation was
achieved on a reversed-phase Luna C18 column and step
gradient elution resulted in a total run time of about 25 min
and the full scan mass spectra of shikonin. The protonated
molecules found for shikonin were m/z 287.12. The cytotoxic
potential of shikonin was assessed through MTT assay. Cellcycle analysis, Reactive Oxygen Species (ROS) and
Mitochondrial Membrane Permeability were performed by
Flow Cytometry. Treatment with 0-20 ppm of shikonin did not
induce significant apoptosis, but rather induced G0/G1-phase
arrest in MCF-7 cells. Flow cytometric analysis indicated that
shikonin directly increased intracellular oxidative stress based
on the cell permeable dye, 2’,7’-dichlorodihydrofluorescein
diacetate(DCFH-DA) acting as an indicator of reactive oxygen
species(ROS) generation. Also, shikonin decreased the
mitochondrial membrane potential (Δψm), in MCF-7 cells.
Overall, our results demonstrated that shikonin treatment
causes cell death by activating pathway inducing G0/G1-phase
arrest and apoptosis.
Abstracts of the 8th International Conference of Anticancer Research, 17-22 October 2008, Kos, Greece
344
IMMUNOTHERAPY OF LUNG CANCER AND
OVERVIEW OF IMMUNOTHERAPY–PAST,
PRESENT AND FUTURE
Hideki Kimura
Chiba Cancer Center Japan, Nitona-Cho 666-2, Chu-o-ku
Chiba City Japan
Introduction: The efficacy of immunotherapy for cancer
patients is still under debate. Although accumulating
evidence indicates that the immune system recognizes
tumors and mounts responses against cancer, immunotherapy
for cancer patients has not gained as much public support as
a standard therapy such as surgery, chemotherapy or
radiation therapy. In our presentation, we report results of
experimental analysis of killer cell and dendritic cell
production from regional lymph nodes of primary lung
cancer patients. In the presence of dendritic cells obtained
from tissue culture of regional lymph nodes of primary lung
cancer patients, we obtained activated killer cells which
demonstrated specific cytotoxic activity against autologous
cancer cells. By adding peripheral blood lymphocytes to
long-term tissue culture of regional lymph nodes, we have
succeeded in generating specific killer cells sufficient for the
immunotherapy of cancer patients. Using these cells as a
source of adoptive immunotherapy, we report promising
results of a phase II study of post-surgical adjuvant chemoimmunotherapy against lung cancer patients. Furthermore we
will discuss future possibilities and limits of immunotherapy.
Patients and Methods: Pathologically diagnosed N2 lung
cancer patients were selected for post-surgical adjuvant
chemo-immunotherapy. The activated killer cells and
dendritic cells (AKT-DC) obtained from tissue cultures of
tumor-draining lymph nodes (TDLN) or from TDLN cocultured with peripheral blood lymphocytes (TDLN-Pb) were
used for the adoptive transfer of immunotherapy. The
patients received surgery and 4 courses of chemotherapy
along with 10 to 12 courses of adoptive immunotherapy
every 2 months for 2 years. Results: There were 31 N2
patients eligible for the study. Three cases were excluded
because of refusal by the patients after 1-2 courses of
immunotherapy. For the 28 cases treated, a total of 313
courses of immunotherapy were administered. The main
toxicities were fever (78.0%), chill (83.4%), fatigue (23.0%)
and nausea (17.0%) on the day of cell transfer. The 2- and
5-year survival rates were 88.9 %(95.9-81.9; 95% confidence
interval, C.I.) and 52.9% (76.4-29.4; C.I.). The 5-year
survival rate of the patients with same stage who received
chemotherapy and surgery without immunotherapy was
12.5%. Conclusion: Adoptive transfer of activated killer cells
and dendritic cells from the tumor-draining lymph nodes of
primary lung cancer patients is feasible, safe, and give us
promising hope for the future prospective study of
immunotherapy.
345
LOW PENETRANCE GENETIC SUSCEPTIBILITY
FACTORS IN HUMAN CARCINOGENESIS
István Kiss1, Zsuzsanna Orsós1, Antal Tibold1,
Zsuzsanna Varga2, József Cseh3,
András Csejtei4 and István Ember1
1Institute
of Preventive Medicine, Faculty of Medicine, Pécs
University of Sciences, Pécs;
2Department of Oncotherapy, Pécs University of Sciences,
Pécs;
3Department of Oncology, Fejér County “Szent György”
Hospital, Veszprém;
4Department of Oncoradiology, Vas County “Markusovszky”
Hospital, Szombathely, Hungary
Cancer is a process caused by gene-environment interactions.
The cancer-related genetic factors can be high-penetrance
genes, causing hereditary tumors and cancer syndromes, or so
called individual susceptibility factors. The latter group
typically consists of minor variants – allelic polymorphisms –
in genes regulating cell cycle, cell division, DNA repair,
apoptosis and metabolism of carcinogenic substances.
The individual susceptibility factors are not strong enough
to cause familial aggregation of tumors, but on a population
level they can significantly alter the risk of certain cancers.
However, in an interaction with each other, or with
environmental exposures, the low penetrance susceptibility
factors might already cause substantial risk increase in “highrisk” individuals. Genotyping for several allelic
polymorphisms might give a possibility for individualized
prevention, by giving complex information on personal
susceptibility traits.
The lecture gives an overview on the most important
categories of low penetrance cancer susceptibility factors, their
mode of action and population level significance. Results of
our molecular epidemiological studies on colorectal cancer,
thyroid cancer and other tumors, concerning the effects of
allelic polymorphisms of metabolizing enzymes, tumor
suppressor genes and DNA repair genes will also be reviewed,
including recent, unpublished works.
346
EXOCRINE PANCREATIC CANCER: NEW
CONCEPTS, NEW DRUGS, PERSPECTIVES
R. Klapdor
Internal Practice, Centre for clinical and experimental
tumour marker diagnosis and therapy (ZeTDT)GmbH,
Hamburg, Germany
3351
ANTICANCER RESEARCH 28: 3157-3556 (2008)
During the past 15 years most of the scientific clinical studies
reported on study protocols following only 1 treatment
regimen. The mean survival of 6-8 months in these studies is
even nowadays accepted as a reference value for survival of
patients suffering from advanced exocrine pancreatic cancer.
Reviewing the literature the main reasons for this disaster
seem to be: 1. The known cytostatic drugs only show a
limited/disappointing efficacy in the case of single agent
therapies. 2. Palliative therapy in general is started too late,
not allowing a second or third line therapy. 3. Follow up only
based on imaging methods performed in more or less long
intervals. 4. Study-protocols to investigate new drugs or drugcombinations mainly base on 1- line- treatment strategies. 5.
Symptomatic supportive treatment with all their actual
facilities is not employed in a way, possible today (nutrition,
pain therapy, endoscopic palliative surgery, palliative resective
surgery etc.). 6. Some kind of treatment nihilism due to the
known limited efficacy of Gemcitabine and it’s combinations
during the past 14 years seem to paralyse some activities in
the oncological field.
Our own experience however suggests that the outcome of
these cancer patients can be improved by earlier diagnosis and
earlier start of palliative tumortherapy, by valid follow-up
based on imaging methods every 6-8 weeks in combination
with tumor marker determinations every 2-4 weeks, by
consequent offer of best supportive care to the patients and by
treatment concepts following the concept of EOSPC (Efficacy
Orientated Sequential Poly-Chemotherapy). Following this
concept we were able to report on median survival rates of 16
months for all patients and of 18 months for locally advanced
and 13 months for metastasized carcinomas resp.. 73% of our
patients allowed to start a second line therapy, 68% also a third
line treatment. M1 patients with >1 effective treatment
sequence (49% of the M1 tumors diseases) showed a median
survival of 18.5 months. As cytotoxic drugs we mainly used
Gemcitabine, 5-FU, Folinic acid, Oxaliplatin, Mitomycin-C
and/or Irinotecan as single drugs or in combinations. New
drugs acting by new mechanisms like e.g. Erlotinib, new
combinations or local regional approaches seem to further
improve the survival.
Summarizing the data support the concept of efficacy
orientated sequential pancreatic cancer therapy. Consequently
also clinical prospective studies should be planned no longer
as 1-line concepts, but at least as 2- or 3- line concepts with
new drugs or drug combinations to be evaluated as 1st-, 2ndor 3rd lines.
347
CHRONIC AND BREAK-THROUGH PAIN IN
CANCER PATIENTS
U.R. Kleeberg
HOPA, Hamburg, Germany
3352
Although the pathophysiology of pain has been studied in
great detail, cancer-related chronic pain syndromes and breakthrough pain are highly complex and difficult to analyze in
individual patients, reflecting the clinical day to day problems
with an optimal and tailored treatment. Several surveys on
patient satisfaction with the quality of pain control, both for
in- as well as in out-patients of specialized oncology units,
leave quite some room for improvement. Roughly 20% of
cancer patients continue to suffer from pain, though improved,
despite optimal interdisciplinary efforts.
The dominant clinical problems stem from the delicate
balance between pain control, treatment-related side-effects
and patient adherence. Increasing dosage and dose intensity of
Opiods, combinations with adjuvants and psychosocial support
may help in most situations, but definitely not in all, especially
in neuropathic and break-through cancer pain (BTCP).
New insights in the pathogenesis of pain and new drugs and
drug combinations have moved us on a little further, still being
unsatisfactory though in difficult clinical situations. Teaching
propaedeutics in Palliative Care remains one of the dominant
tasks in academic medicine: Detailed case history, differential
diagnosis, documentation of the course, and repeated
consultation of all disease-related disciplines under the
guidance of the medical oncologist will ameliorate the cancer
patient’s suffering and allow for new strength “zum
Menschsein”.
An overview about the current state of the art will be given.
348
THE ROLE OF MICROENVIRONMENT IN EBV
ASSOCIATED LYMPHOID MALIGNANCIES
Eva Klein
Department of Microbiology, Tumor and Cell Biology.
Karolinska Institute, 17177, Stockholm, Sweden
Depending on the differentiation and maturation of EBVgenome carrying cells, virally encoded proteins are
expressed in various combinations. These proteins determine
the fate of the viral genome harbouring cells. Virus
transformed B lymphocytes - lymphoblastoid cell lines LCL- express six virally encoded nuclear (EBNA) and three
surface localised (LMP) proteins. This phenotype is
encountered only in B lymphocytes and it is associated with
cell proliferation. Therefore, it is usually referred to as
growth transformation program and also as Type III EBV
expression. Such cells are readily recognized by the immune
response. Their proliferation therefore is inhibited in healthy
individuals. Consequently in immunosuppressed patients this
mechanism does not function and the risk for EBV
associated B cell malignancies is high. In other cell types
which carry the EBV genome the expression of the virally
encoded proteins is restricted, such as in NK cells, T-cells.
Abstracts of the 8th International Conference of Anticancer Research, 17-22 October 2008, Kos, Greece
They express only EBNA-1 and LMP-1, thus they lack the
nuclear protein EBNA-2 that is required for the proliferating
inducing capacity of the virus. In such cells the presence of
the viral genome does not induce proliferation. However it
may affect the phenotype of the cell and alter their
behaviour, by avoidance of apoptosis, by inducing
enrichment of inflammatory cells in their surrounding and/or
their response to growth inducing intercellular contacts or to
cytokines may be intensified. There is evidence for such
mechanisms in EBV associated Hodgkin’s lymphoma and
nasal NK lymphoma.
349
CELLULAR SENESCENCE AND CANCER
DEVELOPMENT
Dimitris Kletsas
radiation, used in several anticancer treatment regimes,
provoke premature senescence in stromal fibroblasts, via a
DNA damage response, and these senescent cells enhance the
growth of cancer cells, both in vitro and in
immunocompromised mice in vivo. The mechanisms
underlying this phenomenon will be discussed. These findings
support the idea that replicative- or stress-induced- senescence
may play a role in tumorigenesis late in life.
This work has been partially supported by KESY.
350
THE NUCLEOTIDE EXCISION REPAIR COMPLEX
ERCC1-XPF AS A POSSIBLE FACTOR FOR REPAIR
DEFICIENCY AND CISPLATIN SENSITIVITY IN
TESTIS TUMOR CELLS
S. Usanova, A. Piée-Staffa, U. Sied,
B. Kaina and B. Köberle
Laboratory of Cell Proliferation and Ageing, Institute of
Biology, National Centre for Scientific Research
“Demokritos”, 15310 Athens, Greece
Institute of Toxicology, University of Mainz, Obere
Zahlbacher Strasse 67, 55131 Mainz, Germany
The majority of normal somatic cells cannot proliferate
indefinitely and after a limited number of duplications they
enter a state called replicative senescence, characterized
mainly by the cell’s inability to proliferate. This phenomenon
is the consequence of a progressive telomere shortening, that
is perceived by the cells as a DNA damage, leading to the
activation of p53 tumor suppressor and thus to cell cycle
arrest. In addition, the cells can senesce prematurely after
exposure to various types of genotoxic stress. Interestingly, the
overexpression of several oncogenes in normal cells leads also
to premature senescence, indicating that senescence is a potent
anticancer mechanism. We have recently shown that this
oncogene-induced senescence is also the outcome of a DNA
damage response, suggesting common mechanisms underlying
replicative and stress-induced senescence. Finally, several
DNA damaging agent provoke a senescent-like phenotype in
tumor cells.
Beyond their inability to proliferate, senescent cells express
a pro-inflammatory phenotype that is believed to contribute to
the ageing process and to the development of age-related
disorders. We have shown that p53 is responsible for the
senescence-associated overexpression of ICAM-1, a crucial
pro-inflammatory molecule, indicating that the various
features of senescence (cell cycle arrest and the proinflammatory phenotype) are, at least in part, linked with the
same molecular mechanisms.
Although cellular senescence is considered an anticancer
mechanism, it has been proposed that senescent cells, due to
their specific phenotype create a permissive environment for
the growth of cancer cells, supporting the idea that the
senescence response is antagonistically pleiotropic. In this
vein, we have shown that subcytotoxic doses of ionizing
Metastatic testicular germ cell tumors (TGCT) are cured in
over 75% of patients using cisplatin-based combination
therapy. The reasons underlying this cisplatin sensitivity are
not yet known. Cell lines derived from TGCTs retain this
cisplatin hypersensitivity in vitro, therefore providing a good
model system for investigating the factors controlling
cisplatin sensitivity. Our earlier data showed that testis
tumor cells have a reduced capacity to repair cisplatininduced DNA damage, suggesting that repair deficiency
might be a factor for the observed cisplatin sensitivity. In
further studies, we found that the nucleotide excision repair
(NER) factor ERCC1-XPF is reduced in testis tumor-cell
lines, indicating a possible role of ERCC1-XPF for repair
deficiency and cisplatin sensitivity of testis tumor cells.
Cisplatin induces both intra-strand adducts (IA) and interstrand crosslinks (ICLs). To investigate repair of IAs, we
used the method of DNA slot blotting, while repair of ICLs
was investigated using the Comet assay. We found that the
repair of IAs was slightly reduced in the two testis tumor
cell lines compared to a cisplatin-resistant bladder cancer
cell line. Repair of ICLs, however, was significantly reduced
in the testis tumor cells compared to the bladder cancer cell
line. To analyse the causal role of ERCC1-XPF for repair
deficiency and cisplatin sensitivity in testis tumor cells, we
overexpressed ERCC1-XPF in the testis tumor cell lines
833K and SuSa using a mammalian expression vector.
Overexpression of ERCC1-XPF increased ICL repair in
833K cells, suggesting that ERCC1-XPF might be ratelimiting for repair of ICLs in testis tumor cells.
Investigations into the effect of ERCC1-XPF overexpression
on cisplatin sensitivity in testis tumor cells are currently
under way.
3353
ANTICANCER RESEARCH 28: 3157-3556 (2008)
351
INVESTIGATION OF THE HERITABILITY OF THE
CANCER RESISTANT PHENOTYPE OF THE SR/CR
MOUSE
Janne Koch1, Anna Boschian1, Jann Hau1
and Klaus Rieneck1,2
1Department
of Experimental Medicine, University of
Copenhagen and University Hospital, 3 Blegdamsvej, 2200
Copenhagen N;
2Department of Clinical Immunology, H:S Blood Bank,
2034, Copenhagen University Hospital, Blegdamsvej 9, DK2100 Ø Copenhagen, Denmark
The SR/CR mouse model of cancer resistance was discovered
in 1999. It is resistant to a number of different cancer cell lines
and the heritable phenotype was demonstrated on different
genetic backgrounds. The cancer resistance is transferable to
other strains of mice by adoptive transfer of innate immune
cells. We independently, for the first time, confirm the findings
of the SR/CR phenotype of cancer resistance to the S180 cell
line in mice of two different genetic backgrounds: BALB/c
and C57BL/6. The SR/CR mice were screened by intra
peritoneal injection of S180 cells. The frequency of the SR/CR
phenotype in the present study was 30% for the BALB/c strain
and 22% for the C57BL/6 strain in the first litters, but the
overall frequency was 8% for both strains. A frequency of
about 30% was reported in the original US-colony. A litter
seriation effect on the frequency of the SR/CR phenotype was
recorded. The phenotype frequency in the first born litters was
similar to the one recorded in the founder colony in the US.
There was no significant difference in the frequency of the
SR/CR phenotype between the two genders, but the overall
frequency of the SR/CR phenotype was significantly higher in
litters from SR/CR mice on BALB/c background compared to
litters from SR/CR mice on C57BL/6 background.
352
REDUCTION OF CHEMOTHERAPY-INDUCED
NAUSEA AND VOMITING (CINV) THROUGH
TREATMENT WITH CLONAZEPAM
Minako Koga1,2, Momoe Nakadozono3, Kazutaka Nukariya2,
Hiroko Nogi4, Tadashi Kobayashi5, Yusuke Ochiai2 and
Kazuhiko Nakayama2
1Department
of Psychiatry, Machida Municipal Hospital, 215-41 Asahi-machi, Machida-shi, Tokyo, 194-0023, Japan;
Department of 2Psychiatry, 3Nursing, 4Surgery and 5Clinical
Oncology, The Jikei University School of Medicine, 3-25-8
Nishi-shimbashi, Minato-ku, Tokyo 105-8461, Japan
Objective: To report on how the prevention of chemotherapyinduced nausea and vomiting (CINV) has been successfully
3354
achieved by administering clonazepam. Methods: We
identified a patient who had recovered from CINV after taking
clonazepam. Based on the outcome of this case, we conducted
an investigation into the cases of 26 patients who still
experienced CINV despite taking 5HT3 and corticosteroids.
Results: Significant differences were found in following
symptoms nausea, vomiting and appetite loss, and the rates of
partial remission and complete remission of the three
symptoms were as follows: 76%/47%, 93%/79% and
72%/50%, respectively. Conclusion: Clonazepam may be
useful in the control of CINV. We believe that clonazepam
contributed to the outcome in the following ways: (i)
anxiolytic effect, (ii) anticonvulsant effect on myoclonus.
353
THE ROLE OF ENDO180 IN THE DEVELOPMENT
OF METASTATIC PROSTATE CANCER BONE
LESIONS
Giolanta Kogianni1, Kyriakos Elefteriou2,
Jonathan Waxman1, Justin P Cobb2 and Justin Sturge1
1Prostate
Cancer Research Group, Department of Oncology,
Division of SORA, Imperial College London, Hammersmith
Hospital Campus, London;
2Department of Orthopaedic Surgery, Division of SORA,
Imperial College London Charing Cross Hospital Campus,
London, UK
Background: Metastasis to bone is a major clinical
complication in patients with advanced prostate cancer (Pca)
and can cause either bone forming or bone degrading lesions.
Evidence from recent in vivo studies has identified an
important regulatory function for the recycling collagenbinding and internalisation receptor Endo180 in bone
development. Here we are investigating whether expression of
this collagen receptor can be regulated in prostate bone
lesions. Materials and Methods: Tissue biopsies from human
prostate bone metastases were analysed by co-staining for
Endo180 with stromal (vimentin) and epithelial (pancytokeratin) markers and immunofluorescence microscopy.
Co-culture of human primary bone osteoblasts (hOBs) and
prostate cells (PCs) derived from benign hyperplasias, primary
tumours and various metastatic lesions were characterised for
temporal changes in mineral deposition, alkaline phosphatase
activity, collagen turnover and Endo180 expression induced
by either direct hOB-PC interaction or soluble factors released
into their conditioned media (CM). Quantification of Endo180
expression was assessed by Western blot and
immunofluorescent staining analysis. Local ethical approval
was given for the use of human tissues in this study. Results:
Endo180
was
strongly
expressed
by
both
osteoblastic/osteocytic and prostate cancer cells located in
metastatic bone lesions. Levels of alkaline phosphatase activity
Abstracts of the 8th International Conference of Anticancer Research, 17-22 October 2008, Kos, Greece
and mineral deposition by OBs were reduced, whereas
collagen production was increased by direct hOB-PC
interaction and soluble factors released by PCs with an
invasive phenotype. The constitutive expression of Endo180
by hOBs was unaltered in co-cultures with all of the PCs
tested. Direct hOB-PC interaction, but not hOB CM, resulted
in the up-regulation of Endo180 expression on PCs with an
invasive phenotype. Conclusion: Endo180 is strongly
expressed in prostate bone metastases where its up-regulation
in prostate cells is mediated by their direct interaction with
osteoblasts. These findings suggest that the constitutively
recycling collagen receptor Endo180 could play an important
role during active collagen remodelling associated with the
pathology of these lesions.
molecular interplay of Endo180 with MT1-MMP and uPARuPA be at distinct stages of prostate cancer progression
provide potential new pathways to targeted in the prevention
of metastasis.
355
PIK3CA AMPLIFICATION IS ASSOCIATD WITH
RESISTANCE TO CHEMOTHERAPY IN OVARIAN
CANCER PATIENTS
Iwona K. Kolasa1, Izabela Ziolkowska-Seta2,
Magdalena Murawska3, Joanna Moes1, Agnieszka Timorek4,
Agnieszka Dansonka-Mieszkowska1 and Jolanta
Kupryjanczyk1
1Department
354
ENDO180 EXPRESSION BY TUMOUR CELLS WITH
AN INVASIVE PHENOTYPE CORRELATES WITH
PROSTATE CANCER PROGRESSION
Giolanta Kogianni, Marjorie M. Walker, Jonathan Waxman
and Justin Sturge
Imperial College London, London, UK
Purpose: In our previous work, Endo180 was found to have
prognostic value for invasive basal breast carcinomas. Here we
investigated Endo180 expression in prostate cancer
progression with its co-functional partners in tissue collagen
remodeling and cell migration: membrane type-1 matrix
metalloproteinase (MT1-MMP); urokinase-type plasminogen
activator receptor (uPAR); and urokinase-type plasminogen
activator (uPA). Materials and Methods: Tissue microarray
(TMA) containing 169 prostate tissue samples clinically
graded as benign prostate hyperplasia (BPH) or Gleason score
6-10 was analysed by immunofluorescent co-staining of
Endo180, pan-cytokeratin (pCk) and complete quantification
of % total stromal (pCk–) and epithelial (pCk+) cells in all
tissue cores. Co-expression of Endo180 with vimentin, MT1MMP and uPAR-uPA was also investigated. Significant
differences and correlations between categorical variables,
including clinical grade and serum prostate-specific antigen
(PSA), were determined using two-sided Tukey test, Pearson
correlation and linear regression. Results: Increased % total
Endo180+/pCk– and Endo180+/pCk+ cells confirmed stromal
and epithelial up-regulation of Endo180 in all Gleason grades
compared to BPH. Epithelial Endo180 expression displayed
strong positive correlation with Gleason grade for which it was
a stronger predictor than serum PSA. Co-staining with
vimentin, MT1-MMP, or uPAR-uPA by invasive tumor and
reactive stromal cells revealed differential patterns of
expression during disease progression. Conclusion: Endo180
is a reliable predictor of clinical grade, supporting its use as a
biomarker for the diagnosis of prostate cancer. The potential
of Molecular Pathology, The Maria
Sklodowska-Curie Memorial Cancer Center and Institute of
Oncology, Roentgena 5, 02-781 Warsaw;
2Department of Gynecologic Oncology, The Maria
Sklodowska-Curie Memorial Cancer Center and Institute of
Oncology, Roentgena 5, 02-781 Warsaw;
3Department of Biostatistics, The Maria Sklodowska-Curie
Memorial Cancer Center and Institute of Oncology,
Roentgena 5, 02-781 Warsaw;
4Department of Obstetrics and Gynecology, Brodnowski
Hospital and II-nd Faculty of Medicine, Medical University,
Kondratowicza 8, 03-242 Warsaw, Poland
The PI3K/AKT signaling pathway controls important cellular
processes such as cell proliferation and apoptosis. The
PIK3CA gene encoding the catalytic subunit of the PI3K is
mutated and/or amplified in various neoplasms, including
ovarian cancer. We aimed to evaluate PIK3CA alterations and
their clinical importance in ovarian cancer patients.
Molecular analysis was performed on 117 ovarian
carcinomas with the use of qPCR, SSCP and sequencing. In a
group of 98 patients with complete clinical data, 62 patients
were treated with standard taxane-platinum regimens and 36
patients with platinum-cyclophosphamide regimens. A
multivariate analysis was performed by Cox and logistic
regression models.
PIK3CA mutations occurred in 5/117 (4.3%) carcinomas,
exclusively in the endometrioid and clear cell types
(p=0.0002); they were also associated with low FIGO stage
(p=0.0003), low tumor grade (p=0.045) and early patient age
at diagnosis (p=0.0005). PIK3CA amplification (predominantly
low-level) was found in 28/117 (24%) ovarian carcinomas and
was more frequent in TP53 mutant tumors (p=0.012). PIK3CA
amplification strongly diminished odds of complete remission
(p=0.033, OR=0.25) and platinum sensitive response (PS,
p=0.004, OR=0.12) in the taxane-platinum treated patients.
The odds of PS were also much lower in all patients with the
PIK3CA amplification evaluated together, regardless of the
treatment applied (p=0.001, OR=0.18).
3355
ANTICANCER RESEARCH 28: 3157-3556 (2008)
Our results suggest that PIK3CA amplification may be a
marker predicting ovarian cancer response to chemotherapy.
356
ARRAY-COMPARATIVE GENOMIC
HYBRIDISATION: A NEW TOOL IN CANCER
DIAGNOSIS AND RESEARCH
Aggeliki Kolialexi
Department of Medical Genetics, Athens University School
of Medicine, Athens, Greece
Genetic alterations are key features of cancer and typically
target biological processes and pathways involved in cancer
pathogenesis. DNA copy number changes are common in
cancer and lead to altered expression and function of genes
residing within the affected region of the genome. Arraycomparative genomic hybridisation (a-CGH) is a
comprehensive, genome-wide screening procedure for
detecting DNA copy number imbalances which can be rapid,
less labour-intensive than karyotype banding analysis and
highly amenable to automation. a-CGH has provided new
information on copy number changes in cancer on a genomewide level and has doubled the detection rate of pathogenic
chromosomal imbalances in patients. A number of new
regions frequently involved in gains and losses have been
identified and data obtained have been utilized in cancer
classification. This has been possible by increasing the
resolution level from the 5 Mb obtained using conventional
cytogenetic techniques to as low as 100 kb by array
technology. More importantly, aCGH analysis has allowed
accurate localization of specific genetic alterations associated
with tumor progression, therapy response, or disease outcome.
Understanding cancer, however, will require profiling of
transcriptome, miRNAome, epigenome, and proteome to fully
comprehend complex tumor behavior.
357
ON THE TRAIL TO A CURE ? – APOPTOSIS VIA
DEATH RECEPTORS IN EWING’S SARCOMA
Udo Kontny
Division of Pediatric Hematology and Oncology, Center for
Pediatrics and Adolescent Medicine, University Medical
Center Freiburg, Freiburg, Germany
Ewing’s sarcoma is the second most common malignant bone
tumor in children and adolescents. Tumors arise from
mesenchymal stem cells and are characterized by fusion of
EWS with a member of the ETS family of transcription
factors. About 30% of patients present with metastatic disease.
For these, as well as for patients with recurrent disease,
survival rates are <20%. In order to identify new targets for
3356
therapy, we have analyzed the extrinsic apoptotic pathway in
Ewing’s sarcoma. Whereas the majority of tumor cells bear
receptors for FasL and TRAIL, only the latter pathway proves
to be intact in most tumor cells. In vitro, about 80% of cell
lines are susceptible to TRAIL-mediated apoptosis. In TRAILresistant cell lines absence of caspase-8 expression has been
identified as a cause of resistance. Deficient expression of
caspase-8 has also been observed in about 25% of Ewing’s
tumor specimens. Resistance to TRAIL-mediated apoptosis
can be overcome by incubating caspase-8-deficient cells with
interferon-gamma at concentrations achievable in humans.
TRAIL has also been shown to be active against Ewing’s
tumors in vivo, in a mouse xenograft model. Whereas in this
model the combination of TRAIL and interferon-gamma did
not increase suppression of tumor growth in primary tumors
when compared to TRAIL alone, it was significantly more
active in preventing the occurrence of metastases. Based on
these findings, the combined application of TRAIL and
interferon-gamma makes it an attractive candidate for
evaluation in clinical trials in patients with Ewing’s sarcoma.
358
IMPACT OF IFN-γ GENE ON THE RISK OF
CERVICAL CANCER
D.M. Kordi Tamandani1, R.C. Sobti2, M.Shekari2,
M. Mukesh2 and V. Suri3
1Department
of Biology, University of Sistan and
Baluchestan, Zahedan, Iran
2Department of Biotechnology, Panjab University,
Chandigrah, India.
3Department of Obstetrics and Gynaecology Post Graduate
Institute of Medical Education and Research, Chandigrah,
India
Background: Cervical cancer, the second most common
malignancy in women worldwide, is almost invariably
associated with infection by human papillomavirus (HPV).
However, although many women are infected with high-risk
types of HPV, only a subset of infected women will ever
develop cervical cancer. Therefore, host genetic factor may
play a role in cervical carcinogenesis. Several studies
suggested that immunological components thus play a key role
in the development of cervical cancer. Interferon gamma (IFNγ) is a cytokine produced by activated T-cells and natural killer
(NK) cells that enhances cellular immune responses by
increasing T-cell cytotoxicity and NK-cell activity. Objectives:
The striking correspondence between the various biological
activities of IFN-γ and the immunological modifications
observed in cervical carcinomas, prompted us to study single
nucleotide polymorphism (SNP), T to A, located at the +874
position and measure IFN-γ messenger RNA (mRNA) at the
tumor site. Methods: DNA was isolated from peripheral blood
Abstracts of the 8th International Conference of Anticancer Research, 17-22 October 2008, Kos, Greece
of 200 patients with cervical cancer and 200 healthy controls.
The allele polymorphism at position +874 in the IFN-γ gene
was studied by ARMS-PCR (Amplification Refractory
Mutation System) and IFN-γ messenger RNA (mRNA) in the
tumor was measured by means of a semi-quantitative
polymerase chain reaction (PCR) assay. Variation in the
promoter region of IFN-γ gene, was investigated through
sequencing. Results: Genotypes AT and AA+AT increased the
risk of cervical cancer (OR=3.3, 95% CI 2.05-5.2,
p=0.0000002; OR=2.9, 95% CI 1.9-4.6, p=0.0000007),
respectively. Thus the semi-quantitative analysis reflected the
similar level of mRNA expression of IFN-γ gene in patients
suffering from cervical carcinoma to that in healthy control.
Conclusion: This is the first study to provide evidence for the
effect of IFN-γ on the risk of cervical cancer in North Indian
population.
359
CLINICOPATHOLOGICAL FEATURES AND
PROGNOSTIC FACTORS OF EPSTEIN-BARR VIRUSASSOCIATED GASTRIC CARCINOMA
Chihaya Koriyama1, Suminori Akiba1, Michiyo Higashi2,
Francia Campos1, Kazunobu Sueyoshi3, Suguru Yonezawa2
and Yoshito Eizuru4
Departments of 1Epidemiology and Preventive Medicine,
2Human Pathology, and 4Division of Oncogenic and
Persistent Viruses, Center for Chronic Viral Diseases,
Kagoshima University Graduate School of Medical and
Dental Sciences, 8-35-1 Sakuragaoka, Kagoshima, 890-8544,
Japan
3Department of Pathology, Kagoshima City Hospital, 20-17
Kajiya-cho, Kagoshima, 892-8580, Japan
Epstein-Barr virus (EBV) is a human carcinogenic virus and is
known to cause Burkitt’s lymphoma, undifferentiated
nasopharyngeal carcinoma, Hodgkin’s disease and some types
of lymphomas. Its involvement was also found some of gastric
adenocarcinoma cases, and about 10% of gastric carcinomas
harbor clonal EBV (EBV-GC). Although LMP1, an important
EBV oncoprotein, is only rarely expressed in EBV-GC, EBVencoded small RNA (EBER) is expressed in almost every
EBV-GC cell, suggesting its importance for developing and
maintaining this carcinoma. A recent study suggested that
EBER activates insulin-like growth factor-1 in EBV-GCs. In
addition, the hypermethylation-driven suppressor gene downregulation, frequently observed in EBV-GC, appears to give a
selective advantage for carcinoma cells. Prognostic
significance of EBV involvement in gastric carcinoma is yet
to be established, although there is a study reporting a
favorable prognosis in EBV-GC.
In addition to p53 and beta-catenin expressions, we
examined 59 EBV-GCs and 120 non-EBV-GCs for
expressions of MUC1, MUC2, and MUC6, which have been
reported as significant prognostic markers as well as
phenotypic markers for gastric carcinoma, by immunostaining.
All the phenotypic markers examined in this study were downregulated in EBV-GC when compared to non-EBV-GCs,
suggesting that most EBV-GCs may be classified
phenotypically as null phenotype or gastric phenotype.
Survival analysis revealed that lymph node metastasis and
depth of invasion were significantly related to poor prognosis
among non-EBV-GCs. On the other hand, intestinal type
Lauren classification and tumor with MUC1-positive and
MUC2-negative expressions, in addition to lymph node
metastasis and depth of invasion, were significantly related to
poor prognosis for EBV-GCs. Interestingly, nuclear and/or
cytoplasmic expression of beta-catenin was associated with
better prognosis of EBV-GC. Factors involved in the prognosis
of EBV-GCs and non-EBV-GCs might be different from each
other.
360
IMMUNOHISTOCHEMISTRY IN THE DIAGNOSIS
OF HPV-RELATED CERVICAL SQUAMOUS
INTRAEPITHELIAL LESIONS: OLD AND NEW
MARKERS
Evanthia Kostopoulou
Pathology Department, Medical School, University of
Thessalia, Larissa, Greece
A large number of molecular studies in recent years has
revealed multiple interactions between HPV oncoproteins and
their cellular targets, which result in alterations of the cell
cycle control, apoptosis and telomerase up-regulation.
Increasing emphasis has been placed on the molecular analysis
of HPV in cervical samples, with HPV typing, viral-load
assessment and detection of HPV integration attracting the
attention of most investigators. Although histopathologic
evaluation remains the basic method for the diagnosis of HPVrelated lesions and several studies have investigated the
relationship of morphological findings to specific molecular
events, the routine application of techniques assisting the
diagnosis is limited.
Immunohistochemistry (IHC) has been employed, targeting
antigens that are secondarily affected by the presence of HPV
through several pathways. Since HPV oncoproteins induce
alterations in the cell cycle, several associated markers have
been investigated for their potential utility in assisting the
histopathologic classification of squamous intraepithelial
lesions and facilitating the distinction from non-HPV induced
alterations. These included Ki67, PCNA, p16, cyclins and
other molecules associated with regulation of the cell cycle.
In most laboratories immunostains for p16, a cyclindependent kinase inhibitor, and Ki-67 are the only routinely
3357
ANTICANCER RESEARCH 28: 3157-3556 (2008)
used, cost effective surrogate markers for histopathologic
diagnosis of HPV-related lesions. A review of published
articles concerning p16 applications reveals several
discrepancies and limitations. Positivity in squamous
intraepithelial lesions varies from 14.3% to 100% in published
studies and this variation could be attributed to: a) differences
in the criteria for lesion diagnosis and for evaluation of
immunohistochemical staining, b) differences in antibodies
and techniques used, and c) geographic differences in the
distribution of HPV types. Nevertheless, with increasing
numbers of cases in different studies there appears a small
group of high grade lesions that do not show any
immunoreactivity. This observation diminishes the utility of
p16 as a screening test.
Our laboratory has been recently involved in a project about
cell cycle deregulation at G2M-transition checkpoint and
beyond. Following some preliminary data we investigated the
potential applications of cyclin B1 IHC in the diagnosis of
cervical lesions and have recently shown that patterns of
immunoreactivity for cyclin B1 correlate to lesion grade, while
a pattern of cyclin B1 immunoreactivity in low-grade
squamous intraepithelial lesions correlates strongly with the
presence of HPV. Moreover, cyclin B1 immunoreactivity
forecasted the detection of HPV by PCR in cases with dubious
morphologic features, probably facilitating the recognition of
“pre-koilocytes”.
INCENP, the archetypal chromosomal passenger protein
and a component of the chromosomal passenger complex, has
been shown to be overexpressed in tumour cells and has
recently been investigated by our group concerning its possible
utility as surrogate marker in cervical biopsy diagnosis and its
relationship with high-risk HPV types.
The potential applications of immunohistochemistry in the
diagnosis of HPV-related cervical squamous intraepithelial
lesions are not restricted to the above markers. Future studies
could identify an ideal test or panel of markers which would
reliably predict progression.
361
SENSITIVE DETECTION OF OVEREXPRESSED
TUMOR-ASSOCIATED STRUCTURES
ON VARIOUS CANCER CELL TYPES
Beatrix Kotlan1,2, Jozsef Timar2 and
Mepur H. Ravindranath3, Mark C. Glassy1,4
1Integrated
Medical Sciences Association Foundation, 10246
Parkdale Avenue, San Diego, CA 92126, USA;
2National Institute of Oncology, 1122 Rath Gy street 7-9,
Budapest, Hungary;
3The Terasaki Laboratories, 11570 W. Olympic Blvd, Los
Angeles, CA 90064, USA;
4University of California, MAE Department, La Jolla, San
Diego; CA 92037, USA
3358
Backgound and Objectives: One aim in cancer research is to
reveal and detect novel tumor-associated membrane structures.
Special acidic glycosphingolipids overexpressed on the
malignant tissue have been shown to be important candidates
for therapeutic issues. Monoclonal antibodies currently
available are restricted in terms of specificities, and unique
types of these antigens fail to be detected this way. The
objective of this project was to overcome the difficulties
concerning the detection of tumor-associated antigens with low
immunogenicity. Methods and Results: Antibodies were
obtained from different tissue origins and by different methods,
that is hybridoma technology, EBV transformation and
antibody engineering. Tumor cells of different hystological
types were investigated in a standardised enzyme-linked
immunosorbent assay (ELISA) and thin layer chromatoraphy
(TLC) with dot blot technique. Indirect immunofluorescence
(IF) assay with FACS analysis and modified chamber slide IF
technique with confocal laser microscopy were performed to
test for fine specificity and the degree of expression. The
specific antibody-based immunological techniques were
suitable to detect special characteristics of these acidic
glycosphingolipids, highly associated with the cancerous tissue.
Conclusion: The applied technique was suitable to define and
bind to those tumor-associated cell surface structures that are
difficult to reveal because of their weak immunogenicity. The
results are promising, as tumor diagnostic and antibody-based
therapy may be better formulated for the control of the disease.
The work was supported by grants from OTKA T048933 and
Fulbright No:120610.
362
LIPOPLATIN PLUS GEMCITABINE VERSUS
CISPLATIN PLUS GEMCITABINE AS FIRST-LINE
TREATMENT AGAINST NSCLC: INTERIM
ANALYSIS OF A PHASE III TRIAL
N. Mylonakis1, A. Athanasiou2, J. Angel3, S. Lampaki4,
C. Kosmas1, A. Rapti5, N. Ziras2, N. Politis6,
S. Kottaridis7 and T. Boulikas7
12nd
Pathology Clinic, Metaxa Anticancer Hospital, Pireaus;
Pathology Clinic, Metaxa Anticancer Hospital, Pireaus;
3Pulmonary Medicine Department, Theageneio Anticancer
Hospital, Thessaloniki;
4Department of Medical Oncology, Aristotle University of
Thessaloniki School of Medicine, Papageorgiou Hospital,
Thessaloniki;
58th Pulmonary Clinic, “Sotiria” Thoracic Hospital, Athens;
6Pulmonary Medicine Clinic, Agios Savvas Anticancer
Hospital, Athens; 7Regulon, Inc. Mountain View, California,
USA and Athens, Greece
21st
Background: Lipoplatin is a liposomal cisplatin, designed to
reduce cisplatin toxicities without reducing efficacy. Its
Abstracts of the 8th International Conference of Anticancer Research, 17-22 October 2008, Kos, Greece
nanoparticles evade immune surveillance, extravasate
preferentially into tumors and metastases and target
endothelial cells of tumor vasculature inducing cell apoptosis
and antiangiogenesis. Human studies have shown a 40-200
fold higher concentration of platinum in tumor specimens after
a single infusion compared to adjacent normal tissue.
Lipoplatin has an orphan drug status for pancreatic cancer in
the EU. This is the initial report of a randomized phase III
trial. Methods: Eligibility criteria included inoperable/
metastatic NSCLC, no previous chemotherapy, WHO PS 0-1,
adequate end-organ function. Patients received Lipoplatin 120
mg/m2 D1,8,15 (Arm A) or cisplatin 100 mg/m2 D1 (Arm B)
with gemcitabine 1 g/m2 D1,8, in 3-week cycles, with disease
evaluation after 3 and 6 cycles. Primary endpoints were OS;
secondary endpoints are ORR, DCR, PFS, and toxicity.
Results: 88 patients treated, 47 with LipoGem and 41 with
CisGem; 80 were evaluable. Response rates were (Arm A vs.
Arm B): PR 37% vs. 28%, SD 34% vs. 31%, PD 29% vs.
41%. ORR was 37 vs. 28%, and DCR was 71% vs. 59%. PFS
range is currently 0.7-16.8+ vs. 0.2-9.8+, and duration of
response is 2.8-14.8+ vs. 2.1-10.4+ (months); final data are
pending. The only grade IV adverse event in LipoGem was
neutropenia in 2% of patients. Toxicities were (Arm A vs. Arm
B): anemia I-III (94% vs. 100%), leucopenia III-IV (9% vs.
17%), neutropenia III-IV (11% vs. 29%), thrombocytopenia
III-IV (9% vs. 22%), nephrotoxicity III (0% vs. 5%),
nausea/vomiting III-IV (2% vs. 12%), neurotoxicity II-III (0%
vs. 7%), asthenia III (4% vs. 17%), anorexia III (2% vs. 15%).
Additionally, less antiemetics and G-CSF were administered
in Arm A. Conclusion: Lipoplatin appears to have lower
toxicity, mainly nephrotoxicity, as well as higher efficacy than
cisplatin, when combined with gemcitabine in advanced
NSCLC. Particularly relevant is that Lipoplatin is administered
without pre- or post-hydration, on an outpatient basis.
evaluated histologically using the silver staining method for
nucleolar organizer regions (NORs). NORs are loops of
ribosomal DNA within the nucleus that transcribe ribosomal
RNA and are usually tightly aggregated within the nucleoli in
interphase cells. Alterations in the number and configuration
of NORs have been demonstrated in several human neoplasms
and related to progression. In our previous study, NOR activity
and morphology has been associated with the mechanism of
the DHFR gene amplification during the development of
resistance to Methotrexate in HeLa cells (Experientia, 39:
1394, 1983, Med Oncol & Tumor Pharmacother, 2(1): 33,
1985, Experimental Cell Biology, 55: 69, 1987). The aim of
this work is to examine the NOR activity and morphology
during development of resistance to Cisplatin in vitro in HeLa
cells. Methods: Acquired resistance to Cisplatin was induced
in HeLa cells by gradually increasing doses of Cisplatin
starting from 0.05 μg/ml. HeLa clones resistant to Cisplatin
0.1 and 0.2 μg/ml were established over a period of 4 months.
AgNO3 staining was applied to resistant HeLa cell lines and
their sensitive counterparts. Morphometric analysis of 100
HeLa cells for each Cisplatin resistance level was applied for
2-D measurement (pixels2) of stained regions using
Axiovision’s LE morphometry application. The organization
patterns of NORs were investigated numerically (mean NOR
count) and morphologically (nuclear size, NORs size,
configuration). Results: Non-resistant HeLa cells exhibited
usually 1-2 large and round and 1-3 small nucleoli (Figure
1AB). HeLa cells resistant to Cisplatin 0.1 μg/ml exhibited a
higher number of nucleoli with irregular shapes (Figure 1CD).
HeLa cells resistant to Cisplatin 0.2 μg/ml exhibited
remarkably fragmented nucleoli. One large irregularly shaped
and numerous small nucleoli were present in 100 % of the
cells (Figure 1EF).
363
ASSOCIATION OF NUCLEOLI FRAGMENTATION
WITH CISPLATIN RESISTANCE
G.K. Koumakis and J.G. Delinassios
International Institute of Anticancer Research, Kapandriti
19014, Greece
Background: Cisplatin has been one of the principal anticancer
drugs for the last 3 decades and is widely used in the treatment
of several cancers. However, it is known to be implicated in
cases of development of drug resistance. It is well established
that there are several mechanisms of drug resistance in cancer
cells mostly involving increased production of specific
proteins. The nucleolus represents a highly dynamic nuclear
compartment, easily visible by light microscopy, directly
involved in the fulfilment of the need for synthesis of large
amounts of ribosomal RNA. Nucleolar morphology can be
Figure 1. NORs in HeLa cells using AgNOR staining. (A,B)
Non-resistant cells [0 μg/ml Cisplatin], (C,D) Resistant cells
[0.1 μg/ml Cisplatin], (E,F) Resistant cells [0.2 μg/ml
Cisplatin].
3359
ANTICANCER RESEARCH 28: 3157-3556 (2008)
Measurement of the total 2-D NOR surface in the non-resistant
and the two resistant HeLa cell lines did not show a significant
difference. However, if the number of individual NORs in each
nucleus were counted separately and independently of size, a
very significant difference was noted between the non-resistant
and the Cisplatin 0.2 μg/ml resistant HeLa cells (Table).
Table. Morphometric analysis measurements of HeLa resistant
and non-resistant cells.
Cisplatin (μg/ml)
Mean AgNOR Count
Morphology/Shape
Mean Size
Total Cell surface
(pixels2)
Mean Size
Total NORs surface
(pixels2)
TOTAL/NOR
[TOTAL-NOR]/NOR
0
0.1
0.2
3.82
4.19
12.36
Regular Irregular
Irregular
598500
594000
581500
79200
78900
79100
7.556
6.556
7.528
6.528
7.351
6.351
The Cisplatin 0.1 μg/ml resistant cell nuclei showed a total
number of NORs rather close to non-resistant cell nuclei.
However, the morphology of the large nucleoli was irregular
and gave the impression of an aggregation of many smaller
nucleoli resembling a “bunch of grapes”. Discussion and
Conclusion: The present results showed that the development
of resistance to Cisplatin is associated with obvious changes
in the morphology of NORs in interphase nuclei of HeLa
cells. The total surface of the nucleoli in the Cisplatin 0.2
μg/ml resistant HeLa cells is obviously larger in comparison
to the non-resistant cells. Therefore, we may infer that the
increased surface of the nucleoli, due to their extensive
fragmentation, is associated with the mechanisms of
resistance to Cisplatin. Whether, or not this feature is
accompanied with a higher production of rRNA should be
investigated.
364
HELICOBACTER PYLORI INVOLVEMENT
IN UPPER AND LOWER GI TRACT
ONCOGENESIS IN GREECE
Jannis Kountouras
Department of Medicine, Second Medical Clinic, Aristotle
University of Thessaloniki, Ippokration Hospital,
Thessaloniki, Greece
3360
Gastric adenocarcinoma not located in the cardia still
remains second only to lung cancer as leading cause of
cancer-related
mortality
worldwide,
although
adenocarcinoma of the cardia and gastroesophageal junction
has been rising rapidly over the past two decades. Gastric
malignancy can be subdivided into diffuse and intestinal
pathological entities that have different epidemiological and
prognostic features. Various genetic and environmental
factors lead to either abnormal genes overexpression or
inappropriate expression of normal genes, whose products
confer the malignant phenotype. Helicobacter pylori (H.
pylori) infection appears to be involved in gastric
carcinogenesis through various molecular mechanisms,
including repopulation of the stomach with bone marrowderived stem cells (BMDSC) that may facilitate gastric
cancer progression, thereby necessitating eradication of this
bacterium. In addition, H. pylori might be involved in the
gastroesophageal reflux disease – Barrett’s esophagus (BE)
– esophageal adenocarcinoma (EA) sequence and its
eradication might inhibit the progress of this sequence.
Although EA is now the most common esophageal
malignancy in Western countries whose incidence is
increasing faster than any other cancer, mortality from
esophageal cancer in Greece is among the lowest in the
world and no clear-cut answer has emerged as to why the
incidence of EA is so low in Greece. Our findings indicate
the possible existence of a balance between cell
proliferation (indicated by Ki-67 increased expression) and
apoptosis (indicated by Bax protein overexpression) in BE
patients, thereby providing an equilibrium between cell
apoptosis and cell proliferation, and this may partly
explain the low EA incidence in Greece. Moreover, some
reports have indicated an increased risk of colorectal
cancer in patients with BE or EA. A possible association
of both diseases might be explained by genetic
predisposition or common environmental risk factors
possibly including H. pylori infection. Our findings
established the presence of H. pylori in cancer tissues of
the majority of colorectal cancer patients, and H. pylori
infection might also recruit BMDSC that may ultimately
facilitate colon cancer progression. Contrary to the data of
other countries, the incidence of cancer in Greek patients
with inflammatory bowel disease (IBD) also appears to be
low. In this respect, our preliminary results also suggest the
possible existence of a balance between cell pro-apoptotic
and anti-apoptotic mechanisms in ulcerative colitis,
indicated by Bax and Bcl-2 overexpression in 50% of the
patients, and a great propensity of pro-apoptotic
mechanisms in Crohn’s disease, indicated by Bax and Bcl2 overexpression in 62% and 25% of the patients
respectively, thereby reflecting a coherent apoptotic process
that might explain, at least in part, the low incidence of
cancer development in Greek IBD patients.
Abstracts of the 8th International Conference of Anticancer Research, 17-22 October 2008, Kos, Greece
365
INFLUENCE OF TWO LEGUMINOSAE
PLANT EXTRACTS ON GROWTH AND
ANTIOXIDANT DEFENSE SYSTEM
OF Hep2 CANCER CELL LINE
C. Spanou and D. Kouretas
University of Thessaly, Department of Biochemistry and
Biotechnology, 41221, Larissa, Greece
Legumes are considered to be a very good source of
phytochemical
compounds
that
may
act
as
chemopreventive agents especially by their antioxidant
properties (1). In a previous report we examined the
antiradical and protective properties against free radicalinduced DNA damage of extracts derived from various
Greek Leguminosae family plants (2). From the results
obtained two extracts showing potent antioxidant
properties were chosen for further study. Aqueous extracts
of aerial parts of Lathyrus laxiflorus and Phaseolus
vulgaris plants were initially examined for their
cytotoxicity properties on Hep2 cancer cell line. Their
cytotoxicity was assessed at concentrations 100, 400, 800
μg/ml after 24h incubation with the extracts. Lathyrus
laxiflorus plant extract exhibited 57% and 74% inhibition
of cell growth at concentrations 400 and 800 μg/ml
respectively, whereas Phaseolus vulgaris extract had no
effect on cell growth in none of the tested concentrations.
IC50 values for Lathyrus laxiflorus were 390 μg/ml and 4.9
μg/ml against OH• and ROO• radicals respectively, whereas
for Phaseolus vulgaris against the same radicals were
>1600 μg/ml and 17 μg/ml (2).
Non cytotoxic concentrations, 100 μg/ml of Lathyrus
laxiflorus and 800 μg/ml of Phaseolus vulgaris extract,
were used for 2, 12, 24 hours incubation of the cells. The
influence of the extracts on the antioxidant defense system
of the cells was assessed by measuring the total
antioxidant capacity of the cells (TAC) and the amounts of
catalase (CAT), glutathione (GSH), oxidized form of
glutathione (GSSG) and thiobarbituric reactive substances
(TBARS) in all times of incubation of the cells. From the
results obtained it seems that only Lathyrus laxiflorus
extract induces oxidative stress in the cells by reducing
TAC, and CAT and inducing TBARS especially in 2 and
12h of incubation. Phaseolus vulgaris extract reduced only
TAC at 2h of incubation indicating also a mild induction
of oxidative stress. These results imply that potent
antioxidant extracts, beyond a critical concentration, may
induce oxidative stress and cytotoxicity in cells which
shows that antioxidant activity of various chemicals should
be considered with caution.
1 Rochfort S et al: J Agric Food Chem 55: 7981-7994, 2007.
2 Spanou C et al: Anticancer Res 27: 3403-3410, 2007.
366
DESIGNING ANTIBODY-MAYTANSINOID
CONJUGATES FOR ANTICANCER THERAPY
Yelena Kovtun
Senior Scientist, ImmunoGen, USA
Conjugation of cytotoxic compounds to antibodies allows
targeted delivery of the cell-killing agents to tumor sites.
Numerous conjugates of antibodies with maytansinoids,
derivatives of a microtubule-binding compound, are in
development and several antibody-maytansinoid conjugates
are in clinical trials. Modifications of the linker that connects
the maytansinoid to the antibody impact the conjugate
metabolism, bystander killing, pharmacokinetic parameters
and intracellular retention of cytotoxic metabolites. The
specific design of conjugates for the treatment of multidrugresistant cancer and tumors that express the target antigen in a
heterogeneous manner is discussed.
367
PRACTICAL USE OF TELEPATHOLOGICAL
CONSULTATION TO IMPROVE CANCER
INCIDENCE STATISTICS
András Huszár, Antal Kricskovics and Ágnes Frick
University of Pécs Faculty of Medicine Department of
Forensic Medicine, 7624 Pécs, Szigeti út 12, Hungary
It is a widely observed fact that the number of clinical
autopsies around the world are decreasing, therefore their
relevance in providing accurate statistics for the incidence
of cancers is also getting weaker. However, the number of
medico-legal autopsies in our Institute are growing. This
tendency has been noted by several other universities. Our
goal is to help improve the accuracy of these statistics by
documenting all accidentally found tumors during a
medico-legal autopsy, because these were not included in
the statistics numbers up to now. To gain useful data from
these specimens, the histological slides have to be
diagnosed by a pathologist, however, there is no one with
such a qualification in our institute. The most promising
solution for our endeavour in telepathological consultation
is the use of digital microscopy. It permits the digital
modelling of routine histological slides and it also allows
measurements by using analysis or stereology software
packages. The digital slide is nowadays a fast and
accessible item due to fully established broadband internet
and local area networks (LAN). The MIRAX Desk (Carl
Zeiss, Germany) scanner we use turned out to be an
effective tool due to its high quality images and fast
scanning process. By using the digital slide database
PathoNet (www.pathonet.org) and the MIRAX Viewer
3361
ANTICANCER RESEARCH 28: 3157-3556 (2008)
software we were able to set up a fast telepathological
consultation process, which can connect us with any
partners around the globe with network access, hereby
providing an exact diagnosis of our specimen.
368
TARGETING CELL SURVIVAL AND APOPTOTIC
SIGNALING PATHWAYS FOR PROSTATE CANCER
MANAGEMENT
Rita Ghosh, Ganapathy Manonmani,
Muralimanoharan Sribalasubashini,
Heather Graham, Paul Rivas, Xie Jianping,
Craig Robson and Addanki P. Kumar
Department of Urology University of Texas Health Science
Center at San Antonio, TX, USA
Prostate cancer (PCA) is the second leading cause of
cancer-related deaths in men in western society. While
African American men have the highest incidence of
prostate cancer in the world Asian men native to their
countries who consume low fat and high fiber diet have the
lowest risk. Migration of Asians to Western countries puts
them at high risk for prostate cancer. Epidemiological
studies also suggest that a reduced risk of cancer is
associated with the consumption of phytochemical-rich diet
that includes fruits and vegetables. Strategies to delay
clinically significant prostate cancer will have a tremendous
impact in reducing the overall incidence of prostate cancer
as well as increasing quality of life for elderly men. The
long latency involved in the development of clinically
significant prostate cancer provides plethora of
opportunities for its management especially using
prevention approaches. In addition cancer arises due to
deregulation of multiple signaling pathways, thus targeting
multiple signaling pathways using a combination of agents
or complex botanicals have an added advantage in
providing synergistic or additive effects. Studies conducted
in our laboratory show that NexrutineR (bark extract from
Phellodendron amurense) inhibits proliferation of prostate
cancer cells and prostate tumor development in the
transgenic adenocarcinoma of mouse prostate (TRAMP)
model through modulation of Akt signaling pathway. To
further define the mechanism of action of NexrutineR and
to identify the active component associated with its
biological activity using activity guided fractionation we
have identified butanol fraction as the active component of
NexrutineR. Butanol fraction recapitulated the activities of
NexrutineR in (i) inhibiting proliferation; (ii) inducing
apoptosis; and (iii) modulating transcriptional activity of
NFκB in prostate cancer cells. Our data also indicates that
both NexrutineR and butanol fraction modulates NFκB
transcriptional activity by inhibiting IκBα phosphorylation.
3362
Expression of p65 and phosphorylated IκBα are high in
tumors from TRAMP mice. In contrast dietary
administration of NexrutineR reduced expression of p65 and
phosphorylated IκBα in prostate from TRAMP mice that
correlated with inhibition of tumor development. In
addition using ultra-performance liquid chromatography we
have identified berberine or closely related compound may
be responsible for the observed biological activities in the
butanol fraction that may induce apoptosis in prostate
cancer cells by targeting critical cell survival signaling
pathways both in vitro and in vivo.
Studies from our laboratory also identified potential role for
Sp1-FLIP (FADD-Like interleukin-1β-converting enzyme
(FLICE) inhibitory protein) signaling for modulation of
apoptosis in prostate cancer cells. Data to demonstrate role for
FLIP signaling or Akt/CREB signaling in prostate cancer
prevention efforts will be discussed. Supported in part by NIH
R21 CA 98744; ACS RSG-04-169-01 (APK).
369
A NOVEL INVESTIGATION OF
PAX3 FUNCTION IN EMBRYONIC
CELL LINES UNDERGOING DIFFERENT
DIFFERENTIATION PATHWAYS AND THE
CORRESPONDING TUMOURS
Patricia Kumar1, Qiuyu Wang1, Hongmei Li1,2,
Wen-hui Fang1,2, Mark Slevin1 and Shant Kumar2
1Department
of Biology, Chemistry and Health Science,
Manchester Metropolitan University, Chester St, Manchester,
M15GD;
2Division of Laboratory and Regenerative Medicine, Faculty
of Medicine and Human Sciences, Manchester University,
Oxford Road, Manchester, M13 9PT, UK
PAX3 is a transcription factor expressed for only a few days
during embryonic development of the neural crest and dorsal
dermomyotome, but re-expressed in tumours of cells derived
from these embryonic populations. We have up-regulated
PAX3 expression by transfection into murine melanocytes,
myocytes and embryonic stem cells for comparison with
PAX3 down-regulation using siRNA in the corresponding
tumours: melanoma, rhabdomyosarcoma and neuroblastoma.
We have studied three of the seven PAX3 isoforms which we
isolated previously- namely PAX3 c, e and g.
The effects of PAX3c, e or g, singly, versus an empty vector
control were determined in transfected cells using assays for
cell proliferation, migration, apoptosis and adhesion.
Affymetrix microarrays identified genes up- or down-regulated
by each of the three isoforms. The relevance of these genes of
interest was confirmed using RT-PCR and western blotting.
Microarray results are being compared between 1) an
embryonic cell line and its corresponding tumour type 2)
Abstracts of the 8th International Conference of Anticancer Research, 17-22 October 2008, Kos, Greece
melanogenesis, myogenesis and embryonic stem cell
differentiation into sympathetic neurones. Genes up-regulated
in embryonic cells while being down-regulated in the
corresponding tumours are likely to be important downstream
targets of PAX3. Genes regulated in the same way by three
different isoforms might also be important. PAX3 might use
different target genes in cells following different differentiation
pathways.
It is hoped that this study will illuminate the role of PAX3
in cancer and identify important molecular targets to be used
in therapy.
370
TELOMERASE ACTIVITY AS A
DIAGNOSTIC AND PROGNOSTIC
FACTOR IN HEAD AND NECK CANCER
Zuzana Kunická1,2, Igor Mucha3 and Jiří Fajkus1,2
1Department
of Functional Genomics and Proteomics,
Institute of Experimental Biology, Faculty of Science,
Masaryk University, Kamenice 5, CZ-62500 Brno;
2Institute of Biophysics, Academy of Sciences of the Czech
Republic, Kralovopolska 135, CZ-61265 Brno;
3St. Ann’s University Hospital, Pekarska 53, CZ 656 91
Brno, Czech Republic
Activation of telomerase is tightly associated with many types
of cancer, including head and neck cancer. We examine the
use of telomerase activity as a diagnostic and prognostic
marker of head and neck cancer development in comparison
with standard histological analysis.
Telomerase activity was determined using quantitative
Dual-Colour Real-Time TRAP. In each of 58 patients, a
sample of tumour tissue and adjacent mucosa was collected.
As a control, we collected samples of normal muscle
tissues.
Telomerase activity was observed in 88% of tumour
tissues and 34% of tumour-adjacent mucosa samples. No
telomerase activity was detected in normal muscle tissues.
Telomerase activity correlated with tumour grade, showing
an average of 4.6 telomerase units (T.U.) in welldifferentiated, 8.3 T.U. in moderately-differentiated and 20
T.U. in poorly differentiated tumours. Relapse occurred in 13
patients and no telomerase activity was detected in 3
recurrent tumours.
Telomerase activity may be used as an objective parameter
inversely related to tumour differentiation. Prognosis in
telomerase-negative tumours is worse than that of the
telomerase-positive group due to a higher frequency of
recurrences.
The research was supported by the Czech Ministry of
Education (MSM0021622415) and the Czech Academy of
Sciences (AV0Z50040507 and AV0Z50040702).
371
BAICALEIN-INDUCED APOPTOSIS AND INHIBITED
METASTASIS OF HUMAN HEPATOMA J5 CELLS
Hsiu-Maan Kuo1, Hung-Jie Tsai1, Ya-Ling Lin1 and JingGung Chung2
Departments of 1Parasitology and 2Biological Science and
Technology, China Medical University, Taichung, Taiwan,
ROC
Although baicalein has been demonstrated to induce apoptosis
in many human cancer cell lines, the exact molecular
mechanism of apoptosis induced by baicalein in human liver
cancer J5 cells is unknown. The purpose of this study was to
investigate whether or not baicalein affects the cell cycle and
induces apoptosis in J5 cells by flow cytometry. DAPI staining
and Comet assay were used to examine the DNA damage.
Confocal laser microscope was used to examine the
translocation of AIF and Endo G from mitochondria to nuclei.
Western blotting was used to examine the associated proteins
in cell cycle and apoptosis. The results indicated that baicalein
induced G2/M-phase arrest through the phosphorylation of
cdc25c and cdc2, and inhibited cdc2-cycin B1 complex.
Baicalein promoted the productions of reactive oxygen species
(ROS) and Ca2+ and reduced the change in the levels of
mitochondrial membrane potential in J5 cells. Baicaleininduced apoptosis also caused AIF and Endo G release from
mitochondria and promoted the activations of caspase-9 and
caspase-3. Baicalein caused oxidative stress and Ca2+ release
from ER and promoted GADD153 and GRP78 expression.
ROS inhibitor (NAC) abrogated baicalein-induced effects on
ROS and apoptosis baicalein led to decrease the production
ROS and percentage of apoptosis. Matrix metalloproteinase
(MMPs), one of the families of enzymes that degrade the
extracellular matrix (ECM), are considered to play an
important role of tumor invasion and spread. We have
demonstrated that baicalein inhibits the invasion of J5 through
the inhibition of MMP-9.
372
DEFINING THE ROLE OF THE TYPE-1 INSULINLIKE GROWTH FACTOR RECEPTOR (IGF-IR)
SIGNALING IN CHILDHOOD
RHABDOMYOSARCOMA CELLS IN VITRO UNDER
HYPOXIC GROWTH CONDITIONS
Raushan T. Kurmasheva and Peter J. Houghton
St. Jude Children’s Research Hospital, Memphis TN 38105,
USA
Background: IGF-IR signaling in rhabdomyosarcoma (RMS)
cell lines is thought to be dysregulated by overexpression of
the IGF-II ligand. However, functional linkage between IGF-
3363
ANTICANCER RESEARCH 28: 3157-3556 (2008)
IR signaling and activation of a critical node in signaling, Akt,
has not been defined. Further, the role of IGF-1R signaling in
secretion of VEGF or IGF-2 is unknown. Methods: RMS cell
lines were grown in vitro under normoxic (21% O2) or
hypoxic (1% O2) conditions. Cells were treated for 24 h with
CP751871 (1 μg/ml), an antibody targeting IGF-IR. IGF-IR,
Akt, GSK-3β, S6 and their phosphorylated derivatives were
determined by Western blot. Levels of VEGF and IGF-2 were
determined by ELISA. Results: Under serum-free conditions
CP751871 treatment completely blocked IGF-I stimulation of
Akt phosphorylation in all cell lines. Under normoxic
conditions in serum-containing media, treatment caused downregulation of IGF-IR in 3 of 4 RMS lines but only slightly
reduced p-Akt levels. Under hypoxic conditions
phosphorylation of IGF-IR was significantly increased and
CP751871 treatment markedly inhibited p-Akt in 3 out of 4
RMS lines. These results indicate the predominant pathway
activating Akt under hypoxia is up-regulation of IGF-IR
signaling. Of note, while cellular proliferation slowed under
hypoxia, signaling through mTORC1 (the mTOR-raptor
complex) was not attenuated, as S6 protein remained
hyperphosphorylated. Under these conditions there was no
increase in apoptosis in any cell line with or without
CP751871. Furthermore, CP751871 had relatively modest
effect in reducing hypoxia-driven increases in VEGF secretion,
and no significant effect on hypoxia-driven increases in IGF2 secretion. Conclusion: Our results suggest that CP751871
treatment potently inhibits IGF-IR signaling in vitro. Under
normoxia, inhibition of IGF-IR has relatively small effect on
p-Akt levels, suggesting alternate receptor-mediated pathways
signal to Akt. In contrast, under hypoxic conditions, secreted
IGF-2 levels increase and activate IGF-IR, leading to
activation of Akt. Under these conditions, there is tighter
linkage between IGF-IR signaling and Akt activation,
suggesting a switch to IGF-IR dependence. Current studies are
focused on defining whether CP751871 equally inhibits IGF1 and IGF-2 ligand activation of IGF-IR under hypoxia.
Supported by USPHS grants CA23099, CA77776 and
CA96696 and by ALSAC.
373
THE DOUBLE HAZARD OF
BLEEDING AND THROMBOSIS
IN CANCER PATIENTS
Hau C. Kwaan and Marjorie Barnett
Hematology-Oncology, Northwestern University Feinberg
School of Medicine, Chicago, IL. 60611, USA
Since Trousseau first pointed out the association between
thrombosis and cancer, both thrombosis and bleeding in
cancer has been extensively studied. Major advances in basic
and clinical investigations have enhanced our understanding
3364
of the pathogenesis of these complications. Recent
epidemiological studies have also clarified the incidence of
thrombo-embolic complications in different types of cancer,
with notably higher incidence in malignant hematological
disorders. The present day concept of thrombogenesis in
cancer remains to be based on Virchow’s original triad of
aberrant blood flow, loss of vascular integrity and altered
blood components, but with added knowledge of the
influence of cytokines, growth factors and prothrombotic
adverse effects of therapeutic agents and vascular access
catheters. Additional prothrombotic risk factors include
hereditary thrombophilia, infection, endothelial cell
activation, antiphospholipid syndrome and acquired activated
protein C resistance. While most cancer patients experience
bleeding at some time during the course of their illness, there
are special situations that increase bleeding diathesis. These
include thrombocytopenia, endothelial injury, disseminated
intravascular coagulation, excessive fibrinolysis, acquired
hemophilia and adverse effects of drugs. Recognition of these
factors will help with the adoption of appropriate prophylactic
and therapeutic measures.
374
RATE-LIMITING MICROENVIRONMENTS IN
TUMOR BIOLOGY
Silvia Doratiotto, Fabio Marongiu, Paolo Pani,
Sergio Laconi and Ezio Laconi
Department of Biomedical Sciences and Technology,
University of Cagliari, Cagliari, Italy
Cancer is often the result of a stepwise, chronic disease
process encompassing an extensive segment of the lifespan of
any species. A common pathway in the natural history of the
disease is the appearance of focal proliferative lesions that are
known to act as precursors for cancer development. It is
becoming increasingly apparent that the emergence of such
lesions is not a cell-autonomous phenomenon, but is heavily
dependent on microenvironmental cues derived from the
surrounding tissue. Specific alterations in the tissue
microenvironment that can foster the selective growth of focal
lesions will be discussed.
Furthermore, we argue that a fundamental property of
focal lesions as it relates to their precancerous nature lies in
their altered growth pattern as compared to the tissue where
they reside. The resulting altered tissue architecture
translates into the emergence of a unique tumor
microenvironment inside these lesions, associated with
altered blood vessels and/or blood supply which in turn can
trigger biochemical and metabolic changes fueling tumor
progression.
From this perspective, the slow build-up of alterations in the
tissue and tumor microenvironments represent rate-limiting
Abstracts of the 8th International Conference of Anticancer Research, 17-22 October 2008, Kos, Greece
steps in cancer development. A deeper understanding of the
role(s) of these changes in the pathogenesis of neoplasia is
essential to design more effective strategies for the
management of this disease.
Supported in part by AIRC, Italy and MIUR-PRIN, Italy.
375
LOW-DOSE PHYTOTHERAPEUTIC COMPLEXES
TO CONTROL CHEMOTHERAPY-INDUCED
PERIPHERAL NEUROPATHY
Alberto Laffranchi
Fondazione IRCCS Istituto Nazionale Tumori di Milano
Via Venezian 1, I-20133 Milano, Italy
For many chemotherapy regimens, neurotoxicity is the most
important non-hematological dose-limiting toxicity and there
are no guidelines for the treatment of chemotherapy-induced
peripheral neuropathy.
We tested the efficacy of a low-dose phytotherapeutic
complex (Arnica compositum, Rhododendroneel S,
Ranunculus homaccord and Colocynthis homaccord), in
patients with peripheral pain following chemotherapy,
prescribing 10 drops of each alcoholic preparation in the
evening. We first tested the treatment in 7 patients with posttaxane neuropathic pain in the hands, present for at least 3
months, refractory to gabapentin. In all cases, we observed
a clinically significant reduction in hand pain about 3
months after initiating the treatment. We next successfully
treated 5 breast cancer patients, with post-taxane
neuropathic pain which had been present for about a month
and 2 lung cancer patients with neuropathy of the hands and
feet who experienced pain reduction within 20 days of
initiating treatment. We subsequently treated two further
patients one with lung cancer and the other with colon
cancer. The former had had neuropathy of the hands and
feet for over a year, the second had a similar complaint for
two years following treatment with oxaliplatin and 5fluorouracil which worsened at night and disturbed sleep.
The patient with lung cancer stopped taking the treatment
after 20 days for lack of benefit. In the patient treated for
colon cancer, the symptoms in the hands resolved within 2
months but the problems in the feet persisted. In this patient
we started weekly treatment with an injectable
phytotherapeutic preparation containing Acer negundo,
Condurango, Fraxinus americana, Gallae, Haematoxylon
campechianum, Lycopodium, Prunus padus, Raphanus,
Scrofularia nodosa, Thuia, Ulmus campestris, and Viscuma
album (P73 Juv 110). The foot paresthesia improved after
the first injection and further improved (no longer
interrupted sleep) after the second injection. A third
injection is planned and after that the oral treatment will
continue.
The encouraging results with these low cost
phytotherapeutic preparations indicate that controlled studies
should be performed to validate their efficacy.
376
RNA TECHNOLOGIES FOR REVERSAL OF ABC
TRANSPORTER-MEDIATED MULTIDRUGRESISTANCE IN CANCER
Hermann Lage
Charité Campus Mitte, Institute of Pathology, Charitéplatz 1,
D-10117 Berlin, Germany
ABC transporters can mediate the multidrug-resistance
(MDR) phenotype of human cancer cells. Thus, disruption
of ABC transporter-mediated drug extrusion results in a resensitization of tumor cells to drug treatment. Low
molecular weight compounds may circumvent MDR by
inhibiting the efflux pump activities of the transporters.
However, the innate side-effects of these compounds must
be carefully considered. Thus, experimental gene
therapeutic approaches using RNA technologies have been
applied for inhibition of different ABC transporters. These
techniques include antisense oligonucleotides, ribozymes
and chemically synthesized small interfering RNAs
(siRNAs) or expression cassette encoded short hairpin
RNAs (shRNAs) mediating the RNA interference (RNAi)
phenomenon. In order to reverse different types of MDR,
different ribozymes and siRNAs were designed to inhibit
the expression of the ABC transporters MDR1/P-gp,
MRP2, and BCRP. These RNA constructs were used to
treat different ABC transporter expressing cancer cell lines
derived from various tissues. All RNA constructs
decreased the level of specific ABC transporter mRNA and
protein expression dramatically, and reduced the cellular
resistance to drug treatment by enhancing the cellular drug
accumulation in vitro. Since all of the anti-ABC
transporter RNA constructs showed gene-silencing activity,
plasmid expression vectors were designed for stable
expression of shRNA molecules. Furthermore, expression
vectors were designed that encode a multitarget
multiribozyme (MTMR) or a multitarget-multisiRNA/ribozyme (MTMsiR) simultaneously directed
against three different ABC transporters, MDR1/P-gp,
MRP2, and BCRP. Transfection of these RNA constructs
into different MDR cell lines fully inhibited ABC
transporter expression at the mRNA and protein level and
completely reversed the drug-resistant phenotypes. For in
vivo application, shRNA encoding DNA was designed to
reverse ABC transporter-mediated MDR phenotype. An
adenovirus- and an Escherichia coli-basing strategy, as
well as a nonviral jet-injection technology were developed
for in vivo delivery of shRNA-vector constructs.
3365
ANTICANCER RESEARCH 28: 3157-3556 (2008)
377
RADIATION FROM SUN AND SUN-BEDS:
CARCINOGENIC AND ANTICARCINOGENIC
EFFECTS
Johan Moan, Z. Lagunova and A.C. Porojnicu
Norwegian Radium Hospital, Institute for Cancer Research,
Department of Radiation Biology, Montebello, 0310 Oslo,
Norway
All life, certainly including human life, has been developed
under solar radiation. Humans and their ancestors have spent
most of their time under the strong fluence rates of the
Equatorial sun, and are adapted to those. In fact, the action of
solar radiation is so important for human health that the skin
color changed from black to white when humans migrated
from their Equatorial home place to higher latitudes. In spite
of this evolutionary fact, the medical literature tells that our
attitude towards solar radiation has oscillated like a pendulum:
from fear and avoidance to love and worship and back to fear
again. The reason for this is certainly that solar radiation has
both positive and negative effects; all depends on exposures
and exposure patterns. With our current knowledge of action
spectra and dose-effect relationships for positive and negative
health effects, we should be able to quench the oscillations and
settle at an intelligent behavior of optimal equilibrium. Skin
carcinogenesis is certainly the major negative effect of sun
exposure, while vitamin D formation is linked to a number of
positive effects, one of which is anticarcinogenesis. Action
spectra for these effects will be reviewed: While those for
vitamin D formation, for pigmentation, for erythema and for
non-melanoma generation are quite similar and located in the
UVB region, that for melanoma generation has a significant
contribution in the UVA region. This has important health
consequences: UVA has a much smaller latitude gradient than
UVB and decays less with time before and after noon. In view
of this it is possible to find a time and an exposure pattern that
is optimal for vitamin D generation at a minimal risk of
melanoma.
From our epidemiological studies we conclude that for
European countries a moderate increase in non-erythemal sun
exposure for those with indoor work would be associated with
much larger positive than negative health effects. For instance,
in Norway an increased exposure, leading to 200 more
melanoma deaths per year (a doubling) if non-optimally
obtained, would probably lead to more than 2000 fewer
internal cancer deaths.
If the early humans had known sun-beds, all of us would
probably still have been black. Our fear of “artificial devices”
like sun-beds, should be reevaluated in view of the fact that at
a given wavelength it is impossible to distinguish photons
from a sun-bed from photons from the sun. It is possible to
construct sun-beds with spectra that are much more “healthy”
3366
than those of the sun. Such spectra would be stable and would
not vary with time and localization like the spectra of the sun.
378
LYSOSOMES AND PROTEOLYTIC SIGNALLING IN
TUMOUR PROGRESSION
Tamara T. Lah, Maria-Beatriz Durán Alonso, Boris Gole,
Saša Kenig, Anja Pucer and Irena Zajc
Department of Genetic Toxicology and Cancer Biology,
National Institute of Biology, Ljubljana, Večna pot 111, 1000
Ljubljana, Slovenia
Altered lysosomal functions in tumour progression have not
yet been completely revealed. These vesicles contain various
hydrolytic enzymes, including cathepsins, which are involved
in several cellular processes, both intracellularly as well as
extracelluly after cathepsin secretion. Therefore, the
interactions of tumour cells with their microenvironment, for
example in angiogenesis, are also mediated via cathepsins in
addition to processes such as tumour cell invasion, apoptosis
and drug resistance. These processes are associated with
partial or extensive degradation of protein substrates,
trafficking and recycling of relevant biological molecules, such
as receptors and growth factors, and post-translational
modifications of secretory proteins. A broad pH optimum and
selective specific activity of these enzymes, being tuned by at
least three cystatins (stefins A and B and cystatin C), allow
them to participate in biochemical mechanisms underlying
tumour progression. Recent experiments using various
methods for knocking out and silencing cathepsin genes in
normal and tumour cells have clearly revealed differential
expression and novel functions of these enzymes. They also
affect gene regulation in the tumour and in the surrounding
cells, clearly depending on the cell type. A review of recent
experimental and clinical findings in glioma will be presented.
It is concluded that, at least in brain tumours, cathepsin B
supports tumour cell invasion and angiogenesis while
cathepsin L is more associated with apoptosis and drug
resistance, whereas the role of cathepsin S is at present less
clear.
379
KEY ISSUE IN RESPECT TO STABILITY OF
CYTOKERATIN18 IN HEPATOCELLUAR
CARCINOMA
Chiung-Chi Cheng1, Yi-Hsiang Liu2,3, Chin-Chin Ho4 and
Yih-Shyong Lai5
1Institute
of Medicine of Chung Shan Medical University,
Taichung, Taiwan;
2Department of pathology, Jen Ai Hospital, Taichung,
Taiwan;
Abstracts of the 8th International Conference of Anticancer Research, 17-22 October 2008, Kos, Greece
3Department
of Pathology, Tzu Chi Hospital and University,
Hualien, Taiwan;
4Department of Nursing, Central Taiwan University of
Science and Technology, Taichung, Taiwan;
5Department of Pathology, Hospital and Medical College of
Chung Shan Medical University, ROC
Intermediate filaments are important in building cellular
architecture. Previously we found cytokeratin18 was
modulated in human hepatocellular carcinoma. Plectin is a
cross-linking protein that organizes the cytoskeleton into a
stable meshwork, which can maintain the uniform size and
shape of hepatocytes. Because the cells of hepatocellular
carcinoma were morphologically different from the
hepatocytes, we speculated that expression of plectin and
organization of intermediate filament might play roles in
the pleomorphism of hepatocellular carcinoma cells. We
studied the plectin expression of hepatocellular carcinoma
and liver tissues by immunohistochemistry and
immunoblot. The results revealed that plectin was deficient
and cytokeratin18 was modulated in hepatocellular
carcinoma. Furthermore, the knockdown the plectin mRNA
in Chang cells, revealed that plectin was deficient and the
organization of cytokeratin18 was altered. Conclusively,
this study offers a hypothesis that plectin deficiently might
play an important role in the tumorigenesis of
hepatocellular carcinoma.
380
STROMAL FGF-2 PARTICIPATES IN HORMONE
INDEPENDENT TUMOR GROWTH
Juan Pablo Cerliani1, Sebastián Giulianelli1,
Victoria T. Fabris1, Virginia Novaro1, Adrián Góngora1,
Alberto Baldi1, Alfredo Molinolo2, Claudia Lanari1 and
Caroline A. Lamb1
1Instituto de Biología y Medicina Experimental, Vuelta de
Obligado 2490, Buenos Aires, Argentina;
2National Institutes of Health/NIDCR, Oral and Pharyngeal
Cancer Branch, Building 30 Room 211, 30 Convent Dr MSC
4340, Bethesda MD 20892-4340, USA
We have developed an experimental model of breast cancer in
BALB/c female mice in which metastatic ductal mammary
carcinomas transit through different stages of hormone
dependence. Hormone-dependent (HD) tumors need the
exogenous administration of progestins to grow while
hormone-independent (HI) carcinomas grow in vivo without
exogenous progestin supply, although they retain high levels
of estrogen and progesterone receptors (PR). In vitro, however,
there are no differences in hormone responsiveness between
both tumor types, suggesting the involvement of host factors
regulating in vivo tumor growth.
The mechanisms by which mammary carcinomas acquire
hormone independence are still unknown. The aim of this
study was to evaluate the role of carcinoma-associated
fibroblasts (CAF) in the acquisition of hormone independence.
We demonstrated that CAF from HI tumors (CAF-HI)
growing in vitro express higher levels of FGF-2 than HD
counterparts (CAF-HD). FGF-2 activated the PR in the tumor
cells, thus increasing cell proliferation. CAF-HI induced a
higher proliferative rate in the tumor cells and in PR activation
than did CAF-HD. The blockage of FGF-2 in the co-cultures,
and the genetic or pharmacological inhibition of FGFR-2
inhibited PR activation and tumor cell proliferation. In vivo,
an FGFR inhibitor reduced HI tumor growth, and exogenous
administration of FGF-2 to HD tumors promoted growth.
T47D human breast cancer cells were also stimulated by
progestins, FGF-2 or CAF-HI, and this stimulation was
abrogated by antiprogestins, suggesting that the murine C4-HI
cells respond as the human T47D cells.
In summary, this is the first study reporting differences
between CAF from HD and HI tumors suggesting that CAFHI actively participate in driving HI tumor growth.
381
OBESITY PROMOTES GASTROINTESTINAL
CANCER IN Apc MUTANT MICE
Claudia Gravaghi, Jin Bo, Krista MD LaPerle, Fred Quimby,
Raju Kucherlapati, Martin Lipkin, Winfried Edelmann and
Sergio Lamprecht
Strang Cancer Research Laboratory, Division of
Gastroenterology and Hepatology, Department of Medicine,
Weill Medical College of Cornell University, New York, NY,
Department of Cell Biology, Albert Einstein College of
Medicine, Bronx, NY, Laboratory of Comparative Pathology,
Memorial Sloan-Kettering Cancer Center, New York, NY,
Laboratory Animal Research Center, The Rockefeller
University, New York, NY, Department of Genetics, HarvardPartners Center for Genetics and Genomics, Boston, MA,
USA
Epidemiological studies indicate a link between obesity and
colon cancer.
The main objective of this study was to produce a new
mouse line that displays both obesity and intestinal
tumorigenesis. To this end we have generated double
Apc1638N/+
mice.
mutant
C57BLKS-mLepr db/db;
Homozygous db/db mice carry a missense mutation
resulting in premature termination of the intracellular
domain of the long form of the leptin receptor associated
with a complex phenotype of obesity and diabetes mellitus.
Mutant Apc1638N/+ mice progressively develop intestinal
neoplasia and serve as a suitable model for human
adenomatous polyposis syndrome.
3367
ANTICANCER RESEARCH 28: 3157-3556 (2008)
Heterozygous Apc1638N/+ and C57BLKS-mLeprdb/+ mice
were crossed. Double heterozygous C57BLKS-mLeprdb/+;
Apc1638N/+ mice were then intercrossed to generate the obese
double mutant offspring used in this study. All animals were
euthanized at 6 months of age. The gastrointestinal tract was
removed and paraffin sections of all regions were stained with
hematoxylin and eosin to identify preneoplastic and neoplastic
lesions.
The main findings were (i) homozygous db/db mice did not
develop gastrointestinal neoplasia, (ii) the introduction of the
db mutation into the mutant Apc1638N/+ background not only
enhanced Apc-driven development of small intestinal polyps
but also induced the formation of gastric and colonic tumors.
It is noteworthy that these tumors do not develop in single
mutant Apc1638N/+ mice at the age of 6 months age and are
only infrequently observed in older Apc1638N/+ mice. All
tumors were adenomas. No gastrointestinal tumors were found
in wild-type littermates.
These findings indicate that the hormonal and metabolic
background of the db/db mouse exacerbates gastrointestinal
neoplasia in the presence of a pre-existing Apc mutation and
provide evidence of a mechanistic link between obesity and
colorectal cancer.
382
SMALL RENAL TUMOURS: SURGICAL
CONSERVATIVE APPROACH
A. Lapini, A. Minervini and M. Carini
Department of Urology, University of Florence, Italy
Introduction: The widespread use of ultrasonography has led
to an increasing number of early detected/incidentally found
small renal masses, which are potentially suitable for nephronsparing surgery (NSS). Presently, NSS is the accepted standard
treatment in patients with small renal tumors and a normal
contralateral kidney. We routinely perform the tumor
enucleation (TE) technique, which consists of excising the
tumor by blunt dissection without a visible rim of normal
parenchyma. We report our experience with tumor enucleation
in 303 patients. Patients and Methods: Between 1986 and
2004 303 patients with sporadic unilaterally RCC underwent
NSS by tumor enucleation. In 232 patients, preoperative
imaging evaluation showed renal mass <4 cm in greatest
dimension,pathological evaluation confirm pT1a Renal cell
cancer. In 71 cases the tumors were >4 cm but <7 cm in
greatest dimension, and pathological review according to the
2002 TNM classification showed that 42% of the tumors (30
of 71) were pT1a, 44% (31 of 71) were pT1b and 14% (10 of
71) were pT3a. Results: ≤4 cm RCC. The mean (median,
range) follow-up was 76 (61, 12-225) months. The 5- and 10year cancer-specific survival were 96.7% and 94.7%,
respectively. The 5- and 10-year progression-free survival
3368
were 96% and 94%, respectively. Overall, 13 (6.4%) patients
had disease progression, three of whom had local recurrences
alone (1.5%). 4-7 cm RCC. The mean follow-up was 74
months (median 51, range 12 to 225). Five and 8-year cancer
specific survival was 85.1% and 81.6%, respectively. Five-year
cancer specific survival in patients with pT1a (4 cm), pT1b
and pT3a disease was 95.7%, 83.3% and 58.3%, respectively).
Overall 10 patients experienced progressive disease (14.9%),
of whom 3 had local recurrence (4.5%) alone or local
recurrence associated with distant metastases. Discussion: To
avoid the risk of local recurrence, the excision of a minimal
and visible margin of normal-appearing parenchyma around
the tumor is considered the standard surgical technique of
NSS. Recent reports concluded that the width of the resection
margins does not correlate with disease progression and that
if the tumor is completely excised, the margin size is
irrelevant, thus providing an intriguing insight into the
possibility of bluntly excising the tumor, such as a tumor
enucleation. Conclusion: Tumor enucleation is a safe and
acceptable nephron-sparing treatment that provides excellent
long-term local control and survival rates.
383
CURRENT CHALLENGES IN TUMOR
IMMUNOLOGY: BETTER UNDERSTANDING
TUMOR/IMMUNE SYSTEM CROSS-TALKS
Réjean Lapointe, Jessica Godin-Ethier, Marie-Andrée Forget,
Sandy Pelletier, Simon Turcotte and Stéphanie Lepage
Tumour immunology laboratory, Institut du cancer de
Montréal, Centre de recherche, Centre hospitalier de
l’Université de Montréal (CRCHUM) Hôpital Notre-Dame,
Montréal, Québec, Canada
Cancer is a major challenge in our society; although early
surgery, radiotherapy and chemotherapy are effective and
recognized, cancer is still a major killer. Alternative strategies
are needed to improve outcomes for affected patients. Cancer
immunotherapy is based on prompting the immune system to
specifically recognize and kill tumours. Tumour regression
mediated by an immunological response has been
demonstrated in multiple clinical trials. However, we have to
face a hard reality: the first generation of human cancer
immunotherapies, especially that emerging from animal
models, is effective in a limited number of patients. Tumours
may negatively influence the cancer-specific immune
response, and the search for major mechanisms mediating
immune tolerance to tumours has been intense. The
mechanisms include a lack of T-cell help, inadequate T
lymphocyte functions (proliferation, lysis, etc.), decreased
TCR signalling, and local production of immunosuppressive
factors with many others (regulatory T-cells [Treg], MHC
expression by tumours, etc.) also being proposed. These
Abstracts of the 8th International Conference of Anticancer Research, 17-22 October 2008, Kos, Greece
mechanisms will be briefly reviewed and our recent data on
tumour-influenced immunological environments will be
presented. Our recent immunotherapeutic strategies to
optimize antigenic presentation will also be described. Cancer
immunotherapy can work, and efficiency could be increased
once we have better control of negative immune regulators
from tumours, and develop more appropriate ways of
triggering a specific immune response.
384
GENETIC AND PROTEOMIC PROFILING OF
PROSTATE CANCER PROGRESSION
S.E.T. Larkin1, I.A. Cree2, S. Holmes3, T. Walker2
and C.L. Hastie1
1School
of Pharmacy and Biomedical Sciences, University of
Portsmouth;
2Department of Histopathology, Queen Alexandra Hospital,
Portsmouth;
3Department of Urology, St Mary’s Hospital, Portsmouth,
UK
Advanced metastatic prostate cancer (PCa) is usually treated
with hormone therapy, though this is rarely curative. In
younger men, with organ-confined disease, radical
prostatectomy is carried out to eliminate the risk of metastasis
in later years. This procedure carries risks of impotence,
urinary incontinence and even death.
The aims of this project, therefore, were to investigate the
genetic and proteomic profiles of PCa in patients with varying
stage and grade of the disease to identify prospective
predictive markers of clinically significant PCa.
To identify prognostic markers in both studies, samples
were split into two groups: Gleason grade ≥7 and Gleason
grade <7. Using Taqman qPCR, a pilot study of gene
expression in FFPE prostate tissue (46 samples) was
examined. Ninety-six genes of interest were identified from
literature reviews and microarray data mining. Results of this
study show a significant difference (p<0.05) in at least 10 of
the genes analysed. Three of these are significant to p<0.025.
These three genes are the first to be analysed further by
immunostaining of tissue microarrays to analyse protein
expression, the results of which will be presented at this
meeting. Additionally, a novel 2D gel electrophoresis method,
encompassing liquid phase IEF followed by large format SDS
PAGE, and mass spectrometry has enabled the study of serum
proteomic profiles. Study of the presence and absence of
proteins between the two patient groups (8 with Gleason <7,
18 with Gleason ≥7) has revealed 6 proteins of interest. Mass
spectrometry analysis has identified 4 of these proteins and
further analysis of two of the most interesting is currently
being undertaken. Western blotting data of the expression of
these proteins will be presented at this meeting.
385
MANNOSE-6-PHOSPHATE/INSULIN-LIKE GROWTH
FACTOR-II RECEPTOR IN HUMAN MELANOMA
CELLS: EFFECT OF LIGANDS AND ANTIBODIES ON
THE RECEPTOR EXPRESSION
Friedemann Laube
Institute of Physiological Chemistry, Martin Luther University
Halle-Wittenberg, D-06097 Halle, Germany
The Mannose-6-phosphate/insulin-like growth factor II
receptor (M6P/IGF-II) R is a multifunctional transmembrane
glycoprotein that induces cellular responses in special cells.
Previous attempts have given controversial results about the
signal transduction capability of the receptor. However, more
recent studies have shown the capability of M6P/IGF-II R to
initiate transmembrane signalling (1).
Human melanoma cells were used to detect the cell surface
expression of M6P/IGF-II R by immunoluminescence. The
incubation of melanoma cells with M6P (5 mM) caused an
increase of the receptor signal of ~50%. Pre-incubation of
M6P-non-stimulated cells with cycloheximide (CHI, 10
μg/ml) reduced the receptor expression of ~15%, whereas
actinomycin D (Act-D, 5 μg/ml) did not. But 30 min preincubation of cells with the inhibitors following M6P
stimulation in the presence of Act-D or CHI caused a
reduction of transcription of 27% and a reduction of receptor
protein synthesis of 31%, respectively. Two monoclonal
antibodies (mAb 2G11 and MEM-238) and a polyclonal Ab
were used for the detection of the receptor. 2G11 was able to
mimic the M6P ligand effect but MEM-238 did not. The
signal released by the 2G11-stimulated receptor up-regulation
was completely quenched by masking the receptor-bound
2G11 with anti-mouse IgG. The additive signal intensity
detected with the combination of M6P and 2G11 and the
failure of 2G11 to compete with the M6P action suggests that
both effectors have different binding sites on the receptor.
Unlike 2G11, the mAb MEM-238 prevented the M6P effect
on receptor expression, confirming partially overlapping
binding epitopes of both effectors on the extracellular receptor
domains 1-3. MEM-238 recognizes an epitope between
domains 2 and 5. Either the M6P binding site between
domains 1-3 is essential for its stimulating effect or both M6P
binding sites (domains 1-3 and 7-9) have to be occupied by
M6P for the receptor up-regulation. It was possible to show
an inhibiting effect of brefeldin A on the vesicular transport
of the receptor protein to the plasma membrane and an
activating effect of forskolin on the receptor secretion or
exocytosis, respectively. Results obtained on the dynamic
behaviour of the M6P/IGF-II R on melanoma cells support
recent data demonstrating its capability of signal transduction.
1 El-Shewy HM, Lee MH, Obeid LM, Jaffa AA and Luttrell
LM: J Biol Chem 282: 26150-26157, 2007.
3369
ANTICANCER RESEARCH 28: 3157-3556 (2008)
386
PATHOLOGICAL ASPECTS OF HETEROGENEITY
OF GLIOBLASTOMA MULTIFORME
25%, respectively)
glioblastomas.
Libero Lauriola
387
THE EMERGING SIGNALING VRK1 PATHWAY AND
ITS IMPLICATIONS IN PROLIFERATION AND DNA
DAMAGE RESPONSE
Institute of Pathology, Faculty of Medicine, Catholic
University of the Sacred Heart, Rome, Italy
Glioblastoma is the most malignant among brain tumours with
astrocytic differentiation. It is also the most frequent glioma
and affects primarily the cerebral hemispheres of adults, with
a peak incidence in the fifth and sixth decades.
The definition of glioblastoma, recalling an embryonal or
poorly differentiated tumour, echoes the uncertainty still
present in the 1979 WHO classification. Glioblastoma is now
considered as derived by the neoplastic transformation of
mature astrocytes or astroglial precursors. The tumour is
characterized by a high cell heterogeneity and pleomorphism,
that complicates the description of all the tissue patterns and
morphologic variations of the neoplastic cells; however,
scattered differentiated astrocytic neoplastic cells are also
frequently present. In addition to the more common pattern,
glioblastomas can be composed of small uniform cells,
whereas other tumours can be prevalently composed of
pleomorphic giant cells. Other variants are sarcoma-like
glioblastoma, glioblastoma with carcinoma-like features and
those containing metaplastic bone or cartilage. Vascular
proliferation, with features of ‘microvascular’ or ‘endothelial’
proliferation, and necrosis, consisting in large areas of tissue
destruction or small foci of ‘pseudopalisading’ are cardinal
features of glioblastoma.
The finding of large areas of well-differentiated astrocytic
neoplastic cells coexisting with glioblastoma in cases of long
clinical duration led to the conceptual distinction, firstly
made by Scherer in 1940, between ‘primary’ and ‘secondary’
glioblastoma. Primary and secondary glioblastomas are now
considered distinct subtypes, affecting different age groups
and developing through different genetic pathways.
Interestingly, they show different expression of some
molecules and different responses to therapy. The diagnosis
of secondary glioblastoma requires clinical and histological
evidence of derivation from a low grade astrocytoma (WHO
grade II) or anaplastic astrocytoma (WHO grade III).
Primary glioblastomas pursue a short clinical course and do
not show histological evidence of a less malignant
component. These glioblastoma subtypes also differ at the
molecular level. Ohgaki et al. (Cancer Res, 64: 6892-6899,
2004) on a large population-based study demonstrated that
TP53 mutations are the most frequent genetic alteration in
secondary glioblastoma and are also present in the precursor
low-grade or anaplastic astrocytoma. On the other hand,
EGFR amplification, a possible target for therapy, and PTEN
mutation were detected more frequently in primary (36% and
3370
but
very
rarely
in
secondary
Pedro A. Lazo, Alberto Valbuena, Marta Sanz-García and
Inmaculada López-Sánchez
Instituto de Biología Molecular y Celular del Cáncer,
Campus Miguel de Unamuno, CSIC-Universidad de
Salamanca, 37007 Salamanca, Spain
The VRK Ser-Thr kinases are a new subgroup in the human
kinome with two active members with a conserved catalytic
domain and unrelated regulatory domains in their C-terminus.
Human VRK1 is the better known member. VRK1 gene
expression is regulated by entry and exit in the cell cycle. The
kinase activity is regulated by phosphorylation by growth
factors. Furthermore, induction of DNA damage by UV light,
doxorubicin, or etoposide induces an additional
phosphorylation that further raises the kinase activity. VRK1 is
mostly located in the nucleus, particularly in proliferating
cells. Among its targets are p53, c-Jun and ATF2. VRK1
specifically phosphorylates p53 in Thr18 preventing its
interaction with Hdm2; thus stabilizing p53 and leading to its
accumulation and induction of growth arrest. This arrest would
be permanent unless an autoregulatory mechanism to
eliminate VRK1 was functional. This mechanism has been
identified as being regulated by a transcriptionally active p53,
and its structure is similar to that of the p53-Hdm2
autoregulatory loop. Active p53 induces a gene, DRAM, that
targets p53 for its proteolytic down-regulation via the
lysosomal pathway; VRK1 requires an inducible proteolytic
degradation because it is a very stable protein with a half-life
of several days. The existence of this pathway predicts that in
tumors with p53 mutations, there should be an accumulation
of VRK1 protein. This was confirmed in a series of lung
carcinomas, where VRK1 accumulates if they harbor a p53
mutation. A similar finding has been detected in breast cancer.
The knock-down of VRK1 by siRNA results in a block in
cell cycle progression, due to the contribution of VRK1 as an
early gene, expressed at the same time as MYC and FOS
oncogenes and required for cyclin D1 expression. VRK1 loss
is accompanied by a loss in phosphorylation of RB suggesting
it is required very early in cell cycle progression, probably in
the G0 exit to G1 and before the restriction point. This loss is
accompanied by accumulation of cell cycle inhibitors, such as
p27, consistent with the cell cycle block. In human head and
neck squamous cell carcinomas, VRK1 positively correlates
with proliferation markers such as Ki 67, CDK2, cdc2,
topoisomerase II, survivin and cyclins. These correlations
Abstracts of the 8th International Conference of Anticancer Research, 17-22 October 2008, Kos, Greece
indicate a role early in the cycle. However, VRK1 can play
additional roles in proliferating cells, such as participating in
responses to DNA damage.
VRK1 activity can also be regulated by interaction with
other proteins. VRK1 interaction with nuclear Ran regulates
VRK1 activity. Interaction with RanGDP inhibits VRK1
kinase activity, but the interaction with RanGTP recovers the
activity. RanGDP inhibits the kinase activity of VRK1 thus
preventing the phosphorylation of Histone H3 in Thr3 and
Ser10, required for chromatin condensation during mitosis. In
this way, an asymmetric distribution of VRK1 activity in the
nucleus can be achieved.
Early during mitosis it is necessary to fragment the Golgi
apparatus in order for it to be redistributed in daughter cells.
VRK1 is a necessary step required for Golgi fragmentation
acting downstream of MEK1 and PLK3. VRK1 is a direct
phosphorylation target of PLK3.
VRK1 is a novel kinase that participates in several
processes related to cell cycle progression.
388
PROTEINPROFILING FOR IDENTIFICATION OF
BREAST CANCER BIOMARKERS IN TEAR FLUID
AND SERUM
A. Lebrecht, D. Boehm, H. Koelbl and F. Grus
Dept. of Gynecology and Obstetrics, Johannes GutenbergUniversity, Mainz, Germany
Introduction: In patients with breast cancer early diagnosis is
important for survival. Actually mammography is the best
available method. Although sensitivity is high, specificity is
relatively low. New biomarkers are needed to improve the
early detection of breast cancer. The aim of the study was to
generate a protein biomarker profile in tear fluid and serum
for breast cancer patients. We used this established biomarker
profile subsequent to discriminate between cancer patients and
healthy controls. Methods: We screened for potential
biomarkers in tear fluid and serum 60 women with breast
cancer (CA) and 60 healthy women (CTRL), matched to the
age. Blood samples and tear fluid were drawn prior to surgery.
We used SELDI – TOF – MS (Surface Enhanced Laser
Desorption Ionisation – Time Of Flight – Mass Spectroscopy)
for protein profiling. Three different active surfaces of the
protein chips were used: cationic exchanger(CM-10),
hydrophobe surface (H50) and metal ionic affinity surface
with different binding properties. The chips were read by mass
spectroscopy and the analyses were done by multivariate
statistics. Results: In a pilot study with 20 patients we found
complex protein and peptide distributions on all three surfaces.
We identified the main proteins in tear fluid, like lysozyme
and lipocalin. Between breast cancer patients and healthy
controls we found statistically significant differences in the
protein profiling (p<0.001). Second we used SELDI-TOF-MS
for protein profiling with two different active surfaces of the
protein chips, a cationic exchanger (CM-10), and a reversephase surface (H50) in 100 patients. The data were analyzed
by multivariate statistical techniques and artificial neural
networks. Both, in tear fluid and in serum, we could generate
statistically significant biomarker panels (p<0.0005). The
diagnostic pattern could differentiate CA from CRTL with a
specificity and sensitivity of about 70% in tear fluid and a
specificity of 77% and a sensitivity of 85% in serum.
Conclusion: It was successful to generate biomarker panels in
tear fluid and blood to discriminate breast cancer patients and
healthy women. With the help of neural networks these panels
show a respectable sensitivity and specificity. The protein chip
technology could greatly facilitate the discovery of new and
better biomarkers. It is a promising approach to analyse a high
number of patients. Analysing tear fluid may be useful for
high-throughput biomarker discovery.
389
INITIAL TUMOR GROWTH AND TUMOR INVASION
ARE MEDIATED BY PDGF-BB AND VEGF-A
ACTIVATED FIBROBLASTS
Wiltrud Lederle1,2 and Margareta M. Mueller1
1Group: Tumor and Microenvironment (A101), German
Cancer Research Center (DKFZ), 69120 Heidelberg;
2Experimental Molecular Imaging, University of Aachen
(RWTH), Germany
Stromal fibroblasts that are activated by tumor-derived
cytokines play a crucial role for tumor growth and invasion.
In the HaCaT-model of skin carcinogenesis, we identified
PDGF-BB and VEGF-A activated fibroblasts as key mediators
driving initial tumor growth and tumor invasion. PDGF-BB
induces the conversion of immortal non tumorigenic HaCaT
cells to benign tumor growth by differentially regulating
cytokine expression in stromal fibroblasts, by promoting their
differentiation into myofibroblasts and by enhancing pericyte
recruitment. De novo expression of murine VEGF-164 induces
malignant and invasive tumor growth of the before non
tumorigenic HaCaT cells, associated with a strong and
ongoing activation of myofibroblasts. However, the VEGFinduced tumors are ulcerated with a disorganized epithelium
that is interrupted by lacunae with limited basement
membrane and endothelial cell coverage. Additionally, vessel
maturation is strongly impaired. Tumor and vessel
micromorphology are markedly improved by the combined
expression of PDGF-BB and VEGF-A, leading to a similar
tumor growth but more compact tumors with a mature
functional tumor vasculature. Invasive growth of the tumor
cells is dependent on the presence of fibroblasts and is
mediated by their VEGF and PDGF induced MMP-expression.
3371
ANTICANCER RESEARCH 28: 3157-3556 (2008)
Specifically the expression of MMP-13 by activated
fibroblasts is essential for ongoing angiogenesis and invasion
of malignant skin SCCs. These data highlight the importance
of cytokine activated fibroblasts in promoting tumor growth
and progression and emphasize the importance of interfering
with the tumor-fibroblast interactions for an efficient tumor
therapy.
390
TUMOR-LOCALIZED LIGATION OF
CD3 AND CD28 WITH SYSTEMIC
REGULATORY T-CELL DEPLETION
INDUCES POTENT INNATE AND
ADAPTIVE ANTITUMOR RESPONSES
Chien-Hsin Lee, Yi-Shen Chiang, Shih-En Chang,
Chin-Liew Chang, Bing-Mae Cheng and Steve R. Roffler
Institute of Biomedical Sciences, Academia Sinica, Taipei,
Taiwan, ROC
Tumor-localized activation of immune cells by membranetethered antibodies is currently under investigation to treat
poorly immunogenic tumors. Here, we investigated the
mechanism of antitumor immunity elicited by tumor-located
expression of a membrane-tethered anti-CD3 single-chain
antibody (CD3L). Expression of CD3L and CD86 on poorly
immunogenic B16 melanoma cells (B16/3L86 cells) activated
naïve T-cells, suppressed tumor growth in subcutaneous,
peritoneal and metastasis models, and protected mice from
rechallenge with B16 melanoma cells. However, in vivo
antitumor activity against primary B16/3L86 tumors
unexpectedly depended on NK cells rather than CD4+ or
CD8+ T-cells. Treatment of mice with low-dose
cyclophosphamide, or anti-CD25 antibody to deplete
regulatory T-cells unmasked latent T-cell antitumor activity;
the number of activated CD8+ T-cells in tumors increased and
B16/3L86 tumors were completely rejected in a CD8+ and
CD4+ T-cell-dependent fashion. Furthermore, fibroblasts
expressing CD3L and CD86 suppressed growth of
neighboring B16 cancer cells in vivo and direct injection of
adenoviral vectors expressing CD3L and CD86 or CD3L and
a membrane-tethered anti-CD28 antibody significantly
suppressed B16 tumor growth.
Taken together, our results show that tumor-located
ligation of CD3 and CD28 can activate both innate (NK
cell) and adaptive (CD4+ and CD8+ T-cell) responses to
create a tumor-destructive environment to control tumor
growth, but modulation of Tregs is necessary to unmask
local adaptive antitumor responses. Depletion of Tregs and
pharmacological stimulation of NK cell activity are potential
avenues to increase efficacy of therapies that activate
lymphocytes via CD3, including bispecific antibody therapy
of cancer.
3372
391
MATRIX METALLOPROTEINASE-9 INDUCES
EPITHELIAL-TO-MESENCHYMAL TRANSITION IN
A HIGHLY INVASIVE A431 TUMOR CELL SUB-LINE
Chun-Yu Lin1, Yung-Sheng Lin1, Lung-Ta Lee2,
Ping-Ping H. Lee3, Wen-Te Kao1, Pei-Hsun Tsai1,
Ferng-Chun Ke4, Jiuan-Jiuan Hwang5 and Ming-Ting Lee1,3
Institutes of 1Biochemical Science and 4Molecular and
Cellular Biology, National Taiwan University, Taiwan;
2Department of Nutrition and Health, ToKo University,
Taiwan;
3Institute of Biological Chemistry, Academia Sinica, Taiwan;
National Taiwan University, Taiwan;
5Institute of Physiology, National Yang Ming University,
Taipei, Taiwan, ROC
Recently, highly invasive tumor cell lines (designated A431I, -II and -III) derived from parental A431 tumor cells (A431P) were isolated in our laboratory by three successive
passages through a Boyden chamber with matrigel-coated
membrane support. The invasive potential and the activity of
secreted MMP-9 of each subline increased significantly
compared to the A431-P (A431-III > A431-II > A431-I) as
evidenced by the in vitro invasion assay, gelatin zymography
and immunoblotting analyses. RT-PCR results also revealed
the elevated expression of MMP-9 in A431-III. We further
characterized the A431-III subline and found that these cells
exhibited a greater potential for attachment and spreading on
fibronectin-coated substratum and for migration. The A431III cells displayed multiple cytoplasmic extensions with focal
contacts (vinculin-positive staining) during cell spreading.
Our results indicate that an increase in MMP-9 secretion
could disrupt the E-cadherin complex of proteins and lead to
the loss of cell adhesion. It is well known that epithelial-tomesenchymal transition (EMT) can result in the loss of Ecadherin. Therefore, we decided to investigate whether MMP9 could induce EMT in a highly invasive A431-III tumor cell
sub-line. In this study, we noticed a strong multigene
signature indicative of EMT as identified by microarray
analysis. The observation of the increase of EMT marker
proteins was further supported by immunoblotting, including
N-cadherin, vimentin, fibronectin, MMP-3, MMP-9, Snail1,
Twist1 and TGF-β2. Taken together, these results demonstrate
that the greater invasion potential exhibited by the highly
invasive. In conclusion, the invasiveness of the A431-III
subline is likely attributed to an increased ability for
attachment, spreading and migration, as well as increased
MMP activity. That action of MMP-9 on cancer cells can
induce EMT provides insight into novel therapeutic targets.
A431-P and the highly invasive A431-III subline could be an
excellent model for studying the mechanism of cancer
metastasis.
Abstracts of the 8th International Conference of Anticancer Research, 17-22 October 2008, Kos, Greece
392
DNA REPAIR PROTEINS ASSOCIATED WITH
PHOTOFRIN RESISTANCE IN U87 GLIOBLASTOMA
CELL LINE
S.Y. Lee, S.P. Yip and S.S.T. To
Dept. of Health Technology and Informatics, The Hong
Kong Polytechnic University, Hung Hom, Kowloon, Hong
Kong SAR, China
Background: Photodynamic therapy (PDT) is a new modality
of cancer therapy which relies on the use of light and the
preferential accumulation of photosensitisers in neoplastic
tissues to kill cancerous cells. PDT is suitable as an adjunct
therapy for glioma. However, the failure of PDT to have any
effect has been reported in some studies, and the underlying
cellular mechanisms leading to failure are still unknown.
DNA repair mechanisms may account for reported PDT
failures. During the course of PDT, reactive oxygen species
generated by the photosensitiser may interact with DNA,
causing chromosomal damage and mutations. This in turn
leads to apoptosis and necrosis in the cancerous cells.
However, if the DNA lesions caused by PDT are repaired, the
cells may survive the damage induced by PDT. We
hypothesise that if the expression of DNA repair proteins is
high in glioma cells, the cells can efficiently repair the DNA
damage caused by PDT. Consequently, these glioma cells
become more resistant to PDT and therefore are not
susceptible to the actions of PDT. Objectives: To investigate
the role of DNA repair mechanisms in glioma cells resistant
to Photofrin-based PDT. Methods: The expression levels of
DNA repair messenger ribonucleic acids (mRNA) and DNA
repair proteins in different grades of Photofrin-PDT-resistant
U87 glioma cells were examined using quantitative real-time
polymerase chain reaction and Western blotting. The mRNA
expression data were further analysed by one-way analysis of
variance followed by Tukey post-test. Six specific genes
representative of six DNA repair mechanisms were examined.
Results: Four of the DNA repair genes investigated have
comparable mRNA expression levels between the controls
and Photofrin-PDT resistant U87 glioma cells. The two
exceptions were the ALKBH2 (alkB, alkylation repair
homolog 2 (E. coli)) gene of DNA damage reversal and the
REV1 (REV1 homolog (S. cerevisiae)) gene of translesion
synthesis. The mRNA transcripts of these two genes were
expressed at a significantly higher level in Photofrin-treated
cells (p<0.01) when compared with the control cells.
Increased expression was observed from 30 minutes to 48
hours post-treatment with Photofrin. These results were also
confirmed at the protein level by Western blotting. This
suggested that induced expression in both genes occurred
immediately in treated cells after irradiation with the light
source. Conclusion: Since high mRNA and protein expression
of ALKBH2 and REV1 were observed in Photofrin-PDT
resistant glioma cells but not in control cells, the results
indicate that both DNA damage reversal and translesion
synthesis mechanisms may play important roles in Photofrin
resistance. High expression of REV1 also indicates that much
DNA damage is produced during Photofrin-PDT and cannot
be repaired. Further work is in progress to investigate the
relationship between the expression of DNA repair proteins
and Photofrin resistance by using silent RNA, and to evaluate
the types of DNA damage generated by Photofrin.
393
RADIATION-INDUCED CHANGES
IN THE MOUSE BRAIN PHOSPHOPROTEOME
ANALYZED BY DIFFERENTIAL
16O/18O LABELING AND UPLC-MS/MS
Dominic Winter1, Joerg Seidler1, Yael Ziv2, Yosef Shiloh2,
and Wolf D. Lehmann1
1Molecular Structure Analysis, German Cancer Research
Center, Im Neuenheimer Feld 280, 69120 Heidelberg,
Germany;
2Department of Human Molecular Genetics and
Biochemistry, Sackler School of Medicine, Tel Aviv
University, Tel Aviv, Israel
Differential 16O/18O proteolytic labeling (1) is a versatile
method in analytical proteomics for relative quantitification of
two samples. The latest version of MASCOT contains a tool
for relative quantification within pairs of 16O/18O labeled
peptides (2). Experimental and procedural parameters for LCMS/MS analysis were set-up, which allowed an accurate
quantification using this tool. This is demonstrated using
standard peptide mixtures and ovalbumin digest mixtures. The
method was then for the first time applied to quantitative
proteomic analyses in a complex sample. Quantitative changes
in the mouse phosphoproteome induced by irradiation-induced
DNA damage before and after treatment with a dose of 10 Gy
were investigated.
For this purpose, mouse brain proteome samples were
prepared and digested with trypsin, using 16O water for the
treated sample and 18O water for the control sample. After
combination of a pair of samples, fractionation of the complex
peptide mixture by mixed-bed ion-exchange chromatography
was performed. Each fraction was subjected to
phosphopeptide enrichment by IMAC and both the flowthrough fractions and the phosphopeptide fractions were
analyzed separately by nanoUPLC-MS/MS. For the
quantitative analysis, all data were combined into a single file
and analyzed by MASCOT. As a result, 342 proteins were
identified. In the analysis of phosphorylation sites, 174
phosphopeptides were identified, of which 24 were up- or
down-regulated by more than a factor of 2.
3373
ANTICANCER RESEARCH 28: 3157-3556 (2008)
Several up-regulated phosphorylation sites observed stem
from proteins known to be involved in signaling cascades or
DNA-binding. These include ERK, MAP tau, MAP 2, MAP
kinase-activating death domain, p130Cas-associated protein,
R3H domain containing protein, etc. The results are discussed
in relation to the involvment of known signaling cascades in
the response to radiation induced DNA damage. It is
concluded, that the 16O/18O method is suitable for monitoring
quantitative changes in the phosphoproteome of complex
protein samples.
1 Schnolzer M, Jedrzejewski P and Lehmann WD: Proteasecatalyzed incorporation of O-18 into peptide fragments and
its application for protein sequencing by electrospray and
matrix-assisted
laser
desorption/ionization
mass
spectrometry. Electrophoresis 17: 945-953, 1996.
2 Zhang GA and Neubert TA: Automated comparative
proteomics based on multiplex tandem mass spectrometry
and stable isotope labeling. Mol. Cell. Proteomics 5: 401411, 2006.
394
ALTERATION OF CHEMOTHERAPEUTIC EFFECT
OF ANTICANCER AGENTS LINKED TO HYPOXIA
OF MDR AND NON-MDR LOVO COLON
CARCINOMA CELLS
Isabelle Lelong-Rebel1, Erwan Pencreach2, Gérard Rebel1
and Jean-Pierre Bergerat1
1UPRES
EA 3430-ULP/CNRS – IRCAD - Hôpital Civil, BP
426, F-67091 Strasbourg;
2INSERM U682, 3 avenue Molière, F-67200 Strasbourg
France
Culture of cancer cells is widely used for testing
antiproliferative drug response in cancer research. Cell
resistance against antineoplastic agents often results from
mobilization of various factors, the modulation of which is
linked to the culture conditions. Most of the protocols utilize
cells growing in [air+5-10%CO2] atmosphere thus achieving
a 19-20%O2 level. Under these conditions, cells are growing in
hyperoxic environment, as the highest physiological partial
oxygen pressure (pO2) found in mammals is 16% (e.g. blood
from hepatocyte artery). Most of the cells within solid tumors
are exposed to a low pO2, this hypoxic condition (e.g. 0.15%O2) being linked to their location within the tumor, the
tumor compaction, and the presence or absence of
lymphovascular tumor emboli. This low pO2 affects notably
cell physiology, the level of ROS generated and the cell
growth in response to various drugs.
In this study we addressed the variation of the
pharmacological response of MDR and non-MDR variants of
LoVo colon carcinoma grown either in hypoxia (5%O2) or in
standard conditions (20%O2), using a multigas incubator. We
3374
have tested the effect of pO2 on the cytotoxicity of
doxorubicin, cisplatin, 5-FU and combinations. Drugs were
continuously present and proliferation was monitored every 3
day during 9 days. In the absence of drugs, all LoVo variants
grew notably faster at 20%O2 than at 5%O2 [3X for MDR, 2X
for non-MDR]. Moreover, respective sensitivities of both
variants to doxorubicin and cisplatin were lowered by about
20% at 5%O2 compared to 20%O2. Non-MDR and MDR cells
that were never exposed to the drug, showed a relative high
resistance to 5-FU (IC50: 0.36 μM; 0.55 μM, respectively) that
was not affected by pO2.
Our results underline the importance of evaluating the role
of hypoxia on the cytotoxic effect of chemotherapeutic agents
and on the proliferative status of cells. These data will be
discussed taking into account the drug metabolism with
respect to environmental oxygen pressure and cell culture
conditions.
395
SPATIAL REDISTRIBUTION OF P-GLYCOPROTEIN
LINKED TO ESTRADIOL TREATMENT IN
ENDOMETRIAL AND PROSTATIC CANCER CELLS
Isabelle Lelong-Rebel, Gérard Rebel and
Jean-Pierre Bergerat
UPRES EA3430-ULP/CNRS-IRCAD Hôpital Civil, BP 426,
F-67091 Strasbourg, France
Chemoresistance in oncology refers to complex and
multifactorial process involving various cellular pathways.
One of the most studied causes of multidrug resistance (MDR)
is related to various ABC transporters being capable of
overcoming cytotoxic xenobiotics e.g. anticancer agents
aggression of the cells by mean of active efflux. Among these,
P-glycoprotein (Pgp, ABCB1) is often representative of
individual cell resistance particularly when overexpressed in
the plasma membrane of multidrug resistant cancer cells.
Although this pericellular location is related to “standard”
MDR phenotype, intracellular location of such transporter(s)
in numerous non-MDR tumor cells has also been described.
It was hypothesized that this peculiar location could be in
relation either with a primary defense mechanism e.g.
involving cytosolic “scavenging” of the drugs or would be
related to another physiological pathway, to date unknown.
Being interested in MDR phenotype emergence in hormonedependent cells, apart from cytotoxic drug challenge and
selection, endometrial cell lines from our laboratory were
screened for presence of P-glycoprotein in conjunction with
estradiol treatment. Variants of Ishikawa endometrial
carcinoma cell lines with differential panel of sensitivity
towards 17-beta-estradiol (E2) and towards tamoxifen were
studied. As E2 plays an important role in male physiology via
the androgen receptor (AR), the prostatic LNCaP cell line was
Abstracts of the 8th International Conference of Anticancer Research, 17-22 October 2008, Kos, Greece
also used in this study. All cell lines showed cytosolic location
of P-glycoprotein in the absence of E2. Estrogen receptor (ER)
was detected in all endometrial cell lines and underwent
cytosol to nuclear location upon E2 treatment of the cells. ER
was present in LNCaP cells as well. By far more intriguing
was the overall spatial tissue redistribution of Pgp from a
patchy-like to an islet-like pattern when Ishikawa monolayers
were treated with E2. Emerging evidence exists to suggest that
some of the pivotal cancer-related biological events depend on
multicellular interactions between cell sub-populations that are
subjected to inter-connective pathways via environmental
stimulations.
found that PDGF induces a rapid proteasomal degradation of
MKP3, which is necessary for Erk1/2 activation to occur.
Moreover, prolonged PDGF stimulation induces expression of
the mkp3 gene and subsequent increase in MKP3 protein level.
The re-synthesis of MKP3 plays an important role in reducing
Erk1/2 signaling at a later stage. Thus, MKP3 has a central
role in two phases of signal transduction: first a rapid feedforward mechanism and second a later feed-back loop.
Furthermore, we have data suggesting that activation of Erk5
and Erk1/2 in response to PDGF negatively regulate each
other in a reciprocal manner, providing an additional level of
MAP kinase activity regulation.
396
SIGNAL TRANSDUCTION AND MODULATION OF
RADIOSENSITIVITY
398
BEDSIDE TO BENCH: PROFILING
BIOLOGICALLY BASED CAM PRODUCTS
IN MALIGNANCY USING THE HERBAL
COMPOUND ESSIAC AS A CASE STUDY
Johan Lennartsson
Ludwig Institute for Cancer Research, Uppsala University,
SE-751 24 Uppsala, Sweden
Blair J.N. Leonard
McMaster University, Hamilton, Canada
The emerging connections between growth factor-induced
signal transduction and the DNA repair machinery will be
described, stressing implications for radiotherapy.
Furthermore, the prospect of developing targeting agents,
which selectively deliver radioactivity to the tumor and at the
same time radiosensitize tumor cells will be discussed. In
addition, the possibility of increasing radiosensitivity by the
use of low molecular weight compounds will be addressed.
397
REGULATION OF MAP KINASE SIGNALING IN
RESPONSE TO PDGF STIMULATION
Aleksandra Jurek, Carl-Henrik Heldin and Johan
Lennartsson
Ludwig Institute for Cancer Research, Uppsala University,
Sweden
The MAP kinase family is evolutionary conserved and
mammalian cells contain several MAP kinase pathways, e.g.
Erk1/2, p38, Jnk and Erk5. Several biological responses are
controlled by MAP kinase activity and both the magnitude and
kinetics of activation encode information for the cell on how to
respond to the stimulus. A large fraction of human tumor cells
have augmented MAP kinase activity, emphasizing the
importance of these pathways in the development of cancer.
Improper MAP kinase signaling can be caused by oncogenic
activation of an upstream component such as Ras or loss of a
negative regulator. This presentation will discuss the
importance of the negative regulator MAP kinase phosphatase
3 in proper Erk1/2 activation in response to PDGF, as well as
cross-talk between the Erk1/2 and Erk5 cascades. We have
The use of biologically based complementary alternative
therapies (CAM) in patients with malignancy is a well
documented phenomenon of international scale, with different
studies estimating use in 20-80% of cancer patients depending
on the studied population. Biologically based CAM use in
malignancy is not benign, with several in vitro and clinical
studies documenting adverse interactions between common
CAM therapies and conventional chemotherapeutic treatments.
Despite widespread use and the establishment of evidencebased practice guidelines in oncology that call for further
research into these therapies, many commonly used therapies
remain largely unstudied.
An archetypal example of such pharmacological therapy is
Essiac tea, a proprietary mixture of four herbal compounds
that has been available without restriction for use in cancer
patients for over 80 years. Several recent large studies of CAM
use in oncology patients have confirmed Essiac as a popular
choice, including documenting its concomitant use during both
conventional radiation and chemotherapeutic management of
malignancy. Despite this, rational and rigorous approaches
adopting the scientific method to understand the
pharmacological, as well as the pathophysiological properties
of Essiac are lacking in the peer reviewed medical literature.
This presentation will outline the body of peer reviewed
basic research involving Essiac that is currently available.
Specific attention will be placed on the recent in vivo and in
vitro series of experiments that investigated several alleged
medicinal qualities of Essiac, as well as the potential for a
harmful side-effect profile. Data derived from these
investigations and others have identified pharmacological
characteristics of Essiac that make it of interest for further
3375
ANTICANCER RESEARCH 28: 3157-3556 (2008)
investigation: data that is freely available for access and
appraisal by health care practitioners and their patients for
informed choice. This last point underscores the overriding
theme of the presentation, as previous studies identified that
patients derive much knowledge on which they base decisions
about their CAM-related health care on unreliable, non-peer
reviewed sources.
399
A TWENTY YEAR JOURNEY TO
UNDERSTANDING AND TREATMENT
OF THE CHRONIC FATIGUE SYNDROME
INCLUDING A LONGITUDINAL STUDY
OF GROUPS A AND B CFS PATIENTS, 2000-2006
A. Martin Lerner
32804 Pierce St, Beverly Hills, MI 48025 USA
The Energy Index point score (EI), (copyright, Lerner AM and
Deeter RG, 1999), (0-10) is a simple reliable metric easily
evaluating the functional capacity at each CFS patientphysician visit. A hanging sign in the examining room, with
physician and patient together, is used. Validation of the EI was
carried out using two methods: a) 20 CFS patients and 22
healthy adults, matched for sex, age, place and time; EI,
CFS=3.6; EI, healthy adults=9.9, p≤0.0001, and b) 55 CFS
patients evaluated at the same time by the EI and Fatigue
Severity Score, correlation 0.67, p=0.0066. Improvement to
disappearance of CFS symptoms correlate with an increasing
EI.
The validated Energy Index (EI) point score (1-10) was
calculated for each CFS patient every 3 months at physician
visits. A CFS patient has an EI≤5. A CFS patient with an EI of
0 is bedridden; a CFS diagnosis is no longer present at an
EI>5. The EI effect size is 0.25, a medium effect size is 0.5. A
large effect size is >0.8. Administrations of antiviral drugs
were given within a defined pharmacokinetic therapeutic
window.
Eighteen CFS patients with elevated serum IgG serum
antibody titers to cytomegalovirus (HCMV) were treated with
intravenous ganciclovir 5 mg/kg q 12 h for 30 days. At
evaluations, 24 weeks later, 13 patients (72%) returned to their
premorbid healthy states (Infectious Diseases in Clinical
Practice, 6: 110-117, 1997). In a second study, 25 CFS
patients with elevated serum antibody titers to Epstein-Barr
virus (EBV), early antigen (Diffuse) and/or EBV, viral capsid
antigen (VCA, IgM) were treated with valacyclovir (14.6
mg/kg po q 6 h) for 6 months. This valacyclovir dose achieved
serum acyclovir Cmax>7 μm and high antiviral activity versus
EBV (ID50, 4.4-13.3 μm), but no antiviral activity versus
HCMV. The CFS patients EI functional capacity as well as
EBV and HCMV serum antibody titers were again assessed
after 1, 3 and 6 months of valacyclovir. We concluded that the
3376
16 CFS patients with EBV persistent infection (EBV singlevirus subset) improved after 6 months, but 9 CFS patients with
elevated serum antibody titers to “both” EBV and HCMV did
not benefit from valacyclovir (Drugs of Today, 38: 549-561,
2002). With this guidance, a randomized double blinded
controlled 6 month study of EBV subset single virus (no
HCMV serum antibody) showed an EI rise after 6 months of
+1.12 units (122 kcal/day), in the valacyclovir group while the
placebo group improved +0.42 units (65 kcal/day), In Vivo 21:
707-714, 2007.
The current inclusive CFS data (May 1, 2001-December 31,
2007) regardless of duration of CFS illness from this treatment
center of 201 CFS patients include 5,700 visits and 44,000
fields of information which reveal demographic and
epidemiologic data, 156 (77.6%) female; 45 (22.4%) male.
The mean age of CFS patients is 45.2 years, BMI 26.4 Kg/m2.
These 201 CFS patients are two distinct groups with similar
demographics; (A) CFS Herpesvirus Illness (EBV, HHV6,
HCMV) with no co-infections, and Group (B) CFS
Herpesvirus Illness (EBV, HCMV, HHV6) “with” mimicking,
co-infections, both A group and B group meeting international
criteria for diagnosis of CFS. (Fukuda, Ann Intern Med, 121:
953-959, 1994). The major co-infections of Group B are Lyme
disease, babesiosis, adult rheumatic fever.
The subsequent data here are those of CFS Group A who
were ill an average of 5.2 years before receiving antiviral
therapy. Data for CFS Group B are not included. There were
138 group A CFS patients, 104 females (75.4%) and 34 males
(24.6%). The mean age was 46.4 years, BMI 26.7 Kg/m2.
Patients were further identified by the presence of elevated
serum antibody titers to EBV, HCMV, or HHV6. CFS patients
(>95%) had abnormal oscillating flat or inverted T-waves at
24 hr ECG monitor and abnormal cardiac wall motion at rest
(11.5%) and stress (24.1%). Cardiac biopsies from CFS
patients seen in 1997 showed a non-inflammatory
cardiomyopathy with myofiber disarray, myofiber drop out,
apoptosis, and cardiac replacement fibrosis.
Among the 138 Group A herpesvirus CFS patients there
were single virus infections, EBV patients (27.5%); HCMV
(13.8%); and HHV6 (1.4%). However, more commonly, each
CFS patient was infected with several herpesviruses
simultaneously: 79 patients with multiple herpesvirus
infections (57.2%). There were EBV/HCMV co-infections
(28.3%); EBV/HHV6 co-infections (10.9%); HCMV/HHV6
co-infections (5.1%); and EBV/HCMV/HHV6 co-infections
(13.0%). Specific long-term pharmacokinetic therapy was
administered to each patient until the EI point score reached
8, at which time, antiviral medicines were tapered, stopped, or
continued, as appropriate with no change in the EI point
score. The EI point score at 3 month intervals for the 6 years
of the study was recorded. There were a mean of 46 EI
patients at each 3 month time interval and 25 time intervals
over the 6 year longitudinal study. The mean EI for the 138
Abstracts of the 8th International Conference of Anticancer Research, 17-22 October 2008, Kos, Greece
CFS patients at baseline was 4.5. The mean final EI point
score was 6.0, an increase of 1.5 EI units and, therefore, a
large EI effect size change (Spearman’s p nonparametric
correlation test, Spearman’s p=0.562, p=0.0019). These data
indicate
that
specific
long-term
anti-herpesvirus
pharmacokinetic
administration
of
valacyclovir/
valganciclovir provides long-term significant benefit to Group
A CFS patients. There was no toxicity to this long-term
antiviral therapy as given. For the evidence-based physician
requiring placebo controlled double blinded trials for
veritude, without recognition of the differences between
Group A and Group B CFS patients, as defined here, it is
likely that the evidence based trial may have falsely yielded
“no benefit” from the antiviral therapy.
400
CANCER AND INFLAMMATION:
NEW INSIGHTS TO THE ROLE OF
NF-KAPPAB AND COX-2 IN CARCINOGENESIS
Shahar Lev-Ari
Tel-Aviv Sourasky Medical Center, affiliated to the Sackler
Faculty of Medicine, Tel-Aviv University, Tel Aviv, Israel
Cumulative experimental and epidemiologic evidence
indicates that nuclear factor kappaB (NF-κB), a proinflammatory transcription factor, plays a significant role in
carcinogenesis.
Activation of NF-κB was shown to regulate the synthesis
of cyclooxygenase-2 (COX-2), as well as other signaling
pathways which enhance tumor cell proliferation,
angiogenesis, invasiveness and resistance to apoptosis-based
tumor surveillance mechanisms and chemo-radiation therapies.
Research aimed at developing chemical and natural
inhibitors that block NF-κB activation is currently flourishing.
Several non-steroidal anti-inflammatory drugs (NSAID) and
natural compounds, such as Aspirin and curcumin, have shown
to inhibit NF-κB activity. Other agents targeting the IKK, and
other upstream kinases involved in NF-κB activation such as
bortezomib (Millennium Pharmaceuticals) and PS-1145
(Bristol-Myers) are under development. Several of these
agents have shown anticancer activity in clinical or preclinical
studies with acceptable safety profiles. Recent research has
demonstrated that concurrent inhibition of NF-κB may
increase chemo-radiotherapy efficacy. This could lead to novel
therapeutic modalities in cancer therapy.
401
IN VITRO AND IN VIVO EVALUATION
OF [64CU-NOTA-8-AOC-BBN(7-14)NH2]
RADIOPHARMACEUTICAL FOR
PET IMAGING OF HUMAN BREAST
AND PROSTATE CANCER TUMORS
Michael R. Lewis, Adam F. Prasanphanich,
Lauren Retzloff, Stephanie R. Lane, Prasant K. Nanda,
Gary L. Sieckman, Tammy L. Rold, Lixin Ma,
Said D. Figueroa, Samantha V. Sublett,
Timothy J. Hoffman and Charles J. Smith
The Radiopharmaceutical Sciences Institute, University of
Missouri School of Medicine, Columbia, Missouri, 65211,
USA
Introduction: Human prostate and breast cancers are known
to express the gastrin-releasing peptide receptor (GRPr) in
very high numbers. In this study, a derivative of bombesin
(BBN) peptide, an agonist for the GRPr, has been
complexed with Cu-64 radionuclide, making the conjugate
a potential candidate for positron-emission tomography
(PET) imaging and therapy of these human cancers. 64CuNOTA-8-Aoc-BBN(7-14)NH 2 produced high-quality
microPET images of GRPR-positive tumors in severely
compromised immunodeficient (SCID) mice. Methods:
Briefly, the unmetallated conjugate was synthesized by
solid-phase peptide synthesis followed by manual
conjugation of NOTA (1,4,7-triazacyclononane-1,4,7triacetic acid) bifunctional chelating agent. Radiolabeling
with Cu-64 radionuclide was performed in buffered,
aqueous solution (pH=7-7.5). The radiolabeled conjugate
was assayed in vitro and in vivo T-47D (human breast) and
PC-3 (human prostate) cell lines in order to determine its
specificity and selectivity for the GRPr and its
corresponding pharmacokinetic profile. In vivo, multimodal,
molecular imaging via microPET/CT and microMRI was
performed in tumor-bearing mice models bearing
xenografted tumors. Results: The 64Cu-NOTA-8-AocBBN(7-14)NH 2 targeting vector was determined to
specifically localize in GRPr-positive tissues. Accumulation
of radioactivity was observed in the tumor in sufficient
quantities to allow for identification of tumors in microPET
imaging procedures. Uptake and retention of conjugate in
T-47D xenografted tumors was determined to be
2.27±0.08%, 1.35±0.14%, and 0.28±0.07% ID/g (Percent
Injected Dose Per Gram Tissue) at 1, 4, and 24 h. Uptake
and retention of conjugate in PC-3 xenografted tumors was
determined to be 3.58±0.70%, 1.64±0.17%, and
1.00±0.19% ID/g at 1, 4, and 24 h, respectively.
Conclusion: The 64Cu-NOTA-8-Aoc-BBN(7-14)NH 2
produced high quality microPET images. The
pharmacokinetic profile of this conjugate justifies further
preclinical evaluation of this new radiopharmaceutical as a
potentially-useful diagnostic agent. Additionally, this new
radiopharmaceutical serves as a good reference for
modification and optimization of similar agents to
maximize tumor uptake and minimize non-target
accumulation of radioactivity in collateral tissues.
3377
ANTICANCER RESEARCH 28: 3157-3556 (2008)
402
RADIOPHARMACEUTICAL IMAGING
AND THERAPY TARGETING THE
BCL-2 ONCOGENE IN B-CELL LYMPHOMA
403
CHARACTERIZATION OF BRIT1/MCPH1’S
FUNCTION IN DNA DAMAGE RESPONSES USING A
KNOCKOUT MOUSE MODEL
Michael R. Lewis1, Fang Jia2, Ethan R. Balkin2,
Said Daibes Figueroa1, Baghavathy S. Balaji2,
Fabio Gallazzi3, Kimberly A. Statham2
and Timothy J. Hoffman1
Yulong Liang, Hong Gao, Shiaw-Yih Lin, Pumin Zhang,
Asha S. Multani, Sandy Chang, John A. Goss,
Francis C. Brunicardi and Kaiyi Li
1Research,
Harry S Truman Memorial Veterans’ Hospital,
Columbia, MO;
2Veterinary Medicine and Surgery, 3Molecular Biology,
University of Missouri, Columbia, MO, USA
Introduction: The B-cell lymphoma/leukemia-2 (bcl-2)
oncogene is a dominant inhibitor of apoptosis, correlating
with resistance to radiation and chemotherapy, high relapse
rate, and poor survival in non-Hodgkin’s B-cell lymphoma
(NHL). NHL also expresses type 2 somatostatin receptors
(SSTR2) in 87% of cases, making it attractive for delivery
of intracellular tumor-targeting agents. Methods: A bcl-2
antisense peptide nucleic acid (PNA) conjugated to a
SSTR2-targeting peptide, anti-bcl-2-Tyr3-octreotate, was
evaluated for 111In gamma scintigraphy and single photon
emission computed tomography (SPECT), 64Cu positron
emission tomography (PET), and 177Lu targeted radiotherapy
(TRT) in NHL cells in culture, mouse models of human
NHL, and dogs with spontaneously occurring NHL. SCID
mice bearing bcl-2 mRNA-positive Mec-1 (n=3) or bcl-2
mRNA-negative Ramos (n=3) xenografts were used for 111In
microSPECT or 64Cu microPET imaging. The 111In conjugate
was also used for gamma scintigraphy of canine NHL
patients (n=15). The 177Lu conjugate was evaluated in vitro
for TRT in Mec-1 cells (n=3). Results: Incubation of Mec-1
cells with anti-bcl-2-Tyr3-octreotate showed a 51% decrease
in bcl-2 protein synthesis, suggesting that the target mRNA
function had been perturbed by a specific antisense effect.
Both 111In microSPECT and 64Cu microPET could detect
Mec-1 tumors, but not Ramos tumors, in SCID mice
(p<0.05). Gamma scintigraphy demonstrated the utility of
the 111In conjugate for molecular staging of bcl-2 in canine
NHL. In vitro Mec-1 cell studies showed that the 177Lu
conjugate had at least an additive effect on cell viability,
compared to controls for targeted radioactivity and bcl-2
antisense activity. Conclusion: 1) Imaging studies
demonstrated that 111In- and 64Cu-anti-bcl-2-Tyr3-octreotate
were specific for bcl-2 mRNA-positive NHL xenografts. 2)
Imaging of canine NHL established bcl-2 expression as a
clinical and molecular model relevant to human disease. 3)
TRT studies of the 177Lu conjugate in Mec-1 cells
demonstrated down-regulation of bcl-2 with radiation insult,
creating a NHL therapy agent acting through two targeted
anti-tumor mechanisms.
3378
Department of Surgery, Baylor College of Medicine,
Houston, TX, 77030, USA
The DNA damage-response pathway is essential for the
maintenance of genomic stability; as a result, it acts as the
barrier for tumorigenesis. Previous studies in cell culture
demonstrated that Brit1 played critical roles in checkpoint
control and DNA damage response. Aberrant expression of
Brit1 was also identified in several types of human cancers.
To address the physiological functions of Brit1 and the effect
of its deficiency on tumorigenesis, we recently generated a
Brit1 knockout (Brit1–/–) mouse model and analyzed its in vivo
function. We found that Brit1–/– mice can survive to adulthood
but with growth retardation and low birth rate. Both Brit1–/–
male and female mice were infertile with much smaller testes
or ovaries. When analyzing Brit1–/– testes, we found that there
were no spermatids and much fewer spermatocytes with
meiosis dysregulation. Consistently, Brit1–/– spermatocytes
exhibited DNA repair defects including reduced Rad51 and
gamma-H2AX foci formation. In addition, both Brit1defecient mice and MEFs (Mouse Embryonic Fibroblasts)
were hypersensitive to gamma-irradiation. MEFs and T
lymphocytes with Brit1–/– genotypes also exhibited severe
chromosome aberrations. Notably, we found that, in contrast to
their wild-type or heterozygote littermates, 45% of Brit1–/–
mice with age one to two years old developed ovarian tumors.
Moreover, tumor incidence in Brit1–/–p53–/– double null mice
is significant earlier than those in Brit1+/+p53–/–, indicating that
loss of Brit1 enhances cancer susceptibility of p53 null mice.
Together, the generation of Brit1 knockout mice provides
convincing evidence that Brit1 is crucial for maintaining
genomic stability in vivo to protect the hosts from both
programmed and irradiation-induced DNA damages. In
addition, our studies provide genetic validation of Brit1’s role
as a novel tumor suppressor gene.
404
RECOMBINANT LEPTIN ADMINISTRATION
IMPROVES EARLY ANGIOGENESIS IN FULLTHICKNESS SKIN FLAPS: AN EXPERIMENTAL
STUDY
I.E. Liapakis1, S. Anagnostoulis2, A.J. Karayiannakis2, D.P.
Korkolis3, M. Lambropoulou4, B.C. Golematis5 and C.E.
Simopoulos2
Abstracts of the 8th International Conference of Anticancer Research, 17-22 October 2008, Kos, Greece
1Department
of Plastic and Reconstructive Surgery,
University of Ghent, Ghent, Belgium;
22d Department of Surgery and 4Department of Pathology,
Medical School, Democritus University of Thrace,
Alexandroupolis;
31st Department of Surgical Oncology, Hellenic Anticancer
Institute, Aghios Savvas Hospital, Athens;
51st Department of Propaedeutic Surgery, Hippokration
Hospital, University of Athens, Greece
Background: Leptin is a potent direct angiogenic factor that
stimulates endothelial cell migration and activation in vitro,
and angiogenesis in vivo. In addition, leptin seems to play an
important role in angiogenesis as it promotes the formation of
new blood vessels. Objective: To determine the effect of local
application of exogenous leptin on the survival of full
thickness skin flaps in an experimental animal model.
Materials and Methods: Ninety Sprague-Dawley rats were
used. A full thickness dorsal flap (10 cm × 2 cm) with the
pedicle located at the level of the iliac crest was designed.
Animals were divided into ten groups of nine animals each.
In the distal two thirds of the flap and by means of subdermal
injection at 8 different locations, rats were injected with 100
ng/ml leptin, 250 ng/ml leptin, 500 ng/ml leptin, 1000 ng/ml
leptin (groups A, B, C and D), 1 μg/ml VEGF (group E), or
1ml saline (control group), respectively. For each of the four
leptin doses used, another animal group was injected with a
combination of leptin/antileptin: 100 ng/ml leptin with 150
ng/ml antileptin, 250 ng/ml leptin with 375 ng/ml antileptin,
500 ng/ml leptin with 750 ng/ml antileptin or 1000 ng/ml
leptin with 1500 ng/ml antileptin (groups A1, B1, C1 and D1,
respectively), in order to study the inhibition of the leptin
factor. Nine rats served as controls and were injected with 1
ml saline solution. Rats were sacrificed 3, 7 and 9 days
postoperatively. After sacrifice of the animals, the skin was
grossly arranged on its appearance, color and texture. Full
thickness skin flaps were dissected for histological
examination. A qualitative analysis of angiogenesis in the flap
was conducted following a standard hematoxylin and eosin
stain. The wound tissue samples from each experimental
group underwent immunohistochemical evaluation of
microvessel density by endothelial cell staining with mouse
anti-rat
CD34
monoclonal
antibody.
Results:
Immunohistochemical staining revealed that more granulation
tissue and improved angiogenesis were observed in group D
(1000 ng/ml leptin) flaps compared to those in the VEGF,
leptin/antileptin and saline groups. In addition, skin flap
survival rate in group D (1000 ng/ml leptin) and group E (1
μg/ml VEGF) were significantly better than those of the other
groups. The most impressive formation of new blood vessels
was noted in the groups with the higher leptin doses. Surgical
wounds in the control, as well as in the leptin/antileptin
groups, did not demonstrate any new vessels. Conclusion:
Exogenous administration of recombinant leptin increases
early skin flap angiogenesis in an experimental animal model.
Local application of leptin could efficiently improve survival
of ischemic skin flaps.
Dr Liapakis has a scholarship from “The Hellenic Anticancer
Institute”.
405
TAMOXIFEN. PHARMACOGENOMICS, DRUG
INTERACTIONS, AND THERAPEUTIC DRUG
MONITORING
Ernst A. Lien
Hormone Laboratory, Haukeland University Hospital, 5021
Bergen, Norway
Tamoxifen is regarded as a pro-drug as two of its metabolites,
4-hydroxytamoxifen and 4-hydroxy-N-demethyltamoxifen
(endoxifen), have a higher affinity for the estrogen receptor
than tamoxifen itself. 4-Hydroxy-N-demethyltamoxifen is
considered the predominant active metabolite of tamoxifen
because its pharmacological potency is equivalent to that of 4hydroxytamoxifen and its concentration in blood and tissues
is several fold that of 4-hydroxytamoxifen. Tamoxifen
metabolism shows considerable inter-individual variation in
normal dose as well as low-dose regimens.
The bioconversion of tamoxifen involves N-oxidation, Ndemethylation and hydroxylation. The N-oxidation of tam is
primarily catalyzed by a flavin-containing monooxygenase.
Tamoxifen N-demethylation to N-demethyltamoxifen and Ndedimethyltamoxifen is catalyzed predominantly by the
inducible cytochrome P450 (CYP) 3A4. CYP2D6
hydroxylates tamoxifen and N-demethyltamoxifen to the
clinically potent metabolites 4-hydroxytamoxifen and 4hydroxy-N-demethyltamoxifen. Furthermore, 4-hydroxy-Ndemethyltamoxifen and 4-hydroxytamoxifen are conjugated
and inactivated by the polymorphically distributed UDPglucuronosyltransferase 2B15 and the sulfotransferase 1A1.
CYP2D6 activity is highly polymorphically distributed in
the population due to inherited mutations in the CYP2D6 gene.
The poor metabolizer phenotype carries a combination of two
non-functional variant alleles, which results in lack of
CYP2D6 activity in the liver. In contrast, the ultrarapid
metabolizer phenotype is associated with an inherited
duplication of the CYP2D6 gene that may increase enzymatic
activity. Although CYP2D6 is the major contributor to the
hydroxylation process of tamoxifen, in vitro studies using
recombinant human CYPs have indicated an additional
contribution by the enzymes CYP2B6, CYP2C9, CYP2C19
and CYP3A4. While the results vary, multiple studies from
different groups have found an association between nonfunctional CYP2D6 alleles and poor outcome among
individuals treated with tamoxifen.
3379
ANTICANCER RESEARCH 28: 3157-3556 (2008)
The observed major interindividual variation in the serum
levels of tamoxifen during steady state treatment has several
causes. Breast cancer patients often use drugs that interact
with CYP2D6 and the inducible CYP3A4. Furthermore, a low
willingness of breast cancer patients to participate in clinical
studies with tamoxifen has been observed. Moreover, the
pharmacokinetics of tamoxifen varies by age.
The tissue levels of tamoxifen and its metabolites are
related to their levels in serum. Accordingly, therapeutic
effects as well as side-effects of the drug may be related to its
serum levels. We therefore propose the inclusion of therapeutic
drug monitoring in clinical tamoxifen studies.
406
TUMORIGENICITY AND ANGIOGENESIS
OF PANCREATIC CANCER ARE
INHIBITED IN FAT1 (ω-3 DESATURASE)
TRANSGENIC MICE
Kyoung-Sub Song1, Eun-Jin Yun1, Hae-Duck Park3,
Jong-Seok Kim1, Jun-Young Heo1, Yeon-Joo Jung1,
Chang Han4, Tong Wu4, Jing X. Kang5, Jong-Il Park1,
Gi-Ryang Kweon1, Wan-Hee Yoon1,
Byung-Doo Hwang1,2 and Kyu Lim1,2
1Department
of Biochemistry, College of Medicine;
Research Institute, Chungnam National University,
Daejeon, Korea;
3Dr. Park’s Breast Clinic, Daejeon, Korea;
4Department of Pathology, University of Pittsburgh, School
of Medicine, Pittsburgh, PA15213, USA;
5Department of Medicine, Massachusetts General Hospital
and Harvard medical School, Boston, MA 02114, USA
2Cancer
ω3-Polyunsaturated fatty acids (ω3-PUFAs) including
docosahexaenoic acid (DHA) are known to inhibit cell growth
through apoptosis in various types of cancer cells. However,
the mechanism of ω3-PUFA-induced cell death is still unclear.
In this study, we have investigated inhibition of tumorigenicity
and angiogenesis of ω3-PUFAs on pancreatic cancer in Fat1
transgenic mice (Fat1 transgenic mice express a
Caenorhabditis elegans ω3 desaturase, converting ω6- to ω3PUFAs endogenously).
Treatment of cells with two ω3-PUFAs, DHA and
eicosapentaenoic acid (EPA), significantly and dosedependently induced inhibition of cell growth and increased
sub-G1 population in SW1990 and PANC-1 cells. The effect
of ω3-PUFAs was due to induction of apoptosis, given that
DHA induced cleavage of PARP and caspase-3 activity; in
contrast, arachidonic acid (AA) had no effect. Moreover,
DHA treatment reduced the level of β-catenin in SW1990
and PANC-1 cells. DHA also induced the association of βcatenin/Axin/GSK-3β complex, which serves as a parallel
mechanism for β-catenin degradation. Increased nuclear
3380
staining for β-catenin was observed in tumor tissues
prepared from human pancreatic cancer patients when
compared with the non-tumor pancreatic tissues. In
immunocytochemical stain of β-catenin, the cytosolic and
nuclear β-catenin expression was reduced in the DHAtreated SW1990 cells as compared to control cells. The
TCF/LEF reporter activity, a β-catenin-controlled
downstream signal, was also reduced by DHA treatment.
DHA also inhibited Cox-2 reporter activity in a dosedependent manner. When mouse pancreatic cancer PANC02 cells were implanted into Fat1 mice and wild-type mice,
respectively, tumor size and volume of Fat1 transgenic mice
was dramatically reduced as compared with wild mice. In
immunohistochemical analysis of tumors of Fat1 mice,
apoptosis was markedly increased and angiogenesis was
significantly reduced as compared with wild-type mice
tumors. Neoangiogenesis in Matrigel was dramatically
inhibited in Fat1 mice compared to wild mice.
These findings suggest that ω3-PUFAs induce apoptotic cell
death through the Cox-2 and β-catenin/wnt signaling pathway
in human pancreatic cancer cells. Furthermore, They also
provide evidence that ω3-PUFAs may inhibit tumorigenicity
and angiogenesis of pancreatic cancer in the Fat1 transgenic
mice model. Therefore, utilization of ω3-PUFAs may
represent a potential effective therapy for the chemoprevention
and treatment of human pancreatic cancer. This work was
supported by Yihang Scholarship Foundation of Chungnam
National University Medical School, and Dr. Park’s Breast
Clinic, Korea.
407
OMEGA-3 POLYUNSATURATED FATTY ACIDS
SUPPRESS CELL INVASION AND ANGIOGENESIS
BY INHIBITION OF MMPs/COX-2/
VEGF THROUGH NF-κB AND
AP-1 SIGNAL IN BREAST CANCER
Eun-Jin Yun1, Kyoung-Sub Song1, Hae-Duck Park3,
Jong-Seok Kim1, Jun-Young Heo1, Yeon-Joo Jung1,
Chang Han4, Tong Wu4, Jing X. Kang5, Jong-Il Park1,
Gi-Ryang Kweon1, Wan-Hee Yoon1,
Byung-Doo Hwang1,2 and Kyu Lim1,2
1Department
of Biochemistry, College of Medicine;
Research Institute, Chungnam National University,
Daejeon, Korea;
3Dr. Park’s Breast Clinic, Daejeon, Korea;
4Department of Pathology, University of Pittsburgh, School
of Medicine, Pittsburgh, PA15213, USA;
5Department of Medicine, Massachusetts General Hospital
and Harvard medical School, Boston, MA 02114, USA
2Cancer
Omega-3 polyunsaturated fatty acids (ω3-PUFAs) are known
to inhibit cancer cells proliferation in animal models and cell
Abstracts of the 8th International Conference of Anticancer Research, 17-22 October 2008, Kos, Greece
lines. In contrast, ω6-PUFAs promote the growth of cancer
cells. However, the molecular mechanisms remain to be
elucidated. This study was designed to investigate action
mechanisms of ω3-PUFAs, especially docosahexaenoic acid
(DHA), on inhibition of invasion and angiogenesis in breast
cancer.
Treatment of human breast cells (MDA-MB-231, T47)
with two ω 3-PUFAs, docosahexaenoic acid (DHA) and
eicosapentaenoic acid (EPA), for 12-48 hours resulted in a
dose- and time-dependent inhibition of cell growth; in
contrast, arachidonic acid (AA), a 6-PUFA, had no
significant effect. The ω3-PUFAs effect are due to the
induction of apoptosis, given that DHA induced the cleaved
form of PARP, and caspase-3. DHA treatment caused a
decline of β-catenin protein. Accordingly, DHA treatment
also reduced the β-catenin-mediated T-cell factor/lymphoid
enhancer factor reporter activity, and inhibited the expression
of cyclin D1, a β-catenin-controlled downstream gene
implicated in breast carcinogenesis. DHA suppressed
motility and invasion of MDA-MB-231 cells in a dosedependent manner; in contrast, AA had no effect. In gelatinembedded zymography, activities of MMP-2 and MMP-9
were decreased by DHA treatment and the levels of their
mRNA were also reduced in dose-dependent manner. The
levels of VEGF protein and its promoter activity were
inhibited by DHA treatment. AA- and PGE2-induced VEGF
promoter activity was also inhibited by DHA pretreatment.
The level of NF-κB protein and binding activities of NF-κB
and AP-1 decreased by DHA treatment. DHA inhibited NFκB and Cox-2 reporter activities and PGE2-dependent
increases of NF-κB and MMP-2 promoter activities were
also inhibited by DHA pretreatment. When mouse breast
cancer EO771 cells were implanted into Fat1 mice (Fat1
transgenic mice express a Caenorhabditis elegans ω3
desaturase, converting ω6- to ω3-PUFAs endigenously),
tumor size and volume of Fat1 transgenic mice were
dramatically reduced compared with wild-type mice. In
immunohistochemical analysis of tumors of Fat1 mice,
apoptosis was markedly increased; in contast, angiogenesis
significantly was reduced compared with wild-type mouse
tumor. Binding activites of NF-κB and AP-1 were decreased
in Fat1 mouse tumors. These findings suggest that ω3PUFAs may inhibit tumor invasion and angiogenesis by
reducing MMP activities and VEGF level via reduction of
NF-κB and AP-1 in breast cancer. Thus, utilization of ω3PUFAs may represent an effective and safe therapeutic
approach for the chemoprevention and treatment of human
breast cancer.
This work was supported by the Korea Research Foundation
Grant funded by the Korean Government (MOEHRD) (KRF2007-521-E00014), Yihang Scholarship Foundation of
Chungnam National University Medical School, and Dr.
Park’s Breast Clinic, Korea.
408
ULTRASOUND-INDUCED HYPERTHERMIA
AFFECTS THE CELLULAR UPTAKE
OF P-GLYCOPROTEIN-RECOGNIZED
SUBSTRATES IN
MULTIDRUG-RESISITANT CELLS
Cheong-Weon Cho1, Kyu Lim2 and Sang-Chul Shin3
1College of Pharmacy, Chungnam National University,
Daejeon, 305-764, South Korea;
2Department of Biochemistry, College of Medicine,
Chungnam National University, Daejeon, 301-747, Korea;
3College of Pharmacy, Chonnam National University,
Gwangju, 500-757, South Korea
Ultrasound-induced hyperthermia (USHT: 0.4 watts (W)/cm2
at 41˚C) could increase the cellular uptake of p-glycoprotein
(P-gp) substrates in bovine brain microvessel endothelial cells
(BBMECs). This study was conducted to elucidate the
mechanism of USHT on the cellular accumulation of P-gprecognized substrates in the multi-drug resistant (MDR) cells
since P-gp plays a major role in limiting drug permeability in
MDR cells. When the concentration of P-gp inhibitor,
verapamil or PSC 833, increased from 1 μM to 200 μM,
verapamil and PSC 833 revealed a dose-dependent increase in
R123 accumulation in MDR cells. To determine if USHT
mediated its effect on the cellular accumulation of
hydrophobic molecules by affecting membrane permeability,
we compared the cellular accumulation of a non-P-gp
hydrophobic substrate ([14C]-antipyrine) with that associated
with a P-gp substrate (R123). Antipyrine was chosen as a
hydrophobic permeability marker, because this molecule is not
considered a substrate of P-gp or of any known transporter
proteins in MDR cells. Cellular accumulation of both 4 μM of
R123 (log partition coefficient 0.53) and 0.5 μM of [14C]antipyrine (log partition coefficient 0.4) was increased
immediately after USHT treatment: the accumulation of [14C]antipyrine reached a level that was 2.5-fold higher right after
UHST treatment, whereas R123 accumulated only 33% over
the control (No USHT) right after USHT. The enhanced
permeability was reversible and size-dependent as USHT
produced a much larger effect on cellular accumulation of
[14C]-antipyrine (MW 188) than that of R123 (MW 380.8). It
also took less time after USHT treatment for R123
accumulation in USHT-treated cells to return to that of the
untreated cells (20 min for R123 vs. >60 min for antipyrine).
The results suggest that USHT does not modulate P-gp
activity, but rather it increases cellular accumulation of R123
by altering membrane permeability in a manner that was
selective and reversible. The present results point to the
potential use of USHT to increase cellular uptake of P-gprecognized substrates, especially anticancer agents, into cancer
cells.
3381
ANTICANCER RESEARCH 28: 3157-3556 (2008)
409
INDUCTION OF APOPTOSIS BY
CANTHARIDIN IN COLO 205 HUMAN
COLORECTAL CARCINOMA CELLS
Chin-Chung Lin1, Jai-Sing Yang2, Jing-Gung Chung3
1Fong-Yuan
Hospital, Fong Yuan City 420, Taiwan;
of Pharmacology, China Medical University,
Taichung, Taiwan;
3School of Biological Science and Technology, China
Medical University, Taichung, Taiwan, ROC
2Department
Cantharidin, a natural toxin, is the active substance of
mylabris and has antitumor effects in man. The present
study was designed to investigate whether or not cantharidin
exerts cytotoxic activity against colorectal cancer cells by
inducing apoptosis and to examine the possible mechanism
of the phenomenon. Inhibition of proliferation of cantharidin
on COLO 205 colorectal cancer cells was determined by the
trypan blue dye exclusion test in vitro. Apoptosis of
cantharidin-treated cells was determined by morphological
analysis and quantities by flow cytometry after staining with
propidium iodide. Cell cycle and the cell surface expression
of the CD95/CD95 ligand were evaluated by flow
cytometry. Caspase activities were also analyzed. Results:
Treatment with cantharidin of COLO 205 cells not only
inhibited cell proliferation, but also induced apoptosis.
Cantharidin induced apoptosis mainly in two phases: rapid
apoptosis and delayed apoptosis in G2/M arrested cells.
Treatment with cantharidin in COLO 205 cells resulted in
an up-regulation of the CD95 receptor and CD95L on the
cell surface. Cantharidin-treated cells exhibited the
activation of caspase-8 and caspase-3. The pretreatment of
zVAD-FMK (a broad range caspase inhibitor) and/or IETDFMK (a caspase-8 inhibitor) showed apparent inhibition of
the apoptosis-inducing effect in COLO 205 cells. Our
results suggest that cantharidin triggers apoptosis in
colorectal cancer cells via the activation of the CD95
receptor/ligand system, and that this agent may be useful for
developing new therapeutic regimens for the treatment of
colorectal carcinoma.
410
RUTIN INHIBITS HL-60 LEUKEMIA
CELLS IN VIVO
Jing-Pin Lin1, Guang-Wei Chen2 and Jing-Gung Chung3
1School
of Chinese Medicine, 3Department of Biological
Science and Technology, China Medical University,
Tiachung, Taiwan;
2Traditional Chinese Medical Department, Chung-Ho
Memorial Hospital, Kaohsiung Medical University,
Kaohsiung, ROC
3382
It was reported that rutin, a flavonoid present in onions,
apples, tea and red wine, can induced apoptosis in cancer cells
through the induction of apoptosis, however, the effects of
rutin on human leukemia HL-60 cells is unclear. Therefore,
the purpose of this study was to investigate the effect of rutin
on HL-60 cells in vitro as well as in vivo systems. Nude mice
bearing HL-60 leukemia tumors were treated once per 3 days
with i.p. administration of 30 and or 50 mM rutin in 0.9%
NaCl solution for 4 weeks. Tumor volume and survival time
were recorded. TUNEL assay and CD34 vessel staining were
conducted in tumor tissue. Antiangiogenesis in vivo was
determined by sponge assay. Antiproliferative and apoptosisinducing activities of rutin in vitro were examined on HL-60
cells. The results of the administration of rutin were significant
inhibition (60%-80% maximum inhibition relative to controls)
of the growth of HL-60 tumor xenografts, and prolonged
survival of the treated mice. Complete tumor regression
occurred in rutin-treated nude mice. The antitumor responses
were associated with marked increases in tumor apoptosis and
reductions in tumor size and weight. In conclusion, our data
indicate that rutin may provide an effective approach to inhibit
human leukemia HL-60 cancer both in vitro and in vivo.
411
ORPHAN NUCLEAR RECEPTOR, NURR-77
IS A POSSIBLE TARGET GENE OF
BUTYLIDENEPHTHALIDE CHEMOTHERAPY IN
GLIOBLASTOMA MULTIFORM BRAIN TUMOR
Po-Cheng Lin1, Yi-Lin Chen2, Tzyy-Wen Chiou1
and Horng-Jyh Harn3
1Graduate
Institute of Biotechnology, National Dong Hwa
University, Hualien, Taiwan;
2Graduate Institute of Biotechnology, National Ilan
University, Ilan, Taiwan;
3Pathology Department, China Medical University, Taichung,
Taiwan, ROC
The natural compound n-butylidenephthalide (BP), which is
isolated from the chloroform extract of Angelica sinensis, has
been investigated for its antitumoral effects on glioblastoma
multiform (GBM) brain tumors both in vitro and in vivo. In
order to determine the mechanism of BP-induced growth
arrest and apoptosis, we examined BP-induced changes in
gene expression by microarray screening using human GBM
brain tumor cells. This analysis identified several BP-inducible
genes, including the nuclear receptors NOR-1, Nurr1, and
Nur77. Among these genes, Nur77 is particularly interesting
because it plays an important role in the apoptotic processes in
various tumor cell lines. BP was able to increase Nur77
mRNA and protein expression in a time-dependent manner.
After BP treatment in GBM 8401 cells, Nur77 translocated
from the nucleus to the cytoplasm, cytochrome c was released
Abstracts of the 8th International Conference of Anticancer Research, 17-22 October 2008, Kos, Greece
from the mitochondria, and caspase-3 became activated.
Furthermore, using Nur77 promoter-luciferase assay, BPincreased Nur77 was AP1-related. Inhibition of BP-induced
Nur77 expression by Nur77 short interfering RNA (siRNA)
blocked BP-induced apoptosis in GBM 8401 cells, suggesting
that the induction of Nur77 negatively affected GBM 8401 cell
survival. In summary, our results suggest that up-regulation of
Nur77 may explain the antitumoral activity of BP in brain
tumor cells.
412
DNA DAMAGE AND ENDOPLASMIC RETICULUM
STRESS MEDIATED CURCUMIN-INDUCED CELL
CYCLE ARREST AND APOPTOSIS IN HUMAN
LUNG CARCINOMA A-549 CELLS THROUGH THE
ACTIVATION CASPASES CASCADE AND
MITOCHONDRIAL-DEPENDENT PATHWAY
Song-Shei Lin1, Hsuan-Pang Huang2, W. Gibson Wood3
and Jing-Gung Chung2
1Department of Radiological Technology, Central Taiwan
University of Science and Technology, No 11, Buzih Lane,
Buzih District, Taichung 40605, Taiwan, ROC;
3Department of Pharmacology, University of Minnesota,
School of Medicine, Geriatric Research, Education and
Clinical Center, VA Medical Center, Minneapolis,
Minnesota, USA;
2Departments of Biological Science and Technology, China
Medical University, No 91, Hsueh-Shih Road, Taichung 404,
Taiwan, ROC
Curcumin, a major component of the Curcuma species, is
known to have antioxidant, anti-inflammatory properties and
induce apoptosis of cancer cells, however, the precise
molecular mechanisms of apoptosis in vitro are unclear. In this
study, we showed that curcumin, a plant product containing
the phenolic phytochemical, caused DNA damage and
endoplasmic reticulum (ER) stress and mitochondrialdependent-induced apoptosis through the activation of
caspase-3 at a treatment concentration of 30 μM in human
lung cancer A-549 cells. In contrast, treatment with 5-10 μM
of curcumin did not induce significant apoptosis, but rather
induced G2/M phase arrest in A-549 cells. Flow cytometric
analysis indicated that curcumin directly increased
intracellular oxidative stress based on the cell permeable dye,
2’,7’-dichlorodihydrofluorescein diacetate (DCFH-DA), acting
as an indicator of reactive oxygen species (ROS) generation.
GADD153 and GRP78 were increased by curcumin which
was indicative of ER stress. Curcumin increased Ca2+ levels
and the mitochondrial membrane potential (ΔΨm) decreased
in A-549 cells. Overall, our results demonstrated that curcumin
treatment causes cell death by activating pathways inducing
G2/M phase arrest and apoptosis.
413
THE ROLE OF BRIT1/MCPH1 IN CHROMATIN
REMODELING, DNA DAMAGE RESPONSE, AND
CANCER
Guang Peng and Shiaw-Yih Lin
Department of Systems Biology, The University of Texas
MD Anderson Cancer Center, Houston, TX 77054, USA
We previously identified BRIT1/MCPH1 as a novel tumor
suppressor gene and an early regulator in response to DNA
damage through its regulation of ATM/ATR signaling as well
as the expression of BRCA1 and Chk1. In addition to its role
in DNA damage signaling, our recent endeavor indicated that
BRIT1/MCPH1 was required for both homologous
recombination DNA repair and nonhomologous end joining
repair. Interestingly, using a proteomic approach, we identified
a previously unknown function of BRIT1/MCPH1 as a novel
regulator of ATP-dependent chromatin remodeling complex
SWI/SNF in DNA repair. Our data indicate that
BRIT1/MCPH1 interacts with SWI/SNF and provides a means
by which SWI/SNF can be specifically recruited to and
maintained at DNA lesions, facilitating DNA repair. We
establish that loss of BRIT1/MCPH1 causes impaired
chromatin relaxation in response to DNA damage owing to
reduced association of SWI/SNF with chromatin. This then
explains the observed decreased recruitment of repair proteins
to DNA lesions and reduced efficiency of repair in
BRIT1/MCPH1-deficient cells. Our findings, therefore,
identify BRIT1/MCPH1 as a key molecule that directly links
chromatin remodeling with DNA damage response in the
control of DNA repair, and its dysfunction contributes to
genomic instability and cancer.
414
BREAST CANCER AND GROWTH HORMONE
RECEPTOR EXPRESSION IN YOUNG ARAB
WOMEN
David T. Lincoln1, Fatma Al-Yatama2,
Fawziah M.A. Mohammed2 and Anwar Al-Banaw2
1Entity Systems, Independent Research Foundation, Chapel
Hill, QLD, Australia;
2Department of Medical Laboratory Sciences, Faculty of
Allied Health Sciences, Kuwait University, Kuwait
Growth hormone (GH) exerts its regulatory functions in the
mammary gland by acting on specific receptors, which trigger
a cascade of biochemical signals and dictate gene expression.
However, GH induced neoplastic changes have been reported
in mice and human mammary gland tissue. In this
investigation, the expression of receptors for growth hormone
(GH-R) was undertaken in 122 cases of breast cancer in young
3383
ANTICANCER RESEARCH 28: 3157-3556 (2008)
Arab women. In 24% of the patients, the tumour was very
large, involving half the breast. The majority of cases were
infiltrating ductal carcinomas (66%), of which 59% were
moderately differentiated G2 or were poorly differentiated G3.
The remaining cases included benign breast tumours,
intraductal and lobular carcinomas in situ and invasive lobular
and medullary carcinomas. Using anti GH-R monoclonal
antibody (MAb 263) on routinely formalin-fixed, paraffin waxembedded tissue sections, the cellular and nuclear expression
of human GH-R was demonstrated by the streptavidin-biotin
horseradish peroxidase complex (ABC) technique. The MAb
used in this study was obtained by hybridoma technology from
Balb/c mice immunised with purified rat and rabbit liver GHreceptor. The results show distinct receptor immunoreactivity
in carcinoma cells. GH-R expression was primarily in the
membrane-cytoplasm of cancer cells, but nuclei were also
positive (16-30%) for GH-R. The proportion of membranecytoplasmic and nuclear expression in intraductal carcinomas
was greater than 31% and 5-15% respectively. Strongest
staining intensity was present in the large proliferating tumour
cells. All cases of infiltrating ductal carcinomas were GH-Rpositive with a high (>31%) positive nuclear component in this
tumour etiology. The majority of ductal carcinomas were GHR-positive, the proportion of immunoreactivity ranging from
5% to greater than 31%, while in lobular carcinomas, positive
immunostaining was from 16% to greater than 31%, with
nuclear expression being less than 5%. In signet ring
carcinomas, cellular and nuclear GH-R expression was in
excess of 31% and 16-30% respectively. All metastatic lymph
node cases were positive for GH-R. Expression in normal
breast tissue was generally low or absent. In conclusion, this
study demonstrates the expression of receptors for growth
hormone, an important mammotrophic hormone, in breast
cancer tissue. It is proposed that growth hormone enhances
cellular proliferation by acting on sensitive ductal stem cells,
rendering them targets for the proliferative effects of IGF-I,
resulting in propagation of genetic errors. Growth hormone
also facilitates cell proliferation through paracrine and/or
autocrine mechanism. It also suggests caution in the use of
recombinant GH in the treatment of short stature prepubescent
girls. This applies to those without evidence of classic GH
deficiency, particularly in the presence of a family history of
breast cancer.
415
EXPRESSION OF GROWTH HORMONE
RECEPTORS IN HUMAN LYMPHOMAS
David T. Lincoln1 and Anwar Al-Banaw2
1Entity
Systems, Independent Research Foundation, Chapel
Hill, QLD., Australia;
2Department of Medical Laboratory Sciences, Faculty of
Allied Health Sciences, Kuwait University, Kuwait
3384
The classification of non-Hodgkin’s lymphoma is controversial
in histopathology. The Kiel and the Lukes-Collins
classifications are widely used for the diagnosis of B-cell and
T-cell lymphomas. In contrast, peripheral T-cell lymphomas are
less well characterized and their identification is often difficult
as the result of a multiplicity of immunological, histological
and clinical characteristics. There is a growing appreciation of
the role of the immune response in preventing the emergence
and progression of cutaneous lymphomas, particularly with
respect to local imbalances in immune regulations, creating an
environment for tumourigenesis.
Growth hormone (GH) has been amply implicated as
having a modulatory role in immune functions.
Hyophysectomised rats and dwarf mice have suppressed
immune responses, which can be restored by GH. Human GH
stimulates T-cell proliferation, possibly via induction of
insulin-like growth factor-I (IGF-I) synthesis, and the
generation of cytotoxic T-cells is enhanced by GH. IGF-I
synthesis in Epstein-Barr virus-transformed B cell lines is
increased in response to GH. Furthermore, GH has been
shown to stimulate B-cell immunoglobulin synthesis and
proliferation. Clinically, GH treatment results in a number of
changes in lymphocyte subpopulations and stimulates the
proliferation as well as the transformation of normal and
leukaemic lymphocytes in vitro and significantly increases the
expression of c-myc proto-oncogene. GH induced neoplastic
changes have been reported in lymphosarcoma of the lung and
in plasma cell tumours.
To address the site/mode of action through which GH exerts
these effects in a variety of human lymphomas, in this study
we have applied a well-characterized monoclonal antibody to
the GH-receptor (GHR), directed against the hormone-binding
site of the receptor. Tumours investigated consisted of
malignant non-Hodgkin’s lymphoma (n-14), large cell
malignant non-Hodgkin’s lymphoma (n=11), non-Hodgkin’s
lymphoma-plasmacytoma (n=1), mycosis fungoides (n=11),
low grade skin lymphoma (n=7), lymphoma/Kaposi’s sarcoma
(n=4), malignant lymphoid neoplasm (n=2), polymorphic
lymphoid cells (n=1), cutaneous T-cell lymphoma (n=4) and
adult T-cell leukaemia/lymphoma (n=7). Tumours were
categorized for different lymphocyte subpopulations by
immunomorphological diagnosis.
The results show strong GHR expression in the great
majority of CD20+ B-lymphocyte lymphomas, whereas CD2+
lymphomas, including T-cell lymphomas, exhibited
considerably lower levels of expression. The different levels
of GHR expression observed on B- vs. T-lymphocytes were
previously confirmed on peripheral lymphocytes by analysis
of the GHR mRNA transcript. Cutaneous lymphomas,
identified as highly malignant Ki-lymphoma of large
anaplastic cells, expressed intense GHR immunoreactivity.
Possibly the tumours presented here are a separate entity
within the group of peripheral T-cell lymphomas, closely
Abstracts of the 8th International Conference of Anticancer Research, 17-22 October 2008, Kos, Greece
related to Mycosis fungoides d’emblee. GHR staining was
localized in a homogenous pattern and most of the neoplastic
cells were positive. At times, nuclei were GHR positive in the
tumour cells.
In conclusion, this study confirms ubiquitous expression of
GHR on peripheral lymphomas and reveals discretely higher
GHR levels in cutaneous B-cell compared to T-cell
lymphomas. It strongly supports the idea that GH is directly
involved in the control of the development and/or activation
of specific cell populations of the immune system and that Band T-cells may exhibit differential sensitivity to GH. The
effects of GH may be particularly important at ages when the
lymphoid compartment is still, to a certain extent, immature.
On this basis, it would be of interest to reevaluate the
biological effect of GH on the immune system of children
with growth retardation undergoing GH treatment, and the
possible carcinogenic and/or tumour growth stimulating
effects of this treatment. A possible relationship is postulated
between exogenous GH therapy and an increased risk of
lymphoproliferative malignancy, including leukaemia growthstimulating effects.
416
HISTOPATHOLOGICAL ASPECTS AND RISK
FACTORS OF BREAST CANCER
IN YOUNG ARAB WOMEN
David T. Lincoln1, Fatma Al-Yatama2,
Fawziah M.A. Mohammed2 and Anwar Al-Banaw2
1Entity Systems, Independent Research Foundation, Chapel
Hill QLD 4069, Australia;
2Department of Medical Sciences, Faculty of Allied Health
Sciences, Kuwait University, Kuwait
Breast cancer is characterized by a long history and marked
heterogeneity in growth rates and clinical manifestations. In
Western women, peaks between the ages of 60-65 years, with
only 14% occurring below the age of 40 years. In contrast, in
Arab women the mean age is 48 years and the peak
occurrence is 45-50 years. Only 14% of breast cancer occurs
above the age of 60 years. However, a significant proportion of
breast cancers occur below the age of 30 years and the
incidence is increasing. The combination of obesity,
hypertension and diabetes mellitus seems to be in close
correlation with onset of the disease. Furthermore, the tumour
size and the number of positive lymph nodes reflect the status
of the cancer.
This study evaluates the expression of different prognostic
tumour markers, including HER-2/neu oncoprotein, growth
hormone receptor (GH-R), p53 oncoprotein, oestrogen
receptor (OR), progesterone receptor (PR), cathepsin D,
microvascular density (MVD), tumour cell proliferation
(PCNA, Ki-67), thioredoxin (TRX) and thioredoxin reductase
(TR). A total of 122 cases of breast cancer in young (<30
years old) Arab women were investigated and correlated with
histopathological grade and lymph node status.
In 24% of the patients the tumour was very large, involving
half of the breast; 80% presented without distant metastasis.
According to the TNM staging system, most cases were T2,
with an average tumour size of 3.5 cm (1.5-6.5).The larger the
size of breast tumour, the more likely was the involvement of
axillary lymph nodes. Stage I represented 14% of the patients,
44% were in stage II, 24% in stage III and 13% in stage IV.
The average number of lymph nodes dissected was 18 (6-43).
Results from this investigation show strong expression of
HER-2/neu was present in 65.6% of breast carcinomas.
Immunoreactivity was concentrated in the cell membranes of
tumour cells. Among the 14 cases of infiltrating ductal
carcinomas, 10 were strongly HER-2/neu positive and
associated with lymph node involvement, while only 4 cases
were moderately positive. The intensely positive cases of the
intraductal carcinomas were all lymph node positive,
indicating a relationship between HER-2/neu overexpression
and lymph node involvement. The strongly positive cases of
lobular, infiltrating lobular and signet ring carcinomas
correlate with lymph node involvement.
Growth hormone receptor (GH-R) was expressed in all
cases of infiltrating ductal carcinomas with a high (>31%)
positive nuclear component in this tumour etiology. The
majority of ductal carcinomas were positive with proportion
of membrane-cytoplasmic and nuclear expression ranging
from 5% to greater than 31%. In signet ring carcinomas, the
proportion of GH-R immunoreactivity was in excess of 31%
in the membrane-cytoplasmic component and 16-30% of the
nuclei of tumour cells. The proportion of membranecytoplasmic and nuclear expression in the intraductal
carcinomas was greater than 31% and 5-15% respectively.
With 57.4%, distinct nuclear p53 staining was high, indicating
alterations in p53 tumour suppressor gene of breast
carcinomas in young patients, and while 63.7% of these
tumours were aneuploid, 93.6% of these were negative for OR
and 64.8% of the p53-positive tumours were lymph node
negative. The vast majority of p53-positive carcinomas were
Grade III (76.6%), 21.3 % were Grade II and only 2.1 %
Grade I, but neither tumour grade (p=0.066) nor tumour size
(p=0.53) showed a correlation with p53 expression. A total of
60.9% of the p53-positive breast carcinomas had positive
lymph node involvement. A significant negative correlation
between OR and PR content (p=0.006) and p53 was observed.
Of the breast carcinomas from patients of young age
investigated, 39% stained positive for cathepsin D, which was
present in all grades of malignancy, including low Grade I
tumours. Generally, only a small number of the carcinoma
cells displayed distinct Cathepsin D immunoreactivity, which
was confined to the cytoplasm only. Immunoreactivity of the
MVD marker CD-31 was present in the vascular endothelial
3385
ANTICANCER RESEARCH 28: 3157-3556 (2008)
cells of the larger blood vessels and capillaries. All other
components of the breast carcinoma tissue, including tumour
cells, stromal cells, adipocytes and nerve cells, were CD-31negative. Ki-67 cell cycle immunoreactivity was present to
varying degree in all breast carcinomas investigated and was
mostly confined to the nuclei of the tumour cells. Cells in
mitosis at times also displayed weak staining in their
cytoplasm. The number of cells displaying Ki-67-positive
nuclei varied between 9% and 89% of all malignant cells in a
given tumour specimen. PCNA immunoreactivity was present
in all breast carcinomas investigated (2% to 100%). The range
of positive cells in the majority of carcinomas was between 20
to 35% of the tumour cells. Immunostaining of Ki-67 and
PCNA specifically demonstrated proliferating tumour cells
and correlated with tumour grade. The histochemical analysis
of both TRX and TR shows they were overexpressed in the
cytoplasm and nuclei in the majority of mammary carcinomas.
TRX was found in 100% of the signet ring carcinomas, 100%
of the mucin-producing carcinomas, 80% of the infiltrating
ductal carcinomas, 70% of the ductal carcinomas, 60% of the
intraductal carcinomas and 40% of the lobular carcinomas. In
contrast, only 20% of the fibrocystic breast diseases
investigated was TRX positive. Thioredoxin reductase (TR),
the enzyme involved in the reduction of TRX, was also present
in large amounts in the breast tumours, indicating that a large
amount of its substrate (TRX) is also present. TR was present
in 100% of the signet ring carcinomas and in the mucin
producing carcinomas, 80% of the infiltrating ductal
carcinomas, 60% of both the ductal and intraductal carcinomas
and 30% of all lobular carcinomas investigated.
Patients <30 years of age have a worse prognosis than older
patients. Only 6.5% of the tumours were classified as Grade 1,
while 25.4% were of Grade II and 68.1% were Grade III.
Furthermore, 14.6% of all carcinomas were <2 cm in size,
53.3% were between 2.1 and 5.0 cm and 28% were larger than
5 cm in size. In 42.8% of all cases, there was no lymph node
involvement, 15.9% had one to three and 41.4% had four or
more lymph node metastases, while 41.8% of all carcinomas
were diploid and 58.4% were aneuploid. Grading correlated
significantly with ploidy (p=0.008). DNA aneuploidy was more
common in high-grade tumours. All of Grade I tumours, 47.4%
of Grade II and 61.6% of Grade III tumours were aneuploid.
In conclusion, there are highly significant trends for the
prevalence of poor prognostic features such as Grade 3
histology, extensive intraductal component and vascular and
lymphatic invasion. The application of new biochemical
markers for the diagnosis of breast cancer is valuable in
therapeutic assessment and in clinical prognosis and has
influenced the treatment selection. Expression of Ki-67, PCNA,
p53 and HER-2/neu correlated significantly with each other
and with the histological grade. Many of the carcinomas
showed a high Ki-67 and PCNA proliferative activity,
indicative of poor prognosis. A positive correlation was also
3386
demonstrated between tumour grade, nuclear proliferation and
expression of GH-R, HER-2/neu, TRX and TR. A direct role
for GH in breast cancer cell and in vascular epithelial cells
proliferation suggests caution in the use of recombinant GH in
the treatment of short stature prepubertal girls. This applies to
those without evidence of classic growth hormone deficiency,
particularly in the presence of a family history of breast cancer.
Secreted TRX can regulate the redox state of specific cell
surface receptors and of the extracellular environment.
Consequently, TRX may exert a redox control over cellular
mechanisms that are involved with cell attachment, invasion
and metastasis and that the extracellular TRX system
contributes to the invasive capacity of breast cancer cells. Given
the association of the thioredoxin system with the process of
tumourigenesis and malignancy reported here, the targeted
inhibition of the TRX system is suggested as a novel approach
for the treatment of aggressive breast cancer phenotypes.
Indeed, specific chemical inhibitors of TRX and TR are known
to inhibit cancer cell growth and exhibit antitumour activity in
vivo. MVD was prognostically significant in univariate analysis
of disease-free status and overall survival, as were stage of the
disease, tumour size, nodal status and histological grade. Highgrade carcinomas contained greater MVD than low-grade
carcinomas. On the other hand, a negative correlation existed
with OR and PR status and a weak correlation was found
between HER-2/neu, Ki-67, PCNA, GH-R and p53 on one
hand and Cathepsin D on the other. The association of both
oestrogen and progesterone receptor-negative hormone status
and positive p53 expression points to a greater tumour
aggressiveness. This may reflect changes in steroid metabolism
and usually excludes tamoxifen therapy. Most early recurrences
and aggressive growth were present in high grade tumours with
size of more than 3 cm. Development of recurrent metastatic
disease was 22% of patients at intervals ranging from 1 month
up to 12 years.
417
HOW DO WE DEVELOP EFFECTIVE CYTOTOXIC
DRUGS FOR SOLID TUMORS?
Stig Linder
Cancercenter Karolinska, R8:00, Department of OncologyPathology, Karolinska Institute, Stockholm, Sweden
Clinically used anticancer agents such cisplatin induce both
tumor cell death and terminal growth arrest. They do so by
complex mechanisms, involving both nuclear and cytoplasmic
targets (Mandic et al: J Biol Chem 278, 9100, 2003;
Berndtsson et al: Int J Cancer 120: 175, 2007). Despite
considerable potency (and toxicity), these drugs do generally
not cure metastatic disease.
Most currently used anticancer agents were develop using
tumor cell lines grown in monolayer culture. Our group has
Abstracts of the 8th International Conference of Anticancer Research, 17-22 October 2008, Kos, Greece
used a cell-based high-throughput apoptosis assay to identify
agents that induce apoptosis in p53-defective cells (Erdal et
al: PNAS 102: 192, 2005), that induce the lysosomal cell
death pathway and agents that induce apoptosis in cells
overexpressing AKT.
A problem in this field is that monolayer cultures of tumor
cells poorly reflect the properties of in vivo tumors. Tumor
cells in vivo grow in a three dimensional matrix, and are often
hypoxic and poorly nutritioned. Many currently used
anticancer drugs are ineffective on 3-D multicellular
spheroids. We have sucessfully adapted spheroids for drug
screening using the M30-Apoptosense assay (Herrmann et al:
J Biomol Screening 13: 1, 2008). We have identified natural
products and other compounds that induce efficient apoptosis
of multicellular spheroids, and have characterized the mode of
action of these drugs. We hope that agents that induce
apoptosis of spheroids will also be effective in vivo.
Clinical testing represents an important part of the drug
development process. Our laborarory has together with a
biotech company, developed a method for determination of an
apoptosis product released from dead tumor cells (Kramer et
al: Cancer Res 64: 1751, 2004). This method has proven
useful for determination of clinical response after treatment
with effective drugs (Hägg Olofsson et al: Clin Cancer Res
13: 3198, 2007).
In conclusion, it is hope that improved cell-based screening
systems together with effective determination of drug response
in clinical trials will result in the development of more
effective drugs against solid tumors.
418
LRIG AND CERVICAL CANCER
Annika K. Lindström
Ventrum Clinic, Skovägen 2, 79021 Bjursås, Sweden
Cancer results from a multistep process in which acquisition
of self sufficiency in growth signals is an important step.
Growth factor receptors are frequently amplified and/or
inappropriately activated in carcinoma cells. Three human
leukokine-rich repeats and immunoglobulin like domains
(LRIG) genes and proteins, named LRIG1-3, that may act on
as promoters and/or suppressors of tumor growth have been
characterized recently. We analyzed the LRIG gene family
members in human cervical cancer. The relationship between
LRIG protein expression and clinical parameters, ten other
tumor markers, smoking, endogenous sex hormones and
survival rate were investigated. LRIG1 appears to be a
significant prognosis predictor in early-stage squamous cervical
cancer. Diminished expression in advanced stages and the
inverse correlation to serum progesterone and smoking
indicates that LRIG1 is a tumor suppressor in cervical cancer.
Expression of LRIG2 was strongly associated to poor
prognosis, particularly in early stage squamous cell cervical
cancer. There were correlations between LRIG2 expression and
expression of the tumor suppressor LRIG1, the oncoprotein cmyc, the cell-adhesion molecules E-cadherin and CD44, and
the immunological marker CD4. A combination of high LRIG2
expression and absence of LRIG1 expression identified women
with a very poor prognosis The results of this study suggest
that LRIG2 act as a tumor promoter in cervical cancer.
According to our preliminary results LRIG 3 does not have any
clinical importance in cervical cancer.
419
TUMOUR MARKERS AND PROGNOSIS OF
RECURRENCE AND SURVIVAL AFTER LIVER
SURGERY FOR COLORECTAL LIVER
METASTASES – A DYNAMIC STUDY
V. Liška1, L. Holubec Jr.2,3, V. Třeška1, T. Skalický1,
A. Sutnar1, S. Kormunda3, J. Fínek2 and O. Topolčan3
Departments of 1Surgery, 2Oncology, 3Central Isotopic
Laboratory, University Hospital Pilsen, Charles University
Prague, Prague, Czech Republic
Aim: Statistical analysis of dynamic of tumour markers and
comparison of tumour markers and their dynamics in patients
without or with liver surgery. Methods: Log-rank test and
Wilcoxon test were used for statistical evaluation. Survival rate
and disease free interval (DFI) were computed by KaplanMeier method. We analysed serum levels of tumor markers
conventionally used in clinical praxis (CA19-9, CEA, CA724) and markers informing us of the proliferative activity of
malignancy (TK, TPA, TPS). The authors studied 51 patients
who underwent explorative laparotomy or laparoscopy without
any surgical therapy for colorectal liver metastases (CLM) and
82 patients who underwent radical liver surgery for CLM
between September 1999 and June 2005. Results: The
statistical analysis proved conventional tumour markers as
prognostic factors of survival rate for patients after explorative
laparotomy (p<0.05). The survival rate did not depend on the
proliferative activity of malignancy. The statistical analysis of
the dynamics of tumour markers after liver surgery (speed and
power of recurrence) proved the dynamics of CA19-9 and
CEA to be excellent prognostic factors of early recurence of
CLM, contrary to proliferative tumor markers. Conclusion:
The results of this study suggest the importance of tumor
markers for the prediction of a short survival rate or DFI. It
seems to be very helpful for planning of palliative oncological
therapy for patients with liver malignancies who could not be
treated by surgical therapy. Patients with a high tendency to
recurrence of CLM after liver surgery should be followed-up
more thorougly to increase the possibility of reoperation.
Supported by grant VZ MSM 0021620819 “Replacement of
and support to some vital organs”.
3387
ANTICANCER RESEARCH 28: 3157-3556 (2008)
420
USE OF CYTOKINES OF INFLAMMATORY
RESPONSE IN PROCESS OF LIVER
REGENERATION IN PORCINE MODEL
OF PARTIAL PORTAL VEIN LIGATION
V. Liska1, V. Treska1, H. Mirka2, J. Kobr3, R. Sykora4,
T. Skalicky1, A. Sutnar1, J. Bruha1, O. Fiala1, O. Vycital1,
A. Chlumska5, L. Holubec6, M. Matejovic4, J. Racek7,
L. Trefil7 and O. Topolcan6
Departments of 1Surgery, 2Radiology, 3Pediatrics and
7Biochemistry, 4First Department of Medicine, 5Institute of
Pathology and 6Central Radioicotope Laboratory, Charles
University Prague, Medical School and Teaching Hospital
Plzen, Prague, Czech Republic
Background: Portal vein ligation (PVL) could multiply the
future liver remnant volume. TNF-α and IL-6 are cytokines of
inflammatory response and are connected with initial phase of
liver regeneration. Aim: The aim of this study was to accelerate
regeneration of liver parenchyma after PVL. The experimental
porcine model was developed to be as compatible as possible
with PVE in human medicine. Methods: The animals were
divided into three groups: 10 piglets in a TNF-α group, 9
piglets in an IL-6 group and 8 piglets in a control group. After
ligation of portal branches of caudate and right lateral and right
medial liver lobes, recombinant porcine TNF-α, IL-6 or
physiological solution (control group) were applied into nonoccluded portal vein branches. The blood samples were
collected from central vein catheter (1) before operation, (2)
after ligation of the last portal branch, (3) during application of
cytokine, (4) 2 hours after application of cytokine, (5) 1st
postoperative day (p.d.), (6) 3rd p.d., (7) 7th p.d., (8) 10th p.d.
and (9) 14th p.d. The following biochemical and
immunoanalytical parameters were assessed: bilirubin, urea,
creatinine, alkaline phosphatase, gammaglutamyltransferase,
cholinesterase,
aspartate
aminotransferase,
alanine
aminotransferase, albumin, C-reactive protein, studied
cytokines (TNF-α and IL-6) and growth factors (HGF, TGFβ1, TGF-α, IGF). After termination of the experiment, tissue
samples for histological examination were acquired.
Ultrasonographic examinations were undertaken immediately
after operation and on 3rd, 7th, 10th and 14th p.d. day to
evaluate the compensatory hypertrophy. Results: The
acceleration of growth of hypertrophic liver lobes measured by
ultrasonography was maximal between the 3rd and 7th
postoperative day in the TNF-α group and on the 7th
postoperative day in the IL-6 group in comparison with the
control group (p<0.05), nevertheless this stimulating effect was
lost at the end of experiment. Important differences in the
biochemical, immunoanalytical or histological parameters
studied were not proven. Conclusion: The presented study
describes a newly developed experimental model of portal vein
3388
ligation in a large animal. The achieved acceleration of growth
of hypertrophic liver lobes after application of TNF-α or IL-6
confirmed their key roles in priming of regenerating liver
parenchyma after portal vein ligation.
This experimental work was supported by grant IGA CR NR
8860/1-3 and grant MSM 0021620819 (Replacement of and
support to some vital organs).
421
NEW DEVELOPMENTS IN EPIGENETIC
THERAPY OF CANCER
Delong Liu and Shundong Cang
Division of Hematology/Oncology, New York Medical
College, Valhalla, NY 10595, USA
Aberrant DNA methylation and histone acetylation play very
important roles in carcinogenesis. Gene silencing through
epigenetic mechanisms are now well established as a hallmark
of cancer cells. Histone deacetylase inhibitors (HDACIs) and
hypomethylating agents (HMAs) can reverse these processes
through epigenetic therapies. To date, one HDACI (vorinostat)
and two HMAs (azacitidine and decitabine) have been approved
for clinical treatment of malignancies (Table). More than 13
new agents are in clinical trials for therapy of a variety of cancer
types (Table). This report will summarize new findings from
clinical trials and provide updates on the new epigenetic agents.
Number of trials
Agent
Azacytidine
Azacytidine +
Decytabine
Decytabine +
Vorinostat
Vorinostat +
CI-994
FK228
FK228 +
ITF2357
LBH589
LBH589+
PCI-24781
Phenylbutyrate
MGCD103
MGCD103+
MS-275
PXD101
PXD101+
SNDX-275+
Valproic acid
Valproic acid +
Phase I
Phase II
Phase III
1
6
4
4
6
8
3
3
1
2
2
5
2
8
1
1
2
3
1
1
1
4
4
1
2
2
1
1
1
2
2
1
1
1
2
1
1
+ indicates that the agent was in combination with another
agent in the clinical trials.
Abstracts of the 8th International Conference of Anticancer Research, 17-22 October 2008, Kos, Greece
422
A NOVEL FLUOROMETRIC ASSAY OF
HUMAN 3’-PHOSPHOADENOSINE
5’-PHOSPHOSULFATE SYNTHETASE
Tzu-An Liu1 and Yuh-Shyong Yang1,2
1Department
of Biological Science and Technology and
Institute of Biochemical Engineering, National Chiao Tung
University, Hsinchu, Taiwan;
2Instrument Technology Research Center and National Nano
Device Laboratories, NARL, Hsinchu, Taiwan, ROC
Posttranslational modifications of proteins have been
recognized as critical modulators of various physical activities
in health and disease. Sulfation, catalyzed by
sulfotransferases, is a key posttranslational modification
modulates the extracellular cell-host and cell-matrix
interactions, cell adhesion, as well as cell recognition and
invasion, which are generally thought to remarkably influence
carcinogenesis. 3’-phosphoadenosine 5’-phosphosulfate
synthetase (PAPSS) catalyzes the biosynthesis of 3’Phosphoadenosine 5’-phosphosulfate (PAPS), which serves
as the universal sulfate donor compound for all
sulfotransferase reactions. In an attempt to explore the
enzymatic characteristics of PAPSS, we have developed and
optimized a rapid, coupled fluorometric assay for the
determination of PAPSS activity. This assay replaced endpoint radioisotopic method and is the first continuous method.
PAP-free phenol sulfotransferase proved to be ideal under the
present situation because of its higher tolerance to substrate
inhibition by PAP and MU, and exhibited the relative
resistance to the inhibition by ATP, a substrate for PAPSScatalyzed step. The selective phenol sulfotransferase was
therefore utilized to catalyze the sulfate conjugation of an
acceptor, MU, served as fluorometric indicator for
determining PAPSS activity, by transferring the sulfuryl group
from PAPS formed from ATP and inorganic sulfate by
PAPSS. This rapid and continuous method can be used in the
detailed pharmacogenetic and toxicological studies of PAPSS,
and will allow for investigation of other pathological
mechanisms for a better understating of the regulation
between sulfation and tumor procession.
423
HMJ-38 INTERACTS WITH MICROTUBULE
POLYMERIZATION, PROMOTE G2/M ARREST AND
INDUCES APOPTOSIS IN HUMAN TONGUE
CANCER CAL27 CELL LINE
Chi-Cheng Lu1, Jai-Sing Yang2, Sheng-Chu Kuo3, MingChing Kao4, Mann-Jen Hour5 and Jing-Gung Chung4
1Department
of Life Sciences, National Chung Hsing
University, Taichung, Taiwan;
2Department of Pharmacology, China Medical University,
Taichung, Taiwan;
3Graduate Institute of Pharmaceutical Chemistry, China
Medical University, Taichung, Taiwan;
4School of Biological Science and Technology, China
Medical University, Taichung, Taiwan;
5School of Pharmacy, China Medical University, Taichung,
Taiwan, ROC
We reported that HMJ-38 was the most potent 2-phenyl-4quinozolinone derivative in inhibiting tubulin polymerization
and it showed significant cytotoxicity against human
leukemia HL-60 cell. In this study, HMJ-38 was examined for
its growth inhibition effect on human tongue cancer CAL27
cells. After 48 hours treatment of HMJ-38 on CAL27 cells,
the MTT method was applied to determine the proliferation
rate and a dose- and time-dependent decrease in cell
proliferation was observed. The IC50 of HMJ-38 for CAL27
cells was 2.5 μM. Cell cycle analysis and microscopic
examination of CAL27 cells showed that HMJ-38 induced
significant G2/M arrest and apoptosis. We found that HMJ-38
up-regulated the protein levels of p-CDK1 (Thr161), Chk1,
Chk2 and p21, and increased cyclin B and CDK1 kinase
activity. HMJ-38-treated CAL27 cells presented typical
characteristics of apoptosis as further evidenced by
DAPI/TUNEL staining and increase of internucleosomal
DNA cleavage. In addition, apparent release of cytosolic
cytochrome c, pro-caspase-9, Apaf-1 and AIF, downregulation of Bcl-2, Bcl-xL, xIAP, up-regulation of phosphoBcl-2, Bax and Bad, and cleavage of pro-caspase-3 and procaspase-9 were detected by Western blotting. Caspase activity
assay and sub-G1 nuclei analysis of HMJ-38-treated CAL27
in the absence or the presence of caspases inhibitors indicated
that the HMJ-38-induced apoptosis was mainly mediated by
the activation of caspase-9 and caspase-3. Our results suggest
a mechanism of cytotoxic action of HMJ-38 and indicate that
HMJ-38 may be a promising chemotherapy agent against
human tongue cancer.
424
GALECTIN-3: A USEFUL TUMOR MARKER
IN THYROID AND COLORECTAL CANCER
Marie Ludviková1,3, Luboš Holubec Jr.2, Ivana Kholová4,
Josef Reischig1 and Ondřej Topolčan2
1Institute
of Biology, Medical Faculty, Charles University,
Karlovarská 48, 301 66 Plzeň;
2Department of Oncology, Medical Faculty, Charles
University, Plzen;
3Department of Pathology, 1st Medical Faculty, Charles
University, Prague, Czech Republic;
4A.I.Virtanen Institute for Molecular Sciences, University of
Kuopio, Finland
3389
ANTICANCER RESEARCH 28: 3157-3556 (2008)
This review aims to summarize diagnostic and prognostic
difficulties in thyroid and colorectal cancer from a
pathologist’s point of view, with emphasis on the role of
galectin-3 in diagnosis and/or prognosis of these tumors.
Results of our current galectin-3 studies will also be presented.
Galectin-3 (endogenous β-galactoside-binding protein) is a
member of a group of widely distributed carbohydrate-binding
proteins that have been implicated in a spectrum of
physiological and pathobiological processes including
malignant transformation. Galectin-3 was proven to be
expressed in various cancer cells, mainly of thyroid and
colorectal cancer. Its expression in these tumors has been
intensively studied with respect to the diagnostic and
prognostic role of this tumor marker.
Thyroid tumors of follicular cell origin represent a
diagnostically and prognostically a difficult group of
neoplasms. In particular differentiation between follicular
adenoma and carcinoma, and between follicular tumor and
follicular variant of papillary carcinoma await additional
methods. Galectin-3 was produced in both benign and
malignant thyroid tumors of follicular cell origin, but galectin3 was significantly up-regulated in papillary carcinomas only
in comparison with the other tumors (p<0.0001).
The main task at the time of a pathologist’s diagnosis is the
of assessment of the metastatic potential of colorectal cancer
using several tumor markers. Liver metastatic lesions as well
as primary tumors showed up-regulated mutually correlating
levels of galectin-3.
Galectin-3 seems to be a promising diagnostic marker in
malignant thyroid tumors of follicular cell origin, as well as a
prognostic marker predicting metastasis in colorectal
carcinomas.
Supported by research project VZ MSM 0021620819
of epithelial ovarian cancer elucidating clinical course has
been proposed. Moreover, cancer stem cell theory could
provide a unifying model of ovarian cancer, reflecting
histologic heterogeneity and metastatic potential, as well as
resistance to chemotherapy. However, molecular pathogenesis
and progression of this disease are yet been definitively
understood.
Currently histological diagnosis of ovarian neoplasms is
based on their features in hematoxylin-eosin-stained sections,
which continue to be the fundamental substrate of surgical
pathology. Immunohistochemistry has assumed the prominent
role in diagnostic ovarian pathology. Diagnostic tissue tumor
markers serve for discrimination between microscopically
similar pathological ovarian lesions. Unlike breast and
colorectal cancer, no useful prognostic and predictive tissue
tumor markers have been identified yet in ovary. Several
promising prognostic and predictive ovarian tumor tissue
markers (e.g. proliferative and angiogenetic markers, p53
overexpression, p16 decreased expression) have been studied
so far, but none has proven to be useful for clinical
application.
The clinical course of advanced disease is therefore difficult
to predict in an individual patient. Dissimilarity of clinical
outcome in patients with ovarian carcinoma suggests that
reliable prognostic and/or predictive (tissue and/or circulatory)
biological markers would be of potential clinical value and
new treatment options are warranted.
Supported by research project VZ MSM 0021620819.
425
CLINICAL IMPLICATIONS OF EPITHELIAL
OVARIAN CANCER PATHOBIOLOGY:
AN OVERVIEW
1Department
Marie Ludvíková
Institute of Biology, Medical Faculty, Charles University,
Karlovarská 48, 301 66 Plzen, Czech Republic
Ovarian tumors are heterogeneous neoplasms from
morphological, pathobiological, and clinical aspects. Epithelial
tumors of the ovary comprise about 60% of all ovarian
neoplasms and more then 90% of ovarian malignancies.
Epithelial ovarian cancer is the most lethal neoplasm of the
gynecological malignancies. The early stage of ovarian cancer
is often asymptomatic and more than two-thirds of patients are
diagnosed with advanced disease.
The clinical outcome reflects the histological type and
pathobiology of ovarian cancer. A dualistic molecular model
3390
426
MALIGNANCY-RELATED HYPERCALCEMIA.
PATHOPHYSIOLOGY AND TREATMENT
Franco Lumachi1 and Umbertoi Basso2
of Surgical and Gastroenterological Sciences,
University of Padua, School of Medicine, 35128 Padova;
2Division of Medical Oncology, Istituto Oncologico Veneto
(IOV) IRCCS, 35128 Padova, Italy
Background: Hypercalcemia is a frequent complication of
malignancy. Malignancy-related hypercalcemia (MRH) may
occur in 5% to 30% of patients with cancer during the course
of their disease, but its incidence varies with type of tumor.
Lung cancer (i.e. squamous cell carcinoma), breast cancer and
myeloma have the higher incidence of MRH, accounting for
more than 50%, while the disease occurs rarely in patients
with colorectal and prostate cancers. Usually, the prognosis
of cancer patients with MRH is poor, with a mean survival
rate of 2-3 months. However, in patients with breast
carcinoma and multiple myeloma the course of the disease is
characterized by self-limited episodes of hypercalcemia,
which may be treated. Pathophysiology: Different
mechanisms are responsible for hypercalcemia, enclos-ing (1)
Abstracts of the 8th International Conference of Anticancer Research, 17-22 October 2008, Kos, Greece
degradation of bone matrix in patients with osteolitic lesions
(i.e. lung, renal and head and neck cancer), (2) abnormal
conversion of vitamin D3 within lymphoma cells and (3)
secretion of parathyroid hormone-related protein (PTHrP),
which repre-sents the principal pathway leading to
hypercalcemia in cancer patients. Most hyper-calcemic
patients with bone metastases may have also increased levels
of PTHrP and the serum PTH measurement represents the
first step in the differential diagnosis from benign (i.e.
primary
hyperparathyroidism)
versus
malignant
hypercalcemia. Unfortu-nately, signs and symptoms (nausea,
weackness, polyuria, lethargy, depression) are aspecific, but
low PTH levels together with high calcium levels in a cancer
patient may suggest a malignancy-related hypercalcemic
syndrome. Medical Treatment: Vigorous intravenous
hydration along with loop diuretics (i.e. furosemide)
administration, which enhance renal excretion of calcium,
represents usually the first step of the medical treatment. Old
agents such as mithramycin, eth-ylphosphorothoric acid,
calcitonin and gallium nitrate have practically been abandoned due to their limited activity and huge side-effects,
especially for the kidney. Bisphosphonates: Several
bisphosphonates have shown to decrease serum calcium levels
by inhibiting PTH-dependent osteoclast activation. Both
clodronate and etidro-nate proved to be of some efficacy in
patients with parathyroid cancer when given intravenously,
while the oral formulation is inactive. Subsequently, more
potent agents (i.e. pamidronate and zoledronate) have become
available, and currently they represent the drugs of choice.
Zoledronate is the most potent drug of this class, al-though
periodical monitoring of renal function is strongly
recommended for some cases of acute renal insufficiency
have been reported. Calcimimetic Drugs: Since the
production of PTH is negatively controlled by ionised
calcium, agents able to potentiate this homeostatic control
might be effective in sup-pressing PTH levels and reducing
serum hypercalcemia. The prototype of these “cal-cimimetic”
agents is cinacalcet, a new drug which interacts with the
membrane-spanning segments of the CaSR and enhances
signal transduction, presumably by inducing conformational
changes in the caSR receptor which reduce the thres-hold for
activation by ionised calcium and suppress PTH secretion in
the absence of a change in the level of extracellular calcium.
Experimental Therapy: A new experimental approach to treat
malignant hyper-calcemia involves the blockade of receptor
activator of nuclear factor-kappa B ligand, usually abbreviated
as RANKL. RANKL is a key element in the differentiation,
func-tion, and survival of osteoclasts, which play an essential
role in removing Ca++ from the bone in response to PTH
stimulation. Denosumab (AMG 162) is a new, fully hu-man
monoclonal antibody against RANKL, which has been
developed to antagonize osteolysis and PTH-related
hypercalcemia.
427
GENETIC MODELS IN BREAST CANCER
RESEARCH
Leif R. Lund, Kasper Almholt, Boye S. Nielsen
and John Rømer
Finsen Laboratory, Rigshospitalet, Copenhagen Biocenter,
Denmark
Growth and invasion of breast cancer require extracellular
proteolysis in order to physically restructure the tissue
microenvironment of the mammary gland. This pathological
tissue remodeling process depends on a collaboration of
epithelial and stromal cells. In fact, the majority of
extracellular proteases are provided by stromal cells rather
than cancer cells. This distinct expression pattern is seen in
human breast cancers and also in transgenic mouse models of
breast cancer. The similar expression patterns suggest that
transgenic mouse models are ideally suited to study the role
of extracellular proteases in cancer progression. Indeed, these
studies demonstrate that proteases are involved in all stages of
breast cancer progression from carcinogenesis to metastasis.
Particular matrix metalloproteinases (MMP) have several
roles that influence cancer progression and dissemination.
However, low molecular weight metalloproteinase inhibitors
(MPI) have not yet been tested in transgenic/spontaneous
metastasis models. We have tested Galardin/GM6001,a potent
MPI that reacts with most MMPs, in the polyoma virus middle
T oncogene mouse model (MMTV-PymT) transgenic breast
cancer model. Galardin treatment significantly reduced
primary tumor growth. Final tumor burden in Galardin-treated
mice was 1.69 cm3 compared with 3.29 cm3 in placebo-treated
mice (t-test, p=0.0014). We quantified the total lung metastasis
volume in the same cohort of mice and found that the
metastasis burden was reduced more than 100-fold, whereas
primary tumor size was reduced only 2-fold. We also found
that primary tumors from Galardin-treated mice exhibited a
lower histo pathologic tumor grade, increased collagen
deposition, and increased MMP-2 activity.
During progression of mammary carcinomas in the MMTVPymT model, MMP13 mRNA was strongly upregulated
concurrently with the transition to invasive and metastatic
carcinomas. As in human tumors, MMP13 mRNA was found
in myofibroblasts of invasive grade II and III carcinomas, but
not in benign grade I and II mammary intraepithelial
neoplasias. To determine if MMP13 plays a role in tumor
progression, we crossed MMTV-PymT mice with MMP13
deficient mice. The absence of MMP13 did not influence
tumor growth, vascularization, progression to more advanced
tumor stages, or metastasis to the lungs, and the absence of
MMP13 was not compensated for by expression of other
MMPs or tissue inhibitor of metalloproteinases. However, an
increased fraction of thin collagen fibrils was identified in
3391
ANTICANCER RESEARCH 28: 3157-3556 (2008)
MMTV-PymT;MMP13(-/-)
compared
to
MMTVPymT;MMP13(+/+) tumors, showing that collagen
metabolism was altered in the absence of MMP13. We
conclude that the expression pattern of MMP13 mRNA in
myofibroblasts of invasive carcinomas in the MMTV-PymT
breast cancer model recapitulates the expression pattern
observed in human breast cancer. Our results suggest that
MMP13 is a marker of carcinoma-associated myofibroblasts
of invasive carcinoma, even though it does not make a major
contribution to tumor progression in the MMTV-PyMT breast
cancer model.
428
EVALUATION OF THE CYTOTOXIC AND
GENOTOXIC EFFECTS OF ORTHODONTIC
BONDING ADHESIVES UPON A HUMAN GINGIVAL
PAPILLAE THROUGH IMMUNOHISTOCHEMICAL
EXPRESSION OF P53, P63 AND P16
Francesca Angiero1, Enrico Dessy2, Giampietro Farronato3,
Elisa Rossi2, Sarah Magistro3, Davide Farronato3,
Rossella Seramondi3 and Stefano Tetè4
1Università
degli Studi Milano-Bicocca, Anatomia
Patologica;
2Università degli Studi di Brescia, Anatomia Patologica;
3Università degli Studi di Milano, Clinica Odontoiatrica;
4Università degli Studi di Chieti, Italy
Purpose: Numerous in vitro studies have shown that the
composite materials have cytotoxic and genotoxic effects on
cells they come into contact with. These materials are
commonly used for restorations in conservative dentistry, and
in orthodontics to anchor brackets to the tooth enamel. The
study determined expression of p53, p63 and p16, biomarkers
that are useful for predicting the potential genotoxicity of the
monomeric adhesives used to anchor orthodontic brackets.
Patients and Methods: Histological examination and P53, p63
and p16 expression were determined immunohistochemically
on the gengival papillae of 99 patients, of which 69 had been
banded orthodontically for one year; 30 patients without
orthodontic banding were used as controls; brackets were
bonded to teeth with a filled flowable composite resin. The
papillae were removed surgically from patients and controls
and examined both to evaluate morphological alterations and
using immunohistochemistry to examine biological alterations.
Associations between protein expression patterns and
development of clinicopathologic parameters during followup were examined. Results: No case showed morphological
alterations visible by microscope. Of the 69 banded patients, 4
(5.80%) were positive to p53, 2 exhibited positivity for p63
expression in the basal and suprabasal layers and were
classified as p63 positive (2.90%). P16 was positive in one
patient (1.45%). Of the control cases, no subject was positive
3392
for any of the biomarkers (0.00%). Conclusion: The
significance of this positivity, together with histology, and
whether these may serve as biomarkers to predict the risk of
developing oral lesion (dysplasia, oral cancer) is still an open
question. From this study it appears that, although the details
of the mechanisms leading to cell death, genotoxicity, and
cell-cycle delay are not fully understood, resin monomers may
alter the functions of the cells of the oral cavity.
429
DETECTION OF MINIMAL RESIDUAL
DISEASE OF ACUTE CHILDHOOD LEUKEMIA
BY FOLLOWING WT1 GENE EXPRESSION
IN THE PERIPHERAL BLOOD
Edina Magyarosy and Erzsébet Rásó
Tumor Progression Department of the National Institute for
Oncology, Budapest
Cytomorphology and Southern blot technique are not sensitive
enough to detect minimal residual disease and to diagnose
relapse, and the different DNA markers, which are detected by
other PCR techniques are present only in 20-30% of childhood
leukemias. Several authors are of the opinion that monitoring
WT gene expression in the peripheral blood can be used to
monitor the progression of the disease, to detect minimal
residual disease and to diagnose relapse early. The WT1 gene
has two splice regions and four different isoforms, which may
play different roles in the disrupted expression of all WT1
isoforms. WT1 gene expression in the bone marrow and in the
peripheral blood in leukemia patients is well known in the
literature, but the expression of WT1 isoforms has not been
investigated yet.
The aim of our study was to investigate if monitoring WT1
gene expression in the peripheral blood was an appropriate
method to monitor the progression of acute childhood
leukemias. In the course of the study, the peripheral blood of
27 newly diagnosed, 17 previously diagnosed and 21
nonleukemic children was tested for WT1 gene expression.
Twenty consecutive pediatric patients were included in this
study for the analysis of the peripheral blood samples and the
initial diagnosis of ALL for WT1 isoforms expression.
In agreement with the literature, we found that all ALL cases
except one expressed the WT1 gene (23/24, 96%). The level of
WT1 expression did not correlate to the ratio of the blast cells
in the peripheral blood. The initial high rate of WT1 positivity
(23/24) became low (~21%) at the end of the induction phase
of the therapy (day 15: 7/24, day 33: 5/24), although remission
occurred in all the patients under treatment except one.
Twenty patients were followed for 12 months following
induction therapy and 16 of them were further monitored for
the second year (14-21 month). Clinical relapse occurred in
two cases during the first year where the WT1 expression at
Abstracts of the 8th International Conference of Anticancer Research, 17-22 October 2008, Kos, Greece
the periphery was maintained for 11-15 months and both
patients died. On the other hand, there was no WT1 gene
expression found in the peripheral blood of non-leukemic
hematological diseases, except myelodysplasia.
We were the first to examine the expression of different
WT1 isoforms in the peripheral blood of children and we
observed that the WT1 pattern is constant. We found that the
5 patients in the low-risk group expressed the 17AA(+) WT1
isoform, but 2 patients had the 17AA(–) WT1 isoform. We
found the presence of 17AA(–) WT1 isoform in the high-risk
group. The expression rates of 17AA(+) or 17AA(–) were the
same in the medium risk group. This point of view was
intermediate between the low-risk and high-risk group; no
overexpression of 17AA(–) or 17AA(+) were observed. In two
ALL cases, the suspicion of mutation in the WT1-17AA
region arose, because we did not find PCR products in the
17AA region, but there was WT1 positivity in the KTS region.
Our results suggest that WT1 assays alone are not
sufficient, but combined with the detection of other, widely
used DNA markers, are useful to detect minimal residual
disease. Following WT1 gene expression levels in initially
WT1-positive children enables us to diagnose relapse early,
before it would be detectable with other existing methods.
430
PRO AND CONS FOR CA-125 MONITORING IN THE
FOLLOW UP MANAGEMENT
Sven Mahner
University Medical Center Hamburg-Eppendorf, Department
of Gynecology and Gynecologic Oncology, 20246 Hamburg,
Germany
Despite radical surgical and chemotherapeutic treatment of
ovarian cancer, the majority of patients develop recurrent
disease within two to three years. Because of this high
likelihood of disease progression, most women are closely
monitored after completing treatment. In case of disease
recurrence, serum concentration of the tumor marker CA-125
usually rises 3-4 months prior to the development of
symptoms or clinical and radiological signs of relapse.
Although a cure of patients with relapsed ovarian cancer is
rarely possible, it is still unclear whether an early reinduction
of therapy could yield extended survival.
Potential benefits of an early treatment of recurrent disease
could be the possible delay of symptoms and improved
survival. The toxic side-effects and decreased interval without
treatment in an otherwise asymptomatic patient are potential
disadvantages.
Depending on the duration of response to previous therapy
and the length of the treatment free interval, patients should
be counselled on the advantages and disadvantages of serial
measurement of CA-125 during follow up.
431
CRITICAL FUNCTIONS OF HUMAN BILIVERDIN
REDUCTASE IN INSULIN/IGF-1 AND MAPK
SIGNALING: POTENTIAL APPLICATIONS IN
TREATMENT OF DIABETES AND CANCER
Mahin D. Maines
Department of Biochemistry and Biophysics, University of
Rochester School of Medicine, Rochester, NY 14642, USA
Degradation of heme to bilirubin involves stepwise conversion
to biliverdin (BV) by heme oxygenases-1&2 followed by
reduction of BV to the anti-inflammatory/antioxidant bilirubin
by biliverdin reductase (BVR). In addition to its reductase
activity, recent studies have revealed a diverse and expansive
spectrum of functions of the human BVR, that is unmatched
by any other protein. The wide assortment of structural
features of hBVR underlies its function in multiple capacities
in the cell . In this presentation, the current understanding of
functions of hBVR that are highlighted below will be
discussed.
hBVR is a dual-specificity kinase (S/T/Y) upstream
activator of insulin/IGF-1 and MAPK signaling pathways. The
hBVR is also a bZip DNA/chromatin binding transcription
factor, an activator and anchor protein for translocation of
PKC enzymes and transcriptional factors within cell
compartments, and a kinase-kinase for activation of PKCs.
Activation of the MEK/ERK/Elk-signaling cascade is a
mechanism for relaying mitogenic and stress stimuli for gene
activation. MEK1 is the proximate kinase for activation of
ERK1/2, and nuclear targeting of ERK1/2 is obligatory for
Elk1 transcriptional activity. Formation of a ternary complex
between hBVR/MEK/ERK is essential for activation of ERK
by MEK, and for transport of activated ERK into the nucleus,
wherein another ternary complex is formed between
hBVR/ERK/Elk that results in Elk1 activation and induction
of gene expression. hBVR, its variants and small fragments
have demonstrated ability to modulate cell signaling and,
hence, the wide range of functions that are regulated by
protein kinases that include growth, differentiation, gene
transcription and metabolism. hBVR is nearly as effective as
IGF in activating MEK-1-ERK axis, while eight-residue
peptides, one flanking P165 and another containing S230 block
the activation of ERK by IGF and PKC-ζ, by TNF-α,
respectively, suggesting their utility as effectors of cell cycle
progression and cell differentiation. Furthermore, because
seven-residue peptide, KYCCSRK, can specifically bind
hematin, it offers a rational approach to design compounds,
based on the ligand-binding property, for delivering heme or
synthetic heme analogues to induce or inhibit heme-regulated
gene expression. The hBVR substrate, BV, and its product,
BR, display notable effects in the cell. BV is an inhibitor of
kinase and NF-κB activities, while BR is a quencher of
3393
ANTICANCER RESEARCH 28: 3157-3556 (2008)
oxygen free radicals. BV inhibits NF-κB, and hBVR reverses
this inhibition. This finding has the likely potential of
providing a foundation for therapeutic intervention in
inflammatory diseases and cancer that may be attained by
preventing reduction of BV. On the other hand, by increasing
BVR levels the beneficial functions of NF-κB might be
augmented. In addition, the cytoprotective of BR against
oxidative stress and free radical-linked diseases, as well as its
cytotoxicity, are now amply documented. Conclusion:
Regulation of glucose uptake, induction of HO-1, and cytokine
and Toll-like receptor signaling are potential target candidates
for hBVR-based therapeutic strategies. Because hBVR blocks
free radical-promoted apoptosis, regulation of its activity
presents a novel drug development strategy to prolong cell
survival. Given the finding that hBVR-based 7or 8 residue
peptides can effectively modulate cell-signaling networks, they
bear the promise of developing into powerful tools for
inhibiting or potentiating transmission of extracellular stimuli
that control gene expression and cellular functions and to
combat diseases that are associated with disruption of normal
kinase-mediated functions such as diabetes and cancer .As
additional functions of hBVR in cell signaling are uncovered,
the prospect of the utility of hBVR-derived structures in
therapeutic settings becomes increasingly more realistic.
Studies were supported by NIH grants ES-012187 and ES004066.
432
CURCUMIN SYNERGIZES WITH COLON CANCER
THERAPEUTICS: A STRATEGY TO ELIMINATE
CANCER STEM CELLS
Althea A. Elliott, Bhaumik B. Patel, Deep-Shikha Gupta,
Vivek Sengupta and Adhip P. N. Majumdar
John D. Dingell VA Medical Center, Karmanos Cancer
Center, Department of Medicine, Wayne State University
School of Medicine, Detroit, MI, USA
Despite the use of surgical resection and aggressive
chemotherapy, nearly 50% of patients with colorectal
carcinoma develop recurrent disease, highlighting the need for
improved therapies. 5-Fluorouracil (5-FU) or 5-FU plus
oxaliplatin (FOLFOX) remains the backbone of colorectal
cancer chemotherapeutics, but produces incomplete response,
resulting in survival of cells (chemo-surviving cells) that often
leads to cancer recurrence, which could partly be due to
proliferation of colon cancer stem cells. It is becoming
increasingly evident that a cancer treatment that fails to
eliminate cancer stem cells may allow regrowth of the tumor.
The current treatment strategy for recurrent cancer consists
mainly of aggressive screening, which is in itself costly,
potentially morbid, and controversial. There is also a cost of
3394
additional toxicities, some of which are even fatal. Therefore,
validation of a non-toxic agent that could improve upon the
current chemotherapeutic regimen would be highly desirable.
Curcumin (diferuloylmethane), the major active ingredient
of turmeric (Curcuma longa), used in South Asian cuisine,
with no discernable toxicity, inhibits the growth of
transformed cells and colon carcinogenesis at the initiation,
promotion and progression stages in carcinogen-induced
rodent models. Curcumin has also been shown to prevent the
development of adenomas in the intestinal tract of Min+/–
mice, a model of human familial adenomatous polyposis. In a
Phase I clinical trial, curcumin was found to be effective in
inhibiting the growth of a variety of tumors. The present
investigation was, therefore, undertaken to examine whether
addition of curcumin to FOLFOX will be a superior
therapeutic strategy for colon cancer chemo-surviving cells, in
part by eliminating colon cancer stem cells.
Forty-eight hour treatment of colon cancer HCT-116 or HT29 cells (which contain 30-40% colon cancer stem cells) with
FOLFOX (25 μM 5-FU+0.625 μM oxaliplatin) resulted in 6070% cell survival, accompanied by a marked activation of IGF1R and minor to moderate increase in EGFR, HER-2, as well
as AKT, COX-2 and Cyclin-D1. However, inclusion of
curcumin in continued FOLFOX treatment for another 48 h
greatly reduced survival of these cells, compared to those
subjected or not subjected to continued FOLFOX treatment
(control). These changes were accompanied by concomitant
reduction in expression and activation of EGFR, HER-2 and
IGF-1R, as well as expression of down-stream signaling
effectors such as AKT, COX-2 and Cyclin-D1. Moreover, 48 h
treatment of chemo-surviving colon cancer HCT-116 cells with
the combination of curcumin and FOLFOX markedly reduced
the cancer stem cell population, as evidenced by their failure
to form colonies, and a marked reduction in CD166 expression.
In conclusion, our data suggest that inclusion of curcumin
to conventional chemotherapeutic regimen could be one of the
effective strategies to prevent the emergence of chemoresistant colon cancer cells by markedly reducing/eliminating
the cancer stem cells.
433
FUNCTIONALISATION OF APTAMERS FOR THE
DEVELOPMENT OF EFFECTIVE CANCER
THERAPEUTICS
V. Makwana1, H. Khan1, N. Courtenay-Luck2
and S. Missailidis1
1Department
of Chemistry and Analytical Sciences, The
Open University, Walton Hall, Milton Keynes, MK7 6AA;
2Antisoma Research Ltd, Welwyn Garden City, UK
Introduction: Aptamers, short oligonucleotide therapeutic,
diagnostic and imaging agents, possess great affinity and
Abstracts of the 8th International Conference of Anticancer Research, 17-22 October 2008, Kos, Greece
selectivity for their targets. However, they are limited in terms
of application due to their rapid renal clearance and
degradation from nucleases in the blood. Thus, it is often
necessary to incorporate appropriate modifications for
achieving their full potential. Aptamer labelling with
appropriate fluorescent moieties or radioisotopes can confer
diagnostic and imaging potential, respectively. Various
chemical modifications, such as PEGylation, can improve their
pharmacokinetic properties and retain aptamers longer in
circulation, making them suitable for therapeutic applications.
We now present a range of chemical modifications on our
tumour-targeting aptamers that have allowed us to develop
them as diagnostic or therapeutic agents. Methods: The
functionalisation of aptamers entails a covalent reaction
between the fluorescent label, chelator or polyethylene glycol
(PEG) polymer modified with an activated functional group
and the previously selected aptamers in an aqueous solution
at optimal pH and temperature. It is, however, possible to
loose affinity to the target following extensive modification to
the aptamer backbone or coupling to various agents.
Fluorescence Resonance Energy Transfer (FRET), flow
cytometry and cell cytotoxicity assays were carried out,
following chemical modification, to determine the modified
affinity and efficacy of the purified aptamer-conjugate for their
target and ensure that modified aptamers retain their
therapeutic properties. Results and Conclusion: Polyethylene
glycol (PEG), a polymer varying in size and comprised of
polymerized ethylene oxide monomers, has become a popular
agent for modifying physiochemical and pharmacokinetic
characteristics of therapeutic biological macromolecules.
Conjugating therapeutic biological molecules to PEG has
many positive attributes for clinical utilisation. The overall
increase in the molecular weight of the targeting molecule
enhances its residential and circulatory time within the body,
thereby reducing renal clearance, which can be improved from
hours to days, hence improving therapeutic efficacy. Other
advantages include lower immunogenicity, increased
protection from enzyme degradation and reduced toxicity.
Similarly, the coupling of appropriately chosen fluorescent
moieties can offer valuable immunoassay development
potential for the identification and quantification of the target
biomarker in biological media.
434
INTRAUTERINE GROWTH RESTRICTION:
PERINATAL PARAMETERS ASSOCIATED WITH
FUTURE DEVELOPMENT OF THE METABOLIC
SYNDROME
Ariadne Malamitsi-Puchner and Despina Briana
Neonatal Division, 2nd Department of Obstetrics and
Gynecology, University of Athens, 76, Vas. Sophias Ave,
11528 Athens, Greece
Intrauterine growth restriction (IUGR) is the failure of the
fetus to achieve his/her intrinsic growth potential, due to
anatomical and/or functional disorders and diseases in the
feto-placental-maternal unit. IUGR results in significant
perinatal and long-term complications, including development
of insulin resistance/metabolic syndrome in adult life.
The thrifty phenotype hypothesis suggests that intrauterine
malnutrition leads to adaptational changes of the
endocrine/metabolic mechanisms (programming), in order to
secure fetal survival. In this respect, in IUGR fetuses, blood
flow redistribution takes place, resulting in reduced
mass/impaired function of pancreatic β-cells. Moreover, IUGR
infants present with permanent changes in adipose tissue
metabolic and hormonal functions. Adipose tissue regulates
whole body metabolism, by secreting various hormones,
named adipocytokines. The latter play a major role in the
mechanisms linking obesity to insulin resistance/metabolic
syndrome and were recently implicated in intrauterine growth.
A number of recent studies from our group explored the
implication of adipocytokines (leptin, adiponectin, visfatin,
resistin and apelin -also expressed by the human placenta) in
fetal growth, by investigating and comparing circulating
concentrations of these hormones in IUGR and appropriate for
gestational age (AGA) fetuses and neonates. The relationship
of the circulating concentrations of the above adipocytokines
with respective insulin ones was also studied.
Our results, particularly referring to the novel
adipocytokines indicate that resistin and apelin concentrations
did not differ between IUGR cases and AGA controls and did
not correlate with respective insulin ones, possibly indicating
lack of direct involvement in perinatal insulin resistance and
adipogenesis. In contrast, visfatin concentrations were higher
in IUGR neonates, possibly implying increased visceral fats
stores, as well as predisposition to insulin resistance. In this
respect, visfatin may serve as an early marker with prognostic
value for later development of insulin resistance/ metabolic
syndrome. However, circulating insulin concentrations were
lower in IUGR cases, possibly indicating reduced β-cell mass
and/or impaired β-cell function. Furthermore, concentration of
visfatin and apelin are high in the fetus, possibly due to
placental expression. On the other hand, the fetus per se may
contribute to its circulating resistin concentrations, as the latter
did not decline after birth.
435
EPIGENETIC CHANGES IN WILMS’ TUMOURS
Anthony R. Dallosso, Anne L. Hancock, Laxmi
Chilukamarri, Sally Malik, Keith W. Brown and Karim Malik
Cancer and Leukaemia in Childhood (CLIC) Sargent
Research Unit, Department of Cellular and Molecular
Medicine, School of Medical Sciences, University of Bristol,
University Walk, Bristol BS8 1TD, UK
3395
ANTICANCER RESEARCH 28: 3157-3556 (2008)
In addition to genetic events, Wilms’ tumour (WT) aetiology
has been closely linked with epigenetic lesions. WTs display
epigenetic gene silencing, involving aberrant hypermethylation
of tumour suppressor gene 5’-CpG islands. Our laboratory has
previously
demonstrated Wilms’ tumour
specific
hypomethylation occurring at the WT1 antisense regulatory
region (WT1 ARR) associated with loss of imprinting and
increased expression of a regulatory RNA, WT1-AS and AWT1.
We have extended our studies with a genome-wide
methylation analysis of WT and foetal kidney samples using
human promoter microarrays hybridized with methylated
DNA purified by 5-methyl-cytosine immunoprecipitation.
Putative targets for epigenetic deregulation in WTs were then
validated by COBRA analysis and gene expression quantified
using real-time PCR. We report identification of long range
epigenetic silencing (LRES) in Wilms’ tumour. WTs display
extensive hypermethylation of a large cluster of paralogous
genes in this region. Further, on a distinct genetic locus, we
show activation of gene expression associated with
hypomethylation of GLIPR1. Our data show that WTs exhibit
a wide range of epigenetic abnormalities, including
hypermethylation, hypomethylation and loss of imprinting.
conventional cell culture. Steric cell-to-cell connections were
observed throughout the culture and the culture showed
characteristics of in vivo glioma cells. When the three gliomas
were compared, each cell line presented a different form.
U118MG cells were unpiled and attached to the scaffold with
numerous fiber formations, whereas KNS42 cells aggregated,
adhering to each other, thereby leading to the formation of
built balloon-like structures. T98G cells showed an
intermediate appearance. Discussion: Glioma cells grew threedimensionally in the current culture. There were differences
between the two- and three-dimensional cultures. Cell lines
used for the study were representatives of standard gliomas.
Although these cells are frequently used for many
experiments, their features were quite different. This became
evident only after using our culture. Under such
circumstances, we conclude that three-dimensional cultures
might be useful for further investigation of gliomas.
436
THREE-DIMENSIONAL CELL CULTURE OF
HUMAN GLIOMA CELLS AND MORPHOLOGICAL
DIFFERENCES
Department of Pharmacology, Medical School, University of
Patras, Patras, Greece
Yoshinobu Manome and Michiko Watanabe
Department of Molecular Cell Biology, Institute of DNA
Medicine Research Center for Medical Sciences, Jikei
University School of Medicine 6-8-27 Nishishinbashi,
Minato-ku, Tokyo, Japan 105-8461
Introduction: In vivo glioma grows three-dimensionally and
spreads continuously by infiltrating the surrounding tissues. In
contrast, cultured glioma cells lose their three-dimensional
conformation and cease their proliferation when they reach
confluence. In addition, vital cellular functions that are present
in tissues or organs might be overlooked with ordinary ‘culture
dishʼ-based cell cultures. From this viewpoint, we attempted
to establish a three-dimensional culture that mimics the local
environment within the human body. We applied the method to
human glioma cells and investigated their features. Materials
and Methods: Bio-adaptable and degradable gelatin was
meshed and used as a scaffold. Three malignant glioma cell
lines, T98G, KNS42, and U118MG, were chosen for the
experiments. Dispersed cells (1×104 cells/100 μl of DMEM)
were attached to the 5-mm cubes of the scaffold. Cells were
then further cultivated for 5 to 10 days. Specimens were
examined by SEM, TEM, stereoscopy, and light microscopy.
Results: Morphological examination of the three-dimension
culture revealed features that were barely detectable in
3396
437
PARSTATIN: A NEW CRYPTIC ANTI-ANGIOGENIC
PEPTIDE
Michael E. Maragoudakis and Nikos E. Tsopanoglou
Thrombin, the serine protease best known for its pivotal role in
haemostasis, has been proposed to play an important role in
the initiation of angiogenesis by a mechanism mostly
independent of its coagulant activity and more dependent on
signaling via the protease-activated receptors (PARs). PARs
consist a novel family of G protein-coupled receptors, which
are activated by proteolytic cleavage of their N-terminal
extracellular domain. PAR-1 is the first member of this family
to be cloned in which proteolytic cleavage at the R41/S42 bond
by thrombin releases a 41 aminoacid peptide and unveils a
tethered peptide ligand with the recognition sequence
SFLLRN. Despite the wealth of information relating to the
role of thrombin and PAR-1 in physiology and disease states,
a potential biological role of cleaved peptide remains
unknown. We evaluated the effect of the 41-aa cleaved peptide
in human endothelial cells as well as in in vivo and ex vivo and
in vitro angiogenesis models. We have designated this
fragment of PAR-1 as “parstatin”. Exposure of endothelial
cells to parstatin resulted in a concentration-dependent
inhibition of serum-mediated proliferation, as well as of
bFGF- and VEGF-induced cell growth. Consistently, parstatin
blocked the serum-, bFGF- and VEGF-triggered Erk1/2
activation. In contrast, no effect was observed in cells treated
with EGF or heparin-binding EGF. Growth inhibition of
endothelial cells by parstatin was further confirmed by flowcytometric cell cycle analysis. In addition, the Annexin
V/propidium iodide apoptosis assay provided strong evidence
Abstracts of the 8th International Conference of Anticancer Research, 17-22 October 2008, Kos, Greece
that the inhibition of cell growth is likely associated with
induction of apoptosis. Parstatin increased the percentage of
endothelial cells in early and late apoptotic stages in a
concentration-dependent manner. Parstatin also triggered the
activation of caspase 3 and the induction of poly (ADPribose)polymerase cleavage to its signature 85-kDa fragment.
In addition, the apoptotic effect of parstatin was mostly
reversed in the presence of caspase inhibitor Z-VAD-FMK.
Parstatin abrogated tube formation in in vitro Matrigel and
fibrin angiogenesis model and suppressed both the basic
angiogenesis and that stimulated by VEGF or bFGF in rat
aortic rings and in chick chorioallontoic membrane model in
vivo. We have also shown that parstatin acts as a cellpenetrating peptide, exerting its biological effects
intracellularly. These results provide a plausible evidence for a
negative role of PAR-1 cleaved peptide in angiogenic cascade
and suggest parstatin as target for developing anti-angiogenic
agents with potential therapeutic application in cancer and
other angiogenesis-related diseases.
438
CONSTITUENTS OF CARPOBROTUS EDULIS
INHIBIT P-GLYCOPROTEIN OF HUMAN MDR1
GENE TRANSFECTED MOUSE LYMPHOMA CELLS
A. Martins1,2, A. Vasas3, Zs. Schelz4, M. Viveiros1, J.
Molnár4, J. Hohmann3, G. Spengler1,2 and L. Amaral1,2
1Unit of Mycobacteriology, 2UPMM, Instituto de Higiene e
Medicina Tropical, Universidade Nova de Lisboa
(IHMT/UNL), Rua da Junqueira, 96 1349-008 Lisbon,
Portugal; 3Institute of Pharmacognosy, Faculty of Pharmacy,
University of Szeged, H-6720 Szeged, Eötvös u. 6, Hungary;
4Department of Medical Microbiology and Immunobiology,
Faculty of Medicine, University of Szeged, H-6720 Szeged,
Dóm tér 10, Hungary
Multidrug resistance is a major health problem that affects the
therapy of cancer (eukaryotic cells) and MDR infections
caused by Escherichia coli, Staphylococcus aureus,
Mycobacterium tuberculosis, etc. Our findings suggest a new
approach for the therapy of MDR cancer and bacterial
infections that involves the use of these compounds as
adjuvants to conventional therapies and have the potential to
increase the usage of existing antibiotics that have fallen by
the wayside due to MDR causes.
The methanolic extract of Carpobrotus edulis reverses
resistance of mouse lymphoma cells that carry the human mdr1
gene to chemotherapeutic agents and increases the killing
activity of Staphylococcus aureus infected macrophages (1, 2).
The aim of the present work was the identification of the
compound(s) responsible for the MDR reversal activity.
A bioassay guided purification protocol was performed,
testing the extracts, fractions and pure compounds for their
ability to inhibit the p-glycoprotein (the efflux pump
responsible for the multidrug resistance of this cell line) of
mouse lymphoma cells containing the human efflux pump
gene mdr1. The assay was performed following extrusion or
retention of rhodamine 123 inside the cancer cells, by flow
cytometry.
The compounds were isolated from the chloroform soluble
fraction of the methanolic extract by means of multistep
chromatographic separations, including CC, VLC, CPC, PLC
and HPLC. The structures were determined by NMR
investigations as triterpens (β-amyrin and oleanolic acid)
monogalactosyldiacylglycerol and phenolic compounds.
The efflux pump inhibitory activities of some of these
compounds against MDR mouse lymphoma cell were
evaluated.
Ana
Martins
was
supported
by
FCT
grant
SFRH/BD/19445/2004 and by a short period FCG grant.
Váradi Anikó and Hadámé Berta Erzsébet for their precious
technical contribution. Imre Ocsovszki for the flow cytometry
measurements.
1 Martins M et al: Fitoterapia 96-99, 2005.
2 Ordway D et al: Phytother Res 17: 512-519, 2003.
439
THE TENSIN FAMILY OF PUTATIVE METASTASIS
SUPPRESSOR PROTEINS ARE DOWN-REGULATED
IN HUMAN KIDNEY CANCER
Danuta Martuszewska1, Börje Ljungberg2,
Martin Johansson3, Cecilia Oslakovic1,
Björn Dahlbäck1 and Sassan Hafizi1
1Lund University, Dept. of Laboratory Medicine, Section for
Clinical Chemistry, University Hospital Malmö, SE-205 02,
Malmö;
2Umeå University, Department of Surgical and Perioperative
Sciences, SE-901 85, Umeå;
3Lund University, Dept. of Laboratory Medicine, Section for
Pathology, University Hospital Malmö, SE-205 02, Malmö,
Sweden
Background: Renal cell carcinoma (RCC) is the most common
form of kidney cancer in adults. In RCC, transformation and
uncontrolled growth of epithelial cells occurs as a result of
multiple molecular changes, part of which can be due to loss
of tumor suppressor proteins. The Tensin family of
intracellular proteins (Tensin1, -2, -3 and -4), are thought to
mediate signal transduction of cell motility and growth and act
as important links between the extracellular matrix and the
cytoskeleton. Dysregulation of Tensin proteins has previously
been implicated in various human cancers. Thus we
hypothesize that at least some of the Tensins are novel tumor
suppressors that may be dysregulated in RCC. Aims: The aim
of the current study was to evaluate the significance of all four
3397
ANTICANCER RESEARCH 28: 3157-3556 (2008)
Tensin isoforms in a study of human kidney cancer subjects.
Methods: Quantitative real-time reverse transcriptase PCR was
used to analyse mRNA expression of Tensins1-4 in human
kidney samples, normal (n=48) vs. RCC (n=223). We also
screened various human cancer cell lines for Tensin mRNA as
well as protein expression by Western blot. Moreover, we
performed immunohistochemical analysis of Tensin3 in
human kidney tumors and generated stable Tensin3 expressing
cells for migration assay. Results: Tensin2 and Tensin3
expression were found to be low or largely absent at both
mRNA and protein levels in a panel of diverse human cancer
cell lines. Messenger RNA expression of all four Tensin genes
was significantly lower in human kidney tumors as compared
to normal kidney tissue. Correlation studies revealed
expression of the Tensins to correlate positively amongst each
other, whilst they correlated negatively with tumor grade, but
not tumor size. Immunohistochemical analysis revealed
Tensin3 to be present in the cytoplasm of tubular epithelium in
normal human kidney sections, and 40% of patient kidney
tumor sections analyzed in microarrays showed Tensin3
expression to be low or absent. Overexpression of Tensin3 in
human kidney 293 cells resulted in a significant reduction in
migration capacity versus mock-transfected cells. Conclusion:
Our findings indicate that the expression of all Tensins is
downregulated in human kidney tumors and that loss of
Tensins may lead to uncontrolled cell migration during
metastasis. Furthermore anticancer therapies may benefit from
inducing up-regulation of Tensins as a favourable side-effect.
440
REGULATION OF C/EBPα BY HYPOXIA AND
ESTROGEN IN BREAST CANCER CELLS
Liliane Massaad-Massade
Liliane Massade, Institut Gustave-Roussy, UMR 8121
Pavillon de recherche 2, 94805 Villejuif CEDEX, France
Experimental and clinical studies showed that both estrogen
(E2) and hypoxia (H) were involved in tumour development
and progression. First, we undertake a study to determine
whether these factors could interact to modulate gene
expression using a microarray approach. We screened the
transcript levels of over 8,000 genes in the estrogen receptor
(ERα) positive T-47D human breast cancer cell line
maintained at 21% O2 or at 1% O2 with or without E2 cotreatment. Treatment by E2 or hypoxia alone altered the
expression of 26 and 9 genes, respectively, whilst the
expression of 31 genes was modulated by H-E2 combination.
Of the 31 genes modulated by the H-E2 combination, 21 of
them were found to be down-regulated. Microarray data was
validated for 19 by quantitative real-time PCR and a good
correlation noted (r2=0.8). Five out of these 19 genes were
assayed for protein expression by Western blot and a good
3398
correlation was found between mRNA and protein levels.
Statistical analysis showed that the gene expression
modulation by the combined H and E2 treatment was additive
in most cases. Interestingly, the transcription factor
CCAAT/enhancer binding protein-α (C/EBPα), involved in
control of cell differentiation and proliferation, was found to
be down-regulated by hypoxia and E2. Therefore, we
examined the mechanism by which the down-regulation by
hypoxia and by E2 takes place. Using the specific RNA
polymerase II inhibitor 5,6-dichlorobenzimidazole 1-β-Dribofuranoside (DRB), the mRNA stability was analyzed
under normoxia and hypoxia, with and without E2 cotreatment. Hypoxia and the H-E2 combination but not E2 alone
reduced the half-life of the C/EBPα mRNA by ~30%.
C/EBPα gene promoter studies indicated that hypoxia but not
E2 repressed the transcription of the gene and identified a
hypoxia response element (-522; -527 bp) which binds to HIF1α as essential for down-regulation of C/EBPα transcription
in hypoxia. Immunocytochemical analysis showed that
C/EBPα was localized in the nucleus at 21% O2 with or
without E2 co-treatment, but was mostly cytoplasmic under
1% O2 in the presence or in the absence of E2. Knockdown of
HIF-1α by RNAi restored C/EBPα to normal levels under
hypoxic conditions. Immunohistochemical studies of 10
tumour samples did not show any colocalization of C/EBPα
and GLUT1 (used as a marker for hypoxia). Taken together,
these results show that hypoxia downregulates C/EBPα
expression in breast cancer cells by several mechanisms,
including transcriptional and post-transcriptional effects. The
down-regulation of C/EBPα in hypoxia is mediated by HIF-1
that by the H-E2 combination is mainly due to hypoxic effect.
This justifies further examination of C/EBPα as a possible
therapeutic target in breast cancer with large hypoxic regions.
441
ROLE OF 2B4 (CD244) AND CS1 (CD319) IN
NATURAL KILLER CELL-MEDIATED
KILLING OF CANCER CELLS
Porunelloor A. Mathew and Stephen O. Mathew
Department of Molecular Biology and Immunology and
Institute for Cancer and Blood Disorders, University of
North Texas Health Science Center, 3500 Camp Bowie
blvd., Fort Worth, TX, 76107, USA
Natural killer (NK) cells are components of the innate immune
system and form the first line of defense against various
cancer and viral infections. NK cells have the ability to kill
certain cancer cells and their function is regulated by a delicate
balance between activating and inhibitory signals received
through cell surface receptors. 2B4 (CD244) and CS1
(CD319, CRACC) are members of the signaling lymphocyteactivation molecule (SLAM) family of receptors expressed on
Abstracts of the 8th International Conference of Anticancer Research, 17-22 October 2008, Kos, Greece
NK cells. Activation of NK cells through surface 2B4 or CS1
enhanced the killing of several tumor cells including K562 and
DU145 prostate cancer cells. Studies using 2B4 gene knockout
mice revealed an in vivo role for 2B4 in rejection of B16
melanoma cells. 51Cr-release cytotoxicity assays showed that
human NK cell line NK92MI activated with the 2B4 and CS1
monoclonal antibodies (mAb) were more effective in killing
DU145 prostate cancer cells than unstimulated NK cells.
Understanding the expression and function of these receptors
will shed more light on how these receptors stimulate NK cells
to effectively target and kill cancer cells. This will allow us to
make attempts towards developing better immunotherapy
treatments for cancer.
442
ANTI-CANCEROGENIC ACTIVITIES AND
ESSENTIAL BIOCHEMICAL PROPERTIES OF
PLANT BIFUNCTIONAL NUCLEASE TBN1
Jaroslav Matoušek1, Tomáš Podzimek1,2, Pavla Poučková3,
Lidmila Orctová1, Josef Souček4, Jiří Škvor5,
Petra Lipovová2 and Josef Matoušek6
1Biology Centre of the ASCR v.v.i., Institute of Plant
Molecular Biology, Academy of Sciences of the Czech
Republic, 370 05 České Budějovice;
2Department of Biochemistry and Microbiology, Institute of
Chemical Technology Prague, 166 28 Prague;
3Institute of Biophysics and Information, Medical Faculty of
the Charles University, 128 00 Prague;
4Institute of Hematology and Blood Transfusion, 128 00
Prague;
5Laboratory of Genetics, department of Anthropology,
Faculty of Science of the Charles University, 128 20 Prague;
6Institute of Animal Physiology and Genetics, Academy of
Sciences of the Czech Republic, 277 21 Liběchov, Czech
Republic
Recombinant tomato bifunctional nuclease 1 (TBN1)
(E.C.3.1.30.x) that was cloned previously (1) was produced in
planta by leaf agroinfiltration biotechnology, purified and
analyzed for its antitumour and biological effects.
Anticancerogenic and biological activities of TBN1 were
analyzed in comparison with other plant nucleases and bovine
ribonuclease (BS-RNase).
TBN1 displays cytotoxicity for human melanoma, prostatic
carcinoma and neuroblastoma, growing in athymic mice. In
vitro antiproliferative effect tested on ML-2 cell line was,
however, negative. This enzyme in comparison with mung
bean nuclease (PhA) (3) and (BS-RNase) was in vivo a little
less effective on the melanoma tumours, however, more
effective on melanoma in comparison to black pine pollen
nuclease (PN) (4). The most antitumorous and antiproliferative
effects were observed on prostatic carcinoma after intravenous
application of TBN1 conjugated to polyethylene glycol (PEG)
for its stabilization, suggesting selective action of TBN1 on
cancer cells in vivo. It was found that TBN1 exhibits lower
side-effects, e.g. aspermatogenesis of ICR mice, relative to
other nucleases studied. As the most important fact, it was
found that immunosuppressivity caused by TBN1 was almost
zero in comparison to the high MCL immunosuppressivity
characteristic.
As detected by immunofluorescence microscopy and by
biochemical methods, TBN1 penetrates tumor cells within
several hours after its application. The following biochemical
properties that could be essential for the specific nuclease
action on tumors are characteristic for purified TBN1. Mature
nuclease TBN1 is a glycoprotein ~36 kDa. It has a pI of 5.42
and a pH optimum of 5.9 for double-stranded (ds) DNA and
6.3 for single-stranded (ss)RNA and DNA. It cleaves
substrates ssRNA:dsDNA:ssDNA at the ratio 1:1.4:1.6. TBN1
exhibits 3’nucleotidase activity 0.54±0.02 μmol Pi/min/μg of
protein at pH 6.0. The nuclease has capability to destroy
human 28S, 18S, 7S and 5.8S RNA in vitro, as well as dsRNA
producing oligo and mononucleotides. The enzyme shows
maximum activity around 60˚C suggesting its high thermoand structural stability. Hence, TBN1 can act on various
cellular RNA species, genomic DNA, as well as on RNA
induced during posttranscriptional gene silencing. Moreover,
3’nucleotidase activity of TBN1 can dephosphorylate some
nucleoprotein receptor(s) or other cellular components.
This work was supported by GAČR 521/06/1149,
MŠMT:MSM6046137305, ASCR 1QS500510558 and
AV0Z50510513 projects.
1 Matoušek J: e.a. Biol Chem 388: 1, 2007.
2 Matoušek J: Comp Biochem Physiol Part C 129: 175, 2001.
3 Souček J: e.a. Neoplasma 53: 402, 2006.
4 Lipovová P: e.a. Neoplasma 55: 158, 2008.
443
CULTIVATION OF PRIMARY MAMMARY
EPITHELIAL CELLS FROM BREAST
CANCER PATIENTS, BRCA1/2 CARRIERS,
AND HEALTHY CONTROLS: USEFUL
MODEL FOR BREAST CANCER RESEARCH
Eva Matouskova1,2, Eva Bursikova1,2, Jan Sevcik1
and Zdenek Kleibl1
1Institute
of Biochemistry and Experimental Oncology, First
Faculty of Medicine, Charles University Prague, Prague 2,
121 08;
2Prague Burn Centre, Third Faculty of Medicine, Charles
University Prague, Prague 10, 100 00, Czech Republic
In vitro cultured primary mammary epithelial cells (MECs)
from oncological patients and healthy women represent one of
the best models for studies of malignant transformation. We
3399
ANTICANCER RESEARCH 28: 3157-3556 (2008)
have developed and optimized a feeder layer technique for
cultivation of human MECs. More than 200 primary MEC
cultures were established from normal and malignant tissue of
the mammary gland. Among them, 26 cell populations from
the mammary gland of BRCA1 or BRCA2 mutation carriers
were prepared. Spontaneous immortalization occurred in two
cell populations. The first one, EM-G3 cell line, was derived
from primary breast carcinoma tissue and exerts characteristics
of mammary progenitor cells. Recently, a second cell line from
MECs has been established. Primary cells and cell lines were
characterized by proliferative activity, morphology, dynamic
activity (time-lapse cinemicrography), imunocytochemistry,
cytogenetics and molecular biology. The MECs were used for
development of the "Non-destructive Test of Cellular Activity"
that can be used for individual tumors’ chemosensitivity testing
and for screening of new potentially antitumor drugs. The
clonal cell line EM-G3 was able to partially differentiate in vivo
as well as in vitro. It represents a unique spontaneously
immortalized clonal cell line evidently derived from
premalignant breast cancer progenitors. The study of
differences in biological behavior between BRCA1 mutationcarrying MACs and BRCA1-wt MACs in vitro allows us to
trace effects of BRCA1 haploinsufficiency in early stages of
mammary cancerogenesis in BRCA1 mutation carriers.
The work was supported by grant NR 8345-4 from the Grant
Agency of the Ministry of Health of the Czech Republic.
tumors, including our recent results of an analysis of the
clinical significance of telomere factors. Recent findings: The
prevalence of ALT varied greatly among different soft tissue
sarcoma subtypes and the proportion of ALT also differed
among previous reports. In addition, the frequency of
telomerase activity expression in mesenchymal tumors differed
among previous reports. The telomere maintenance
mechanism has recently emerged as a prognostic factor for
sarcomas, although some of the data are controversial. Our
findings: In giant cell tumors of bone, telomere length
correlated with roentgenographic grade due to frequency of
cell division, and high telomerase activity indicated the
aggressiveness. In desmoids tumors, decreasing telomere
length correlated with tumor size due to increased duration of
proliferation in the tumor, and tumor aggressiveness. In
sarcomas, ALT is a very significant prognostic risk factor for
sarcoma patients. In ALT-negative sarcoma patients,
telomerase expression is a significant prognostic risk factor.
Summary: Although recent studies indicate a positive
correlation between the telomere maintenance mechanism and
tumor aggressiveness in mesenchymal tumors, there are
different and controversial data among previous reports.
Therefore, further study is necessary to clarify telomere
maintenance mechanisms in bone and soft tissue mesenchymal
tumors.
444
TELOMERE MAINTENANCE MECHANISMS IN
MESENCHYMAL TUMORS
445
PYRUVATE KINASE TYPE M2: A TARGET
OF DIFFERENT ONCOGENES WITH HIGH
THERAPEUTIC POTENTIAL
Toshihiro Matsuo1, Takashi Sugita1, Shoji Shimose1,
Tadahiko Kubo1, Yuji Yasunaga2 and Mitsuo Ochi1
S. Mazurek1,2, W. Zwerschke3, U. Rapp4, J.L. Rosa5
and E. Eigenbrodt1
Departments of 1Orthopaedic Surgery and 2Artificial Joints
and Biomaterials, Graduate School of Biomedical Sciences,
Hiroshima University, 1-2-3 Kasumi, Minami-ku, Hiroshima
734-8551, Japan
1Institute
Background and Aim: Telomere maintenance is regarded as an
important mechanism in evading senescence in tumor cells,
and two types of telomere maintenance mechanisms have been
described in human tumors: telomerase activation and
alternative lengthening of telomeres (ALT). Approximately
85% of carcinomas engage a mechanism to maintain stable
telomere length by telomerase activity. ALT is characterized
by a heterogeneous pattern of telomere length, usually ranging
from very short to abnormally long, and a substantial
proportion of some types of sarcomas have been reported to
have elongated telomeres consistent with ALT in the absence
of telomerase activity. Therefore, sarcomas are distinct from
carcinomas in that a substantial portion of them use the ALT
mechanism to maintain their telomeres. We review the role of
telomere maintenance mechanisms in bone and soft tissue
3400
of Biochemistry and Endocrinology, Veterinary
Medicine, University of Giessen;
2ScheBo Biotech AG, Giessen, Germany;
3Institute for Biomedical Aging Research of the Austrian
Academy of Sciences, Innsbruck, Austria;
4Institute for Medical Radiation and Cell Research,
University of Würzburg, Germany;
5Department of Physiological Sciences, University of
Barcelona, Hospitalet del Llobregat, Spain
Pyruvate kinase catalyzes the last step within glycolysis, the
dephosphorylation of phosphoenolpyruvate (PEP) to pyruvate,
and is responsible for net ATP production within the glycolytic
pathway. Tissues with different metabolic functions express
different isoenzymes of pyruvate kinase (type M1, M2, R or L,
respectively). All proliferating cells, i.e. normal proliferating
cells, embryonic cells, adult stem cells and tumor cells in
particular, express pyruvate kinase isoenzyme type M2 (M2PK, PKM2), which plays a key role in the regulation of the
Warburg effect. M2-PK may occur in a highly active
Abstracts of the 8th International Conference of Anticancer Research, 17-22 October 2008, Kos, Greece
tetrameric form, with a high affinity to its substrate PEP,
which favors the breakdown of glucose to pyruvate and lactate
with production of energy. It may also exist in a nearly
inactive dimeric form with a low PEP affinity, which channels
glucose carbons into synthetic processes, which debranch from
glycolytic intermediates, i.e. nucleic-acid, amino acid and
phospholipid synthesis. In tumor cells, the dimeric form of
M2-PK, termed Tumor M2-PK, is always predominant and is
favored by direct interaction with various oncogenes. The E7
oncoprotein of the human papilloma virus type 16 binds to
M2-PK. pp60v-src kinase, the transforming principle of the
Rous sarcoma virus, phosphorylates M2-PK in tyrosine. A-Raf
kinase induces an increase in serine phosphorylation of M2PK. The effect of A-Raf on the quaternary structure of M2-PK
is secondarily influenced by the amino acid metabolism
(glutamine, serine and alanine) of the individual cell line. The
physiological function of the interaction of M2-PK with
HERC 1 is still unknown.
However, the tetramer: dimer ratio of M2-PK may fluctuate
in tumor cells depending upon the concentrations of signal
metabolites, e.g. fructose 1,6-P2 which induces a re-association
of the dimeric form of M2-PK to the tetrameric form. The M2PK isoenzyme, with its ability to switch between a highly
active tetrameric and inactive dimeric form, is an important
metabolic sensor which adapts tumor metabolism to varying
nutrient supply. Peptide aptamers which specifically bind to
M2-PK and not the M1-PK isoenzyme (96% homology) were
found to obstruct re-association of M2-PK to the tetrameric
form thereby reducing ATP levels and tumor cell proliferation.
(www.metabolic-database.com).
446
PYRUVATE KINASE TYPE M2: AN IMPORTANT
REGULATOR OF THE WARBURG EFFECT
WITH HIGH DIAGNOSTIC POTENTIAL
S. Mazurek1,2, P.D. Hardt3, H.W. Wechsel4, G. Fischer5, D.
Lüftner6, G. Schulze7 and J. Schneider8
1ScheBo
Biotech AG, Giessen;
of Biochemistry and Endocrinology,
Veterinary Medicine, University of Giessen,
3Third Medical Department, University Hospital Giessen;
4Department of Urology, Reinard-Nieter-Hospital,
Wilhelmshaven;
5Institute for Pathology, Reinhard-Nieter-Hospital,
Wilhelmshaven;
6Medical Clinic II, University Hospital Charité, Berlin,
7Institute for Laboratory Diagnosis, Helios Hospital, Berlin;
8Institute for Occupational and Social Medicine, University
of Giessen, Germany
2Institute
Proliferating cells - particularly tumor cells - express a special
isoenzyme of pyruvate kinase termed type M2 (M2-PK,
PKM2) which plays a key role in the regulation of the
glycolytic flux rate and the Warburg effect. Pyruvate kinase
catalyzes the dephosphory-lation of phosphoenolpyruvate
(PEP) to pyruvate and is responsible for net ATP production
within the glycolytic pathway. M2-PK may occur in a highly
active tetrameric form and a nearly inactive dimeric form. The
tetramer:dimer ratio of M2-PK determines whether glucose
carbons are converted to pyruvate and lactate with the
production of energy (tetrameric form), or are channeled into
synthetic processes which debranch from glycolytic
intermediates, such as nucleic acid, amino acid and
phospholipid synthesis. (http://www.metabolic-database.com).
In tumor cells, M2-PK was found to be mainly in the
dimeric form which has therefore been termed Tumor M2-PK.
Immunohisto-logical studies of various tumors with
monoclonal antibodies (Clone DF4, ScheBo Biotech, Giessen)
which specifically recognize the dimeric form of M2-PK
revealed a heterogeneous distribution of Tumor M2-PK in
primary tumors, whereas their metastases are always
characterized by homogeneously large amounts of Tumor M2PK. The dimeric form of M2-PK is released from tumors into
the patients’ blood, most likely by tumor cell necrosis.
To quantify Tumor M2-PK in EDTA-plasma samples, a
sandwich ELISA (ScheBo Biotech, Giessen) based on two
monoclonal antibodies which specifically recognize the dimeric
form of M2-PK has been developed. In accordance with the
immunohistological results an increase in Tumor M2-PK in
EDTA plasma samples, and a correlation with tumor stage, was
found for renal cell carcinoma, thyroid, lung, breast, cervical,
ovarian, pancreatic, gastric and colorectal cancer, as well as
melanoma. When taken together these results show that Tumor
M2-PK is an organ-unspecific marker, which reflects the
metabolic activity of the tumors. A major application for
Tumor M2-PK in EDTA plasma is patient follow-up to monitor
success, failure and relapses during therapy.
447
IMMUNOLOGICAL SIMILARITIES BETWEEN
CANCER PATIENTS AND CHRONIC FATIGUE
SYNDROME PATIENTS
Mira Meeus1,2 and Jo Nijs1,2
1Department of Human Physiology, Faculty of Physical
Education and Physiotherapy; Vrije Universiteit Brussel
(VUB);
2Division of Musculoskeletal Physiotherapy, Department of
Health Sciences, University College Antwerp (HA), Belgium
Background: Cancer and chronic fatigue syndrome (CFS) are
both characterised by fatigue and severe disability. Fatigue is
the hallmark of CFS, and fatigue is a common symptom
experienced by people undergoing treatment for cancer.
Although cancer is a well-known and recognized disease and
3401
ANTICANCER RESEARCH 28: 3157-3556 (2008)
CFS is rather unknown and underestimated, the fatigue is not
the only link between the two diseases. By comparing the two
diseases we might gain more insight into the physiopathology
and the cause of some common complaints.
Methods: Based on our own findings and on literature results
the intracellular immune dysfunctions in CFS will be
explained, the hypothesised relation with fatigue will be
elucidated and finally the link with cancer patients will be
made. Results: Both in cancer and in CFS, the immune system
has shown important and partly overlapping changes. One of
the major intracellular immune dysfunctions in CFS is the
deregulation of the RNase L antiviral pathway. This
deregulation may lead to channelopathies that in turn might
be responsible for some of the CFS symptoms. Also in cancer
patients abnormalities in the RNase L pathway are already
documented. The R462Q variant of RNase L, having about 3fold reduced catalytic activity in vitro, is the most prevalent
genetic marker for prostate cancer. Malfunctioning of natural
killer (NK) cells (i.e. decreased natural killer cell cytotoxicity)
has long been recognised as an important factor in the
development and reoccurrence of cancer, and has been
documented repeatedly in people with CFS. Besides these
major interfaces disturbed apoptotic mechanisms and oxidative
stress or excessive nitric oxide may play a role in the two
diseases and in the common symptom fatigue. With regard to
these immunological abnormalities prudence is called for
during the rehabilitation of these patients. Exercise is currently
recommended as a conservative intervention for both fatigued
cancer patients and CFS patients, but based on literature
findings and our own results we know that too vigorous
exercise may worsen the immune system and the complaints
in CFS patients. The exercise response to intensive activity in
cancer patients is less understood. On the other hand, it is well
known that moderate exercise has beneficial effects on the
immune system and may even have preventive effects on
cancer in all disease stages. Therefore physical rehabilitation
should be carefully balanced. Conclusion: Despite the high
mortality rates in cancer, cancer and CFS present several
similarities. The immunological abnormalities, such as a
deregulated RNase L pathway, reduced NK cytotoxicity,
increased oxidative stress etc are present in both diseases.
These anomalies may be responsible for some of the common
complaints, like fatigue, and should be considered in the
physical rehabilitation of these patients.
448
CURRENT STANDARDS IN
PSYCHOSOCIAL CANCER CARE
Anja Mehnert
Department of Medical Psychology, University Medical
Center Hamburg-Eppendorf, Martinistr. 52 – S35, 20246
Hamburg, Germany
3402
Over the past thirty years, psychosocial cancer care has
become an integral part of cancer treatment in many countries
around the world, a development that has been accompanied
by research findings and meta-analyses showing that
psychosocial care enhances the well-being and quality of life
of cancer patients. This increasing integration is reflected in
the rising number of new institutions for psychosocial care,
the increase in research programs, the large number of
scientific publications and conferences, as well as in the
increased acceptance of psychosocial oncology among
medical professions, cancer patients and the general public.
First approaches to offer cancer patients psychological help
in various European countries started in the middle of the
1970s. Experience in these approaches demonstrate that in
most cases major problems in understanding and acceptance
arose. Medical doctors and nurses expressed their critical
attitudes towards psycho-oncology. Only very few clinical
institutions reported a successful implementation of
psychosocial interventions. There were various reasons for the
problems of implementing psychosocial services into clinical
practice. Knowledge about the relevance of psychological and
social factors for the development and the course of diseases
such as cancer were not as widespread as today among health
care professionals. Thus, the understanding of disease was
strongly determined by biological models. Furthermore,
medical health care professionals often showed a lack of
willingness to let new professions such as psychologists or
psychotherapists participate within the care of patients.
Since then, the situation has substantially changed.
Comprehensive models of diseases and treatment are prevalent
among the general population, as well as among health care
professionals. Psycho-oncological interventions and programs
have gained increasing interest, addressing various aspects of
cancer survivorship such as psychological comorbidity,
psychosocial care needs and return to work in cancer survivors.
One major factor that contributes to this development is the
well-established psycho-oncological research. Nevertheless,
psycho-oncological services are not well implemented in many
health care institutions and facilities for cancer patients. Today,
as important as the above mentioned historical barriers is the
lack of personal and financial resources to meet the psychooncological needs of cancer patients.
449
PATIENT-TO-PATIENT AND INTRA-PATIENT
SUB-SAMPLING VARIATION IN GENE
EXPRESSION PROFILES IN NSCLC
M. Meister1, A. Belousov5, E.C. Xu1, P. Schnabel4,
A. Warth4, H. Hoffmann2, H. Dienemann2,
H. Bodenmueller5, W. Zolg5, F.J.F. Herth3 and T. Muley1
1Translational
2Department
Research Unit;
of Surgery;
Abstracts of the 8th International Conference of Anticancer Research, 17-22 October 2008, Kos, Greece
3Department
of Pulmonary Medicine, Thoraxklinik,
University of Heidelberg;
4Institute of Pathology, University of Heidelberg;
5Roche Diagnostics, Penzberg, Germany
We assessed the influence of tumor cell composition on gene
expression in non-small cell lung cancer (NSCLC) analyzing
patient-to-patient and intra-patient variations. Four different
sites of individual tumors from 20 patients undergoing
resection for primary lung cancer were used to establish the
gene expression pattern captured by Affymetrix HG-U133
Plus 2.0 arrays. Inter-patient (patient-to-patient) and intrapatient (tumor site to tumor site) variability of gene
expression were determined in an uni-variant and multivariate setting using linear mixed effect model approach and
partial least squares regression, respectively. The majority of
probe sets revealed consistently larger differences in
expression among the patients than seen within the different
tumor sub-samples of the same patient. Considering the 0.6%
of the probes sets which showed sensible tumor site
variability, gene ontology analysis revealed that these genes
were ‘at random’. No association to TNM status, tumor
stage, patient gender/age, or other study co-variates was
detected. A small number of genes were identified to be
associated with tumor cell or stroma tissue content. In
conclusion, expression profiles based on single tumor tissue
pieces from NSCLC patients are representative of the entire
tumor, if viable tumor cell content is equal to or greater fifty
percent.
450
ATHEROSCLEROSIS AND CANCER: A
COINCIDENCE OR A CAUSAL LINK?
Bohuslav Melichar, Hana Kalábová and Hana Študentová
Department of Oncology, Palacký University Medical
School and Teaching Hospital, Olomouc, and Department of
Oncology and Radiotherapy, Charles University Medical
School and Teaching Hospital, Hradec Králové, Czech
Republic
Cancer and the complications of atherosclerosis represent two
leading causes of death in the industrialized nations. Cancer
and atherosclerosis share risk factors and commonly affect
the same individuals. A causal link in the pathogenesis of
these two disorders that would exist in addition to the shared
risk factors (e.g. age or smoking) is a matter of dispute.
Inflammatory response, both local and systemic, plays an
important role in the progression of both atherosclerosis and
cancer. For example, systemic inflammatory response
resulting from chronic infections that is reflected in increased
serum concentrations of C-reactive protein has been
postulated to play an important role in the progression of
atherosclerosis. Advanced/metastatic cancer is also commonly
associated with systemic inflammatory response and elevation
of serum C-reactive protein, but poor prognosis of patients
with advanced/metastatic cancer might have prevented the
clinical manifestation of accelerated atherosclerosis in this
group of patients. The progress in the therapy of some tumors
in the past decades may lead to unmasking of the effect of
systemic inflammatory response associated with advanced/
metastatic cancer on the progression of atherosclerosis.
Moreover, the toxicity of anticancer therapy may result in the
progression of atherosclerosis. The clinical data so far
indicate increased incidence of cardiovascular disorders in
survivors of childhood cancer or germ-cell tumors that is
associated with a history of chemotherapy. The data on more
common adult tumors are more scarce. Hormonal therapy
may have an adverse effect on the risk factors of
atherosclerosis. However, the adverse effect of aromatase
inhibitors, now commonly used in the adjuvant therapy of
breast carcinoma, on serum lipid concentrations may reflect
the effect of tamoxifen withdrawal rather than the action of
aromatase inhibitors themselves. More pronounced adverse
effects on the progression of atherosclerosis could be
expected from the use of drugs targeting the vascular
endothelial growth factor or its receptors, but these drugs
were introduced only recently and are now used almost
exclusively in patients with incurable metastatic tumors. In
conclusion, we are just beginning to appreciate the extent to
which advanced/metastatic cancer and/or anticancer therapy
causes progression of atherosclerosis. With improved therapy
of more common tumors, a causal link between cancer and
atherosclerosis mediated by inflammatory response may
become obvious. The impact of new biologic agents on the
progression of atherosclerosis has yet to be determined.
451
CHEMOTHERAPY RESISTANCE IN GLIOMAS
M. Mellai, L. Annovazzi, V. Caldera,
E. Andreoli and D. Schiffer
Neuro-bio-oncology Center of Policlinico di
Monza/University of Turin, Vercelli, Italy
Tumor cell resistance to radio – and chemotherapy is the
major bias in tumor treatment. The mechamisms are today
topics of intense study. In its clinical applications, MGMT (O6
- methylguanine DNA methylatransferase) is very important.
Promoter hypermethylation of the MGMT gene blocks the
removal of methyl groups from the O6 position of guanine
produced by alkylating agents. Methylated tumors show better
outcome in comparison with unmethylated ones. Methylation
can be assessed by Methylation Specific PCR (MSP) or by
immunohistochemistry and it is used today in association with
Temozolomide.
3403
ANTICANCER RESEARCH 28: 3157-3556 (2008)
In the absence of functional MGMT, an important
additional mechanism of resistance to alkylating agents is
DNA Mismatch Repair (MMR) deficiency. This pathway
functions as a mismatch excision repair leading to additional
DNA double strand breaks and apoptotic cell death in cells
lacking MGMT activity.
Alternative mechanisms involve Nucleotide and Base
Excision Repair pathways (NER and BER, respectively). The
latter refers to the Poly(ADP-ribose) polymerase-1 (PARP-1)
enzymes which are activated by DNA damage.
The ATP-Binding Cassette (ABC) genes are responsible for
the multidrug resistance (MDR) to the topoisomerase
inhibitors VP-16 as well as to vincristine in a number of
cancers. Our experience in gliomas is discussed.
452
RNA AND DNA QUADRUPLEXES
Jean-Louis Mergny
INSERM U565, CNRS UMR 5153, Muséum National
d’Histoire Naturelle USM 503, 43 rue Cuvier, 75005 Paris,
France
Evidence is growing that unusual nucleic acid structures called
G-quadruplexes (G4) play important biological roles, either at
the DNA or RNA level. G-quadruplexes result from the
hydrophobic stacking of guanine quartets (Figure); each
quartet being a planar association of 4 guanines (or guanine
analogs (1)) held together by 8 hydrogen bonds. A cation
(typically K+) is located between two quartets and forms
cation-dipole interactions with 8 guanines.
I will present some of the properties and applications of G4
structures in areas ranging from nanotechnology (2),
biotechnology to medicinal chemistry. Two quadruplex-related
compounds (a G-rich oligonucleotide and a G4 ligand) are
currently in phase II clinical trials. G4 structures are very
stable under physiological conditions and it is likely that
nature designed proteins such as helicases or chaperones to
control their formation.
Quadruplexes may be involved in telomere regulation.
The 3’ G-rich telomeric overhang from a variety of species
may adopt a G-quadruplex structure. We analyzed several
series of G4 ligands that recognize the human telomeric
quadruplex and were initially considered as telomerase
inhibitors. However, we demonstrated that inhibitory effect
of such molecules has been overestimated and that G4
ligands rather constitute a different class of biologically
active compounds (3, 4). Finally, RNA sequences may also
form quadruplexes. The transcribed telomeric repeats
(TERRA) and the RNA component of telomerase (called
hTERC or hTR) may form very stable intramolecular
guanine quadruplexes (5).
3404
Figure. Presentation of a G-quartet, with four coplanar
guanines.
1 Gros J, Avino A, Lopez de la Osa J, Gonzalez C, Lacroix L,
Perez A, Orozco M, Eritja R and Mergny JL: Chem Comm,
2008, 2926, 2008.
2 Monchaud D, Yang P, Lacroix L, Teulade-Fichou MP and
Mergny JL: Angew Chem Int Ed 57, 4858, 2008.
3 De Cian A, Cristofari G, Reichenbach P, De Lemos E,
Monchaud D, Teulade-Fichou MP, Shin-Ya K, Lacroix L,
Lingner J and Mergny JL: Proc Natl Acad Sci USA 104,
17347, 2007.
4 De Cian A, Lacroix L, Douarre C, Temime-Smaali N,
Trentesaux C, Riou JF and Mergny JL: Biochimie 90, 131,
2008.
5 Gros J, Guédin A, Mergny JL and Lacroix L: Chembiochem
9, 2075, 2008.
453
RELATIONSHIP BETWEEN PSYCHONCOLOGY
AND PSYCHONEUROENDOCRINOIMMUNOLOGY
(PNEI): EVALUATION OF ANTICANCER IMMUNITY
IN RELATION TO THE PSYCHOSPIRITUAL
STATE OF CANCER PATIENTS
Giusy Messina
Psychological Service, Policlinico Maggiore Hospital,
University of Milan, Italy
It is long known that the psychospiritual status may influence
tumour growth and the prognosis of the neoplastic disease.
However, only with the development of psychoneuroendocrinoimmunology (PNEI) has it been possible to
characterize
the
neuroimmunochemical
mechanism
responsible for the influence of the psychospiritual condition
on tumour growth, namely through the modulation of the
immune system, which appears to be able to control cancer
Abstracts of the 8th International Conference of Anticancer Research, 17-22 October 2008, Kos, Greece
cell proliferation. Anticancer immunity is stimulated by IL-2
and IL-12, whereas it is inhibited by IL-10 and IL-6.
According to recent advances in tumour immunobiology, at
present the most important cell suppressing the anticancer
immunity is the T regulatory lymphocyte (T reg), which may
identify CD4+CD25+ cells. At present it is possible to monitor
the clinical history of a neoplastic disease by evaluating not
only tumor marker concentration but also the
immunobiological status of cancer patients by measuring
immune parameters related to anticancer immunity, such as
IL-2, IL-12, lymphocyte count and the different lymphocyte
subpopulations. In particular, it has been observed that low IL6 and IL-10, a low number of lymphocytes and T-helper
lymphocytes (CD4) and an increased number of T reg is
associated with poor prognosis. Stress, chronic pain,
depression and anxiety, which have a negative influence on the
prognosis of cancer, appear to act through the opioid system,
whose activation may suppress anticancer immunity. On the
contrary, pleasure and spirituality may stimulate the anticancer
immunity through the activation of the pineal gland and the
brain endocannabinoid system. Thus PNEI may allow us to
explain the overall clinical evidence shown by psychooncological studies. However within the great number of
psychological variables, spirituality has to be considered as
being different from the psychological profile. The spirituality
would act through the pineal gland and the brain
endocannabinoid system, whereas the psychological status
would be mediated by the opioid system. Several tests have
been used to investigate the psychological profile of cancer
patients but according to our experience the most appropriate
psychological examination could be represented by the
Rorschach’s test, because of rational objectivity. In contrast,
at present the investigation of spirituality remains difficult,
since most questionnaires proposed up to now are generally
limited to the investigation of religious practice. We have
performed several studies to investigate the different
psychological profile of cancer patients in relation to their
psychoneuroendocrinoimmune status. The psychological
profile was investigate by the Rorschach’s test and the spiritual
status was analyzed by a special spiritual test. We performed
five main studies, obtaining the following relationships: i) low
numbers of lymphocytes and T-helper lymphocytes (CD4) in
patients was associated with solid tumour and suppression of
spiritual and sexual sensitivity; the study was carried out in 60
patients, 30 of them showed a metastatic disease. Colon, lung
and breast cancer were the most frequent tumours in our
patients. ii) Low efficacy of IL-2 immunotherapy and low
lymphocyte response to IL-2, occurring in cancer patients,
were associated with anxiety and/or loss of sexual identity.
The study was performed in 30 patients with renal cancer. iii)
A low number of lymphocytes was associated with alteration
in the circadian rhythm of cortisol and hypercortisolemia in
cancer patients with a low spiritual profile. The study was
carried out in 30 patients with metastatic non-small cell lung
cancer. iv) An abnormally high percent of T-regulatory
lymphocytes (CD4CD25) in patients with solid tumour was
associated with a self-punishment’ status. The study was carried
out in 40 patients with locally limited or metastatic neoplasm. v)
Lack of surgery induced-hyperprolactinemia in operable breast
cancer patients was associated with suppression of the maternal
behaviour. The study was performed in 30 women.
These results would suggest the possibility to investigate
the psychoneuroimmune basis of the overall psychological
profile, characterizing cancer patients during the clinical
history of their disease. Further studies by investigating the
brain endocannabinoid system through the detection of the
blood concentration of the main endocannabinoid agent,
anandamide, will clarify the neurochemical alteration
responsible for the progressive loss of pleasure occurring
during neoplastic disease.
454
TREATMENT AND COFACTOR STUDIES FOR
HUMAN PAPILLOMAVIRUS-ASSOCIATED
CERVICAL CANCER
Samina Alam, Brian Bowser and Craig Meyers
Department of Microbiology and Immunology, H107,
Pennsylvania State University College of Medicine, Hershey,
PA. 17033 USA
One of the major goals of our laboratory is to identify factors
and their inherent targeting mechanisms which affect
progression of human papillomavirus (HPV)-associated
cervical cancers. Two types of cofactor studies are currently
underway in our laboratory which have addressed these
issues. The first set of studies deals with the development of
therapeutics for cervical as well as other types of cancer.
Epidemiological studies indicate a negative correlation
between adeno-associated virus type 2 (AAV2) infection and
the incidence of HPV associated cervical cancer. The
oncosuppressive properties of AAV2 is linked to the ability
of this virus to perturb cell-cycle progression by decreasing
cellular proliferation rates and mediating growth arrest. One
of the hallmarks of HPV infection is the abrogation of key
cell cycle regulatory proteins. We utilized HPV infected
human keratinocytes as well as normal human foreskin
keratinocytes, which are natural hosts for both AAV2 and
HPV. Cultures co-infected with HPV31b and AAV2
displayed reduced p16INK4, p21WAF1 and p27KIP1 CDK
inhibitor protein levels culminating in apoptotic cell death,
as determined by DNA laddering. Cell death could be
correlated with an increased percentage of cells with S-phase
DNA content, concurrent with AAV2 Rep protein expression.
Simultaneously, pRb protein levels were stabilized in its
hypophosphorylated form and HPV E7 oncoprotein
3405
ANTICANCER RESEARCH 28: 3157-3556 (2008)
expression was severely diminished. In addition, other cell
lines infected with different HPV types from both low- and
high-grade lesions were also sensitive to AAV2-induced cell
death. Interestingly, HPV-negative carcinoma lines, including
a squamous cell carcinoma line, the MCF-7 breast cancer
line, and the PC3 prostate cancer line, also underwent
apoptotic cell death following infection with AAV2. In sharp
contrast, primary foreskin keratinocytes infected with AAV2
were resistant to apoptosis. The ability of AAV2 to
exclusively target deregulated cells indicates its potential for
being developed as an anticancer agent in gene therapy
protocols.
The second set of studies is also based on
epidemiological studies which suggest that HPV-infected
women who smoke face an increased risk for developing
cervical cancer. We are the first laboratory to demonstrate a
molecular link between exposure of HPV-infected tissue to
cigarette smoke carcinogens and its effect on the viral life
cycle. Benzo[a]pyrene (BaP) is a well-characterized
cigarette smoke carcinogen and has been found to be
concentrated in the cervical mucus. HPV genome
amplification was enhanced at low concentrations of BaP,
whereas higher concentrations induced significant increases
in the synthesis of infectious virus. We have also studied
host cell cycle and differentiation gene expression, and have
correlated changes to the increase in viral genomes and
production of infectious viral particles. Since most HPV
infections are spontaneously cleared, our data suggests that
BaP induction of increased virion synthesis and genome
amplification give rise to an increased viral load, affecting
the persistence of the viral infection and level of oncogene
expression.
455
METHYLATION PROFILE OF hMLH1,
MGMT, APC AND CDH1 GENES
IN GREEK PATIENTS WITH
COLON ADENOCARCINOMA
Christina I. Michailidi1, Stamatios E. Theocharis2,
Gregorios P. Kouraklis3, Paraskevas Katsaronis3
and Constantinos Troungos1
1Department
of Biological Chemistry,
Medical School, University of Athens; Athens;
2Department of Forensic Medicine and Toxicology,
Medical School, University of Athens; Athens;
3Second Department of Propedeutic Surgery, Medical
School, University of Athens; Athens, Greece
Introduction: Colon cancer is a common malignancy
usually arising from a benign neoplasm which is developed
into adenocarcinoma through a certain histological
progression sequence. Genomic instability and epigenetic
3406
alterations - with hypermethylation of cytosine in CpG
islands in the promoter of certain genes- play an important
role in carcinogenesis and tumour progression of this type
of cancer. Epigenetic changes conduce to cancer formation
through the transcriptional silencing of certain genes. The
aim of this study was to analyze the promoter methylation
of genes related with mismatch repair as hMLH1; repair
genes like MGMT which interferes in the repair of damages
in O6 position of guanine by removing alkyl groups; tumour
suppressor genes as APC and possible tumour suppressor
genes like CDH1 which encodes epithelial cadherin
preventing cells from growing and dividing in an
uncontrolled way to form a malignant tumour. Materials
and Methods: Genomic DNA was isolated from 28 colon
cancer patients (14Male/14Female), with mean age 64
years. DNA was then subjected to chemical modification
with sodium bisulfate and followed by Methylation Specific
PCR (MSP) amplified by primer pairs specific for the
methylated and unmethylated sequences. PCR products
were analyzed on 2% agarose gel, stained with ethidium
bromide and visualized in UV. The methylation results were
associated with patients’ gender and age, tumours’
histological grade and stage. Results: Promoter methylation
for hMLH1 gene was observed in 1 out of 28 (3%), for
MGMT in 15 out of 28 (53%), for APC in 5 out of 28
(18%) and for CDH1 in 24 out of 28 (86%). In 15 out of
28 (61%) cases methylation in 2 or more of the examined
genes was noted. Methylation profiles were also associated
with clinicopathological characteristics of the colon cancer
patients. A statistically significant association between
methylation of CDH1 gene and Dukes’ stage (stage A, B,
C vs. D; p=0.002) was found. Moreover, an association
(although not statistically significant) between methylation
status in two or more genes with either tumour histological
grade (well and moderately vs. poorly differentiated) or
Dukes’ stage (stage A, B, C vs. D) was also noted (p=0.055
and p=0.063, respectively). Conclusion: Our data confirmed
alterations in the methylation status of hMLH1, APC and
MGMT genes in colon cancer, although no significant
association was noticed with any of the examined
clinicopathological parameters. Additionally, the promoter
of CDH1 gene was found to be very frequently methylated,
being related with Dukes’ stage. Furthermore
hypermethylation in two or more genes seemed to be
related with tumour characteristics. By expanding our
research effort in the examination of methylation status
during the whole procedure from normal tissue to early
adenoma and carcinoma formation, we may further
delineate whether methylation can be used as a possible
target therapy in colon cancer, since demethylation can
restore gene expression.
This work and Christina I. Michailidi supported by grants of
Stavros Niarchos Foundation.
Abstracts of the 8th International Conference of Anticancer Research, 17-22 October 2008, Kos, Greece
456
FOCAL ADHESION KINASE (FAK) EXPRESSION IN
HUMAN BENIGN AND MALIGNANT THYROID
LESIONS
Christina Michailidi1, Nikolaos Chatzizacharias1,
Vassilios Stolakis1, Paraskevi Alexandrou2,
Jerzy Klijanienko3, Ioanna Delladetsima2
and Stamatios Theocharis1,3
1Department
of Forensic Medicine and Toxicology,
University of Athens, Athens;
2First Department of Pathology, Medical School, University
of Athens, Athens, Greece;
3Department of Pathology, Institut Curie, Paris, France
Background: Focal adhesion kinase (FAK), a non-receptor
tyrosine kinase protein, acts as an early modulator of integrin
signaling cascade, regulating basic cellular functions. In
transformed cells unopposed FAK signaling has been
considered to promote tumor growth, progression and
metastasis. The aim of the present study was to evaluate the
clinical significance of FAK expression in human benign and
malignant thyroid lesions. Design: FAK protein expression
was assessed immunohistochemically in formalin-fixed,
paraffin-embedded thyroid tissues from 116 patients with
benign (46 hyperplastic nodules and 9 Hashimoto thyroiditis)
and malignant (49 papillary, 6 medullary, 5 follicular and 1
anaplastic thyroid carcinomas) lesions. Immunohistochemical
evaluation was based on both staining intensity and the
amount of positive stained cells within thyroid lesion, graded
in a two step scale as weak or no staining and moderate or
strong staining. Statistical analysis was performed to compare
the expression of FAK protein between benign and malignant
thyroid lesions, as well as between Hashimoto thyroiditis and
hyperplastic thyroid lesions within benign subgroup. In the
subgroup of malignant thyroid tumors, FAK protein
expression was statistically analyzed in relation to TNM stage
and tumor proliferative capacity, assessed by Ki-67 labeling
index. Results: FAK protein expression was characterized as
weak or no staining in 83 (72%) and moderate or strong
staining in 33 (28%) out of 116 cases. In malignant thyroid
lesions, FAK protein expression was characterized as weak or
no staining in 35 (57%) and moderate or strong staining in 26
(43%) out of 61 cases. In benign thyroid lesions, FAK protein
expression was characterized as weak or no staining in 48
(87%), moderate or strong staining in 7 (13%) out of 55 cases.
The level of FAK protein expression was statistically
significantly higher in malignant thyroid lesions compared
with benign ones (p=0.001). In malignant thyroid lesions,
FAK protein expression was statistically significantly
associated with the presence of nodal metastasis (p=0.047).
Additionally, a borderline association between FAK protein
expression and tumor cells’ proliferating capacity was noted
(p=0.065). Regarding the benign thyroid lesions, FAK protein
expression was not statistically significantly associated with
histological type, in order to provide a distinct discrimination
between Hashimoto thyroiditis and hyperplastic nodules.
Conclusion: The current data confirm the expression of FAK
protein in thyroid lesions that can significantly distinguish
benign from malignant cases, being also associated with
disease stage (N) and proliferative capacity in thyroid
malignant cells. Further studies are needed in order to
delineate the clinical importance of FAK expression in thyroid
neoplasia and its possible use as a target for future therapy
applications.
457
ANTICANCER PROPERTIES AND MDR
MODULATORY EFFECT OF PLANT
POLYPHENOLS AND THEIR INTERACTION
WITH MEMBRANE COMPONENTS
Krystyna Michalak1, Olga Wesołowska1, Jerzy Wiśniewski1,
Kamila Środa1, Andrzej Teisseyre1, Michał Kużdżał1,
Janez Štrancar2, Noélia Duarte3 and Maria-José U. Ferreira3
1Department
of Biophysics, Wrocław Medical University, ul.
Chałubińskiego 10, 50368 Wrocław, Poland; 2Laboratory of
Biophysics, Jozef Stefan Institute, Jamova 39, Ljubljana,
Slovenia;
3CECF/iMed. UL, Faculty of Pharmacy, University of
Lisbon, Av. das Forças Armadas, 1600-083 Lisbon, Portugal
Many compounds of plant origin have been identified to be
interesting for potential application in cancer prevention or
chemotherapy. Such agents were found among flavonoids and
stilbenes. In broad in vitro and in vivo studies, the ability of
plant-derived polyphenols to interact with different cellular
targets was revealed. Resveratrol (trans-3,4,5’-trihydroxystilbene) influences many cellular signaling pathways and
affects all three stages of carcinogenesis. In this work the
effect of several stilbenes (resveratrol, its analogue
piceatannol, and piceatannol derivatives) and some flavonoids
on activity of ABC multidrug transporters and potassium
channels Kv1.3 was examined. Recently the role of potassium
channel activity in cancer has emerged. Several of the
compounds studied were found to be potent potassium channel
inhibitors. Strong inhibition of membrane transporters and ion
channels was often observed for hydroxy-, methoxy-, acetoxyand prenyl- derivatives in relation to the parent compounds.
Piceatannol, naringenin and some of their derivatives were the
most active inhibitors of MRP1 multidrug transporter. The
influence of plant polyphenols on integral membrane proteins
such as MDR transporters and ion channels can be mediated at
least in part by non-specific membrane effects. Flavonoids and
stilbene interactions with lipid bilayers was determined by
fluorescence and ESR spectroscopy. Simulation of the
3407
ANTICANCER RESEARCH 28: 3157-3556 (2008)
experimental ESR spectra and application of GHOST
condensation method were applied to study the effect of
polyphenols on membrane domain structure. The significance
of interaction of studied phytochemicals with membrane
transporters, channels and lipid bilayer for their anticancer
properties was discussed.
Antiproliferative properties of the compounds were tested in
sensitive and doxorubicin-resistant, P-gp overexpressing colon
cancer cell lines LoVo and LoVo/Dx, respectively. Tangeretin,
natural polymethoxylated flavone and 8-prenylnaringenin most
effectively inhibited cell growth both in sensitive and resistant
cancer cell lines. Antiproliferative action was compared with
pro-apoptic properties of the compounds.
458
SEX STEROID-ACTIVATED NON GENOMIC
SIGNALLING AS A TARGET FOR HORMONE
DEPENDENT CANCER THERAPY
A. Migliaccio, G. Castoria, L. Varricchio, A. de Falco,
M. Di Domenico and F. Auricchio
Department of General Pathology. II University of Naples.
Via L. De Crecchio, 7 – 80138 – Naples, Italy
In human mammary and prostate cancer cells, steroid
hormones and EGF trigger association of the androgen
receptor (AR)-estradiol receptor (ER-α or -β) complex with
Src. This interactions activates Src and drives the cell into the
G1-S phase progression. This suggests that such an interaction
can be targeted to control cancer cell growth.
In view of this, we identified the AR sequence responsible
for the androgen receptor/Src interaction and synthesized a 10
amino acid peptide derived from this sequence, which inhibits
this interaction. Treatment of human prostate or mammary
cancer cells (LNCaP or MCF-7, respectively) with nanomolar
concentrations of this peptide prevented the androgen- or
estradiol-induced association between AR or ER and Src. The
peptide also inhibited the Src/Erk pathway, cyclin D1
expression and DNA synthesis in steroid-stimulated LNCaP
and MCF-7 cells, without interfering with receptor-dependent
transcriptional activity. Similarly, the peptide prevented the Sphase entry of LNCaP and MCF-7 cells treated with EGF as
well as mouse embryo fibroblasts stimulated with androgen or
EGF. Interestingly, the peptide did not inhibit S-phase entry
or cytoskeletal changes induced by EGF treatment of ARnegative prostate cancer cell lines. The interest of these
findings is highlighted by the fact that the peptide strongly
inhibited the growth of LNCaP xenografts established in nude
mice.
The AR/ER/src association induced by steroid hormones
and EGF was also abolished in whole cells and in vitro by
a six amino acid peptide, which mimics the sequence
around the phosphotyrosine residue in position 537 of ER-
3408
α. This sequence is homologous to that surrounding the
phosphotyrosine 443 of ERβ. The phoshorylated peptide,
at nanomolar concentrations, hindered ER/Src interaction
and inhibited Src/Erk pathway, cyclin D1 expression and
DNA synthesis induced by estradiol, or androgen, or
triggered by EGF in MCF-7 and LNCaP cells. In contrast,
no inhibition of the Src-mediated EGF action on DNA
synthesis was detectable in human mammary cancer cells
which did not express ER (MDA-MB231), indicating that
this peptide specifically targets the ER-associated Src. Like
the AR-derived peptide, the ER-derived peptide, in contrast
to classical steroid antagonists, did not interfere in ER- or
AR-dependent transcriptional activity. Nevertheless, it
markedly inhibited the growth of MCF-7 cell xenografts
induced in estradiol-treated nude mice. Both peptides
represent the first example of specific inhibitors of steroid
receptor-dependent signal transducing activity. More
importantly, these findings suggest that inhibition of
association of steroid receptors with Src or other signalling
effectors may have therapeutic applications for patients
with hormone-dependent tumors.
459
THERAPEUTIC AND DIAGNOSTIC
APPLICATIONS OF APTAMERS IN CANCER
S. Missailidis
Department of Chemistry and Analytical Sciences, The Open
University, Walton Hall, Milton Keynes, MK5 7AS, UK
Aptamers were first described in 1990, and during the past 18
years they have found a number of applications, as research
tools or as therapeutic and diagnostic entities in the fight
against disease.
Aptamers are single stranded RNA or DNA molecules
selected through evolutionary processes for high binding
affinity and exceptional specificity against a variety of
targets, including enzymes, cell surface receptor proteins,
cytokines and chemokines, antibodies, as well as small
organic compounds. Although the majority of work on
aptamers has not focused on cancer, one of the early
aptamers against the VEGF has recently received FDA
approval against Macular Degeneration, as a PEGylated
preparation, and has been in clinical trials against tumour
angiogenesis. Aptamers against novel angiogenesis targets
have also been prepared by our group and are currently in
preclinical testing. Some aptamers have demonstrated direct
therapeutic effect due to their apoptotic potential, resulting
from blocking vital cellular pathways. The aptamer against
nucleolin, a dimeric G-quadruplex oligo, has shown great
therapeutic potential in phase I clinical trials and has now
entered phase II trials for treatment for acute myeloid
leukemia and renal cancer. An aptamer against an epithelial
Abstracts of the 8th International Conference of Anticancer Research, 17-22 October 2008, Kos, Greece
tumour cell marker developed by our group, has also shown
great therapeutic potential on a 6 day treatment regime
(results presented), as has an anti-HER3 aptamer. With the
exception of the nucleolin aptamer, which is dimeric in
nature, most therapeutic aptamers have been PEGylated, to
increase their circulation time. These include the PDGF, the
tenascin-C and our MUC1 aptamers, currently in various
stages of clinical development. Furthermore, aptamers have
unique properties as delivery vehicles and have been
successfully coupled to small chemotherapy agents, such as
the aptamers against neutrophil elastase, or to appropriate
chelators loaded with radionuclides, exemplified by own
MUC1 aptamer work. The later can function both as
imaging agents in medical imaging using gamma camera,
allowing fast clearance from the system and good tumour
localisation and penetration or PEGylated, as therapeutic
radiopharmaceuticals when loaded with a beta emitter, such
as Re188 in the treatment of breast and bladder cancer.
Finally, the unique binding properties of aptamers are being
utilised in the development of medical sensors, for targets
such as PSA, MUC1 and others, where current detection
limitations have restricted application.
Aptamers remain a complicated field in terms of intellectual
property, with strong control of intellectual property by two
US companies, which has deterred the pharmaceutical industry
from actively developing in this field. However, as the field is
about to open in the next few year, more and more aptamers
are being developed therapeutically or diagnostically.
460
DYSTROGLYCAN FUNCTION
IN PROSTATE CANCER
Andrew Mitchell1, Simon Cross2, Freddie Hamdy2
and Steve Winder1
Departments of 1Biomedical Sciences and 2Academic
Urology, Section of Oncology, University of Sheffield, UK
Prostate cancer (PCa) is a significant cause of morbidity and
mortality in the Western world. In its most aggressive forms,
there is rapid growth and metastasis during which cells detach
from the primary tumour and migrate within the blood and
lymphatic system to form secondary tumours.
Dystroglycan (DG) is a ubiquitously expressed cell
adhesion molecule that provides a link between the
extracellular matrix and the actin cytoskeleton. It is important
for cell motility, polarity and possibly signal transduction. We
have examined the function, distribution and localisation of
DG in several PCa cell lines including LNCaP, PC3 and
DU145. We found that DG is extensively modified during
increases in cell confluency in vitro, through both MMPmediated proteolysis and changes in glycosylation pattern.
Furthermore, anchorage-independent growth assays and
Transwell invasion studies revealed that colony-forming and
invasive capabilities of PCa cells are significantly affected by
changes in DG levels. Reduced DG levels promoted growth in
soft agar, whereas increased DG promoted Transwell invasion.
Immunohistochemically, there was also a significant reduction
in DG immunoreactivity within PCa primary tumour samples.
However, in metastatic PCa samples from bone, in 5 samples
with reduced DG levels in the primary tumour, DG levels were
increased at the secondary site. DG would therefore appear to
be important for maintaining normal epithelial structure.
Reduction in DG levels possibly contribute to the early stages
of cancer progression, however DG might need to be reexpressed in order for tumours to metastasise and establish at
secondary sites. Further investigations will help better
understand the complexities and role(s) of DG in PCa and also
aid in elucidating the mechanism(s) and consequences of DG
alteration in the disease.
461
REGULATORY ROLE OF HUMAN APENDONUCLEASE (APE1/REF-1)
IN YB-1-MEDIATED ACTIVATION OF
MULTIDRUG RESISTANCE (MDR1) GENE
Kishor K. Bhakat1, Ranajoy Chattopadhyay1, Soumita Das1,
Amit K. Maiti1, Istvan Boldogh1, Jingwu Xie1,
Tapas K. Hazra1, Kimitoshi Kohno2 and Sankar Mitra1
1Department of Biochemistry and Molecular
Biology, University of Texas Medical Branch,
Galveston, TX 77555, USA;
2University of Occupational and Environmental Health
School of Medicine, Iseigaoka, Kitakyushu, Japan
Resistance to multiple chemotherapeutic agents is the major
failure for chemoprevention of cancer. Multidrug resistance
often occurs due to enhanced expression of p-glycoprotein
(p-gp)/MDR1, the product of multidrug resistance gene,
MDR1. MDR1 belongs to a family of exporters which
mediate efflux of a variety of xenobiotics including cancer
chemotherapeutic drugs. MDR1 overexpression often
observed in tumor cells contributes to failure of cancer
chemotherapy. The mammalian AP-endonuclease (APE1/
Ref-1), a central enzyme involved in repair of oxidative base
damage and DNA strand breaks, has a second activity as a
transcriptional co-regulator when it complexes with a
number of transcription factors, including AP-1, p53 and
NF-κB and regulates their function via redox-dependent and
-independent mechanisms. APE1 overexpression, often
observed in tumor cells, is associated with resistance to
various anticancer drugs; its down-regulation sensitizes
tumor cells to such agents. Because the drug resistance of
many tumor cells could not be explained by APE1’s DNA
repair activity which can not repair the DNA lesions
3409
ANTICANCER RESEARCH 28: 3157-3556 (2008)
induced by such drugs, APE1’s transcriptional regulatory
function must be involved in drug resistance. We have
shown that APE1, preferably in acetylated form, stably
interacts with the Y-box-binding protein-1 (YB-1), and
enhances its binding to the Y-box element, leading to MDR1
activation. Enhanced MDR1 level due to ectopic expression
of WT APE1, but not of its nonacetylable mutant,
underscores the importance of APE1’s acetylation in its coactivator function. APE1 down-regulation sensitizes MDR1overexpressing tumor cells to cisplatin or doxorubicin,
showing APE1’s critical role in YB-1-mediated gene
expression and thus drug resistance in tumor cells. A
systematic increase in both APE1 and MDR1 expression
was observed in non-small cell lung cancer tissue samples.
Thus our study has established the novel role of acetylationmediated transcriptional regulatory function of APE1,
making it a potential target for drug sensitization of tumor
cells.
Research supported by U.S. Public Health Service grants R01
ES08457, R01 CA53791, ES P3006676 and American Heart
Association grant #0565008Y).
462
HOMOLOGOUS RECOMBINATION AND
CHROMOSOME INSTABILITY IN CANCER
Kiyoshi Miyagawa
Laboratory of Molecular Radiology, Graduate School of
Medicine, The University of Tokyo, 7-3-1 Hongo, Bunkyoku, Tokyo 113-0033, Japan
A double-strand break is a critical lesion that can promote
genome instability. It is well established that double-strand
breaks induced by ionizing radiation are mainly repaired by
nonhomologous
end-joining,
whereas
homologous
recombination plays a critical role in the repair of replicationassociated DNA breaks. Because defects in these pathways
lead to chromosome aberrations ranging from translocations
to aneuploidy, altered repair pathways are assumed to
contribute to tumor initiation and progression. Rad51 and its
associated proteins are major players at early stages of
homologous recombination. Because the breast cancer
susceptibility protein BRCA2 directly associates with Rad51,
impaired homologous recombination is assumed to contribute
to tumor development in BRCA mutation-associated cancer.
In addition, Rad51 and BRCA2 are functionally associated
with other protein complexes. Among the complexes, Rad51
paralogs are involved in homologous recombination by
assisting Rad51 functions. A link of Rad51 paralog with
chromosome instability has been proposed from the
observations that the frequency of aneuploidy is increased in
their mutant cells. To understand the mechanism underlying
chromosome instability induced by defective homologous
3410
recombination, we have generated colon cancer cell lines in
which each Rad51 paralog is deleted. This study revealed that
impaired centrosome integrity plays a role in chromosome
instability induced by Rad51 paralog mutations. Moreover, we
show that the p53-dependent checkpoint plays a role in the
maintenance of genome integrity in cells deficient in Rad51B
or Rad51C but not in XRCC3, indicating functional
differences in Rad51 paralogs.
463
OVEREXPRESSION OF HER-2/NEU PROTOONCOGENE IN BREAST CARCINOMAS
OF YOUNG ARAB WOMEN
Fawziah M.A. Mohammed1, Fatma Al-Yatama1,
Anwar Al-Banaw1 and David T. Lincoln2
1Faculty
of Allied Health Sciences, Kuwait University,
Kuwait;
2Entity Systems, Independent Research Foundation, Chapel
Hill, Australia
Breast cancer is characterized by a long history and marked
heterogeneity in growth rates and clinical manifestations.
In Europe and USA, occurence peaks between the ages of
60-65 years, with only 14% occurring below the age of 40
years. In contrast, in Gulf Arab women the mean age is
48.7 years and the peak occurrence of breast cancer is at
the age of 45-50 years. A significant proportion of 26% of
breast cancer occurs below the age of 30 years and the
incidence is increasing. Only 14.1% of breast cancer in
Arab women occurs above the age of 60 years. Breast
cancer patients younger than 30 years have a worse
prognosis than older patients. There are highly significant
trends for the prevalence of poor prognostic features (Grade
3) histology, extensive intra-ductal component, lymphatic
and vascular invasion to decrease with increasing age. In
this study, we evaluated the expression of the HER-2/neu
oncoprotein in breast cancer of young Arab women. The
HER-2/neu gene codes for a putative transmembrane
protein, similar in structure to the epidermal growth factor
receptor (EGFR). A total of 122 patients were selected. The
average size of the tumours was 5.6 cm, the majority of
cases (76.2%) were invasive ductal carcinoma. The
amplification/ overexpression of HER-2/neu from paraffin
wax embedded breast tumour tissues was analyzed by
immunohistochemistry using antiserum for presence of the
HER-2/neu protein. A chemical detection system was
applied to identify the antibody. A high degree of
immunoreactivity indicated overexpression of this protein.
From the 122 breast cancer cases investigated, 70 cases
were positive, with different degrees of intensity ranging
from weak (27 cases), moderate (23 cases) to strong (19
cases). The most intense HER-2/neu expression of the 70
Abstracts of the 8th International Conference of Anticancer Research, 17-22 October 2008, Kos, Greece
total positive cases were found in ductal carcinomas (16
cases) and infiltrating ductal carcinomas (14 cases). Some
cases (n=8) showed a correlation between the strongly
positive HER-2/neu protein expression and the lymph node
involvement. Only 6.8% of all cases investigated were
Grade I well differentiated tumours, 41% were Grade II
moderately differentiated and 22% were Grade III. In
conclusion, the results of this study show that the degree of
expression of HER-2/neu oncoprotein may prove to be an
additional prognostic marker of breast cancer, particularly
in young women. This applies in the histological diagnosis
of ductal and infiltrating ductal carcinomas, followed by
lobular, intraductal and infiltrating lobular carcinomas. The
majority of these tumour etiologies were HER-2/neu
positive.
464
POTENTIAL ANTICANCER AGENTS
FROM LINUM GRANDIFLORUM LEAVES
Magdy M.D. Mohammed1, Ming Chen2, Lin Zhai2 and
Nabaweya A. Ibrahim1
1Pharmacognosy Department, National Research Center,
Dokki-12311, Cairo, Egypt;
2Department of Clinical Microbiology, University Hospital
of Copenhagen (Rigshospitalet), Tagensvej 20, DK-2200
Copenhagen N, Denmark
The CHCl3 and MeOH fractions of the leaves of Linum
grandiflorum showed in vitro anticancer activity with IC50
against EL4 (Murine Leukemia) cell line at 60 and 250 μg/ml
respectively, using a standard high-flux anticancer-drug
screening method. A bioassay guided fractionation was used
to find out the active constituents, which resulted in the
isolation of 10 compounds from the MeOH fraction classified
as: 5 flavone glycosides (one novel compound known as
luteolin 7-O-α-D-(6’’’-E-feruloyl)glucopyranosyl (1¡2)-β-Dglucopyranoside with IC50 against EL4 at 125 μg/ml, together
with, luteolin 7-O-glucosides, vicenin-1, vicenin-2 and
vicenin-3) with IC50 against EL4 at 100, 500, 500 and 500
μg/ml respectively, and 4 cyanogenic glycosides (one novel
compound
known
as
2-[(3’-isopropoxy-O-β-Dglucopyranosyl)oxy]-2-methylbutanenitrile with IC50 against
EL4 at 100 μg/ml, together with, linamarin, lotaustralin and
neolinustatin) with IC50 against EL4 at 100 μg/ml for each,
and one alkyl glycoside (butan-2-O-β-D-glucopyranoside)
with IC50 against EL4 at 100 μg/ml. From the CHCl3 fraction
three lignans were isolated and identified as podophyllotoxin,
deoxypodophylotoxin and 6-methoxypodophyllotoxin with
IC50 against EL4 at 90, 35 and 100 μg/ml respectively. The
obtained results revealed the potent in vitro anticancer activity
of Linum grandiflorum leaves and may suggest that the
isolated active compounds could be used as anticancer agents.
465
INHIBITION OF CARCINOEMBRYONIC
ANTIGEN RELEASE FROM
COLORECTAL CANCER CELLS
TO PREVENT CRC-LIVER METASTASIS
Naghibalhossaini F. and P. Mokarram
Department of Biochemistry, Shiraz University of Medical
Sciences, School of Medicine, Zand Street, Shiraz, Iran
Background: Elevated carcinoembryonic antigen (CEA)
blood levels are found in a wide variety of epithelial
neoplasms. CEA normal function(s) and its relevance to
malignant transformation are not clear. Recent studies show
that CEA might have an instrumental role in cancer
progression and human colon cancer liver metastasis. The
latter function has been suggested to be facilitated by
soluble CEA through induction of cytokine production by
Kupffer cells. We were the first group to provide evidence
for CEA release from human colon cancer cells by an
endogenous GPI-PLD enzyme. Previous studies have shown
that purified GPI-PLD can be inhibited by micromolar
concentrations of phosphatidic acid (PA) and
lysophosphatidic acid (LPA). Therefore, blocking CEA
release from cancer cells using GPI-PLD inhibitor might
also prevent CRC-liver metastasis. Methods: A duplicate
aliquot of LS180 cells was seeded into four-well plates
(200,000 cells/well in 250 μl medium) and allowed to grow
to sub-confluence. Then they were incubated in fresh
DMEM medium with or without FBS containing GPI-PLD
inhibitors, Didecanoyl phosphatidic acid (DP) and crude
phosphatidic acid (CP). DP and CP were used at doses of
10-100 μM. The cells were incubated at 37˚C for 4-8 h in a
humidified incubator. The media of controls were
replenished with media without chemicals. The cell culture
media from a duplicate set of wells was collected after every
2 h of incubation. The effect of inhibitors on the secretion of
GPI-anchored proteins was determined by measuring CEA,
and alkaline phosphatase (ALP) in cell culture supernatant
by ELISA. The non-GPI-anchored CA19-9 tumor marker
level in medium was also measured as a control. Results:
LS-180 treatment with 20-100 μM concentrations of DP and
CP reduced the release of CEA and ALP (p<0.05). No
measurable alteration was observed at 10 μM PA
concentration. A 19-57% decrease in CEA and ALP
secretion was observed after 4-8 h continuous exposure of
LS-180 cells to PA. Conclusion: GPI-anchored CEA and
ALP, but not TM-anchored CA-19-9, release is inhibited
efficiently by micromolar concentration of PA. Since
secreted CEA acts as a signaling molecule that promotes
liver metastasis, PA inhibition of CEA release from cancer
cells may have therapeutic application to prevent CRC-liver
metastasis.
3411
ANTICANCER RESEARCH 28: 3157-3556 (2008)
466
THERMODYNAMIC PROSPECTS TO INTERVENE
CANCER PROGRESSION
Joseph Molnar1, A. Zalatnai2, B.S. Thornton3,
Elysia Thornton-Benko4 and L. Amaral5
1Albert
Szent-Györgyi Medical Center, Department of
Medical Microbiology and Immunobiology, University of
Szeged;
21st Department of Pathology, Semmelweis University,
Budapest, Hungary;
3Applied Mathematics, Faculty of Science UTS and School
of Physics, University of Sydney;
4Key Centre for Health Technologies, UTS, Sydney,
Australia;
5Unidade de Micobacterias, UMM, Instituto de Hygiene e
Medicina Tropical, Lisboa, Portugal
During tumor growth there are many differences between the
healthy tissue and growing tumor, including metabolic,
structural and thermodynamic differences. The healthy state
tends towards “entropy minimum”, while the cancerous one
tends towards “entropy maximum” by disrupting normal
structures and functions invading host tissues based on
different energy conservations and entropy productions.
Indefinite growth of tumor cells can be inhibited by
chemotherapy combined with resistance modifiers, but kinetic
resistance of a solid tumor may needs an alternative solution
involving thermodynamics.
The second law of thermodynamics does not exclude
changes in the direction of components of entropy flow from
tumor to the normal tissues under special conditions. Entropy
productions due to various dissipation mechanisms based on
temperature differences, chemical potential gradient, chemical
affinity and exerted field as driving forces are promising tools
to be calculated as potential targets for tumor demarcation.
The relative importance of various terms of entropy production
(migration of electric charges, the flow of matter, chemical
reaction, heat transport) were compared as driving forces in
tumor-host relationships through numerical estimation.
Different entropy production rates between two kinds of cells
determine the direction of entropy flow among corresponding
tissues. The entropy flow carries the harmful information of a
cancerous cell, propagating its toxic action to normal cells.
Some inhibitors of quorum sensing-like signal transmission
between tumor and normal cells can block the information
flow.
External forces (ultrasound and electric fields) enhance
entropy production of normal cells above cancer and
consequently can reverse the direction of entropy flow. The
entropy difference between exponential growth phase and
Gompertzian phase is a possible target to eliminate tumor
cells.
3412
From topics in this review, new theories on the reduction of
entropy production and negative entropy in-flow are now
created in various biomedical fields, which may contribute to
therapy.
467
MDR INHIBITORY ACTIVITY OF
NEW JATROPHANE DITERPENES
FROM EUPHORBIA ESULA L.
E. Sulyok1, A. Vasas1, P. Forgo1,
J. Molnár2 and J. Hohmann1
1Institute
of Pharmacognosy, Faculty of Pharmacy,
University of Szeged, H-6720 Szeged, Eötvös str. 6;
2Department of Medical Microbiology and Immunobiology,
Faculty of Medicine, University of Szeged, H-6720 Szeged,
Dóm tér 10, Hungary
In continuing our search for biologically active new
compounds from Euphorbiaceae species, four new
jatrophane-type diterpene polyesters have been isolated
along with three known components from the methanol
extract of Euphorbia esula. The inhibition of efflux
activity of the isolated compounds was determined by
measuring the accumulation of the substrate analogue
rhodamine in tumor cells. The isolation was carried out by
VLC, CPC, preparative TLC and HPLC. The structure
elucidation was performed by extensive spectroscopic
analysis, including 1D and 2D NMR ( 1H- 1H COSY,
HSQC, and HMBC) experiments. The stereochemistry of
the compounds was studied by NOESY measurements.
Structural investigations demonstrated that compounds are
penta-, hexa- and heptaesters of jatrophane polyols
acylated with acetic, benzoic, isobutanoic and nicotinic
acids. Four compounds are new natural products, two
components were isolated earlier from Euphorbia
salicifolia (1, 2) and one is identical with a diterpene
obtained previously from E. peplus (3).
The effect of the isolated diterpenes on the reversal of
multidrug resistance in MDR-1 gene-transfected L5178
mouse lymphoma cells was determined. The assay was
performed following extrusion of rhodamine 123 inside the
cancer cells, by flow cytometry. Verapamil was used as a
positive control. As a result of our investigations it can be
stated that almost all of the tested compounds are able to
increase drug accumulation and display a significant
concentration dependent effect. These results provided
further information for the characterisation of the structural
requirements of jatrophane diterpenes as resistance
modifiers.
1 Hohmann J et al: Tetrahedron 57: 211-215, 2001.
2 Hohmann J et al: Tetrahedron Lett 42: 6581-6584, 2001.
3 Hohmann J et al: Planta Med 66: 291-294, 2000.
Abstracts of the 8th International Conference of Anticancer Research, 17-22 October 2008, Kos, Greece
468
PATHOLOGY BEYOND HISTOLOGY: PROGNOSTIC
AND PREDICTIVE MARKERS IN GLIOMA TISSUE
SAMPLES
intact downsteam signally pathway for EGFR seems to be
necessary to confer inhibitor sensitivity to EGFR amplified or
mutated tumors
Patrizia Morbini
469
CONTROL OF ANTI-TUMOR CD8+ T-CELL
RESPONSES
Department of Pathology, University of Pavia, Pavia, Italy
Despite the huge amount of research done in the last decade
on markers predictive of response to therapy and on targetspecific drugs, only a few agents have so far been approved
for target-based therapy of different malignancies, none of
which involves the central nervous system, and a limited
number of response predictors have been introduced into
clinical practice.
On the verge of research for prognostic and predictive
factors, pathologists’ role has evolved in the last decade from
she/he who provides a histological classification to a highly
interactive player in the therapeutic decisions. The
identification, by a constantly increasing range of molecular
techniques, of predictive factors and potential targets in the
tumor tissue is becoming the first step of the therapeutic
approach for many tumor types and locations. Pathologists are
also involved in ongoing research for new molecules and
targets, in all fields of cancers research, including central
nervous system tumor. A review of all recent data on the
subject would require a lot of space, but MGMT and EGFR
played so far the foremost role in the research of predictive
and targetable pathways in GBL.
MGMT is a DNA repair protein that counteracts DNA
damage induced by alkylating agents. In the majority of GBL,
only one copy of the gene is left after chromosome 10 loss, and
it can be epigenetically silenced by promoter hypermethylation.
MGMT inactivation is responsible of GBL sensitivity to
temozolomide, and its assessment has been proposed as a
stratification criterion for therapy with alkylating agents.
EGFR is the transmembrane receptor of epidermal growth
factor, and is the target of two FDA approved classes of
inhibitors: monoclonal antibody cetuximab, targeting the
extracellular receptor domain, approved for the treatment of
intestinal adenocarcinomas, and small molecules gefitinib and
erlotinib, which inhibit the intracellular ATP-binding domain
of the receptor, and are used for the treatment of non small
cell lung cancer.
GBL have been largely demonstrated to overexpress EGFR,
mainly due to polisomy or gene amplification, as observed in
bowel cancers, but also to mutations in EGFR gene, giving
origin to the truncated, constitutively activated mutant
EGFRvIII. Both EGFR overexpression and truncated protein
variant are negative prognostic factors for GBL. Phase I and II
clinical trials with small molecule EGFR inhibitors failed to
show survival gain with respect to standard treatment with
radiation and temozolomide. However, the presence of an
David J. Morgan
Department of Cellular and Molecular Medicine, School of
Medical Sciences, University Walk, Bristol, BS8 1TD, UK
Priming of naïve tumour-specific CD8+ T-cells can occur
either through direct interaction with metastatic tumours in the
tumour draining lymph nodes (TDLN), or indirectly via
dendritic cells (DC), cross-presenting tumour-derived antigens
to naïve CD8+ T-cells within the TDLN. However, the nature
of CD8+ T-cell response resulting from such interactions is
determined by the overall level of T-cell activation. In the
steady state, it was considered that high levels of T-cell
activation tended to result in productive CTL responses to
foreign antigens; whereas low levels of activation resulted in
abortive responses leading to T-cell tolerance induction.
However recent data, from our laboratory, has determined that
the overall response following priming is, in fact, under
dynamic control by a combination of several signals delivered
through: the T-cell receptor TcR (signal 1), through receptors
of costimulatory molecules and other accessory molecules
(signal 2), as well as through several other molecular
interactions, which collectively are referred to as signal 3.
Critically, we have determined that altering the level of any
one of these signals can result in a shift in the balance of the
overall response between either abortive or productive
activation. Based on these findings, we therefore suggest that
tolerance induction and the formation of effective anti-tumour
CTL responses actually represent discreet clinical readouts
amongst a broad range of different CD8+ T-cell responses.
470
THE STUDY OF MANGANESE, CHROMIUM AND
OXIDATION STATUS IN BLADDER CANCER
A. Movahedian, H. Mazdak, N. Mirkheshti, F. Yazdekhasti,
E. Behzad, M. Shafian and Z. Shamszadeh
Department of Clinical Biochemistry, Isfahan
Pharmaceutical Sciences Research Center, School of
Pharmacy and Pharmaceutical Sciences, Isfahan University
of Medical Sciences, Isfahan, Iran
It seems that chromium (Cr) and manganese (Mn), by the
mechanism of affecting oxidative status in cells, can play an
important role in cancer induction. We decided to study the
serum concentration of Mn and Cr and malondialdehyde
3413
ANTICANCER RESEARCH 28: 3157-3556 (2008)
(MDA) as a biomarker of lipid peroxidation and total
antioxidant capacity (TAC) as an antioxidant marker, in
patients with bladder cancer, as compared with healthy
individuals.
This case–control study was conducted on 52 patients with
bladder cancer and 58 healthy volunteers after being matched
by their age, sex and smoking habits. Fasting samples were
collected and serum concentration of Cr, Mn, MDA and TAC
were determined by spectrophotometric methods and
comparisons were made using the Student t-test.
MDA (p<0.001) and Cr concentration (p<0.05) were
significantly increased in bladder cancer patients. There was
a significant decrease in Mn (p<0.001) and TAC (p<0.001) of
patients in comparison with healthy individuals.
471
STANDARDIZED TISSUE AND BLOOD BANKING –
PREANALYTICAL REQUIREMENTS FOR
HIGH QUALITY GENE AND PROTEIN
EXPRESSION PROFILES
T. Muley1, C. Traschütz1, H. Hoffmann2, H. Dienemann2,
P.A. Schnabel3 and M. Meister1
A piece of tissue is withdrawn from the freezer and cut into
several 10 μm slices in a cryostat device before RNA, DNA
or protein extraction and subsequent analysis. The first and last
cryo-section of a series are Hematoxilin/Eosin-stained and
analysed for tumor, stroma, necrosis and parenchyma content
by two experienced investigators. Only tissues with greater
than 50% viable tumor cell content enter RNA extraction and
subsequent microarray analysis. RNA, DNA, and hybridisation
products are analysed for integrity (RNA integrity numbers
>8.0) and amount by capillary electrophoresis (Agilent
Bioanalyzer) and micro photometry (Nano drop).
Basic patient data together with data of the freezing
conditions are stored in a tissue bank data file. The inclusion
of respective identification items (pseudonymized) allows us to
combine tissue bank data to prospective data collected in the
various data bases of our institution, i.e. tumour documentation
files, documentation of surgery, laboratory data files, tumour
biology/pathology data bases and postoperative follow-up files.
Taken together, standardized sample collection, sample
preparation and data management is required to produce
reliable high quality gene expression results which might in
future guide new therapeutic approaches in lung cancer
treatment.
1Translational
Research Unit;
of Surgery, Thoraxklinik, University of Heidelberg;
3Institute of Pathology, University of Heidelberg, Germany
2Dept.
The identification of new prognostic factors, potential genes
for targeting therapy, as well as genes that might cause
resistance to chemotherapy are present goals in lung cancer
research. The actual developments in molecular biology
require high quality bio materials such as tumor tissue, serum,
plasma or biopsy samples, since the quality of results directly
depends on the quality of materials.
Currently, all necessary infrastructural requirements to
achieve these goals have been installed and tested at our
institution. Standard operation procedures have been
implemented to provide the surgeons, pathologists and
technicians with sampling protocols, ensuring high quality
samples of tumour tissue and normal lung tissue pairs from
each surgically treated patient. On average, 300–350 patients
per year undergo surgical resection for primary lung cancer at
our institution.
In brief, immediately after the tumour resection,
representative pieces of tissue are macro dissected by an
experienced pathologist from both the tumour and the distant
normal lung tissue and cut into 16-20 pieces of 0.5 cm length.
The pieces of tissue are distributed into sterile cryo tubes and
immediately snap-frozen in liquid nitrogen. Long-term storage
is performed at −80≥C. The time between resection and
freezing is usually less than 30 min. In addition, in selected
patients further tissue probes (pleural, lymph nodes, metastatic
sites etc.) are withdrawn and prepared in an identical manner.
3414
472
BIOMARKERS FOR ASSESSING POTENTIAL
CARCINOGNEIC EFFECTS OF CHRONIC ARSENIC
EXPOSURSE IN INNER MONGOLIA, CHINA
Judy L. Mumford
National Health and Environmental Effects Research
Laboratory, U.S. Environmental Protection Agency, Research
Triangle Park, North Carolina 27711, USA
Arsenic is ubiquitous in the environment. Chronic arsenic
exposure has been associated with carcinogenic,
cardiovascular, neurological and diabetic effects in humans
and has been of great public health concern worldwide. In
2001, the U.S. Environmental Protection Agency adopted an
arsenic standard of 10 μg/l from 50 μg/l in drinking water.
However, there are still great uncertainties on the health effects
of arsenic at low doses. Due to the lack of appropriate animal
models for extrapolation to human risk, research needs include
a better understanding of the mechanisms of arsenic
carcinogenesis and assessing health effects of arsenic in
humans at low dose. The major modes of action (MOA)
proposed for arsenic effects in humans are increasing oxidative
stress, altering signal transduction pathways, inducing DNA
and chromosomal damage, affecting DNA repair, promoting
cell proliferation, and DNA methylation. The objectives of this
research were to apply biomarkers to assess arsenic exposure
and cancer risks and identify biomarkers useful for assessing
arsenic effects in humans.
Abstracts of the 8th International Conference of Anticancer Research, 17-22 October 2008, Kos, Greece
The residents of Ba Men in Inner Mongolia have been
exposed to a wide range of arsenic concentrations via well water
and showed adverse health effects. This population provides us
with an opportunity to assess the relationships between arsenic
exposure and health effects. Based on the proposed MOA, we
selected biomarkers to assess potential carcinogenic effects of
arsenic in the Inner Mongolia population. A total of 324 Ba
Men residents, exposed to arsenic via well water ranging from
non-detectable levels to 826 μg/l of arsenic participated in this
study. Samples of well water, urine and toe nail were collected
to assess arsenic exposure and investigate metabolic profiles in
urine. Human buccal cells and blood samples were collected
and the health effects investigated were arsenic-related dermal
effects, DNA fragmentation, micronucleus frequency for
chromosomal damage, and mRNA expression of the genes
(OGG1 and ERCC1) responsible for DNA repair of oxidative
damage and human telomerase reverse transcriptase (hTERT)
for cell proliferation.
The results showed significant associations between arsenic
exposure and increase in DNA damage, micronucleus frequency
and gene expression of OGG1 and ERCC1 and hTERT. This
paper will report the results of these studies and provide some
insights into arsenic MOA and human dose-response data.
This is an abstract of a presentation and does not necessarily
reflect U.S. EPA policy.
473
CHEMOPREVENTIVE EFFECTS OF DIALLYL
TRISULFIDE DERIVED FROM GARLIC:
FOCUS ON MOLECULAR MECHANISMS
Hye-Kyung Na and Young-Joon Surh
National Research Laboratory of Molecular Carcinogenesis
and Chemoprevention, College of Pharmacy, Seoul National
University, Seoul 151-742, South Korea
Multiple lines of compelling evidence from epidemiological
and laboratory studies support an inverse association between
consumption of garlic and the risk of cancer. Chemopreventive
effects of garlic have been attributed to its oil-soluble sulfur
ingredients, such as diallyl sulfide, diallyl disulfide, and diallyl
trisulfide (DATS), but their underlying molecular mechanisms
remain largely unresolved. In the present study, we observed
that DATS inhibited the growth of human breast carcinoma
(MCF-7) cells to a greater extent than did the other allyl
sulfides as determined by the MTT assay. DATS also induced
apoptosis in MCF-7 cells, which was mediated through
accumulation of reactive oxygen species with subsequent
activation of JNK that catalyzes phosphorylation of Bcl-2. In
another experiment, DATS prevented tumor formation in a
mouse xenograft model. Aberrant upregulation of COX-2 has
been frequently observed in several types of cancer cells and
is considered as a molecular target for cancer
chemoprevention. Topically applied DATS inhibited the 12-Otetradecanoylphorbol-13-acetate (TPA)-induced COX-2
expression in dorsal skin of female ICR mice. DATS inhibited
the DNA binding activity of AP-1 which is one of key
transcription factors regulating the inflammation and
expression of COX-2. DATS inhibited TPA-induced
phosphorylation of Akt and JNK, which are major MAPKs
regulating AP-1. A pharmacologic Akt inhibitor LY294002
and a JNK inhibitor SP600125 abrogated the TPA-induced
COX-2 expression, suggesting that suppression of COX-2
expression by DATS in TPA stimulated mouse skin is
mediated by blocking the PI3K-Akt and JNK signaling.
Topical application of DATS protected against mouse skin
carcinogenesis induced by 7,12-dimethylbenz[a]anthracene
plus TPA. In addition, DATS strongly inhibited DNA binding
activity of NF-κB compared with other allyl sulfides in human
mammary epithelial (MCF10A) cells treated with TPA. DATS
inhibited the transcriptional activity of NF-κB,
phosphorylation of IκBα, and activity of IKKβ. Inhibition of
NF-κB DNA binding activity and IKKβ activity by DATS
were blunted by addition of the antioxidant N-acetyl-Lcysteine (NAC) and the reducing agent dithiothreitol.
474
CLINICAL SIGNIFICANCE OF WNT-INDUCED
SECRETED PROTEIN-1 (WISP-1/CCN4) IN
ESOPHAGEAL SQUAMOUS CELL CARCINOMA
Youhei Nagai1, Shinji Ishikawa2, Yoshihumi Baba3,
Ryuichi Karashima1, Nobutaka Sato1, Yu Imamura1,
Yukiharu Hiyoshi1, Naoya Yoshida1, Eiichirou Toyama1,
Naoko Hayashi1, Masayuki Watanabe1 and Hideo Baba1
1Department
of Gastroenterological Surgery, Graduate
School of Medical Sciences, Kumamoto University 1-1-1
Honjyo, Kumamoto City, Kumamoto 860-8556;
2Department of Surgery, Kumamoto Regional Hospital,
Kumamoto 860-0811, Japan;
3Dana-Farber Cancer Institute, 35 Binney Street JF208E
Boston, MA 02115, USA
Background: Wnt-induced secreted protein-1 (WISP-1/CCN4),
a member of the CCN family, has been studied in several
cancers. However, the correlation of WISP-1 expression with
clinical features of esophageal squamous cell carcinoma
remains unknown. Patients and Methods: The expression of
WISP-1 was analyzed by immunohistochemistry on paraffinembedded tissues from 105 cases of esophageal squamous cell
carcinoma. The effect of WISP-1 on esophageal carcinoma
cell growth was examined by cell proliferation assay using
WISP-1 transfectants. Results: In vitro, WISP-1-transfected
esophageal cells showed significantly increased proliferation
compared to their parent cells. Immunohistochemical analysis
showed that WISP-1 positive cases were closely associated
3415
ANTICANCER RESEARCH 28: 3157-3556 (2008)
with tumor size, lymph node metastasis, stage and worse
prognosis. Conclusion: WISP-1 may play a important role in
tumor growth and development of esophageal squamous cell
carcinoma.
475
THE HAMSTER BUCCAL POUCH
CARCINOGENESIS MODEL AS A PARADIGM FOR
ORAL ONCOGENESIS AND CHEMOPREVENTION
S. Nagini
Department of Biochemistry and Biotechnology Annamalai
University, Annamalainagar-608 002, Tamil Nadu, India
Oral squamous cell carcinoma (OSCC), a common
malignancy worldwide, is an important contributor to the
overall international cancer burden. Squamous cell carcinomas
(SCCs) induced by 7,12-dimethylbenz[a]anthracene (DMBA)
in the HBP reiterate many of the features observed in human
OSCCs. The major risk factors associated with human oral
cancer such as tobacco, betel quid and alcohol promote HBP
carcinogenesis. SCCs induced by DMBA in the cheek pouch
of Syrian hamsters are morphologically and histologically
similar to human OSCC. Like human oral carcinogenesis,
HBP carcinogenesis is a multistep process that involves
sequential progression from hyperplasia to invasive carcinoma
through varying degrees of dysplasia. In addition, HBP
tumours express several biochemical and molecular markers
that are also expressed in human OSCC. Multiple signaling
pathways are dysfunctional in both human and hamster
OSCCs. In particular, cell proliferation, apoptosis and
angiogenesis are intricately interlinked in malignant
transformation of the HBP mucosa by DMBA. The HBP
carcinogenesis model is the best-known animal system for
intervention by chemopreventive agents because of easy
accessibility for examination, and follow-up of lesions. A
number of synthetic and natural products have been
documented to exhibit chemopreventive efficacy in the HBP
model. Chemoprevention studies in the HBP model can serve
as a crucial link in the potential efficacy assessment of
candidate agents for oral cancer prevention and therapy.
476
ORAL CANCER AND ITS RELATIONSHIPS WITH
SALIVA, CIGARETTE SMOKING AND FREE
RADICALS – PREVIOUS FINDINGS AND
FUTURE TSPO-RELATED DIRECTIONS
R. Nagler
Department of Oral and Maxillofacial Surgery, Oral
Biochemistry Laboratory and Salivary Clinic, Rambam
Medical Center and Faculty of Medicine, Technion-Israel
Institute of Technology, Haifa, Israel
3416
Oropharyngeal (OP) cancer, which is usually squamous cell
carcinoma, is the most common head and neck malignancy
and accounts for 2-4% of all new cancer cases. It is primarily
induced by exposure to tobacco. The paradigm of cigarette
smoke (CS)-induced OP cancer pathogenesis is based on the
assumption that a constant direct attack by various CS
carcinogens causes widespread accumulating cellular and
DNA aberrations in the OP mucosal cells, in turn eventually
resulting in malignant transformation. However, there is never
direct contact between CS and the OP mucosa. Saliva, bathing
the mucosa from the oral cavity to the larynx, always
intervenes, and CS must first interact with saliva before it
reaches the mucosa.
The current study investigated the role of saliva in the
pathogenesis of OP cancer. A synergistic effect of CS and
saliva on oral cancer cells was demonstrated. This
synergism is based on the reaction between redox active
metals in saliva and low reactive free radicals in CS, which
results in production of highly active hydroxyl free
radicals. Thus when exposed to CS, salivary behavior is
reversed and the saliva loses its antioxidant capacity and
becomes a potent pro-oxidant milieu. The devastating role
of CS-borne aldehydes was demonstrated as well. Based
on these results and on our recent reports demonstrating
that CS destroys various salivary components, including
protective ones such as peroxidase, the most important
salivary antioxidant enzyme, a comprehensive view of the
pivotal role of saliva in the pathogenesis of CS induced OP
cancer is suggested.
477
EFFECT OF mTOR INHIBITOR ON HUMAN
OSTEOSARCOMA CELL LINES
Osamu Nakamura, Kanji Sasaki, Toshiaki Hitora,
Yoji Kawaguchi and Tetuji Yamamoto
Kagawa University, Orthopedic Surgery, 1750-1 Ikenobe,
Miki-cho, Kita-gun, Kagawa-ken, Japan 761-0701
Introduction: The mammalian Target Of Rapamycin (mTOR)
is the downstream of the PI3K/Akt signaling pathway. It
plays an important role in cell proliferation and apoptosis.
Rapamycin is commonly used as an immunosuppressor,
however, it also has an inhibitory effect on mTOR. Several
authors have reported the antitumor effects of Rapamycin on
many human malignancies. The inhibition of mTOR is
involved in the pathway-mediated transcription and
translation, leading to cell cycle arrest, antiangiogenesis, and
apoptosis. We examined the expression of mTOR-gene, and
the inhibitory effects of Temsirolimus, a selective mTOR
inhibitor, in human osteosarcoma cell lines. Materials and
Methods: Cell lines and reagents. Three human
osteosarcoma cell lines (KTHOS, MG63 and KHOS) were
Abstracts of the 8th International Conference of Anticancer Research, 17-22 October 2008, Kos, Greece
used. KTHOS was previously established in our laboratory.
All cell lines were grown in Dulbecco’s Modified Eagle
Medium (DMEM; Sigma-Aldrich, St. Louis, MO)
supplemented with 10% fetal bovine serum (FBS; SigmaAldrich). The cell lines were routinely maintained at 37˚C in
a humidified 5% CO2 atmosphere. Temsirolimus, an inhibitor
of mTOR was purchased from Wyeth Pharmaceuticals.
mRNA expression of mTOR. Total RNAs were eluted by
selective binding to a silica-gel-based membrane using an
RNeasy Mini Kit® (QIAGEN Inc., Valencia, CA).
Reverse transcription of RNA into cDNA was performed by
using Reverse Transcription System (Promega, Madison,
WI). mRNA of mTOR expression were examined by reverse
transcription (RT-) PCR. After PCR amplification, 8 μl
aliquots of the PCR products were electrophoresed in a 2%
agarose gel, followed by ethidium bromide dye. The
inhibitory effect of mTOR inhibitor. Cell proliferation was
determined using the MTS assay (CellTiter 96® Aqueous
One Solution Cell Proliferation Assay; Promega, Madison,
WI). Cells were seeded in 96-well cell culture plates. After
24 hours (h), the medium was refreshed with 1% FBS
containing Temsirolimus at various concentrations. After 24
and 48h, the medium was removed and washed with
phosphate buffered saline, then refreshed with fresh medium
containing MTS reagent. The optical density was measured
at 490 nm using an automatic microplate reader after 2 h of
further incubation. The percent viability of each well was
calculated. At least three independent cultures were
performed for each study. Results: The mRNA of mTOR was
strongly expressed in all cell lines. Temsirolimus inhibited
the cell proliferation of all 3 human osteosarcoma cell lines
in a dose- and time-dependent manner. Conclusion: These
results suggest that through the mTOR dependent
intracellular signaling pathway, mTOR- targeting agents
become an important chemotherapeutic strategy for human
osteosarcomas.
478
EVALUATION OF IMATINIB MESYLATE
(STI571) EFFECTS ON GLIOBLASTOMA
CELL PROLIFERATION AND MIGRATION
E. Ranza1, G. Mazzini2, A. Facoetti3,4 and R. Nano1,4
1Department
of Animal Biology, University of Pavia;
Istochem. and Cytometry Section, Pavia;
3Department of Nuclear and Theoretical Physics, University
of Pavia;
4INFN Pavia, Italy
2IGM-CNR,
Glioblastoma is a highly malignant brain tumour with limited
therapeutic options, a high recurrence rate and mortality.
Therefore the search of improved treatment is urgently
needed.
The fundamental insight into signal transduction generated
during the past decade is being translated into a new
generation of specific inhibitors. These drugs can be very
selective in action and may provide opportunities for
glioblastoma treatment. One of these new drugs is imatinib
mesylate (STI571), a small molecule, inhibitor of PDGF
receptor, implicated in astrocytoma carcinogenesis. In this
study, two human glioblastoma cell lines (T98G and A172)
were analysed for their sensitivity to treatment with imatinib
mesylate (kindly provided by Dr E. Alessandrino). In
particular, we have focused our attention on the analysis of
the effects on cell proliferation and migration after imatinib
treatment. Our results show that STI571 is able to induce
growth arrest in the G0/G1 phase of the cell cycle at all
concentrations tested already 24 hours after treatment and
apoptosis after 48 hours at 20-30 μM. Moreover, we have
seen that the imatinib treatment determines an evident
decrease of migrating cells. These data suggest that at low
concentrations STI571 could act as a cytostatic agent but at
high concentration it behaves mainly as a cytotoxic agent.
479
EFFECT OF IMATINIB MESYLATE
(STI571) IN COMBINATION
WITH γ-IRRADIATION ON
ASTROCYTOMA CELL SURVIVAL
E. Ranza1, A. Bertolotti2,3, A. Facoetti2,3, F. Pasi1,3,
A. Ottolenghi2,3 and R. Nano1,3
1Departments of Animal Biology, and 2Nuclear and
Theoretical Physics, University of Pavia;
3INFN Pavia, Italy
Imatinib mesylate is a small molecule inhibitor of the c-Abl, cKit, platelet-derived growth factor (PDGF) receptor tyrosine
kinases that is approved for the treatment of chronic myeloid
leukemia and gastrointestinal stromal tumors and is under
investigation for several other malignant tumors. Malignant
astrocytomas are brain tumours with an extremely poor
prognosis that are usually treated with surgery and/or
radiotherapy. Recently, we have found that imatinib is able to
induce a growth arrest in G0/G1 phase of cell cycle in
astrocytoma cells, suggesting a possible cytostatic effect of
this new drug. In this study, we focused our attention on the
potential role of imatinib (kindly provided by Dr E.
Alessandrino) in radiotherapy of astrocytoma by determining
the response of human malignant astrocytoma cell lines
(MOG-G-UVW and T98G) to combination treatment with
imatinib and γ-rays. The effect of irradiation with and without
imatinib pre-treatment on cell survival was tested with
clonogenic assay.
Our results demonstrate that PDGFR inhibition by
imatinib only partially decrease the viability of glioblastoma
3417
ANTICANCER RESEARCH 28: 3157-3556 (2008)
cells, but in combination with γ-irradiation there is a
significant increase of this effect. In particular, we have
found that low-concentrations of imatinib are able to
specifically enhance the radiosensitivity of astrocytoma
cells. These results suggest that imatinib may have clinical
utility as a radiosensitizer in the treatment of human
astrocytoma.
480
IMMUNOBIOLOGICAL ASPECTS
OF GLIOMA AND IMPLICATIONS
FOR IMMUNOTHERAPY
Rosanna Nano1 and Enrica Capelli2
Departments of 1Animal Biology and 2Genetic and
Microbiology, University of Pavia, Pavia, Italy
Today various findings indicate that a multifactor strategy
is the best strategy for treating cancer. Immunotherapy could
be a role in this fight as evidence suggests that the immune
system has a role in the control of malignant growth and
metastasis. Whether the immune system can target tumours
has been debated for nearly a century. Various
investigations, clinical trials and animal based studies have
produced important scientific knowledge for the
development of a really effective immunotherapy Actually
immunotherapy could be a promising approach for the
development of integrative therapies for cancer. Cancer
immunotherapy has progressed towards clinical applications
and various approaches have been developed, such as
adoptive transfer of tumour specific cytotoxic T
lymphocytes and the administration of tumour-associated
antigens-component vaccine, genetically modified tumour
cell-based vaccine, TAA-coding DNA vaccine on TAAdelivered dendritic cell (DC)-based vaccine. Compared to a
drug delivery system, which delivers the optimal amount of
drug to the target site and subsequently elicits its effect via
a chemical compound or by biologic macromolecules such
as plasmids, a cell based system which uses smart cells
existing in the body is a potentially, not yet completely
studied, approach. It requires a precise knowledge of the
immune network that involves cytokines, chemokines,
effector function of leukocytes subsets such as NK and T
cytotoxic cells
Many scientific centres in the world studied the
immunological aspects of tumour-host interactions and
experienced therapeutic trials. The data obtained from these
studies are now an important source for further strategies
In some cancers as glioblastoma, a chemo- and radioresistant tumour, immune recruitment could be a basis to
develop new approaches. It is necessary to focus studies on
the tumour-host relationship between and on cytokines that
regulate these relationships in the micro environment.
3418
481
DEVELOPMENT OF ANTICANCER
NANOPARTICLES TO ENHANCE SELECTIVITY,
APOPTOSIS, IMAGING, AND THERAPY
Arutselvan Natarajan, Gary Mirick, Gerald L. DeNardo and
Sally J. DeNardo
Radiodiagnosis and Therapy, University of California Davis
Medical Center, 1508. Alhambra Blvd, Sacramento, CA 95816, USA
Objectives: Dextran and PEG-coated iron oxide nanoparticles
(NPs), and gold nanoparticles (GNPs) have been widely used
to target cancer cells when suitably modified with moleculartargeting ligands and/or apoptosis-inducing agents. Anticancer
monoclonal antibodies, scFvs, microRNAs, peptides, cytotoxic
molecules, and small high affinity ligands (SHAL) have been
conjugated to NPs and GNPs to increase valency and
circulation time to enhance the cancer-targeting effect and
specificity for imaging and therapy. We have developed a
series of cancer-targeting multifunctional nanoparticles
(MNPs) to enhance the ligand concentration in tumor cells for
imaging, therapy, and to induce apoptosis. MNPs were
characterized by PAGE, transmission electron microscopy
(TEM), cellulose acetate electrophoresis (CAE), inductively
coupled plasma mass spectroscopy (ICPMS) and live cellbinding assays. Pharmacokinetics in athymic mice bearing
human breast cancer (HBT 3477) and lymphoma (Raji)
xenografts were studied. Results: Four tumor targeting MNPs
were prepared: MAb-NP (20 nm), di-scFv-NP (20 nm) and
SHAL-GNP (10 nm) and miRNA-GNP (10 nm). The first
three MNPs have been used for animal studies. They were
>90% monomeric by PAGE and CAE. The amount of
anticancer agents conjugated to each NP was 3-10 μg/mg of
NPs and 0.05-1 μg of SHAL or miRNA/mg of GNPs. Tumor
uptake of (% ID/g ± SD) for each MAb-NP, di-scFv-NP and
SHAL-GNP at 48 h was 13±0.12 (20 nm), 5±0.08 (20 nm)
and 5±0.3 (10 nm), respectively. The miRNA-GNP was
effectively transfected into cells to kill cancer cells in vitro.
Conclusion: Four anticancer MNPs were generated,
characterized and evaluated for their cancer-targeting effect.
PK and WBAR demonstrated 20 nm NPs and 10 nm GNPs
targeted tumor in vivo. Apoptosis-inducing mRNA and small
high-affinity ligand (SHAL) were conjugated to10 nm GNPs.
MAb and di-scFvs linked to NPs and SHAL-GNPs, targeted
tumors 5-13% at tumor in mice. MiRNA-conjugated GNPs
enhanced the apoptotic effect in cancer cells by >30%
compared to miRNA alone. Development of imaging and
therapy strategies for these novel anticancer MNPs are
ongoing.
482
EXPRESSION, MUTATION, AND FUNCTION
OF MET RECEPTOR TYROSINE KINASE AND
Abstracts of the 8th International Conference of Anticancer Research, 17-22 October 2008, Kos, Greece
DOWNSTREAM TARGETS IN NORMAL
HUMAN BRONCHIAL EPITHELIAL
CELLS AND LUNG CANCER
Viswanathan Natarajan and Ravi Salgia
Department of Medicine, The University of Chicago,
Chicago, IL-60637, USA
Lung cancer is a devastating illness and usually occurs as
non-small cell lung cancer (NSCLC, incidence of 85%) and
sometimes as small cell lung cancer (SCLC, incidence of
15%). Even with the best therapies with chemotherapy,
radiation therapy, and surgery, we have not made considerable
strides in overall survival. The prognosis for NSCLC is 16%
over 5 years and 6% for SCLC. Most recently, novel targeted
therapies have come to fruition in lung cancer. As an
example, the epidermal growth factor receptor (EGFR) has
been targeted with small molecule inhibitors such as gefitinib
or erlotinib, or with an antibody against EGFR such as
cetuximab. Even with this novel target, the response rate is
still only 15%. Thus, we had to find other molecular targets
for lung cancer. The MET receptor tyrosine kinase has been
shown to be important in cell proliferation, growth,
angiogenesis, invasion, and metastasis for a number of
tumors. We have shown that MET and its activated form (pMET against the juxtamembrane domain–pY1003) are
overexpressed in lung cancer tumor tissues (as compared to
adjacent normal lung tissues). The ligand for MET is the
hepatocyte growth factor (HGF), and can be either expressed
in the stroma or the tumor tissues. Expression of MET in
tumor tissue microarrays was quantified in a 4-tier score
system as negative (0), weak (1+), moderate (2+), or strong
staining. In lung cancer, forty percent (16/40) of lung cancer
tissues overexpressed MET. In the tissue microarray, 20%
(1/40) had no expression (0), whereas 20% (8/40) had 1+,
35% (14/40) had 2+, and 5% (2/40) had 3+ MET expression.
In lung cancer, 73% expressed phosphor-MET (1+, 14/40; 2+,
13/40; 3+, 2/40) while 27% (11/40) did not. HGF was also
expressed in lung cancer (47% (19/40) had 1+, 45% (18/40
had 2+, and 5% (2/40) had 3+). We have also analyzed
mutations/single nucleotide polymorphisms (SNPs) of MET
in lung cancer, and have identified novel mutations in the
semaphorin (SEMA) ligand-binding domain and the
juxtamembrane (JM) domains and not the tyrosine kinase
domain. In determining the JM domain function, we show
that there was activation of the downstream target paxillin
(focal adhesion protein). MET activation also led to
downstream signaling with signaling through the focal
adhesion proteins (such as paxillin), PKC pathway, and AKT
pathway. This was true both for normal human bronchial
epithelial cells and lung cancer cells. We are currently
investigating the therapeutic inhibition of MET in lung
cancer, and show that small molecule inhibitors such as
SU11274 and PHA665752 lead to a decrease in cell growth
as well as a decrease in angiogenesis for the mouse model.
In summary, the MET pathway is important and will be a
crucial therapeutic target in lung cancer.
Supported in part by NIH grants RO1HL079396 (V.N) and
NCI RO1 CA100750 and CA125541 (RS).
483
TARGETED CANCER THERAPY WITH CATIONIC
LIPOSOMES, CURRENT ACHIEVEMENTS VERSUS
CLINICAL NEEDS AND FUTURE OPTIONS
Kurt W. Naujoks
Pharma Research Consulting Comm. V., Square de Meeus
37 - 4th Floor, 1000 Brussels, Belgium
All cancer therapies developed so far suffer more or less from
two main problems: i) induction of severe side-effects and ii)
induction of tolerance to the respected drug.
Multiple attempts to cope with these problems resulted in
the development of target-specific therapeutics. Most
successful are monoclonal antibodies (mab) and kinase
inhibitors. Both drug concepts helped to improve cancer
treatments, but benefits fade after 3 to 12 months due rising
drug tolerance. In addition, it turned out that there are indeed
side-effects to be coped with.
Another target associated with new hope was the tumor
vasculature as a non-tumor tissue, but with vital functions for
the tumor. Several approaches using small molecules failed
due to the complex biology; monoclonal antibodies (e.g.
Bevazicumab - rhuMAb-VEGF) however made it successfully
to the clinics. But here also, side-effects do require specific
attention.
A totally different approach used a simple physicalchemical interaction to target the neovasculature of tumours.
Based on an observation that cationic liposomes exhibit a
preferential binding to activated or proliferating endothelial
cells, a new system of target-specific delivery of drugs and
contrast agents was developed. Tumor-specific binding was
demonstrated in various preclinical models and in a diagnostic
Phase I study in bladder carcinoma patients. Subsequently
therapeutic studies in various indications demonstrated
therapeutic effects at doses which were well tolerated.
Surprisingly, it could be shown that prolonged treatment
improved therapeutic benefits rather than showing induction
of tolerance. In a Phase II study in pancreatic cancer, a new
drug, EndoTAG 1 (formerly LipoPac) demonstrated a
prolonged survival compared to that with best standard of
treatment. However this experimental drug so far fails to meet
the standard requirement for successful drugs as the treatment
requires infusions of 4 litres or more over several hours. In
addition, preparation of the infusion requires specific
instructions of the respective hospital pharmacy to dissolve the
3419
ANTICANCER RESEARCH 28: 3157-3556 (2008)
lyophilised product. Pharmaceutically, the production process
is not optimized either.
This presentation will outline the approach taken to develop
such a promising drug from a prototype formulation to a drug
matching the day to day requirements of a cancer care unit and
the new technology to meet pharmaceutical production
requirements.
Progress achieved to date: Drug volume reduced to 15%;
the encapsulation efficacy of therapeutic drugs in cationic
liposomes could be greatly enhanced using different
compositions and lipids.
Infusion reactions and overall tolerability could be
significantly improved by adding an outer layer to the
liposomes; thereby creating a new kind of nanoparticle which
has no tendency to form aggregates when injected into the
blood.
A new way to stabilise these nanoparticles allows for both
better scaling-up of production and better reconstitution of the
resulting powder as a drug for infusion.
Preclinical results with this new nanoparticle will be
presented.
484
QUANTITATIVE STUDIES OF THE CELLULAR
IMMUNE RESPONSE IN CERVICAL CANCER
B.S. Nedergaard1, M. Ladekarl2, H.F. Thomsen3,
J.R. Nyengaard4 and K. Nielsen5
Departments of 1Oncology and 5Pathology, Aalborg Hospital,
Aarhus University Hospital;
Departments of 2Oncology and 3Clinical Epidemiology,
Aarhus University Hospital;
4Stereology and Electron Microscopy Laboratory and MIND
Center, University of Aarhus, Denmark
Using stereology we presented a method to obtain basic
biological data on the in situ cellular immune response
towards cancer. We estimated the density and frequency of
immune cells of 10 different phenotypes in cone biopsies from
patients with stage I cervical squamous cell carcinoma
(APMIS 115: 1321-1330, 2007). Using this method, we
performed a study to investigate differences in the primary in
situ cellular immune response between patients with and
without relapse of stage IB cervical squamous cell carcinoma.
We found significantly lower densities of CD3+, CD4+ and
CD8+ cells (both intra- and peritumoral) in tissue from
patients who had relapse (Gynecologic Oncology 108 (2008)
106-111). To validate the results, a cohort study including 102
patients treated for cervical squamous cell carcinoma stage IB
and IIA between 1990 and 2000 at Aalborg Hospital, Denmark
was carried out. The in situ cellular immune response was
investigated with respect to densities of T-cells (CD3+), T
helper/regulatory cells (CD4+) and cytotoxic T-cells (CD8+)
3420
in intra- and peritumoral tissue. We found an increase in the
density of both CD3+ and CD8+ cells to decrease the hazard
ratio for relapse of disease. The decrease in hazard ratio was
highly significant for both intra- and peritumoral cells. The
largest decrease in hazard ratio was found for peritumoral
CD3+ cells and it was 0.27 when increasing the cell density
from 795 to 2043 cells/mm2 (25 to 75 percentile). According
to this study, a low density of particularly peritumoral CD3+
cells is associated with increased risk of relapse in squamous
cell cervical cancer (BJC 97: 1135-1138, 2007).
485
EXPRESSION OF THE TMPRSS2:ERG FUSION
GENE AND PROSTATE CANCER PROGRESSION
Gabriella Nesi1, Lorella Bonaccorsi2, Milena Paglierani1,
Csilla Krausz2, Marco Carini3, Yuqiang Fang4,
Suresh C. Jhanwar4, Gianni Forti2,
Elisabetta Baldi2 and Lucio Luzzatto5
Departments of 1Human Pathology and Oncology, 2Clinical
Physiopathology, Unit of Andrology, 3Critical Care Medicine
and Surgery, Unit of Urology, University of Florence, Italy;
4Department of Pathology, Memorial Sloan-Kettering Cancer
Center, New York, USA;
5Istituto Toscano Tumori, Florence, Italy
The TMPRSS2:ERG fusion is a common recurrent
chromosomal aberration in prostate cancer. Some data suggest
that ERG expression is higher in less aggressive prostate
carcinomas, while others show an association between
TMPRSS2:ERG fusion gene and more aggressive disease. We
assessed the TMPRSS2:ERG fusion status in tumour samples
from 84 patients undergoing radical prostatectomy from 1998
to 2000. Sixty patients had surgery alone (group A), while 24
patients received androgen ablation therapy for 3 months
before surgery (group B). The presence of the TMPRSS2:ERG
gene fusion product was demonstrated by reverse transcription
polymerase chain reaction (PCR) in 84% of group A patients
and in 54% of group B patients (p=0.01). The levels of
TMPRSS2:ERG and ERG, measured by means of real-time
quantitative PCR, did not show significant association with
clinicopathological characteristics of the tumours, except for
a negative correlation of ERG overexpression with Gleason
score (R=0.457; p=0.0001), observed in group A alone. The
lower proportion of group B patients harbouring
TMPRSS2:ERG fusion suggests that androgen ablation
inhibits the expression of TMPRSS2:ERG, underscoring the
key role of androgen-mediated transcription control of the
gene fusion. Differently to group A, group B patients
expressing the fusion gene experienced earlier biochemical
(PSA) recurrence (p=0.007). In this specimen set, we observed
that tumours in which androgen ablation prior to surgery fails
to suppress expression of the fusion gene have a greater risk of
Abstracts of the 8th International Conference of Anticancer Research, 17-22 October 2008, Kos, Greece
recurrence. Further studies in larger cohorts of tissue are under
way to confirm these findings.
486
DENDRITIC CELL-BASED IMMUNOTHERAPY:
INFLUENCE OF THE MICROENVIRONMENT ON
THE IMMUNE RESPONSE
Thomas Neßelhut, Dagmar Marx, Constanze Matthes,
Dirk Lorenzen and J. Neßelhut
Institute for Tumour Therapy, Hinterstraße 53, 37115
Duderstadt;
Department of Immunology, University of Göttingen,
Germany
Especially in advanced stages of cancer, common therapy
strategies show insufficient results accompanied by a reduced
quality of life due partly to strong side-effects. Today, one of
the most promising innovative therapy approaches in treatment
of various types of human cancer is a specific immunotherapy
with dendritic cells. Several groups have shown that
immunotherapy with monocyte-derived dendritic cells
(MoDC) loaded either with tumor-cell–lysate, known tumorspecific peptides, or with specific RNA or DNA can induce a
clinical antitumor response in patients with various types of
cancer accompanied by fewer side-effects and good
tolerability. Nevertheless, most of the treated patients fail to
respond to the therapy. The ineffective clinical antitumor
response to a dendritic cell-based therapy may be partly due to
an inflammatory tumor microenvironment. Several
investigations showed increasing evidence of a strong
association between chronic infection, inflammation and
cancer development as well as in tumor progression. Many of
the same inflammatory mediators that are secreted by wounds
are found in the tumor microenvironment. It is known that also
tumors themselves can change the immunological balance into
an inflammatory microenvironment leading not only to
promotion of tumor growth but also to inhibition of an
efficient immune response and thus resulting in an
unsuccessful immunotherapy based on dendritic cells.
Besides several cytokines which promote an immune
suppressive microenvironment, such as for example IL-10,
regulatory T-cells (T-reg) play an important role in regulation
of an immune response. An increase of regulatory T-cells is
often found in cancer patients and may limit the antigenspecific immune response. To reduce these T-reg cells to a
normal range, a metronomic chemotherapy should be
considered as pretreatment prior to an immune therapy with
dendritic cells, which may enhance the antigen-specific CD8-T-cell response. Moreover, an anti-inflammatory treatment
should be accompanied by a noninflammatory
microenvironment, which can promote DC activation and can
enhance tumor immunity as well as the clinical antitumor
response. An efficient induction of a clinical antitumor
response requires, beside a change of the immune suppressive
tumor-associated microenvironment, a polarization of MoDC
in a TH1 direction. However, less IL-12 and high IL-10
production by the MoDC favoring a TH2 immune response
rather than a TH1 response is often found in cancer patients.
Culture conditions with supplement of certain TLR ligands
can signal the presence of infection (“danger signal”) and may
overcome the possible defective MoDC of cancer patients.
Using culture conditions with sequential supplementation of a
synthetic lipopeptide and LPS, we are able to change an IL12/IL-10 production profile <1 to an IL12/IL-10 production
profile >1, which favours a TH-1 response. Furthermore we
show that activation of the Toll-like receptor 3 by adding (poly
I:C), to the cultures as well as NDV can lead to DC, which
are able to produce IL-12 p70 at a higher level than IL-10. The
IL-12/1L10 ratio seems to be correlated to the clinical
response. Thus, addition of TLR agonists can effectively
improve the maturation status as well as the TH1-polarisation
of MoDC. Taken together, a successful dendritic cell based
immunotherapy requires more information on the cancer
characteristics to define the appropriate patient.
487
RADIONUCLIDE BASED TUMOUR TARGETING
OF CD44-POTENTIAL APPLICATIONS
IN HEAD AND NECK CANCER
Marika Nestor
Unit of Otolaryngology and Head and Neck Surgery,
Department of Surgical Sciences, Uppsala University,
Uppsala, Sweden
CD44 is one of the most complex molecules in all biology. It
is a multistructural and multifunctional cell surface molecule
involved in cell-cell and cell-matrix interactions and signal
transduction. Alternative splicing can theoretically generate
hundreds of CD44 isoforms, and posttranslational
modifications further enrich the structural variability of the
molecule. CD44 is essential to multiple biological functions
of normal cells, but is also crucial to many tumour cell
activities. Malignant cells often express unique patterns of
CD44 isoforms, and CD44 is one of the most common
markers used for isolation of cancer stem-like cells. This
makes it a highly interesting candidate for selective cancer
targeting.
We have assessed the CD44 isoform CD44v6 for
radionuclide based tumour targeting of head and neck cancer.
Radionuclide conjugates were created using the anti-CD44v6
chimeric monoclonal antibody (cMAb) U36 as a targeting
molecule. The conjugates 211At-cMAb U36 and 131I-cMAb
U36 were preclinically evaluated for therapeutic use in
squamous cell carcinoma (SCC) cells. A combination of the
3421
ANTICANCER RESEARCH 28: 3157-3556 (2008)
anti EGFR-antibody cetuximab and 211At-cMAb U36 was also
evaluated to further improve the therapeutic efficacy. Results
proved the astatinated conjugate to be most efficient,
demonstrating a specific and dose-dependent cytotoxicity.
Cetuximab influenced the therapeutic efficacy, but did not
mediate the same reaction in all cell lines, demonstrating the
wide variability of SCCs. Finally, the conjugates 124I-cMab
U36 and 111In-cMab U36 were evaluated for diagnostic use in
tumour bearing mice. Results were promising, with favourable
biodistributions and good visualizations in micro-PET and
planar gamma camera, respectively.
488
NEW UNDERSTANDINGS OF CANCER AND
PROLIFERATION FROM NANOGENOMICS
AND NANOPROTEOMICS
Claudio Nicolini
Nanoworld Institute, University of Genova, Corso Europa
30, 16132 Genoa, Italy and Fondazione ELBA, Piazza SS.
Apostoli 66, 00100 Rome, Italy
A new approach for cancer research is emerging from
nanogenomics (1) and nanoproteomics (2) as interplay of
bioinformatics, mass spectrometry and biomolecular
microarrays proceeds to a previously unforeseeable level. We
summarize here its major features with a few key applications,
such as the cell cycle progression of human T lymphocytes
(3), the reverse transformation of CHO-K1 hamster fibroblasts
(4), human organ transplant (5) and cancer (2, 4).
While investigation of the whole CHO-K1 proteome during
c-CAMP reverse transformation appear problematic by 1D or
2D SDS PAGE, HPLC and MALDI-TOF after a subcellular
fractionation in four distinct fractions (4), nanogenomics (1)
and nanoproteomics (2) allow the study of an immense
number of genes and/or proteins with only one experiment and
can therefore draw unique picture of the whole genome and
proteome. The huge volume of data arising from pangenomic
and panproteomic microarray experiments may often increase
experimental complications and difficulties in the analysis.
Despite the power of combined ab-initio analysis and
experimental analysis (1) genomics does however suffer many
pitfalls and only functional proteomics, called nucleic acid
programable protein array detecting the human proteins
produced by genes directly in a mammalian milieu during the
assay (2), represents the long-term answer to the basic
molecular understanding and to the clinical control of human
cancer, mainly in the Label-Free approach jointly developed
within the framework of an ongoing cooperation between
Harvard Institute of Proteomics and Genova NanoWorld
Institute.
These microarrays are produced by printing the proteins of
interest on the array using methods designed to maintain the
3422
integrity and activity of the protein, allowing hundreds to
thousands of target proteins to be simultaneously screened for
function using a wide range of gene collections. The focus of
function-based microarrays is to study the biochemical
properties and activities of the target proteins printed on the
array. Function-based microarrays can be used to examine
protein interactions with other proteins, nucleic acids, lipids,
small molecules and other biomolecules. NAPPA and
DNASER microarrays are introduced here to identify the key
proteins and key genes in the G0/G1, G1/S, S/G2, G2/M and
M/G0 transitions induced by PHA in resting lymphocytes.
Kidney transplantation is another medical problem
successfully approached with nanogenomics, permitting a
microarray- and bioinformatic-based identification of key
genes controlling tolerance and rejection of human kidney
transplant respectively. The whole proteome is instead
approached with mass spectrometry and with Label-Free
technologies (AFM, Nanogravimetry and Anodic Porous
Alumina electrochemistry). The extremely high density and
aspect ratio of APA represent the future challenges of
Nanoproteomics (6).
1 Nicolini C: Nanomedicine 1: 147-151, 2006; Sivozhelevov
V et al: Journal Cellular Biochemistry 97: 1137-1150, 2006;
Nicolini et al: IEEE on Nanobiosciences 1: 2, 67-72, 2002.
2 LaBaer J and Ramachandran N: Current Opinion in
Chemical Biology 9: 14-19, 2005; Spera R, Nicolini C,
Essential in Nanoscience Booklet Series (Taylor & Francis
Group, LLC), 2008; Ramachandran N et al: Nature
Methods, 1-4, 2008.
3 Nicolini C et al: Journal Cellular Biochemistry 97: 11511159, 2006; Giacomelli and Nicolini: Journal Cellular
Biochemistry 99: 1326-1333, 2006.
4 Spera R, Nicolini C, Journal Cellular Biochemistry 102:
473-482, 2007.
5 Sivozhelevov V et al: Journal Cellular Biochemistry 103:
1693-1706, 2008; Braud et al: Journal Cellular Biochemistry
103: 1681-1692, 2008.
6 Stura E et al: Bioelectronics and Biosensors 23: 655-660
2007; Grasso V et al: Nanotechnology 17: 795-798, 2006.
489
CALCIUM AS MODULATOR OF
VITAMIN D MEDIATED ANTI-TUMOUR
POTENTIAL IN THE COLON
Thomas Nittke, Heide S. Cross and Enikö Kállay
Department of Pathophysiology, Medical University Vienna,
Austria
Epidemiological and experimental studies emphasise the
importance of adequate vitamin D and calcium intake for
prevention of colorectal cancer. The active vitamin D
metabolite 1,25-(OH)2D3 plays an important role in
Abstracts of the 8th International Conference of Anticancer Research, 17-22 October 2008, Kos, Greece
differentiation and apoptosis of several cells, having a strong
anti-proliferative effect. In the colon 1,25-(OH)2D3 bound
VDR regulates also the expression of key detoxifying
enzymes, contributing to the elimination of mutagenic
compounds. In early colon tumuorigenesis, expression of the
enzyme catalysing synthesis of the active vitamin D3, 25
hydroxyvitamin D 1α hydroxylase (CYP27B1) is increased
whereas that of the catabolising hydroxylase CYP24A1 is very
low. In advanced tumours it is vice versa the expression of
CYP24A1 is highly elevated. Calcium might support local,
colonic 1,25-(OH)2D3 accumulation by regulation of
CYP27B1 and CYP24A1 expression and thereby affect
tumour progression. In this context we analysed the expression
patterns of Cyp27b1, Cyp24a1 and, the detoxifying enzyme
Cyp3a11 in the colon mucosa of mice fed either low or high
calcium diet. In parallel we measured 1,25-(OH)2D3 levels and
apoptosis with respect to functional relevance of the obtained
mRNA profile. Mice fed with low calcium exhibited high
Cyp24a1 mRNA levels in the right colon. At the same site,
expression of Cyp27b1 was also upregulated, but only in
females. This was accompanied by an increased level of 1,25(OH)2D3 and by increased apoptotic activity. The same gender
preference was observed for the Cyp3a11 expression in the
right colon: in females Cyp3a11 was upregulated by low
dietary calcium.
Our data suggest that in healthy colon mucosa the adverse
effects of low nutritional calcium could be counteracted by
enhanced synthesis of 1,25-(OH)2D3. This might be
responsible for increased apoptosis and possible improvement
of detoxification. Those defence mechanisms against tumour
development appear to be restricted to the right colon and are
more effective in females.
490
INFLAMMATION AND INFLAMMATORY
PROCESSES IN TUMOR ANGIOGENESIS AND
METASTASIS, MECHANISMS AND PREVENTION
Adriana Albini1, Girieca Lorusso1,2, Agostina Ventura3,
Lorenzo Mortara2, Michael B. Sporn4, Antonio Sica5
and Douglas M. Noonan2
1IRCCS
Multimedica, Milan;
degli Studi dell’Insubria, Varese;
3Centro Biotecnologia Avanzate, Genova, Italy;
4Dartmouth Medical School, Hanover, New Hampshire,
USA;
5Istituto Clinico Humanitas, Milan, Italy
2Università
It is now clear that components of the innate immune system
are one of the driving forces of tumor angiogenesis. This
suggests that these cells may be effective targets for therapies
aimed at curbing tumor progression, however their potential
has yet to be fully explored. For example, the angiogenesis
inhibitor angiostatin, identified by functional assays in vivo,
appears to preferentially target immune cells. Angiostatin is
unable to exert angiogenesis inhibition in the presence of
function blocking antibodies to IL-12 or in mice with genetargeted deletions of either the IL-12-specific receptor IL12Rβ2, or the IL-12 p40 subunit. In vitro, treatment of human
macrophages with angiostatin alone induced mRNA
significantly to elevate synthesis of the two IL-12 subunits, as
determined by real-time PCR. These data indicate that
macrophages are a primary target of angiostatin and place the
immune system at a central fulcrum in the regulation of
angiogenesis in vivo. Furthermore, they indicate that
endogenous angiogenesis inhibitors appear to function by
targeting immune cells rather than endothelial cells, which
indicates these cells are attractive targets for combination antiangiogenic therapies.
Our studies on the mechanisms of cancer chemoprevention
compounds, indicate that a key and common activity is a block
of angiogenesis, a concept known as angioprevention. We have
also found that angioprevention compounds, including the
flavonoids epigallocatechin 3 gallate and xanthohumol, often
inhibit the NF-κB pathway, a central molecular hub for
inflammation. Since synthetic oleanane triterpenoids have
been observed to inhibit the NF-κB pathway, we investigated
the anti-angiogenic potential of a series of synthetic
triterpenoids, including CDDO, CDDO-Im and the CDDOmethyl ester (CDDO-Me, methyl 2-cyano-3,12-dioxoolean1,9-dien-28-oate). While all inhibited angiogenesis, CDDOMe showed remarkable potency while being well tolerated in
vivo, effective at doses as low as 0.003 mg/kg of body weight.
In addition to the NF-κB axis, CDDO-Me and related
triterpenoids also inhibit STAT and TGFβ signaling. The
particularly potent anti-angiogenic activity seen in vivo
suggests that CDDO-Me may be interacting with an entire
network of molecular and cellular targets, rather than at a
single molecular locus or in a single cell type.
491
THE EFFECT OF ANDROSTENEDIONE ON
PROLIFERATION OF OVARIAN EPITHELIAL
CANCER CELLS
M. Nourbakhsh1, M. Zahraei1, A. Golestani1,
MH. Modarressi2 and F. Karami-Tehrani3
Departments of 1Clinical Biochemistry and 2Medical
Genetics, School of Medicine, Medical Sciences/University
of Tehran, Tehran;
3Department of Clinical Biochemistry, School of Medical
Sciences, Tarbiat Modarres University, Tehran, Iran
Introduction: Ovarian cancer is the leading cause of
gynecological cancer mortality, and more than 85% of this
malignancy arises from the ovarian surface epithelium. The
3423
ANTICANCER RESEARCH 28: 3157-3556 (2008)
etiology of epithelial ovarian cancer and the mechanism of its
progression are poorly understood, but there is increasing
evidence that reproductive hormones regulate the growth of
ovarian cancer cells. Epidemiological studies have revealed
that high levels of androgens are implicated in increasing the
risk of ovarian cancer. The aim of this study was to determine
the proliferation of ovarian cancer cells in response to
androstenedione which is the main androgen of the ovary.
Materials and Methods: Ovarian carcinoma cells (OVCAR3)
were cultured in RPMI-1640 containing 10% FBS in 24- and
96-well plates and allowed to adhere for 24 hours. Then the
cells were switched to medium supplemented with dextrancoated charcoal-treated FBS in the presence or absence of
10–5-10–9 M 4-Androstene-3,17-dione. Cellular proliferation
was assessed by means of MTT assay and cell counts with
hemocytometer and trypan blue. Results: The proliferation of
ovarian cancer cells was significantly increased by
androstenedione in a time-dependent manner, and all applied
concentrations of androstenedione resulted in significantly
higher numbers of cells than the untreated control.
Conclusion: We have demonstrated that androgens can cause
an increase in proliferation of ovarian cancer cells.
492
NBS1 GENE MUTATIONS AS
A CANCER RISK FACTOR
Jerzy Nowak, Maria Mosor, Iwona Ziółkowska,
Agnieszka Dzikiewicz-Krawczyk and Danuta Januszkiewicz
Institute of Human Genetics Polish Academy of Sciences,
60-479 Poznan, Strzeszynska 32, Poland
MRE11, RAD50 and NBS1 (MRN) complex is involved in
DNA repair and cell cycle checking signaling. NBS1 being a
part of MRN complex plays an important role in genome
stabilization. Molecular variants of NBS1 gene may therefore
constitute a cancer risk factor. Homozygous mutation
657del5 of the NBS1 gene is responsible for the majority of
Nijmegen breakage syndrome. Several studies have focused
on searching for an association between NBS1 gene
mutations and cancer incidence. Heterozygous carriers of the
NBS1 657del5 mutation have been shown to have an
increased risk for breast cancer, melanoma, colon and rectum
cancer. Other studies have found no association between
NBS1 gene mutations Hodgkins’s or non-Hodgkin’s
lymphomas. The aim of the study was to analyze the
frequency of a panel mutations of NBS1 gene by screening
all 16 exons of this gene along with polymorphisms
examination. DNA was isolated from peripheral blood of 135
children with acute lymphoblastic leukemia, 270 women
with breast cancer, 176 patients with larynx cancer, 93 with
second primary tumors of head and neck, 131 with colorectal
carcinoma and 1274 healthy individuals. I171V mutation of
3424
NBS1 gene was the most frequent and has been found in 23
patients compared to only 8 in healthy individuals. Other
mutations of the NBS1 gene have been observed in lower
frequencies. Genotyping data from the six polymorphic loci
in NBS1 gene, were used to impute haplotypes. Two of the
evaluated haplotypes were associated with significantly
increased leukaemia risk (p=0.0038 and p<0.0001). Our
results suggest that some specific haplotypes of the NBS1
gene may be associated with malignancies. Since DNA was
also isolated from non-malignant cells, all mutations found
in cancer patients appeared to be of germinal origin. It can
be concluded that I171V mutation of NBS1 gene is
associated with predisposition to malignancies and NBS1
allele I171V may be a general cancer susceptibility gene of
low or middle risk.
Supported by grant No N N407 016235 Ministry of Science
and Higher Education.
493
THE IN VIVO EFFECT OF FENUGREEK ON
METABOLISM OF ARACHIDONIC ACID
IN AN ANIMAL EXPERIMENT
Ghodratollah Nowrasteh, Timea Varjas, Ferenc Budán,
Krisztina Amrein, Gabor Horváth and Istvan Ember
Institute of Public Health, Faculty of Medicine, University of
Pécs, 12 Szigeti st., H-7643 Pécs, Hungary
The main bioactive compounds of Trigonella foenum graecum
(fenugreek) seeds are protodioscin, trigoneoside, diosgenin and
yamogenin. These have been found to have anticarcinogenic
potency in different settings, such as inhibition of cell
proliferation and inhibition of prostaglandin synthesis e.g.
metabolic pathway with lipoxygenase (ALOX) and
cyclooxygenase (COX) enzymes. The seed extracts of
fenugreek can also be of help in chemoprevention.
In our experimental set up we examined the antiinflammatory effect of fenugreek on fatty acid metabolizing
enzymes (ALOXs and COXs) in AKR/J H-2k mice exposed to
carcinogen dimethylbenz[α]anthracene (DMBA). We also
determined the gene expression pattern of enzymes involved
in arachidonic acid metabolism based on detecting the mRNA
expression in various tissues (lung, liver, spleen and kidney)
in four groups of mice. Two groups were fed with a normal
diet (control) and two of them consumed fenugreek-containing
diet, and each group received DMBA treatment. All groups
were autopsied on the 7th day, 24 hours post carcinogenic
exposure, and mRNA from target organs was isolated. Gene
expression did not change in the tissues of mice on the
fenugreek diet in comparison with mice on a normal diet in
control group.
DMBA exposure increased the expression of ALOX12
mRNA in the liver, lung and spleen of the mice consuming
Abstracts of the 8th International Conference of Anticancer Research, 17-22 October 2008, Kos, Greece
fenugreek, but in the kidney, fenugreek diet suppressed gene
expression to a normal level. ALOX15 gene expression was
increased by carcinogen in all organs examined, but in the
liver, lung and kidney fenugreek consumption reduced the
elevated gene expression to a normal level. ALOX5 gene
expression was increased by 2.5 to 4-fold in all organs due to
carcinogen exposure; the inhibitory effect of fenugreek was
detected only in the liver and kidney. The expression of COX1
enzyme (exception of spleen) increased in response to DMBA
exposure in all examined organs and the fenugreek diet
suppressed gene expression independently of carcinogen
exposure. The increased expression of COX2 in response to
DMBA was suppressed by fenugreek in all of the four tissues
examined.
The arachidonic acid metabolism pathway is one of the
possible targets of specific molecular prevention therapy.
According to the literature, prostate, lung, and other cancer
cell lines express ALOX5, with a metabolism that leads to
the formation of a variety of metabolically active products
with different roles in carcinogenesis. Fenugreek can be a
supplementary factor in chemoprevention.
494
PROTEASES AND COLLAGEN-DERIVED
ANGIOGENESIS INHIBITORS IN THE
TUMOR MICROENVIRONMENT
Pia Nyberg and Tuula Salo
Department of Diagnostics and Oral Medicine, Institute of
Dentistry PO Box 5281, FIN-90014 University of Oulu,
Finland
It has become clearly evident that tumor growth does not
just depend on the carcinoma cells, but instead various cell
types, such as fibroblasts and endothelial cells, as well as
extracellular matrix (ECM) components affect the outcome.
The ECM is both a backbone and a barrier for cells as well
as a storage place for biologically active molecules.
Therefore proteases cleaving ECM component are crucially
important. Proteases can be either protective or destructive
in cancer. We have studied tumor-associated trypsin-2 that
is a protease that correlates with the aggressiveness of
cancer. Trypsin-2 increases metastasis formation by
activating other downstream proteases as well as by
disturbing tight junction molecules. The turnover of ECM
liberates many biologically active cryptic molecules that
possess anti-angiogenic activity. Arresten and endostatin are
examples of such endogenous angiogenesis inhibitors that
are derived from collagen IV and XVIII, respectively. They
inhibit angiogenesis and tumor growth, but their
mechanisms are not completely known. It is important to
note that even though the collagen-derived endogenous
angiogenesis inhibitors are molecules of about the same
size, come from similar parent molecules and have sequence
homologies, they function via distinct mechanisms, bind
different cell surface receptors, and affect angiogenesis and
the tumor microenvironment in distinct ways. We have
shown that arresten affects endothelial cell proliferation,
migration and apoptosis via integrin α1β1. Here we aimed
to elucidate how arresten and endostatin affect the behaviour
of aggressive oral carcinoma cells and normal and cancerassociated fibroblasts. We have previously shown that
endostatin inhibits the activity of matrix metalloprotease-9
(MMP-9). Here we show that arresten has quite the opposite
effect: it increases gelatinase (MMP-9 and -2) production by
oral carcinoma cells and normal and carcinoma-associated
fibroblasts. Furthermore, arresten increases oral carcinoma
cell migration, whereas endostatin inhibits carcinoma cell
migration. However, in an organotypic model, arresten
inhibits the invasion of carcinoma cells. In conclusion, our
data demonstrates how different the effects of collagenderived angiogenesis inhibitors can be in the tumor
microenvironment despite of the similar effects on
endothelial cells. When designing treatment strategies for
cancer, the effects on all the components of the tumor
microenvironment need to be elucidated. The organotypic
carcinoma models are a great tool to achieve this goal.
495
RADIONUCLIDE DETECTION OF
NEUROENDOCRINE TUMORS
USING 111In PENTETREOTIDE
Vladimir Obradović, Vera Artiko, Nebojša Petrović,
Dragana Šobić, Milan Petakov, Ivana Božić,
Tatjana Isailović and Svetozar Damjanović
Institute for Nuclear Medicine , Institute for Endocrinology
and Metabolic Diseases, Clinical Center of Serbia,
Belgrade, Serbia
Aim: The aim of the study is the detection of primary and
metastatic neuroendocrine tumors using 111In pentetreotide
(OctreoScan), which is a long-acting analog of somatostatin.
Patients and Methods: A total of 30 patients was
investigated. Scintigraphy of the whole body, (and
tomography 360˚/6˚ if necessary) was performed 4h - 48 h
after i.v. administration of 111MBq 111In pentetreotide.
Results: In the group with 12 neuroendocrine carcinomas of
unknown origin, there were 10 true positive (TP) findings (6
with liver metastases, one with liver, lung, and bone
metastases, one with liver and mediastinal lymph node
metastases and 2 with liver and retroperitoneal lymph node
metastases), while 2 were false negative (FN) (poorly
differentiated carcinoma with retroperitoneal metastases). In
6 patients scintigraphy influenced further patient
management. From the group of 12 pancreatic
3425
ANTICANCER RESEARCH 28: 3157-3556 (2008)
neuroendocrine tumors, in 8 neuroendocrine pancreatic
carcinomas, there were 6 TP (4 with liver metastases) and 2
FN (poorly differentiated). In 2 patients with pancreatic
gastrinomas findings were TP, while in 2 patients with
insulinoma one was TP and in the other TN. In 6 patients
scintigraphy influenced further patient management while in
4 only contributed. From the group of 6 neuroendocrine lung
tumors there were 4 TP (4 patients with bronchial carcinoid,
two with liver metastases and the other two with liver, lung
and bone metastases), in 1 patient with atypical lung
carcinoid after surgery, findings were TN, while in one with
neuroendocrine lung tumor (ACTH secreting) it was FN
(small mediastinal tumor. In 2 patients scintigraphy
influenced further patient management while in 2 only
contributed. Because of the high uptake of
radiopharmaceutical, and widespread metastases, six patients
were indicated for radionuclide therapy with 90Y-DOTA
TATE, and three of them received it. Conclusion:
Preliminary results show that scintigraphy of neuroendocrine
tumors is a useful method in diagnosis, staging and follow
up of the patients suspected to have neuroendocrine tumors
in the lungs. It is also helpful in the appropriate choice of
therapy, including radionuclides.
496
PARASPORIN, A NEW ANTICANCER PROTEIN
GROUP FROM BACILLUS THURINGIENSIS
Michio Ohba1, Eiichi Mizuki2 and Akiko Uemori1,3
1Graduate
School of Bioresource and Bioenvironmental
Sciences, Kyushu University, Fukuoka;
2Biotechnology and Food Research Institute, Fukuoka
Industrial Technology Center, Kurume;
3Fresenius Medical Care Japan K.K., Tokyo, Japan
Bacillus thuringiensis was first isolated in 1901 from Japan
as a silkworm pathogen. It produces proteinaceous
parasporal inclusions during sporulation. The inclusions
often exhibit strong and specific insecticidal activity. This
makes B. thuringiensis an environmentally safe agent for
control of medically and agriculturally important insect
pests. Earlier studies, however, have also demonstrated that
B. thuringiensis strains with non-insecticidal inclusions are
more widely distributed than insecticidal ones. Mizuki et al.
(1999) first reported that strong cytocidal activities against
human cancer cells are often associated with the noninsecticidal inclusion proteins. Subsequently, we obtained a
cytocidal protein gene, leading to the establishment of a new
functional protein group, parasporin (Mizuki et al., 2000).
Currently, parasporin is defined as "parasporal proteins
produced by B. thuringiensis and related bacteria that are
non-hemolytic but capable of preferentially killing cancer
cells."
3426
At present, parasporin (PS) is classified by its amino acid
identity into four subgroups, PS1 to PS4, consisting of a total
of 13 proteins. PS1 and PS3 have structural features of threedomain insecticidal Cry proteins. PS2 and PS4 are small-type
parasporins with no structural similarity to the known Bacillus
parasporal proteins. PS1 is synthesized as an 81-kDa precursor
protein that is proteolytically converted into an active
heterodimer of 15 and 56-kDa polypeptides. It exhibits
specific toxicity against uterine cancer cells (HeLa) but is not
active on normal uterus smooth muscle cells (UtSMC) and
normal T-cells. PS1 induces extracellular Ca2+ influx into
cytoplasm and subsequent apoptotic cell death of susceptible
cells. The PS2 precursor of 37 kDa is changed into a 30-kDa
active form through proteolysis. The protein is not toxic to
normal hepatocytes (HC) but is highly toxic to hepatocyte
cancer cells (HepG2) and leukemic T-cells (Jurkat). PS2
molecules target lipid rafts, oligomerize and form pores in the
rafts of cell membrane of the susceptible cancer cells. The
precursor of PS3, an 88-kDa protein, is converted into a 64kDa active protein by protease. PS3 has a structural similarity
to the insecticidal three-domain Cry proteins. It exhibits
preferential toxicities against limited numbers cancer cells,
including myeloid leukemic cells (HL60). The mode of action
of PS3 is less characterized, while poreformation seems to be
key action of this protein. PS4 is a small-type parasporin, a
31-kDa precursor and a 27-kDa active form. The protein exerts
cytotoxicity on colon cancer cells (CaCO-2) and leukemic Tcells (MOLT-4), but not on normal T-cells. It is very likely that
PS4 molecules, like PS2, oligomerize and form pores in
cancer cell membranes. Elucidation of the origin of the
specificity associated with PSs is currently under way, and the
identification of specific receptors, if any, may lead to the use
of these unique proteins for medical purposes.
497
IRINOTECAN IN THE TREATMENT
OF COLORECTAL CARCINOMA:
LIGHTS AND SHADOWS
Cristiano Oliva, Paola Bergnolo and Alessandro Comandone
Department of Medical Oncology, Presidio Sanitario
Gradenigo, Torino, Italy
In the last five years the introduction of the so called
“biological drugs” has moved the attention of the researchers
on this new kind of compounds. This is probably due to new
mechanisms of action, new fields of interest, new toxicities,
new drug combinations.
Irinotecan is an S-phase-specific derivative of camptothecin
which interferes with DNA replication and cell division by
inhibiting topoisomerase-I. It has demonstrated antitumor
activity against metastatic colorectal cancer. Irinotecan is a
versatile drug, it can be administered at different doses every
Abstracts of the 8th International Conference of Anticancer Research, 17-22 October 2008, Kos, Greece
three weeks, every two weeks and following weekly
schedules. It has a well known spectrum of toxicities, that are
not cumulative and that can be mostly predicted and treated.
Adverse events most frequently recorded were neutropenia,
acute cholinergic syndrome, fatigue, nausea and vomiting,
delayed diarrhea and alopecia. It has been approved by FDA
for the first line treatment of colorectal cancer since 1997 and
remains stil nowadays one of the three fundamental cytotoxic
drugs for this disease. The mechanism of action and single
agent efficacy of IRI, combined with the apparent absence of
any cross resistance with FU provided the rationale for
combining IRI with FU and Folinic Acid as the first line
therapy for metastatic colorectal cancer.
Irinotecan has thus been tested in combination with the
infusional Fluorouracil (FU)/Folinic Acid (FA) schedule at
different dosages and different intervals of administration.
Vanhoefer et al. tested IRI in a weekly setting in combination
with the AIO German FU/FA schedule in a phase I study. They
reached the maximum tolerated dose (MTD) of weekly IRI at
100 mg/m2 in association and recommended further studies
with a lower dose (80 mg/m2). Ducreux associated IRI with the
FU/FA de Gramont schedule and defined the recommended
bimonthly dose of IRI at 180 mg/m2. In a large phase III study
by Douillard et al. this association was statistically superior to
the de Gramont regimen alone in terms of response rate (34.8%
vs. 21.9%), time to progression (TTP) (6.7 vs. 4.4 months) and
survival (17.4 vs. 14.1 months). From that time the fact that
Irinotecan combination with FU/FA significantly increases
response rates, TTP and survival in patients with metastatic
colorectal cancer has become always more evident.
The other effective drugs in Colorectal cancer are FU and
Oxaliplatin. Following the results of the well known “Mosaic”
study, the Oxaliplatin’s use has progressively moved toward the
adjuvant setting. Moreover Oxaliplatin is a “one bullet gun”
and its use is strongly conditioned by its cumulative
neurotoxicity. Its use is restricted to the adjuvant setting or first
line treatment. However, the improvements in the results of the
treatment of advanced disease lead patients to receive also three
or more different lines of chemotherapy in this setting.
Therefore, patients with advanced colorectal cancer will receive
therapies mostly based on the combination 5FU (or oral
fluoropyrimidines) plus Irinotecan, variously administered.
In our phase II study we choose to combine the weekly
schedule of IRI (80 mg/m2) with a 28 days protracted venous
infusion of FU. This resulted in an active combination with a
mild toxicity profile. 52 pts were accrued in the trial. We
recorded 5 Complete Responses (9.6%) and 15 Partial
Responses (28.8%) with an overall response rate of 38.5%
(95% C.I. 25% to 52%). Moreover, we had 17 patients with
Stable Disease (32.7%) for a disease control rate of 71.2%
(95% C.I. 58% to 84%). We detected a median PFS of 8.2
months (95% C.I. 6.1 to 10.1 months) and an OS of 16.3
months (range 4-58+ months, 95% C.I. 14.8 to 17.9 months).
In our daily Clinical Practice we usually prescribe the WiFi regimen also to patients already treated with one line of
chemotherapy not containing Irinotecan (mostly FOLFOX or
Oxaliplatin plus Capecitabine). Data from this second line
slighty differ from the first line results both for response rate
and overall survival. Interesting data regarding similar
symptoms and free survival are available.
Thus resection was judged not feasible before therapy.
Thirteen patients (25%) underwent surgical resection for their
metastatic disease after 4 to 6 courses of chemotherapy.
Although in only 10 cases resection was considered
macroscopically radical. After the resection of their metastatic
disease patients received at least two courses of Wi-Fi with a
IV stage adjuvant purpose. In this setting a phase III
randomized trial by M. Ychou et al. has recently been
reported. The Authors randomised pts with completely
resected liver metastases, to receive 12 courses of FU/FA
according to DeGramont schedule versus 12 courses of
FOLFIRI. Primary endpoint was Disease Free Survival. No
differences were observed in the DFS between the two arms,
adjusted or not for important prognostic factors. The role of
Irinotecan in the adjuvant setting has been established in a lot
of large randomized clinica trials. Neither the Saltz’s trial
(CALGB C89803) nor the ACCORD-2 and the PETAC-3
trials were able to find significant differences between FU/FA
based chemotherapy and FU/FA plus Irinotecan regimens.
In our study the toxicities recorded were mild and a median
number of 5 courses of chemotherapy was administered.
However, 11 patients had to interrupt the treatment because of
toxicity. 4 of them had problems related to central venous
catheter. In three cases the patients developed a deep venous
brachial or jugular thrombosis and one patient had rupture of
the venous catheter. In this latter case, the subsequent
procedures to recover the broken part induced the patient to
decide to stop the treatment. In our opinion, the problems with
the venous catheters are a field in which the substitution of the
protracted infusion of FU with oral fluoropyrimidine could
result in a better cost-effectiveness ratio. However, the recent
data from the BICC-C study, a randomized trial comparing the
standard FOLFIRI regimen to irinotecan and bolus FU/FA
(IFL regimen) and to an association of IRI plus capecitabine,
reports the control arm to be superior in terms of response
rate, PFS and OS with a better toxicity profile. These findings
were confirmed in the EORTC study 40015 in which C. H.
Köhne et al. compared the classical FOLFIRI regimen versus
a Capecitabine plus Irinotecan schedule called CAPIRI. Both
regimens were randomly assigned to a therapy with celecoxib
or placebo. The trial was prematurely closed because of an
unexpected number of deaths unrelated to disease progression
but it was possible to establish that both TTP and OS were
shorter for CAPIRI than for FOLFIRI. These findings can
reaffirm the importance of the infusional FU-based therapies
even in the era of oral fluoropyrimidines.
3427
ANTICANCER RESEARCH 28: 3157-3556 (2008)
In our opinion the Wi-Fi combination is an active schedule
that well matches with the weekly administration of Cetuximab.
A phase II study of the combination Wi-Fi plus Cetuximab has
already started in our Department. On the basis of recent
advances in the use of Cetuximab we decided to reserve this
treatment to patients with wild-type K-RAS disease.
A lot of trials established that Capecitabine is at least active
as infusional FU. On the contrary why Irinotecan seems to
work better when combined with FU than when associated
with Capecitabine? Irinotecan works well in the advanced
setting but it does not seem to be equally active in the adjuvant
setting, either stage II-III or stage IV.
498
VARIOUS POSSIBLE METHODS FOR INDUCING
UROTHELIAL TUMOURS IN RATS AND MICE
USING CHEMICAL COMPOUNDS
P.A. Oliveira
CECAV, Department of Veterinary Sciences, University of
Trás-os-Montes and Alto Douro, 5001-801 Vila Real, Portugal
The bladder is one of the most common sites for the
appearance of cancer in the urinary tract. Bladder tumours are
manifestations of a multifocal disease whose natural history
has not yet been completely elucidated. Animal models provide
a system that can enhance our understanding of basic biology.
To induce the development of urothelial tumours, it is essential
to select correctly the model that is most analogous to the
clinical settings so that observations can be readily transferred
to clinical studies for validation. Over the past few decades,
research efforts have focused on the development of rodent
models that permit the reproducible induction of bladder cancer
with minimal or no induction of tumours in other organs.
Several chemicals, such as N-butyl-N-(4-hydroxybutil)nitrosamine, N-methyl-N-nitrosourea and N-[4-(5-nitro-2furyl)-2-thiazolyl]-formamide, have proven particularly
effective at this, and when administered via the appropriate
route, at the appropriate dosage and in the appropriate strain of
animal, all produce a high incidence of bladder tumours. By
monitoring responses to chemical carcinogens using
experimental models, it has been possible to identify many of
the mechanisms through which tumours develop and to
evaluate new therapeutic strategies. In our oral communication,
the various possible methods for inducing urothelial tumours
in rats and mice using chemical compounds, the spectrum of
histological lesions observed in each model and the results of
my recent research will be presented.
499
CHEMO-PREVENTION OF: PROSTATE
CANCER: THE RATIONALE BEHIND
DESIGN OF PILOT STUDIES
3428
Tim Oliver, Attila Lorincz and Jack Cuzick
Wolfson Institute of Preventive Medicine, Queen Mary
University London, Charterhouse Square, London EC1M
6BQ, UK
12 years ago one of us (TO) first proposed the hypothesis that
prostate cancer was caused by a life-time of "sub-clinical"
prostatitis. The article also speculated on the basis of the first
results from use of intermittent hormone therapy that shortterm (1-3 months) androgen blockade given at age 45 (to the
one third of the population known from post mortem studies to
have latent prostate cancer at that stage) could be a very
effective form of chemo-prevention. The hypothesis was based
on a considerable paucity of hard facts and mainly rested on
three borderline significant aetiological similarities in common
between prostate and cervix cancer – i.e., risk of malignancy
was increased by 1) early onset of sexual activity, 2) reduced
by circumcision, and 3) increased in Afro-Caribbean’s. Further
support came from the observation that 1 in 5 patients with
advanced metastatic prostate cancer treated by intermittent
androgen blockade (IAB) survived for prolonged periods (5 or
more years) without further need for treatment. Subsequently,
studies on a cohort of predominantly 25-35 year old South
African Gold miners demonstrated a correlation between both
early initiation of sexual activity and evidence of chlamydial
infection with increased PSA levels and provided additional
support for the hypothesis that repeated episodes of minor
sexually transmitted diseases (STD) might cause lasting
damage to the prostate. The subsequent demonstration by
others that at the age of 45 those with a PSA above the median
level had a 3.75 higher risk of death from prostate cancer
provided further evidence of the value of PSA as a screening
tool for prostate cancer detection. However, it also raised
questions whether this is because PSA level also reflects the
degree of persistent sub-clinical prostatitis and that is
associated with cancer development rather than a direct
measure of existing prostate cancer.
Today, with five reviews in major journals, the concept of
chronic inflammation of the prostate as a major cause of
prostate cancer has become mainstream. The failure to
associate a single major pathogen with cause, unlike
helicobacter gastritis in stomach cancer, has so far resulted in
few therapeutic endeavours and led to the conclusion that the
association is multi-factorial including non-specific infections,
autoimmunity and dietary/environmentally acquired chemical
toxins. The demonstration in a rat model that intra-urethral E.
coli leads to the development of proliferative inflammatory
atrophy and also Prostatic Intra-epithelial Neoplasia (PIN) has
demonstrated how a non-specific infection can become a
major driving force in the clonal development of this disease.
This presentation will review supporting data prior to
focusing on the major paradox of medical therapy of
Abstracts of the 8th International Conference of Anticancer Research, 17-22 October 2008, Kos, Greece
prostate cancer, ie that PSA testing leads to over diagnosis
and thus active monitoring to select those in need of radical
treatment is acceptable. However, a recent meta-analysis of
immediate vs deferred androgen blockade randomised trials
has shown survival advantage though an unacceptable
burden of side effects for immediate treatment. The past
year has seen the publication of the first results from The
International Study of IAB for Carcinoma of the Prostate
(ISICaP) Group that has undertaken an individual patient
data meta-analysis of IAB studies This has provided the first
solid evidence that short course (3 months) IAB offers a
potentially safe alternative to continuous anti-androgen
therapy. More importantly from the point of view of the
chemo-preventative potential of short course treatment, this
analysis has also demonstrated that a higher proportion of
earlier cases remain progression free for 3 or more years off
treatment. In addition good progress has been reported in
development of urine and semen based tests for diagnosing
prostate cancer.
Based on these observsations and recognition of the high
cancer risk of PSA positive biopsy negative individuals
possible chemo-prevention protocols for such patients
combining short term anti-androgens, anti-Cox 2s and high
dose Vitamin D are under consideration. The rationale behind
these proposals and their design will be reviewed
500
MULTIPLE MYELOMA – CHEMOKINE NETWORK:
CCL27/ CTACK – A NEW PLAYER IN MYELOMA
PROGRESSION
Angelika Olivier1, Michael Unger1, Eva Maizner1,
Daniel Neureiter2, Richard Greil1,3 and Karin Jöhrer1
1Tyrolean Cancer Research Institute, Innrain 66, A 6020
Innsbruck;
2Institute of Pathology at the Private Medical University
Hospital Salzburg, Müllner Hauptstrasse 48, A 5020
Salzburg;
33rd Medical Department with Hematology, Medical
Oncology, Hemostaseology, Rheumatology and Infectious
Disease at the Private Medical University Hospital Salzburg,
5020 Salzburg, Austria
Multiple myeloma is a still incurable B cell neoplasm
characterized by the monoclonal expansion of plasma cells in
the bone marrow. The physical interaction of multiple
myeloma cells with compartments of the bone marrow
microenvironment has a crucial role in the pathogenesis of the
disease. In detail, promotion of tumor growth and survival,
angiogenesis or the homing of the malignant clone are
sustained by the bone marrow milieu. Chemokines have
currently been shown to be major players in shaping the tumor
microenvironment of multiple myeloma cells.
Investigating the bone marrow supernatants of multiple
myeloma patients we found the chemokine CCL27/ CTACK
distinctly produced. This chemokine, which has so far only
been correlated with skin associated tumors, was significantly
upregulated in myeloma bone marrow compared to MGUS
patient samples. Additionally its expression could be
correlated with the stage of the disease. Immunohistochemical
data revealed that myeloma plasma cells as well as endothelial
cells are the major source for the production of this protein.
Due to the known implications of the chemokine network
in multiple myeloma, we started to reveal the possible role of
this chemokine in tumor biology. What we found so far was
the induction of some tumor promoting qualities. In detail the
chemokine CCL27 induced the migratory capacity of
myeloma cell lines, augments their susceptibility to IL-6 -a
major growth factor for myeloma tumor cells- and enhances
proliferation.
An alternative way of myeloma cells to progress is the
modulation of immune cell subsets in order to favour the
tumor. With regard to the supporting role of dendritic cells in
myeloma disease, and since they are the most potent antigen
presenting cells inducing T cell responses, we focused on this
cell subset. Monocyte derived dendritic cells – differentiated
and matured in the presence of CCL27- exhibited a reduced
capacity to activate T cells and this correlated with reduced
cytokine production on the T cell side. Further these dendritic
cells exhibited an impairment in migrative behaviour but at the
same time induced proliferation in our myeloma cell lines.
To summarize, we found that the myeloma cell produced
chemokine CCL27 exerts tumor progressive effects: In detail
we found an induced migratory capacity, augmentation of the
susceptibility to IL-6, and enhanced proliferation on the
myeloma cells themselves. Concerning the effects on immune
modulation, an impairment of dendritic cell function which
results in decreased T cell activation potential and the
impairment of dendritic cell migration could be observed.
All these findings led us to the conclusion that targeting
CCL27 would be a potent tool for future antitumor therapies.
501
DAMAGE OF HORMONAL FUNCTION AND BONE
METABOLISM IN LONG-TERM SURVIVORS OF
TESTICULAR CANCER
Dalibor Ondrus1,2,3, Ladislav Dusek2, Martina Ondrusova2,3,4
and Beata Spanikova5
11st Department of Oncology, Comenius University Medical
School, St. Elisabeth Cancer Institute, Bratislava, Slovak
Republic;
2Institute of Biostatistics and Analyses, Masaryk University,
Brno, Czech Republic;
3National Cancer Registry, National Health Information
Center; Bratislava, Slovak Republic;
3429
ANTICANCER RESEARCH 28: 3157-3556 (2008)
4Cancer
Research Institute, Slovak Academy of Sciences,
Bratislava, Slovak Republic;
5Out patient’s Department of Osteology, St. Elisabeth Cancer
Institute, Bratislava, Slovak Republic
Background: Improved survival of testicular cancer patients
during recent years has led to rising interest on the disease
consequences of the whole organism. Not only the tumor
alone, but also its treatment may have an impact on a patient’s
hormonal status and bone metabolism. The aim of this study
was to assign the hormonal profile and complete osteologic
examination into algorithm of follow-up not only in patients
with bilateral disease, but also in patients with unilateral
testicular tumor. Patients and Methods: During the period of
11/2005-6/2008, we examined 828 patients diagnosed with
testicular cancer after a mean follow-up of 87 months (range
9-260). Of these 776 patients were with unilateral (group A)
and 52 with bilateral (group B) disease. Each patient was
examined for hormonal profile (serum testosterone and LH
level), marker of bone resorption – S-CTx (serum C-terminal
cross-linking telopeptides of type I collagen) and serum
calcium. Dual energy x-ray absorptiometry (DEXA) was
performed on a Holoxic Explorer machine, focused on
measurement of the hips and lumbar spine bone mineral
density (BMD). Results of the osteological examination and
hormonal profile examination were analyzed for associations
with therapy following orchiectomy (orchiectomy alone,
chemotherapy, radiotherapy, chemotherapy and radiotherapy)
and with the time interval since the primary therapy. All key
analyses were carried out separately for unilateral and bilateral
tumors. Standard univariate statistical techniques were used to
test the differences between groups of patients (ML chi-square
test, one-way ANOVA). Unconditional logistic regression was
used to relate potential risk factors to osteopenia and/or
osteoporosis. All odds ratio estimates were adjusted for
patient’s age at the time of examination. Results: Group A: 776
patients with unilateral testicular cancer were followed-up for a
mean 83 months (9-244) since therapy and were on average 39
years old (range 24-57) at the time of examination.
Testosterone deficiency (<10.0 nmol/l) was observed in 34
patients (4.4%). Increased level of serum LH (>8.2 mU/ml)
was observed in 122 patients (15.7%). Increased S-CTx was
observed in 385 patients (49.6%). DEXA showed osteopenia
and/or osteoporosis in 384 patients (49.5%). Serum calcium
levels were in all cases normal. Group B: 52 patients with
bilateral testicular cancer were followed-up for a mean 160
months (range 21-322) (average follow-up related to the 2nd
tumor was 68 months, range 1-242) since the beginning of the
therapy and were on average 41 years old (range 24-58).
Testosterone deficiency was observed in 43 patients (82.7%).
Increased level of serum LH was observed in 42 patients
(80.8%). Increased S-CTx was observed in 33 patients
(63.5%). DEXA showed osteopenia and/or osteoporosis in 38
3430
patients (73.1%). Serum calcium levels were in all cases
normal. Influence of age at examination and time to
examination: Age at the time of examination was significantly
increased in patients with osteoporosis (on average by 7 years)
both in unilateral (p<0.001) and bilateral (p=0.022) tumors.
The risk of osteoporosis increased with time since primary
therapy (OR 1.08, p<0.05) and furthermore significant time
cut-off points were found both for unilateral tumors (>8 years,
OR 1.27) and bilateral tumors (>10 years, OR 3.90). In
bilateral tumors, time >10 years since 2nd testicular cancer
diagnosis was proven as an additional component increasing
risk of osteoporosis (OR 2.85, 95% CI 1.07-7.61). Influence of
primary therapy: In unilateral disease, applied CHT and/or RT
increased significantly age-adjusted risk of osteopenia and/or
osteoporosis (ORs ranged from 1.28 to 2.96). Application of
radiotherapy further specifically increased age-adjusted risk of
lumbal spine BMD impairment (OR 1.31; p<0.05).
Radiotherapy was also significantly associated with increased
TST and decreased LH levels at the time of examination in
unilateral disease. In bilateral tumors, no significant association
between therapy and risk of osteoporosis was found. This can
be explained by highly significant risk potential of cancer
bilaterality itself. Bilaterality reached highly significant odds
ratio (p<0.001) for osteoporosis (3.32, 95% CI 1.48-7.42) and
for osteoporosis + osteopenia (2.77; 95% CI 1.47-5.19).
Conclusion: Examination of the hormonal profile and
testosterone replacement therapy may be recommended as an
important aspect of a patient’s follow-up not only in bilateral
disease (without consideration of the patient’s sexual life), but
also in patients with unilateral testicular cancer. The important
part of a standard examination algorithm should also be an
osteological examination to prevent osteopenia or even
osteoporosis development. Particular attention should be paid to
patients treated by radiotherapy.
502
FUNCTIONAL STUDIES OF S100A6 USING
PROTEOMICS
Lukas M. Orre1, Erik Vernet2, Johan Lengqvist1,
Torbjörn Gräslund2, Rolf Lewensohn1 and Janne Lehtiö1
1Karolinska
Biomics Center (KBC), Department of
Oncology and Pathology, Karolinska Institutet, Z5 plan 02,
Karolinska University Hospital Solna, 171 76 Stockholm;
2Department of Biotechnology, Royal Institute of
Technology, KTH, Roslagstullsbacken 21, 106 91
Stockholm, Sweden
We previously used proteomic profiling to identify S100A6 as
a protein up-regulated in response to DNA damage. Our
studies also showed that S100A6 was expressed in a p53dependent manner and that the post-translational modification
pattern and subcellular localisation of S100A6 was altered
Abstracts of the 8th International Conference of Anticancer Research, 17-22 October 2008, Kos, Greece
following irradiation. We and others have shown that S100A6
is overexpressed in a number of different tumor types. The
connection between S100A6, cancer, p53 and DNA damaging
treatment inspired us to investigate the cellular functions of
S100A6 in depth.
As the functions of S100 proteins are believed to be through
interactions with other proteins and regulation of these target
proteins functions, we used proteomics to discover novel
S100A6 interacting proteins. Immunoprecipitation using an
S100A6 specific antibody was followed by proteomic analysis
of the S100A6 precipitate using nano-LC MALDI-MS/MS.
Using this approach we discovered Ubiquilin-1 as a novel
S100A6 interacting protein.
To further investigate the function of S100A6 we generated
stable S100A6 shRNA expressing lung cancer cell lines. These
cell lines were then used in proteomics experiments to
evaluate the effect of S100A6 silencing on the cellular
proteome. Using this approach we were able to show
connections of S100A6 with regulation of protein degradation,
and in addition S100A6 silencing increased the cellular
sensitivity to ionizing radiation.
503
PRO AND CONS FOR SYSTEMATIC THERAPY
IN RECURRENT OVARIAN CANCER?
Gülten Oskay-Özcelik, Werner Lichtenegger and
Jalid Sehouli
Department of Obstetrics and Gynecology, Charite Medical
University, Germany
The treatment of recurrent disease in ovarian cancer patients is
an important aspect in the overall management. Ovarian cancer
patients who do not respond to their initial chemotherapy or
who relapse after achieving a response are generally incurable.
Treatment goals after failure of first-line treatment for ovarian
cancer are: (a) controlling or preventing disease-related
symptoms, (b) maintaining quality of life with choosing an
effective treatment with low toxicity potential and (c)
prolonging progression-free survival. In contrast to the situation
in previously untreated patients in whom prospective
randomized phase III trials have established the current
standard, in patients with recurrent disease there have been few
randomized trials that have clearly demonstrated a survival
advantage for a particular drug or regimen. In addition, a series
of agents have been shown to have clinical activity in recurrent
ovarian cancer, including topotecan, pegylated liposomal
doxorubicin, gemcitabine, and oral etoposide. It has also been
demonstrated that re-treatment with a platinum drug and taxane
has been associated with significant clinical activity in patients
with “sensitive” (treatment free interval >6 months) recurrent
disease. The role of antihormonal therapy is unclear. However
evidence-based treatment for recurrent ovarian cancer will
require prospective randomized trials comparing efficacy,
toxicity and quality of life.
504
ROLE OF DNA CONTENT ANALYSIS AND
IMMUNOHISTOCHEMISTRY IN THE
EVALUATION OF THE RISK OF
UNFAVOURABLE OUTCOME IN WILMS’ TUMOURS
Maria-Chiara Osterheld, Liette Caron and
Kathleen Meagher-Villemure
Institut Universitaire de pathologie, Bugnon 25, 1011
Lausanne-CHUV, Switzerland
Background: Wilms’ tumour (WT) is the most common solid
tumour affecting young children. Its histological diversity
leads to difficulties in predicting the outcome. Materials and
Methods:
Image
analysis
cytometry
and
immunohistochemistry with a selected panel of antibodies
were performed in 23 cases of WT considered intermediate
risk tumours according to the revised International Society of
Pediatric Oncology (SIOP) working classification of renal
tumours of childhood. In this series, a tumour was considered
aggressive according to its propensity for metastases or its
recurrence. Results: Out of the 14 non-aggressive WT, 4 were
found to be diploid and 10 were aneuploid, including 6 that
were heterogeneous for DNA-ploidy. All the tumours
presented a low proliferative index and were negative for p53
and p57kip2 immunostaining. Out of the 9 aggressive
tumours, all were aneuploid and 4 were found to be
heterogeneous for DNA-ploidy. They all presented a high
degree of cell proliferation and 7 were positive for p53
immunostaining. Only two were positive for p57kip2 marker.
The only fatal case revealed an aneuploid-homogeneous DNAploidy analysis, was p53- and p57kip2- positive and presented
a high cell proliferation index. Conclusion: A significant
correlation between the presence of focal DNA-aneuploidy in
Wilms’ tumours and adverse prognosis was not established,
but some immunohistochemical markers may be useful for the
clinical evaluation of these tumours and to help in predicting
the risk of unfavourable outcome.
505
INTERSTITIAL RADIOSURGERY
FOR BRAIN TUMOURS
Christoph B. Ostertag
Abt.Stereotaktische Neurochirurgie, Universtätsklinikum
Freiburg, 79106 Freiburg i.Br., Germany
Interstitial radiosurgery is a local treatment modality and
therefore aims at the treatment of localized tumours.
Experimental interstitial radiosurgery produces well defined
3431
ANTICANCER RESEARCH 28: 3157-3556 (2008)
small volumes of tissue necrosis which develop centrifugally
from the implant and which are subsequently removed by
macrophage activity. The perifocal toxicity is attributed to
secondary effects, namely temporary changes in capillary
permeability and regional cerebral blood flow. The damaged
capillary surface area product increases with the square of the
radius of the irradiated volume. The combination of temporary
perifocal vasogenic edema and reduced blood flow in relation
to volume limits the application of radiosurgery in the brain.
The clinical application requires the direct temporary
placement of single or multiple radioactive sources in the form
of seeds into the tumor volume. Tumour volume and target
volume ideally are identical. Tissue inhomogeneities are of
minor concern. The dose administered is confined with a steep
dose gradient when compared with standard radiotherapy.
Radioactive sources such as Iodine-125 (I-125) deliver the
dose at a constant low-dose rate (1-100 cGy/h) compared with
+ 200 cGy/min by external beam radiotherapy or ± 5 Gy with
focussed beam radiosurgery. As with other radiosurgical
procedures, interstitial radiosurgery requires a precise
knowledge of the relationship between the energy of the
radioactive source, the radiation dose, the volume treated and
the subsequent response of normal tissue surrounding the
lesion. Only a small subgroup of patients with low-grade
gliomas are appropriate candidates for interstitial radiosurgery,
namely those with circumscribed tumors with only limited
spread of tumor cells into the periphery. For this subgroup,
which usually comprises not more than 25 % of all low-grade
gliomas, interstitial radiosurgery competes with surgical
resection. Interstitial radiosurgery is also be used to effectively
treat gelastic epilepsy due to hypothalamic hamartomas with
less invasiveness and side-effects compared with open surgery.
506
A REVIEW ON FIRST-GENERATION HEPOXILIN
ANALOGS (PBTs) AS CANCER THERAPEUTICS
Cecil R. Pace-Asciak
Programme in Physiology and Experimental Medicine,
Research Institute, The Hospital for Sick Children, 555
University Avenue, Toronto, Ontario, Canada M5G 1X8
(primary address) and Department of Pharmacology, Faculty
of Medicine, University of Toronto, Toronto, Ontario,
Canada M5S 1A8
In this review, the utility of stable first-generation analogs
(PBT) of the hepoxilins in controlling the growth of neoplastic
cells is discussed from in vivo xenograft animal studies (nude
mice) and from in vitro studies. The PBTs cause apoptosis of
solid tumors in leukemic (human CML) and human breast
cancer animal models in vivo with a threshold effect at 1.2
mg/kg in the CML model. The compounds are well tolerated
even at doses 10×above threshold, are stable and have long-
3432
term efficacy (up to 50 days) after an 8-day treatment. This
delay in tumour growth can be doubled if treatment is carried
out during two interrupted 8-days periods. The PBTs are
active in vitro on several human neoplastic cell lines tested
derived from chronic myelogenous leukemia (K562), breast
cancer (MDA MB231, MCF-7 and MT-3), prostate cancer
(DU-145), primary keratinocytes (HPK) and cervical cancer
(HeLa). The PBTs have no effect on normal cells (3T3-L1 and
smooth muscle). The PBTs are effective in causing apoptosis
of K562 cells that were resistant to Gleevec. These studies
point to an effective PBT base structure which may allow
modification to afford second-generation compounds with
improved pharmaceutical properties as cancer therapeutics
with minimal or no side-effects.
Supported by the Ontario Cancer Research Network (OCRN).
507
FORTY YEARS WITH SERUM CANCER MARKERS.
A RETROSPECTIVE AND PROSPECTIVE ANALYSIS
Michel Pagé
Faculty of Medicine, Université Laval, Québec, Canada
The first serum cancer markers, such as alphafoetoprotein and
carcinoembryonic antigen, described more than forty years ago
are also present at various developmental stages of the foetus or
the embryo. Following the enthusiasm of the first reports on
the sensitivity and specificity of these markers, elevated
concentrations of these proteins were soon reported in certain
benign diseases. Many new markers, such as CA 125, CA 15.3,
CA 19.9, were developed following the advent of monoclonal
antibodies and these are still in use today. Prostate-specific
antigen (PSA) was rapidly accepted as a serum marker for this
cancer. After a few years of experience with these markers, it
became evident that these assays were neither specific nor
sensitive enough to be used for cancer screening but they could
be used efficiently for the follow-up of treated patients.
Recently developed markers are now intended for individual
therapy. More recently, serum proteins and peptides have been
analyzed by protein array or MALDI-TOF-MS to obtain a
profile and predict the outcome of targeted therapies. With the
advent of these new technologies, the clinician may not only
confirm a diagnosis but may soon be able to plan the best
treatment and predict the most probable outcome.
508
BIOTINYLATED CISPLATIN-LOADED PAMAM
DENDRIMERS FOR CHEMOTHERAPY
OF OVARIAN CANCER
Venkata K. Yellepeddi, Ajay Kumar and Srinath Palakurthi
Irma Lerma Rangel College of Pharmacy, Texas A&M
Health Science, Center, Kingsville, Texas-78363, USA
Abstracts of the 8th International Conference of Anticancer Research, 17-22 October 2008, Kos, Greece
Objective: Biotin, also known as vitamin H, is a growth
promoter of cells and biotin levels were found significantly
higher in cancer cells as compared to normal tissue. Rapidly
proliferating cells need higher amounts of biotin. We
hypothesized that conjugation of biotin to polyamidoamine
(PAMAM) dendrimers and their use as carriers for cisplatin
therapy would provide targeted therapeutic effect and reduce
the side effects of cisplatin. Cisplatin-loaded biotinylated
dendrimers of different generations were used and their
encapsulation efficiency, in vitro release profile and in vitro
cellular uptake were studied. Materials and Methods:
Dendrimers were biotinylated using Sulfo-NHS-LC-Biotin.
Cisplatin was loaded into the biotin dendrimer conjugates by
aqueous reaction for 4 hrs and unencapsulated cisplatin was
separated by column chromatography. Encapsulation
efficiency and in vitro release of cisplatin loaded biotin
dendrimers was performed using HPLC. Cytotoxicity of
cisplatin-dendrimer conjugates in OVCAR-3, SKOV, A2780
(wild-type) and CP 70 (cisplatin resistant) cell lines was
assessed using MTT (methylthiazole tetrazolium) assay and
the results were compared with simple cisplatin. Cellular
uptake of the dendrimers was studied in A2780 and CP70 cell
lines using HPLC. Statistical analysis of the data was
performed using ANOVA and p<0.05 was considered
significant. Results and Discussion: The biotin-dendrimer (G4
PAMAM-NH2 and G4-PAMAM-COOH) conjugates were
synthesized and characterized using 1H NMR and MALDI
spectral analysis. Encapsulation efficiency biotin-G4-NH2 and
biotin-G4-COOH dendrimers was 1.97% and 10.85%
respectively. Cytotoxicity of biotinylated dendrimers (IC5034.44 μM) was 3 fold higher than free cisplatin (IC50-106.21
μM), validating our hypothesis that these conjugated
dendrimers can be used for targeting ovarian cancer with
minimum amount of cisplatin required to elicit desired
cytotoxic activity. In vitro cellular uptake experiments in CP70
showed significantly higher cisplatin levels as compared to
cisplatin (p<0.01).
509
A NOVEL NONSENSE MUTATION IN KRAS GENE
Raffaele Palmirotta1, Annalisa Savonarola1, Vincenzo
Formica2, Giorgia Ludovici1, Roberta D’Alessandro1,
Barbara Leone1, Marco Ciancia1, Raffaella Liberatore1,
Stella D’Angelo1, Mario Roselli2 and Fiorella Guadagni1
1Laboratory
of Molecular Diagnostics, Department of
Laboratory Medicine and Advanced Biotechnologies, IRCCS
San Raffaele Pisana, Via Della Pisana 235, 00163 Rome;
2Medical Oncology, "Tor Vergata" Clinical Center,
University of Rome “Tor Vergata”, Rome, Italy
Cancer development and progression is a multi-step process
based on the accumulation and clonal selection of somatic
mutations in key cancer-related genes, corresponding to
activation of oncogenes and inactivation of tumor suppressor
genes. One of the most well studied cellular genes involved in
the pathogenesis of human cancer is the K-ras proto-oncogene,
which encodes a 21-kDa GTP-binding protein that controls the
mechanisms of cell growth and differentiation. Point mutations
in the K-ras gene lead to uncontrolled stimulation of ras-related
functions by the altering p21 ras protein-related pathway.
Mutations in the K-ras oncogene are frequently found in
human cancers, such as colorectal cancer, pancreatic cancer,
lung adenocarcinoma, gall bladder cancer, bile duct cancer and
thyroid cancer. Activating mutations occur in hot-spots mainly
of codons 12 and 13. These mutations may be predictive of
drug response and can also indicate prognosis. In particular,
recent publications have shown that the successful treatment of
metastatic colorectal cancer (mCRC), using monoclonal
antibody therapies such as Panitumumab is directly linked to
the oncogenic activation of the K-ras signaling pathway. In our
laboratory, molecular analysis of K-ras is routinely carried out
on genomic DNA extracted by paraffin-embedded tumor
samples after microdissection. Exons 1 and 2 of K-ras are
individually amplified by PCR using specific primers for the
K-ras gene and then sequencing analysis is performed. Here,
we report a case of a patient with mCRC, who referred to our
laboratory in order to evaluate K-ras somatic cancer mutations.
Molecular analysis performed on paraffin-embedded samples
showed a mutation in the first exon of the K-ras gene
(CAG>TAG), that determines a premature stop signal at codon
22 (Gln22Stop). Such inactivation of K-ras gene is a
mechanism not reported before, suggesting a possible
involvement of other genes or epigenetic factors. Indeed, all
mutations reported in literature, to date, are hot-spots missense
point mutations at codons 12, 13, 59, 61, 117, while recently a
novel 15-bp insertion, resulted in tandem duplication of codons
62-66, was reported. There are no other reports that describe
mutations of K-ras gene resulting in a premature stop signal.
These data help to clarify the importance to evaluate K-ras
mutation, in order to identify not only the molecular
mechanisms of cancer progression but also subjects who are
likely to benefit from targeted therapies and to avoid costly and
potentially toxic treatments in non-responder patients.
Partially supported by Grant LILT – Lega Italiana per la Lotta
contro i Tumori.
510
IS BREAST CANCER AN INTEGRAL
BHD-RELATED TUMOR?
R. Palmirotta1, A. Savonarola1, G. Ludovici1, P. Donati2, A.
Spila1, B. Leone1, M. Ciancia1, L. Polce1, M.G. Pera1, P.
Ferroni1 and F. Guadagni1
1Department Of Laboratory Medicine and Advanced
Biotechnologies, IRCCS San Raffaele Pisana, Rome;
3433
ANTICANCER RESEARCH 28: 3157-3556 (2008)
2Unit
Of Skin Histopathology, IRCCS San Gallicano
Dermatologic Institute, Rome, Italy
The Birt-Hogg-Dubé syndrome (BHD) (OMIM 135150) is a
rare autosomal dominant genodermatosis predisposing patients
to develop multiple, small papules on the face, neck, and
upper thorax after the age of 25 years. These lesions, called
“fibrofolliculomas” (FFs), are histologically classified as
benign hamartomas of the hair follicle. The syndrome is
caused by germline mutations in the folliculin (FLCN) gene
(also known as BHD–OMIM607273) which encodes a tumorsuppressor protein. Numerous mutations have been described
in the FLCN gene, the most frequent occurring within a C8
tract of exon 11, resulting in a truncated folliculin; this “hot
spot” mutation has been found in the germline of 44% BHD
patients. This hypermutability is probably due to a “slippage”
in the DNA polymerase during DNA replication, resulting in
gains or losses of repeat units, as happens for other genes
causing cancer predisposition. However, recent reports suggest
that all translated exons might be mutated.
The main phenotypic manifestations related to this disease,
as reported in the literature, are lung cysts leading to
pneumothorax, and an increased risk for renal neoplasia. Also
discussed is the genotype/phenotype correlation between
FLCN mutations and risk of colon cancer. While some reports
describe this correlation, a recent risk-assessment study of
BHD-affected patients concluded that a diagnosis of BHD
conferred a 7-fold increased risk of developing renal neoplasia
and a 50-fold increased risk of spontaneous pneumothorax but
no increased risk of colon polyps or colon cancer.
Other reports describe additional phenotypic manifestations
in BHD-affected individuals, including lipomas, angiolipomas,
parathyroid adenomas and parotid oncocytomas.
Among the BHD-affected families referring to our
Institutions, we selected two families; genetic counseling was
performed in order to obtain family trees and molecular
analysis of the FLCN gene was performed. The proband of the
first family had a history of breast cancer at the age of 44 and
of colon cancer at the age of 56; molecular analysis showed
the occurrence of a frameshift mutation, not previously
reported, located in exon 9 (1345delAAAG) of the FLCN
gene. 1345delAAAG was associated with a wide variety of
tumors, including stomach, colon and parotid cancer found in
other family members. The proband of the second family had
a history of breast cancer at the age of 42; molecular analysis
showed the occurrence of a missense mutation in exon 12
(G1788A). Studies are currently ongoing to assess the
occurrence of a possible “second hit” somatic mutation in
breast cancer tissues. To date, there are no reports describing
a possible association between germline FLCN mutation and
risk of breast cancer. The genes so far associated with
hereditary forms of breast cancer are BRCA1 and BRCA2,
while a small fraction of risk can currently be attributed to
3434
germline mutations in other genes, such as p53, mismatch
repair genes, ATM, PTEN and LKB1. Our data, in association
with the early age of onset of breast cancer in patients with
mutations in the FLCN gene, suggest for the first time the
possible association between germline FLCN mutation and
risk of breast cancer.
Partially supported by Grant LILT – Lega Italiana per la Lotta
contro i Tumori
511
ALL TRANS-RETINOIC ACID REVERSES THE
PROTUMORAL EFFECT OF HEPATOCYTE
GROWTH FACTOR ON THE HIGHLY METASTATIC
S4MH RABDOMYOSARCOMA CELL LINE
Teodoro Palomares, Roberto Sanisidro,
Ignacio García-Alonso and Ana Alonso-Varona
Departments of Surgery and Radiology and Physical
Medicine, and Cell Biology and Histology, School of
Medicine and Dentistry, University of the Basque Country,
Leioa, Vizcaya, Spain
Purpose: We previously demonstrated the tumour-enhancing
effect derived from hepatic resection of liver metastases,
which could be exerted through growth factors (GF) related
with liver regeneration, such as hepatocyte growth factor
(HGF). The aim of this work was to study the role of HGF on
the growth of the highly metastatic S4MH rabdomyosarcoma
(RMS) cell line, and to analyze the possible preventive effect
of all-trans-retinoic acid (ATRA) on the HGF pro-tumour
effect. Materials and Methods: The poorly differentiated and
highly metastatic S4MH RMS cell line was used. Cells were
cultured in 24-well microplates at a density of 104 cells/well in
the presence or absence of different concentrations (5-40
ng/ml) of HGF, in order to determine the optimal
concentration of HGF on cell proliferation. Afterwards, ATRA
(10–6 M) or the control solvent was also administered every
48 h to cells cultured in presence of HGF, and the
chemopreventive effects of ATRA on the pro-tumour effect of
this GF was analyzed. Proliferation was measured by using a
haemocytometer. Results: HGF significantly enhanced cell
proliferation in a concentration-dependent manner up to a dose
of 10 ng/ml. Higher concentrations were toxic. In the presence
of 10 ng/ml of HGF, the number of cells at 24 and 72 h were
1.3 and 1.2 times higher than in control cultures. The increase
in proliferation rate induced by HGF was mainly apparent in
the first 24 h of culture (1.3 times higher than that of the
controls); afterwards, this rate was similar in HGF and control
cultures (proliferation rate close to 2.5 at 48 and 72 h). ATRA
significantly reduced (1.3- and 1.2-fold at 24 and 72 h,
respectively) the growth of S4MH cells. Moreover, ATRA also
significantly reduced the pro-tumour effect of HGF; thus, with
respect to cells cultured with HGF alone, ATRA treatment
Abstracts of the 8th International Conference of Anticancer Research, 17-22 October 2008, Kos, Greece
reduced cell proliferation 1.8- and 1.7-fold at 24 and 72 h,
respectively (p<0.05). Conclusion: These results suggest that
ATRA could be a useful chemopreventive agent to prevent the
pro-tumour effects of HGF on RMS.
This work has been supported by grants of the University of
the Basque Country/EHU, Basque Government and the Jesús
Gangoiti Barrera Foundation.
512
L-2-OXOTHIAZOLIDINE-4-CARBOXYLATE
REVERSES THE TUMOUR GROWTH-PROMOTING
EFFECT OF THE GROWTH FACTORS HGF, VEGF
AND EGF ON HUMAN COLON CANCER WIDR
CELLS
Teodoro Palomares, Marta Caramés and Ana Alonso-Varona.
Departments of Surgery and Radiology and Physical
Medicine, and Cell Biology and Histology, School of
Medicine and Dentistry, University of the Basque Country,
Leioa, Vizcaya, Spain
Purpose: Gluthathione (GSH), the most prevalent intracellular
non-protein thiol, is involved in the growth factor-induced
proliferative activity. The present study investigated the effect
of manipulation of GSH using the cysteine prodrug L-2oxothiazolidine-4-carboxylate (OTZ) on the response of colon
cancer cells to growth factors (GF). Materials and Methods: A
highly metastatic human colon cancer WiDr cell line was
selected. Cell were seeded in 24-well microplates at a density
of 104 cells/well and allowed to grow for 24 h. The cells were
treated with OTZ for 4 h. Afterwards, the cells were exposed
to hepatocyte growth factor (HGF), vascular endothelial
growth factor (VEGF) and epidermal growth factor (EGF).
Proliferation was measured by using a haemocytometer. In the
GSH assay, the cells were stained with 100 μM
monochlorobimane and the GSH content was determined
using the CytoFluor-2350 system. Results: The three GFs
significantly enhanced cell proliferation. In the presence of 7.5
ng/ml of HGF, 10 ng/ml of VEGF and 25 ng/ml of EGF, the
number of cells at 48 h was 1.7, 1.2 and 1.2 times higher,
respectively, than in control cultures. Whereas exposure of
cells to VEGF and EGF resulted in a 50% reduction in GSH
levels after 1 h of incubation and increased them at 2 h (50%
increase compared with control cells), the addition of HGF for
2 h produced a significant GSH depletion (30%) and a 45%
increase after 4 h compared with non-exposed cells. However,
treatment with 5 mM OTZ produced a 42.6% reduction in the
cellular GSH content after 4 h of incubation and a 1.3-fold
reduction in the growth rate. Moreover, exposure to OTZ
abrogated the pro-tumour effects of the GFs. Thus, OTZ
treatment reduced by 1.6-fold the growth rate of cells in the
presence of HGF and VEGF and by 1.4-fold in the case of
EGF with respect to untreated cells at 72 h. Conclusion: OTZ
is capable of reversing the growth-promoting effects of GFs.
This fact could be important in the design of therapeutic
strategies involving intracellular GSH level modification as a
mechanism for tumour cell sensitization to cytotoxic drugs.
513
CONSTITUTIONAL STRUCTURAL
CHROMOSOMAL ABNORMALITIES AND
HEMATOLOGICAL MALIGNANCIES
Anna D. Panani
Critical Care Department, Medical School of Athens
University, Cytogenetics Unit, Εvangelismos Ηοspital,
Athens, Greece
Over the past four decades, it has become clear that acquired
recurrent chromosomal changes are associated with specific
malignant diseases. Among acquired structural chromosomal
abnormalities, reciprocal translocations have been identified
in a variety of malignant diseases, mainly including leukemias,
lymphomas and sarcomas and they have been implicated in
the etiology of the neoplastic process with involvement of
specific genes. On the other hand, it is now well recognized
that certain constitutional chromosomal aberrations confer a
tumor predisposition.
The observation that constitutional structural chromosomal
aberrations are associated with a predisposition to cancer has
led to a two-hits hypothesis for cancer development. The first
hit is a constitutional abnormality involving a specific gene
and the second hit is an acquired inactivation of the other
allele by mutation or other genetic change. Investigations of
families with hereditary cancer and constitutional
chromosomal abnormalities have been key observations
leading to the molecular identification of specific genes
implicated in tumorigenesis, such as the loci involved in
retinoblastoma patients with 13q deletion and the loci in
Wilms tumor patients with 11p deletion. Large studies have
been reported on the incidence of constitutional chromosomal
aberrations in patients with hematological malignancies, but
they could not confirm an increased risk for hematological
malignancy among carriers of structural chromosomal
changes. However, it is of particular interest that constitutional
structural chromosome aberrations with breakpoints similar to
leukemia-associated specific breakpoints have been reported
in patients with hematological malignancies. This might
indicate that the constitutional anomaly itself probably plays a
role in the neoplastic process.
There is substantial discussion in the literature about
mechanisms involved in constitutional structural
chromosomal abnormalities. The documentation of more
patients with hematological malignancies and constitutional
structural chromosomal changes could be of major
importance. Most importantly, the molecular cloning of the
3435
ANTICANCER RESEARCH 28: 3157-3556 (2008)
chromosomal breakpoints involved in constitutional
rearrangements in patients with hematological disorders
could give useful information on the genetic events
underlying constitutional anomalies contributing to isolation
of genes important in the development of the neoplastic
process.
may suggest a new view on the mode of action and possible
application of trace elements in cancer treatment.
514
THE GROWTH INHIBITORY EFFECTS OF
CADMIUM AND COPPER ON MDA-MB468
HUMAN BREAST CANCER CELLS
Evangelia Papadimitriou, Constantinos Mikelis,
Evgenia Lampropoulou, Marina Koutsioumpa,
Katerina Theochari, Sotiria Tsirmoula,
Christina Theodoropoulou, Margarita Lamprou,
Evanthia Sfaelou, Dionyssios Vourtsis and
Panagiotis Mpountouris
Mojtaba Panjehpour, Masih-Allah Taher and Mortaza
Bayesteh
School of Pharmacy and Isfahan Pharmaceutical Sciences
Research Center, Isfahan University of Medical Sciences,
Isfahan, Iran
Background: Cadmium chloride is an important
occupational and environmental pollutant but under certain
conditions can also be anticarcinogenic. Copper is an
essential trace element. Moreover it was shown that
apoptotic potential of copper is associated with its ability to
generate reactive oxygen species. The aim of this study was
to determine the ability of cadmium chloride and copper
chloride to cause cell death in a human breast cancer cell
line (MDA-MB-468). Methods: MDA-MB-468 cells were
grown in RPMI-1640 medium supplemented with 10% FCS,
Penicillin/ streptomycin (100 U/ml, 100 μg/ml) at 37˚C in
5% CO2/95% air. The cells were plated in 96-well plates.
After 24 hours, different concentrations of cadmium
chloride and copper chloride were added to plates which
were then incubated for 48 and 72 hours. MTT cell viability
test was used to study the cytotoxic effects of cadmium and
copper. Results: Exposure of monolayers to different metal
concentrations (1-1000 μM) for different times showed a
significant decrease (p<0.05) of viable cells when compared
with that of controls in a dose-dependent manner; a
significant cytotoxicity was observed at 200 μM for
cadmium chloride at 48 hours and 1 μM at 72 hours. For
copper chloride, significant cytotoxicity was best observed
at 1000 μM at 48 hours and 1 μM during 72 hours. The
maximum synergic cytotoxic effect was observed at 0.5 μM
cadmium chloride and 0.5 μM copper chloride during 72
hours exposure. Conclusion: In this study it has been shown
that there is differential sensitivity of the cell line to the
antitumor activity of cadmium chloride and copper chloride.
The results of the present study also indicated that the
cytotoxic effect of copper chloride is somewhat less than
that of cadmium chloride. This may be due to vital
physicological role of copper, none of which are known for
cadmium as yet. In other words, copper is used for natural
consumption by the cells also. Altogether, these findings
3436
515
THE ROLE OF THE GROWTH FACTOR
PLEIOTROPHIN AND ITS RECEPTORS IN
TUMOR GROWTH AND ANGIOGENESIS
Laboratory of Molecular Pharmacology, Department of
Pharmacy, University of Patras, Patras GR26504, Greece
Pleiotrophin (PTN), also known as heparin affin regulatory
peptide or heparin binding growth associated molecule, is
an 18 kDa growth factor that has high affinity for heparin,
and together with midkine forms a family of structurally
related heparin binding growth factors. The two proteins
share 45% homology in their amino acid sequence and
many, but not all, biological activities. The first described
biological activity of PTN is stimulation of neurite
outgrowth and a role in the growth and maturation of brain.
PTN also induces proliferation of several types of cells, is
involved in a variety of processes in bone formation, seems
to play a critical role in chondrogenesis and participates in
normal spermatogenesis and fertility. Screening of various
human tumour cell lines and tumour speciments of different
origin revealed that PTN is expressed in many types of
cancer, such as gliomas, melanomas, meningiomas,
neuroblastomas, choriocarcinomas, leukemias and cancer of
pancreas, prostate, stomach, colon, breast, ovaries and lungs.
Concerning the biological activity of PTN in cancer, there
is ample evidence that it is a tumor-promoting factor,
enhancing tumor cell proliferation, migration, anchorageindependent growth and angiogenesis in vivo or in vitro.
PTN receptors are also up-regulated in a plethora of tumors
and are being tested as targets for anticancer therapy. We
have recently identified ανβ3 integrin as an important
mediator of PTN-induced endothelial and tumor cell
migration and the molecular mechanisms involved in this
pathway, as well as its involvement in tumor growth and
angiogenesis are being investigated. We are also working on
the regulation of PTN expression, as well as
structure–function relationships, knowledge that could lead
to identification of new target(s) and the possible
development of new therapeutic tools.
This research project is co-financed by E.U. European Social
Fund (75%) and the Greek Ministry of Development-GSRT
(25%).
Abstracts of the 8th International Conference of Anticancer Research, 17-22 October 2008, Kos, Greece
516
NLCQ-1 (NSC 709257): A WEAK DNAINTERCALATING BIOREDUCTIVE DRUG. NEW
PROSPECTS
M.V. Papadopoulou, W.D. Bloomer, B. Fitzpatrick,
R.L. Cowen, I.J. Stratford and K.J. Williams
Evanston Northwestern Healthcare, Evanston, IL, USA and
University of Manchester, UK
Numerous studies have confirmed the value of the
bioreductive compound NLCQ-1 as a tumor hypoxiatargeting agent and as an enhancer of radiotherapy,
radioimmunotherapy and chemotherapy. In addition, studies
using rat liver microsomes have suggested a role for
cytochrome p450 reductase (P450R) in NLCQ-1
bioactivation. As human tumor levels of P450R are
heterogeneous and not substantially elevated versus those of
normal tissue, exploitation of P450R in a therapeutic context
requires a gene therapy-based approach unless other enzymes
overexpressed in tumors, such as inducible nitric oxide
synthase (iNOS) can be exploited in the activation of NLCQ1. Therefore, in our recent studies we investigated the effect
of NLCQ-1 in tumors overexpressing P450 reductase, DTdiaphorase (DTD) and iNOS. In addition, the ability of
NLCQ-1 to prevent tumor-micrometastasis, alone or in
combination with radiotherapy was evaluated. Finally, we
have investigated the effect of NLCQ-1 against resistant,
latent TB-bacilli, since TB latency is related to anaerobiosis.
MDA231 (breast) and HT1080 (fibrosarcoma) cells were
stably transfected to overexpress P450R, DTD or iNOS and
exposed to NLCQ-1 in air or hypoxia (3 h) 48 h posttransfection. NLCQ-1 cytotoxicity was determined 3-days
later by MTT assay. Metastatic studies were conducted in
mice bearing subcutaneous KHT tumours (250 mm3). Tumors
were irradiated with a single dose of 25 Gy whereas NLCQ-1
was administered 72 h post-radiotherapy (10 mg/kg/day × 4).
Metastatic dissemination to the lungs was analysed 21 days
post radiotherapy. Antitubercular activity was evaluated in
H37Rv bacteria by using the luminescence-based low oxygen
recovery assay (LORA) and toxicity was assessed in Vero cells
by using the MTT assay.
Improved hypoxic selectivity was observed for NLCQ-1 in
P450R and iNOS transfected cells, suggesting a therapeutic
advantage of combining NLCQ-1 with gene therapy. NLCQ-1
proved very efficacious in the metastatic studies, with 7/9
animals showing no visible signs of lung metastasis and in
addition it improved tumor local control. Finally, NLCQ-1 was
selectively active against latent TB mycobacteria, normally
localized in the lungs. These data suggest that NLCQ-1 not
only can prevent metastatic lesions in the lungs as an adjuvant
to radiotherapy but also can be beneficial in combination with
gene therapy and in the treatment of latent tuberculosis.
517
LIPID CORE MICELLES FOR IN VIVO WHOLE
BODY TUMOR TARGETING AND IMAGING
A. Papagiannaros, D. Chovatia, J. Upponi, P. Shah, A. Kale,
D. Mongayt, W. Hartner, T. Levchenko and V. Torchilin
Department of Pharmaceutical Sciences and Center for
Pharmaceutical Biotechnology and Nanomedicine,
Northeastern University, 312 Mugar Life Sciences Building,
Boston, MA 02115, USA
Introduction: Whole body in vivo imaging of nanoparticles,
macromolecules, quantum dots and living cells can be carried
out in the near infrared region of the spectrum and offers
results with high sensitivity and precision. This method’s
advantages over more conventional techniques, such as the use
of radioisotopes, include easier handling, improved versatility
and cost effectiveness. This IR whole body imaging is
noninvasive, and the images are captured in real time. The
quantification of the bio-distribution of the micelles was only
semi-quantitative at best, due to the intense scattering and
absorption of the fluorescence. The aims of the study are to
use near infrared whole body imaging to visualize and
quantify the bio-distribution of nanoparticles, and to develop
nanosized contrast agents for the detection of cancer and
disease sites with high sensitivity and precision. Materials and
Methods: Micelles encapsulating Near Infra Red emitting
Quantum dots (Qdot800) or Alexa 750-PE were produced and
their size distribution was estimated by dynamic light
scattering (Beckman Coulter N4). Actively targeted quantum
dot micelles were also produced by direct conjugation of the
anti-nucleosome specific antibody 2C5 to PEG-PE. Tumor
bearing animals (1.5×106 4T1 cells, s.c., right flank) were
anesthetized and micelles or quantum dots were injected via
the tail vein. Mice were visualized in a Kodak IN VIVO
IMAGE STATION FX (excitation filter 720 nm, emission 790
nm). The fluorescence from the lipid nanoparticles was
compared with commercially available formulations. Images
were analyzed using the Kodak Molecular Imaging Software
or NIH ImageJ. Results and Discussion: Tumor fluorescence
in mice injected with the quantum dot micelles was higher
than the commercially available pegylated quantum dots, so
the images were sharply contrasted. The signal form the lipid
coated quantum dots maximized within one hour from the
injection while the fluorescence from commercially available
pegylated quantum dots reached similar levels after four hours.
Overall the signal of the lipid QD micelles was higher while to
dose is half. The variability of the bio-distribution was smaller
in the case of the lipid coated nanoparticles and the cost was
also smaller. The lipid contrast agent seems to accumulate to
the tumor, liver, spleen and kidneys. The results of the
quantification for the micelles were similar to those previously
reported using radioisotopes. The actively targeted
3437
ANTICANCER RESEARCH 28: 3157-3556 (2008)
nanoparticles accumulation to the tumor was double that of
the non targeted quantum dot micelles, producing even more
sharp images at one hour after the injected. Alexa encapsulated
micelles contrast was high enough to localize readily the
tumor within one hour, but afterwards the contrast of the
images decreased due to a high abdominal signal, due to the
secretion of the lipids. Conclusion: We have developed an
optical molecular imaging system in the near infrared
spectrum for the in vivo visualization of nanoparticles biodistribution and for the imaging of tumors. The active
targeting of the quantum dot immuno-micelles in metastatic
tumor models is under investigation.
This work was supported by NIH grant RO1 EB001961 to
Prof. V.P. Torchilin. We thank Prof. M. Amiji for the use of the
Kodak Image Station In Vivo FX.
518
PALLIATIVE CARE IN GERMANY
Jens Papke
Praxis for Internal Medicine and Oncology, RosaLuxemburg-Strasse 6, D – 01844 Neustadt/Sachsen,
Germany
The history of palliative care (PC) in Germany is not very
long. The hospice movement from Great Britain has
influenced German medicine since the 1970s. In this “decade
of ignorance” nothing more happened in Germany. In the
1980s, the “decade of the pioneers”, the first department for
PC of a hospital started in Koeln in 1983 and the first hospice
opened in Aachen in 1986. In the following “decade of
establishment”, as in other European countries, many hospices
and PC services started working and developed. For example,
the outpatient PC project “Home Care Berlin”, a specialised
medical PC service working since 1994, cares for more than a
thousand patients every year. Data and experiences of this
service are presented and compared with data from
international PC services.
In 1994, the German Society of Palliative Medicine was
founded, the first professorship in PC was founded in 1999.
In this time, the civic hospice movement started in Germany
and the number of hospices and PC units in hospitals grew
rapidly.
In the last year, the government passed a bill for
reformation of the health care system. Part of this bill was the
acceptance of PC as a part of obligatory health insurance.
Now, very different models are developed to provide and
improve PC in the country. One model, the Home Care
Sachsen Association, is presented with first data. Conclusion:
After a quarter of a century PC in Germany is still developing.
Nationwide provision has still not been achieved. Models for
PC differ regionally and structurally. Current strategies aimed
at standardising the concepts have to be reconsidered.
3438
519
A MOUSE MODEL OF HUMAN HEAD AND NECK
SQUAMOUS CELL CARCINOMA THROUGH
THE SOMATIC ACTIVATION OF
AKT AND TP53 DEFICIENCY
Marta Moral, Carmen Segrelles, Corina Lorz,
Ramón García-Escudero, Mirentxu Santos,
Mª Fernanda Lara, Cristina Saiz, Ana Belén Martínez-Cruz,
Clotilde Costa, Águeda Buitrago and Jesús M. Paramio
Molecular Oncology Unit. Division of Biomedicine,
CIEMAT. Ave. Complutense 22, E28040 Madrid, Spain
Akt/PKB is a key element in the PI3K/PTEN/Akt pathway
that is overactivated in many tumor types including head and
neck squamous cell carcinoma (HNSCC). Here we show that
transgenic mice expressing a constitutively active form of Akt
in the basal layer of stratified epithelia, using the control of
keratin K5 promoter sequences (K5MyrAkt), develop
pretumoral lesions and carcinomas in situ in the oral cavity
which resemble human oral dysplasias and in situ carcinomas.
However they do not progress into advanced aggressive
carcinomas due to the induction of p53-dependent senescence.
Accordingly, a transgenic mouse line in which active Akt is
combined with the somatic deletion of the TP53 gene in
stratified epithelia (p53F/FK14Cre;K5myrAkt mice) develops
malignant aggressive oral tumors. These tumors display
multiple molecular and histopathological characteristics that
phenocopy human oral SCC and can be followed through in
vivo imaging by PET. Overall, these models should help in
understanding the pathogenesis of human HNSCC and will
likely prove useful tools for preclinical testing of therapies
targeting the Akt and p53 signaling pathways.
520
TP53 LOSS IN EPIDERMIS GENERATES
AGGRESSIVE METASTATIC TUMORS AND
PROVIDES A GENOMIC TOOL FOR PREDICTION
OF CLINICAL OUTCOME OF HUMAN CANCER
Ramón García-Escudero, Ana-Belén Martínez-Cruz,
Mirentxu Santos, Carmen Segrelles, Marta Moral,
Corina Lorz, Clotilde Costa, Águeda Buitrago-Pérez,
Cristina Saiz-Ladera and Jesús M. Paramio
Molecular Oncology Unit. Division of Biomedicine,
CIEMAT, Ave. Complutense, 22, E-28040 Madrid, Spain
Squamous cell carcinomas represent the most aggressive type
of non-melanoma skin cancer. Here we report that using the
Cre-loxP system, loss of p53, but not pRb, in epidermis leads
to the development of spontaneous tumors, whose occurrence
is severely accelerated in doubly deficient mice. The tumors
are aggressive, undifferentiated and display a hair follicle
Abstracts of the 8th International Conference of Anticancer Research, 17-22 October 2008, Kos, Greece
origin. Moreover they also display a high metastatic potential
to the lungs. Using expression profiling and statistical tools
for transcript set enrichment analysis, we performed a crossspecies comparison of epidermal p53-deficient models and
human cancer samples. The results demonstrated that the
mouse p53 tumors recapitulate molecular features of p53mutated human cancer samples, undifferentiated and
aggressive human tumors from different anatomical locations,
and human embryonic stem cells. In addition, we
demonstrated that mouse p53-deficient primary tumors contain
molecular determinants for metastatic progression, which has
allowed us to develop a 40-gene predictor for human breast
cancer clinical outcome. Our gene profiling analyses validate
mouse p53 tumor models as tools for preclinical tests of
targeted therapies against human aggressive tumors. Moreover,
we demonstrated that animal models with aggressive cancer
can be used to develop genomic predictors for clinical
outcome of human cancer.
521
RHEUMATOID ARTHRITIS: CORRELATION
BETWEEN RHEUMATOID FACTOR LEVELS AND
CA-125 TUMOUR MARKER ELEVATION
N. Tsavaris, C. Mavragani, A. Ntokou,
J. Syrios, Th. Paraskevopoulos and D. Pikazis
Department of Pathophysiology, Oncology Unit, Athens
University School of Medicine, Laikon General Hospital,
Athens, Greece
Objectives: We aimed at examining whether patients with RFpositive rheumatoid arthritis and absence of clinical or
laboratory evidence of a neoplastic disorder could have
“falsely” elevated levels of some commonly applied serum
tumor markers. Methods: Patients fulfilling the American
Rheumatology Association (ARA) diagnostic criteria for
rheumatoid arthritis entered the present study. Data were
collected for patients with rheumatoid arthritis who had
increased indices of ovarian cancer (CA-125>33 U/ml)
without the presence of cancer. Moreover, data were also
collected for the following variables: RF-test, CRP, and serum
tumor marker levels; CEA, and CA-19.9 measured by ELISA.
Relationships between ordinal variables were studied with the
use of Spearman non-parametric tests. Results: Fifty-three
consecutive patients fulfilling the diagnostic criteria of
rheumatoid arthritis were entered; 45 women and 8 men, with
a median age 51 years (range, 23-58). The associations
between Ra-test and CRP with CEA, CA-125 and CA-19.9
were studied and non-significant relationships were detected
between Ra-test, CRP and any of the tumor markers. Two
patients (3.8%) had high values of CEA and 7 patients
(13.2%) of CA-125. There was one patient (1.9%) found with
high value of CA-19.9 index. No significant relationship was
detected between Ra-test and CEA, CA-125 while a near
significant correlation was found between CRP and CA-125
(p=0.08). No significant relationship was detected between
Ra-test and CEA, CA-125, CA-19.9. None of the patients
included in the present study developed cancer after a
minimum period of 3-year follow-up. Conclusion: The present
report raises the issue of serum tumor marker, in particular
CA-125, false elevation in the presence of circulating RFs.
However, none of the patients appear to develop cancer after
adequate follow-up. It is expected that future studies should
attempt to develop methods eliminating RF binding.
522
STUDY OF CYTOKINES BYSTANDER SIGNALLING
IN HUMAN GLIOBLASTOMA CELLS AFTER
EXPOSURE TO GAMMA RADIATION
F. Pasi1,3, A. Bertolotti2,3, A. Facoetti2,3, L. Mariotti2,3,
A. Ottolenghi2,3 and R. Nano1,3
1Department
2Department
of Animal Biology, University of Pavia;
of Nuclear and Theoretical Physics, University
of Pavia;
3INFN Pavia, Italy
Radiation-induced bystander effect is defined as the
induction of biological effects in cells that are not directly
traversed by radiation but are receiving signals from the
irradiated cells that are in close proximity to them. Although
the bystander effects have been well described over the past
decade, the precise mechanisms of the process remain
unclear. Soluble extracellular factors which are released
from irradiated cells are involved in bystander responses and
in particular cytokines are considered to be good candidates
for signalling between irradiated and non-irradiated cells.
The aim of this study was to investigate the modulation of
intercellular communication, mainly mediated by alteration
of cytokine release into the culture medium and of its
receptor expression in human glioblastoma cells (T98G)
after exposure to gamma radiation. For this purpose, we
used the ELISA technique to characterize the time-and
dose-dependence of concentration of IL6, IL8 and TGFβ in
the culture medium of sham irradiated and irradiated cells.
In parallel, the expression of the corresponding cell
membrane receptors was evaluated by immunocytochemistry both in irradiated glioma cells and in cells
cultured with medium collected and filtered from irradiated
cultures. The results suggest that gamma radiation affects
the release kinetic of cytokines, each with particular
features, from irradiated cells and the receptor profiles in
irradiated and bystander cells.
This work was partially supported by the European
Commission (EC Contract FP6-36465, ‘‘NOTE’’) and by the
Italian Space Agency (ASI, “Mo-Ma/COUNT” project).
3439
ANTICANCER RESEARCH 28: 3157-3556 (2008)
523
RENAL CANCER: PATHOLOGICAL DIAGNOSIS
AND MOLECULAR CHARACTERIZATION
Carlo Patriarca and Carmelo Arizzi
Department of Pathology, Azienda Ospedaliera Melegnano,
Via Pandina 2, 20070, Vizzolo Predabissi, Milan, Italy
Kidney cancer has the highest incidence in North America,
Australia/New Zealand and Western and northern Europe. Each
year in Europe about 45,000 deaths are caused by kidney
cancer. Renal cell carcinoma (RCC) is the most common (8085%) primary cancer of the kidney and 40% of patients with
clinically localized RCC develop local recurrence or metastatic
disease. Current research projects cover genetic and protein
expression profile of various histological subtypes, as well as
molecular profiling (prognostic and predictive) of individual
tumors aimed for patient selection. Hence, to tailor the
diagnosis for future tailoring of the treatment is one of the main
goals. Moreover, the increase in detection of small (<4 cm)
tumors incidentally identified in asymptomatic patients with a
DSS of 95% raises the question of the real aggressiveness of
small renal tumors. The main histotypes of RCC will be
presented as well as the role of immunohistochemistry.
The anatomical prognostic factors encompass: 1) Tumor size:
key component of the TNM staging system, remains one of the
most important prognostic factors (4 cm: threshold for partial
nephrectomy); 2) Perinephric/sinus fat involvement: portends a
worse prognosis, but renal sinus fat involvement is associated
with sarcomatoid differentiation and a higher risk of death; 3)
Adrenal gland invasion: pT3a/M1: differentiate between direct
invasion and metastatic deposit (prognostic difference not clear);
4) Venous tumor thrombus extention (RV or IVC): high risk for
recurrent disease; 5) Lymph node involvement: portends a poor
prognosis. N1-N2 subclassification remains controversial; 6)
Presence of distant metastasis: portends a poor prognosis; 7)
Number of metastatic sites, rather than actual location, dictates
overall prognosis. Metachronous metastases are a favorable
factor over synchronus metastases.
Among the histopathological prognostic factors are: 1)
Nuclear grade; 2) Histological subtype; 3) Sarcomatoid
differentiation; 4) Tumor necrosis; 5) Collecting system
invasion; 6) Microvascular invasion. Weak points of each of
these factors will be discussed briefly.
Molecular abnormalities in RCC involve proliferation,
survival and tumour angiogenesis. Alterations in the VHL gene
are the most common genetic abnormalities in RCC and lead
to increased angiogenesis. The Raf/MEK/ERK pathway is
activated by signalling through multiple cell surface receptors,
leading to increased cell proliferation and survival. The
phosphatidylinositol 3-kinase (PI3K) pathway includes
sequential activation of several kinases and is also involved in
signalling through many growth factor receptors. Activation of
3440
the PI3K pathway also leads to increased cell survival.
Mutation of the VHL gene is a common genetic change that
leads to RCC. Inactivation of VHL leads to dysregulation of
the VEGF pathway. As a consequence of VHL gene mutation,
the VHL gene product complex is disrupted and does not bind
to HIF, allowing accumulation of HIF1-a and HIF2-a. This
results in the transcription HIF-regulated genes, including
those encoding VEGF, PDGF, transforming growth factoralpha (TGF-a) and chemokine receptor 4. These factors act to
induce angiogenesis, whose pathologic basis will be discussed,
endothelial cell stabilisation, autocrine growth stimulation and
organ-specific metastasis.
524
NEW AVENUES FOR CANCER RESEARCH
FROM PROTEIN NANOCRYSTALLOGRAPHY
Eugenia Pechkova
Nanoworld Institute University of Genova, Corso Europa 30,
16132 Genoa, Italy and Fondazione ELBA, Piazza SS.
Apostoli 66, 00100 Rome, Italy
As a result of cooperation between the Nanoworld Institute
and the European Synchrotron Radiation Facility in Grenoble,
after the initial discovery of the atomic structure of human
kinase CK2alpha (1-4) we have introduced new further
developments in protein nanocrystallography, appearing to
have profound potential impact in cancer research (5-9).
First of all, new details in protein crystal topography appear
evident in conjuction also with AFM experimentations. The
obtained images point to the existence of clear domains in the
crystal 3D organization, quite pronounced and different in size
and number between the classical protein crystals and the
crystals grown by LB (Langmuir-Blodgett) protein
nanotemplate. This result is furthermore in perfect accordance
with that obtained by laser cutting of the corresponding
protein crystals down to the nanosize and along the crystal
domains. X-ray diffraction with highly focused synchrotron
radiation down to 500 nm diameter strikingly provides unique
and detailed atomic structure information in protein
microcrystals down to the submicron size in several model
systems, opening new avenues in protein crystallography.
With radiation damage being the most critical issue for
protein structure determination under the intense synchrotron
radiation, LB crystals were indeed confirmed as the most
stable to radiation damage in a wide range of model systems.
Crystals grown by nanotemplate still diffract at good
resolution even after several steps of X-ray “burning”, while
the classic crystals decay very quickly at the same exposure.
Finally due to this encouraging result, the LB method has also
been successfully adapted to the EMBL advanced robotics
system for protein crystallography and to the study of yet
unsolved protein systems such as ribosomal proteins.
Abstracts of the 8th International Conference of Anticancer Research, 17-22 October 2008, Kos, Greece
1 Pechkova E et al: Acta Crystal. D 59: 2133-2139, 2003.
2 Pechkova E and Nicolini C: Trends in Biotechnology 22:
117-122, 2004.
3 Pechkova E et al: Spectrochimica Acta B 59: 1687-1693,
2004.
4 Pechkova E and Nicolini C: Nanotechnology 13: 460-464,
2002.
5 Pechkova E et al: Journal of Crystal Growth, in press 2008.
6 Vasile F et al: Proteins: Structure, Function and
Bioinformatics 70: 1112-1115, 2008.
7 Pechkova E et al: Archives of Biochemistry and Biophysics
466: 40-48, 2007.
8 Pechkova E et al: Review of Scientific Instruments 78,
093704_1-093704-7, 2007.
9 Nicolini C and Pechkova E: Journal of Cellular
Biochemistry 97: 544-552, 2006.
525
MUC5AC EXPRESSION AND ITS PROGNOSTIC
VALUE IN CHOLANGIOCELLULAR CARCINOMA
F. Pedica1, L. Bortesi1, P. Capelli1, S. Pachera2,
A. Ruzzenente2, A. Guglielmi2, G. Martignoni1,
M. Chilosi1, A. Scarpa1 and F. Menestrina1
1Department
of Pathology, University of Verona, Verona;
of Surgery and Gastroenterology, University of
Verona Medical School, Verona, Italy
2Department
Cholangiocarcinoma (CC) is a malignant tumour composed of
cells resembling those of the bile ducts and the second most
common primary hepatic tumor after hepatocellular
carcinoma, comprising 5-10% of primary liver neoplasms.
Worldwide, cholangiocarcinoma accounts for 3% of all
gastrointestinal cancer. Several studies have shown that the
incidence and mortality rates of intrahepatic CC are rising, and
those of extrahepatic cholangiocarcinoma are declining
internationally (1). To date, radical surgery is the only therapy
offering a potential cure for CC patients, whose prognosis is
generally poor with survival limited to few months (2). At
present, the lack of a sensitive and specific early diagnostic
marker is an important reason why CC has a fairly late
presentation. CC is classified according to its anatomic
location into intrahepatic and extrahepatic, and, according to
WHO classification, the term CC is used exclusively for
carcinomas of intrahepatic origin, while tumors arising from
the extrahepatic bile duct should be considered extrahepatic
bile duct carcinomas (3).
Recently the Liver Cancer Study Group of Japan divided
intrahepatic CC into three morphological types: massforming (MF), periductal infiltrating (PI) and intraductal
growth (IG) (4). MF type is characterized by the presence
of a spherical mass with a distinct border in the liver
parenchyma, PI type presents tumor infiltration along the
bile duct, occasionally involving the surrounding blood
vessels and/or hepatic parenchyma, IG is characterized by
papillary and/or granular growth into the bile duct lumen.
PI type of CC presents a significantly higher frequence of
perineural invasion, lymph node metastasis and extrahepatic
recurrence than the MF type (5). The 5-year survival rates
of patients with IG tumors or with MF tumors is
significantly better than those of patients with MF plus PI
tumors PI type alone (6).
Extrahepatic CC can further be subdivided into four types
based on its location according to the Bismuth classification:
type I, tumor involves the common hepatic duct distal to the
biliary confluence; type II, tumor involves the biliary
confluence; type IIIa, tumor involves the biliary confluence
plus the right; hepatic duct; type IIIb, tumor involves the
biliary confluence plus the left hepatic duct; type IV,
multifocal or tumor involves the confluence and both the right
and left hepatic ducts (7).
Although the entire biliary tree is at risk, tumors involving
the bifurcation of the hepatic duct (Klatskin tumors) are the
most common and account for 40% to 60% of all cases (8).
Hilar cholangiocarcinoma as a specific entity was first
described by Klatskin in 1965 and it has a PI type growth.
Hilar invasive-type cholangiocarcinomas have been observed
to often exhibit perineural invasion and nodal involvement.
Moreover, extrahepatic CC display a sclerosing, nodular, and
papillary phenotype of which the sclerosing or PI type is the
most common.
Our aim was to find a sensitive and specific marker which
could be detected in patient serum and be correlated with the
tumor burden. Boonla C et al. (9) recently showed that
MUC5AC mucin is present in significant concentrations in
serum from patients with CC. MUC5AC is a secretory mucin
normally expressed by the surface mucous cells of the human
stomach and in the bronchial tract. In a recent report (10),
MUC5AC resulted significantly correlated with neural
invasion and advanced CC stage.
We investigated MUC5AC in intrahepatic CC and
extrahepatic CC and found that it has a different expression
depending on the type of growth in PI type, MF type and PI
plus MF type. Our results suggest that MUC5AC is a specific
prognostic marker and these three morphological type of CC
have different immunophenotypes. Moreover MUC5AC is
significantly correlated with a more aggressive pattern and
with perineural invasion. MUC5AC is expressed in severe
biliary epithelial dysplasia, so if it could be part of a
carcinogenetic pathway should be investigated. Moreover, our
results also suggest that both intrahepatic PI type and
extrahepatic CC are probably the same pathology but arise in
different locations. Further studies are needed to understand if
this different expression may be an epiphenomenon of
different carcinogenetic patterns between PI type and MF type
of CC.
3441
ANTICANCER RESEARCH 28: 3157-3556 (2008)
1 Khan SA, Thomas HO, Davidson BR et al:
Cholangiocarcinoma. Lancet 366: 1303-1314, 2005.
2 Blechacz BRA and Gores GJ: Cholangiocarcinoma. Clin
Liver Dis 12: 131-150, 2008.
3 Hamilton SR and Aaltonen LA: Pathology and Genetics of
Tumours of the Digestive System: WHO Classification of
Tumours. IARC Press, Lyon, 2000.
4 Liver Cancer Study Group of Japan. Classification of
Primary Liver Cancer, 1st ed. Tokyo: Kanahara, 1997.
5 Aishima S, Kuroda Y, Nishihara Y et al: Proposal of
progression model for intrahepatic cholangiocarcinoma:
clinicopathologic differences between hilar type and
peripheral type. Am J Surg Pathol 31: 1059-1067, 2007.
6 Yamamoto M, Takasaki K, Yoshikawa T et al: Does gross
appearance
indicate
prognosis
in
intrahepatic
cholangiocarcinoma? J Surg Oncol 69: 162-167, 1998.
7 Bismuth H and Corlette MB: Intrahepatic cholangioenteric
anastomosis in carcinoma of the hilus of the liver. Surg
Gynecol Obstet 140(2): 170-178, 1975.
8 Byrnes V and Afdhal N: Cholangiocarcinoma of the hepatic
hilum (Klatskin tumor). Curr Treat Options Gastroenterol 5:
87-94, 2002.
9 Boonla C, Wongkham S, Sheehan JK et al: Prognostic value
of serum MUC5AC mucin in patients with cholangiocarcinoma. Cancer 98: 1438-1443, 2003.
10 Boonla C, Sripa B, Thuwajit P et al: MUC1 and MUC5AC
mucin expression in liver fluke-associated intrahepatic
cholangiocarcinoma. World J Gastroenterol 28;11(32):
4939-4946, 2005.
526
EFFECT OF 1,25-DIHYDROXYVITAMIN D3 ON DNA
DAMAGE AND SURVIVAL OF PLATINUM-TREATED
HUMAN CANCER CELLS
Fábio Pereira1,2, María Jesús Larriba1, Mercedes Herrera3,
María J. Muñoz-Alonso1, Félix Bonilla3 and Alberto Muñoz1
1Instituto
de Investigaciones Biomédicas “Alberto Sols”,
Consejo Superior de Investigaciones Científicas Universidad Autónoma de Madrid, Madrid, Spain;
2Faculty of Nutrition and Food Sciences of the
University of Porto, Porto, Portugal;
3Hospital Universitario Puerta de Hierro, Madrid, Spain
Introduction: 1,25-Dihydroxyvitamin D3 (1,25(OH)2D3) has
antiproliferative, antiangiogenic and pro-differentiative effects
in a broad range of cancer cells. In addition, 1,25(OH)2D3
potentiates the effects of many antitumour agents. Platinum
drugs are commonly used as anticancer agents. The
development of new platinum-based agents and clinical
combination studies has resulted in a growing interest of
platinum-based cancer chemotherapy. These drugs act by the
alkylation of DNA forming platinum-DNA adducts, leading to
3442
the interruption of essential cellular processes, and ultimately to
cell death via activation of apoptotic pathways associated with
DNA damage. Aim and Methods: The aim of this study was to
investigate the influence of 1,25(OH)2D3 on the sensitivity of
human colon (SW480-ADH and HCT116) and lung (A549)
cancer cells to oxaliplatin and cisplatin, which are respectively
used in the clinic against these neoplasias. Global DNA damage
was evaluated using the comet assay. The expression and
localization of two DNA damage markers (H2AX and 53bp1)
were studied by immunofluorescence. We performed cell
proliferation and viability assays using different drug
concentrations to calculate the IC50. Known 1,25(OH)2D3 target
genes (E-cadherin, p21CYP21, c-MYC) and two apoptosis
markers (PARP and active caspase-3) were evaluated by
Western Blotting (WB). We also performed flow cytometry
analysis to study the putative effect of 1,25(OH)2D3, oxaliplatin,
and their combination on the cell cycle. Results: We observed
that 1,25(OH)2D3 moderately increased DNA damage caused
by oxaliplatin (20 μM) in SW480-ADH cells (% tail DNA vehicle = 4.6±1.7 vs. 1,25(OH)2D3 = 3.0±1.2; p<0.001).
According to the median-effect principle analysis of Chou and
Talalay using CalcuSyn software (Biosoft, Ferguson, MO),
1,25(OH)2D3 Pre-treatment slightly increased the sensitivity of
SW480-ADH cells to oxaliplatin (IC50 vehicle vs. 1,25(OH)2D3
= 1.3 vs. 0.8 μM) and of A549 cells to cisplatin (IC50=8.9 vs.
4.4 μM). However, 1,25(OH)2D3 increased the survival of
SW480-ADH cells treated with oxaliplatin at concentrations of
20 and 30 μM (% cells = 13.4±1.4 vs. 21.4±1.5 and 10.8±0.3
vs. 15.9±0.8, respectively). No differences were observed for
HCT116 cells. 1,25(OH)2D3 did not change the expression
and/or localization of the studied proteins by WB or
immunofluorescence. In SW480-ADH cells, pre-treatment with
1,25(OH)2D3 diminished apoptosis induced by oxaliplatin (10
and 20 μM), as observed by a reduction in the sub-G1 fraction
in flow cytometry analysis (% cells = 10.5 vs. 2.7 and 12.8 vs.
7.2, respectively). Conclusion: 1,25(OH)2D3 Treatment slightly
increased global DNA damage and the sensitivity of SW480ADH and A549 cells to oxaliplatin and cisplatin, respectively.
However, at high oxaliplatin concentrations (10-30 μM)
1,25(OH)2D3 increased survival of SW480-ADH cells.
Altogether, these findings show that 1,25(OH)2D3 may
modulate the action of platinum anticancer drugs in human
cancer cells, which merits further investigation.
527
β-CATENIN, SURVIVIN AND CYCLIN-D1
EXPRESSION IN HUMAN HEPATOCELLULAR
CARCINOMA
Stavros Peroukides, Alexandros Alexopoulos
and Helen Papadaki
Department of Anatomy, School of Medicine, University of
Patras, Rio, Patras, 26500, Greece
Abstracts of the 8th International Conference of Anticancer Research, 17-22 October 2008, Kos, Greece
Introduction: β-Catenin is a downstream effector of the Wnt
signalling pathway, regulating cell growth/survival. Activation
of this pathway is caused mainly by mutations that stabilize
β-catenin, allowing it to accumulate in the cytoplasm, then
translocate to the nucleus and activate genes such as survivin
and cyclin-D1. Survivin belongs to the inhibitors of apoptosis
and current studies suggest its implication in both control of
apoptosis and regulation of cell division. Cyclin-D1 is a
regulator of G1/S-phase progression and its overexpression is
linked to the development and progression of cancer. Aim: The
investigation of the correlation between β-catenin, survivin
and cyclin-D1 in human hepatocellular carcinoma (HCC).
Materials and Methods: Immunohistochemical staining for βcatenin, survivin and cyclin-D1 was performed in 69 cases of
HCC and adjacent normal liver tissue. Results: Normal liver
showed diffuse membranous staining of β-catenin in
hepatocytes. In contrast, cytoplasmic and nuclear
accumulation of β-catenin was found in 42 (60.9%) and 33
(47.8%) out of 69 HCCs respectively. Loss of membranous βcatenin expression was observed in 53/69 (76.8%) HCCs and
only 16/69 (23.1%) tumors showed a focal weak or moderate
membranous staining. In normal liver, survivin and cyclin-D1
expression was absent. Nuclear survivin immunostaining was
observed in 63/69 HCCs (91.3%) and nuclear cyclin-D1
expression in 46/69 (66.7%). There was no statistical
correlation between β-catenin, survivin and cyclin-D1
expression. Conclusion: In HCC, overexpression of β-catenin,
survivin and cyclin-D1 was detected. Activation of β-catenin
was observed in our cases of HCC, while loss of membranous
staining probably implies its role in tumor invasion. The
nuclear localization of survivin and cyclin-D1 in tumor cells
reflects their role in cell proliferation. In our study we failed to
find an association between expression of β-catenin with
survivin and cyclin-D1. The fact that overexpression of βcatenin did not correlate with survivin and cyclin-D1, probably
suggests that another pathway works in human
hepatocarcinogenesis.
528
MULTIPLE CELLULAR MECHANISMS IN
PROSTATE CANCER INVASION AND METASTASIS
Barbara Wegiel, Anders Bjartell, Johanna Tuomela,
Nishtman Dizeyi, Martina Tinzl, Leszek Helczynski,
Elise Nilsson, Leo E. Otterbein,
Pirkko Härkönen and Jenny Liao Persson
Division of Experimental Cancer Research, Department of
Laboratory Medicine, Clinical Research Center, Lund
University, University Hospital, 205 02 Malmö, Sweden
Once prostate cancer becomes hormone refractory, cancer
cells may rapidly gain the ability to invade and to metastasize
to lymph nodes and distant organs. The progression through
hormone-dependent to hormone-refractory and metastatic
prostate cancer is poorly understood. Cyclin A1 is a cell cycle
regulator that has been implicated in the progression of
prostate cancer. We assessed protein and mRNA expression of
cyclin A1, vascular endothelial growth factor (VEGF), matrix
metalloproteinase (MMP)-2 and MMP-9 in primary malignant
tumor and adjacent benign prostate tissue samples from 482
prostate cancer patients.
Prostate cancer samples had significantly higher cyclin A1
protein and mRNA expression than adjacent benign tissues.
There was a significant correlation between expression of
cyclin A1 and that of MMP-2, MMP-9, and VEGF, which
have previously been found to influence cancer cell
invasiveness. In addition, the effects of altered cyclin A1
expression in PC3 prostate cancer cells were studied via
transient transfection and viral vector infection.
Overexpression of cyclin A1 in PC3 prostate cancer cells was
linked to increased invasiveness, whereas inhibition of cyclin
A1 expression via short hairpin RNA expression led to a
reduction of invasiveness. We further tested the impact of
increased cyclin A1 expression in tumor invasion and
metastasis in a mouse model of prostate cancer. We found that
80% of mice carrying PC3 cells overexpressing cyclin A1 had
lymph node, liver, and lung infiltration, whereas all mice with
tumors expressing control vector were free of liver and lung
metastases and only one had lymph node metastases. In
concert with androgen receptor, cyclin A1 increased VEGF
and MMP2 promoter expression. Our results suggest that
prostate cancer invasion is promoted by cyclin A1 via the
alteration of the expression of specific signalling proteins and
extracellular proteins. Furthermore, our findings that cyclin
A1 regulates the expression of a growth factor signaling
molecule (VEGF) and extracellular proteases (MMPs) and
promotes tumor cell invasion and metastasis in part through
MMPs and uPA(urokinase-type plasminogen activator)
suggest that cyclin A1 may be a key regulator of tumor
invasion and metastasis.
Wegiel B, Bjartell A, Tumolea J, Helczynski L, Harkonen P
and Persson JL: Multiple cellular mechanisms related to cyclin
A1 in prostate cancer invasion and metastasis. Journal of
National Cancer Institute 100: 1022-1036, 2008.
529
DD3/PCA3 (DIFFERENTIAL DISPLAY CODE 3) IN
PROSTATE CANCER DIAGNOSIS (EXPERIENCE
FROM CZECH REPUBLIC)
M. Pesta, J. Klecka, L. Holubec, O. Topolcan,
V. Eret, M. Chottova-Dvorakova, M. Babjuk,
K. Novak, J. Stolz and M. Hora
University Teaching Hospital, Plzen and Charles University,
Medical Faculty, Plzen, E. Benese 13, 305 99, Czech
Republic
3443
ANTICANCER RESEARCH 28: 3157-3556 (2008)
Introduction: Prostatic specific antigen (PSA) is very helpful
in the early diagnosis of prostate cancer (Pca) but the main
disadvantage is a low positive predictive value, which results
in a high number of useless biopsies. For that reason we need
new tests with better parameters. PCA3 is a prostate-specific
non-coding mRNA that is highly over-expressed in prostate
tumor cells. The aim of this study was to evaluate the
diagnostic potential of PCA3 for PCa diagnosis. Materials and
Methods: We examined altogether 199 patients. In the group
of patients with suspicion of PCa we collected one tissue
specimen core for PCA3 expression examination. According
to the histologically verification 103 patients had benign
prostatic hyperplasia (BPH), 12 patients prostatic
intraepithelial neoplasia (PIN) and 84 patients prostate cancer.
Total RNA was isolated and PCA3 and PSA expression
quantified using Q RT PCR method. The PCA3/PSA mRNA
ratio distribution was determined for both subject groups. The
assess the ability of the PCA3 assay to predict biopsy
outcome, the % biopsy positive was determined for different
PCA3/PSA ratio ranges and PCA3 Ct. Results: In our study,
the fraction of specimens yielding sufficient RNA for RT PCR
analysis was only 75%. It was found that the levels of mRNA
expression of PCA3 (Ct) were significantly higher (p<0.045)
in patients with prostate cancer than in patients with benign
prostatic hyperplasia. We found also statistically significant
differences in the levels of mRNA expression of PCA3 (Ct)
between patients with benign prostate cancer and patients with
prostatic intraepithelial neoplasia (PCA3 Ct, p<0.023).
Conclusion: The specificity of the PCA3 assay for prostate
cancer seems to be useful for early detection of prostate cancer
and also for differential diagnosis between patients with BPH
and patients with prostate cancer.
Supported by the grant IGA NR/8918-3 and the research
project VZ MSM 0021620819.
530
CALCIUM, VITAMIN D AND CANCER
Meinrad Peterlik1, William B. Grant2 and Heide S. Cross1
1Department
of Pathophysiology, Medical University Vienna,
Waehringer Guertel 18-20, A-1090 Vienna, Austria;
2Sunlight, Nutrition, and Health Research Center
(SUNARC), P.O. Box 641603, San Francisco, CA 941641603, USA
A low vitamin D status and inadequate calcium intake are
important risk factors for various types of cancer. Ecological
studies using solar UV-B exposure as an index of vitamin D3
photoproduction in the skin found a highly significant inverse
association between UV-B and mortality in fifteen types of
cancer. Of these, colon, rectal, breast, gastric, endometrial,
renal and ovarian cancers exhibit a significant inverse
relationship between incidence and oral intake of calcium. In
3444
addition, lung and endometrial cancer as well as multiple
myeloma are considered calcium- and vitamin D-sensitive.
Studies on tissue-specific expression of the CYP27B1-encoded
25-hdroxyvitamin D-1α-hydroxylase and of the extracellular
calcium-sensing receptor (CaR) have led to an understanding
of how locally produced 1,25-dihydroxyvitamin D3 (1,25(OH)2D3) and extracellular Ca++ act jointly as key regulators
of cellular proliferation, differentiation and function. Thus,
impairment of anti-mitogenic, pro-apoptotic and prodifferentiating signaling from the 1,25-(OH)2D3-activated
vitamin D receptor (VDR) and from the CaR in vitamin D and
calcium insufficiency has been implicated in the pathogenesis
of the aforementioned types of cancer. 1,25-(OH)2D3 and
calcium interact in modulating cell growth in different ways:
(i) Signaling pathways from the VDR and the CaR converge
on the same downstream elements, e.g. of the canonical Wnt
pathway; (ii) high extracellular calcium modulates extra-renal
vitamin D metabolism in favor of higher local steady-state
concentrations of 1,25(OH)2D3; (iii) 1,25(OH)2D3 may upregulate expression of the CaR and thus augment CaRmediated anti-proliferative responses to high extracellular
Ca2+. This can explain why combined supplementation is
required for optimal chemoprevention of cancer by calcium
and vitamin D.
531
HAEMANGIOPOIETIC STEM CELLS AND TUMOR
ANGIOGENESIS
S.O. Peters, T. Seifert, C. Huber, P. Dombach,
P. Kuta, T. Wagner and S. Stoelting
Hämatologie/Onkologie, Universitätsklinikum S.-H.Luebeck, Germany
Endothelial cell linings in the vessels of most tumors largely
derive from non-malignant circulating progenitor cells.
Autologous somatic endothelial precursors, procured by
marrow aspiration or apheresis, may be used to introduce
therapeutic principles into tumors.
We have studied endothelial development in cultured E14
murine embryonic stem cells (ECS), which provide a unique
homogeneous cell system for studying early vasculogenic cell
differentiation in vitro, and mapped the effects of vascular
endothelial growth factor (VEGF) on these cells (Seifert T,
Peters SO et al. Differentiation, 2008). After removal of
leukemia inhibitory factor (LIF) a high proportion (36
percent) of undifferentiated state ESCs show positivity for
endothelial CD31. This system allows for the describtion of
characteristic endothelial differentiation patterns in embryoid
bodies (EB) kept in culture for up to 30 days in differentiation
culture medium, with or without supplemental VEGF.
Directly after preculture and at day two in unsupplemented
culture ELISA analysis showed no endogenous VEGF,
Abstracts of the 8th International Conference of Anticancer Research, 17-22 October 2008, Kos, Greece
therafter VEGF levels rise. Early vasculogenic development
and expression of selected genes were characterized using
flow cytometry for specific antigens and quantitative RTPCR. VEGF supplementation lead to qualitative changes in
the EB vessels, specific activation of vasculogenesis-related
genes (CD31, CD144 and ERG) and temporary
downregulation of the VEGF receptor gene flk-1. VEGF
supplementation did not produce measurable changes in the
endothelial cell fractions as judged by surface antigen
presence. This shows that that early ESCs may undergo
endothelial differentiation through VEGF-independent
pathways, whereas endothelial cell patterns in EBs are
cytokine-dependent and fully stimulated by endogenous
cytokine levels. Studies to characterize these pathways in
embryonic and adult systems are underway. Translation of
these results may enable us to manipulate adult
heamangioblasts for tumor angiogenesis.
Another line of studies showed that JC and WEHI tumors
transplanted into female mice displaying complete marrow
chimerism, after receiving male bone marrow cells can serve
as a murine experimental model to study manipulated and
cultured endothelial precursors in vitro (Stoelting, Peters SO
et al. Anticancer Research 2008). Using fluorescent in situ
hybridization (FISH) analysis of adjacent cuts of the tumors,
assigning CD31 and Y-chromosomes as markers gender origin
of the perivascular endothelial cells can be determined. High
proportions of male cells can be found in the perivascular
endothelial cell linings of JC (60±4%) and WEHI (67±4%)
tumors after implantation into normal male mice and in
marrow chimeric female mice. This model allows for the study
of in vitro treated marrow on tumorangiogenesis.
We also explore the potential of (PR3), which is responsible
for a chronic vasculitis of small blood vessels in case of
Wegener’s Granulomatosis, to provoke inflammatory reactions
within tumors. Others have shown that both overexpression of
PR3 respectively it’s subunit PR1 generate a neutrophilic
inflammation In blood stem cells of patients suffering from
chronic myeoloid leukemia. We isolated and introduced a prepro-form of PR3 into a pTracer™ -SV40 plasmid containing
GFP. In ten experiments using human embryonic kidney cell
line HEK-293, which was established from a human primary
embryonal kidney transformed by adenovirus type 5 (Ad 5),
using Nanofectin transfection kits (PAA) we observed
transfection efficiency (rates) of approximately 85% after 14
days judged by fluorescence-microscopical registration of
GFP-including cells. For transfections of CD 133 positive
progenitor cells obtained after apheresis of peripheral blood
stem cells mobilized after chemotherapy and G-CSF
stimulation, we used the Amaxa Nucleofector device using an
Amaxa programm. Here we observed GFP positivity in 6070% of the viable cells after ten days in 3 different
experiments. Analysis of the expression of plasmid-carried
proteins is currently under way. We conclude that a pre-pro-
form of PR3 may be transfected into HEK cells and CD133
positive precursors.
532
ESTABLISHMENT AND CHARACTERIZATION OF
THREE NOVEL CELL LINES DERIVED FROM
HUMAN METASTATIC NEUROENDOCRINE TUMOR
(NET)
Roswitha Pfragner1, Annemarie Behmel2, Harald Höger3,
Elisabeth Ingolic4, Alfred Beham5, Veronika Siegl1,
Oskar Haas6 and Bruno Niederle7
1Department
of Pathophysiology and Immunology, Medical
University of Graz, Graz;
2Department of Human Genetics, Medical University of
Graz, Graz;
3Core Unit of Biomedical Research, Division of Laboratory
Animal Science and Genetics, University of Vienna,
Himberg;
4Research Institute for Electron Microscopy and Fine
Structure Research, Technical University of Graz, Graz;
5Department of Pathology, Medical University of Graz,
Graz;
6Medgen.at, Vienna;
7Department of Surgery, Medical University of Vienna,
Vienna, Austria
Carcinoids are uncommon neoplasms derived from
enterochromaffin (EC) cells of the neural crest. They have
malignant potential and their incidence is steadily increasing.
The only curative treatment option is surgery. We have focused
on cultivation of these human neuroendocrine tumors (NET)
as the most relevant models for the study of potential modes
of therapy. Only few cell lines from human carcinoids have
been established so far, among them our earlier established cell
line, KRJ-I (1). The reason for the rare success in establishing
carcinoid-cultures is due to the small amount of tissue available
and the low mitotic activity in primary cultures. We have
successfully established three continuously growing cell lines
from tissue obtained from a metastatic human carcinoid of the
terminal ileum: P-STS was derived from the primary tumor, LSTS from a lymph node metastasis, and H-STS from a liver
metastasis. Immunocytochemical characterization proved the
maintenance of characteristic neuroendocrine properties. The
ultrastructure of the cells demonstrated the presence of
neuroendocrine granules in the cytoplasm. Transplantation of
the cell lines into SCID-mice proved their tumorigenicity.
Cytogenetic analyses were done and mutation screening of PSTS excluded a MEN1-gene-associated genetic predisposition.
Our data delineate the novel cell lines P-STS, L-STS and HSTS as neoplastic EC cell lines and demonstrate their utility as
in vitro- and in vivo-models of small intestine carcinoids.
1 Pfragner R et al: Int J Oncol 8: 513-520, 1996.
3445
ANTICANCER RESEARCH 28: 3157-3556 (2008)
533
GAL3BP REGULATES CELL MOTILITY AND
INVASION IN BREAST CANCER CELLS
Enza Piccolo, Nicola Tinari, Maurizia D’Egidio,
Daniela Semeraro, Albana Cumashi,
Cosmo Rossi and Stefano Iacobelli
Department of Oncology and Neurosciences, and Foundation
University “G. D’Annunzio”, University “G. D’Annunzio”,
Chieti, Italy
Background: 90K/Mac-2 BP is a secreted glycoprotein
originally identified in the supernatant of a breast cancer cell
line (1). High serum and tumor tissue levels of the protein
are associated with a shorter survival and a reduced response
to chemotherapy in patients with different types of
malignancy (2-6). Although the role of 90K/Mac-2 BP is not
fully understood, it plays an important role in cell-cell and
cell-extracellular matrix adhesive processes thanks to its
binding to galectin1, -3 and -7 (2) and to several proteins of
the extracellular matrix like collagens, fibronectin and
nidogen (7). However, it is still not clear how the proadhesive features of 90K/Mac-2 BP affect tumor growth and
progression. To address this issue, we generated and
characterized a 90K/Mac-2 BP knocked-down clone of
MDA-MB-231 human breast cancer cell line. Methods and
Results: A stably 90K/Mac-2 BP silenced clone of MDAMB-231 was obtained by siRNA. The level of expression of
90K/Mac-2 BP, evaluated at the mRNA and protein level by
Real time PCReaction and ELISA respectively, was reduced
by about 80% as compared to the mock transfected cells. As
compared to controls, silenced cells showed no significant
differences in terms of doubling time, indicating that
90K/Mac-2 BP is not involved in cell proliferation; on the
other hand, silenced cells exhibited a reduced adhesiveness
to fibronectin and collagenV, increased motility and
increased matrigel invasiveness. Tumors derived from
silenced cells xenografted in nude mice did not differ from
controls in terms of growth rate, but produced a significantly
higher number of lung metastases. Although preliminary,
these data seems to indicate 90k/MAC-2 BP as an important
molecule involved in tumor dissemination at least in breast
cancer.
1 Koths K, Taylor E, Halenbeck R, Casipit C and Wang A:
Cloning and characterization of a human Mac-2-binding
protein, a new member of the superfamily defined by the
macrophage scavenger receptor cysteine-rich domain, J Biol
Chem 268: 14245-14249, 1993.
2 Grassadonia A, Tinari N, Iurisci I, Piccolo E, Cumashi A,
Innominato P, D’Egidio M, Natoli C, Piantelli M and
Iacobelli S: 90K (Mac-2 BP) and galectins in tumor
progression and metastasis Glycoconjugate Journal 19: 551556, 2004.
3446
3 Iacobelli S, Bucci I, D’Egidio M, Giuliani C, Natoli C,
Tinari N, Rubistein M and Schlessinger J: Purification and
characterization of a 90 kDa protein released from human
tumors and tumor cell lines FEBS Lett 319: 59-65, 1993.
4 Marchetti A, Tinari N, Buttitta F, Chella A, Angeletti CA,
Sacco R, Mucilli F, Ullrich A and Iacobelli S: Expression of
90K (Mac-2 BP) correlates with distant metastasis and
predicts survival in stage I non-small cell lung cancer
patients. Cancer Res 62: 2535-2539, 2002.
5 Iacobelli S, Sismondi P, Giai M, D'Egidio M, Tinari N,
Amatetti C, Di Stefano P and Natoli C: Prognostic value of
a novel circulating serum 90K antigen in breast cancer Br J
Cancer 69(1): 172-176, 1994.
6 Ulmer TA, Keeler V, Loh L, Chibbar R, Torlakovic E, André
S, Gabius HJ and Laferté S: Tumor-associated antigen
90K/Mac-2-binding protein: possible role in colon cancer J
Cell Biochem 98(5): 1351-1366, 2006.
7 Sasaki T, Brakebush C, Engel J and Timpl R: Mac-2 binding
protein is a cell-adhesive protein of the extracellular matrix
which self-assembles into ring-like structures and binds β1
integrin, collagens and fibronectin, The EMBO Journal 17:
1606-1613, 1998.
534
SPECIAL ASPECTS OF SENTINEL NODE BIOPSY
Janusz Piekarski, Dariusz Nejc and Arkadiusz Jeziorski
Department of Surgical Oncology, Medical University of
Lodz, Poland, Ul. Paderewskiego 4, 93-509 Lodz, Poland
Sentinel node biopsy (SNB) is a standard care in patients with
breast cancer and patients with skin melanoma. Apart from use
of SNB in our everyday clinical practice, in the Department
of Surgical Oncology, Medical University of Lodz, Poland,
numerous studies on special aspects of sentinel node biopsy
procedure were conducted. In these studies, authors were
focused mainly on (1) safety of medical staff, performing
SNB; (2) possibility of the use of imprint touch cytology in
assessment of SNB status in skin melanoma patients; (3) ex
vivo use of SNB technique; and (4) the use of SNB technique
in special clinical situations.
In order to assess the safety of medical staff performing
SNB in patients with breast cancer and in patients with skin
melanoma, authors measured the absorbed doses of radiation
to the hands of medical staff. During lymphoscintigraphy and
during surgical procedure on different parts of hands of
medical staff, a total of 57 highly sensitive thermoluminescent
dosimeters were placed. Altogether, 2065 measurements were
performed during 35 procedures. The results revealed that the
maximum recorded dose during the study was 1900 times
smaller than the current one-year dose limit recommended by
the International Commission on Radiological Protection.
To assess whether the reliability of imprint touch cytology
Abstracts of the 8th International Conference of Anticancer Research, 17-22 October 2008, Kos, Greece
(ITC) of sentinel nodes in skin melanoma patients allows
intraoperative decisions to be made regarding simultaneous
radical lymphadenectomy we performed a study on 148
sentinel nodes removed from 85 skin melanoma patients. We
found that ITC of sentinel nodes is a reliable method. The risk
of overtreatment due to false-positive results of ITC of sentinel
node was absent in our study.
We performed ex vivo blue-dye SN mapping in
postmastectomy specimens to assess whether the main
lymphatic tract leading from periareolar plexus to SN is
completely removed during mastectomy. We assumed that ex
vivo identification of SN may be possible only if entire
lymphatic tract leading to sentinel node is removed within the
postmastectomy specimen. Our experiment revealed that the
use of transverse skin incision during modified radical
mastectomy may not be a best choice for breast cancer
patients; when the transverse incision was used, we were able
to identify sentinel nodes only in 31% of cases.
We considered the use of SNB in a patient with five
synchronous primary skin melanomas, a special clinical
situation. The patient underwent excisions of all five primary
tumors along with five simultaneous sentinel node biopsies.
We successfully identified lymph flow from all skin areas to
three different lymph node basins and successfully retrieved
six sentinel nodes from these basins. In our opinion, this case
illustrates that performing multiple sentinel node biopsies in
patients with multiple primary skin melanoma is possible.
535
BRAIN METASTASES IN OVARIAN CANCER:
OVERVIEW AND OPTIMAL TREATMENT
Klaus Pietzner, Khalid El Khalfaoui, Gülten Oskay-Özcelik,
Dirk Boehmer, Werner Lichtenegger and Jalid Sehouli
Department of Gynecology and Obstetrics, Division of
Gynecologic-Oncology, Charité-Campus Virchow Klinikum,
University Medicine of Berlin, Augustenburger Platz 1,
13353 Berlin, Germany
Ovarian cancer is one of the leading causes of mortality in the
field of gynecologic oncology. Central nervous system (CNS)
involvement however is rare in presentation and seems to be
associated with a very poor prognosis. Clinical as well as
autopsy studies in the last decades have confirmed the rarity of
occurrence of brain metastases in ovarian cancer, but several
authors have recently observed a sharp rise in incidence. While
most authors attribute this increase of CNS involvement to
prolonged survival achieved through advances in
chemotherapy and surgical management, others see it resulting
from improved imaging or chemotherapeutic impairment of
the blood-brain barrier. Brain metastases from ovarian cancer
can present with a panel of often unspecific symptoms which
usually results in a late diagnosis of CNS relapse, since
cerebral imaging is not part of the routine follow-up. Even
serum-CA-125 levels, a valuable tool in predicting recurrence
of distant disease, was shown to be incapable of reliable
detection in regard to metastatic brain manifestation, leaving
the clinician with the need for close patient observation for
neurological symptoms in order to diagnose brain metastasis at
an early stage. While some reports only indicate the presence
of extracranial disease at CNS relapse and time from diagnosis
of ovarian cancer to development of brain metastases as
prognostic factors for survival, other studies demonstrate the
negative impact of multiple cerebral lesions on survival, when
compared to single brain metastases. Though great efforts have
been made to develop multimodal therapeutic strategies to
challenge the rising incidence of brain metastasis in ovarian
cancer, CNS involvement is still related with a very poor
prognosis. It was shown that a multi-modal approach,
combining surgical resection with radiation therapy and even
chemotherapy promises the best prolongation of survival and
did result in long-term remissions in a few cases. But this
aggressive strategy is not applicable to all patients, often due
to overall status or inaccessibility of brain metastases to the
neurosurgical approach. In these cases stereotactic radiation
therapy or gamma-knife-surgery is recommended by many
authors to remove single metastatic brain lesions. These
techniques should be further discussed as an alternative for
whole-brain radiation therapy, as several studies expand its use
to other indications such as multiple lesions and with
promising results. Based on our large multicenter study
including 73 patients with brain metastases from ovarian
cancer, we will discuss predictive and prognostic factors as
well the current best treatment.
536
EXPLOITATION OF THE BIOLOGICAL FEATURES
OF BRAIN TUMOURS IN PURSUIT OF NEW
THERAPEUTIC STRATEGIES: IN VITRO STUDIES
Geoffrey J. Pilkington, Samantha A. Murray,
Samantha Higgins, Kathryn Fry, Laura Donovan,
Suzanne Birks, Zaynah Maherally and Naif Alsiweheri
Cellular and Molecular Neuro-oncology Group, Cellular and
Molecular Medicine Research Division, Institute of
Biomedical and Biomolecular Sciences, School of Pharmacy
and Biomedical Sciences, University of Portsmouth, St
Michael’s Building, White Swan Road, Portsmouth PO1
2DT, UK
Primary, malignant brain tumours are among the most
therapeutically-resistant of all cancer. This resistance is a
consequence of the unique biological properties which
characterise them. The blood–brain barrier (B-BB) poses a
specific obstacle to chemotherapy, while neoplastic glial cells
are particularly efficient at repairing DNA damage breaks
3447
ANTICANCER RESEARCH 28: 3157-3556 (2008)
caused by both chemo- and radiotherapy. In addition, the
ability of glioma cells to diffusely invade the contiguous
normal brain adds to this resistance. During invasion, tumour
cells transiently arrest from the cell cycle, rendering them
refractory to radiotherapy. Moreover, while certain cytotoxic
drugs can reach the major tumour mass by virtue of
disruptions of the B-BB, cells which have invaded deep into
the brain are protected from them since they are invested in
regions of intact B-BB. Tumour resistance is also thought to
be facilitated by the existence of small populations of selfrenewing stem cell-like cancer cells (SC-LCS) within glial
tumours. There is increasing evidence that this population of
cells are also highly migratory and thus may contribute to both
resistance and local dissemination. To contribute to the
complexity surrounding neurological tumours, in addition to
primary brain tumours, the brain is a fertile site for the growth
of secondary tumours, indeed up to a quarter of all tumours
will spread to the central nervous system at some stage.
In order to study this complex biological picture we have
established – from human cells and under human serum
supplementation conditions – three-dimensional live cell
model systems of both tumour invasion and the B-BB (for
studies on cancer cell metastasis to the brain). We have also
segregated CD133-positive SC-LCSs by use of AutoMACS
immunobead separation from early passage, biopsy-derived
glioblastoma and studied their complex behaviour, lineage
properties and response to microenvironmental factors. We
have used these cells and the above models to investigate four
putative therapeutic targets: CD155 (poliovirus receptor),
CD44 (hyaluronic acid receptor), GD3 (cell surface
disialoganglioside 3) and NG2 (neuronal-glia2 chondroitin
sulphate proteoglycan), which may provide a means of either
selectively killing tumour cells or inhibiting their invasive
properties. We have also examined the tumour cell
mitochondrion as a possible target for enhanced therapeutic
effect by way of tricyclic drug mediated apoptosis. We believe
that each of these approaches may carry potential for future
clinical studies.
537
EPIDEMIOLOGY OF VITAMIN D
DEFICIENCY AND CANCER MORTALITY
Stefan Pilz
Department of Internal Medicine, Division of Endocrinology
and Nuclear Medicine, Medical University of Graz,
Auenbruggerplatz 15, 8036 Graz, Austria
There is growing evidence that vitamin D exerts
anticarcinogenic effects. Ultraviolet-B (UV-B) radiation,
which is required for vitamin D production in the skin, was
found to be inversely associated with cancer incidence and
mortality. Recent studies have largely but not consistently
3448
shown that low 25-hydroxyvitamin D [25(OH)D] levels,
which are considered to be the best indicator of vitamin D
status, are a significant risk factor for cancer mortality.
Circulating 25(OH)D levels were also associated with
improved overall survival in colorectal and lung cancer
patients and vitamin D deficiency was observed in patients
with autoimmune, infectious and cardiovascular diseases.
Significant seasonal variations in 25(OH)D levels and the
association of vitamin D deficiency with reduced physical
activity are, however, possible sources of confounding in
epidemiological studies. Randomized controlled trials are
therefore urgently needed to evaluate whether vitamin D
supplementation reduces cancer incidence and mortality. The
optimal 25(OH)D levels for human health, that should be
achieved by vitamin D supplementation, still remain to be
elucidated but there exists a wide consensus that every adult
should have 25(OH)D levels of at least 30 ng/ml.
538
CHARACTERIZATION OF NON-SMALL
CELL LUNG CANCER USING TILING
RESOLUTION BACTERIAL ARTIFICIAL
CHROMOSOME MICROARRAYS
Sofi Isaksson1, Annette Salomonsson1,
Pär-Ola Bendahl1, Linda Ivarsson1, Leif Johansson2,
Per Jönsson3, Anna Karlsson1, Maria Soller4,
Göran Jönsson1 and Maria Planck1
Departments of 1Oncology, 2Pathology, 3Thoracic Surgery
and 4Clinical Genetics at Lund University Hospital, Sweden
Lung cancer is the leading cause of cancer death in the world
and, although diagnostics and therapeutics have improved
during the past two decades, the overall 5-year survival rate is
still below 15%. Eighty percent of all lung cancer is of the
non-small cell type (NSCLC) and of these, about one fourth
are stage I-IIIA tumors and thus accessible for surgery. The 5year survival after successful resection is approximately 50%,
but the outcome is heterogeneous, even within the same
clinicopathological stage.
Development of new techniques in molecular biology, such
as efficient characterization of tumors at the gene level with
subsequent correlations to diagnostics and prognostics, is
therefore of great importance. However, our knowledge of
genomic imbalances in lung cancer and the oncogenic
consequences of these alterations are still limited.
The use of whole-genome tiling resolution bacterial
artificial chromosome (BAC) microarrays allows for
characterization of DNA copy number changes at a resolution
only limited by the number of BAC clones used for the arrays.
In the present study, 32,433 overlapping BAC clones covering
the whole genome were used, implying that the tumor DNA
could be analyzed with an average resolution of 70 kbp. This
Abstracts of the 8th International Conference of Anticancer Research, 17-22 October 2008, Kos, Greece
is, to our knowledge, the first study using this approach on
clinical specimens of primary lung cancer. Freshly frozen
biopsies of primary NSCLCs were obtained from patients
operated in 1989-2003 at the Lund University Hospital,
Sweden. In all, 62 early stage primary NSCLCs (48
adenocarcinomas and 14 squamous cell carcinomas) were
profiled to allow for subclassification, identification of
recurrent changes, and search for candidate genes. Alterations
were observed in all chromosomes and the tumors displayed
complex DNA copy number profiles with numerous gains and
losses. Frequent amplifications and homozygous deletions
were observed in regions harboring oncogenes and tumor
suppressor genes, respectively. Thus, the use of whole-genome
tiling resolution BAC microarrays is applicable for
identification of novel candidate genes in lung cancer
development.
539
GAMMA/DELTA (γδ) T-CELL RECEPTOR (TCR)+ T
CELLS IN EPITHELIAL OVARIAN CARCINOMA
(EOC): CLONAL EXPANSIONS, TUMOR CELL LYSIS
AND POTENTIAL FOR γδ TCR-BASED
IMMUNOTHERAPY
C.D. Platsoucas1,2, W.-J. Jung1, F. Whitfield1, A. Tsygankov1,
E. Hernadez3, R.S. Freedman4 and E.L. Oleszak1,2
1Department
of Microbiology and Immunology and
of Obstetrics and Gynecology, Temple
University School of Medicine, Philadelphia, PA;
2Center for Molecular Medicine and Department of
Biological Sciences, College of Sciences, Old Dominion
University, Norfolk, VA and 4Department of Gynecologic
Oncology, M.D. Anderson Cancer Center, Houston, TX,
USA
3Department
Alpha/beta TCR+ T-cells recognize primarily peptides in
association with self-MHC, whereas, most Vδ1+ T-cells
recognize whole proteins, and most Vδ2+ T-cells recognize
phosphoantigens, lipids, and other ligands, both in an MHCindependent manner. We examined whether clonally expanded
γδ TCR+ T-cells are present in tumor infiltrating lymphocytes
(TIL) and PBMC from patients with EOC. VγI, VγII, Vδ1 and
Vδ2 TCR transcripts were amplified from TIL and PBMC by
two sided V region subgroup specific PCR, followed by
cloning and sequencing. Sequencing analysis revealed the
presence of substantial proportions of identical copies of VγI
(in 8 of 12 patients; 67%), VγII (in 9 of 11 patients; 82%),
Vδ1 (in 6 of 6 patients; 100%), and Vδ2 (in 4 of 7 patients;
57%) TCR transcripts in TIL from patients with EOC. γ- and
δ-chain TCR transcripts were also clonally expanded in the
PBMC from patients with EOC (in all 3 patients examined). In
certain patients identical TCR transcripts were clonally
expanded in both PBMC and TIL from the same patient.
These γ- and δ-chain TCR clonal expansions were very strong
and statistically significant. T-cells are comprised of a very
large number of different T-cell clones, each expressing a
different TCR. Because of their large numbers, the probability
of finding by chance substantial proportions of individual TCR
transcripts in an independent sample of T-cells is negligible.
The appearance of multiple identical copies of TCR transcripts
must be the result of specific antigen-driven proliferation and
clonal expansion of individual T-cell clones. Full length copies
of clonally expanded γ- and δ-chain TCR transcripts were
constructed by PCR-mediated four-segment ligation and
appropriate combinations were expressed into TCR beta-chain
negative mutant Jurkat T-cells (which stain positive with antigranzyme B antibody) using a retroviral expression system.
Expression of the γδ TCR was determined using an anti-γδ
TCR mab. These transduced Jurkat T-cells expressing the
clonally expanded γ- and δ-chain TCR transcripts: (i) induced
apoptosis via caspase-9 activation on ovarian tumor cells; and
(ii) exhibited strong cytolytic activity against ovarian tumor
cells. These results provide the basis for the development of
new approaches for γδ TCR+ T-cell immunotherapy.
540
COMBINATION IMMUNOTHERAPY:
NEUTRALIZATION OF THE TUMOR ESCAPE AND
IMMUNOSUPPRESSIVE MECHANISMS MAY BE
REQUIRED FOR CLINICALLY EFFECTIVE TUMOR
VACCINES AND ADOPTIVE IMMUNOTHERAPY
APPROACHES (AN OVERVIEW)
Chris D. Platsoucas
Center for Molecular Medicine and Department of
Biological Sciences, College of Sciences, Old Dominion
University, Norfolk, VA, USA
Tumor cells have been very appropriately called masters in
disguise and deceit from detection and destruction by the cells
of the immune system. Tumors employ a variety of
mechanisms to achieve this purpose. These mechanisms are
collectively designated as tumor escape mechanisms and have
been shown to be active in patients with a variety of cancers.
Although substantial progress has been made in identifying
tumor antigens, in determining their molecular structure and
characteristics and in developing tumor vaccines, they have
been so far in general ineffective for the treatment of patients
with cancer. These cancer vaccines induced biological
responses in as many as 50% of the patients, but objective
clinical responses in less than 4%. In contrast to cancer
vaccines, adoptive immunotherapy approaches, which involve
the transfer to the host of large numbers of in vitro grown
activated autologous T-cells able to destroy the tumor, have
been shown to be effective and induce objective clinical
responses in 50-70% of patients with metastatic melanoma.
3449
ANTICANCER RESEARCH 28: 3157-3556 (2008)
The effectiveness of both cancer vaccines and adoptive
immunotherapy approaches is substantially hindered by tumor
escape mechanisms, which include: (i) increased numbers and
proportions of CD4+CD25+ immunoregulatory suppressor Tcells (Tregs) at the tumor site and the peripheral blood.
Reduction of the Tregs in patients with cancer using ONTAK
resulted in significantly increased responses to tumor vaccines.
Extensive lymphodepletion is required for effective adoptive
immunotherapy approaches, and may involve reduction of
Treg, and other tumor escape mechanisms (see below); (ii)
increased numbers and proportions of tumor-associated
macrophages/monocytes;
(iii)
production
of
immunosuppressive factors, such as TGF-beta and IL-10, by
tumor cells and mononuclear cells (non-malignant cells)
infiltrating the tumor or present in the peripheral blood; (iv)
increased expression of cell surface molecules (PD-1 and
CTLA-4) inhibitory of the effector function of tumor
infiltrating lymphocytes; (v) lack of co-stimulatory molecules
on tumor cells; (vi) downregulation of HLA class I expression
on the surface of the tumor cells. We believe that the
simultaneous neutralization of several of these complex and
highly effective tumor escape mechanisms is very likely
required for the development of clinically effective cancer
vaccines and for increasing the effectiveness of adoptive
immunotherapy approaches.
541
THE PROMYELOCYTIC LEUKEMIA PROTEIN:
FROM ANTIVIRAL RESPONSE TO CANCER
Pavlina Plevova1,2, Ivana Jeziskova1, Sylwia Walczyskova1,
Anna Krepelova3, Kristyna Pavlikova3,
Alena Puchmajerova3, Jana Zapletalova4 and Eva Silhanova1
involved in the BRCA pathway activated in response to
double-strand DNA damage. This also suggests there might be
functional association between these systems. This could
explain why breakage of some proteins of the BRCA pathway
leads to an increased sensitivity to infections and also other
clinical aspects. We are going to present a hypothesis on the
essence of potential cooperation between PML nuclear
domains and the BRCA pathway and its possible biological,
clinical and evolutionary consequences.
We have studied the PML gene in patients with hereditary
or familial breast and colon cancer, colon polyposis and
stomach cancer in order to test a hypothesis that germline
PML gene mutations might predispose to cancer. We found a
single nucleotide substitution in the alternatively spliced exon
7b, c.1710+1355G>C (p.A570+232>P570+232) in about one
third of patients with colon cancer and/or colon polyposis and
the majority of patients with gastric cancer (the results were
statistically significant). We suggest a new hypothesis on the
pathogenesis of these tumors.
In conclusion, it is highly probable that an important
interplay exists between PML nuclear domains and the BRCA
pathway. Germline carriers of the c.1710+1355G>C
substitution in the alternatively spliced exon 7b of the PML
gene are at an increased risk of gastrointestinal polyposis and
cancer.
The project was supported by IGA MZ ČR NR9092-3/2006.
542
HETEROGENEITY OF HEMOGLOBIN IN BLOOD IN
THE MODEL OF TUMOR GROWTH
Tatiana Polishko and Natalia Shtemenko
1Department
Dnipropetrovs’k National University, 13 Naukoviy by-street,
49050 Dnipropetrovs’k, Ukraine
The PML (promyelocytic leukemia) gene encodes a
multifunctional protein involved in antiviral response,
transcription control, induction of apoptosis, growth arrest,
cellular senescence, and DNA damage repair. We have found
down-regulated PML protein expression in about one fifth of
colon cancer and one third of breast cancer tissues. Breast
cancer tissues from germline BRCA1 gene mutation carriers
rarely down-regulate the PML protein, suggesting a functional
relationship between the BRCA1 and PML proteins. There are
several proteins both bound in PML nuclear domains and
The energy metabolism of tumor cells is quite different from
that of normal cells. A characteristic property of malignant
cells is their high rate of glycolysis. Normal cells depend on
oxidative phosphorylation to synthesize ATP, but even in the
presence of oxygen, cancer cells exhibit an increased capacity
for lactate production. The enhanced rate of aerobic glycolysis
correlates in general with the degree of malignancy. Although
the production of ATP via aerobic glycolysis is inefficient, this
selective adaptation may be a mechanism of survival for tumor
cells under conditions of poor vascularization.
Normal adult human red blood cells (RBC) generate energy
almost exclusively through the metabolism of glucose
primarily via the Embden-Meyerhof pathway and the pentose
phosphate shunt. These pathways produce the cellular energy
crucial to RBC survival and maintenance of proper cell
function. Malignant cells show an increased glucose uptake in
vitro and in vivo. This process is thought to be mediated by
Gluts, the human erythrocyte glucose transporter, the
of Medical Genetics, Faculty Hospital of
Ostrava, Tr. 17. listopadu 1790, 708 52 Ostrava 8;
2Institute of Pathology and Laboratory of Molecular
Pathology, Medical Faculty, Palacky University, Hnevotinska
3, 775 15 Olomouc;
3Institute of Biology and Genetics, 2nd Medical Faculty of
Charles University, V Úvalu 84, 150 00 Prague-Motol;
4Institute of Biophysics, Palacky University, Hnevotinska 3,
775 15 Olomouc, Czech Republic
3450
Abstracts of the 8th International Conference of Anticancer Research, 17-22 October 2008, Kos, Greece
expression and activity of which is regulated by oncogenes
and growth factors. In our previous work, we have described
the new Re-Pt antitumor system, where cisplatin and cluster
rhenium compounds were used against Guerin’s carcinoma
development in rats. In this work, we present Glu levels and
some types of Hb in blood under influence of the Re-Pt
system with the use of three rhenium substances.
The following Cluster rhenium compounds with organic
ligands were investigated: Re1 [Re2(i-C3H7CO2)4Cl2]; Re2
cis-[Re2(AdCOO) 2Cl4].2CH 3CN; Re3 [Re2(GABA) 2Cl5
(H 2O)]2H 2O. Wistar rats were inoculated with tumor
Guerin’s carcinoma (T8) cells. A single intraperitoneal
administration of cisplatin at the dose of 8 mg/kg was made
on 9 day after the tumor inoculation. The intraperitoneal
administration of the Re1-3 at the dose of 7 μM/kg in
liposome forms began on day 3 after the inoculation of the
tumor cells and was repeated every 2 days until day 21.
Concentrations of red blood cells and their morphological
forms were measured. Fetal Hb (FHb) and glycosylated Hb
(HbA1c) were assayed by column liquid chromatography.
Investigations of the Hb heterogeneity showed that in the
blood of animals of T8 + cisplatin group the concentration
of HbA1c was much higher (up to 7%) than in the control
group (4.2-4.5%). In some cases, where the inhibition of the
tumor by cisplatin was not so strong, we observed the
presence of FHb (0.3%), which was almost absent in the
other groups. Higher level of HbAc1 is known to appear in
RBC and plasma of the patients with some types of cancer.
FHb is an established serological indicator of cancer. Cluster
rhenium compounds may influence the energy metabolism
of RBC and the process of Hb forms expression. Further
investigation of Hb heterogeneity in this model may lead to
propositions of markers for the effectiveness of anticancer
therapy.
543
GAMMA-GLUTAMYLTRANSFERASE OF CANCER
CELLS AT THE CROSSROADS OF REDOX
REGULATION, TUMOR PROGRESSION, DRUG
RESISTANCE AND DRUG TARGETING
A. Corti1, T.L. Duarte2, A. Paolicchi1, S. Dominici1,
G.D.D. Jones2, P. Dilda3, P.J. Hogg3 and A. Pompella1
1Department
of Experimental Pathology, University of Pisa,
Italy;
2Radiation and Oxidative Stress Group, Department of
Cancer Studies and Molecular Medicine, University of
Leicester, UK;
3UNSW Cancer Research Centre, University of New South
Wales, Sydney, Australia
Gamma-glutamyltransferase (GGT) is often significantly
increased in human malignancies and its role in tumor
progression, invasion and drug resistance has been repeatedly
suggested (Pompella et al: Curr Opin Pharmacol 7: 360,
2007). Previous studies have repeatedly documented a role of
GGT in cellular redox balance, through the production of a
low but persistent oxidative stress (see e.g. Paolicchi et al:
Biochem. Pharmacol 64: 1029, 2002). When GGToverespressing cells were incubated in the presence of GGT
substrates and a source of catalytic iron, increased levels of
DNA damage were observed (Comet assay). This
phenomenon was suppressed by specific GGT inhibitors such
as ABBA, as well as by iron chelator DFO and antioxidants
BHT and Trolox C. Interestingly, higher levels of basal DNA
damage were observed in GGT-overexpressing cells as
compared to low-expressing ones. These results suggest thus a
role of GGT expression per se in tumor progression.
On the other hand, GGT has been implicated in cancer drug
resistance as it participates in the reconstitution of cellular
glutathione and related antioxidant/antitoxic defences.
However, more complex effects of GGT expression can take
place, both intra- and extracellularly. In fact the enzyme can
play as a factor both in drug resistance and drug sensitivity, as
documented by the results of our latest studies: i) The
protective effects of GGT against cisplatin cytotoxicity are
independent of intracellular glutathione, and depend rather on
extracellular reactions of cisplatin with GGT-derived thiol
metabolites, leading to formation of adducts which are far less
cell permeable (Franzini et al: Eur J Cancer 42: 2623, 2006);
ii) On the contrary, in the case of 4-[N-(S-glutathionylacetyl)amino] phenylarsinous acid (GSAO) – a promising antiangiogenic drug – cell membrane GGT activity acts as a
sensitizing factor. The gamma-glutamyl residue of GSAO is
in fact cleaved at the surface of GGT-expressing cells, thus
producing the metabolite GCAO. The latter is transported
across the plasma membrane, and eventually reacts with its
mitochondrial targets (Dilda et al: 2008, manuscript
submitted). This information can also explain GSAO kidney
toxicity at high doses: GGT is in fact expressed at high levels
in tubular epithelia; iii) Recent observations highlight NO and
NO-donor agents (e.g. S-nitroso-glutathione, GSNO) as
chemosensitizing agents, capable of potentiating the action of
several anticancer drugs (Sullivan et al: Curr Pharm Des 14:
1113, 2008). As GGT possesses the selective ability to
metabolize GSNO – thus releasing its NO load – its
expression may well be exploited to target NO to GGTexpressing tumor cells. We have investigated the kinetics of
GGT with respect to GSNO using our innovative fluorimetric
method® based on copper decomposition of nitrosothiol
metabolites and reaction of released NO with 4,5diaminofluorescein (Angeli et al: Arch Biochem Biophys
2008, in press). The results indicate a Km of GGT for GSNO
of ~0.4 mM, comparable with the Km value for glutathione,
which confirms the feasibility of using GSNO as an efficient
pro-drug in order to perform selective NO treatment of GGT-
3451
ANTICANCER RESEARCH 28: 3157-3556 (2008)
expressing tumors. Future studies will substantiate the
applicability and usefulness of such an approach to therapy.
Supported by University of Pisa, Istituto Toscano Tumori
(ITT, Firenze) and Fondazione Fibrosi Cistica (FFC, Verona),
Italy.
544
VITAMIN D AND CANCER: AN OVERVIEW
Alina Carmen Porojnicu1, Zoya Lagunova1, Arne Dahlback2
and Johan Moan1,2
1Department
of Radiation Biology, Rikshospitalet Radiumhospitalet HF, Oslo;
2Department of Physics, Oslo University, Norway
After Garland and Garland in 1980 reported that the mortality
of colon cancer increases with increasing latitude and
hypothesized that this may be explained by induction of
vitamin D by solar radiation, a large number of studies have
been devoted to this association. Multiple approaches have
been chosen, from ecological studies to randomized clinical
trials. Eventhough some studies have shown no correlation,
most of them support the concept that a good vitamin D status
is anticarcinogenic by either reducing the risk of developing
cancer or preventing cancer progression. Our main finding is
that prognosis of a number of cancer forms in Norway is
dependent on season of diagnosis. Generally, diagnosis in
summer and autumn leads to the best prognosis. Most likely,
this can be explained by the higher concentrations of vitamin
D we observe in serum in summer and autumn than winter
and spring. Solar ultraviolet radiation, UV, is believed to
contribute by up to 90% of the circulating levels of vitamin D,
the rest being obtained from diet. Vitamin D, activated through
hydroxylations, has anti-cancer properties. Some of the
molecular and genetic mechanisms behind its biological
functions are known, while some remain unclear. The annual
previtamin D photosynthesis is larger in the southern part of
the country than in the northern part. Due to climatic
differences, the real sun exposure of people can be different
from the ambient ones. We investigated this by determining
the incidence rates of squamous cell carcinoma, which are
related to the real UV exposures. These are a factor of about
three larger in south than in north. Unexpectedly, there were
no significant differences in survival for different latitudes and
annual UV exposures. This may be due to the 20% higher
vitamin D intake in North Norway than in South Norway. We
found that over a larger range of latitudes (from Scandinavia to
Australia), the ratio of death rates to incidence rates (a crude
measure of survival) decreases with decreasing latitude. The
epidemiological evidence together with the biological
knowledge of the anticancer effects of vitamin D should
prompt more studies aimed at defining an optimal vitamin D
status and the safest ways to achieve this.
3452
545
CHROMOGRANIN A
M. Prazakova, O. Topolcan, L. Holubec,
J. Vrzalova, M. Pesek, M. Casova and J. Safranek
Faculty Hospital and Medical School in Pilsen, E. Benese
13, 305 99 Plzen, Czech Republic
Aim: To find out the rate of CgA serum level positivity in
patiens with lung cancer, colorectal cancer and prostate cancer.
Materials and Methods: Serum levels of CgA were assessed
using immunoradiometric analysis (IRMA) with commercially
available assay kit from Schering – CIS BioInternational
(France). Groups of patients: i) Control group – 57 patients
with no history and no evidence of cancer disease at the time
of serum examination; ii) Patients with malignant disease of
the lung (I-III stage) – 90 patients at the time of primary
diagnosis (prior to any treatment) 112 patients with non small
cell lung cancer (NSCLC) during follow-up; iii) Patients with
carcinoid tumor – 18 patients; iv) Patients with prostate
cancer; v) Patients with non-tumor disease – renal failure,
chronic liver failure. Results: The group of patients with lung
cancer had significantly higher serum levels of CgA in
comparison to the control group (p 0,001). Serum values of
CgA in patients with progression were significantly higher
than those in patients with remission and in the control group,
we did not observe any statistically significant difference
between the control group and the group of patients in
complete remission. During the follow-up period, remission
values were significantly different from levels examined at the
time of primary diagnosis (p 0.001) and from the values of
CgA in patients with progressive disease (p 0.001). CgA
serum levels were elevated above cut-off levels in 56% of
patients with SCLC, 43% of patients with non-small cell lung
cancer and in more than 80% of patients with carcinoid
tumors. CgA serum level changes correlated with therapy
effect, as demonstrated in several case reports. False higher
values of CgA could be seen in patients with chronical liver
failure and renal failure. It appears that chromogranin values
correlate with prognosis in the case of prostate cancer,
colorectal cancer and breast cancer. Conclusion:
Chromogranin A serum levels could be used in the diagnosis
of lung cancer of a neuroendocrine character. Based on this
study, CgA seems to be a helpful parameter for the follow-up
and therapy monitoring of these diseases.
Supported with the research project VZ MSM 0021620819
and the grant IGA MZ CR 9343-3.
546
INHIBITION OF TOPOISOMERASE I BY
ERLOTINIB IN CANCER CELL LINES: EFFICACY
OF COMBINED TREATMENTS WITH ERLOTINIB
AND TOPOISOMERASE INHIBITOR
Abstracts of the 8th International Conference of Anticancer Research, 17-22 October 2008, Kos, Greece
Refael Peleg1, Dmitri Bobilev2 and Esther Priel1
1The Shraga Segal Department of Microbiology and
Immunology, Faculty of Health Sciences, Ben Gurion
University of the Negev;
2Department of Oncology, the Soroka Hospital Medical
Center, Beer Sheva, 84105, Israel
Erlotinib is a tyrosine kinase inhibitor used to target the
epidermal growth factor receptor (EGFR) and is currently in
clinical use as an anticancer drug. We previously showed that
certain tyrosine kinase antagonists, tyrphostins, inhibited the
catalytic activity of cellular topoisomerase I (topo I).
Therefore, it may be assumed that erlotinib exerts its
anticancer activity by also inhibiting topo I. Purified and
nuclear extract-derived topo I were added to topo I reaction
mixture in the presence or absence of erlotinib (10–4-10–12 M).
Here we show that erlotinib inhibited the DNA relaxation
activity of purified topo I as well as topo I derived from breast
cancer (MCF7) and prostate cancer (PC3) cell lines.
To examine the effect of erlotinib on the cellular topo I,
MCF7 and PC3 cells were treated with different doses of
erlotinib and the effect on topo I was determined. Erlotinib
treatment significantly reduced the cellular DNA relaxation
activity of topo I but did not affect the level of topo I protein.
Examination of the mode of action revealed that erlotinib
reduced the DNA-binding ability of topo I. The MCF7 cells
demonstrated a relatively high resistance to treatment with
erlotinib, and with camptothecin (CPT), a topo I inhibitor,
administered separately. A combined treatment based on
erlotinib and CPT increased the anticancer effect of CPT as
well as the CPT-mediated inhibition of topo I activity.
The results of this study show that topo I is a novel target of
erlotinib and suggest that a combination of erlotinib with topo
I inhibitors may demonstrate an effective anticancer treatment.
547
IMMUNOSUPPRESSIVE DRUG FTY720 SENSITIZES
PROSTATE CANCER CELLS TO RADIOTHERAPY
BY INHIBITION OF SPHINGOSINE KINASE-1
Dmitry Pshezhetskiy1, Torsten Boehler2, Nicolas Doumerc3,
Muriel Golzio4, Justin Tessie4, Volker Brinkmann5, Bernard
Malavaud3,4, Jonathan Waxman1 and Olivier Cuvillier4
1Department
of Oncology, Imperial College London,
London, UK;
2U466, INSERM, Toulouse, France;
3Department of Urology, Rangueil Hospital, Toulouse, France;
4Department of therapeutic targets, IPBS, Toulouse, France
5Novartis Pharma, Basel, Switzerland
A sphingolipid analogue, FTY720, is a novel immunosuppressive drug – an agonist of sphingosine 1-phosphate
(S1P) receptors. Recently we identified sphingosine kinase-1
(SphK1)/S1P pathway as a therapy target in prostate cancer.
In the current study, we demonstrate that FTY720 can
radiosensitize prostate cancer in cell and animal models.
FTY720 induced apoptosis in several hormone- and
radioresistant prostate cancer cell lines. FTY720 treatment
induced a sustained inhibition of SphK1 and a decrease in the
intracellular S1P content. Enforced expression of SphK1 in
prostate cancer cells rendered them resistant to FTY720. In
vitro sub-lethal concentrations of FTY720 dramatically
sensitized PC-3 cells to radiotherapy.
Mice orthotopically engrafted with fluorescent PC-3 cells
were treated with FTY720 with or without γ-irradiation.
FTY720 demonstrated a synergy with γ-irradiation (notably
through SphK1 inhibition), significantly reducing tumor size,
angiogenesis and formation of micrometastases as
demonstrated by fluorescent in vivo imaging.
In conclusion, FTY720 can sensitize prostate cancer cells
to radiotherapy both in vitro and in vivo, through inhibition of
SphK1 and modification of intracellular levels of lipid second
messengers.
548
THE SK1/S1P PATHWAY AS A POTENTIAL
DIAGNOSTIC/PROGNOSTIC MARKER IN
PROSTATE CANCER
Maria Naymark, Lysann Sauer, Jonathan Waxman and
Dmitry Pshezhetskiy
Department of Oncology, Imperial College London, London,
UK
The sphingosine kinase-1/sphingosine-1-phosphate (SK1/S1P)
pathway regulates several fundamental processes that are
integral to cancer pathogenesis (cell proliferation, resistance
to apoptosis, angiogenesis and the pro-inflammatory
response). In the current study using a prostate cancer model,
we hypothesize that elevation of SK1/S1P can serve as a
potential diagnostic/prognostic marker.
In a preclinical study on 30 prostate cancer patients
undergoing radical prostatectomy, we have demonstrated that
SK1 is strongly up-regulated in human prostate tumours in
comparison to non-tumour controls. SK1 elevation correlated
with the Gleason score and the advanced stage of the disease.
In several patients, prostate cancer cells obtained from known
lymph node metastases had elevated activity of SK1 in
contrast to the cells in the primary tumour providing a link
between the SK1 activation and acquiring of the metastatic
potential. Mice xenografted with human prostate cancer cells
had increased levels of blood serum extracellular S1P in
comparison with mice not bearing prostate tumours. Following
docetaxel treatment, serum levels of S1P fell in parallel with
the reduction of tumour volume.
3453
ANTICANCER RESEARCH 28: 3157-3556 (2008)
In this study, for the first time we demonstrate that the SK1
activity and expression are correlated with the onset,
progression and metastasis of human prostate cancer.
Additionally, using an animal prostate cancer model we show
that the levels of secreted S1P correspond to the tumour
burden, which provides a rationale for proposing S1P as a
novel tumour marker assessable in blood serum. Although not
prostate specific, when combined with other methods, the
SK1/S1P test may have a significant diagnostic and prognostic
value.
549
ESCAPE FROM FAILSAFE PROGRAMS
BY TWIST ONCOPROTEINS AND EMT
Alain Puisieux
INSERM U590 Centre Léon Bérard, Université Claude
Bernard Lyon 1, 69373 Lyon Cedex 08, France
A major obstacle to the expansion of abnormal cells with
aberrant proliferative potential is the induction of innate
defense mechanisms that initiate the cellular failsafe
programs of senescence or apoptosis. The mechanisms by
which pre-cancerous cells escape these protective barriers
remain to be determined. Recently, we identified the Twist
proteins as potential early drivers of tumorigenesis (1).
Twist1 and Twist2 proteins are highly conserved basic helixloop-helix (bHLH) transcription factors that have important
regulatory functions during embryogenesis. Twist1 and/or
Twist2 overexpression is a frequent event in multiple solid
human tumors including many types of carcinomas as well
as sarcomas, gliomas, neuroblastomas, and melanomas.
Twist proteins inhibit both Rb- and p53-dependent pathways,
thereby preventing apoptosis and oncogene-induced
senescence (1, 2). Strikingly, in epithelial cells, the failsafe
program escape facilitated by Twist1 or Twist2 coincides
with complete epithelio-mesenchymal transition (EMT), a
process associated with the acquisition of stem cell
properties and invasive potential (1, 3). Collectively, these
observations suggest that some metastatic capabilities of
cancer cells can be acquired during malignant conversion as
a side-effect of the inactivation of primary failsafe
mechanisms.
1 Ansieau S, Bastid J, Doreau A, Morel AP, Bouchet BP,
Thomas C, Fauvet F, Puisieux I, Doglioni C, Piccinin S,
Maestro R, Voeltzel T, Selmi A, Valsesia-Wittmann S, Caron
de Fromentel C and Puisieux A: Induction of EMT by twist
proteins as a collateral effect of tumor-promoting
inactivation of premature senescence. Cancer Cell 14: 7989, 2008.
2 Valsesia-Wittmann S, Magdeleine M, Dupasquier S, Garin
E, Jallas AC, Combaret V, Krause A, Leissner P and
Puisieux A: Oncogenic cooperation between H-Twist and N-
3454
Myc overrides failsafe programs in cancer cells. Cancer Cell
6: 625-630, 2004.
3 Morel AP, Lièvre M, Thomas C, Hinkal G, Ansieau S,
Puisieux A: (2008) Generation of breast cancer stem cells
through epithelial-mesenchymal transition. PLoS ONE 3:
e2888, 2008.
550
PULSE IL-2 WITH FAMOTIDINE AND
CYCLOPHOSPHAMIDE HAS
ACTIVITY IN PREVIOUSLY TREATED
METASTATIC MELANOMA
Walter Quan Jr., Charles Knupp, Darla Liles, Francine
Quan, Linda King and Paul Walker
Loma Linda University School of Medicine, Loma Linda,
CA;
Leo Jenkins Cancer Center, East Carolina University School
of Medicine, Greenville, NC, USA
Interleukin-2 (IL-2) is able to induce T-lymphocyte
cytotoxicity against melanoma in vitro and in vivo. Famotidine
may further enhance the activity of T-cells by allowing for
increased Interleukin-2 internalization by the IL-2 receptor on
lymphocytes. Previously, we reported the activity of IL-2 in
combination with famotidine in stage IV melanoma (Quan,
2007).
Cyclophosphamide
may
decrease
the
immunosuppressive effects of regulatory T-cells. We utilized
daily short intravenous infusions (pulses) to treat 13 patients
with metastatic melanoma. Patients received 21.6x106 IU/m2
pulse IL-2 intravenously over 15-30 minutes preceded by
famotidine 20 mg i.v. daily for 5 days. Twelve patients
received cyclophosphamide 350 mg/m2 intravenously on day 1
(1 patient did not). Nine patients were treated at an oncology
inpatient unit while, most recently, 4 have received therapy on
an outpatient basis. Cycles were repeated every 3 weeks until
disease progression. Patient characteristics: 7 males, median
age-53 (range: 31-87) years, median ECOG performance
status-1 (range: 0-1). Common metastatic sites: lymph nodes,
13; lungs, 9; subcutaneous, 4; liver, 3. Prior systemic therapy:
IL-2, 10; interferon, 5; chemotherapy, 5; none, 2. Median
number of cycles received (range) = 2 (1-7). Most common
toxicities were fever, rigors, nausea/emesis, hypomagnesemia
and hypophosphatemia. One complete and three partial
responses were seen (31% response rate; 95% confidence
interval: 17-60%). Responses occurred in lung, liver, lymph
nodes, and subcutaneous sites. Median response duration = 3.4
months. Median survival = 9 months for the entire group.
Seven patients remain alive with a median survival >10.5
months. Pulse Interleukin-2 with famotidine and
cyclophosphamide has activity in previously treated patients
with melanoma and may be given on an outpatient basis to
selected individuals.
Abstracts of the 8th International Conference of Anticancer Research, 17-22 October 2008, Kos, Greece
551
CANINE MAMMARY TUMOURS AS A MODEL TO
STUDY HUMAN BREAST CANCER: RECENT
FINDINGS
Felisbina Luisa Queiroga
CECAV, University of Trás-os-Montes and Alto Douro, Vila
Real, Portugal
Clinical and molecular similarities between canine mammary
tumours (CMT) and human breast cancer have been described.
Clinically, the similarities are very strong: spontaneous
tumours, hormonal aetiology, age of onset and identical
clinical course of the disease. The clinical characteristics that
have an impact on the clinical outcome are also identical:
tumour size, growth rate, lymph node invasiveness and clinical
stage.
In both species, the search for prognostic factors to define
those patients with higher risk of developing recurrence or
death due to the tumour is essential. Nevertheless, nowadays
as far as human medicine is concerned, the goal is to identify
prognostic factors that could be used as therapeutic targets to
support a better outcome in the clinical management of the
neoplastic disease. Moreover, in this area, CMT seems to
mimic human breast cancer. In fact, some of the recently
established prognostic factors are molecular targets of new
anticancer therapies acting as predictive factors that can
identify patients which might benefit from specific anticancer
drugs.
Clinical and molecular data that support CMT as a model to
study human breast cancer are analysed in this review.
Additionally it is shown that some recent molecular targets in
CMT may be seen as indicators for similar research to be
performed in the corresponding human disease.
552
ACTIVATION/MATURATION OF CANINE
CUTANEOUS HISTIOCYTOMA CELLS: A SWITCH
TO ITS REGRESSION?
I. Pires1, F.L. Queiroga1, A. Alves1, P. Rodrigues1, F. Silva1
and C. Lopes2
1CECAV,
Department of Veterinary Sciences, University of
Trás-os-Montes and Alto Douro, Vila Real;
2Institute of Biomedical Sciences, Porto, Portugal
Canine cutaneous histiocytoma (CCH) is an epidermotropic
Langerhans cell histiocytosis which occurs mostly in young
dogs. The regression phenomena, to which it is associated,
makes it an attractive system for analysis of Langerhans cell
histiocytosis behaviour and could be regarded as a unique
model to understand the pathogeny of the enigmatic disease
of human Langerhans cell histiocytosis.
In order to contribute to the understanding of the CCH
regression, 93 tumours were analysed. We evaluated the
immunoexpression of MHC class II molecules and E-cadherin
in tumoural cells. MHC class II were also studied by
immunoelectron microscopy methods. Inflammatory infiltrate
were also analysed (CD3, CD79 and MAC387).
In the study of the immunocytochemistry of MHC class II
antigen, visualized by light microscopy and by electronic
microscopy, two principal patterns of MHC class II antigens
expression were observed: a focal juxtanuclear cytoplasmic
reaction associated to endosomal and lysosomal
compartments, or a rim-like staining in the cell periphery
associated to membranes outlines. The first occurred,
principally, in tumours with poor lymphoid inflammatory
infiltrate and the second in tumours with abundant lymphoid
inflammatory infiltrate, either by T-lymphocytes or Blymphocytes. These findings seem to reflect different phases
of MHC class II biosynthesis during activation/maturation of
normal Langerhans cells.
The intensity of the immunoreaction to E-cadherin
decreased with lymphoid infiltration. The decreased of Ecaherin expression was also associated with a membranar
expression of MHC II molecules.
This data suggests that pathological Langerhans cells in
CCH appears in an immature state in early lesions and
undergo a maturation process, characterized by an increase of
membranar MHC class II molecules and a decrease in Ecadherin expression. In the regression lesions these cells had a
mature phenotype and could interact them self with B and Tlymphocyte. CCH is a dynamic lesion that changes its
phenotype and determines its own regression.
In dogs and humans, Langerhans cell histiocytosis has a
distinct clinical behaviour. In dogs, regression is the natural
course of the process. However, in humans, only a limited
number
of
lesions
undergo
regression.
The
activation/maturation of pathological Langerhans cells could
be one explanation for this fact.
553
ENDOPLASMIC RETICULUM-RESIDENT HEATSHOCK PROTEIN GP96 AS REGULATOR OF
NORMAL AND MALIGNANT GROWTH
Biserka Radosevic-Stasic, Hrvoje Jakovac, Damir Grebic and
Ines Mrakovcic-Sutic
Department of Physiology and Immunology, Medical
School, University of Rijeka, 51000 Rijeka, B. Branchetta
22, Croatia
Background: Various kinds of tissue disintegration lead the
endoplasmic reticulum (ER) to activation of adaptive pathways
known as the ER stress response, which is directed to correction
of unfolded proteins, to the activation of proteasome-dependent
3455
ANTICANCER RESEARCH 28: 3157-3556 (2008)
ER-associated degradation of the misfolded proteins and to
activation of protein translation that modulate the polypeptide
traffic into the ER. A crucial role in these events is played by
gp96, which acts not only as a molecular chaperone, but also as
an adjuvant, able to induce the specific immune response
against some self and foreign antigens. Materials and Methods:
To illustrate the multipotential functions of gp96 in this study,
we investigated its participation in conditions of: 1) normal
growth (liver regeneration after partial hepatectomy, pregnancy
and fetal organogenesis), 2) autoimmunity (experimental
allergic encephalomyelitis) and 3) pre-malignant growth
(cervical intraepithelial neoplastic lesions). Tissue expression of
gp96, detected by immunohistochemistry and RT-PCR in
animal models was correlated with phenotype and cytotoxicity
of hepatic and splenic mononuclear lymphatic cells against the
NKT-sensitive (syngeneic thymocytes) and NK-sensitive targets
(YAC-1 cells), while in CIN lesions (gradus I-III) it was
correlated with the intensity of the neoplastic process. Results:
Tissue expression of gp96 was highly up-regulated in fetal and
adult rapidly proliferating tissue (regenerating liver and in
several fetal organs), at the fetoplacental barrier, in injured
tissues after autoimmune attack (on astrocytes, microglia and
neurons in the brain and spinal cord during EAE), as well as in
dysplastic areas of cervix (on hyperplastic epithelial cells,
vascular epithelia, and glandular epithelium). Kinetic studies
made in the model of liver regeneration also showed that gp96overexpression in the liver and thymus was followed by
maturation
of
dendritic
cells,
accumulation
of
in
the
liver
and
CD3intermediate/NK1.1+/CD69+cells
CD4+CD25+Fox3+ cells in the liver and thymus, as well as by
augmentation of NKT- and NK-mediated cytotoxicity in the
liver and in the spleen. Conclusion: The data imply that during
the disturbance of morphostasis and structural integrity of the
cell gp96 may protect the cells against the proteotoxic damage
and serve as a natural adjuvant for chaperoning of antigenic self
or oncogenic peptides into the immune surveillance pathways,
contributing during the normal growth to survival of cells and
reestablishment of self tolerance, and in pathological growth to
both development of cancer and initiation of antitumour
immune response.
Supported by grant 0621341-1337 from Croatian Ministry of
Science.
554
LYMPHANGIOGENESIS AS A POTENTIAL
TARGET FOR TUMOR THERAPY
Marius Raica and Anca Maria Cimpean
“Victor Babes” University of Medicine and Pharmacy,
Department of Histology and Cytology, Romania
Lymphangiogenesis is the process of lymphatic vessel (LV)
formation, but despite the interest on this topic in
3456
physiological and pathological conditions, the mechanisms are
still to be elucidated. Renewed interest in the lymphatic
system began less than 10 years ago and was based on the
introduction of some specific markers of lymphatic endothelial
cells (LECs). Various human tumors preferentially metastasize
by a lymphatic route and lymphovascular invasion is known
for years as an element that accurately predicts lymph node
metastasis. On the other hand, the intimate mechanism/s by
which tumor cells initially enter LVs is largely unknown. In
this context, there are several questions (Q) to be answered
regarding tumor lymphangiogenesis.
Q1: How specific are LEC markers? The most frequently
used LEC markers are VEGFR3, LYVE-1, Prox-1, and
podoplanin. It was shown that in postnatal life, these markers
are expressed by LECs and not by blood vessel ECs. They
have no absolute specificity, as their expression was reported
in some normal and pathological cells/tissues.
Q2: Can LVs be found in tumors? The best results were
obtained with D2-40 that recognizes an epitope of podoplanin.
Peritumoral LVs were found in a large variety of tumors and
intratumoral LVs were reported in SCC, melanoma, urothelial
and gastric carcinoma. In patients with breast cancer, specific
identification of LVs increased detection of lymphovascular
invasion from 11 to 26%.
Q3: Du tumor associated-LVs preexist or are they newly
formed? Do they have proliferative potential? Proliferating
LECs were demonstrated by double immunostaining (MIB1/Ki67) in SCC, pancreatic endocrine carcinoma, and
malignant melanoma.
Q4: Does lymphatic microvascular density (LMVD) have a
real prognostic impact? Present data are controversial. LMVD
correlates with the risk for metastasis in SCC, melanoma,
endometrial, uterine cervix, pancreatic and gastric carcinoma.
No correlation was found in cases with hepatocellular and
ductal pancreatic carcinoma, and divergent results were
obtained for breast cancer.
Q5: What is the status of the main lymphangiogenic factors
(VEGF-C/D) and of their specific receptor (VEGFR3)? All
data strongly support the major role of the VEGF-C –
VEGFR3 axis in induction of lymphangiogenesis. VEGF-C
may be secreted by tumor cells themselves and/or by activated
macrophages. VEGF-C overexpression in tumors induces LV
hyperplasia.
Q6: What is the significance of LECs specific markers
expression by tumor cells? The best example is represented by
podoplanin expression in mesothelioma, angiosarcoma,
Kaposi sarcoma, seminoma, diffuse gastric carcinoma,
mastocytoma, and some tumors of the brain. Podoplanin
expression by tumor cells is usually associated with invasion
and progression and in some cases is useful in the differential
diagnosis. Could it be a potential therapeutic target? At
present, the answer is no, because it is also expressed by many
normal cells.
Abstracts of the 8th International Conference of Anticancer Research, 17-22 October 2008, Kos, Greece
Q7: Can lymphangiogenesis be inhibited? Preliminary
results in experimental models using anti-VEGF-C, antiVEGFR3, or rapamycin showed the reduction in the rate of
lymph node metastasis and a decrease in LMVD. Therefore,
attractive targets for cancer therapy could be both LVs and
some tumor cells.
555
COMPARATIVE THERAPEUTIC AND ADJUVANT
EFFECTS OF CURCUMIN AND TURMERIC
FORCE™ AGAINST HUMAN CANCER
C. Ramachandran, A. Resek, E. Escolan and S.J. Melnick
Department of Pathology, Miami Children’s Hospital, 3100
SW 62nd Avenue, Miami, FL 33155, USA
Curcumin, the yellow colored chemotherapeutic agent from
the Indian spice turmeric (Curcuma longa) has antitumor, antiinflammatory, immunostimulative and antioxidant effects. Of
the 214 apoptosis-associated genes studied in cancer cells, we
found that 104 genes were altered by curcumin. Despite its
anticancer effects, one of the major problems with the
therapeutic use of curcumin is its poor biological availability
and limited efficacy. Our studies have also shown that
curcumin and doxorubicin combination treatments have
synergistic cytotoxicity, with combination index values less
than 1 in human leukemia cell lines. These two compounds in
combination induced increased G2/M arrest and apoptosis in
tumor cells. While DOX treatment up-regulated NF-κB in
both CEM and CEM/VLB cell lines, curcumin inhibited the
NF-κB activity.
Turmeric Force™ (TF) is the supercritical CO2 and
hydroethanolic extract of turmeric rhizomes that is marketed
as a nutraceutical by New Chapter Inc., VT, USA. It contains
45% turmerones, 11% curcuminoids and other compounds
that may represent the full potency of turmeric, unlike
curcumin. TF is equally cytotoxic in tumor cell lines with IC50
values ranging from 6.7-12.6 μg/ml. MDR cells do not have
any resistance towards TF, whereas normal lymphocytes are
generally protected against this agent. TF inhibits NF-κB
activity and IL-8 expression leading to induction of apoptosis
in tumor cell lines. TF showed better cytotoxicity than
curcumin in two pancreatic carcinoma cell lines (Bx-PC3 and
Panc-1), with mean IC50 values of 1.00 and 1.22 μg/ml,
respectively. Gemcitabine, which is currently used as standard
chemotherapeutic agent against pancreatic cancer, has an IC50
value of 0.03 ug/ml, although the higher concentration (50
μg/ml) was unable to induce not more than 60% cell death.
When the cytotoxic data were analyzed by CalcuSyn software,
gemcitabine and TF combination showed strong synergism,
with combination index (CI) values of 0.216 and 0.236 in
BxPC3 and Panc-1 cell lines, respectively. Flow cytometric
analysis of DNA content using propidium iodide staining
showed that TF induced G2/M block and a sub G0/G1
population in a dose-dependent manner. Data on cell cycle
arrest and annexin–V staining confirmed the involvement of
apoptosis on TF cytotoxicity in tumor cells. Both gemcitabine
and TF down-regulated NF-κB activity and the combination
treatment showed a higher degree of inhibition than either
agent alone, although the NF-κB mRNA level remained the
same in all treatment groups. Our in vitro studies indicate that
TF can be used as a single agent or an adjuvant with
gemcitabine for the treatment of pancreatic carcinomas. Since
TF contains other molecules, especially turmerones, and
represents the full potency of raw turmeric, TF may be better
than curcumin and more biologically available.
556
PRE-CLINICAL STUDIES ON A NOVEL
IMMUNE-STIMULATING POLYSACCHARIDE
FROM TINOSPORA CORDIFOLIA
C. Ramachandran, P.K. Raveendran Nair, E. Escolan
and S.J. Melnick
Department of Pathology, Miami Children’s Hospital,
Miami, FL 33186, USA
Polysaccharides are known immune stimulants, of which betaglucans have received considerable attention. We have isolated
and characterized an α-D-glucan (RR1) that is comprised of
1-4 linked back bone and 1-6 linked branches with a
molecular mass of 550 kDa from the medicinal plant
Tinospora cordifolia. This novel polysaccharide is noncytotoxic and non-proliferating to normal lymphocytes as well
as tumor cell lines, even up to 1 mg/ml. RR1 activates subsets
of lymphocytes such as natural killer (NK) cells (331%), T(102%) and B-cells (30%) at 100 μg/ml. Immune activation
by RR1 in normal lymphocytes elicited the synthesis of
interleukin (IL)-1β, IL-6, IL-12p70, IL-12p40, IL-18, IFN-γ,
TNF-α and MCP-1, while it did not induce the production of
IL-2, IL-4, IL-10, INF-α or TNF-β. The cytokine profile
clearly demonstrates the Th1 pathway of T-helper cell
differentiation essential for cell-mediated immunity with a
self-regulatory mechanism for the control of its
overproduction. RR1 stimulation did not produce any
oxidative stress or inducible nitric oxide synthase (iNOS) in
the lymphocytes or any significant increase in nitric oxide
production. The water solubility, high molecular mass,
activation of lymphocytes especially NK cells, complement
activation, Th1 pathway-associated cytokine profile, together
with a low level of nitric oxide synthesis and absence of
oxidative stress confer immunoprotective potential on this
novel α-D-glucan. RR1 inhibits the phagocytosis of
unopsonized zymosan A bioparticles in a dose-dependent
manner in macrophages. Incubation of macrophages with antiCD11b mAb followed by RR1 failed to show any inhibitory
3457
ANTICANCER RESEARCH 28: 3157-3556 (2008)
effect on RR-1-induced TNF-α synthesis, confirming that
complement factor 3 (CR3) is not involved in the opsonic
binding and internalization of RR1 in macrophages. RR1
activated NF-κB in a time- and dose-dependent manner and
this modulation is associated with degradation of I-κB-α thus
facilitating the translocation of NF-κB into the nucleus. RR1induced NF-κB activity peaks at 8 h of RR1 stimulation while
I-κB alpha degradation occurred within 1 h of stimulation.
RR1-induced NF-κB activation occurred through TLR6
signaling as evidenced by the synthesis of IL-8 in TLR6transfected HEK293 cells. These results show that the novel
(1,4) α-D-glucan from T. cordifolia activates the immune
system through the activation of macrophages that occurs
through TLR6 signaling, NF-κB translocation and cytokine
production. Our preclinical studies indicate the potential use
of RR1 as an adjuvant against human malignancies which may
work through modulation of native immunity.
557
MDA-7/IL-24: A NOVEL GENE DRUG
FOR HUMAN CANCER THERAPY
Rajagopal Ramesh1, Manish Shanker1,
Tomohisa Yokoyama1, Cynthia D. Branch1,
Mingzhong Zheng2, Ailing W. Scott1, Jiankin Jin1,
Dora Bocangel,2 and Sunil Chada2
1Department
of Thoracic and Cardiovascular Surgery, M.D.
Anderson Cancer Center, Houston, Texas, 77030;
2Introgen Research Institute, Houston, Texas 77030, USA
The melanoma differentiation-associated gene-7 (mda-7), also
known as interleukin-24, is a unique tumorsuppressor/cytokine that belongs to the interleukin-10 (IL-10)
family. MDA-7/IL-24 encodes a protein of 206 amino acids
(a.a) in length and has limited homology (19%) with IL-10
protein, and appears to function antagonistically to IL-10.
MDA-7/IL-24 protein, unlike IL-10 or other cytokines,
undergoes extensive post-translational modifications and
exhibits phosphorylation, glycosylation and ubiquitination.
The modifications are frequently reported for tumor
suppressor proteins and regulate function and potency.
Glycosylated MDA-7/IL-24 is secreted and binds to two
heterodimeric receptors, termed type 1 and type 2 IL-20
receptors (IL-20R1/IL-20R2 or IL-22R1/IL-20R2). Detection
of endogenous MDA-7/IL-24 protein has not been reported to
date in tumor cell lines (>60 lines evaluated). However,
immune cells upon stimulation with PHA, LPS or IL-2 family
cytokines potently induce expression of MDA-7/IL-24 protein
or mRNA in T-cells and monocytes.
Studies have shown that mRNA but not the protein product
of mda-7 is detectable in human lung cancer and melanoma
cell lines. Additionally, an inverse correlation between MDA7 protein expression and cancer progression and patient
3458
survival has been reported in both lung cancer and melanoma,
suggesting MDA-7/IL-24 is a novel tumor suppressor protein.
Further evidence was provided in preclinical studies when
exogenous expression of MDA-7/IL-24 protein using
adenovirus and nanoparticles selectively killed human cancer
cells both in vitro and in vivo, with little to no effect on normal
cells. Additionally, MDA-7/IL-24, when combined with
chemotherapy, radiation therapy or biological therapies,
demonstrated enhanced killing of tumor cells. The molecular
mechanism of tumor cell killing is cell-type dependent and
culminates in apoptotic cell death. Furthermore, MDA-7/IL24 showed antiangiogenic activity both in vitro and in vivo
which was enhanced when combined with other
antiangiogenic agents, such as bevacizumab (avastin). All of
these features classify MDA-7/IL-24 as a tumor suppressor
protein-cytokine and a promising cancer drug.
Preclinical studies in our laboratory have focused on
investigating the role of secreted MDA-7/IL-24 protein on
anticancer activity, molecular mechanisms and the contribution
of receptor-mediated cell death. Analysis of receptor
expression by RT-PCR and Western blot in human cancer cells
identified receptor-negative (H1299, A549) and receptorpositive (e.g. MeWo, A375, 2008, AsPC3) cell lines.
Treatment of tumor cells with MDA-7/IL-24 protein showed
dose-dependent and time-dependent killing of receptorpositive, but not receptor-negative cells. Furthermore, blocking
studies using neutralizing antibodies to the receptors or MDA7/IL-24 protein resulted in abrogation of the killing effect.
Molecular analysis showed transient activation of STAT-3
upon ligand binding to its receptors. These results showed
MDA-7/IL-24 protein kills tumor cells in a receptor-dependent
manner. However, the requirement of type 1 or type 2 IL-20
receptors varied and was observed to be cell-type dependent.
Treatment of receptor-positive normal cells with MDA-7/IL24 protein showed no cell killing, suggesting intracellular
signaling following ligand-receptor binding is different in
normal and tumor cells. Similarly, treatment of receptorpositive human microvascular endothelial cells (HMVECs)
and human umbilical vein endothelial cells (HUVECs) with
the protein in vitro inhibited differentiation, tube-formation,
cell migration and invasion. The antiangiogenic activity was
mediated via the IL-22R1 subunit of type 2 IL-20R. In vivo,
MDA-7/IL-24 protein inhibited tumor angiogenesis, resulting
in delay of tumor growth. Thus, secreted MDA-7/IL-24
protein is selective for receptor-positive cells and kills only
tumor cells while sparing normal cells. The sensitivity of
receptor-positive tumor cells and resistance of receptorpositive-normal cells to MDA-7/IL-24 appears to be regulated
by differences in the intracellular signaling following
ligand–receptor interaction and warrants further investigation.
A Phase I clinical trial testing an adenovirus-based mda-7
(Ad-mda7; INGN241) gene drug for cancer therapy showed
patients tolerated the drug well with no significant toxicity,
Abstracts of the 8th International Conference of Anticancer Research, 17-22 October 2008, Kos, Greece
with clinical responses observed in few patients. In conclusion,
MDA-7/IL-24 with potent tumor killing activities is a novel
cancer drug that warrants further clinical testing.
558
VIRUS-LIKE PARTICLES (VLPS) CARRYING
TUMOUR-ASSOCIATED ANTIGENS AS TUMOURSPECIFIC VACCINES EXEMPLIFIED FOR HER2EXPRESSING TUMOURS
Torbjörn Ramqvist
Department of Oncology-Pathology, Karolinska Institutet,
Cancer Centrum Karolinska, SE-171 76 Stockholm, Sweden
Vaccines based on virus-like particles (VLPs) have recently
come into special focus by the use of VLP-based vaccines
against human papilloma viruses (HPV). However, this
application of VLPs is just one of many possible uses for
VLPs both in the field of tumour prevention and as vaccines
against different viruses. Another type of application is to
utilize VLPs as antigen carriers for different tumour antigens,
both of viral and non-viral origin for the use as tumour
vaccines in preventive or therapeutic settings. We have
constructed VLPs based on different types of murine polyoma
viruses carrying the extracellular and transmembrane domain
of human Her2/neu fused to the polyoma capsid protein VP2.
One single injection of these Her2PyVLPs efficiently
immunized against a Her2-carrying tumor in a transplantable
model and against the development of mammary cancer in
mice transgenic for mutated rat neu gene. We have further
improved the immune response by loading Her2PyVLPs into
dendritic cells (DCs) and by inoculating Her2PyVLPs together
with CpG. Inoculation of Her2 VLPs together with CpG
strengthens the in vivo response and confers protection against
Her2 carrying tumours also in a therapeutic setting.
559
A NEW ANTI-TUMOUR VACCINATION STRATEGY:
ADENOVIRAL VECTOR ENCODING INVARIANT
CHAIN LINKED TO THE TUMOUR
ASSOCIATED ANTIGEN
Maria Rathmann Sørensen, Peter Johannes Holst,
Jan Pravsgaard Christensen and Allan Randrup Thomsen
University of Copenhagen, Institute of International health,
Immunology, and Microbiology, The Panum Institute, Build.
22.5, Blegdamsvej 3c, 2200 Copenhagen N, Denmark
another successful approach, namely linkage of the relevant
antigen to the invariant chain (Ii). To test this vaccination
strategy we used a mouse model system, in which a an epitope
of the glycoprotein (GP33-41) of a virus (lymphocytic
choriomeningitis virus (LCMV)), works as a tumour
associated antigen (TAA). Mice (C57BL/6) vaccinated
prophylactic with adenovector expressing GP linked to Ii (AdIi-GP) were completely protected against growth of B16.F10
melanoma cells expressing GP33-41. Furthermore, a single
therapeutic vaccination 5 days after tumour challenge delayed
tumour growth by approximately 14 days compared to
irrelevant vaccination. This tumour control was as good as a
prophylactic or therapeutic “vaccination” with infectious virus.
Therapeutic vaccination with the linked construct was
moreover significantly better than vaccination with an
adenovector expressing GP only (Ad-GP). The improved
therapeutic vaccination efficiency of the linked vaccine
appeared to be due to an increased TAA specific CD8 T cell
response. Furthermore, vaccination experiments using mice
deficient in expression of IFNγ, perforin, or both, indicated
that the improved vaccination efficiency is dependent on IFNγ,
which reduces cell cycle entry of the melanoma cells. In
contrast,
perforin
was
redundant
in
otherwise
immunocompetent mice, but not in IFNγ deficient mice.
Tumour regression was followed by regained tumour growth,
and this correlated with a contraction of the tumour specific
CD8 T cells. To delay this contraction, and thus to further
improve the therapeutic efficiency of the vaccine, we combined
the vaccination with agonistic anti-CD40 antibodies to provide
additional DC activation, and with anti-CTLA-4 antibodies to
block CTLA-4 interaction with ligands on the APCs. Together
with an additional Ad-Ii-GP vaccine booster, these antibody
treatments improved the vaccination efficiency significantly, and
about one third of the vaccinated mice became long-term nonprogressors. From this we conclude that combination of a strong
CD8 T cell inducing anti-tumour vaccine and antibody therapy
inhibiting key immunosuppressive circuits might be a way to
improve current protocols for immunotherapy of cancer.
560
MICRORNA MIR-16 LINKED TO THE
DEVELOPMENT AND PROGRESSION OF B-CELL
MALIGNANCIES IN THE NZB MURINE MODEL OF
CHRONIC LYMPHOCYTIC LEUKEMIA
Erica Salerno1, Brian Scaglione1, Frederick Coffman1,
Helen Fernandes1, Gerald Marti2 and Elizabeth Raveche1
1University
Antigen-specific immunotherapy is an attractive strategy for
cancer control. In the context of antiviral vaccines, adenoviral
constructs have emerged as the most favourable means for
immunization. For this reason, we have selected an innovative
approach that combines the use of this vector system with
of Medicine and Dentistry of New Jersey –
Newark, NJ 07103;
2NIH, Bethesda, MD 20812, USA
The NZB mouse serves as a de novo model for CLL and in
vivo imaging has been performed by CT and MRI to observe
3459
ANTICANCER RESEARCH 28: 3157-3556 (2008)
splenomegaly and lymphadenopathy. Alterations in the 13q14
genomic region containing microRNAs miR-15a and miR-161 have been found in human CLL, resulting in the deletion or
down-regulation of these miRNAs in 60% of patients. We
found the development of CLL in NZB backcrosses was
linked to a point mutation in the 3’ flanking region of mir-161, similar to the one described in human CLL. In ex vivo NZB
lymphoid tissue, as well as in an NZB-derived in vitro
malignant B cell-line (LNC), the levels of mature miR-16 are
decreased by half relative to levels in non-NZB control strain
spleens or lymphoid cell lines. Lower expression of miR-16
results in increased expression of miR-16 target genes, such
as CCND1 (cyclin D1), contributing to uncontrolled tumor
growth. When NZB malignant B-cells are separated by cell
cycle phase (by elutriation), and then transfected with
exogenous miR-16, lower proliferation is observed and an
accumulation in G0/G1 phase with the most sensitive phase in
the S/G2 fraction. In addition, when miR-16 was added back
to LNC, the cyclin D1 levels decreased, returning to the
normal range. Spleens and lymph nodes from NZB and
control mice were sorted by FACS into conventional B220
bright B-cells or malignant B220 null B-1 cells. Both sources
of NZB B-cells had lower miR-16 expression relative to
C57Bl/6 purified B cells. Interestingly, among NZB B cells,
the malignant B-cells had higher expression of miR-16 than
did the non-malignant B-cells (B220 bright). In addition,
spleens, peritoneal cells and lymph nodes from old NZB mice
exhibited a dramatic increase in the ‘side population’ present
relative to young NZB and control mice, suggesting an
increase in cancer stem cells as NZB mice age. Our data
further support that the miRNA, miR-16, has an important role
in the development and progression of B-cell malignancies.
The presence of the increased ‘side population’, reduced miR16 levels, and the miR-16-1 3’ flanking region mutation in
NZB present clues to CLL development.
561
AGE-ASSOCIATED INCREASE IN CANCER STEM
CELLS DETECTED AS THE SIDE POPULATION IN
THE NZB MODEL OF CLL
Elizabeth Raveche1, Sivasubramanian Baskar2,
Erica Salerno1, Brian Scaglione1, Christoph Rader2,
Steven Bauer, Rameet Hundle1 and Gerald Marti2
1University
of Medicine and Dentistry of New Jersey –
Newark, NJ 07103;
2NIH, Bethesda, MD 20812, USA
As NZB mice age they develop a malignant clonal expansion
of B-cells and serve as a de novo model of B-cell chronic
lymphocytic leukemia (CLL). Analysis of the spleens from
old NZB mice demonstrated the presence of a unique
population of cells that are able to efflux the DNA-binding
3460
dye, Hoechst 33342, and are referred to as the side
population (SP). The SP was lost in the presence of
verapamil, which prevents efflux of Hoechst and defines the
SP. In addition, most of these SP cells expressed cell surface
markers of stem cell progenitors such as c-Kit and/or Sca-1.
The percentage and absolute number of SP cells in spleen,
lymph node, peritoneal cavity, blood and bone marrow of old
(12-month) NZB was increased when compared to young (1to 3-month) NZB. By contrast, old DBA/2 and C57Bl/6
control mice, which do not develop leukemia, had low levels
of SP cells in all the organs tested. The increase in SP cells
in old NZB mice correlate with the development of CLL and
the SP cells may be cancer stem cells which are resistant to
apoptosis.
To further study the SP, the spleen cells from old NZB
mice were sorted into non-SP and SP cells and subjected to
microRNA(miR) analysis by qRT-PCR. Previously, we had
shown the development of CLL in NZB backcrosses was
linked to a point mutation in the 3’ flanking region of mir16-1. A similar mutation in the 13q14 region of human CLL
containing the mir-16-1 has been described by others. In the
present studies, we found that the sorted NZB SP cells had
lower expression of miR-16 when compared to the non-SP
cells. Decreased miR-16 in the NZB SP population resulted
in increased expression of miR-16 target genes in the NZB
SP cells, many of which could contribute to uncontrolled
tumor growth and failure to undergo apoptosis. Our data
further supports that miR-16 has an important role in the
development and progression of B-cell malignancies. The
presence of the increased ‘side population’ in old NZB tissue
sources suggest that these cells may be a target for the
elucidation of new strategies to control CLL growth.
562
HORMONAL CHANGES AS POTENTIAL
BIOMARKERS OF PROGNOSIS IN HEAD AND
NECK SQUAMOUS CELL CANCER PATIENTS
É. Remenár, B. Vincze, I. Számel, B. Budai,
A. Ladányi, J. Timár and M. Kásler
National Institute of Oncology, Budapest, Hungary
Background: Head and neck squamous cell cancer (SCCHN)
is characterized by rapid progression and poor prognosis. The
most reliable prognostic factors are tumor (T) and node (N)
stage. There is some evidence that circulating hormone levels
might predict prognosis in SCCHN. The aim of this study
was to assess hormone levels in 289 male patients and
evaluate them in association with the clinical parameters.
Methods: Age, primary tumor site, tumor stage, histologic
grade, and serum levels of estradiol (E2), progesterone
(PROG), testosterone (TE), dehydroepiandrosterone (DHEA),
dehydroepiandrosterone sulfate (DHAS), steroid hormone
Abstracts of the 8th International Conference of Anticancer Research, 17-22 October 2008, Kos, Greece
binding globulin (SHBG), follicle-stimulating hormone
(FSH), luteinizing hormone (LH) and prolactin (PROL) of
289 patients operated for cancer of the oral cavity, oro-, and
hypopharynx and the larynx in one cancer center were
recorded. The median follow-up was 37 months (19-71).
Results: Age <46 years vs. older (p=0.0055), stage I-II vs. III
(p=0.014), and stage III vs. IV (p=0.0004), N0 vs. N+ stage
(p<0.0001) and Gr.I-II vs. Gr.III histology grade (p=0.03)
were of prognostic importance. Of the hormones studied,
lower than normal levels of TE (p=0.02), TE/SHBG
(p=0.0031) and DHAS (p=0.04), as well as high levels of
FSH (p=0.022), LH (p=0.0083) and PROL (p=0.0043)
predicted poor prognosis. In multivariate analysis of all cases,
T stage, N stage and grade proved to be independent
prognostic factors, PROL level had borderline significance
(p=0.07). In the N0 stage subgroup PROL (p=0.0013), and
in the N+ stage subgroup histology grade (p=0.0004) and TE
(p=0.0053) emerged as independent prognostic factors by
multivariate analysis. Conclusion: Our results suggest that
abnormal levels of some circulating hormones in head and
neck cancer predicts worse survival, therefore hormonal
imbalance cannot be excluded to have a role in the course
and/or development of HNSCC.
563
A NEW CANCER RESISTANT
MOUSE MODEL (SR/CR)
Klaus Rieneck
University Hospital of Copenhagen, Denmark
The SR/CR mouse model of cancer resistance was
fortuitously discovered by Cui and co-workers (2003). This
mouse strain has been shown to be resistant to various
tumour cell lines, which cause cancer in other mouse strains
into which they have been administered. The mouse model
constitutes an opportunity to attain insight into the interplay
between cancer and the innate immune system. Through a
more detailed immunological and genetic examination of this
mouse model, novel anti-tumour immunological mechanisms
may be unravelled.
What makes the SR/CR mouse unique in cancer research is
its ability to specifically target and kill a number of different
injected cancer cells, and thereby prevent the cancer
development without harming normal host cells. The tumour
resistance of the SR/CR mouse has been shown to be mediated
by three innate immune cell populations, i.e. neutrophils, NK
cells and macrophages. The SR/CR phenotype is transferable
to wild-type mice by adoptive transfer and established tumours
in wild-type mice will regress following transfer of these three
cell types from SR/CR mice.
Furthermore the lifespan of the SR/CR mouse is normal
without any signs of autoimmunity. The genetic basis of this
phenotype is unknown but the phenotype is heritable as a
mendelian trait. It is intriguing that older SR/CR mice, which
are injected with cancer cells for the first time, will develop
cancer and will regress completely after two-three weeks.
In summary the phenotype of the SR/CR mouse points to
the importance of innate cellular immunity as a mediator of
one or more significant anti-cancer mechanisms.
564
BREAST CANCER AND CIRCULATING
TUMOR CELLS
M. Tartary1 and M. Rigaud2
1Laboratoire
2Faculté
Astralab, Limoges;
de Médecine de Limoges, France
Death of most patients is caused by metastatic spread of
cancer cells from the primary tumor to distant organ. Some
data indicated that approximatively 106 tumor cells per gram
of tumor tissue per day shed into the blood stream (1).
Tumor cell shedding is an early event in tumorogenesis (2).
A great number of cells move to the circulation but only a
minority of them can form metastasis. One of 40 cells give rise
to micrometastases and 0.01% proliferate into.
Macrometastasis (3). In the blood stream a large fraction of
circulating tumor cells (CTCs) die quickly, anoïkis being one of
the major factors. To move to the circulation, tumor cells
undergo the phenotype switch, "Epithelial to mesenchymal
transition" (EMT) and then acquire mobile propensities (4).
These CTCs are out of cell cycle and do not proliferate.
Unrestrained CTCs’ proliferation give rise to metastasis via the
phenotypical reversion, "mesenchymal epithelial transition" and
angiogenesis.
Although metastasis formation from CTCs is a highly
inefficient process, as breast tumor size increases, their
number in the blood increases and a fraction of them can
evolve to a full-fledged metastasis (5). From 25,000 CTCs in
the whole blood, 625 are candidate to give rise to a
micrometastasis and at least 2 of them will be the origin of a
metastasis. This could explain that the presence of CTCs in
primary and metastatic breast cancer is associated with poor
prognosis (6).
CTCs can be considered as new markers in oncology, but
before introduction of their detection into clinical use, much
work remains to be done. A major requirement is the
standardization of detection systems (the different methods
will be discussed) and the establishment of an agreement on
threshold values. Another crucial step is the definition of
optimal multi-markers assays, as no single ideal marker
exists for CTCs detection. The choice of markers should take
into consideration the cancer stem cell markers. In the near
future, the establishment of the clinical usefulness of CTCs
detection in oncology will be a challenge.
3461
ANTICANCER RESEARCH 28: 3157-3556 (2008)
1 Butler P and Gullino PM: Quantitation of cell shedding
into efferent blood of mammary adenocarcinoma. Cancer
Res 35: 512-516, 1975.
2 Pantel K, Cote RJ and Fodstad O: Detection and clinical
importance of micrometastatic disease. J Natl Cancer Inst
91: 1113-1124, 1999.
3 Luzzi KJ, Mac Donald IC, Schmidt EE et al: Multistep
nature of metastatic inefficiency: Dormancy of solitary
cells after successful extravasation and limited survival of
early micrometastases. Am J Pathol 153: 865-873, 1998.
4 Morel AP, Lièvre M,Thomas C et al: Generation of breast
cancer stem cells through epithelial-mesenchymal
transition. Plos One August 3, e 2888, 2008.
5 Chambers AF: Dormancy and growth of tumor cells in
ectopic sites. Am Assoc Cancer Res Edu Book, 120-125,
April, 2006.
6 Xenidis N, Perrak M, Kafousi M et al: Predictive and
pronostic value of peripheral blood Cytokeratin-19mRNApositive cells detected by real-time polymerase chain
reaction in node negative breast cancer patients. J Clin
Oncol 24(23): 3756-3762, 2006.
565
MOLECULAR IMAGING, RADIATION
THERAPY, AND THE MARRIAGE
OF CADMUS AND HARMONY
Arturo Chiti1, Marta Scorsetti2, Marcello Rodari1,
Mario Bignardi2, Pierina Navarria2 and Gianluigi Ciocia1
1Nuclear Medicine Division and 2Radiation Oncology
Division, Istituto Clinico Humanitas, Milano, Italy
Positron Emission Tomography (PET) has been demonstrated
to be of great value in the management of cancer patients. In
recent years its use has been extended to the optimization
radiation therapy treatment planning, with the aim of
improving patient outcome. The radiopharmaceutical which is
most often employed is the glucose analogue 18F-fluorodeoxy-glucose (FDG). Several studies reported the usefulness
of FDG-PET for RT target volume determination, particularly
in non-small cell lung cancer (NSCLC). The use of FDG PET
demonstrated to change the RT planning also in head and neck
cancers, lymphoma and esophageal cancer. These applications
are possible thanks to the use of integrated PET/CT images,
acquired according to radiotherapy treatment position. Besides
FDG other radiopharmaceutical can be used, like 11C-choline
for prostate cancer and 11C-methionine for brain tumors. Some
issues are of particular importance in order to have an accurate
treatment planning. In particular, the optimization of images
within the RT planning system and the rules implemented for
contouring tumor volumes are the most critical issues.
The use of FDG PET in RT planning for some different
types of cancer is now implemented in many centers in
3462
Europe and US, using different protocols for imaging and
contouring. The advent of PET-CT hybrid imaging not only
revolutionized the medical imaging, but also gave rise to a
new and accurate method to increase accuracy of RT
planning system. Although available data demonstrated the
use of PET-CT in RT planning is able to modify the CT
based RT planning in a high percentage of cases, no data are
yet available to demonstrate that this change has an impact
on patients outcome. In Humanitas we are currently using
PET-CT as an aid to RT planning in NSCLC and brain
tumors with promising results. The presentation will show
the general needs for an effective use of PET in radiation
planning and our experience in the field.
566A
ALTERED PROPERTIES OF PHOSPHORYLATED
OR NITROSYLATED THYMIDYLATE SYNTHASE
Tomasz Fraczyk1, Tomasz Ruman2, Dagmara Rut2,
Elzbieta Dabrowska-Mas2, Joanna Ciesla1,
Zbigniew Zielinski1, Katarzyna Sieczka1,
Jacek Sikora3, Elzbieta Walajtys-Rode2,
David Shugar3 and Wojciech Rode1,2
1Nencki
Institute of Experimental Biology, Polish Academy
of Sciences, Warszawa;
2Rzeszow University of Technology, Faculty of Chemistry,
Rzeszow;
3Institute of Biochemistry and Biophysics, Polish Academy
of Sciences, Warszawa, Poland
Thymidylate synthase (TS; EC 2.1.1.45), a major target in
cancer chemotherapy, catalyzes the N5,10-methylenetetrahydrofolate (meTHF)-assisted C(5)-methylation of 2’deoxyuridine-5’-monophosphate (dUMP), leading to
formation of 2’-deoxythymidine-5’-monophosphate.
Possible phosphorylation of TS in cultured rat cells,
previously reported (Samsonoff et al: J Biol Chem 272: 1328113285, 1997), prompted us to examine this in more detail. TS
preparations from various sources, all highly purified in the
presence of phosphatase inhibitors, included L1210 parental
and FdUrd-resistant forms, as well as mouse, rat, human and
Trichinella spiralis recombinant enzymes. They were analyzed,
following SDS-PAGE, with the Pro-Q® Diamond
Phosphoprotein Gel Stain, and all were found to include a low
proportion of phosphorylated forms. However, MS analysis of
the SDS-PAGE bands did not reveal any phosphorylated amino
acid residues. By contrast, MS analysis of IEF fractions of TS
preparations from parental and FdUrd-resistant mouse
leukemia L1210 cells, whose differing sensitivity to
inactivation by FdUMP and its analogues was previously found
not due to mutations (Ciesla et al: Acta Biochim Pol 53: 189198, 2006), demonstrated phosphorylation of Ser10 and Ser16
in the resistant, but not the parental, enzyme.
Abstracts of the 8th International Conference of Anticancer Research, 17-22 October 2008, Kos, Greece
Each of the four recombinant TS preparations, expressed
in bacterial cells, was separated into phosphorylated and
non-phosphorylated fractions, using metal oxide/hydroxide
affinity chromatography on Al(OH)3 beads, yielding
phosphorylated fractions corresponding to ≈1% of the total.
Each phosphorylated form exhibited a 3- to 4-fold lower
Vmaxapp, but unaltered Kmapp with either substrate or cofactor
relative to the non-phosphorylated form, and ability to
repress translation (catalyzed by a rabbit reticulocyte
preparation) of its own (as well as luciferase) mRNA.
Surprisingly, MS analyses did not reveal the presence of
phosphorylated amino acid residues in any of the fractions
investigated. In striking contrast, 31P NMR spectroscopy
clearly demonstrated the presence of phosphorylated residues
in the phosphorylated enzyme fractions, and their absence in
non-phosphorylated. Further analyses of the 31P NMR
spectra (including their time-dependent changes following
acidification), and comparison with those of synthetic
phosphoramide derivatives of basic amino acids (Lys, Arg
and His), and commercially available phospho-serine,
phospho-threonine and phospho-tyrosine, revealed the
presence of phosphorus in a phosphoramide (acid-labile)
bond, pointing to modification of histidine residue(s).
Biological nitration of protein tyrosine residues, which
may lead to modulation of protein function, is associated
with many diseases, including cancer, and is correlated with
intensified NO biosynthesis. Human, mouse and
Caenorhabditis elegans recombinant TS preparations, each
incubated in vitro in the presence of NaHCO3, NaNO2 and
H2O2, underwent nitration of tyrosine residues, resulting in
a distinctly diminished rate of the enzyme-catalyzed reaction.
The Vmaxapp value was 2-fold lower when 1 tyrosine residue
per monomer was nirated (with human or C. elegans TS) or
2 tyrosine residues per monomer (with mouse TS). No
distinct effect on enzyme interactions with substrate
(dUMP), cofactor (meTHF) or inhibitor (5-fluoro-dUMP)
was apparent.
Supported by the Ministry of Science and Higher Education
(Grant number N401 0612 33).
566B
DIHYDROFOLATE REDUCTASE EXPRESSION IN
METHOTREXATE-TREATED HUMAN
ADENOCARCINOMA CELLS
Magdalena Dąbrowska and Wojciech Rode
Nencki Institute of Experimental Biology, Polish Academy
of Sciences, Warszawa, Poland
Dihydrofolate reductase (DHFR) plays an important role in
de novo nucleotide biosynthesis, and thus DNA replication,
its expression growing at the entrance to the S phase of the
cell cycle. Inhibition of DHFR results in cessation of
thymidylate and purine synthesis, ultimately evoking a
cytostatic effect (Schornagel and McVie: Cancer Treatment
Rev 10: 53-75, 1983). The classic antifolate methotrexate
(MTX), a strong DHFR inhibitor, has been used in cancer
chemotherapy for nearly 60 years, its chemotherapeutic
effectiveness being hindered by resistance to the drug
underlain by various mechanisms. DHFR translational autoregulation is assumed to constitute one of the main
modalities of MTX resistance (Schmitz et al: Cancer Met
Rev 20: 33-41, 2001). Treatment of human adenocarcinoma
C85 cells with 1 μM MTX was previously demonstrated to
cause growth arrest in G1 phase of the cell cycle (Dąbrowska
et al: Eur J Pharmacol 555: 93-99, 2007). The present study
was aimed at regulation of DHFR expression in the context
of MTX treatment outcome.
Patterns of DHFR expression, determined by real-time
PCR and Western blot techniques, and specific activity, were
followed in C85 cells treated with 1 μM MTX for 48 h. The
influence of MTX on putative DHFR translation autoregulation was monitored using a reporter system where 89nt long DHFR region (designated L-region), identified
elsewhere as sufficient to compete with full length DHFR
mRNA for binding to DHFR protein (Ercikan Abali et al:
Biochemistry 36: 12317-12322, 1997), was placed at the 5’
end of the gene coding the reporter protein, EGFP. Two
sublines were constructed by stable transfection of C85 cells
with either pEGFP-N1 (Clontech Takara) vector (pEGFPC85 subline) or its derivative, containing the L-region at the
5’ end of EGFP (L-pEGFP-C85 subline). Fluorescence
intensity was studied, applying flow cytometry and
fluorescence microscopy.
During 48 h exposure of C85 parental cells to 1 μM MTX,
and the following 96 h growth in the regular medium, DHFR
mRNA level remained unchanged. The enzyme protein level
showed a slight (1.5-fold) increase, considered negligible and
pointing to a general change in translation attributed to the
outcome of MTX treatment, rather than specific influence of
MTX on DHFR translation, as similar slight increase (1.2fold) was also noted for EGFP level in pEGFP-C85 cells
treated with the same dose of MTX. Enzyme specific activity
dropped 2.2-fold in cells exposed to 1 μM MTX for 48 h with
no further drop apparent following subsequent 96 h growth in
regular medium. Compared to pEGFP-C85 cells, L-pEGFPC85 cells demonstrated a considerable decrease in EGFP
expression, assayed by fluorescence intensity studies, when
both sublines were grown in the regular medium. However
upon exposure to 1 μM MTX for 48 h, an 8-fold increase in
EGFP fluorescence was observed for L-pEGFP-C85 cells,
similar to a 5-fold increase found for pEGFP-C85 cells.
Conclusion: Analysis of DHFR expression in human
adenocarcinoma C85 cells exposed to 1 μM MTX for 48 h
demonstrated that the resulting G1 growth arrest is
associated with a negligible increase in DHFR protein level
3463
ANTICANCER RESEARCH 28: 3157-3556 (2008)
and ~2-fold decrease in DHFR specific activity, the latter
apparently resulting from MTX tightly binding to DHFR
molecule that persists in crude extract preparation. A distinct
(8-fold) increase of EGFP fluorescence intensity in MTXtreated L-pEGFP-C85 cells confirmed the previously
postulated suitability of employing EGFP as a reporter for
imaging cellular response to MTX treatment, identified as
G1 growth arrest. The present study demonstrates that the
G1 phase cell cycle arrest of C85 cells, caused by MTX,
does not involve any specific DHFR expression regulation.
567
AN INTEGRATED APPROACH
TO CANCER PROTEOMICS
Karin D. Rodland, Cheryl Baird, David Camp,
Richard D. Smith and Richard Zangar
Pacific Northwest National Laboratory, Richland, WA
99352, USA
An exciting new trend in cancer research is the use of massspectrometry based proteomics to discover new protein-based
biomarkers for early diagnosis, therapeutic response, and
prognosis that promise to revolutionize management of
patients with cancer. However, biomarker discovery efforts
are impeded by analytical limitations in sensitivity and
throughput of proteomic methods to define the complexity
of the human plasma or tissue proteome. The most effective
program to discover protein biomarkers requires team
science, an integrated informatics platform, identification and
quantitation of candidate biomarkers in disease tissue, and
standardized procedures for analyzing candidate biomarkers
in bodily fluids. We have developed a tiered approach to
biomarker discovery that leverages unique instrumentation,
including highly powerful mass spectrometers available at
PNNL. Biomarker validation is achieved through custom
designed, high-throughput, quantitative sandwich ELISA
microarray analysis. Antibody pairs can be readily generated
through the use of a novel yeast surface display system for
recombinant antibodies developed at PNNL. These tools are
currently being applied to problems in breast, ovarian,
prostate and liver cancers, as well as other chronic diseases.
568
PROTEOMICS STRATEGIES FOR MARKER
DISCOVERY IN LUNG CANCER
M. Roeßler1, M.-L. Hagmann1, I. Lindner1, J. Klöckner1,
T. Muley2, F. Herth2, P. Schnabel3, J. Karl1, B. Risse1,
M. Tacke1, G. Pestlin1 and P. Heiss1
1Roche
Professional Diagnostics, Roche Diagnostics
GmbH, Penzberg;
2Thoraxklinik Heidelberg, Heidelberg;
3464
3Patholog.
Institut, University Heidelberg, Heidelberg,
Germany
Lung cancer is one of the most common malignancies in the
Western population and 30% of all cancer deaths are caused
by lung cancer, making it the number one killer among all
cancer-related diseases. Today, less than 35% of lung cancer
cases are diagnosed at an early stage and despite many recent
achievements in imaging technologies, there is no
appropriate screening tool available. To fill this diagnostic
gap, accurate, non-invasive diagnostic markers in body fluids
indicating early-stage disease would fulfil an urgent medical
need. We are actively seeking such markers combining
several proteomics technologies.
Despite many recent technological advances, especially in
the field of mass spectrometry (MS), none of the currently
available proteomics technologies offers the possibility to
identify a comprehensive proteome of a given sample.
Instead, it is necessary to combine several prefractionation
methods with different MS technologies. Here, we present
our approach to identify new potential marker candidates for
lung cancer from tissue. This approach includes conventional
two-dimensional gel electrophoresis (2-DE) and
identification of proteins by MALDI-MS as well as liquid
chromatography coupled to ESIMS. Additionally, samples
were prefractionated by affinity chromatography and on
preparative 1-DE gels.
After marker discovery programs applying proteomics
technologies, it is of utmost importance to validate the
findings with orthogonal methods. We apply immunoblot
analyses, as well as immunohistochemistry to scrutinize the
value of the identified marker candidates. Using these
technologies it is possible to assess the potential of the
identified marker candidates in a larger panel of lung cancer
tissue samples as well as in other malignancies.
For the most promising candidates, highly sensitive
immunoassays were developed to assess their presence in
blood. Subsequently, we analyzed panels of wellcharacterized clinical blood samples of lung cancer patients
and healthy controls. Data on the diagnostic performance of
selected marker candidates will be presented.
569
ASSOCIATION BETWEEN INFLAMMATORY
MEDIATORS, D-DIMER LEVELS AND VASCULAR
ENDOTHELIAL GROWTH FACTOR (VEGF) IN
PATIENTS WITH ADENOCARCINOMA
M. Roselli1, V. Formica1, F. Martini2, I. Portarena1,
S. Mariotti1, G. Del Monte1, F. La Farina2, I. Lucci2,
S. D’Angelo2, P. Ferroni2 and F. Guadagni2
1Medical
Oncology, Department Internal Medicine,
University of Rome “Tor Vergata”, Rome;
Abstracts of the 8th International Conference of Anticancer Research, 17-22 October 2008, Kos, Greece
2Laboratory
of Thrombosis and Haemostasis, Department
of Laboratory Medicine and Advanced Biotechnologies,
IRCCS San Raffaele, Rome, Italy
Cancer cells release procoagulant activities responsible for
thrombin generation and platelet activation. Platelet
activation by thrombin, in turn, causes release of vascular
endothelial growth factor (VEGF) a potent angiogenic factor
essential for tumor growth and metastasis. It is also known
that tumor cells and/or tumor-associated leukocytes may
produce inflammatory cytokines, such as IL-6 and TNFalpha. The release of inflammatory cytokines is also involved
in activation of the fibrinolytic/ coagulation system. Based
on these observations, a model has been proposed in which
disturbance of the anti-inflammatory, anti-thrombotic state
of endothelium by tumor cells would be responsible for
platelet activation and release of angiogenesis-related factors.
Thus, aim of this study was to investigate whether a
correlation exists between inflammation, coagulation
activation and VEGF release in patients with
adenocarcinoma. Plasma VEGF, TNF-alpha, IL-6 and Ddimer levels were analyzed in 68 patients with lung (n=32,
63±8 years), colon (n=20, 62±17 years) or breast (n=16,
54±12 years) adenocarcinoma treated at the “Tor Vergata”
Clinical Center. Thirty-four unrelated healthy controls (65±8
years) recruited from the same geographical area as the
patients, served as controls. Written informed consent was
obtained from each subject. The results obtained showed that
median VEGF (30.4 vs. 24.3 pg/ml; p=0.054), TNF (2.5 vs.
0.3 pg/ml, p<0.0001), IL-6 (3.2 vs. 1.0 pg/ml, p<0.0001) and
D-dimer levels (0.93 vs. 0.34 mg/ml, p<0.0001) were higher
in patients than controls. Correlation analysis showed that
plasma VEGF correlated with D-dimer (rho=0.24, p<0.05),
TNF (rho=0.31, p<0.01) and IL-6 (rho=0.40, p<0.001) levels
in adenocarcinoma patients. D-dimer, in turn, strongly
correlated with both TNF (rho=0.57, p<0.001) and IL-6
(rho=0.60, p=0.03) levels. Positive VEGF levels (>41 pg/ml)
were found in 63% of lung compared to 31% of breast, 20%
of colon adenocarcinoma and 4% of controls (p<0.0001).
Moreover, positive VEGF levels were associated to node
involvement (60% vs. 30%, p=0.02) and positive D-dimer
(67% vs. 25%, p<0.001), TNF (80% vs. 25%, p<0.0001) and
IL-6 (78% vs. 27%, p<0.01) levels. Thus, to further analyze
the relationship between VEGF and clinical and laboratory
variables of adenocarcinoma patients, multiple regression
analyses including age, gender, histological diagnosis, tumor
size, node involvement, presence of distant metastasis, Ddimer, TNF and IL-6 levels were performed. Final models
by stepwise analysis showed that TNF levels were
independently associated to VEGF (beta=0.41, p=0.003) and
D-dimer levels (beta=0.44, p<0.001).
The significant association found between plasma VEGF,
TNF-alpha and D-dimer levels, suggests that the host
inflammatory response to cancer cells, and/or their released
products, as well as tumor-derived cytokines, could be
responsible for an activation of the fibrinolytic/coagulation
pathway and subsequent platelet VEGF release in patients
with adenocarcinoma, especially of the lung.
Partially supported by Grant RFPS-2006-7-342220 by the
Italian Ministry of Health.
570
ROLE OF PHARMACEUTICAL EXCIPIENTS IN
THE TAMOXIFENE ACTIVITY ON MCF-7 AND
VERO CELL CULTURES
Tiziana Rossi1, Valentina Iannuccelli2, Gilberto Coppi2,
Elisa Bruni1 and Giosué Baggio1
1Department
of Biomedical Sciences, Section of
Pharmacology, and
2Department of Pharmaceutical Sciences, University of
Modena and Reggio Emilia, Modena, Italy
Pharmaceutical excipients are substances used in the
commercial formulation of a drug to improve the efficacy of
the active agent. Oral administration of the non-steroidal
anti-estrogen tamoxifen is the treatment of choice for
metastatic estrogen receptor-positive breast cancer.
Tamoxifen shows a fairly good oral bioavailability combined
with large inter-individual variations and few side-effects.
With the aim of improving tamoxifen bioavailability and
achieving the active dosage at a tumour site for a long
period, we studied the in vitro activity of a tamoxifen
formulation in calcium alginate/chitosan microparticles.
Moreover, the influence of alginate mannuronic/glucuronic
ratio affecting a probable interaction with the cationic drug
was evaluated by comparing two types of sodium alginate
(from Kelco, France, with 62% mannuronic acid and 38%
guluronic acid; and from Fluka, Switzerland, with 30%
mannuronic acid and 70% guluronic acid) for the
microparticle preparation. MCF-7 and Vero cells were
cultured in Eagle’s Minimum Essential Medium and treated
with growing concentrations (from 10 to 100 μM/ml
medium) of tamoxifen alone, microparticles loaded with
tamoxifen, and microparticles alone as control. MTT test was
performed on both the cultures.
The results observed after 24, 48 and 72 hours showed
that both types of sodium alginate improved cell growth in
a dose-dependent way. Tamoxifen LD50 values were similar
(38 μM/ml) in Vero and MCF-7 cells only after a 24 h
incubation time. The values we observed after 48 and 72 h
showed a higher toxicity on Vero cells (LD50=10 μM/ml)
with respect to MCF-7 cells (25 μM/ml). Interesting results
came from the comparison between the two types of
microparticles loaded with tamoxifen. Microparticles
released the drug after 48 hours and LD50 were significantly
3465
ANTICANCER RESEARCH 28: 3157-3556 (2008)
changed both with respect to the drug alone and, in
particular, to the type of alginate. When Kelco alginate was
used, LD50 was enhanced: 25 μM/ml on Vero cultures and
48 μM/ml on MCF-7 cells; when Fluka alginate was used,
LD50 was reduced: 25 μM/ml on Vero cells and 10 μM/ml
on MCF-7 cells, thus showing a stronger activity of the
formulation on both cells, but with a lower cytotoxicity on
Vero cells.
In conclusion these preliminary results confirm that the
microparticle formulation of tamoxifen can be useful in
improving its bioavailability but we outline that the
therapeutic dosages must be revised according to the
excipients employed in the formulation since their link to the
active compound can dramatically change both drug activity
and toxicity.
571
MORPHOLOGICAL AND MOLECULAR EVENTS
AT THE ADVANCING EDGE OF COLORECTAL
CARCINOMAS IN HUMANS
C.A. Rubio
Gastrointestinal and Liver Pathology Research Laboratory,
Department of Pathology, Karolinska Institute and
University Hospital, Stockholm, Sweden
The mechanisms whereby colorectal adenocarcinomas
(CRC) invade the extracellular matrix (ECM) remain elusive.
In a series of studies, we found at the growing edge of CRC,
dilated neoplastic glands, some with a layer of flat tumor
cells, and some lacking one or more groups of consecutively
lining tumor cells (called glandular pores, GPs). Through the
GPs, the retained glandular material was siphoned off
directly into the juxtaposed ECM. The substance secreted by
the tumor cells, rich in proteolytic enzymes, disrupted the
paratumoral anatomy of the ECM. To remodel the defective
glands, the malignant cells, proliferating from the tip of the
free borders of the pores, invade the enzymatically disrupted
matrix to achieve glandular continuity. We reported a similar
sequence of events in colonic carcinomas in rats and in CRC
in baboons. The sealing of the GPs permits the intraglandular
accumulation of new proteolytic material, a mechanism that
replicates a new wave of host invasion at the invading front,
thus ensuring a stepwise but everlasting tumor progression
in untreated patients. In recent studies, we found that
laminin-5, an adhesion-migration macromolecule is
frequently overexpressed in the tumor cells at the free ends
of the GPs, indicating increased production of laminin-5. A
close interaction between this adhesion-migration
macromolecule, PG formation and the local progression of
colonic carcinomas seems to occur. In more recent studies,
we found that the flat tumor cells in the neoplastic glands at
the advancing edge failed to express the proliferation marker
3466
Ki-67 but expressed mutated p53 protein. This paradoxical
biological behaviour of tumor cells may be connected with
the subsequent formation of glandular pores and strongly
suggests that the arrested cell proliferation at the advancing
tumor edge of CRC occurs independently of p53 mutation.
It is suggested that at the advancing tumor edge of CRCs,
two independent molecular systems exist, one supervising
cell proliferation and the other actively transferring the
mutated p53 protein to daughter cells. These mechanisms of
action would also explain the clinical appearance of
metastasis many years after the surgical “curative”
eradication of colorectal carcinomas, conveyed by
“awakening” dormant cells.
572
IMMUNE EVASION BY TUMOUR: LET’S GET
BACK TO THE “ROOT” OF THE PROBLEM
Gaurisankar Sa1, Tanya Das1 and Charles S. Tannenbaum2
1Division
of Molecular Medicine, Bose Institute, Kolkata,
India;
2Department of Immunology, Cleveland Clinic, Cleveland,
OH, USA
Immune dysfunction is well-documented in cancer patients,
and likely contributes to tumour evasion. Often tumour
targets and directs T-cell function to escape from
immunosurveillance. This dysfunction includes loss of
effector T-cells, type-2 cytokine bias and T-regulatory (Treg)
cell expansion. To account for immune escape by tumours,
multiple mechanisms have been proposed including tumourinduced T-cell apoptosis. However, the molecules involved
in these processes still remain controversial. We observed
that tumour-shed various soluble factors play critical role in
suppression of anti-tumour immunity. One of the factors was
prostaglandin E2, which severely affected cytokine receptor γ
chain-mediated Jak-3/Stat-5a-signalling in T-cells resulting
in T-cells demise. It was also observed that tumour-shed
ganglioside-induced oxidative-stress perturbed NF-κB,
thereby, leaving T-cells vulnerable to tumour-secreted TNFα-induced apoptosis. Further investigation revealed that
tumour burden up-regulated Treg populations that
contributed to the decreased T-cell activation and Th-1 type
of immune response.
The true therapeutic benefit of the use of plant products,
especially acceptable dietary components, such as curcumin,
has opened new horizons in cancer prevention and
treatment. We observed that this yellow pigment of the spice
turmeric not only regressed cancer, but also rejuvenated
intrinsic defense machineries of the host, which become
jeopardized during cancer. In fact, the entire immune
dysfunction could be ameliorated by curcumin, indicating
that this phytochemical has the ability to restore Jak-3/Stat-
Abstracts of the 8th International Conference of Anticancer Research, 17-22 October 2008, Kos, Greece
5a- as well as NF-κB-signalling pathways in T-cells.
Curcumin also blocked Treg cell augmentation via downregulation of TGF-β in cancer cells and thus prevented
tumour-induced loss of T-effector cells and reversed type-2
cytokine bias. The active component in the root of turmeric
could re-educate the cellular signalling components and
blocked immune evasion by tumor. Curcumin, therefore,
may have a possible therapeutic potential in cancer patients
in whom the immune capacity is affected not only by the
disease itself, but also by the treatment measures. Thus,
modern medical research seems to confirm the ancient
wisdom that therapy of many diseases may reside in this
inexpensive spice.
573
EVALUATION OF SYNERGISTIC CYTOTOXICITY
OF CO-ADMINISTRATION OF TAXOL AND
ATORVASTATIN ON MDA-MB-468 CELL LINE
H. Sadeghi-Aliabadi1, M. Minaiian2 and M. Analoii3
1Department of Pharmaceutical Chemistry, 2Department of
Pharmacology, School of Pharmacy, 3Isfahan
Pharmaceutical Sciences Research Center, Isfahan
University of Medical Sciences, Isfahan, Iran
Background: Taxol is one of the cytotoxic drugs used for a
wide range of cancers, but has some problems such as low
permeability through the cell membrane and high price.
Statins with low side-effects can potentially be used as
cytotoxic agents acting with different mechanisms. In this
study, synergic cytotoxic effects of co-administration of taxol
and atorvastatin on the MDA-MB-468 cell line were
evaluated. Materials and Methods: The MDA-MB-468 cells
were cultured on RPMI medium. The cytotoxic activity of
co-administration of taxol and atorvastatin were screened at
0.1, 1 and 2 μM and 0.25, 0.5, 1, 2, 4, 8, 16 and 32 μM,
respectively. Cytotoxic activity of taxol 24 h after incubation
of cells with atorvastatin was screened, using MTT method.
Results: Atorvastatin had no effect on cells at a low
concentration (0.25 and 0.5 μM), but growth was inhibited
100% at high concentrations (8, 16 and 32 μM). Synergic
cytotoxic effect was observed when taxol was added 24 h
after incubation of cells with atorvastatin. It has been shown
that there is differential sensitivity of different cell lines to
antitumor activity of statins. The results of the present study
indicated that the MDA-MB-468 cell line has a low
sensitivity to low concentrations of atorvastatin. Conclusion:
Consistent with findings of other studies, the results of the
present study indicated that addition of Taxol 24h after
incubation of cells with atorvastatin had synergic cytotoxic
effect on MDA-MB-468 by at least 20%. Consequently it
may be possible to recommend in vivo co-administration of
statins with cytotoxic drugs.
574
CYTOTOXIC EVALUATION OF COADMINISTRATION OF DOXORUBICIN
WITH SIMVASTATIN AGAINST A
HUMAN CANCER CELL LINE
(HeLa) USING MTT ASSAY
H. Sadeghi-Aliabadi, M. Minaiyan and A. Dabestan
Isfahan Research Center of Pharmaceutical Sciences,
Isfahan University of Medical Sciences, Isfahan, Iran
Background: Doxorubicin is a broad spectrum antitumor
antibiotic in the treatment of cancers. Its dose-dependent
cardiotoxicity is the most serious side-effect causing drug
withdrawal from hard chemotherapeutic regimens. Statins
have been shown to be cytotoxic in concentrations that are
higher than effective doses for hypercholesterolemia
treatment (40 mg/day). Co-administration of statins and
chemotherapeutic agents, such as doxorubicin was shown to
be synergic. By this protocol, lower dose of cytotoxic agent
can be used, and, hence, reduce the risk of cardiotoxicity. In
this study, the cytotoxic effects of doxorubicin and
simvastatin co-administration (in combination or alone) on
HeLa tumor cell line were evaluated. Materials and
Methods: HeLa cells were cultured in RPMI medium and
cytotoxic effects of different concentrations of doxorubicin
and simvastatin either alone or in combination were
evaluated, using standard MTT assay. Briefly, after seeding
cells (3×104 cell/ml) in 96-well plates and 24 h preincubation, compounds were added and plates were
incubated (37˚C, 5% CO2). After 72 h, 20 μl MTT solutions
were added and incubated for another 3 h. Media were
replaced with 150 μl of DMSO and absorbance was read at
540 nm using ELISA plate reader. Finally, cell survival was
calculated as compared with control (100% viable cells).
Results: Results showed that simvastatin at low concentration
(0.25 μM) seems to be a growth stimulator (cell viability
112%, p<0.05), although at a concentration of 2 μM or
more, cell viability was reduced by at least 20% (p<0.5).
Doxorubicin (0.1, 1, 2 μM) reduced cell survival between 40
to 83%. Co-administration of two compounds at highest
tested concentrations (2 μM) after 72 h killed 97% of cells
(p<0.05). Incubation of cells with simvastatin after 24 h with
doxorubicin seems to be a more effective protocol than the
converse (14-76% cytotoxicity versus 12-61%). Conclusion:
Between 3 tested protocols in these studies, coadministration of doxorubicin and simvastatin after 72 h
incubation showed the highest cytotoxicity against HeLa
cells. On the other hand, incubation of cells with
doxorubicin, 24 h prior to addition of simvastatin was more
effective. Co-administration of drugs for longer periods of
time might help apoptosis more than each drug alone or
incubation with one compound prior to other one.
3467
ANTICANCER RESEARCH 28: 3157-3556 (2008)
575
TUMOR SPECIFICITY AND TYPE OF CELL DEATH
INDUCED IN ORAL SQUAMOUS CELL
CARCINOMA CELL LINES BY NATURAL AND
SYNTHETIC COMPOUNDS
Hiroshi Sakagami
Division of Pharmacology, Department of Diagnostic and
Therapeutic Sciences, Meikai University School of
Dentistry, Sakado, Saitama 350-0283, Japan
This is the review of our recent study on the tumor specificity
and the type of cell death induced by more than 1,000 natural
and synthetic compounds, using human normal oral cells
(gingival fibroblast, pulp cell, periodontal ligament fibroblast)
and human oral squamous cell carcinoma (OSCC) (HSC-2,
HSC-3, HSC-4, Ca9-22, NA) and human glioblastoma (T98G,
U87). Anthracyclines, such as doxorubicin, showed the highest
tumor-specificity, but this was mostly, but not completely,
related to the expression of mdr1 mRNA expression in the
target cells. Most of the lower molecular weight flavonoids
and monomeric tannins showed little or no tumor specificity.
On the other hand, oligomeric tannins showed slightly higher
tumor specificity. There was no clear-cut relation between the
tumor-specificity and apoptosis-inducing activity. α,βUnsaturated ketones, such as 4,4-dimethyl-2-cyclopenten-1one, trichloroacetylazulenes, α-trifluoromethyl acyloins,
morphinone and codeinone, induced non-apoptotic cell death
(little or no activation of caspase or internucleosomal DNA
fragmentation) or autophagy (accompanying the formation of
autophagosome, and occasionally secondary lysosome
engulfing broken organelles). However, α,β-unsaturated
ketones showed weak tumor specificity except for 3-arylidene1-(4-nitrophenylmethylene)-3,4-dihydro-1H-naphthalen-2-ones
that showed comparable tumor specificity with anthracyclines.
Nocobactins, mycobactin-like siderophores, also showed
higher tumor specificity, but their cytotoxicity was neutralized
by chelation with iron. Five OSCC cell lines showed
considerable variability in their sensitivity against antitumor
agents. Inhibition of autophagy by epigallocatechin gallate or
autophagy inhibitor enhanced apoptotic cell death in
RAW264.7 macrophages, suggesting the interaction between
apoptosis and autophagy.
A semi-empirical molecular orbital method may be useful
to estimate the most stable structure of candidate compounds
and explore compounds with greater tumor specificity.
576
LARYNGEAL CARCINOMA IN MOSUL
AbdulMuhsen Y. Saleem and Muna Muneer
Mosul General Hospital, Mosul Medical College, Mosul,
Iraq
3468
Laryngeal carcinoma is a common malignant tumor among
Asian races. Laryngeal carcinoma is regarded as the
commonest upper aero-digestive tract cancer and the
commonest head and neck cancer. More than 90% of
laryngeal tumors are squamous cell carcinoma (SCC). Our
aim was to present data about the incidence of various
laryngeal carcinomas in Mosul after 1991 and to compare
the results with previous studies. Materials and Methods: A
retrospective study was carried out at the Oncology and
Nuclear Medicine Hospital, Mosul Military Hospital, AlZahrawi Teaching Hospital and Alrahma Private Hospital,
over an eight-year period from January 1994 - December
2002. Four hundred and twenty patients with laryngeal
carcinoma were included in the study. Clinical data including
age and gender of the patients, in addition to the histological
reports from the case files were collected and analyzed.
Statistical analysis using Z-test concerning male and female
distributed cancer cases was carried out. Results: There were
a total of 420 patients with laryngeal carcinoma, with a male
to female ratio of 3.6:1. Of all cases, 97.2% were SCC and
1.4% adenocarcinoma. The age range was 36-85 years, with
a mean age of 60 years. Z-test revealed a statistically
significant gender difference (male vs. female, 78.3% vs.
21.7%, p<0.01) for laryngeal cancer. Conclusion: This study
revealed a higher frequency of laryngeal cancer than that of
previous studies performed in the same locality (Mosul)
during the previous decade and this could be attributed to the
general effect of the Gulf war in 1991 and the type of
weapons used in it. There is a need for further studies in
different parts of Iraq as to the cause of the increase in
incidence of malignancy after the War of 1991.
577
EVALUATION OF MLH1 AND MSH2 GENE
MUTATIONS IN A SUBSET OF IRANIAN FAMILIES
WITH HEREDITARY NON-POLYPOSIS
COLORECTAL CANCER (HNPCC)
Mansoor Salehi and Shahnaz Amani
Department of Genetics, Medical School, Isfahan
University of Medical Sciences, Isfahan 81744/176, Iran
Hereditary non-polyposis colorectal cancer is the most
common form of hereditary colorectal cancer, accounting for
5 to 10% of all colon carcinomas. It is inherited in an
autosomal dominant mode and caused by germline mutations
in mismatch repair genes (MMR), chiefly MLH1 and MSH2.
The lifetime risk of colon cancer in affected persons is 80%.
Screening, prevention strategies and consequently treatment
options will be improved by understanding of the genetic
basis of this disorder. The aim of this study was to assess
mutations in MLH1 and MSH2 genes in a subset of Iranian
HNPCC patients.
Abstracts of the 8th International Conference of Anticancer Research, 17-22 October 2008, Kos, Greece
Families fulfilling the Amsterdam criteria were selected as
HNPCC families. Genomic DNA was extracted from the
peripheral blood samples and germline mutations of MLH1
and MSH2 were detected by PCR-single strand conformation
polymorphism (PCR-SSCP) and DNA sequencing
techniques. Germline mutations were found in 20 cases. The
mutation rate in our study (62.5%) was higher in comparison
with countries, such as Latvia or Taiwan. Of these mutations,
14 were found in MLH1 and 6 in MSH2 genes thus MLH1
gene had a higher mutation rate than MSH2. Eighteen out of
20 detected mutations in our population were previously
reported and two were novel.
Our results demonstrated that the mutation range, as well
as genes involved in HNPCC is different from one region to
other and characterizing mutations could be very helpful in
diagnosis of the at-risk individuals.
578
AN ORGANOTYPIC MYOMA MODEL FOR
ANALYSING CARCINOMA INVASION
Sini Nurmenniemi1, Pia Nyberg1, Meeri Sutinen1,
Juha Risteli2 and Tuula Salo1,3
1Institute of Dentistry and 2Department of Clinical
Chemistry, University of Oulu;
3Oulu University Hospital, Oulu, Finland
Traditionally human carcinoma invasion is studied using
three-dimensional organotypic culture model using rat type
I collagen gel disc with or without embedded human
fibroblasts. Since carcinoma cells behaviour depends largely
on their surroundings a more natural environment for cancer
cell invasion studies should be created. In this study a novel
organotypic culture model based on human leiomyoma tissue
was established.
Commercial highly invasive human tongue squamous cell
carcinoma cell line HSC-3 was cultured on top of bovine
collagen gels and on human uterine leiomyoma discs for two
weeks in the presence or absence of a gelatinase-specific
peptide inhibitor CTT-2. Uterine leiomyoma tissues were
obtained from the routine surgical treatments in the hospital
and either processed immediately or frozen for later use.
Organotypic culture media samples were collected every
three days and were analyzed by radioimmunoassay for type
I collagen, Western blotting of collagenases or using gelatin
zymography. The organotypic tissue discs were formalin
fixed and paraffin embedded sections were studied by
immunostaining and in situ hybridization.
From myoma discs a wide variety of cell types, including
myofibroblasts, endothelial and inflammatory cells were
identified. In the extracellular matrix type I, III and IV
collagen and laminins were present and synthesized by the
invading carcinoma cells. Interestingly, in myoma model,
particularly using frozen-thaw discs, carcinoma cells invaded
and proliferated significantly more efficiently than in
traditional collagen gels with fibroblasts. The invasive
potential of the carcinoma cells and the inhibitory effect of
CTT-peptide could also be analyzed from the culture media
samples.
We have developed a novel human organotypic culture
model based on human myoma tissue discs. This model is
practical and convenient for analysing easily the effects of
various invasion inhibiting substances on carcinoma cells.
579
THE ACTIVATING ROLE OF SRC AND
STAT3 ON HGF TRANSCRIPTION IN
HUMAN BREAST CANCER CELLS
Michelle R. Sam1, Bruce E. Elliott2,3 and
Christopher R. Mueller2,3
1Cancer
Genomics Platform, Ontario Institute for Cancer
Research, Toronto, Ontario, Canada;
2Department of Pathology and Molecular Medicine, and
3Division of Cancer Biology and Genetics, Queen’s Cancer
Research Institute, Kingston, Ontario, Canada
Hepatocyte growth factor (HGF) participates in normal
mammary development through tightly regulated paracrine
signaling. Aberrant regulation of HGF and its receptor Met is
thought to contribute to tumorigenesis, and overexpression
of both proteins is frequently observed in breast cancer.
Active Src and Stat3 are mediators of HGF/Met signaling,
and previous studies have demonstrated that cooperative
Src/Stat3 signaling activates HGF transcription in mouse
mammary carcinoma cells. Characterization of the HGF
promoter led to the identification of a Stat3 consensus site
located at -95nt which was shown to be required for full
HGF transcriptional activity. To extend this work in the
context of human breast cancer, activated Src and Stat3 were
overexpressed in human epithelial cell lines and their
signaling effects on HGF activation assessed.
Results from this study demonstrate that human breast
cells provide a permissive environment for HGF
transactivation mediated by activated Src/Stat3 interaction.
Endogenous protein expression patterns were also
characterized for the proteins involved in HGF/Met signaling
across a variety of epithelial cell lines. Furthermore, use of
Stat3 shRNA approaches to knockdown Stat3 expression
show that Stat3 mediates HGF transcription through
interactions at the -95nt site on the HGF promoter. The
generation and use of inducible Stat3 fusion proteins also
allowed for the independent evaluation of Stat3 dimerization,
activation and transcriptional regulation of the HGF/Met
signaling pathway. Results from this study support the
suggested model of a cooperative activating role of Src/Stat3
3469
ANTICANCER RESEARCH 28: 3157-3556 (2008)
signaling, and their participation in the formation of an HGF
autocrine loop. This may in turn lead to sustained activation
of the HGF/Met signaling pathway thereby promoting an
oncogenic phenotype in human mammary epithelial cells.
Better understanding of these proteins and their interactions
within the signal transduction pathway can further aid in the
target and design of therapeutic approaches to breast cancer
treatment.
580
A NOVEL RADIOIMMUNOCONJUGATE FOR
POSSIBLE USE IN THE DETECTION OF HNSCC
Karl Sandström1, Marika Nestor1, Tomas Ekberg1,
Mats Engström1, Matti Anniko1 and Hans Lundqvist2
1Unit
of Otolaryngology and Head and Neck Surgery,
Department of Surgical Sciences, Uppsala University,
Akademiska Sjukhuset, Uppsala;
2Unit of Biomedical Radiation Sciences, Department of
Oncology, Radiology, and Clinical Immunology, Uppsala
University, Uppsala, Sweden
The presence or absence of lymph node and distant metastases
has a major impact on the preference of treatment in patients
with head and neck squamous cell carcinoma (HNSCC).
Radioimmunodiagnosis could offer a more specific and
sensitive diagnostic method than those available today. Our
aim was to label cMAb U36 with 111In and study the
biodistribution of the labelled compound in HNSCC
xenografts and selected normal organs of nude mice. We also
wanted to evaluate imaging of HNSCC using the same
compound in a planar gamma camera. Materials and
Methods: In this study we used the chimeric monoclonal
antibody U36 (cMAb U36) targeting CD44v6, expressed in
many squamous cell carcinomas, and the humanized antibody
huA33 targeting A33, expressed in colorectal carcinomas, as a
negative control. The antibodies were labeled with the Auger
electron emitter Indium-111 (111In), using the chelator
CHXA’’-DTPA. In vitro binding characteristics of the 111In
labeled cMAbU36 and huA33 conjugates were made with an
immunoreactivity assay and binding studies in order to
determine the specificity of the labeled antibodies and the
presence of the antigens CD44v6 and A33 on SCC9 cells.
Biodistribution and tumor imaging studies were conducted
after intravenous injection of the radiopharmaceuticals in nude
mice bearing HNSCC xenografts expressing CD44v6. Results:
The antibody tolerated labeling conditions very well. The
immunoreactive fraction was very high (>95%), and blocking
experiments verified that the binding was CD44v6-specific. In
vivo results demonstrated a promising biodistribution, with
tumor being the only tissue to clearly accumulate radioactivity
with time. All organs had substantially lower radioactivity than
the blood. The blood-to-tumor ratio of cMAb U36 increased
3470
continuously during the study, from 0.24±0.10, 6 h p.i., to
4.45±1, 172 h p.i. The targeting specificity of cMAb U36 was
further supported by the significantly (p<0.038) higher uptake
72 h p.i. compared to huA33. The static images of the tumor
xenografts showed good visualization of the tumors.
Conclusion: We have produced a novel radioimmunoconjugate
targeting CD44v6, for possible use in radioimmunodiagnosis
of HNSCC. The conjugate was evaluated both in vitro and in
vivo, demonstrating no adverse effects from labeling, and a
favorable biodistribution. The planar gamma camera images
showed good visualization of the tumors. The specific, high,
and accumulating blood-to-tumor ratio indicated a favorable
retention of the conjugate, a promising property for future
imaging studies.
581
POSSIBLE ROLE OF DIFFERENTIAL
METALLOPROTEINASE 1 EXPRESSION
IN SIGNET RING CELL AND INTESTINAL
COLORECTAL CARCINOMA HISTOTYPES
R. Sanguedolce1, D. Cabibi2, A. Martorana2, F. Aragona2
and A. Calascibetta1
Dipartimenti di 1Scienze Farmacologiche e di 2Anatomia
Patologica, Policlinico, Facoltà di Medicina e Chirurgia,
Università degli Studi di Palermo, Italy
Background: Signet ring cell colorectal carcinoma (SRCC)
pure is an infrequent and highly malignant variant of
colorectal cancer, while this histological component is
present in 30% of all colorectal carcinomas. In our previous
studies, we compared the E-cadherin, β-catenin, fibronectin,
Ki-67 and thymidylate synthase (TS) expression of SRCC
with those of the intestinal type of colorectal carcinoma
(ICRC) to try to show the pathogenesis, aggressiveness and
low 5-fluorouracil (5-FU) responsiveness of these tumours.
We found that all SRCCs had very low levels of all markers
and were in the post-mitotic phase of the cell cycle. To
understand their high metastatic capability we assessed the
SRCC expression of matrix metalloproteinase-1 (MMP1), a
proteolytic enzyme, suspected to play an important role in
the progression of various types of cancer and compared it
to the ICRC one. Materials and Methods: We tested MMP1
expression immunohistochemically on formalin-fixed,
paraffin-embedded samples of 32 SRCC and 70 ICRC.
Differences in the distribution of the study variables, and
associations between variables were assessed by means of
the χ2 test. Results: SRCC showed a high expression of
MMP1 over all the invasion front of the tumour and in the
neoplastic embolus, rather than the ICRC (p<0.001).
Conclusion: As MMPs seem to play important role in tumour
invasion and metastasis, recently they have gained attention
as targets for new anticancer therapy strategies. MMP
Abstracts of the 8th International Conference of Anticancer Research, 17-22 October 2008, Kos, Greece
inhibitors have been shown to prevent tumour spread both in
vitro and in vivo and to inhibit tumour angiogenesis and
some of them are being developed for clinical use. In this
study we demonstrated that SRCCs showed a different
MMP1 expression pattern compared to ICRC, for this reason
an anti-MMP therapy should be advisable in these patients
because of their poor prognosis.
This work was supported by an ex 60%, 2006, and by MIU
grants.
582
MULTI-SCALE MODELLING OF THE IMMUNE
SYSTEM: APPLICATIONS TO CANCER
IMMUNOTHERAPY
C.E. Sansom1, A. Shepherd1, V. Brusic2,3,
S. Motta4, P.L. Lollini5, M.-P. Lefranc6 and D.S. Moss1
1School
of Crystallography, Birkbeck College, London
WC1E 7HX, UK;
2Dana-Farber Cancer Institute, Harvard Medical School,
Boston, MA 02115, USA;
3LCAFS, University of Queensland, Brisbane, Australia;
4Department of Mathematics and Informatics, University of
Catania;
5Department of Hematology and Oncological Science,
University of Bologna, Italy;
6IMGT®, Institut de Génétique Humaine, CNRS,
Montpellier, France
Vaccination and monoclonal antibody (mAb) immunotherapy
are becoming increasingly important and effective strategies
for the treatment of some types of cancer (1), with over
1,850 clinical trials for vaccines and immunotherapy
currently
listed
in
the
international
registry
ClinicalTrials.gov. Many of these studies were based on
computer modelling. Immunoinformatics is a growing subdiscipline, bridging bioinformatics and immunology. It is
concerned with modeling and computational analysis of the
human immune response at the molecular, cellular and
system levels.
The best-established area of immunoinformatics is
probably molecular level modeling, which has clinical
implications in predicting prognosis in CLL (2) and
evaluating humanized antibodies for immunogenicity (3).
Predictions of peptide-MHC binding have contributed to the
development of therapeutic vaccines, although this approach
cannot be used in isolation (4). At the system level, the in
silico mouse model has been used to predict the optimum
vaccination schedule for preventing mammary tumor
development in ERBB2/HER-2/NEU transgenic mice (5).
Recently, we have been combining these approaches by
developing and implementing an integrated model of the
human immune system in the ImmunoGrid project
(http://igrid-ext.cryst.bbk.ac.uk/immunogrid/site/index.html),
funded through Framework 6. An enormous amount of data
related to the immune response at different levels is being
collected and curated in a repository and fed back into our
simulators. Many of the calculations required are
computationally intensive and are distributed between
systems that our partners have access to using Grid
technology. We are now seeking funding to develop this
basic science into novel computational tools that will be
accessible and useful in the clinic. In this presentation, both
our current applications of immunoinformatics to cancer
vaccine development, and our future plans will be described.
1 Weiner LM: NEJM 358: 2664-2665, 2008.
2 Ghia P et al: Leukemia 21: 1-3, 2007.
3 Magdelaine-Beuzelin C et al: Crit Rev Oncol Hematol 64:
210-225, 2007.
4 Halling-Brown M et al: Trends Immunol, in press, 2008.
5 Lollini PL et al: BMC Bioinformatics 7: 352, 2006.
583
CANCER COMMUNICATION:
SHARING BENEFITS, EXPLAINING RISKS
C.E. Sansom
School of Crystallography, Birkbeck College, London
WC1E 7HX, UK
The subject of cancer is always newsworthy and often
emotionally charged. Researchers and clinicians working in
this area may be relatively fortunate in their funding
environment, but they have to cope with the glare of
publicity. Cancer researchers, like all scientists, inhabit a
world of slow advances and statistical uncertainty, but it is
not unusual for such incremental advances to be reported by
journalists in glowing terms, involving clichés such as
“boffin” and “miracle cure”. And in the age of the Internettaught “expert patient”, some patients will rapidly become
aware of these “breakthroughs” and demand novel
treatments, sometimes before they have even been licensed.
It is important that both basic and clinical cancer
researchers take the issue of communication seriously.
Unlike most scientists, who have to battle for media
attention, cancer specialists will often be addressing a large
audience who are not scientifically literate – who may lack
the training to interpret figures about, for example, the risks
of contracting certain cancers or the benefits of a particular
drug. People are prepared to accept risks most if the hazard
is familiar, if there is an associated benefit, and if they have
some control over whether they are exposed to it (1). This
may go some way to explain why, when the connection
between smoking and cancer is so widely recognized, about
13 million UK adults still smoke. It is also difficult for
people to understand the complex linkages between genetics
3471
ANTICANCER RESEARCH 28: 3157-3556 (2008)
and cancer. Those who may be at risk cannot always judge
the benefits (and the reverse) of genetic tests. Within the
professional cancer community, too, all cannot readily
understand each other’s jargon, and even researchers and
clinicians in different sub-disciplines can seem to be
speaking different languages.
The traditional “deficit model” (2) – which would mean a
one-way flow of technical information from researchers and
oncology specialists to general practitioners, and thence to
patients – cannot be the whole story. Generalist physicians,
who lack specialist oncology training but are closest to
individual patients’ experiences (3), can develop
communication skills that the specialists often lack. In this
presentation I will discuss the need for, and benefits of,
improving communication between different cancer
professionals and between those professionals and those they
seek to serve, and discuss how best to foster this important
skill.
1 Adams J: Risk. UCL Press, London, 1995.
2 Turney J: Understanding and engagement: the changing
face of science and society. Wellcome News 32: 6–7, 2002.
3 Noble I: Tumour diary. Online, 2002-2005.
http://news.bbc.co.uk/1/hi/health/4211475.stm
584
THE ROLE OF ABC TRANSPORTERS IN
RESISTANCE TO ANTICANCER
TYROSINE KINASE INHIBITORS
Balázs Sarkadi, Csilla Özvegy-Laczka and Csilla Hegedűs
Membrane Research Group; Hungarian Academy of
Sciences, Semmelweis University, 1113 Budapest, Dioszegi
u. 64, Hungary
The three major types of multidrug-resistance (MDR)
transporter proteins in humans include members of the
ABCB, the ABCC, and the ABCG subfamily. These pumps
recognize a wide range of drug substrates, mostly
hydrophobic compounds, but also a variety of amphipathic
anions and cations. MDR-ABC proteins play an important
role in cancer drug resistance, but also in the absorption,
distribution, metabolism and toxicity (ADME-tox) of several
pharmaceutical agents.
The ABCG2 transporter provides tissue protection against
numerous toxic compounds and accounts for a multidrugresistant phenotype in cancer cells. It has been documented
by us and others that ABCG2 displays a high affinity
interaction with several clinically effective small molecule
tyrosine kinase inhibitors. These include Iressa® (Gefitinib),
an inhibitor of EGF-receptor dependent signalling, and
Imatinib (Glivec®) which inhibits the Bcr-Abl fusion protein,
the molecular basis of chronic myeloid leukemia (CML).
In this study, we investigated the interaction of ABCG2
3472
with two second-generation Bcr-Abl inhibitors already in
clinical trials, Nilotinib and Bosutinib. We examined the
effects of these compounds on the ATPase activity of the
human ABCG2, on Hoechst 33342 dye extrusion and on the
survival of Bcr-Abl+ K562 cells, overexpressing the ABCG2
protein (K562/ABCG2). Our data indicate that the novel BcrAbl inhibitors have major differences in their interaction
profiles with ABCG2. While Nilotinib is a high affinity
substrate and at higher concentrations is an effective inhibitor
of the transporter, Bosutinib does not significantly interact
with ABCG2 at therapeutically relevant concentrations.
These findings may provide important information regarding
the anticancer effects and ADME-Tox properties of novel
tyrosine kinase inhibitors.
Özvegy-Laczka et al: High-affinity interaction of tyrosine
kinase inhibitors with the ABCG2 multidrug transporter. Mol
Pharmacol 65: 1485-1495, 2004.
Özvegy et al: Tyrosine kinase inhibitor resistance in cancer:
Role of ABC multidrug transporters. Drug Resist Update 8:
15-26, 2005.
Elkind et al: The multidrug transporter ABCG2 prevents
tumor cell death induced by the EGF receptor inhibitor
Iressa® (ZD1839, Gefitinib). Cancer Res 65: 1770-1777,
2005.
Sarkadi et al: Human multidrug resistance abcb and abcg
transporters: Participation in a chemoimmunity defense
system. Physiol Rev 86: 1179-1236, 2006.
585
ASTROCYTE ELEVATED GENE-1 (AEG-1):
A NOVEL REGULATOR OF
HEPATOCELLULAR CARCINOMA
Devanand Sarkar
Department of Human and Molecular Genetics,Massey
Cancer Center,Virginia Commonwealth University,
Richmond, VA, USA
Hepatocellular carcinoma (HCC) is a highly aggressive
vascular cancer characterized by diverse etiology, activation
of multiple signal transduction pathways and mutations in a
plethora of genes with no effective treatment. We presently
document that expression of Astrocyte Elevated Gene-1
(AEG-1) is extremely low in human hepatocytes and it
gradually increases with the stages and grades of human
HCC by analyzing Affymetrix microarray data from 144
HCC patients and immunostaining of tissue microarray from
109 HCC patients. Stable overexpression of AEG-1 converts
non-tumorigenic human HCC cells into highly aggressive
vascular tumors and inhibition of AEG-1 abrogates
tumorigenesis by highly aggressive HCC cells. Microarray
analysis identifies that AEG-1 modulates expression of genes
associated with invasion, metastasis, chemoresistance,
Abstracts of the 8th International Conference of Anticancer Research, 17-22 October 2008, Kos, Greece
angiogenesis and senescence, all intimately relevant to HCC
pathogenesis. AEG-1 activates Wnt/β-catenin signaling via
ERK42/44 activation and up-regulates LEF-1/TCF-1, the
ultimate executor of Wnt pathway. Inhibition studies
demonstrate that activation of Wnt signaling plays a key
event in mediating AEG-1 function. AEG-1 also activates
NF-κB pathway that might be relevant to chronic
inflammatory changes preceding HCC development. These
pleiotrophic modulation of multiple signaling pathways and
gene expression place AEG-1 as a central molecule
regulating diverse aspects of HCC pathogenesis. Thus
targeted inhibition of AEG-1 might lead to the shutdown of
key elemental characteristics of HCC and be an effective
therapeutic strategy for HCC.
586
THE ROLE OF MAPK SIGNALING PATHWAY IN
MALIGNANT BONE AND SOFT TISSUE TUMORS
Kanji Sasaki, Toshiaki Hitora, Osamu Nakamura,
Yoji Kawaguchi and Tetuji Yamamoto
Kagawa University, Orthopedic Surgery, 1750-1 Ikenobe,
Miki-cho, Kita-gun, Kagawa-ken, 761-0701, Japan
Background: Raf-1 and MEK1/2 which is an essential
serine/threonine kinase, consist a downstream of the central
signal transduction mediator Ras in the MAPK (mitogenactivated protein kinase) signaling pathway (RAF/MEK/ERK
pathway). Furthermore, various growth factors such as VEGF
stimulate Ras and activate the MAPK signaling pathway.
Therapeutics targeting anti-VEGF, Raf-1 and MEK are
currently undergoing clinical evaluation on some human
malignancies. We consider that MAPK signaling pathway
play an important role in malignant bone and soft tissue
tumors. We therefore examined the expression of VEGF, Raf1 and MEK 1/2 genes and the inhibitory effects of MAPK
signaling pathway. Materials and Methods: Specimens, cell
lines and reagent. We used the 20 specimens of human
malignant bone and soft tissue tumors, which had been
clinically and historogically diagnosed. Three human
osteosarcoma cell lines (KHOS, KTHOS and MG-63) and 3
human malignant fibrous histocytoma (MFH) cell lines
(GBS-1, Nara-F and Nara-H) were used. All cell lines were
grown in Dulbecco’s Modified Eagle Medium (DMEM;
Sigma-Aldrich, St. Louis,MO) supplemented with 10% fetal
bovine serum (FBS;Sigma-Aldrich). The cells were routinely
maintained at 37˚C in a humidified 5% CO2 atmosphere.
Bevacizumab, a humanized anti-VEGF monoclonal antibody
was purchased from Genentech. GW5074, a specific Raf-1
inhibitor was purchased from Sigma-Aldrich. U0126, a
selective MEK1/2 inhibitor, was purchased from Promega.
mRNA expression of VEGF, Raf-1 and MEK1/2. Total RNAs
were eluted by selective binding to a silica-gel-based
membrane using an RNeasy Mini Kit® (QIAGEN Inc.,
Valencia, CA). Reverse transcription of RNA into cDNA was
performed by using Reverse Transcription System (Promega,
Madison, WI). Raf-1 and MEK1/2 mRNA expression were
examined by reverse transcription (RT-)PCR. After PCR
amplification, 8-μl aliquots of the PCR products were
electrophoresed in a 2% agarose gel, followed by ethidium
bromide dye. The inhibitory effect of Bevacizumab and
GW5074 and U0126. Cell proliferation was assayed using the
MTS assay (CellTiter 96® Aqueous One Solution Cell
Proliferation Assay; Promega, Madison, WI). Cells were
seeded in 96-well cell culture plates. After 48 hours (h), the
medium was renewed and Bevacizumab or GW5074 or
U0126 was added at the indicated concentrations. After 12,
24, 48h, the optical density was measured. The percent
viability of each well was calculated. Results: mRNA
expression of VEGF, Raf-1 and MEK 1/2. The mRNA of Raf1 and MEK 1/2 was strongly expressed in all 20 specimens
and all 6 cell lines. The mRNA of VEGF was expressed in all
6 cell lines. The effect of Bevacizumab. Bevacizumab
inhibited cell proliferation of all 6 cell lines at the viability
of 80%. The effect of MAPK signaling pathway inhibitors.
GW5074 and U0126 inhibited cell proliferation of all 6 cell
lines in a dose- and time-dependent manner. 10 μM GW5074
and 50 μM U0126 inhibited cell proliferation by 50% or less.
Discussion: The MAPK pathway is very important as a target
of molecular therapy, because it is specific in malignant
tumors. In our study, the mRNA of Raf-1 and MEK1/2 were
strongly expressed in all the specimens of malignant bone and
soft tissue tumors, and all osteosarcoma and MFH cell lines.
MAPK inhibitors GW5074 and U0126 showed an inhibitory
effect on cell proliferation. These results suggest that the
MAPK signaling pathway exists in all malignant bone and
soft tissue tumors and plays an important role in the
proliferation of osteosarcoma and MFH. In our study, all cell
lines exhibited VEGF-gene expression, and inhibition of
VEGF also decreased cell proliferation. These results suggest
that VEGF stimulate not only the vascular growth but also the
MAPK signaling pathway. Thus we suggest that both VEGF,
and the downstream of Ras have a relationship with the
control of cell proliferation in osteosarcoma and MFH.
587
LONG-RANGE EPIGENETIC SILENCING AND CPG
ISLAND METHYLATOR PHENOTYPE (CIMP) – A
KEY MECHANISM IN COLORECTAL
CARCINOGENESIS?
Pawel Karpinski1, Nikolaus Blin2 and Maria M. Sasiadek1
1Department
of Genetics, Wroclaw Medical University,
Poland;
2Division of Molecular Genetics, Institute of Human
Genetics, University of Tuebingen, Germany
3473
ANTICANCER RESEARCH 28: 3157-3556 (2008)
Colorectal cancer (CRC) belongs to the group of most
frequent cancers in humans. Among all cases of CRC, about
75% are sporadic, 5-10% hereditary, while 15% are familial.
To date, two main molecular pathways have been revealed as
being critical in CRC: i) specific for familial adenomatous
polyposis (FAP), which is characterized by loss of function
of APC gene and thereafter chromosomal instability; and ii)
specific for hereditary nonpolyposis colon cancer (HNPCC),
which is characterized by loss of function of one of the
mutator genes (usually MLH1 or MSH2), followed by
microsatellite instability. These pathways are also revealed
as specific for 85% and 15% of sporadic CRC, respectively.
The involvement of epigenetic alternations in molecular
etiology of CRC has been discussed for more then 20 years.
Thereafter, much of our current knowledge on epigenetic
alterations in cancerogenesis comes from studies on CRC.
Two epigenetic phenomenon connected with CpG island
methylation are observed in CRC: i) CpG island methylator
phenotype (CIMP) which is characterized by exceptionally
high frequency of methylated CpG islands specifically
localized in promoter regions of a number of genes; and ii)
recently discovered long-range epigenetic silencing (LRES),
which is associated with DNA/histone methylation. LRES can
span large chromosomal domains and involves broad
heterochromatin formation accompanied by hypermethylation
of clusters of contiguous CpG islands within the region,
demonstrating that DNA hypermethylation can span larger
chromosomal regions and can lead to silencing of flanking,
unmethylated genes. Recently, two LRES domains have been
reported in CRC. One at 2q14.2 by Frigola et al. (2006) and
a second localized at 3p22 by Hitchins et al. (2007).
It is also noteworthy that both examples of LRES are
associated with transcriptional silencing of genes that that
are known to play an important role in carcinogenesis e.g.
hMLH1, EN1 (Wnt signaling pathway), GLI2 (sonic
hedgehog signaling pathway), DLEC1 (tumor suppressor)
and CTDSPL (tumor suppressor). Moreover, aberrant
methylation which expands thorough tumor progression is
potentially reversible, opening therefore new perspectives in
cancer diagnosis and therapy.
Altogether these results suggest the interrelationship
between MSI, CIMP and LRES in the etiology of CRC.
We investigated whether these two phenotypes (CIMP and
LRES) are interrelated in CRCs. Both CIMP and methylation
of MLH1 gene as well as of three CpG islands (EN1, SCTR
and INHBB, corresponding to three distinct clusters along
2q14.2) were determined by methylation-specific PCR while
BRAF V600E mutation was sought by mutated allele-specific
amplification PCR. A total of 88% of cases showed
hypermethylation of at least one of the three CpG islands
along 2q.14.2. The average number of these sites showing
methylation in CIMP+ tumors was 2.21 compared to 1.22 for
CIMP– individuals (p=3.5×10–8, Mann-Whitney test).
3474
Moreover, all CIMP+ tumors showed hypermethylation of at
least one of these loci in contrast to CIMP– tumors, where
16% of samples remained unmethylated. The mean number
of simultaneously hypermethylated CpG islands at 2q14.2
differed significantly for CIMP– and CIMP+ tumors,
suggesting different effects of domain silencing in this
region. Given that the number of hypermethylated loci at
2q14.2 likely affects the range of silenced flanking genes, a
high frequency of simultaneous hypermethylation of three
CpG islands (EN1, SCTR and INHBB) may have potential
influence on specific characteristics of CIMP+ CRCs.
588
E2F7 EXHIBITS BOTH TUMOUR
SUPPRESSIVE AND ONCOGENIC
ACTIVITIES IN HUMAN KERATINOCYTES
Liliana Endo-Munoz1, Alison Dahler1, Danny Rickwood1,
Anthony Griffin2, Geoffrey Strutton3
and Nicholas Saunders1
1Diamantina
Institute for Cancer, Immunology and
Metabolic Medicine, University of Queensland, Princess
Alexandra Hospital, Queensland;
Departments of 2Surgery and 3Pathology, Princess
Alexandra Hospital, Queensland, Australia
We have previously shown that inhibition of E2F activity is
essential for the initiation of squamous differentiation (1, 2).
For this reason, we postulated that endogenous inhibitors of
E2F may exist that are involved in the initiation of squamous
differentiation. In the present study, we examined the
potential role of E2F7 in regulating E2F-dependent functions
in human keratinocytes (proliferation, differentiation and
apoptosis). We found that E2F7b was the most highly
expressed splice variant of E2F7, whose expression was
restricted primarily to proliferating keratinocytes. In a series
of reporter assays, we were able to show that E2F7 could
inhibit E2F1-dependent proliferation markers and could
sensitise keratinocytes to subsequent differentiation stimuli.
Based on these data, we propose that E2F7b is likely to be a
physiologically-relevant regulator of the initiation of
squamous differentiation. We next went on to show that
E2F7b was a potent suppressor of E2F1-induced keratinocyte
apoptosis. Combined, these data suggest that the
antiproliferative, pro-differentiative activity of E2F7 is
consistent with a tumour suppressor function, whilst the
antiapoptotic activity is consistent with that of an oncogene.
This situation is the opposite to that reported for E2F1. This
proposition takes on more significance when combined with
our observation that E2F7b and E2F1 are highly expressed
(10- to 100-fold) in human cutaneous squamous cell
carcinomas (SCC). This would suggest that the
overexpression of E2F7 could contribute to SCC formation.
Abstracts of the 8th International Conference of Anticancer Research, 17-22 October 2008, Kos, Greece
These data would also suggest that the inhibition of E2F7
could be a novel way to induce apoptosis or sensitise SCCs
to cytotoxic drugs.
1 Wong CF, Barnes LM, Dahler AL, Smith L, SerewkoAuret MM, Popa C, Jabbar IA and Saunders NA: J Biol
Chem 278(31): 28516-28522, 2003.
2 Wong CF, Barnes LM, Dahler AL, Smith L, Popa C,
Serewko-Auret MM and Saunders NA: Oncogene 24:
3525-3534, 2005.
589
TREATMENT OF METASTATIC MELANOMA
PATIENTS WITH TUMOR INFILTRATING
LYMPHOCYTES: CLINICAL DEVELOPMENT
Jacob Schachter, Michal J. Besser,
Ronny Shapira-Frommer, Avraham J. Treves,
Dov Zippel, Orit Itzhaki, Ester Schallmach,
Adva Kubi, Naama Zabari,
Bruria Shalmon-Zifroni, Izhar Hardan,
Eran Segal, Raphael Catane and Arnon Nagler
(day 0), followed by bolus high-dose IL-2 (720 000IU/kg
every 8 h) to a maximum of 15 doses. Results: Until today,
20 melanoma patients have been enrolled to the protocol.
Twelve were treated by the selected TIL protocol and 8 were
treated by the "young" TIL protocol. The preliminary results
are encouraging. No treatment-related death or major toxicity
(grade 3 or 4, besides from expected pancytopenia) were
observed. All patients had neutropenic fever. Conclusion: We
demonstrate that admission of this novel protocol is feasible.
The preliminary results are encouraging but further clinical
studies are necessary in order to prove the clinical benefit of
this program.
1 Dudley ME. J Clin Oncol 23: 2346-2357, 2005.
2 Shen X. J Immunother 30: 123-129, 2007.
3 Zhou J. J Immunol 175: 7046-7052, 2005.
590
REFINING NON-HUMAN PRIMATE CANCER
MODELS: BEHAVIORAL FACTORS
Steven J. Schapiro
Ella Institute for Treatment and Research of Melanoma and
Skin Cancer, Sheba Medical Center, Tel Hashomer 52621,
Israel
Department of Veterinary Sciences, The University of
Texas M.D. Anderson Cancer Center, 650 Cool Water Dr.,
Bastrop, TX 78602, USA
Background and Purpose: After the Surgery Branch/NCI (1),
the "Ella Institute" at the Sheba Medical Center in Israel, is
the second center worldwide that successfully adopted the
tumor-infiltrating-lymphocytes (TIL) technology, which
consists of the adoptive transfer of large numbers of selected
anti-tumor reactive TIL to lympho-depleted melanoma
patients. This protocol requires the generation of multiple
individual TIL cultures from one patient and the in vitro
selection of TIL cultures, which specifically secrete IFNγ
after co-culture with melanoma cells. The establishment of
multiple, relatively homogenic TIL cultures demands often
prolonged culture times and many fail the selection criteria.
Preclinical animal models and clinical studies have shown
that lymphocytes that spend less time in culture tend to have
longer telomeres and less-differentiated phenotypes, which
can translate into objective response as well as persistence
in vivo (2, 3). Furthermore, extended culture time leads to
reduced TIL heterogeneity. Considering these facts a
modified clinical protocol using "young" TIL, with shortterm cultures was applied. This technology furthermore does
not require the IFNγ selection criteria, which impact is not
fully verified yet. Clinical Study: The eligibility criteria
include stage IV melanoma patients, previously treated with
chemotherapy and IL-2, a good performance status (PS-0,1)
and no brain metastasis. Clinical Protocol: Patients receive
non-myeloablative lympho-depleting chemotherapy with
cyclophosphamide (60 mg/kg) on days -7 and -6 and
fludarabine (25 mg/m2) on days -5 to -1 prior to TIL infusion
The use of non-human primates as models in cancer
research is increasing in frequency and importance. Given
the social and cognitive complexity of the species of nonhuman primates likely to be utilized in cancer-related
investigations, it is of the utmost importance to refine the
techniques used to manage and handle these animals. While
physiological measures are often used to assess effects of
manipulations in many experiments, behavioral factors that
may influence these physiological measures are too
frequently overlooked. We have demonstrated that
behavioral factors, such as social housing conditions, the
techniques used to anesthetize the animals, the techniques
used to attain blood samples, and the relocation of animals
from one facility to another, can all significantly alter
physiological readouts in a number of non-human primate
species. Our data indicate that not every behavioral factor
will result in statistically significant changes in all relevant
physiological measures, but many factors will alter variables
vital for assessing disease state. One of the primary values
of understanding the effects of behavioral factors is to refine
management, handling, and research techniques so as to
minimize intersubject variability due to potential behavioral
confounds, especially in a Good Laboratory Practices
environment. By implementing behavioral refinements that
minimize variability between subjects, critical, and
expensive, experiments involving non-human primate
subjects can be conducted with fewer subjects without a
reduction in statistical power.
3475
ANTICANCER RESEARCH 28: 3157-3556 (2008)
591
NEOADJUVANT CHEMOTHERAPY
IN BARRETT’S CARCINOMA –
PROGNOSIS AND RESPONSE
PREDICTION
M. Schauer, K.P. Janssen, B. Holzmann,
M. Feith, J. Theisen and W.T. Knoefel
592
CROSSING THE BARRIER: FROM INTRAVENOUS
TO EFFECTIVE ORAL FORMULATIONS
OF CHEMOTHERAPY
Jan H.M. Schellens
Klinikum rechts der Isar, Technische Universität Munich,
Germany
The Netherlands Cancer Institute, Plesmanlaan 121, 1066
CX Amsterdam, NL;
Science Faculty, University Utrecht, Utrecht, the
Netherlands
It has been shown that the incidence of esophageal
adenocarcinoma is increasing at an alarming rate in
Western countries. More than 50% of patients present with
locally advanced disease. In these patients, preoperative
chemotherapy appears to increase the chance for a curative
resection and enhance survival in responding patients.
Unfortunately Barrett’s carcinoma shows a very
heterogenous behaviour in progression and response to
neoadjuvant chemotherapy. Response occurs in only 50%
of patients after chemotherapy with cisplatin, 5-fluorouracil
or leucovorin. If patient outcome could be predicted
accurately, treatments could be tailored individually to
avoid chemotherapeutic induced side-effects in nonresponding patients. Prediction of the final response seems
to be possible by measuring the metabolic response by PET
scans at the beginning and after two weeks of
chemotherapy. Differentiation of responders from nonresponders even before starting chemotherapy might be
possible in the future using microarray technology and
immunohistology in endoscopically obtained biopsies of
the tumor.
We found a pattern of 86 genes that were at least 2-fold
differentially regulated comparing responding and nonresponding adenocarcinomas of the esophagus. The
predominant genes encoded for the regulation of the cell
cycle, transduction, translation, cell–cell interaction,
cytoskeleton and the signal transduction. The strongest
difference was seen for the ephrin B3 receptor, a tyrosin
kinase that is already known in other tumor entities for its
role in cell growth, migration and invasion. The receptor is
negatively controlled by the β-catenin/TCF-complex. Ephrin
B3 signaling couples cell contraction with cell-to-cell
adhesion by promoting the recruitment of E-cadherin to the
membrane.
In conclusion our results suggest that it could be possible
to characterize patients responding to chemotherapy before
starting the treatment using customized microarray analysis.
Ephrin B3 receptor may serve as an important new biological
tumor marker for local invasion and chemotherapy response
or even as a therapeutically relevant target. Further
examinations are necessary to evaluate these results and a
possible therapeutic utility.
Oral bioavailability of many anticancer drugs is poor and
highly variable. This is a major impediment to the
development of new generation drugs in oncology,
particularly those requiring a chronic treatment schedule, a.o.
the tyrosine kinase inhibitors and oral angiogenesis
inhibitors. Limited bioavailability is mainly due to: 1)
cytochrome P450 (CYP, especially CYP3A) activity in gut
wall and liver, and 2) drug transporters, such as P-gp and
breast cancer resistance protein (BCRP, ABCG2) in gut wall
and liver. Shared substrate drugs are affected by the
combined activity of these systems. Preclinical in vitro and
in vivo models have in many cases been poorly predictive for
oral drug uptake in patients because of a.o. interspecies
differences in CYP drug metabolism and intestinal drugtransporting systems. For this reason, we have developed
novel and in part humanized systems that allow reliable
translation of preclinical results to the clinic (Drug Metab
Dispos 33: 892-895, 2005; J Clin Invest 117: 3583-3592,
2007).
Our previous work, also using P-gp knockout (KO) mice,
already showed that P-gp has a major effect on the oral
bioavailability of several drugs and that blockers of P-gp can
drastically improve oral bioavailability of the important
anticancer drug paclitaxel and other drugs in mice and
humans (Cell 77: 491, 1994; PNAS 94: 2031, 1997; Lancet
352: 285, 1998; J Clin Oncol 19: 1160-1166, 2001). This
work revealed, however, that apart from P-gp, other drugtransporting systems and CYP effects also determine overall
oral drug uptake. Indeed, we demonstrated that blockade of
ABCG2 profoundly increased the oral bioavailability of
topotecan in mice and man (J Natl Cancer Inst 92: 16511656, 2000; J Clin Oncol 20: 2943-2950, 2002).
In addition, we demonstrated in four phase II activity
studies that ‘boosting’ of the oral bioavailability of the
widely applied anticancer drugs paclitaxel and docetaxel by
the P-gp and CYP3A inhibitor cyclosporin A (CsA) resulted
in high antitumor activity in advanced breast, non-small cell
lung (NSCLC) and gastric cancer (J Clin Oncol 20: 45084516, 2002; reviewed by us in TIPS 27: 17-24, 2006). More
recently we demonstrated that in order to enable oral
therapy with docetaxel, the boosting agent CsA could well
be replaced by the more effective and selective CYP3A
3476
Abstracts of the 8th International Conference of Anticancer Research, 17-22 October 2008, Kos, Greece
inhibitor ritonavir; this concept has been proven in our
mouse models (Cancer Res 62: 6158-6164, 2002) and in
patients (BCPT, 2007; Br J Clin Pharmacol, 2008, in press).
For the preclinical and clinical studies the intravenous
(i.v.) solutions of paclitaxel and docetaxel have been used, as
these drugs are only available for i.v. use. However, these
formulations are highly unsuitable for further oral clinical
development for practical and safety reasons and due to
limited pharmaceutical stability. For this reason, we have
developed a range of novel capsule formulations of docetaxel
and paclitaxel that need urgently to be tested in patients with
cancer. Preclinical pharmaceutical tests performed by us
reveal excellent dissolution of active drug.
593
TRANSGENIC STRATEGIES TO
STUDY HUMAN DISEASES
Johannes Schenkel
German Cancer Research Centre and University,
Heidelberg, Germany
Transgenic mice exhibit an enormous scientific potential for
many purposes, including serving as a specific in vivo model
for human diseases. Different techniques are used to generate
genetically modified animals harbouring a gain or a loss of
function. The number of transgenic mice is increasing
rapidly. Small populations, continued danger of loss, the
need to keep these mutants in stock and frequent interchange
of transgenic mice between different facilities are some of
the major challenges for laboratory animal scientists when
dealing with these unique mutants.
Two transgenic mouse models for human diseases will be
presented: The regulation of the human papilloma virus
(HPV) 11: About 100 HPVs; are described, some of them
are associated with malignant growth, others with benign
proliferations. Subsequently it is of paramount interest to
understand their regulation, but these viruses show a high
host-specificity. To study HPV-regulation in a human-free in
vivo-system transgenic mice were generated carrying a
reporter gene under control of the key regulatory element
(URR) of HPV11. A developmentally regulated, inducible,
and specific transcription was observed, but the expression
pattern in the original target (skin) was not satisfying in this
host and virus free system. To be closer to the in vivo
conditions, a transgenic mouse model was established
expressing the virus activity influencing protein: HPV11-E2.
The transgenic expression of the E2 did not lead to
phenotypic changes. E2/URR11 double-transgenic mice are
already bred to study the HPV11 regulation in more detail.
Signal transduction in a mouse model for neuro-degenerative
diseases: Neurodegenerative diseases often result in an
(excessive) neuronal cell death, leading often to a large, non-
reversible injury. However, the molecular mechanisms or
pathways responsible are not fully understood.
The c-Jun transcription factor plays a crucial role in
promoting apoptosis, inhibition of its activation might reduce
the size of cell death and thus increase functional outcome.
Several genetically modified mice influencing c-Jun and its
pathways at various steps and were investigated in a model
for experimental stroke and other neurodegenerative diseases.
Our data suggest that attenuation rather than a complete block
of c-Jun action appears more promising for therapy of stroke.
594
ORIGIN AND DEVELOPMENT
OF GLIOMAS IN RELATION
WITH PROGNOSIS AND THERAPIES
D. Schiffer, M. Mellai, V. Caldera, L. Annovazzi
and E. Andreoli
Neuro-bio-oncology Center, Policlinico di Monza,
University of Turin, Vercelli, Italy
The origin of gliomas is discussed in the light of the
classic experiments of transplacental induction of tumors
by nitrosoureas in the rat and their development from
germinative and subventricular zones. Today this origin
became a general knowledge supported by an extensive
literature on stem cells, progenitors and precursors with
the recognition of the existence of brain tumor stem cells.
Two concepts are fundamental: the relationship between
factors regulating cytogenesis and the genetic alterations
which characterize tumor transformation and the
importance of epigenetic events. The possibility that
differentiated cells may revert to a stem cell-like status and
that undifferentiated cells may acquire the same status,
assume a particular significance in tumor progression. All
these considerations affect histological diagnosis,
prognosis and therapy of gliomas, including their cell
resistance. The problem becomes more complicated not
only if other characteristics of tumor malignancy are
considered, such as cell motility and migration, but also
the recently acquired knowledge that stem cells from SVZ
or hemispheric adult cells of the astrocytic lineage can
move toward the tumor or that non tumor adult astrocytes
can be recruited into the tumor. To the observations
concerning the different molecular pathways leading to
tumor transformation, those based on the recent use of
siRNA and those carried out on the apoptosis/autophagy
system must be added.
595
DOWNSTREAM AKT REGULATION OF
PROLIFERATION, APOPTOSIS AND
AUTOPHAGY IN GLIOBLASTOMAS
3477
ANTICANCER RESEARCH 28: 3157-3556 (2008)
D. Schiffer1, L. Annovazzi1, V. Caldera1,
M. Mellai1, L. Tessitore2 and G. Valente3
1Neuro-bio-oncology
Center, Policlinico di Monza,
University of Turin, Vercelli;
2DISCAF and 3Clinical and Experimental Medical
Department, University of East Piedmont, Novara, Italy
PI3/AKT pathway plays an important role in the process of
transformation of gliomas. Under the control of growth
factors, it terminates by regulating proliferation and
apoptosis. Two steps in the pathway, STAT3 and mTOR
(target for Rapamycin) have been recognized as possible
targets for tumor therapy, but in human gliomas their
correlation with proliferation and apoptosis are not
completely known. In 64 gliomas STAT3 and mTOR have
been investigated by molecular genetics, immunohistochemistry and Western blotting procedures in relation with
EGFR, EGFRvIII, PTEN, AKT, Caspase-3, PARP.1, S6,
Beclin 1 and Ki.67/MIB.1. STAT3, mTOR and AKT together
with S6 increased with malignancy grade, but only S6
correlated with the proliferation index, whereas there was a
good correlation of EGFR/EGFRvIII with AKT. Both STAT3
and mTOR correlated with AKT and in the terminal part of
the pathway S6 indicated SK1 as an important step toward
proliferation. No correlation was found of STAT3 and mTOR
with apoptosis, maybe for technical difficulties of its
demonstration in tumor tissues. On the contrary, both were
inversely correlated with Beclin 1, in line with the knowledge
that autophagy is not activated in malignant gliomas. The
rationale for the identification of STAT3 and mTOR as
therapy targets seems to be well-grounded in human gliomas.
596
ELECTRON EMISSION FROM GENISTEIN IN
RELATIONSHIP TO ITS ANTICANCER
PROPERTIES
N. Getoff, H. Schittl and R.M. Quint
Section of Radiation Biology, Department of Nutrition
Sciences, The University of Vienna, Althanstr. 14, UZA II,
A-1090 Vienna, Austria
Genistein (GEN; 4’,5,7-Trihydroxyisoflavone) is a
phytohormone with biological properties similar to those of
estradiol. It has been established that GEN shows
antiangiogenetic and antitumor effects in vivo (1). Very
recently it was observed that under the influence of oxidizing
(OH, O2•–), as well as reducing free radicals (e–aq, H etc.),
GEN features a strongly expressed antitumor ability in vitro
and acts synergistically on mitomycin C (2).
On the other hand it has been demonstrated that sexual
hormones such as 17β-estradiol, progesterone (3), as well as
3478
testosterone (4) can eject electrons from their excited singlet
state in polar media. Under certain biological conditions this
ability of the hormones can result into metabolites involved
in the initiation of breast and prostate cancer, respectively.
The present work reports the electron ejection from in
singlet state excited GEN, initiated by monochromatic UVlight (λ=254 nm; 4.85 eV/hν) in aqueous solution (pH~7.4
at 37˚C).
Comparing the molar extinction coefficients (ε in
L.mol–1.cm–1) at the absorption maxima (270 nm) it was
proved that GEN has a tendency to form “associates”
(labile GEN-complexes) at concentrations above 5×10–6
mol.L–1. On the other hand GEN possesses high reactivity
towards e–aq, k(e–aq + GEN) = 6.2×109 L.mol–1.s–1 (5). As a
result of this fact solvated electrons could not be found
using 1×10–5 mol.L–1 GEN. By application of 5×10–5,
7.5×10–5 and 1×10–4 mol.L–1 GEN at pH~7.5 were
obtained: Q(e–aq) = 2.4×10–3, 1.6×10–3 and 1.3×10–3,
respectively. On the other hand using air-free, aqueous
5×10–5 mol.L-1 GEN at 30˚, 37˚ and 45˚C, increasing
quantum-yields (Q(e–aq) = 1.9×10–3, 2.4×10–3, 4.8×10–3,
respectively) were observed, indicating that the Q(e–aq)yield also depends on temperature.
The biological consequences of the bifunctional property of
GEN: electron emission and electron consumption in respect
to cancer are discussed. Its bifunctional ability enables GEN to
communicate with other systems in the organism.
1 Wietrzyk J et al: Antiangiogenic and antitumor effects in
vivo of genistein applied alone or combined with
cyclophosphamide. Anticancer Res 12: 3893-3896, 2001.
2 Hartmann J and Getoff N: Effect of free radicals on the
biological action of genistein in vitro and synergism with
mitomycin C. Anticancer Res 28: 2008, in press.
3 Getoff N et al: Photo-induced electron emission from 17βestradiol and progesterone and possible biological
consequences. J Photochem Photobiol, B: Biology 92: 3841, 2008.
4 Getoff N et al: Electron emission from photo-excited
testosterone in water-ethanol solution. J Photochem
Photobiol., B: Biology: submitted.
5 Cai Z et al: Interaction of hydrated electron with dietary
flavonoids and phenolic acids: Rate constants and transient
spectra studied by pulse radiolysis. Free Radic Biol Med
27: 822-829, 1999.
597
TISSUE MICROARRAYS ARE RELIABLE TOOLS
FOR THE CLINICOPATHOLOGICAL
CHARACTERIZATION OF LUNG CANCER TISSUE
Lars Henning Schmidt1, Stefan Biesterfeld2,
Andreas Kümmel1, Andreas Faldum3, Martin Sebastian1,
Christian Taube1, Roland Buhl1 and Rainer Wiewrodt1
Abstracts of the 8th International Conference of Anticancer Research, 17-22 October 2008, Kos, Greece
1Pulmonary
Division, III. Medical Clinic, 2Institute of
Pathology and 3Institute of Medical Biostatistics,
Epidemiology and Informatics, Johannes GutenbergUniversity, 55101 Mainz, Germany
Background: The advantage of tissue microarray (TMA) is
its ability to efficiently analyze large numbers of tissue
specimens in a methodologically uniform way. The reliability
of TMAs especially with regard to clinicopathological
characterizations when compared to conventional
immunohistochemistry (IHC) was evaluated. Materials and
Methods: Seventy two embedded tissue sections from lung
cancer patients were stained with monoclonal antibodies
against the tumor-associated markers TA-MUC1 and Lewis
Y. Three representative cores of every tumor were embedded
in a paraffin array multiblock. The IHC was evaluated by the
immunoreactive score (IRS). Results: The data for the TMA
IHC and the conventional IHC were concordant (kappa
≥80%) for both markers. Likewise, discordance (McNemar’s
test) was low and sensitivity and specificity were above 80%
for both markers. In the samples with high positive
expression, the concordance increased (kappa ≥90%)
discordance disappeared (McNemar p=1.0) and sensitivity
and specificity increased above 90% for both markers. Using
Cox regression models, all the clinicopathological
dependencies were equivalent for both techniques and both
markers. Conclusion: Immunohistochemistry with tissue
microarrays is valid and provides results equivalent to
conventional immunohistochemistry with respect to
expression patterns and clinicopathological characterizations.
598
BCL-2, BCL-XL, AND PP32/PHAPI IN RESECTED
NON-SMALL CELL LUNG CANCER PATIENTS
Lars Henning Schmidt1, Andreas Kümmel1,
Martin Schuler M.2, Stefan Biesterfeld3, Andreas Faldum4,
Martin Sebastian1, Christian Taube1, Roland Buhl1 and
Rainer Wiewrodt1
1Pulmonary
Division, III. Medical Clinic, 3Institute of
Pathology, and 4Institute of Medical Biostatistics,
Epidemiology and Informatics, Johannes GutenbergUniversity Medical Center, 55101 Mainz;
2Department of Medicine (Cancer Research), West German
Cancer Center, University Hospital Essen, 45122 Essen,
Germany
Deregulation of apoptosis signaling is commonly found in
cancer cells. Some studies suggest that overexpression of the
anti-apoptotic proteins Bcl-2 and Bcl-xL in non-small cell lung
cancer (NSCLC) is associated with adverse prognosis. This is
thought to result from their function as cell death suppressors
and resistance factors in the mitochondrial pathway. Another
important factor in this pathway is pp32/PHAPI, as it seems to
sensitize NSCLC cells to apoptotic stimuli and thus permitting
an improved outcome in patients following chemotherapy for
advanced NSCLC. However, contradicting observations have
been described by other groups. Against this background, we
have evaluated the prognostic effect of Bcl-2, Bcl-xL, and
pp32/PHAPI expression in tumor samples from 87 surgically
resected NSCLC patients using tissue microarray
immunohistochemistry. Bcl-xL expression was immunohistochemically detectable in 20 cases (23%), Bcl-2 in 25 cases
(29%) and pp32/PHAPI in 78 cases (90%). Using Cox
proportional hazards models, Bcl-xL and pp32/PHAPI
expression, normal lung function and early stage were
identified as independent favorable prognostic factors in
NSCLC patients. This contrasted the established role of antiapoptotic proteins as resistance factors in patients receiving
chemotherapy. Interestingly, impairment of lung function was
associated with Bcl-2 expression, which may suggest a
biological involvement of Bcl-2 family proteins in the
pathogenesis of chronic obstructive pulmonary disease, which
commonly precedes the development of NSCLC.
599
FIBROBLAST-DERIVED TUMOR MARKERS:
FROM PROTEASES TO microRNA
Boye Schnack Nielsen
Exiqon A/S, Diagnostic Product Development, Skelstedet
16, 2950 Vedbaek, Denmark
Cancer cell invasion is a multicellular process involving a
heterogeneous group of stromal cells in addition to the
cancer cells themselves. The fibroblasts constitute a basic
component among stromal cells that contribute to matrix
remodeling, synthesis and degradation. In most
adenocarcinomas, the fibroblasts are found as activated and
myo-differentiated fibroblasts, myofibroblast. Myofibroblasts
are found in benign, pre-invasive (in situ) and invasive
carcinomas, and thus, are not an indication of malignancy
itself. However, myofibroblasts start expressing novel matrix
degrading proteases, such as matrix metalloprotease 13
(MMP13), and urokinase plasminogen activator (uPA),
during the transition from noninvasive (DCIS) to invasive
breast cancer, and therefore are likely to promote the
transition to invasion by degrading basement membrane
collagen and laminin. We have recently identified some
microRNAs in cancer associated fibroblasts. MicroRNAs
represent a new and relatively uncharacterized group of 2024nt long RNA sequences that show great promise as
biomarkers in cancer. They can be detected in tissue
sections by in situ hybridization using locked nucleic acid
(LNA)-modified oligos. Although little is known about the
precise functional aspects of microRNA, they have already
3479
ANTICANCER RESEARCH 28: 3157-3556 (2008)
been shown to be important regulators that influence major
biological processes, including tumorigenesis.
600
MULTIPLEXED PROTEIN ANALYSIS
APPLIED TO BREAST CANCER BIOPSIES
Nicole Schneiderhan-Marra1, Georg Sauer2,
Helmut Deissler2 and Thomas Joos1
1NMI,
Natural and Medical Sciences Institute at the
University of Tuebingen, Markwiesenstraße 55, 72770
Reutlingen;
2Department of Obstetrics and Gynaecology, University of
Ulm Medical School, Frauensteige 14, 89075 Ulm,
Germany
One of the most promising approaches in cancer research is
the identification of biomarkers that allow defining of patient
subgroups that will benefit from specific treatment schemes.
Potential biomarkers or pattern of biomarkers can be
identified using a target-driven approach. Protein microarrays
can be applied to simultaneously quantify numerous target
proteins from minimal amounts of sample material.
We have used the bead-based Luminex technology to
develop multiplexed sandwich immunoassays to analyze a
set of 54 pre-defined breast cancer relevant proteins: 113
lysates of shock-frozen large core needle biopsies were
analysed using these assays. Validation of the bead-based
immunoassays was carried out by comparing HER2 and ER
protein expression with data obtained by the corresponding
immunohistochemical routine assessment.
Concordance of the generated protein expression data sets
with results of conventional immunohistochemical staining
was demonstrated for the expression of the estrogen receptor
and of HER 2. Furthermore, a set of five proteins was
identified, which allows the prediction of nodal
involvement. Further methodological refinement of
multiparametric protein analyses and associated clinical
studies will most likely lead to parameter sets which define
subgroups of patients who will benefit from specific
treatment regimens.
601
CONTEMPORARY TREATMENT OF PRIMARY
ADVANCED EPITHELIAL OVARIAN CANCER
Susanne E. Schneuber, Heinz S. Scholz,
Vesna Bjelic-Radisic and Raimund Winter
University of Graz, Department of Obstetrics and
Gynecology, Auenbruggerplatz 14, A - 8036 Graz, Austria
Ovarian cancer continues to be one of the major causes of
death from cancer among women in the Western world. The
majority of patients present with stage III or IV disease and
3480
the advanced stage of disease at the time of diagnosis is the
main factor contributing to the overall poor prognosis.
In this review we give an overview on screening, FIGO
staging, survival rates, prognostic factors and on
contemporary treatment in early and advanced ovarian cancer.
In particular we report on our experience with multivisceral
cytoreductive surgery in advanced epithelial ovarian cancer.
Additionally, we outline the role of adjuvant chemotherapy as
a standard of care and the role of neoadjuvant chemotherapy,
intraperitoneal chemotherapy and hyperthermic intraperitoneal
chemotherapy (HIPEC) as possible prospective standards of
care in patients with ovarian cancer.
602
MIGRATION STIMULATING FACTOR (MSF) AS A
MEDIATOR OF EPITHELIAL-STROMAL
INTERACTIONS IN HUMAN TUMOURS
Ana M. Schor, Ian R. Ellis, Sarah J. Jones,
Stephane Perrier, Go Ohe and Seth S. Schor
Unit of Cell and Molecular Biology, The Dental School,
University of Dundee, Dundee DD1 4HR, UK
Migration stimulating factor (MSF) is a 70 kDa truncated
isoform of fibronectin. It is generated from a foreshortened
pre-message produced by the transcriptional read through of
the intron separating fibronectin exons III-1a and III-1b.
MSF is an oncofetal regulatory molecule constitutively
expressed by three cell populations (epithelial, fibroblast and
endothelial) during fetal development, not expressed in the
majority of healthy adult tissues, and re-expressed by both
tumour and tumour-associated stromal cells in common
human cancers. MSF is also systemically re-expressed by
skin fibroblasts derived from distant, uninvolved sites in
breast cancer patients. Recent data indicate that the level of
MSF expression by carcinoma cells and tumour-associated
fibroblasts is inversely related to survival in patients with
oral and breast tumours.
Cultured fibroblasts maintain the MSF production status
of their tissue of origin. We have recently developed
experimental protocols that enable us to induce MSFproducing fibroblasts to switch-off MSF expression and,
conversely, to induce normal adult fibroblasts to switch-on
MSF. These changes in MSF expression are hereditable
(persistent in the absence of further treatment), but
completely reversible, suggesting that the switch-on and-off
of MSF expression is controlled by epigenetic mechanisms.
Recombinant MSF displays a number of bioactivities of
relevance to cancer development and metastasis, including
stimulation of cell invasion through 3D matrices, hyaluronan
synthesis, angiogenesis and proteolytic activity. Two MSF
isoforms have been cloned, and inhibitors produced by
epithelial and endothelial cells have been identified. Our data
Abstracts of the 8th International Conference of Anticancer Research, 17-22 October 2008, Kos, Greece
indicate that MSF acts as a paracrine and autocrine factor on
three cell populations (epithelial, endothelial and fibroblasts)
and its bioactivity is modulated by the type of isoform
produced, the presence of other soluble factors and the
nature of the extracellular matrix in contact with the cells.
603
MYTHS AND FACTS IN THE SURGICAL
MANAGEMENT
Guido Schumacher
Department of General-, Visceral-, and Transplantation
Surgery, Charité Campus Virchow Klinikum, Berlin,
Germany
Indication, surgical procedures, and postoperative
management has been developed during the last centuries to
reach the modern standards of patient care. Since the
introduction of evidence based medicine, many clinical trials
have been performed to prove or disprove effects of certain
steps of surgical management. However, many of the actual
diagnostic and therapeutic steps have never been proven,
even though their necessity and usefulness is considered to
be essential for a successful treatment. A major reason may
be the opinion of individual specialists who internationally
report on their personal experiences as given facts. This has
a particular impact if a leading specialist is able to teach
other specialists who then spread certain techniques in
patient care and surgery. The value of personal experience
appears to be valuable, since the disease and presents with a
very large individual variability, which makes clinical trials
often difficult and cause criticism. Examples of nonevidence-based diagnostic and therapeutic steps are the use
of certain drainages, certain anastomotic techniques,
strategies for the treatment of anastomotic leakages and
peritonitis and others. We will discuss important steps of the
perioperative management with emphasis on the actual
evidence, which is based on clinical trials or personal
experiences of specialists.
604
PRO AND CONS FOR RADICAL SURGERY IN
OVARIAN CANCER?
Jalid Sehouli, Guelten Oskay-Oezcelik, Guido Schumacher
and Werner Lichtenegger
Department of Obstetrics and Gynecology, Charite Medical
University, Germany
Despite maximal cytoreduction and adjuvant chemotherapy
with paclitaxel and carboplatin, a large number of patients
with epithelial ovarian cancer will suffer from tumor
recurrence within 3 years after their initial diagnosis.
In contrast to the situation of patients with primary ovarian
cancer the value of surgery in the salvage setting is
controversially discussed.
Two prognostic groups should be differentiated: patients
with platinum-sensitive ovarian cancer and those with
platinum-resistant ovarian cancer. The indication for surgery
is palliation to control clinical symptoms (e.g. bowel
obstruction) and to increase the progression free survival and
overall survival. Nevertheless, the pros and cons arguments
base on retrospective data, only. Based on the available
evidence from the literature and a large series of data from
our center, all surgical aspects are discussed in detail.
605
ROLE OF BLM AND 53BP1 DURING
HOMOLOGOUS RECOMBINATION
Vivek Tripathi, Sarabpreet Kaur, Tirunelvely Nagarjuna and
Sagar Sengupta
National Institute of Immunology, Aruna Asaf Ali Marg,
New Delhi 110067, India
Mutations in BLM helicase causes Bloom Syndrome,
characterized by predisposition to all forms of cancer. Hence
lack of BLM and its interactions with its partners can lead to
deregulation of RAD51-mediated homologous recombination.
We have demonstrated that BLM, signal transducer 53BP1 and
RAD51 form a trimeric complex both in vitro and in vivo.
Phosphorylation in specific domains of the three proteins
mediated this interaction. Presence of BLM enhanced the
interaction between 53BP1 and RAD51. The interactions
between the three proteins had functional consequences. Lack
of 53BP1 decreased cell survival and enhanced chromosomal
aberration after replication arrest. 53BP1 exhibited both BLMdependent and independent anti-recombinogenic functions. Both
BLM and 53BP1 abrogated endogenous RAD51 foci formation
and disrupted RAD51 polymerization. The disruption of
RAD51 polymerization was abrogated when non-binding or
phosphorylation-deficient mutants of BLM and 53BP1 were
used. As a result, loss of BLM and 53BP1 synergistically
enhanced stress-dependent HR. These results provide evidence
regarding the cooperation between two signal transducers, BLM
and 53BP1, during maintenance of genomic integrity.
606
ELECTROCHEMOTHERAPY – CLINICAL
EFFECTIVENESS ON CUTANEOUS AND
SUBCUTANEOUS TUMOR NODULES AND ITS
VASCULAR DISRUPTING EFFECT
Gregor Sersa
Institute of Oncology Ljubljana, Zaloška 2, SI-1000
Ljubljana, Slovenia
3481
ANTICANCER RESEARCH 28: 3157-3556 (2008)
Electrochemotherapy is a local drug delivery approach aimed
at treatment with palliative intent of cutaneous and
subcutaneous tumor nodules of different histology.
Electrochemotherapy, via cell permeabilizing electric pulses
potentiates the cytotoxicity of non-permeant or poorly
permeant anticancer drugs with high intrinsic cytotoxicity,
such as bleomycin or cisplatin, at the site of electric pulse
application.
Physicochemical basis of this therapy allows prediction
that electrochemotherapy has good antitumor effect on all
tumor types, which was demonstrated in several clinical
studies. The results of the clinical trial demonstrated that an
objective response rate of 85% (73.7% complete response
rate) was achieved on the electrochemotherapy-treated tumor
nodules, regardless of tumor histology, and drug used
(bleomycin, cisplatin) or route of its administration
(intravenous, intratumoral). Most frequently it is used in the
treatment of multiple cutaneous metastases of melanoma
when they cannot be surgically excised due to their number
or localization. In such cases, long-term remission up to
several years can be obtained. Electrochemotherapy can also
be used as a cytoreductive treatment before surgical resection
in an organ-sparing attempt.
Bleeding skin melanoma metastases are a common but
difficult management problem. Many patients are in poor
physical condition, and therefore electrochemotherapy is
very convenient, as it is quick, outpatient-based and
effective. The effectiveness on bleeding tumors is due to
vascular disrupting effect of electrochemotherapy. The
underlying mechanism of blood flow reduction and vascular
disrupting action has been studied extensively. In
electrochemotherapy, where endothelial cells are in direct
contact with the chemotherapeutic drugs, they undergo cell
death due to the increased drug uptake.
Electrochemotherapy is now a clinically acknowledged
method for the treatment of cutaneous and subcutaneous
tumors. Its advantages are high effectiveness on tumors with
different histology, simple application, minimal side-effects
and the possibility of effective repetitive treatment.
607
MOLECULAR ANALYSIS OF BREAST CANCER
METASTASIS TO BONE IN AN “ALL HUMAN”
NOD/SCID MOUSE MODEL
W. Yang, P. Lam, Y. Amemiya, H. Kahn, A. Yee,
C. Holloway and A. Seth
Sunnybrook Research Institute, University of Toronto,
Toronto, ON, Canada
Background: Bone is the most common site of metastasis in
breast cancer, affecting up to 80% of women with advanced
disease, leading to bone complications or skeletal-related
3482
events. Current studies on the bone metastasis process have
been hampered by the lack of preclinical models to evaluate
novel therapeutics and to study the biology of the disease.
Materials and Methods: To create an “all human” mouse
model that explicitly investigate the bone metastatic behavior
of human breast tumors, we first engrafted human bone
fragments into the both flanks of NOD/SCID mice and
subsequently transplanted primary human breast tumor under
only left flanks of the hu-bone NOD/SCID mice. Results: We
found that engrafted human bone remains functional for
more than 20 weeks of implantation and that approximately
30% of primary breast tumors survived and generated tumors
when placed into hu-bone NOD/SCID mice. After
performing serial re-transplantation experiments using
primary breast tumors, we observed metastasis to the
opposite tumor-free human bone fragments and some host
tissues including kidney, lung and lymph nodes.
Interestingly, none of the human breast tumors metastasized
to the mouse skeleton, providing evidence that speciesspecies osteotropism is essential for bone metastasis. Gene
expression profiles using whole genome microarrays were
generated from engrafted patient breast tumors to identify
genes that correlate with growth and metastasis. Two groups
of clinically significant genes are emerging from our ongoing
results. One group represents genes associated with the
future biological behavior of the original patient tumors.
They are found by comparing gene levels between patient
breast tumors that did and did not metastasize in the hu-bone
NOD/SCID model. A second set of genes associated with the
metastatic phenotype, but not necessarily predictive of that
state, are revealed by comparing gene expression levels
between the original patient tumors and the tumors that form
in the human bone implants and mouse tissues. In the first
group, relative to the non-metastatic tumor, 36 genes with
significantly altered expression pattern were found in the
primary tumors that subsequently metastasized in the mouse
model. In the second group, relative to the original patient
tumors, 205 genes were found to be significantly altered in
tumors that grew in first human bone implants. Of these, 183
were also found in tumors that metastasized to second
initially tumor-free human bone implants and in lung
metastases. Two of these include CSF1R which is upregulated and IGFBP7 which is down-regulated. Both
IGFBP-7 and CSF1R are important in mammary gland
development and have been implicated in breast
carcinogenesis and associated with poor outcome in breast
cancer patients. Conclusion: By using the “all human”
NOD/SCID mouse model we have identified many potential
targets that are up- or down-regulated in bone metastatic
breast tumor samples. We anticipate that our study will help
in developing breast cancer biomarkers for patients that are
at high risk for bone metastasis and will be valuable for
clinical diagnosis and treatment.
Abstracts of the 8th International Conference of Anticancer Research, 17-22 October 2008, Kos, Greece
This work was supported by the Canadian Breast Cancer
Research Alliance special program grant on metastasis.
608
THE ANTICARCINOGENIC ACTIVITY OF
VITAMIN D WITH AND WITHOUT IONIZING
RADIATION
Shraga Shany
Department of Clinical Biochemistry, Ben-Gurion
University of the Negev, Beer Sheva, 84105, Israel
Recent data suggest that besides its major role in mineral
homeostasis, the active metabolite of vitamin D, 1.25dihydroxyvitamin-D3 (1.25(OH)2D3) has an anti-carcinogenic
activity. However, its therapeutic use is limited, since it
causes hypercalcemia in the concentrations effective for cell
growth inhibition. In order to overcome this limitation, the
present study have checked two attitudes: i) The possible use
of the less-calcemic vitamin D synthetic analog 1.25dihydroxy,16-ene,24-oxo,vitamin D3 (JK-1624-3) and to
compare its anti-carcinogenic activity, in vitro, with that of
the native vitamin D active metabolite, 1.25(OH)2D3. ii) The
possible use of lower concentrations of 1.25(OH)2D3 in
combinations with other anti-carcinogenic agents, in order to
get an additive or even synergistic effects. Similarly, the
combination of vitamin D treatment with ionizing radiation
was tested in vitro on prostate cancer cells.
Radiotherapy, by itself, is a common effective
anticarcinogenic treatment. However, this treatment is
accompanied by many complications. The possibility that
pretreatment with vitamin D and other anticarcinogenic
agents will potentiate the therapeutic effect of radiation was
assessed in the present study. Incubation of cancer cells (HL60, HT-29, LNCaP cell lines) with JK-1624-3 revealed a
significant inhibition of cell proliferation, similar to that
obtained by 1.25(OH)2D3. These effects were found to be
dose- and time-dependent. These vitamin D compounds
cause a significant induction of cell cycle arrest in the G1phase, as determined by FACS analysis. Incubations of HL60 cells with either 1.25(OH)2D3, or the synthetic analog,
revealed a very significant differentiation to monocyte-like
cells, as expressed by the increased levels of CD-11b and
CD-14 in the treated cells. The combined treatment of
vitamin D, valproic acid and radiation was tested on
androgen-refractory prostate cancer cell line DU-145. While
radiation alone caused 30.6% cell growth inhibition,
pretreatment with 1.25(OH)2D3, valproic acid, or both
agents, revealed cell growth inhibition of 46.4%, 83.0% and
87.9%, respectively. Cell cycle analysis showed that radiation
following the combined treatment resulted in an increase in
apoptosis and cell accumulation mainly in the S-phase of cell
cycle.
In conclusion, the present results confirm the
anticarcinogenic activity of the native vitamin D active
metabolite. These results emphasize the possible therapeutic
use of less calcemic vitamin D analogs, such as JK-1624-3.
The combined pretreatment potentiates the effect of radiation
and therefore may allow the use of lower concentrations of
1.25(OH)2D3, on one hand, and lower radiation doses, on the
other hand. This combined treatment may be more effective
with fewer side-effects.
609
COMBINED PRETREATMENT OF VITAMIN D AND
HISTONE DEACETYLASE INHIBITOR ENHANCES
SENSITIVITY TO RADIATION IN PROSTATE
CANCER CELLS
Vladimir Gavrilov1, Yaron Leibovich2, Olga Belochitski2,
Samuel Ariad2 and Shraga Shany1
Departments of 1Clinical Biochemistry and 2Oncology,
Soroka Medical Center and Faculty of Health Sciences,
Ben-Gurion University of the Negev, Beer-Sheva, Israel
Radiotherapy is known to be an effective treatment of
prostate cancer (PCa). However, many complications are
involved including rectal bleeding, erectile dysfunction and
urinary incontinence. Therefore, it is important to develop
PCa-sensitizing pretreatments that could potentiate the
therapeutic effect of radiation, allow the use of lower
radiation doses and limit the side-effects.
Toward these aims, we suggest combining the
anticarcinogenic vitamin D active metabolite, 1,25(OH)2D3,
and sodium valproate (an antiepileptic drug that inhibits
histone deacetylase activity) in order to sensitize PCa cells
to radiation. The rationale of this notion is based on
preclinical studies reporting increased efficiency of radiation
after 1,25(OH)2D3 or sodium valproate pretreatment (Dunlap
et al., 2003; Camphausen et al., 2005). We evaluated the
effect of the suggested treatment on the androgen-refractory
PCa cell line DU145. Cancer cells were grown in RPMI1640 medium containing 10% FCS. DU145 cells were
pretreated for three days with 100 nM 1,25(OH)2D3 or 1 mM
sodium valproate, or their combination. After that, PCa cells
were irradiated with a dose of 4 Gy and grown for additional
four days. Irradiation by itself decreased DU145 cell growth
by 30.6% (p<0.0001). However, pretreatment with
1,25(OH)2D3, sodium valproate or with a combination of
both drugs reduced PCa cell growth by 46.4%, 83.0% and
87.9%, respectively (p<0.0001). Cell-cycle analysis showed
that the cell growth-inhibiting effect of these treatments was
a result of increased apoptosis and altered cell-cycle
distribution.
Irradiation induced apoptosis and caused accumulation of
DU145 cells in the S-phase and to a lesser extent in the
3483
ANTICANCER RESEARCH 28: 3157-3556 (2008)
G2/M-phase of the cell-cycle in both untreated and
pretreated cells. These changes were found to be maximal in
the cells pretreated with sodium valproate alone. However,
irradiation after combined pretreatment with 1,25(OH)2D3
and sodium valproate had the greatest effect in suppressing
PCa cell growth.
In conclusion, the results support our hypothesis that a
combination of 1,25(OH)2D3 and sodium valproate is highly
efficient in potentiating the anticancer activity of ionizing
radiation. As such, we believe that this combined
pretreatment may provide the basis for the clinical
application of radiotherapy for the treatment of hormonerefractory prostate cancer.
610
EFFECT OF ANTI-INFLAMMATORY (IL-4, IL-10)
CYTOKINE GENES IN RELATION TO RISK OF
CERVIX CARCINOMA
Mohammad Shekari1, Ranbir Chander Sobti1,
Dor Mohammad Kordi Tamandani1 and Vanita Suri2
1Department
of Biotechnology, Panjab University,
Chandigarh;
2Department of Obstetrics and Gynecology, Post Graduate
Institute of Medical Education and Research, Chandigarh,
India;
3Research Laboratory, Faculty of Medicine, Hormozgan
University of Medical Science, Iran- Bandar-Abbas.
Objectives: Cervical cancer is rated the second most
common malignant tumour globally and is an etiologically
linked to human papillomavirus (HPV) infection. Interleukin4 (IL-4) and IL-10 are cytokines with anti-inflammatory
properties. The purpose of this study was to determine the
relationship of different alleles of IL-4 and IL-10 genes as
passive smokers and use of oral contraceptives to risk of
cervical cancer. Materials and Methods: We investigated the
association of cervical cancer with two anti-inflammatory
(IL-4, IL-10) cytokine genes in a case-control study. The
study sample comprised 200 cases of cervical cancer and an
equal number of matched controls by variables number of
tandem repeat (VNTR) and RFLP analysis. Results: In this
study the Rp1/Rp2 genotype of IL-4 gave a borderline
increased risk of developing cervical cancer (OR-1.3,
95%CI-0.45-3.64, p=0.8). In the case of passive smokers, we
also found a marginal increased risk of cervical cancer with
AC and combined AC+CC genotypes (OR-1.7, 95%CI-0.903.34, p=0.1, and OR-1.7, 95%CI-0.90-3.17, p=0.1,
respectively). However, non-significant association was
observed between the use of oral contraceptives and risk of
cervical cancer with these two anti-inflammatory cytokines
with different genotypes. Conclusion: The present study
suggested an increased risk for developing cervical cancer in
3484
North Indian female passive smokers having IL-4 Rp1/Rp2
and IL-10 (AC) genotypes.
611
HERBAL TRADITIONAL SELLER’S
PRESCRIPTIONS FOR CANCER
Mahdieh Shojaa, Leila M. Jouybari and Akram Sanagoo
Golestan University of Medical Sciences, Gorgan, Iran
Introduction: Medicinal plants have been used for the
treatment of disease in many countries. Traditional medicine
has a long history in Iran. Medicinal plants are used to treat
some of cancer symptoms, such as pain, which is common
with all kinds of cancers. The aim of this study was to
explore the medicinal plants prescribed by the traditional
herbal sellers in North of Iran, Gorgan. Materials and
Methods: The study was undertaken in Golestan province in
the North of Iran. We conducted open interviews with all of
traditional sellers of medicinal plants in Gorgan. All of the
interviews were tape recorded. The data were coded and
categorized as it is usual in qualitative methods. Results: The
current survey revealed that thirteen medicinal plants and
also some of the vegetables and fruits such as carrot, tomato
and garlic are prescribed by the traditional sellers for the
cancer remedy. Rosemary, Borage, Salix aegyptiaca are wellknown plants for pain remedy of cancer. Milk Thistle,
Common Corncokle, Fumitory, Milfoil, Quercus, and Rubra
also are recommended for a variety of cancers, such as skin
and stomach cancer. Conclusion: The data indicated that the
use of herbal remedies is very common. Their use seems to
be cultural, rather than attributable to decreased access to
health care. Most herbs used pose no threat to health. In
some cases, remedies may be blended with traditional
medical treatments to ensure better patient compliance.
612
FURTHER EXPERIMENTAL EVIDENCE
OF THE NOVEL RHENIUM AND
PLATINUM ANTITUMOR SYSTEM
Natalia Shtemenko1, Philippe Collery2
and Alexander Shtemenko3
1Dnipropetrovs’k
National University, Dnipropetrovs’k;
State Chemical Technology University,
Dnipropetrovs’k, Ukraine;
2Service de Cancérologie, Polyclinique Maymard, Bastia,
France
3Ukrainian
In our previous publications the antitumor properties of
dichlorotetra-μ-isobutyratodirhenium(III)
(Re1)
and
dichlorotetra-μ-adamantylcarboxylatedirhenium(III) (Re2)
alone and together with cisplatin were shown in the model of
Abstracts of the 8th International Conference of Anticancer Research, 17-22 October 2008, Kos, Greece
rat-specific Guerin’k carcinoma (T8). Especially good results
were obtained when cisplatin was used together with rhenium
substances introduced according to the scheme of antioxidant
therapy via a new Re-Pt antitomor system. Data on
applications of heavy metal compounds in medicine are very
significant and a dirhenium cis-dicarboxylate compound with
propionate ligands was found to be active against some types
of cancer in animal models. We found the nature of the
ligands situated around the cluster fragments played a role in
the phenomena. Here, the data about structure and antitumor
properties of cis-[Re2(GABA)2Cl5(H2O)]2H2O (Re3) alone
and in the Re-Pt system was shown and the possible impact
of the size and nature of the acid radicals in the molecule of
the rhenium cluster to that properties is discussed.
It was shown that Re3 had its own anticancer properties in
this model (stronger than that of Re1 and Re2), but enhanced
cisplatin action on tumor growth less effectively than these
substances. Application of Re3 as a biochemical modulator
of cisplatin action was especially successful under application
of liposomal forms of Re3 and in the majority of experiments,
led to disappearance of tumor cells, and to an increase of
quantities of normal RBC forms, their stability and Hb level
in blood of tumor-bearing animals. Interaction of liposomal
forms of Re3 with red blood cells in experiments in vitro
showed its cell-stabilizing properties. In the models of tumor
growth and hemolytic anemia in vivo, liposomal forms had
better therapeutic effect in comparison with their solutions.
The process of formation of liposomes of Re3 was
investigated by the method of electronic absorption spectra
and mechanism of the interaction with lipids is proposed.
Encapsulation of a cluster rhenium compounds to lipid
coating may have an activation significance for the quadruple
Re-Re bond. Antitumor properties of the rhenium
dicarboxylates with cis-carboxylate groups around cluster
rhenium fragment may be explained first of all by the
antiradical properties of the quadruple metal-to-metal bond
between the two rhenium atoms. The binuclear cluster Re26+fragment is a part of these compounds and includes multiple
rhenium – rhenium bonds with δ-component, which plays
the role of free radical "scavenger" by virtue of minor energy
δ-δ* cleavage. The role of the ligands may be revealed by
the rate of interactions with phosphate groups of lipid
membranes and other molecules of living cells.
613
BIOMOLECULAR CHARACTERIZATION
OF GLIOBLASTOMA MULTIFORME AND
PERITUMORAL TISSUE
Gigliola Sica
Institute of Histology and Embryology, Faculty of
Medicine, Catholic University of the Sacred Heart, Rome,
Italy
In recent years, a new level of understanding into the biology
of glioblastoma multiforme (GBM) has been reached.
Alterations of several tumor suppressor genes and oncogenes
have been reported to be critical to the initial steps of
neoplastic transformation. The relevance of some growth
factor pathways to the development and progression of GBM
has been recognized and significant efforts have been made
to clarify the mechanisms driving angiogenesis which
represents a key event in tumor growth. A possible
relationship between GBM stem cells and neural stem cells
persisting in the neurogenic zones of the adult brain has been
hypothesized. On the contrary, a research delay occurred
concerning the biomolecular characterization of peritumoral
tissue which may have relevant clinical implications due to
the peculiar growth pattern of GBM.
We previously reported the presence of activated MAP
kinases in tumor (1st area) and peritumoral tissue of GBM.
In particular, we found that phosphorylated ERK1/2 is
expressed in tissue surrounding GBM at a distance from < 1
cm to 3.5 cm from the tumor margin. No statistically
significant difference existed in the expression between the
1st area and the surrounding tissue. Phosphorylated ERK1/2
immunoreactivity was independent of the presence of
neoplastic elements and present not only in activated
astrocytes but in apparently normal glial cells also.
Phosphorylated (p) JNK followed the same expression
pathway. In addition, we demonstrated that the stem cell
marker nestin is present in peritumoral tissue even if in a
very low cell percentage including neoplastic cells, activated
astrocytes and again apparently normal glial cells. Finally,
we reported that the ratios pJNK/nestin and (pJNK/total
JNK)/nestin in the area located at a distance <1 cm from the
tumor margin have a prognostic significance in GBM
patients. Nestin was also expressed in the vessel endothelium
both in GBM and in peritumoral tissue.
Since it is believed to be a marker for endothelial cells in
active proliferation, we hypothesized that a foundation of
neoangiogenesis occurred in the tissue surrounding GBM.
For this reason, we studied the expression of nestin in
association with CD105 (endoglin) in tissue localized at a
distance <1 cm (2nd area) and between 1 cm and 3.5 cm
from the tumor border (3rd area). CD105 is a proliferationassociated
and
hypoxia-inducible
transmembrane
glycoprotein abundantly expressed in proliferating
endothelial cells involved in tumoral neoangiogenesis. To
quantify the degree of neoangiogenesis, the most
vascularized areas in the tissue (hot-spots) were localized
and each nestin- or CD105-positive endothelial cell or group
of endothelial cells was counted as an individual vessel at
×200 magnification. The mean value of the vessel count in
five fields was considered the final value of the microvessel
density (MVD). CD105 was exclusively expressed in
endothelial cells. CD105-MVD was higher in GBM than in
3485
ANTICANCER RESEARCH 28: 3157-3556 (2008)
the peritumoral tissue, no statistically significant difference
existing between the 2nd and the 3rd area. A similar trend
was observed for nestin-MVD in peritumoral areas. A
positive correlation was found for both nestin and CD105MVD in the 2nd and 3rd areas. A correlation between
survival and CD105-MVD was found in the 3rd area. In fact,
the median survival time was longer for patients with
CD105-MVD values <8.0 compared with patients with
higher values. The survival difference was present in the first
period of follow-up.
Our results suggest that in the peritumoral tissue a
transformation occurs which is probably induced by growth
factors produced by the tumor mass and that this process is
supported by an activation of vascularization.
614
DEVELOPING APTAMERS AS EFFECTIVE
ANTICANCER AGENTS OR RECOGNITION
UNITS IN BIOSENSOR TECHNOLOGIES
S.C. Simmons1, M.N. Velasco-Garcia1, P.E.C. Brenchley2,
E. McKenzie3 and S. Missailidis1
1Department
of Chemistry and Analytical Sciences, The
Open University, Walton Hall, Milton Keynes, MK7 6AA;
2Renal Research Laboratories, Manchester Institute of
Nephrology and Transplantation;
3Faculty of Life Sciences, Michael Smith Building, Oxford
Road, University of Manchester, M13 9PT, UK
Background: Aptamers are lengths of single or double
stranded nucleotides, typically between 22 and 100 bases
long, which can be generated to recognise specific small
molecules, peptides, proteins, or even cells and tissues.
They have shown great potential as diagnostic and
therapeutic agents in anticancer treatment, due to their high
specificity and affinity to their target molecules. They have
also recently found a niche in the field of biosensing due
to their advantages over antibodies; being simpler to
synthesise, modify and image, as well as their reported
superior affinities and ease of use. Methods: Single
stranded DNA aptamers were selected using a modified
SELEX protocol to an enzymatic tumour marker of
commercial interest, and were eluted based on their affinity
for the target. Using techniques such as ELISA,
immunofluorescence and immunohistochemistry, aptamers
were shown to specifically recognise their target in vitro,
whilst affinity constants were measured using fluorescence
quenching and quartz crystal microbalance techniques.
Functional assays were employed to demonstrate enzyme
inhibition and inhibition of cell motility and tissue
remodelling, using cell and tissue cultures to demonstrate
the aptamers’ antagonistic properties prior to the
introduction of any modification. Introduction of the
3486
aptamers onto screen-printed carbon electrodes offers a
further practical application for easy diagnosis at health
care point. Results and Conclusion: Sandwich ELISA’s
showed the initial recognition of the aptamers for the target
and our studies demonstrated that aptamers did not bind at
the same site as a polyclonal antibody raised for the target.
Immunohistochemistry and immunofluorescence studies
showed a specific recognition of the target by the aptamers,
and compared favourably with the polyclonal antibody.
Affinity constants ranged from 7×107 to 8×107, measured
by the fluorescence quenching experiments and quartz
crystal microbalance. Once applied to the screen-printed
carbon electrodes, these results will form the basis for a
facilitated practical approach in the diagnosis of cancer.
We thank The Open University and The University of
Manchester for their support in this project.
615
CHRONOMICS OF CIRCULATING PLASMA LIPID
PEROXIDES, ANTIOXIDANT ENZYMES AND
OTHER RELATED MOLECULES IN CERVICAL
CANCER PATIENTS
R.K. Singh, R. Singh, V.K. Singh, S. Singh,
S. Mehrotra, A.K. Tripathi, U. Singh,
O. Schwartzkopff, G. Cornelissen and F. Halberg
Departments of Biochemistry, and Obstetrics and
Gynecology, CSM Medical University and Halberg
Chronobiology Center, University of Minnesota,
Minneapolis, MN, USA
Background: Chronomics ( an outgrowth of chronobiology,
the study of diversity in time ), is the inferential statistical
mapping, “imaging’’ of time structures in variables in and
around us, consisting of rhythms, chaos and trends i.e., of
the chronome. The chronome (from chronos, time, and
nomos, rule; time structure) of lipid peroxidation and
antioxidant defense mechanisms may relate to prevention
and curative chronochemotherapeutic efficacy and
management. Patients and Methods: Thirty five newly
diagnosed women with cervical cancer, 30-60 years of age,
and 30 age-matched clinically healthy women were
synchronized for 1 week with diurnal activity from about
06:00 to about 22:00 and nocturnal rest. Breakfast was
around 08:30, lunch around 13:30 and dinner around 20:30.
Drugs known to affect the free-radical system were not
taken. Blood samples were collected at 6-h intervals for 24
h under standardized conditions. Plasma malondialdehyde
(MDA), total lipid hydroperoxide (LOOH), protein
carbonyl (PC), superoxide dismutase (SOD), catalase
(CAT), glutathione peroxidase (GPx), glutathione reductase
(GR) activities, and serum ascorbate, urate and high-density
lipoprotein cholesterol (HDL-C) concentrations and urinary
Abstracts of the 8th International Conference of Anticancer Research, 17-22 October 2008, Kos, Greece
MDA and Melatonin were also determined. Results: A
marked circadian variation was demonstrated for each
variable in each group by population-mean cosinor
(p<0.01). In addition to anticipated differences in overall
mean value (MESOR), patients differed from healthy
volunteers also in terms of their circadian pattern.
Conclusion: Mapping the broader time structure
(Chronome) with age and multifrequency rhythm
characteristics of antioxidants and pro-oxidants is needed
for exploring their putative chemotherapeutic role as
markers in cancer chronoprevention and management of
cervical cancer.
616
OXIDATIVE STRESS AND ANTIOXIDANT
DEFENCE SYSTEM IN CHRONIC MYELOID
LEUKEMIA
Anil K. Tripathi, Rizwan Ahmad, Payal Tripathi,
Raj K. Singh and Vinod K. Singh
Departments of 1Biochemistry and 2Hemato-Oncology
Unit, Department of Medicine, C.S.M. Medical University,
Lucknow, India
Background: Chronic myeloid leukemia (CML) is a
myeloproliferative disorder with a characteristic genetic
rearrangement, the Philadelphia chromosome. Oxidative
stress, a pervasive condition of increased amount of free
radicals is now recognized to be prominent feature of
various diseases including leukemias and their progression.
The relationship between the levels of well known oxidative
stress markers and antioxidants status reflect better health
indices and postures. The present study was planned to
review the role of oxidative stress and antioxidant defense
system in patho-biology of CML. Oxidative stress was
assessed in terms of malondialdehyde (MDA), total lipid
hydroperoxide (LOOH) and protein carbonyl (PC) content
whereas antioxidant status was evaluated in term of reduced
glutathione (GSH) and total thiol (T-SH) and total
antioxidant status (TAS) levels in plasma of CML patients.
Melatonin (MEL) level was measured in urine. Patients and
Methods: The present study included 82 (male: female;
1.8:1) CML patients and 70 (male: female; 1.5:1) age-sex
matched healthy volunteers. Out of 82 CML patients, 66
were in chronic phase (CML-CP) and 16 in accelerated
phase (CML-AP). The median age of CML patients was 35
years and that of healthy participants 34 years. Oxidative
stress and antioxidant defense system markers in plasma
were evaluated by spectro-photometric procedures whereas
MEL level was determined in terms of 6sulphatoxymelatonin excreted in urine by ELISA kit (IBLHamburg). Results: There was a significant increase
(p<0.05) in plasma MDA, LOOH and PC levels in CML
patients as compared to healthy subjects. Our results also
showed that plasma MDA, LOOH and PC levels were
markedly elevated (p<0.05) in both CML-CP and CML-AP
as compared to healthy volunteers. Antioxidant defense
system which was measured in term of reduced GSH, T-SH,
TAS and MEL was found to be significantly decreased
(p<0.05) in CML patients and its phases (CML-CP, CMLAP) as compared to healthy participants. During the followup of total 66 CML-CP patients for 12 months, 15 patients
of CML-CP progressed to the accelerated phase whereas 51
patients remain in CML-CP phase. The mean plasma levels
of MDA, LOOH and PC in patients with CML-CP who
progressed to CML-AP were found to be higher than in
patients with CML-CP who did not progress to the
accelerated phase. An elevation in the plasma levels of
MDA, LOOH, and PC was observed in CML-CP patients
who progressed to CML-AP. The antioxidant defense
system in patients with CML-CP who advanced to CML-AP
was found to be decreased than in patients with CML-CP
who did not progress to the accelerated phase. The
antioxidant defense profiles remained decreased in those
CML-CP patients who progressed to CML-AP. Conclusion:
It could be implicated that plasma MDA, LOOH and PC
levels may reveal the magnitude of oxidative stress in CML
patients whereas reduced GSH, T-SH, TAS and MEL
explain the antioxidant defense system against oxidative
stress. All these parameters for oxidative stress and
antioxidant defense mechanism may precisely reflect the
proliferative signal transduction, disease phenotype and its
subsequent disease progression. Plasma MDA, LOOH and
PC may serve as indices for oxidative stress and disease
progression in patients with chronic myeloid leukemia
whereas antioxidant defense system plays an important role
in nullifying the oxidative stress.
617
ROLE OF PROSTATE STEM CELLS IN
DEVELOPMENT AND CANCER
Fred Sinowatz, Rebecca Kenngott,
David Lincoln and Anwar G. Al-Banaw
Institute of Histology and Embryology, Department of
Veterinary Sciences, University of Munich, Munich,
Germany
The normal prostate gland displays a high degree of cellular
organization. The prostatic epithelium consists of basal cell,
now regarded as stem cells of normal prostate growth and
fully differentiated secretory cells. The importance of the
stem cells varies at different stages of life and prostate
development. Prostate development in the foetus occurs
when small epithelial cell buds intrude into the stroma and
eventually form a complex branched ductular structure. A
3487
ANTICANCER RESEARCH 28: 3157-3556 (2008)
hypothesis about the initiation of benign prostatic tumours
(BPH), and possibly also about the beginning of neoplastic
transformation, suggests that glandular budding may be
reactivated in the adult prostate (Schalken and van Leenders,
2003).
Prostate cancer is the most frequently diagnosed cancer in
men. Despite advances in the detection of early prostate
cancer there is little effective therapy for patients with locally
advanced and/or metastatic disease. The majority of patients
with advanced prostate cancer respond initially to androgen
ablation therapy, however most go on to develop androgen
independent tumours that are finally fatal. A similar response
is seen to chemotherapy and radiotherapy. As a result,
metastatic prostate cancer remains an incurable disease by
current treatment strategies.
Recent reports of cancer stem cells have prompted
questions regarding the involvement of normal
stem/progenitor cells in prostatic cancer. Although still
controversial, the cancer stem cell may be a target in the
treatment of prostate cancer and a thorough understanding
of its biology, particularly of how the cancer stem cells
differs from normal stem cells, might allow it to be targeted
selectively and eliminated. Recent work on immunophenotyping of prostate cancer support the hypothesis that
prostrate cancer arises from malignant transformation of
intermediate stem cells. In this lecture I will review the
molecular mechanism of prostate epithelial cell
differentiation during development and cancer. It becomes
obvious that the pattern of transcription factor expression
controls epithelial cell determination, where the cell is
assigned a developmental fate and subsequently cell
differentiation, and where the assigned cell now emerges
with its own unique character.
618
BACKGROUND, REASONS AND BENEFITS
USING THE VIENNA PROTOCOL FOR
THE TREATMENT OF PAINFUL BONE
RECURRENCES WITH 153SAMARIUM-EDTMP
H. Sinzinger1,2, S. Granegger2, K. Weiss3 and J. Hiltunen2
1Institute
for Diagnosis and Treatment of Lipid Disorders
and Atherosclerosis (ATHOS), Vienna;
2Department of Nuclear Medicine, Medical University of
Vienna;
3Department of Radiology and Nuclear Medicine, Hospital
Wr. Neustadt, Austria
In the 1980s 153Samarium-EDTMP i.v. was introduced into
pain palliation of late stage cancer. It fastly became
evident that the strategy “the earlier the better” is
preferable. Based upon the finding that a dose of 1 mCi/kg
is not more beneficial as compared to 0.5 mCi/kg
3488
concerning bone pain palliation but significantly more
affects the bone marrow, in 1996 we described the Vienna
protocol for the first time based on repeated treatments on
a given schedule (Europ J Nucl Med 27: 86, 2000).
Contraindication for the treatment is a platelet count
<100×103/μl, a white blood cell count <100×103/μl, a red
blood cell count <3×10 6/μl, haematocrit <30% and
haemoglobin <12 g/l Hg. However, if an abnormally low
blood cell count is due to bone marrow suppression by
tumor cell infiltration, a beneficial response and even an
increase in peripheral blood cell count after therapy has
been seen. Platelets are most affected by 153Sm-EDTMP
treatment followed by white and red blood cells. Usually,
within 3 months, the peripheral blood cell count almost
completely returns to the pre-treatment values.
Therapy is performed 5 times at 3-month intervals,
followed by 6-, 9- and 12-month intervals with 5 treatments
each. The respective treatment intervals are shortened in
case of proven disease progression (scintigraphy, MRI).
Blood cell count is performed 3 and 6 weeks after therapy
as well as immediately before the next one scheduled.
Treatment is indicated when more than 1 bone lesion and/or
bone pain exists. Bone scintigraphy is performed on the day
after therapeutic application. Repeated application clearly
shows benefits beyond pain palliation such as tumor marker
decrease and lesion regression monitored and proven by
various imaging techniques (scintigraphy, MR). PSA after a
few weeks may show a temporary increase, while in most
of the patients (71%) it decreased after 3 months. To date,
however, there is no individual predictor of response
available. While the interindividual 153Sm-EDTMP uptake
greatly varies, the intraindividual one is rather stable.
Concomitant application of biphosphonates does not
significantly affect the uptake. Bone uptake does not
correlate with treatment response. A significant
improvement in quality of life, analgesics consumption,
pain score, Karnovsky score and WHO questionnaire has
been documented.
Variable response towards treatment indicates that early
lesions are more prone to respond as compared to the ones
appearing later during treatment. Even osteoclastic lesions
respond as far as they show up positively on bone
scintigraphy. Pretherapetuic dosimetry makes no sense as
at short-term intervals there are signs of stunning. There is
some reason to believe that concomitant statin treatment
improves benefit as does a higher red blood cell count and
higher haemoglobin. Preliminary concomitant chemotherapeutic and radiotherapeutic treatment data suggest that
this design might even induce better results. Although,
prospective large studies are lacking so far to define and
improve potential therapeutic benefits of this promising
approach, preliminary data suggest 153Sm-EDTMP to be a
widely underused therapeutic option.
Abstracts of the 8th International Conference of Anticancer Research, 17-22 October 2008, Kos, Greece
619
USING GENETIC MARKERS TO DETERMINE
PROGNOSIS OF UVEAL MELANOMA
Karen Sisley
University of Sheffield, Academic unit of Ophthalmology
and Orthoptics, K-Floor School of Medicine and
Biomedical Sciences, Beech Hill Road, Sheffield, S10RX,
UK
Uveal melanomas are ocular tumours affecting the iris,
ciliary body and choroid, and are distinctly different from
cutaneous melanomas. Their highly aggressive nature and
lack of effective treatment for secondary disease, makes
understanding their development and genetic background a
high priority. Over twenty years ago karyotypic analysis of a
few isolated cases, initially reported the consistent
involvement of chromosomes 1, 3, 6 and 8. The presence of
these chromosome changes in isolation, or sometimes in
association, was shown early to correlate with poor
prognosis; and perversely also for one chromosome
abnormality with a good prognosis. Now twenty years on the
focus of research still centres on these changes, but the
approach to studying them has changed focus and adapted to
include molecular cytogenetics and array based
methodologies. By combining other methods and building on
these initial studies the use of these genetic markers is
providing a highly reliable indictor of prognosis, but is 100%
accuracy ever likely to be obtainable?.
620
PROGNOSTIC FACTORS IN PATIENTS WITH
LOCALLY ADVANCED (UNRESECTABLE) OR
METASTATIC PANCREATIC ADENOCARCINOMA:
A RETROSPECTIVE ANALYSIS
N. Papadoniou, C. Kosmas, K. Gennatas A. Polyzos,
D. Mouratidou, E. Skopelitis, A. Ntokou, J. Sarantonis,
M. Tzivras, S. Sougioultzis and N. Tsavaris
HELGO (Hellenic Group of Oncology), Athens, Greece
Background: Most patients with pancreatic adenocarcinoma
are diagnosed with locally advanced (unresectable) or
metastatic disease. The aim of this study was to investigate
possible prognostic factors of survival in such patients.
Patients and Methods: Two hundred and fifteen patients were
studied retrospectively. Twenty-four potential prognostic
variables (demographics, clinical parameters, biochemical
markers, treatment modality) were examined. Results: Mean
survival was 29.0 weeks. 21.9% survived more than 36
weeks. On multivariate analysis, 10 factors had an
independent effect on survival: tumour localisation,
metastasis, performance status, jaundice, weight loss, C
reactive protein, CEA, CA 19-9, palliative surgery and
chemotherapy. Patients managed only with palliative care
had a hazard ratio of 8.94 versus those offered a combination
of palliative surgery and chemotherapy. Conclusion:
Chemotherapy and palliative surgery are associated with
increased survival, and should be offered to all eligible
patients.
621
ASPECTS OF THE ASSOCIATION BETWEEN
LEISHMANIASIS AND MALIGNANT DISORDERS
P. Kopterides, E.G. Mourtzoukou, E. Skopelitis,
N. Tsavaris and M.E. Falagas
Alfa Institute of Biomedical Sciences (AIBS), Department
of Pathophysiology, Oncology Unit, Laiko General
Hospital, University of Athens, School of Medicine,
Athens, Greece
The aim of this review is to summarise the occurrence of
leishmaniasis as an opportunistic infection associated with
malignant disorders and to present the available literature
potentially linking this infection with the development of
cancerous lesions. Materials and Methods: We searched
electronic databases and evaluated 37 studies involving 44
patients. Results: Four different types of association between
leishmaniasis and cancer were established: leishmaniasis
mimicking a malignant disorder, such as lymphoma;
leishmaniasis arising as a difficult to diagnose and treat
infection among patients receiving chemotherapy for various
malignant disorders; simultaneous diagnosis of leishmaniasis
and a neoplastic disorder in the same tissue samples of
immunocompromised patients; and direct involvement of
Leishmania spp. in the pathogenesis/occurrence of malignant
lesions, especially of the skin and mucous membranes.
Conclusion: Leishmaniasis can directly or indirectly affect
the presentation, diagnosis and course of various malignant
disorders and it should be considered in the differential
diagnosis of malignancies in geographic areas where it is
endemic and/or in patients with travel history to these areas.
622
72-GENE SIGNATURE PREDICTS RECURRENCE
IN LUNG CANCER – RESULTS FROM THE
EUROPEAN MICROARRAY CONSORTIUM
AMSTERDAM-BIALYSTOK-GDANSK-HEIDELBERG
Marcin Skrzypski
Department of Oncology and Radiotherapy, Medical
University of Gdansk, Gdansk, Poland
Background: Current staging methods are imprecise for
predicting prognosis of early stage non-small cell lung
3489
ANTICANCER RESEARCH 28: 3157-3556 (2008)
cancer (NSCLC). We aimed to develop a gene expression
profile for stage I and II NSCLC, allowing identification of
patients with a high risk of disease recurrence within 2-3
years after initial diagnosis. Materials and Methods: We
used whole-genome gene expression microarrays to
analyze frozen tumor samples from 172 NSCLC patients
(pT1-2, N0-1, M0) from 5 European institutions, who had
undergone complete pulmonary resection. Median followup was 89 months (1.2-389) and 64 patients developed a
recurrence. A random two-thirds of the samples were
assigned as the training cohort with the remaining samples
set aside for independent validation. Cox proportional
hazard models were used to evaluate the association
between expression levels of individual genes and patient
recurrence-free survival. A nearest mean analysis was used
to develop a gene-expression classifier for disease
recurrence. Results: We have developed a 72 gene
expression prognostic NSCLC classifier. Based on the
classifier score, patients were classified as either high or
low risk of disease recurrence. Patients classified as lowrisk showed a significantly better recurrence-free survival
in both the training set (p<0.001; n=103) and in the
independent validation set (p<0.01; n=69). Genes in our
prognostic signature were strongly enriched for genes
associated with immune response. Conclusion: Our 72gene signature is closely associated with recurrence-free
and overall survival in early-stage NSCLC patients and
may become a tool for patient selection for adjuvant
therapy.
smoking status. Materials and Methods: The study group
included 25 non-smoking NSCLC patients and 45 smokers
who underwent pulmonary resection with curative intent.
Analysis of expression of 27 genes (including genes
associated with smoking, kinases, hormonal receptors,
growth factor receptors, transcription factors, genes
indirectly involved in HPV infection pathways and other)
was performed using mRNA derived from tumour tissue for
the quantitative analysis of selected genes by RT-PCR with
the use of microfluid cards (MFC). Analysis of RT-PCR
was performed with relative quantification 2–ΔΔCt. Subunit
18S, POLR2A and ESD were used as normalization genes.
Results: In univariate analysis, three genes were
particularly overexpressed in tumors of non-smokers:
RRAD (p=0.0002), TGF-beta receptor-2 (TGFBR2;
p=0.002) and progesterone receptor (PgR; p=0.007). TGFbeta receptor-3 (TGFBR3; p=0.02), SOX9 (p=0.02) and
androgen receptor (AR; p=0.03) were also significantly
overexpressed in these tumors. After correction for the
impact of sex, histopathology, stage of disease, and
multiple comparisons, RRAD and TGFBR2 were
independently correlated with smoking history. Conclusion:
NSCLC in non-smokers is characterized by a specific gene
expression signature. Overexpression of TGFBR2 provides
the basis for developing new targeted therapies.
623
GENE EXPRESSION PROFILING IN NON-SMALL
CELL LUNG CANCER CELLS ACCORDING TO
SMOKING STATUS
Jill E. Slansky, Kimberly R. Jordan and
Charles B. Kemmler
M. Skrzypski1, A. Szymanowska1, R. Rosell2, M. Taron2,
T. Muley3, H. Dienemann3, W. Rzyman1, R. Rzepko2,
M. Jarzab4, E. Jassem1 and J. Jassem1
1Medical
University, Gdansk;
4Institute of Oncology, Gliwice, Poland;
2Catalan Institute of Oncology, Barcelona, Spain;
3University, Heidelberg, Germany
Background: Epidemiological and experimental studies
confirm that cigarette smoking is the principal causal agent
of lung cancer. It is estimated that about 2-5% of all lung
cancer patients have never smoked. Knowledge on
molecular features of lung cancers not related to smoking
might lead to better understanding of their carcinogenesis
and allow development of new therapeutic targets. The aim
of the study was to assess the feasibility of gene expression
profiling to delineate the surgically treated non-small cell
lung cancer (NSCLC) patients according to cigarette
3490
624
CHARACTERIZATION OF TUMOR-SPECIFIC
T-CELLS RESPONDING TO ANTITUMOR
MIMOTOPE VACCINES
University of Colorado Denver, Department of
Immunology, 1400 Jackson Street K511, Denver, CO
80206, USA
Multiple approaches are being explored to activate T-cells
that specifically recognize and kill tumor cells. We are using
mimotopes, peptides that mimic tumor epitopes, to activate
T-cell-mediated antitumor immunity. Our ultimate goal is to
combine these mimotopes with effective adjuvants resulting
in potent antitumor vaccines.
Using a T-cell clone specific for the CT26 transplantable
tumor, we showed that increasing the affinity of the T-cell
receptor (TCR) for the mimotope/MHC complex can
augment antitumor immunity. However, not all mimotopes
generate effective antitumor immunity. We have shown that
increasing the affinity of the interaction too far also ablates
the antitumor response. Interestingly, recent experiments
showed that relative to vaccination with ineffective
mimotopes, vaccination with effective mimotopes generates
T-cells with a focused repertoire encoding TCR genes that
Abstracts of the 8th International Conference of Anticancer Research, 17-22 October 2008, Kos, Greece
are more similar in sequence to the T-cell clone used to
identify the mimotopes.
One mechanism that may contribute to improved
antitumor immunity is that the T-cells responding to effective
mimotopes also produce more IFN-gamma (IFNγ) in
response to the tumor antigen. These results were consistent
in both the spleen after vaccination and in the developing
tumor as determined by intracellular cytokine assays. In
IFNγ-deficient mice, we showed that IFNγ is not required
for an effective primary response to mimotopes as
determined in a tumor protection assay and tetramer staining
of tumor-specific T-cells. However, IFNγ may be required
for an effective memory response. Specifically, mimotopes
protect wild type mice, but not IFNγ-deficient mice, from
tumor challenge if challenged 3 weeks after the first vaccine.
Thus, our future experiments are to determine the predictable
sequence of mimotopes that generate a focused repertoire of
responding CTL that produce IFNγ upon secondary
challenge.
625
MOLECULAR MECHANISMS
RESPONSIBLE FOR THE
ANTICANCER ACTIVITY OF EDIBLE
AND MEDICINAL MUSHROOMS
lucidum (Reishi), and Phellinus linteus (Meshimakobu, PLFraction). Thus, D-Fraction inhibits proliferation and
suppresses invasiveness of breast cancer cells. Moreover,
PL-Fraction (PLF) inhibits proliferation as well as colony
formation through the cell cycle arrest and the up-regulation
of p27Kip1 expression. PLF also inhibits invasive behavior
of breast cancer cells through the suppression of secretion
of urokinase-plasminogen activator (uPA). PLF inhibits the
early event in angiogenesis, capillary morphogenesis of the
human aortic endothelial cells (HAEC), through the downregulation of secretion of vascular endothelial growth factor
(VEGF) from cancer cells. These effects are mediated by the
inhibition of serine-threonine kinase AKT signaling because
PLF suppresses phosphorylation of AKT. In summary,
edible as well as medicinal mushrooms contain biologically
active compounds with anti-proliferative, anti-invasive and
anti-angiogenic activities, suggesting their potential
therapeutic effect against invasive cancers. Finally, we have
identified the most active fraction responsible for the PLF
activity, and this fraction is currently evaluated in animal
experiments.
626
CANCER ASSOCIATED FIBROBLASTS: FACTOR
OF TUMOR PROGRESSION AND SPREADING
Daniel Sliva
Karel Smetana Jr.
Cancer Research Laboratory, Methodist Research Institute,
Indianapolis, IN;
Department of Medicine, and Indiana University Simon
Cancer Center, School of Medicine, Indiana University,
Indianapolis, IN, USA
Charles University, First Faculty of Medicine, Institute of
Anatomy and Second Faculty of Medicine, Center of Cell
Therapy and Tissue Repair, Prague, Czech Republic
Cancer metastasis is among the major reasons for a high
mortality of cancer patients. Therefore, inhibition of growth,
invasive behavior and cancer-cell mediated angiogenesis
will lead to the suppression of cancer metastasis. Although
some of the anticancer drugs were originally identified and
developed from a variety of natural products, the discovery
of novel biologically active compounds is still of vital
interest. From the total of estimated 1.5 million Earth’s
fungi only 100,000 have been described. Some of these
fungi gained significant recognition as the part of nutrition
or as medicinal mushrooms in the traditional Oriental
medicine. Polysaccharides, mainly beta-glucans, are usually
associated with the anticancer activities of mushrooms
through the stimulation of immune system. Moreover, the
biologically active compounds in mushrooms can directly
modulate aberrantly activated signaling pathways
responsible for growth and invasive behavior of cancer cells.
Here, we compare the activity of edible and medicinal
mushrooms and their extracts Pleurotus ostreautus (Oyster),
Grifola frondosa (Maitake, D-Fraction), Ganoderma
Malignant tumors are widely spread in humans and form a
serious medical, economical and social burden. Aging of the
population can be related to the increased incidence of
malignancies. Despite progress in cancer therapy, the prognosis
of many patients does not seem to be optimistic. Remarkable
progress in stem cell research delineated new horizons of
possible future improvement of cancer therapy. A paradigm of
existence of cancer stem cell has been established in solid
tumors and is based on the remarkable parallel between tissue
stem cells and population of cancer cells responsible for tumor
spreading. Normal tissue stem cells require highly specialized
microenvironment that is necessary for the maintenance of their
stemness; a disorder of such a microenvironment drives the
stem cell population to enter into the process of final
differentiation. Experiments based on embryonic stem cell
introduction into adult organisms resulting in tumor
development are well-known. On the other hand, tumor cells
in embryos frequently normalize their function.
These observations indicate the importance of
microenvironment in tumor biology. The positive role of tumor
stroma in course of vascularisation of tumor bed has already
been well described. The sum of evidence that cancer-
3491
ANTICANCER RESEARCH 28: 3157-3556 (2008)
associated stromal fibroblasts exert an important role in cancer
progression is growing and their participation in cancer stem
cell niche formation seems to be highly probable. The
differences between the cancer stroma and normal tissue
fibroblasts were established in e.g. tumors of breast,
pancreas, colon, prostatic gland, skin and oral cavity. When
co-cultured with cancer-associated fibroblasts, tumor cell
lines harden their cancerous phenotype and the inoculation
into immunodeprived mice leads to the rapid tumor
progression including metastasis. Normal keratinocytes
subsequently alter their phenotype to resemble cancer cells
when co-cultured with stromal fibroblasts prepared from
basal or squamous cell carcinoma. Modern analytical
technologies, such as DNA microarrays and proteomic
analysis, indicated differences in production of regulatory
factors/cytokines that are significant in the biological activity
of cancer-associated fibroblasts. The nature of these
fibroblasts is not well understood yet, but principally they
can originate in local mesenchyme under the control of
cancer cells. However, they can also arise from tumor cells
undergoing epithelial-mesenchymal transition or in cells
formed by fusion of cancer cells with local fibroblasts.
Summarizing these data, similarly to embryonic
development, mesenchymal-epithelial interaction can play an
important role in tumor progression and its management may
be a promising future anticancer therapeutic tool.
627
NUCLEIC ACID CONFORMATION
AND HOTSPOTS FOR
DNA METHYLATION
Steven S. Smith
City of Hope, 1500 E. Duarte, CA 91010, USA
Nucleic acid conformation space is extraordinarily vast. The
conformations that DNA can adopt are nearly uncountable.
Modern living organisms utilize only a fraction of the
available conformations, probably because of the constraints
placed on DNA by fidelity in genetic inheritance. I will
summarize evidence suggesting that DNA methylation is one
of the systems that allows higher organisms to incorporate
sequences with difficult-to-manage conformations into their
genomes. In particular we will discuss evidence suggesting
that a non-B DNA structural polymorphism detected in human
tumors near the c-Ha-ras VNTR is a self-perpetuating
epigenetic mark that manifests itself spontaneously during
breast carcinogenesis in a hotspot for DNA methylation.
Available evidence suggests that DNA hypermethylation and
concurrent DNA hypomethylation in carcinogenesis can be
understood as consequences of loss-of-function in the
suppression of non-B DNA and unusual DNA structure
formation.
3492
628
PHOTODAMAGE TO PROTEINS OF DNA
REPLICATION AND REPAIR BY TOPOISOMERASE
INHIBITORS
Soo In Bae, Ran Zhao and Robert M. Snapka
Department of Radiology, Division of Radiobiology, The
Ohio State University, Columbus, Ohio USA
We have found that commonly studied drugs, including
topoisomerase II and topoisomerase I inhibitors, cause
covalent damage to proliferating cell nuclear antigen
(PCNA) and SV40 large T antigen when cells treated with
micromolar levels of these drugs are exposed to fluorescent
light. PCNA and large T antigen function as circular
oligomers, and the subunits are covalently cross-linked by
photodamage from these drugs. With some drugs, significant
cross-linking of PCNA or large T antigen can be detected
after 5-minute exposures of drug-treated cells to laboratory
room lighting. Heterologous proteins are photo-cross-linked
to the PCNA oligomers at much lower rates. Photodynamic
drugs known to localize in cytoplasmic organelles also
caused photo-cross-linking of PCNA and large T antigen,
suggesting that small amounts of these drugs, or long-lived
reactive species generated in the cytoplasm can reach the
nucleoplasm. PCNA and large T antigen can serve as very
sensitive markers of photodynamic damage in the nucleus.
Tests for specific reactive oxygen species suggest that
singlet oxygen is involved in PCNA photo-cross-linking.
Nuclear photodamage is unlikely to be limited to protein
cross-linking or to be limited to these two proteins. Damage
to proteins of DNA replication and repair has the potential
to disrupt DNA replication as well as DNA damage
signaling and processing, resulting in genetic instability.
This work was supported by NIH/NCI RO1-CA097107 to
RMS and the Ohio State University Comprehensive Cancer
Center.
629
CLINICAL AND TUMOR BIOLOGICAL ASPECTS
OF APOLIPOPROTEIN–D IN OPERABLE BREAST
CANCER
Håvard Søiland
Stavanger University Hospital, Stavanger, Norway
Apolipoprotein D (ApoD) is a small glycoprotein of 24
kDa, which belongs to the lipocalin family, unlike other
apolipoproteins. ApoD is linked to high-density lipoprotein
in plasma. It may also be highly expressed in breast,
adrenal and nerve, tissue, where transportation of steroids
and lipophilic substances is abundant. The affinity of ApoD
to arachidonic acid, progesterone and tamoxifen makes it
Abstracts of the 8th International Conference of Anticancer Research, 17-22 October 2008, Kos, Greece
relevant in breast cancer. The emerging understanding of
the relationship between ApoD and cellular signaling
pathways (e.g. estrogen receptor-alfa) and also the
connections to cellular stress and senescence will be
addressed.
Recent studies on qualitative and quantitative
immunohistochemical aspects of ApoD determination in
breast cancer tissue will be presented. Moreover, recent
observations indicate a prognostic value of ApoD in certain
subgroups of breast cancer patients. Furthermore, we
hypothesize on the possible predictive value of ApoD for
effect of adjuvant tamoxifen in a subset of women with
operable breast cancer.
630
DEMONSTRATION OF THE ACTIVITY OF
P-GLYCOPROTEIN BY A FULLY AUTOMATED
ETHIDIUM BROMIDE METHOD
Gabriella Spengler1,2, Miguel Viveiros1, Ana Martins1,
Liliana Rodrigues1,2, Marta Martins1,2, Joseph Molnar3,
Isabel Couto1,4 and Leonard Amaral1,2
We developed an automated method that utilized the
fluorochrome ethidium bromide (EB) which is considered as a
universal substrate of bacterial efflux pumps. Because EB is
also recognized and extruded by ABC type transporters that
rely on the ATP binding cassette of Gram positive bacteria,
and this transporter has similarity to the Pgp-1, we have
extended the method for the evaluation of agents that can
inhibit the extrusion of EB by mouse lymphoma cells that
contain the human mdr-1 gene, and are therefore multi-drug
resistant. The data presented shows that phenothiazines, such
as thioridazine and its derivatives inhibit the extrusion of EB
under physiological conditions. The activity of other unrelated
agents such as reserpine, verapamil, SILA compounds, etc.,
has also been evaluated and will be presented.
631
SULINDAC SULFIDE: POTENT
INTERACTION WITH CYTOSTATICS
Sylwia Flis and Jacek Spławiński
National Medicine Institute, 34 Chelmska Str, 00-725
Warsaw, Poland
1Unit
of Mycobacteriology and 2Unidade de Parasitologia e
Microbiologia Médicas (UPMM), Instituto de Higiene e
Medicina Tropical, and 4Centro de Recursos
Microbiológicos (CREM), Faculdade de Ciências e
Tecnologia, Universidade Nova de Lisboa (IHMT/UNL),
Lisboa, Portugal;
3Institute of Medical Microbiology and Immunobiology,
Faculty of Medicine, University of Szeged, Szeged,
Hungary
The major reason for the failure of chemotherapy of cancer is
the refractory nature of the cell that resulted from prior
exposure to the same or another chemotherapeutic agent. The
refractory nature of that cell is due to over-expression of the
mdr-1 gene that codes for the transporter Pgp-1 that promotes
the extrusion of widely dissimilar cytotoxic agents employed
in cancer therapy. Agents which inhibit this extrusion render
the cancer cell susceptible to the agent to which it had become
resistant. Obviously, targeting this transporter is of interest.
The effect of an agent on the Pgp-1 is normally assessed
using flow cytometry. This involves the employment of a
fluorochrome substrate, such as rhodamine 123, which is
extruded by the P-gp-1 transporter and which is increasingly
retained if the transporter is inhibited. Although the
sensitivity of this method is quite good, it does not lend itself
to physiological conditions, it is very time consuming, data is
not readily reproduced and hence of limited use for its
standardization, and of course, utilizes a very expensive
instrument at its core. Furthermore, the method does not lend
itself for the evaluation of large numbers of assays to be
conducted within a working day.
Objectives: To compare the effects of sulindac sulfide (SD)
with other COX inhibitors on survival of colorectal carcinoma
(CRC) cells in various cell lines (Colo 205, SW48, HT 29).
Results: SD (a metabolite of sulindac) [at conc. of 25 to 150
μM], celecoxib, and SC58125 dose dependently inhibited
growth with G1-phase arrest, while rofecoxib, valdecoxib, and
indomethacin were ineffective. The arrest of cell cycle
progression was accompanied by increased level of p21
protein, accumulating in G1-phase, and decreased level of
cyclin B1. Cell cycle arrest was accompanied by strong
apoptosis (65.7% of apoptotic cells). SD induced increase of
transcript of caspase-3 gene, as well as, reduction of pro
caspase 8 and 3 proteins level. In addition, incubation of Colo
205 cells with SD led to decrease of Bid and Bax protein level
and PARP protein cleavage. Our results indicated that both
mitochondral and death receptor pathways of apoptosis were
stimulated. In contrast to celecoxib and SC58125 no
cytotoxicity in normal Balb/c 3T3 was observed with SD.
Thus, SD appeared as an optimal candidate to study
interactions with 5 fluorouracil (5 FU) and oxaliplatin (OXA)
in CRC cell lines. SD synergistically with 5 FU and OXA
inhibited CRC survival, in contrast to celecoxib, which gave
additive or antagonistic (depending on the line studied) effects.
Dose reduction effect of SD with studied cytostatics was in the
range of 5 to 14 fold, when compared with single agent.
Synergistic effect of SD with 5 FU and OXA on growth of
CRC cells was paralleled by changes in the cell cycle
progression and induction of apoptosis. Conclusion: Strong
apoptotic signal induced by SD via both intrinsic and extrinsic
pathways may explain observed inhibitory synergism with 5
3493
ANTICANCER RESEARCH 28: 3157-3556 (2008)
FU and OXA on CRC cells and superiority to combination of
5 FU and OXA with celecoxib. Since SD may be formed in
intestines from sulindac and is preferentially concentrated in
the colon in vivo, sulindac may constitute a candidate for the
“fourth line” therapy of patients with CRC.
632
PULSE-MEDIATED CHEMOTHERAPY OF SOLID
TUMORS IN PETS (ELECTROCHEMOTHERAPY):
RECENT DEVELOPMENTS OF A NOVEL
ANTICANCER THERAPY
Enrico P. Spugnini, Alfonso Baldi and Gennaro Citro
Regina Elena Cancer Institute, Rome, Italy
Electrochemotherapy (ECT) couples the administration of an
anticancer agent (usually bleomycin or cisplatin) to the delivery
of electric pulses having appropriate waveforms. The
application of permeabilizing pulses leads to perturbation of
the cell membrane, thus resulting in increased uptake of
chemotherapeutic drugs, ultimately leading to cell apoptotic
death. Different waveforms have been adopted by investigators:
exponentially decaying, square, rectangular or biphasic. In
general the number of pulses delivered is set in 8 single pulses
applied per cm of tumor area at a voltage of 1300 V/cm (800
V/cm for intraoperative use), with a duration of 100 μs and a
frequency of 1 Hz. Treatments are repeated until the whole
tumor area is covered. Our group investigated in the past 8
years the feasibility of electrochemotherapy in companion
animals affected by different neoplasms. We adopted trains of
biphasic pulses delivered as a burst instead of single impulses.
The electric waveform was generated by Chemopulse
equipment. In the first trial, ECT was used to directly attack
neoplasms (1). Overall response rate was 80%, with 40% long
lasting remissions (in excess of 1 year). On the basis of the
preliminary studies, cohorts of dogs and cats affected by
melanoma, soft tissue sarcoma, mast cell tumor, squamous cell
carcinoma and cutaneous lymphoma were enrolled in phase II
studies, obtaining response rates and remissions that positively
compared with those reported in the literature using standard
protocols (2-10). Electrochemotherapy is a safe and efficacious
approach to veterinary soft tissue and cutaneous neoplasms. Its
low cost and ease of administration make it a valuable addition
to the currently available oncological therapies. Results
obtained in companion animals could be instrumental in
planning new protocols for humans.
This work was supported by “Grant 2006”, ISS-ACC grant
and “PROJECT FIRB/MUR (RBIPO6LCA9-009) Grant”of
the Italian Ministry of Health to E.P.S and G.C.
1 Spugnini EP et al: J Exp Clin Canc Res 22: 571-580, 2003.
2 Spugnini EP et al: Melanoma Res 16: 23-27, 2006.
3 Spugnini EP et al: Cancer Chemother Pharmacol 59(3):
375-381, 2007.
3494
4 Spugnini EP et al: Anticancer Res 26(6B): 4585-4889,
2006.
5 Spugnini EP et al: In Vivo 21: 819-822, 2007.
6 Spugnini EP et al: In Vivo 21: 897-900, 2007.
7 Spugnini EP et al: J Exp Clin Cancer Res 26: 343-346,
2007.
8 Spugnini EP et al: J Transl Med 5(1): 48, 2007.
9 Spugnini EP et al: Vet J, 2007, in press; Epub ahead of
print.
10 Spugnini EP et al: J Biochem Cell Biol 40: 159-163,
2008.
633
FEEDBACK REGULATION BETWEEN
HOXC GENES AND ESTROGEN/RTK
SIGNALING IN MAMMARY GLAND
DEVELOPMENT AND CANCER
Alejandra García-Gasca1, Carola A. Neumann2,
Carlos S. Moreno3, Ioanna G. Maroulakou4,
Steven A. Rosenzweig2
and Demetri D. Spyropoulos5
1Laboratorio
de Biología Molecular, CIAD Mazatlán,
Mazatlán Sinaloa, México;
2Pharmacology, and 5Pathology and Laboratory Medicine,
Medical University of South Carolina, Charleston, SC;
3Pathology and Laboratory Medicine, Emory University
School of Medicine, Atlanta, GA;
4Molecular Oncology Research Institute, Tufts-New
England Medical Center, Boston, MA, USA
Background: Early menarche and breast development are
increasingly common risk factors for breast cancer. In utero
and neonatal exposure to natural and anthropogenic steroids,
such as estrogens, can recapitulate early menarche and
aberrant mammary development in animal models.
Strikingly however, a proliferative response to estrogens is
not observed in mammary epithelium until just before
puberty. HoxC6 knockout mouse studies indicate essential
roles in postnatal mammary development and suggest
mechanisms for the actions of estrogens in aberrant breast
development and increased carcinogenic potential.
Objectives: To determine the molecular basis for the
essential roles of HoxC6 and to identify other Hox genes
essential in mammary development. Results: HoxC6 is
expressed in mammary epithelium and stroma and therein
differentially repressed by ovarian hormones. This
repression can also be modulated in vivo by phytoestrogens.
Thoracic mammary glands fail to develop post-natally in
HoxC6 knockout mice. Epithelial-stromal reconstitution
experiments (surgical and genetic) show that epithelialspecific, activated Her2/Neu expression is sufficient to
rescue ductal elongation defects in the knockout, but that
Abstracts of the 8th International Conference of Anticancer Research, 17-22 October 2008, Kos, Greece
stromal HoxC6 expression is required for ductal sidebranching. Embryonic and neonatal induction of epithelialspecific HoxC6 expression in transgenic mice leads to
precocious terminal end bud formation, suggesting distinct
cell-autonomous and non-autonomous functions. In human
breast epithelial cell lines, real time gene expression
analyses (RT-qPCR) reveal that HoxC6 expression is
elevated in well-differentiated cell lines (MCF10A and
MCF7) and reduced in more aggressive cell lines (e.g.
MDA-MB-231) and tumors. Consistent with in vivo HoxC6
knockout results, siRNA-mediated HoxC6 knockdown in
MCF10A cells results in an inhibition of growth and
branching in 3-dimensional cultures. Rescue of growth (but
not morphological) defects in knockdown MCF10A cells is
achieved to varying extents through myristoylated Akt
isoform up-regulation. Estrogen-mediated repression of
HoxC6 in MCF7 cells can be suppressed via Akt isoformspecific up-regulation. In addition, estrogen-mediated
changes in MCF7 cellular growth and migration are reversed
via Akt isoform-specific up-regulation. This Akt isoformspecific activity does not appear to function via alterations
in ERα (ESR1) subcellular localization. These results will
be discussed in relation to wortmannin, tamoxifen and ICI
treatments. In vitro induction of adipogenesis and/or
senescence in fetal fibroblasts (WI-38 human fetal lung &
mouse embryonic day E14) are profoundly altered via
siRNA-mediated HoxC6 knockdown. Using chromatin
immunoprecipitation (ChIP), we have identified several
direct targets of HoxC6 repression (IGFBP3, IGFBP7) and
activation (CD44, FGFR2). In vivo and in vitro disruption
of HoxC6 expression (either directly by knockdown/out or
indirectly via estrogen treatment) leads to a disruption of
target gene expression. Estrogen-mediated repression and
mammary gland defects observed in HoxC6 knockout mice
are recapitulated in HoxC5 knockout mice. Of note, these
phenotypes are partially rescued in HoxC6 knockout mice
bearing a homeobox-defective, truncated HoxC5 allele,
suggesting functional redundancy and dosage dependence
of phenotype. Collectively, these studies implicate HoxC6
and HoxC5 as essential regulators of postnatal mammary
gland development. This regulation is likely to entail
growth, survival and differentiation of epithelium and
stromal fibroblasts and adipocytes. Conclusion:
Identification and modulation of key network regulators
hold future promise for the prevention, diagnosis and
treatment of various disorders. Dysregulation in steroid
hormone/growth factor networks have been implicated in
cardiovascular diseases, cancers, diabetes and obesity. Hox
genes, their targets and their regulation (e.g. via histone
methylation/acetylation) can be modeled in the context of
ESR signaling: a) the "classical" nuclear-initiated signaling;
and, b) membrane-initiated (IGF1R/EGFR/GPCR)
signaling. One such model involves a feedback loop in
which prepubertal exposure to estrogens causes upregulation of both IGF1 (via ESR1) and IGFBPs (via
HoxC6 repression) and ensuing aberrant mammary
epithelial growth associated with elevated carcinogenic
potential.
634
IDENTIFICATION OF POTENTIAL
BIOMARKERS TO DIFFERENTIATE
HUMAN CHOLANGIOCARCINOMA AND
HEPATOCELLULAR CARCINOMA
FROM CELL LINES
Chantragan Srisomsap1,2, Pantipa Subhasitanont1, Phannee
Sawangareetrakul1, Daranee Chokchaichamnankit1,
Khajeelak Chiablaem1 and Jisnuson Svasti1,2,3
1Laboratory
of Biochemistry, Chulabhorn Research
Institute, Bangkok;
2Chulabhorn Graduate Institute, Bangkok;
3Department of Biochemistry and Center for Protein
Structure and Function, Faculty of Science, Mahidol
University, Bangkok, Thailand
Cholangiocarcinoma (CCA), a malignant tumor derived from
bile duct epithelium, occurs with a higher incidence in
tropical countries such as Thailand. Distinguishing CCA
from hepatocellular carcinoma (HCC) of the liver often
requires the use of histochemistry, so molecular markers for
diagnosis and prognosis are still required. More in depth
analyses using subproteomic approaches were performed to
facilitate the identification of potential biomarkers
undetected by regular proteomic methods. The twodimensional protein map of a Thai human bile duct epithelial
carcinoma cell line (HuCCA-1) was compared to those of
human hepatocellular carcinoma cell lines (HepG2 and
HCC-S102). The major proteins were identified by
LC/MS/MS.
Cytokeratins CK8 and CK18 were overexpressed in both
HuCCA-1 and HCC, while CK7 and CK19 were only
expressed in HuCCA-1. Galectin-3 showed high expression
in HuCCA-1 by 1-DE immunodetection. Thus, certain
proteins, namely CK7, CK19 and galectin-3, may be good
markers useful for differential diagnosis of CCA from HCC.
Proteins secreted (the secretome) from cancer cells are
potentially useful as biomarkers of the disease.
Subproteomes enriched in membrane proteins or in cytosolic
proteins from the HuCCA-1 and the HCC-S102 cell lines
were prepared. Protein patterns of differential protein
expression were determined. Ten membrane proteins were
found in HuCCA-1 but not in HCC-S102, including integrin
alpha-6 precursor, ezrin, hippocalcin-like protein 1,
mitogen-activated protein kinase kinase kinase 2
(MAPK/ERK kinase kinase 2) and calgizzarin. We
3495
ANTICANCER RESEARCH 28: 3157-3556 (2008)
identified proteins in the conditioned media of HuCCA-1,
HCC-S102, HepG2 and two other hepatocellular carcinoma
cell lines (SK-Hep1 and Alexander). The secretomes of
CCA and HCC cell lines were analyzed by SDS-PAGE
combined with LC/MS/MS. Procathepsin B was found to be
highly expressed in SK-Hep1 and HepG2 but slightly
expressed in HCC-S102 and Alexander, while heavy chain
cathepsin B was slightly expressed in both cell lines. These
results suggest analysis of the proteome and secretome are
useful for identification of potential biomarkers of human
CCA and HCC cell lines.
Supported by the Chulabhorn Research Institute.
635
DNA MICROARRAYS AS TOOLS FOR CANCER
STEM CELL RESEARCH
Martin S. Staege
Department of Paediatrics, Martin-Luther-University HalleWittenberg, Halle, Germany
DNA microarrays are powerful tools for the characterisation
of gene expression profiles from cancer cells and their
normal counterparts. However, for many cancer types, the
cell of origin (the mother cell) is still unknown. Examples
are tumours of the Ewing tumour family (EFT). Since the
first descriptions of EFT in the late 19th century different
cell types have been implicated as the EFT mother cells,
ranging from endothelial cells to primitive mesenchymal
cells. Recently, similarities between DNA microarray data
from bone marrow-derived mesenchymal stem cells
(bmMSC) and EFT suggest that bmMSC are highly
attractive candidates as EFT mother cells. However, not all
EFT associated genes are up-regulated in MSC after
transgenic expression of EFT-specific EWSR1-ets
oncogenes. Likewise, not all EFT-associated genes are downregulated in EFT after knockdown of these oncogenes. EFTspecific expression of EWSR1-ets independent genes might
be a consequence of in vivo selection. In addition, the
number of so-called secondary alterations in EFT is very
high, rendering the possibility likely that other factors
significantly modulate the gene expression profile of EFT.
Moreover, other cell types, e.g. neuroblastoma cells, acquire
features of EFT after transgenic expression of EWSR1-ets,
suggesting that the effect of EWSR1-ets on gene expression
is not absolutely specific for bmMSC. Alternatively, this
behaviour may only reflect the susceptibility of bmMSC to
EWSR1-ets mediated transformation.
We analyzed the expression profile of EWSR1-etsindependent genes in more detail. Surprisingly, we found a
very high similarity between EFT and embryonic stem cells
(ESC). Unsupervised clustering indicated that the similarity
between EFT and ESC was even higher than the similarity
3496
between EFT and bmMSC. In addition, we observed weak
expression of ESC-specific markers, e.g. the transcription
factor NANOG in EFT. ESC-like cells have been detected in
adult tissues. In addition, mesenchymal stem cells from
different sources are highly heterogeneous and more
primitive mesenchymal stem cells with ESC like
differentiation capacities have been described. Our data
suggest that primitive ESC-like stem cells, e.g. the recently
described very small embryonic-like stem cells (VSEL)
might be interesting candidates as EFT mother cells.
636
CHARACTERIZATION OF TUMOUR ASSOCIATED
AND TISSUE SPECIFIC GENE EXPRESSION
PROFILES
Daniela Max, Grit Weißflog, Christoph Hutter,
Jenny Kaftan, Christine Mauz-Körholz,
Dieter Körholz and Martin S. Staege
Department of Paediatrics, Martin-Luther-University HalleWittenberg, 06097 Halle, Germany
DNA microarray-detected signal intensities of tumour
associated genes are characterized by a high variance in the
total group of samples (including normal and tumour
samples) compared with the variance in normal tissues alone.
Therefore, the ratio of the variance in normal tissues and the
total variance (Wilks’ lambda score, WLS) can be used for
the identification of tumour specific genes. These genes are
characterized by a low WLS. Vice versa, a high WLS
characterizes tissue specific genes that are only expressed in
a subset of normal samples. We used this approach for the
characterization of gene expression profiles of Ewing family
tumours (EFT) and Hodgkin’s lymphoma (HL). For this end,
we combined published microarray data from tumour
samples and normal tissues from our own lab and from the
GEO data base. In our analysis of EFT we found among the
genes with low WLS the complete set of EFT associated
genes that we had identified in our previous studies,
indicating that the method gives reliable results. Similar
results were obtained during analysis of HL samples. One of
the genes with lowest WLS in this analysis was interleukin
26 (IL26), despite the fact that IL26 was expressed only in a
subset of HL cell lines. Interestingly, IL26 expression was
induced in other cells after incubation with culture
supernatants from IL26 positive HL cells, suggesting that HL
cells secrete soluble factors that induce IL26 in bystander
cells. In addition, we identified a set of tissue specific genes
(high WLS) that were expressed only in small subsets of
normal samples, e.g. insulin (expressed only in pancreas) or
the Charcot-Leyden crystal protein (expressed in blood and
bone marrow). Among these genes we found several testis
specific genes (e.g. protamines or the glyceraldehyde-3-
Abstracts of the 8th International Conference of Anticancer Research, 17-22 October 2008, Kos, Greece
phosphate dehydrogenase S), as well as cancer/testis antigens
(CTA). These CTA include members of the GAGE (G
antigen) family, members of the SPANX (sperm protein
associated with the nucleus, X chromosome) family, lactate
dehydrogenase C, and the outer dense fiber of sperm tails
protein 2. Our results demonstrate that WLS can be used not
only for the identification of tumour associated genes but
also for the identification of tissue specific genes including
cancer/testis antigens.
637
PROTEOMICS AND PATHWAY ANALYSIS
IDENTIFIES JNK-SIGNALING AS CRITICAL FOR
HIGH-LET RADIATION-INDUCED APOPTOSIS IN
NON-SMALL LUNG CANCER CELLS
Sara Ståhl1, Eva Fung2, Christopher Adams2, Johan
Lengqvist1, Birgitta Mörk1, Bo Stenerlöw3, Rolf
Lewensohn1, Janne Lehtiö1, Roman Zubarev2 and Kristina
Viktorsson1
1Department
of Oncology/Pathology, Karolinska Biomics
Center, Karolinska Institutet, Stockholm;
2Division of Molecular Biometry, Institute for Cell and
Molecular Biology, and 3Unit of Biomedical Radiation
Sciences, Department of Oncology, Radiology and Clinical
Immunology, Rudbeck Laboratory, Uppsala University,
Uppsala, Sweden
Low linear energy transfer (LET) radiation is used on regular
basis for cancer therapy. However, an improved efficiency of
radiotherapy in non-small-cell lung carcinomas (NSCLC) by
using high-LET radiation has been described. To date, little
is known about which signaling pathways are responsible for
this increased efficiency. Here we have used proteomics and
pathway analysis to reveal signaling networks of importance
for proapoptotic signaling in response to high-LET radiation.
The NSCLC cell line U-1810, resistant to low-LET but
sensitive to high-LET radiation was used as model system.
Cells were harvested 4h after irradiation with low and highLET radiation, respectively. An unsupervised approach was
applied using shotgun proteomics where high resolution
mass
spectrometry
coupled
to
nanoflow-liquid
chromatography determined the identity and relative
abundance of expressed proteins. A newly developed
pathway search engine (PSE) was then employed to
determine the pathway status in both low and high-LET
irradiated cells. The observed differences in the pathway
domain were used to generate hypotheses which were
validated in vitro.
Based on the 650 proteins quantified in each sample, the
JNK-pathway was identified (p=6•10–6) as a key event in
response to high-LET radiation-induced apoptotic signaling.
In addition, the Fas-pathway was activated (p=3•10–5) and
the p38-pathway was found deactivated (p=0.001) compared
to untreated cells. Western blot, ELISA and immunofluorescence analyses confirmed that high-LET radiation
caused an increase in phosphorylation of JNK. Moreover,
pharmacological inhibition of JNK blocked high-LET
induced apoptotic signaling. In contrast, neither an activation
of p38 nor a role for p38 in high-LET radiation induced
apoptotic signaling was found.
We conclude that in contrast to conventional low-LET
radiation, high-LET radiation can trigger activation of the
JNK-pathway which in turn is critical for induction of
apoptosis in these cells. Thus PSE predictions were largely
confirmed, and PSE was proven to be a useful hypothesisgenerating tool.
638
DETECTION OF BIOLOGICAL PROFILE OF
CUTANEOUS MALIGNANT MELANOMA: A ROLE
FOR CAF-1/P60 PROTEIN AND STEM-CELL
MARKER CD133 EXPRESSION?
Stefania Staibano1,3, Massimo Mascolo1,
Maria Di Benedetto2, Gennaro Ilardi1, Maria Luisa
Vecchione1, Gaetano Salvatore2, Loredana Nugnes1
and Gaetano De Rosa1,3
1Department
of Biomorphological and Functional Sciences,
Pathology Section, 2Department of Medicine, and
3Cooperative Melanoma Group, “Federico II” University,
School of Medicine, Naples, Italy
Cutaneous malignant melanoma (CMM) is the most
aggressive and lethal among skin cancers. To date, no
reliable molecular prognostic marker exists for the evaluation
of the biological behaviour of this tumor. Recently, a great
interest has been devoted to the inter-relationship between
chromatin organization, DNA damage processing and the
control of the “cell cycle checkpoint machinery”. The
resetting of the pre-existing chromatin structure during DNA
synthesis, DNA replication, and/or DNA repair is driven, in
part, to the Chromatin Assembly Factor 1 (CAF-1). CAF-1
is a heterotrimeric protein complex formed of three subunits
(p48, p60 and p150). CAF-1 interacts directly with
proliferating cell nuclear antigen (PCNA), and the p60 CAF1 subunit expression has been recently correlated with cell
proliferation in cell lines and human tissue, and it has been
proposed as a novel sensible proliferation and prognostic
marker in some tumours.
We aimed to establish if CAF-1p60 could have a role as a
new prognostic indicator in a selected series of cutaneous
malignant melanomas (CMM). 80 formalin-fixed, archival
paraffin-embedded surgical specimens of CMM were retrieved
from the files of the Department of Biomorphological and
Functional Sciences, Section of Pathology, University Federico
3497
ANTICANCER RESEARCH 28: 3157-3556 (2008)
II of Naples. Immunohistochemistry with anti-CAF-1 p60 was
performed on four-micron-thick tissue sections for all cases,
and the staining was evaluated semi-quantitatively. Results
were compared with clinicopathological features of tumours
and with follow-up data of patients. Moreover, we compare
the results with the immunostaining pattern of the same cases
for the stem–cells CD133 antibody. Recent studies, in fact,
have pointed the attention on the possible role of stem-cells
derivation in conditioning the malignant progression of some
cases of CMM.
We found CAF-1/p60 overexpressed in almost all CMM
of our series, with values exceeding from two-to ten fold the
level of expression of melanocytes of normal control skin.
The statistical analysis of results demonstrated a significant
association between the hyperexpression of CAF-1/p60 and
the occurrence of node and/or distant metastases in CMM
patients (p<0.01). On the contrary, only a minority of CMM
(9 out 80 cases) showed an appreciable reactivity for the
stem-cell marker CD133, without any convincing
relationship with the biological behavior of tumors and/or the
main classical clinical and pathological prognostic
parameters. These results indicate that CAF-1/p60 may have
a role as new sensible proliferation and prognostic marker in
CMM, whereas the derivation from the stem-cell
compartment does not seem useful for the prediction of
clinical outcome in CMM patients.
639
WHICH ABC-TRANSPORTERS SHOULD WE
TARGET IN LEUKEMIA?
Daniel Steinbach
Universitätskinderklinik Ulm, Germany
ABC-transporters are a large family of proteins involved in
active transport across biological membranes. Some members
of this family cause drug resistance in malignant diseases via
ATP-dependent drug efflux from malignant cells. This
phenomenon was intensively analyzed in leukemia.
ABCB1 (P-g) and ABCG2 (BCRP) were shown to be
associated with poor response to chemotherapy in adult acute
myeloid leukemia (AML). Both proteins confer resistance to
a wide range of chemotherapeutic drugs in vitro. Therefore,
they represent possible therapeutic targets. In pediatric AML,
this is the case for ABCG2 but not for ABCB1. In acute
lymphoblastic leukemia (ALL), both proteins appear less
relevant with the probable exception of ABCB1 in adult
patients.
ABCC3 (MRP3) has a strong prognostic impact in AML
and ALL, independent of age group. However, ABCC3 does
not cause much drug resistance in vitro. Therefore, it remains
to be elucidated whether its correlation with poor response
to therapy is causative or just an epiphenomenon.
3498
ABCA3 might be an additional cause of drug resistance
in AML. It is associated with in vitro drug resistance and
response to therapy. Interestingly it causes drug resistance
via intracellular drug sequestration instead of drug efflux
from the malignant cell.
Specific inhibitors of ABC-transporters can sensitize
leukemic cells to chemotherapy. For some types of leukemia
it would be desirable to develop drugs that inhibit a set of
ABC-transporters.
640
USE OF MULTIVARIATE MODELS TO IMPROVE
PROSTATE CANCER DETECTION
C. Stephan, H. Cammann, M. Lein, M. Schrader,
S. Deger, K. Miller and K. Jung
Department of Urology, Charité, Universitätsmedizin
Berlin, Germany
Multivariate models including prostate specific antigen
(PSA), percent free PSA (%fPSA) and other clinical data
such as prostate volume, age, status of digital rectal exam
(DRE) have been shown to improve prostate cancer (PCa)
detection. This summary gives an overview of PSA and
%fPSA-based artificial neural networks (ANNs) and logistic
regression (LR) models to reduce unnecessary prostate
biopsies. New serum markers like subforms of PSA (e.g.
proPSA) or other kallikreins show additional value within
different models. Recently, the urine marker PCA3, a noncoding RNA, has been shown to detect PCa independently
from other markers. Also, the majority of PCa harbour a
chromosomal rearrangement that fuses the gene for an
androgen-regulated prostate-specific serine protease,
TMPRSS2, with a member of the ETS family of
transcription factors, most commonly ERG. The addition of
PCA3 and gene fusion data within PSA and %fPSA models
may further substantially improve PCa detection.
641
THE GENE MUTATED IN THE RIDDLE
SYNDROME REGULATES A UBIQUITINDEPENDENT SIGNALLING CASCADE
AT SITES OF DNA DAMAGE
Grant S. Stewart1, Stephanie Panier2,3, Kelly Townsend1,
Abdallah K. Al-Hakim2, Nadine K. Kolas2, Edward S.
Miller1, Shinichiro Nakada2, Jarkko Ylanko2,3, Signe
Olivarius2, Megan Mendez2, Andrea Tagliaferro2, Laurence
Pelletier2,3, Nadine Taubenheim4, Anne Durandy4, Philip J.
Byrd1, Tatjana Stankovic1, A. Malcolm R. Taylor1 and
Daniel Durocher2,3
1Cancer
Research UK, Institute for Cancer Studies,
University of Birmingham, Vincent Drive, Edgbaston,
Abstracts of the 8th International Conference of Anticancer Research, 17-22 October 2008, Kos, Greece
Birmingham B15 2TT, UK;
2Samuel Lunenfeld Research Institute, Mount Sinai
Hospital, 600 University Avenue, Toronto, M5G 1X5,
Ontario;
3Department of Molecular Genetics, University of Toronto,
Toronto, Ontario, Canada;
4INSERM U768, Hopital Necker-Enfants Malades, 149, rue
de Sevres, 75015-Paris, France
The biological response to DNA double-strand breaks acts
to preserve genome integrity. Individuals bearing inactivating
mutations in components of this response exhibit a range of
clinical phenotypes that include cellular radiosensitivity,
immunodeficiency, infertility, progressive neurological
dysfunction and cancer predisposition. The archetype for
such disorders is ataxia-telangiectasia (A-T) caused by
biallelic mutation in ATM, a central component of the DNA
damage response. Here, we report that the E3 ubiquitin
ligase RIDDLIN is mutated in a recently described
immunodeficiency and radiosensitivity disorder called
RIDDLE syndrome. RIDDLIN acts downstream of RNF8 to
orchestrate the accumulation of 53BP1 and BRCA1 at sites
of DNA damage. RIDDLIN is itself recruited to the
chromatin that surrounds DNA lesions by binding to RNF8dependent conjugated ubiquitin. Therefore, RIDDLIN and
RNF8 define a protein ubiquitination cascade at sites of
DNA damage that is important for the overall DNA damage
response.
642
CELL CYCLE DISTURBANCES AND MITOTIC
CATASTROPHES IN CELL LINES FOLLOWING
LOW DOSE RATE BETA-IRRADIATION
Torgny Stigbrand1, David Eriksson1 ,Theres Lindgren1, PerOlov Löfroth2, Lennart Johansson2 and Katrine Åhlström
Riklund3
Departments of 1Immunology, 2Radiophysics and
3Diagnostic Radiology, Umeå University, SE-901 85 Umeå,
Sweden
Aims: Antibodies specific for tumour-antigens and labelled
with 131I can deliver low dose, low dose irradiation to
tumours and cause growth retardation at experimental
radioimmunotherapy. The aim was to elucidate the sequential
molecular and cellular events occurring in 4 cell lines with
different origin that have been exposed to continuous low
dose-rate radiation. Materials and Methods: Activation of
cell cycle checkpoints and mitotic behaviour was
investigated in four cell lines: HeLa Hep2, Jurkat, LS174T,
and HT29 following low dose irradiation delivered by 131I in
cell culture media. Western blots, FACS analysis and
immunofluorescence stainings were performed for detection
of mitotic aberrations and apoptotic induction. Results: A
G2/M arrest was demonstrated by FACS analysis. The G2/M
arrest was transient and the cells reentered the cell cycle still
containing unrepaired cellular damage. This premature entry
caused an increase of anaphase bridges, lagging
chromosomal material and multipolar mitotic spindles as
visualised
by
propidium
iodide
staining
and
immunofluorescence staining with a-tubulin antibodies.
Furthermore a dose dependent significant increase in
centrosome numbers, as well as a dose dependent increase
of polyploid cells were detected. These disturbances caused
the cells to progress into mitotic catastrophe and a fraction of
these dying cells demonstrated apoptotic features as
displayed by TUNEL staining 5-7 days following irradiation.
Conclusion: Low dose rate irradiation was demonstrated to
force all four cell lines into mitotic catastrophe and delayed
apoptosis. This phenomenon might be important in cell death
mechanisms involved in tumour growth retardation following
radioiommunotherapy of tumours.
643
GENOMIC TOOLS FOR DISSECTING THE
LEUKAEMIA GENOME
Jonathan C. Strefford
Cancer Genomics Group, University of Southampton, UK
The detection of chromosomal abnormalities by conventional
cytogenetic analysis is an essential component of the
multidisciplinary approach to the diagnosis, classification
and risk-stratification of patients with leukemia. The clinical
utility of cytogenetics has been expanded with the
development of fluorescence in situ hybridization (FISH) and
comparative genomic hybridization (CGH). The latter allows
the detection of copy number alterations (CNA) throughout
the entire genome in a single reaction. While CGH was
capable of highlighting recurrent chromosomal regions and
facilitating positional cloning studies, the technique lacked
resolution, and it was not until the development of arraybased CGH (aCGH) that became possible to determine the
gene content of these CNA. Several haematological
malignancies have been investigated with this approach and
this has significantly advanced our understanding of the
molecular mechanisms underlying leukaemogenesis.
We have been using a combination of classical
cytogenetics and state-of-the-art genomic profiling
technologies to identify novel aberrations in patients with
leukaemia. Initially, we performed parallel expression and
aCGH profiling to characterized a clinically-relevant
chromosome aberration in childhood acute lymphoblastic
leukaemia (ALL), termed intrachromosomal amplification of
chromosome 21 (iAMP21). With metaphase FISH, including
mBAND analysis, we show that iAMP21 is likely the result
3499
ANTICANCER RESEARCH 28: 3157-3556 (2008)
of a series of breakage-fusion-bridge cycles. Profiling
different patient sub-groups identified evidence of retinoic
acid pathway disruption in ETV6-RUNX1-positive ALL, and
a novel ETV6-mediated mechanism of oncogenic activation.
With multiplex ligation-dependant probe amplification
(MLPA), we have revealed novel methylation target genes in
high-hyperdiploidy ALL. By applying FISH, molecular copy
number counting (MCC) and breakpoint cloning to patients
with unbalanced dicentric chromosomal abnormalities, we
reveal PAX5 disruption as a key molecular event and show
how our strategy could be applied to solid tumours, where
unbalanced chromosomes are particularly prevalent. By
investigating novel IGH@ partner genes, we show
overexpression of members of the CEBP family, a finding in
contrast to that described in acute myeloid leukaemia
(AML).
Here, several examples of novel chromosomal
abnormalities in patient with acute leukaemia are described,
clearly demonstrating the power of this approach in
elucidating molecular events involved in the initiation or
maintenance of the leukaemic phenotype. Further studies will
surely expand our understanding of cancer pathogenesis and
improve the treatment of patients with cancer.
644
IMMUNOHISTOCHEMICAL DETECTION AND
POSSIBLE PROGNOSTIC VALUE OF CD68 AND
KALLIKREIN 6 EXPRESSION IN HUMAN GLIOMA
Tadej Strojnik1, Rajko Kavalar2 and Irena Zajc3
1University
Clinical Centre Maribor, Department of
Neurosurgery, Ljubljanska 5, 2000 Maribor, Slovenia;
2University Clinical Centre Maribor, Department of
Pathology, Ljubljanska 5, 2000 Maribor, Slovenia;
3National Institute of Biology, Department of Genetic
Toxicology and Cancer Biology, Večna pot 111, 1000
Ljubljana, Slovenia
Objectives: CD68 is a marker for microglia. The role of
microglia in malignant glioma biology remains unclear.
Kallikreins are a subgroup of serine proteases and have
recently been strongly associated with tumour progression.
Previously, we revealed a strong positive reaction with the
CD68 and kallikrein 6 antibodies in most of the cells in a
U87 human glioblastoma cell suspension, precultured U87
tumour spheroids and in a rat tumour model. The aim of this
study was to evaluate the expression of CD68 and kallikrein
6 in human gliomas, and to investigate the possible
prognostic significance. The expression was compared with
the expression of some other markers in the same set of
glioma patients. Materials and Methods: Using
immunohistochemical analysis and specific monoclonal
antibodies, we evaluated the levels of CD68, cathepsin B,
3500
CD31, kallikrein 6 and Ki-67 in histological sections of
patients
with
primary
astrocytic
tumours.
Immunohistochemical scores were determined as the sum of
the frequency (0-3) and intensity (0-3) of immunolabeling of
the tumour cells. CD68 and kallikrein 6 expression was also
analyzed with real-time PCR in 9 brain tumour biopsies.
Results: Of the 51 patients included, 11 had benign tumours
and 40 had malignant ones. A high immunohistochemical
score (4-6) for CD68 and cathepsin B was more frequent in
malignant tumours than in benign ones, p=0.036 and 0.014,
respectively. We found higher levels of Ki-67 antigen in the
malignant group compared with the benign, p=0.035. In
contrast, the benign group presented a stronger immune
reaction for proteolytic enzyme kallikrein 6 in tumour cells,
compared with the malignant group, p=0.013. Staining with
the CD31 antibody revealed no significant difference in
staining of the endothelial cells in malignant vs. benign
tumours. Univariate survival analysis indicated that
imunohistochemical CD68 score above 3 was a significant
predictor for shorter overall survival (p<0.01). In the
malignant group a higher CD68 score (4-6) also indicated
worse outcome, although the difference was of boundary
significance, p=0.057. We confirmed the prognostic
significance of cathepsin B in tumour cells. Cathepsin B
score above 3 was significant for shorter overall survival
(p=0.04). Other markers had no prognostic impact.
Conclusion: Strong immune reaction for CD68 in U87
suspension, spheroids, rat tumour model and also in human
malignant glioma samples indicates the important role of
CD68 expression in glioma progression. We conclude that
specific immunostaining of CD68 and cathepsin B, but not
callikrein 6, in tumour cells can be used to predict the risk
of death in patients with primary tumours of the central
nervous system.
645
DRUG RESISTANCE IN CHILDHOOD ACUTE
LEUKEMIA AND THE CONCEPT OF LEUKEMIC
STEM CELLS
Jan Styczynski
Department of Pediatric Hematology and Oncology,
Collegium Medicum, Nicolaus Copernicus University, ul.
Curie-Sklodowskiej 9, 85-094 Bydgoszcz, Poland
In spite of the significant progress in pediatric oncology
made over last 50 years, still about 20% of children with
acute lymphoblastic leukemia (ALL) and 50% with acute
myelogenous leukemia (AML) relapse. This may be due to
(1) drug resistance, (2) unfavorable cytogenetics, (3) minimal
residual disease, (4) presence of leukemic stem cells. Various
aspects of drug resistance are different in childhood ALL and
AML, as well as in age groups and in comparison to adults
Abstracts of the 8th International Conference of Anticancer Research, 17-22 October 2008, Kos, Greece
with leukemia. In vitro and in vivo aspects of the cellular
drug resistance profile and mechanisms of resistance to
anticancer drugs might have clinical relevance and
prognostic value in acute leukemia.
A new concept of cancer stem cells (CSCs) may explain
the phenomenon of tumor resistance. CSCs are a population
of rare cancer cells exhibiting stem cell properties such as
self-renewing, differentiation, tissue reconstitution and
multiple drug-resistance. Putative leukemic stem cells
(LSCs) have been reported both in ALL and AML.
Several experimental strategies have been utilized to
identify and/or isolate putative CSCs: cell surface markerbased analysis, side population (SP) analysis, drug resistance
properties, sphere-formation assays, label-retaining
properties and microarray technology. Cancer stem cells like
normal stem cells share several common features. Side
population (SP), as defined by Hoechst exclusion in flow
cytometry, represents a small fraction of the whole cell
population, expressing high levels of various members of the
ABC transporter family (including MDR1 and BCRP),
which are responsible for drug resistance. Malignant
transformation results from dysregulation of self-renewal
pathways. Distinct sets of “self-renewal” genes have been
associated with stem cells. The mutations accumulated in
normal stem cells could inappropriately activate self-renewal
signaling pathways and could potentially lead to cancer.
CSCs are intrinsically drug resistant. In the CSCs model,
drug resistance can be mediated by stem cells. Cancer might
have a built-in population of drug-resistant pluripotent cells
that can survive chemotherapy and repopulate the tumor.
Most CSCs have quiescent cell cycle status, reduced
sensitivity to cell cycle-dependent agents, express ABC
transporters, cause drug efflux, have an active DNA-repair
capacity and a resistance to apoptosis. Identification of
phenotype and molecular properties of CSCs enable
development of the best strategies to target CSCs (supported
by grant MNiSW N407 078 32/2964).
646
ANTITUMOR ACTIVITY OF CURCUMIN IN A
HUMAN NON-SMALL CELL LUNG CANCER
XENOGRAFT MODEL
Chin-Cheng Su, Guang-Wei Chen, Jai-Sing Yang,
Chang-Lin Wu, Chi-Cheng Lu and Jing-Gung Chung
Division of General Surgery, Department of Surgery,
Buddhist Tzu Chi al Hospital, General Hospital, Hualien;
Traditional Chinese Medical Department, Chung-Ho
Memorial Hospital, Kaohsiung Medical University,
Kaohsiung; Departments of Chinese Medicine Resources,
Pharmacology, Biological Science and Technology and
Microbiology, China Medical University, Taichung 404,
Taiwan, ROC
Curcumin (diferuloylmethane), a phenolic compound from
the plant Curcuma longa (Linn.) has been shown to exhibit
antitumor activity, such as induced cell cycle arrest and
apoptosis, in many human cancer cell lines, including lung
and liver cancer cells in vitro. However, the efficacy and in
vivo mechanism of action of curcumin in human lung cancer
cells have not been well investigated. In this study, we
assessed the in vivo therapeutic effects of curcumin on lung
cancer cells. In a primary study, we used MTT assay and
determined that curcumin inhibits proliferation of H460 lung
adenocarcinoma cells. Furthermore, the cancer cells showed
increased levels of activated caspase-3 and an increased ratio
of Bax/Bcl-2, suggesting that the cells were undergoing
apoptosis. At the same time, cell cycle analysis showed that
there was an increased number of cells in the G2/M phase.
For in vivo studies, female athymic Nu/nu mice were
xenografted with H460 tumors and on day 4 onwards
curcumin was administered orally at dose of 300, 450 and
550 mg/kg/day for 24 days. As a control, xenografted tumors
were separately treated with docetaxel (10 mg/kg i.v. bolus
on day 5, 11, 17, 23). The tumor volumes and animal body
weight were measured every three days. Expression of PARP,
Bcl(2), Bax, and caspase-3 families of proteins was
measured by Western Blotting (WB), while TUNEL and
immunohistochemical methods were utilized to determine
DNA fragmentation and cleaved caspase-3 levels
respectively. Curcumin inhibited growth of H460 cells and
caused apoptosis as evidenced by nuclear condensation in
treated H460 cells.
Curcumin caused 38 and 63% reduction in the xenografted
tumor volumes at a dose of 100 (p<0.05) and 300 (p<0.01)
mg/kg/day, respectively, when compared to controls.
Curcumin-dependent suppression of xenografted tumor growth
involved up-regulation of PARP, Bax, caspase-3 and repression
of Bcl(2) expression thus suggesting induction of apoptosis by
a mitochondrial pathway. In conclusion, our studies suggest the
potent antitumor activity of curcumin against NSCLC cells.
Thus, curcumin may be a promising novel chemotherapeutic
agent for the treatment of human lung cancer.
647
MOLECULAR MECHANISM OF THE
PROGRESSION FROM PRE-NEOPLASTIC GROUND
GLASS HEPATOCYTES TO HEPATOCELLULAR
CARCINOMA: IMPLICATION FOR
CHEMOPREVENTION AND TARGETED
THERAPY OF HCC
Ih-Jen Su, Juei-Chu Yang, Hang-Chieh Wu
and Wen-Ya Huang
Division of Clinical Research, National Health Research
Institutes, and Graduates Institutes of Basic Medicine and
Biotechnology, Tainan, Taiwan, ROC
3501
ANTICANCER RESEARCH 28: 3157-3556 (2008)
The discovery of ground glass hepatocytes (GGH) that
contain hepatitis B virus (HBV) surface antigens by
Hadziyannis and Popper in 1972 represents a historic
landmark in the pathology of chronic HBV infection.
Different types of GGHs have been correlated to the
expression patterns of core/surface antigens and stages of
virus replication. The original two types (designated Type I
and II) of GGHs were found by us to contain specific pre-S
mutants, with deletions over the pre-S1 or pre-S2 regions,
respectively. Both types of pre-S mutants are accumulated in
endoplasmic reticulum (ER) and induce ER stress response,
oxidative intermediates and DNA damage. Type II GGHs
consistently harbor pre-S2 mutants, which may escape from
immune attack and grows preferentially into clusters in the
liver, usually of advanced-stage disease. The pre-S2 mutants,
albeit inducing a weaker level of ER stress response than
pre-S1 mutants, could additionally initiate ER stressindependent JAB1/p27/RB/cyclin A, D signals to initiate
proliferation of hepatocytes, explaining the clustering of
Type II GGHs. Recently, we further demonstrated that there
is activation of the VEGF/Akt/mTOR signal pathway in
GGH, the precursor neoplastic lesion, and in the early-stage
livers of 3 to 6-month-old transgenic mice harboring pre-S2
mutant which develops into HCC at 2 years of age. The
prevalence of pre-S mutants in chronic HBV carriers also
carries a higher risk of developing HCC or recurrence after
HCC resection. Combining these data, we conclude that
GGHs, particularly Type II GGH, represent pre-neoplastic
lesions in chronic HBV infection. Targeting the Akt/mTOR
pathway or JAB1/RB pathway by natural products or drugs
may provide prevention for the development or therapy of
HCC in chronic HBV carriers.
648
THE BCL2 MAJOR BREAKPOINT REGION (MBR)
WITHIN THE 3’-UNTRANSLATED REGION
REGULATES GENE EXPRESSION
C. Ma1,2, J. Zhang1, L.K. Durrin4, J. Lv1, F Gong1,
L. Sun1, N. Yang1,2, D. Zhu3, X. Han1 and Y. Sun1,2
1Key
Laboratory of Human Functional Genomics of
Jiangsu Province, 2Department of Cell Biology and
Medical Genetics, 3School of Pharmacy, Nanjing Medical
University, Nanjing, PR China and 4Department of
Molecular Medicine, City of Hope National Medical
Center, Duarte, CA, USA
BCL2 is a key regulator of apoptosis and has additional roles
in cell cycle control, differentiation and DNA damage repair.
Disrupted expression of BCL2 has been implicated in a wide
variety of human cancers, including breast, pancreas,
colorectal, lung, and both acute and chronic leukemias.
Diverse mechanisms are likely to account for the
3502
dysregulation of BCL2 gene expression in these different
neoplasms. The 279-bp major breakpoint region (mbr) within
the 3’-untranslated region (3’-UTR) of BCL2 gene is a hot
breakage spot in t(14;18) (q32;q21) chromosome
translocation occurring in follicular lymphoma. The mbr is
also a matrix attachment region (MAR). A special AT-rich
sequence binding protein 1 (SATB1), a MAR binding
protein, binds to the mbr. SATB1 regulates multiple genes
during development and also sequesters chromatin
remodeling proteins and transcription factors to MAR
elements. In vivo mbr binding by SATB1 strongly implicates
that this BCL2 region could be involved in BCL2 regulation.
In this study we first explored the regulatory function of the
mbr in BCL2 transcription and its correlation to SATB1. We
demonstrated that the mbr within the 3’-UTR of BCL2 gene
upregulated the reporter gene expression. Deletion of the mbr
by homologous recombination significantly decreased the
transcriptional activity of the corresponding allele in the
mbr-/mbr+ heterozygous cells. Furthermore, the BCL2 allele
deleted of the mbr had a slower response to apoptotic stimuli
than did the wild-type allele, implying the mbr is required
for regulation of the BCL2 gene in response to apoptosis
stimulation. The regulatory function of the mbr was mediated
through SATB1. Overexpression of SATB1 increased BCL2
expression, while knockdown of SATB1 with RNAi
decreased BCL2 expression. These observations clearly
indicated that the mbr could positively regulate BCL2 gene
expression and this regulatory function was dependent on
SATB1.
To explore the mechanism underlying the mbr regulatory
function, we began to test our hypothesis that the mbr
regulates the BCL2 gene by forming a special chromatin
loop structure through SATB1. Based on bioinformatics
analysis five SATB1 binding sequences have been identified
upstream of the BCL2 promoter using EMSA and ChIP
assays. 3C analysis revealed that two of them had specific
interaction with the mbr, indicating that BCL2 gene could
form chromatin loop between mbr and promoter region by
anchoring its base to SATB1. Additional experiments are
undergoing to correlate the chromatin loop structure to the
regulation of BCL2 transcription. Our present work provides
an excellent opportunity to study the interplay of protein
interactions and DNA sequence determinants in the function
of a MAR associated with a locus critical for programmed
cell death and carcinogenesis.
649
ABERRANT NOTCH SIGNALING IN ACUTE
LEUKEMIA
Kazumi Suzukawa, Noriko Nemoto and Shigeru Chiba
Department of Clinical and Experimental Hematology,
Major of Clinical Medicine, Graduate School of
Abstracts of the 8th International Conference of Anticancer Research, 17-22 October 2008, Kos, Greece
Comprehensive Human Sciences, University of Tsukuba,
Tennoudai, 1-1-1, Tsukuba, Ibaraki 305-8575, Japan
Notch signaling influences cellular proliferation,
differentiation and apoptosis in diverse biological processes.
Consistent with diverse effects of Notch signaling in multiple
tissues, abnormalities of Notch pathway molecules are
associated with malignant neoplasms. In humans, these
include gain-of-function mutations of NOTCH1, the gene for
a receptor, and loss-of-function mutations of FBW7, the gene
for an E3 ubiquitin ligase, in T-cell acute lymphoblastic
leukemias (T-ALL), and generation of a fusion gene
involving a chromatin regulator gene MLL and a Notchspecific coativator gene, mastermind like-2 (MAML2; MLLMAML2), in T-ALL as well as acute myeloid leukemias.
Results of luciferase assay revealed that the MLL-MAML2
fusion gene caused aberrant Notch signaling. Interestingly,
MLL-MAML2 conferred interleukin-3 (IL-3)-independent
growth on cells that were originally dependent on IL-3
through the activation of IL-3 gene transcription. Activation
of an autocrine cytokine circuit might be one of the
mechanisms of leukemogenesis by MLL-MAML2.
650
NEW CONCEPTS ON RISK FACTORS OF HPV AND
NOVEL SCREENING STRATEGIES FOR CERVICAL
CANCER PRECURSORS
Kari Syrjänen
Department of Oncology and Radiotherapy,
Turku University Hospital, Turku, Finland
During the past several years, the author has been engaged
in co-ordinating two major multi-centre trials testing
optional screening tools for cervical cancer (CC) in lowresource settings both in East Europe and in Latin America.
These international trials include the NIS (New
Independent States of the former Soviet Union) cohort
(n=3,187 women) and the LAMS (Latin American
Screening) study (n=12,114 women). In both studies, a
sizeable cohort of women (887 and 1,011, respectively)
have been prospectively followed-up to assess the natural
history of high-risk human papillomavirus (HR-HPV)
infections and the role of implicated risk factors as
potential predictors of disease outcome (acquisition,
persistence and clearance).
We will discuss some of the key observations recently
reported from the NIS and LAMS studies, with special
emphasis on i) risk factors that are still controversial (i.e.,
oral contraception, OC; and smoking) or not previously
studied (drug addiction); ii) reproductive factors as potential
co-factors of HPV infections in cervical carcinogenesis (i.e.,
age at menarche, menopause); and finally on iii) the
performance of different screening strategies among young
and older women.
The NIS Cohort failed to establish OC as a risk factor of
CC. In all future studies, the strong confounding from the
life-style behavioural factors must be taken into account
while interpreting the data on OCs as potential risk factors
of CC. Similarly, it now seems that the increased risk (if any)
of CC among smokers seems to be attributed to the increased
acquisition of HR-HPV infections, of which the smoking
status is an independent predictor in a multivariate model.
The same seems to apply to drug addiction as a risk factor
of CC. The recent LAMS data show that drug abuse itself is
not a risk factor of i) contracting HR-HPV infection, or ii)
developing high-grade CIN. Instead, drug abuse seems to be
closely associated with several of the indicators of risky
sexual behavior, which predisposes women to oncogenic
HPV infections and thus indirectly contributes to the
development of CIN2+ lesions.
Data from the NIS Cohort clearly implicate that menarche
age is not associated with increased risk of HR-HPV
infection, or development of high-grade CIN, feasibly
explained by the fact that menarche age does not have any
effect on the outcome of CIN lesions or HR-HPV infections
in a longitudinal setting. Another special group are postmenopausal women, recently shown to have a second peak
of HR-HPV prevalence in many populations. The NIS
Cohort data suggest that among women who fail to eradicate
their HR-HPV infection by the menopause, there is i) a
transition from multiple infections to single-type infections,
and ii) selection of an integrated viral clone already taken
place, driving the process towards an aggressively
progressing cervical disease.
Finally, these special features of HR-HPV infections
among young and elderly women lead us to consider whether
different screening strategies should be needed for younger
and older women. Concordantly with other recent reports,
data from the LAMS study show that conventional Pap and
HC2, but not LBC and VIA, perform significantly differently
among younger and older women. However, the choice of
optimal screening test for young and older women depends
on whether the highest positive predictive value (PPV) (Pap
test) or the best balance between sensitivity and specificity
(SE/SP) (HC2) is used as the selection criteria.
Both the NIS Cohort and LAMS Study have significantly
contributed to solving several of the open issues in the
natural history of HR-HPV infections as well as in sorting
out the optional screening strategies in low-resource settings
and for women of different age groups. In the long term, it is
most likely the cost-effectiveness that is the decisive factor
of which screening test will be selected. Needless to say,
screening for cervical cancer precursors will be mandatory
in the foreseeable future, even in this emerging era of
prophylactic HPV vaccination.
3503
ANTICANCER RESEARCH 28: 3157-3556 (2008)
651
CHLOROPHYLL b REVERSES MULTIDRUG
RESISTANCE OF CANCER CELLS
M. Szabo1, L. Tanacs2, I. Ocsovszki3, P. Molnar4 and
J. Molnár5
1Department of Plant Biology, 2Department of Chemistry,
Faculty of Engineering, 3Institute of Biochemistry,
University of Szeged, Szeged, 4Institute of Pharmacognosy,
University of Pécs, Pécs, 5Institute of Medical
Microbiology and Immunobiology, University of Szeged,
Hungary
Various plant compounds and metabolites have been
identified and described as potential anticancer agents or
modifiers of multidrug resistance. Among these active
compounds there are chemicals, like carotenoids and
terpenoids. The aim of this study was to evaluate the effect
of chlorophylls freshly isolated from the leaves of bean
plants. The effects of chlorophyll a and b were studied on
the drug accumulation in human MDR1 gene transfected
mouse lymphoma cells. Chlorophyll a and b had a similar
dose dependent effect on cell membrane structure without
altering the cell size measured by flow cytometry.
Chlorophyll b was able to elevate moderately Rhodamine
123 accumulation of MDR tumor cells. In addition the
combination of chlorophyl b and capsorubin showed a
remarkable increase in the inhibition of Pgp 170 while the
chlorophyll a reduced the effect of capsorubin.
MDR reversal effect of chlorophyll b can be explained by
energetically favorable electron charge transfer complex
formation between chlorophyll b and the carotenoid
pigments on the Pgp170. The energy gradient is in the
optimum range from carotenoid to chlorophyll b, but low
binding energy of chlorophyll a does not modify the
functionally active conformation of the Pgp 170 membrane
protein. In a checkerboard experiment the combination of
doxorubicine and chlorophyll b resulted in a synergistic
interaction on inhibition of proliferation of MDR tumor cells
in vitro. The MDR cells were re-sensitized to the
antiproliferative effect of anticancer drug, namely to
doxorubicine.
652
QUESTIONS OVER HEAD AND NECK
MALIGNANCIES AND ADVANCES ON
BIOLOGICAL TUMOROLOGY (UNDERSTANDING,
TREATMENT AND FOLLOW UP)
György Szalai1, Joseph Molnar2 and Peter Grandics3
1MONMED,
Budapest, 1056-, Hungary;
of Medical Microbiology and Immunobiology,
University of Szeged, Hungary;
2Institute
3504
3A-D
Research Foundation 5922 Farnsworth Ct, Carlsbad,
CA 92008, USA
Over half a million malignant tumors of the head and neck
are diagnosed each year worldwide, about 4,000 of them in
Hungary. Nine tenth of them approximately are cancers of
squamous cell origin and first diagnosed at stage III or IV.
An overall 5-year survival rate is below 50% for nearly
three decades. Current therapies on selected patients permit
organ preservation. Despite aggressive combination of
chemotherapy with CDDP and 5-FU and external-beam
radiation therapy, local and regional recurrence is 30% and
distant recurrence occurs in 25% of the patients. The high
mortality and morbidity encourage the pursuit alternative
therapeutic strategies. The immune system of advanced
stage head and neck cancer (HNC) patients is frequently
suppressed. Poor immune function has been correlated with
poor clinical outcome. We have linked the development of
cancer to infection(s) during which antigenic determinants
from pathogens mimicking self-antigens are co-presented
to the immune system, leading to breaking T-cell tolerance.
Some level of autoimmunity is normal and necessary for
effective pathogen eradication. However, autoreactive Tcells must be eliminated by apoptosis when the immune
response is terminated. Apoptosis can be deficient in the
event of a weakened immune system, the causes of which
are multifactorial. Some autoreactive T-cells suffer genomic
damage in this process. The resulting cancer stem cell still
retains some functions of an inflammatory T-cell, so it
seeks out sites of inflammation inside the body. Due to its
defective constitutive production of inflammatory cytokines
and other growth factors, a stroma is built at the site of
inflammation similar to the temporary stroma built during
wound healing. The cancer cells grow inside this stroma,
forming a tumor that provides their vascular supply and
protects them from cellular immune response.
Immunotherapeutic strategies have been previously
attempted in an effort to enhance immune function and
improve survival. Covalently linking proteins and cytokines
could have enormous potential for the in vivo manipulation
of the immune system. Human carcinoembryonic antigen
(CEA) is an oncofetal glycoprotein over-expression of
which by gastrointestinal carcinomas is well known.
Expression of CEA in HNC is not widely recognized. It is
important to note that most of these studies used polyclonal
antibodies that may have cross-reactivity with CEA-related
antigens. Recent studies evaluated CEA in preclinical and
clinical levels as a target for specific immunotherapy
against HNC. Follow up CEA and HNC correlations by
monoclonal antibody presented positive at mRNA, CEAprotein and in tumor lysates, too. Because cell-surface
expression of CEA is low in the SCC cells and strong
cytoplasmic staining that direct research show a possible
Abstracts of the 8th International Conference of Anticancer Research, 17-22 October 2008, Kos, Greece
way to a vaccine mediated immunotherapy against HNCs.
Over the past 10 years great amount of research and
clinical data have appeared from many organizations but
many challenges remain. Evidence based medicine,
research and integration of data directly into approaches
based on mathematical modeling. Case studies will be
presented.
653
KRN951, A HIGHLY POTENT AND SELECTIVE
PAN-VEGFR TYROSINE KINASES INHIBITOR
E. Taguchi, K. Takahashi, Y. Tazunoki and T. Miura
Development Research Laboratories, Kirin Pharma Co.,
Ltd., Takasaki, Gunma 370-1295, Japan
Sustained growth of solid tumor is dependent on
angiogenesis. Vascular endothelial growth factor (VEGF)
and its receptors are promising targets for antitumor
therapy because of its major role in the tumor angiogenesis.
We discovered KRN951, a novel orally active inhibitor of
VEGF receptor tyrosine kinases, and elucidated its in vitro
and in vivo characteristics. KRN951 potently and
specifically inhibited in vitro VEGF-stimulated
phosphorylation of all three critical VEGF receptors
VEGFR-1, -2 and -3, at picomolar concentrations, while it
inhibited c-Kit and PDGFR at 10-times higher
concentrations. This inhibition profile of KRN951 contrasts
with other approved oral antiangiogenic drugs; they inhibit
not only VEGFRs at naomolar level but also other kinases,
such as c-Kit, PDGF, Raf and so on. Because of multitarget inhibition activity in these drugs, various toxicities
are seen in humans. In contrast, due to the high specificity
of KRN951, it is assumed that KRN951 may have a mild
toxicity profile in humans. KRN951 also showed inhibitory
activity against VEGF-driven, mitogen-activated protein
kinases and the proliferation of endothelial cells at
picomolar concentrations, but affected neither FGF-driven
nor EGF-driven cellular responses even at 100 nM.
KRN951 did not show antiproliferative effects in vitro on
various tumor cells.
Daily oral administration of KRN951 in athymic mice
and rats resulted in significant growth inhibition of various
types of human tumor xenografts at extraordinarily low
doses without obvious toxicity. Effective doses of KRN951
that exerted significant inhibitory activity on tumors were 5
mg/kg/day in nude mice and 0.2 mg/kg/day in nude rats.
Significant inhibitory activity on tumors were also exerted
in combination with cytotoxic drugs, without additional
toxicity. In a syngeneic peritoneal disseminated tumor
model, KRN951 suppressed intraperitoneal tumor growth
and accumulation of ascites, and consequently prolonged
survival. KRN951 also normalized the architecture of
tumor-induced neovasculature with aberrant structure. In
newly established multiple myeloma xenograft model,
KRN951 also efficiently inhibited tumor-dependent
osteolysis of bone marrow. Noteworthy was the superior
efficacy of KRN951 over bevacizumab against tumorassociated onset of hind leg paralysis at equivalent survival
benefit doses.
In conclusion, it was demonstrated that KRN951 is a
highly potent and selective triple-VEGFR inhibitor
associated with in vivo antitumor activity in wide variety of
tumor models. The highly potent, specific unique profile of
KRN951 will allow it to be easily combined with other
agents at low doses and suggests the potential for a superior
therapeutic index beyond the current multi-targeting tyrosine
kinase inhibitors. Encouraging results of a Phase I clinical
trial will also be presented.
654
A NOVEL MULTIMODALITY TREATEMENT
FOR PANCREATIC CANCER
Hiroshi Takamori, Hiroshi Tanaka, Yasuo Sakamoto,
Yoshiaki Ikuta, Osamu Nakahara, Satoshi Furuhashi, Toru
Beppu, Masahiko Hirota, Keiichiro Kanemitsu and Hideo
Baba
Department of Gastroenterological Surgery, Graduate
School of Medical Sciences, Kumamoto University, 1-1-1
Honjo, Kumamoto 860-8556, Japan
Background: Patients with pancreatic cancer often suffer
from tumor recurrence despite curative resection, which
indicates that systemic therapy added to local control might
be required to cure pancreatic cancer. The aim of this study
was to assess the feasibility and response to a novel
multimodality therapy composed of pancreatic resection and
intraoperative radiation therapy (IORT) combined with preand post-operative chemotherapy of 5-Fluorouracil (5-FU)
intra-arterial continuous infusion and systemic gemcitabine
administration for pancreatic cancer. Patients and Methods:
Forty-two patients with potentially resectable pancreatic
cancer underwent this multimodality therapy. Enroll criteria
were: i) age<80, ii) PS<1, iii) no evidence of distant
metastases, iv) no evidence of tumor extension to the celiac
axis or the superior mesenteric artery, v) major organ
function preserved. For preoperative chemotherapy, 5-FU
was administered at a dose of 125 mg/m2/day on days 1-5
every week as a continuous pancreatic and hepatic arterial
infusion, and gemcitabine was infused intravenously at a
dose of 1000 mg/m2 for 30 min once weekly. Pancreatic
resection combined with IORT (30 Gy, 12 Mev of electron
beam) was performed after a one-week rest following the
completion of preoperative chemotherapy. Postoperative
chemotherapy was performed in the same way as
3505
ANTICANCER RESEARCH 28: 3157-3556 (2008)
preoperative chemotherapy after the recovery from surgery.
Results: In preoperative chemotherapy, the most common
toxicities of grade 3/4 were hematological events including
neutropenia (15 pts.), leukocytopenia (7 pts), and
thrombocytopenia (2 pts). Only one patient experienced a
delay in surgery because of preoperative chemotherapyrelated neutropenia. All 42 patients underwent surgery. In
postoperative chemotherapy, grade 3/4 toxicities included
neutropenia (22 pts.), leukocytopenia (13 pts), anemia (4
pts.), thrombocytopenia (3 pts), liver abscess (3 pts.), cardiac
ischemia (2 Pts.), perforation of small intestine (1 pt), and
renal failure (1pt), although no chemotherapy-related death
was observed. The median follow-up period was 26.2
months. The 1-year, 3-year and 5-year overall survival rates
were 79.9 %, 54.8% and 30.4%, respectively, with MST of
36.5 months. Conclusion: This new multimodality treatment
is feasible and tolerable, and may contribute to further
improve the survival of patients with pancreatic cancer.
655
EXPRESSION ANALYSIS TO
IDENTIFY GENES INVOLVED IN
ACQUIRED RESISTANCE TO
CISPLATIN IN OSTEOSARCOMA CELLS
Koutarou Takazawa1, Hiroyuki Tsuchiya1,
Ueda Yoshimichi2, Yoshimitsu Kanazawa1,
Sadao Ii1 and Katsuro Tomita1
1Department
of Orthopaedic Surgery, Graduate School of
Medical Science, Kanazawa University, 13-1 Takara-machi,
Kanazawa;
2Department of Pathology, Kanazawa Medical University,
1-1 Uchidana-machi, Kahoku-gun, Ishikawa, Japan
Background: Clinical observations indicate that tumour cells
can acquire tolerance when an anticancer drug is
administered repeatedly. Gene expression in cisplatinresistant cells was analysed to identify changes in gene
expression particularly early in the course of cisplatin
exposure. Materials and Methods: After establishing a
cisplatin-resistant human osteosarcoma subline (OST/R) and
establishing two additional sublines by more brief repeated
exposure, cDNA expression microarrays were used to study
genes linked with prolonged exposure to cisplatin of human
cancer cells. Results: OST/R cells showed increased
expression of 17 genes and reduced expression of 14. Genes
associated with DNA repair, apoptosis, cell cycle
progression, and proliferation were associated with the
acquired resistance. Genes showing early changes were also
identified. Conclusion: Identification of genes showing
altered expression in the early stages of development of
resistance to cisplatin may help to improve the therapeutic
effectiveness of this drug.
3506
656
SURVIVIN EXPRESSION IN ESOPHAGEAL
SQUAMOUS CELL CARCINOMA; ITS
PROGNOSTIC IMPACT AND SPLICE VARIANT
EXPRESSION
Shinsuke Takeno, Shin-ichi Yamashita, Kiyoshi Ono,
Kentaro Anami, Keita Tokuishi, Mirei Kamei,
Shuji Suehiro, Michiyo Miyawaki, Ei-ichi Tanaka,
Masao Chujo, Satoshi Yamamoto and Katsunobu Kawahara
Department of Oncological Science (Surgery II), Oita
University Faculty of Medicine, Oita, Japan
Purpose: The present study examined the clinicopathological
impact of survivin expression in esophageal squamous cell
carcinoma (ESCC). In addition, the biological role of antiapoptosis parameters in ESCC was examined
immunohistochemically. Patients and Methods: Subjects
comprised 71 patients followed for 5 years after surgery for
ESCC and analyzed immunohistochemically to examine the
clinicopathological impact of survivin expression. Separately,
37 fresh frozen samples of ESCC obtained recently were
examined concerning splicing variant expression of survivin
using reverse-transcription polymerase chain reaction (RTPCR). Results: Immunohistochemical survivin expression was
detected in nuclei of 10 ESCC specimens (14.1%) and
cytoplasm of 22 specimens (31.0%). Nuclear expression
displayed no clinicopathological implications, but
cytoplasmic expression correlated with histological
differentiation (p=0.002) and tumor invasion (p=0.073), and
showed prognostic impacts in uni- (p=0.0184) and
multivariate (p=0.0299) analyses. Survivin, survivin-2B and
survivin-deltaEx3 mRNA were amplified in 31 (83.8%), 23
(62.2%) and 26 (70.3%), respectively, by RT-PCR. Survivin2B level correlated significantly with histological
differentiation (p=0.038), but no other significant correlations
were identified between any mRNA and clinicopathological
factors. Conclusion: As a molecular biological anti-apoptotic
factor, survivin expression was of use in assessing clinical
outcomes in ESCC. Inhibition of survivin may be useful as a
molecular biological therapy in ESCC.
657
BIO-IMMUNOTHERAPY, A COMBINED
BIOLOGICAL AND IMMUNOLOGICAL
CANCER THERAPY MODALITY
Thomas Tallberg and Jan Dabek
The Institute for Bio-Immunotherapy, Helsinki 00200
Finland
Tumours may spontaneously regress which implies that
mammals possess a natural intrinsic regulatory capability to
Abstracts of the 8th International Conference of Anticancer Research, 17-22 October 2008, Kos, Greece
control the de-differentiation of specialized organ cells, “The
metabolic triumph of the host” (Dr. W.M. Cole 1974). Thus
a novel paradigm is that cancer represents a complex chronic
metabolic deficiency disease which can be compensated by
biological dietary means. The aim was consequently to
analyze if the disturbed interior milieu can be
corrected/compensated for leading to a biological cure
without side-effects. In randomized clinical studies with
hundreds of cancer patients, over 30 years, highly significant
(p=0.001) improvement in the survival rate has been
obtained by feeding them a specific combination of
nutritional amino acids, trace-element ions, inductional
central nervous system lipids (CNS), thus supporting
hormonal balance and specifically activating the patients
autologous immune-defence. The role of these natural
aetiological biomodulating factors regulating three major
forms of cancer: leukaemia, adenocarcinoma, and sarcoma,
have primarily been outlined (Figure).
improvement has been achieved from dietary correction
alone in renal cancer (p=0.04), and high risk (T3) uveal
melanoma (p=0.001), but clinical results are usually further
improved if the therapy is combined with active specific
immunotherapy utilizing polymerized autologous tumour
tissue (except for prostate cancer). Tumour tissue should
therefore always be saved at surgery to facilitate the
preparation of individual vaccines since a patient’s malignant
cells contain a fingerprint of antigenic tumour markers (J
Biol Chem, 242: 1651-1659, 1967). Similar good therapeutic
results have also been obtained with other forms of cancer
(J Austr Coll Nutr & Env Med, 22(1): 1-20, 2003). This
healing reaction does not involve apoptosis or lysis of
tumour cells as they regain normal healthy function, with
complete regression (CR) even of large tumours, without a
scar. Regular immune reactions do not have such a capacity.
Actually activated regulatory organ-specific mitochondria
have in fact been found to be involved in the healing process.
Metabolic bio-modulation can also prevent recurrent cancer
because it actively strives to correct the aetiological
deficiency. Our standard therapy primarily related only to
symptoms of this metabolic deficiency disease. It is as if
only the loose teeth of a scurvy patient were removed instead
of giving him vitamin-C. Malignant transformation caused
by genetic weaknesses (e.g. HNPCC) is out of reach for gene
therapy, since it involves aberrations in more than three
genes, but malignant transformation can be prevented by
dietary supplementation administering small amounts of
pertinent essential metabolic components aimed at regaining
the physiological internal milieu in the patient’s body.
Healthy persons attain this balance from their normal diet.
All bio-modulating components involved are natural
substances, and thus ethical, inexpensive, easy to administer,
with a long shelf life. Bio-immunotherapy entails no sideeffects, but does have also prophylactic potential.
Significantly better disease-free intervals were achieved
with long-term use of powders containing these vital dietary
supplements to correct the complex aetiological metabolic
deficiency causing cancer. In a randomized study with 127
patients suffering from metastasized renal cancer, dietary
supplements were also able to arrest recurrent disease.
Pertinent bio-modulating dietary components were: L-amino
acids: Ala, Arg, Asp, Lys; the trace-elements: Cr, Mo, Se, Sn,
V; central nervous system (CNS) lipids, and physiological
doses of vitamins. Significantly improved clinical results
were also obtained with cutaneous (102 cases) and uveal
melanoma (54 patients) ingesting Gly, Glu, Ala, Asp, Ile,
Lys, Cr, Se, Sn, V, W, and CNS-lipids.
Ready-made powders made to treat prostate cancer
(decreasing Gleason scores) are available from our Institute,
at a cost of only 2-4 €/ day (Int J Biotechnology, 9: 3/4;
391-410, 2007). In bio-immunotherapy, significant clinical
658
PROSTATE CANCER, AETIOLOGICAL,
THERAPEUTIC, PROGNOSTIC AND
PROPHYLACTIC FACTORS
Thomas Tallberg and Mervi Dabek
The Institute for Bio-Immunotherapy, Helsinki 00200
Finland
In the eighties, prostate cancer (PCa) was justly considered a
hormone-dependent disease (Huggins & Hobbs 1941), but
was lacking curative treatments and a comprehensible
aetiology. Several signs for adrenal involvement coupled
with metabolic factors impelled this analysis on its aetiology.
PCa seems to stem from a deficient production of two
neuroendocrine components produced by adrenal zonareticularis cells (ZR). One increases FSH, the other prolactin
3507
ANTICANCER RESEARCH 28: 3157-3556 (2008)
(PRL) levels. A curative ZR feed-back reaction can be
activated in PCa patients by dietary supplementation utilizing
ready-made powders (for 2€/day) compensating the
aetiological metabolic deficiency. Natural components
prescribed are: amino-acids serine (Ser), arginine (Arg);
trace-element ions, strontium (Sr) and vanadium (V), in
addition to ingestion of vital central nervous system, CNSlipids, as canned “Neurofood” Ltd. Helsinki (cans of 220g)
mixed with fruits for the sake of taste. The full recipe for
these powders is published in Int J Biotechnology, 9: 3/4,
401, 2007. This non-invasive biological treatment schedule
specifically activates an adrenal feed-back cycle controlling
prostate cells (Figure).
Disease progression is arrested, ultimately curatively,
evidenced as complete regression of multiple bone
metastases (CR >17 years). Levels of PSA - a serine protease
–may become stable or regress since the ingested substrate
(Ser) causes enzyme inhibition. Gleason scores may decline
from 8 to 4, paired with reduced urinary distress. PCa found
incidentally, or by screening should primarily be treated
utilizing dietary supplementation since PSA may decrease in
a dose-response manner, whereby serious side-effects caused
by invasive treatments could be avoided. A good prognosis
is usually registered as increased FSH, PRL and SHBG
levels, declining DHEAS and PSA. In patients with
metastases, or initially a PSA exceeding 15 ng/ml,
intermittent total androgen ablation therapy (for only 10
days) is prescribed in synergy with continuous dietary
supplementation using PCa powders to sustain the adrenal
ZR feed-back reaction. We prescribe only Zoladex (3.6 mg)
implants shielded by Androcur 50 mg x 2/day for ten days
around the LHRH injection. Androgen ablation intervals vary
from 2-24 months, based on patient response permitting time
3508
for the adrenal feed-back reaction to function. This biomodulating schedule has been sustained already for decades
without emergence of a hormone refractory state (HRPC).
An increase in FSH is strived for preferably reaching in
excess of normal levels (>10 IU), while PSA may remain
normal or also increase before the next hormone treatment.
Androgen ablation should not attain a PSA nadir since
excessive androgen suppression also decreases FSH to
dangerously low levels (<1 IU) when the adrenal feed-back
cycle has been exhausted, instigating HRPC. This fatal
exhaustion is not due to pituitary dysfunction since PRL is
then markedly increased in patients. Watchful waiting, even
performed as active surveillance omitting any effort to
prevent the disease progression is equivalent to Russian
roulette. A rare form of PCa is diagnosed from soft tissue
metastases and their activin levels are excessively increased
while inhibin stays low, but patients respond positively to our
bio-modulating treatment. Orchiectomized patients have
immeasurable inhibin, although normal activin levels as in
pregnant females or ladies on oestrogen substitution therapy.
There is a new incentive for screening since PCa in the early
phase can be arrested by non-invasive dietary means alone.
Improved diagnostic serum markers such as EPCA-2,
kinases, PSA velocity, coupled with MRI and constructive
dietary trials inciting ZR feed-back reactions, should
diminish the need for 12 biopsy cores, as the latter may
actually spread malignant cells effecting even a higher
incidence of recurrent PCa, than the already disturbing
incident of >35%.
659
CANCER REGULATED BY ORGAN-SPECIFIC
MITOCHONDRIA VIA LIPIDOMICS, GENOMICS
AND PROTEOMICS
Thomas Tallberg and Raija Hallamaa
The Institute for Bio-Immunotherapy, Helsinki 00200
Finland
The observation was made in 1975 that in the serum of
cancer patients there could transiently appear some of the
billions of vital lipids, the “lipidome”, in the central nervous
system and spinal cord (CNS). Lipidomics depicts studies on
neurobiology describing the clinical and psychodynamic
function of these billions of vital lipids contained in our
brain, articulated as harmonious synaptogenesis. The aim of
our study was to relate certain clinical features of this
immensely complex panel of neurological functions
synchronized by this multifaceted brain-lipid network. In
embryogenesis construction of a functional CNS is linked to
organ-specific mitochondria – present especially in brain
capillaries. Our daily mental function and stress consumes
certain of these vital CNS-lipid molecules resulting in
Abstracts of the 8th International Conference of Anticancer Research, 17-22 October 2008, Kos, Greece
various clinical psychological and stress conditions. Healthy
reconstruction of this physiologic consumption of CNSlipids proceeds during our sleep providing that our serum
contains certain vital CNS-lipid components supplied via our
diet. Blood-brain barrier lesions causing a leaking of
essential vital lipids into blood could tilt the inductional
control exercised by the injured axon, and new malignant
cells could appear in the affected enervated area. Dietary
supplementation utilizing vital, prion-free CNS-lipids can
restore normal cell induction, improve the motor and mental
balance of patients, and led also to physiological therapeutic
effects in cancer patients. A short survey of these CNS
entities will be presented. The human genome project
revealed the surprising nucleotide sequence analogy in
chromosomes of mammalian species. Consequently
mitochondrial mtDNA must have been involved in
constructing the chromosomes as a “memory of evolution”.
Random mutations would exclude such interspecies
nucleotide analogies. Mitochondria produce energy for the
nucleus but also regulate the genomes they have created over
eons of their phylogenetic toil (Trends Biol Med Finland,
ISBN 951-98382-1-X, 36-38, 2000). They have numerous
biological functions. When mitochondria are activated,
caused by bio-immunotherapy, they transform to become
electron dense since their cristae gather metallo-enzymes
detected as a significant increase in Cr, Fe, Zn, Ti, content,
while strontium (Sr) declines. In mammalian cancer cells
such transformed mitochondria are involved in biological
regulation and repair of the genome (and oncogenes) as
cancer cells are forced back into healthy transcription
without apoptosis. Organ-specific mitochondria may also
specifically activate stem cell maturation (Lancet online
2005, Aug 18, 1-3). They seem to correct mutations as if
they have a memory of what they created (Nature 2005:
435,903-910). They may also alter the expression of
neuronal genes and mental function in co-operation with
billions of vital lipid molecules forming our inductional
central nervous system “Lipidomics”, acting in concert with
Genomics and Proteomics in this triumvirate sustaining
normal health. The rare mitochondrial genome mutations are
found to be closely linked to lipid metabolism resulting in
expression of various forms of neurodegenerative protein and
brain-lipid disorders. Mitochondrial mtDNA seems to have
a central role in induction and regeneration of the billions of
lipids in the CNS, but its short length restricts the
transcription capacity, though it is sufficient to induce the
200 organ-specific mitochondria required to regulate all our
tissue-specific cells. Organ-specific mitochondria in
mammalians can prevent induction of experimental
leukemia, cause complete regression of equine sarcoid skin
tumours in horses, cure human malignant histiocytoma,
melanoma and prostate cancer cells. In electron microscopy
they are seen to gather around the dividing nucleus of tumour
cells as these regain healthy transcription (Figure). Organspecific mitochondria may in the future be developed to be
utilized as physiological precision medical remedies.
660
IDENTIFICATION OF MITOGEN-ACTIVATED
PROTEIN KINASE 13 (MAPK13) AS A NOVEL
PROGNOSTIC MARKER IN HUMAN
CHOLANGIOCARCINOMA
Felicia Tan Li-Sher, Ooi Aik Seng, London Ooi,
Tan Yu-Meng, Alexander Chung, Cheow Peng Chung,
Soo KC and Teh Bin Tean
Department of General Surgery, Singapore General
Hospital;
Department of Surgical Oncology, National Cancer Centre;
NCCS-VARI Translational Cancer Research Laboratory,
Singapore
Aim: Cholangiocarcinoma is the second most common type
of primary hepatobiliary cancer. It is prevalent in Southeast
Asia and worldwide incidence is increasing. Currently, only
surgical resection has been shown to improve survival rates.
Neither radiation nor chemotherapy significantly improves
survival or quality of life. Mechanisms of carcinogenesis
remain poorly understood. Prognosis of patients with
cholangiocarcinoma is unsatisfactory as there is no reliable
tumour marker to facilitate early detection of the disease and
no effective chemotherapeutic drugs are available. Our
research aims to uncover a biomarker(s) and a prognostic
marker(s) for human cholangiocarcinoma using gene
expression profiling to enable identification of potential
targets for targeted therapeutic therapy. Methods: We utilized
DNA microarray technology to determine the expression
profile in 17 fresh-frozen human cholangiocarcinoma
samples. Immunohistochemical staining was then performed
on 53 paraffin-embedded cholangiocarcinoma samples. The
3509
ANTICANCER RESEARCH 28: 3157-3556 (2008)
data obtained from microarray and IHC was correlated with
our clinical data. Results: Mitogen-activated protein kinase
13 (MAPK13) overexpression was observed in all our
tumour specimens. Subgroup analysis showed that MAPK 13
overexpression correlated with shorter survival time, and
survival gradually worsened with increasing MAPK13
scores. MAPK13 overexpression was found to correlate with
tumour stage. Conclusion: MAPK13 overexpression is a
reliable prognostic marker for human cholangiocarcinoma
and represents a potential target for targeted therapeutic
interventions.
661
DEVELOPMENT OF TWO IN VITRO ASSAY
SYSTEMS: SEPARATION OF CANCER
SUBPOPULATIONS AND EVALUATION OF
THE MALIGNANT POTENTIALS OF CANCER
Kunihiko Tanaka1, Yoshihiro Takaya1, Chiasa Hirakawa1,
Yutaka Tagawa2,3 and Masami Niwa1,2
1Department
of Pharmacology, Nagasaki University
Graduate School of Biomedical Sciences and
2PharmaCo-Cell Company Limited, 1-12-4 Sakamoto,
Nagasaki 852-8523;
3Department of Nursing, Nagasaki University Graduate
School of Biomedical Sciences, 1-7-1 Sakamoto, Nagasaki
852-8520, Japan
To obtain phenotypically distinct subpopulations of cancer
cells in vitro, we established a new method to separate cancer
subpopulations using the Boyden chamber. Two
subpopulations of DLD-1 (colon cancer cell line) were
separated in which the intercellular junctions differed. Next,
we took advantage of the principle and the new assay system
(Can kit) which can evaluate the malignant potentials in
multistep cancer progression was developed. Can kit was
made of two membrane filter chambers, NIH3T3 (mouse
fibroblast cell line) and GP8.3 (rat endothelial cell line).
HeLa (cervical cancer cell line), B16-F0 (mouse malignant
melanoma cell line) and B16-F10 (mouse malignant
melanoma cell line) were selected to evaluate Can kit. Each
cancer cell line was seeded on Can kit and cultured. After
several days, upper chamber was removed and cells dropped
in the lower chamber were cultured. MDCK cells (dog
kidney epithelial cell line) were seeded on the lower
chamber, and transepithelial electrical resistance (TEER) of
MDCK was measured after 7 days. HeLa and B16-F10
induced significant reductions of TEER of MDCK, while
B16-F0 did not alter it. TEER reductions correlated with the
colony areas of dropped cancer cells on the lower chamber.
In conclusion, we developed two different in vitro assay
systems, which are valuable tools to understand the
heterogeneity and the malignant potentials of cancer.
3510
662
INVOLVEMENT OF THE ESTROGEN RECEPTOR β
IN GENISTEIN-INDUCED EXPRESSION OF
P21WAF1/CIP1 IN PC-3 PROSTATE CANCER CELLS
Tomoaki Tanaka, Kentaro Matsumura,
Hidenori Kawashima and Tatsuya Nakatani
Department of Urology, Osaka City University Graduate
School of Medicine, Osaka, Japan
Background: Dietary genistein, a phytoestrogen derived from
soybean, has been suggested as a chemopreventive agent for
prostate cancer. Genistein has been reported to exert its
anticancer effects via a variety of functional pathways, but the
upstream signaling of molecules regulated by genistein
remains unclear. In this study, estrogen receptor (ER) β
involvement in genistein-induced expression of cell cycle
inhibitors in PC-3 prostate cancer cells was investigated.
Materials and Methods: The proliferation of PC-3 cells
exposed to genistein was measured by the water-soluble
tetrazolium salt (WST-1) proliferation assay. The expression
of p21, p27 and ERβ in the PC-3 cells was assessed by
quantitative real-time reverse transcription-PCR. ERβ
silencing was performed using a small interfering RNA
(siRNA). The transcriptional activity of the p21 promoter was
determined by the luciferase reporter assay. Results: Genistein
caused marked inhibition of proliferative activity and induced
the expression of p21 and ERβ in the PC-3 cells. The siRNA
against ERβ suppressed the genistein-induced expression of
p21 and reduced the transactivation activity of the p21
promoter induced by genistein. Conclusion: ERβ is involved
in genistein-induced expression of p21 in PC-3 cells.
663
COPPER TRANSPORTER ATP7A AND CTR1
EXPRESSIONS IN RELATION TO ACQUIRED
RESISTANCE TO CISPLATIN
Toshiko Tanaka1, Shinobu Matsumoto2, Hideo Kurokawa3
and Yutaka Hayashida4
1Division
of Multidisciplinary Studies, Department of
Bioscience, 2Division of Diagnostic Radiology, Department
of Oral Diagnostic Science, and 4Division of Surgery,
Department of Control for Physical Functions, Kyushu
Dental College, 2-6-1 Manazuru, Kokurakita-ku,
Kitakyushu 803-8580; 3Department of Oral and
Maxillofacial Surgery, Oita Red Cross Hospital, 3-2-37
Chiyo-machi, Oita 870-0033, Japan
Objectives: Recently, it has been suggested that Cu
transporters such as hCTR1, ATP7A, and ATP7B are related
to the transfer of CDDP across the cellular membranes,
although how CDDP enters and exits tumor cells has
Abstracts of the 8th International Conference of Anticancer Research, 17-22 October 2008, Kos, Greece
remained poorly understood for years. We investigated
whether the expression of CTR1 and ATP7A was related to
acquired resistance using CDDP-resistant KBR/0.8 and
KBR/1.2 cells, characterized by an impaired intracellular
accumulation of CDDP, and CDDP-resistant 2780CP cells,
whose mechanisms of CDDP resistance depend on an
increased DNA repair ability and not CDDP accumulation.
Methods: Sensitivity of CDDP was determined using the
MTT assay. Intracellular and DNA-bound platinum were
measured using atomic absorption spectrophotometry. ATP7A
and CTR1 expressions were detected by Western blot
analysis. Results: KBR/0.8, KBR/1.2, and 2780CP cells were
5.2-, 9.6-, and 4.4-fold more resistant to CDDP compared to
parent cell lines, KB, and A2780 cells, respectively. The
intracellular CDDP levels in KB, KBR/0.8, and KBR/1.2
cells decreased depending on the degree of resistance after 2h treatment with 40 and 80 μM CDDP, and those in KBR/1.2
cells were 33% (40 μM) and 27% (80 μM) of that of KB
cells. The levels of platinum bound to DNA in KBR/0.8 and
KBR/1.2 cells were markedly lower than that of KB cells.
The removal of platinum bound to DNA in 2780CP cells was
increased by 25.3 and 41.9% at 12 and 24 h after treatment
with 40 μM CDDP despite the slight reduction of 15.2% in
A2780 cells at 24 h after treatment. The ATP7A level was
similar in 2780CP and A2780 cells; however, much lower
levels of ATP7A in KBR/1.2 and KBR/0.8 cells were
observed compared with KB cells. In cells except for
KBR/1.2 and KBR/0.8 cells, ATP expression increased after
2-h exposure to 40 μM CDDP. The level of CTR1 decreased
more in 2780CP cells than in A2780 cells. The levels of
CTR1 were almost equal among KB, KBR/1.2, and KBR/0/8
cells. Treatment with CDDP hardly had any effect on CTR1
expression in all cell lines. Conclusion: ATP7A plays an
important role in acquired resistance to CDDP attributed to a
decreased intracellular accumulation of CDDP.
664
METASTATIC POTENTIAL OF MULTIDRUGRESISTANT TUMOUR CELLS
Jolanta Tarasiuk and Anna Nowakowska
Department of Biochemistry, University of Szczecin, 3c
Felczaka St, 71-412 Szczecin, Poland
Multidrug resistance (MDR) constitutes a major problem in
cancer chemotherapy. Tumour cells become resistant to a
wide array of chemotherapeutic agents (e.g. anthracyclines,
vinca alkaloids, podophylotoxins, colchicine), structurally
diverse and having different mechanisms of action. The
occurrence of multidrug resistance (MDR) is conferred by
multiple mechanisms, in particular it is associated with the
overexpression of membrane transporters (e.g. P-glycoprotein,
P-gp; MRP1; BCRP/MXR1). These transporters are
responsible for the active ATP-dependent efflux of drugs out
of resistant cells resulting in reduced intracellular
accumulation insufficient to inhibit resistant cell proliferation.
Additional multidrug resistance mechanisms of tumour cells
are related to: i) drug sequestration into intracellular vesicles,
ii) conformational changes of cellular targets (e.g. nuclear
DNA and topoisomerase II), iii) increase in repair of druginduced DNA damages, iv) intensification of detoxification
processes and v) inhibition of apoptosis. Moreover, in the
case of many clinical tumours, it is observed that multidrugresistant tumour cells have higher invasive and metastatic
properties than cells sensitive to chemotherapy. In these cells,
the secretion of proangiogenic molecules (e.g. vascular
endothelial growth factor, VEGF), important changes in cell
adhesion molecule expressions and interactions (e.g. integrins
and E-cadherins) as well as increase in the activity of
hydrolytic enzymes responsible for the proteolysis of
extracellular matrix proteins such as collagen, laminin and
fibronectin (e.g. metalloproteinases MMP, cathepsins,
enzymes of plasminogen activator system) are often observed.
Identification of mechanisms responsible for MDR
phenotype of tumour cells having a high metastatic potential
is the main condition in order to develop novel strategies for
overcoming multidrug resistance and metastasis of tumour
cells. Thus, there are numerous studies focused on the
validation of MDR/metastasis targets and identification of
new molecular mechanisms responsible for the high
metastatic activity of multidrug resistant tumour cells using
model MDR metastatic cell lines as well as various clinical
drug-resistant metastasis samples (e.g. breast, prostate and
colorectal carcinomas).
It is proposed that several signal transduction pathways (e.g.
NF-κB, HIF-1, PI3K/Akt and p53) play a crucial role in the
regulation of gene expression involved simultaneously in
multidrug resistance and metastasis of tumour cells. This
overview addresses recent advances in the understanding of
cellular mechanisms responsible for the metastatic potential of
multidrug-resistant tumour cells at the gene expression level.
665
CONTINUOUS BPH FINASTERIDE THERAPY
VS. INTERMITTENT TREATMENT: THE
UPGRADE OF NED AND THUS OF
AGGRESSIVE PROSTATE CANCER
M. Tarle, B. Spajić, I. Kraljić, B. Ruzic,
A. Reljic and Z. Kusić
University Hospital Sestre Milosrdnice, Zagreb, Croatia
Introduction and Objectives: Finasteride has been recognized
as a drug suitable for the chemoprevention of prostate cancer
(PC) by reducing intracellular dihydrotestosterone (DHT)
level. Prostate Cancer Prevention Trial (PCPT) data based on
3511
ANTICANCER RESEARCH 28: 3157-3556 (2008)
continuous finesteride treatment of almost 19 thousands
patients indicated the reduction in cancer prevalence by about
25%. However, in this same study more than a two-fold
increase in high grade aggressive prostate tumors was recorded
when compared to controls thus arising serious doubts upon
the real benefits of the protocol. Materials and Methods:
During three years a continuous versus intermittent (six month
treatment followed by 6 months resting period) finasteride
treatment in 125 BPH patients (pts) each has been investigated
as well as 125 control BPH pts. Results: The overall PC
prevalence in both finasteride-treated groups was lower than
in untreated controls and thus being in accordance with the
PCPT data. However, continuous therapy gave significantly
higher incidence in Gleason score (GS)>6 carcinomas
compared to intermitted therapy and controls (44.5%, 25%
and 18.2% of total acquired PC, respectively). In addition, the
acquired elevated chromogranin A (CgA) values were also
more than doubled in pts treated continuously compared to
other two groups (13.6%, 5.6% and 6.4%, respectively).
Acquired PC GS>6 recorded in pts with a raise in CgA was
higher in continuously treated pts (50%) than in other two
studied groups (20% and 25%, respectively). In pts with the
retained normal CgA concentration highest PC incidence was
found in controls (5.1%) and lower prevalence was recorded in
continuously (2.8%) and intermittently treated pts (2.5%)
while the respective PC GS>6 incidence was lower in controls
than in treated pts. Conclusion: Seemingly, finasteride
treatment reduces PC prevalence in pts free of NED but
elevates the number of aggressive carcinomas in CgA-positive
pts only if continuous treatment is applied. In conclusion,
current chemoprevention protocols need to be carefully
reconsidered prior to the selection between continuous and
discontinued finasteride treatment.
The authors are indebted to many colleagues and in
particular to Drs. Kraus, Anzulovic, Trnski and Ahel who
participated in various stages of the study.
666
BLOOD LDH AND CGA VALUES IN HRPC
PATIENTS AFTER TEN CYCLES OF
CHEMOTHERAPY: MARKERS OF SOFT
TISSUE LESIONS AND OSTEOLYSIS
M. Tarle1, K. Kovacic1, S. Buhic2, Z. Kusic1,
I. Kraljic1 and P. Bouffette3
1University
Hospital Sestre Milosrdnice, Zagreb, Croatia;
2General Hospital, Dubrovnik, Croatia;
3American Hospital, Paris, France
Introduction and Objectives: Circulating LDH level was
examined as a marker of either soft tissue or bone metastases
in prostate cancer (PC) patients (pts) refractory to hormonal
control (HRPC pts). Materials and Methods: HRPC pts were
3512
given chemotherapy (estramustine, docetaxel, corticosteroids,
etoposide and related combinations). Serial assessments of
clinical, biochemical and hematological data were analyzed
either after 8-10 cycles of treatment or maximally eight
months. Pts were divided into four groups according to their
LDH data (normal, 0-241 U/L) and metastases status.
Elevated LDH level was tested both against pro bnp as a
cardiac failure marker and as being an EPO administration
side-effect. Results: i) 79 pts with bone metastases and no
more than 6% increase in LDH level. In 6 months 5 of these
pts were switched to group C; ii) 11 pts with bone metastases
and elevated LDH value (17-188% increase). Within 6
months lymph node and soft tissue positivity was clinically
found in 5/11 (45%) of them. Other 6 pts were followed for
possible micrometastases. iii) 14 pts with bone metasteses,
soft tissue lesions (lymph nodes, liver/lung), highly elevated
LDH (>1000 U/L) and PSA (>500 ng/ml) values were
followed. The CrP value was elevated in 10/14 (71%) of
these pts. Five pts from group A were added to these 11
subjects due to liver metastases; iv) 8 pts with both bone and
soft tissue metastases were found with normal LDH level
and an elevated PSA level (92-458 ng/ml); v) In 15/122
(12%) pt with bone lesions osteolysis was recorded and in
13 out of 15 chromogranin A (CgA) serotest level was
elevated (>100 ng/ml) together with the elevation of the
LDH level. Conclusion: According to the ROC curve
analysis of the above data both sensitivity and specificity of
LDH values in respect to soft tissue lesions are 85-90% thus
indicating the interconnection between these two parameters.
The simultaneous elevation of CgA and LDH values is
indicative of osteolysis. These data open the way for a more
detailed analysis of the LDH level in monitoring HRPC pts
referred to chemotherapy with the possible extend of the
marker to both osteolysis and soft tissue micrometastases.
667
CHROMOSOME COPY-NUMBER
VARIATION AND BREAST CANCER RISK
Sandrine Tchatchou and Barbara Burwinkel
Helmholtz-University Group Molecular Epidemiology,
German Cancer Research Center, DKFZ, Heidelberg,
Germany
Breast cancer is the most frequent cancer among women. It is
caused by genetic and environmental factors. Whereas
mutations in high-penetrance susceptibility genes have been
identified in familial breast cancer and several single nucleotide
polymorphisms (SNPs) have been shown to be associated with
both familial and sporadic breast cancer risk, the impact of
genomic copy-number variants (CNVs) on breast cancer risk
has so far poorly been studied. An example of a CNV affecting
the tumor suppressor gene MTUS1 that has been to be
Abstracts of the 8th International Conference of Anticancer Research, 17-22 October 2008, Kos, Greece
associated with familial breast cancer risk is given. Moreover,
we discuss CNVs affecting detoxification genes such as
GSTM1 and GSTT1 that were controversially associated with
breast cancer risk. Finally, the potential of array-based genomewide CNV association studies is discussed.
are more active both in primary tumors and in lung samples
of hamsters injected with HET-SR1 cells.
uPA, MMP-2 and MMP-9 activities are critical for the
development of highly metastatic cell phenotype in the
studied experimental model.
668
EXTRACELLULAR PROTEASES ACTIVITY IN A
TUMOR PROGRESSION EXPERIMENTAL MODEL
669
APE1/REF-1: A DNA REPAIR PROTEIN
WITH PLEIOTROPIC ACTIONS
E.M. Tchevkina, A.V. Knizhnik, V.A. Rybko, Y.A. Kainov
and A.V. Komelkov
Gianluca Tell
Department of Oncogene Regulation, Carcinogenesis
Research Institute, N.N. Blokhin Memorial Cancer
Research Center, Moscow, Russia
The study was focused on comparative analysis of
extracellular proteases activity in vitro in high and low
metastatic lines of transformed hamster fibroblasts, as well
as in vivo in primary tumors and metastatic lung samples of
experimental animals followed by subcutaneous injection of
studied cell lines. We compared extracellular proteases
activity in highly tumorigenic cell lines of the same origin
(RSV transformed hamster embryo fibroblasts) with different
levels of lung metastatic activity. We also analysed this
characteristic in primary tumors and lungs of hamsters after
subcutaneous injection of studied cells. Activity of
extracellular proteases, such as urokinase type plasminogen
activator (uPA) and matrix metalloproteinases MMP-1, -2
and -9, was determined using casein-plasminogen and
gelatinase zymography in cell culture media, cell lysates,
lysates of tumour samples and lung metastatic lesions,
respectively. uPA receptor (uPAR) expression was detected
by Western-blot analysis.
We showed that uPA activity (both intracellular and
secreted) is significantly elevated in high metastatic HET-SR1
line in comparison with low metastatic HET-SR line. An
increase of uPA activity was also found in primary tumours as
well as in the samples of metastatic lungs of animals after
injection of HET-SR1 cells in comparison with hamsters
injected with HET-SR cells. Both lines demonstrated similar
high level of uPAR protein expression. MMP-1, -2 and -9
activity analysis revealed that in vitro in culltured cells,
MMP-2 is the most active secreted gelatinase, MMP-1 is less
active and MMP-9 activity is practically undetectable. In vivo,
MMP-9 activity is stimulated so that in tumor samples MMP9 and MMP-2 demonstrate comparable levels of activity.
MMP-9 is the most active gelatinase in lungs. Under the
conditions of carcinogenesis and metastasis, MMP-9 activity
in lung cancer increases in comparison with that of healthy
animals from control group. MMP-2 secretion in vitro is
elevated in the high metastatic HET-SR1 cell line in
comparison with HET-SR cells. In vivo, MMP-9 and MMP-2
Molecular Biology Section, School of Medicine,
Department of Biomedical Sciences and Technologies,
University of Udine, P.le Kolbe 4, 33100 Udine, Italy
APE1/Ref-1 (APE1), the mammalian ortholog of E. coli Xth,
and a multifunctional protein possessing both DNA repair and
transcriptional regulatory activities, has pleiotropic role in
controlling cellular response to oxidative stress. APE1 is a vital
protein. It is the main apurinic/apyrimidinic endonuclease in
eukaryotic cells playing a central role in the DNA base excision
repair pathway of all DNA lesions (uracil, alkylated and
oxidized and abasic sites), including single-strand breaks, and
has also co-transcriptional activity by modulating gene
expression directly regulated by either ubiquitous (i.e. AP-1,
Egr-1, NF-κB, p53, HIF) or tissue-specific (i.e. PEBP-2, Pax-5
and -8, TTF-1) transcription factors. Thus it plays a central role
in controlling different, and apparently contrasting, cellular
processes such as apoptosis, proliferation and differentiation. It
may also have quite diversified roles depending on the cell type,
whether normally dividing, postmitotic, or cancer cells. In
addition, it controls the intracellular redox state by inhibiting
reactive oxygen species (ROS) production. We speculate that
the essentiality of APE1 may be due to its pleiotropic biological
effects rather than merely to its DNA-repair activity. To this aim,
the biological relevance of APE1 in eukaryotic transcriptional
regulation of gene expression has yet to be elucidated, but
progress is being made using inhibitors of specific APE1
functions. The ability of APE1 to activate transcription factors,
such as p53 and Egr-1, which are mainly involved in controlling
cell-cycle-arrest and apoptotic programs, leaves the debate open
about the mechanisms responsible for controlling its different
functions in several contexts. At present, information is still
inadequate regarding the molecular mechanisms responsible for
the coordinated control of its several activities. However, change
in the expression level, subcellular distribution, posttranslational modifications and modulation of its interacting
partners may significantly contribute to the fine-tuning of its
different activities. Both expression and/or subcellular
localization are altered in several metabolic and proliferative
disorders such as in tumors and aging. In the present review, we
have attempted to relate the most relevant informations,
including our most recent findings on the APE1 interactome and
3513
ANTICANCER RESEARCH 28: 3157-3556 (2008)
gene networking concerning different functions of APE1 in
order to shed new light and to focus current and future studies
to fully understand this unique molecule that is acquiring more
and more interest and translational relevance in the field of
molecular cancer therapeutics.
670
UV BIODOSIMETER FOR ANTICANCER
UV EXPOSURE – VISUAL DETECTION
OF VITAMIN D SYNTHESIS
Irina Terenetskaya
Institute of Physics, National Academy of Sciences of
Ukraine, 02028, Kiev, Ukraine
As is well known, high energy ultraviolet (UV) photons may
produce positive or negative health effects depending on the
received UV dose. Excessive UV exposures are generally
associated with acute and chronic effects, and most
commonly used UV detectors have spectral sensitivity which
is a close match to the CIE erythema action spectrum.
Nevertheless, in proper dose UV radiation is beneficial: in
addition to psychological benefits, exposure to UV-B light
(280-315 nm) helps the body to produce vitamin D, which is
recognized as a critical factor of cells’ growth. Epidemiological
studies show that cancer mortality rates are correlated inversely
with local solar UV-B doses for 13 types of cancer, and the
most likely mechanism whereby solar UV-B radiation provides
protection against cancer is natural production of vitamin D.
In the meantime, the vitamin D deficiency has become a
neglected epidemic in most adults who are not exposed to
adequate sunlight. With due regard to recent data on the
Europe's darker atmosphere in the UV-B, it is believed
vitamin D deficiency can be treated by artificial irradiation
on condition that the vitamin D synthetic capacity is properly
detected to avoid both either UV deprivation or acute and
chronic UV injury (Figure).
To determine quantitatively the boundaries near area B,
the so-called “comfort UV dose”, we have developed a bioequivalent UV dosimeter1) that is based on the same
molecular photochemistry from which vitamin D is
synthesized in human skin, i.e. 7-dehydrocholesterol (7DHC, provitamin D3) photoconversion. Furthermore, to
visualize previtamin D photosynthesis, 7-DHC was dissolved
in liquid crystalline matrix. Under UV irradiation the
molecular conformation of 7-DHC molecule is altered, and
the LC sample changes its colour. This enables quantitative
estimation of previtamin D synthesized per cm2 using
calibrated color strips (like a litmus paper measures pH)
providing the easiest detection of vitamin D synthesis and
simple estimation in situ of the accepted “antirachitic” UV
dose.
1 Orlova T and Terenetskaya I: “UV-biosensor for visual
indication of vitamin D synthesis". SPIE “Optical Sensors
2008”, v.7003, (70031O-1).
671
PROSPECTIVE EVALUATION OF SEXUAL
FUNCTION AFTER “OPEN” AND LAPAROSCOPIC
SURGERY FOR RECTAL CANCER
Paraskevas Stamopoulos1, George E. Theodoropoulos1,
Joanna Papailiou1, Dimitris Savidis2, Christina Golemati1,
Konstandinos Bramis3, Sotirios-George Panoussopoulos1
and Emmanouil Leandros1
1First
Department of Propaideutic Surgery of Athens
Medical School, Hippocration University Hospital, 114 Vas
Sofias Ave, 11527, Athens;
2Department of Urology, Hippocration University Hospital,
114 Vas Sofias Ave, 11527, Athens;
3First Department of Surgery of Athens Medical School,
Laikon University Hospital, 17 Ag. Thoma Str, 11527,
Athens, Greece
Background: Sexual function may be harmed after treatment
for rectal cancer. Aim of this study is to prospectively
evaluate the incidence of sexual dysfunction after rectal
cancer treatment and to compare the effects of laparoscopic
and traditional “open” approaches in postoperative sexual
function. Methods: Baseline, 3, 6 and 12 month assessments
of sexual dysfunction using the International Index of
Erectile Function (IIEF) and its specific domains
prospectively took place in 56 patients who underwent rectal
cancer surgery (38 “open” procedures, 38 low anterior
resections). The preliminary results are presented. Results:
The average total IIEF and isolated IIEF response domain
scores were significantly decreased after surgery (p<0.01),
except for “intercourse satisfaction” and “overall
satisfaction” scores at 12 months. An improvement of IIEF
scores was observed between the 3- and 6-month assessment
3514
Abstracts of the 8th International Conference of Anticancer Research, 17-22 October 2008, Kos, Greece
points (p<0.01), except for the “erectile function” and
“orgasmic function” scores. No significant differences were
observed between the “open” and laparoscopic group when
comparing total IIEF and domain scores at preoperative, 3and 6-month assessment points. Rates of sexual dysfunction
did not differ significantly preoperatively and at 3 months
postoperatively when “open” and laparoscopic procedures
were compared, although there was a trend in favour of
laparoscopic surgery at 6 months (p=0.076). Baseline IIEF
score and baseline, 3- and 6-month “sexual desire” scores
were better (p=0.035, p=0.004, p=0.017 and p=0.061,
respectively) between the low anterior resection vs. the
abdominoperineal resection groups. Conclusion: Rectal
cancer resections were postoperatively associated with
significant reduction of IIEF scores and high rates of sexual
dysfunction at 3 and 6 months. IIEF and domain scores at
different assessment points were comparable between the
laparoscopic and “open” surgery groups. Extending the
monitoring period and adding more patients in this ongoing
prospective study will further elucidate the postoperative
sexual dysfunction after rectal cancer surgery.
672
PROSPECTIVE EVALUATION OF HEALTHRELATED QUALITY OF LIFE IN A SOLID
MEDITERRANEAN GROUP OF COLORECTAL
CANCER PATIENTS
significant improvement of SF-36 domains was noted
between 6 and 12 months (p=0.0001). Scores for general
health, pain, emotional wellbeing, role limitations due to
emotional problems at 1 year were better than preoperative
(p<0.001). Better role limitations due to physical health and
due to emotional problems domains scores at baseline and at
1 year were found when laparoscopic were compared to open
resections (p<0.05). Patients that received chemotherapy,
proved to be more susceptible regarding their energy, social
functioning and role limitations at 3 months (p<0.05). Older
patients had diminished physical functioning at 3 and 6 and
12 months (p<0.05). Conclusion: Colorectal cancer patients
remain fragile up to 6 months postoperatively, with
significant improvements at 1 year. Certain aspects of health
related quality of life at 1 year may be even better than
before surgery.
673
p53 AND EGFR EXPRESSION IN COLORECTAL
CANCER: A REAPPRAISAL OF “OLD” TISSUE
MARKERS IN PATIENTS WITH LONG FOLLOW-UP
George E. Theodoropoulos1, Eleni Karafoka2,
Joanna Papailiou1, Paraskevas Stamopoulos1,
Konstantinos Zaibirinis1, Konstandinos Bramis3,
Sotirios-George Panoussopoulos1 and John Bramis1
1First
1First
Department of Propaideutic Surgery of Athens
Medical School, Hippocration University Hospital, 114 Vas
Sofias Ave, 11527, Athens;
2Lefkos Stavros Hospital,1 Sisini Str, 11528, Athens;
3First Department of Surgery of Athens Medical School,
Laikon University Hospital 17 Ag. Thoma Str, 11527,
Athens, Greece
Background: The primary aims of colorectal cancer surgery
are to achieve oncological clearance and to prolong survival.
Health-Related Quality of Life must not be forgotten in the
quest for oncological excellence. Ethnic background affects
the patients’ perception of quality of life. This study was
designed to prospectively evaluate Health Related Quality of
Life, in a solid Mediterranean group of colorectal cancer
patients. Methods: Ninety-five colorectal cancer patients
were preoperatively assessed and followed up in repetitive
postoperative fixed time-points. The Short Form-36 Health
Survey questionnaire was used by skilled investigators.
Results: Overall, patients showed deterioration in all
domains, except for pain, when baseline values were
compared to 3 and 6 months postoperatively (p=0.0001). A
Background: Extensive research into the biology of
colorectal cancer has identified a plethora of molecular
markers reputed to provide prognostic information. During
the last two decades conflicting results have been drawn on
the role of the p53 tumor suppressor gene and of the first
identified member of the type receptor tyrosine kinase
family, the EGFR on colorectal cancer prognosis. p53
mutational status has been associated with both improved
and reduced survival. EGFR has been associated with
decreased length of survival, increasing Dukes stage or
lymph node metastases in several reports, but as many
studies have reported no association with unfavourable
prognostic parameters. The aim of the study was to evaluate
the p53 and EGFR expression in patients with an at least 5year follow-up. Materials and Methods: Paraffin-embedded
material was retrospectively collected from 164 colorectal
adenocarinoma (50 rectal cancers) patients, who had been
operated between 1994 and 2003. Median follow-up was 5
years (range: 1-14). p53 and EGFR expression was evaluated
George E. Theodoropoulos1, Joanna Papailiou1,
Paraskevas Stamopoulos1, Christina Golemati1,
Konstandinos Bramis2, Sotirios-George Panoussopoulos1
and Emmanouil Leandros1
Department of Propaideutic Surgery of Athens
Medical School, Hippocration University Hospital, 114 Vas
Sofias Ave, 11527, Athens;
2First Department of Surgery of Athens Medical School,
Laikon University Hospital 17 Ag. Thoma Str, 11527,
Athens, Greece
3515
ANTICANCER RESEARCH 28: 3157-3556 (2008)
by immunohistochemistry. Results: Positive p53
immunostaining and EGFR expression was observed at 62%
and 43%, respectively. P53 and EGFR positivity rates were
significantly interrelated (p=0.004). No significant
correlation was found with the examined clinicopathological
parameters except for the advanced T-stage, which
demonstrated significant associations with the p53
expression (p=0.004), the EGFR expression (p=0.0001) and
the p53/EGFR co-expression (p=0.001). In univariate
survival analysis (Log rank test) the stage (p=0.0001), the
lymphovascular invasion (p=0.005), the perineural
infiltration (p=0.004) were associated with the overall
cancer-specific survival, while a trend existed for EGFR
(p=0.06) and p53/EGFR co-expression (p=0.07). At
multivariate analysis only stage was associated with
increased risk of cancer death (Cox regression analysis
p=0.0001, b coefficient (SE): 1.898 (0.383). Conclusion: P53
and EGFR were overexpressed in this colorectal cancer
patient population and were significantly associated with
advanced T stage. In the context of new therapeutic strategies
using EGFR-targeted therapies, although EGFR remains a
controversial prognostic factor, this expression–stage
association may play a crucial role in a decision to initiate
an adjuvant treatment.
674
HEALTH-RELATED QUALITY OF LIFE
ISSUES AFTER LAPAROSCOPIC AND OPEN
RESECTIONS FOR COLORECTAL CANCER:
THE INTERNATIONAL PERSPECTIVES AND
THE EXPERIENCE FROM A GREEK
UNIVERSITY HOSPITAL
George E. Theodoropoulos
Department of Colon and Rectal Surgery, Athens Medical
School, Greece
Colorectal cancer (CRC) is one of the most common
malignancies in the Western part of the world. Surgery is the
mainstay of treatment, and it may be combined with
preoperative radiotherapy or adjuvant chemotherapy.
Although surgery offers a good chance of cure, it also has
short and long-term detrimental impacts on patients’ healthrelated quality of life (HRQL). For several post-operative
months, patients experience fatigue, pain and reduced
activity levels. Many struggle with an altered bowel habit,
and the patient may need to adapt to life with a permanent
or temporary stoma. After rectal surgery, sexual and urinary
dysfunction frequently occurs, and these problems may
persist. The diagnosis and treatment of CRC also has a
psychosocial impact; patients worry about disease
recurrence, and the combination of physical and emotional
difficulties inevitably impact on social well-being.
3516
Laparoscopic colorectal surgery for cancer offers shortterm advantages such as earlier diet re-establishment, less
postoperative pain, less narcotic use and shorter hospital stay.
Slowly accumulating and rather controversial is the
information in regards to the effect of laparoscopic colorectal
resections on HRQL. Four randomized controlled trials exist
in the literature comparing “open” and laparoscopic
colectomies for cancer. Analyzing the early results of the US
COST study, Weeks et al. reported that laparoscopic surgery
resulted in slightly better overall HRQL 2 weeks postprocedure and less pain. The small trial by King et al.
reported no HRQL differences between treatment groups as
did the larger UK multi-centre trial (CLASSIC). CLASSIC
study is probably the most informative, as it contains
information on HRQL derived from repetitive assessments at
fixed intervals. In this study, more problems than at baseline
were reported for physical functioning by both “open” and
laparoscopic arms at 6 months postoperatively. This
continued in the laparoscopic arm up to 3 years, but returned
to baseline levels at 18 months for the open arm. Fewer
problems than at baseline were reported by both arms for
emotional functioning. Social functioning was worse than at
baseline for the laparoscopic arm up to 3 years
postoperatively, but remained the same as baseline for the
open arm. There was more fatigue for both arms at 6 months
but levels returned to baseline for both arms by 18 months.
In a small study, Schwenk et al. reported significantly less
pain and fatigue after laparoscopic colon resections.
Eight studies in the international literature report data on
sexual dysfunction after laparoscopic total mesorectal
excision (TME) for rectal cancer.A retrospective,
questionnaire-based study by Quah et al. showed a higher
rate of male sexual dysfunction after laparoscopic resection
compared with open resection Analyzing the prospectively
collected data of the CLASSIC study, Jayne et al. found that
overall sexual function tended to be worse after laparoscopic
than “open” rectal surgery. A recent Turkish study between
the two approaches, though, demonstrated that impotency
rates were higher after “open” surgery. Focusing on patients
with low-lying rectal cancers undergoing sphincterpreserving operations, Yang et al. demonstrated that
laparoscopic TME male patients had better sexual function
and less sexual problems during 12-18 months and better
sexual enjoyment than “open” TME patients. In a small
series recently published by Breukink et al., erectile function
was maintained in 71% and ejaculation function in 89%,
while a significant deterioration in intercourse satisfaction
with unchanged the overall satisfaction was observed after
radiotherapy and laparoscopic TME.
In our Institution, 95 colorectal cancer patients were
preoperatively assessed and followed up in repetitive
postoperative fixed time-points. The Short Form-36 Health
Survey questionnaire was used for HRQL assessment.
Abstracts of the 8th International Conference of Anticancer Research, 17-22 October 2008, Kos, Greece
Colorectal cancer patients remain fragile up to 6 months
postoperatively, with significant improvement at 1 year.
Certain aspects of health related quality of life at 1 year may
be even better than before surgery. Better role limitations due
to physical health and due to emotional problems domains
scores at baseline and at 1 year were found when
laparoscopic were compared to open resections. In 56
patients who underwent rectal cancer surgery (38 “open”
procedures, 18 laparoscopic), a significant reduction of
International Index for Erectile Function (IIEF) scores and
high rates of sexual dysfunction at 3 and 6 months were
observed. IIEF and domain scores at different assessment
points were comparable between the laparoscopic and
“open” surgery groups
Although the primary aims of colorectal cancer surgery
are to achieve oncological clearance and to prolong survival.
Health-Related Quality of Life must not be forgotten in the
quest for oncological excellence.
675
EXPRESSION OF PROSTAGLANDIN
METABOLIZING ENZYMES IN
CORRELATION WITH VITAMIN D
RECEPTOR IN BENIGN AND MALIGNANT
BREAST CELL LINES AND BREAST TISSUE
M. Thill1, D. Fischer1, S. Becker1, T. Cordes1,
K. Diedrich1 and M. Friedrich2
1Department of Obstetrics and Gynecology, University
Schleswig-Holstein, Campus Luebeck, Ratzeburger Allee
160, 23538 Luebeck;
2Department of Gynecology and Obstetrics, Helios
Hospital Krefeld, Lutherplatz 40, 47805 Krefeld, Germany
Background: The antiproliferative effects of calcitriol
[1,25(OH)2D3] make the biologically active form of vitamin
D to a promising target in breast cancer therapy. It is well
known, that these effects are mediated via the vitamin D3
receptor (VDR). Furthermore breast cancer is associated with
inflammatory processes based on an up-regulation of
cyclooxygenase-2 (COX-2) expression, the prostaglandin E2
(PGE2) synthesizing enzyme. The PGE2 metabolizing
enzyme, 15 hydroxyprostaglandin dehydrogenase (15PGDH)
is described as a tumor suppressor in cancer. First references
suggest a correlation between vitamin D and prostaglandin
metabolism through the impact of 1,25(OH)2D3 on the
expression of COX-2 and 15PGDH. Thus we evaluated the
expression of COX-2 and 15PGDH in correlation with VDR.
Materials and Methods: The Expression of VDR, COX-2
and 15PGDH in MCF10F, a human benign epithelial cell line
and the breast cancer cell line, MCF-7 was determined by
real-time PCR and western blot analysis. Furthermore, we
determined mRNA levels of COX-2 and 15PGDH and VDR
in healthy and malignant breast sample tissues. Results:
Although our data from real-time PCR were divergent from
those obtained from the Western-blot analysis, COX-2
protein expression increased in MCF-7 2-fold compared to
MCF10F. These data were confirmed in breast cancer tissue
samples, where COX-2 mRNA level increased by 1.44 in
comparison to healthy tissues. No correlation of 15PGDH
was detected in either cell line, but in malignant tissues,
15PGDH increase dramatically compared to healthy tissue
samples. The expression of VDR differed at the protein and
mRNA level in benign and malignant cell lines. VDR protein
levels were inversely correlated to 15PGDH expression and
revealed that the benign tissues as well as the MCF10F cells
have the highest VDR expression. Conclusion: We found a
basically inverse correlation between VDR and 15PGDH
protein level expression. These findings suggest a possible
link between VDR, associated target genes and prostaglandin
metabolism. Gaining further insight into mechanisms
regulating VDR, COX-2 and 15PGDH expression in healthy
and malign tissue might open new therapeutic approaches in
breast cancer therapy.
676
ASSOCIATION BETWEEN XRCC 1
POLYMORPHISMS AND HEAD AND NECK
CANCER IN HUNGARIAN POPULATION
Andras Csejtei1, Antal Tibold2, Katalin Koltai3,
Zsuzsa Varga4, Istvan Szanyi5, Gyula Gobel5, Ida Prantner2,
Denes Steffler2, Istvan Ember2 and Istvan Kiss2
1Department
of Oncoradiology, Markusovszky Hospital,
Hungary, Szombathely, Markusovszky Lajos str. 3;
2Department of Public Health, University of Pécs, Medical
School, Hungary, Pécs, Szigeti str. 12;
31st Department of Medicine, University of Pécs, Medical
School, Hungary, Pécs, Ifjúság str. 13;
4Department of Oncology, Baranya County Hospital,
Hungary, Pécs, Rákóczi str. 2;
5Department of Oto-rhino-laryngology, University of Pécs,
Medical School, Hungary, Pécs, Munkácsy M. str. 2,
Hungary
Background: The head and neck cancer is the fifth most
common newly diagnosed cancer in the Hungarian
population, with a mortality that increased by 265% in the
last thirty years. Tobacco use and alcohol consumption are
the most important risk factors of head and neck cancer.
Because of the important role of the XRCC1 gene in DNA
repair, we tested the effects of the Arg194Trp and
Arg399Gln polymorphisms of XRCC1 to the clinical
outcome of the head and neck cancer. Materials and
Methods: A PCR-RFLP method was used. 108 samples
were taken from intraoperatively removed formalin fixed,
3517
ANTICANCER RESEARCH 28: 3157-3556 (2008)
and paraffin embedded blocks of tissue. After
deparaffination by microwave extraction, samples were
digested with proteinase-K. For PCR amplification the
following primers were used: 5’-GCC AGG GCC CCT
CCT TCA A-3’ and 5’-TAC CCT CAG ACC CAC GAG T3’ for Arg194Trp polymorphism and 5’-TGC TTT CTC
TGT GTC CA-3’ and 5’-TCC AGC CTT TTC TGA TA-3’
for Arg399Gln polymorphism. The restriction enyzyme
PvuII was used to distinguish the Arg194Trp polymorphism
and MspI enzyme to distinguish the Arg399Gln
polymorphism. An age-and sex-matched healthy control
group was used to compare the frequency of polymorphic
variants with cancer-free population. Results and
Discussion: No significant difference was found between
patients and controls regarding the investigated
polymorphisms of XRCC1 gene. In the second part of our
study we tested the effects of genotype effects on overall
survival. We investigated the effects of the XRCC1 gene
polymorphisms in respect to the patients clinical stage. We
found a significant difference between patients with
different XRCC1 194 polymorph status in clinical stage
SIII. The patients with Arg194Arg genotype had
significantly lower survival rate than patients with
Arg194Trp genotype. The complex analysis of these factors
may be a way for the personal risk assesement and
treatment.
matched controls. After deparaffination, samples were
digested with proteinase-K. DNA solutions were used for
PCR amplification. For amplification the following primers
were used: GSTT1 forward primer 5’-TT CCT TAC TGG
TCC TCA CAT CTC-3’; GSTT1, reverse primer 5’-TCA
CCG GAT CAT GGC CAG CA -3’; and GST M1 forward
primer: 5’-GAA CTC CCT GAA AAG CTA AAG C-3’,
GSTM1 reverse primer 5’-GTT GGG CTC AAA TAT ACG
GTG G-3’. P53 genotyping (codon 72, Arg/Pro
polymorphism) was performed using 3’ primer: GC AAC
TGA CCG TGC AAG TCA and 5’ primers for Arg variant
ATGCCAGAGGCTGCTCCCCG and for the Pro allele ATG
CCA GAG GCT GCT CCC CC. Results and Discussion: No
significant difference was found between cancer patients and
controls in respect to GSTM1, GSTT1 and p53
polymorphisms. Kaplan–Meier curves were defined in all
Dukes’ stages. Significant association was found in stage
Dukes’ B patients between the GSTM1 and p53 gene variant
and survival. The chance of survival was significantly lower
in patients with GSTM1 0 genotype and in p53 Arg/Pro
heterozygotes or Pro/Pro homozygotes than in the case of
GSTM1+ and p53 Arg/Arg variants (p=0.0089 and
p=0.0008). The relevance of the investigated polymorphisms
on prognosis is dependent on the tumor stage. These
parameters might be used in certain cases as prognostic
biomarkers and in the planning of individualized therapy.
677
ALLELIC POLYMORPHISMS AS MODIFILERS OF
CLINICAL OUTCOME IN COLORECTAL CANCER
678
METASTATIC GENE SIGNATURE OF THE
MOST AGGRESSIVE HUMAN CANCER:
CUTANEOUS MELANOMA
Antal Tibold1, Andras Csejtei2, Zsuzsa Varga3,
Katalin Koltai4, Agoston Ember5, Zsuzsa Orsos1,
Istvan Ember1 and Istvan Kiss1
J. Tímár1,2, L. Mészáros1, A. Ladányi1,
L. Puskás3 and E. Rásó1
1Department
1National
of Public Health, University of Pécs, Medical
School, Hungary, Pécs, Szigeti str. 12;
2Department of Oncoradiology, Markusovszky Hospital,
Hungary, Szombathely, Markusovszky Lajos str. 3;
3Department of Oncology, Baranya County Hospital,
Hungary, Pécs, Rákóczi str. 2;
41st Department of Medicine, University of Pécs, Medical
School, Hungary, Pécs, Ifjúság str. 13;
5Department of Surgery, University of Pécs, Medical
School, Pécs, Ifjúság str. 13, Hungary
Background: Cancers of the colorectal region are the second
most frequent cause of death among malignant diseases. We
investigated the influence of two allelic polymorphisms of
the GSTM1 and GSTT1 metabolyzing enzymes and that of
p53 tumor suppressor gene codon 72 polymorphisms on
colon cancer. Materials and Methods: 102 intraoperatively
removed tissue samples from patients with colorectal cancer
were processed. Cancer–free human samples were used as
3518
Institute of Oncology, Budapest;
of Pathology, Semmelweis University,
2Department
Budapest;
3Center of Biology, Hungarian Academy of Sciences,
Szeged, Hungary
Most of the melanoma markers used today are melanocytic
markers or pigmentation pathway-associated genes driven
by the microphthalmia transcription factor, MITF, and
include, among others, tyrosinase, dopachrome
tautomerase, DCT, melan-A and S100B. Genomic studies
repeatedly revealed several novel melanoma marker genes
including those of the transcription factor NOTCH2,
WNT5A, proliferation-associated genes TOPO2A and
CDC2, membrane receptors FGFR and EphA3, adhesion
molecules N-cadherin, β3 integrin and syndecan-4, and the
cell surface antigens CD59/protectin and MIA. Other
genomic analyses tried to define the gene signature of the
metastatic disease but failed to find a consistent one except
Abstracts of the 8th International Conference of Anticancer Research, 17-22 October 2008, Kos, Greece
the gold standard genes of β3 integrin, syndecan-4 and
WNT5a. Studies on the gene signatures of chemoresistance
and cytokine sensitivity of melanoma clearly defined
apoptosis-resistance as one of the key elements of the
above biological properties, but the data are controversial,
mostly because of the use of inappropriate model systems
and the lack of confirmation on clinical samples. Recently
a meta-analysis of the published array data (involving eight
hundred genes) identified only a few-gene set of IGFBP,
CMET, FGFR1 and CDK2 which repeatedly (at least in 3
cases) occured in the various genomic studies on metastatic
melanoma suggesting that without proper validation of the
gene sets and proper selection of the histological variants
of melanoma it would not be feasible to define a better
prognostic signature.
We have used three genetically unrelated human
melanoma cell lines grown as s.c. xenografts in SCID mice
to reveal a metastatic melanoma gene signature in the
primary tumor. To identify relevant genes, we used
newborn host (metastatic condition) and adult host
(nonmetastatic condition). Since the stroma is murine, it is
possible to separate the human (melanoma) genes from the
stromal genes without microdissection. Expression profiles
of primary human melanomas were obtained by the 41k
Agilent Whole Human Genome Oligo Microarray. The
gene set significantly different in all the three cell lines
was further validated by qPCR using Taqman card of 96
genes (Applied Biosystem). Using this model, we have
identified a large 832 metastatic melanoma gene signature
(p<0.05), from which we were able to derive a 39-gene set
validated by qPCR. This melanoma metastasis gene
signature contained 9 previously reported metastasis genes
including transmembrane heparan sulphate proteoglycan,
β3 integrin, AKT and TOPO2A. The largest group of
metastasis genes belongs to those involved in the
regulation of apoptosis (8) and those involved in
developmental regulation (NOTCH1, FOXD3, FZD9,
HOXC13). This 39-gene set was validated on a clinical
cohort of twenty primary SSM melanoma samples where
the 5-year history of clinical behaviour was known
(visceral metastatic progression or locoregional
dissemination/no progression). Using the TaqMan
technology we were able to identify a 17-gene metastatic
melanoma gene signature of ten up-regulated and 7 downregulated genes. The signature contains integrin av, RXRγ,
TOPO2A, NOTHCH1 and IGFBP7, all claimed previously
to be involved in melanoma progression. The signature
also contains a 4-gene set, members of which are involved
in apoptosis regulation. This novel metastastatic melanoma
gene signature revealed the apoptotic pathway, TOPO2A
and β3 integrin as valid molecular therapeutic targets of
melanoma progression. This study was supported by
NKFP1a-0024-05.
679
A ROLE FOR NON-CODING RNA
IN CANCER EPIGENETICS
Angela H. Ting
Cleveland Clinic, Ohio, USA
Epigenetic abnormalities, which involve modifications to the
DNA and histones, have long been recognized for their
pivotal role in silencing protein coding genes (tumor
suppressors) to allow cancer development. The involvement
of non-coding RNAs will be discussed in the context of
aberrant epigenetic silencing in cancer and data on RNAdependent transcriptional silencing as a potential mechanism
for the initiation/maintenance of cancer epigenetics will be
presented. We found that synthetic double-stranded RNA is
able to effectively initiate transcriptional gene silencing in
human cancer cell lines. Furthermore, loss of DICER, an
essential non-coding RNA processing enzyme, results in the
loss of localized promoter hypermethylation and gene
silencing. Together, these data support our hypothesis that an
RNA-mediated pathway is responsible for at least some of
the epigenetic regulation in human cancer.
680
EXPRESSION OF ANGIOPOIETINS AND
TIE-2 RECEPTOR IN GASTROINTESTINAL
CARCINOMAS
Paola Tonino1, Elizabeth Valdivieso2 and Carmen Abreu3
1Centro
de Microscopía Electrónica “Dr. Mitsuo Ogura”,
Facultad de Ciencias, Universidad Central de Venezuela,
Apartado 76963, El Marques 1070, Caracas, Venezuela;
2Instituto de Biología Experimental, Facultad de Ciencias,
3Instituto Anatomopatológico, Facultad de Medicina,
Universidad Central de Venezuela
The angiopoietins 1-4 (Ang1 – Ang4) are a family of growth
factors identified as ligands for Tie2 receptor tyrosine kinase,
critically involved in angiogenesis by their regulation of
endothelial survival. Ang1 acts as an agonist, activating the
Tie2 signaling pathways, whereas Ang2 acts as an
antagonist, specifically blocking the Ang1 dependent
activation in endothelial cells. Ang3 (mouse) and Ang4
(human) also show context-dependent actions as antagonistic
and agonistic ligands, respectively. The biological actions of
the Angs in tumor growth and metastasis in gastrointestinal
cancer are still not fully understood. The aim of the present
study was to evaluate the expression of Ang1, Ang2, Ang4
and Tie2 receptor in human gastrointestinal carcinomas
(GITC), and their relation to clinicopathological factors.
Immunohistochemical and Western blot analysis were
performed in surgically resected specimens from patients
3519
ANTICANCER RESEARCH 28: 3157-3556 (2008)
(n=27). Normal gastrointestinal mucosa was examined as
normal controls (n=5). Intensity of immunostaining was
scored as negative, weak, moderate and high. Mann-Whitney
and Chi-square test were used for statistical comparisons
with a significance defined as p<0.05. Normal
gastrointestinal epithelium showed a negative or weak
immunoreactivity for Ang1, Ang2, Ang4 and Tie2 receptor.
Of the GITC, 77.78% (21/27), 74.07% (20/27), 85.19%
(23/27) and 59.26% cases (16/27) showed positive
immunostaining in the cytoplasm and nucleus of tumor cells,
and endothelial cells for Ang1, Ang2, Ang4 and Tie2,
respectively. A moderate Ang4 > Ang2 > Ang1
immunoreactions was seen in most GITC, however the
higher intensity of immunostaining was observed as Ang1 >
Ang2 > Ang4 when compared to non-malignant epithelial
cells. The expression of Ang1, Ang2, Ang4 and Tie2 was
significantly correlated to the venous invasion (p<0.01,
p<0.001, p<0.05 and p<0.001, respectively) and lymph node
metastasis (p<0.001, p<0.01, p<0.01 and p<0.001,
respectively). Western blot analysis (n=13) from GITC
revealed an upregulation of Ang1 (92.30%; 12/13), Ang2
(84.61%, 11/13), Ang4 (92.30%, 12/13), and Tie2 receptor
(76.92%,
10/13)
in
correspondence
with
the
immunohistochemical expression. The overexpression of
Ang1, Ang2, Ang4 and Tie2 in human GITC suggests that
signaling pathways via Ang-Tie2 ligand-receptor is involved
in the invasion and metastatic potential of these tumors, and
certainly highlights that these factors represent important
therapeutic targets to regulate angiogenesis.
This work was supported by CDCH-UCV (03-00-6630-2006
to PT).
681
THE BIOLOGICAL ACTIVITY OF
TUMOR IN ROUTINE PRACTICE
O. Topolčan, L. Holubec, V. Třeška, M. Pešek and J. Fínek
Faculty Hospital and Medical School in Pilsen, E. Benese
13, 305 99 Plzen, Czech Republic
Aim: The aim of the study is to demonstrate a potential
clinical use of tumor marker assessment. A current indication
for the tumor markers assessment for the primary diagnosis,
follow-up and therapy monitoring is based on ROC of
individual markers, obtained from multicenter study results.
This study proposes an opposite approach: to estimate
clinician’s needs and to propose the optimal combination of
tumor markers. Results and Discussion: On the basis of the
evaluation of results from more than 300,000 routine
analyses, an optimal multiparametric diagnostic procedure
for follow up of 10 most common tumor diseases has been
elaborated. The possibility of its use in diagnostics using
multiplex diagnostic methods is discussed. Conclusion: A
3520
combination of at least 4 parameters seems to be highly
optimal: an established tumor marker, a cytokeratin
fragment, a marker of proliferation and a growth factor. The
choice of an optimal combination of parameters differs
depending on the histological type of tumor and the clinical
diagnosis purpose (primary diagnosis, early detection of the
disease, progression during the follow-up therapy
monitoring, etc.).
Supported by the research project VZ MSM 0021620819.
682
WHY SOMETIMES RESULTS OF TUMOR
MARKERS STUDIES ARE SO VARIOUS?
COMPARING OF RULES FROM CLINICAL
RESEARCH STUDIES WITH STANDARDS OF
NON-INTERVENTIONAL TUMOR MARKER
STUDIES ADVANTAGES OF APPLICATION
OF NEW STATISTICAL TOOLS
L. Pecen and O. Topolcan
1Academy
of Science, Prague;
Hospital and Medical School in Pilsen, E. Benese
13, 305 99 Plzen, Czech Republic
2Faculty
Why sometimes results of tumor markers studies are so
various? Weaker rules and standards applied in noninterventional tumor marker studies are applied comparing
them with rules from clinical research (new drug
development). An application of strict rules could decrease
the variability of published results. In clinical research it is
required to define many important steps in advance (prior
first patient enters into study) mainly the primary goal of the
study. The primary goal includes a definition of the primary
endpoint or endpoints and secondary endpoint(s). Only
results concerning the primary endpoint will be analysed
confirmatorily, secondary endpoint/s will be analysed
exploratorily only. If more than one primary endpoints exist
in the study, adjustment of statistical testing for multiple
comparison has to be applied. It means alpha level for all
confirmatory testing has to be 5% (0.05) in total for all
comfirmatory testing. In clinical research the sample size has
to be optimized with a specified significance level and power
according selected primary endpoint/s and proposed study
design. Variability of results will be decreased if null
hypothesis and alternative hypothesis will be formally
formulated in advance as well as statistical model will be
selected in advance. Important issue is also the statistical
monitoring of the quality of the data. Special emphasis has to
be given to items entered manually into computer where
recommended standard is double data entry by two
independent persons and to compare results. Analysis of
possible confounding and/or interacting factor could also
help to explain difference between study’ results and other
Abstracts of the 8th International Conference of Anticancer Research, 17-22 October 2008, Kos, Greece
published papers with similar topic. Some promising new
statistical tools (new in tumor markers analysis) as CART
(Classification And Regression Trees) models, RECPAM
(Recursive Partitioning and Amalgamation), Hidden Markov
Chain Models, multiple events/endpoints Wei & Lachin-test
etc.
Study was supported by the research project VZ MSM
0021620819.
683
MICROIMAGING FT-IR OF HEAD AND NECK
TUMOURS THE CASE OF SALIVARY GLAND
PATHOLOGIES
C. Conti1, P. Ferraris1, E. Giorgini1, C. Rubini2,
S. Sabbatini1 and G. Tosi1
1Dipartimento
di Scienze e Tecnologie Chimiche,
2Dipartimento di Neuroscienze, Università Politecnica delle
Marche, Ancona, Italy
The potential role of infrared (IR) spectroscopy in
biomedical science has been exploited to distinguish
different biomolecules by probing chemical bond vibrations
and using these molecular and sub-molecular patterns to
define and differentiate pathological from healthy samples.
IR spectroscopy provides a spectral signature of the intensity
and spatial location of the chemical components, so
highlighting biochemical changes. FT-IR microimaging
spectroscopy is particularly suitable to characterize tissue
structures owing to the capability of generating maps or
images of sample areas. The use of multivariate data and
artificial neural network analysis can afford an unsupervised
classification of biochemical components.
For a decade, we have been applying IR spectroscopy to
study pathological states in breast, colon and, mainly, head
and neck tissues characterizing various biochemical
components with the aim to detect pathological states.
This contribution aims to further prove the potential of IR
in isolating and defining characteristic spectral profiles in
salivary glands attributable to various kinds of cancer: IR
spectra of warthin tumour, oral epithelium with dysplasia,
lymphoma, polymorphous low-grade adenocarcinoma,
myoepithelioma, adenoid cystic carcinoma were compared
with the corresponding healthy tissues. Using the intensity
ratios 1660/1650 cm–1 of Amide I and II absorption bands,
the νasymCH3/νsymCH2 and νasymCH2/νasymCH3 bands and
1240/970 cm–1 as well as the absorption of the C-Oasym
stretching mode and the shape of the band at about 1080
cm–1 we found a realtionship with histological classification
data.
In order to further verify the reliability of our
classification, all the spectra from SK regions were mixed
with those from zones characterized by other tumours
obtaining a new HCA grouping in excellent agreement with
their biochemical and histological characterization.
The results presented here show subtle biochemical and
morphological changes distinguishing various kinds and
grades of neoplasia in tissues from a specific region of the
human body. The diagnosis of a pathology at a molecular
level especially in the early stage is dependent on a defailed
spectral analysis of infrared spectra, which contributes to the
clinical histopathological and immuno-histochemical
screening.
684
EXOGENOUS ERYTHROPOIETIN MODIFIES
TUMOR-INDUCED NEOANGIOGENESIS IN
HUMAN TUMOR MODELS
József Tóvári
National Korányi Institute of TB and Pulmonology,
Budapest, Hungary
Numerous clinical data suggest that hypoxia in tumors
enhances the aggressiveness of a tumor and promotes
malignant progression. Moreover, hypoxia is an independent
prognostic factor in several types of malignant cancer.
Correction of anemia and an increase oxygen level inside the
tumor not only result in the improvement of quality of life
but also enhance the success of cancer therapy, leading to
improved survival of patients. Erythropoietin (EPO) has long
been recognized as the major hematopoietic cytokine
regulating normal erythropoiesis. However, recent studies
indicated that, beside erythroid progenitor cells, tumor and
endothelial cells express erythropoietin receptor (EPOR) as
well, therefore recombinant human erythropoietin (rHuEPO)
may affect their functions.
We reported that rHuEPO administration modulates tumor
vasculature in human squamous cell and colorectal
carcinoma xenograft models. In vivo rHuEPO treatment of
xenografts at human-equivalent dose significantly increased
the proliferation index of the tumor-associated endothelial
cells and the size of CD31-positive intratumoral blood
vessels. Moreover, rHuEPO administration resulted in
reduced expression of vascular endothelial growth factor
(VEGF) and hypoxia inducible factor 1-alfa (HIF-1α) but
had no direct effect on the growth of EPOR-positive tumor
xenografts. Due to the morphological alterations in tumoral
microvessels, rHuEPO treatment led to a significantly
improved efficacy of 5-fluorouracil (5-FU) chemotherapy. At
the same time rHuEPO treatment significantly increased the
efficacy of radiotherapy in vivo, mediated by increased
tumoral blood vessel destruction.
Summarizing our data, rHuEPO treatment may modulate
the efficacy of cancer chemo- and radiotherapy not only by
reducing systemic hypoxia and tumoral HIF-1α expression,
3521
ANTICANCER RESEARCH 28: 3157-3556 (2008)
but also by the regulation of intratumoral vessel formation
and function.
685
PIPOXOLAN INDUCES APOPTOSIS OF HUMAN
U937 LEUKEMIA CELLS VIA MITOCHONDRIALMEDIATED PATHWAY
Huei-Yann Tsai1,2,4, Jai-Sing Yang2 and Yuh-Fung Chen2,3,4
1College
of Pharmacy, 2Department of Pharmacology and
Institute of Chinese Pharmaceutical Sciences,
China Medical University, 91 Hseuh-Shih Road, Taichung,
40402, Taiwan;
4Department of Pharmacy, China Medical University
Hospital, 2 Yuh-Der Road, Taichung, 40402 Taiwan, ROC
3Graduate
We investigated the anti-leukemia effects of pipoxolan on the
U937 leukemia cell line. Cell viability, reactive oxygen
species (ROS) production, mitochondrial membrane
potential, apoptosis induction, and caspases-1, -3 activity
were examined by flow cytometry and caspase-activity assay.
Apoptosis-associated Bcl-2 family proteins were examined
by Western blotting. Our data showed that pipoxolan
inhibited U937 cell proliferation in a dose- and timedependent manner. The morphological assessment and cell
cycle/apoptosis analysis by flow cytometry indicated that
U937 leukemia cell line incubated with 10 μM pipoxolan
induced cell apoptosis. Pipoxolan induced an increase of
reactive oxygen species (ROS) in 1 h and thereafter a loss of
mitochondrial membrane potential by flow cytometry.
Pretreatment with N-Acetyl-L-Cysteine (ROS chelator) in
pipoxolan-treated cells led to decline of ROS. We
demonstrated an increase in the levels of Bax and decrease in
the level of Bcl-2 and Bcl-xL, which were associated with
the induction of apoptosis after 24 h treatment with
pipoxolan in U937 leukemia cells. Our data suggest that
pipoxolan could serve as a potent anticancer
chemotherapeutic agent for human leukemia.
686
PROTEOMICS IN CANCER RESEARCH
George Th. Tsangaris
Proteomics Research Unit, Center of Basic Research II,
Biomedical Research Foundation of the Academy of Athens,
Athens, Greece
Proteomics aim is to characterize, discriminate and identify
the proteins in biological materials such as plasma and
serum, urine, cell lines, tumors, biopsies etc in order to
identify novel diagnostic biomarkers and therapeutic targets.
The major proteomic technologies applied in cancer samples
include two-dimensional polyacrylamide gel electrophoresis
3522
(2D-PAGE) and mass spectrometry (MS) while other
methods
including
surface-enhanced
laser
desorption/ionization time-of-flight (SELDI-TOF)-MS,
liquid chromatography combined to MS, isotope-coded
affinity tag technology, reverse-phase protein arrays, and
antibody microarrays are emerging as alternative proteomic
technologies. Since there is little overlap between these
approaches, the utility of these advanced technologies in
cancer remains an elusive goal. Nowadays many proteomics
studies have generated numerous datasets of potential
diagnostic, prognostic, and therapeutic significance in human
cancer. Despite the technological limitations of these
technologies, there is little doubt that the proteomic approach
has the potential to identify novel diagnostic biomarkers and
therapeutic targets in cancer.
In accordance with the above statements the first part of
that presentation refers to the proteomics technologies
applied to the analysis of the entire proteome, to the
identification and characterization of single protein
molecules or protein complexes. The second part of the
presentation refers to the most important areas that
proteomics have contributed which are the prevention,
diagnosis and treatment of cancer. The high throughput
proteomic technologies applied lead to the elucidation of the
pathways of carcinogenesis, to the characterization of
specific biological markers for cancer diagnosis and to
identification of new therapeutic targets. Furthermore, in
order to answer clinical questions in cancer research, the
accumulation of recent data is crucial to shift the emphasis of
cancer proteomics from technology development to careful
study design and data mining. The exploitation of these data
will offer a deep knowledge of the mechanisms and the
specific characteristics of the different types of the
malignancy, greatly enhancing accurate prognosis and
effective treatment.
687
TOPOISOMERASE I PROTEIN EXPRESSION IN
PRIMARY COLORECTAL CANCER AND
RECURRENCES AFTER 5-FU-BASED ADJUVANT
CHEMOTHERAPY
P. Gouveris, A. Lazaris, T. Papathomas, A. Nonni,
V. Kyriakou, J. Delladetsima, ES. Patsouris,
S. Tsaousi, J. Syrios, E. Patsouris and N. Tsavaris
Medical Oncology Unit, Department of Pathophysiology,
Medical School, National and Kapodistrian University of
Athens, Athens, Greece
Objectives: Our aim was to investigate whether
chemotherapy with 5-FU induces an alteration in the levels
of topoisomerase I (topo I) in colorectal neoplastic tissues
Methods: Twenty-five colorectal cancer patients were
Abstracts of the 8th International Conference of Anticancer Research, 17-22 October 2008, Kos, Greece
included in the study; patients had undergone surgical
resection of the primary tumor, received post-operatively 5FU-based adjuvant chemotherapy and then suffered from
recurrences. In a standard three-step immunohistochemical
procedure, a monoclonal antibody to topo I was applied in
both specimens from each patient (one from the primary
location and a second one from the recurrence). Statistical
analysis was subsequently performed. Results: Malignant
cells from the recurrences displayed a statistically significant
increase, concerning the levels of topoisomerase I, by
comparison with the primary tumors (p=0.01). The increase
in topo I levels did not demonstrate significant correlations
with Duke’s stage (Fisher’s Exact Test p=0.496),
differentiation grade (p=0.661), localization (p=0.072),
patient sex (p=0.434), nor with relapse free interval
(p=0.493). There was a statistically significant relationship
between the age of patients and increase in topo I levels
(p=0.011). Conclusion: Topo I expression may be part of the
malignant cells’ phenotype in recurrent colorectal
carcinomas, suggesting a potential role for Topo I in the
acquisition of a metastatic phenotype. The increase of topo I
immunohistochemical status is likely to be attributed to 5FU and given the fact that high levels of topo I correlate with
sensitivity to camptothecin, advanced colorectal cancer
patients seem to benefit from topo I targeted anticancer drug
therapy.
688
TOPOISOMERASE I AND IIα PROTEIN
EXPRESSION IN PRIMARY COLORECTAL
CANCER AND RECURRENCES FOLLOWING 5FLUOROURACIL-BASED ADJUVANT
CHEMOTHERAPY. IMPLICATIONS FOR NEW
APPROACHES IN CHEMOTHERAPY FOR CANCER
AND INFECTION
Nicolas Tsavaris1, Elias Skopelitis1, Andreas Lazaris2 and
Christos Kosmas3
1Medical
Oncology Unit, Department of Pathophysiology,
“Laikon” University General Hospital, Medical School,
National and Kapodistrian University of Athens;
2First Department of Pathology, “Laikon” University
General Hospital, Medical School, National and
Kapodistrian University of Athens;
3Second Department of Medical Oncology, “Metaxa”
Cancer Hospital, Piraeus, Greece
Human DNA topoisomerases I and II (topo-I and -II) are
essential for vital cellular processes such as DNA replication,
transcription, translation, recombination and repair.
Following a chain of observations and pilot studies, we
present the findings of a pioneer study, in which topo-I and
-II expression was correlated with outcome after
chemotherapy in primary and relapsed colorectal cancer.
Patients with colorectal cancer that had recurred following
surgery and adjuvant chemotherapy and WHO underwent a
second operation were included in the present study. All had
undergone surgical resection of the primary tumor and
received post-operatively 5-FU-based (5FU+Leucovorin,
Mayo Clinic regimen) adjuvant chemotherapy. Tumor tissue
was collected at the initial operation from the primary tumor
and at the time of recurrence (during the second operation
following chemotherapy). All tissues samples were analyzed
for levels of expression of both topo-I and topo-IIa using
standard three-step immunohistochemistry on paraffin
sections. Forty patients were included in the study. Levels of
expression of topo-I and topo-II were higher in malignant
cells from tumor recurrences compared to primary tumors
(p=0.0001 for both). There was a statistically significant
positive relationship between patients’ age and levels of
topo-I (p=0.011) and topo-II (p=0.011) expression. The study
results reported here underscore the role of topoisomerase
expression in colorectal cancer and suggest a potential role in
tumor recurrence. This model could be further studied to
include other forms of neoplasia and infection, in an effort
to elucidate the development of chemotherapy drug
resistance, thus optimizing treatment strategies and
improving cancer patient care.
689
HER2/NEU OVEREXPRESSING BREAST
TUMORS WITH INCREASED PAKT HAVE POOR
OUTCOME AND DEVELOP DRUG RESISTANCE
Jay Vadgama, Yanyuan Wu, Hezla Mohamed, Ram Chillar,
Ishrat Ali, Sheila Clayton and Dennis Slamon
Divisions of Cancer Research and Training,
Hematology/Oncology, Department of Medicine Charles R.
Drew University of Medicine and Science, and David
Geffen UCLA School of Medicine, Los Angeles, CA, USA
Introduction: Breast cancer patients with HER2/neu
overexpression have poor outcomes, with a decrease in
disease-free (DFS) and overall survival. The biology of
HER2/neu overexpression in breast tumors in AfricanAmerican and Latina women is poorly understood. The
purpose of this study is to understand the clinical significance
of activated Akt (phospho-Akt or pAkt) expression in breast
tumors from African-American and Latina patients with
corresponding tissue HER2/neu over expression. Cellular and
molecular studies have shown that activation of the cell
signaling phosphatidylinositol-3-kinase/Akt cascade via the
HER2/neu and other receptor tyrosine kinases induces cell
proliferation. Materials and Methods: A total of 234 AfricanAmerican and Latina patients were selected retrospectively.
From this group, 141 tumor tissue samples were analyzed for
3523
ANTICANCER RESEARCH 28: 3157-3556 (2008)
tissue pAkt by immunohistochemistry (IHC). This cohort
consisted of 46 HER2/neu-positive (3+ by IHC) and 95
HER2/neu-negative tumors. The prognostic value of activated
tissue Akt in relation to HER2/neu over expression for DFS
was determined. Results: Patients with low pAkt and HER2negative tumors had the best DFS. As expected, patients with
HER2/neu-overexpressing tumors with low pAkt had a
decrease in DFS. Similarly, those with high pAkt and HER2negative tumors also had poor DFS. However, those with an
increase in both HER2 and pAkt had the worst DFS. An
increase in pAkt was significantly associated with HER2/neupositive and lymph node-positive breast tumors. Tumors with
high HER2 and high pAkt were metastatic. Multivariate
analysis demonstrated that, in addition to the common risk
factors such as larger tumor size, lymph node involvement,
estrogen receptor/progesterone receptor-negative tumors, and
HER2/neu-positive tumors, overexpression of pAkt was
significantly associated with a decrease in 5-year DFS. A
decrease in DFS with an increase in pAkt was observed in
both HER2/neu-positive and -negative groups. However, the
DFS was similar in HER2/neu-positive/pAkt-negative and
HER2/neu-negative/pAkt-positive groups. Conclusion: Our
data suggest that there may be differences in tumor
phenotypes within patients with HER2/neu-overexpressing
breast cancer. The overexpression of pAkt may be a powerful
prognostic marker for predicting DFS and overall survival of
breast cancer patients.
690
ANTITUMOR EVENTS IN ENDOCRINE TUMORS
Zs. Valkusz2, M. Radács1, A. Juhász3, J. Jojárt1,
J. Gardi2, J. Julesz2, J. Molnár4 and M. Gálfi1
University of Szeged, Faculty of Juhász Gyula Teacher
Education, 1Institute of Applied Natural Science, Department
of Environmental Biology, Faculty of Medical School, 2First
Department of Medicine Endocrine Unit, 3Department of
Psychiatry, 4Institute of Microbiology, Szeged, Hungary
Introduction:
Persistent
agents
(e.g.:
halogenated
hydrocarbones) are cummulated in various biological
organisms. These chemicals originate from industrial and
agricultural section of the society. Chlorobenzenes have
strenghtened stabilized structures responsible for dose
dependent effects on human population. Aim: to investigate (1)
the transformation activity of endocrine tissues
(Adenohypophysis-/Adh/, Neurohypophysis – /Nh/) altered by
different doses chlorobenzenes (2) the effects of in vivo and in
vitro given antitumor agents (retinoic acid, krocin extract,
interferon – β, algae -extract). Methods: Wistar rats (
10
animals/group) were treated (by gastorintestinal tube) with 1
mg/bwkg
¡
A
chlorobenzenes
mix
(ClBM:
/hexachlorobenzenes: trichlorobenzenes = 1:1/); 1 μg/bwkg
3524
ClBM ¡ B; 0,1 μg/bwkg ClBM ¡ C, for 30, 60 and 90 days.
Our control system was absolute control – untreated – (AC);
Positive control – treated by solvent /0,0015% ethanol/ of
ClBM – (+C); Negative 1 control – treated by drinking water –
(-C1), Negative 2 Control – stress control with gastric tube only
– (-C2). In the treatment protocol the nutrition scheme was
simulated a daily utilization of a gastric tube. At the end of
treatment the morphology (number of tumors) and the function
(hormones content –by RIA-) of Adh and Nh tissues were
detected. The antiproliferative treatment in vitro included (10–6
M) retinoic acid (RA)/Sigma/, (1 μg/ml) crocus extract (CE), (1
μg/ml) algae extract (AE), (10–6 M) interferon-β (IF-β).
Morphological analyses were carried out from paraffin cuts
with Gills-Haematoxilin-Eosin stains. Protein was measured by
the modified Lowry method. Hormones were detected by RIA
methods. Statistical analysis of the data was made with the
ANOVA program. Results: The ClBM A and B treatment
tranformed the cells of Adh and Nh tissues. The
RA>CE>AE>IF β showed antitumor effects on Adh and Nh.
The hormone release was increased in the ClBM induced
endocrine cell cultures. The antitumor agents could modify the
increased hormone release. Conclusion: At the end of in vivo
treatments no tumors were found in the pituitary tissues.
However Adrenocorticotropin, Prolactin, Oxytocin and
Vasopressin release were shown in the primary Adh, Nh cell
cultures, in the cases of A30, A60 and A90. In vivo ClBM
pretreatment caused cell transformation in A60, A90, B60 and
B90. In these cases promotion and initiation effects of ClBM
could be detected in the pituitary tissue.
This work was supported ba ETT-345/2006.
691
THE ANTIPROLIFERATIVE EFFECTS OF
EXTRACELLULAR BIVALENT CATIONS ON
PROLACTINOMAS
Zs. Valkusz2, M. Radács1, Gy. Nagyéri1, J. Gardi2,
J. Julesz2, J. Juhász3, J. Molnár4 and M. Gálfi1
University of Szeged, Faculty of Juhász Gyula Teacher
Education, 1Institute of Applied Natural Science, Department
of Environmental Biology, Faculty of Medical School, 2First
Department of Medicine Endocrine Unit, 3Department of
Psychiatry, 4Institute of Microbiology, Szeged, Hungary
Introduction: Endocrine cell transformation can be induced by
disturbing the endocrine regulation (f.e.: chaotic feed-back), and
can be initiated (f.e.: benz-c-acridine, chlorobenzenes) or/and
promoted (f.e.: chlorobenzenes, electromagnetic field) with
agents and energy. Aim: To investigate the behaviour of different
origin Prolactinomas (P). Methods: Wistar rats were used.
Untreated animals were the controls, the in vivo oestron-acetate
(subcutaneous implantate 1 μg/bw/week; for 6 months) treated
rats were the disregulated P. From the two groups the
Abstracts of the 8th International Conference of Anticancer Research, 17-22 October 2008, Kos, Greece
adenohypophysis (Adh) and the prolactinomas (P) were
separated by enzymatic and mechanical dissociations as primer
Adh and P cell cultures. The Adh cultures were treated with
(0.01 μ/ml) benz-c-acridine (BcAT), and (0.1 fg/mg protein)
chlorobenzenes mix (hexachlorobenzene: trichlorobenzene=1:1)
(ClBT) for 6 days. After the treatment the cell cultures showed
tumorous formations (BcAT; ClBT). The cultures were
examined for hormon secreting function (Adrenocorticotroph
hormone: ACTH; prolactin: PRL; growth hormon: GH –by
RIA-) and for cell biological markers (membrane fluidity /–with
fluorescense anizotropy-/, Na+-K+-ATP-ase activity /-by
spectrophotometric method-/, Mg++-dependent ATP-ase activity
/-with spectrophotometric method-/, cAMP content /-with
Amersham KIT-/). The different cell cultures were treated with
extracellular calcium and magnesium in lower than the
physiologic concentration (0.25 mM).The data were analyzed
by ANOVA system. Results: The hormonal secretion was
increased in all treated animals (BcAT > ClBT > P) compared to
controls. However, the use of low concentration bivalent cations
(Ca2+, Mg2+) decreased the hormone-release P > ClBT > BcAT.
The cell-markers were lower than in controls. Conclusion: The
pituitary cells show different parameters depending on the type
of transforming treatment. Antitumor effects of low
concentration of bivalent cations can be observed in
prolactinomas.
This work was supported by ETT-345/2006.
692
CONTROL OF THE CELL CYCLE BY NITRIC OXIDE
IN HUMAN NEUROBLASTOMA CELLS
Marlies Van de Wouwer and Antonio Villalobo
Instituto de Investigaciones Biomédicas, Consejo Superior de
Investigaciones Científicas, Arturo Duperier 4, E-28029
Madrid, Spain
Nitric oxide (NO) has been recognized as a bi-modal
regulator of cell proliferation, inducing either an increase in
the proliferative rate or the arrest of the cell cycle at low and
high concentrations, respectively. Exposure of tumor cells
to both endogenously produced and exogenously added NO
has been shown to exert both anti-tumor and pro-tumor
actions. Nevertheless, the potential therapeutic effects of NO
in cancer are currently under intense scrutiny. To get further
insight into the action of NO on cell proliferation, we tested
the effect of an exogenous NO donor on the expression and
activation/deactivation of different regulators controlling cell
cycle progression in human neuroblastoma NB69 cells. We
demonstrate in this work that the chronic exposure (17-19
h) of these tumor cells to 2,2’-(hydroxynitrosohydrazono)bis-ethanimine (DETA/NO), a slow NO
releaser (t1/2=20 h) belonging to the NONOate family,
induces a decrease in the expression and/or the
phosphorylation of the transcriptional repressor pRb, which
controls the G1/S transition, and a decrease in the
phosphorylation of two cyclin-dependent kinases, Cdk2 and
Cdk1(cdc2). This is accompanied by a decreased expression
of cyclins (Cdks regulatory subunits), particularly cyclins
D1, A and B1. We have found a variable effect of DETA/NO
on cyclin E expression, consistent with reports in other cells.
In addition, NO-induced changes in the phosphorylation
pattern of cyclin E were noticed, as well as a decrease in the
phosphorylation of cyclins D1 and B1. DETA/NO treatment
also induces a slight decrease in the expression of the Cdks
inhibitors p16Ink4a and p27Kip1, in contrast to the enhanced
expression of p21Cip1/Waf1. We have also observed NOmediated activation of the tumor suppressor protein p53,
which might account for the up-regulation of p21Cip1/Waf1.
Taken together, our results highlight some of the molecular
mechanisms subjacent to the observed proliferative arrest of
cells exposed to NO. The anti-proliferative role of NO does
not appear to be limited to its well-known action controlling
the G1/S transition, affecting systems such as pRb, Cdk2
(with cyclin E as a partner), cyclin D (a Cdk4/Cdk6
partner), and p21Cip1/Waf1, but also affects systems
controlling the S phase and the G2/M transition, such as
Cdk2 (with cyclin A as a partner), Cdk1(cdc2), and cyclins
A and B itself. Moreover, our results could point to the
possible entry of cells in apoptosis because of the observed
upregulation of p53. This could occur after arrest of the cell
cycle whenever the exposure to NO is sufficiently high in
concentration and prolonged in time.
This work was financed by grants (to A.V.) from the Ministerio
de Ciencia e Innovación (SAF2005-00631 & SAF2008-00986),
the Consejería de Educación de la Comunidad de Madrid (SBIO-0170-2006), and the European Commission (MRTN-CT2005-19561).
693
THE PRENYLATED CHALCONE XANTHOHUMOL
INDUCES UNFOLDED PROTEIN RESPONSE,
AUTOPHAGY, AND CELL DEATH IN BREAST
CANCER CELLS BY PROTEASOME INHIBITION
Barbara Vanhoecke1, Mireille Van Gele2, Wim Martinet3,
Anne-Sophie Vercoutter-Edouart4, Sofie Lust5,
Delphine Debruyne1, Denis De Keukeleire6,
Fritz Offner5 and Marc Bracke1
1Laboratory
of Experimental Cancer Research, Department of
Radiotherapy and Nuclear Medicine, 2Department of
Dermatology, 5Department of Hematology, Ghent University
Hospital, Ghent, 9000, Belgium, 6Laboratory of
Pharmacognosy and Phytochemistry, Ghent University,
Ghent, 9000, Belgium;
3Division of Pharmacology, University of Antwerp, Wilrijk,
2610, Belgium; 4Unity of Structural and Functional
3525
ANTICANCER RESEARCH 28: 3157-3556 (2008)
Glycobiology, University of Lille 1, 59655 Villeneuve
d’Ascq, France
In this study, we report a new proteasome inhibitor
xanthohumol that induced endoplasmic reticulum stress,
autophagy and apoptosis in a panel of human breast cancer cell
lines but, remarkably, not in human pimary normal breast
epithelial cells. Using a proteomic approach, we found that
xanthohumol stimulated the transcription and expression of the
ER chaperone GRP78 and the activation of the ER stress
transducers PERK, IRE1 and ATF6. Sustained ER stress was
associated with oxidative stress and apoptotic events such as
processing of caspases, down-regulation of anti-apoptotic bclxL and mcl-1, and PARP cleavage. Susceptibility to
xanthohumol-induced apoptosis correlated with GRP78
expression levels. Furthermore, treatment with xanthohumol
triggered the formation of autophagosomes, as evidenced by
monodansyl cadaverin staining, transmission electron
microscopy and the conversion of LC3-I into the
autophagosome-specific isoform LC3-II. We also found that
xanthohumol was able to inhibit 20S proteasomal activity
resulting in an accumulation of polyubiquinated proteins.
Altogether, our results indicate that the endoplasmic reticulum
and the proteasome are interesting targets for selective drugs
against breast cancer.
694
MICROARRAY ANALYSIS OF MCF-7 BREAST
CANCER CELLS TREATED WITH 1,25DIHYDROXYVITAMIN D3 OR THE SECO-9,11BISNOR-17-METHYL ANALOG WY1112
E. Vanoirbeek1, G. Eelen1, I. Beullens1, M. Van Camp1,
K. Engelen2, K. Marchal2, P. De Clercq3, R. Bouillon1
and A. Verstuyf1
1Laboratorium
voor Experimentele Geneeskunde en
Endocrinologie, Katholieke Universiteit Leuven, 3000
Leuven;
2CMPG-ESAT, Katholieke Universiteit Leuven, 3000 Leuven,
3Vakgroep Organische Chemie, Universiteit Gent, 9000 Gent,
Belgium
The biologically active form of vitamin D is 1α,25dihydroxyvitamin D3 [1,25-(OH)2D3]. 1,25-(OH)2D3 functions
through the vitamin D receptor (VDR). After dimerization of
the VDR with the Retinoid X Receptor [RXR] receptor, the
complex binds to vitamin D response elements [VDREs],
recruits coregulators and the transcriptional preinitiation
complex to initiate target gene transcription 1,25-(OH)2D3 is
an important regulator of calcium metabolism (classical
effects), but has also antiproliferative and prodifferentiating
effects on both normal and tumorous cells (non-classical
effects). Consequently, 1,25-(OH)2D3 is an interesting drug for
3526
the treatment of hyperproliferative disorders such as cancer.
The therapeutic dose however causes severe side-effects such
as hypercalcemia and hypercalciuria. For this reason, structural
analogs of 1,25-(OH)2D3 such as the seco-9,11-bisnor-17methyl analog, WY1112 have been developed with increased
antiproliferative capacities .
To identify key regulatory genes involved in the
antiproliferative action of 1,25-(OH)2D3 and to distinct the
molecular activities of 1,25-(OH)2D3 and WY1112, total RNA
was extracted from MCF-7 breast cancer cells that were treated
with 1,25-(OH)2D3 or WY1112 and was used for microarray
analysis. The experiments revealed that WY1112 induced the
same set of genes as 1,25-(OH)2D3 but the induction level of
the individual genes was higher. Microarray analysis did not
reveal genes that were exclusively regulated by WY1112.
Altered sensitivities to metabolism or changed VDRcoactivator interactions may account for its superagonistic
characteristics.
Genes that were up-regulated can be divided into groups that
are involved in proliferation and apoptosis (14%), gene
transcription (13%), cytoskeleton organization (11%), immune
respons (7%), transmembrane transport (6%), ubiquitination
(4%), extracellular matrix (4%) and lipid metabolism (3%).
695
THE EFFECT OF UNCARIA EXTRACT ON
MOLECULAR BIOMARKERS IN PATIENTS
WITH COLORECTAL CANCER
T. Varjas1, F. Budán1, Á. Ember2, K. Amrein1,
Ő.P. Horváth2, L. Illényi2, D. B. Antonio1,
T. Dávid4, P. Perjési5, E. Pázsit6 and I. Ember1
1Institute of Public Health, University Medical School of
Pécs, Szigeti str. 12, H-7643 Pécs;
2Institute of Surgery, University Medical School of Pécs,
Ifjuság str. 13, H-7624 Pécs;
3Institute of Otolaryngology Head and Neck Surgery, Faculty
of Medicine, University of Pécs, Munkácsy str. 2, H-7621
Pécs;
4LtdCoD™ Kft., Vörösmarty str. 15, H- 9155 Lébény;
5Institute of Pharmaceutical Chemistry, University of Pécs
School of Medicine, Rókus str. 2, H-7623 Pécs, Hungary;
6Hospital And Clinic of Diósgyőr, Obstetrical Ward, H-3520,
Miskolc, Hungary
We investigated the combined effect of surgical treatment and
the influence of consumption of CoD™ tea (which contains
Uncaria guianensis and U. tomentosa also known as cat’s claw
bark extract) on the expression of c-myc, Ha-ras, Bcl-2, Ki-ras
and p53 key onco/suppressor genes and CA199, CEA tumor
markers in blood samples of patients with colorectal cancer
(CRC) in a “one-year follow up study”. These key
onco/suppressor genes are good molecular epidemiological
Abstracts of the 8th International Conference of Anticancer Research, 17-22 October 2008, Kos, Greece
biomarkers of the exposure carcinogenic agents or early
biological effects in peripheral blood and are also good
biomarkers of potential chemopreventive effect as well. Their
expression enables the effect of surgical treatment combined
with neoadjuvant chemotherapy to be followed and may predict
the outcome of carcinoma. Moreover, their expression can
show the possible additional curative/preventive effect of
CoD™ consumption. The scavenger type antioxidant capacity
of blood was assessed by deoxyribose degradation test. Blood
samples were taken at the day of surgical treatment, then 1
week, 3 and 6 months and 1 year later, by which time patients
were consuming 0.2 l standard portion of CoD tea three times
a day. There were 2 groups of 20 individuals: CRC patients
(CoD™ consumers) and a control group of healthy individuals
(they were not consumers of CoD™). Before surgical treatment
all CRC patients received Ca-folate and 5-FU and 45 Gy
radiation therapy; after the resection they were treated
according to de Gramont protocol. Surgical treatment and
neoadjuvant therapy are able to suppress the expression of cmyc, Ha-ras, Bcl-2, Ki-ras, p53 onco/supressor gene FOR 12
months. Moreover CoD™ tea together with conventional
treatment caused a strong and significant decrease of the
expression of c- myc and Ha- ras oncogen in comparison with
the nonconsumer controls.
696
THE MYELODYSPLASTIC SYNDROME –
QUESTIONS AND ANSWERS. THE BUDAPEST
STUDY GROUP EXPERIENCE
J. Varkonyi, P. Farkas, G. Varga, G. Kollai, G. Szombath,
A. Tordai, H. Andrikovics, B. Schoket, I. Karádi,
K. Kádár, G. Füst and Z. Prohászka
Semmelweis University, Budapest, Hungary
The myelodysplastic syndromes (MDS) are a heterogeneous
group of myeloid stem cell disorders characterized by
refractory cytopenias, previously known as preleukemia. In the
primary form, the etiology is still unknown. However, the
multiple hit pathogenesis is considered valid for this condition,
and provides a possible explanation for the evolution of
refractory cytopenia into acute leukemia.
In an attempt to find answers to questions of MDS
pathogenesis, the Budapest Study Group has compared certain
genetic features of patients with multiple myeloma (MM), a Bcell malignancy with a similar prevalence in the elderly with
those of MDS.
We analyzed approximately 100 patient samples from both
conditions for genetic polymorphism regarding the
metabolizing enzymes GST especially those participating in the
detoxification of carcinogens. We also compared the incidence
of mutations of the hemochromatosis gene (HFE, C282Y and
H63D), and IL-6/IL-6R and TNF-α polymorphisms.
We found a significant difference in incidence of only the
HFE gene polymorphism between the two groups, with a
higher mutation rate in the MDS group, whereas the HFE
mutation was even less frequent in the MM group compared to
healthy controls.
That the HFE gene mutation has an impact on iron
absorption, even in its heterozygote form, is a well known
phenomenon. Iron excess confers oxidative stress tissues
leading to bone marrow impairment. On the other hand,
prolonged uncorrected deficiency states, such as low copper
levels and vitamin B12 deficiency, might be as harmful for
tissues with a high cell turnover such as bone marrow stem
cells. Iron overload or other toxic compounds injuring
mitochondria, or deficiency in trace elements and vitamins with
importance in cell respiration, might both give rise to more
primitive cells – thus conferring a selection advantage for them.
The literature includes data to support this concept.
According to this model, one should question the priority of
the genetic events and consider them as secondary to an
unbalanced metabolism that instead can be considered as the
primary etiological factor in the disease pathogenesis in a
certain group of MDS patients.
697
SUN EXPOSURE AND USE OF SOLARIUMS DURING
THE FIRST FIVE DECADES OF LIFE AND RISK OF
CUTANEOUS MALIGNANT MELANOMA: THE
NORWEGIAN-SWEDISH WOMEN’S LIFESTYLE AND
HEALTH COHORT STUDY
Marit B. Veierød1, Hans-Olov Adami2,3, Eiliv Lund4,
Bruce Armstrong5 and Elisabete Weiderpass2,4,6,7
1Department of Biostatistics, Institute of Basic Medical
Sciences, University of Oslo, Oslo, Norway;
2Department of Medical Epidemiology and Biostatistics,
Karolinska Institutet, Stockholm, Sweden;
3Department of Epidemiology, Harvard School of Public
Health, Boston, MA;
4Institute of Community Medicine, University of Tromsø,
Tromsø, Norway;
5School of Public Health, University of Sydney, Sydney,
Australia;
6Department of Etiological Research, Cancer Registry of
Norway, Oslo, Norway;
7Department of Genetic Epidemiology, Folkhälsan Research
Center, Helsinki, Finland
Background: Sun exposure is the major established and
modifiable risk factor for cutaneous malignant melanoma. Use
of indoor tanning equipment has also been associated with
increased risk, but less consistently. The importance of
exposure to ultraviolet (UV) radiation in different periods of
life and possible effect modification by an individual’s
sensitivity to UV exposure is not completely understood.
3527
ANTICANCER RESEARCH 28: 3157-3556 (2008)
Materials and Methods: The Norwegian-Swedish Women’s
Lifestyle and Health Cohort Study included more than 100 000
women aged 30-50 years in 1991/92. Information on sun
exposure, use of a solarium (i.e. a sunbed or sunlamp) and
individual characteristics were collected at cohort enrolment
through a self-administered questionnaire. Frequency of
sunburns, sunbathing vacations and use of a solarium were
recorded for the age periods 0-9, 10-19, 20-29, 30-39 and 4049 years. Complete follow-up is achieved by linkage of the
study database to national registries in Norway and Sweden.
Relative risks are estimated by Poisson regression. Results: The
first results from this cohort study were published in 2003
(Veierød et al. J Natl Cancer Inst 95: 1530-1538, 2003) and
included follow-up through 1999 i.e. a short follow-up period
to estimate the effects of midlife exposure. We present now
new results with follow-up through 2005. A total of 106,366
women were followed up to14 years and 412 incident cases of
cutaneous malignant melanoma were reported to the national
Cancer Registries. The mean age at diagnosis was 49 years. A
twofold increased risk of melanoma was found for sunburns in
childhood, teenage years and early adulthood (≥2 sunburns per
year vs. none). In this cohort, solarium use in childhood and
teenage years was rare. Solarium use in early adulthood and
midlife increased the risk of melanoma. We will also discuss
the potential impact of national regulations on indoor tanning
devices implemented in 1982/83 resulting in changes in the
UVB to UVA ratio.
698
TARGETING CANCER CELLS BY AN
OXIDANT-BASED THERAPY
J. Verrax, R. Beck, C. Lannoy, H.S. Taper and
P. Buc Calderon
PMNT unit, School of Pharmacy, Université Catholique de
Louvain, 73 Avenue E.Mounier 1200 Brussels, Belgium
Among all the different features of cancer cells, two are of
particular interest: their nearly universal glycolytic phenotype
and their sensitivity towards oxidative stress. By using the
combination of menadione (vitamin K3) and ascorbate
(vitamin C), we took advantage of these features to develop an
original approach that consists of the exposure of cancer cells
to an oxidant insult. The results we obtained can be
summarized as follows:
The combination exhibits a synergistic antitumor activity in
vivo as well as in vitro through the potentiation of the
menadione redox cycling by ascorbate, resulting in the
generation of reactive oxygen species (1, 2). Importantly, nontransformed cells are not affected by this treatment, likely
because of their better antioxidant defences.
The oxidant insult rapidly induces DNA strand breaks which
provoke the activation of an enzyme participating in DNA
3528
repair, poly(ADP-ribose) polymerase (PARP). Activated PARP
consumes cytosolic NAD+, and because NAD+ is required for
glycolysis, this render cells unable to use glucose as a
metabolic substrate. Due to the high energetic dependence of
cancer cells on glycolysis, this leads to an energetic crisis
which ultimately results in necrotic cell death (3).
Interestingly, the oxidative stress provoked by the
ascorbate/menadione combination also induces the disruption
of the chaperone function of Hsp90, resulting in the
degradation of important oncogenic proteins essential for
cancer cell survival, such as Bcr-abl. This phenomenon is only
observed in tumour cells and represents a second pathway that
participates in the anticancer activity of the combination.
Taken together, our data suggest that the combination of
ascorbate and menadione could represent a new and interesting
auxiliary cancer therapy. Since both compounds are of low
toxicity, they can easily be included in a classic anticancer
protocol without any supplementary risk for the patients, as
shown in the recent phase I/IIa study performed in prostate
cancer patients who failed standard therapy (4).
1 Verrax J, Delvaux M, Beghein N, Taper H, Gallez B and Buc
Calderon P: Enhancement of quinone redox cycling by
ascorbate induce a caspase-3 independent cell death in
human leukaemia cells. An in vitro comparative study. Free
Radic Res 39: 649-657, 2005.
2 Verrax J, Stockis J, Tison A, Taper HS and Buc Calderon P:
Oxidative stress by ascorbate/menadione association kills
K562 human chronic myelogenous leukaemia cells and
inhibits its tumour growth in nude mice. Biochem Pharmacol
72: 671-680, 2006.
3 Verrax J, Vanbever S, Stockis J, Taper H and Calderon PB:
Role of glycolysis inhibition and poly(ADP-ribose)
polymerase activation in necrotic-like cell death caused by
ascorbate/menadioneinduced oxidative stress in K562 human
chronic myelogenous leukemic cells. Int J Cancer 120: 11921197, 2007.
4 Tareen B, Summers JL, Jamison JM, Neal DR, McGuire K,
Gerson L and Diokno A: A 12-week, open label, phase I/IIa
study using apatone for the treatment of prostate cancer
patients who have failed standard therapy. Int J Med Sci 5:
62-67, 2008.
699
CARDIAC HORMONES:
NEW ANTICANCER AGENTS
David L. Vesely
University of South Florida Health Sciences Center/VA
Hospital, Tampa, Florida, USA
Cardiac hormones are a family of peptide hormones
synthesized mainly in the atrium of the heart. One gene in the
heart of this peptide hormone family synthesizes a 126 amino
Abstracts of the 8th International Conference of Anticancer Research, 17-22 October 2008, Kos, Greece
acid (a.a.) prohormone which contains four cardiac peptide
hormones consisting of a.a. 1-30 (long-acting natriuretic
peptide, LANP), a.a. 31-67 (vessel dilator, VDL), a.a. 79-98
(kaliuretic peptide, KP) and a.a. 99-126 (atrial natriuretic
peptide, ANP).
These peptide hormones decrease in up to 97% of human
pancreatic, breast, colon, ovarian, kidney and prostate
adenocarcinomas, glioblastomas of the brain and melanomas,
as well as small-cell and squamous cell lung carcinoma cells
in vitro.
When infused subcutaneously for 28 days with fresh
hormones weekly at 3 nM min–1 kg–1 body weight in athymic
mice bearing human pancreatic adenocarcinomas, they
eliminate up to 80% of the human pancreatic adenocarcinomas.
Even in the treated animals which did not have a total
elimination of the pancreatic carcinoma, their tumor volume
decreased to less than 10% (and with vessel dilator to 2%) of
that of the untreated animals and the treated animals achieved
a normal lifespan.
Similarly, these peptide hormones eliminate two-thirds of
human breast adenocarcinomas growing in athymic mice
without any surgery. The mechanism(s) of action cardiac of
these hormones in cancer cells includes a 97% inhibition of the
phosphorylation of extracellular-signal regulated kinases 1/2
(ERK 1/2) and of the upstream mitogen-activated protein
kinases (MEK 1/2). These inhibitions are mediated by the
intracellular mediator cyclic GMP. The final step in their
mechanism of action is a strong ability to inhibit DNA
synthesis within the nucleus of the cancer cells, also mediated
by cyclic GMP.
700
MYZITIRAS AND VTHELA MORPHOTYPES AS NEW
SIGNATURES OF NEOPLASTIC PROGRESSION?
Ondřej Tolde1, Daniel Rösel1, Jan Brábek1
and Pavel Veselý2,3
1Department
of Cell Biology, Faculty of Science, Charles
University in Prague, Prague;
2Institute of Molecular Genetics AS CR Prague 6, 166 37;
3Prague Burn Centre, 3rd Medical Faculty, Charles
University, Prague 10, 100 00 Czech Republic
EM-G3, a new clonal cell line (1) was derived from a primary
lesion of human infiltrating ductal breast carcinoma and shown
to originate with high probability from common progenitors of
luminal and myoepithelial cells that were immortalized in an
early stage of tumorigenesis. Such presumably low malignant
cells attract efforts focused on in vitro induction of neoplastic
progression. If this is successfully achieved new traits/markers
of malignancy could be revealed. With this aim in mind EMG3 have been in vitro exposed to chronic nutritional stress that
was at the beginning intermittent and supported by two
subsequent treatments of an activator of the protein kinase C,
12-O-tetradecanoylphorbol-13-acetate (TPA). After six month
of this challenging procedure resulting G3S1 cells grew in
standard culture medium without growth factors needed for
EM-G3 cells. Both cell populations were then compared. It was
found that in Matrigel invasion chambers G3S1 cells exhibited
ca 2.5 fold enhancement of the invasion capacity over a 24 h
period as compared to parental EM-G3 cells. Also the
degradation of FITC-gelatine was substantially increased in
G3S1 cells. F-actin rich structures resembling podosomes were
present in both EM-G3 and G3S1 cells and to considerable
extent colocalized with the sites of degradation. These
podosome-like structures were enriched in phosphotyrosine;
however, they did not contain phosphorylated cortactin
suggesting they are at least in part different from podosomes.
Interestingly, in some small holes in gelatine indicating their
early stage, the F-actin structures were observed hinting that
there could be only a slight difference between invadopodia
and podosomes consisting in an availability of a penetrable
substrate. Examination of G3S1 cells nascent morphology one
hour after seeding in HBSS on gelatine covered coverslip
revealed an increased incidence of myzitiras (sucker) and
vthela (leech) morphotypes described earlier (2). Coincidence
of apparent neoplastic progression of G3S1 cells with the
appearance of these distinguished morphotypes leads to a
possibility of exploiting these morphological traits in selection
of individual cells for targeted examination of gene expression.
Such an approach can enrich our knowledge of mechanisms of
neoplastic progression.
This work was supported by project no. AV0Z50520514
awarded by the Academy of Sciences of the Czech Republic.
1 Brozova M, Kleibl Z, Netikova I, Sevcik J, Scholzova E,
Brezinova J, Chaloupkova A, Vesely P, Dundr P, Zadinova
M, Krasna L and Matouskova E: Establishment, growth and
in vivo differentiation of a new clonal human cell line, EMG3, derived from breast cancer progenitors.Breast Cancer
Res Treat 103(2): 247-257, 2007.
2 Vesely P, Blase C, Tolde O, Brabek J, Matouskova E,
Bereiter-Hahn J and Vydra J: Mysitiras cell shape as in vitro
indicator of malignancy? In: Book of Abstract of FEBS
workshop Invadopodia, Podosomes and Focal Adhesions in
Tissue Invasion, Ortona, Italy, September 8-13, 2007, p. 122
701
LOW-LEVEL RADIATION AND CANCER
A.C. Vikis
3251 Carriage Hill Place, Ottawa,
Ontario, Canada K1T 3X6
The medical applications of radiation are the largest source of
radiation exposures, following natural background radiation.
They include diagnostic radiology, radiotherapy, nuclear
3529
ANTICANCER RESEARCH 28: 3157-3556 (2008)
medicine and interventional radiology. Ionizing radiation (xrays, alpha, beta, gamma) is known to cause chemical changes
to biological molecules, which may lead to cancer. Damage to
DNA, particularly double-strand breaks is the main initiating
event; however, damage to other cellular components may
influence cell functioning and progress to the malignant state.
Sources of information about the health effects of ionizing
radiation include theoretical and experimental studies
(including animal studies) of the underlying science, especially
biology, and epidemiological studies of humans exposed to
radiation. This presentation will examine the current
understanding of the harmful effects of ionizing radiation.
Special emphasis will be given to low levels of ionizing
radiation, below about 100 mSv, where there is considerable
uncertainty of the risks and, in some cases, there have been
claims of likely beneficial effects.
702
GENETIC SUSCEPTIBILITY TO LUNG CANCER
Haris G. Vikis1, Pengyuan Liu1, Ming You1,
Marshall W. Anderson2 and Genetic Epidemiology
of Lung Cancer Consortium
1Washington
University School of Medicine,
St. Louis, Missouri;
2University of Cincinnati, Cincinnati, OH, USA
Three recent genome-wide association studies identified
associations between markers in the chromosomal region
15q24-25.1 and the risk of lung cancer. We conducted a
genome-wide association analysis to investigate associations
between single-nucleotide polymorphisms (SNPs) and the
risk of lung cancer, in which we used blood DNA from 194
case patients with familial lung cancer and 219 cancer-free
control individuals. We identified associations between
variants on chromosomes 1, 3, 6, 9, 12, 15, and 20. Here we
describe common sequence variants on 15q24-25.1 (which
spanned LOC123688 (a hypothetical gene), PSMA4,
CHRNA3, CHRNA5, and CHRNB4) and lung cancer. The
risk of lung cancer was more than five-fold higher among
those subjects who had both a family history of lung cancer
and two copies of high-risk alleles rs8034191 (OR=7.20, 95%
CI=2.21 to 23.37) or rs1051730 (OR=5.67, CI=2.21 to 14.60)
that were located in the 15q24-25.1 locus, than among
controls. Thus, further research in elucidating causal variants
in the 15q24-25.1 locus that are associated with lung cancer
is warranted.
703
CANCER DIAGNOSIS BASED IN
THEDIFFERENTIAL EXPRESSION OF A NOVEL
FAMILY OF NON CODING MITOCONDRIAL RNAS
3530
J. Villegas1,2,3, V. Burzio1,2,3, E. Landerer1,3, E. Villota2,3,
C. López1, S. Vidaurre1, M. Araya1, A. Rivas1,
L. Cruz1 and L.O. Burzio1,2,3
1Andes BioScience S.A., Fundación Ciencia para la Vida,
Fundación Instituto Milenio (MIFAB), 2Grupo BIOS,
3Facultad de Ciencias de la Salud, Universidad Andrés Bello.
Santiago, Chile
We describe a novel transcript which is overexpressed in
human proliferating cells but not in resting cells. The
transcript contains a hairpin structure comprising an IR of
815 nt linked to the 5’ end of the 16S mtrRNA, forming a
long double-stranded structure. This novel transcript is a
non-coding RNA (ncRNA) and experimental evidence
suggests that the transcript is synthesized in mitochondria.
Therefore, we named this transcript “sense non-coding
mitochondrial RNA” (sncmtRNA). The expression of this
transcript can be induced in resting lymphocytes by
stimulation with phytohaemagglutinin (PHA). On the other
hand, proliferating cells treated with aphidicolin repress
the expression of the transcript. The cells resume
proliferation if the drug is removed and over-express the
ncmtRNA again. These results suggest that this ncmtRNA
may play a role in cell proliferation. In situ hybridization
(ISH) using oligonucleotide (ODN) probes revealed that
the transcript is expressed in tumor cells from biopsies and
also in tumor cell lines from a variety of human cancers,
but is not present in normal quiescent cells. However, to
our surprise, normal proliferating cells also express
another
transcript,
named
antisense
ncmtRNA
(AsncmtRN). The differential expression of the sense and
antisense ncmtRNAs allow for the selective discrimination
between normal proliferating, quiescent and tumor cells.
The study performed in a hundred of biopsies suggests that
these molecules could constitute a new and specific
biomarker.
PBF-16; MIFAB P-04-071-F; FONDEF D04I1338, UNAB
DI32-06/R, DI30-06/R, DI46-06/R; DI31-06/R.
704
MICROFLUIDIC MAGNETIC CELL SORTING
SYSTEM FOR CTC DETECTION AND TYPING
A.-E. Saliba1, L. Saias1, J. Salamero1, V. Fraisier1,
J.-Y. Pierga2, F.C. Bidard2, C. Mathiot2, P. Vielh3,
F. Farace3 and J.-L. Viovy1
1Institut Curie, Section de Recherche, 2Institut Curie, Section
Médicale, and 3Institut Gustave Roussy, UPRES EA3535,
France
We present a new integrated microfluidic system for the high
throughput, high content sorting and analysis of cancer cells.
Abstracts of the 8th International Conference of Anticancer Research, 17-22 October 2008, Kos, Greece
705
STATINS AND CANCER – ARE ALL STATINS THE
SAME?
Libor Vítek
Institute of Clinical Biochemistry and Laboratory
Diagnostics and 4th Department of Internal Medicine, 1st
Faculty of Medicine, Charles University in Prague, Czech
Republic
Figure. Principle of the method: a microfluidic channel with
microfabricated magnetic domains, on which columns of
magnetic beads bearing antibodies directed toward cancer
cells surface antigens (orange) self-assemble under a
magnetic field. The sample containing cancer cells (reddish
blue) and normal haematopoietic cells (light blue) is then
flown in the channel. Upon collision with the magnetic
columns, the cancer cells are captured and normal cells
resume their motion.
It is able to capture tumour cells with specific antibodies, like
circulating tumour cells in whole blood or cells from Fine
Needle Aspirates, with high specificity and efficiency. Cell
separation in this system, is based on a new concept
developed in our group (1). It involves an immunoaffinity
separation matrix made of magnetic beads, self-assembled
onto a pattern of magnetic traps prepared by microcontact
printing (2) (Figure).
Recent work (3) did show that the microfluidic format is
able to considerably enhance the yield of CTC capture,
opening new routes for diagnosis, prognosis of metastatic
relapses, and selection of the most adapted treatment based
on a molecular typing of the CTC. In addition to the high
efficiency described in this earlier work, in our new system
the captured cells can be visualized using the most
sophisticated tools of cell microscopy, allowing for extensive
automated phenotyping by multicolour antibody labelling
and morphological analysis. In a near future, the technology
will also allow genotyping. Quantitative characterization of
the efficiency and specificity of capture, obtained with model
cell lines, and our first applications to cancer cell typing
from patient’s blood samples will be presented in the
conference.
1 Doyle et al: Science 295: 2237, 2002.
2 Saliba et al: Proc. Micro Total Analysis Systems 2007, pp.
355-357, 2007.
3 Nagrath et al: Nature 450: 1235, 2007.
Despite supporting theory as well as experimental evidence,
there is still clinical controversy as to whether statins can
prevent from cancer. These contradictory views are based on
large epidemiological studies and their meta-analyses which,
however, have been focused primarily on cardiovascular
outcomes. In addition to these limitations, there are also
other reasons to account for different anticancer effects of
statins. These are related to the physico-chemical properties
of statins (lipophility/hydrophility), as well as to different
pharmacokinetic and pharmacodynamic properties. In fact,
we were able to detect large differences in antiproliferative
effects on experimental pancreatic cancer among statins used
for clinical purposes. The least efficient statins in our studies
were pravastatin and atorvastatin, while rosuvastatin,
cerivastatin and fluvastatin were the most potent compounds.
These data may account for inconclusiveness of cancer
prevalence/incidence among statin users in cardiovascular
trials. Provided that pravastatin might be the least efficient
statin, recent meta-analytic studies might have been
confounded by pravastatin trials. This, indeed, is the case for
meta-analysis of 7 trials by Hebert et al. [JAMA 1997],
where 3 out of 7 studies involved were pravastatin trials. The
same is true for a study by Bjerre et al. [Am J Med 2001] (3
out of 5 studies involved), CTT Collaborator’s study [Lancet
2005] (5 out of 14 studies involved), as well as meta-analysis
by Dale et al. [JAMA 2006] (10 out of 20 studies).
It is clear that further large and well-designed
epidemiological studies are definitely needed to determine
any potential chemopreventive role of individual statins.
706
POSSIBLE INFLUENCE OF NQO1
POLYMORPHISMS IN THE DEVELOPMENT
OF HPV-RELATED CERVICAL CANCER
Milene Volpato
Section of Experimental Therapeutics, Leeds Institute for
Molecular Medicine, Wellcome Trust Brenner Building, StJames University Hospital, University of Leeds, Leeds LS9
7TF, UK
NAD(P)H:Quinone oxidoreductase 1 (NQO1) has multiple
functions in cells. It is best known for its involvment in
3531
ANTICANCER RESEARCH 28: 3157-3556 (2008)
detoxification processes. However, it was more recently
shown to play a role in p53 via an mdm2-independent route.
Such interaction of NQO1 with p53 can partially abrogate
p53 degradation by human papilloma virus (HPV) protein
E6. There are two characterised polymorphic variants of
NQO1, namely NQO1*2 and *3, which cause loss of NQO1
activity, raising the possibility that individuals harboring
these variants may have reduced p53 activity and increased
susceptibility to HPV-mediated cervical cancers. A study was
therefore designed to survey NQO1 polymorphism incidence
in a population of patients with pre-neoplastic and cancerous
lesions of the cervix.
Genomic DNA was extracted from histological blocks of
cervical cancer (n=90) and precancerous CIN lesions
(n=293) and NQO1 polymorphic status determined by realtime PCR. No significant difference existed between the
distribution of NQO1*2 and p53*72 in either patient group
or the distribution reported in healthy individuals. In
contrast, a significant increase in the incidence of the
mutated form of the NQO1*3 polymorphism with a risk ratio
of 2.53 (95% conf. interval=3.52, p<0.0001) was observed
in patients with cervical cancer. Additionally, no relationship
was established between the NQO1 polymorphic variants and
the CIN grade of the patients.
The higher incidence of the NQO1*3 polymorphism
observed within the cancerous group compared to both
healthy and pre-cancerous groups was surprising as
variations in the NQO1*2 incidence have been previously
reported in various cancer types but no association had been
established between NQO1*3 polymorphism and cancer risk
to date. Whilst the mechanistic basis for this observation is
not known, this study suggests that individuals who harbour
NQO1*3 may be at greater risk of progressing from
preneoplastic to malignant cervical cancer. If confirmed in
further experiments, such result scould provide a basis for
implementing NQO1 polymorphism screening of patients
with dysplasia of the cervix.
707
PRESERVATION OF GAMETES IN
GYNECOLOGICAL CANCERS
Sören von Otte and Safaa Al-Hasani
Department of Obstetrics and Gynecology, University of
Schleswig-Holstein, Campus Luebeck, Ratzeburger Allee
160, 23538 Luebeck, Germany
With an increase in the efficacy of anticancer therapy and
quite efficient early diagnosis in gynecological cancer,
increased long-term survival of cancer patients and long-term
complications of anticancer treatments are being encountered
(1). The lost of ovarian reserve or function due to gonadal
toxicity is a major problem.
3532
A wide range of new fertility preservation options
and/or techniques, although the majority of them are
experimental, are now available for female gamete
preservation prior to oncological treatments (2). Ovarian
transposition, a surgical preservation technique, is one of
these methods that prevents gonadal toxicity due to
radiotherapy. Partial and/or total (experimental) extraction,
subsequent cryopreservation and re-transplantation of
ovarian tissue, another surgical preventive option both for
radiotherapy and chemotherapy side-effects, is expected to
be a paramount method in the future that was performed
in selective cases previously (2-4). In particular, medical
methods with such agents as GnRH analog or antagonists,
and Danazole have been reported to prevent chemo or
radiotherapy related gonadal toxicity. Cryopreservation of
oocytes, zygotes and embryos either by vitrification or
slow-rate freezing subsequent to ovarian stimulation and
oocyte pick-up, along with/without traditional IVF and
intracytoplasmic sperm injection are other common
preventive techniques (3, 4).
Currently cryopreservations of the oocyte, zygote and/or
embryos seem to be the most effective methods in fertility
preservation, especially in women of reproductive age (5).
In regard of the cryopreservation techniques vitrification
has been claimed as the most appropriate and efficient
technique due to simplicity and cost-effectiveness (6, 7).
On the contrary, surgical methods are still accepted as
difficult, and costly alternatives, as well experimental ones
such as re-transplantation are not reported to be
significantly efficient and reliable alternatives. In parallel,
the effects of medical preventive alternatives, those
generally resulting in a pseudo-menopausal status and
mainly recommended to patients prior to child-bearing, are
still controversial concerning side-effects, reduced
effectiveness.
The number of available techniques for conserving fertility
has increased in the last decade, but large studies are still
needed to draw any conclusions. Some of these effective
options such as vitrification of embryos is not allowed in
Germany. Other technical issues remain unresolved, as is the
question of medical insurance reimbursement for the most
efficient procedures. All current aspects and techniques
should be compared in order to define the best method and
standardization in female fertility preservation. New
approaches and current management on fertility preservation
in gynecological cancer were discussed in this presentation.
1 Marhhom E and Cohen I: Fertility preservation options for
women with malignancies. Obstet Gynecol Surv 62(1): 5872, 2007.
2 Davis VJ: Female gamete preservation. Cancer 107(7
Suppl): 1690-1694, 2006.
3 Lornage J and Salle B: Ovarian and oocyte cryopreservation.
Curr Opin Obstet Gynecol 19(4): 390-394, 2007.
Abstracts of the 8th International Conference of Anticancer Research, 17-22 October 2008, Kos, Greece
4 Practice Committee of the American Society for
Reproductive Medicine; Practice Committee of the Society
for Assisted Reproductive Technology. Ovarian tissue and
oocyte cryopreservation. Fertil Steril 86(5 Suppl): S142147, 2006
5 Homburg R, van der Veen F and Silber SJ. Oocyte
vitrification-Women’s emancipation set in stone. Fertil
Steril, 2008.
6 Cobo A, Domingo J, Pérez S, Crespo J, Remohí J and
Pellicer A: Vitrification: an effective new approach to
oocyte banking and preserving fertility in cancer patients.
Clin Transl Oncol 10(5): 268-273, 2008
7 Orief Y, Dafopoulos K and Al-Hasani S: Cryopreservation
of human ovarian tissue and oocyte banking: An eye to the
future. Pan Arab Med J 3: 17-22, 2005.
708
MULTIPLE MARKERS IN THE FOLLOW-UP OF
OVARIAN CANCER
Jindra Vrzalová, Ondřej Topolčan, Markéta Pražáková,
Miroslava Čásová and Zdeněk Novotný
Teaching Hospital and Medical Faculty in Pilsen, E.
Benese 13, 305 99 Plzen, Czech Republic
Introduction: Gil Mor et al. developed after a proteomic
study a multiplex panel for ovarian cancer including
Macrophage Migration Inhibitory Factor (MIF), prolactin,
CA-125, leptin, osteopontin (OPN) and a IGF-II. Aim: To
use this multiplex panel for follow up monitoring of ovarian
cancer patients. Methods: Two groups of patients were
studied: Control gr. 0: pat. with benign ovarian cyst (20
patients) and patients with ovarian carcinoma, stage III-IV
(19). Serum levels of biological activity markers of ovarian
carcinoma were measured by Beadlyte® Human Cancer
Biomarker Panel kit from Millipore-Upstate (USA) and
Luminex 100 instrument (Luminex corp., USA).
Simultaneously, levels of other markers (CA125, TK, TPS,
HE4 and Monototal) were measured by routine
immunoanalytic methods. Results: From the multiplex
markers, the best ROC characteristics were observed for
CA125, IGFII and OPN. HE4 marker had the best ROC
characteristic from all measured markers. In the multiplex
panel, significant differences (Wilcoxon test) in marker levels
between groups were found only for CA125 (higher level in
carcinoma), OPN (higher level in carcinoma) and IGFII
(lower level in carcinoma). Conclusion: Multiplex analysis
enables an easy simultaneous measurement of multiple
markers and so enables the use of a scoring system in future.
Supported by the research project VZ MSM 0021620819.
Mor G et al: Serum protein markers for early detection of
ovarian cancer. Proc Natl Acad Sci USA 102: 7677-7682,
2005.
709
WHEN HISTOLOGY MEETS SYSTEMS BIOLOGY
Mathias Wagner1, Frank Weichert2, Andreas Groh3,
Sally Said Kamel Awad4, Ali Shamaa5, Tereza Richards6,
Roland Linder7 and Constantin A. Landes8
1Institut
fuer Pathologie, Universitaet des Saarlandes;
VII, Technische Universitaet Dortmund;
3Institut für Angewandte Mathematik, Universitaet des
Saarlandes, Germany;
4Department of Maxillofacial Surgery, University of
Mansoura;
5Department of Oral Biology, Minia University, Egypt;
6University of the West Indies, Kingston, Jamaica;
7Institut für Medizinische Informatik, Universität zu
Lübeck;
8Klinik fuer Mund-, Kiefer- und Plastische
Gesichtschirurgie, Johann Wolfgang Goethe-Universitaet
Frankfurt am Main, Germany
2Informatik
Computer generated cells and tissues may be used to predict
biological behaviour for example of cancer. Virtual objects
can be created by the employment of a variety of
approaches such as Quaoaring. A systematic evaluation of
these steps leading to applicability in systems biological
mathematical modeling is overdue. A preliminary overview
and comparison of methods however can be given. The
results of such a survey suggest that to date no single
approach meets all requirements in systems biology. Visions
of developing a gold standard therefore remain far off which
might have considerable impact on the possible use of
computer generated cells and tissues in the context of
quality control in systems biological mathematical
modeling. Ongoing and future studies should conclusively
address this issue.
710
TARGETING OF TUMORS WITH
RADIOLABELED VITAMINS
Robert Waibel, Cristina Müller, Thomas L. Mindt,
P. August Schubiger and Roger Schibli
CRS, Paul Scherrer Institute, CH-5232 Villigen PSI,
Switzerland
Rapidly growing cells show an increased demand for
nutrients and vitamins. We exploited the supply route of
vitamin B12 and folate to deliver radiolabeled derivatives to
hyperproliferative cells. However, the tumor uptake of
vitamin B12 and folate-based radiotracers was shown to be
low compared with the high renal retention of radioactivity.
For clinical application of radiopharmaceuticals, it is known
3533
ANTICANCER RESEARCH 28: 3157-3556 (2008)
that high kidney uptake of radiolabeled compounds may lead
to radiation toxicity.
In order to obtain better tumor to non tumor ratios, we
interfered with the biological properties of these vitamins to
be stored in normal organs like liver and kidney.
For vitamin B12 targeting, we designed new vitamin B12
conjugates that do not bind to their main transport protein
transcobalamin II (TCII) and thus tumor to background ratios
were tremendously increased.
For radiofolate targeting preadministration of the
antifolate drug Pemetrexed led to an almost complete
blockade of radioactivity uptake in folate receptor positive
kidneys whereas the tumor uptake remained unchanged and
thus tumor to kidney ratios were significantly improved.
Obviously, Pemetrexed interacts differently with the uptake
mechanism of the 99mTc-folate on the tumor tissue and
kidneys respectively.
In vivo SPECT/CT studies in mice demonstrated the
specific accumulation of 99mTc-PAMA-vitamin B12 and
99mTc-PAMA-folate in tumors and an almost complete
absence or significant reduction of radioactivity in the renal
tissue. Clinical trials to prove these concepts started this fall
in collaboration with the University Hospital Zurich.
Waibel R et al: New Derivatives of Vitamin B12 Show
Preferential Targeting of Tumors. Cancer Res 68: 2904-2911,
2008.
Müller C et al: Pemetrexed Improves Tumor Selectivity of
111In-DTPA-Folate in Mice with Folate Receptor–Positive
Ovarian Cancer. J Nucl Med 49: 623-629, 2008.
Mindt TL et al: “Click-to-Chelate”: In Vitro and In Vivo
Comparison of a 99mTc(CO)3-Labeled N(τ)-Histidine Folate
Derivative with Its Isostructural, Clicked 1,2,3-Triazole
Analogue. Bioconjugate Chem 19: 1689-1695, 2008.
711
INTAKE OF RED WINE POLYPHENOLS PREVENTS
TUMOR GROWTH AND NEOVASCULARIZATION
IN A SYNGENIC MODEL OF COLON CANCER
Allison Walter1, Nelly Etienne-Selloum1, David Brasse2,
Hadeel Khallouf1, Alain Beretz1 and
Valérie B. Schini-Kerth1
1Institut
Gilbert-Laustriat, UMR 7175 CNRS, Université
Louis Pasteur, Département de Pharmacologie et
Physicochimie, Faculté de Pharmacie, 74 route du Rhin,
67401 Illkirch;
2Pluridisciplinaire Hubert Curien, UMR 7178 CNRSIN2P3, Université Louis Pasteur, 23 rue du Loess, 67000
Strasbourg, France
Introduction: The growth of a tumor and its ability to
develop metastases is angiogenesis-dependent. In Europe,
colon cancer is the second and the third cause of mortality
3534
due to cancer in women and men, respectively, and it was
estimated that an effective nutritional prevention, namely to
eat more fruit and vegetables, would prevent more than 60
to 80% of colon cancer. Since epidemiological studies have
indicated that a moderate and regular consumption of wine
is associated with a reduced risk of cancer, we hypothesize
that red wine polyphenols (RWPs) may prevent tumor
growth by controlling tumor angiogenesis. Methods: C26
cells, derived from colon carcinomas (chemically induced
in BALB/c mice), were subcutaneously injected in each
flank of 9-week-old BALB/c mice. Two days after the
injection, RWPs or vehicle were given in the drinking water
at a dose of 100 mg/kg/day for the following 26 days. At
the end of the treatment period, we investigated the
macrovessel density in tumors by high definition microCT
system using radio opaque silicon rubber and the
microvessel density by immunohistochemistry (anti-CD31)
on frozen sections. In parallel, we measured an index of
proliferation (Ki-67) and apoptosis (TUNEL, activated
caspase-3) and we determined the expression level of proangiogenic factors (VEGF, MMPs) and tumor suppressor
genes (p21, p16, p53 and p73) on paraffin sections. Results:
After one month of treatment with RWPs, tumor size was
significantly reduced by 30% compared to the control
group. On the one hand, the vessel density assessed by
microCT and immunohistochemistry, was reduced by 40%
and by 47%, respectively in the RWPs-treated group. We
observed a concomitant decreased expression levels of the
major pro-angiogenic factors VEGF and MMPs 2 and 9
(MMP-2,9) in tumor cells. On the other hand, RWP
treatment reduced the proliferating index (Ki-67) of tumor
cells by 61% and increased the apoptotic index (TUNEL)
associated with high caspase-3 activity in tumor cells by
81%. Finally, RWPs also induce the expression of tumor
suppressor genes such as p16, p21, p53 and p73 in tumor
cells. Conclusion: RWPs reduce tumor growth by
preventing tumor neovascularisation and by inducing tumor
cell apoptosis through the expression of tumor suppressor
genes. Altogether, these findings indicate that RWPs have
potent anticancer properties. As this syngenic model is very
remote from the human physiopathology, further studies are
necessary to highlight the anticancer properties of RWPs in
a more relevant model of colon cancer.
712
PRECANCEROUS CARCINOGENESIS–CELLULAR
MODEL OF HUMAN BREAST EPITHELIAL CELLS
FOR DIETARY PREVENTION
Hwa-Chain Robert Wang
Department of Pathobiology, College of Veterinary
Medicine, The University of Tennessee, Knoxville, TN
37996, USA
Abstracts of the 8th International Conference of Anticancer Research, 17-22 October 2008, Kos, Greece
Carcinogenesis of human breast epithelial cells from noncancerous to precancerous and cancerous stages is a multiyear,
multistep, and multipath disease process. Exposure to
environmental carcinogens has been postulated to increase the
risk of developing human breast cancer. However, the role of
environmental carcinogens in the chronic carcinogenesis of
human breast epithelia has not been fully addressed.
Conversely, epidemiological and experimental evidence
suggests that dietary constituents in fruits and vegetables
prevent human cancer. Still, the mechanisms for dietary
prevention of human breast cells from precancerous
carcinogenesis induced by chronic exposure to environmental
carcinogens remain to be elucidated. To investigate dietary
prevention of cellular carcinogenesis, we studied potential
preventative biological, biochemical, and transcriptomic target
endpoints induced by long-term exposure of human breast
epithelial cells to environmental pollutions with low doses of
carcinogens. Immortalized, non-cancerous human breast
epithelial MCF10A cells were repeatedly exposed to
combined environmental carcinogens, 4-(methylnitrosamino)1-(3-pyridyl)-1-butanone (NNK) and benzo[a]pyrene (B[a]P),
each at picomolar concentrations, resulting in the induction of
an increased acquisition of cancer-related biological,
biochemical, and transcriptomic changes as target endpoints.
However, long-term exposure to these carcinogens did not
induce
cellular
tumorigenicity.
Accordingly,
our
carcinogenesis-cellular system mimics chronic carcinogenesis
of breast cells to progressively produce precancerous cells in
an accumulative manner as it occurs at the precancerous stage,
ductal carcinoma in situ, of human breast cancer. We then used
this precancerous model to reveal the ability of dietary grape
seed proanthocyanidin and green tea catechins to block
acquisition of target endpoints in the suppression of cellular
carcinogenesis. Thus, our precancerous carcinogenesis-cellular
model can serve as a cost-efficient, in vitro system to identify
bioactive dietary components that are able to suppress human
breast cell carcinogenesis associated with long-term exposure
to carcinogens. This research is expected to benefit society by
identifying molecular targets for bioactive dietary components
to formulate dietary supplements that are able to reduce the
health risk of cancer caused by long-term exposure to
carcinogens in environmental pollution.
713
ROLE OF REACTIVE OXYGEN SPECIES IN THE
PRO-APOPTOTIC ABILITY OF ONCOGENIC H-RAS
TO FACILITATE APOPTOSIS INDUCED BY
HISTONE DEACETYLASE INHIBITORS
Hwa-Chain Robert Wang
Department of Pathobiology, College of Veterinary
Medicine, The University of Tennessee, Knoxville, TN
37996, USA
More than 35% of human urinary bladder cancer involves
oncogenic H-Ras activation. Expression of oncogenic H-Ras
not only promotes tumorigenesis of human urinary bladder
cancer cells, but also increases cellular susceptibility to
histone deacetylase inhibitors (HDACI), such as FK228 (a
depsipeptide also known as FR901228 and romidepsin) and
trichostatin A, for inducing selective apoptosis. The novel
pro-apoptotic ability of oncogenic H-Ras should be seriously
considered in therapeutic designs for controlling oncogenic
H-Ras-involved cancer. However, the mechanisms behind the
proapoptotic ability of oncogenic H-Ras to enhance cell
susceptibility to HDACI remain unclear. Our recent studies
revealed that ectopic expression of oncogenic H-Ras
increased intracellular reactive oxygen species (ROS) in
human urinary bladder cancer J82 cells, enhanced FK228increased intracellular ROS production from mitochondria,
and increased cell susceptibility to exogenous ROS for
inducing apoptosis and caspases. The extrinsic caspase-8 and
intrinsic caspase-9 pathways were sequentially induced by
FK228-increased ROS to cooperatively induce a profound
activation of the executioner caspase-3/7 for inducing
selective apoptosis of oncogenic H-Ras-expressing cells
versus parental cells. Although FasL expression was induced
by FR901228 in J82 cells in an ROS-dependent manner, the
ROS-dependent activation of caspase pathways and cell
death were induced by FR901228 in a FasL-independent
manner. Our results led us to a suggestion that increased
ROS played a contributing role in the proapoptotic ability of
oncogenic H-Ras to enhance FK228-induced activation of
caspases for inducing selective apoptosis in a dose-dependent
manner.
714
DOWN-REGULATION OF GRP78 IS ASSOCIATED
WITH THE SENSITIVITY OF CHEMOTHERAPY TO
VP-16 IN SMALL CELL LUNG CANCER NCI-H446
CELLS
Yingyan Wang1, Wei Wang2, Jiarui Wang3 and Qi Wang4
1Diagnostics
Laboratory Center, 3Postgraduate School,
Dalian Medical University, 2Department of Respiratory
Medicine, The Third People’s Hospital of Dalian,
4Department of Respiratory Medicine, The Second Hospital
Affiliated to Dalian Medical University, Dalian, Liaoning,
116023, PR China
Background: Lung cancer is currently the leading cause of
cancer deaths worldwide. Small cell lung cancer (SCLC) is
the main type of lung cancer. Chemotherapy is an important
means of treatment for SCLC. However, the treatment is
limited by the development of drug resistance. An important
mechanism of chemotherapy resistance is the synthesis of a
kind of evolutionarily conserved proteins, named as glucose-
3535
ANTICANCER RESEARCH 28: 3157-3556 (2008)
regulated proteins (GRPs). GRP78/BiP, a well-characterized
GRP member with molecular weight of 78 kda, can be down
or up-regulated by some agents such as inhibitors of Ca2+ chelator BAPTA-AM or inducers of calcium ionophore
A23187. Many reports have shown that GRP78 plays a
protective role in maintaining cell viability against several
kinds of stress in a variety of cancers. However, most of the
reports focus on the up-regulation of GRP78, whereas only
few of them examine the down-regulation of GRP78,
especially whether the suppression of GRP78 is associated
with the sensitivity of chemotherapy in cancer. Herein, we
intended to investigate the down-regulation of GRP78 by the
inhibitor of BAPTA-AM and the function of this inhibition in
the resistance to VP-16 in SCLC NCI-H446 cells. Methods:
NCI-H446 cells were divided into three groups: BAPTAAM-treated group, A23187-treated group and control-group.
Immunofluorescence and RT-PCR were used to assess the
expression of GRP78 at both protein and mRNA levels for
the three cell groups. Then the cells were treated with VP16 at the concentration of 30 μM, and percentages of
apoptosis and the cycle distributions of the cells were
detected by flow cytometry. Results: Compared with
A23187-treated and control group cells, the expression of
GRP78 at both protein and mRNA levels for the BAPTAAM- treated cells were greatly decreased in a dose-depended
manner. After treatment with VP-16, the percentage of
apoptotic cells for BAPTA-AM-treated group were:
33.4±1.01%, 48.2±1.77%, 53.0±1.43%, 56.5±2.13%,
respectively, corresponding to the concentrations of BAPTAAM 10, 15, 25, 40 μM, which was statistically significant
high in comparison with the A23187-treated group and
untreated-group (7.18±1.03 % and 27.8±1.45%, respectively,
p<0.05). The cell cycle distributions assayed by flow
cytometry showed that there was a great decrease in G1
phase and a dramatic increase in S phase for the BAPTAAM-treated cells compared with the untreated cells.
Conclusion: BAPTA-AM is a strong inhibitor of GRP78 in
NCI-H446 cell line. This suppression of GRP78 is
significantly associated with the sensitivity to VP-16 in NCIH446 cells through the alteration of cell cycle distributions.
These results indicate that down-regulation of GRP78 or the
inhibition of GRP78 activity may offer a new therapeutic
approach to the clinical management of lung cancer.
715
CONSTRUCTION OF AN ARTIFICIAL RADIATIONGUIDED SYNCHRONIZING GENE CIRCUIT USING
NITRIC OXIDE SIGNALING PATHWAY IN HUMAN
LUNG CANCER CELLS
Wei-dong Wang, Zheng-tang Chen and De-zhi Li
Cancer Center of PLA, Xinqiao Hospital, Third Military
Medical University, Chongqing 400037, China
3536
Aim: Radio-genetic therapy is a novel strategy for cancer
treatment, however, the expression level of therapeutic genes
induced by radiation is too low to completely eradicate the
tumor, especially under the routine clinical doses of
radiation. Gene circuits are some simple gene networks
characterized by special regulatory properties. Methods: In
the present study, a synchronous amplifying gene circuit
controlled by nitric oxide (NO) signaling elements was
generated by coupling c-fos promoter with inducible nitric
oxide synthase (iNOS), which is induced by ionizing
radiation owing to the radiation-responsive of c-fos promoter.
Results: The synchronous amplifying property of the
constructed gene circuit was demonstrated by assaying of
green fluorescence protein with three-fold enhanced
expression. In a further study, the suicide gene HSV-TK
substituted the reporter gene; the duration and level of
expression of target genes increased and the enhanced
radiosensitivity and therapeutic effects on human lung cancer
were also shown in this experiment. Conclusion: The study
will improve the radio-genetic therapy in future by
promoting the expression level and prolonging the duration
of expression of target genes.
716
CHROMATIN RESTORATION FOLLOWING
GENOMIC REPAIR
Qianzheng Zhu, Gulzar Wani, Hany Arab,
Mohamed A. El-Mahdy, Alo Ray and Altaf A. Wani
Department of Radiology, The Ohio State University
Medical Center, Columbus, OH 43210, USA
DNA damage provokes activation of cell cycle checkpoint
response allowing time for DNA repair to maintain
genomic integrity. During DNA damage response and
repair, the chromatin is transiently disrupted to overcome
the structural barrier and provide repair machinery access
to damaged sites. Thus, restoration of functionally intact
chromatin structure following DNA damage processing is
crucial for retaining genetic as well as epigenetic
information coded within modified histones. Our recent
research has delved into how chromosomal incorporation
of ubiquitinated histone H2A (uH2A) occurs following
damage repair and the characteristic of this process in the
context of nucleotide excision repair (NER) sub-pathways
of global genomic repair (GGR) and transcription-coupled
repair (TCR).
We demonstrate that UV-induced uH2A foci formation
occurs at cyclobutane pyrimidine dimer (CPD) sites in cells
lacking XPC, DDB2, CSA or CSB, but not in cells lacking
XPA, XPG or XPF. This repair-proficient and -deficient cell
response indicated that uH2A incorporation strictly relies
on successful damage repair occurring through either GGR
Abstracts of the 8th International Conference of Anticancer Research, 17-22 October 2008, Kos, Greece
or TCR sub-pathway. In contrast, XPA, XPG or XPF were
not required for the formation of γH2AX foci in
asynchronous cells, affirming this event as a pre-incision
process. Notably, the H2A ubiquitin ligase Ring1B, a
component of Polycomb repressor complex 1, did not
localize at DNA damage sites. However, histone chaperone
Caf-1 showed distinct localization to the damage sites.
Knockdown of Caf-1 p60 abolished Caf-1 as well as uH2A
foci formation. Caf-1 p150 was found to associate with
NER factors TFIIH, RPA p70 and PCNA in chromatin.
Overall data demonstrate that prompt Caf-1-mediated
chromatin restoration following NER puts uH2A marks at
the sites of repaired damage within chromatin. Our
observations on CPD repair, and recent report on acetylated
histone H3 driving the chromatin assembly after DSB
repair, unfolds a novel phenomenon related to DNA repairmediated alterations of epigenetic information within
chromatin.
This work is supported by Grants from NIH.
717
HD-PTP IS IMPORTANT REGULATOR
OF PDGFRβ DEGRADATION
Piotr Wardega and Johan Lennartsson
Ludwig Institute for Cancer Research, Uppsala University,
Box 595, SE-751 24 Uppsala, Sweden
Human His-domain-containing protein tyrosine phosphatase
(HD-PTP) is a novel protein that has been implicated in
sorting of internalized proteins towards degradation, although
the molecular mechanism remain unclear. Previous studies
have suggested that HD-PTP may interact with several
components sorting machinery such as TSG101 (member of
endosomal sorting compexes required for transport- I,
ESCRT-I), CHMP4 (forms ESCR-III complex together with
other proteins), endophilin A1, but not with CIN85. We have
investigated the role of HD-PTP in down-regulation and
degradation of platelet-derived growth factor receptor β
(PDGFRβ). Our data indicate that HD-PTP is able to interact
in a constitutive manner with PDGFRβ. We observed that
HD-PTP is tyrosine phosphorylated under steady-state
conditions, but this phosphorylation can be further increased
by PDGF-BB stimulation. Elevated expression of HD-PTP
increased PDGF-induced tyrosine phosphorylation of
PDGFRβ, but decreased receptor ubiquitination.
Furthermore, we observed that HD-PTP overexpression
reduced the level of c-Cbl phosphorylation, consistent with
the decreased level of PDGFRβ ubiquitination. In
conclusion, our findings suggest that HD-PTP interferes with
c-Cbl’s ability to induce PDGF dependent receptor
ubiquitination and thereby the process of receptor downregulation.
718
PREDICTION OF RESPONSE IN MULTIMODALITY
TREATMENT OF UPPER GASTROINTESTINAL
CANCER: IMPACT OF MOLECULAR MARKERS
Ute Warnecke-Eberz1, Elfriede Bollschweiler1,
Uta Drebber2, Lukas Heukamp3, Stephan E. Baldus4,
Hakan Alakus1, Daniel Vallböhmer1, Paul M. Schneider5,
Arnulf H. Hoelscher1 and Ralf Metzger1
1Department
of General, Visceral and Cancer Surgery,
of Pathology, 3University of Cologne, Institute of
Pathology, University of Bonn, 4Institute of Pathology,
Heinrich-Heine-University Duesseldorf, Germany;
5Department of Visceral and Transplantation Surgery,
University Hospital Zurich, Switzerland
2Institute
Malignant tumors arise when cells change their
developmental program and replicate independently from
signal cascades and cellular control mechanisms. The
malignant development is genetically directed. The aim of
our work was to exploit these genetical changes for
diagnosis, response prediction and monitoring for clinical
purposes. Since only 30 to 50% of patients with locally
advanced esophageal cancer (cT2-4, Nx, M0) benefit from
neoadjuvant radiochemotherapy (cisplatin, 5-FU, 36 Gy)
there is a need for predictive markers.
The predictive impact of a selection of genes was analyzed
by real-time RT-PCR quantification. Expression levels were
compared with the degree of histopathological tumor
regression. Tumor regression was defined as major response
when resected specimens contained fewer than 10% residual
vital tumor cells. The excision repair gene ERCC1 is essential
for removal of DNA damage, caused by radiation and
chemotherapy. The predictive impact of ERCC1 mRNA levels
was demonstrated. An increased level of ERCC1 mRNA in
pre-therapeutical tumor biopsies was not compatible with a
major response (sensitivity 62.5%, specificity 100%). A total
of 42% of patients were identified for non-response to the
neoadjuvant treatment by quantification of ERCC1 mRNA. cerbB-2 mRNA expression proved to be an additional
predictive marker of minor histopathological response to
neoadjuvant therapy in patients with esophageal cancer.
Complementing gene expression analysis, single
nucleotide polymorphisms proved to be associated with
therapy response. By genetic variants of polymorphism
rs11615, 38% of the patients were identified as minor
responders and could be prevented from a non-effective
neoadjuvant treatment. A minor group of 9.6% would miss
a potentially successful therapy. XRCC1 is part of the base
excision repair system (BER) repairing small lesions around
the damaged base. The rarely appearing genotypes AA and
AG of XRCC1 polymorphism rs1799782 proved to be
additional markers for response prediction. These data
3537
ANTICANCER RESEARCH 28: 3157-3556 (2008)
confirm that DNA repair capacity is a critical mechanism for
resistance to platin-based therapeutics.
Since analysis of single molecular markers allows response
prediction only at a low sensitivity and specificity, co-expression
of different candidate genes was applied. For prediction of
therapy response in esophageal cancer, the predictive impact of
a panel of 17 target genes was analyzed. Expression of mRNA
in paired pretherapeutical tumor/normal biopsies was quantified
by TaqMan Low Density Array (LDA) analysis. LDA proved to
be a standardized and reproducible method for clinical practice.
Combination of a gene panel consisting of c-erbB-2, cdc25b,
DPD, ERCC1, p21, p16, PAI-1 and VEGF increased the
predictive accuracy. Construction of a predictive model by
artificial neuronal network analysis for prediction of major
histopathological response provided an accuracy of 90.5%, at a
sensitivity of 80% and a specificity of 90.5%.
For identification of novel markers not yet associated with
response prediction, human genome microarrays were applied.
Verification experiments confirmed the response predictive
impact of two genes: Cullin 2, a member of SCF E3 ubiquitin
ligase complex, modifying proteins involved in cell cycle
progression, and STK11, a serine/thereonine kinase tumor
suppressor gene. An LDA consisting of an optimized gene
panel could be applied to customize treatment strategies by
quantification of gene expression patterns.
Regarding esophageal, lung and pancreatic cancer
overexpression of survivin, an inhibitor of apoptosis, proved to
be a marker for detection of cancer. In esophageal cancer, we
were able to show that survivin is additionally a marker for
monitoring of the therapy. Detection of survivin mRNA was
also established for blood samples. Survivin mRNA was
monitored in 88% of the patients with gastrointestinal tumors.
A total of 59% of the patients showed a significantly lower
median survivin mRNA expression after surgical resection than
before. Following neoadjuvant therapy and tumor resection, in
38% of the patients there was no survivin mRNA detectable at
all. The data confirm the impact of survivin mRNA expression
for detection of dissiminating tumor cells in peripheral blood
and for monitoring of the therapy.
accuracy of FNA has increased, 20% of cases still require
further investigation to determine if the lesion is benign or
malignant. Other diagnostic procedures such as echography,
scintigraphy, and CTscanning are of little help. Therefore,
development of a more accurate system is required.
A monoclonal antibody, JT95, was established by
Takeyama, Watanabe et al., which specifically reacts to human
thyroid cancer. The immunohistochemical reactivity of JT95
was 96% to papillary carcinoma and 75% to follicular
carcinoma, but it showed hardly any reaction to normal tissues.
This specific reactivity was confirmed on 288 cases of thyroid
cancer in 13 medical facilities. The efficacy was studied under
the jurisdiction of the Japanese Society of Thyroid Surgery.
This antibody recognized a glycoprotein containing sialic
acid and which had a molecular weight of 250 kDa. Aminoacid sequencing revealed that the antigen was glycosylated
fibronectin. An approximately half-sized, 105-kDa tumorrelated antigen was found to be circulating in the body of the
patients and was detected in the blood by an immunoblot
assay. In the serodiagnosis using an enzyme-linked
immunosorbent assay, JT95 detected 80% of relapsed or
metastasized thyroid cancer. In contrast, the detection rate was
merely 51% in the primary patients. To improve the sensitivity
and enable precise quantification, we are currently attempting
to label the antibody with nano-particles. In addition,
immunohistochemical investigation using the antibody
contributes to the understanding of tumor antigen distribution
and biological activities in thyroid diseases. Increased
sensitivity of JT95 will raise the potential for use of JT95 in
diagnosis and treatment. Monoclonal antibodies have become
more important in both research and clinical applications. We
consider that clinical use of the JT95 antibody might be
another therapeutic application.
719
DEVELOPMENT AND APPLICATION OF A SPECIFIC
MONOCLONAL ANTIBODY
FOR THYROID CANCER
Medical Oncology, Heuberg 16, CH-4051 Basel, Switzerland
Michiko Watanabe1, Hiroshi Takeyama2 and
Yoshinobu Manome1
1Department of Molecular Cell Biology, 2Department of
Surgery, Jikei University School of Medicine. 3-25-8
Nishishin-bashi, Minato-ku, Tokyo 104-8461, Japan
Thyroid cancer has been diagnosed conventionally by fineneedle aspiration (FNA). However, even though the diagnostic
3538
720
FAMILIAL CANCER SUSCEPTIBILITY SYNDROMES
HAVE DISTINCTIVE
CLINICAL FEATURES
Walter Weber, Jacqueline Estoppey and Hansruedi Stoll
Introduction: Every human disease clusters in families to
some extent. This is also true for cancer. An excess of
cancers of the same site exists among relatives, with thyroid
and colon cancers and lymphocytic leukaemia showing the
highest familial risks (1). There is also familial clustering
of malignancies originating from different primary sites (2).
Primary care physicians approve syndrome-specific
germline mutation testing and want to play a central role in
the management of cancer families (3). Therefore,
characteristics of hereditary cancer predisposition
syndromes have to be known (4). Methods: In Basel
Abstracts of the 8th International Conference of Anticancer Research, 17-22 October 2008, Kos, Greece
families with conspicuous cancer aggregations can be
referred for work-up and counseling to medical oncology in
the University Hospital or in a private practice nearby.
Results: In 10 cancer families with germline mutations (4
breast-ovarian ca., 4 colorectal ca., one gastric ca. and one
Cowden syndrome) and one renal cancer family with a
balanced translocation (t(3;11) (q13,3;q21) the following
distinctive features were observed: multiple primary tumors,
multifocality, younger-than-usual age at tumor diagnosis,
association with muco-cutaneous lesions (genodermatoses)
and histological pecularities (rare histology, lobular breast
cancer, mucinous adenocarcinomas of colorectum and
diffuse type gastric cancer). Conclusion: Distinctive features
of familial cancer susceptibility syndromes should be known
in the light of growing evidence of the efficacy of medical
and surgical interventions.
1 Goldgar DE et al: J Natl Cancer Inst 86: 1600-1608, 1994.
2 Hemminki K et al: Genet Epidemiol 15: 225-236, 1998.
3 Pichert G et al: Fam Cancer 2: 153-158, 2003.
4 Lindor NM et al: JNCI Monograph No. 38, 2008.
721
DETECTION AND CHARACTERIZATION
OF CTC IN CARCINOMAS: NEW INSIGHTS
Janine Wechsler1 and Yvon Cayre2
1Department of Pathology, Henri Mondor University
Hospital, Créteil and 2Department of Clinical Hematology,
Robert Debré University Hospital, Paris, France
Despite the advances in oncology, the mechanisms by which
circulating tumor cells (CTC) are generated, and their
involvement in the metastatic process are still under debate.
Carcinomas representing 80% of all cancers are used as a
model to elucidate the important question of systemic tumor
cell dissemination. Although extremely rare, CTC represent
a potential alternative to invasive biopsies as a source of
tumor tissue. Several methods for detecting CTC in peripheral
blood from patients with various carcinomas have been
developed over the past few decades. Immunocytochemical
and molecular assays now enable the specific detection of
CTC even at the single-cell stage. In the present review, we
provide a critical review of the current methods used for
detection of CTC and data on their morphological and
molecular characterization. In a variety of carcinomas
including breast cancer, it is now well established that CTC
counts predict overall survival and provide independent
prognostic information to predict disease progression. The
next challenge of CTC characterization will be to detect, in a
non-invasive and serial manner, resistance/sensitivity of tumor
cells to novel targeted therapies. Such a genetic-based
analysis appears as a critical step in the development of a
personalized medicine.
722
INHIBITION OF SURVIVAL SIGNALING
BY AN INDOLE-3-CARBINOL-DERIVED
ANTITUMOR AGENT
Jing-Ru Weng1,2,3, Yuan-Yin Chen1, Chang-Fang Chiu3,
Ming-Hsui Tsai3 and Ching-Shih Chen4
1Department
2Research
of Biological Science and Technology,
Center for Biodiversity, China Medical University,
Taiwan;
3Terry Fox Cancer Research Laboratory, China Medical
University Hospital, Taichung 404, Taiwan, ROC;
4Division of Medicinal Chemistry, College of Pharmacy, The
Ohio State University, Columbus, OH 43210, USA
The chemopreventive potential of indole-3-carbinol has
attracted much attention because of its demonstrated ability to
protect against chemical-induced carcinogenesis in different
experimental animal models. From a mechanistic perspective,
the ability of indole-3-carbinol to target a broad range of
signaling pathways underlies its translational potential for
cancer prevention and/or treatment. However, its clinical use
might be compromised by its complicated pharmacokinetic
behaviors, poor bioavailability, and low antiproliferative
potency in vitro, which render therapeutic concentrations
difficult to achieve in the body. Therefore, this study was aimed
at pharmacologically exploiting indole-3-carbinol as a
molecular platform to develop structural variants with
improved chemical stability and apoptosis-inducing potency.
Among a series of indole-3-carbinol derivatives examined,
OSU-A9 represented the optimal agent, with an IC50 of 3.8 μM
and 2.0 μM for reducing the viability of SCC9 and SCC2095
human oral cancer cell lines, respectively. Cell viability,
apoptosis and signaling targets were determined by MTT,
ELISA, immunoblotting and cell counting. Despite a 100-fold
difference in antitumor potency, the pharmacological profiles
of OSU-A9 and indole-3-carbinol in interfering with target
signaling pathways were virtually identical. OSU-A9 is a
potent antitumor agent with pleotropic mechanisms of action
by affecting multiple signaling pathways, which might have
translational potential in oral cancer therapy.
723
CELL SIGNALING AND CANCER-POSSIBLE
TARGETS FOR THERAPY
C.E. Wenner
Department of Molecular and Cellular Biology, Roswell
Park Cancer Institute, Buffalo, NY. 14263, USA
Metabolic reprogramming in tumor cells involves acquisition
of properties which include growth-factor independent cell
proliferation, failure of inhibition by growth-inhibitory signals,
3539
ANTICANCER RESEARCH 28: 3157-3556 (2008)
ability to invade surrounding tissues, and to evade apoptosis,
etc. Characterization of the profile or molecular signature of
the tumor facilitates the development of rational therapies that
target the aberrant pathways. Rapidly growing tumor cells are
usually associated with high rates of glycolysis and in these
cells, it appears advantageous to exploit this pathway which
most likely is required for optimal synthetic needs. Glycolysis
is regulated at several control points and the association of
hexokinase with mitochondria is observed with rapidly
growing, highly glycolytic cells. Hexokinase II (HK-II) is
overexpressed in a number of rapidly growing tumors and
binds to the outer mitochondrial membrane. Phosphorylation
of Voltage–Dependent Anion Channel (VDAC) plays a role in
the regulation of HK-II binding (Pastorino-J Bioenerg
Biomembr, 2008) The disruption of hexokinase/ mitochondrial
interaction impairs anti-apoptotic and mitochondrial integritypromoting functions of PKB/Akt. It is our view that the
metabolic regulatory functions of PKB/Akt have evolved into
an adaptive sensing system involving mitochondrial
hexokinases. Therefore, targeting HK enzyme activity and its
association with integral membrane components such as VDAC
offers potential therapeutic benefit. Recent studiesl by Chiara et
al. (Plos One 3: 1852, 2008) demonstrated that Hexokinase II
detachment from mitochondria triggers apoptosis through the
permeability transition pore but independent of VDAC.
Although these results imply that VDAC–hexokinase
interaction are not irreplaceable constituents of the
permeabilization process, it is possible that alternate membrane
constituents can act as binding partners for the HK II in the
absence of VDAC. Alternate constituents could also be capable
of opening of the permeability transition pore. The studies of
Chiara et al. contribute greatly to our understanding of the
pathways of outer mitochondrial membrane permeabilization
and their inactivation of tumors. For example, a hexokinase-II
N-terminal peptide selectively detaches HK-II from
mitochondria and induces apoptosis. The development of
highly specific inhibitors in conjunction with combinatorial
therapeutic agents which target the growth factor signal
transduction pathways as well as apoptotic signaling pathways
should provide an opportunity for maximal therapeutic benefit.
724
ANTICANCER PROPERTIES AND MULTIDRUG
RESISTANCE MODULATORY EFFECT OF PLANT
POLYPHENOLS AND THEIR INTERACTION WITH
MEMBRANE COMPONENTS
2Laboratory
of Biophysics, Jozef Stefan Institute, Jamova
39, Ljubljana, Slovenia;
3CECF/iMed. UL, Faculty of Pharmacy, University of
Lisbon, Av. das Forças Armadas, 1600-083 Lisbon,
Portugal
Many compounds of plant origin were formed to be interesting
for potential application in cancer prevention or chemotherapy.
Such agents were found among flavonoids and stilbenes. In
broad in vitro and in vivo studies, the ability of plant-derived
polyphenols to interact with different cellular targets was
revealed. Resveratrol (trans-3,4,5’- trihydroxystilbene)
influences many cellular signaling pathways and affects all three
stages of carcinogenesis. In this work the effect of several
stilbenes (resveratrol, its analogue piceatannol, and piceatannol
derivatives) and some flavonoids on the activity of ATP-binding
cassette (ABC) multidrug transporters and potassium channels
Kv1.3 was examined. Recently the role of potassium channel
activity in cancer has emerged. Several of the compounds
studied were potent potassium channel inhibitors. Strong
inhibition of membrane transporters and ion channels was often
observed in case of hydroxy-, methoxy-, acetoxy- and prenylderivatives in relation to the parent compounds. Piceatannol,
naringenin and some of their derivatives occurred to be the most
active inhibitors of MRP1 multidrug transporter. The influence
of plant polyphenols on integral membrane proteins such as
MDR transporters and ion channels can be mediated at least in
part by non-specific membrane effects. Flavonoids and stilbene
interactions with lipid bilayers were determined by fluorescence
and ESR spectroscopy. Simulation of the experimental ESR
spectra and application of GHOST condensation method were
applied to study of the effect of polyphenols on membrane
domain structure. The significance of the interaction of studied
phytochemicals with membrane transporters, channels and lipid
bilayer for their anticancer properties was discussed
Antiproliferative properties of the compounds were tested
in doxorubicin-sensitive and -resistant, P-gp overexpressing
colon cancer cell lines LoVo and LoVo/Dx, respectively.
Tangeretin, natural polymethoxylated flavone and 8prenylnaringenin most effectively inhibited cell growth both
in sensitive and resistant cancer cell lines. Antiproliferative
action was compared with pro-apoptic properties of the
compounds.
725
8-PRENYLNARINGENIN INHIBITS BOTH PGLYCOPROTEIN AND MULTIDRUG
RESISTANCE-ASSOCIATED PROTEIN 1
Krystyna Michalak1, Olga Wesołowska1,
Jerzy Wiśniewski1, Kamila Środa1, Andrzej Teisseyre1,
Michał Kużdżał1, Janez Štrancar2,
Noélia Duarte3 and Maria-José U. Ferreira3
Olga Wesołowska1, Jerzy Wiśniewski1, Maria Paprocka2,
Danuta Duś2 and Krystyna Michalak1
1Department
1Department
of Biophysics, Wrocław Medical University,
ul. Chałubińskiego 10, 50368 Wrocław, Poland;
3540
of Biophysics, Wrocław Medical University,
ul. Chałubińskiego 10, 50368 Wrocław;
Abstracts of the 8th International Conference of Anticancer Research, 17-22 October 2008, Kos, Greece
2Laboratory
of Cellular Interactions, Department of
Medical Immunology, Institute of Immunology and
Experimental Therapy, Polish Academy of Sciences, ul.
Weigla 12, 53-114 Wrocław, Poland
8-Prenylnaringenin (8-isopentenylnaringenin) is a potent
phytoestrogen isolated from hop (Humulus lupulus). Apart
from binding to estrogen receptors α and β this flavonoid
was also recognized as an inhibitor of angiogenesis and a
chemopreventive agent. In the present work we have
studied the interaction of 8-prenylnaringenin with two
multidrug-resistance-associated transporters, P-glycoprotein
and MRP1. Functional test based on the transport of
fluorescent substrate BCECF revealed that the flavonoid
significantly inhibited MRP1 transport activity in human
erythrocytes (IC50=5.76±1.80 μM). The influence of 8prenylnaringenin on P-glycoprotein was investigated in two
human colon cancer cell lines, drug-sensitive LoVo and
doxorubicin-resistant LoVo/Dx. By means of flow
cytometry it was shown that the studied flavonoid
significantly increased the accumulation of rhodamine 123
in drug-resistant cancer cell line. The ability of 8prenylnaringenin to inhibit P-glycoprotein was also
demonstrated by confocal microscopy. Sulforhodamine B
(SRB) assay was employed to study the cytotoxicity of 8prenylnaringenin. It was found that the flavonoid was more
toxic to LoVo than to LoVo/Dx cell line, however in
concentrations higher than 25 μM its toxicity to both cell
lines was considerable. In conclusion, 8-prenylnaringenin
was identified as a new potent multidrug resistance
modulator. The flavonoid effectively inhibited two main
MDR transporters: P-glycoprotein and MRP1 in
concentrations that were not seriously toxic to the cells. In
concentrations above 50 μM 8-prenylnaringenin acted as an
anticancer agent, effectively killing the cancer cells.
726
HOST POLYMORPHISMS AS RISK
FACTORS FOR GASTRIC CANCER
Thomas Wex and Peter Malfertheiner
Clinic of Gastroenterology, Hepatology and Infectious
Diseases, Leipziger Str. 44, D-39120 Magdeburg, Germany
Infection of the stomach with the gram-negative bacterium
Helicobacter pylori is the main risk factor for the
development of gastric cancer (GC) leading to its
classification as a “definite carcinogen” by the World Health
Organization in 1994. Since then, the pathophysiological
mechanisms linked to this infection have been studied
extensively in clinical and basic science. The current
paradigm of gastric carcinogenesis is based on a
multifactorial risk factors, the virulence factors of the
bacterium (e.g. CagA, VacA), environmental factors (diet,
smoking) and host factors (gene polymorphisms). The
complex interplay among these factors determines the
clinical outcome of the infection, leading to 3 major
diseases in 1 out of 7 infected persons, namely ulcer
disease, GC and mucosa-associated lymphoid tissue
lymphoma in 15%, 1% and 0.1% of all persons infected
with H. pylori, respectively.
In 2000, El-Omar and co-workers identified a gene
polymorphism of the interleukin (IL)-1 gene that is
associated with an increased risk for gastric cancer and shed
light into the pathophysiology of the H. pylori infection and
its molecular links to gastric carcinogenesis. In recent years,
this work has been tremendously extended and various
genomic variants, carrying a risk for the development of
gastric cancer, were identified. Among them are cytokine
genes (IL-8, IL-10) and receptors for the recognition of the
bacterium (TLR-4). Besides the identification of novel gene
polymorphisms linked to GC, it has become clear that there
is no general genomic risk pattern for all GC patients. Most
of the established host factors are restricted either to the
histological type (intestinal vs. diffuse), ethnical background
(Caucasian vs. Asian) on tumor localization (non-cardia vs.
proximal GC). Here, we will review the current knowledge
of the role of these host factors for gastric carcinogenesis
and present our data concerning the role of IL-1beta and
NOD-2 gene polymorphisms in German patients with gastric
cancer.
727
kPCR-BASED IDENTIFICATION OF LOW-RISK
AND HIGH-RISK BREAST CANCER PATIENTS
FOR ALTERNATIVE TREATMENT OPTIONS
Ralph M. Wirtz, Mathias Gehrmann, Udo Stropp,
Guido Hennig, Christian von Törne, Karsten Weber,
Ralf Kronenwett and Christoph Petry
Siemens Healthcare Diagnostics; Molecular Research
Germany; Nattermann Allee 1, 50829 Köln, Germany
Genomic approaches have revolutionized our understanding
of tumor biology. Employing microarray analysis of fresh
tissue tumor samples in a groundbreaking study Perou and
co-workers (1) were first to identify subtypes intrinsic to
breast cancer. Importantly, these molecular subtypes do not
only differ fundamentally in their general aggressiveness, but
also in their responsiveness to different anticancer therapies.
However, tests to define these intrinsic subtypes have not yet
been adapted to formalin-fixed tumor tissue, an obstacle to
their use in routine clinical practice.
At Siemens Healthcare Diagnostics, we have analyzed gene
expression and genomic alterations were examined in fresh and
fixed tumor tissue samples of thousands of breast cancer
3541
ANTICANCER RESEARCH 28: 3157-3556 (2008)
patients treated as part of clinical trials or in clinical practice.
First, we identified a gene signature, consisting of twelve
genes, that identifies node-negative breast cancer patients
having a low-risk of developing distant metastasis within 5
years. The respective breast cancer prognosis score reached a
sensitivity of 90% and a specificity of 35% for death after
recurrence within 10 years in an independent validation cohort
of 236 patients. The breast cancer prognosis score can be
assessed by kPCR in formalin-fixed tumor tissue and therefore
could be implemented into routine clinical practice.* This may
help to spare low-risk breast cancer patients from harsh
systemic treatments such as chemotherapy.
Second, we identified a gene signature consisting of only
4 genes that identifies high-risk patients in the nodenegative and node-positive situation (>60% recurrence
within 3 years) by molecular classification. Again, this gene
signature was identified in fresh tissue specimens and then
transferred to kPCR detection in formalin-fixed tissue
samples. Importantly, this 4 gene algorithm not only
identified the high-risk patient population in the validation
cohort (p<0.0001; n=210), but also discriminated between
low risk and high risk patients in the triple negative breast
cancer subtype (p=0.006). As these patients were already
treated with anthracycline and taxol-containing
chemotherapy, alternative regimens might be applied to
these high risk patients early on. Interestingly, the 4 gene
algorithm comprises the detection of angiogenic activities
in tumors and therefore might be helpful for selecting
patients for antiangiogenic treatment options.
1 Perou CM, Sørlie T, Eisen MB, van de Rijn M, Jeffrey SS,
Rees CA, Pollack JR, Ross DT, Johnsen H, Akslen LA,
Fluge O, Pergamenschikov A, Williams C, Zhu SX,
Lønning PE, Børresen-Dale AL, Brown PO and Botstein
D: Molecular portraits of human breast tumours. Nature.
406(6797): 747-752, 2000.
728
THE TUMOR MICROENVIRONMENT:
CONCEPTS AND GENERAL CHARACTERISTICS
Isaac P. Witz
Department o Cell Research and Immunology, Tel Aviv
University, Tel Aviv, 69978, Israel
The tumor tissue is composed of 2 compartments intimately
associated with each other. The first compartment constitutes
the malignant cells. The second is the tumor
microenvironment. This compartment is composed of resident
cells such as fibroblasts, endothelial cells and other nonmalignant cells; of infiltrating cells such as lymphocytes or
macrophages and of numerous molecules such as those of the
extracellular matrix, growth factors, cytokines, chemokines,
antibodies, proteases, other types of enzymes and various
3542
metabolites. All these molecules may be released from the
tumor cells and/or from the non malignant cells. Some
artificially administered molecules, for example drugs, may
also be present in the microenvironment. The
microenvironment of many solid tumors may be characterized
by hypoxia; low extracellular pH and by low glucose
concentration.
The contemporary concept of tumor microenvironment
postulates that it functions as an active “educational/
inductive/selection” venue in which the tumor is directed
into one of several molecular evolution pathways by
microenvironmental factors. However the interaction
between microenvironmental components and tumor cells is
bidirectional. In addition to the regulation of genes in tumor
cells by microenvironmental factors, tumor cells and their
products are capable of regulating gene expression in nontumor cells residing in or infiltrating into the
microenvironment thereby altering their phenotype. There
are scores of tumor-microenvironment interactions that play
anti or pro malignancy roles. These include interactions that
lead to or drive cell proliferation or death, angiogenesis,
motility, chemotaxis, invasion, protective immunity,
inflammation and metastasis to name a few. Many such
interactions await their discovery and the significance of
other interactions has still to be elucidated.
Interactions of cancer cells with components of their
microenvironment are pivotal determinants in the decision
making process that determines if cancer cells will progress
towards metastasis or whether they will stay dormant or
disappear altogether. The realization that metastasis is
controlled by interactions of tumor cells with
microenvironmental components has allowed for the
establishment of a new paradigm, namely intervention in the
metastatic process by targeting interactions between the tumor
cell and its microenvironment. Numerous preclinical and
clinical trials attempt, on the one hand, to block tumormicroenvironment interactions that boost tumor progression
and metastasis and on the other hand enhance interactions that
counteract malignancy.
In order to develop effective anti metastasis therapies and
in view of the complexity of tumor-microenvironment
interactions, combinatorial approaches used in the analysis
of hyper complex systems will have to be employed.
729
THE DYNAMIC SYSTEM [TELOMERESTELOMERASE-PROLIFERATION] UNDERLIES
PERENNIAL GROWTH OF CANCER CELLS
AND EPISODES OF DRUG RESISTANCE
J. Deschatrette and C. Wolfrom
CNRS UMR8080 “Développement et évolution”
Université Paris-Sud. 91405 Orsay, France
Abstracts of the 8th International Conference of Anticancer Research, 17-22 October 2008, Kos, Greece
For a long time, regular progressive growth and resistance to
anticancer drugs have been considered as invariant
characteristics of a tumor. However, there are indications that
both cell growth and drug resistance can display discontinuous
patterns over months, although the mechanisms underlying
these fluctuations are unclear. Our hypothesis is that telomere
regulation plays an important role in such fluctuations. In rat
hepatocarcinoma cells in vitro, we observed that every part of
the small complex system [Telomeres-Telomerase-Proliferation]
displayed deterministic oscillations. These oscillations were
coordinated and resulted in an oscillatory conservative behavior
of the whole system. This global dynamic equilibrium was
found critical for perennial growth of hepatocarcinoma cells and
for peaks of cell resistance to methotrexate.
730
PHYSICAL ACTIVITY AND CANCER
Alicja Wolk
Karolinska Institutet, Department of Environmental
Medicine, Division of Nutritional Epidemiology, Sweden
Physical activity promotes health, wellbeing and longevity
through decreased risk for cardiovascular disease, cancer,
other chronic diseases and all, as well as that for cancer,
mortality.
Accumulating evidence from epidemiological studies shows
that physical activity is of significance for reducing cancer
incidence. The most consistent associations between physical
activity and reduced cancer risk have been observed for colon
and breast cancer. Growing evidence also indicates a reduced
risk for endometrial and lung cancer. There has not been clear
support for an inverse association between physical activity
and prostate cancer risk in previous studies; however, more
specific new analyses indicate that such an association may
exist. Furthermore, growing evidence supports the role of
physical activity in improving cancer prognosis and quality of
life in cancer survivors. Less evidence is available on cancer
recurrence.
Current recommendations regarding a required “dose” of
daily physical activity in prevention of cancer development
and cancer mortality are specified as 30-60 minutes per day
of moderately-to-vigorously intense physical activity. They
are further supported by new results from prospective
studies of men and women in Sweden.
731
HELICOBACTER PYLORI ERADICATION
IN THE PREVENTION OF GASTRIC CANCER
Benjamin C. Y. Wong
Department of Medicine, University of Hong Kong, Queen
Mary Hospital, Hong Kong
Gastric cancer remains one of the top cancer killers in the
World. Chronic Helicobacter pylori infection increases the
risk of gastric cancer, by stepwise progression from chronic
active gastritis to gastric atrophy, intestinal metaplasia,
dysplasia and finally cancer. These stepwise progressions
may take many years, and at present there is no proven
effective treatment for the presence of premalignant lesions
including intestinal metaplasia or dysplasia. Hence the two
prevailing questions in gastric cancer prevention are (a)
whether treatment of H. pylori-related gastritis can reduce
the risk of gastric cancer, and (b) whether treatment of H.
pylori-related IM or dysplasia can both reverse the
premalignant lesions and reduce the risk of gastric cancer.
Our randomized placebo controlled trial in China started
in year 1994 included both patients with H. pylori related
gastritis and patients with H. pylori related premalignant
lesions (1). After 7.5 years of follow up, patients receiving
H. pylori treatment showed a non-significant trend of having
less gastric cancer than those patients that received placebo.
The sub-group analysis showed that patients with H. pylori
related gastritis benefited most from treatment, with no
cancer developing in 7.5 years. However, in patients with H.
pylori related premalignant lesions, there was no difference
in the risk of gastric cancer in both treatment and placebo
groups. Hence our study suggests that the benefit of treating
H. pylori in cancer prevention may be restricted to patients
with gastritis only.
Correa et al. performed another randomized placebo
controlled trial in Columbia which included mainly patients
with H. pylori- related premalignant lesions (2). Their 12year follow up result suggested that subjects who were H.
pylori negative after treatment had 14.8% more regression
and 13.7% less progression than patients who were positive
at 12 years (p=0.001). Hence he concludes that it is
beneficial to treat H. pylori in patients with premalignant
lesions. However the magnitude of benefit may be in the
range of 15% only.
Based on these and other studies, the recommendation is
that treatment of H. pylori is beneficial in prevention of
gastric cancer. The benefit is greater in patients without
premalignant lesions. Hence treatment earlier in life may
give better results.
1 Wong BCY, Lam SK, Wong WM et al: Helicobacter
pylori eradication to prevent gastric cancer in a high-risk
region in China: A randomized controlled trial. JAMA
291(2): 187-194, 2004.
2 Mera R, Fontham ET, Bravo LE et al: Long term follow
up of patients treated for Helicobacter pylori infection.
Gut 54: 1536, 2006.
732
SIMVASTATIN INDUCTION OF BCL-2 EXPRESSION
AND NEUROPROTECTION IN MOUSE PRIMARY
3543
ANTICANCER RESEARCH 28: 3157-3556 (2008)
NEURONS AND HUMAN NEUROBLASTOMA
CELLS INDEPENDENT OF THE
MEVALONATE/CHOLESTEROL PATHWAY
W. Gibson Wood
Department of Pharmacology, University of Minnesota
School of Medicine, Minneapolis, Minnesota, USA
There are data, albeit with some controversy, indicating that
the cholesterol lowering drugs, statins, may prevent certain
types of cancer, are proapoptotic and may arrest cell growth.
However, we and others have shown that statins afford
protection to cells under various treatment conditions.
Moreover, this protection is due in part to upregulation of Bcl2. Simvastatin stimulated murine neuronal Bcl-2 gene
expression and protein levels in vivo and in vitro. Simvastatin
pretreatment resulted in a significant reduction in cytotoxicity
(caspase-3 activation, lactate dehydrogenate release) following
a challenge with amyloid beta-protein compared with
unchallenged neurons. G3139, an antisense oligonucleotide
directed against Bcl-2, abolished the protective effects of
simvastatin and eliminated simvastatin-induced up-regulation
of Bcl-2 protein. Effects of simvastatin on Bcl-2 stimulation
not only occurred in mice but were replicated in another
species, the guinea pig. We demonstrated up-regulation of Bcl2 in cerebral cortex of drug-treated guinea pigs and dissociated
brain cells from simvastatin-treated guinea pigs were protected
from neurotoxicity induced by sodium nitroprusside ex vivo.
Simvastatin-induced neuroprotection was reduced by
inactivation of the Bcl-2 protein, similar to effects observed
when Bcl-2 protein levels were reduced by G3139. Effects of
simvastatin on Bcl-2 stimulation were independent of
inhibition of HMG-CoA reductase and data indicated the
potential role of endothelin-1 on statin-induced stimulation of
Bcl-2. Here, we provide novel evidence showing that
simvastatin can stimulate expression of Bcl-2 both in vivo and
in vitro. These findings provide one of the potential
mechanisms for the purported neuroprotective effects of statins
and do not support a proapoptotic mechanism of action of this
class of drugs. Supported in part by NIH grants AG-18357 and
AG-23524.
733
BENZYL ISOTHIOCYANATE AND PHENETHYL
ISOTHIOCYANATE INDUCE APOPTOSIS IN
HUMAN OSTEOSARCOMA U-2 OS CELLS
THROUGH THE PRODUCTION OF REACTIVE
OXYGEN SPECIES AND MITOCHONDRIA- AND
CASPASE-3-DEPENDENT PATHWAYS
Chang-Lin Wu and Jing-Gung Chung
Department of Biological Science and Technology, China
Medical University, Taichung, Taiwan, ROC
3544
From animal model studies, it has been shown that benzyl
isothiocyanate (BITC) and phenethyl isothiocyanate (PEITC)
inhibit carcinogenesis and tumorigenesis. However, the
effects of BITC and PEITC on human osteosarcom U-2 OS
cells are still not clear. In this study, we investigated whether
or not BITC and PEITC can induce apoptosis in U-2 OS
cells. U-2 OS cell proliferation was examined by MTT assay
after exposure to BITC and PEITC in vitro. BITC at 7.5 μM
and PEITC at 10 μM were used for different time treatments
of U-2 OS cells for determination of cell viability. DAPI
staining and comet assay were used for examining DNA
damage and the results indicated that BITC and PEITC
induced U-2 OS cell DNA damage in time- and dosedependent manners. Flow cytometry was used for cell cycle
analysis, sub-G1 group, production of reactive oxygen
species (ROS) and Ca2+ and changes of mitochondrial
membrane potential (ΔΨm) in U-2 OS cells after treatment
with BITC or PEITC for various time periods. BITC and
PEITC reduced ΔΨm and increased the production of ROS
and Ca2+ in U-2 OS cells in a time-dependent manner. BITC
and PEITC induced G2/M phase arrest in U-2 OS cells. In
conclusion, BITC and PEITC promoted the production of
ROS and Ca2+ and caused DNA damage and G2/M phase
arrest, reducing ΔΨm of mitochondria, resulting in
activation of caspase-3 that finally led to apoptosis in U-2
OS cells.
734
THE EFFECTS OF GAN-LUH-YIN ON THE
PROLIFERATION OF LYMPHOCYTES AND
SECRETIONS OF CYTOKINES FROM ORAL
CANCER CELL LINES
Chia-Chun Wu1, Jai-Sing Yang2 and Jing-Gung Chung1
1School
of Biological Science and Technology,
of Pharmacology, China Medical University,
Taichung, Taiwain, ROC
2Department
Oral cancer is one of the major causes of death in the male
population of Taiwan. It was reported that the number of Tand B-cells and the levels of interleukin (IL)-2 in oral cancer
patients is lower then that of healthy individuals. However,
the level of IL-4, IL-6 and tumor necrosis factor (TNF)-α in
oral cancer patient is higher than that of healthy individuals.
Gan-Luh-Yiin (GLY) is usually used for promoting cure by
Chinese medicine in patients. Whether or not GLY can
inhibit inflammation of oral cancer cells is not clear.
Therefore, the purpose of our study was to investigate the
proliferation of spleen cells from mice and also to examine
the levels of cytokines from oral cancer cell lines such as
CAL 27, SCC-4, HSC-3 and TW206. Celltiter kit was used
for analysis of the total number of T- and B-cells. The CBA
method and flow cytometry (FACS) were used to analyze 6
Abstracts of the 8th International Conference of Anticancer Research, 17-22 October 2008, Kos, Greece
cytokines (IL-2, IL-4, IL-6, IL-10, TNF and interferon
(IFN)-γ). The results indicate that GLY at 200, 500 and 1000
μg/ml promoted the proliferation of T- and B-cells under
Con A and lipopolysaccharide stimulation, respectively. The
results from CBA and FACS examinations indicated that: (1)
GLY promoted the secretion of IL-2 from SCC-4 and
TW206 cells; (2) GLY promoted the secretion of IL-4 from
SCC-4, CAL 27, HSC-3 and TW206 cells; 3) GLY inhibited
IL-6 secretion of SCC-4 cells; (4) GLY inhibited the
secretion of TNF from CAL 27, SCC-4, HSC-3 and TW206
cells; and (5) it promoted the secretion of IFN-γ from CAL
27, SCC-4, HSC-3 and TW206 cells. In addition, GLY
suppressed TNF mRNA level as examined by real-time PCR.
GLY also suppressed the levels of proteins such as
phosphorylated Akt, NF-κB p65 and ERK1/2 which were
examined by Western blotting, NF-κB promoter assay and
immunostaining in CAL 27 cells. Taken together, we suggest
the effects of GLY on oral cancer may be mediated through
anti-inflammatory action via TNF.
735
MICRORNA ANALYSIS OF FORMALIN FIXED
PARAFFIN–EMBEDDED BREAST CANCER
TISSUES WITH DIFFERENT STAGES
Y. Zhao1, C. Deng2, H. Zhang1, J. Xiao1, R. Recker1,
Z. Gatalica2, E. Silva3 and G. Xiao1
1Genomics
and Functional Proteomics Laboratories,
Department of Medicine, Creighton University, Omaha,
NE;
2Department of Pathology, Creighton University, Omaha,
NE;
3Department of Surgery, Creighton University, Omaha, NE.
Introduction: Breast cancer still has the highest incidence
among women in the United States. Our understanding of its
molecular and cellular mechanisms is limited. Recently,
microRNAs have gained favorable status as upstream
regulators of breast cancer progression since then it can
posttranscriptionally regulate sets of genes. It is now
estimated that there are about 1000 miRNAs in the human
genome, but only about 300 miRNAs have been identified in
humans now. Much of miRNAs and their roles in cancer
formation still await discovery. Methods: Formalin fixed
paraffin–embedded (FFPE) breast tissues from different
stages of the cancer were de-waxed before performing total
RNA extraction. Tissues, from normal breast, in situ ductal
carcinoma (DCIS), and invasive ductal carcinoma (IDC,
stage II), with 15 subjects in each group were analyzed. The
total RNA was extracted with acid-phenol: chloroform.
MicroRNAs were isolated from total RNA. MicroRNA
microarray profiling was performed using LC Sciences
technology (LC Sciences, LLC). The Bioconductor
implementation of Limma was used to analyze the data.
Results: MicroRNA profiling experiments have been
performed from 45 FFPE breast tissues of breast cancer
subjects. By comparing the endogenous miRNA level in
normal to that in DCIS, we found that numbers of miRNAs
(e.g. mir-21) were significantly induced, while some of
miRNAs (e.g. mir-205) were suppressed, in DCIS stage. In
subjects with IDC stage, we observed some up-regulated
miRNA species (e.g. mir-21) and more down-regulated
miRNA species (e.g. mir-126), indicating that those miRNAs
could be important candidate mediators that regulate
progressive process of the breast cancer. These findings were
confirmed by real time microRNA RT-PCR using breast
cancer patient samples. Further functional studies are still
under investigation.
736
ASSOCIATION OF THE TOB ANTIPROLIFERATIVE
PROTEIN WITH THE CCR4-NOT COMPLEX,
A PLATFORM OF DEADENYLASE-BASED GENE
REGULATION
Masahiro Morita, Kentaro Ito, Takashi Miyasaka,
Toru Suzuki and Tadashi Yamamoto
The Institute of Medical Science, The University of Tokyo,
Tokyo 108-8639, Japan
The Tob/BTG family of antiproliferarive proteins is involved
in multiple biological events that include cell growth
suppression, apoptosis, and bone formation. To understand the
underling mechanism by which Tob/BTG family proteins are
involved in various biological events, we planned to identify
Tob-interacting proteins. For this purpose, we established Flagtagged Tob-expressing stable cell lines and applied a proteomic
approach. We found that Tob interacts with the CCR4-NOT
complex that is a multi-protein complex conserved from yeast
to human. The human CCR4-NOT complex contains four
enzymatic subunits, Cnot6, Cnot6L, Cnot7, and Cnot8,
carrying the deadenylase activity, and at least five core and/or
regulatory subunits: Cnot1 to -4 and Cnot9. We showed that
the amino-terminal half of Tob interacts with Cnot7 and the
carboxyl-terminal half interacts with Cnot1, a scaffold protein
of the CCR4-NOT complex. Although we previously showed
that Tob functions in the transcription machinery, the above
finding suggests that Tob is also involved in the control of
mRNA metabolism. We then addressed biological significance
of the CCR4-NOT complex by depleting each component of
the complex either by RNAi or targeted gene disruption in
mice. Interestingly, we found that RNAi-mediated depletion of
Cnot6L results in growth retardation of NIH 3T3 cells
accompanied by elevation of both p27Kip1 mRNA and p27Kip1
protein. We showed that p27Kip1 mRNA is stabilized and its
poly (A) tail is preserved in Cnot6L-depleted cells. The data
3545
ANTICANCER RESEARCH 28: 3157-3556 (2008)
suggest that Cnot6L regulates cell growth in a manner
dependent on its deadenylase activity targeted to p27Kip1
mRNA. We also found unique phenotypes in mice lacking
Cnot3 and Cnot7, respectively. Cnot7–/– males are sterile owing
to oligo-astheno-teratozoospermia, suggesting that Cnot7
deadenylase is essential for spermatogenesis. Cnot3–/– mice are
embryonic lethal. Heterozygous mice for Cnot3 are viable and
fertile, but displayed severe leanness and hypersensitivity to
insulin. We also showed Cnot3 positively regulates the CCR4NOT-associated deadenylase activity. To clarify the underlying
molecular mechanisms, we searched for the mRNA species
whose abundance is altered in these gene manipulated mice.
Taking all findings together, we will discuss the fundamental
function of the CCR4-NOT complex in relation to the activity
of Tob.
737
DIFFERENTIAL PROGNOSTIC FACTORS
INDEPENDENT OF TNM STAGE IN GASTROINTESTINAL CANCERS IN JAPAN
Keishi Yamashita, Akira Ooki, Hiroshi Katoh, MD, Mina
Waraya and Masahiko Watanabe
The Department of Surgery, Kitasato University Hospital,
Sagamihara, Kanagawa, Japan
Aim: To know the most important prognostic factors
independent of TNM stage in advanced cancers such as
esophageal, gastric, colorectal, and pancreatic cancer among
the daily feasible clinicopathological factors. Materials:
Advanced cancers of esophageal squamous cell carcinoma
(ESCC); n=121, gastric adenocarcinoma (GAD); n=510,
colorectal adenocarcinoma (CAD); n=596, pancreatic tubular
adenocarcinoma (PAD); n=89. Methods: Univariate and
multivariate analysis were used for prognostic relevance.
TNM factors were excluded from the multivariate analysis
in order to know the independent prognostic factors (IPF).
Results: i) In ESCC, multivariate prognostic analysis
revealed that lymph node metastasis density (ND)-factor and
growth pattern were the strongest in more and less advanced
ESCC, respectively. ii) In GAD, IDF was the ND-factor in
stage II, III, and IV, reproducibly in both retrospective and
prospective analysis. iii) On the other hand, in CAD, IDF
was preoperative CA19-9 and multiple liver metastasis only
in stage IV, and there were no other prognostic factors
identified in curable cases. We will present diminishing
prognostic impact of serum CEA in the recent patients. iv)
In PAD, the strongest IDF was preoperative CA19-9, and the
higher it was, the worse the patient prognosis was. Intraoperative dissected pancreatic margin (DPM) positivity was
another IPF, and we could identify the long survivor group
for advanced PAD. Conclusion: In ESCC and GAD, lymph
node metastasis density (ND-factor) was the most life-
3546
threatening phenotype, while ND-factor in either CAD or
PAD did not show such relevance for prognosis. On the other
hand, preoperative CA19-9 was the most important
prognostic factor in both CAD with stage IV and advanced
PAD. We will describe the difference of such discrete types
of cancers and present a putative mechanism to explain the
difference. Therapeutic targets among the major gastrointestinal cancers, will also be discussed.
738
DYRK2 EXPRESSION CAN BE A PREDICTIVE
MARKER FOR CHEMOTHERAPY IN NON-SMALL
CELL LUNG CANCER
Shin-ichi Yamashita, Toshihiko Moroga, Kentaro Anami,
Keita Tokuishi, Michiyo Miyawaki, Yozo Kawano, Masao
Chujo, Satoshi Yamamoto and Katsunobu Kawahara
Department of Surgery II, Faculty of Medicine, Oita
University, 1-1 Idaigaoka, Hasama, Yufu, Oita, 879-5593,
Japan
Background: Several predictive markers of treatment and
survival were reported such as ERCC1 in NSCLC (nonsmall-cell lung cancer). We report the possibility of DYRK2,
a dual-specificity tyrosine-(Y)-phosphorylation regulated
kinase gene to predict benefit from chemotherapy for
patients with recurrent NSCLC. Materials and Methods:
Forty patients with recurrent disease after surgery received
several combinations of platinum-based chemotherapy.
Chemotherapy effectiveness was evaluated according to
RECIST criterion. We used immunohistochemical analysis
to determine the expression of the DYRK2 protein with
operative specimens of NSCLC. Results: We could not find
any correlation between age, sex, pathological stage, tumor
size, nodal status, histological type and DYRK2 expression.
The overall response rate was 22.2% (4 out of 18) in DYRK2
positive group compared with 4.5% (1 out of 22) in negative
group. On the other hand, the group of 17 PD (progressive
disease) patients was consisted of 3 DYRK2 positive patients
and 14 DYRK2 negative patients (p=0.0086). The median
time to the progression of disease was 120 days in the
DYRK2 negative group, as compared with 310 days in the
DYRK2 positive group(HR=1.984, 95% CI=[1.039-3.788],
p=0.034). Conclusion: Patients with recurrent NSCLC and
DYRK2-positive tumors showed a substantial benefit from
chemotherapy, as compared with patients with DYRK2negative tumors.
739
HMJ-30 SUPPRESSES MMP-2 EXPRESSION VIA
RECEPTOR TYROSINE KINASE INHIBITION AND
PKB/AKT, NF-KB, ERK SIGNALING PATHWAYS IN
U2OS CELLS
Abstracts of the 8th International Conference of Anticancer Research, 17-22 October 2008, Kos, Greece
Jai-Sing Yang1, Yu-Jen Chiu1, Kuan-Ting Chen1, Mann-Jen
Hour2, Wen-Wen Huang3 and Jing-Gung Chung3
1School
of Medicine, 2Graduate Institute and School of
Pharmacy, 3Department of Biological Science and
Technology, China Medical University, Taichung, Taiwan,
ROC
In this study, we examined the efficacy of HMJ-30, a
quinazoline derivative, on cell metastasis of human
osteosarcoma U2OS cells in vitro and explored its associated
molecular mechanisms. The effects of HMJ-30 on U2OS cell
viability, migration and invasion were detected by MTT,
wound scratch assays and transwell invasion assays,
respectively. Metastasis-relative protein expression and
activity were determined by Western blotting and gelatin
zymography. Our data showed that HMJ-30 inhibited U2OS
cell proliferation, migration and invasion in a concentrationdependent manner. HMJ-30 inhibited protein expression of
MMP-2 on HMJ-30-treated U2OS cells which were
examined in Western blotting. HMJ-30 also suppressed
MMP-2 activity in HMJ-30-treated U2OS cells as shown by
gelatin zymography. HMJ-30 suppressed proteins of the
receptor tyrosine kinase, including EGFR, ErbB2/neu and
Met. HMJ-30 also suppressed Akt phosphorylation, NF-κB
p65 and ERK1/2 protein expression in U20S cells. Taken
together, our data indicate a possible role of HMJ-30 as a
potential antitumor agent with the marked inhibition of
metastatic and invasive capacity of human osteosarcoma
U2OS cells.
740
THE ROLE OF ENDOPLASMIC RETICULUM
STRESS ON CELL CYCLE ARREST AND
APOPTOSIS INDUCED BY CRUDE EXTRACT OF
EUPHORBIA FORMOSANA RADIX IN HUMAN
PROSTATE CANCER CELLS
Jiun-Long Yang1, Chao-Lin Kuo2 and Jing-Gung Chung3
1Graduate
Institute of Chinese Pharmaceutical Science,
of Chinese Medicine Resources, 3Department of
Biological Science and Technology, China Medical
University, Taichung, Taiwan, ROC
2School
Prostate cancer is the one of the major causes of death by
cancer in older man worldwide. Euphorbia formosana radix
(EFR) has long been used as an anti-snake venom in
traditional Taiwanese medicine. However, there is no
available information to address the effects of EFR on human
prostate cancer cells. In this study, we investigated the
cytotoxicity of EFREC in human prostate cancer DU 145
cells. The results showed that EFREC decreased the
percentage of viable DU 145 cells in dose- and time-
dependent manners. The IC50 of EFR is 50 μg/ml and this
concentration was used for further study. Flow cytometry
was used for examining cell cycle arrest and the proportion
of sub-G1 DU 145 cells and results showed that EFREC
induced significant S-phase arrest and sub-G1 groups appear.
Comet assay demonstrated that EFREC induced significant
DNA damage in DU 145 cells and DNA gel electrophoresis
indicated that EFREC induced apoptosis due to the present of
DNA fragmentation. EFREC Induced the productions of
cytosolic reactive oxygen species (ROS) and calcium ions
but reduced the changes in mitochondria membrane potential
(ΔΨm) in examined cells. Results from Western blotting
indicated that EFREC reduced pro-caspase-3, pro-caspase-9,
pro-caspase-8 and Bcl-2, but increased Bax, cytochrome-c,
Endo-G, catalase, glutathion transferase, SOD-2, caspase-3,
caspase-8 and casepase-9 proteins. In conclusion, EFREC
induced apoptosis of DU 145 cells through mitochondriaand caspase-3-dependent pathways.
741
HUMAN CELLS COMMONLY ACQUIRE DNA
DAMAGE DURING MITOTIC ARREST
W. Brian Dalton, Mandayam O. Nandan and Vincent W.
Yang
Division of Digestive Diseases, Department of Medicine,
Emory University School of Medicine, 615 Michael Street,
Atlanta, Georgia 30322, USA
The mitotic checkpoint is a mechanism which arrests the
progression to anaphase until all chromosomes have
achieved proper attachment to mitotic spindles. In cancer
cells, satisfaction of this checkpoint is frequently delayed
or prevented by various defects, some of which have been
causally implicated in tumorigenesis. At the same time,
deliberate induction of mitotic arrest has proven clinically
useful, as antimitotic drugs which interfere with proper
chromosome-spindle interactions are effective anticancer
agents. However, how mitotic arrest contributes to
tumorigenesis or antimitotic drug toxicity is not well
defined. Here we report that mitotic chromosomes can
acquire DNA breaks during both pharmacological and
genetic induction of mitotic arrest in human cancer cells.
These breaks activate a DNA damage response, occur
independently of cell death, and subsequently manifest as
karyotype alterations. Such breaks can also occur
spontaneously, particularly in cancer cells containing
mitotic spindle abnormalities. Moreover, we observed
evidence of breakage in primary human cells. Our findings
thus describe a novel source of DNA damage in human
cells. They also suggest that mitotic arrest may promote
tumorigenesis and antimitotic toxicity by provoking DNA
damage.
3547
ANTICANCER RESEARCH 28: 3157-3556 (2008)
742
HIPPOCRATES OF KOS, THE FATHER OF
CLINICAL MEDICINE AND ASCLEPIADES OF
BITHYNIA, THE FATHER OF MOLECULAR
MEDICINE
Christos Yapijakis
University of Athens Medical School, Athens, Greece
Hippocrates of Kos (460-377 BC) is universally recognized as
the father of modern medicine, which is based on observation of
clinical signs and rational conclusions. Before him therapeutic
attempts were based on religious or magical beliefs. He
belonged to a family of physicians who claimed their ancestry
from Asclepius, the god of medicine. Hippocrates worked
mainly in the Aegean island of Kos and the nearby Minor Asia
coast, but he also traveled extensively visiting Athens, Thessaly
and Thrace. His contribution to medical practice (collectively
found in the Hippocratic Corpus) is characterized by ethical
rules of conduct (Hippocratic Oath), close observation of
clinical symptoms, an open mind for any ideas, and a
willingness to explain the cause of diseases. Hippocrates and
his followers, for about two and a half millennia, based
medicine on the notion that nature was made of four elements
(established by the philosopher Empedocles), namely water,
earth, wind and fire. In an analogous way, the body consisted
of four fluids or “humors” (black bile, yellow bile, phlegm and
blood) and four elemental conditions (cold, hot, dry and moist).
The state of health according to Hippocrates existed when these
humors and qualities were in balance. The physician had to
make a diagnosis and then facilitate the healing work of
“benevolent Nature” by use of bleeding or purgatives. Despite
some wrong assumptions, the contribution of Hippocrates to
clinical medicine is immense. The clinical and ethical basics of
medical practice, as well as most clinical terms used even today
have their origins in Hippocrates.
Asclepiades of Bithynia (124-40 BCE) was the first
physician who spoke about what is known today as molecular
medicine. Asclepiades was the first famous physician who
established Hellenic Medicine in Rome. He was born in
Prousa, Bithynia in the northwest region of Minor Asia, he was
educated at the Epicurean School in Athens and at the age of
33 years he moved to Rome, where he first taught philosophy
and later on practiced medicine. In contrast to the Hippocratic
dogma of four elements and humors, he adhered to atomic
theory, change and evolution, and did not accept the theory of
a “benevolent Nature”. He suggested that the human body is
composed of void spaces (poroi), as well as molecules (meri
or corpuscula) made of atoms (anarmoi ongoi). According to
Asclepiades, diseases are caused by alteration of form or
position of a patient’s molecules. In order to restore health, he
favored mild therapeutic methods such as healthy diet,
exposure to light, hydrotherapy, massage, physical exercise,
3548
and above all the friendly support of patients. Asclepiades was
the first physician who made the highly important division of
diseases into acute and chronic ones and was the first to
perform an elective non-emergency tracheotomy. He was a
pioneer in treating women (previously thought to be inferior
beings) and in the humane treatment of patients with mental
disorders, using labor and music therapy. His humane and
naturalistic approach, as well as his medical skills gave him a
great reputation. His influence lasted for six centuries through
the Methodic Medical School, which was established by his
students. Some ideas of Asclepiades have been rediscovered in
the past century and represent the molecular basis of medicine.
743
INHERITED GENE POLYMORPHISMS OF
FACTORS RELATED TO ANGIOGENESIS,
INFLAMMATION AND THROMBOSIS THAT
INFLUENCE RISK FOR ORAL CANCER
C. Yapijakis1,2, D. Avgoustidis1, Z. Serefoglou1, A.
Vylliotis1, S. Spyridonidou1, E. Critselis1, E. Nkenke2, FW.
Neukam2, E. Patsouris3 and E. Vairaktaris1
Departments of 1Oral and Maxillofacial Surgery,
and 3Pathology, University of Athens Medical
School, Athens, Greece;
4Department of Oral and Maxillofacial Surgery, University
of Erlangen, Nürnberg, Germany
2Neurology
Introduction: Recent genetic association studies performed by
our group and others have provided evidence that inherited
functional DNA polymorphisms in genes of factors related to
angiogenesis, inflammation and thrombosis are associated
with increased risk for oral squamous cell carcinoma (OSCC).
The present study examined the possible combinatory effect
of 31 such gene polymorphisms in predicting the occurrence
of OSCC in Europeans using multivariate logistic regression
analysis. Materials and Methods: A total of 330 individuals of
Greek and German origin were studied, consisting of 162
OSCC cases and 168 healthy controls of comparable age,
gender, and ethnicity. DNA was isolated from blood samples
of studied individuals. Functional DNA polymorphisms in 31
genes that encode cytokines and their receptors, matrix
metalloproteinases and their inhibitors, platelet glycoproteins
and coagulation factors were investigated. They included IL1b
(+3953C/T), IL-4 (-590C/T), IL-6 (-174G/C), IL-8 (-251A/T),
IL-10 (-1082A/G), IL–18 (-607C/A), TNF-α (-308G/A), TNFβ (+252G/A), VEGF (+936C/T), Leptin (-2548G/A), Leptin
Receptor (223Gln/Arg), MMP-1 (-16071G/2G), MMP-3 (11715A/6A), MMP-7 (-181A/G), MMP-9 (-1562C/T), MMP13 (-77A/G), TIMP-2 (-418C/G), GPIα (807C/T), GPIbα
(VNTR), PAI-1 (4G/5G), AGT (325Met/Thr), ACE (intron
16D/I), TAFI (+325C/T), Thrombomodulin (-33G/A), Protein
Z (-13G/A), SDF1 (801G/A), Factor II (20210G/A), Factor V
Abstracts of the 8th International Conference of Anticancer Research, 17-22 October 2008, Kos, Greece
(1691G/A), Factor XII (46C/T), Factor XIII (34Val/Leu), and
MTHFR (677C/T). A series of regression models (adjusted for
age and gender) was constructed in order to assess the
contribution of homozygous or heterozygous variant
polymorphic genotypes upon overall, early and advanced
stages of OSCC development. Results: In almost all
multivariate logistic regression models, the contribution of
TNF-α and IL-6 polymorphisms was consistent and robust.
Furthermore, when the mode of inheritance of each variant
allele was taken into account in a model, five polymorphisms
emerged as primary predictors for all OSCC stages: TIMP-2
(OR=26.33; 95%CI=12.39–55.95), TNF-α (OR=15.27;
95%CI=7.30–31.96), IL-6 (OR=8.33; 95%CI=3.95–17.58),
IL-8 (OR=3.54; 95%CI=1.69–7.43) and IL-10 (OR=2.65;
95%CI=1.28–5.46). Conclusion: The present regression
analysis revealed a highly significant contribution of 5 out of
31 studied factors in the occurrence of OSCC. Based on these
findings and previous reports, possible interactions of the
implicated factors leading to OSCC development, as well as
an algorithm of risk estimation will be discussed.
744
EFFECT OF CORDYCEPS SINENSIS ON
SPONTANEOUS METASTATIC MODEL MICE
Noriko Yoshikawa, Erika Kubo, Satomi Kagota, Kazumasa
Shinozuka, Masaru Kunitomo and Kazuki Nakamura
Department of Pharmacology, School of Pharmacy and
Pharmaceutical Sciences, Mukogawa Women’s University,
Nishinomiya, Hyogo 663-8179, Japan
Cordyceps sinensis has been used as a herbal tonic in
traditional Chinese medicine. We previously reported that the
water extract of the fruiting bodies of cultured Cordyceps
sinensis (WECS), when administered to a hematogenic lung
metastatic mouse model concomitantly with methotrexate
(MTX), a folic acid antagonist, indicated a combined antimetastatic effect. In this study, we investigated the effect of
WECS on a spontaneous metastatic mouse model, and also
examined the combined effect of hydroxyurea, a ribonucleotide
reductase inhibitor, with WECS. Highly metastatic B16-BL6
mouse melanoma cells (1×106) were injected subcutaneously
into the footpad of the right hind leg in syngeneic C57BL/6Cr
mice. Two weeks after inoculation, the mice were anesthetized
with diethyl ether and the massively enlarged primary tumor
was amputated. WECS (3 and 10 mg/kg/day) and hydroxyurea
(500 mg/kg/day) were intraperitoneally administered to the
mice for 7 days after inoculation and for another 7 days after
amputation. To evaluate the anti-metastatic effect of WECS, we
measured the survival of mice. As a result, mice that had been
administered WECS 10 mg/kg showed significantly prolonged
survival compared with that in control mice. Furthermore,
hydroxyurea reinforced the anti-metastatic effect of WECS. In
conclusion, WECS may be useful for the treatment of
metastatic tumors, and a promising adjuvant with conventional
anti-tumor agents such as hydroxyurea.
745
THE ROLES OF REACTIVE OXYGEN SPECIES
AND CALCIUM IN CAPSAICIN-INDUCED
APOPTOSIS IN MDA-MB-231 HUMAN BREAST
CANCER CELLS THROUGH MITOCHONDRIADEPENDENT PATHWAY
Chun-Shu Yu1, Yu-Ping Lin2, Hsu-Feng Lu3 and
Jing-Gung Chung4
1School
of Pharmacology, Departments of 2Nutrition and
Science and Technology, China Medical
University, Taichung, Taiwan;
3Department of Clinical Pathology, Cheng Hsin
Rehabilitation Medical Center, Taipei, Taiwan, ROC
4Biological
Capsaicin (8-methyl-N-vanillyl-6-nonenamide), the main
pungent ingredient of red pepper, has been reported to
possess biological activities such as anticarcinogenic and
anticancer activities. In the present study, the effects of
capsaicin on human breast cancer MDA-MB-231 cells and
the signaling pathways involved in apoptosis it induces were
investigated. Treatment of MDA-MB-231 cells with capsaicin
inhibited cell growth and induced apoptosis through reactive
oxygen species (ROS) and Ca2+ generation, down-regulation
of Bcl-2 and activation of caspase-3. The increases in both
Ca2+ and ROS production were abolished by BAPTA (Ca2+
chelator) and N-acetylcysteine (ROS scavenger) and
pretreatment with both compounds also prevented capsaicininduced cell death. Capsaicin-promoted activation of ERK
was prevented with all the inhibitors tested. Interestingly,
capsaicin induced morphological alterations and reduced the
percentage of viable cells. Moreover, capsaicin increased the
protein levels of Bax, cytochrome c and active-caspase-3 but
reduced the levels of Bcl-2 and Bcl-xl. We conclude that
capsaicin induces apoptosis in MDA-MB-231 cells via ROS
and Ca2+ generation and caspase-3 activation.
746
NOTI MICROARRAYS (NMA) FOR EPIGENETIC
PROFILING OF CANCER CELLS
V. Kashuba, T. Pavlova, K. Haraldson, I. Skrypkina,
S.P. Yenamandra, V. Senchenko, V. Zabarovska, E. Braga,
T. Eschenko, E. Grigorieva, M.I. Lerman, G. Klein and
E. Zabarovsky
MTC, Karolinska Institute, Stockholm, Sweden
We have developed restriction site tagged microarrays
(RSTM) and used NotI microarrays (NMA) for pilot
3549
ANTICANCER RESEARCH 28: 3157-3556 (2008)
experiments. Creation of microarrays on the genomic level
would be very important as it may give information
unavailable on mRNA/cDNA level (e.g. methylation, histone
acetylation, hemizygous deletions, epigenetic factors). NMA
are the only existing microarrays giving the opportunity to
detect simultaneously and differentially copy number and
methylation changes. Thus they allow to check cancer cells for
genetic and epigenetic abnormalities. These NMA can be used
for individuals, normal/tumor pairs, different cell types etc. At
present, we analyzed over 400 samples representing various
cancers: breast, kidney, cervical, colon, ovarian, lung, prostate,
nasopharyngeal carcinoma and leukemia. In the study 190
genes from human chromosome 3 were analyzed. For all
studied cancers we found genes specifically methylated in
malignant cells. Many genes were found to be methylated in a
very high fraction of cancer samples (more than 80%). These
genes can be divided in two classes: cancer specific and
common for several types of cancer. Some examples of genes
involved in several cancers: MINT24 (AF135524), BHLB2,
LOC285205, NBEAL2 (KIAA0540), FLJ44898 (AK126846),
GATA-2, RARbeta1, RBSP3 (CTDSPL), VHL. Many
methylated genes were unknown previously to be involved in
the development of epithelial cancers. Methylation of more
than 15 genes was confirmed by methyl-specific PCR and
bisulfite sequencing. Methylation status of the genes correlated
with expression (more than 15 genes were tested). For
example, expression of RBSP3 was strongly suppressed (more
than 100-fold) in cervical samples and degree of the
expression decrease was tumor progression dependent. Four
genes were tested functionally and demonstrated growth
inhibiting activity proving that NMA are efficient instrument
to discover cancer causing genes and especially tumor
suppressor genes. We found that several tumor suppressor
genes in AP20 and LUCA 3p21.3 regions were co-regulated
in tumors. For example, real-time PCR was used to measure
mRNA level of RBSP3, NPRL2/G21, RASSF1A, ITGA9,
HYAL1 and HYAL2 in basic types of NSCLC – squamous
cell lung cancer (SCC, 41 samples) and lung adenocarcinoma
(ADC, 18 tumors). Significant (from 2 to 100 times) and
frequent (from 44 to 100%) mRNA level decrease was shown
in the tumors. Down-regulation of RASSF1A and ITGA9 was
associated significantly with ADC progression. Simultaneous
decrease of all six genes’ mRNA level was found in the same
tumor samples and was not depended on their localization in
3p21.3 and functions of the proteins. These results supported
the hypothesis on simultaneous inactivation of cluster cancercausing genes in AP20 and LUCA regions during the
development and progression of lung cancer and other
epithelial tumors. The data could be important for
development of specific biomarker sets for early cancer
diagnosis and new therapeutic approaches/strategies for cancer
treatment. Genes specifically demethylated in tumors were
also found. They could represent oncogene-like genes.
3550
747
COMBINATION OF SYNTHETIC ORGANOSILICON
COMPOUNDS (SILA-409 AND SILA 421) WITH
CYTOSTATIC DRUGS IN XENOGRAFT MODELS
OF HUMAN PANCREATIC CANCER
Attila Zalatnai1 and József Molnár2
1First
Department of Pathology and Experimental Cancer
Research, Semmelweis University, Faculty of Medicine, 26
Üllői Rd., Budapest, Hungary, H-1085;
2University of Szeged, Department of Medical
Microbiology and Immunobiology, Szeged, Hungary
Introduction: Pancreatic cancer is characterized by an
aggressive behavior, poor prognosis and the main obstacle
is its chemoresistance. In more than 70% of these tumors
the P-glycoprotein encoded by the Multidrug-resistance
(MDR)- gene is overexpressed. Several mdr-revertant
molecules have been synthesized, among them the patented
organosilicon compounds (SILA-409, SILA-421) showed
promising in vitro and in vivo activities. We have
investigated the combination of these compounds with
various cytostatic drugs to achieve a better tumor-inhibiting
effect. Materials and Methods: Human pancreatic cancer
xenografts (PZX-40) subcutaneously growing in
immunosuppressed mice have been continuously treated
with intraperitoneal administration of SILA-409 and SILA421, together with gemcitabine, vincristine, irinotecan or
paclitaxel for a month. Tumor volumes were weekly
calculated, the expression of P-170 and Ki-67 were assessed
by immunohistochemistry. Results: These organosilicon
compounds are not toxic in mice even at high doses (10
mg/kg) and they are well tolerable drugs. Although
gemcitabine is not a P-gp substrate, combination with these
organosilicons resulted in a tumor growth delay, a volume
reduction or volume stabilization. Growth delay was also
found in SILA + vincristine, SILA + paclitaxel groups, but
not after SILA + irinotecan treatment. Irinotecan by itself has
abolished the P-gp expression, but the other combination
treatments all have led to significantly diminished P-170
immunopositivity. The Ki-67 proliferative index was
reduced in all treated tumors. Conclusion: SILA-409 and
SILA-421 synthetic organosilicon compounds showing an
MDR-revertant activity in vitro, were also effective in in
vivo experimental systems. They can be administered safely,
with no side-effects. Decreased P-gp expression was also
demonstrated in the tumors. These drugs can be effectively
combined with cytostatics. The organosilicon compounds
are promising molecules in the oncology research.
748
UNDERLYING MOLECULAR ALTERATIONS IN
PROGRESSION OF NSCLC
Abstracts of the 8th International Conference of Anticancer Research, 17-22 October 2008, Kos, Greece
I. Zborovskaya, K.K. Lactionov, B. Polotsky, D. Yudin,
I. Favorskaya, E. Musatkina, M. Kochetkova, O. Kovaljova,
V. Mochalnikova, K. Arhipova, E. Stepanova,
B. Ahmetov and A. Telezhkina
N.N.Blokhin’ Cancer Research Center of RAMS,
Moscow, Russia
Molecular changes, during different steps of tumor
progression were compared in group of tumors with
different morphology and level of cell differentiation. The
significance of individual gene alterations and certain set
of molecular markers in clinical trials were evaluated in
various stages of non-small cell lung cancer in patients
radically operated in Blokhin's RCRC of RAMS in 19852006 (RAS gene polymorphism, deletion in loci 1p32-36,
7q31 and 11p15, expression of MMPs, CAV-1, BIRC5,
CDH1, CTNNB1, uPA/uPAR, RALA, DAPk1, BCL-2,
BAX, p53, VEGF/VEGFR etc.). These results point to a
subgroup of tumors with complex molecular abnormalities
that correlate with worst prognosis. The study focuses on
the prognosis of 120 patients with different metastatic
status. The panel of molecular markers consisted of
deletion in loci 1p32-36, expressions of mutant р53, BCL2, BAX, VEGF. The simple statistical and regressivefactorial analysis of molecular markers shown in NSCLC
indicated that expression of mutant р53 and VEGFа,
deletion in 1р32.1 and 1р36.3 and reduction of BАХ
expression can be reliable adverse prognostic factors for
NSCLC. On the basis of the calculated values of weight
factors and clinical, morphological and molecularbiological markers, it is possible to differentiate between
patients with poor (less two years) and favorable prognosis
(more than five years).
The results allow the individual prognosis of survival rate
for each patient with NSCLC. The potential clinical utility
of these findings and the possible direction for further study
are discussed.
749
CONTROVERSIES IN THE MANAGEMENT OF
OVARIAN CANCER PRO AND CONS OF
INTRAPERITONEAL (IP) CHEMOTHERAPY
Alain G. Zeimet
Department of Obstetrics and Gynecology, Innsbruck
Medical University, Austria
Ovarian cancer generally remains confined to the abdominal
cavity throughout its course. Three randomized trials have
shown superiority of intraperitoneal (IP) over conventional
intravenous (IV) chemotherapy in optimally debulked
patients(residual disease ≤1 cm). Thus, in the last two years
the route of administration of the cytotoxic agents became a
subject of major debate in the treatment of ovarian cancer.
Based on the outcome of the International Consensus
Meeting on IP Chemotherapy in Ovarian Cancer held in
Innsbruck in February 2006, in our institution, IP
chemotherapy is routinely applied in appropriate patients
and we even extended the indications for IP chemotherapy
from FIGO stage III to earlier stages. The two-years
experience of the Austrian-wide AGO observational study
will be reported. A steeply increasing learning curve in
adequate catheter implantation, in the management of
complications with IP administration and treatment-related
toxicities were noticed. The most mentioned side-effects
were long lasting neurotoxicity, abdominal pain, fatigue,
gastro-intestinal, metabolic toxicities and infrequently
catheter-related complications. Apart from side-effects
related to the catheter, most toxicities were identified to
mirror the toxicity profile of high-dose cisplatin (≥100
mg/m2) and were independent from the route of drug
administration. Therefore the classic cisplatin/paclitaxel IPregimen used in the GOG-172 trial was changed to an
alternative regimen comprising carboplatin AUC 5 (d.1) and
weekly paclitaxel 60 mg/m2 (d.1,8,15) In this therapeutic
approach all drugs were administered via intraperitoneal
route. This treatment was by far better tolerated and quality
of life, during and after therapy, was significantly less
compromised. However, the toxicity profile of this novel
approach was different from that observed when the
included drugs were given intravenously. The most relevant
and limiting side-effect of this IP-regimen was
myelotoxicity with a high rate of thrombocytopenia leading
frequently to a delay in drug administration. Furthermore,
new data on cost effectiveness comparing both IP and IV
chemotherapy in advanced ovarian cancer will be discussed
on the basis of comparable large randomized IV and IP
GOG-trials. Conclusion: In cases, where optimal
cytoreduction with residual disease ≤1 cm was achieved
during primary surgery and disease was confined to the
peritoneal cavity, IP-chemotherapy should seriously be taken
into consideration even at the expense of significantly
increased, but manageable toxicity. A more favorable
therapeutic index should be expected in IP regimens, when
cisplatin is substituted by the better tolerable carboplatin.
750
ANTICANCER ACTIVITIES OF WILD AND
CULTIVATED EDIBLE DANISH MUSHROOMS
Lin Zhai1, Ming Chen1, Henning Knudsen2,
Henrik Hoff-Hansen3 and Arsalan Kharazmi1
1Department
of Clinical Microbiology, 7602, University
Hospital of Copenhagen (Rigshospitalet), Tagensvej 20,
Copenhagen, DK-2200 N;
3551
ANTICANCER RESEARCH 28: 3157-3556 (2008)
2Botanical
Museum, Gothersgade 130, Copenhagen, DK1123 K;
3Rosbaeksvej 4, DK-2100 Copenhagen Ø, Denmark
Coprinus comatus, Meripilus giganteus, Flammulina
velutipes, Grifola frondosa, and other 17 wild edible Danish
mushrooms were collected from North Zealand, Denmark.
Agaricus bisporus, Pleurotus eryngii, Pleurotus ostreatus,
and other three cultivated mushrooms were purchased from
Danish supermarkets. Fresh mushrooms were dried in an
atmosphere of 37˚C ventilation. Water extractions of these
mushrooms were made and were sterile filtered through a
0.22-μm-pore-size Millipore filter.
The in vitro anticancer activity of the water extractions of
these mushrooms have been tested against four different
cancer cell lines, K562, EL4 (both are leukemic cell lines),
MCF7 (human breast cancer cell line), and PC3 (human
prostate cancer cell line). A standard assay (sulforhodamine B
staining method) for anticancer-drug screening recommended
by National Cancer Institute has been employed for the study.
The results show that some mushrooms exhibit potent
inhibitory activity on the in vitro growth of the four different
cancer cell lines. Among the tested wild edible Danish
mushrooms, C. comatus, G. frondosa, and M. giganteus, show
potent in vitro anticancer activity against all four different
cancer cell lines. At the concentration of 0.01 g/ml, G. frondosa
and F. velutipes inhibited the in vitro growth of EL-4 cell line
by 92% and 70%, respectively. A. bisporus, P. eryngii, P.
ostreatus and other three cultivated edible Danish mushrooms
exhibit moderate inhibitory effect on the in vitro growth of
K562 and EL4, and slight effect on PC3. However, they have
no effect on the in vitro growth of MCF7. Preliminary
mechanism of action study indicates that the in vitro anticancer
activity of these mushrooms is probably via apoptosis.
In many parts of the world, wild mushrooms are regularly
collected and used directly as a main source of food or added
to soups, stews and teas. Our data indicate that some wild
edible Danish mushrooms have potent anticancer activity in
vitro and there is a great potential to find new anticancer
agents from these mushrooms. Recommendation of these
edible mushrooms to cancer patients as functional foods
should be discussed.
751
INDUCTION OF MEGAKARYOCYTIC
DIFFERENTIATION AND GROWTH INHIBITION
OF K562 ERYTHROLEUKEMIA CELLS BY OVEREXPRESSION OF CYP2E1
Weiqiang Zhao, Yan Tang, Maureen E. Baird,
Gerard Lozanski and Frederick K. Racke
Department of Pathology, Ohio State University, Columbus,
OH 43210, USA
3552
Cytochrome P450 2E1 (CYP2E1), found predominantly in
hepatic cells involved in xenobiotic metabolism, has been
occasionally found to be up-regulated in other cells, including
certain types of leukemia. In the current study, the role of
CYP2E1 in leukemic K562 cells was investigated. Overexpression of CYP2E1 reduced proliferation compared to
empty vector control cells. Cell cycle analysis indicated
CYP2E1 cells produced maximum G2/M arrest of 33% and
28% at 24 hr and 48 hr, respectively, in comparison with
control cells (10% and 19%, 24 and 48 hr, respectively).
Growth arrest was accompanied by induction of
megakaryocytic differentiation as evidenced by cell
enlargement, polyploidization, and CD41 expression. Induction
of megakaryocytic differentiation of K562 cells by phorbol
myristate acetate (PMA) was accompanied by increased
expression of CYP2E1 at both the protein and mRNA levels.
Expression of BCR-ABL mRNA was not affected by
overexpression of CYP2E1; however, the pBCR-ABL and
pSTAT5 were suppressed in CYP2E1 in overexpressors
compared to control cells. When CYP2E1 K562 was treated
with a dual kinase inhibitor, NS187 at 1 μM, a synergistic
inhibitory effect on cell growth was observed at all time points
checked from 24 to 72 hr. The mechanisms of effect of ectopic
expression of CYP2E1 in K562 cells are not understood yet;
however, recent studies have shown that production of reactive
oxygen species (ROS) in normal hematopoietic progenitors
promotes megakaryocytic differentiation. Therefore, we
postulate that over-expression of CYP2E1 might increase ROS
production and this will be tested in the future studies. In
summary, over-expression of CYP2E1 in K562
erythroleukemia cells resulted in a cell growth arrest due to a
G2/M phase arrest, megakaryocytic differentiation, and a
synergistic cell growth inhibition with pBCR-ABL inhibitor.
The results from this study might have clinical implications.
For instance, drugs that inhibit CYP2E1 activity might inhibit
megakaryocytic growth and be applied in the treatment of
myeloproliferative disorders with abnormal megakaryocytic
proliferation; in contrast, strategies to increase CYP2E1 activity
might be applied to promote thrombopoeisis in cases of the
acquired thrombocytopenia. Finally, strategies to increase
CYP2E1 activity may act synergistically with bcr-abl kinase
inhibitors as novel therapy for Ph+ leukemia.
752
BLOOD TEST FOR CUTANEOUS MALIGNANT
MELANOMA
M. Ziman, S. Medic, R. Slattery and R. Pearce
School of Exercise, Biomedical and Health Science,
Edith Cowan University, Joondalup, Perth, 6027, Australia
Finding sensitive markers to detect dissemination of
metastatic melanoma cells is an important research focus as
Abstracts of the 8th International Conference of Anticancer Research, 17-22 October 2008, Kos, Greece
metastasis may be undetected clinically and recurrence can
occur many years after surgery.
Here we have used RT-PCR and real-time RT-PCR to assess
the presence of several molecular markers of circulating
melanoma cells in peripheral blood from 200 melanoma
patients and 50 healthy volunteers. The frequency and level of
expression of markers was correlated to Breslow tumour
thickness and tumour progression, and results were statistically
analysed.
Results show that markers of circulating melanoma cells
were detected in blood of 79% of melanoma patients and in
only 11% of healthy volunteers. Several markers showed a
higher detection rate overall, regardless of tumour thickness,
although levels were highest in those patients with thicker
tumours. Notably, migrating melanoma cells were found in
peripheral blood of patients with early-stage tumours and in
patients from whom tumours were removed several years
previously. Further research is progressing to increase the
sensitivity of detection and characterise the gene expression
profile of migrating metastatic melanoma cells.
753
HYPERTHERMIC ISOLATED LIMB PERFUSION
(HILP) WITH MELPHALAN PLUS TNF
O. Zoras, C. Ioannou, S. Koukouraki, K. Perisynakis,
A. Theodosakis, Th. Moschovos and G. Chalkiadakis
Surgical Department, University of Crete Medical School,
Herakleion, Crete, Greece
Introduction: After completion of a trial period in which
leakage control and surgical skills were assessed by Experts
in the Surgical Department, University of Crete, our team
was accreditated the use of TNF (Beromun) in local
regional treatment for inoperable or recurrent sarcomas and
melanomas of the extremities. Purpose: To depict our
experience, as well as our technique with the use of
Melphalan and TNF in HILP in inoperable or recurrent
sarcomas and melanomas of the extremities as performed
in the Surgical Department, University of Crete between
2006 and today. Patients and Methods: A total of eight
cases were treated. Three sarcomas of which 1
leiomysarcoma located just above the left external
malleolus, 1 leiomysarcoma in the right tibia and the last, a
liposarcoma, in the right femorus. All of the previous cases
were initially treated elsewhere and were referred to us
after recurrence. Furthermore, five intransit melanomas of
the lower limb were treated. Chemotherapy dosages for
Melphalan were calculated according to common protocol
(10 mg/liter of limb volume) and TNF was 2 mg in total
dose. All patients were recovered in the ICU for 24 hours in
accordance to protocol. Results: Although statistical
comparison is not applicable, we observed a notable
shrinkage of the tumor and a very good partial response of
the sarcomas and complete response of the melanomas. No
systemic toxicity was observed. Limb toxicity as measured
by the Wieberdink scale was 0 in six cases and 2 in two
cases. Functional disability was minimal in all cases.
Conclusion: Our experience verifies that the use of
Melphalan and TNF in HILP is safe when guidelines and
safety rules are followed.
754
GENE AND STEM CELL CANCER THERAPY
USING TRAIL
Ralf Zwacka1,2, Chirlei Bueneker1, Laura Deedigan1 and
Andrea Mohr1
1NCBES,
Molecular Therapeutics Group, National
University of Ireland, Galway, and 2Regenerative Medicine
Institute (REMEDI), University Road, Galway, Ireland
The tumour necrosis factor-related apoptosis-inducing
ligand (TRAIL) is a potent inducer of apoptosis in cancer
cells. We have tried several ways of delivering TRAIL to
tumours including adeno-associated viral (AAV) vectors.
Recently we have used mesenchymal stem cells (MSCs) to
deliver TRAIL to sites of malignant growth. The
prerequisite for the use of MSCs is that they can withstand
the apoptosis-inducing activity of TRAIL. Indeed, we found
that MSCs are completely resistant to the effects of TRAILinduced apoptosis. Analyses of TRAIL receptor expression
revealed that MSCs do not have any detectable levels of the
four TRAIL-receptors on their surface. The forced
expression of TRAIL-R1 in MSC using an adenoviral
vector rendered them sensitive to TRAIL, demonstrating
that lack of TRAIL-receptor expression is the cause for the
observed unresponsiveness. Co-treatment of MSCs with
TRAIL and IFN-γ or 5-FU showed no increase in the
apoptotic response, pointing to the safety of potential future
TRAIL-based cancer therapies even in combination with
other anti-tumour agents. We then transduced MSCs with
an adenoviral vector expressing TRAIL (Ad.TR) and
showed the apoptosis-inducing activity of these TRAILcarrying MSCs on A549 lung carcinoma cells, which are
normally resistant to the effects of recombinant TRAIL
protein. We observed the same effect in various other types
of cancer cells. Apoptosis was also induced in A549 cells
by Ad.TR-transduced MSCs in the presence of
physiological concentrations of white blood cells,
erythrocytes and sera from human donors, factors that often
inhibit conventional viral vector approaches. Moreover, we
demonstrated tumour growth reduction with TRAIL-loaded
MSCs in an A549 xenograft mouse model. However,
despite these encouraging results several hurdles exist for
successful TRAIL-based therapies. These include the
3553
ANTICANCER RESEARCH 28: 3157-3556 (2008)
presence of several anti-apoptotic NF-κB target genes such
as XIAP, Bcl-xL, c-Flip and MnSOD in cancer cells. We
found varying contributions of these factors to apoptosis
resistance and we are currently trying to identify which of
these factors are good targets for inhibitory approaches that
could be combined with our gene-cell therapeutic tumour
targeting strategies.
755
AIR POLLUTION AND CANCER
Michael Theophanides1, Jane Anastassopoulou2
and Theo Theophanides2
1CAE,
Saint Laurent, Montreal, Quebec, Canada H42 4x4;
Technical University of Athens, Chemical
Engineering Department, Radiation Chemistry and
Biospectroscopy, Zogragou Campus, 15780 Zografou,
Athens, Greece
2National
Air Quality Studies are becoming an essential element of
operations, since the chemical pollutants present serious
health concerns. The existence of human, animal and plant
life on earth is dependent upon keeping the atmosphere in
a reasonable state of purity. This paper presents a
comparative study of mortality statistics attributed to
cancer, cardiac and pulmonary diseases in the last 30 years
in Kavala, other cities of Greece, and at the National level.
The objective of this work is to demonstrate the aboveaverage trends in mortality due to cancer, cardiac and
pulmonary diseases in areas of high industrial pollution
attributed to air pollution, water pollution and food
contamination. Statistical analysis of the data indicates that
the prefecture of Kavala, Greece has a higher rate of
mortality (per 1000) by approximately 20% due to cancer,
cardiac and pulmonary diseases compared to the National
average. There is also a trend indicating a growing
disparity of death rates between the National average and
polluted areas. Other trends will be analysed that show the
increase in the percentage of cancer-related mortalities
compared to total mortalities in polluted areas. For
example, in 1980, Kavala had a lower percentage (30%) of
mortalities attributed to cancer for ages less than 65 years
old compared to the National average (36%). However, in
1998, Kavala had an equal amount of percentage of
mortalities (36%) attributed to cancer compared to the
National average (28%) indicating that the significant
decrease during 1980-1998 in cancer-related mortalities for
younger age groups represented in the National average are
not exhibited for the Kavala area. For the higher age group
of 65 to 74 years old, the results show that while the
National average has remained steady at 32%, the Kavala
average has increased during 1980 to 1998 from 36% to
40%.
3554
756
THE IMPORTANCE OF BIOMARKERS IN
PROSTATE CANCER DIAGNOSTICS
(A PILOT STUDY)
L. Holubec, J. Vrzalova, J. Klecka, M. Pesta,
O. Topolcan, V. Eret and M. Hora
University teaching hospital, Plzen and Charles University
of Plzen, E.Benese 13, 305 99, Plzen, Czech Republic
Background: Early diagnosis of prostate cancer (PCa) in
organ confined stage with following radical treatment is the
only potential currative approach in PCa. PSA is a leading
marker in diagnosis, follow up, and therapy control. The aim
of the present pilot study was to evaluate diagnostic potential
of selected biomarkers for Pca diagnostics. Materials and
Methods: We examined altogether 66 patients. 27 patients
with benign prostatic hyperplasia (BPH), 9 patients with
prostatic intraepithelial neoplasia (PIN) and 30 patients with
prostate cancer (Pca). By means of immunoanalytical
methods and methods of multiplex analysis we assessed the
following biomarkers: PSA, TK, Chromogranin A, ICAM-1,
VCAM-1, MMP-9, VEGF, IL-6, IGFBP3, IGF1. Results:
Patients with BPH and patients with PCa exhibited
statistically significant differences in the levels of PSA
(0.0001), IGFBP3 (0.0027) and IGF1 (0.0148). We found
also statistically significant differences between patients with
BPH and PIN in the levels of PSA (0.0271), VEGF (0.0235)
and TK (0.0426). IGFBP3 was also significantly higher in
patients with PCa in comparison to patients with PIN. The
levels of PSA, TK and Chromogranin A correlated with stage
of disease, and levels of MMP-9 correlated with Gleason
score of prostate cancer. Conclusion: The results of the
present pilot study point out that PSA is a leading biomarker
for the diagnosis of prostate cancer. But also other
biomarkers can improve diagnostic accuracy and prognosis.
This work was supported by grant IGA NR/8918-3 and by
the Research project VZ MSM 0021620819.
757
MECHANISMS OF CHEMOTHERAPY RESISTANCE
IN HEAD AND NECK CANCER
Robert Mandic
Department of Otorhinolaryngology, Head and Neck
Surgery, University Hospital Giessen and Marburg, Campus
Marburg, Germany
Head and neck squamous cell carcinomas (HNSCCs)
account for over 90% of all malignancies in the upper aerodigestive tract. Despite multimodal treatment options that
include surgery, radio- and chemotherapy overall survival of
HNSCC patients did not improve to a significant extent
Abstracts of the 8th International Conference of Anticancer Research, 17-22 October 2008, Kos, Greece
within the past 30 years. The major cause for lack of
improvement lies in the development of tumor cell resistance
to treatment by radio- and chemotherapy. Particularly after
exhausting radiotherapy, chemotherapy often remains the
only treatment option. Cisplatin is the major compound used
in HNSCC chemotherapy treatment, therefore resistance to
platinum-based compounds is of central interest. In this short
survey we discuss the problem of chemotherapy resistance
in head and neck cancer treatment. The underlying
mechanisms conferring chemotherapy resistance to HNSCC
cells such as overexpression of antiapototic proteins, p53
mutations and up-regulation of efflux pumps will be pointed
out. Lastly the role of cancer stem cells (CSCs) in the
development of tumor cell resistance will be discussed. New
targeting strategies focusing on CSCs are an exciting new
perspective for future anticancer research.
758
AN OPERATIVE GAMMA CAMERA DEDICATED
TO THE OPTIMIZATION OF SENTINEL
LYMPH NODE PROCEDURE IN BREAST
CANCER SURGERY
1Z. Francis, 1V. Bekaert, 1S. Salvador, 1D. Brasse, 1D.
Huss, 2C. Mathelin
1Institut
pluridisciplinaire Hubert Curien, 23 avenue du
Loess, 67037 Strasbourg;
2Unité de sénologie, CHRU, Hôpitaux Universitaires de
Strasbourg, 1 place de l’hôpital, 67091 Strasbourg
Cedex, France
A close collaboration between the “Hôpitaux Universitaires
de Strasbourg” (Strasbourg, France) and the “Institut
Pluridisciplinaire Hubert Curien” (Strasbourg, France) led to
the development of a small gamma camera covering a field
of view of 100 °— 100 mm2, dedicated for breast cancer
surgery. This on-demand device is dedicated to per-operative
imaging aiming to identify and localise the Sentinel Lymph
Nodes (SLN). Nowadays, surgeons try to use the SLN
procedure avoiding the classical axillary lymph node
dissection which causes several side effects notably
lymphoedema after surgery. The procedure (used in 70% of
breast cancer cases) consists on localising the SLN as
precisely as possible and taking them off making sure no
residual SLN remains in the axillary area. Our first
experiment was a small field gamma camera (50 °— 50
mm2) built according to the dimensions of the H8500
Hamamatsu’s multianode photomultiplicator. Its small size
makes it flexible and easy to use in the operating room. It
was successfully tested on 25 patients treated for an
infiltrative breast cancer. However, despite its small practical
size, this detector’s field of view turned out to be small and
surgeons had to proceed acquiring up to 4 different images to
cover the entire axillary area, which led to the idea of a 100
°— 100 mm2 gamma camera. This study reveals the details
and the characteristics of our device shedding the light on its
performances and the unique dimensions of its field of view
covering the entire axillary area and the advantages of its use
during surgical operations.
759
MALIGNANT GROWTH IN THE BONE MARROW
CREATES ABNORMAL HEMATOPOIETIC
PROGENITOR CELL NICHES
Angela Colmone, Maria Amorim, Andrea Pontier, Sheng
Wang, Elizabeth Jablonski, Dorothy A. Sipkins
Department of Medicine, Section of Hematology/Oncology,
The Universityof Chicago, 5841 S Maryland Ave MC 2115,
Chicago, IL, 60605 USA
The host tissue microenvironment is known to influence
malignant cell proliferation and metastasis, but little is known
about how tumor-induced changes in the microenvironment
impact benign cellular ecosystems. Using dynamic in vivo
imaging, we show that leukemic cell growth disrupts normal
hematopoietic progenitor cell (HPC) bone marrow (BM)
niches and creates abnormal microenvironments that sequester
transplanted HPCs. HPCs in leukemic mice decline in number
over time and fail to mobilize into the peripheral circulation
in response to cytokine stimulation. Neutralization of SCF
secreted by leukemic cells inhibits HPC migration into
malignant niches, normalizes HPC numbers, and restores HPC
mobilization in leukemic mice. Our data provide evidence
that the tumor microenvironment can cause HPC dysfunction
by usurping normal HPC niches, and that inhibiting HPC
interaction with tumor niches may maintain normal progenitor
cell function in the setting of malignancy.
760
EPITHELIAL-MESENCHYMAL TRANSFORMATION
IN SOLID TUMORS WITH EMPHASIS ON HEAD
AND NECK SQUAMOUS CARCINOGENESIS
Adel K. El-Naggar
The University of Texas M.D.
Anderson Cancer Center, Houston, TX, USA
Phenotypic and conformational changes in the epithelial/host
interface during development and progression of head and
neck squamous carcinoma are unknown. However, it is
generally believed as in other epithelial carcinomas, the cells
undergo structural and morphologic modifications in response
3555
ANTICANCER RESEARCH 28: 3157-3556 (2008)
to host cell interaction leading to Epithelial to Mesenchymal
Transformation (EMT). This process appears to play a crucial
role in tumor invasion, progression, and metastasis of
squamous carcinogenesis. Identifying the key regulators of
this process in HNSC may provide critical information on
tumor host interactions in early and progressive stages of these
3556
tumors. Although, several pathways have been linked to the
induction of EMT in several human carcinomas, differential
involvement of specific pathways in each tumor type exist.
The presentation will highlight the significance of EMT in
early and invasive HNSC and discuss the potential therapeutic
and biological implications.